The	O
Physiological	O
Role	O
and	O
Regulation	O
of	O
Aquaporins	O
in	O
Teleost	O
Germ	O
Cells	O
The	O
unicellular	O
germ	O
cells	O
and	O
gametes	O
of	O
oviparous	O
teleosts	O
lack	O
the	O
osmoregulatory	O
organs	B-T023
present	O
in	O
juveniles	O
and	O
adults	O
,	O
yet	O
during	O
development	O
and	O
particularly	O
at	O
spawning	O
,	O
they	O
face	O
tremendous	O
osmotic	O
challenges	B-T033
when	O
released	O
into	O
the	O
external	O
aquatic	O
environment	O
.	O
Increasing	O
evidence	O
suggests	O
that	O
transmembrane	O
water	O
channels	O
(	O
aquaporins	O
)	O
evolved	O
to	O
play	O
vital	O
adaptive	O
roles	O
that	O
mitigate	O
the	O
osmotic	O
and	O
oxidative	O
stress	O
problems	B-T033
of	O
the	O
developing	O
oocytes	O
,	O
embryos	B-T018
and	O
spermatozoa	O
.	O
In	O
this	O
chapter	O
,	O
we	O
provide	O
a	O
short	O
overview	O
of	O
the	O
diversity	O
of	O
the	O
aquaporin	O
superfamily	O
in	O
teleosts	O
,	O
and	O
summarize	O
the	O
findings	O
that	O
uncovered	O
a	O
highly	O
specific	O
molecular	O
regulation	O
of	O
aquaporins	O
during	O
oogenesis	O
and	O
spermatogenesis	O
.	O
We	O
further	O
review	O
the	O
multiple	O
functions	O
that	O
these	O
channels	O
play	O
during	O
the	O
establishment	O
of	O
egg	O
buoyancy	O
and	O
the	O
activation	O
and	O
detoxification	B-T061
of	O
spermatozoa	O
in	O
the	O
marine	O
environment	O
.	O
      
A	O
Double	O
-	O
Blind	O
Randomized	O
Controlled	O
Trial	O
of	O
Maternal	B-T047
Postpartum	I-T047
Deworming	B-T061
to	O
Improve	O
Infant	O
Weight	B-T033
Gain	I-T033
in	O
the	O
Peruvian	O
Amazon	O
Nutritional	B-T061
interventions	I-T061
targeting	O
the	O
critical	O
growth	B-T033
and	I-T033
development	I-T033
period	I-T033
before	O
two	O
years	O
of	O
age	O
can	O
have	O
the	O
greatest	O
impact	O
on	O
health	O
trajectories	O
over	O
the	O
life	O
course	O
.	O
Compelling	O
evidence	O
has	O
demonstrated	O
that	O
interventions	B-T061
investing	O
in	O
maternal	O
health	O
in	O
the	O
first	O
1000	O
days	O
of	O
life	O
are	O
beneficial	O
for	O
both	O
mothers	O
and	O
their	O
children	O
.	O
One	O
such	O
potential	O
intervention	B-T061
is	O
deworming	B-T061
integrated	O
into	O
maternal	O
postpartum	O
care	O
in	O
areas	O
where	O
soil	O
-	O
transmitted	O
helminth	O
(	O
STH	O
)	O
infections	B-T047
are	O
endemic	B-T047
.	O
From	O
February	O
to	O
August	O
2014	O
,	O
1010	O
mother	O
-	O
infant	O
pairs	O
were	O
recruited	O
into	O
a	O
trial	O
aimed	O
at	O
assessing	B-T058
the	O
effectiveness	O
of	O
maternal	B-T047
postpartum	I-T047
deworming	B-T061
on	O
infant	O
and	O
maternal	O
health	O
outcomes	O
.	O
Following	O
delivery	O
,	O
mothers	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
single-	O
dose	O
400	O
mg	O
albendazole	B-T121
or	O
placebo	O
.	O
Participants	O
were	O
followed	B-T058
-	I-T058
up	I-T058
at	O
1	O
and	O
6	O
months	O
postpartum	O
.	O
There	O
was	O
no	B-T033
statistically	I-T033
significant	I-T033
difference	O
in	O
mean	O
weight	B-T033
gain	I-T033
between	O
infants	O
in	O
the	O
experimental	O
and	O
control	O
groups	O
(	O
mean	O
difference	O
:	O
-0.02	O
;	O
95	O
%	O
CI	O
:	O
-0.1	O
,	O
0.08	O
)	O
at	O
6	O
months	O
of	O
age	O
.	O
Further	O
,	O
deworming	B-T061
had	O
no	O
effect	O
on	O
measured	O
infant	O
morbidity	O
indicators	O
.	O
However	O
,	O
ad	O
hoc	O
analyses	O
restricted	O
to	O
mothers	O
who	O
tested	O
positive	B-T033
for	O
STHs	O
at	O
baseline	O
suggest	O
that	O
infants	O
of	O
mothers	O
in	O
the	O
experimental	O
group	O
had	O
greater	O
mean	O
length	O
gain	O
in	O
cm	O
(	O
mean	O
difference	O
:	O
0.8	O
;	O
95	O
%	O
CI	O
:	O
0.1	O
,	O
1.4	O
)	O
and	O
length	O
-	O
for	O
-	O
age	O
z	O
-	O
score	O
(	O
mean	O
difference	O
:	O
0.5	O
;	O
95	O
%	O
CI	O
:	O
0.2	O
,	O
0.8	O
)	O
at	O
6	O
months	O
of	O
age	O
.	O
In	O
a	O
study	O
population	O
composed	O
of	O
both	O
STH	B-T047
-	I-T047
infected	I-T047
and	O
uninfected	O
mothers	O
,	O
maternal	B-T047
postpartum	I-T047
deworming	B-T061
was	O
insufficient	O
to	O
impact	O
infant	O
growth	O
and	O
morbidity	O
indicators	O
up	O
to	O
6	O
months	O
postpartum	O
.	O
Among	O
STH	B-T047
-	I-T047
infected	I-T047
mothers	O
,	O
however	O
,	O
important	O
improvements	O
in	O
infant	O
length	O
gain	O
and	O
length	B-T033
-	I-T033
for	I-T033
-	I-T033
age	I-T033
were	O
observed	O
.	O
The	O
benefits	O
of	O
maternal	B-T047
postpartum	I-T047
deworming	B-T061
should	O
be	O
further	O
investigated	O
in	O
study	O
populations	O
having	O
higher	O
overall	O
prevalences	O
and	O
intensities	O
of	O
STH	B-T047
infections	I-T047
and	O
,	O
in	O
particular	O
,	O
where	O
whipworm	B-T047
and	O
hookworm	B-T047
infections	I-T047
are	O
of	O
public	B-T058
health	I-T058
concern	I-T058
.	O
ClinicalTrials.gov	O
(	O
NCT01748929	O
)	O
.	O
      
Agglomeration	O
of	O
Luminescent	O
Porous	O
Silicon	O
Nanoparticles	O
in	O
Colloidal	O
Solutions	O
We	O
have	O
prepared	B-T033
colloidal	O
solutions	O
of	O
clusters	O
composed	O
from	O
porous	O
silicon	O
nanoparticles	O
in	O
methanol	O
,	O
water	B-T121
and	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
.	O
Even	O
if	O
the	O
size	O
of	O
the	O
nanoclusters	O
is	O
between	O
60	O
and	O
500	O
nm	O
,	O
due	O
to	O
their	O
highly	O
porous	O
"	O
cauliflower"-like	O
structure	O
,	O
the	O
porous	O
silicon	O
nanoparticles	O
are	O
composed	O
of	O
interconnected	O
nanocrystals	O
having	O
around	O
2.5	O
nm	O
in	O
size	O
and	O
showing	O
strong	O
visible	O
luminescence	O
in	O
the	O
orange	O
-	O
red	O
spectral	O
region	O
(	O
centred	O
at	O
600	O
-	O
700	O
nm	O
)	O
.	O
Hydrophilic	O
behaviour	O
and	O
good	O
solubility	O
of	O
the	O
nanoclusters	O
in	O
water	B-T121
and	O
water	B-T121
-	O
based	O
solutions	O
were	O
obtained	O
by	O
adding	O
hydrogen	B-T121
peroxide	I-T121
into	O
the	O
etching	O
solution	O
during	O
preparation	O
and	O
16	O
min	O
long	O
after	O
-	O
bath	O
in	O
hydrogen	B-T121
peroxide	I-T121
.	O
By	O
simple	O
filtration	O
of	O
the	O
solutions	O
with	O
syringe	O
filters	O
,	O
we	O
have	O
extracted	O
smaller	O
nanoclusters	O
with	O
sizes	O
of	O
approx	O
.	O
60	O
-	O
70	O
nm	O
;	O
however	O
,	O
these	O
nanoclusters	O
in	O
water	B-T121
and	O
PBS	O
solution	O
(	O
pH	O
neutral	O
)	O
are	O
prone	O
to	O
agglomeration	O
,	O
as	O
was	O
confirmed	B-T033
by	O
zeta	O
potential	O
measurements	O
.	O
When	O
the	O
samples	O
were	O
left	O
at	O
ambient	O
conditions	O
for	O
several	O
weeks	O
,	O
the	O
typical	O
nanocluster	O
size	O
increased	O
to	O
approx	O
.	O
330	O
-	O
400	O
nm	O
and	O
then	O
remained	O
stable	O
.	O
However	O
,	O
both	O
freshly	O
filtered	O
and	O
aged	O
samples	O
(	O
with	O
agglomerated	O
porous	O
silicon	O
nanoparticles	O
)	O
of	O
porous	O
silicon	O
in	O
water	B-T121
and	O
PBS	O
solutions	O
can	O
be	O
further	O
used	O
for	O
biological	O
studies	O
or	O
as	O
luminescent	O
markers	O
in	O
living	O
cells	O
.	O
      
Strategies	O
for	O
Successful	O
Clinical	O
Teaching	O
This	O
article	O
is	O
one	O
in	O
a	O
series	O
on	O
the	O
roles	O
of	O
adjunct	O
clinical	O
faculty	O
and	O
preceptors	O
,	O
who	O
teach	O
nursing	O
students	O
and	O
new	O
graduates	O
to	O
apply	O
knowledge	O
in	O
clinical	O
settings	O
.	O
This	O
article	O
describes	O
teaching	O
strategies	O
as	O
well	O
as	O
the	O
importance	O
of	O
the	O
learning	O
environment	O
.	O
      
Is	O
Total	B-T061
Elbow	I-T061
Arthroplasty	I-T061
Safe	O
as	O
an	O
Outpatient	B-T061
Procedure	I-T061
?	O
Ambulatory	O
surgery	O
centers	O
are	O
the	O
preferred	O
setting	O
for	O
many	O
procedures	O
formerly	O
performed	O
in	O
a	O
hospital	O
setting	O
.	O
This	O
study	O
sought	O
to	O
determine	O
whether	O
outpatient	O
total	B-T061
elbow	I-T061
arthroplasty	I-T061
(	O
TEA	B-T061
)	O
is	O
as	O
safe	O
as	O
inpatient	O
TEA	B-T061
.	O
A	O
retrospective	O
analysis	O
was	O
performed	O
of	O
inpatient	O
(	O
IP	O
)	O
versus	O
outpatient	O
(	O
OP	O
)	O
TEA	B-T061
by	O
a	O
single	O
surgeon	O
over	O
a	O
period	O
of	O
18	O
years	O
.	O
Demographic	O
,	O
social	O
,	O
and	O
comorbidity	O
measures	O
as	O
well	O
as	O
complication	O
rates	O
were	O
analyzed	O
and	O
stratified	O
by	O
IP	O
or	O
OP	O
status	O
.	O
Bivariate	O
comparison	O
showed	O
increased	O
prevalence	O
of	O
coronary	B-T047
artery	I-T047
disease	I-T047
in	O
the	O
OP	O
group	O
(	O
32	O
%	O
vs.	O
7	O
%	O
)	O
and	O
increased	O
age	O
in	O
the	O
IP	O
group	O
(	O
68	O
years	O
vs.	O
58	O
years	O
)	O
.	O
All	O
other	O
demographic	O
,	O
social	O
,	O
and	O
comorbidity	O
factors	O
were	O
comparable	O
between	O
the	O
IP	O
and	O
OP	O
groups	O
,	O
although	O
more	O
infections	O
were	O
seen	O
in	O
the	O
IP	O
group	O
.	O
The	O
surgeons	O
'	O
initial	O
learning	O
curve	O
occurred	O
mostly	O
within	O
the	O
IP	O
group	O
.	O
Most	O
important	O
,	O
no	B-T033
difference	I-T033
in	O
complication	O
rate	O
was	O
observed	O
between	O
the	O
IP	O
and	O
OP	O
groups	O
.	O
      
Structural	O
Basis	O
for	O
Simvastatin	B-T121
Competitive	O
Antagonism	O
of	O
Complement	O
Receptor	O
3	O
The	O
complement	O
system	O
is	O
an	O
important	O
part	O
of	O
the	O
innate	O
immune	O
response	O
to	O
infection	B-T047
but	O
may	O
also	O
cause	O
severe	B-T033
complications	I-T033
during	O
inflammation	O
.	O
Small	O
molecule	O
antagonists	O
to	O
complement	O
receptor	O
3	O
(	O
CR3	O
)	O
have	O
been	O
widely	O
sought	O
,	O
but	O
a	O
structural	O
basis	O
for	O
their	O
mode	O
of	O
action	O
is	O
not	O
available	O
.	O
We	O
report	O
here	O
on	O
the	O
structure	O
of	O
the	O
human	O
CR3	O
ligand	O
-	O
binding	O
I	O
domain	O
in	O
complex	O
with	O
simvastatin	B-T121
.	O
Simvastatin	B-T121
targets	O
the	O
metal	O
ion	O
-	O
dependent	O
adhesion	O
site	O
of	O
the	O
open	O
,	O
ligand	O
-	O
binding	O
conformation	O
of	O
the	O
CR3	O
I	O
domain	O
by	O
direct	O
contact	O
with	O
the	O
chelated	B-T121
Mg(2	I-T121
+	I-T121
)	I-T121
ion	I-T121
.	O
Simvastatin	B-T121
antagonizes	B-T033
I	O
domain	O
binding	O
to	O
the	O
complement	O
fragments	O
iC3b	O
and	O
C3d	O
but	O
not	O
to	O
intercellular	O
adhesion	O
molecule-1	O
.	O
By	O
virtue	O
of	O
the	O
I	O
domain	O
's	O
wide	O
distribution	O
in	O
binding	O
kinetics	O
to	O
ligands	O
,	O
it	O
was	O
possible	B-T033
to	O
identify	O
ligand	O
binding	O
kinetics	O
as	O
discriminator	O
for	O
simvastatin	B-T121
antagonism	O
.	O
In	O
static	O
cellular	B-T059
experiments	O
,	O
15	O
-	O
25	O
μm	O
simvastatin	B-T121
reduced	O
adhesion	O
by	O
K562	O
cells	O
expressing	O
recombinant	B-T001
CR3	O
and	O
by	O
primary	O
human	O
monocytes	O
,	O
with	O
an	O
endogenous	O
expression	O
of	O
this	O
receptor	O
.	O
Application	B-T058
of	O
force	O
to	O
adhering	O
monocytes	O
potentiated	O
the	O
effects	O
of	O
simvastatin	B-T121
where	O
only	O
a	O
50	O
-	O
100	O
nm	O
concentration	O
of	O
the	O
drug	B-T121
reduced	O
the	O
adhesion	O
by	O
20	O
-	O
40	O
%	O
compared	O
with	O
untreated	O
cells	O
.	O
The	O
ability	O
of	O
simvastatin	B-T121
to	O
target	O
CR3	O
in	O
its	O
ligand	O
binding	O
-	O
activated	O
conformation	O
is	O
a	O
novel	O
mechanism	O
to	O
explain	O
the	O
known	O
anti	O
-	O
inflammatory	O
effects	O
of	O
this	O
compound	O
,	O
in	O
particular	O
because	O
this	O
CR3	O
conformation	O
is	O
found	O
in	O
pro	O
-	O
inflammatory	O
environments	O
.	O
Our	O
report	O
points	O
to	O
new	O
designs	O
of	O
CR3	O
antagonists	O
and	O
opens	O
new	O
perspectives	O
and	O
identifies	B-T033
druggable	O
receptors	O
from	O
characterization	O
of	O
the	O
ligand	O
binding	O
kinetics	O
in	O
the	O
presence	O
of	O
antagonists	O
.	O
      
Network	O
analysis	O
reveals	O
why	O
Xylella	B-T007
fastidiosa	I-T007
will	O
persist	O
in	O
Europe	O
The	O
insect	O
vector	O
borne	O
bacterium	B-T007
Xylella	B-T007
fastidiosa	I-T007
was	O
first	O
detected	O
in	O
olive	O
trees	O
in	O
Southern	O
Italy	O
in	O
2013	O
,	O
and	O
identified	O
as	O
the	O
main	O
culprit	O
behind	O
the	O
'	O
olive	B-T047
quick	I-T047
decline	I-T047
syndrome	I-T047
'	O
.	O
Since	O
then	O
,	O
the	O
disease	B-T047
has	O
spread	O
rapidly	O
through	O
Italy	O
's	O
main	O
olive	O
oil	O
producing	O
region	O
.	O
The	O
epidemiology	O
of	O
the	O
outbreak	O
is	O
largely	O
unstudied	O
,	O
with	O
the	O
list	O
of	O
X.	B-T007
fastidiosa	I-T007
hosts	B-T001
and	O
vectors	O
in	O
Europe	O
likely	O
incomplete	O
,	O
and	O
the	O
role	O
humans	O
play	O
in	O
dispersal	O
unknown	O
.	O
These	O
knowledge	O
gaps	O
have	O
led	O
to	O
management	O
strategies	O
based	O
on	O
general	O
assumptions	O
that	O
require	O
,	O
among	O
others	O
,	O
local	O
vector	O
control	O
and	O
,	O
in	O
certain	O
areas	O
,	O
the	O
destruction	O
of	O
infected	O
plants	O
and	O
healthy	O
ones	O
around	O
them	O
in	O
an	O
attempt	O
to	O
eradicate	O
or	O
halt	O
the	O
spreading	O
pest	B-T047
.	O
Here	O
we	O
show	O
that	O
,	O
regardless	O
of	O
epidemiological	O
uncertainties	B-T033
,	O
the	O
mere	O
distribution	O
of	O
olive	O
orchards	O
in	O
Southern	O
Italy	O
makes	O
the	O
chances	O
of	O
eradicating	O
X.	B-T007
fastidiosa	I-T007
from	O
the	O
region	O
extremely	O
slim	O
.	O
Our	O
results	O
imply	O
that	O
Southern	O
Italy	O
is	O
becoming	O
a	O
reservoir	O
for	O
X.	B-T007
fastidiosa	I-T007
.	O
As	O
a	O
consequence	O
,	O
management	O
strategies	O
should	O
keep	O
the	O
prevalence	O
of	O
X.	B-T007
fastidiosa	I-T007
in	O
the	O
region	O
as	O
low	O
as	O
possible	O
,	O
primarily	O
through	O
vector	O
control	O
,	O
lest	O
the	O
pathogen	B-T001
,	O
that	O
has	O
also	O
been	O
detected	O
in	O
southern	O
France	O
and	O
the	O
island	O
of	O
Mallorca	O
(	O
Spain	O
)	O
,	O
continues	O
spreading	O
through	O
Italy	O
and	O
Europe	O
.	O
      
Effect	O
of	O
constitutive	O
inactivation	O
of	O
the	O
myostatin	O
gene	O
on	O
the	O
gain	O
in	O
muscle	O
strength	O
during	O
postnatal	O
growth	O
in	O
two	O
murine	O
models	O
The	O
effect	O
of	O
constitutive	O
inactivation	O
of	O
the	O
gene	O
encoding	O
myostatin	O
on	O
the	O
gain	O
in	O
muscle	O
performance	O
during	O
postnatal	O
growth	O
has	O
not	O
been	O
well	O
characterized	O
.	O
We	O
analyzed	O
2	O
murine	O
myostatin	O
knockout	O
(	O
KO	O
)	O
models	O
,	O
(	O
i	O
)	O
the	O
Lee	O
model	O
(	O
KO(Lee	O
)	O
)	O
and	O
(	O
ii	O
)	O
the	O
Grobet	O
model	O
(	O
KO(Grobet	O
)	O
)	O
,	O
and	O
measured	O
the	O
contraction	O
of	O
tibialis	B-T023
anterior	I-T023
muscle	I-T023
in	O
situ	O
.	O
Absolute	O
maximal	O
isometric	O
force	O
was	O
increased	O
in	O
6	O
-	O
month	O
-	O
old	O
KO(Lee	O
)	O
and	O
KO(Grobet	O
)	O
mice	O
,	O
as	O
compared	O
to	O
wild	O
-	O
type	O
mice	O
.	O
Similarly	O
,	O
absolute	O
maximal	O
power	O
was	O
increased	O
in	O
6	O
-	O
month	O
-	O
old	O
KO(Lee	O
)	O
mice	O
.	O
In	O
contrast	O
,	O
specific	O
maximal	O
force	O
(	O
relative	O
maximal	O
force	O
per	O
unit	O
of	O
muscle	O
mass	B-T033
was	O
decreased	O
in	O
all	O
6	O
-	O
month	O
-	O
old	O
male	O
and	O
female	O
KO	O
mice	O
,	O
except	O
in	O
6	O
-	O
month	O
-old	O
female	O
KO(Grobet	O
)	O
mice	O
,	O
whereas	O
specific	O
maximal	O
power	O
was	O
reduced	O
only	O
in	O
male	O
KO(Lee	O
)	O
mice	O
.	O
Genetic	O
inactivation	O
of	O
myostatin	O
increases	O
maximal	O
force	O
and	O
power	O
,	O
but	O
in	O
return	O
it	O
reduces	O
muscle	O
quality	O
,	O
particularly	O
in	O
male	O
mice	O
.	O
Muscle	O
Nerve	O
55	O
:	O
254	O
-	O
261	O
,	O
2017	O
.	O
      
Concordant	O
but	O
Varied	O
Phenotypes	O
among	O
Duchenne	B-T047
Muscular	I-T047
Dystrophy	I-T047
Patient	O
-Specific	O
Myoblasts	O
Derived	O
using	O
a	O
Human	O
iPSC	O
-Based	O
Model	B-T050
Duchenne	B-T047
muscular	I-T047
dystrophy	I-T047
(	O
DMD	B-T047
)	O
remains	O
an	O
intractable	O
genetic	B-T047
disease	I-T047
.	O
Althogh	O
there	O
are	O
several	O
animal	B-T050
models	I-T050
of	O
DMD	B-T047
,	O
there	O
is	O
no	O
human	O
cell	O
model	O
that	O
carries	O
patient	O
-specific	O
DYSTROPHIN	O
mutations	O
.	O
Here	O
,	O
we	O
present	O
a	O
human	O
DMD	B-T047
model	B-T050
using	O
human	O
induced	O
pluripotent	O
stem	O
cells	O
(	O
hiPSCs	O
)	O
.	O
Our	O
model	O
reveals	O
concordant	O
disease	B-T047
-	O
related	O
phenotypes	O
with	O
patient	O
-	O
dependent	O
variation	O
,	O
which	O
are	O
partially	O
reversed	O
by	O
genetic	O
and	O
pharmacological	O
approaches	O
.	O
Our	O
"	O
chemical	O
-	O
compound	O
-based	O
"	O
strategy	O
successfully	O
directs	O
hiPSCs	O
into	O
expandable	O
myoblasts	O
,	O
which	O
exhibit	O
a	O
myogenic	O
transcriptional	O
program	O
,	O
forming	O
striated	O
contractile	O
myofibers	O
and	O
participating	O
in	O
muscle	B-T033
regeneration	I-T033
in	O
vivo	O
.	O
DMD	B-T047
-	O
hiPSC	O
-derived	O
myoblasts	O
show	O
disease	B-T047
-	O
related	O
phenotypes	O
with	O
patient	O
-to-	O
patient	O
variability	O
,	O
including	O
aberrant	O
expression	O
of	O
inflammation	O
or	O
immune	O
-	O
response	O
genes	O
and	O
collagens	O
,	O
increased	O
BMP	O
/	O
TGFβ	O
signaling	O
,	O
and	O
reduced	O
fusion	O
competence	O
.	O
Furthermore	O
,	O
by	O
genetic	O
correction	O
and	O
pharmacological	O
"	O
dual-	O
SMAD	O
"	O
inhibition	O
,	O
the	O
DMD	B-T047
-	O
hiPSC	O
-derived	O
myoblasts	O
and	O
genetically	O
corrected	O
isogenic	O
myoblasts	O
form	O
"	O
rescued	O
"	O
multi	O
-	O
nucleated	O
myotubes	O
.	O
In	O
conclusion	O
,	O
our	O
findings	O
demonstrate	O
the	O
feasibility	O
of	O
establishing	O
a	O
human	O
"	O
DMD	B-T047
-in	O
-	O
a	O
-	O
dish	O
"	O
model	B-T050
using	O
hiPSC	O
-based	O
disease	B-T050
modeling	I-T050
.	O
      
Effects	O
of	O
Binge	O
-	O
Like	O
Ethanol	O
Exposure	O
During	O
Adolescence	O
on	O
the	O
Febrile	B-T184
Response	O
in	O
Rats	O
Ethanol	O
(	O
EtOH	O
)	O
exposure	O
during	O
different	O
phases	O
of	O
life	O
may	O
increase	O
the	O
risk	B-T033
of	I-T033
infections	I-T033
and	O
cause	O
alterations	O
in	O
the	O
central	O
nervous	O
system	O
.	O
The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
binge	O
-	O
like	O
EtOH	O
exposure	O
in	O
adolescent	O
rats	O
on	O
the	O
febrile	B-T184
response	O
that	O
was	O
induced	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
interleukin-1β	O
(	O
IL-1β	O
)	O
.	O
Male	O
rats	O
were	O
exposed	O
to	O
EtOH	O
from	O
postnatal	O
days	O
25	O
to	O
38	O
in	O
a	O
binge	O
-	O
like	O
pattern	O
.	O
Fever	B-T184
was	O
induced	O
by	O
LPS	O
(	O
5	O
and	O
50	O
μg	O
/	O
kg	O
,	O
intraperitoneally	O
)	O
and	O
evaluated	O
on	O
postnatal	O
days	O
51	O
and	O
63	O
,	O
or	O
by	O
IL	O
-	O
β	O
(	O
3	O
ng	O
)	O
and	O
evaluated	O
on	O
postnatal	O
day	O
51	O
.	O
Hematological	O
parameters	O
,	O
the	O
status	O
of	O
peritoneal	O
macrophages	O
,	O
and	O
plasma	O
and	O
cerebrospinal	O
IL-1β	O
levels	O
were	O
also	O
evaluated	O
on	O
postnatal	O
day	O
51	O
.	O
EtOH	O
exposure	O
during	O
adolescence	O
did	O
not	O
alter	O
normal	B-T033
body	I-T033
temperature	I-T033
.	O
However	O
,	O
a	O
significant	O
reduction	O
in	O
the	O
febrile	B-T184
response	O
that	O
was	O
induced	O
by	O
LPS	O
at	O
both	O
doses	O
was	O
observed	O
on	O
postnatal	O
day	O
51	O
.	O
However	O
,	O
no	O
changes	O
in	O
the	O
febrile	B-T184
response	O
were	O
observed	O
on	O
postnatal	O
day	O
63	O
in	O
EtOH	O
-	O
exposed	O
animals	O
.	O
The	O
febrile	B-T184
response	O
that	O
was	O
induced	O
by	O
intracerebroventricular	O
IL-1β	O
also	O
significantly	O
decreased	O
in	O
animals	O
that	O
received	O
binge	O
-	O
like	O
EtOH	O
exposure	O
during	O
adolescence	O
.	O
Acute	O
oral	O
treatment	O
with	O
EtOH	B-T121
24	O
h	O
prior	O
to	O
LPS	O
administration	B-T061
did	O
not	O
alter	O
the	O
febrile	B-T184
response	O
that	O
was	O
induced	O
by	O
LPS	O
.	O
Binge	O
-	O
like	O
EtOH	O
exposure	O
during	O
adolescence	O
did	O
not	O
alter	O
hematological	O
parameters	O
or	O
the	O
number	O
or	O
viability	O
of	O
peritoneal	O
macrophages	O
.	O
Binge	O
-	O
like	O
EtOH	O
exposure	O
did	O
not	O
alter	O
plasma	O
IL-1β	O
levels	O
but	O
reduced	O
the	O
cerebrospinal	O
fluid	O
levels	O
of	O
this	O
cytokine	O
.	O
These	O
results	O
suggest	O
that	O
binge	O
-	O
like	O
EtOH	O
exposure	O
during	O
adolescence	O
causes	O
changes	O
in	O
the	O
central	O
nervous	O
system	O
that	O
can	O
impair	O
the	O
febrile	B-T184
response	O
that	O
can	O
be	O
observed	O
after	O
the	O
cessation	O
of	O
EtOH	O
exposure	O
.	O
These	O
changes	O
were	O
reversible	O
and	O
appeared	O
to	O
involve	O
the	O
LPS	O
/	O
IL-1β	O
system	O
.	O
      
Advanced	O
interlocking	O
systems	O
to	O
improve	B-T033
heavy	O
-	O
load	O
-	O
bearing	O
characteristics	O
of	O
flexible	O
intramedullary	B-T061
nailing	I-T061
Flexible	O
intramedullary	B-T061
nailing	I-T061
(	O
FIN	B-T061
)	O
is	O
a	O
minimally	B-T061
invasive	I-T061
and	O
widespread	O
standard	O
method	B-T061
for	O
osteosynthesis	B-T061
of	O
pediatric	O
long	B-T033
bone	I-T033
fractures	I-T033
.	O
In	O
the	O
case	O
of	O
unstable	O
fractures	O
of	O
the	O
lower	B-T023
extremity	I-T023
,	O
interlocking	O
systems	O
need	O
to	O
be	O
used	O
to	O
prevent	O
axial	O
shortening	B-T061
and	O
subsequent	O
perforation	O
of	O
the	O
nail	O
at	O
its	O
insertion	O
site	O
.	O
In	O
the	O
present	O
study	O
,	O
four	O
different	O
screw	O
-fixed	O
interlocking	O
systems	O
for	O
FINs	B-T061
(	O
Hofer	O
TwinPlug	O
with	O
two	O
3	O
-	O
mm	O
titanium	O
interlocking	O
screws	O
,	O
Hofer	O
FixPlug	O
with	O
3	O
-	O
mm	O
titanium	O
interlocking	O
screw	O
,	O
Hofer	O
Plug	O
with	O
3.5	O
-	O
mm	O
titanium	O
interlocking	O
screw	O
,	O
and	O
Hofer	O
Plug	O
with	O
3	O
-	O
mm	O
titanium	O
interlocking	O
screw	O
)	O
in	O
comparison	O
with	O
the	O
commonly	O
used	O
Ender	O
stainless	O
steel	O
nails	O
(	O
locked	O
with	O
3.5	O
-	O
mm	O
screw	O
)	O
were	O
experimentally	O
investigated	O
in	O
cadaveric	B-T017
lamb	O
tibiae	B-T023
,	O
regarding	O
their	O
load	O
characteristics	O
and	O
failure	O
modes	O
in	O
the	O
case	O
of	O
heavy	O
loading	O
.	O
The	O
specimens	O
were	O
subjected	O
to	O
sequential	O
axial	O
cyclic	O
loading	O
of	O
5000	O
cycles	O
with	O
stepwise	O
increase	O
of	O
the	O
load	O
amplitude	O
until	O
failure	O
.	O
Migration	O
of	O
locking	O
screws	O
and	O
internal	O
damage	O
of	O
bone	O
tissue	O
was	O
quantified	O
by	O
micro	B-T060
-	I-T060
computed	I-T060
tomography	I-T060
(	I-T060
CT	I-T060
)	I-T060
imaging	I-T060
.	O
Ender	O
nails	O
failed	O
on	O
average	O
at	O
a	O
peak	O
load	O
of	O
800	O
N	O
,	O
TwinPlugs	O
at	O
1367	O
N	O
,	O
FixPlugs	O
at	O
1222	O
N	O
,	O
Plugs	O
3.5	O
mm	O
at	O
1225	O
N	O
and	O
Plugs	O
3.0	O
mm	O
at	O
971	O
N.	O
TwinPlugs	O
,	O
FixPlugs	O
,	O
and	O
Plugs	O
3.5	O
mm	O
failed	O
in	O
a	O
slow	O
manner	O
over	O
several	O
hundred	O
loading	O
cycles	O
,	O
whereas	O
Ender	O
nails	O
and	O
Plugs	O
3.0	O
mm	O
exhibited	O
abrupt	O
failure	O
without	O
any	O
prior	O
indication	O
.	O
Our	O
results	O
confirm	O
that	O
axial	O
stability	O
of	O
FIN	B-T061
can	O
be	O
further	O
improved	B-T033
by	O
screw	O
-fixed	O
plugs	O
by	O
simultaneously	O
avoiding	O
shortcomings	O
of	O
an	O
eye	O
-	O
locked	O
system	O
,	O
which	O
the	O
Ender	O
nails	O
are	O
.	O
Considering	O
biomechanical	O
results	B-T033
,	O
plug	O
interlocking	O
systems	O
with	O
3.5	O
-	O
mm	O
screws	O
should	O
be	O
favored	O
over	O
conventional	O
Ender	O
nails	O
and	O
plugs	O
with	O
3	O
-	O
mm	O
screws	O
.	O
      
FGF21	O
is	O
a	O
biomarker	O
for	O
mitochondrial	O
translation	O
and	O
mtDNA	O
maintenance	O
disorders	B-T047
To	O
validate	O
new	O
mitochondrial	B-T019
myopathy	I-T019
serum	O
biomarkers	O
for	O
diagnostic	B-T060
use	I-T060
.	O
We	O
analyzed	O
serum	O
FGF21	O
(	O
S	O
-	O
FGF21	O
)	O
and	O
GDF15	O
from	O
patients	O
with	O
(	O
1	O
)	O
mitochondrial	B-T047
diseases	I-T047
and	O
(	O
2	O
)	O
nonmitochondrial	B-T047
disorders	I-T047
partially	O
overlapping	O
with	O
mitochondrial	B-T047
disorder	I-T047
phenotypes	O
.	O
We	O
(	O
3	O
)	O
did	O
a	O
meta	O
-	O
analysis	O
of	O
S	O
-	O
FGF21	O
in	O
mitochondrial	B-T047
disease	I-T047
and	O
(	O
4	O
)	O
analyzed	O
S	O
-	O
Fgf21	O
and	O
skeletal	O
muscle	O
Fgf21	O
expression	O
in	O
6	O
mouse	O
models	O
with	O
different	O
muscle	O
-	O
manifesting	O
mitochondrial	B-T033
dysfunctions	I-T033
.	O
We	O
report	O
that	O
S	O
-	O
FGF21	O
consistently	O
increases	O
in	O
primary	O
mitochondrial	B-T019
myopathy	I-T019
,	O
especially	O
in	O
patients	O
with	O
mitochondrial	O
translation	O
defects	B-T019
or	O
mitochondrial	B-T033
DNA	I-T033
(	I-T033
mtDNA	I-T033
)	I-T033
deletions	I-T033
(	O
675	O
and	O
347	O
pg	O
/	O
mL	O
,	O
respectively	O
;	O
controls	O
:	O
66	O
pg	O
/	O
mL	O
,	O
p	O
<	O
0.0001	O
for	O
both	O
)	O
.	O
This	O
is	O
corroborated	O
in	O
mice	O
(	O
mtDNA	B-T033
deletions	I-T033
1,163	O
vs	O
379	O
pg	O
/	O
mL	O
,	O
p	O
<	O
0.0001	O
)	O
.	O
However	O
,	O
patients	O
and	O
mice	O
with	O
structural	B-T019
respiratory	I-T019
chain	I-T019
subunit	I-T019
or	I-T019
assembly	I-T019
factor	I-T019
defects	I-T019
showed	O
low	O
induction	O
(	O
human	O
335	O
pg	O
/	O
mL	O
,	O
p	O
<	O
0.05	O
;	O
mice	O
335	O
pg	O
/	O
mL	O
,	O
not	B-T033
significant	I-T033
)	O
.	O
Overall	O
specificities	O
of	O
FGF21	O
and	O
GDF15	O
to	O
find	O
patients	O
with	O
mitochondrial	B-T019
myopathy	I-T019
were	O
89.3	O
%	O
vs	O
86.4	O
%	O
,	O
and	O
sensitivities	O
67.3	O
%	O
and	O
76.0	O
%	O
,	O
respectively	O
.	O
However	O
,	O
GDF15	O
was	O
increased	O
also	O
in	O
a	O
wide	O
range	O
of	O
nonmitochondrial	O
conditions	O
.	O
S	O
-	O
FGF21	O
is	O
a	O
specific	O
biomarker	O
for	O
muscle	O
-	O
manifesting	O
defects	B-T019
of	O
mitochondrial	O
translation	O
,	O
including	O
mitochondrial	O
transfer	O
-	O
RNA	O
mutations	O
and	O
primary	O
and	O
secondary	O
mtDNA	B-T033
deletions	I-T033
,	O
the	O
most	O
common	O
causes	O
of	O
mitochondrial	B-T047
disease	I-T047
.	O
However	O
,	O
normal	O
S	O
-	O
FGF21	O
does	O
not	B-T033
exclude	O
structural	B-T019
respiratory	I-T019
chain	I-T019
complex	I-T019
or	I-T019
assembly	I-T019
factor	I-T019
defects	I-T019
,	O
important	O
to	O
acknowledge	O
in	O
diagnostics	B-T060
.	O
This	O
study	O
provides	O
Class	O
III	O
evidence	O
that	O
elevated	O
S	O
-	O
FGF21	O
accurately	O
distinguishes	O
patients	O
with	O
mitochondrial	B-T019
myopathies	I-T019
from	O
patients	O
with	O
other	O
conditions	O
,	O
and	O
FGF21	O
and	O
GDF15	O
mitochondrial	B-T019
myopathy	I-T019
from	O
other	O
myopathies	B-T047
.	O
      
Habitual	O
physical	O
activity	O
is	O
associated	O
with	O
improved	O
anthropometric	O
and	O
androgenic	B-T121
profile	B-T059
in	O
PCOS	B-T047
:	O
a	O
cross	O
-	O
sectional	O
study	O
To	O
examine	O
the	O
effect	O
of	O
habitual	O
physical	O
activity	O
(	O
PA	O
)	O
on	O
the	O
metabolic	O
and	O
hormonal	B-T060
profiles	I-T060
of	O
women	O
with	O
polycystic	B-T047
ovary	I-T047
syndrome	I-T047
.	O
Anthropometric	O
,	O
metabolic	B-T059
and	O
hormonal	B-T060
assessment	I-T060
and	O
determination	O
of	O
habitual	O
PA	O
levels	O
with	O
a	O
digital	O
pedometer	O
were	O
evaluated	O
in	O
84	O
women	O
with	O
PCOS	B-T047
and	O
67	O
age-	O
and	O
body	O
mass	O
index	O
(	O
BMI)-matched	O
controls	O
.	O
PA	O
status	O
was	O
defined	O
according	O
to	O
number	O
of	O
steps	O
(	O
≥7500	O
steps	O
,	O
active	O
,	O
or	O
<	O
7500	O
steps	O
,	O
sedentary	O
)	O
.	O
BMI	O
was	O
lower	O
in	O
active	O
women	O
from	O
both	O
groups	O
.	O
Active	O
PCOS	B-T047
women	O
presented	O
lower	O
waist	O
circumference	O
(	O
WC	O
)	O
and	O
lipid	O
accumulation	O
product	O
(	O
LAP	O
)	O
values	O
versus	O
sedentary	O
PCOS	B-T047
women	O
.	O
In	O
the	O
control	O
group	O
,	O
active	O
women	O
also	O
had	O
lower	O
WC	O
,	O
lower	O
values	O
for	O
fasting	O
and	O
120	O
-	O
min	O
insulin	B-T121
,	O
and	O
lower	O
LAP	O
than	O
sedentary	O
controls	O
.	O
In	O
the	O
PCOS	B-T047
group	O
,	O
androgen	B-T121
levels	O
were	O
lower	O
in	O
active	O
versus	O
sedentary	O
women	O
(	O
p	O
=	O
0.001	O
)	O
.	O
In	O
the	O
control	O
group	O
,	O
free	O
androgen	O
index	O
(	O
FAI	O
)	O
was	O
also	O
lower	O
in	O
active	O
versus	O
sedentary	O
women	O
(	O
p	O
=	O
0.018	O
)	O
.	O
Homeostasis	B-T058
model	I-T058
assessment	I-T058
of	O
insulin	O
resistance	O
and	O
2000	O
daily	O
step	O
increments	O
were	O
independent	O
predictors	O
of	O
FAI	O
.	O
Each	O
2000	O
daily	O
step	O
increment	O
was	O
associated	O
with	O
a	O
decrease	O
of	O
1.07	O
in	O
FAI	O
.	O
Habitual	O
PA	O
was	O
associated	O
with	O
a	O
better	O
anthropometric	O
and	O
androgenic	B-T121
profile	B-T059
in	O
PCOS	B-T047
.	O
      
New	O
metabolites	O
from	O
the	O
sponge	O
-derived	O
fungus	O
Aspergillus	O
sydowii	O
J05B-7F-4	O
Two	O
new	O
metabolites	O
,	O
diorcinolic	O
acid	O
(	O
1	O
)	O
and	O
β	O
-	O
d	O
-	O
glucopyranosyl	O
aspergillusene	O
A	O
(	O
8)	O
,	O
together	O
with	O
six	O
diphenylethers	O
(	O
2	O
-	O
7	O
)	O
,	O
a	O
diketopiperazine	B-T121
(	O
9	O
)	O
,	O
a	O
chromone	O
(	O
10	O
)	O
and	O
a	O
xanthone	O
(	O
11	O
)	O
were	O
isolated	O
from	O
the	O
fungus	O
Aspergillus	O
sydowii	O
derived	O
from	O
the	O
marine	O
sponge	O
Stelletta	O
sp	O
.	O
The	O
planar	O
structures	O
and	O
their	O
relative	O
configurations	O
were	O
elucidated	O
by	O
analysing	O
1D	O
,	O
2D	O
NMR	O
and	O
HRESIMS	B-T059
data	O
.	O
Compound	O
8	O
is	O
the	O
first	O
glycoside	O
of	O
phenolic	B-T121
bisabolane	O
sesquiterpenes	O
.	O
Compounds	B-T121
1	I-T121
and	I-T121
8	I-T121
exhibited	O
mild	O
cytotoxicity	O
against	O
KB	O
(	O
human	O
nasopharyngeal	O
carcinoma	O
cells	O
)	O
,	O
HepG2	O
(	O
human	O
liver	O
cancer	O
cells	O
)	O
and	O
HCT	O
116	O
(	O
human	O
colon	O
cancer	O
cells	O
)	O
.	O
All	O
compounds	B-T121
were	O
evaluated	B-T058
for	O
antibacterial	O
activity	O
and	O
their	O
abilities	O
to	O
suppress	O
LPS	O
-induced	O
nitric	B-T121
oxide	I-T121
(	O
NO	B-T121
)	O
production	O
.	O
Compounds	B-T121
2	I-T121
and	I-T121
4	I-T121
-	I-T121
7	I-T121
showed	O
mild	O
antibacterial	B-T033
activity	I-T033
against	O
human	O
pathogen	B-T001
Staphylococcus	B-T007
aureus	I-T007
and	O
fish	O
pathogens	B-T001
Streptococcus	B-T007
iniae	I-T007
and	O
Vibrio	B-T007
ichthyoenteri	I-T007
,	O
and	O
compounds	O
4	O
and	O
7	O
weakly	O
suppressed	O
NO	B-T121
production	O
.	O
      
Neurotrophins	O
and	O
specific	O
receptors	O
in	O
the	O
oviduct	B-T023
tracts	I-T023
of	O
Japanese	O
quail	O
(	O
Coturnix	O
coturnix	O
japonica	O
)	O
Neurotrophins	O
(	O
NGF	O
,	O
BDNF	O
and	O
NT-3	O
)	O
and	O
their	O
specific	O
receptors	O
(	O
TrkA	O
,	O
TrkB	O
and	O
TrkC	O
)	O
were	O
studied	O
in	O
the	O
oviduct	B-T023
of	O
egg	O
laying	O
quails	O
.	O
Neurotrophins	O
(	O
NTs	O
)	O
are	O
mainly	O
involved	O
in	O
the	O
development	O
and	O
maintenance	O
of	O
neuronal	O
populations	O
in	O
the	O
central	O
and	O
peripheral	O
nervous	O
system	O
,	O
but	O
also	O
in	O
reproductive	O
system	O
.	O
In	O
this	O
survey	O
,	O
we	O
first	O
studied	O
the	O
morphological	O
organization	O
of	O
the	O
quail	O
oviduct	B-T023
,	O
distinguished	O
in	O
infundibulum	B-T023
,	O
magnum	B-T023
,	O
isthmus	B-T023
,	O
uterus	B-T023
and	O
vagina	B-T023
,	O
and	O
then	O
we	O
analyzed	O
the	O
expression	O
and	O
localization	O
of	O
NTs	O
and	O
Trks	O
receptors	O
in	O
the	O
whole	O
tracts	B-T023
.	O
By	O
western	B-T059
blotting	I-T059
we	O
detected	O
that	O
the	O
investigated	O
NTs	O
and	O
Trks	O
receptors	O
are	O
expressed	O
in	O
all	O
oviductal	B-T023
tracts	I-T023
.	O
By	O
immunohistochemistry	B-T060
we	O
were	O
able	O
to	O
define	O
the	O
distribution	O
of	O
NTs	O
and	O
Trks	O
.	O
Specifically	O
,	O
NGF	O
,	O
BDNF	O
and	O
NT3	O
were	O
localized	O
in	O
lining	O
and	O
ductal	O
epithelial	O
cells	O
,	O
and	O
NGF	O
was	O
also	O
detected	O
in	O
secretory	O
cells	O
of	O
tubular	B-T023
glands	I-T023
and	O
in	O
nervous	O
fibers	O
of	O
vessel	B-T023
wall	I-T023
.	O
TrkA	O
and	O
TrkB	O
were	O
present	O
in	O
the	O
lining	O
and	O
ductal	O
epithelium	O
;	O
TrkA	O
and	O
TrkC	O
were	O
present	O
in	O
nervous	O
fibers	O
of	O
vessel	B-T023
wall	I-T023
in	O
all	O
oviductal	B-T023
tracts	I-T023
.	O
Furthermore	O
,	O
we	O
also	O
observed	O
NGF	O
and	O
BDNF	O
co	O
-	O
localized	O
with	O
TrkA	O
and	O
TrkB	O
in	O
cells	O
of	O
the	O
lining	O
and	O
ductal	O
epithelium	O
,	O
suggesting	O
an	O
autocrine	O
mechanism	O
of	O
action	O
.	O
      
Knocking	O
down	O
TCF8	O
inhibits	O
high	B-T033
glucose	I-T033
-	O
and	O
angiotensin	B-T121
II	I-T121
-	O
induced	O
epithelial	O
to	O
mesenchymal	O
transition	O
in	O
podocytes	O
Epithelial	O
to	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
is	O
a	O
physiological	O
phenomenon	O
in	O
mammalian	O
embryogenesis	O
by	O
which	O
epithelial	O
cells	O
become	O
mesenchymal	O
stem	O
cells	O
.	O
Studies	O
have	O
indicated	O
that	O
an	O
inappropriate	O
EMT	O
plays	O
a	O
key	O
role	O
in	O
a	O
variety	O
of	O
pathogenic	B-T033
processes	O
such	O
as	O
embryonic	O
development	O
and	O
tumor	B-T191
metastasis	I-T191
.	O
Moreover	O
,	O
recent	O
studies	O
have	O
indicated	O
EMT	O
also	O
plays	O
an	O
important	O
role	O
in	O
renal	B-T047
fibrosis	I-T047
.	O
In	O
the	O
current	O
study	O
,	O
glucose	B-T121
and	O
angiotensin	B-T121
II	I-T121
promoted	O
EMT	O
in	O
podocytes	O
as	O
well	O
as	O
changes	O
in	O
the	O
cellular	O
morphology	O
of	O
podocytes	O
.	O
A	O
high	O
concentration	O
of	O
glucose	B-T121
and	O
angiotensin	B-T121
II	I-T121
also	O
promoted	O
podocyte	O
movement	O
and	O
migration	O
.	O
Moreover	O
,	O
a	O
high	O
concentration	O
of	O
glucose	B-T121
and	O
angiotensin	B-T121
II	I-T121
promoted	O
TCF8	O
expression	O
.	O
Inhibiting	O
TCF8	O
expression	O
with	O
siRNA	O
reversed	O
EMT	O
in	O
podocytes	O
in	O
the	O
presence	O
of	O
a	O
high	O
concentration	O
of	O
glucose	B-T121
and	O
angiotensin	B-T121
.	O
Inhibiting	O
TCF8	O
expression	O
also	O
reversed	O
changes	O
in	O
cellular	O
morphology	O
and	O
podocyte	O
movement	O
and	O
migration	O
.	O
Therefore	O
,	O
glucose	B-T121
and	O
angiotensin	B-T121
II	I-T121
may	O
promote	O
EMT	O
in	O
podocytes	O
via	O
TCF8	O
.	O
      
Reduction	O
in	O
Hospital	O
-	O
Wide	O
Clinical	B-T059
Laboratory	I-T059
Specimen	I-T059
Identification	I-T059
Errors	O
following	O
Process	O
Interventions	O
:	O
A	O
10-	O
Year	O
Retrospective	O
Observational	O
Study	O
Accurate	O
patient	B-T058
identification	I-T058
and	O
specimen	B-T058
labeling	I-T058
at	O
the	O
time	O
of	O
collection	O
are	O
crucial	O
steps	O
in	O
the	O
prevention	O
of	O
medical	O
errors	O
,	O
thereby	O
improving	O
patient	B-T058
safety	I-T058
.	O
All	O
patient	O
specimen	O
identification	O
errors	O
that	O
occurred	O
in	O
the	O
outpatient	O
department	O
(	O
OPD	O
)	O
,	O
emergency	O
department	O
(	O
ED	O
)	O
,	O
and	O
inpatient	O
department	O
(	O
IPD	O
)	O
of	O
a	O
3,800-	O
bed	O
academic	O
medical	O
center	O
in	O
Taiwan	O
were	O
documented	B-T058
and	O
analyzed	B-T058
retrospectively	O
from	O
2005	O
to	O
2014	O
.	O
To	O
reduce	O
such	O
errors	O
,	O
the	O
following	O
series	O
of	O
strategies	O
were	O
implemented	O
:	O
a	O
restrictive	O
specimen	O
acceptance	O
policy	O
for	O
the	O
ED	O
and	O
IPD	O
in	O
2006	O
;	O
a	O
computer	B-T059
-	I-T059
assisted	I-T059
barcode	O
positive	O
patient	O
identification	O
system	O
for	O
the	O
ED	O
and	O
IPD	O
in	O
2007	O
and	O
2010	O
,	O
and	O
automated	O
sample	B-T058
labeling	I-T058
combined	O
with	O
electronic	B-T058
identification	I-T058
systems	I-T058
introduced	O
to	O
the	O
OPD	O
in	O
2009	O
.	O
Of	O
the	O
2000345	O
specimens	O
collected	O
in	O
2005	O
,	O
1023	O
(	O
0.0511	O
%	O
)	O
were	O
identified	B-T033
as	O
having	O
patient	B-T058
identification	I-T058
errors	O
,	O
compared	O
with	O
58	O
errors	O
(	O
0.0015	O
%	O
)	O
among	O
3761238	O
specimens	O
collected	O
in	O
2014	O
,	O
after	O
serial	O
interventions	B-T058
;	O
this	O
represents	O
a	O
97	O
%	O
relative	O
reduction	O
.	O
The	O
total	O
number	O
(	O
rate	O
)	O
of	O
institutional	B-T058
identification	I-T058
errors	O
contributed	O
from	O
the	O
ED	O
,	O
IPD	O
,	O
and	O
OPD	O
over	O
a	O
10-	O
year	O
period	O
were	O
423	O
(	O
0.1058	O
%	O
)	O
,	O
556	O
(	O
0.0587	O
%	O
)	O
,	O
and	O
44	O
(	O
0.0067	O
%	O
)	O
errors	O
before	O
the	O
interventions	B-T058
,	O
and	O
3	O
(	O
0.0007	O
%	O
)	O
,	O
52	O
(	O
0.0045	O
%	O
)	O
and	O
3	O
(	O
0.0001	O
%	O
)	O
after	O
interventions	B-T058
,	O
representing	O
relative	O
99	O
%	O
,	O
92	O
%	O
and	O
98	O
%	O
reductions	O
,	O
respectively	O
.	O
Accurate	O
patient	B-T058
identification	I-T058
is	O
a	O
challenge	O
of	O
patient	B-T058
safety	I-T058
in	O
different	O
health	O
settings	O
.	O
The	O
data	B-T033
collected	I-T033
in	O
our	O
study	O
indicate	O
that	O
a	O
restrictive	O
specimen	O
acceptance	O
policy	O
,	O
computer	B-T059
-	I-T059
generated	I-T059
positive	O
identification	O
systems	O
,	O
and	O
interdisciplinary	O
cooperation	O
can	O
significantly	O
reduce	O
patient	B-T058
identification	I-T058
errors	O
.	O
      
Cultivation	B-T059
of	O
four	O
microalgae	O
species	O
in	O
the	O
effluent	O
of	O
anaerobic	O
digester	O
for	O
biodiesel	O
production	O
This	O
study	O
investigated	O
if	O
an	O
effluent	O
from	O
anaerobic	O
digestion	O
(	O
AD	O
)	O
system	O
can	O
be	O
used	O
as	O
a	O
nutrients	O
source	B-T033
for	O
the	O
microalgae	O
cultivation	B-T059
,	O
and	O
in	O
so	O
doing	O
,	O
if	O
the	O
effluent	O
can	O
be	O
properly	O
treated	O
.	O
Nitrogen	O
and	O
phosphorus	O
in	O
the	O
AD	O
effluent	O
well	O
supported	O
microalgal	O
growth	O
,	O
and	O
their	O
removal	O
efficiency	O
reached	O
>	O
97.9	O
%	O
and	O
99.2	O
%	O
,	O
respectively	O
.	O
Among	O
four	O
different	O
algal	O
species	O
tested	O
,	O
Micractinium	O
inermum	O
particularly	O
stood	O
out	O
,	O
showing	O
the	O
highest	O
biomass	O
and	O
FAME	O
productivity	O
:	O
0.16gL(-1)d(-1	O
)	O
with	O
3.23gL(-1	O
)	O
of	O
dry	O
cell	O
weight	O
,	O
and	O
0.04gL(-1)d(-1	O
)	O
with	O
27.54	O
%	O
(	O
w	O
/	O
w	O
)	O
of	O
FAME	O
contents	O
,	O
respectively	O
.	O
As	O
the	O
concentrations	O
of	O
the	O
nutrients	O
decreased	O
over	O
time	O
,	O
the	O
FAME	O
contents	O
were	O
increased	O
and	O
its	O
quality	O
as	O
well	O
,	O
satisfying	O
several	O
biodiesel	O
quality	O
standards	O
.	O
This	O
study	O
supports	O
that	O
the	O
AD	O
effluent	O
can	O
indeed	O
serve	O
as	O
a	O
cheap	O
and	O
nutrient	O
-	O
rich	O
medium	O
for	O
microalgae	O
cultivation	B-T059
,	O
and	O
equally	O
importantly	O
,	O
microalgae	O
can	O
be	O
a	O
workable	O
treatment	O
option	O
for	O
it	O
.	O
      
Enhancing	O
Doctors	O
'	O
Competencies	O
in	O
Communication	O
With	O
and	O
Activation	O
of	O
Older	O
Patients	O
:	O
The	O
Promoting	O
Active	O
Aging	O
(	O
PRACTA	B-T058
)	O
Computer	B-T058
-	I-T058
Based	I-T058
Intervention	I-T058
Study	I-T058
Demographic	O
changes	O
over	O
the	O
past	O
decades	O
call	O
for	O
the	O
promotion	O
of	O
health	O
and	O
disease	O
prevention	O
for	O
older	O
patients	O
,	O
as	O
well	O
as	O
strategies	O
to	O
enhance	O
their	O
independence	O
,	O
productivity	O
,	O
and	O
quality	O
of	O
life	O
.	O
Our	O
objective	O
was	O
to	O
examine	O
the	O
effects	O
of	O
a	O
computer	B-T061
-	I-T061
based	I-T061
educational	I-T061
intervention	I-T061
designed	O
for	O
general	O
practitioners	O
(	O
GPs	O
)	O
to	O
promote	O
active	O
aging	O
.	O
The	O
Promoting	O
Active	O
Aging	O
(	O
PRACTA	B-T058
)	O
study	O
consisted	O
of	O
a	O
baseline	O
questionnaire	O
,	O
implementation	O
of	O
an	O
intervention	B-T061
,	O
and	O
a	O
follow	O
-	O
up	O
questionnaire	O
that	O
was	O
administered	O
1	O
month	O
after	O
the	O
intervention	B-T058
.	O
A	O
total	O
of	O
151	O
primary	O
care	O
facilities	O
(	O
response	O
rate	O
151/767	O
,	O
19.7	O
%	O
)	O
and	O
503	O
GPs	O
(	O
response	O
rate	O
503/996	O
,	O
50.5	O
%	O
)	O
agreed	O
to	O
participate	O
in	O
the	O
baseline	O
assessment	O
.	O
At	O
the	O
follow	O
-	O
up	O
,	O
393	O
GPs	O
filled	O
in	O
the	O
questionnaires	O
(	O
response	O
rate	O
,	O
393/503	O
,	O
78.1	O
%	O
)	O
,	O
but	O
not	O
all	O
of	O
them	O
took	O
part	O
in	O
the	O
intervention	B-T061
.	O
The	O
final	O
study	O
group	O
of	O
225	O
GPs	O
participated	O
in	O
3	O
study	O
conditions	O
:	O
e	O
-	O
learning	O
(	O
knowledge	O
plus	O
skills	O
modelling	O
,	O
n=42	O
)	O
,	O
a	O
pdf	O
article	O
(	O
knowledge	O
only	O
,	O
n=89	O
)	O
,	O
and	O
control	O
(	O
no	O
intervention	B-T058
,	O
n=94	O
)	O
.	O
We	O
measured	O
the	O
outcome	O
as	O
scores	O
on	O
the	O
Patients	O
Expectations	O
Scale	O
,	O
Communication	O
Scale	O
,	O
Attitude	O
Toward	O
Treatment	O
and	O
Health	O
Scale	O
,	O
and	O
Self	O
-	O
Efficacy	O
Scale	O
.	O
GPs	O
participating	O
in	O
e	O
-	O
learning	O
demonstrated	O
a	O
significant	O
rise	O
in	O
their	O
perception	O
of	O
older	O
patients	O
'	O
expectations	O
for	O
disease	O
explanation	O
(	O
Wald	O
χ(2)=19.7	O
,	O
P<.001	O
)	O
and	O
in	O
perception	O
of	O
motivational	O
aspect	O
of	O
older	O
patients	O
'	O
attitude	O
toward	O
treatment	O
and	O
health	O
(	O
Wald	O
χ(2)=8.9	O
,	O
P=.03	O
)	O
in	O
comparison	O
with	O
both	O
the	O
control	O
and	O
pdf	O
article	O
groups	O
.	O
We	O
observed	O
additional	O
between-	O
group	O
differences	O
at	O
the	O
level	O
of	O
statistical	O
trend	O
.	O
GPs	O
participating	O
in	O
the	O
pdf	O
article	O
intervention	B-T061
demonstrated	O
a	O
decline	O
in	O
self	O
-	O
assessed	O
communication	O
,	O
both	O
at	O
the	O
level	O
of	O
global	O
scoring	O
(	O
Wald	O
χ(2)=34.5	O
,	O
P<.001	O
)	O
and	O
at	O
the	O
level	O
of	O
20	O
of	O
26	O
specific	O
behaviors	O
(	O
all	O
P<.05	O
)	O
.	O
Factors	O
moderating	O
the	O
effects	O
of	O
the	O
intervention	B-T061
were	O
the	O
number	O
of	O
patients	O
per	O
GP	O
and	O
the	O
facility	O
's	O
organizational	O
structure	O
.	O
Both	O
methods	O
were	O
suitable	O
,	O
but	O
in	O
different	O
areas	O
and	O
under	O
different	O
conditions	O
.	O
The	O
key	O
benefit	O
of	O
the	O
pdf	O
article	O
intervention	B-T061
was	O
raising	O
doctors	O
'	O
reflection	O
on	O
limitations	O
in	O
their	O
communication	O
skills	O
,	O
whereas	O
e	O
-	O
learning	O
was	O
more	O
effective	O
in	O
changing	O
their	O
perception	O
of	O
older	O
patients	O
'	O
proactive	O
attitude	O
,	O
especially	O
among	O
GPs	O
working	O
in	O
privately	O
owned	O
facilities	O
and	O
having	O
a	O
greater	O
number	O
of	O
assigned	O
patients	O
.	O
Although	O
we	O
did	O
not	O
achieve	O
all	O
expected	O
effects	O
of	O
the	O
PRACTA	B-T058
intervention	I-T058
,	O
both	O
its	O
forms	O
seem	O
promising	O
in	O
terms	O
of	O
enhancing	O
the	O
competencies	O
of	O
doctors	O
in	O
communication	O
with	O
and	O
activation	O
of	O
older	O
patients	O
.	O
      
Biochemical	O
and	O
proteomic	O
analyses	O
of	O
the	O
physiological	O
response	O
induced	O
by	O
individual	O
housing	O
in	O
gilts	O
provide	O
new	O
potential	O
stress	O
markers	O
The	O
objective	O
assessment	B-T058
of	O
animal	O
stress	O
and	O
welfare	O
requires	O
proper	O
laboratory	O
biomarkers	O
.	O
In	O
this	O
work	O
,	O
we	O
have	O
analyzed	O
the	O
changes	O
in	O
serum	O
composition	O
in	O
gilts	O
after	O
switching	O
their	O
housing	O
,	O
from	O
pen	O
to	O
individual	O
stalls	O
,	O
which	O
is	O
generally	O
accepted	O
to	O
cause	O
animal	O
discomfort	B-T184
.	O
Blood	O
and	O
saliva	O
samples	O
were	O
collected	O
a	O
day	O
before	O
and	O
up	O
to	O
four	O
days	O
after	O
changing	O
the	O
housing	O
system	O
.	O
Biochemical	O
analyses	O
showed	O
adaptive	O
changes	O
in	O
lipid	O
and	O
protein	O
metabolism	O
after	O
the	O
housing	O
switch	O
,	O
whereas	O
cortisol	B-T121
and	O
muscular	O
markers	O
showed	O
a	O
large	O
variability	O
between	O
animals	O
.	O
2D	B-T059
-	I-T059
DIGE	I-T059
and	O
iTRAQ	O
proteomic	O
approaches	O
revealed	O
variations	O
in	O
serum	O
protein	O
composition	O
after	O
changing	O
housing	O
and	O
diet	O
of	O
gilts	O
.	O
Both	O
techniques	O
showed	O
alterations	O
in	O
two	O
main	O
homeostatic	O
mechanisms	O
:	O
the	O
innate	O
immune	O
and	O
redox	O
systems	O
.	O
The	O
acute	O
phase	O
proteins	O
haptoglobin	O
,	O
apolipoprotein	O
A	O
-	O
I	O
and	O
α1	O
-	O
antichymotrypsin	O
3	O
,	O
and	O
the	O
antioxidant	B-T121
enzyme	O
peroxiredoxin	O
2	O
were	O
found	O
differentially	O
expressed	O
by	O
2D	B-T059
-	I-T059
DIGE	I-T059
.	O
Other	O
proteins	O
related	O
to	O
the	O
innate	O
immune	O
system	O
,	O
including	O
lactotransferrin	O
,	O
protegrin	B-T121
3	I-T121
and	O
galectin	O
1	O
were	O
also	O
identified	O
by	O
iTRAQ	O
,	O
as	O
well	O
as	O
oxidative	O
stress	O
enzymes	O
such	O
as	O
peroxiredoxin	O
2	O
and	O
glutathione	O
peroxidase	O
3	O
.	O
Proteomics	O
also	O
revealed	O
the	O
decrease	O
of	O
apolipoproteins	O
,	O
and	O
the	O
presence	O
of	O
intracellular	O
proteins	O
in	O
serum	O
,	O
which	O
may	O
indicate	O
physical	O
injury	O
to	O
tissues	O
.	O
Housing	O
of	O
gilts	O
in	O
individual	O
stalls	O
and	O
diet	O
change	O
increase	O
lipid	O
and	O
protein	O
catabolism	O
,	O
oxidative	O
stress	O
,	O
activate	O
the	O
innate	O
immune	O
system	O
and	O
cause	O
a	O
certain	O
degree	O
of	O
tissue	O
damage	O
.	O
We	O
propose	O
that	O
valuable	O
assays	O
for	O
stress	B-T060
assessment	I-T060
in	O
gilts	O
may	O
be	O
based	O
on	O
a	O
score	O
composed	O
by	O
a	O
combination	O
of	O
salivary	O
cortisol	O
,	O
lipid	O
metabolites	O
,	O
innate	O
immunity	O
and	O
oxidative	O
stress	O
markers	O
and	O
intracellular	O
proteins	O
.	O
      
Potentiation	B-T061
of	O
LPS	O
-	O
Induced	O
Apoptotic	O
Cell	O
Death	O
in	O
Human	O
Hepatoma	O
HepG2	O
Cells	O
by	O
Aspirin	B-T121
via	O
ROS	O
and	O
Mitochondrial	B-T033
Dysfunction	I-T033
:	O
Protection	B-T033
by	O
N	B-T121
-	I-T121
Acetyl	I-T121
Cysteine	I-T121
Cytotoxicity	O
and	O
inflammation	O
-	O
associated	O
toxic	O
responses	O
have	O
been	O
observed	O
to	O
be	O
induced	O
by	O
bacterial	O
lipopolysaccharides	O
(	O
LPS	O
)	O
in	O
vitro	O
and	O
in	O
vivo	O
respectively	O
.	O
Use	O
of	O
nonsteroidal	B-T121
anti	I-T121
-	I-T121
inflammatory	I-T121
drugs	I-T121
(	O
NSAIDs	B-T121
)	O
,	O
such	O
as	O
aspirin	B-T121
,	O
has	O
been	O
reported	B-T058
to	O
be	O
beneficial	O
in	O
inflammation	O
-	O
associated	O
diseases	O
like	O
cancer	B-T191
,	O
diabetes	B-T047
and	O
cardiovascular	B-T047
disorders	I-T047
.	O
Their	O
precise	O
molecular	O
mechanisms	O
,	O
however	O
,	O
are	O
not	O
clearly	O
understood	O
.	O
Our	O
previous	O
studies	O
on	O
aspirin	B-T121
treated	B-T061
HepG2	O
cells	O
strongly	O
suggest	O
cell	O
cycle	O
arrest	O
and	O
induction	O
of	O
apoptosis	O
associated	O
with	O
mitochondrial	B-T033
dysfunction	I-T033
.	O
In	O
the	O
present	O
study	O
,	O
we	O
have	O
further	O
demonstrated	O
that	O
HepG2	O
cells	O
treated	B-T061
with	I-T061
LPS	O
alone	O
or	O
in	O
combination	O
with	O
aspirin	B-T121
induces	O
subcellular	O
toxic	O
responses	O
which	O
are	O
accompanied	O
by	O
increase	O
in	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
production	O
,	O
oxidative	O
stress	O
,	O
mitochondrial	B-T033
respiratory	I-T033
dysfunction	I-T033
and	O
apoptosis	O
.	O
The	O
LPS	O
/	O
Aspirin	B-T121
induced	O
toxicity	O
was	O
attenuated	O
by	O
pre	O
-	O
treatment	O
of	O
cells	O
with	O
N	B-T121
-	I-T121
acetyl	I-T121
cysteine	I-T121
(	O
NAC	B-T121
)	O
.	O
Alterations	O
in	O
oxidative	O
stress	O
and	O
glutathione	O
-	O
dependent	O
redox	O
-	O
homeostasis	O
were	O
more	O
pronounced	O
in	O
mitochondria	O
compared	O
to	O
extra	O
-	O
mitochondrial	O
cellular	O
compartments	O
.	O
Pre	O
-	O
treatment	O
of	O
HepG2	O
cells	O
with	O
NAC	B-T121
exhibited	O
a	O
selective	O
protection	B-T033
in	O
redox	O
homeostasis	O
and	O
mitochondrial	B-T033
dysfunction	I-T033
.	O
Our	O
results	B-T033
suggest	O
that	O
the	O
altered	O
redox	O
metabolism	O
,	O
oxidative	O
stress	O
and	O
mitochondrial	O
function	O
in	O
HepG2	O
cells	O
play	O
a	O
critical	O
role	O
in	O
LPS	O
/	O
aspirin	B-T121
-	O
induced	O
cytotoxicity	O
.	O
These	O
results	B-T033
may	O
help	O
in	O
better	O
understanding	O
the	O
pharmacological	O
,	O
toxicological	O
and	O
therapeutic	O
properties	O
of	O
NSAIDs	B-T121
in	O
cancer	O
cells	O
exposed	O
to	O
bacterial	O
endotoxins	O
.	O
      
Variation	O
analysis	O
of	O
PRIM1	O
gene	O
in	O
Chinese	O
patients	O
with	O
primary	B-T047
ovarian	I-T047
insufficiency	I-T047
Insights	O
into	O
common	O
genetic	O
susceptibility	O
between	O
primary	B-T047
ovarian	I-T047
insufficiency	I-T047
(	O
POI	B-T047
)	O
and	O
natural	O
or	O
early	B-T047
menopause	I-T047
have	O
delivered	O
an	O
innovative	O
way	O
of	O
assessing	O
the	O
genetic	O
mechanisms	O
involved	O
in	O
POI	B-T047
.	O
PRIM1	O
plays	O
a	O
crucial	O
role	O
in	O
DNA	O
replication	O
by	O
synthesizing	O
RNA	O
primers	O
for	O
Okazaki	O
fragments	O
.	O
It	O
is	O
closely	O
associated	O
with	O
age	O
at	O
natural	O
menopause	O
,	O
early	B-T047
menopause	I-T047
and	O
POI	B-T047
in	O
European	O
women	O
.	O
In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
whether	O
mutations	O
in	O
PRIM1	O
contribute	O
to	O
POI	B-T047
in	O
Chinese	O
women	O
.	O
All	O
exons	O
and	O
exon	O
-	O
intron	O
boundaries	O
of	O
PRIM1	O
gene	O
were	O
sequenced	B-T059
in	O
192	O
Han	O
Chinese	O
women	O
with	O
non	O
-	O
syndromic	O
POI	B-T047
.	O
No	O
plausible	O
mutations	O
were	O
identified	O
.	O
The	O
results	O
suggest	O
that	O
the	O
perturbations	O
in	O
PRIM1	O
gene	O
are	O
not	O
a	O
common	O
explanation	O
for	O
POI	B-T047
in	O
Chinese	O
women	O
.	O
      
Correlations	O
between	O
physical	O
activity	O
and	O
neurocognitive	O
domain	O
functions	O
in	O
patients	O
with	O
schizophrenia	B-T048
:	O
a	O
cross	O
-	O
sectional	O
study	O
Neurocognitive	B-T048
dysfunction	I-T048
is	O
a	O
critical	O
target	O
symptom	B-T184
of	O
schizophrenia	B-T048
treatment	B-T061
.	O
A	O
positive	O
correlation	O
between	O
physical	O
activity	O
level	O
and	O
neurocognitive	O
function	O
has	O
been	O
reported	O
in	O
healthy	O
individuals	O
,	O
but	O
it	O
is	O
unclear	O
whether	O
such	O
a	O
correlation	O
exists	O
in	O
patients	O
with	O
schizophrenia	B-T048
and	O
whether	O
the	O
relationship	O
is	O
different	O
according	O
to	O
inpatients	O
or	O
outpatients	O
.	O
This	O
study	O
aimed	O
to	O
examine	B-T058
the	O
differences	O
in	O
the	O
correlations	O
between	O
physical	O
activity	O
and	O
multiple	O
neurocognitive	O
domains	O
in	O
inpatients	O
and	O
outpatients	O
with	O
schizophrenia	B-T048
and	O
obtain	O
suggestions	O
for	O
further	O
study	O
to	O
facilitate	O
this	O
field	O
.	O
Twenty	O
-	O
nine	O
patients	O
with	O
schizophrenia	B-T048
were	O
examined	B-T058
(	O
16	O
inpatients	O
and	O
13	O
outpatients	O
,	O
56.0	O
±	O
11.4	O
years	O
of	O
age	O
)	O
.	O
Current	O
symptoms	B-T184
were	O
assessed	O
using	O
the	O
Positive	B-T033
and	O
Negative	B-T033
Symptom	O
Scale	O
and	O
neurocognitive	O
functions	O
using	O
Cognitrax	O
,	O
which	O
yields	O
a	O
composite	O
neurocognitive	B-T060
index	I-T060
(	O
NCI	B-T060
)	O
and	O
11	O
domain	O
scores	O
.	O
After	O
testing	O
,	O
participants	O
wore	O
an	O
HJA-750C	O
accelerometer	O
for	O
one	O
week	O
to	O
measure	O
physical	O
activity	O
levels	O
and	O
durations	O
.	O
Partial	O
correlation	O
analyses	O
were	O
performed	O
between	O
exercise	O
and	O
cognitive	O
parameters	B-T033
.	O
In	O
the	O
outpatient	O
group	O
,	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
faster	O
Motor	O
and	O
Psychomotor	O
Speeds	O
in	O
outpatients	O
.	O
However	O
,	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
lower	O
overall	O
NCI	B-T060
,	O
Attention	O
score	O
,	O
and	O
Memory	O
scores	O
in	O
inpatients	O
.	O
Although	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
better	O
neurocognitive	O
functions	O
of	O
outpatients	O
,	O
in	O
inpatients	O
with	O
non	O
-	O
remitted	O
schizophrenia	B-T048
,	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
worsening	O
of	O
several	O
cognitive	O
domains	O
.	O
In	O
a	O
future	O
study	O
examining	B-T058
the	O
relationship	O
between	O
physical	O
activity	O
and	O
neurocognitive	O
function	O
for	O
facilitating	O
this	O
research	O
field	O
,	O
separation	O
between	O
inpatients	O
and	O
outpatients	O
are	O
needed	O
because	O
the	O
relationship	O
is	O
different	O
between	O
inpatients	O
and	O
outpatients	O
.	O
      
Comparison	O
of	O
a	O
new	O
visual	B-T061
stylet	I-T061
(	I-T061
Discopo)-guided	I-T061
laryngeal	B-T061
mask	I-T061
airway	I-T061
placement	I-T061
vs	O
conventional	B-T061
blind	I-T061
technique	I-T061
:	O
a	O
prospective	O
randomized	O
study	O
To	O
compare	O
the	O
ease	O
of	O
laryngeal	B-T061
mask	I-T061
airway	I-T061
(	I-T061
LMA	I-T061
)	I-T061
insertion	I-T061
and	O
fiberoptic	O
view	O
of	O
LMA	O
after	O
placement	O
using	O
the	O
Discopo	B-T061
visual	I-T061
stylet	I-T061
-	I-T061
guided	I-T061
insertion	I-T061
and	O
conventional	B-T061
blind	I-T061
technique	I-T061
.	O
Prospective	O
,	O
randomized	O
controlled	O
study	O
.	O
Operating	O
room	O
in	O
a	O
university	O
hospital	O
.	O
One	O
hundred	O
adult	O
patients	O
scheduled	O
for	O
elective	B-T061
surgery	I-T061
under	O
LMA	O
general	B-T061
anesthesia	I-T061
were	O
enrolled	O
.	O
Patients	O
were	O
randomly	O
allocated	O
to	O
2	O
groups	O
:	O
GLMA	O
group	O
using	O
a	O
visual	B-T061
stylet	I-T061
-	I-T061
guided	I-T061
technique	I-T061
(	O
n=50	O
)	O
and	O
BLMA	O
group	O
using	O
standard	O
blind	B-T061
technique	I-T061
(	O
n=50	O
)	O
.	O
Correct	O
placement	O
of	O
the	O
LMA	O
was	O
confirmed	O
using	O
clinical	O
test	O
along	O
with	O
fiberoptic	O
assessment	B-T058
.	O
Unblinded	O
data	O
were	O
collected	O
about	O
the	O
insertion	B-T061
time	O
,	O
the	O
first	O
attempt	O
success	O
rate	O
,	O
the	O
LMA	O
position	O
adjustment	O
rate	O
,	O
fiberoptic	O
view	O
of	O
LMA	O
anatomical	O
position	O
,	O
hemodynamic	O
responses	O
,	O
and	O
the	O
adverse	O
insertion	B-T061
responses	O
(	O
bucking	O
,	O
breathholding	B-T033
,	O
and	O
laryngospasm	O
)	O
.	O
Blinded	O
data	O
were	O
recorded	O
about	O
postoperative	O
airway	B-T047
morbidity	I-T047
(	O
visible	O
blood	O
staining	O
on	O
LMA	O
at	O
removal	O
,	O
sore	B-T184
throat	I-T184
,	O
and	O
hoarseness	B-T184
)	O
.	O
Insertion	B-T061
was	O
more	O
frequently	O
successful	O
at	O
the	O
first	O
attempt	O
in	O
GLMA	O
than	O
that	O
in	O
BLMA	O
group	O
(	O
100	O
%	O
vs	O
92	O
%	O
;	O
P=.041	O
)	O
.	O
The	O
time	O
taken	O
for	O
establishing	O
effective	O
airway	O
was	O
shorter	O
in	O
GLMA	O
than	O
that	O
in	O
BLMA	O
(	O
54.8	O
vs	O
62.9	O
seconds	O
;	O
P=.001	O
)	O
.	O
The	O
patients	O
in	O
BLMA	O
group	O
required	O
more	O
readjustment	O
and	O
reinsertion	B-T061
than	O
those	O
in	O
GLMA	O
group	O
(	O
38	O
%	O
vs	O
0	O
%	O
;	O
P=.000	O
)	O
.	O
The	O
fiberoptic	O
view	O
was	O
significantly	O
better	O
in	O
GLMA	O
group	O
(	O
P<.001	O
)	O
.	O
No	O
difference	O
between	O
the	O
2	O
groups	O
existed	O
regarding	O
hemodynamic	O
stress	O
responses	O
,	O
incidences	O
of	O
adverse	O
insertion	B-T061
responses	O
,	O
and	O
postoperative	O
airway	B-T047
morbidity	I-T047
.	O
By	O
direct	O
visualizing	O
the	O
whole	O
process	O
of	O
LMA	O
insertion	B-T061
,	O
the	O
Discopo	B-T061
visual	I-T061
stylet	I-T061
increases	O
the	O
success	O
rate	O
and	O
accuracy	O
rate	O
of	O
LMA	O
placement	O
without	O
increasing	O
hemodynamic	O
stress	O
response	O
or	O
incidences	O
of	O
adverse	O
events	O
.	O
      
Flexible	O
Coordination	O
of	O
Stationary	O
and	O
Mobile	O
Conversations	O
with	O
Gaze	B-T033
:	O
Resource	O
Allocation	O
among	O
Multiple	O
Joint	O
Activities	O
Gaze	B-T033
is	O
instrumental	O
in	O
coordinating	O
face	O
-	O
to	O
-	O
face	O
social	B-T033
interactions	I-T033
.	O
But	O
little	O
is	O
known	O
about	O
gaze	B-T033
use	O
when	O
social	B-T033
interactions	I-T033
co	O
-	O
occur	O
with	O
other	O
joint	O
activities	O
.	O
We	O
investigated	O
the	O
case	O
of	O
walking	O
while	O
talking	O
.	O
We	O
assessed	O
how	O
gaze	B-T033
gets	O
allocated	O
among	O
various	O
targets	O
in	O
mobile	O
conversations	O
,	O
whether	O
allocation	O
of	O
gaze	B-T033
to	O
other	O
targets	O
affects	O
conversational	O
coordination	O
,	O
and	O
whether	O
reduced	O
availability	O
of	O
gaze	B-T033
for	O
conversational	O
coordination	O
affects	O
conversational	O
performance	O
and	O
content	O
.	O
In	O
an	O
experimental	O
study	O
,	O
pairs	O
were	O
videotaped	O
in	O
four	O
conditions	O
of	O
mobility	B-T033
(	O
standing	O
still	O
,	O
talking	O
while	O
walking	B-T060
along	I-T060
a	I-T060
straight	I-T060
-	I-T060
line	I-T060
itinerary	I-T060
,	O
talking	O
while	O
walking	O
along	O
a	O
complex	O
itinerary	O
,	O
or	O
walking	O
along	O
a	O
complex	O
itinerary	O
with	O
no	B-T033
conversational	I-T033
task	O
)	O
.	O
Gaze	B-T033
to	O
partners	O
was	O
substantially	O
reduced	O
in	O
mobile	O
conversations	O
,	O
but	O
gaze	B-T033
was	O
still	O
used	O
to	O
coordinate	O
conversation	O
via	O
displays	O
of	O
mutual	O
orientation	O
,	O
and	O
conversational	O
performance	O
and	O
content	O
was	O
not	O
different	O
between	O
stationary	O
and	O
mobile	O
conditions	O
.	O
Results	O
expand	O
the	O
phenomena	O
of	O
multitasking	O
to	O
joint	O
activities	O
.	O
      
Low	O
-	O
intensity	O
pulsed	O
ultrasound	O
reduces	O
periodontal	B-T047
atrophy	I-T047
in	O
occlusal	O
hypofunctional	O
teeth	B-T023
To	O
clarify	O
whether	O
low	O
-	O
intensity	O
pulsed	O
ultrasound	O
(	O
LIPUS	O
)	O
exposure	O
has	O
recovery	O
effects	O
on	O
the	O
hypofunctional	O
periodontal	B-T023
ligament	I-T023
(	O
PDL	B-T023
)	O
and	O
interradicular	B-T023
alveolar	I-T023
bone	I-T023
(	O
IRAB	B-T023
)	O
.	O
Twelve-	O
week	O
-old	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
divided	O
into	O
three	O
groups	O
(	O
n	O
=	O
5	O
each	O
):	O
a	O
normal	O
occlusion	O
(	O
C	O
)	O
group	O
,	O
an	O
occlusal	O
hypofunction	O
(	O
H	O
)	O
group	O
,	O
and	O
an	O
occlusal	O
hypofunction	O
group	O
subjected	O
to	O
LIPUS	O
(	O
HL	O
)	O
treatment	B-T061
.	O
Hypofunctional	O
occlusion	O
of	O
the	O
maxillary	B-T023
first	I-T023
molar	I-T023
(	O
M1	B-T023
)	O
of	O
the	O
H	O
and	O
HL	O
groups	O
was	O
induced	O
by	O
the	O
bite	B-T058
-	I-T058
raising	I-T058
technique	I-T058
.	O
Only	O
the	O
HL	O
group	O
was	O
irradiated	O
with	O
LIPUS	O
for	O
5	O
days	O
.	O
The	O
IRAB	B-T023
and	O
PDL	B-T023
of	O
M1	B-T023
were	O
examined	O
by	O
microcomputed	B-T060
tomography	I-T060
(	O
micro	B-T060
-	I-T060
CT	I-T060
)	O
analysis	O
.	O
To	O
quantify	O
mRNA	O
expression	O
of	O
cytokines	O
involved	O
in	O
PDL	B-T023
proliferation	O
and	O
development	O
,	O
real	O
-	O
time	O
reverse	O
transcription	O
quantitative	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
was	O
performed	O
for	O
twist	O
family	O
bHLH	O
transcription	O
factor	O
1	O
(	O
Twist1	O
)	O
,	O
periostin	O
,	O
and	O
connective	O
tissue	O
growth	O
factor	O
(	O
CTGF	O
)	O
in	O
the	O
PDL	B-T023
samples	O
.	O
Micro	B-T060
-	I-T060
CT	I-T060
analysis	O
showed	O
that	O
the	O
PDL	B-T023
volume	O
was	O
decreased	O
in	O
the	O
H	O
group	O
compared	O
with	O
that	O
of	O
the	O
C	O
and	O
HL	O
groups	O
.	O
Both	O
bone	O
volume	O
per	O
tissue	O
volume	O
(	O
BV	O
/	O
TV	O
)	O
of	O
IRAB	B-T023
was	O
decreased	O
in	O
the	O
H	O
group	O
compared	O
with	O
that	O
in	O
the	O
C	O
group	O
.	O
LIPUS	O
exposure	O
restored	O
BV	O
/	O
TV	O
in	O
the	O
IRAB	B-T023
of	O
the	O
HL	O
group	O
.	O
qRT	O
-	O
PCR	O
analysis	O
showed	O
that	O
Twist1	O
,	O
periostin	O
,	O
and	O
CTGF	O
mRNA	O
levels	O
were	O
decreased	O
in	O
the	O
H	O
group	O
and	O
increased	O
in	O
the	O
HL	O
group	O
.	O
LIPUS	O
exposure	O
reduced	O
the	O
atrophic	O
changes	O
of	O
alveolar	B-T023
bone	I-T023
by	O
inducing	O
the	O
upregulation	O
of	O
periostin	O
and	O
CTGF	O
expression	O
to	O
promote	O
PDL	B-T023
healing	O
after	O
induction	B-T061
of	O
occlusal	O
hypofunction	O
.	O
      
LDL	O
particle	O
number	O
and	O
size	O
and	O
cardiovascular	O
risk	O
:	O
anything	O
new	O
under	O
the	O
sun	O
?	O
We	O
provide	O
here	O
an	O
up	O
-	O
to	O
-	O
date	O
perspective	O
on	O
the	O
potential	O
use	O
of	O
LDL	O
particle	O
number	O
and	O
size	O
as	O
complementary	O
risk	B-T033
factors	I-T033
to	O
predict	O
and	O
manage	O
cardiovascular	B-T047
disease	I-T047
(	O
CVD	B-T047
)	O
risk	O
in	O
the	O
clinical	O
realm	O
.	O
Studies	O
show	O
that	O
a	O
significant	O
proportion	O
of	O
the	O
population	O
has	O
discordant	O
LDL	O
particle	O
number	O
and	O
cholesterol	O
indices	O
[	O
non	O
-	O
HDL	O
cholesterol	O
(	O
HDL	O
-	O
C	O
)	O
]	O
.	O
Data	O
also	O
show	O
that	O
risk	O
prediction	O
may	O
be	O
improved	O
when	O
using	O
information	O
on	O
LDL	O
particle	O
number	O
in	O
patients	O
with	O
discordant	O
particle	O
number	O
and	O
cholesterol	O
data	O
.	O
Yet	O
,	O
most	O
of	O
the	O
current	O
CVD	B-T047
guidelines	O
conclude	O
that	O
LDL	O
particle	O
number	O
is	O
not	O
superior	O
to	O
cholesterol	O
indices	O
,	O
including	O
non	O
-	O
HDL	O
-	O
C	O
concentrations	O
,	O
in	O
predicting	O
CVD	B-T047
risk	O
.	O
LDL	O
particle	O
size	O
,	O
on	O
the	O
other	O
hand	O
,	O
has	O
not	O
been	O
independently	O
associated	O
with	O
CVD	B-T047
risk	O
after	O
adjustment	O
for	O
other	O
risk	B-T033
factors	I-T033
such	O
as	O
LDL	O
cholesterol	O
,	O
triglycerides	O
,	O
and	O
HDL	O
-	O
C	O
and	O
that	O
routine	O
use	O
of	O
information	O
pertaining	O
to	O
particle	O
size	O
to	O
determine	O
and	O
manage	O
patients	O
'	O
risk	O
is	O
not	O
yet	O
justified	O
.	O
Additional	O
studies	O
are	O
required	O
to	O
settle	O
the	O
debate	O
on	O
which	O
of	O
cholesterol	O
indices	O
and	O
LDL	O
particle	O
number	O
is	O
the	O
best	O
predictor	O
of	O
CVD	B-T047
risk	O
,	O
and	O
if	O
such	O
measures	O
should	O
be	O
integrated	O
in	O
clinical	B-T061
practice	I-T061
.	O
      
Identification	O
of	O
In	O
-	O
Chain	O
-	O
Functionalized	O
Compounds	O
and	O
Methyl	O
-	O
Branched	O
Alkanes	O
in	O
Cuticular	O
Waxes	O
of	O
Triticum	O
aestivum	O
cv	O
.	O
Bethlehem	O
In	O
this	O
work	O
,	O
cuticular	O
waxes	O
from	O
flag	O
leaf	O
blades	O
and	O
peduncles	O
of	O
Triticum	O
aestivum	O
cv	O
.	O
Bethlehem	O
were	O
investigated	O
in	O
search	O
for	O
novel	O
wax	O
compounds	O
.	O
Seven	O
wax	O
compound	O
classes	O
were	O
detected	B-T033
that	O
had	O
previously	O
not	O
been	O
reported	O
,	O
and	O
their	O
structures	O
were	O
elucidated	O
using	O
gas	B-T059
chromatography	I-T059
-	I-T059
mass	I-T059
spectrometry	I-T059
of	O
various	O
derivatives	O
.	O
Six	O
of	O
the	O
classes	O
were	O
identified	O
as	O
series	O
of	O
homologs	O
differing	O
by	O
two	O
methylene	O
units	O
,	O
while	O
the	O
seventh	O
was	O
a	O
homologous	O
series	O
with	O
homologs	O
with	O
single	O
methylene	O
unit	O
differences	O
.	O
In	O
the	O
waxes	O
of	O
flag	O
leaf	O
blades	O
,	O
secondary	O
alcohols	O
(	O
predominantly	O
C27	O
and	O
C33	O
)	O
,	O
primary	O
/	O
secondary	O
diols	O
(	O
predominantly	O
C28	O
)	O
and	O
esters	O
of	O
primary	O
/	O
secondary	O
diols	O
(	O
predominantly	O
C50	O
,	O
combining	O
C28	O
diol	O
with	O
C22	O
acid	O
)	O
were	O
found	O
,	O
all	O
sharing	O
similar	O
secondary	O
hydroxyl	O
group	O
positions	O
at	O
and	O
around	O
C-12	O
or	O
ω-12	O
.	O
7-	O
and	O
8	O
-	O
hydroxy-2	O
-	O
alkanol	O
esters	O
(	O
predominantly	O
C35	O
)	O
,	O
7-	O
and	O
8	O
-	O
oxo-2	O
-	O
alkanol	O
esters	O
(	O
predominantly	O
C35	O
)	O
,	O
and	O
4	O
-	O
alkylbutan-4	O
-	O
olides	O
(	O
predominantly	O
C28	O
)	O
were	O
found	O
both	O
in	O
flag	O
leaf	O
and	O
peduncle	O
wax	O
mixtures	O
.	O
Finally	O
,	O
a	O
series	O
of	O
even	O
-	O
and	O
odd	O
-	O
numbered	O
alkane	O
homologs	O
was	O
identified	O
in	O
both	O
leaf	O
and	O
peduncle	O
waxes	O
,	O
with	O
an	O
internal	O
methyl	O
branch	O
preferentially	O
on	O
C-11	O
and	O
C-13	O
of	O
homologs	O
with	O
even	O
total	O
carbon	O
number	O
and	O
on	O
C-12	O
of	O
odd	O
-	O
numbered	O
homologs	O
.	O
Biosynthetic	O
pathways	O
are	O
suggested	O
for	O
all	O
compounds	O
,	O
based	O
on	O
common	O
structural	O
features	O
and	O
matching	O
chain	O
length	O
profiles	O
with	O
other	O
wheat	O
wax	O
compound	O
classes	O
.	O
      
Adenoviral	B-T005
Delivery	B-T061
of	O
Tumor	O
Necrosis	O
Factor	O
-	O
α	O
and	O
Interleukin-2	O
Enables	O
Successful	O
Adoptive	B-T061
Cell	I-T061
Therapy	I-T061
of	O
Immunosuppressive	B-T121
Melanoma	B-T191
Adoptive	B-T061
T	I-T061
-	I-T061
cell	I-T061
transfer	I-T061
is	O
a	O
promising	O
treatment	O
approach	O
for	O
metastatic	B-T191
cancer	I-T191
,	O
but	O
efficacy	O
in	O
solid	B-T191
tumors	I-T191
has	O
only	O
been	O
achieved	O
with	O
toxic	O
pre-	O
and	O
postconditioning	O
regimens	O
.	O
Thus	O
,	O
adoptive	B-T061
T	I-T061
-	I-T061
cell	I-T061
therapies	I-T061
would	O
benefit	O
from	O
complementary	O
modalities	O
that	O
enable	O
their	O
full	O
potential	O
without	O
excessive	O
toxicity	O
.	O
We	O
aimed	O
to	O
improve	O
the	O
efficacy	O
and	O
safety	O
of	O
adoptive	B-T061
T	I-T061
-	I-T061
cell	I-T061
transfer	I-T061
by	O
using	O
adenoviral	O
vectors	O
for	O
direct	O
delivery	O
of	O
immunomodulatory	B-T061
murine	O
cytokines	O
into	O
B16.OVA	O
melanoma	B-T050
tumors	I-T050
tumors	B-T191
with	O
concomitant	O
T	O
-	O
cell	O
receptor	O
transgenic	B-T061
OT	I-T061
-	I-T061
I	I-T061
T	I-T061
-	I-T061
cell	I-T061
transfer	I-T061
.	O
Armed	O
adenoviruses	B-T005
expressed	O
high	O
local	O
and	O
low	O
systemic	O
levels	O
of	O
cytokine	O
when	O
injected	O
into	O
B16.OVA	O
tumors	B-T191
,	O
suggesting	O
safety	O
of	O
virus	B-T005
-	I-T005
mediated	I-T005
virus	B-T061
-	I-T061
mediated	I-T061
cytokine	I-T061
delivery	I-T061
.	O
Antitumor	O
efficacy	O
was	O
significantly	O
enhanced	O
with	O
adenoviruses	B-T005
coding	O
for	O
murine	O
interleukin-2	O
(	O
mIL-2	O
)	O
and	O
tumor	O
necrosis	O
factor	O
-	O
α	O
(	O
mTNFα	O
)	O
when	O
compared	O
with	O
T	B-T061
-	I-T061
cell	I-T061
transfer	I-T061
alone	O
or	O
viruses	B-T005
alone	O
.	O
Further	O
improvement	O
in	O
efficacy	O
was	O
achieved	O
with	O
a	O
triple	O
combination	O
of	O
mIL-2	O
,	O
mTNFα	O
,	O
and	O
OT	O
-	O
I	O
T	O
-	O
cells	O
.	O
Mechanistic	O
studies	O
suggest	O
that	O
mIL-2	O
has	O
an	O
important	O
role	O
in	O
activating	O
T	O
-	O
cells	O
at	O
the	O
tumor	B-T191
,	O
while	O
mTNFα	O
induces	O
chemokine	O
expression	O
.	O
Furthermore	O
,	O
adenovirus	B-T005
treatments	B-T061
enhanced	O
tumor	B-T191
-	O
infiltration	O
of	O
OT	O
-	O
I	O
T	O
-	O
cells	O
as	O
demonstrated	O
by	O
SPECT	B-T060
/	I-T060
CT	I-T060
imaging	I-T060
of	O
(	O
111)In	O
-	O
labeled	O
cells	O
.	O
Our	O
results	O
suggest	O
the	O
utility	O
of	O
cytokine	O
-	O
coding	O
adenoviruses	B-T005
for	O
improving	O
the	O
efficacy	O
of	O
adoptive	B-T061
T	I-T061
-	I-T061
cell	I-T061
therapies	I-T061
.	O
      
Sleep	B-T033
Loss	I-T033
Promotes	O
Astrocytic	O
Phagocytosis	O
and	O
Microglial	O
Activation	O
in	O
Mouse	O
Cerebral	O
Cortex	O
We	O
previously	O
found	O
that	O
Mertk	O
and	O
its	O
ligand	O
Gas6	O
,	O
astrocytic	O
genes	O
involved	O
in	O
phagocytosis	O
,	O
are	O
upregulated	O
after	O
acute	O
sleep	B-T033
deprivation	I-T033
.	O
These	O
results	O
suggested	O
that	O
astrocytes	O
may	O
engage	O
in	O
phagocytic	O
activity	O
during	O
extended	O
wake	O
,	O
but	O
direct	O
evidence	O
was	O
lacking	O
.	O
Studies	O
in	O
humans	O
and	O
rodents	O
also	O
found	B-T033
that	O
sleep	B-T033
loss	I-T033
increases	O
peripheral	O
markers	O
of	O
inflammation	O
,	O
but	O
whether	O
these	O
changes	O
are	O
associated	O
with	O
neuroinflammation	O
and/or	O
activation	O
of	O
microglia	O
,	O
the	O
brain	B-T023
's	I-T023
resident	O
innate	O
immune	O
cells	O
,	O
was	O
unknown	O
.	O
Here	O
we	O
used	O
serial	B-T059
block	I-T059
-	I-T059
face	I-T059
scanning	I-T059
electron	I-T059
microscopy	I-T059
to	O
obtain	O
3D	O
volume	O
measurements	O
of	O
synapses	O
and	O
surrounding	O
astrocytic	O
processes	O
in	O
mouse	O
frontal	B-T023
cortex	I-T023
after	O
6	O
-	O
8	O
h	O
of	O
sleep	O
,	O
spontaneous	O
wake	O
,	O
or	O
sleep	B-T033
deprivation	I-T033
(	O
SD	B-T033
)	O
and	O
after	O
chronic	O
(	O
∼5	O
d	O
)	O
sleep	O
restriction	O
(	O
CSR	O
)	O
.	O
Astrocytic	O
phagocytosis	O
,	O
mainly	O
of	O
presynaptic	O
components	O
of	O
large	O
synapses	O
,	O
increased	O
after	O
both	O
acute	O
and	O
chronic	O
sleep	B-T033
loss	I-T033
relative	O
to	O
sleep	O
and	O
wake	O
.	O
MERTK	O
expression	O
and	O
lipid	O
peroxidation	O
in	O
synaptoneurosomes	O
also	O
increased	O
to	O
a	O
similar	O
extent	O
after	O
short	O
and	O
long	O
sleep	B-T033
loss	I-T033
,	O
suggesting	O
that	O
astrocytic	O
phagocytosis	O
may	O
represent	O
the	O
brain	B-T023
's	I-T023
response	O
to	O
the	O
increase	O
in	O
synaptic	O
activity	O
associated	O
with	O
prolonged	O
wake	O
,	O
clearing	O
worn	O
components	O
of	O
heavily	O
used	O
synapses	O
.	O
Using	O
confocal	B-T059
microscopy	I-T059
,	O
we	O
then	O
found	B-T033
that	O
CSR	O
but	O
not	O
SD	B-T033
mice	O
show	O
morphological	O
signs	B-T184
of	O
microglial	O
activation	O
and	O
enhanced	O
microglial	O
phagocytosis	O
of	O
synaptic	O
elements	O
,	O
without	O
obvious	O
signs	B-T184
of	O
neuroinflammation	O
in	O
the	O
CSF	O
.	O
Because	O
low	O
-	O
level	O
sustained	O
microglia	O
activation	O
can	O
lead	O
to	O
abnormal	B-T033
responses	O
to	O
a	O
secondary	O
insult	O
,	O
these	O
results	O
suggest	O
that	O
chronic	O
sleep	B-T033
loss	I-T033
,	O
through	O
microglia	O
priming	O
,	O
may	O
predispose	O
the	O
brain	B-T023
to	O
further	O
damage	O
.SIGNIFICANCE	O
STATEMENT	O
We	O
find	B-T033
that	O
astrocytic	O
phagocytosis	O
of	O
synaptic	O
elements	O
,	O
mostly	O
of	O
presynaptic	O
origin	O
and	O
in	O
large	O
synapses	O
,	O
is	O
upregulated	O
already	O
after	O
a	O
few	O
hours	O
of	O
sleep	B-T033
deprivation	I-T033
and	O
shows	O
a	O
further	O
significant	O
increase	O
after	O
prolonged	O
and	O
severe	O
sleep	B-T033
loss	I-T033
,	O
suggesting	O
that	O
it	O
may	O
promote	O
the	O
housekeeping	O
of	O
heavily	O
used	O
and	O
strong	O
synapses	O
in	O
response	O
to	O
the	O
increased	O
neuronal	O
activity	O
of	O
extended	O
wake	O
.	O
By	O
contrast	O
,	O
chronic	O
sleep	O
restriction	O
but	O
not	O
acute	O
sleep	B-T033
loss	I-T033
activates	O
microglia	O
,	O
promotes	O
their	O
phagocytic	O
activity	O
,	O
and	O
does	O
so	O
in	O
the	O
absence	O
of	O
overt	O
signs	B-T184
of	O
neuroinflammation	O
,	O
suggesting	O
that	O
like	O
many	O
other	O
stressors	O
,	O
extended	O
sleep	B-T033
disruption	I-T033
may	O
lead	O
to	O
a	O
state	O
of	O
sustained	O
microglia	O
activation	O
,	O
perhaps	O
increasing	O
the	O
brain	B-T023
's	I-T023
susceptibility	O
to	O
other	O
forms	O
of	O
damage	O
.	O
      
P	O
-	O
glycoprotein	O
traffics	O
from	O
the	O
nucleus	O
to	O
the	O
plasma	O
membrane	O
in	O
rat	B-T023
brain	I-T023
endothelium	O
during	O
inflammatory	B-T184
pain	I-T184
P	O
-	O
glycoprotein	O
(	O
PgP	O
)	O
,	O
a	O
drug	B-T121
efflux	O
pump	O
in	O
blood	B-T023
-	I-T023
brain	I-T023
barrier	I-T023
endothelial	O
cells	O
,	O
is	O
a	O
major	O
clinical	O
obstacle	O
for	O
effective	O
central	O
nervous	O
system	O
drug	B-T061
delivery	I-T061
.	O
Identifying	B-T058
PgP	O
regulatory	O
pathways	O
that	O
can	O
be	O
exploited	O
clinically	O
is	O
critical	O
for	O
improving	O
central	O
nervous	O
system	O
drug	B-T061
delivery	I-T061
.	O
We	O
previously	O
found	O
that	O
PgP	O
activity	O
increases	O
in	O
rat	B-T023
brain	I-T023
microvessels	B-T023
concomitant	O
with	O
decreased	O
central	O
nervous	O
system	O
drug	B-T061
delivery	I-T061
in	O
response	O
to	O
acute	O
peripheral	O
inflammatory	B-T184
pain	I-T184
.	O
In	O
the	O
current	O
study	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
PgP	O
traffics	O
to	O
the	O
luminal	O
plasma	O
membrane	O
of	O
the	O
microvessel	B-T023
endothelial	O
cells	O
from	O
intracellular	O
stores	O
during	O
peripheral	O
inflammatory	B-T184
pain	I-T184
.	O
Using	O
immunofluorescence	B-T059
microscopy	I-T059
,	O
we	O
detected	B-T033
PgP	O
in	O
endothelial	O
cell	O
nuclei	O
and	O
in	O
the	O
luminal	O
plasma	O
membrane	O
in	O
control	O
animals	O
.	O
Following	O
peripheral	O
inflammatory	B-T184
pain	I-T184
,	O
luminal	O
PgP	O
staining	B-T059
increased	O
while	O
staining	B-T059
in	O
the	O
nucleus	O
decreased	O
.	O
Biochemical	B-T059
analysis	I-T059
of	O
nuclear	O
PgP	O
content	O
confirmed	O
our	O
visual	O
observations	O
.	O
Peripheral	O
inflammatory	B-T184
pain	I-T184
also	O
increased	O
endothelial	O
cell	O
luminal	O
staining	B-T059
of	O
polymerase	O
1	O
and	O
transcript	O
release	O
factor	O
/	O
cavin1	O
and	O
serum	O
deprivation	O
response	O
protein	O
/	O
cavin2	O
,	O
two	O
caveolar	O
scaffold	O
proteins	O
,	O
without	O
changing	O
caveolin1	O
or	O
protein	O
kinase	O
C	O
delta	O
binding	O
protein	O
/	O
cavin3	O
location	O
.	O
Our	O
data	O
(	O
a	O
)	O
indicate	O
that	O
PgP	O
traffics	O
from	O
stores	O
in	O
the	O
nucleus	O
to	O
the	O
endothelial	O
cell	O
luminal	O
membrane	O
in	O
response	O
to	O
peripheral	O
inflammatory	B-T184
pain	I-T184
;	O
(	O
b	O
)	O
provide	O
an	O
explanation	O
for	O
our	O
previous	O
observation	O
that	O
peripheral	O
inflammatory	B-T184
pain	I-T184
inhibits	O
central	O
nervous	O
system	O
drug	B-T121
uptake	O
;	O
and	O
(	O
c	O
)	O
suggest	O
a	O
novel	O
regulatory	B-T033
mechanism	I-T033
for	O
PgP	O
activity	O
in	O
rat	B-T023
brain	I-T023
.	O
      
A	O
completely	O
calcified	O
prostate	B-T023
Prostatic	B-T047
calcification	I-T047
and	O
prostatic	B-T047
calculus	I-T047
formation	O
is	O
commonly	O
seen	O
in	O
adult	O
population	O
with	O
chronic	B-T047
prostatitis	I-T047
,	O
however	O
,	O
gross	O
prostatic	B-T047
calcification	I-T047
which	O
involves	O
more	O
than	O
3	O
cm(2	O
)	O
of	O
the	O
gland	B-T023
is	O
quite	O
rare	O
.	O
We	O
are	O
presenting	O
here	O
one	O
such	O
case	O
in	O
which	O
almost	O
whole	O
glandular	B-T023
prostate	I-T023
was	O
converted	O
into	O
stone	O
which	O
is	O
never	O
reported	O
so	O
far	O
.	O
      
Antenatal	O
Stressful	O
Life	O
Events	O
and	O
Postpartum	O
Depressive	B-T184
Symptoms	I-T184
in	O
the	O
United	O
States	O
:	O
The	O
Role	O
of	O
Women	O
's	O
Socioeconomic	O
Status	O
Indices	O
at	O
the	O
State	O
Level	O
Approximately	O
10%-20	O
%	O
of	O
women	O
suffer	B-T048
from	O
postpartum	B-T048
depression	I-T048
(	O
PPD	B-T048
)	O
,	O
important	O
predictors	O
of	O
which	O
are	O
antenatal	O
stressful	O
life	O
event	O
(	O
SLE	O
)	O
experiences	O
.	O
The	O
association	O
between	O
women	O
's	O
state	O
-	O
level	O
socioeconomic	O
status	O
(	O
SES	O
)	O
and	O
PPD	B-T048
has	O
not	O
been	O
explored	O
.	O
This	O
study	O
aimed	O
to	O
examine	O
whether	O
the	O
association	O
between	O
antenatal	O
SLE	O
and	O
PPD	B-T048
symptoms	B-T184
was	O
moderated	O
by	O
women	O
's	O
state	O
-	O
level	O
SES	O
.	O
Data	O
from	O
the	O
2009	O
-	O
2011	O
Pregnancy	O
Risk	O
Assessment	O
Monitoring	O
System	O
(	O
PRAMS	O
)	O
were	O
used	O
.	O
State	O
-	O
level	O
women	O
's	O
employment	O
/	O
earnings	O
and	O
social	O
/	O
economic	O
autonomy	O
indices	O
were	O
computed	O
from	O
indicators	O
published	O
by	O
the	O
Institute	O
of	O
Women	O
's	O
Policy	O
Research	O
(	O
IWPR	O
)	O
.	O
Multilevel	O
multivariable	O
logistic	O
regression	O
analyses	O
were	O
performed	O
.	O
Among	O
91,253	O
women	O
with	O
valid	O
responses	O
,	O
11.3	O
%	O
had	O
PPD	B-T048
symptoms	B-T184
,	O
prevalence	O
ranging	O
from	O
7.1	O
%	O
in	O
Illinois	O
to	O
17.1	O
%	O
in	O
Arkansas	O
.	O
Women	O
who	O
experienced	O
all	O
four	O
stressor	O
categories	O
,	O
including	O
partner	O
related	B-T033
,	O
traumatic	O
,	O
emotional	B-T033
,	O
and	O
financial	O
,	O
had	O
the	O
highest	O
odds	O
(	O
adjusted	O
odds	O
ratio	O
[	O
aOR	O
]	O
:	O
5.43	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
5.36	O
-	O
5.51	O
)	O
of	O
PPD	B-T048
symptoms	B-T184
.	O
The	O
odds	O
of	O
experiencing	O
PPD	B-T048
symptoms	B-T184
decreased	O
with	O
an	O
increase	O
in	O
the	O
state	O
-	O
level	O
social	O
/	O
economic	O
autonomy	O
index	O
(	O
aOR	O
:	O
0.75	O
;	O
95	O
%	O
CI	O
:	O
0.64	O
-	O
0.88	O
)	O
.	O
There	O
was	O
significant	O
cross	O
-	O
level	O
interaction	O
between	O
number	O
of	O
stressor	O
categories	O
experienced	O
and	O
state	O
-	O
level	O
index	O
.	O
Screening	O
for	O
antenatal	O
SLEs	O
can	O
help	O
identify	O
women	O
at	O
risk	O
for	O
PPD	B-T048
symptoms	B-T184
.	O
That	O
the	O
odds	O
of	O
having	O
PPD	B-T048
symptoms	B-T184
decreased	O
with	O
increasing	O
state	O
-	O
level	O
social	O
/	O
economic	O
autonomy	O
and	O
women	O
residing	O
in	O
states	O
with	O
lower	O
indices	O
were	O
more	O
vulnerable	O
to	O
the	O
impacts	O
of	O
antenatal	O
stressors	O
,	O
could	O
have	O
policy	O
implications	O
related	O
to	O
improving	O
the	O
SES	O
of	O
women	O
in	O
these	O
states	O
.	O
      
Interprofessional	B-T033
Barriers	I-T033
:	O
A	O
Study	O
of	O
Quality	O
Improvement	O
Work	O
Among	O
Nurses	O
and	O
Physicians	O
This	O
article	O
studies	O
interprofessional	B-T033
barriers	I-T033
between	O
nurses	O
and	O
physicians	O
in	O
the	O
context	O
of	O
quality	O
improvement	O
work	O
.	O
A	O
total	O
of	O
17	O
nurses	O
and	O
10	O
physicians	O
were	O
interviewed	O
at	O
2	O
hospitals	O
in	O
Sweden	O
.	O
The	O
study	O
uncovered	O
a	O
number	B-T033
of	I-T033
barriers	I-T033
relating	O
to	O
both	O
the	O
relative	O
status	O
of	O
each	O
group	O
and	O
their	O
defined	O
areas	O
of	O
responsibility	O
.	O
      
Draft	O
Genome	O
Sequence	O
of	O
Bacillus	B-T007
cereus	I-T007
LA2007	I-T007
,	O
a	O
Human	O
-	O
Pathogenic	O
Isolate	O
Harboring	O
Anthrax	O
-Like	O
Plasmids	O
We	O
present	O
the	O
genome	O
sequence	O
of	O
Bacillus	B-T007
cereus	I-T007
LA2007	I-T007
,	O
a	O
strain	B-T001
isolated	O
in	O
2007	O
from	O
a	O
fatal	B-T047
pneumonia	I-T047
case	O
in	O
Louisiana	O
.	O
Sequence	B-T059
-	I-T059
based	I-T059
genome	I-T059
analysis	I-T059
revealed	O
that	O
LA2007	B-T007
carries	B-T033
a	O
plasmid	O
highly	O
similar	O
to	O
Bacillus	B-T007
anthracis	I-T007
pXO1	I-T007
,	O
including	O
the	O
genes	O
responsible	O
for	O
the	O
production	O
and	O
regulation	O
of	O
anthrax	O
toxin	O
.	O
      
Psychological	B-T048
Distress	I-T048
Is	O
More	O
Prevalent	O
in	O
Fertile	O
Age	O
and	O
Premenopausal	O
Women	O
with	O
PCOS	B-T047
Symptoms	B-T184
-15	O
-	O
yr	O
Follow	B-T058
-	I-T058
up	I-T058
Polycystic	B-T047
ovary	I-T047
syndrome	I-T047
(	O
PCOS	B-T047
)	O
is	O
associated	O
with	O
increased	O
psychological	B-T048
distress	I-T048
;	O
obesity	B-T047
and	O
hyperandrogenism	B-T047
being	O
suggested	O
as	O
key	O
promoters	O
.	O
To	O
investigate	O
the	O
prevalence	O
of	O
anxiety	B-T048
/	O
depression	B-T048
and	O
their	O
coexistence	O
in	O
women	O
with	O
PCOS	B-T047
/	O
PCOS	B-T047
symptoms	B-T184
at	O
age	O
s	O
31	O
and	O
46	O
.	O
The	O
roles	O
of	O
obesity	B-T047
,	O
hyperandrogenism	B-T047
and	O
awareness	O
of	O
PCOS	B-T047
on	O
psychological	B-T048
distress	I-T048
were	O
also	O
assessed	O
.	O
Population	O
based	O
follow	O
-	O
up	O
.	O
Northern	O
Finland	O
Birth	O
Cohort	O
1966	O
with	O
15-	O
year	O
follow	B-T058
-	I-T058
up	I-T058
.	O
At	O
age	O
31	O
a	O
questionnaire	O
-	O
based	O
screening	O
for	O
oligoamenorrhea	O
(	O
OA	O
)	O
and	O
hirsutism	B-T047
(	O
H	B-T047
):	O
2188	O
asymptomatic	B-T033
(	O
controls	O
)	O
,	O
331	O
OA	O
,	O
323	O
H	B-T047
,	O
125	O
OA	O
+	O
H	B-T047
(	O
PCOS	B-T047
)	O
.	O
46	O
year	O
old	O
follow	B-T058
-	I-T058
up	I-T058
:	O
1576	O
controls	O
,	O
239	O
OA	O
,	O
231	O
H	B-T047
and	O
85	O
PCOS	B-T047
.	O
Questionnaire	O
-	O
based	O
screening	O
for	O
anxiety	B-T048
and	O
depression	B-T184
symptoms	I-T184
(	O
Hopkins	O
Symptom	O
Checklist-25	O
)	O
and	O
previously	O
diagnosed	B-T033
/	O
treated	B-T033
depression	B-T048
at	O
age	O
31	O
and	O
46	O
.	O
BMI	O
,	O
serum	B-T059
testosterone	I-T059
/	O
free	B-T059
androgen	I-T059
index	I-T059
(	O
FAI	B-T059
)	O
and	O
awareness	O
of	O
polycystic	B-T047
ovaries	I-T047
/	O
PCOS	B-T047
on	O
psychological	B-T048
distress	I-T048
were	O
also	O
assessed	O
.	O
Population	O
-	O
based	O
prevalence	O
of	O
anxiety	B-T048
and/or	O
depression	B-T048
in	O
women	O
with	O
PCOS	B-T047
/	O
PCOS	B-T047
symptoms	B-T184
at	O
age	O
s	O
31	O
and	O
46	O
.	O
Anxiety	B-T048
and/or	O
depression	B-T184
symptoms	I-T184
,	O
their	O
coexistence	O
and	O
rate	O
of	O
depression	B-T048
were	O
increased	O
at	O
age	O
31	O
and	O
46	O
in	O
women	O
with	O
PCOS	B-T047
or	O
isolated	O
H	B-T047
compared	O
with	O
controls	O
.	O
High	O
BMI	O
or	O
hyperandrogenism	B-T047
did	O
not	O
associate	O
with	O
increased	O
anxiety	B-T048
or	O
depression	B-T184
symptoms	I-T184
.	O
The	O
awareness	O
of	O
PCOS	B-T047
was	O
associated	O
with	O
increased	O
anxiety	B-T048
.	O
Women	O
with	O
PCOS	B-T047
or	O
isolated	O
H	B-T047
present	O
more	O
often	O
with	O
anxiety	B-T048
and/or	O
depression	B-T184
symptoms	I-T184
and	O
their	O
coexistence	O
compared	O
with	O
controls	O
.	O
High	O
BMI	O
or	O
hyperandrogenism	B-T047
did	O
not	O
provoke	O
psychological	B-T048
distress	I-T048
in	O
PCOS	B-T047
.	O
The	O
awareness	O
of	O
PCOS	B-T047
increased	O
anxiety	B-T048
but	O
did	O
not	O
associate	O
with	O
severe	O
anxiety	B-T048
or	O
depression	B-T048
.	O
      
Medication	B-T061
regimen	I-T061
complexity	O
and	O
prevalence	O
of	O
potentially	O
inappropriate	O
medicines	O
in	O
older	O
patients	O
after	O
hospitalisation	B-T058
Background	O
There	O
is	O
a	O
relative	O
paucity	O
of	O
information	O
to	O
characterise	O
potential	O
changes	O
in	O
medication	B-T061
regimen	I-T061
complexity	O
and	O
prevalence	O
of	O
prescribing	B-T058
of	O
potentially	O
inappropriate	O
medications	O
after	O
hospitalisation	B-T058
,	O
both	O
in	O
Australia	O
and	O
elsewhere	O
.	O
Objective	O
To	O
evaluate	B-T058
medication	B-T061
regimen	I-T061
complexity	O
and	O
the	O
prevalence	O
of	O
potentially	O
inappropriate	O
medications	O
before	O
and	O
after	O
admission	B-T058
to	I-T058
hospital	I-T058
.	O
Setting	O
General	O
medical	O
units	O
of	O
a	O
tertiary	O
care	O
hospital	O
in	O
Australia	O
.	O
Methods	O
Retrospective	O
cohort	O
study	O
of	O
patients	O
aged	O
65	O
years	O
and	O
above	O
.	O
Medication	B-T058
complexity	O
was	O
measured	O
by	O
using	O
the	O
Medication	O
Regimen	O
Complexity	O
Index	O
(	O
MRCI	O
)	O
.	O
Main	O
outcome	O
measure	O
The	O
primary	O
outcome	O
was	O
the	O
change	O
in	O
the	O
Medication	O
Regimen	O
Complexity	O
Index	O
for	O
all	O
prescribed	B-T121
medications	I-T121
after	O
hospitalization	B-T058
.	O
Results	O
A	O
convenience	O
sample	O
of	O
100	O
patients	O
was	O
included	O
in	O
the	O
study	O
.	O
There	O
was	O
a	O
significant	O
change	O
in	O
the	O
mean	O
medication	B-T058
complexity	O
score	O
(	O
as	O
measured	O
using	O
the	O
MRCI	O
)	O
,	O
increasing	O
from	O
29	O
at	O
the	O
time	O
of	O
admission	O
to	O
32	O
at	O
the	O
time	O
of	O
discharge	O
(	O
p	O
<	O
0.05	O
)	O
.	O
Factors	O
such	O
as	O
baseline	O
medication	B-T061
regimen	I-T061
complexity	O
(	O
pre	O
-	O
admission	O
MRCI	O
)	O
and	O
length	O
of	O
stay	O
in	O
the	O
hospitals	O
appear	O
to	O
influence	O
the	O
change	O
in	O
medication	B-T058
complexity	O
.	O
However	O
,	O
the	O
proportion	O
of	O
patients	O
prescribed	B-T058
at	O
least	O
one	O
potentially	O
inappropriate	O
medicine	O
(	O
PIM	O
)	O
decreased	O
significantly	O
,	O
from	O
52	O
%	O
pre	B-T058
-	I-T058
hospitalization	I-T058
to	O
42	O
%	O
at	O
discharge	O
(	O
p	O
=	O
0.04	O
)	O
.	O
Conclusions	O
Relative	O
to	O
the	O
time	O
of	O
admission	O
,	O
overall	O
medication	B-T058
complexity	O
increased	O
and	O
the	O
proportion	O
of	O
patients	O
who	O
were	O
prescribed	B-T058
PIMs	O
decreased	O
after	O
hospitalisation	B-T058
.	O
      
The	O
role	O
of	O
the	O
hippocampus	B-T023
and	O
the	O
function	O
of	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
in	O
the	O
mechanism	O
of	O
traumatic	O
brain	O
injury	O
accelerating	O
fracture	O
-	O
healing	O
This	O
research	O
attempts	O
to	O
identify	O
the	O
part	O
the	O
hippocampus	B-T023
plays	O
in	O
accelerated	O
fracture	O
-	O
healing	O
after	O
traumatic	O
brain	O
injury	O
as	O
well	O
as	O
to	O
test	O
functions	O
of	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
CGRP	O
)	O
during	O
this	O
process	O
.	O
Experiments	O
were	O
carried	O
out	O
on	O
Male	O
Sprague	O
-	O
Dawley	O
rats	O
that	O
were	O
split	O
into	O
four	O
groups	O
at	O
random	O
:	O
TBI	O
-	O
fracture	O
group	O
,	O
fracture	O
-	O
only	O
group	O
,	O
TBI	O
-	O
only	O
group	O
,	O
and	O
control	O
group	O
.	O
In	O
the	O
first	O
week	O
,	O
blood	O
specimen	O
would	O
be	O
drawn	O
from	O
rats	O
among	O
the	O
groups	O
except	O
those	O
of	O
the	O
control	O
group	O
at	O
three	O
-	O
time	O
points	O
(	O
24	O
,	O
72	O
and	O
168	O
hours	O
)	O
post	O
-	O
damage	O
.	O
These	O
rats	O
would	O
be	O
assessed	O
from	O
the	O
neurological	O
perspective	O
based	O
on	O
their	O
grades	O
of	O
performance	O
in	O
a	O
sequence	O
of	O
tests	O
24	O
hours	O
before	O
and	O
12	O
hours	O
after	O
brain	O
injury	O
.	O
Blood	B-T059
samples	I-T059
were	O
also	O
taken	O
from	O
the	O
control	O
group	O
24	O
hours	O
before	O
the	O
injury	O
,	O
and	O
whole	O
brain	B-T023
tissues	I-T023
in	O
the	O
injured	O
groups	O
were	O
harvested	B-T061
at	O
72	O
and	O
168	O
hours	O
post	O
-	O
injury	O
.	O
We	O
compared	O
the	O
serum	O
CGRP	O
concentration	O
,	O
the	O
distribution	O
of	O
CGRP	O
,	O
the	O
CGRP	O
expression	O
,	O
and	O
the	O
expression	O
of	O
CGRP	O
in	O
the	O
hippocampus	B-T023
,	O
the	O
expression	O
of	O
CGRP	O
in	O
the	O
hippocampus	B-T023
,	O
the	O
expression	O
of	O
CGRP	O
in	O
the	O
hippocampus	B-T023
,	O
and	O
the	O
expression	O
of	O
CGRP	O
in	O
the	O
brain	B-T023
by	O
immunohistochemistry	B-T060
,	O
Western	B-T059
blotting	I-T059
,	O
RT	O
-	O
Of	O
CGRP	O
RNA	O
expression	O
levels	O
.	O
Neurological	B-T060
examinations	I-T060
suggested	O
that	O
the	O
functions	O
of	O
the	O
cerebral	B-T023
cortex	I-T023
,	O
cerebellum	B-T023
,	O
and	O
brain	B-T023
stem	I-T023
showed	O
significant	O
differences	O
pre	O
-	O
and	O
post	O
-	O
injury	O
(	O
p	O
<	O
0.001	O
)	O
.	O
ELISA	B-T059
analysis	I-T059
indicated	O
a	O
great	O
density	O
of	O
CGRP	O
in	O
TBI	O
-	O
fracture	O
group	O
at	O
different	O
time	O
points	O
.	O
Furthermore	O
,	O
in	O
the	O
TBI	O
-	O
fracture	O
group	O
,	O
CGRP	O
in	O
both	O
hippocampus	B-T023
and	O
the	O
whole	B-T023
brain	I-T023
showed	O
a	O
noticeable	O
augment	O
in	O
RT	O
-	O
PCR	O
and	O
western	B-T059
blot	I-T059
analysis	I-T059
at	O
72	O
and	O
168	O
h	O
post	O
-	O
injury	O
,	O
and	O
only	O
in	O
this	O
group	O
,	O
immunohistochemistry	B-T060
analysis	I-T060
indicated	O
that	O
CGRP	O
was	O
present	O
in	O
the	O
hippocampus	B-T023
at	O
168	O
hours	O
post	O
-	O
injury	O
.	O
We	O
observed	O
that	O
the	O
hippocampus	B-T023
and	O
CGRP	O
were	O
responsible	O
for	O
quick	O
bone	B-T047
-	I-T047
healing	I-T047
mechanisms	O
.	O
We	O
suggest	O
a	O
role	O
for	O
the	O
hippocampus	B-T023
in	O
accelerated	O
fracture	O
healing	O
.	O
CGRP	O
expression	O
,	O
as	O
determined	O
by	O
IHC	B-T060
,	O
can	O
not	O
be	O
observed	O
in	O
other	O
groups	O
,	O
indicating	O
that	O
the	O
hippocampus	B-T023
may	O
be	O
the	O
specific	O
component	O
of	O
the	O
brain	B-T023
that	O
responds	O
to	O
"	O
big	O
stress	O
"	O
.	O
      
Acute	B-T047
Complicated	I-T047
Sinusitis	I-T047
:	O
Ten	O
Years	O
Experience	O
from	O
the	O
University	O
Hospital	O
of	O
the	O
West	O
Indies	O
Complicated	B-T047
sinusitis	I-T047
is	O
rare	B-T047
.	O
It	O
might	O
not	O
be	O
identified	O
early	O
and	O
might	O
expose	O
the	O
patient	O
to	O
an	O
unfavourable	O
outcome	O
.	O
There	O
is	O
a	O
paucity	O
of	O
data	O
regarding	O
this	O
condition	B-T047
in	O
the	O
Caribbean	O
.	O
This	O
study	O
was	O
undertaken	O
to	O
describe	O
the	O
clinical	O
characteristics	O
and	O
treatment	O
outcomes	O
of	O
patients	O
admitted	B-T058
with	O
this	O
condition	B-T047
.	O
A	O
retrospective	O
chart	O
review	O
was	O
performed	O
on	O
patients	O
admitted	B-T058
to	O
the	O
University	O
Hospital	O
of	O
the	O
West	O
Indies	O
(	O
UHWI	O
)	O
with	O
complicated	B-T047
sinusitis	I-T047
between	O
1999	O
to	O
2011	O
.	O
The	O
data	O
was	O
analysed	O
using	O
SPSS	O
statistics	O
22	O
software	O
.	O
There	O
were	O
30	O
patients	O
(	O
23	O
males	O
and	O
7	O
females	O
)	O
.	O
The	O
mean	O
(	O
SD	O
)	O
age	O
was	O
19	O
(	O
13.96	O
)	O
years	O
.	O
Twenty	O
-	O
two	O
had	O
orbital	O
complications	O
,	O
two	O
had	O
intracranial	O
complications	O
and	O
one	O
had	O
both	O
.	O
The	O
most	O
common	O
organisms	B-T001
isolated	O
were	O
streptococcus	B-T007
and	O
the	O
most	O
common	O
sensitivity	O
was	O
to	O
amoxicillin	B-T195
and	O
clavulinic	B-T195
acid	I-T195
.	O
Sixteen	O
patients	O
who	O
had	O
an	O
external	O
surgical	O
approach	O
had	O
a	O
mean	O
(	O
SD	O
)	O
hospital	O
stay	O
of	O
8.8	O
(	O
3.71	O
)	O
days	O
compared	O
to	O
three	O
patients	O
who	O
had	O
a	O
purely	O
endoscopic	O
approach	O
who	O
had	O
a	O
mean	O
(	O
SD	O
)	O
hospital	O
stay	O
of	O
7.67	O
(	O
0.577	O
)	O
days	O
.	O
There	O
was	O
no	B-T033
statistical	O
difference	O
in	O
mean	O
hospital	O
stay	O
between	O
these	O
two	O
groups	O
(	O
95	O
%	O
CI,-3.49	O
-	O
5.78	O
;	O
p	O
=	O
0.609	O
)	O
.	O
The	O
mean	O
duration	O
of	O
hospital	O
stay	O
for	O
those	O
treated	B-T058
medically	I-T058
was	O
six	O
days	O
versus	O
ten	O
days	O
for	O
the	O
surgical	O
group	O
.	O
The	O
mean	O
difference	O
was	O
three	O
days	O
(	O
95	O
%	O
CI	O
,	O
0.193	O
-	O
6.595	O
;	O
p	O
=	O
0.039	O
)	O
.	O
Acute	B-T047
complicated	I-T047
sinusitis	I-T047
is	O
seen	O
more	O
commonly	O
in	O
adolescent	O
males	O
.	O
The	O
most	O
common	O
complication	O
was	O
orbital	O
.	O
Surgical	B-T061
treatment	I-T061
is	O
indicated	O
for	O
those	O
patients	O
who	O
fail	O
medical	O
management	O
and	O
should	O
consist	O
of	O
an	O
endoscopic	O
approach	O
which	O
may	O
be	O
combined	O
with	O
open	O
approaches	O
if	O
indicated	O
.	O
      
Nitrogen	O
utilization	O
efficiency	O
and	O
prediction	O
of	O
nitrogen	O
excretion	O
in	O
sheep	O
offered	B-T033
fresh	O
perennial	O
ryegrass	O
(	O
)	O
Nitrogen	O
excretion	O
from	O
sheep	O
production	O
systems	O
is	O
an	O
important	O
source	O
of	O
nitrate	O
,	O
ammonia	B-T121
,	O
and	O
nitrous	B-T121
oxide	I-T121
responsible	O
for	O
groundwater	O
pollution	O
and	O
global	O
warming	O
.	O
The	O
present	O
study	O
aimed	O
to	O
identify	O
key	O
parameters	O
influencing	O
N	O
utilization	O
efficiency	O
and	O
develop	O
prediction	O
equations	O
for	O
manure	O
N	O
,	O
feces	O
N	O
,	O
and	O
urine	O
N	O
outputs	O
in	O
sheep	O
.	O
Data	O
used	O
were	O
collected	O
from	O
82	O
sheep	O
offered	B-T033
fresh	O
perennial	O
ryegrass	O
(	O
)	O
as	O
the	O
sole	O
diet	O
in	O
6	O
metabolism	O
experiments	O
(	O
data	O
from	O
non	O
-	O
grass	O
-	O
only	O
diets	O
were	O
not	O
used	O
)	O
.	O
Sheep	O
were	O
from	O
breeds	O
of	O
Highlander	O
,	O
Texel	O
,	O
Scottish	O
Blackface	O
,	O
and	O
Swaledale	O
at	O
the	O
age	O
of	O
5	O
to	O
18	O
mo	O
and	O
weighing	O
from	O
24.5	O
to	O
62.7	O
kg	O
.	O
Herbage	O
was	O
harvested	O
daily	O
from	O
6	O
swards	O
of	O
contrasting	O
harvest	O
dates	O
(	O
May	O
to	O
December	O
)	O
,	O
offering	B-T033
wide	O
variation	O
in	O
feed	O
value	O
to	O
cover	O
the	O
range	O
that	O
would	O
be	O
offered	B-T033
in	O
most	O
practical	O
farm	O
situations	O
.	O
Before	O
the	O
commencement	O
of	O
each	O
study	O
,	O
the	O
experimental	O
sward	O
was	O
harvested	O
at	O
a	O
residual	O
height	O
of	O
4	O
cm	O
and	O
allowed	O
to	O
grow	O
for	O
2	O
to	O
4	O
wk	O
to	O
target	O
an	O
average	O
pregrazing	O
sward	O
height	O
in	O
a	O
range	O
of	O
8	O
to	O
15	O
cm	O
depending	O
on	O
the	O
time	O
of	O
year	O
.	O
Sheep	O
were	O
housed	O
in	O
individual	O
pens	O
for	O
14	O
d	O
and	O
then	O
transferred	B-T033
to	I-T033
individual	O
metabolism	O
crates	O
for	O
4	O
d	O
with	O
feed	O
intake	O
and	O
feces	O
and	O
urine	O
outputs	O
measured	O
.	O
Data	O
were	O
analyzed	O
using	O
the	O
linear	O
mixed	O
model	O
procedure	O
to	O
develop	O
prediction	O
equations	O
for	O
feces	O
N	O
,	O
urine	O
N	O
,	O
and	O
manure	O
N	O
outputs	O
using	O
N	B-T033
intake	I-T033
,	O
herbage	O
chemical	O
composition	O
,	O
and	O
digestibility	O
with	O
effects	O
of	O
sex	O
,	O
breed	O
,	O
and	O
experimental	O
periods	O
removed	O
.	O
Nitrogen	O
intake	O
was	O
the	O
best	O
single	O
predictor	O
for	O
N	O
output	O
in	O
feces	O
,	O
urine	O
,	O
and	O
manure	O
,	O
and	O
the	O
value	O
for	O
prediction	O
of	O
manure	O
N	O
output	O
was	O
greater	O
than	O
those	O
for	O
feces	O
N	O
and	O
urine	O
N	O
(	O
0.86	O
vs.	O
0.70	O
and	O
0.77	O
,	O
respectively	O
;	O
<	O
0.001	O
)	O
.	O
Animal	O
BW	O
and	O
herbage	O
DM	O
,	O
ether	O
extract	O
,	O
NDF	O
,	O
ADF	O
,	O
water	B-T059
soluble	I-T059
carbohydrate	I-T059
,	O
and	O
DE	O
concentrations	O
and	O
N	O
digestibility	O
were	O
also	O
used	O
to	O
predict	O
N	O
outputs	O
because	O
N	O
intake	O
may	O
not	O
be	O
available	O
in	O
commercial	O
practice	O
.	O
The	O
prediction	O
equations	O
for	O
N	O
utilizatio	O
n	O
efficiency	O
indicated	O
that	O
increasing	O
feeding	O
level	O
and	O
ME	O
concentration	O
and	O
reducing	O
N	B-T033
concentration	I-T033
could	O
improve	B-T033
N	O
utilization	O
efficiency	O
and	O
shift	O
N	O
excretion	O
into	O
feces	O
rather	B-T033
than	I-T033
urine	O
(	O
<	O
0.001	O
)	O
.	O
The	O
equations	O
developed	O
in	O
the	O
current	O
study	O
provide	O
an	O
approach	O
for	O
sheep	O
producers	O
to	O
quantify	O
N	O
excretion	O
against	O
production	O
and	O
,	O
consequently	O
,	O
to	O
develop	O
their	O
own	O
mitigation	O
strategies	O
to	O
reduce	O
the	O
environmental	O
impact	O
of	O
sheep	O
production	O
systems	O
.	O
      
DRG1	O
is	O
a	O
potential	O
oncogene	O
in	O
lung	B-T191
adenocarcinoma	I-T191
and	O
promotes	O
tumor	B-T191
progression	I-T191
via	O
spindle	O
checkpoint	O
signaling	O
regulation	O
Developmentally	O
regulated	O
GTP	O
binding	O
protein	O
1	O
(	O
DRG1	O
)	O
,	O
a	O
member	O
of	O
the	O
DRG	O
family	O
,	O
plays	O
important	O
roles	O
in	O
regulating	O
cell	O
growth	O
.	O
However	O
,	O
the	O
molecular	O
basis	O
of	O
DRG1	O
in	O
cell	O
proliferation	O
regulation	O
and	O
the	O
relationship	O
between	O
DRG1	O
and	O
tumor	B-T191
progression	I-T191
remain	O
poorly	O
understood	O
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
DRG1	O
is	O
elevated	O
in	O
lung	B-T191
adenocarcinomas	I-T191
while	O
weakly	O
expressed	O
in	O
adjacent	O
lung	B-T023
tissues	O
.	O
DRG1	O
knockdown	O
causes	O
growth	O
inhibition	O
of	O
tumor	O
cells	O
by	O
significantly	O
increasing	O
the	O
proportion	O
of	O
cells	O
in	O
M	O
phase	O
.	O
Overexpression	O
of	O
DRG1	O
leads	O
to	O
chromosome	O
missegregation	O
which	O
is	O
an	O
important	O
index	O
for	O
tumorigenesis	B-T191
.	O
Interestingly	O
,	O
ectopic	O
of	O
DRG1	O
reduces	O
taxol	B-T121
induced	O
apoptosis	O
of	O
lung	B-T191
adenocarcinoma	I-T191
cells	O
.	O
Mechanistic	O
analyses	O
confirm	O
that	O
DRG1	O
localizes	O
at	O
mitotic	O
spindles	O
in	O
dividing	O
cells	O
and	O
binds	O
to	O
spindle	O
checkpoint	O
signaling	O
proteins	O
in	O
vivo	O
.	O
These	O
studies	O
highlight	O
the	O
expanding	O
role	O
of	O
DRG1	O
in	O
tumorigenesis	B-T191
and	O
reveal	O
a	O
mechanism	O
of	O
DRG1	O
in	O
taxol	B-T121
resistance	O
.	O
      
Influence	O
of	O
Different	O
Levels	O
of	O
Lipoic	O
Acid	O
Synthase	O
Gene	O
Expression	O
on	O
Diabetic	B-T047
Nephropathy	I-T047
Oxidative	O
stress	O
is	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
diabetic	B-T047
nephropathy	I-T047
(	O
DN	B-T047
)	O
but	O
outcomes	O
of	O
many	O
clinical	O
trials	O
are	O
controversial	O
.	O
To	O
define	O
the	O
role	O
of	O
antioxidants	B-T121
in	O
kidney	B-T023
protection	O
during	O
the	O
development	O
of	O
diabetic	B-T047
nephropathy	I-T047
,	O
we	O
have	O
generated	O
a	O
novel	O
genetic	B-T050
antioxidant	I-T050
mouse	I-T050
model	I-T050
with	O
over-	O
or	O
under	O
-	O
expression	O
of	O
lipoic	O
acid	O
synthase	O
gene	O
(	O
Lias	O
)	O
.	O
These	O
models	B-T050
have	O
been	O
mated	O
with	O
Ins2Akita/+	O
mice	O
,	O
a	O
type	B-T047
I	I-T047
diabetic	I-T047
mouse	B-T050
model	I-T050
.	O
We	O
compare	O
the	O
major	O
pathologic	O
changes	O
and	O
oxidative	O
stress	O
status	O
in	O
two	O
new	O
strains	O
of	O
the	O
mice	O
with	O
controls	O
.	O
Our	O
results	O
show	O
that	O
Ins2Akita/+	O
mice	O
with	O
under	O
-	O
expressed	O
Lias	O
gene	O
,	O
exhibit	O
higher	O
oxidative	O
stress	O
and	O
more	O
severe	O
DN	B-T047
features	O
(	O
albuminuria	B-T033
,	O
glomerular	B-T033
basement	I-T033
membrane	I-T033
thickening	I-T033
and	O
mesangial	B-T033
matrix	I-T033
expansion	I-T033
)	O
.	O
In	O
contrast	O
,	O
Ins2Akita/+	O
mice	O
with	O
highly	O
-	O
expressed	O
Lias	O
gene	O
display	O
lower	O
oxidative	O
stress	O
and	O
less	O
DN	B-T047
pathologic	O
changes	O
.	O
Our	O
study	O
demonstrates	O
that	O
strengthening	O
endogenous	O
antioxidant	B-T121
capacity	O
could	O
be	O
an	O
effective	O
strategy	O
for	O
prevention	O
and	O
treatment	O
of	O
DN	B-T047
.	O
      
Alcohol	B-T058
brief	I-T058
intervention	I-T058
in	O
primary	B-T058
care	I-T058
:	O
Blood	O
pressure	O
outcomes	B-T033
in	O
hypertensive	B-T047
patients	O
In	O
clinical	O
trials	O
alcohol	B-T058
brief	I-T058
intervention	I-T058
(	O
BI	B-T058
)	O
in	O
adult	O
primary	B-T058
care	I-T058
has	O
been	O
efficacious	O
in	O
reducing	O
alcohol	O
consumption	O
,	O
but	O
we	O
know	O
little	O
about	O
its	O
impact	O
on	O
health	O
outcomes	O
.	O
Hypertension	B-T047
is	O
a	O
prevalent	O
and	O
costly	O
chronic	B-T033
condition	I-T033
in	O
the	O
U.S.	O
and	O
worldwide	O
,	O
and	O
alcohol	O
use	O
is	O
a	O
modifiable	O
hypertension	B-T047
risk	B-T033
factor	I-T033
.	O
To	O
evaluate	O
the	O
effect	O
of	O
receiving	O
BI	B-T058
for	O
unhealthy	O
drinking	O
on	O
blood	O
pressure	O
(	O
BP	O
)	O
control	O
among	O
adult	O
hypertensive	B-T047
patients	O
by	O
analyzing	O
secondary	O
data	O
from	O
a	O
clustered	O
,	O
randomized	O
controlled	O
trial	O
on	O
alcohol	B-T058
screening	I-T058
,	O
brief	B-T058
intervention	I-T058
and	O
referral	O
to	O
treatment	O
(	O
SBIRT	B-T058
)	O
implementation	O
by	O
primary	O
care	O
physicians	O
(	O
PCP	O
intervention	O
arm	O
)	O
and	O
non	O
-	O
physician	O
providers	O
and	O
medical	O
assistants	O
(	O
NPP	O
&	O
MA	O
intervention	O
arm	O
)	O
in	O
a	O
large	O
,	O
integrated	O
health	O
care	O
delivery	O
system	O
.	O
Observational	O
,	O
prospective	O
cohort	O
study	O
.	O
3811	O
adult	O
hypertensive	B-T047
primary	O
care	O
patients	O
screening	B-T058
positive	O
for	O
past	O
-	O
year	O
heavy	B-T048
drinking	I-T048
at	O
baseline	O
,	O
of	O
which	O
1422	O
(	O
37	O
%	O
)	O
had	O
an	O
electronic	O
health	O
record	O
BP	O
measure	O
at	O
baseline	O
and	O
18	O
-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
.	O
Change	B-T033
in	I-T033
BP	I-T033
and	O
controlled	O
BP	O
(	O
systolic	O
/	O
diastolic	O
BP	O
<	O
140/90	O
mmHg	O
)	O
.	O
Overall	O
no	O
significant	O
associations	O
were	O
found	O
between	O
alcohol	B-T058
BI	I-T058
and	O
BP	B-T033
change	I-T033
at	O
18	O
-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
when	O
analyzing	O
the	O
combined	O
sample	O
of	O
subjects	O
in	O
both	O
intervention	O
arms	O
.	O
However	O
,	O
moderation	O
analyses	O
found	O
that	O
receiving	O
BI	B-T058
for	O
positive	O
past	O
-	O
year	O
unhealthy	O
drinking	O
was	O
positively	O
associated	O
with	O
better	O
BP	O
control	O
at	O
18months	O
in	O
the	O
PCP	O
intervention	O
arm	O
,	O
and	O
for	O
those	O
with	O
lower	O
heavy	B-T048
drinking	I-T048
frequency	O
and	O
poor	O
BP	O
control	O
at	O
the	O
index	B-T058
screening	I-T058
.	O
Our	O
findings	O
suggest	O
that	O
hypertensive	B-T047
patients	O
may	O
benefit	O
from	O
receiving	O
physician	O
brief	B-T058
intervention	I-T058
for	O
unhealthy	O
alcohol	O
use	O
in	O
primary	B-T058
care	I-T058
.	O
Findings	O
also	O
highlight	O
potential	O
population	O
-	O
level	O
benefits	O
of	O
alcohol	B-T058
BI	I-T058
if	O
widely	O
applied	O
,	O
suggesting	O
a	O
need	O
for	O
the	O
development	O
of	O
innovative	O
strategies	O
to	O
facilitate	O
SBIRT	B-T058
delivery	I-T058
in	O
primary	B-T058
care	I-T058
settings	O
.	O
      
Pharmacological	O
Actions	O
of	O
Glucagon	O
-	O
Like	O
Peptide-1	O
,	O
Gastric	B-T121
Inhibitory	I-T121
Polypeptide	I-T121
,	O
and	O
Glucagon	B-T121
Glucagon	B-T121
family	I-T121
of	O
peptide	O
hormones	O
is	O
a	O
group	O
of	O
structurally	O
related	O
brain	O
-	O
gut	O
peptides	O
that	O
exert	O
their	O
pleiotropic	O
actions	O
through	O
interactions	O
with	O
unique	O
members	O
of	O
class	O
B1	O
G	O
protein	O
-	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
.	O
They	O
are	O
key	O
regulators	O
of	O
hormonal	O
homeostasis	O
and	O
are	O
important	O
drug	O
targets	O
for	O
metabolic	B-T047
disorders	I-T047
such	O
as	O
type-2	B-T047
diabetes	I-T047
mellitus	I-T047
(	O
T2DM	B-T047
)	O
,	O
obesity	B-T047
,	O
and	O
dysregulations	B-T047
of	I-T047
the	I-T047
nervous	I-T047
systems	I-T047
such	O
as	O
migraine	B-T047
,	O
anxiety	B-T048
,	O
depression	B-T048
,	O
neurodegeneration	O
,	O
psychiatric	B-T048
disorders	I-T048
,	O
and	O
cardiovascular	B-T047
diseases	I-T047
.	O
The	O
current	O
review	O
aims	O
to	O
provide	O
a	O
detailed	O
overview	O
of	O
the	O
current	O
understanding	O
of	O
the	O
pharmacological	O
actions	O
and	O
therapeutic	B-T061
advances	I-T061
of	O
three	O
members	O
within	O
this	O
family	O
including	O
glucagon	O
-	O
like	O
peptide-1	O
(	O
GLP-1	O
)	O
,	O
gastric	B-T121
inhibitory	I-T121
polypeptide	I-T121
(	O
GIP	B-T121
)	O
,	O
and	O
glucagon	B-T121
.	O
      
Fairness	O
:	O
the	O
hidden	O
challenge	B-T058
for	O
competency	O
-	O
based	O
postgraduate	O
medical	O
education	O
programs	O
Competency	O
-	O
based	O
medical	O
education	O
systems	O
allow	O
institutions	O
to	O
individualize	O
teaching	O
practices	O
to	O
meet	O
the	O
needs	O
of	O
diverse	O
learners	O
.	O
Yet	O
,	O
the	O
focus	O
on	O
continuous	O
improvement	O
and	O
individualization	O
of	O
curricula	O
does	O
not	O
exempt	O
programs	O
from	O
treating	O
learners	O
in	O
a	O
fair	B-T033
manner	I-T033
.	O
When	O
learners	O
fail	O
to	O
meet	O
key	O
competencies	O
and	O
are	O
placed	O
on	O
probation	O
or	O
dismissed	O
from	O
training	O
programs	O
,	O
issues	B-T033
of	O
fairness	O
may	O
form	O
the	O
basis	O
of	O
their	O
legal	O
claims	O
.	O
In	O
a	O
literature	O
search	O
,	O
we	O
found	O
no	O
in	O
-	O
depth	O
examination	O
of	O
fairness	O
.	O
In	O
this	O
paper	O
,	O
we	O
utilize	O
a	O
systems	O
lens	O
to	O
examine	B-T033
fairness	O
within	O
postgraduate	O
medical	O
education	O
contexts	O
,	O
focusing	O
on	O
educational	B-T033
opportunities	I-T033
,	O
assessment	B-T058
practices	I-T058
,	O
decision	O
-	O
making	O
processes	O
,	O
fairness	O
from	O
a	O
legal	O
standpoint	O
,	O
and	O
fairness	O
in	O
the	O
context	O
of	O
the	O
learning	O
environment	O
.	O
While	O
we	O
provide	O
examples	O
of	O
fairness	O
issues	B-T033
within	O
US	O
training	O
programs	O
,	O
concerns	O
regarding	O
fairness	O
are	O
relevant	O
in	O
any	O
medical	O
education	O
system	O
which	O
utilizes	O
a	O
competency	O
-	O
based	O
education	O
framework	O
.	O
Assessment	O
oversight	O
committees	O
and	O
annual	O
programmatic	O
evaluations	O
,	O
while	O
recommended	O
,	O
will	O
not	O
guarantee	O
fairness	O
within	O
postgraduate	O
medical	O
education	O
programs	O
,	O
but	O
they	O
can	O
provide	O
a	O
window	O
into	O
'	O
hidden	O
'	O
threats	O
to	O
fairness	O
,	O
as	O
everything	O
from	O
training	O
experiences	O
to	O
assessment	B-T058
practices	I-T058
may	O
be	O
examined	B-T033
by	O
these	O
committees	O
.	O
One	O
of	O
the	O
first	O
steps	O
programs	O
can	O
take	O
is	O
to	O
recognize	O
that	O
threats	O
to	O
fairness	O
may	O
exist	O
in	O
any	O
educational	O
program	O
,	O
including	O
their	O
own	O
,	O
and	O
begin	O
conversations	O
about	O
how	O
to	O
address	O
these	O
issues	B-T033
.	O
      
Mesenchymal	O
stromal	O
cells	O
in	O
clinical	O
kidney	B-T061
transplantation	I-T061
:	O
how	O
tolerant	O
can	O
it	O
be	O
?	O
Progress	O
in	O
the	O
improvement	O
of	O
short	O
-	O
term	O
and	O
long	O
-	O
term	O
outcomes	O
of	O
kidney	B-T061
transplantation	I-T061
seems	O
to	O
have	O
reached	O
a	O
plateau	O
,	O
partially	O
due	O
to	O
consequences	O
of	O
very	O
efficient	O
,	O
but	O
nonspecific	O
immunosuppressive	B-T121
drugs	I-T121
.	O
In	O
recent	O
years	O
,	O
various	O
forms	O
of	O
cell	B-T061
therapy	I-T061
,	O
including	O
the	O
use	O
of	O
mesenchymal	O
stromal	O
cells	O
,	O
have	O
been	O
put	O
forward	O
as	O
an	O
alternative	O
strategy	O
for	O
more	O
defined	O
therapy	B-T061
.	O
It	O
is	O
thought	O
that	O
these	O
therapies	B-T061
will	O
not	O
only	O
allow	O
controlled	O
tapering	B-T058
of	O
immunosuppressive	B-T121
medication	I-T121
,	O
but	O
might	O
bring	O
us	O
also	O
closer	O
to	O
the	O
ambition	O
of	O
generating	O
donor	O
-specific	O
immune	O
regulation	O
and	O
tolerance	O
.	O
Different	O
forms	O
of	O
alloimmunity	O
,	O
including	O
direct	O
,	O
indirect	O
and	O
semi	O
-	O
direct	O
alloantigen	O
presentation	O
have	O
to	O
be	O
controlled	O
before	O
donor	O
-specific	O
immune	O
regulation	O
can	O
be	O
reached	O
.	O
Several	O
mechanisms	O
have	O
been	O
described	O
how	O
mesenchymal	O
stromal	O
cells	O
can	O
affect	O
alloimmunity	O
.	O
Especially	O
,	O
the	O
interaction	O
with	O
professional	O
antigen	O
presenting	O
cells	O
,	O
like	O
dendritic	O
cells	O
,	O
is	O
of	O
critical	O
importance	O
.	O
This	O
review	O
will	O
discuss	O
the	O
current	O
status	O
of	O
ongoing	O
clinical	O
trials	O
with	O
mesenchymal	O
stromal	O
cells	O
in	O
kidney	B-T061
transplantation	I-T061
and	O
specifically	O
concentrate	O
on	O
the	O
possibilities	O
and	O
impossibilities	O
of	O
how	O
these	O
therapeutic	B-T061
strategies	I-T061
can	O
contribute	O
to	O
control	O
of	O
the	O
different	O
forms	O
of	O
alloreactivity	O
operation	O
in	O
organ	B-T061
transplantation	I-T061
.	O
      
Total	O
Arsenic	B-T121
,	O
Cadmium	O
,	O
and	O
Lead	O
Determination	B-T059
in	O
Brazilian	O
Rice	O
Samples	O
Using	O
ICP	B-T059
-	I-T059
MS	I-T059
This	O
study	O
is	O
aimed	O
at	O
investigating	O
a	O
suitable	O
method	O
for	O
rice	O
sample	O
preparation	O
as	O
well	O
as	O
validating	O
and	O
applying	O
the	O
method	O
for	O
monitoring	O
the	O
concentration	O
of	O
total	O
arsenic	B-T121
,	O
cadmium	O
,	O
and	O
lead	O
in	O
rice	O
by	O
using	O
Inductively	B-T059
Coupled	I-T059
Plasma	I-T059
Mass	I-T059
Spectrometry	I-T059
(	O
ICP	B-T059
-	I-T059
MS	I-T059
)	O
.	O
Various	O
rice	O
sample	O
preparation	O
procedures	O
were	O
evaluated	O
.	O
The	O
analytical	O
method	O
was	O
validated	O
by	O
measuring	O
several	O
parameters	B-T033
including	O
limit	O
of	O
detection	O
(	O
LOD	O
)	O
,	O
limit	O
of	O
quantification	O
(	O
LOQ	O
)	O
,	O
linearity	O
,	O
relative	O
bias	O
,	O
and	O
repeatability	O
.	O
Regarding	O
the	O
sample	O
preparation	O
,	O
recoveries	B-T033
of	O
spiked	O
samples	O
were	O
within	O
the	O
acceptable	O
range	O
from	O
89.3	O
to	O
98.2	O
%	O
for	O
muffle	O
furnace	O
,	O
94.2	O
to	O
103.3	O
%	O
for	O
heating	O
block	O
,	O
81.0	O
to	O
115.0	O
%	O
for	O
hot	O
plate	O
,	O
and	O
92.8	O
to	O
108.2	O
%	O
for	O
microwave	O
.	O
Validation	O
parameters	B-T033
showed	O
that	O
the	O
method	O
fits	O
for	O
its	O
purpose	O
,	O
being	O
the	O
total	O
arsenic	B-T121
,	O
cadmium	O
,	O
and	O
lead	O
within	O
the	O
Brazilian	O
Legislation	O
limits	O
.	O
The	O
method	O
was	O
applied	O
for	O
analyzing	O
37	O
rice	O
samples	O
(	O
including	O
polished	O
,	O
brown	O
,	O
and	O
parboiled	O
)	O
,	O
consumed	O
by	O
the	O
Brazilian	O
population	O
.	O
The	O
total	O
arsenic	B-T121
,	O
cadmium	O
,	O
and	O
lead	O
contents	O
were	O
lower	O
than	O
the	O
established	O
legislative	O
values	O
,	O
except	O
for	O
total	O
arsenic	B-T121
in	O
one	O
brown	O
rice	O
sample	O
.	O
This	O
study	O
indicated	O
the	O
need	O
to	O
establish	O
monitoring	O
programs	O
for	O
emphasizing	O
the	O
study	O
on	O
this	O
type	O
of	O
cereal	O
,	O
aiming	O
at	O
promoting	O
the	O
Public	O
Health	O
.	O
      
Meta	O
-	O
Analysis	O
of	O
29	O
Experiments	O
Evaluating	B-T058
the	O
Effects	O
of	O
Rapamycin	B-T195
on	O
Life	O
Span	O
in	O
the	O
Laboratory	O
Mouse	O
Rapamycin	B-T195
has	O
favorable	O
effects	O
on	O
aging	O
in	O
mice	O
and	O
may	O
eventually	O
be	O
applied	O
to	O
encourage	O
"	O
healthy	O
aging	O
"	O
in	O
humans	O
.	O
This	O
study	O
analyzed	O
raw	O
data	O
from	O
29	O
survival	O
studies	O
of	O
rapamycin	B-T195
-	O
and	O
control	O
-	O
treated	O
mice	O
,	O
with	O
the	O
goals	O
of	O
estimating	O
summary	O
statistics	O
and	O
identifying	O
factors	O
associated	O
with	O
effect	O
size	O
heterogeneity	O
.	O
Meta	O
-	O
analysis	O
demonstrated	O
significant	O
heterogeneity	O
across	O
studies	B-T059
,	O
with	O
hazard	O
ratio	O
(	O
HR	O
)	O
estimates	O
ranging	O
from	O
0.22	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
0.06	O
-	O
0.82	O
)	O
to	O
0.92	O
(	O
95	O
%	O
CI	O
:	O
0.65	O
-	O
1.28	O
)	O
.	O
Sex	O
was	O
the	O
major	O
factor	O
accounting	O
for	O
effect	O
size	O
variation	O
,	O
and	O
mortality	O
was	O
decreased	O
more	O
in	O
females	O
(	O
HR	O
=	O
0.41	O
;	O
95	O
%	O
CI	O
:	O
0.35	O
-	O
0.48	O
)	O
as	O
compared	O
with	O
males	O
(	O
HR	O
=	O
0.63	O
;	O
95	O
%	O
CI	O
:	O
0.55	O
-	O
0.71	O
)	O
.	O
Rapamycin	B-T195
effects	O
were	O
also	O
genotype	O
dependent	O
,	O
however	O
,	O
with	O
stronger	O
survivorship	O
increases	O
in	O
hybrid	B-T001
mice	O
(	O
14.4	O
%	O
;	O
95	O
%	O
CI	O
:	O
12.5	O
-	O
16.3	O
%	O
)	O
relative	O
to	O
pure	B-T001
inbred	O
strains	O
(	O
8.8	O
%	O
;	O
95	O
%	O
CI	O
:	O
6.2	O
-	O
11.6	O
%	O
)	O
.	O
Number	O
needed	O
to	O
treat	O
was	O
applied	O
as	O
an	O
effect	O
size	O
metric	O
,	O
which	O
consistently	O
identified	O
early	O
senescence	B-T033
as	O
the	O
age	O
of	O
peak	O
treatment	O
benefit	O
.	O
These	O
results	O
provide	O
synthesis	O
of	O
existing	O
data	O
to	O
support	O
the	O
potential	O
translation	O
of	O
findings	B-T033
from	O
mouse	O
to	O
primate	O
species	O
.	O
Because	O
rapamycin	B-T195
's	I-T195
effect	O
on	O
survival	O
depends	O
on	O
sex	O
and	O
genotype	O
,	O
further	O
work	O
is	O
justified	O
to	O
understand	O
how	O
these	O
factors	O
shape	O
treatment	O
response	O
.	O
      
Inhibition	O
of	O
STEP61	O
ameliorates	O
deficits	O
in	O
mouse	O
and	O
hiPSC	O
-based	O
schizophrenia	B-T048
models	B-T050
The	O
brain	B-T023
-	O
specific	O
tyrosine	O
phosphatase	O
,	O
STEP	O
(	O
STriatal	O
-	O
Enriched	O
protein	O
tyrosine	O
Phosphatase	O
)	O
is	O
an	O
important	O
regulator	O
of	O
synaptic	O
function	O
.	O
STEP	O
normally	O
opposes	O
synaptic	O
strengthening	O
by	O
increasing	O
N	O
-	O
methyl	O
D	O
-	O
aspartate	O
glutamate	O
receptor	O
(	O
NMDAR	O
)	O
internalization	O
through	O
dephosphorylation	O
of	O
GluN2B	O
and	O
inactivation	O
of	O
the	O
kinases	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
1	O
/	O
2	O
and	O
Fyn	O
.	O
Here	O
we	O
show	O
that	O
STEP61	O
is	O
elevated	O
in	O
the	O
cortex	B-T023
in	O
the	O
Nrg1(+/-	O
)	O
knockout	B-T050
mouse	B-T050
model	I-T050
of	O
schizophrenia	B-T048
(	O
SZ	B-T048
)	O
.	O
Genetic	O
reduction	B-T061
or	O
pharmacological	O
inhibition	O
of	O
STEP	O
prevents	O
the	O
loss	O
of	O
NMDARs	O
from	O
synaptic	O
membranes	O
and	O
reverses	O
behavioral	B-T048
deficits	I-T048
in	O
Nrg1(+/-	O
)	O
mice	O
.	O
STEP61	O
protein	O
is	O
also	O
increased	O
in	O
cortical	B-T023
lysates	O
from	O
the	O
central	O
nervous	O
system	O
-	O
specific	O
ErbB2	O
/	O
4	O
mouse	B-T050
model	I-T050
of	O
SZ	B-T048
,	O
as	O
well	O
as	O
in	O
human	O
induced	O
pluripotent	O
stem	O
cell	O
(	O
hiPSC)-derived	O
forebrain	B-T023
neurons	O
and	O
Ngn2	O
-	O
induced	O
excitatory	O
neurons	O
,	O
from	O
two	O
independent	O
SZ	B-T048
patient	O
cohorts	O
.	O
In	O
these	O
selected	O
SZ	B-T048
models	B-T050
,	O
increased	O
STEP61	O
protein	B-T059
levels	I-T059
likely	O
reflect	O
reduced	O
ubiquitination	O
and	O
degradation	O
.	O
These	O
convergent	O
findings	B-T033
from	O
mouse	O
and	O
hiPSC	O
SZ	B-T048
models	B-T050
provide	O
evidence	O
for	O
STEP61	O
dysfunction	O
in	O
SZ	B-T048
.Molecular	O
Psychiatry	O
advance	O
online	O
publication	O
,	O
18	O
October	O
2016	O
;	O
doi:10.1038	O
/	O
mp.2016.163	O
.	O
      
The	O
Maternal	B-T033
Legacy	O
:	O
Female	O
Identity	O
Predicts	O
Offspring	O
Sex	O
Ratio	O
in	O
the	O
Loggerhead	O
Sea	O
Turtle	O
In	O
organisms	B-T001
with	O
temperature	O
-	O
dependent	O
sex	O
determination	O
,	O
the	O
incubation	O
environment	O
plays	O
a	O
key	O
role	O
in	O
determining	O
offspring	O
sex	O
ratios	O
.	O
Given	O
that	O
global	O
temperatures	O
have	O
warmed	O
approximately	O
0.6	O
°	O
C	O
in	O
the	O
last	O
century	O
,	O
it	O
is	O
necessary	O
to	O
consider	O
how	O
organisms	B-T001
will	O
adjust	B-T033
to	O
climate	O
change	O
.	O
To	O
better	O
understand	O
the	O
degree	O
to	O
which	O
mothers	O
influence	O
the	O
sex	O
ratios	O
of	O
their	O
offspring	O
,	O
we	O
use	O
24	O
years	O
of	O
nesting	O
data	O
for	O
individual	O
female	O
loggerhead	O
sea	O
turtles	O
(	O
Caretta	O
caretta	O
)	O
observed	O
on	O
Bald	O
Head	O
Island	O
,	O
North	O
Carolina	O
.	O
We	O
find	O
that	O
maternal	B-T033
identity	O
is	O
the	O
best	O
predictor	O
of	O
nest	O
sex	O
ratio	O
in	O
univariate	O
and	O
multivariate	O
predictive	O
models	O
.	O
We	O
find	O
significant	O
variability	O
in	O
estimated	O
nest	O
sex	O
ratios	O
among	O
mothers	O
,	O
but	O
a	O
high	O
degree	O
of	O
consistency	O
within	O
mothers	O
,	O
despite	O
substantial	O
spatial	O
and	O
temporal	O
thermal	O
variation	O
.	O
Our	O
results	O
suggest	O
that	O
individual	O
differences	O
in	O
nesting	O
preferences	O
are	O
the	O
main	O
driver	O
behind	O
divergences	O
in	O
nest	O
sex	O
ratios	O
.	O
As	O
such	O
,	O
a	O
female	O
's	O
ability	O
to	O
plastically	O
adjust	O
her	O
nest	O
sex	O
ratios	O
in	O
response	O
to	O
environmental	O
conditions	O
is	O
constrained	O
,	O
potentially	O
limiting	O
how	O
individuals	O
behaviorally	O
mitigate	O
the	O
effects	O
of	O
environmental	B-T033
change	I-T033
.	O
Given	O
that	O
many	O
loggerhead	O
populations	O
already	O
show	O
female	O
-	O
biased	O
offspring	O
sex	O
ratios	O
,	O
understanding	O
maternal	O
behavioral	O
responses	O
is	O
critical	O
for	O
predicting	O
the	O
future	O
of	O
long	O
-	O
lived	O
species	O
vulnerable	O
to	O
extinction	O
.	O
      
Using	O
melanopsin	O
to	O
study	O
G	O
protein	O
signaling	O
in	O
cortical	B-T023
neurons	O
Our	O
understanding	O
of	O
G	O
protein	O
-	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
has	O
been	O
hampered	O
by	O
the	O
limited	O
availability	O
of	O
tools	O
allowing	O
for	O
the	O
study	O
of	O
their	O
signaling	O
with	O
precise	O
temporal	O
control	O
.	O
To	O
overcome	O
this	O
,	O
we	O
tested	O
the	O
utility	O
of	O
the	O
bistable	O
mammalian	O
opsin	O
melanopsin	O
to	O
examine	O
G	O
protein	O
signaling	O
in	O
CNS	O
neurons	O
.	O
Specifically	O
,	O
we	O
used	O
biolistic	O
(	O
gene	O
gun	O
)	O
approaches	O
to	O
transfect	O
melanopsin	O
into	O
cortical	B-T023
pyramidal	O
cells	O
maintained	O
in	O
organotypic	B-T059
slice	I-T059
culture	I-T059
.	O
Whole	O
cell	O
recordings	O
from	O
transfected	O
neurons	O
indicated	O
that	O
application	O
of	O
blue	O
light	O
effectively	O
activated	O
the	O
transfected	O
melanopsin	O
to	O
elicit	O
the	O
canonical	O
biphasic	O
modulation	O
of	O
membrane	O
excitability	B-T184
previously	O
associated	O
with	O
the	O
activation	O
of	O
GPCRs	O
coupling	O
to	O
Gαq-11	O
Remarkably	O
,	O
full	O
mimicry	O
of	O
exogenous	O
agonist	B-T121
concentration	O
could	O
be	O
obtained	O
with	O
pulses	O
as	O
short	O
as	O
a	O
few	O
milliseconds	O
,	O
suggesting	O
that	O
their	O
triggering	O
required	O
a	O
single	O
melanopsin	O
activation	O
-	O
deactivation	O
cycle	O
.	O
The	O
resulting	O
temporal	O
control	O
over	O
melanopsin	O
activation	O
allowed	O
us	O
to	O
compare	O
the	O
activation	O
kinetics	O
of	O
different	O
components	O
of	O
the	O
electrophysiological	O
response	O
.	O
We	O
also	O
replaced	O
the	O
intracellular	O
loops	O
of	O
melanopsin	O
with	O
those	O
of	O
the	O
5	O
-	O
HT2A	O
receptor	O
to	O
create	O
a	O
light	O
-	O
activated	O
GPCR	O
capable	O
of	O
interacting	O
with	O
the	O
5	O
-	O
HT2A	O
receptor	O
interacting	O
proteins	O
.	O
The	O
resulting	O
chimera	O
expressed	O
weak	O
activity	O
but	O
validated	O
the	O
potential	O
usefulness	O
of	O
melanopsin	O
as	O
a	O
tool	O
for	O
the	O
study	O
of	O
G	O
protein	O
signaling	O
in	O
CNS	O
neurons	O
.	O
      
Laceration	O
of	O
a	O
branch	O
of	O
the	O
profunda	B-T023
femoris	I-T023
artery	I-T023
caused	O
by	O
a	O
spike	B-T033
of	O
the	O
displaced	O
lesser	B-T023
trochanter	I-T023
in	O
an	O
inter	O
-	O
trochanteric	O
femoral	O
fracture	O
.	O
A	O
case	O
report	O
Injury	O
of	O
femoral	B-T023
vessels	I-T023
is	O
an	O
extremely	O
rare	O
complication	O
in	O
intertrochanteric	O
femoral	O
fractures	O
.	O
In	O
most	O
cases	O
reported	B-T058
,	O
the	O
vascular	B-T047
lesion	I-T047
involves	O
the	O
superficial	B-T023
femoral	I-T023
artery	I-T023
,	O
whereas	O
in	O
very	O
few	O
cases	O
does	O
it	O
involve	O
the	O
profunda	B-T023
femoris	I-T023
artery	I-T023
.	O
We	O
report	O
a	O
case	O
of	O
acute	O
bleeding	O
due	O
to	O
laceration	O
of	O
a	O
perforating	B-T033
branch	O
of	O
the	O
profunda	B-T023
femoris	I-T023
artery	I-T023
caused	O
by	O
a	O
sharp	B-T033
fragment	O
of	O
the	O
displaced	O
lesser	B-T023
trochanter	I-T023
in	O
an	O
intertrochanteric	O
femoral	O
fracture	O
;	O
the	O
lesion	B-T033
was	O
treated	O
by	O
transcatheter	B-T061
embolization	I-T061
.	O
The	O
arterial	O
injury	O
may	O
be	O
iatrogenic	O
,	O
occurring	O
during	O
intramedullary	O
internal	B-T061
fixation	I-T061
,	O
or	O
less	O
frequently	O
,	O
the	O
injury	O
may	O
be	O
due	O
to	O
the	O
fracture	O
itself	O
,	O
caused	O
by	O
a	O
sharp	B-T033
bone	O
fragment	O
that	O
damages	O
the	O
profunda	B-T023
femoris	I-T023
artery	I-T023
or	O
one	O
of	O
its	O
perforating	B-T033
branches	O
.	O
We	O
believe	O
that	O
intertrochanteric	O
femoral	O
fractures	O
with	O
avulsed	O
lesser	B-T023
trochanter	I-T023
are	O
at	O
risk	O
for	O
femoral	B-T023
vessel	I-T023
injuries	O
caused	O
by	O
the	O
displaced	O
bone	B-T023
spike	B-T033
,	O
and	O
we	O
advise	O
meticulous	O
clinical	O
and	O
laboratory	B-T058
monitoring	I-T058
pre-	O
and	O
post	O
-	O
operatively	O
to	O
prevent	B-T061
serious	I-T061
complications	I-T061
.	O
      
Percutaneous	B-T061
coronary	I-T061
intervention	I-T061
and	O
heart	B-T061
surgery	I-T061
learning	O
needs	O
of	O
patients	O
in	O
Jordan	O
This	O
study	O
aimed	O
to	O
identify	O
and	O
prioritize	O
the	O
perceived	O
learning	O
needs	O
of	O
patients	O
who	O
underwent	O
percutaneous	B-T061
coronary	I-T061
intervention	I-T061
or	O
open	B-T061
-	I-T061
heart	I-T061
surgery	I-T061
.	O
Identifying	O
learning	O
needs	O
for	O
post	B-T061
-	I-T061
cardiac	I-T061
intervention	I-T061
patients	O
is	O
essential	O
to	O
establish	O
successful	O
health	B-T058
education	I-T058
programmes	I-T058
based	O
on	O
patient	O
central	B-T058
care	I-T058
.	O
A	O
descriptive	O
comparative	O
design	O
was	O
employed	O
on	O
a	O
convenience	O
sample	O
of	O
260	O
patients	O
who	O
underwent	O
a	O
percutaneous	B-T061
coronary	I-T061
intervention	I-T061
and	O
105	O
patients	O
who	O
underwent	O
open	B-T061
-	I-T061
heart	I-T061
surgery	I-T061
patients	O
.	O
Participants	O
had	O
completed	O
the	O
Patient	O
Learning	O
Needs	O
Scale	O
.	O
Data	O
were	O
collected	O
between	O
1	O
October	O
2014	O
and	O
31	O
June	O
2015	O
.	O
Patients	O
from	O
the	O
two	O
groups	O
highly	O
requesting	O
health	B-T058
and	I-T058
recovery	I-T058
related	I-T058
information	I-T058
.	O
They	O
scored	O
all	O
learning	O
need	O
topics	O
as	O
important	O
or	O
highly	O
important	O
for	O
them	O
.	O
The	O
top	O
priority	O
learning	O
need	O
for	O
both	O
patient	O
groups	O
was	O
'	O
information	O
about	O
wound	B-T061
care	I-T061
'	O
,	O
and	O
the	O
lowest	O
priority	O
learning	O
need	O
topic	O
was	O
'	O
physical	O
activity	O
'	O
.	O
The	O
learning	O
needs	O
of	O
both	O
groups	O
were	O
very	O
close	O
,	O
which	O
indicated	O
that	O
educational	O
secondary	O
prevention	O
programmes	O
'	O
content	O
can	O
be	O
prepared	O
in	O
a	O
unified	O
structure	O
for	O
those	O
patients	O
.	O
Although	O
,	O
specific	O
headings	O
can	O
be	O
used	O
to	O
address	O
the	O
unique	O
needs	O
that	O
emerge	O
from	O
having	O
a	O
specific	O
cardiac	B-T023
interventional	B-T061
procedure	I-T061
.	O
The	O
fact	O
that	O
wound	B-T061
care	I-T061
and	O
medications	B-T058
are	O
areas	O
of	O
highest	O
learning	O
needs	O
for	O
patients	O
requires	O
health	O
policy	O
decision	O
makers	O
to	O
address	O
these	O
topics	O
at	O
the	O
time	O
of	O
hospital	B-T058
discharge	I-T058
.	O
In	O
addition	O
,	O
a	O
policy	O
focus	O
on	O
considering	O
patients	O
'	O
actual	O
learning	O
needs	O
requires	O
establishment	O
and	O
managerial	O
support	O
.	O
As	O
patients	O
'	O
learning	O
needs	O
might	O
change	O
later	O
after	O
discharge	B-T058
,	O
the	O
health	B-T058
services	I-T058
should	O
be	O
proactive	O
and	O
focus	O
on	O
continuous	O
support	O
for	O
patients	O
after	O
hospital	B-T058
discharge	I-T058
.	O
Secondary	O
prevention	O
programmes	O
should	O
incorporate	O
health	O
education	O
topics	O
based	O
on	O
patients	O
'	O
own	O
views	O
.	O
This	O
can	O
be	O
done	O
by	O
giving	O
higher	O
priority	O
to	O
understand	O
patients	O
'	O
needs	O
,	O
put	O
much	O
more	O
effort	O
into	O
how	O
to	O
meet	O
patients	O
'	O
information	O
needs	O
and	O
to	O
create	O
a	O
more	O
engaging	O
learning	O
environment	O
for	O
patients	O
and	O
their	O
families	O
.	O
      
Fabrication	O
of	O
gelatin	O
methacrylate	O
/	O
nanohydroxyapatite	O
microgel	O
arrays	O
for	O
periodontal	B-T061
tissue	I-T061
regeneration	I-T061
Periodontitis	B-T047
is	O
a	O
chronic	B-T047
infectious	I-T047
disease	I-T047
and	O
is	O
the	O
major	B-T033
cause	I-T033
of	O
tooth	B-T020
loss	I-T020
and	O
other	O
oral	B-T058
health	I-T058
issues	B-T033
around	O
the	O
world	O
.	O
Periodontal	B-T061
tissue	I-T061
regeneration	I-T061
has	O
therefore	O
always	O
been	O
the	O
ultimate	O
goal	O
of	O
dentists	O
and	O
researchers	O
.	O
Existing	O
fabrication	O
methods	O
mainly	O
focused	O
on	O
a	O
top	B-T061
-	I-T061
down	I-T061
tissue	I-T061
engineering	I-T061
strategy	O
in	O
which	O
several	O
drawbacks	O
remain	B-T033
,	O
including	O
low	O
throughput	O
and	O
limited	O
diffusion	O
properties	O
resulting	O
from	O
a	O
large	O
sample	O
size	O
.	O
Gelatin	O
methacrylate	O
(	O
GelMA	O
)	O
is	O
a	O
kind	O
of	O
photocrosslinkable	O
and	O
biocompatible	O
hydrogel	B-T121
,	O
with	O
the	O
capacities	O
of	O
enabling	O
cell	B-T059
encapsulation	I-T059
and	O
regeneration	O
of	O
functional	O
tissues	O
.	O
Here	O
,	O
we	O
developed	O
a	O
novel	O
method	O
to	O
fabricate	O
GelMA	O
/	O
nanohydroxylapatite	O
(	O
nHA	O
)	O
microgel	O
arrays	O
using	O
a	O
photocrosslinkable	O
strategy	O
.	O
The	O
viability	O
,	O
proliferation	O
,	O
and	O
osteogenic	O
differentiation	O
and	O
in	O
vivo	O
osteogenesis	O
of	O
human	O
periodontal	B-T023
ligament	I-T023
stem	O
cells	O
(	O
hPDLSCs	O
)	O
encapsulated	O
in	O
microgels	O
were	O
evaluated	B-T058
.	O
The	O
results	O
suggested	O
that	O
such	O
microgels	O
provide	O
great	O
potential	O
for	O
periodontal	B-T061
tissue	I-T061
repair	I-T061
and	I-T061
regeneration	I-T061
.	O
Microgel	O
arrays	O
were	O
fabricated	O
by	O
blending	O
different	O
weight	O
ratios	O
of	O
GelMA	O
and	O
nHA	O
.	O
hPDLSCs	O
were	O
encapsulated	O
in	O
GelMA	O
/	O
nHA	O
microgels	O
of	O
various	O
ratios	O
for	O
a	O
systematic	O
evaluation	B-T058
of	O
cell	O
viability	O
,	O
proliferation	O
,	O
and	O
osteogenic	O
differentiation	O
.	O
In	O
vivo	O
osteogenesis	O
in	O
nude	O
mice	O
was	O
also	O
studied	O
.	O
The	O
GelMA	O
/	O
nHA	O
microgels	O
exhibited	O
appropriate	O
microarchitecture	O
,	O
mechanical	O
strength	O
,	O
and	O
surface	O
roughness	O
,	O
thus	O
enabling	O
cell	O
adhesion	O
and	O
proliferation	O
.	O
Additionally	O
,	O
the	O
GelMA	O
/	O
nHA	O
microgels	O
(	O
10%/2	O
%	O
w	O
/	O
v	O
)	O
enhanced	O
the	O
osteogenic	O
differentiation	O
of	O
hPDLSCs	O
by	O
elevating	O
the	O
expression	O
levels	O
of	O
osteogenic	O
biomarker	O
genes	O
,	O
such	O
as	O
ALP	O
,	O
BSP	O
,	O
OCN	O
,	O
and	O
RUNX2	O
.	O
In	O
vivo	O
ectopic	O
transplantation	B-T061
results	O
showed	O
that	O
GelMA	O
/	O
nHA	O
microgels	O
(	O
10%/2	O
%	O
w	O
/	O
v	O
)	O
increased	O
mineralized	O
tissue	O
formation	O
with	O
abundant	O
vascularization	O
,	O
compared	O
with	O
the	O
1	O
%	O
,	O
3	O
%	O
,	O
and	O
the	O
pure	O
GelMA	O
group	O
.	O
The	O
GelMA	O
/	O
nHA	O
microgels	O
(	O
10%/2	O
%	O
w	O
/	O
v	O
)	O
facilitated	O
hPDLSCs	O
viability	O
,	O
proliferation	O
,	O
and	O
osteogenic	O
differentiation	O
in	O
vitro	O
and	O
further	O
promoted	O
new	O
bone	O
formation	O
in	O
vivo	O
,	O
suggesting	O
that	O
the	O
GelMA	O
/	O
nHA	O
microgels	O
(	O
10%/2	O
%	O
w	O
/	O
v	O
)	O
provide	O
great	O
potential	O
for	O
periodontal	B-T061
tissue	I-T061
regeneration	I-T061
.	O
      
Conservation	O
education	O
and	O
habitat	O
restoration	O
for	O
the	O
endangered	O
Sagalla	O
caecilian	O
(	O
Boulengerula	O
niedeni	O
)	O
in	O
Sagalla	O
Hill	O
,	O
Kenya	O
The	O
Sagalla	O
caecilian	O
(	O
Boulengerula	O
niedeni	O
)	O
is	O
an	O
endangered	O
amphibian	O
endemic	O
to	O
Sagalla	O
Hill	O
in	O
the	O
Taita	O
Hills	O
.	O
This	O
burrowing	O
worm	O
-like	O
species	O
prefers	O
soft	O
soil	O
with	O
high	O
moisture	O
and	O
organic	O
matter	O
.	O
The	O
major	O
threats	O
to	O
the	O
Sagalla	O
caecilian	O
are	O
soil	O
erosion	O
caused	O
by	O
steep	O
slopes	O
,	O
bare	O
ground	O
and	O
water	O
siphoning	O
/	O
soil	O
hardening	O
from	O
exotic	O
eucalyptus	O
trees	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
get	O
a	O
better	O
understanding	O
of	O
the	O
local	O
people	O
's	O
attitude	O
towards	O
this	O
species	O
and	O
how	O
they	O
can	O
contribute	O
to	O
its	O
continued	O
conservation	O
through	O
restoration	O
of	O
its	O
remaining	O
habitat	O
.	O
In	O
this	O
study	O
,	O
it	O
was	O
found	B-T033
that	O
96	O
%	O
of	O
Sagalla	O
people	O
are	O
aware	O
of	O
the	O
species	O
,	O
its	O
habits	O
and	O
its	O
association	O
with	O
soils	O
high	O
in	O
organic	O
matter	O
.	O
It	O
was	O
also	O
found	B-T033
that	O
96	O
%	O
of	O
Sagalla	O
people	O
use	O
organic	O
manure	O
from	O
cow	O
dung	O
in	O
their	O
farms	O
.	O
Habitat	O
restoration	O
through	O
planting	O
of	O
indigenous	O
plants	O
was	O
found	B-T033
to	O
be	O
ongoing	O
,	O
especially	O
on	O
compounds	O
of	O
public	O
institutions	O
as	O
well	O
as	O
on	O
private	O
lands	O
.	O
Although	O
drought	O
was	O
found	B-T033
to	O
be	O
a	O
challenge	O
for	O
seedlings	O
development	O
especially	O
on	O
the	O
low	O
elevation	O
sites	O
,	O
destruction	O
by	O
livestock	O
especially	O
during	O
the	O
dry	O
season	O
is	O
also	O
a	O
major	O
threat	O
.	O
In	O
this	O
study	O
,	O
it	O
was	O
recommended	O
that	O
any	O
future	O
habitat	O
restoration	O
initiative	O
should	O
include	O
strong	O
chain	O
-	O
link	O
fencing	O
to	O
protect	O
the	O
seedlings	O
from	O
livestock	O
activity	O
.	O
Recognizing	O
that	O
the	O
preferred	O
habitats	O
for	O
the	O
species	O
are	O
in	O
the	O
valleys	O
,	O
systematic	O
planting	O
of	O
keystone	O
plant	O
species	O
such	O
as	O
fig	O
trees	O
(	O
Ficus	O
)	O
creates	O
the	O
best	O
microhabitats	O
.	O
These	O
are	O
better	O
than	O
general	O
woodlots	O
of	O
indigenous	O
trees	O
.	O
      
Chemical	O
composition	O
and	O
amino	B-T121
acid	I-T121
digestibility	O
of	O
soybean	O
meal	O
produced	O
in	O
the	O
United	O
States	O
,	O
China	O
,	O
Argentina	O
,	O
Brazil	O
,	O
or	O
India	O
An	O
experiment	O
was	O
conducted	O
to	O
compare	O
nutritional	O
composition	O
of	O
soybean	O
meal	O
(	O
SBM	O
)	O
produced	O
in	O
China	O
,	O
Argentina	O
,	O
Brazil	O
,	O
the	O
U.S	O
.	O
,	O
or	O
India	O
and	O
the	O
apparent	O
ileal	O
digestibility	O
(	O
AID	O
)	O
and	O
the	O
standardized	O
ileal	O
digestibility	O
(	O
SID	O
)	O
of	O
CP	O
and	O
AA	B-T121
in	O
these	O
SBM	O
when	O
fed	O
to	O
growing	O
pigs	O
.	O
Five	O
sources	O
of	O
SBM	O
from	O
China	O
,	O
Argentina	O
,	O
Brazil	O
,	O
and	O
the	O
U.S	O
.	O
,	O
and	O
4	O
sources	O
from	O
India	O
were	O
collected	O
for	O
a	O
total	O
of	O
24	O
sources	O
of	O
SBM	O
.	O
All	O
samples	O
were	O
analyzed	O
for	O
energy	O
,	O
DM	O
,	O
and	O
nutrients	O
,	O
and	O
each	O
source	O
was	O
included	O
in	O
a	O
cornstarch	B-T121
based	I-T121
diet	I-T121
in	O
which	O
SBM	O
was	O
the	O
only	O
AA	B-T121
contributing	O
ingredient	O
.	O
An	O
N	O
-	O
free	O
diet	O
was	O
also	O
formulated	O
.	O
Twenty	O
-	O
five	O
barrows	O
(	O
initial	O
BW	O
:	O
30.53	O
±	O
1.73	O
kg	O
)	O
were	O
equipped	O
with	O
a	O
T	O
-	O
cannula	O
in	O
the	O
distal	O
ileum	O
and	O
randomly	O
allotted	O
to	O
a	O
25	O
×	O
8	O
Youden	O
square	O
design	O
with	O
25	O
diets	O
and	O
8	O
periods	O
.	O
Results	O
indicate	O
that	O
the	O
concentration	O
of	O
CP	O
was	O
greater	O
(	O
<	O
0.05	O
)	O
in	O
SBM	O
from	O
Brazil	O
and	O
India	O
(	O
49.3	O
and	O
49.5	O
%	O
,	O
respectively	O
)	O
than	O
in	O
SBM	O
from	O
China	O
,	O
Argentina	O
,	O
or	O
the	O
U.S.	O
(	O
45.1	O
,	O
46.7	O
,	O
and	O
47.3	O
%	O
,	O
respectively	O
,	O
as	O
-	O
fed	O
basis	O
)	O
.	O
The	O
concentration	O
of	O
most	O
indispensable	O
AA	B-T121
followed	O
the	O
same	O
pattern	O
as	O
CP	O
with	O
the	O
exception	O
that	O
SBM	O
from	O
the	O
U.S.	O
contained	O
more	O
(	O
<	O
0.05	O
)	O
indispensable	O
AA	B-T121
than	O
SBM	O
from	O
China	O
or	O
Argentina	O
.	O
However	O
,	O
SBM	O
from	O
India	O
contained	O
more	O
(	O
<	O
0.05	O
)	O
trypsin	B-T121
inhibitors	I-T121
than	O
SBM	O
from	O
the	O
other	O
countries	O
.	O
A	O
greater	O
(	O
<	O
0.05	O
)	O
AID	O
and	O
SID	O
of	O
CP	O
and	O
most	O
AA	B-T121
was	O
observed	O
in	O
SBM	O
from	O
the	O
U.S.	O
compared	O
with	O
SBM	O
from	O
Brazil	O
,	O
Argentina	O
,	O
and	O
India	O
,	O
but	O
there	O
were	O
no	O
differences	O
between	O
SBM	O
from	O
the	O
U.S.	O
and	O
SBM	O
from	O
China	O
.	O
However	O
,	O
because	O
of	O
the	O
lower	O
concentration	O
of	O
AA	B-T121
in	O
SBM	O
from	O
China	O
,	O
the	O
concentration	O
of	O
standardized	O
ileal	O
digestible	O
AA	B-T121
in	O
SBM	O
from	O
China	O
was	O
less	O
(	O
<	O
0.05	O
)	O
than	O
in	O
SBM	O
from	O
the	O
U.S.	O
Soybean	O
meal	O
from	O
the	O
U.S.	O
or	O
Brazil	O
had	O
less	O
(	O
<	O
0.05	O
)	O
variability	O
in	O
SID	O
values	O
than	O
SBM	O
from	O
Argentina	O
,	O
China	O
,	O
or	O
India	O
.	O
In	O
conclusion	O
,	O
the	O
SID	O
of	O
CP	O
and	O
AA	B-T121
is	O
dependent	O
on	O
the	O
country	O
where	O
the	O
SBM	O
is	O
produced	O
.	O
This	O
difference	O
and	O
the	O
variability	O
within	O
each	O
country	O
should	O
be	O
evaluated	O
when	O
formulating	B-T061
diets	I-T061
for	O
pigs	O
.	O
      
Preparation	O
and	O
characterization	O
of	O
gastrointestinal	O
wafer	O
formulations	O
Many	O
active	B-T121
pharmaceutical	I-T121
ingredients	I-T121
(	O
API	B-T121
)	O
have	O
a	O
very	O
poor	O
or	O
highly	O
variable	O
bioavailability	O
after	O
oral	B-T061
administration	I-T061
.	O
One	O
possibility	O
to	O
overcome	O
this	O
problem	O
might	O
be	O
found	O
in	O
the	O
application	O
of	O
mucoadhesive	O
dosage	O
forms	O
like	O
gastrointestinal	O
wafers	O
.	O
However	O
,	O
a	O
currently	O
unsolved	O
challenge	O
is	O
the	O
control	O
of	O
the	O
adhesion	O
of	O
the	O
wafer	O
to	O
the	O
intestinal	O
mucus	O
.	O
One	O
suggested	O
solution	O
might	O
be	O
the	O
combination	O
of	O
gastrointestinal	O
wafers	O
and	O
expanding	O
systems	O
.	O
Such	O
a	O
combination	O
requires	O
thin	O
and	O
elastic	O
wafers	O
which	O
are	O
further	O
characterized	O
by	O
an	O
unidirectional	O
drug	O
release	O
.	O
In	O
this	O
study	O
gastrointestinal	O
,	O
twolayered	O
wafers	O
containing	O
a	O
water	O
-	O
insoluble	O
backing	O
layer	O
and	O
a	O
drug	O
-	O
loaded	O
,	O
mucoadhesive	O
layer	O
were	O
fabricated	O
by	O
casting	O
solvent	O
technique	O
.	O
The	O
backing	O
layer	O
consists	O
of	O
Ethocel	B-T121
™	I-T121
Standard	I-T121
10	I-T121
Premium	I-T121
and	O
the	O
mucoadhesive	O
layer	O
was	O
prepared	O
using	O
a	O
mixture	O
of	O
Methocel	O
™	O
E15	O
Premium	O
LV	O
,	O
polyvinyl	O
alcohol	O
and	O
Macrogol	O
400	O
.	O
The	O
wafers	O
were	O
characterized	O
regarding	O
their	O
appearance	O
,	O
mechanical	O
properties	O
and	O
dissolution	O
profiles	O
as	O
well	O
as	O
the	O
influence	O
of	O
backing	O
layer	O
thickness	O
on	O
drug	O
transfer	O
and	O
their	O
ability	O
of	O
unidirectional	O
drug	O
release	O
.	O
The	O
wafers	O
with	O
backing	O
layer	O
thickness	O
of	O
500μg	B-T121
Ethocel	I-T121
™	O
/cm(2	O
)	O
presented	O
adequate	O
mechanical	O
properties	O
,	O
a	O
drug	O
transfer	O
about	O
73	O
%	O
and	O
unidirectional	O
drug	O
release	O
.	O
      
Patient	O
Satisfaction	O
with	O
Pharmacist	O
-Led	O
Collaborative	O
Follow	B-T058
-	I-T058
Up	I-T058
Care	I-T058
in	O
an	O
Ambulatory	O
Rheumatology	O
Clinic	O
Patient	O
satisfaction	O
is	O
known	O
to	O
increase	O
with	O
pharmacist	O
intervention	B-T061
in	O
general	O
outpatient	O
clinics	O
and	O
with	O
nurse	B-T058
-	I-T058
led	I-T058
care	I-T058
in	O
rheumatology	O
clinics	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
describe	O
and	O
compare	O
patient	O
satisfaction	O
with	O
two	O
different	O
types	O
of	O
care	B-T058
:	O
a	O
pharmacist	O
physician	O
collaborative	O
model	O
and	O
a	O
traditional	O
physician	O
model	O
in	O
a	O
rheumatology	O
clinic	O
setting	O
.	O
A	O
cross	O
-	O
sectional	O
survey	O
of	O
inflammatory	B-T047
arthritis	I-T047
patients	O
seen	O
during	O
a	O
follow	B-T058
-	I-T058
up	I-T058
visit	I-T058
in	O
Edmonton	O
,	O
Alberta	O
,	O
Canada	O
,	O
was	O
conducted	O
over	O
a	O
ten	O
-	O
week	O
period	O
.	O
Patient	O
satisfaction	O
was	O
measured	O
using	O
a	O
modified	O
version	O
of	O
the	O
validated	O
Leeds	B-T058
Satisfaction	I-T058
Questionnaire	I-T058
,	O
which	O
uses	O
a	O
five	O
-	O
point	O
Likert	O
scale	O
to	O
measure	O
six	O
dimensions	O
of	O
satisfaction	O
,	O
and	O
compared	O
between	O
the	O
collaborative	B-T058
care	I-T058
and	O
traditional	O
physician	O
models	O
.	O
A	O
total	O
of	O
62	O
patients	O
completed	O
the	O
questionnaire	O
(	O
21	O
collaborative	B-T058
care	I-T058
and	O
41	O
traditional	O
physician	O
model	O
)	O
.	O
The	O
average	O
age	O
of	O
respondents	O
was	O
52	O
years	O
and	O
the	O
majority	O
were	O
female	O
.	O
The	O
mean	O
score	O
for	O
satisfaction	O
across	O
the	O
six	O
dimensions	O
was	O
4.56	O
in	O
the	O
collaborative	O
care	O
group	O
and	O
4.30	O
in	O
the	O
traditional	O
physician	O
group	O
(	O
p	O
=	O
0.02	O
)	O
.	O
Patient	O
satisfaction	O
in	O
the	O
collaborative	O
care	O
group	O
was	O
consistently	O
higher	O
across	O
all	O
dimensions	O
.	O
No	B-T033
difference	I-T033
was	O
noted	O
between	O
participants	O
seen	O
for	O
the	O
first	O
time	O
compared	O
with	O
those	O
seen	O
two	O
or	O
more	O
times	O
by	O
the	O
pharmacist	O
.	O
A	O
collaborative	O
care	O
model	O
can	O
exceed	O
the	O
already	O
high	O
expectations	O
for	O
care	B-T058
of	I-T058
patients	I-T058
with	O
inflammatory	B-T047
arthritis	I-T047
.	O
Our	O
findings	O
support	O
the	O
role	O
of	O
pharmacists	O
using	O
a	O
collaborative	B-T058
care	I-T058
approach	O
to	O
care	B-T058
for	I-T058
patients	I-T058
in	O
rheumatology	O
clinics	O
.	O
      
Opioids	B-T121
for	O
chronic	B-T184
pain	I-T184
:	O
The	O
CDC	O
's	O
12	O
recommendations	O
The	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
has	O
issued	O
12	O
recommendations	O
to	O
help	O
clinicians	O
prescribe	B-T058
an	O
optimal	O
and	O
safe	O
course	O
of	O
treatment	B-T061
for	O
patients	O
.	O
      
Incidence	O
of	O
environmental	O
and	O
genetic	O
factors	O
causing	O
congenital	B-T019
cataract	I-T019
in	O
Children	O
of	O
Lahore	O
To	O
check	O
the	O
incidence	O
of	O
environmental	O
and	O
genetic	O
factors	O
causing	O
congenital	B-T019
cataract	I-T019
in	O
infants	O
.	O
The	O
descriptive	O
study	O
was	O
conducted	O
at	O
Layton	O
Rahmatullah	O
Benevolent	O
Trust	O
,	O
Lahore	O
,	O
Pakistan	O
,	O
from	O
October	O
2013	O
to	O
April	O
2014	O
,	O
and	O
comprised	O
children	O
under	O
15	O
years	O
of	O
age	O
who	O
had	O
rubella	B-T047
syndrome	I-T047
,	O
herpes	B-T047
simplex	I-T047
,	O
birth	B-T033
trauma	I-T033
,	O
trisomy	O
21	O
,	O
Nance	B-T047
-	I-T047
Horan	I-T047
syndrome	I-T047
or	O
Lowe	B-T047
's	I-T047
syndrome	I-T047
.	O
Of	O
the	O
38,000	O
cases	O
examined	O
,	O
120(0.3	O
%	O
)	O
patients	O
were	O
diagnosed	B-T033
with	O
congenital	B-T019
cataract	I-T019
.	O
Of	O
them	O
,	O
52(43.33%)were	O
aged	O
between	O
2	O
and	O
5	O
years	O
,	O
22(18.33	O
%	O
)	O
<	O
11	O
years	O
and	O
10(8.33	O
%	O
)	O
?	O
15	O
years	O
.	O
Bilateral	B-T047
congenital	I-T047
cataract	I-T047
was	O
observed	O
in	O
91(75.83	O
%	O
)	O
patients	O
and	O
unilateral	B-T047
congenital	I-T047
cataract	I-T047
in	O
29(24.17	O
%	O
)	O
.	O
Environmental	O
factors	O
caused	O
72(62.07	O
%	O
)	O
cases	O
and	O
genetic	O
factors	O
caused	O
44(37.93	O
%	O
)	O
..	O
Congenital	B-T019
cataract	I-T019
predominated	O
in	O
boys	O
compared	O
to	O
girls	O
.	O
Early	O
diagnosis	B-T033
and	O
adequate	O
therapy	B-T061
requires	O
specific	O
technology	O
,	O
as	O
well	O
as	O
long	O
-	O
term	O
and	O
permanent	O
care	O
..	O
      
Pre	B-T033
-	I-T033
Activation	I-T033
Negativity	I-T033
(	O
PrAN	B-T033
)	O
in	O
Brain	B-T023
Potentials	O
to	O
Unfolding	O
Words	O
We	O
describe	O
an	O
event	O
-	O
related	O
potential	O
(	O
ERP	O
)	O
effect	O
termed	O
the	O
"	O
pre	B-T033
-	I-T033
activation	I-T033
negativity	I-T033
"	O
(	O
PrAN	B-T033
)	O
,	O
which	O
is	O
proposed	O
to	O
index	O
the	O
degree	O
of	O
pre	O
-	O
activation	O
of	O
upcoming	O
word	O
-	O
internal	O
morphemes	O
in	O
speech	O
processing	O
.	O
Using	O
lexical	O
competition	O
measures	O
based	O
on	O
word	O
-	O
initial	O
speech	O
fragments	O
(	O
WIFs	O
)	O
,	O
as	O
well	O
as	O
statistical	O
analyses	O
of	O
ERP	O
data	O
from	O
three	O
experiments	O
,	O
it	O
is	O
shown	O
that	O
the	O
PrAN	B-T033
is	O
sensitive	O
to	O
lexical	O
competition	O
and	O
that	O
it	O
reflects	O
the	O
degree	O
of	O
predictive	O
certainty	O
:	O
the	O
negativity	B-T033
is	O
larger	O
when	O
there	O
are	O
fewer	O
upcoming	O
lexical	O
competitors	O
.	O
      
Evaluation	O
of	O
Mathisen	O
's	O
technique	O
for	O
ureteral	B-T061
reimplantation	I-T061
in	O
children	O
with	O
primary	O
vesicoureteral	B-T047
reflux	I-T047
Although	O
cross	B-T061
-	I-T061
trigonal	I-T061
ureteral	I-T061
reimplantation	I-T061
(	I-T061
Cohen	I-T061
)	I-T061
is	O
a	O
commonly	O
used	O
technique	O
in	O
children	O
,	O
it	O
represents	O
a	O
non	O
-	O
physiological	O
transfer	O
of	O
the	O
ureteral	O
orifices	O
and	O
may	O
prove	O
challenging	O
with	O
regard	O
to	O
endoscopic	B-T061
ureteral	I-T061
operations	I-T061
in	O
later	O
life	O
.	O
In	O
1964	O
,	O
Mathisen	O
described	O
an	O
alternative	O
method	O
of	O
ureteral	B-T061
reimplantation	I-T061
with	O
lateralization	O
of	O
the	O
neohiatus	O
,	O
creating	O
an	O
orthotopic	O
course	O
of	O
the	O
submucosal	B-T023
ureter	I-T023
.	O
We	O
have	O
evaluated	O
success	O
and	O
complication	O
rates	O
of	O
both	O
techniques	O
that	O
were	O
applied	O
sequentially	O
at	O
our	O
departments	O
.	O
Forty	O
-	O
eight	O
consecutive	O
patients	O
(	O
83	O
ureters	O
,	O
24	O
males	O
/24	O
females	O
)	O
following	O
Mathisen	B-T061
reimplantation	I-T061
were	O
compared	O
with	O
53	O
consecutive	O
patients	O
(	O
98	O
ureters	O
,	O
30	O
males	O
/23	O
females	O
)	O
following	O
Cohen	B-T061
reimplantation	I-T061
.	O
Inclusion	O
criteria	O
were	O
primary	O
vesicoureteral	B-T047
reflux	I-T047
(	O
VUR	B-T047
)	O
and	O
no	O
previous	O
intervention	B-T061
.	O
Reflux	B-T047
grades	O
(	O
Mathisen	O
58	O
ureters	O
/69.9	O
%	O
VUR	B-T033
≥	I-T033
III	I-T033
;	O
Cohen	O
66	O
ureters	O
/66.7	O
%	O
VUR	B-T033
≥	I-T033
III	I-T033
)	O
and	O
the	O
occurence	O
of	O
other	O
complicating	O
factors	O
(	O
ureteroceles	B-T020
,	O
megaureters	B-T190
,	O
posterior	B-T019
urethral	I-T019
valves	I-T019
)	O
in	O
both	O
groups	O
were	O
comparable	O
.	O
After	O
Cohen	B-T061
's	I-T061
reimplantation	I-T061
there	O
were	O
no	O
immediate	O
complications	O
requiring	O
intervention	B-T061
;	O
during	O
follow	B-T058
-	I-T058
up	I-T058
(	O
mean	O
28.2	O
months	O
)	O
three	O
patients	O
(	O
5.6	O
%	O
)	O
suffered	B-T048
febrile	B-T047
urinary	I-T047
tract	I-T047
infections	I-T047
(	O
UTIs	B-T047
)	O
,	O
of	O
which	O
one	O
(	O
1.8	O
%	O
)	O
was	O
diagnosed	B-T033
with	O
a	O
persisting	O
VUR	B-T047
.	O
Persistent	O
hydronephroses	B-T047
(	O
≥II	O
SFU	B-T047
)	O
were	O
recorded	O
in	O
six	O
patients	O
(	O
13.2	O
%	O
)	O
.	O
After	O
reimplantation	B-T061
using	O
Mathisen	O
's	O
technique	O
,	O
two	O
patients	O
(	O
4.1	O
%	O
)	O
suffered	B-T048
significant	O
intravesical	B-T047
bleeding	I-T047
;	O
during	O
follow	B-T058
-	I-T058
up	I-T058
(	O
mean	O
23.06	O
months	O
)	O
four	O
patients	O
(	O
8.3	O
%	O
)	O
suffered	B-T048
febrile	B-T047
UTIs	I-T047
,	O
and	O
seven	O
patients	O
(	O
14.5	O
%	O
)	O
were	O
diagnosed	B-T033
with	O
persisting	O
VUR	B-T047
after	O
a	O
mean	O
follow	B-T058
-	I-T058
up	I-T058
of	O
10.8	O
months	O
.	O
The	O
patients	O
with	O
persistent	O
VUR	B-T047
had	O
more	O
commonly	O
high	O
-	O
grade	O
(	O
IV	O
and	O
V	O
)	O
VUR	B-T047
initially	O
,	O
compared	O
to	O
the	O
whole	O
group	O
.	O
Two	O
patients	O
(	O
4.1	O
%	O
)	O
had	O
persistent	O
hydronephroses	B-T047
(	O
≥II	O
SFU	B-T047
)	O
.	O
Mathisen	O
's	O
technique	O
for	O
ureteral	B-T061
reimplantation	I-T061
yielded	O
a	O
significantly	O
(	O
p	O
=	O
0.0256	O
patients	O
,	O
p	O
=	O
0.006	O
ureterorenal	O
units	O
)	O
lower	O
success	O
rate	O
(	O
85.5	O
%	O
patients	O
,	O
89.2	O
%	O
ureterorenal	O
units	O
)	O
in	O
comparison	O
with	O
Cohen	O
's	O
technique	O
(	O
98.2	O
%	O
patients	O
,	O
99	O
%	O
ureterorenal	O
units	O
)	O
.	O
Although	O
there	O
was	O
no	O
intervention	B-T061
for	O
obstruction	O
,	O
persistent	O
hydronephrosis	B-T047
was	O
more	O
common	O
in	O
the	O
Cohen	O
group	O
(	O
13.2	O
%	O
vs.	O
4.1	O
%	O
,	O
n.s	O
.	O
)	O
.	O
Despite	O
the	O
advantages	O
of	O
an	O
orthotopic	O
ureteral	O
orifice	O
close	O
to	O
the	O
bladder	B-T023
neck	I-T023
,	O
as	O
achieved	O
by	O
Mathisen	B-T061
's	I-T061
reimplantation	I-T061
,	O
cross	B-T061
-	I-T061
trigonal	I-T061
ureteral	I-T061
reimplantation	I-T061
proved	O
more	O
reliable	O
for	O
VUR	B-T047
correction	O
.	O
As	O
regards	O
optimizing	O
the	O
results	O
,	O
patient	O
selection	O
for	O
either	O
technique	O
could	O
prove	O
essential	O
.	O
Nevertheless	O
,	O
as	O
regards	O
the	O
difficulties	O
with	O
ectopic	O
ureteral	O
orifices	O
in	O
the	O
Cohen	O
technique	O
in	O
the	O
long	O
-	O
term	O
follow	B-T058
-	I-T058
up	I-T058
,	O
the	O
concept	O
of	O
anatomic	O
,	O
orthotopic	O
ureteral	B-T061
reimplantation	I-T061
should	O
be	O
pursued	O
and	O
the	O
technique	O
should	O
be	O
further	O
refined	O
.	O
      
Diabetic	B-T047
nephropathy	I-T047
as	O
the	O
cause	O
of	O
end	B-T047
-	I-T047
stage	I-T047
kidney	I-T047
disease	I-T047
reported	O
on	O
the	O
medical	O
evidence	O
form	O
CMS2728	O
at	O
a	O
single	O
center	O
Background	O
:	O
End	B-T047
-	I-T047
stage	I-T047
renal	I-T047
disease	I-T047
(	O
ESRD	B-T047
)	O
incidence	O
due	O
to	O
Type	O
2	O
diabetic	B-T047
nephropathy	I-T047
(	O
DN	B-T047
)	O
is	O
35	O
-	O
50	O
%	O
,	O
according	O
to	O
the	O
United	O
States	O
Renal	O
Data	O
System	O
.	O
Methods	O
:	O
A	O
single-	O
center	O
,	O
retrospective	O
cohort	O
study	O
to	O
determine	O
incidence	O
and	O
diagnostic	O
accuracy	O
for	O
Type	O
2	O
DN	B-T047
as	O
the	O
primary	O
cause	O
of	O
ESRD	B-T047
(	O
Code	O
250.40	O
)	O
on	O
the	O
Center	O
for	O
Medicare	O
&	O
Medicaid	O
(	O
CMS	O
)	O
Medical	O
Evidence	O
Report	O
form	O
(	O
CMS2728	O
)	O
submitted	O
at	O
renal	B-T061
replacement	I-T061
therapy	I-T061
initiation	O
.	O
All	O
patients	O
≥18	O
years	O
of	O
age	O
with	O
a	O
CMS2728	O
submitted	O
between	O
1	O
March	O
2006	O
and	O
31	O
March	O
2015	O
at	O
a	O
single	O
academic	O
military	O
medical	O
center	O
(	O
ESRD	B-T047
Network	O
5	O
)	O
were	O
included	O
.	O
Medical	O
records	O
of	O
those	O
with	O
a	O
Code	O
250.40	O
diagnosis	B-T033
were	O
reviewed	O
to	O
determine	O
whether	O
they	O
met	O
the	O
Kidney	O
Disease	O
Outcomes	O
Quality	O
Initiative	O
(	O
KDOQI	O
)	O
2007	O
criteria	O
for	O
DN	B-T047
.	O
Results	O
:	O
ESRD	B-T047
incidence	O
secondary	O
to	O
Type	O
2	O
DN	B-T047
was	O
18.7	O
%	O
(	O
56/299	O
individual	O
CMS2728	O
submissions	O
over	O
9.09	O
years	O
)	O
.	O
In	O
all	O
,	O
12/56	O
(	O
21.4	O
%	O
)	O
did	O
not	O
meet	O
KDOQI	O
criteria	O
for	O
Type	O
2	O
DN	B-T047
.	O
Although	O
all	O
had	O
diabetes	B-T047
,	O
those	O
not	O
meeting	O
criteria	O
had	O
shorter	O
disease	O
duration	O
(	O
P	O
=	O
0.007	O
)	O
,	O
were	O
more	O
likely	O
to	O
have	O
active	O
urine	O
sediment	O
(	O
P	O
=	O
0.006	O
)	O
,	O
and	O
were	O
less	O
likely	O
to	O
have	O
macroalbuminuria	B-T033
(	O
P	O
=	O
0.037	O
)	O
or	O
retinopathy	B-T047
(	O
P	O
=	O
0.002	O
)	O
prior	O
to	O
ESRD	B-T047
.	O
On	O
exact	O
logistic	O
regression	O
,	O
retinopathy	B-T047
was	O
significantly	O
associated	O
with	O
KDOQI	O
-predicted	O
DN	B-T047
[	O
odds	O
ratio	O
=	O
19.16	O
(	O
confidence	O
interval	O
2.76	O
-	O
223.7	O
)	O
,	O
P	O
=	O
0.0009	O
]	O
.	O
Conclusions	O
:	O
In	O
this	O
single-	O
center	O
cohort	O
,	O
21.4	O
%	O
identified	O
as	O
having	O
Type	O
2	O
DN	B-T047
as	O
the	O
primary	O
cause	O
of	O
ESRD	B-T047
were	O
incorrectly	O
assigned	O
per	O
KDOQI	O
2007	O
clinical	O
criteria	O
.	O
If	O
replicated	O
in	O
larger	O
populations	O
,	O
this	O
could	O
have	O
substantial	O
implications	O
regarding	O
the	O
epidemiology	O
of	O
ESRD	B-T047
in	O
the	O
USA	O
.	O
      
AAV9	B-T005
-	O
NPC1	O
significantly	O
ameliorates	B-T033
Purkinje	O
cell	O
death	O
and	O
behavioral	B-T048
abnormalities	I-T048
in	O
mouse	O
NPC	B-T047
disease	I-T047
Niemann	B-T047
-	I-T047
Pick	I-T047
type	I-T047
C	I-T047
(	I-T047
NPC	I-T047
)	I-T047
disease	I-T047
is	O
a	O
fatal	O
inherited	O
neurodegenerative	B-T047
disorder	I-T047
caused	O
by	O
loss	B-T033
-	I-T033
of	I-T033
-	I-T033
function	I-T033
mutations	O
in	O
the	O
NPC1	O
or	O
NPC2	O
gene	O
.	O
There	O
is	O
no	O
effective	O
way	O
to	O
treat	O
NPC	B-T047
disease	I-T047
.	O
In	O
this	O
study	O
,	O
we	O
used	O
adeno	B-T005
-	I-T005
associated	I-T005
virus	I-T005
(	O
AAV	B-T005
)	O
serotype	O
9	O
(	O
AAV9	B-T005
)	O
to	O
deliver	O
a	O
functional	O
NPC1	O
gene	O
systemically	O
into	O
NPC1(-/-	O
)	O
mice	O
at	O
postnatal	B-T061
day	I-T061
4	I-T061
.	O
One	O
single	O
AAV9	B-T061
-	I-T061
NPC1	I-T061
injection	I-T061
resulted	O
in	O
robust	O
NPC1	O
expression	O
in	O
various	O
tissues	O
,	O
including	O
brain	B-T023
,	O
heart	B-T023
,	O
and	O
lung	B-T023
.	O
Strikingly	O
,	O
AAV9	O
-	O
mediated	O
NPC1	O
delivery	O
significantly	O
promoted	O
Purkinje	O
cell	O
survival	O
,	O
restored	O
locomotor	O
activity	O
and	O
coordination	O
,	O
and	O
increased	O
the	O
lifespan	O
of	O
NPC1(-/-	O
)	O
mice	O
.	O
Our	O
work	O
suggests	O
that	O
AAV	B-T061
-	I-T061
based	I-T061
gene	I-T061
therapy	I-T061
is	O
a	O
promising	O
means	O
to	O
treat	O
NPC	B-T047
disease	I-T047
.	O
      
Can	O
inorganic	B-T121
phosphate	I-T121
explain	O
sag	O
during	O
unfused	O
tetanic	O
contractions	O
of	O
skeletal	O
muscle	O
?	O
We	O
test	O
the	O
hypothesis	O
that	O
cytosolic	O
inorganic	B-T121
phosphate	I-T121
(	O
Pi	B-T121
)	O
can	O
account	O
for	O
the	O
contraction	O
-	O
induced	O
reductions	O
in	O
twitch	B-T033
duration	O
which	O
impair	O
summation	O
and	O
cause	O
force	O
to	O
decline	O
(	O
sag	O
)	O
during	O
unfused	O
tetanic	O
contractions	O
of	O
fast	O
-	O
twitch	O
muscle	O
.	O
A	O
five	O
-	O
state	O
model	O
of	O
crossbridge	O
cycling	O
was	O
used	O
to	O
simulate	O
twitch	B-T033
and	O
unfused	O
tetanic	O
contractions	O
.	O
As	O
Pi	B-T121
concentration	O
(	O
[	O
Pi	B-T121
]	O
)	O
was	O
increased	O
from	O
0	O
to	O
30	O
mmol·L(-1	O
)	O
,	O
twitch	B-T033
duration	O
decreased	O
,	O
with	O
progressive	O
reductions	B-T061
in	O
sensitivity	O
to	O
Pi	B-T121
as	O
[	O
Pi	B-T121
]	O
was	O
increased	O
.	O
When	O
unfused	O
tetani	O
were	O
simulated	O
with	O
rising	O
[	O
Pi	B-T121
]	O
,	O
sag	O
was	O
most	O
pronounced	O
when	O
initial	O
[	O
Pi	B-T121
]	O
was	O
low	O
,	O
and	O
when	O
the	O
magnitude	O
of	O
[	O
Pi	B-T121
]	O
increase	O
was	O
large	O
.	O
Fast	B-T033
-	I-T033
twitch	I-T033
extensor	B-T023
digitorum	I-T023
longus	I-T023
(	I-T023
EDL	I-T023
)	I-T023
muscles	I-T023
(	O
sag	O
-	O
prone	O
,	O
typically	O
low	O
basal	O
[	O
Pi	B-T121
]	O
)	O
and	O
slow	B-T033
-	I-T033
twitch	I-T033
soleus	B-T023
muscles	I-T023
(	O
sag	O
-	O
resistant	O
,	O
typically	O
high	O
basal	O
[	O
Pi	B-T121
]	O
)	O
were	O
isolated	O
from	O
14	O
female	O
C57BL/6	O
mice	O
.	O
Muscles	O
were	O
sequentially	O
incubated	B-T059
in	O
solutions	O
containing	O
either	O
glucose	B-T121
or	O
pyruvate	O
to	O
create	O
typical	O
and	O
low	O
Pi	B-T121
environments	O
,	O
respectively	O
.	O
Twitch	B-T033
duration	O
was	O
greater	O
(	O
P	O
<	O
0.05	O
)	O
in	O
pyruvate	O
than	O
glucose	B-T121
in	O
both	O
muscles	O
.	O
Stimuli	O
applied	O
at	O
intervals	O
approximately	O
three	O
times	O
the	O
time	O
to	O
peak	O
twitch	B-T033
tension	B-T033
resulted	O
in	O
sag	O
of	O
35.0	O
±	O
3.7	O
%	O
in	O
glucose	B-T121
and	O
50.5	O
±	O
1.4	O
%	O
in	O
pyruvate	O
in	O
the	O
EDL	B-T023
(	O
pyruvate	O
>	O
glucose	B-T121
;	O
P	O
<	O
0.05	O
)	O
,	O
and	O
3.9	O
±	O
0.3	O
%	O
in	O
glucose	B-T121
and	O
37.8	O
±	O
2.7	O
%	O
in	O
pyruvate	O
in	O
the	O
soleus	B-T023
(	O
pyruvate	O
>	O
glucose	B-T121
;	O
P	O
<	O
0.05	O
)	O
.	O
The	O
influence	O
of	O
Pi	B-T121
on	O
crossbridge	O
cycling	O
provides	O
a	O
tenable	O
mechanism	O
for	O
sag	O
.	O
Moreover	O
,	O
the	O
low	B-T033
basal	I-T033
[	O
Pi	B-T121
]	O
in	O
fast	B-T033
-	I-T033
twitch	I-T033
relative	O
to	O
slow	B-T033
-	I-T033
twitch	I-T033
muscle	I-T033
has	O
promise	O
as	O
an	O
explanation	O
for	O
the	O
fiber	O
-	O
type	O
dependency	O
of	O
sag	O
.	O
      
Ocular	B-T047
hypotensive	I-T047
effect	O
of	O
the	O
novel	O
EP3	O
/	O
FP	O
agonist	B-T121
ONO-9054	O
versus	O
Xalatan	B-T121
:	O
results	O
of	O
a	O
28-	O
day	O
,	O
double	O
-	O
masked	O
,	O
randomised	O
study	O
ONO-9054	O
is	O
being	O
developed	O
for	O
the	O
reduction	O
of	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
in	O
patients	O
with	O
ocular	B-T047
hypertension	I-T047
(	O
OHT	B-T047
)	O
and	O
open	B-T047
-	I-T047
angle	I-T047
glaucoma	I-T047
(	O
OAG	B-T047
)	O
.	O
This	O
study	O
compared	O
the	O
novel	O
dual	O
EP3	O
/	O
FP	O
agonist	B-T121
ONO-9054	O
with	O
the	O
FP	O
agonist	B-T121
Xalatan	B-T121
.	O
Adults	O
(	O
n=123	O
)	O
with	O
bilateral	O
mild	O
/	O
moderate	O
OAG	B-T047
or	O
OHT	B-T047
,	O
with	O
unmedicated	O
IOP	O
of	O
≥24	O
mm	O
Hg	O
at	O
8:00	O
hours	O
,	O
≥21	O
mm	O
Hg	O
at	O
10:00	O
hours	O
and	O
≤36	O
mm	O
Hg	O
,	O
were	O
randomised	O
1:1	O
to	O
receive	O
ONO-9054	O
(	O
0.003	O
%	O
,	O
30	O
μg	O
/	O
mL	O
)	O
or	O
Xalatan	B-T121
(	O
0.005	O
%	O
,	O
50	O
μg	O
/	O
mL	O
)	O
once	O
daily	O
for	O
28	O
days	O
.	O
Day	O
29	O
mean	O
diurnal	O
IOP	O
was	O
-7.2	O
mm	O
Hg	O
for	O
ONO-9054	O
vs	O
-6.6	O
mm	O
Hg	O
for	O
Xalatan	B-T121
.	O
At	O
08:00	O
hours	O
,	O
the	O
IOPs	O
were	O
comparable	O
,	O
and	O
at	O
all	O
later	O
time	O
points	O
the	O
decrease	O
in	O
IOP	O
was	O
greater	O
for	O
ONO-9054	O
.	O
On	O
day	O
29	O
,	O
the	O
odds	O
of	O
a	O
mean	O
IOP	O
reduction	O
of	O
≤-25	O
%	O
,	O
≤-30	O
%	O
and	O
≤-35	O
%	O
for	O
ONO-9054	O
were	O
2.39	O
,	O
2.37	O
and	O
4.85	O
times	O
more	O
,	O
respectively	O
,	O
than	O
the	O
odds	O
for	O
Xalatan	B-T121
(	O
p<0.05	O
,	O
post	O
hoc	O
analyses	O
)	O
.	O
The	O
percentage	O
of	O
subjects	O
achieving	O
target	O
IOPs	O
on	O
day	O
29	O
(	O
≤17	O
,	O
≤16	O
and	O
≤15	O
mm	O
Hg	O
)	O
was	O
greater	O
for	O
ONO-9054	O
than	O
for	O
Xalatan	B-T121
;	O
the	O
odds	O
of	O
achieving	O
an	O
IOP	O
≤15	O
mm	O
Hg	O
for	O
ONO-9054	O
were	O
2.4	O
times	O
more	O
than	O
the	O
odds	O
for	O
Xalatan	B-T121
(	O
p<0.01	O
,	O
post	O
hoc	O
analysis	O
)	O
.	O
Subjects	O
randomised	O
to	O
receive	O
ONO-9054	O
were	O
more	O
likely	O
to	O
achieve	O
a	O
greater	O
per	O
cent	O
reduction	O
in	O
IOP	O
and	O
were	O
more	O
likely	O
to	O
achieve	O
target	O
IOPs	O
than	O
those	O
receiving	O
Xalatan	B-T121
.	O
The	O
effects	O
of	O
ONO-9054	O
in	O
reducing	O
IOP	O
appear	O
to	O
persist	O
longer	O
than	O
those	O
of	O
Xalatan	B-T121
.	O
NCT02083289	O
,	O
Results	O
.	O
      
Fabrication	O
and	O
modelling	O
of	O
fractal	O
,	O
biomimetic	O
,	O
micro	O
and	O
nano	O
-	O
topographical	O
surfaces	O
Natural	O
surface	O
topographies	O
are	O
often	O
self	O
-	O
similar	O
with	O
hierarchical	O
features	O
at	O
the	O
micro	O
and	O
nanoscale	O
,	O
which	O
may	O
be	O
mimicked	O
to	O
overcome	O
modern	O
tissue	B-T061
engineering	I-T061
and	O
biomaterial	O
design	O
limitations	O
.	O
Specifically	O
,	O
a	O
cell	O
's	O
microenvironment	O
within	O
the	O
human	O
body	O
contains	O
highly	O
optimised	O
,	O
fractal	O
topographical	O
cues	O
,	O
which	O
directs	O
precise	O
cell	O
behaviour	O
.	O
However	O
,	O
recreating	O
biomimetic	O
,	O
fractal	O
topographies	O
in	O
vitro	O
is	O
not	O
a	O
trivial	O
process	O
and	O
a	O
number	O
of	O
fabrication	O
methods	O
have	O
been	O
proposed	O
but	O
often	O
fail	O
to	O
precisely	O
control	O
the	O
spatial	O
resolution	O
of	O
features	O
at	O
different	O
lengths	O
scales	O
and	O
hence	O
,	O
to	O
provide	O
true	O
biomimetic	O
properties	O
.	O
Here	O
,	O
we	O
propose	O
a	O
method	O
of	O
accurately	O
reproducing	O
the	O
self	O
-	O
similar	O
,	O
micro	O
and	O
nanoscale	O
topography	O
of	O
a	O
human	O
biological	O
tissue	O
into	O
a	O
synthetic	O
polymer	O
through	O
an	O
innovative	O
fabrication	O
process	O
.	O
The	O
biological	O
tissue	O
surface	O
was	O
characterised	O
using	O
atomic	B-T059
force	I-T059
microscopy	I-T059
(	O
AFM	B-T059
)	O
to	O
obtain	O
spatial	O
data	O
in	O
X	O
,	O
Y	O
and	O
Z	O
,	O
which	O
was	O
converted	O
into	O
a	O
grayscale	O
'	O
digital	O
photomask	O
'	O
.	O
As	O
a	O
result	O
of	O
maskless	O
grayscale	O
optical	O
lithography	O
followed	O
by	O
modified	O
deep	O
reactive	O
ion	O
etching	O
and	O
replica	O
molding	O
,	O
we	O
were	O
able	O
to	O
accurately	O
reproduce	O
the	O
fractal	O
topography	O
of	O
acellular	O
dermal	O
matrix	O
(	O
ADM	O
)	O
into	O
polydimethylsiloxane	O
(	O
PDMS	O
)	O
.	O
Characterisation	O
using	O
AFM	B-T059
at	O
three	O
different	O
length	O
scales	O
revealed	O
that	O
the	O
nano	O
and	O
micro	O
-	O
topographical	O
features	O
,	O
in	O
addition	O
to	O
the	O
fractal	O
dimension	O
,	O
of	O
native	O
ADM	O
were	O
reproduced	O
in	O
PDMS	O
.	O
In	O
conclusion	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
fractal	O
topography	O
of	O
biological	O
surfaces	O
can	O
be	O
mimicked	O
in	O
synthetic	O
materials	O
using	O
the	O
novel	O
fabrication	O
process	O
outlined	O
,	O
which	O
may	O
be	O
applied	O
to	O
significantly	O
enhance	O
medical	O
device	O
biocompatibility	O
and	O
performance	O
.	O
      
Methylation	O
status	O
of	O
the	O
promoter	O
region	O
of	O
the	O
human	O
frizzled	O
9	O
gene	O
in	O
acute	B-T191
myeloid	I-T191
leukemia	I-T191
The	O
FZD9	O
gene	O
is	O
located	O
at	O
chromosome	O
7q11.23	O
,	O
and	O
has	O
been	O
indicated	O
to	O
be	O
a	O
tumor	O
suppressor	O
gene	O
.	O
The	O
present	O
study	O
examined	B-T033
the	O
involvement	O
of	O
FZD9	O
promoter	O
methylation	O
in	O
the	O
downregulation	O
of	O
FZD9	O
expression	O
in	O
leukemia	B-T191
cells	O
.	O
The	O
expression	O
of	O
the	O
FZD9	O
gene	O
was	O
absent	O
in	O
various	O
leukemic	B-T191
cell	O
lines	O
,	O
while	O
it	O
was	O
restored	O
following	O
treatment	O
with	O
DNA	O
demethylating	O
agent	O
5	O
-	O
aza-2'-deoxycytidine	O
.	O
Bisulfite	O
sequencing	O
analysis	O
of	O
the	O
FZD9	O
promoter	O
region	O
showed	O
that	O
it	O
was	O
partially	O
methylated	O
in	O
cell	O
lines	O
in	O
which	O
FZD9	O
gene	O
was	O
not	O
expressed	O
.	O
Thus	O
,	O
DNA	O
methylation	O
in	O
the	O
promoter	O
region	O
may	O
lead	O
to	O
inactivation	O
of	O
the	O
FZD9	O
gene	O
,	O
which	O
may	O
represent	O
and	O
aberration	O
associated	O
with	O
leukemia	B-T191
,	O
since	O
DNA	O
was	O
not	O
methylated	O
in	O
normal	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
Methylation	O
-specific	O
polymerase	O
chain	O
reaction	O
analysis	O
revealed	O
that	O
the	O
promoter	O
region	O
of	O
the	O
FZD9	O
gene	O
was	O
frequently	O
methylated	O
in	O
primary	O
or	O
relapse	O
acute	B-T191
myeloid	I-T191
leukemia	I-T191
(	O
52.9	O
%	O
;	O
excluding	O
acute	B-T191
promyelocytic	I-T191
leukemia	I-T191
)	O
;	O
however	O
,	O
methylation	O
was	O
infrequent	O
in	O
B	O
-	O
cell	O
acute	B-T191
lymphocytic	I-T191
leukemia	I-T191
(	O
5.6	O
%	O
)	O
.	O
In	O
conclusion	O
,	O
the	O
present	O
study	O
indicated	O
that	O
the	O
methylation	O
profile	B-T059
of	O
the	O
FZD9	O
gene	O
corresponded	O
to	O
that	O
of	O
a	O
candidate	O
tumor	O
-	O
suppressor	O
gene	O
in	O
acute	B-T191
myeloid	I-T191
leukemia	I-T191
.	O
      
Role	O
of	O
Oxidative	O
Stress	O
and	O
Inflammatory	O
Factors	O
in	O
Diabetic	B-T047
Kidney	I-T047
Disease	I-T047
Diabetic	B-T047
nephropathy	I-T047
(	O
DN	B-T047
)	O
is	O
a	O
serious	O
complication	O
of	O
diabetes	B-T047
mellitus	I-T047
,	O
and	O
its	O
prevalence	O
has	O
been	O
increasing	O
in	O
developed	O
countries	O
.	O
Diabetic	B-T047
nephropathy	I-T047
has	O
become	O
the	O
most	O
common	O
single	O
cause	O
of	O
end	B-T047
-	I-T047
stage	I-T047
renal	I-T047
disease	I-T047
worldwide	O
.	O
Oxidative	O
stress	O
and	O
inflammation	O
factors	O
are	O
hypothesized	O
to	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
late	O
diabetes	B-T047
complications	I-T047
.	O
Chronic	O
hyperglycemia	O
increases	O
oxidative	O
stress	O
,	O
significantly	O
modifies	O
the	O
structure	O
and	O
function	O
of	O
proteins	O
and	O
lipids	O
,	O
and	O
induces	O
glycoxidation	O
and	O
peroxidation	O
.	O
Therefore	O
,	O
hyperglycemia	B-T047
causes	O
auto	O
-	O
oxidation	O
of	O
glucose	B-T121
,	O
glycation	O
of	O
proteins	O
,	O
and	O
activation	O
of	O
polyol	O
mechanism	O
.	O
Overproduction	O
of	O
intracellular	O
reactive	O
oxygen	O
species	O
contributes	O
to	O
several	O
microvascular	O
and	O
macrovascular	O
complications	O
of	O
DN	B-T047
.	O
On	O
the	O
other	O
hand	O
,	O
reactive	O
oxygen	O
species	O
modulates	O
signaling	O
cascade	O
of	O
immune	O
factors	O
.	O
An	O
increase	O
in	O
reactive	O
oxygen	O
species	O
can	O
increase	O
the	O
production	O
of	O
inflammatory	O
cytokines	O
,	O
and	O
likewise	O
,	O
an	O
increase	O
in	O
inflammatory	O
cytokines	O
can	O
stimulate	O
the	O
production	O
of	O
free	O
radicals	O
.	O
Some	O
studies	O
have	O
shown	O
that	O
kidney	B-T047
inflammation	I-T047
is	O
serious	O
in	O
promoting	O
the	O
development	O
and	O
progression	O
of	O
DN	B-T047
.	O
Inflammatory	O
factors	O
which	O
are	O
activated	O
by	O
the	O
metabolic	O
,	O
biochemical	O
,	O
and	O
hemodynamic	O
derangements	O
are	O
known	O
to	O
exist	O
in	O
the	O
diabetic	B-T047
kidney	I-T047
.	O
This	O
review	O
discusses	O
facts	O
for	O
oxidative	O
stress	O
and	O
inflammatory	O
factors	O
in	O
DN	B-T047
and	O
encompasses	O
the	O
role	O
of	O
immune	O
and	O
inflammatory	O
cells	O
,	O
inflammatory	O
cytokines	O
,	O
and	O
stress	O
oxidative	O
factors	O
.	O
      
Challenging	B-T058
some	O
assumptions	O
about	O
empathy	O
In	O
New	O
Zealand	O
little	O
nursing	O
or	O
medical	O
curricula	O
time	O
,	O
if	O
any	O
,	O
is	O
specifically	O
devoted	O
to	O
the	O
enhancement	O
of	O
empathy	O
.	O
If	O
being	O
empathic	B-T033
is	O
important	O
in	O
the	O
context	O
of	O
patient	B-T058
care	I-T058
,	O
it	O
is	O
a	O
quality	O
that	O
is	O
already	O
present	O
in	O
students	O
or	O
is	O
learned	O
by	O
students	O
during	O
their	O
practicum	O
in	O
the	O
company	O
of	O
experienced	O
clinicians	O
.	O
This	O
study	O
aimed	O
to	O
compare	O
self	O
-	O
reported	O
empathy	O
ratings	O
between	O
different	O
groups	O
of	O
medical	O
students	O
and	O
one	O
cohort	O
of	O
nursing	O
students	O
who	O
were	O
either	O
exposed	O
or	O
not	O
exposed	O
to	O
explicit	O
empathy	O
training	O
or	O
learning	O
in	O
clinical	O
settings	O
in	O
the	O
presence	O
of	O
patients	O
.	O
The	O
Jefferson	O
Scale	O
of	O
Physician	O
Empathy	O
(	O
JSPE	O
)	O
was	O
completed	O
before	O
and	O
after	O
groups	O
of	O
medical	O
and	O
nursing	O
students	O
had	O
been	O
exposed	O
to	O
various	O
extended	O
periods	O
of	O
practicum	O
.	O
Some	O
medical	O
student	O
cohorts	O
undertook	O
brief	O
empathy	O
training	O
,	O
whereas	O
others	O
had	O
no	O
exposure	O
.	O
The	O
nursing	O
student	O
cohort	O
had	O
no	B-T033
formal	I-T033
,	O
explicit	O
empathy	O
training	O
.	O
Irrespective	O
of	O
profession	O
,	O
length	O
of	O
practicum	O
or	O
exposure	O
to	O
specific	O
empathy	O
training	O
,	O
there	O
were	O
no	B-T033
significant	I-T033
differences	I-T033
in	O
the	O
self	O
-	O
reported	O
JSPE	O
scores	O
across	O
the	O
seven	O
different	O
cohorts	O
of	O
students	O
.	O
Empathy	O
is	O
a	O
quality	O
that	O
is	O
already	O
present	B-T033
in	O
students	O
or	O
is	O
learned	O
by	O
students	O
during	O
their	O
practicum	O
DISCUSSION	O
:	O
If	O
empathy	O
is	O
caught	O
rather	O
than	O
taught	O
,	O
then	O
brief	O
efforts	O
to	O
enhance	O
empathy	O
may	O
be	O
futile	B-T033
.	O
To	O
optimise	O
the	O
inherent	B-T033
empathic	I-T033
qualities	I-T033
of	O
aspirant	O
health	O
professionals	O
,	O
explicit	O
consideration	B-T033
should	O
be	O
given	O
to	O
how	O
empathy	O
is	O
influenced	O
by	O
the	O
practicum	O
experience	O
.	O
      
Intraoperative	O
ketamine	B-T121
reduces	O
immediate	O
postoperative	O
opioid	B-T121
consumption	O
after	O
spinal	B-T061
fusion	I-T061
surgery	I-T061
in	O
chronic	B-T184
pain	I-T184
patients	O
with	O
opioid	B-T121
dependency	O
:	O
a	O
randomized	O
,	O
blinded	O
trial	O
Perioperative	O
handling	B-T033
of	O
surgical	O
patients	O
with	O
opioid	B-T121
dependency	O
represents	O
an	O
important	O
clinical	O
problem	B-T033
.	O
Animal	O
studies	O
suggest	O
that	O
ketamine	B-T121
attenuates	O
central	B-T047
sensitization	I-T047
and	O
hyperalgesia	B-T184
and	O
thereby	O
reduces	O
postoperative	O
opioid	B-T121
tolerance	O
.	O
We	O
hypothesized	O
that	O
intraoperative	O
ketamine	B-T121
would	O
reduce	O
immediate	O
postoperative	O
opioid	B-T121
consumption	O
compared	O
with	O
placebo	O
in	O
chronic	B-T184
pain	I-T184
patients	O
with	O
opioid	B-T121
dependency	O
undergoing	O
lumbar	B-T061
spinal	I-T061
fusion	I-T061
surgery	I-T061
.	O
Primary	O
outcome	O
was	O
morphine	B-T121
consumption	O
0	O
to	O
24	O
hours	O
postoperatively	O
.	O
Secondary	O
outcomes	O
were	O
acute	B-T184
pain	I-T184
at	I-T184
rest	I-T184
and	O
during	O
mobilization	B-T061
2	O
to	O
24	O
hours	O
postoperatively	O
(	O
visual	B-T060
analogue	I-T060
scale	I-T060
)	O
,	O
adverse	O
events	O
,	O
and	O
persistent	O
pain	B-T184
6	O
months	O
postoperatively	O
.	O
One	O
hundred	O
fifty	O
patients	O
were	O
randomly	O
assigned	O
to	O
intraoperative	O
S	B-T121
-	I-T121
ketamine	I-T121
bolus	B-T061
0.5	I-T061
mg	I-T061
/	I-T061
kg	I-T061
and	I-T061
infusion	I-T061
0.25	O
mg·kg·h	O
or	O
placebo	O
.	O
Postoperatively	O
,	O
patients	O
received	O
their	O
usual	O
opioids	B-T121
,	O
paracetamol	B-T121
and	O
IV	O
patient	B-T061
-	I-T061
controlled	I-T061
analgesia	I-T061
with	O
morphine	B-T121
.	O
In	O
the	O
final	O
analyses	O
,	O
147	O
patients	O
were	O
included	O
.	O
Patient	B-T061
-	I-T061
controlled	I-T061
analgesia	I-T061
IV	O
morphine	B-T121
consumption	O
0	O
to	O
24	O
hours	O
postoperatively	O
was	O
significantly	O
reduced	O
in	O
the	O
ketamine	B-T121
group	O
compared	O
with	O
the	O
placebo	O
group	O
:	O
79	O
(	O
47	O
)	O
vs	O
121	O
(	O
53	O
)	O
mg	O
IV	O
,	O
mean	O
difference	O
42	O
mg	O
(	O
95	O
%	O
confidence	O
interval	O
-59	O
to	O
-25	O
)	O
,	O
P	O
<	O
0.001	O
.	O
Sedation	B-T033
was	O
significantly	O
reduced	O
in	O
the	O
ketamine	B-T121
group	O
6	O
and	O
24	O
hours	O
postoperatively	O
.	O
There	O
were	O
no	B-T033
significant	I-T033
differences	I-T033
regarding	O
acute	B-T184
pain	I-T184
,	O
nausea	B-T184
,	O
vomiting	B-T184
,	O
hallucinations	B-T048
,	O
or	O
nightmares	B-T184
.	O
Back	B-T184
pain	I-T184
at	O
6	O
months	O
postoperatively	O
compared	O
with	O
preoperative	O
pain	B-T184
was	O
significantly	O
more	O
improved	B-T033
in	O
the	O
ketamine	B-T121
group	O
compared	O
with	O
the	O
placebo	O
group	O
,	O
P	O
=	O
0.005	O
.	O
In	O
conclusion	O
,	O
intraoperative	O
ketamine	B-T121
significantly	O
reduced	O
morphine	B-T121
consumption	O
0	O
to	O
24	O
hours	O
after	O
lumbar	B-T061
fusion	I-T061
surgery	I-T061
in	O
opioid	B-T121
-	O
dependent	O
patients	O
.	O
The	O
trend	O
regarding	O
less	O
persistent	O
pain	B-T184
6	O
months	O
postoperatively	O
needs	O
further	O
investigation	O
.	O
      
Two	O
-	O
stage	O
reconstructive	B-T061
overlapping	O
stent	O
LEO+	O
and	O
SILK	O
for	O
treatment	B-T061
of	O
intracranial	O
circumferential	O
fusiform	B-T190
aneurysms	I-T190
in	O
the	O
posterior	O
circulation	O
Intracranial	O
circumferential	O
fusiform	B-T190
aneurysms	I-T190
of	O
the	O
posterior	O
circulation	O
involving	O
arterial	B-T023
branches	I-T023
or	O
perforating	B-T033
vessels	B-T023
vessels	B-T023
are	O
difficult	O
to	O
treat	O
.	O
This	O
article	O
shows	O
an	O
endovascular	O
reconstruction	B-T061
technique	I-T061
not	O
yet	O
described	O
,	O
using	O
a	O
telescoping	O
self	O
-	O
expandable	O
stent	O
(	O
LEO+	O
)	O
and	O
flow	O
-	O
diverter	O
device	O
(	O
SILK	O
)	O
at	O
different	O
surgical	O
times	O
.	O
Two	O
patients	O
with	O
circumferential	O
fusiform	B-T190
aneurysm	I-T190
,	O
one	O
being	O
an	O
aneurysm	B-T047
of	O
the	O
segments	O
P2	O
and	O
P3	O
of	O
the	O
posterior	B-T023
cerebral	I-T023
artery	I-T023
,	O
diagnosed	B-T033
after	O
a	O
headache	B-T184
,	O
and	O
the	O
other	O
a	O
partially	O
thrombosed	B-T047
aneurysm	I-T047
of	O
the	O
lower	O
basilar	B-T023
artery	I-T023
,	O
diagnosed	B-T033
following	O
ischemia	O
of	O
the	O
brain	B-T023
stem	I-T023
.	O
Endovascular	O
treatment	B-T061
was	O
performed	O
by	O
means	O
of	O
a	O
vascular	B-T023
reconstruction	B-T061
technique	I-T061
that	O
used	O
at	O
different	O
surgical	O
times	O
:	O
overlapping	B-T061
;	I-T061
a	I-T061
telescoped	I-T061
self	I-T061
-	I-T061
expandable	I-T061
stent	I-T061
,	O
LEO+	O
;	O
and	O
a	O
flow	O
-	O
diverter	O
device	O
,	O
SILK	O
.	O
Angiographic	B-T060
control	O
was	O
carried	O
out	O
at	O
6	O
and	O
12	O
months	O
,	O
to	O
evaluate	O
arterial	O
patency	O
,	O
flow	O
maintenance	O
in	O
the	O
arterial	B-T023
branches	I-T023
and	O
perforating	B-T033
vessels	B-T023
,	O
and	O
thrombosis	O
of	O
the	O
aneurysm	B-T047
.	O
The	O
combined	O
use	O
at	O
different	O
surgical	O
times	O
of	O
the	O
self	O
-	O
expandable	O
stent	O
and	O
flow	O
-	O
diverter	O
device	O
was	O
technically	O
successful	O
in	O
both	O
patients	O
.	O
There	O
were	O
no	O
complications	O
during	O
the	O
procedure	O
,	O
nor	O
in	O
the	O
long	O
-	O
term	O
follow	B-T058
-	I-T058
up	I-T058
with	O
full	O
arterial	B-T023
vascular	B-T023
reconstruction	B-T061
,	O
maintenance	O
of	O
cerebral	B-T061
perfusion	I-T061
and	O
complete	O
aneurysm	B-T047
occlusion	O
at	O
the	O
6-	O
and	O
12-	O
month	O
angiographic	B-T060
follow	B-T058
-	I-T058
up	I-T058
.	O
There	O
was	O
no	O
aneurysm	O
recanalization	O
nor	O
intra	O
-	O
stent	O
stenosis	O
.	O
Circumferential	O
fusiform	B-T190
aneurysm	I-T190
of	O
the	O
posterior	O
circulation	O
involving	O
arterial	B-T023
branches	I-T023
or	O
perforating	B-T033
vessels	B-T023
to	O
the	O
brain	B-T023
stem	I-T023
may	O
be	O
treated	O
with	O
this	O
arterial	B-T023
reconstruction	B-T061
technique	I-T061
at	O
different	O
surgical	O
times	O
,	O
using	O
the	O
self	O
-	O
expandable	O
stent	O
called	O
LEO+	O
and	O
the	O
flow	O
-	O
diverter	O
device	O
SILK	O
,	O
minimizing	O
the	O
risk	O
of	O
complications	O
and	O
failure	O
of	O
the	O
endovascular	O
technique	B-T061
,	O
with	O
the	O
potential	O
for	O
arterial	B-T061
reconstruction	I-T061
with	O
thrombosis	O
of	O
the	O
aneurysmatic	B-T047
sac	I-T047
,	O
as	O
well	O
as	O
flow	O
maintenance	O
in	O
the	O
eloquent	B-T023
arteries	I-T023
,	O
in	O
this	O
type	O
of	O
cerebral	B-T047
aneurysm	I-T047
.	O
      
Clinical	B-T033
value	I-T033
of	O
pathologic	B-T060
examination	I-T060
of	O
non	B-T023
-	I-T023
neoplastic	I-T023
kidney	I-T023
in	O
patients	O
with	O
upper	O
urinary	O
tract	O
malignancies	B-T191
While	O
surgical	B-T061
resection	I-T061
remains	O
the	O
standard	O
of	O
care	O
in	O
the	O
treatment	B-T061
of	O
upper	O
urinary	O
tract	O
malignancies	B-T191
,	O
nephrectomy	B-T061
is	O
a	O
risk	B-T033
factor	I-T033
for	O
the	O
development	O
of	O
chronic	B-T047
kidney	I-T047
disease	I-T047
(	O
CKD	B-T047
)	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
histologic	O
evaluation	B-T058
of	O
non	B-T023
-	I-T023
neoplastic	I-T023
kidney	I-T023
could	O
enable	O
early	B-T061
identification	I-T061
of	O
unrecognized	O
kidney	B-T047
disease	I-T047
and	O
could	O
be	O
of	O
prognostic	O
value	O
in	O
predicting	O
postoperative	O
renal	B-T023
outcomes	O
.	O
We	O
retrospectively	O
analyzed	O
51	O
patients	O
with	O
upper	O
urinary	O
tract	O
malignancies	B-T191
who	O
received	O
uninephrectomy	B-T061
or	O
uninephroureterectomy	B-T061
.	O
A	O
thorough	O
pathologic	O
evaluation	B-T058
of	O
non	B-T023
-	I-T023
neoplastic	I-T023
kidney	I-T023
including	O
special	B-T061
stains	I-T061
,	O
immunofluorescence	B-T059
,	O
and	O
electron	B-T059
microscopic	I-T059
studies	I-T059
was	O
performed	O
.	O
The	O
degree	O
of	O
parenchymal	B-T023
changes	O
was	O
graded	O
from	O
0	O
to	O
15	O
.	O
Of	O
51	O
patients	O
,	O
only	O
13	O
showed	O
normal	O
kidney	B-T023
pathology	O
.	O
Fifteen	O
patients	O
showed	O
glomerular	B-T047
abnormalities	I-T047
,	O
14	O
showed	O
diabetic	B-T047
nephropathy	I-T047
,	O
and	O
11	O
showed	O
vascular	B-T023
nephropathy	B-T061
.	O
There	O
was	O
one	O
case	O
each	O
of	O
reflux	B-T047
nephropathy	I-T047
and	O
chronic	B-T047
pyelonephritis	I-T047
.	O
The	O
median	O
histologic	O
score	O
was	O
5	O
points	O
.	O
Only	O
25.4	O
%	O
of	O
patients	O
had	O
≤	O
3	O
points	O
.	O
Score	O
more	O
than	O
5	O
was	O
observed	O
in	O
47.1	O
%	O
of	O
patients	O
.	O
Postoperative	O
estimated	B-T059
glomerular	I-T059
filtration	I-T059
rate	I-T059
(	O
eGFR	B-T059
)	O
at	O
3	O
to	O
36	O
months	O
were	O
obtained	O
from	O
90.2	O
%	O
of	O
patients	O
,	O
and	O
of	O
those	O
,	O
34.8	O
%	O
had	O
de	O
novo	O
CKD	B-T047
.	O
Since	O
no	O
one	O
had	O
CKD	B-T047
in	O
partial	O
nephrectomized	O
patients	O
,	O
we	O
determined	O
risk	B-T033
factors	I-T033
for	O
CKD	B-T047
in	O
radical	O
nephrectomized	O
patients	O
.	O
Cox	O
regression	O
analysis	O
revealed	O
that	O
postoperative	O
AKI	O
,	O
preoperative	O
eGFR	B-T059
,	O
and	O
histologic	O
score	O
of	O
non	B-T023
-	I-T023
neoplastic	I-T023
kidney	I-T023
were	O
the	O
independent	O
predictors	O
for	O
CKD	B-T047
.	O
We	O
conclude	O
that	O
routine	O
pathologic	O
evaluation	B-T058
of	O
non	B-T023
-	I-T023
neoplastic	I-T023
kidney	I-T023
provides	O
valuable	O
diagnostic	O
and	O
prognostic	O
information	O
.	O
      
Synaptic	O
and	O
Neuronal	O
Autoantibody	O
-	O
Associated	O
Psychiatric	B-T048
Syndromes	I-T048
:	O
Controversies	O
and	O
Hypotheses	O
Autoimmune	B-T047
encephalitis	I-T047
(	O
AE	B-T047
)	O
mediated	O
by	O
antibodies	O
against	O
synaptic	O
and	O
neuronal	O
surface	O
targets	O
frequently	O
presents	B-T033
with	O
a	O
psychiatric	B-T048
syndrome	I-T048
.	O
In	O
these	O
patients	O
,	O
removal	B-T061
of	I-T061
autoantibodies	O
treats	O
the	O
disease	B-T047
and	O
outcomes	O
are	O
closely	O
linked	O
to	O
early	O
intervention	B-T061
.	O
The	O
discovery	O
of	O
these	O
autoantibodies	O
in	O
isolated	O
psychiatric	B-T048
syndromes	I-T048
has	O
raised	O
the	O
possibility	O
that	O
these	O
patients	O
may	O
derive	O
similar	O
benefits	O
from	O
immunotherapy	B-T061
,	O
a	O
potentially	O
transformational	O
approach	O
to	O
the	O
treatment	O
of	O
mental	B-T048
illness	I-T048
.	O
Although	O
open	O
-	O
label	O
case	O
series	O
suggest	O
impressive	O
therapeutic	O
outcomes	O
,	O
the	O
pathological	O
relevance	O
of	O
these	O
autoantibodies	O
outside	O
of	O
canonical	O
presentations	O
is	O
debated	O
.	O
The	O
advent	O
of	O
diagnostic	O
criteria	O
for	O
AE	B-T047
attempts	O
to	O
facilitate	O
its	O
prompt	O
identification	O
but	O
risks	O
prematurely	O
neglecting	O
the	O
potential	O
scientific	O
and	O
clinical	B-T033
significance	I-T033
of	O
isolated	O
syndromes	B-T047
that	O
do	O
not	O
satisfy	O
these	O
criteria	O
.	O
Here	O
,	O
we	O
propose	O
using	O
a	O
syndrome	B-T047
-	O
level	O
taxonomy	O
that	O
has	O
occasional	O
,	O
but	O
not	O
necessary	O
,	O
overlap	O
with	O
AE	B-T047
:	O
synaptic	O
and	O
neuronal	O
autoantibody	O
-	O
associated	O
psychiatric	B-T048
syndromes	I-T048
or	O
"	O
SNAps	B-T048
"	O
.	O
This	O
will	O
prevent	O
confusion	O
with	O
AE	B-T047
and	O
act	O
heuristically	O
to	O
promote	O
active	O
investigation	B-T058
into	O
this	O
rare	O
example	O
of	O
psychopathology	O
defined	O
on	O
a	O
molecular	O
level	O
.	O
We	O
suggest	O
that	O
this	O
concept	O
would	O
have	O
application	O
in	O
other	O
autoantibody	O
-	O
associated	O
syndromes	B-T047
including	O
seizure	B-T184
,	O
cognitive	O
,	O
and	O
movement	B-T047
disorders	I-T047
,	O
in	O
which	O
similar	O
issues	B-T033
arise	O
.	O
We	O
review	O
putative	O
direct	O
and	O
indirect	O
mechanisms	O
and	O
outline	O
experimentally	O
testable	O
hypotheses	O
that	O
would	O
help	O
to	O
determine	O
prospectively	O
in	O
whom	O
autoantibody	O
detection	B-T061
is	O
relevant	O
,	O
and	O
as	O
important	O
,	O
in	O
whom	O
it	O
is	O
not	O
.	O
We	O
summarize	O
a	O
pragmatic	O
approach	O
to	O
autoantibody	O
testing	O
and	O
management	B-T058
in	O
severe	O
mental	B-T048
illness	I-T048
in	O
order	O
to	O
promptly	O
diagnose	B-T033
AE	B-T047
and	O
advocate	O
a	O
research	O
-	O
orientated	B-T033
experimental	O
medicine	B-T121
paradigm	O
for	O
SNAps	B-T048
,	O
where	O
there	O
is	O
greater	O
equipoise	B-T121
.	O
We	O
conclude	O
that	O
SNAps	B-T048
remains	O
a	O
nascent	O
area	O
of	O
clinical	O
neuroscience	O
with	O
great	O
potential	O
and	O
in	O
ongoing	O
need	O
of	O
psychiatry	O
-led	O
basic	O
and	O
clinical	O
research	O
.	O
      
Ceftaroline	B-T195
fosamil	I-T195
for	O
community	B-T047
-	I-T047
acquired	I-T047
pneumonia	I-T047
and	O
skin	O
and	O
skin	O
structure	O
infections	O
:	O
a	O
systematic	O
review	O
Background	O
Ceftaroline	B-T195
is	O
a	O
parentally	O
administered	O
cephalosporin	B-T195
that	O
has	O
an	O
in	O
vitro	O
expanded	O
spectrum	O
of	O
activity	O
compared	O
with	O
other	O
cephalosporins	B-T195
yet	O
data	O
is	O
conflicting	O
regarding	O
its	O
place	O
in	O
therapy	B-T061
.	O
Aim	O
of	O
the	O
Review	O
To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
ceftaroline	B-T195
against	O
standard	O
antibiotic	B-T195
regimens	B-T061
for	O
community	B-T047
-	I-T047
acquired	I-T047
pneumonia	I-T047
(	O
CAP	B-T047
)	O
and	O
complicated	O
skin	O
and	O
skin	O
structure	O
infections	O
(	O
cSSSIs	O
)	O
.	O
Method	O
The	O
databases	O
of	O
MEDLINE	O
,	O
EBSCO	O
,	O
and	O
Embase	O
were	O
searched	O
up	O
to	O
June	O
2016	O
.	O
Manual	O
review	O
of	O
references	O
was	O
completed	O
and	O
experts	O
in	O
the	O
field	O
were	O
contacted	O
for	O
unpublished	O
data	O
.	O
Randomized	O
controlled	O
trials	O
of	O
ceftaroline	B-T195
in	O
CAP	B-T047
or	O
cSSSI	O
populations	O
were	O
included	O
.	O
Outcomes	O
included	O
clinical	B-T033
cure	I-T033
,	O
mortality	O
,	O
adverse	O
events	O
,	O
serious	B-T033
adverse	I-T033
events	I-T033
,	O
and	O
discontinuation	B-T061
due	O
to	O
adverse	O
events	O
.	O
Meta	O
-	O
analysis	O
was	O
used	O
to	O
pool	O
results	O
for	O
these	O
outcomes	O
.	O
We	O
performed	O
subgroup	O
analyses	O
for	O
gram	B-T047
positive	I-T047
infections	I-T047
in	O
CAP	B-T047
and	O
infections	O
caused	O
by	O
methicillin	B-T007
-	I-T007
resistant	I-T007
Staphylococcus	I-T007
aureus	I-T007
in	O
cSSSIs	O
.	O
Risk	O
of	O
bias	O
was	O
assessed	O
for	O
all	O
studies	O
.	O
Results	O
Six	O
trials	O
(	O
three	O
for	O
each	O
indication	O
)	O
were	O
included	O
,	O
each	O
of	O
which	O
had	O
an	O
unclear	O
or	O
high	O
risk	O
of	O
bias	O
in	O
at	O
least	O
one	O
domain	O
.	O
For	O
CAP	B-T047
,	O
ceftaroline	B-T195
was	O
significantly	O
more	O
efficacious	O
in	O
achieving	O
clinical	B-T033
cure	I-T033
than	O
ceftriaxone	B-T195
[	O
risk	O
ratio	O
(	O
RR	O
)	O
1.11	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.04	O
-	O
1.19	O
;	O
I(2	O
)	O
=	O
47	O
%	O
]	O
.	O
For	O
cSSSIs	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
clinical	B-T033
cure	I-T033
between	O
ceftaroline	B-T195
and	O
vancomycin	B-T195
plus	O
aztreonam	B-T195
(	O
RR	O
1.01	O
,	O
95	O
%	O
CI	O
0.97	O
-	O
1.05	O
;	O
I(2	O
)	O
=	O
0	O
%	O
)	O
.	O
No	O
differences	O
were	O
found	O
for	O
overall	O
mortality	O
,	O
serious	B-T033
adverse	I-T033
events	I-T033
,	O
discontinuation	B-T061
due	O
to	O
adverse	O
events	O
,	O
and	O
overall	O
adverse	O
events	O
.	O
Conclusion	O
Ceftaroline	B-T195
is	O
a	O
viable	O
therapeutic	B-T061
alternative	I-T061
for	O
patients	O
with	O
CAP	B-T047
and	O
cSSSIs	O
,	O
yet	O
identified	O
risks	O
of	O
bias	O
and	O
poor	B-T033
external	I-T033
validity	I-T033
preclude	O
it	O
from	O
being	O
recommended	O
as	O
a	O
first	B-T195
-	I-T195
line	I-T195
agent	I-T195
.	O
      
CD84	O
mediates	O
CLL	B-T191
-	O
microenvironment	O
interactions	O
Chronic	B-T191
lymphocytic	I-T191
leukemia	I-T191
(	O
CLL	B-T191
)	O
is	O
a	O
malignant	B-T047
disease	I-T047
of	O
small	O
mature	O
lymphocytes	O
.	O
Signals	O
from	O
the	O
CLL	B-T191
microenvironment	O
promote	O
progression	O
of	O
the	O
disease	O
and	O
induce	O
drug	O
resistance	O
.	O
This	O
phenomenon	O
is	O
largely	O
dependent	O
on	O
direct	O
contact	O
between	O
the	O
malignant	B-T191
B	I-T191
cells	I-T191
and	O
stromal	O
cells	O
.	O
CD84	O
belongs	O
to	O
the	O
signaling	O
lymphocyte	O
activation	O
molecule	O
family	O
of	O
immunoreceptors	O
,	O
which	O
self	O
-	O
associates	O
,	O
forming	O
an	O
orthogonal	O
homophilic	O
dimer	O
.	O
We	O
therefore	O
hypothesized	O
that	O
CD84	O
may	O
bridge	O
between	O
CLL	B-T191
cells	O
and	O
their	O
microenvironment	O
,	O
promoting	O
cell	O
survival	O
.	O
Our	O
in	O
vitro	O
results	O
show	O
that	O
CD84	O
expressed	O
on	O
CLL	B-T191
cells	O
interact	O
with	O
CD84	O
expressed	O
on	O
cells	O
in	O
their	O
microenvironment	O
,	O
inducing	O
cell	O
survival	O
in	O
both	O
sides	O
.	O
Blocking	O
CD84	O
in	O
vitro	O
and	O
in	O
vivo	O
disrupt	O
the	O
interaction	O
of	O
CLL	B-T191
cells	O
with	O
their	O
microenvironment	O
,	O
resulting	O
in	O
induced	O
cell	O
death	O
.	O
Thus	O
,	O
our	O
findings	B-T033
suggest	O
novel	O
therapeutic	O
strategies	O
based	O
on	O
the	O
blockade	B-T121
of	O
this	O
CD84	O
-	O
dependent	O
survival	O
pathway	O
.	O
      
Understanding	O
the	O
interrelationship	O
between	O
the	O
synthesis	O
of	O
urea	B-T121
and	O
gluconeogenesis	O
by	O
formulating	O
an	O
overall	O
balanced	O
equation	O
It	O
is	O
well	O
known	O
that	O
a	O
strong	O
metabolic	O
interrelationship	O
exists	O
between	O
ureagenesis	O
and	O
gluconeogenesis	O
.	O
In	O
this	O
paper	O
,	O
we	O
present	O
a	O
detailed	O
,	O
overall	O
equation	O
,	O
describing	O
a	O
possible	O
metabolic	O
link	O
between	O
ureagenesis	O
and	O
gluconeogenesis	O
.	O
We	O
adopted	O
a	O
guided	O
approach	O
in	O
which	O
we	O
strongly	O
suggest	O
that	O
students	O
,	O
when	O
faced	O
with	O
the	O
problem	B-T033
of	O
obtaining	O
the	O
overall	O
equation	O
of	O
a	O
metabolic	O
pathway	O
,	O
carefully	O
account	O
for	O
all	O
atoms	O
and	O
charges	O
of	O
the	O
single	O
reactions	O
,	O
as	O
well	O
as	O
the	O
cellular	O
localizations	O
of	O
the	O
substrates	O
,	O
and	O
the	O
related	O
transport	O
systems	O
.	O
If	O
this	O
suggestion	O
is	O
always	O
taken	O
into	O
account	O
,	O
a	O
balanced	O
,	O
overall	O
equation	O
of	O
a	O
metabolic	O
pathway	O
will	O
be	O
obtained	O
,	O
which	O
strongly	O
facilitates	O
the	O
discussion	O
of	O
its	O
physiological	O
role	O
.	O
Unfortunately	O
,	O
textbooks	O
often	O
report	O
unbalanced	O
overall	O
equations	O
of	O
metabolic	O
pathways	O
,	O
including	O
ureagenesis	O
and	O
gluconeogenesis	O
.	O
Most	O
likely	O
the	O
reason	O
is	O
that	O
metabolism	O
and	O
enzymology	O
have	O
been	O
neglected	O
for	O
about	O
three	O
decades	O
,	O
owing	O
to	O
the	O
remarkable	O
advances	O
of	O
molecular	O
biology	O
and	O
molecular	O
genetics	O
.	O
In	O
this	O
paper	O
,	O
we	O
strongly	O
suggest	O
that	O
students	O
,	O
when	O
faced	O
with	O
the	O
problem	O
of	O
obtaining	O
the	O
overall	O
reaction	O
of	O
a	O
metabolic	O
pathway	O
,	O
carefully	O
control	O
if	O
the	O
single	O
reactions	O
are	O
properly	O
balanced	O
for	O
atoms	O
and	O
charges	O
.	O
Following	O
this	O
suggestion	O
,	O
we	O
were	O
able	O
to	O
obtain	O
an	O
overall	O
equation	O
describing	O
the	O
metabolic	O
interrelationship	O
between	O
ureagenesis	O
and	O
gluconeogenesis	O
,	O
in	O
which	O
urea	B-T121
and	O
glucose	B-T121
are	O
the	O
final	O
products	O
.	O
The	O
aim	O
is	O
to	O
better	O
rationalize	O
this	O
topic	O
and	O
to	O
convince	O
students	O
and	O
teachers	O
that	O
metabolism	O
is	O
an	O
important	O
and	O
rewarding	O
chapter	O
of	O
human	O
physiology	O
.	O
      
Sex	O
Life	O
and	O
Impact	O
of	O
Operative	O
Intervention	B-T061
on	O
Sex	B-T184
Life	I-T184
-	I-T184
related	I-T184
Pain	I-T184
in	O
Degenerative	O
Spinal	B-T023
Conditions	O
:	O
An	O
Analysis	O
of	O
the	O
SPORT	O
Study	O
This	O
study	O
is	O
a	O
therapeutic	O
retrospective	O
cohort	O
study	O
OBJECTIVES	O
.	O
:	O
This	O
study	O
aims	O
to	O
determine	O
whether	O
sexual	O
function	O
is	O
relevant	O
for	O
patients	O
with	O
spinal	B-T020
stenosis	I-T020
(	O
SPS	B-T020
)	O
and	O
degenerative	B-T047
spondylolisthesis	I-T047
(	O
DS	B-T047
)	O
and	O
to	O
determine	O
the	O
impact	O
of	O
operative	O
inter	O
vqAvention	O
on	O
sexual	O
function	O
for	O
these	O
patients	O
.	O
The	O
benefits	O
of	O
nonoperative	O
versus	O
operative	O
treatment	O
for	O
patients	O
with	O
SPS	B-T020
and	O
DS	B-T047
with	O
regards	O
to	O
sexual	O
function	O
are	O
unknown	O
.	O
Demographic	O
,	O
treatment	O
,	O
and	O
follow	B-T058
-	I-T058
up	I-T058
data	O
,	O
including	O
the	O
Oswestry	O
Disability	O
Index	O
(	O
ODI	O
)	O
,	O
were	O
obtained	O
on	O
patients	O
enrolled	O
in	O
the	O
SPORT	O
study	O
.	O
Based	O
on	O
the	O
response	O
to	O
question	O
#	O
9	O
in	O
the	O
ODI	O
,	O
patients	O
were	O
classified	O
into	O
a	O
sexual	O
life	O
relevant	O
(	O
SLR	O
)	O
or	O
sexual	O
life	O
not	O
relevant	O
(	O
NR	O
)	O
group	O
.	O
Univariate	O
and	O
multivariate	O
analysis	O
of	O
patient	O
characteristics	O
comparing	O
the	O
NR	O
and	O
SLR	O
group	O
were	O
performed	O
.	O
Operative	O
treatment	O
groups	O
were	O
compared	O
to	O
the	O
nonoperative	O
group	O
with	O
regards	O
to	O
response	O
to	O
ODI	O
question	O
#	O
9	O
to	O
determine	O
the	O
impact	O
of	O
surgery	B-T061
on	O
sexual	O
function	O
.	O
A	O
total	O
of	O
1235	O
patients	O
were	O
included	O
to	O
determine	O
relevance	O
of	O
sex	O
life	O
.	O
Three	O
hundred	O
sixty	O
-	O
six	O
patients	O
(	O
29	O
%	O
)	O
were	O
included	O
in	O
the	O
NR	O
group	O
.	O
Eight	O
hundred	O
sixty	O
-	O
nine	O
patients	O
(	O
71	O
%	O
)	O
were	O
included	O
in	O
the	O
SLR	O
group	O
.	O
Patients	O
that	O
were	O
older	O
,	O
female	O
,	O
unmarried	O
,	O
had	O
three	O
or	O
more	O
stenotic	O
levels	O
,	O
and	O
had	O
central	O
stenosis	O
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
NR	O
group	O
.	O
Eight	O
hundred	O
twenty	O
-	O
five	O
patients	O
were	O
included	O
in	O
the	O
analysis	O
comparing	O
operative	O
versus	O
nonoperative	O
treatment	O
.	O
At	O
all	O
follow	B-T058
-	I-T058
up	I-T058
time	O
points	O
,	O
the	O
operative	O
groups	O
had	O
a	O
lower	O
percentage	O
of	O
patients	O
reporting	O
pain	B-T184
with	O
their	O
sex	O
life	O
compared	O
to	O
the	O
nonoperative	O
group	O
(	O
P	O
<	O
0.05	O
at	O
all	O
time	O
points	O
except	O
between	O
more	O
than	O
one	O
level	O
fusion	O
and	O
nonoperative	O
at	O
4	O
years	O
'	O
follow	B-T058
-	I-T058
up	I-T058
)	O
.	O
Sex	O
life	O
is	O
a	O
relevant	O
consideration	O
for	O
the	O
majority	O
of	O
patients	O
with	O
DS	B-T047
and	O
SPS	B-T020
;	O
operative	O
treatment	O
leads	O
to	O
improved	B-T033
sex	B-T184
life	I-T184
-	I-T184
related	I-T184
pain	I-T184
.	O
3	O
.	O
      
Esomeprazole	B-T121
-	O
or	O
rabeprazole	B-T121
-based	O
triple	O
therapy	B-T061
eradicated	O
Helicobacter	B-T007
pylori	I-T007
comparably	O
regardless	O
of	O
clarithromycin	B-T195
susceptibility	O
and	O
CYP2C19	O
genotypes	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
efficacy	O
of	O
esomeprazole	B-T121
-based	O
triple	O
therapy	B-T061
compared	O
with	O
rabeprazole	B-T121
-based	O
triple	O
therapy	B-T061
according	O
to	O
CYP2C19	O
genotype	O
and	O
clarithromycin	B-T195
susceptibility	O
status	O
for	O
first	O
-	O
line	O
eradication	B-T061
therapy	I-T061
of	I-T061
Helicobacter	I-T061
pylori	I-T061
(	O
H.	B-T007
pylori	I-T007
)	O
in	O
Japan	O
.	O
We	O
enrolled	O
219	O
H.	B-T007
pylori	I-T007
-	O
infected	O
patients	O
,	O
and	O
randomly	O
allocated	O
patients	O
to	O
the	O
EAC	O
group	O
(	O
esomeprazole	B-T121
20	O
mg	O
,	O
clarithromycin	B-T195
200	O
mg	O
,	O
amoxicillin	B-T195
750	O
mg	O
for	O
one	O
week	O
,	O
with	O
all	O
drugs	B-T121
given	O
twice	O
daily	O
)	O
or	O
RAC	O
group	O
(	O
rabeprazole	B-T121
10	O
mg	O
,	O
clarithromycin	B-T195
200	O
mg	O
,	O
amoxicillin	B-T195
750	O
mg	O
for	O
one	O
week	O
,	O
with	O
all	O
drugs	B-T121
given	O
twice	O
daily	O
)	O
.	O
The	O
H.	B-T007
pylori	I-T007
eradication	O
rate	O
according	O
to	O
the	O
PP	O
analyses	O
was	O
75.0	O
%	O
(	O
95	O
%	O
CI	O
:	O
65.2	O
-	O
82.8	O
%	O
)	O
in	O
the	O
EAC	O
group	O
and	O
71.4	O
%	O
(	O
95	O
%	O
CI	O
:	O
61.4	O
-	O
79.1	O
%	O
)	O
in	O
the	O
RAC	O
group	O
.	O
There	O
were	O
no	O
statistically	O
significant	O
differences	O
.	O
The	O
eradication	O
rates	O
of	O
the	O
clarithromycin	B-T195
-resistant	O
/-	O
sensitive	O
strains	B-T007
were	O
,	O
respectively	O
,	O
45.0	O
%	O
(	O
95	O
%	O
CI	O
:	O
30.7	O
-	O
60.2%)/98.0	O
%	O
(	O
95	O
%	O
CI	O
:	O
88.7	O
-	O
100	O
%	O
)	O
in	O
the	O
EAC	O
group	O
and	O
39.5	O
%	O
(	O
95	O
%	O
CI	O
:	O
25.6	O
-	O
55.3%)/93.5	O
%	O
(	O
95	O
%	O
CI	O
:	O
81.9	O
-	O
98.4	O
%	O
)	O
in	O
the	O
RAC	O
group	O
.	O
The	O
eradication	O
rate	O
of	O
the	O
clarithromycin	B-T195
-	O
sensitive	O
strains	B-T007
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
resistant	O
strains	O
in	O
both	O
groups	O
.	O
In	O
conclusion	O
,	O
EAC	O
and	O
RAC	O
therapies	B-T061
show	O
a	O
comparable	O
efficacy	O
regardless	O
of	O
the	O
CYP2C19	O
genotype	O
and	O
clarithromycin	B-T195
susceptibility	O
status	O
in	O
Japan	O
.	O
      
Hospital	O
clowning	O
:	O
a	O
paediatrician	O
's	O
view	O
This	O
study	O
investigates	O
the	O
current	O
position	O
of	O
hospital	O
clowns	O
from	O
the	O
perspective	O
of	O
paediatricians	O
and	O
paediatric	O
residents	O
.	O
A	O
total	O
of	O
14	O
attending	O
paediatricians	O
and	O
paediatric	O
residents	O
participated	O
in	O
two	O
focus	O
group	O
sessions	O
.	O
Data	O
were	O
analysed	O
using	O
Atlas.ti	O
5.0	O
.	O
In	O
general	O
,	O
physicians	O
reported	O
positive	B-T033
experiences	O
regarding	O
the	O
interaction	B-T033
between	O
hospital	O
clowns	O
and	O
paediatric	O
patients	O
on	O
the	O
ward	O
.	O
Physicians	O
were	O
more	O
interested	O
in	O
research	O
on	O
children	O
's	O
perception	O
of	O
hospital	O
clowns	O
than	O
in	O
research	O
on	O
the	O
clinical	O
efficacy	O
of	O
hospital	O
clowning	O
.	O
No	O
direct	O
collaboration	O
between	O
physicians	O
and	O
hospital	O
clowns	O
was	O
reported	O
.	O
However	O
,	O
physicians	O
proposed	O
conditions	O
which	O
may	O
streamline	O
their	O
encounters	O
with	O
hospital	O
clowns	O
such	O
as	O
clear	O
communication	O
prior	O
to	O
hospital	O
clown	O
visits	B-T058
,	O
and	O
the	O
condition	O
that	O
visits	O
do	O
not	O
impede	O
medical	B-T061
interventions	I-T061
.	O
Overall	O
,	O
paediatricians	O
and	O
paediatric	O
residents	O
view	O
the	O
positive	B-T033
impact	O
on	O
paediatric	O
patients	O
as	O
the	O
most	O
important	O
aspect	O
of	O
hospital	O
clown	O
visits	B-T058
,	O
rather	O
than	O
the	O
clinical	O
efficacy	O
of	O
hospital	O
clowning	O
.	O
In	O
light	O
of	O
the	O
growing	O
number	O
of	O
hospital	O
clowns	O
worldwide	O
,	O
this	O
article	O
provides	O
recommendations	O
for	O
arranging	O
their	O
encounters	O
with	O
paediatricians	O
and	O
paediatric	O
residents	O
to	O
maintain	O
optimal	O
health	B-T058
care	I-T058
.	O
What	O
is	O
known	O
:	O
•	O
Previous	O
studies	O
show	O
a	O
clinically	O
significant	O
pain	B-T184
-	O
and	O
anxiety	B-T033
-	O
reducing	O
effect	O
of	O
hospital	O
clowning	O
in	O
paediatric	O
patients	O
admitted	B-T058
to	I-T058
hospitals	I-T058
or	O
undergoing	O
(	O
invasive	O
)	O
medical	B-T058
procedures	I-T058
.	O
•	O
In	O
general	O
,	O
paediatricians	O
have	O
positive	B-T033
ideas	O
about	O
hospital	O
clowns	O
,	O
aside	O
from	O
personal	O
prejudices	O
.	O
What	O
is	O
new	O
:	O
•	O
This	O
novel	O
study	O
gives	O
deeper	O
insight	O
into	O
day	O
-	O
to	O
-	O
day	O
interaction	B-T033
between	O
paediatricians	O
and	O
hospital	O
clowns	O
on	O
the	O
ward	O
.	O
•	O
This	O
study	O
provides	O
recommendations	O
for	O
clinical	O
practice	O
to	O
arrange	O
encounters	O
between	O
physicians	O
and	O
hospital	O
clowns	O
during	O
hospital	O
clown	O
visits	B-T058
.	O
      
Quo	O
vadis	O
G	O
protein	O
-	O
coupled	O
receptor	O
ligands	O
?	O
A	O
tool	O
for	O
analysis	O
of	O
the	O
emergence	O
of	O
new	O
groups	O
of	O
compounds	O
over	O
time	O
Exponential	O
growth	O
in	O
the	O
number	O
of	O
compounds	O
with	O
experimentally	O
verified	O
activity	O
towards	O
particular	O
target	O
has	O
led	O
to	O
the	O
emergence	O
of	O
various	O
databases	O
gathering	O
data	O
on	O
biological	O
activity	O
.	O
In	O
this	O
study	O
,	O
the	O
ligands	O
of	O
family	O
A	O
of	O
the	O
G	O
Protein	O
-	O
Coupled	O
Receptors	O
that	O
are	O
collected	O
in	O
the	O
ChEMBL	O
database	O
were	O
examined	B-T033
,	O
and	O
special	O
attention	O
was	O
given	O
to	O
serotonin	O
receptors	O
.	O
Sets	O
of	O
compounds	O
were	O
examined	B-T033
in	O
terms	O
of	O
their	O
appearance	O
over	O
time	O
,	O
they	O
were	O
mapped	O
to	O
the	O
chemical	O
space	O
of	O
drugs	B-T121
deposited	O
in	O
DrugBank	O
,	O
and	O
the	O
emergence	O
of	O
structurally	O
new	O
clusters	O
of	O
compounds	O
was	O
indicated	B-T033
.	O
In	O
addition	O
,	O
a	O
tool	O
for	O
detailed	O
analysis	O
of	O
the	O
obtained	O
visualizations	O
was	O
prepared	B-T033
and	O
made	O
available	O
online	O
at	O
http://chem.gmum.net/vischem	O
,	O
which	O
enables	O
the	O
investigation	O
of	O
chemical	O
structures	O
while	O
referring	O
to	O
particular	O
data	B-T033
points	I-T033
depicted	O
in	O
the	O
figures	O
and	O
changes	O
in	O
compounds	O
datasets	O
over	O
time	O
.	O
      
Abnormal	B-T033
metabolic	O
brain	B-T023
network	O
associated	O
with	O
Parkinson	B-T047
's	I-T047
disease	I-T047
:	O
replication	O
on	O
a	O
new	O
European	O
sample	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
specific	O
metabolic	O
brain	B-T023
pattern	O
characteristic	O
for	O
Parkinson	B-T047
's	I-T047
disease	I-T047
(	O
PD	B-T047
):	O
Parkinson	O
's	O
disease	O
-	O
related	O
pattern	O
(	O
PDRP	O
)	O
,	O
using	O
network	O
analysis	O
of	O
[	B-T060
18F]-fluorodeoxyglucose	I-T060
positron	I-T060
emission	I-T060
tomography	I-T060
(	O
FDG	B-T060
-	I-T060
PET	I-T060
)	O
brain	B-T023
images	O
in	O
a	O
cohort	O
of	O
Slovenian	O
PD	B-T047
patients	O
.	O
Twenty	O
PD	B-T047
patients	O
(	O
age	O
70.1	O
±	O
7.8	O
years	O
,	O
Movement	O
Disorder	O
Society	O
Unified	O
Parkinson	O
's	O
Disease	O
Motor	O
Rating	O
Scale	O
(	O
MDS	O
-	O
UPDRS	O
-	O
III	O
)	O
38.3	O
±	O
12.2	O
;	O
disease	O
duration	O
4.3	O
±	O
4.1	O
years	O
)	O
and	O
20	O
age	O
-	O
matched	O
normal	O
controls	O
(	O
NCs	O
)	O
underwent	O
FDG	B-T060
-	I-T060
PET	I-T060
brain	B-T060
imaging	I-T060
.	O
An	O
automatic	O
voxel	O
-	O
based	O
scaled	O
subprofile	O
model	O
/	O
principal	O
component	O
analysis	O
(	O
SSM	O
/	O
PCA	O
)	O
was	O
applied	O
to	O
these	O
scans	B-T060
for	O
PDRP	O
-	O
Slovenia	O
identification	O
.	O
The	O
pattern	O
was	O
characterized	O
by	O
relative	O
hypermetabolism	B-T033
in	O
pallidum	B-T023
,	O
putamen	B-T023
,	O
thalamus	B-T023
,	O
brain	B-T023
stem	I-T023
,	O
and	O
cerebellum	B-T023
associated	O
with	O
hypometabolism	B-T033
in	O
sensorimotor	B-T023
cortex	I-T023
,	O
posterior	B-T023
parietal	I-T023
,	O
occipital	O
,	O
and	O
frontal	B-T023
cortices	I-T023
.	O
The	O
expression	O
of	O
PDRP	O
-	O
Slovenia	O
discriminated	O
PD	B-T047
patients	O
from	O
NCs	O
(	O
p	O
<	O
0.0001	O
)	O
and	O
correlated	O
positively	O
with	O
patients	O
'	O
clinical	O
score	O
(	O
MDS	O
-	O
UPDRS	O
-	O
III	O
,	O
p	O
=	O
0.03	O
)	O
.	O
Additionally	O
,	O
its	O
topography	O
agrees	O
well	O
with	O
the	O
original	O
PDRP	O
(	O
p	O
<	O
0.001	O
)	O
identified	O
in	O
American	O
cohort	O
of	O
PD	B-T047
patients	O
.	O
We	O
validated	O
the	O
PDRP	O
-	O
Slovenia	O
expression	O
on	O
additional	O
FDG	B-T060
-	I-T060
PET	I-T060
scans	B-T060
of	O
20	O
PD	B-T047
patients	O
,	O
20	O
NCs	O
,	O
and	O
25	O
patients	O
with	O
atypical	B-T047
parkinsonism	I-T047
(	O
AP	B-T047
)	O
.	O
We	O
confirmed	O
that	O
the	O
expression	O
of	O
PDRP	O
-	O
Slovenia	O
manifests	O
good	O
diagnostic	O
accuracy	O
with	O
specificity	O
and	O
sensitivity	O
of	O
85	O
-	O
90	O
%	O
at	O
optimal	O
pattern	O
expression	O
cutoff	O
for	O
discrimination	O
of	O
PD	B-T047
patients	O
and	O
NCs	O
and	O
is	O
not	O
expressed	O
in	O
AP	B-T047
.	O
PDRP	O
-	O
Slovenia	O
proves	O
to	O
be	O
a	O
robust	O
and	O
reproducible	O
functional	B-T060
imaging	I-T060
biomarker	O
independent	O
of	O
patient	O
population	O
.	O
It	O
accurately	O
differentiates	O
PD	B-T047
patients	O
from	O
NCs	O
and	O
AP	B-T047
and	O
correlates	O
well	O
with	O
the	O
clinical	O
measure	O
of	O
PD	B-T047
progression	O
.	O
      
Derivation	O
of	O
a	O
Predictive	O
Score	O
for	O
Hemorrhagic	O
Progression	O
of	O
Cerebral	O
Contusions	O
in	O
Moderate	O
and	O
Severe	O
Traumatic	O
Brain	O
Injury	O
After	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
,	O
hemorrhagic	O
progression	O
of	O
contusions	O
(	O
HPCs	O
)	O
occurs	O
frequently	O
.	O
However	O
,	O
there	O
is	O
no	O
established	O
predictive	O
score	O
to	O
identify	O
high	B-T033
-	I-T033
risk	I-T033
patients	O
for	O
HPC	O
.	O
Consecutive	O
patients	O
who	O
were	O
hospitalized	B-T033
(	O
2008	O
-	O
2013	O
)	O
with	O
non	O
-	O
penetrating	O
moderate	O
or	O
severe	O
TBI	O
were	O
studied	O
.	O
The	O
primary	O
outcome	O
was	O
HPC	O
,	O
defined	O
by	O
both	O
a	O
relative	O
increase	O
in	O
contusion	O
volume	O
by	O
≥30	O
%	O
and	O
an	O
absolute	O
increase	O
by	O
≥10	O
mL	O
on	O
serial	O
imaging	O
.	O
Logistic	O
regression	O
models	O
were	O
created	O
to	O
identify	O
independent	O
risk	B-T033
factors	I-T033
for	O
HPC	O
.	O
The	O
HPC	O
Score	O
was	O
then	O
derived	O
based	O
on	O
the	O
final	O
model	O
.	O
Among	O
a	O
total	O
of	O
286	O
eligible	O
patients	O
,	O
61	O
(	O
21	O
%	O
)	O
patients	O
developed	O
HPC	O
.	O
On	O
univariate	O
analyses	O
,	O
HPC	O
was	O
associated	O
with	O
older	O
age	O
,	O
higher	B-T033
initial	I-T033
blood	I-T033
pressure	I-T033
,	O
antiplatelet	B-T121
medications	I-T121
,	O
anticoagulants	B-T121
,	O
subarachnoid	B-T047
hemorrhage	I-T047
(	O
SAH	B-T047
)	O
subdural	O
hematoma	O
(	O
SDH	O
)	O
,	O
skull	O
fracture	O
,	O
frontal	B-T023
contusion	O
,	O
larger	O
contusion	O
volume	O
,	O
and	O
shorter	O
interval	O
from	O
injury	O
to	O
initial	B-T060
CT	I-T060
.	O
In	O
the	O
final	O
model	O
,	O
SAH	B-T047
(	O
OR	O
6.33	O
,	O
95	O
%	O
CI	O
,	O
1.80	O
-	O
22.23	O
)	O
,	O
SDH	O
(	O
OR	O
3.46	O
,	O
95	O
%	O
CI	O
,	O
1.39	O
-	O
8.63	O
)	O
,	O
and	O
skull	O
fracture	O
(	O
OR	O
2.67	O
,	O
95	O
%	O
CI	O
,	O
1.28	O
-	O
5.58	O
)	O
were	O
associated	O
with	O
HPC	O
.	O
Based	O
on	O
these	O
factors	O
,	O
the	O
HPC	O
Score	O
was	O
derived	O
(	O
SAH	B-T047
=	O
2	O
points	O
,	O
SDH	O
=	O
1	O
point	O
,	O
and	O
skull	O
fracture	O
=	O
1	O
point	O
)	O
.	O
This	O
score	O
had	O
an	O
area	O
under	O
the	O
receiver	O
operating	O
curve	O
of	O
0.77	O
.	O
Patients	O
with	O
a	O
score	O
of	O
0	O
-	O
2	O
had	O
a	O
4.0	O
%	O
incidence	O
of	O
HPC	O
,	O
while	O
patients	O
with	O
a	O
score	O
of	O
3	O
-	O
4	O
had	O
a	O
34.6	O
%	O
incidence	O
of	O
HPC	O
.	O
A	O
simple	O
HPC	O
Score	O
was	O
developed	O
for	O
early	O
risk	O
stratification	O
of	O
HPC	O
in	O
patients	O
with	O
moderate	O
or	O
severe	O
TBI	O
.	O
      
Decompression	B-T061
Surgery	I-T061
Alone	O
Versus	O
Decompression	B-T061
Plus	O
Fusion	B-T061
in	O
Symptomatic	O
Lumbar	B-T047
Spinal	I-T047
Stenosis	I-T047
:	O
A	O
Swiss	O
Prospective	O
Multi	O
-	O
center	O
Cohort	O
Study	O
with	O
3	O
Years	O
of	O
Follow	O
-	O
up	O
Retrospective	O
analysis	O
of	O
a	O
prospective	O
,	O
multicenter	O
cohort	O
study	O
.	O
To	O
estimate	O
the	O
added	O
effect	O
of	O
surgical	B-T061
fusion	I-T061
as	O
compared	O
to	O
decompression	B-T061
surgery	I-T061
alone	O
in	O
symptomatic	O
lumbar	B-T047
spinal	I-T047
stenosis	I-T047
patients	O
with	O
spondylolisthesis	B-T047
.	O
The	O
optimal	B-T058
surgical	I-T058
management	I-T058
of	O
lumbar	B-T047
spinal	I-T047
stenosis	I-T047
patients	O
with	O
spondylolisthesis	B-T047
remains	O
controversial	O
.	O
Patients	O
of	O
the	O
LSOS	O
with	O
confirmed	O
DLSS	B-T047
and	O
spondylolisthesis	B-T047
were	O
enrolled	O
in	O
this	O
study	O
.	O
The	O
outcomes	O
of	O
this	O
study	O
were	O
Spinal	B-T020
Stenosis	I-T020
Measure	O
(	O
SSM	O
)	O
symptoms	B-T184
(	O
score	O
range	O
1	O
-	O
5	O
,	O
best	O
-	O
worst	O
)	O
and	O
function	O
(	O
1	O
-	O
4	O
)	O
over	O
time	O
,	O
measured	O
at	O
baseline	O
,	O
6	O
,	O
12	O
,	O
24	O
and	O
36	O
months	O
follow	O
-	O
up	O
.	O
In	O
order	O
to	O
quantify	O
the	O
effect	O
of	O
fusion	B-T061
surgery	I-T061
as	O
compared	O
to	O
decompression	B-T061
alone	O
and	O
number	B-T033
of	I-T033
decompressed	I-T033
levels	I-T033
,	O
we	O
used	O
mixed	O
effects	O
models	O
and	O
accounted	O
for	O
the	O
repeated	O
observations	O
in	O
main	O
outcomes	O
(	O
SSM	O
symptoms	B-T184
and	O
SSM	O
function	O
)	O
over	O
time	O
.	O
In	O
addition	O
to	O
individual	O
patients	O
'	O
random	O
effects	O
,	O
we	O
also	O
fitted	O
random	O
slopes	O
for	O
follow	B-T033
-	I-T033
up	I-T033
time	O
points	O
and	O
compared	O
these	O
two	O
approaches	O
with	O
Akaike	O
's	O
Information	O
Criterion	O
(	O
AIC	O
)	O
and	O
the	O
chi	O
-	O
squared	O
test	O
.	O
Confounders	O
were	O
adjusted	O
with	O
fixed	O
effects	O
for	O
age	O
,	O
gender	O
,	O
BMI	O
,	O
diabetes	B-T047
,	O
CIRS	O
musculoskeletal	B-T047
disorders	I-T047
and	O
duration	B-T121
of	O
symptoms	B-T184
.	O
One	O
hundred	O
and	O
thirty	O
-	O
one	O
patients	O
undergoing	O
decompression	B-T061
surgery	I-T061
alone	O
(	O
n	O
=	O
85	O
)	O
or	O
decompression	B-T061
plus	O
fusion	B-T061
surgery	I-T061
(	O
n	O
=	O
46	O
)	O
were	O
included	O
in	O
this	O
study	O
.	O
In	O
the	O
multiple	O
mixed	O
effects	O
model	O
the	O
adjusted	O
effect	O
of	O
fusion	B-T061
versus	O
decompression	B-T061
alone	I-T061
surgery	I-T061
on	O
SSM	O
symptoms	B-T184
was	O
0.06	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
CI	O
:	O
-0.16	O
to	O
0.27	O
)	O
and	O
-0.07	O
(	O
95	O
%	O
CI	O
:	O
-0.25	O
to	O
0.10	O
)	O
on	O
SSM	O
function	O
,	O
respectively	O
.	O
Among	O
the	O
patients	O
with	O
degenerative	B-T047
lumbar	I-T047
spinal	I-T047
stenosis	I-T047
and	O
spondylolisthesis	B-T047
our	O
study	O
confirms	O
that	O
in	O
the	O
two	O
groups	O
,	O
decompression	B-T061
alone	O
and	O
decompression	B-T061
plus	O
fusion	B-T061
,	O
patients	O
distinctively	O
benefited	O
from	O
surgical	B-T061
treatment	I-T061
.	O
When	O
adjusted	O
for	O
confounders	O
,	O
fusion	B-T061
surgery	I-T061
was	O
not	O
associated	O
with	O
a	O
more	O
favorable	O
outcome	O
in	O
both	O
SSM	O
scores	O
as	O
compared	O
to	O
decompression	B-T061
alone	I-T061
surgery	I-T061
.	O
3	O
.	O
      
Biogeochemical	O
Controls	O
of	O
Uranium	O
Bioavailability	O
from	O
the	O
Dissolved	O
Phase	O
in	O
Natural	O
Freshwaters	O
To	O
gain	O
insights	O
into	O
the	O
risks	O
associated	O
with	O
uranium	O
(	O
U	O
)	O
mining	O
and	O
processing	O
,	O
we	O
investigated	O
the	O
biogeochemical	O
controls	O
of	O
U	O
bioavailability	O
in	O
the	O
model	O
freshwater	O
species	O
Lymnaea	O
stagnalis	O
(	O
Gastropoda	O
)	O
.	O
Bioavailability	O
of	O
dissolved	O
U(VI	O
)	O
was	O
characterized	O
in	O
controlled	O
laboratory	O
experiments	O
over	O
a	O
range	O
of	O
water	B-T121
hardness	O
,	O
pH	O
,	O
and	O
in	O
the	O
presence	B-T033
of	O
complexing	O
ligands	O
in	O
the	O
form	O
of	O
dissolved	O
natural	O
organic	O
matter	O
(	O
DOM	O
)	O
.	O
Results	O
show	O
that	O
dissolved	O
U	O
is	O
bioavailable	O
under	O
all	O
the	O
geochemical	O
conditions	O
tested	O
.	O
Uranium	O
uptake	O
rates	O
follow	O
first	O
order	O
kinetics	O
over	O
a	O
range	O
encompassing	O
most	O
environmental	O
concentrations	O
.	O
Uranium	O
uptake	O
rates	O
in	O
L.	O
stagnalis	O
ultimately	O
demonstrate	O
saturation	O
uptake	O
kinetics	O
when	O
exposure	O
concentrations	O
exceed	O
100	O
nM	O
,	O
suggesting	O
uptake	O
via	O
a	O
finite	O
number	O
of	O
carriers	O
or	O
ion	O
channels	O
.	O
The	O
lack	O
of	O
a	O
relationship	O
between	O
U	O
uptake	O
rate	O
constants	O
and	O
Ca	B-T121
uptake	O
rates	O
suggest	O
that	O
U	O
does	O
not	O
exclusively	O
use	O
Ca	B-T121
membrane	O
transporters	O
.	O
In	O
general	O
,	O
U	O
bioavailability	O
decreases	B-T033
with	O
increasing	O
pH	O
,	O
increasing	O
Ca	B-T121
and	O
Mg	O
concentrations	O
,	O
and	O
when	O
DOM	O
is	O
present	B-T033
.	O
Competing	O
ions	O
did	O
not	O
affect	O
U	O
uptake	O
rates	O
.	O
Speciation	O
modeling	O
that	O
includes	O
formation	O
constants	O
for	O
U	O
ternary	O
complexes	O
reveals	O
that	O
the	O
aqueous	O
concentration	O
of	O
dicarbonato	O
U	O
species	O
(	O
UO2(CO3)2(-2	O
)	O
)	O
best	O
predicts	O
U	O
bioavailability	O
to	O
L.	O
stagnalis	O
,	O
challenging	O
the	O
free	O
-	O
ion	O
activity	O
model	O
postulate	O
.	O
      
Wiedemann	B-T047
-	I-T047
Rautenstrauch	I-T047
Syndrome	I-T047
With	O
Bilateral	O
Tarsal	B-T019
Kink	I-T019
:	O
Three	O
Sutures	B-T061
for	O
Correction	O
The	O
authors	O
describe	O
a	O
5-	O
month	O
-	O
old	O
male	O
infant	O
with	O
Wiedemann	B-T047
-	I-T047
Rautenstrauch	I-T047
syndrome	I-T047
,	O
which	O
is	O
an	O
extremely	O
rare	O
condition	B-T047
.	O
He	O
had	O
tarsal	B-T019
kink	I-T019
in	O
upper	B-T023
eyelids	I-T023
in	O
both	B-T023
eyes	I-T023
.	O
The	O
authors	O
treated	O
bilateral	O
tarsal	B-T019
kink	I-T019
with	O
an	O
everting	B-T058
suture	B-T061
via	O
a	O
transconjunctival	O
approach	O
under	O
local	B-T061
anesthesia	I-T061
.	O
      
Direct	O
effects	O
of	O
glucose	B-T121
,	O
insulin	B-T121
,	O
GLP-1	O
,	O
and	O
GIP	B-T121
on	O
bulbospinal	O
neurons	O
in	O
the	O
rostral	B-T023
ventrolateral	I-T023
medulla	I-T023
in	O
neonatal	O
wistar	O
rats	O
Although	O
patients	O
with	O
diabetes	B-T047
mellitus	I-T047
(	O
DM	B-T047
)	O
often	O
exhibit	O
hypertension	B-T047
,	O
the	O
mechanisms	O
responsible	O
for	O
this	O
correlation	O
are	O
not	O
well	O
known	O
.	O
We	O
hypothesized	O
that	O
the	O
bulbospinal	O
neurons	O
in	O
the	O
rostral	B-T023
ventrolateral	I-T023
medulla	I-T023
(	O
RVLM	B-T023
)	O
are	O
affected	O
by	O
the	O
levels	O
of	O
glucose	B-T121
,	O
insulin	B-T121
,	O
or	O
incretins	B-T121
(	O
glucagon	O
like	O
peptide-1	O
[	O
GLP-1	O
]	O
or	O
glucose	B-T121
-	I-T121
dependent	I-T121
insulinotropic	I-T121
peptide	I-T121
[	O
GIP	B-T121
]	O
)	O
in	O
patients	O
with	O
DM	B-T047
.	O
To	O
investigate	O
whether	O
RVLM	B-T023
neurons	O
are	O
activated	O
by	O
glucose	B-T121
,	O
insulin	B-T121
,	O
GLP-1	O
,	O
or	O
GIP	B-T121
,	O
we	O
examined	O
changes	O
in	O
the	O
membrane	O
potentials	O
of	O
bulbospinal	O
RVLM	B-T023
neurons	O
using	O
whole	O
-	O
cell	O
patch	O
-	O
clamp	O
technique	O
during	O
superfusion	O
with	O
various	O
levels	O
of	O
glucose	B-T121
or	O
these	O
hormones	O
in	O
neonatal	O
Wistar	O
rats	O
.	O
A	O
brainstem	B-T023
-	O
spinal	B-T023
cord	I-T023
preparation	O
was	O
used	O
for	O
the	O
experiments	O
.	O
A	O
low	O
level	O
of	O
glucose	B-T121
stimulated	O
bulbospinal	O
RVLM	B-T023
neurons	O
.	O
During	O
insulin	B-T121
superfusion	O
,	O
almost	O
all	O
the	O
RVLM	B-T023
neurons	O
were	O
depolarized	O
,	O
while	O
during	O
GLP-1	O
or	O
GIP	B-T121
superfusion	O
,	O
almost	O
all	O
the	O
RVLM	B-T023
neurons	O
were	O
hyperpolarized	O
.	O
Next	O
,	O
histological	B-T059
examinations	I-T059
were	O
performed	O
to	O
examine	O
transporters	O
for	O
glucose	O
and	O
receptors	O
for	O
insulin	B-T121
,	O
GLP-1	O
,	O
and	O
GIP	B-T121
on	O
RVLM	B-T023
neurons	O
.	O
Low	O
-	O
level	O
glucose	B-T121
-	O
depolarized	O
RVLM	B-T023
neurons	O
exhibited	O
the	O
presence	O
of	O
glucose	O
transporter	O
3	O
(	O
GLUT3	O
)	O
.	O
Meanwhile	O
,	O
insulin	B-T121
-	O
depolarized	O
,	O
GLP-1	O
-	O
hyperpolarized	O
,	O
and	O
GIP	B-T121
-	O
hyperpolarized	O
RVLM	B-T023
neurons	O
showed	O
each	O
of	O
the	O
respective	O
specific	O
receptor	O
.	O
These	O
results	O
indicate	O
that	O
a	O
low	O
level	O
of	O
glucose	B-T121
stimulates	O
bulbospinal	O
RVLM	B-T023
neurons	O
via	O
specific	O
transporters	O
on	O
these	O
neurons	O
,	O
inducing	O
hypertension	B-T047
.	O
Furthermore	O
,	O
an	O
increase	O
in	O
insulin	B-T121
or	O
a	O
reduction	O
in	O
incretins	B-T121
may	O
also	O
activate	O
the	O
sympathetic	O
nervous	O
system	O
and	O
induce	O
hypertension	B-T047
by	O
activating	O
RVLM	B-T023
neurons	O
via	O
their	O
own	O
receptors	O
.	O
      
Detection	B-T061
of	O
AMA	O
-	O
M2	O
in	O
human	O
saliva	O
:	O
Potentials	O
in	O
diagnosis	B-T033
and	O
monitoring	B-T058
of	O
primary	B-T047
biliary	I-T047
cholangitis	I-T047
Serum	O
anti	O
-	O
mitochondrial	O
antibody	O
type	O
2	O
(	O
AMA	O
-	O
M2	O
)	O
is	O
considered	O
as	O
a	O
pivotal	O
biomarker	O
for	O
the	O
diagnosis	B-T033
of	O
primary	B-T047
biliary	I-T047
cholangitis	I-T047
(	O
PBC	B-T047
)	O
.	O
However	O
,	O
serological	B-T059
tests	I-T059
have	O
many	O
limitations	O
,	O
including	O
inconvenience	B-T033
,	O
invasiveness	O
,	O
and	O
infection	B-T033
risks	I-T033
.	O
Thus	O
,	O
a	O
less	O
invasive	O
approach	O
to	O
detect	B-T033
AMA	B-T059
-	I-T059
M2	I-T059
titer	I-T059
is	O
desirable	O
.	O
We	O
examined	O
salivary	O
AMA	O
-	O
M2	O
of	O
potential	O
PBC	B-T047
patients	O
and	O
found	O
that	O
AMA	O
-	O
M2	O
could	O
be	O
detected	B-T033
only	O
in	O
saliva	O
of	O
serum	O
AMA	B-T033
-	I-T033
M2	I-T033
-	I-T033
positive	I-T033
PBC	B-T047
patients	O
,	O
but	O
not	O
in	O
saliva	O
of	O
serum	O
AMA	B-T033
-	I-T033
M2	I-T033
-	I-T033
negative	I-T033
PBC	B-T047
patients	O
,	O
oral	B-T047
lichen	I-T047
planus	I-T047
patients	O
(	O
OLP	B-T047
)	O
patients	O
,	O
or	O
healthy	O
controls	O
.	O
Furthermore	O
,	O
the	O
concentration	O
of	O
salivary	O
AMA	O
-	O
M2	O
was	O
positively	O
correlated	O
with	O
the	O
amount	O
of	O
serum	O
AMA	O
-	O
M2	O
in	O
patients	O
.	O
The	O
salivary	O
inflammatory	O
cytokines	O
were	O
increased	O
in	O
the	O
PBC	B-T047
,	O
consistent	O
with	O
the	O
results	O
of	O
serum	O
test	B-T059
.	O
These	O
findings	O
indicated	O
that	O
saliva	O
might	O
be	O
a	O
less	O
invasive	O
and	O
cost	O
-	O
effective	O
medium	O
to	O
accurately	O
test	O
for	O
AMA	B-T059
-	I-T059
M2	I-T059
levels	I-T059
and	O
this	O
is	O
a	O
promising	O
development	O
for	O
the	O
diagnosis	B-T033
and	O
monitoring	B-T058
of	O
PBC	B-T047
.	O
      
Pyoderma	B-T047
gangrenosum	I-T047
:	O
A	O
clinician	O
's	O
nightmare	B-T184
Pyoderma	B-T047
gangrenosum	I-T047
(	O
PG	B-T047
)	O
is	O
a	O
rare	B-T047
disease	I-T047
and	O
that	O
affecting	O
specifically	O
the	O
sole	O
of	O
the	O
foot	O
,	O
is	O
even	O
rarer	O
.	O
Here	O
,	O
we	O
report	O
the	O
case	O
of	O
a	O
54	O
-	O
year-	O
old	O
female	O
admitted	B-T058
with	O
a	O
painful	B-T184
ulcer	B-T047
on	O
the	O
sole	O
of	O
the	O
right	O
foot	O
which	O
was	O
initially	O
treated	B-T061
with	I-T061
empirical	O
antibiotics	B-T195
and	O
debridement	B-T061
.	O
The	O
disease	B-T047
was	O
found	O
to	O
spread	O
rapidly	O
after	O
each	O
debridement	B-T061
.	O
The	O
culture	O
reports	O
were	O
negative	B-T033
;	O
rheumatology	O
workup	B-T060
and	O
Doppler	B-T060
study	I-T060
were	O
within	O
normal	B-T033
limits	I-T033
.	O
A	O
clinical	O
suspicion	O
of	O
PG	B-T047
was	O
made	O
and	O
was	O
confirmed	O
with	O
tissue	B-T060
biopsy	I-T060
.	O
She	O
was	O
started	B-T061
on	I-T061
oral	I-T061
steroids	I-T061
following	O
which	O
she	O
dramatically	O
improved	B-T033
.	O
Thus	O
,	O
when	O
a	O
patient	O
presents	O
with	O
a	O
rapidly	O
expanding	O
painful	B-T184
ulcer	B-T047
in	O
a	O
vascular	B-T023
limb	I-T023
that	O
is	O
refractory	O
to	O
antibiotic	B-T061
treatment	I-T061
and	O
exacerbating	O
on	O
debridement	B-T061
,	O
it	O
is	O
imperative	O
to	O
consider	O
the	O
possibility	O
of	O
PG	B-T047
.	O
      
Injury	O
surveillance	O
of	O
female	O
adult	O
Zumba	B-T058
®	O
dancers	O
We	O
sought	O
to	O
describe	O
the	O
patterns	O
of	O
injury	O
and	O
to	O
establish	O
the	O
injury	O
incidence	O
rates	O
associated	O
with	O
Zumba	B-T058
®	O
.	O
Zumba	B-T058
®	O
dancers	O
were	O
invited	O
to	O
complete	O
an	O
anonymous	O
web	O
-	O
based	O
survey	O
containing	O
13	O
demographic	O
background	O
and	O
14	O
(	O
1	O
yr	O
retrospective	O
)	O
injury	O
history	O
questions	O
.	O
Inclusion	O
criteria	O
stated	O
that	O
the	O
respondents	O
had	O
to	O
be	O
aged	O
18	O
-	O
64	O
yr	O
and	O
currently	O
involved	O
in	O
group	O
-based	O
classes	O
of	O
Zumba	B-T058
®	O
,	O
either	O
as	O
a	O
registered	O
instructor	O
or	O
class	O
participant	O
.	O
Binomial	O
logistic	O
regression	O
analysis	O
was	O
used	O
to	O
predict	O
the	O
odds	O
of	O
injury	O
during	O
Zumba	B-T058
®	O
and	O
Mann	O
-	O
Whitney	O
tests	O
were	O
employed	O
to	O
ascertain	O
differences	O
between	O
groups	O
.	O
The	O
survey	O
response	O
rate	O
was	O
74	O
%	O
.	O
The	O
final	O
sample	O
of	O
respondents	O
(	O
N	O
=	O
138	O
;	O
female	O
=	O
100	O
%	O
)	O
included	O
19	O
registered	O
instructors	O
and	O
119	O
class	O
participants	O
,	O
of	O
which	O
58	O
%	O
and	O
16	O
%	O
,	O
respectively	O
,	O
sustained	O
≥	O
1	O
injury	O
during	O
Zumba	B-T058
®	O
in	O
the	O
past	O
year	O
.	O
The	O
odds	O
of	O
injury	O
was	O
7	O
(	O
95	O
%	O
CI	O
2	O
-	O
19	O
)	O
times	O
greater	O
(	O
p	O
<	O
0.01	O
)	O
for	O
registered	O
instructors	O
than	O
for	O
class	O
participants	O
.	O
Zumba	B-T058
®	O
dancers	O
had	O
a	O
17	O
(	O
95	O
%	O
CI	O
7	O
-	O
28	O
)	O
%	O
greater	O
(	O
p	O
<	O
0.01	O
)	O
odds	O
of	O
injury	O
for	O
every	O
1	O
h	O
of	O
non-	O
Zumba	B-T058
®	O
-	O
related	O
moderate	O
to	O
vigorous	O
physical	O
activity	O
(	O
MVPA	O
)	O
engagement	O
per	O
week	O
.	O
The	O
injury	O
incidence	O
rate	O
for	O
registered	O
instructors	O
and	O
class	O
participants	O
was	O
5.7	O
(	O
95	O
%	O
CI	O
3.1	O
-	O
8.2	O
)	O
and	O
3.9	O
(	O
95	O
%	O
CI	O
2.5	O
-	O
5.3	O
)	O
injuries	O
per	O
1000	O
h	O
of	O
exposure	O
,	O
respectively	O
.	O
Zumba	B-T058
®	O
presents	O
a	O
low	O
risk	O
of	O
injury	O
;	O
for	O
registered	O
instructors	O
,	O
the	O
increased	O
risk	O
of	O
injury	O
is	O
likely	O
due	O
to	O
the	O
high	O
total	O
volume	O
of	O
MVPA	O
participated	O
in	O
weekly	O
.	O
      
Comparison	O
of	O
pulse	O
wave	O
velocity	O
derived	O
from	O
accelerometer	O
and	O
reflective	B-T060
photo	I-T060
-	I-T060
plethysmography	I-T060
signals	I-T060
placed	O
at	O
the	O
carotid	B-T023
and	O
femoral	B-T023
artery	I-T023
Carotid	B-T023
-	O
femoral	B-T023
pulse	O
wave	O
velocity	O
is	O
an	O
established	O
measure	O
to	O
assess	B-T058
cardiovascular	B-T033
risk	I-T033
and	O
an	O
interesting	O
surrogate	O
parameter	O
towards	O
non	O
-	O
invasive	O
continuous	O
blood	O
pressure	O
inference	O
.	O
Due	O
to	O
progress	O
in	O
sensing	O
technologies	O
for	O
wearable	O
wrist	O
worn	O
sensors	O
,	O
there	O
are	O
low	O
cost	O
sensor	O
combinations	O
of	O
photo	B-T060
-	I-T060
plethysmography	I-T060
and	O
high	O
fidelity	O
accelerometer	O
s	O
available	O
offering	O
access	O
to	O
pulse	B-T058
information	I-T058
from	O
larger	B-T023
arteries	I-T023
complemented	O
by	O
blood	O
volume	O
changes	O
in	O
the	O
superficial	O
tissue	O
.	O
In	O
this	O
work	O
we	O
compare	O
pulse	O
wave	O
velocities	O
derived	O
from	O
accelerometer	O
and	O
reflective	B-T060
photo	I-T060
-	I-T060
plethysmography	I-T060
signals	I-T060
placed	O
at	O
the	O
carotid	B-T023
and	O
femoral	B-T023
artery	I-T023
.	O
We	O
discuss	O
the	O
different	O
underlying	O
physiological	O
processes	O
for	O
the	O
two	O
sensing	O
principles	O
and	O
present	O
experimental	B-T033
results	I-T033
obtained	O
in	O
a	O
study	O
with	O
healthy	O
subjects	O
.	O
      
A	O
rare	O
cause	O
of	O
gastric	B-T047
obstruction	I-T047
:	O
Lighters	O
swallowing	O
The	O
majority	O
of	O
swallowed	B-T033
foreign	I-T033
bodies	I-T033
are	O
thrown	O
spontaneously	O
without	O
causing	O
complications	O
in	O
the	O
digestive	O
system	O
.	O
Multiple	O
number	O
of	O
foreign	O
bodies	O
may	O
be	O
swallowed	O
by	O
psychiatric	O
patients	O
which	O
delay	O
diagnosis	O
and	O
increase	O
the	O
complication	O
rate	O
.	O
Long	O
and	O
hard	O
objects	O
can	O
not	O
pass	O
through	O
the	O
pylorus	B-T023
,	O
and	O
may	O
cause	O
obstruction	O
,	O
ulceration	O
,	O
bleeding	O
and	O
perforation	B-T033
.	O
Endoscopy	B-T060
is	O
used	O
as	O
an	O
effective	O
method	O
in	O
such	O
cases	O
.	O
An	O
exploratory	B-T060
laparatomy	I-T060
was	O
performed	O
after	O
unsuccessful	O
endoscopic	O
foreign	O
object	O
removal	B-T061
in	O
a	O
28	O
-	O
year	O
-	O
old	O
schizophrenic	B-T048
patient	O
with	O
gastric	B-T047
outlet	I-T047
obstruction	I-T047
due	O
to	O
multiple	O
cigarette	O
lighter	O
swallowing	O
.	O
Ten	O
lighters	O
were	O
removed	O
from	O
the	O
stomach	B-T023
through	O
gastrotomy	B-T061
and	O
one	O
more	O
lighter	O
was	O
removed	O
from	O
the	O
descending	B-T023
colon	I-T023
by	O
milking	B-T061
through	O
the	O
anus	B-T023
.	O
The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
discuss	O
encountered	O
difficulties	B-T033
in	O
psychiatric	O
patients	O
who	O
underwent	O
surgery	B-T061
due	O
to	O
intake	O
of	O
foreign	O
bodies	O
.	O
      
Visualization	B-T033
and	O
targeting	O
of	O
LGR5(+	O
)	O
human	O
colon	B-T023
cancer	O
stem	O
cells	O
The	O
cancer	O
stem	O
cell	O
(	O
CSC	O
)	O
theory	O
highlights	O
a	O
self	O
-	O
renewing	O
subpopulation	O
of	O
cancer	O
cells	O
that	O
fuels	O
tumour	B-T191
growth	I-T191
.	I-T191
The	O
existence	O
of	O
human	O
CSCs	O
is	O
mainly	O
supported	O
by	O
xenotransplantation	B-T061
of	O
prospectively	O
isolated	B-T033
cells	I-T033
,	O
but	O
their	O
clonal	O
dynamics	O
and	O
plasticity	O
remain	O
unclear	O
.	O
Here	O
,	O
we	O
show	O
that	O
human	O
LGR5(+	O
)	O
colorectal	O
cancer	O
cells	O
serve	O
as	O
CSCs	O
in	O
growing	O
cancer	B-T191
tissues	O
.	O
Lineage	O
-	O
tracing	B-T059
experiments	I-T059
with	O
a	O
tamoxifen	B-T121
-inducible	O
Cre	O
knock	O
-	O
in	O
allele	O
of	O
LGR5	O
reveal	O
the	O
self	O
-	O
renewal	O
and	O
differentiation	O
capacity	O
of	O
LGR5(+	O
)	O
tumour	O
cells	O
.	O
Selective	O
ablation	B-T061
of	O
LGR5(+	O
)	O
CSCs	O
in	O
LGR5	O
-i	O
Caspase9	O
knock	O
-	O
in	O
organoids	O
leads	O
to	O
tumour	O
regression	O
,	O
followed	O
by	O
tumour	B-T191
regrowth	I-T191
driven	O
by	O
re	O
-	O
emerging	O
LGR5(+	O
)	O
CSCs	O
.	O
KRT20	O
knock	O
-	O
in	O
reporter	O
marks	O
differentiated	O
cancer	O
cells	O
that	O
constantly	O
diminish	O
in	O
tumour	O
tissues	O
,	O
while	O
reverting	O
to	O
LGR5(+	O
)	O
CSCs	O
and	O
contributing	O
to	O
tumour	B-T191
regrowth	I-T191
after	O
LGR5(+	O
)	O
CSC	O
ablation	B-T061
.	O
We	O
also	O
show	O
that	O
combined	O
chemotherapy	B-T061
potentiates	O
targeting	O
of	O
LGR5(+	O
)	O
CSCs	O
.	O
These	O
data	O
provide	O
insights	O
into	O
the	O
plasticity	O
of	O
CSCs	O
and	O
their	O
potential	O
as	O
a	O
therapeutic	O
target	O
in	O
human	O
colorectal	B-T191
cancer	I-T191
.	O
      
Identification	O
of	O
mineral	O
-	O
binding	O
peptides	O
that	O
discriminate	O
between	O
chalcopyrite	O
and	O
enargite	O
Innovative	O
approaches	O
to	O
the	O
separation	O
of	O
minerals	O
and	O
subsequent	O
extraction	B-T059
of	O
metals	O
are	O
imperative	O
owing	O
to	O
the	O
increasing	O
mineralogical	O
complexity	O
of	O
ore	O
deposits	O
that	O
are	O
difficult	O
or	O
even	O
impossible	B-T033
to	O
separate	O
into	O
slurries	O
or	O
solutions	O
containing	O
only	O
the	O
minerals	O
or	O
metals	O
of	O
interest	O
.	O
Low	O
recovery	O
of	O
metal	O
is	O
typical	O
for	O
these	O
complex	O
deposits	O
leading	O
to	O
significant	O
losses	O
to	O
tailings	O
.	O
In	O
addition	O
,	O
the	O
minerals	O
often	O
contain	O
impurities	O
,	O
some	O
toxic	O
,	O
which	O
are	O
difficult	O
and	O
costly	O
to	O
control	O
or	O
manage	O
during	O
the	O
processing	O
of	O
a	O
concentrate	O
or	O
other	O
mineral	O
product	O
.	O
One	O
example	O
of	O
this	O
complex	O
situation	O
is	O
the	O
significant	O
economic	O
and	O
environmental	O
costs	O
associated	O
with	O
diluting	O
and	O
processing	O
copper	B-T121
concentrates	O
containing	O
arsenic	B-T121
(	O
in	O
the	O
form	O
of	O
the	O
mineral	O
enargite	O
,	O
Cu3	O
AsS4	O
)	O
in	O
the	O
production	O
of	O
pure	O
copper	B-T121
.	O
To	O
overcome	O
these	O
separation	O
problems	B-T033
,	O
we	O
have	O
utilized	O
phage	O
display	O
to	O
identify	O
peptides	O
that	O
demonstrate	O
selective	O
recognition	O
of	O
enargite	O
and	O
the	O
arsenic	B-T121
-	O
free	O
copper	O
sulfide	O
,	O
chalcopyrite	O
.	O
Screening	O
of	O
two	O
random	O
peptide	O
phage	O
display	O
libraries	O
resulted	O
in	O
the	O
identification	O
of	O
an	O
enargite	O
-	O
selective	O
peptide	O
with	O
the	O
sequence	O
MHKPTVHIKGPT	O
and	O
a	O
chalcopyrite	O
-	O
selective	O
peptide	O
with	O
the	O
sequence	O
RKKKCKGNCCYTPQ	O
.	O
Mineral	O
-	O
binding	O
selectivity	O
was	O
demonstrated	O
by	O
binding	O
studies	O
,	O
zeta	O
potential	O
determination	B-T059
and	O
immunochemistry	O
.	O
Peptides	O
that	O
have	O
the	O
ability	B-T033
to	O
discriminate	O
between	O
enargite	O
and	O
chalcopyrite	O
provide	O
a	O
greener	O
option	O
for	O
the	O
separation	O
of	O
arsenic	B-T121
containing	O
contaminants	O
from	O
copper	B-T121
concentrates	O
.	O
This	O
represents	O
the	O
first	O
step	O
towards	O
a	O
major	O
advance	O
in	O
the	O
replacement	O
or	O
reduction	O
of	O
toxic	O
collectors	O
as	O
well	O
as	O
reducing	O
the	O
level	O
of	O
arsenic	B-T121
-	O
bearing	O
minerals	O
in	O
the	O
early	O
stages	O
of	O
mineral	O
processing	O
.	O
Biotechnol	O
.	O
Bioeng	O
.	O
2016;9999	O
:	O
1	O
-	O
8	O
.	O
©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc.	O
      
Involvement	O
of	O
intracellular	O
Zn(2	B-T121
+	I-T121
)	I-T121
signaling	O
in	O
LTP	O
at	O
perforant	B-T023
pathway	I-T023
-	O
CA1	B-T023
pyramidal	I-T023
cell	I-T023
synapse	I-T023
Physiological	O
significance	O
of	O
synaptic	O
Zn(2	O
+	O
)	O
signaling	O
was	O
examined	O
at	O
perforant	B-T023
pathway	I-T023
-	O
CA1	B-T023
pyramidal	I-T023
cell	I-T023
synapses	I-T023
.	O
In	O
vivo	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
at	O
perforant	B-T023
pathway	I-T023
-	O
CA1	B-T023
pyramidal	I-T023
cell	I-T023
synapses	I-T023
was	O
induced	O
using	O
a	O
recording	O
electrode	O
attached	O
to	O
a	O
microdialysis	B-T058
probe	O
and	O
the	O
recording	O
region	O
was	O
locally	O
perfused	B-T061
with	O
artificial	O
cerebrospinal	O
fluid	O
(	O
ACSF	O
)	O
via	O
the	O
microdialysis	B-T058
probe	O
.	O
Perforant	B-T023
pathway	I-T023
LTP	O
was	O
not	O
attenuated	O
under	O
perfusion	B-T061
with	O
CaEDTA	O
(	O
10	O
mM	O
)	O
,	O
an	O
extracellular	O
Zn(2	B-T121
+	I-T121
)	I-T121
chelator	O
,	O
but	O
attenuated	O
under	O
perfusion	B-T061
with	O
ZnAF-2DA	O
(	O
50	O
μM	O
)	O
,	O
an	O
intracellular	O
Zn(2	B-T121
+	I-T121
)	I-T121
chelator	O
,	O
suggesting	O
that	O
intracellular	O
Zn(2	B-T121
+	I-T121
)	I-T121
signaling	O
is	O
required	O
for	O
perforant	B-T023
pathway	I-T023
LTP	O
.	O
Even	O
in	O
rat	B-T023
brain	I-T023
slices	I-T023
bathed	O
in	O
CaEDTA	O
in	O
ACSF	O
,	O
intracellular	O
Zn(2	B-T121
+	I-T121
)	I-T121
level	O
,	O
which	O
was	O
measured	O
with	O
intracellular	O
ZnAF-2	O
,	O
was	O
increased	O
in	O
the	O
stratum	B-T023
lacunosum	I-T023
-	I-T023
moleculare	I-T023
where	O
perforant	B-T023
pathway	I-T023
-	O
CA1	B-T023
pyramidal	I-T023
cell	I-T023
synapses	I-T023
were	O
contained	O
after	O
tetanic	B-T061
stimulation	I-T061
.	O
These	O
results	O
suggest	O
that	O
intracellular	O
Zn(2	B-T121
+	I-T121
)	I-T121
signaling	O
,	O
which	O
originates	O
in	O
internal	O
stores/	O
proteins	O
,	O
is	O
involved	O
in	O
LTP	O
at	O
perforant	B-T023
pathway	I-T023
-	O
CA1	B-T023
pyramidal	I-T023
cell	I-T023
synapses	I-T023
.	O
Because	O
the	O
influx	O
of	O
extracellular	O
Zn(2	B-T121
+	I-T121
)	I-T121
,	O
which	O
originates	O
in	O
presynaptic	O
Zn(2	O
+	O
)	O
release	O
,	O
is	O
involved	O
in	O
LTP	O
at	O
Schaffer	O
collateral	O
-	O
CA1	B-T023
pyramidal	I-T023
cell	I-T023
synapses	I-T023
,	O
synapse	O
-dependent	O
Zn(2	B-T121
+	I-T121
)	I-T121
dynamics	O
may	O
be	O
involved	O
in	O
plasticity	O
of	O
postsynaptic	O
CA1	O
pyramidal	O
cells	O
.	O
      
A	O
novel	O
combination	O
treatment	O
to	O
stimulate	B-T061
bone	B-T033
healing	I-T033
and	O
regeneration	O
under	O
hypoxic	O
conditions	O
:	O
photobiomodulation	B-T061
and	O
melatonin	B-T121
Melatonin	B-T121
has	O
anabolic	O
effects	O
on	O
the	O
bone	O
,	O
even	O
under	O
hypoxia	O
,	O
and	O
laser	B-T061
irradiation	I-T061
has	O
been	O
shown	O
to	O
improve	O
osteoblastic	O
differentiation	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
laser	B-T061
irradiation	I-T061
and	O
melatonin	B-T121
would	O
have	O
synergistic	O
effects	O
on	O
osteoblastic	O
differentiation	O
and	O
mineralization	O
under	O
hypoxic	O
conditions	O
.	O
MC3T3	O
-	O
E1	O
cells	O
were	O
exposed	O
to	O
1	O
%	O
oxygen	B-T033
tension	I-T033
for	O
the	O
hypoxia	O
condition	O
.	O
The	O
cells	O
were	O
divided	O
into	O
four	O
groups	O
:	O
G1	O
-	O
osteoblast	O
differentiation	O
medium	O
only	O
(	O
as	O
the	O
hypoxic	O
condition	O
)	O
,	O
G2	O
-	O
treatment	O
with	O
50	O
μM	O
melatonin	B-T121
only	O
,	O
G3	O
-	O
laser	B-T061
irradiation	I-T061
(	O
808	O
nm	O
,	O
80	O
mW	O
,	O
GaAlAs	O
diode	O
)	O
only	O
,	O
and	O
G4	O
-	O
treatment	O
with	O
50	O
μM	O
melatonin	B-T121
and	O
laser	B-T061
irradiation	I-T061
(	O
808	O
nm	O
,	O
80	O
mW	O
,	O
GaAlAs	O
diode	O
)	O
.	O
Immunoblotting	B-T059
showed	O
that	O
osterix	O
expression	O
was	O
markedly	O
increased	O
in	O
the	O
melatonin	B-T121
-	O
treated	O
and	O
laser	B-T061
-	I-T061
irradiated	I-T061
cells	O
at	O
48	O
and	O
72	O
h.	O
In	O
addition	O
,	O
alkaline	O
phosphatase	O
activity	O
significantly	O
increased	O
and	O
continued	O
to	O
rise	O
throughout	O
the	O
experiment	O
.	O
Alizarin	B-T059
Red	I-T059
staining	I-T059
showed	O
markedly	O
increased	O
mineralized	O
nodules	O
as	O
compared	O
with	O
only	O
melatonin	B-T121
-	O
treated	O
or	O
laser	B-T061
-	I-T061
irradiated	I-T061
cells	O
at	O
day	O
7	O
,	O
which	O
significantly	O
increased	O
by	O
day	O
14	O
.	O
Moreover	O
,	O
when	O
melatonin	B-T121
-	O
treated	O
cells	O
were	O
laser	B-T061
-	I-T061
irradiated	I-T061
,	O
the	O
differentiation	O
and	O
mineralization	O
of	O
cells	O
were	O
found	O
to	O
involve	O
p38	O
MAPK	O
and	O
PRKD1	O
signaling	O
mechanisms	O
.	O
However	O
,	O
the	O
enhanced	O
effects	O
of	O
laser	B-T061
irradiation	I-T061
with	O
melatonin	B-T121
were	O
markedly	O
inhibited	O
when	O
the	O
cells	O
were	O
treated	O
with	O
luzindole	O
,	O
a	O
selective	O
melatonin	B-T121
receptor	I-T121
antagonist	I-T121
.	O
Therefore	O
,	O
we	O
concluded	O
that	O
laser	B-T061
irradiation	I-T061
could	O
promote	O
the	O
effect	O
of	O
melatonin	B-T121
on	O
the	O
differentiation	O
and	O
mineralization	O
of	O
MC3T3	O
-	O
E1	O
cells	O
under	O
hypoxic	O
conditions	O
,	O
and	O
that	O
this	O
process	O
is	O
mediated	O
through	O
melatonin	O
1/2	O
receptors	O
and	O
PKRD	O
/	O
p38	O
signaling	O
pathways	O
.	O
      
Serum	B-T059
C	I-T059
-	I-T059
Reactive	I-T059
Protein	I-T059
in	O
Children	O
with	O
Liver	B-T047
Disease	I-T047
and	O
Ascites	B-T033
The	O
diagnosis	O
of	O
peritonitis	O
as	O
a	O
complication	O
of	O
cirrhosis	B-T047
is	O
an	O
important	O
clinical	O
problem	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
serum	B-T059
C	I-T059
-	I-T059
reactive	I-T059
protein	I-T059
levels	I-T059
as	O
a	O
diagnostic	O
factor	O
for	O
spontaneous	B-T047
bacterial	I-T047
peritonitis	I-T047
(	O
SBP	B-T047
)	O
in	O
child	O
patients	O
with	O
liver	B-T047
disease	I-T047
.	O
In	O
this	O
study	O
,	O
150	O
children	O
diagnosed	O
with	O
liver	B-T047
disease	I-T047
and	O
ascites	B-T033
upon	O
admission	B-T058
to	O
Nemazee	O
Teaching	O
Hospital	O
(	O
Shiraz	O
,	O
Iran	O
)	O
were	O
examined	B-T033
.	O
Patients	O
were	O
divided	O
into	O
spontaneous	B-T047
bacterial	I-T047
peritonitis	I-T047
and	O
sterile	O
ascetic	O
fluid	O
groups	O
according	O
to	O
the	O
PMN	B-T059
count	I-T059
≥	O
250	O
/	O
mm(3	O
)	O
in	O
the	O
ascetic	O
fluids	O
.	O
Routine	B-T059
laboratory	I-T059
tests	I-T059
were	O
conducted	O
and	O
quantitative	O
C	B-T059
-	I-T059
reactive	I-T059
protein	I-T059
(	I-T059
CRP	I-T059
)	I-T059
levels	I-T059
were	O
measured	O
for	O
all	O
of	O
the	O
patients	O
.	O
Accuracy	O
,	O
sensitivity	O
,	O
and	O
specificity	O
of	O
CRP	B-T059
was	O
evaluated	O
for	O
diagnosis	O
of	O
SBP	B-T047
.	O
Of	O
150	O
cirrhotic	B-T047
patients	O
,	O
109	O
patients	O
presented	O
without	O
SBP	B-T047
(	O
52.29	O
%	O
male	O
,	O
mean	O
age	O
:	O
5.02	O
±	O
4.49	O
years	O
)	O
and	O
41	O
patients	O
presented	O
with	O
SBP	B-T047
(	O
51.21	O
%	O
male	O
,	O
mean	O
age	O
:	O
4.71	O
years	O
)	O
.	O
Cell	B-T059
counts	I-T059
,	O
protein	O
levels	O
,	O
albumin	O
levels	O
,	O
and	O
lactate	B-T059
dehydrogenize	I-T059
(	I-T059
LDH	I-T059
)	I-T059
levels	I-T059
of	O
the	O
ascetic	O
fluid	O
and	O
serum	O
samples	O
in	O
the	O
SBP	B-T047
group	O
were	O
higher	O
than	O
the	O
rates	O
for	O
those	O
without	O
SBP	B-T047
(	O
P	O
<	O
0.05	O
(	O
.	O
The	O
mean	O
±	O
SD	O
of	O
CRP	B-T059
in	O
the	O
SBP	B-T047
group	O
(	O
36.89	O
±	O
23.43	O
)	O
increased	O
significantly	O
compared	O
to	O
the	O
rate	O
among	O
those	O
without	O
SBP	B-T047
(	O
21.59	O
±	O
15.43	O
,	O
P	O
=	O
0.001	O
)	O
.	O
The	O
percentages	O
for	O
sensitivity	O
and	O
specificity	O
of	O
CRP	B-T059
,	O
the	O
diagnosis	O
of	O
SBP	B-T047
based	O
on	O
the	O
PMN	B-T059
count	I-T059
≥	O
250	O
/	O
mm(3	O
)	O
,	O
and	O
cultured	B-T033
ascites	I-T033
were	O
69.23	O
%	O
,	O
90.25	O
%	O
,	O
88.43	O
%	O
,	O
and	O
84.32	O
%	O
,	O
respectively	O
.	O
The	O
areas	O
under	O
the	O
curve	O
of	O
CRP	B-T059
for	O
SBP	B-T047
based	O
on	O
the	O
PMN	B-T059
count	I-T059
≥	O
250	O
/	O
mm(3	O
)	O
and	O
cultured	B-T033
ascites	I-T033
was	O
0.94	O
(	O
CI	O
95	O
%	O
:	O
0.90	O
to	O
0.96	O
)	O
and	O
0.85	O
(	O
CI	O
95	O
%	O
:	O
0.84	O
to	O
0.92	O
)	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
)	O
.	O
Our	O
study	O
showed	O
that	O
CRP	B-T059
is	O
a	O
marker	O
with	O
high	O
sensitivity	O
and	O
specificity	O
for	O
the	O
diagnosis	O
of	O
SBP	B-T047
in	O
cirrhotic	B-T047
children	O
.	O
      
Epidemiology	O
of	O
polyomavirus	B-T005
BK	I-T005
(	O
BKV	B-T005
)	O
and	O
the	O
emergent	O
African	O
variant	O
in	O
kidney	B-T023
and	O
bone	O
marrow	O
transplant	O
recipients	O
in	O
the	O
Fundacion	O
Valle	O
del	O
Lili	O
in	O
Cali	O
,	O
Colombia	O
To	O
describe	O
the	O
epidemiology	O
of	O
BKV	B-T005
and	O
to	O
assess	O
the	O
presence	B-T033
of	O
the	O
African	O
variant	O
in	O
bone	O
marrow	O
and	O
kidney	B-T033
transplant	I-T033
patients	I-T033
who	O
have	O
suspected	O
BKV	B-T005
reactivation	O
.	O
A	O
descriptive	O
study	O
was	O
conducted	B-T033
,	O
using	O
institutional	O
records	O
,	O
at	O
the	O
Fundación	O
Valle	O
del	O
Lili	O
,	O
Cali	O
-	O
Colombia	O
.	O
The	O
overall	O
prevalence	O
of	O
BKV	B-T005
during	O
the	O
study	O
period	O
was	O
51	O
%	O
.	O
The	O
African	O
variant	O
was	O
identified	O
in	O
49.4	O
%	O
of	O
samples	O
that	O
were	O
positive	B-T033
for	O
BKV	B-T005
.	O
50.6	O
%	O
of	O
the	O
samples	O
were	O
found	O
to	O
have	O
the	O
wild	O
strain	O
of	O
BKV	B-T005
.	O
Among	O
BKV	B-T005
positive	B-T033
patients	O
,	O
57	O
%	O
were	O
kidney	B-T033
transplant	I-T033
recipients	I-T033
and	O
43	O
%	O
were	O
bone	O
marrow	O
transplant	O
recipients	O
.	O
This	O
is	O
the	O
first	O
epidemiological	O
study	O
describing	O
the	O
African	O
variant	O
of	O
BKV	B-T005
in	O
Colombia	O
.	O
      
A	O
Comparison	O
Between	O
Measured	O
Concentration	O
of	O
3H	O
in	O
Kalpakkam	O
Environment	O
with	O
Predicted	O
Atmospheric	O
Dispersion	O
Model	O
The	O
field	O
measurements	O
of	O
3H	O
in	O
the	O
form	O
of	O
HTO	O
present	O
in	O
air	O
moisture	O
carried	O
out	O
around	O
Madras	O
Atomic	O
Power	O
Station	O
were	O
compared	O
with	O
predicted	O
values	O
using	O
atmospheric	O
dispersion	O
modeling	O
.	O
Air	O
3H	O
samples	O
were	O
collected	O
from	O
different	O
sectors	O
at	O
the	O
site	O
boundary	O
of	O
the	O
operating	O
reactors	O
for	O
the	O
period	O
of	O
2	O
y	O
and	O
compared	O
with	O
Gaussian	O
Plume	O
model	O
.	O
The	O
predictions	O
were	O
comparable	O
with	O
the	O
measured	O
value	O
.	O
The	O
slight	O
variation	O
observed	O
between	O
the	O
two	O
methods	O
is	O
attributed	O
to	O
the	O
uncertainty	B-T033
involved	O
in	O
the	O
measurement	O
of	O
air	O
3H	O
concentration	O
and	O
in	O
the	O
measurement	O
of	O
site	O
-	O
specific	O
meteorological	O
parameters	O
.	O
The	O
radiation	O
dose	O
imparted	O
to	O
members	O
of	O
public	O
due	O
to	O
the	O
levels	O
observed	O
is	O
well	O
within	O
station	O
technical	O
specification	O
limit	O
for	O
3H.	O
      
Effect	O
of	O
Xenotransplantation	B-T061
Site	O
on	O
MicroRNA	O
Expression	O
of	O
Human	O
Colon	B-T191
Cancer	I-T191
Stem	O
Cells	O
Cancer	O
stem	O
cells	O
(	O
CSCs	O
)	O
have	O
a	O
high	O
tumorigenic	B-T191
ability	O
to	O
form	O
patient	B-T050
-	I-T050
derived	I-T050
tumor	I-T050
xenografts	I-T050
(	O
PDXs	B-T050
)	O
.	O
PDXs	B-T050
are	O
an	O
attractive	O
pre	O
-	O
clinical	O
model	O
,	O
but	O
gene	O
expression	O
and	O
biological	O
behavior	O
of	O
cancer	O
cells	O
in	O
the	O
tumor	B-T191
will	O
change	O
during	O
establishment	O
and	O
passage	O
of	O
PDXs	B-T050
.	O
Human	O
colon	B-T191
cancer	I-T191
PDX	B-T050
was	O
established	O
and	O
passaged	B-T059
either	O
subcutaneously	O
or	O
orthotopically	O
into	O
the	O
murine	O
intestine	B-T023
.	O
Histology	O
and	O
flow	B-T059
cytometric	I-T059
profile	B-T059
of	O
the	O
surgical	B-T061
specimen	O
and	O
the	O
PDX	B-T050
were	O
analyzed	O
.	O
CSCs	O
were	O
then	O
isolated	O
from	O
the	O
tumors	B-T191
and	O
their	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
was	O
analyzed	O
by	O
semi	B-T059
-	I-T059
quantitative	I-T059
polymerase	I-T059
chain	I-T059
reaction	I-T059
.	O
The	O
surgical	B-T061
specimens	O
and	O
PDXs	B-T050
were	O
histologically	O
similar	O
.	O
The	O
size	O
of	O
CSC	O
population	O
increased	O
and	O
expression	O
of	O
miRNA	O
s	O
in	O
CSCs	O
changed	O
in	O
the	O
passaged	B-T059
PDXs	B-T050
.	O
Expression	O
of	O
oncogenic	O
miRNAs	O
was	O
highly	O
up	O
-	O
regulated	O
in	O
the	O
CSCs	O
of	O
the	O
orthotopically	O
passaged	B-T059
PDXs	B-T050
.	O
The	O
xenotransplantation	B-T061
site	O
and	O
the	O
number	O
of	O
tumor	B-T191
passages	B-T059
affect	O
the	O
miRNA	O
expression	O
of	O
human	O
colon	B-T023
CSCs	O
.	O
      
Unusual	O
asymptomatic	B-T047
presentation	I-T047
of	O
bladder	B-T191
cancer	I-T191
metastatic	B-T191
to	I-T191
the	I-T191
penis	I-T191
Penile	B-T191
metastasis	I-T191
is	O
an	O
extremely	B-T047
rare	I-T047
event	I-T047
and	O
mainly	O
originate	O
from	O
primary	O
pelvic	B-T023
tumor	O
sites	O
such	O
us	O
urinary	B-T023
bladder	I-T023
,	O
gastro	O
-	O
intestinal	O
tract	O
and	O
prostate	B-T023
and	O
more	O
rarely	O
from	O
respiratory	O
system	O
,	O
bone	B-T191
tumors	I-T191
and	O
melanoma	B-T191
.	O
Here	O
we	O
describe	O
the	O
unusual	O
presentation	O
of	O
two	O
bladder	B-T191
urothelial	I-T191
cancer	I-T191
metastatic	O
to	O
the	O
penis	B-T023
with	O
no	B-T033
relevant	I-T033
clinical	I-T033
symptoms	I-T033
.	O
Namely	O
,	O
a	O
69	O
years	O
-	O
old	O
man	O
with	O
a	O
warthy	O
lesions	B-T033
of	O
the	O
foreskin	O
and	O
the	O
glans	O
misunderstood	O
for	O
a	O
condylomata	B-T047
that	O
at	O
histological	B-T059
and	O
immunohistochemical	B-T059
analysis	I-T059
showed	O
a	O
bladder	B-T191
urothelial	I-T191
carcinoma	I-T191
;	O
and	O
a	O
71	O
years	O
-	O
old	O
man	O
with	O
reddish	O
skin	B-T033
lesion	I-T033
of	I-T033
the	I-T033
glans	I-T033
,	O
a	O
previous	O
history	B-T033
of	I-T033
bladder	I-T033
and	O
urethral	B-T191
carcinoma	I-T191
and	O
histological	B-T033
pagetoid	I-T033
spread	I-T033
of	O
urothelial	B-T191
cancer	I-T191
to	B-T023
the	I-T023
glans	I-T023
.	O
Recurrent	B-T191
bladder	I-T191
urothelial	I-T191
carcinoma	I-T191
is	O
usually	O
a	O
visceral	B-T023
disease	B-T047
that	O
rarely	O
presents	O
as	O
a	O
superficial	O
asymptomatic	B-T033
skin	B-T047
lesion	I-T047
.	O
The	O
two	O
reported	O
cases	B-T033
were	I-T033
asymptomatic	I-T033
superficial	B-T191
penis	I-T191
metastases	I-T191
with	O
a	O
relatively	O
slow	O
growth	O
and	O
a	O
fairy	B-T033
good	I-T033
prognosis	I-T033
after	O
conservative	O
surgical	O
approach	O
.	O
Accurate	O
clinical	O
examination	O
of	O
the	O
penis	O
is	O
mandatory	O
for	O
males	O
with	O
history	B-T033
of	I-T033
bladder	I-T033
cancer	I-T033
.	O
      
Visual	B-T060
Analytics	I-T060
for	O
Pattern	O
Discovery	O
in	O
Home	B-T058
Care	I-T058
.	O
Clinical	O
Relevance	O
for	O
Quality	O
Improvement	O
Visualization	O
can	O
reduce	O
the	O
cognitive	O
load	O
of	O
information	O
,	O
allowing	O
users	O
to	O
easily	O
interpret	O
and	O
assess	B-T058
large	I-T058
amounts	I-T058
of	I-T058
data	I-T058
.	O
The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
examine	O
home	O
health	O
data	O
using	O
visual	B-T060
analysis	I-T060
techniques	I-T060
to	O
discover	O
clinically	O
salient	O
associations	O
between	O
patient	O
characteristics	O
with	O
problem	O
-	O
oriented	O
health	O
outcomes	O
of	O
older	B-T058
adult	I-T058
home	I-T058
health	I-T058
patients	I-T058
during	O
the	O
home	B-T058
health	I-T058
service	I-T058
period	O
.	O
Knowledge	O
,	O
Behavior	O
and	O
Status	O
ratings	O
at	O
discharge	B-T058
as	O
well	O
as	O
change	O
from	O
admission	B-T058
to	O
discharge	B-T058
that	O
was	O
coded	O
using	O
the	O
Omaha	O
System	O
was	O
collected	O
from	O
a	O
dataset	O
on	O
988	O
de	O
-	O
identified	O
patient	O
data	O
from	O
15	O
home	O
health	O
agencies	O
.	O
SPSS	O
Visualization	O
Designer	O
v1.0	O
was	O
used	O
to	O
visually	B-T060
analyze	I-T060
patterns	I-T060
between	O
independent	O
and	O
outcome	O
variables	O
using	O
heat	O
maps	O
and	O
histograms	O
.	O
Visualizations	O
suggesting	O
clinical	B-T033
salience	I-T033
were	O
tested	O
for	O
significance	O
using	O
correlation	O
analysis	O
.	O
The	O
mean	O
age	O
of	O
the	O
patients	O
was	O
80	O
years	O
,	O
with	O
the	O
majority	O
female	O
(	O
66	O
%	O
)	O
.	O
Of	O
the	O
150	O
visualizations	O
,	O
69	O
potentially	O
meaningful	O
patterns	O
were	O
statistically	O
evaluated	O
through	O
bivariate	O
associations	O
,	O
revealing	O
21	O
significant	O
associations	O
.	O
Further	O
,	O
14	O
associations	O
between	O
episode	O
length	O
and	O
Charlson	O
co	O
-	O
morbidity	O
index	O
mainly	O
with	O
urinary	O
related	O
diagnoses	B-T047
and	I-T047
problems	I-T047
remained	O
significant	O
after	O
adjustment	O
analyses	O
.	O
Through	O
visual	B-T060
analysis	I-T060
,	O
the	O
adverse	O
association	O
of	O
the	O
longer	O
home	B-T058
health	I-T058
episode	I-T058
length	O
and	O
higher	O
Charlson	O
co	O
-	O
morbidity	O
index	O
with	O
behavior	B-T033
or	I-T033
status	I-T033
outcomes	I-T033
for	O
patients	O
with	O
impaired	B-T047
urinary	I-T047
function	I-T047
was	O
revealed	O
.	O
We	O
have	O
demonstrated	O
the	O
use	O
of	O
visual	B-T060
analysis	I-T060
to	O
discover	O
novel	O
patterns	O
that	O
described	O
high	O
-	O
needs	O
subgroups	O
among	O
the	O
older	O
home	O
health	O
patient	O
population	O
.	O
The	O
effective	O
presentation	O
of	O
these	O
data	O
patterns	O
can	O
allow	O
clinicians	O
to	O
identify	O
areas	O
of	O
patient	O
improvement	O
,	O
and	O
time	O
periods	O
that	O
are	O
most	O
effective	O
for	O
implementing	O
home	B-T058
health	I-T058
interventions	I-T058
to	O
improve	O
patient	B-T058
outcomes	I-T058
.	O
      
Variety	O
of	O
DNA	O
Replication	O
Activity	O
Among	O
Cyanobacteria	B-T007
Correlates	O
with	O
Distinct	O
Respiration	O
Activity	O
in	O
the	O
Dark	O
Cyanobacteria	B-T007
exhibit	O
light	O
-dependent	O
cell	O
growth	O
since	O
most	O
of	O
their	O
cellular	O
energy	O
is	O
obtained	O
by	O
photosynthesis	O
.	O
In	O
Synechococcus	B-T007
elongatus	I-T007
PCC	I-T007
7942	I-T007
,	O
one	O
of	O
the	O
model	O
cyanobacteria	B-T007
,	O
DNA	O
replication	O
depends	O
on	O
photosynthetic	O
electron	O
transport	O
.	O
However	O
,	O
the	O
critical	O
signal	O
for	O
the	O
regulatory	O
mechanism	O
of	O
DNA	O
replication	O
has	O
not	O
been	O
identified	O
.	O
In	O
addition	O
,	O
conservation	O
of	O
this	O
regulatory	O
mechanism	O
has	O
not	O
been	O
investigated	O
among	O
cyanobacteria	B-T007
.	O
To	O
understand	O
this	O
regulatory	O
signal	O
and	O
its	O
dependence	O
on	O
light	O
,	O
we	O
examined	O
the	O
regulation	O
of	O
DNA	O
replication	O
under	O
both	O
light	O
and	O
dark	O
conditions	O
among	O
three	O
model	O
cyanobacteria	B-T007
,	O
S.	B-T007
elongatus	I-T007
PCC	I-T007
7942	I-T007
,	O
Synechocystis	B-T007
sp	I-T007
.	I-T007
PCC	I-T007
6803	I-T007
and	O
Anabaena	B-T007
sp	I-T007
.	I-T007
PCC	I-T007
7120	I-T007
.	O
Interestingly	O
,	O
DNA	O
replication	O
activity	O
in	O
Synechocystis	B-T007
and	O
Anabaena	B-T007
was	O
retained	O
when	O
cells	O
were	O
transferred	B-T033
to	I-T033
the	O
dark	O
,	O
although	O
it	O
was	O
drastically	O
decreased	O
in	O
S.	B-T007
elongatus	I-T007
.	O
Glycogen	O
metabolism	O
and	O
respiration	O
were	O
higher	O
in	O
Synechocystis	B-T007
and	O
Anabaena	B-T007
than	O
in	O
S.	B-T007
elongatus	I-T007
in	O
the	O
dark	O
.	O
Moreover	O
,	O
DNA	O
replication	O
activity	O
in	O
Synechocystis	B-T007
and	O
Anabaena	B-T007
was	O
reduced	O
to	O
the	O
same	O
level	O
as	O
that	O
in	O
S.	B-T007
elongatus	I-T007
by	O
inhibition	O
of	O
respiratory	O
electron	O
transport	O
after	O
transfer	O
to	O
the	O
dark	O
.	O
These	O
results	O
demonstrate	O
that	O
there	O
is	O
disparity	B-T033
in	O
DNA	O
replication	O
occurring	O
in	O
the	O
dark	O
among	O
cyanobacteria	B-T007
,	O
which	O
is	O
caused	O
by	O
the	O
difference	O
in	O
activity	O
of	O
respiratory	O
electron	O
transport	O
.	O
      
Kidney	B-T033
transplant	I-T033
recipients	I-T033
after	O
nonrenal	B-T061
solid	I-T061
organ	I-T061
transplantation	I-T061
show	O
low	O
alloreactivity	O
but	O
an	O
increased	O
risk	O
of	O
infection	O
The	O
number	O
of	O
kidney	B-T033
transplant	I-T033
recipients	I-T033
(	O
KTRs	B-T033
)	O
after	O
nonrenal	B-T061
solid	I-T061
organ	I-T061
transplantation	I-T061
(	O
SOT	B-T061
)	O
has	O
increased	O
to	O
almost	O
5	O
%	O
.	O
Knowledge	O
on	O
patient	O
and	O
allograft	B-T061
outcomes	O
,	O
infections	O
,	O
and	O
alloreactivity	O
,	O
however	O
,	O
remains	O
scarce	O
.	O
We	O
studied	O
40	O
KTRs	B-T033
after	O
nonrenal	B-T061
SOT	I-T061
.	O
Seven	O
hundred	O
and	O
twenty	O
primary	O
KTRs	B-T033
and	O
119	O
repeat	O
KTRs	B-T033
were	O
used	O
for	O
comparison	O
.	O
Samples	O
were	O
collected	O
pretransplantation	O
,	O
at	O
+1	O
,	O
+2	O
,	O
and	O
+3	O
months	O
post	O
-	O
transplantation	O
.	O
Alloreactive	O
and	O
CMV	B-T005
-	I-T005
specific	I-T005
T	O
cells	O
were	O
measured	O
by	O
interferon	B-T059
-	I-T059
γ	I-T059
ELISPOT	I-T059
assay	I-T059
.	O
Patient	O
survival	O
in	O
KTRs	B-T033
after	O
SOT	B-T061
,	O
primary	O
and	O
repeat	O
KTRs	B-T033
was	O
comparable	O
.	O
While	O
death	O
-censored	O
allograft	B-T061
survival	O
was	O
comparable	O
between	O
KTRs	B-T033
after	O
SOT	B-T061
and	O
primary	O
KTRs	B-T033
,	O
KTRs	B-T033
after	O
SOT	B-T061
showed	O
superior	O
5	O
-	O
year	O
death	O
-censored	O
allograft	B-T061
survival	O
of	O
92.5	O
%	O
compared	O
to	O
81.2	O
%	O
in	O
repeat	O
KTRs	B-T033
.	O
Interestingly	O
,	O
KTRs	B-T033
after	O
SOT	B-T061
show	O
less	O
preformed	O
panel	B-T059
-	I-T059
reactive	I-T059
antibodies	I-T059
,	O
frequencies	O
of	O
alloreactive	O
T	O
cells	O
,	O
and	O
acute	B-T033
rejections	I-T033
compared	O
to	O
repeat	O
KTRs	B-T033
.	O
KTRs	B-T033
after	O
SOT	B-T061
,	O
however	O
,	O
show	O
higher	O
incidences	O
of	O
EBV	B-T047
viremia	I-T047
and	O
PTLD	B-T191
,	O
sepsis	B-T047
,	O
and	O
death	O
from	O
sepsis	B-T047
.	O
Impaired	O
CMV	B-T005
-	I-T005
specific	I-T005
cellular	O
immunity	O
was	O
associated	O
with	O
more	O
CMV	B-T005
replication	O
compared	O
to	O
repeat	O
KTRs	B-T033
.	O
Our	O
results	O
suggest	O
comparable	O
patient	O
and	O
allograft	B-T061
outcomes	O
in	O
KTRs	B-T033
after	O
SOT	B-T061
and	O
primary	O
KTRs	B-T033
.	O
The	O
observed	O
low	O
alloreactivity	O
may	O
contribute	O
to	O
excellent	O
allograft	B-T061
outcomes	O
.	O
Caution	O
should	O
be	O
taken	O
in	O
KTRs	B-T033
after	O
SOT	B-T061
regarding	O
infectious	B-T047
complications	I-T047
due	O
to	O
overimmunosuppression	B-T047
.	O
      
Extracorporeal	B-T061
membrane	I-T061
oxygenation	I-T061
outcomes	O
in	O
children	O
with	O
hemophagocytic	B-T047
lymphohistiocytosis	I-T047
Pediatric	O
patients	O
with	O
hemophagocytic	B-T047
lymphohistiocytosis	I-T047
(	O
HLH	B-T047
)	O
may	O
develop	O
refractory	O
respiratory	B-T047
or	O
cardiac	B-T047
failure	I-T047
that	O
warrants	O
consideration	B-T033
for	O
extracorporeal	B-T061
membrane	I-T061
oxygenation	I-T061
(	O
ECMO	B-T061
)	O
support	O
.	O
The	O
purposes	O
of	O
this	O
study	O
were	O
to	O
describe	O
the	O
use	O
and	O
outcomes	O
of	O
ECMO	B-T061
in	O
pediatric	O
HLH	B-T047
patients	O
,	O
to	O
identify	O
risk	B-T033
factors	I-T033
for	O
hospital	O
mortality	O
and	O
to	O
compare	O
their	O
ECMO	B-T061
use	O
and	O
outcomes	O
to	O
the	O
ECMO	B-T061
population	O
as	O
a	O
whole	O
.	O
Pediatric	O
patients	O
(	O
⩽	O
18	O
years	O
)	O
with	O
a	O
diagnosis	B-T033
of	O
HLH	B-T047
in	O
the	O
Extracorporeal	B-T058
Life	I-T058
Support	I-T058
Organization	I-T058
(	O
ELSO	B-T058
)	O
Registry	O
were	O
included	O
.	O
Between	O
1983	O
and	O
2014	O
,	O
data	O
for	O
30	O
children	O
with	O
HLH	B-T047
were	O
available	O
in	O
the	O
ELSO	B-T058
registry	O
and	O
all	O
were	O
included	O
in	O
this	O
study	O
.	O
All	O
cases	O
occurred	O
in	O
the	O
last	O
decade	O
.	O
Of	O
the	O
30	O
HLH	B-T047
patients	O
,	O
24	O
(	O
80	O
%	O
)	O
had	O
a	O
respiratory	B-T047
indication	O
for	O
ECMO	B-T061
and	O
six	O
(	O
20	O
%	O
)	O
had	O
a	O
cardiac	B-T047
indication	O
(	O
of	O
which	O
4	O
were	O
E	O
-	O
CPR	B-T061
and	O
2	O
cardiac	B-T047
failure	I-T047
)	O
.	O
Of	O
the	O
24	O
respiratory	B-T047
ECMO	B-T061
patients	O
,	O
63	O
%	O
were	O
placed	O
on	O
VA	B-T061
ECMO	I-T061
.	O
Compared	O
with	O
all	O
pediatric	O
patients	O
in	O
the	O
ELSO	B-T058
registry	O
during	O
the	O
study	O
period	O
(	O
n=17,007	O
)	O
,	O
HLH	B-T047
patients	O
had	O
worse	O
hospital	O
survival	O
(	O
non	O
-	O
HLH	O
59	O
%	O
vs	O
HLH	B-T047
30	O
%	O
,	O
p	O
=	O
0.001	O
)	O
.	O
In	O
pediatric	O
HLH	B-T047
patients	O
,	O
no	O
pre-	O
ECMO	B-T061
risk	B-T033
factors	I-T033
for	O
mortality	O
were	O
identified	O
.	O
The	O
development	O
of	O
a	O
hemorrhagic	O
complication	O
on	O
ECMO	B-T061
was	O
associated	O
with	O
decreased	O
mortality	O
(	O
p	O
=	O
0.01	O
)	O
.	O
Comparing	O
HLH	B-T047
patients	O
with	O
respiratory	B-T047
failure	I-T047
to	O
patients	O
with	O
other	O
immune	O
compromised	O
conditions	O
,	O
the	O
overall	O
survival	O
rate	O
is	O
similar	O
(	O
HLH	B-T047
38	O
%	O
vs.	O
non	O
-	O
HLH	O
immune	O
compromised	O
31	O
%	O
,	O
p	O
=	O
0.64	O
)	O
.	O
HLH	B-T047
is	O
an	O
uncommon	O
indication	O
for	O
ECMO	B-T061
and	O
these	O
patients	O
have	O
increased	O
mortality	O
compared	O
to	O
the	O
overall	O
pediatric	O
ECMO	B-T061
population	O
.	O
These	O
data	O
should	O
be	O
factored	O
into	O
decision	O
-	O
making	O
when	O
considering	O
ECMO	B-T061
for	O
pediatric	O
HLH	B-T047
patients	O
.	O
      
Facilitating	O
factors	O
and	O
barriers	O
to	O
malaria	B-T047
research	O
utilization	O
for	O
policy	O
development	O
in	O
Malawi	O
Research	O
on	O
various	O
determinants	O
of	O
health	O
is	O
key	O
in	O
providing	O
evidence	O
for	O
policy	O
development	O
,	O
thereby	O
leading	O
to	O
successful	O
interventions	O
.	O
Utilization	O
of	O
research	O
is	O
an	O
intricate	O
process	O
requiring	O
an	O
understanding	O
of	O
contextual	O
factors	O
.	O
The	O
study	O
was	O
conducted	O
to	O
assess	O
enhancing	O
factors	O
and	O
barriers	O
of	O
research	O
utilization	O
for	O
malaria	B-T047
policy	O
development	O
in	O
Malawi	O
.	O
Qualitative	O
research	O
approach	O
was	O
used	O
through	O
in	O
-	O
depth	O
interviews	O
with	O
39	O
key	O
informants	O
that	O
included	O
malaria	B-T047
researchers	O
,	O
policy	O
makers	O
,	O
programme	O
managers	O
,	O
and	O
key	O
stakeholders	O
.	O
Purposive	O
sampling	O
and	O
snowballing	O
techniques	O
were	O
used	O
in	O
identifying	O
key	O
informants	O
.	O
Interview	O
transcripts	O
were	O
entered	O
in	O
QSR	O
Nvivo	O
11	O
software	O
for	O
coding	O
and	O
analysis	O
.	O
Respondents	O
identified	O
global	O
efforts	O
as	O
key	O
in	O
advancing	O
knowledge	O
translation	O
,	O
while	O
local	O
political	O
will	O
has	O
been	O
conducive	O
for	O
research	O
utilization	O
.	O
Other	O
factors	O
were	O
availability	O
of	O
research	O
,	O
availability	O
of	O
diverse	O
local	O
researchers	O
and	O
stakeholders	O
supporting	O
knowledge	O
translation	O
.	O
While	O
barriers	O
included	O
:	O
lack	O
of	O
platforms	O
for	O
researcher	O
-	O
public	O
engagement	B-T033
,	O
politics	O
,	O
researchers	O
'	O
lack	O
of	O
communication	O
skills	O
,	O
lack	O
of	O
research	O
collaborations	O
,	O
funder	O
driven	O
research	O
,	O
unknown	O
World	O
Health	O
Organization	O
policy	O
position	O
,	O
and	O
the	O
lack	O
of	O
a	O
malaria	B-T047
research	O
repository	O
.	O
Overall	O
,	O
the	O
study	O
identified	O
facilitating	O
factors	O
to	O
malaria	B-T047
research	O
utilization	O
for	O
policy	O
development	O
in	O
Malawi	O
.	O
These	O
factors	O
need	O
to	O
be	O
systematically	O
coordinated	O
to	O
address	O
the	O
identified	O
barriers	O
and	O
improve	B-T033
on	O
malaria	B-T047
research	O
utilization	O
in	O
policy	O
development	O
.	O
Malaria	B-T047
research	O
can	O
be	O
key	O
in	O
the	O
implementation	O
of	O
evidence	O
-	O
based	O
interventions	O
to	O
reduce	O
the	O
malaria	B-T047
burden	O
and	O
assist	O
in	O
the	O
paradigm	O
shift	O
from	O
malaria	B-T047
control	O
to	O
elimination	O
in	O
Malawi	O
.	O
      
Chronic	O
adiponectin	B-T047
deficiency	I-T047
leads	O
to	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
-like	O
cognitive	B-T048
impairments	I-T048
and	O
pathologies	O
through	O
AMPK	O
inactivation	O
and	O
cerebral	B-T023
insulin	O
resistance	O
in	O
aged	O
mice	O
Insulin	O
resistance	O
is	O
the	O
major	O
pathogenesis	O
underlying	O
type	B-T047
2	I-T047
diabetes	I-T047
mellitus	I-T047
(	O
T2DM	B-T047
)	O
and	O
these	O
patients	O
have	O
doubled	O
risk	O
of	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
(	O
AD	B-T047
)	O
.	O
Increasing	O
evidence	O
suggests	O
that	O
insulin	O
resistance	O
plays	O
an	O
important	O
role	O
in	O
AD	O
pathogenesis	O
,	O
possibly	O
due	O
to	O
abnormal	O
GSK3β	O
activation	O
,	O
causing	O
intra-	O
and	O
extracellular	O
amyloid	O
-	O
beta	O
(	O
Aβ	O
)	O
accumulation	O
.	O
Adiponectin	O
(	O
APN	O
)	O
is	O
an	O
adipokine	O
with	O
insulin	O
-	O
sensitizing	O
and	O
anti	O
-	O
inflammatory	O
effects	O
.	O
Reduced	O
circulatory	O
APN	O
level	O
is	O
associated	O
with	O
insulin	O
resistance	O
and	O
T2DM	B-T047
.	O
The	O
role	O
of	O
APN	O
in	O
AD	B-T047
has	O
not	O
been	O
elucidated	O
.	O
In	O
this	O
study	O
,	O
we	O
aim	O
to	O
examine	O
if	O
adiponectin	B-T047
deficiency	I-T047
adiponectin	B-T047
deficiency	I-T047
would	O
lead	O
to	O
cerebral	B-T023
insulin	O
resistance	O
,	O
cognitive	B-T048
decline	I-T048
and	O
Alzheimer's	O
-	O
like	O
pathology	O
in	O
mice	O
.	O
To	O
study	O
the	O
role	O
of	O
adiponectin	O
in	O
cognitive	O
functions	O
,	O
we	O
employed	O
adiponectin	B-T050
-	I-T050
knockout	I-T050
(	O
APN	O
-	O
KO	O
)	O
mice	O
and	O
demonstrated	O
chronic	O
APN	B-T047
deficiency	I-T047
in	O
their	O
CNS	O
.	O
Behavioral	B-T060
tests	I-T060
were	O
performed	O
to	O
study	O
the	O
cognitions	O
of	O
male	O
APN	O
-	O
KO	O
mice	O
.	O
Brains	B-T023
and	O
tissue	O
lysates	O
were	O
collected	O
to	O
study	O
the	O
pathophysiological	O
and	O
molecular	O
changes	O
in	O
the	O
brain	B-T023
of	O
APN	O
-	O
KO	O
mice	O
.	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cell	O
line	O
was	O
used	O
to	O
study	O
the	O
molecular	O
mechanism	O
upon	O
APN	O
and	O
insulin	B-T061
treatment	I-T061
.	O
Aged	O
APN	O
-deficient	O
mice	O
displayed	O
spatial	O
memory	O
and	O
learning	O
impairments	O
,	O
fear	O
-	O
conditioned	O
memory	B-T048
deficit	I-T048
as	O
well	O
as	O
anxiety	B-T033
.	O
These	O
mice	O
also	O
developed	O
AD	B-T047
pathologies	O
including	O
increased	O
cerebral	B-T023
Aβ42	O
level	O
,	O
Aβ	O
deposition	O
,	O
hyperphosphorylated	O
Tau	O
proteins	O
,	O
microgliosis	O
and	O
astrogliosis	O
with	O
increased	O
cerebral	B-T023
IL-1β	O
and	O
TNFα	O
levels	O
that	O
associated	O
with	O
increased	O
neuronal	O
apoptosis	O
and	O
reduced	O
synaptic	O
proteins	O
levels	O
,	O
suggesting	O
APN	B-T047
deficiency	I-T047
may	O
lead	O
to	O
neuronal	O
and	O
synaptic	O
loss	O
in	O
the	O
brain	B-T023
.	O
AD	B-T047
pathologies	O
-associated	O
APN	O
-	O
KO	O
mice	O
displayed	O
attenuated	O
AMPK	O
phosphorylation	O
and	O
impaired	O
insulin	O
signaling	O
including	O
decreased	O
Akt	O
induction	O
and	O
increased	O
GSK3β	O
activation	O
in	O
the	O
hippocampus	B-T023
and	O
frontal	B-T023
cortex	I-T023
.	O
Aged	O
APN	O
-KO	O
mice	O
developed	O
hippocampal	B-T023
insulin	O
resistance	O
with	O
reduced	O
pAkt	O
induction	O
upon	O
intracerebral	O
insulin	B-T061
injection	I-T061
.	O
Consistently	O
,	O
APN	O
treatment	B-T061
in	O
SH	O
-	O
SY5Y	O
cells	O
with	O
insulin	O
resistance	O
and	O
overexpressing	O
Aβ	O
induce	O
higher	O
pAkt	O
levels	O
through	O
AdipoR1	O
upon	O
insulin	B-T061
treatment	I-T061
whereas	O
the	O
induction	O
was	O
blocked	O
by	O
compound	O
C	O
,	O
indicating	O
APN	O
can	O
enhance	O
neuronal	O
insulin	O
sensitivity	O
through	O
AMPK	O
activation	O
.	O
Our	O
results	O
indicated	O
that	O
chronic	O
APN	B-T047
deficiency	I-T047
inactivated	O
AMPK	O
causing	O
insulin	O
desensitization	O
and	O
elicited	O
AD	O
-	O
like	O
pathogenesis	O
in	O
aged	O
mice	O
which	O
also	O
developed	O
significant	O
cognitive	B-T048
impairments	I-T048
and	O
psychiatric	B-T184
symptoms	I-T184
.	O
      
Developing	O
elite	O
Neurospora	O
crassa	O
strains	B-T001
for	O
cellulosic	O
ethanol	O
production	O
using	O
fungal	O
breeding	O
The	O
demand	O
for	O
renewable	O
and	O
sustainable	O
energy	O
has	O
generated	O
considerable	O
interest	O
in	O
the	O
conversion	O
of	O
cellulosic	O
biomass	O
into	O
liquid	O
fuels	O
such	O
as	O
ethanol	B-T121
using	O
a	O
filamentous	O
fungus	O
.	O
While	O
attempts	O
have	O
been	O
made	O
to	O
study	O
cellulose	O
metabolism	O
through	O
the	O
use	O
of	O
knock	B-T050
-	I-T050
out	I-T050
mutants	O
,	O
there	O
have	O
been	O
no	O
systematic	O
effort	O
to	O
characterize	O
natural	O
variation	O
for	O
cellulose	O
metabolism	O
in	O
ecotypes	O
adapted	O
to	O
different	O
habitats	O
.	O
Here	O
,	O
we	O
characterized	O
natural	O
variation	O
in	O
saccharification	O
of	O
cellulose	O
and	O
fermentation	O
in	O
73	O
ecotypes	O
and	O
89	O
laboratory	O
strains	B-T001
of	O
the	O
model	O
fungus	O
Neurospora	O
crassa	O
.	O
We	O
observed	O
significant	O
variation	O
in	O
both	O
traits	O
among	O
natural	O
and	O
laboratory	O
generated	O
populations	O
,	O
with	O
some	O
elite	O
strains	B-T001
performing	O
better	O
than	O
the	O
reference	O
strain	B-T001
.	O
In	O
the	O
F1	O
population	O
N345	O
,	O
15	O
%	O
of	O
the	O
population	O
outperformed	O
both	O
parents	O
with	O
the	O
top	O
performing	O
strain	B-T001
having	O
10	O
%	O
improvement	O
in	O
ethanol	O
production	O
.	O
These	O
results	O
suggest	O
that	O
natural	O
alleles	O
can	O
be	O
exploited	O
through	O
fungal	O
breeding	O
for	O
developing	O
elite	O
industrial	O
strains	B-T001
for	O
bioethanol	O
production	O
.	O
      
Unaffected	O
twins	O
discordant	O
for	O
affective	B-T048
disorders	I-T048
show	O
changes	O
in	O
anterior	B-T023
callosal	I-T023
white	O
matter	O
microstructure	O
The	O
neurobiological	O
mechanisms	O
mediating	O
an	O
increased	O
risk	O
to	O
develop	O
affective	B-T048
disorders	I-T048
remain	O
poorly	O
understood	O
.	O
In	O
a	O
group	O
of	O
individuals	O
with	O
a	O
family	B-T033
history	I-T033
of	O
major	B-T048
depressive	I-T048
(	O
MDD	B-T048
)	O
or	O
bipolar	B-T048
disorder	I-T048
(	O
BD	B-T048
)	O
,	O
we	O
investigated	O
the	O
microstructural	O
properties	O
of	O
white	O
matter	O
fiber	B-T023
tracts	I-T023
,	O
that	O
is	O
,	O
cingulum	B-T023
bundle	I-T023
,	O
uncinate	B-T023
fasciculus	I-T023
,	O
anterior	B-T023
limb	I-T023
of	I-T023
the	I-T023
internal	I-T023
capsule	I-T023
,	O
and	O
corpus	B-T023
callosum	I-T023
,	O
that	O
facilitate	O
the	O
communication	O
between	O
brain	O
regions	O
implicated	O
in	O
affective	B-T048
disorders	I-T048
.	O
Eighty	O
-	O
nine	O
healthy	O
mono	O
-	O
or	O
dizygotic	O
twins	O
with	O
a	O
co	O
-	O
twin	O
diagnosed	B-T033
with	O
MDD	B-T048
or	O
BD	B-T048
(	O
high	O
-	O
risk	O
)	O
and	O
57	O
healthy	O
twins	O
with	O
a	O
co	O
-	O
twin	O
with	O
no	B-T033
familial	I-T033
history	I-T033
of	I-T033
affective	B-T048
disorders	I-T048
(	O
low	O
-	O
risk	O
)	O
were	O
included	O
in	O
a	O
diffusion	B-T060
tensor	I-T060
imaging	I-T060
study	I-T060
.	O
The	O
high	O
-	O
risk	O
group	O
showed	O
decreased	O
fractional	B-T060
anisotropy	I-T060
(	O
FA	B-T060
)	O
,	O
a	O
measure	O
of	O
water	B-T121
diffusion	O
directionality	O
,	O
and	O
increased	O
radial	O
diffusivity	O
in	O
the	O
anterior	B-T023
region	I-T023
of	I-T023
corpus	I-T023
callosum	I-T023
compared	O
to	O
the	O
low	O
-	O
risk	O
group	O
.	O
This	O
abnormality	B-T033
was	O
not	O
associated	O
with	O
zygosity	O
or	O
type	O
of	O
depressive	B-T048
disorder	I-T048
of	O
co	O
-	O
twin	O
.	O
The	O
observed	O
decreased	O
anterior	B-T023
callosal	I-T023
fiber	I-T023
FA	B-T060
in	O
the	O
high	O
-	O
risk	O
group	O
may	O
be	O
indicative	O
of	O
a	O
compromised	O
interhemispheric	O
communication	O
between	O
left	B-T023
and	O
right	B-T023
frontal	I-T023
regions	I-T023
critically	O
involved	O
in	O
mood	O
regulation	O
.	O
Reduced	O
anterior	B-T023
callosal	I-T023
FA	B-T060
may	O
act	O
as	O
a	O
vulnerability	O
marker	O
for	O
affective	B-T048
disorders	I-T048
in	O
individuals	O
at	O
familial	O
risk	O
.	O
      
Correlation	O
between	O
the	O
histopathology	O
of	O
chronic	B-T047
urticaria	I-T047
and	O
its	O
clinical	O
picture	O
Chronic	B-T047
urticaria	I-T047
is	O
characterized	O
by	O
transient	O
,	O
pruritic	O
lesions	O
of	O
varying	O
sizes	O
,	O
with	O
central	O
pallor	B-T033
and	O
well	O
-	O
defined	O
edges	O
,	O
with	O
disease	B-T047
duration	O
longer	O
than	O
six	O
weeks	O
.	O
Its	O
cellular	O
infiltrate	O
consists	O
of	O
neutrophils	O
,	O
lymphocytes	O
and	O
eosinophils	O
.	O
There	O
is	O
a	O
subgroup	O
of	O
patients	O
with	O
eosinophilic	O
or	O
neutrophilic	B-T047
urticaria	I-T047
,	O
resistant	O
to	O
the	O
treatment	B-T061
with	O
antihistamines	B-T121
,	O
but	O
that	O
respond	O
to	O
a	O
combination	O
of	O
antihistamine	B-T121
with	O
other	O
drugs	B-T121
.	O
To	O
evaluate	O
the	O
present	O
infiltration	O
in	O
chronic	B-T047
urticaria	I-T047
biopsies	B-T060
and	O
correlate	O
it	O
with	O
the	O
clinical	O
disease	O
activity	O
and	O
response	O
to	O
treatment	O
.	O
Forty	O
-	O
one	O
patients	O
with	O
chronic	B-T047
urticaria	I-T047
were	O
classified	O
according	O
to	O
the	O
score	O
of	O
severity	O
of	O
the	O
disease	B-T047
,	O
response	O
to	O
treatment	O
and	O
type	O
of	O
perivascular	O
infiltrate	O
.	O
Inflammatory	O
infiltrates	O
were	O
divided	O
in	O
eosinophilic	O
(	O
46.30	O
%	O
)	O
,	O
neutrophilic	O
and	O
mixed	O
.	O
An	O
association	O
was	O
found	O
between	O
the	O
eosinophilic	O
infiltrate	O
and	O
clinical	O
scores	O
of	O
greater	O
severity	O
(	O
p	O
=	O
0.002	O
)	O
.	O
This	O
association	O
shows	O
that	O
the	O
eosinophilic	O
inflammatory	O
infiltrates	O
denote	O
high	O
clinical	B-T184
activity	I-T184
,	O
which	O
means	O
more	O
severe	O
and	O
exuberant	O
clinical	O
pictures	O
of	O
the	O
disease	B-T047
.	O
      
A	O
Case	O
of	O
Acute	O
Hepatitis	B-T047
E	I-T047
Infection	I-T047
in	O
a	O
Patient	O
with	O
Non	B-T191
-	I-T191
Hodgkin	I-T191
Lymphoma	I-T191
Treated	B-T061
Successfully	O
with	O
Ribavirin	B-T121
We	O
present	O
the	O
case	O
of	O
a	O
man	O
who	O
,	O
following	O
immunosuppressive	B-T061
treatment	I-T061
for	O
non	B-T191
-	I-T191
Hodgkin	I-T191
lymphoma	I-T191
,	O
became	O
infected	B-T033
with	O
viral	B-T047
hepatitis	I-T047
E	I-T047
E.	O
Acute	O
hepatitis	B-T047
E	I-T047
virus	I-T047
infection	I-T047
should	O
be	O
considered	O
in	O
patients	O
with	O
deranged	O
liver	O
function	O
on	O
a	O
background	O
of	O
haematological	B-T191
malignancies	I-T191
or	O
immunosuppression	B-T047
,	O
even	O
without	O
travel	O
to	O
endemic	O
regions	O
.	O
Whilst	O
clearance	O
is	O
usually	O
spontaneous	O
in	O
immune	O
-	O
competent	O
individuals	O
,	O
these	O
at	O
-	O
risk	O
groups	O
may	O
develop	O
a	O
more	O
complicated	O
and	O
protracted	B-T033
disease	I-T033
course	I-T033
.	O
Thus	O
awareness	O
is	O
important	O
as	O
additional	O
treatment	B-T061
with	O
ribavirin	B-T121
or	O
pegylated	B-T121
interferon	I-T121
may	O
be	O
required	O
,	O
as	O
in	O
this	O
case	O
,	O
in	O
order	O
to	O
help	O
achieve	O
eradication	B-T058
.	O
      
Selected	O
flavonoid	O
compounds	O
as	O
promising	O
inhibitors	O
of	O
protein	O
kinase	O
CK2α	O
and	O
CK2α	O
'	O
,	O
the	O
catalytic	O
subunits	O
of	O
CK2	O
CK2	O
is	O
a	O
ubiquitous	O
protein	O
kinase	O
involved	O
in	O
many	O
cell	O
functions	O
.	O
During	O
the	O
last	O
years	O
it	O
became	O
an	O
interesting	O
target	O
in	O
cancer	O
research	O
.	O
A	O
series	O
of	O
flavonoid	O
compounds	O
was	O
tested	O
as	O
inhibitors	O
of	O
protein	O
kinase	O
CK2	O
.	O
Several	O
substances	O
were	O
found	O
to	O
be	O
highly	O
active	O
against	O
both	O
catalytic	O
subunits	O
with	O
IC50	O
values	O
below	O
1	O
μM	O
in	O
case	O
of	O
CK2α	O
'	O
.	O
The	O
most	O
promising	O
inhibitor	O
we	O
identified	O
is	O
chrysoeriol	O
with	O
IC50	O
values	O
of	O
250	O
and	O
34	O
nM	O
for	O
CK2α	O
and	O
CK2α	O
'	O
,	O
respectively	O
.	O
      
Higher	B-T033
risk	I-T033
of	I-T033
revision	O
for	O
infection	O
using	O
systemic	O
clindamycin	B-T195
prophylaxis	B-T061
than	O
with	O
cloxacillin	B-T195
Background	O
and	O
purpose	O
-	O
Clindamycin	B-T195
has	O
not	O
been	O
compared	O
with	O
other	O
antibiotics	B-T195
for	O
prophylaxis	B-T061
in	O
arthroplasty	B-T061
.	O
Since	O
2009	O
,	O
the	O
Swedish	O
Knee	B-T061
Arthroplasty	I-T061
Register	O
(	O
SKAR	O
)	O
has	O
been	O
collecting	O
information	O
on	O
the	O
prophylactic	B-T061
antibiotic	I-T061
regime	I-T061
used	O
at	O
every	O
individual	O
operation	O
.	O
In	O
Sweden	O
,	O
when	O
there	O
is	O
allergy	O
to	O
penicillin	B-T195
,	O
clindamycin	B-T195
has	O
been	O
the	O
recommended	O
alternative	O
.	O
We	O
examined	O
whether	O
there	O
were	O
differences	O
in	O
the	O
rate	O
of	O
revision	O
due	O
to	O
infection	O
depending	O
on	O
which	O
antibiotic	B-T195
was	O
used	O
as	O
systemic	O
prophylaxis	B-T061
.	O
Patients	O
and	O
methods	O
-	O
Patients	O
who	O
had	O
a	O
total	B-T061
knee	I-T061
arthroplasty	I-T061
(	O
TKA	B-T061
)	O
performed	O
due	O
to	O
osteoarthritis	B-T047
(	O
OA	B-T047
)	O
during	O
the	O
years	O
2009	O
-	O
2015	O
were	O
included	O
in	O
the	O
study	O
.	O
Information	O
on	O
which	O
antibiotic	B-T195
was	O
used	O
was	O
available	O
for	O
80,018	O
operations	O
(	O
55,530	O
patients	O
)	O
.	O
Survival	O
statistics	O
were	O
used	O
to	O
calculate	O
the	O
rate	O
of	O
revision	O
due	O
to	O
infection	O
until	O
the	O
end	O
of	O
2015	O
,	O
comparing	O
the	O
group	O
of	O
patients	O
who	O
received	O
cloxacillin	B-T195
with	O
those	O
who	O
received	O
clindamycin	B-T195
as	O
systemic	O
prophylaxis	B-T061
.	O
Results	O
-	O
Cloxacillin	B-T195
was	O
used	O
in	O
90	O
%	O
of	O
the	O
cases	O
,	O
clindamycin	B-T195
in	O
7	O
%	O
,	O
and	O
cephalosporins	B-T195
in	O
2	O
%	O
.	O
The	O
risk	O
of	O
being	O
revised	O
due	O
to	O
infection	O
was	O
higher	O
when	O
clindamycin	B-T195
was	O
used	O
than	O
when	O
cloxacillin	B-T195
was	O
used	O
(	O
RR	O
=	O
1.5	O
,	O
95	O
%	O
CI	O
:	O
1.2	O
-	O
2.0	O
;	O
p	O
=	O
0.001	O
)	O
.	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
revision	O
rate	O
for	O
other	O
causes	O
(	O
p	O
=	O
0.2	O
)	O
.	O
Interpretation	O
-	O
We	O
advise	O
that	O
patients	O
reporting	O
allergic	O
reaction	O
to	O
penicillin	B-T195
should	O
have	O
their	O
allergic	B-T184
history	I-T184
explored	O
.	O
In	O
the	O
absence	O
of	O
a	O
clear	O
history	B-T184
of	O
type	O
-	O
I	O
allergic	O
reaction	O
(	O
e.g.	O
urticaria	B-T047
,	O
anaphylaxis	B-T047
,	O
or	O
bronchospasm	B-T047
)	O
,	O
we	O
suggest	O
the	O
use	O
of	O
a	O
third	B-T195
-	I-T195
generation	I-T195
cephalosporin	I-T195
instead	O
of	O
clindamycin	B-T195
as	O
perioperative	O
prophylaxis	B-T061
when	O
undergoing	O
a	O
TKR	B-T061
.	O
No	O
recommendation	O
can	O
be	O
given	O
regarding	O
patients	O
with	O
type-1	O
allergy	O
.	O
      
Interaction	O
of	O
the	O
Antimicrobial	B-T121
Peptides	I-T121
Rhesus	B-T121
θ	I-T121
-	I-T121
Defensin	I-T121
and	O
Porcine	O
Protegrin-1	B-T121
with	O
Anionic	O
Phospholipid	O
Monolayers	O
A	O
combination	O
of	O
Langmuir	O
isotherm	O
,	O
Brewster	B-T059
angle	I-T059
microscopy	I-T059
(	O
BAM	B-T059
)	O
,	O
and	O
neutron	O
reflectivity	O
studies	O
have	O
been	O
performed	O
to	O
gain	O
insight	O
into	O
the	O
effects	O
on	O
model	O
bacterial	O
cell	O
membranes	O
of	O
the	O
antimicrobial	B-T121
peptides	I-T121
,	O
Rhesus	B-T121
θ	I-T121
-	I-T121
defensin	I-T121
1	I-T121
(	O
RTD-1	B-T121
)	O
,	O
and	O
porcine	O
protegrin	B-T121
1	I-T121
(	O
PG-1	B-T121
)	O
.	O
The	O
peptides	O
were	O
interacted	O
with	O
monolayers	O
spread	O
at	O
the	O
air	O
-	O
water	B-T121
interface	O
and	O
prepared	O
from	O
a	O
3:1	O
molar	O
mixture	O
of	O
phosphatidylethanolamine	B-T121
and	O
phosphatidylglycerol	O
used	O
to	O
approximate	O
the	O
cell	O
membranes	O
of	O
Gram	B-T007
positive	I-T007
bacteria	I-T007
.	O
The	O
Langmuir	O
film	O
balance	O
measurements	O
show	O
that	O
both	O
peptides	O
perturb	O
the	O
lipid	O
monolayers	O
causing	O
an	O
increase	O
in	O
surface	O
pressure	O
,	O
and	O
the	O
BAM	B-T059
studies	O
show	O
that	O
each	O
results	O
in	O
the	O
formation	O
of	O
small	O
domains	O
within	O
the	O
lipid	O
films	O
,	O
around	O
5	O
μm	O
diameter	O
.	O
The	O
overall	O
change	O
in	O
monolayer	O
surface	O
pressure	O
caused	O
by	O
PG-1	B-T121
,	O
however	O
,	O
is	O
a	O
little	O
more	O
pronounced	O
than	O
that	O
due	O
to	O
RTD-1	B-T121
(	O
+8.5	O
mN·m(-1	O
)	O
vs	O
+5.5	O
mN·m(-1	O
)	O
)	O
,	O
and	O
the	O
rate	O
of	O
its	O
initial	O
interaction	O
with	O
the	O
monolayer	O
is	O
a	O
little	O
more	O
rapid	O
than	O
that	O
for	O
RTD-1	B-T121
.	O
The	O
neutron	O
reflectivity	O
studies	O
also	O
show	O
differences	O
for	O
PG-1	B-T121
and	O
RTD-1	B-T121
,	O
with	O
the	O
model	O
fits	O
to	O
these	O
data	O
showing	O
that	O
the	O
more	O
amphiphilic	B-T121
PG-1	B-T121
becomes	O
fully	O
embedded	B-T059
within	O
the	O
lipid	O
film	O
-causing	O
an	O
extension	O
of	O
the	O
lipid	O
acyl	O
chains	O
but	O
leaving	O
the	O
thickness	O
of	O
the	O
lipid	O
headgroup	O
layer	O
unaffected	O
-	O
while	O
RTD-1	B-T121
is	O
seen	O
to	O
insert	O
less	O
deeply	O
-	O
causing	O
the	O
same	O
extension	O
of	O
the	O
lipid	O
acyl	O
chains	O
as	O
PG-1	B-T121
but	O
also	O
causing	O
a	O
significant	O
increase	O
in	O
thickness	O
of	O
the	O
lipid	O
headgroup	O
layer	O
.	O
The	O
various	O
differing	O
effects	O
of	O
the	O
two	O
peptides	O
on	O
anionic	O
lipid	O
monolayers	O
are	O
discussed	O
in	O
the	O
context	O
of	O
their	O
differing	O
hemolytic	B-T059
activities	I-T059
,	O
and	O
their	O
proposed	O
differing	O
propensities	O
to	O
form	O
transmembrane	O
pores	O
.	O
      
Integrating	O
one	O
health	O
in	O
national	O
health	O
policies	O
of	O
developing	O
countries	O
:	O
India	O
's	O
lost	O
opportunities	O
Globally	O
,	O
the	O
threat	O
of	O
infectious	B-T047
diseases	I-T047
,	O
particularly	O
emerging	B-T047
infectious	I-T047
diseases	I-T047
,	O
originating	O
at	O
the	O
human	O
-	O
animal	O
-	O
environment	O
interface	O
,	O
has	O
caught	O
health	O
systems	O
off	O
guard	O
.	O
With	O
forecasts	O
that	O
future	O
pathogen	B-T001
emergence	B-T047
will	O
be	O
centred	O
in	O
hotspots	O
in	O
Asia	O
,	O
Africa	O
,	O
and	O
Latin	O
America	O
,	O
the	O
need	O
to	O
prepare	O
policy	O
frameworks	O
that	O
can	O
combat	O
this	O
threat	O
is	O
urgent	O
.	O
Emergence	B-T047
of	I-T047
diseases	I-T047
such	O
as	O
avian	B-T047
influenza	I-T047
and	O
Ebola	B-T047
virus	I-T047
disease	I-T047
,	O
which	O
threatened	O
social	O
disruption	O
,	O
have	O
established	O
the	O
need	O
for	O
intersectoral	B-T058
coordination	I-T058
/	I-T058
collaboration	I-T058
.	O
These	O
events	O
led	O
to	O
the	O
initiation	O
of	O
establishing	O
institutionalised	B-T033
collaborative	O
frameworks	O
in	O
India	O
to	O
adopt	O
a	O
One	O
Health	O
approach	O
to	O
disease	B-T058
prevention	I-T058
and	I-T058
control	I-T058
.	O
However	O
,	O
the	O
gains	O
made	O
in	O
influenza	B-T047
control	O
could	O
not	O
be	O
adapted	O
to	O
other	O
infectious	B-T047
diseases	I-T047
.	O
Intersectoral	B-T058
coordination	I-T058
was	O
briefly	O
carried	O
out	O
,	O
more	O
as	O
a	O
reactive	O
response	O
to	O
threats	O
.	O
The	O
systemic	O
failure	O
to	O
sustain	O
such	O
efforts	O
have	O
therefore	O
,	O
only	O
undermined	O
a	O
coordinated	O
response	O
.	O
The	O
recent	O
draft	O
National	O
Health	O
Policy	O
,	O
2015	O
,	O
has	O
also	O
failed	O
to	O
establish	O
the	O
need	O
for	O
intersectoral	B-T058
coordination	I-T058
in	O
disease	B-T058
control	I-T058
approaches	I-T058
.	O
Neglecting	O
the	O
need	O
to	O
endorse	O
linkages	O
between	O
human	O
health	O
,	O
animal	O
health	O
and	O
husbandry	O
,	O
agriculture	O
,	O
and	O
environmental	O
sectors	O
,	O
has	O
led	O
to	O
duplicative	O
and	O
weak	B-T033
response	I-T033
systems	I-T033
.	O
The	O
absence	O
of	O
health	B-T058
impact	I-T058
assessment	I-T058
with	O
respect	O
to	O
the	O
development	O
agenda	O
in	O
policies	O
,	O
has	O
cast	O
negative	B-T033
effects	O
on	O
the	O
health	O
and	O
wellbeing	O
of	O
man	O
,	O
animal	O
,	O
and	O
the	O
environment	O
.	O
Lack	B-T033
of	I-T033
attention	I-T033
to	O
building	O
core	O
capacity	O
in	O
these	O
critical	O
sectors	O
has	O
further	O
raised	O
challenges	B-T058
in	O
designing	O
and	O
deploying	O
mitigation	O
strategies	O
.	O
With	O
developing	O
countries	O
like	O
India	O
being	O
home	O
to	O
a	O
major	O
portion	O
of	O
the	O
world	O
's	O
poorest	O
livestock	O
farmers	O
,	O
the	O
absence	O
of	O
a	O
policy	O
discourse	O
that	O
endorses	O
the	O
One	O
Health	O
approach	O
in	O
development	O
and	O
health	O
policies	O
is	O
a	O
major	O
hurdle	O
in	O
eliminating	O
poverty	O
and	O
poverty	O
-	O
related	O
diseases	B-T047
.	O
The	O
adoption	O
of	O
One	O
Health	O
approaches	O
in	O
health	O
and	O
related	O
sectoral	O
policies	O
is	O
a	O
critical	O
policy	O
requirement	O
for	O
India	O
and	O
other	O
developing	O
countries	O
.	O
The	O
goal	O
should	O
be	O
to	O
not	O
just	O
establish	O
preparedness	B-T033
plans	O
,	O
but	O
also	O
to	O
encourage	O
a	O
policy	O
environment	O
where	O
assessment	B-T058
and	O
mitigation	O
of	O
downstream	O
impacts	O
of	O
different	O
agenda	O
are	O
incorporated	O
.	O
      
Biochemical	O
studies	O
of	O
amylase	B-T121
,	O
lipase	B-T121
and	O
protease	O
in	O
Callosobruchus	O
maculatus	O
(	O
Coleoptera	O
:	O
Chrysomelidae	O
)	O
populations	O
fed	O
with	O
Vigna	O
unguiculata	O
grain	O
cultivated	O
with	O
diazotrophic	B-T007
bacteria	I-T007
strains	I-T007
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
enzymatic	O
activity	O
of	O
homogenates	O
of	O
insects	O
fed	O
on	O
grain	O
of	O
cowpea	O
,	O
Vigna	O
unguiculata	O
(	O
L.	O
)	O
,	O
cultivars	O
grown	O
with	O
different	O
nitrogen	O
sources	O
.	O
For	O
the	O
experiment	O
we	O
used	O
aliquots	O
of	O
the	O
homogenate	O
of	O
100	O
unsexed	O
adult	O
insects	O
,	O
emerged	O
from	O
10	O
g	O
of	O
grain	O
obtained	O
from	O
four	O
cowpea	O
cultivars	O
:	O
'	O
BRS	O
Acauã	O
'	O
,	O
'	O
BRS	O
Carijó	O
'	O
,	O
'	O
BRS	O
Pujante	O
'	O
,	O
and	O
'	O
BRS	O
Tapaihum	O
'	O
grown	O
under	O
different	O
regimes	O
of	O
nitrogen	O
sources	O
:	O
mineral	O
fertilizer	O
,	O
inoculation	B-T059
with	O
strains	B-T007
of	I-T007
diazotrophs	I-T007
(	O
BR	B-T007
3267	I-T007
,	O
BR	B-T007
3262	I-T007
,	O
BR	B-T007
3299	I-T007
;	O
INPA	B-T007
03	I-T007
-	I-T007
11B	I-T007
,	O
03	B-T007
-	I-T007
84	I-T007
UFLA	I-T007
,	O
as	O
well	O
as	O
the	O
control	O
(	O
with	O
soil	O
nitrogen	O
)	O
.	O
The	O
parameters	O
evaluated	O
were	O
enzymatic	O
activities	O
of	O
insect	O
protease	O
,	O
amylase	B-T121
and	O
lipase	B-T121
and	O
the	O
starch	B-T121
content	O
of	O
the	O
grains	O
.	O
There	O
were	O
differences	O
in	O
the	O
enzymatic	O
activity	O
of	O
amylase	B-T121
,	O
lipase	B-T121
and	O
protease	O
of	O
insect	O
homogenate	O
according	O
to	O
the	O
food	O
source	O
.	O
A	O
lower	O
activity	O
of	O
the	O
enzyme	O
amylase	B-T121
from	O
C.	O
maculatus	O
homogenate	O
was	O
observed	O
when	O
insects	O
were	O
fed	O
grain	O
of	O
the	O
cultivar	O
BRS	O
Carijó	O
.	O
A	O
lower	O
activity	O
of	O
lipase	O
enzyme	O
from	O
C.	O
maculatus	O
homogenate	O
was	O
observed	O
when	O
the	O
insects	O
fed	O
on	O
grain	O
from	O
the	O
interaction	O
of	O
the	O
cultivar	O
Tapaihum	O
inoculated	O
with	O
BR	B-T007
3262	I-T007
diazotrophs	I-T007
.	O
The	O
lowest	O
proteolytic	O
activity	O
was	O
observed	O
in	O
homogenate	O
of	O
insects	O
fed	O
on	O
interaction	O
of	O
'	O
BRS	O
Carijó	O
'	O
inoculated	O
with	O
BR	B-T007
3262	I-T007
diazotroph	I-T007
s.	O
Starch	B-T121
content	O
correlated	O
positively	O
with	O
the	O
amylase	O
activity	O
of	O
C.	O
maculatus	O
homogenate	O
.	O
The	O
cultivar	O
BRS	O
Carijó	O
had	O
a	O
different	O
behavior	O
from	O
the	O
other	O
cultivars	O
,	O
according	O
to	O
the	O
cluster	O
analysis	O
.	O
      
Conditional	O
Knockdown	O
of	O
Endogenous	O
MicroRNAs	O
in	O
CHO	O
Cells	O
Using	O
TET	O
-	O
ON	O
-	O
SanDI	O
Sponge	O
Vectors	O
MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
,	O
noncoding	O
RNAs	O
of	O
about	O
22	O
nucleotides	O
in	O
length	O
and	O
have	O
proven	O
to	O
be	O
useful	O
targets	O
for	O
genetic	O
modifications	O
for	O
desirable	O
phenotype	O
in	O
the	O
biotech	O
industry	O
.	O
The	O
use	O
of	O
constitutively	O
expressed	O
"	O
miRNA	O
sponge	O
"	O
vectors	O
in	O
which	O
multiple	O
,	O
tandem	O
miRNA	O
binding	O
sites	O
containing	O
transcripts	O
are	O
transcriptionally	O
regulated	O
by	O
a	O
constitutive	O
promoter	O
for	O
down	O
regulating	O
the	O
levels	O
of	O
endogenous	O
microRNAs	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
has	O
shown	O
to	O
be	O
more	O
advantageous	O
than	O
using	O
synthetic	O
antisense	O
oligonucleotides	O
.	O
The	O
application	O
of	O
miRNA	O
sponges	O
in	O
biotechnological	O
processes	O
,	O
however	O
,	O
could	O
be	O
more	O
effective	O
,	O
if	O
expression	O
of	O
miRNA	O
sponges	O
could	O
be	O
tuned	O
.	O
In	O
this	O
chapter	O
,	O
we	O
present	O
a	O
method	O
for	O
the	O
generation	O
of	O
stable	O
CHO	O
cell	O
lines	O
expressing	O
a	O
TET	O
-	O
ON	O
-	O
SanDI	O
-	O
miRNA	O
-	O
sponge	O
that	O
is	O
in	O
theory	O
expressed	O
only	O
in	O
the	O
presence	O
of	O
an	O
inducer	O
.	O
      
Multitarget	O
sensing	B-T059
of	I-T059
glucose	I-T059
and	O
cholesterol	B-T059
based	O
on	O
Janus	B-T121
hydrogel	I-T121
microparticles	I-T121
A	O
visualized	O
sensing	B-T059
method	I-T059
for	I-T059
glucose	I-T059
and	O
cholesterol	B-T059
was	O
developed	O
based	O
on	O
the	O
hemispheres	O
of	O
the	O
same	O
Janus	B-T121
hydrogel	I-T121
microparticles	I-T121
.	O
Single	O
-	O
phase	O
and	O
Janus	B-T121
hydrogel	I-T121
microparticles	I-T121
were	O
both	O
generated	O
using	O
a	O
centrifugal	O
microfluidic	O
chip	O
.	O
For	O
glucose	B-T059
sensing	I-T059
,	O
concanavalin	O
A	O
and	O
fluorescein	O
labeled	O
dextran	O
used	O
for	O
competitive	B-T059
binding	I-T059
assay	I-T059
were	O
encapsulated	O
in	O
alginate	B-T121
microparticles	O
,	O
and	O
the	O
fluorescence	O
of	O
the	O
microparticles	O
was	O
positively	B-T033
correlated	O
with	O
glucose	B-T121
concentration	O
.	O
For	O
cholesterol	B-T059
sensing	I-T059
,	O
the	O
microparticles	O
embedded	O
with	O
γ	O
-	O
Fe2O3	O
nanoparticles	O
were	O
used	O
as	O
catalyst	O
for	O
the	O
oxidation	O
of	O
3,3',5,5'-Tetramethylbenzidine	O
by	O
H2O2	B-T121
,	O
an	O
enzymatic	O
hydrolysis	O
product	O
of	O
cholesterol	O
.	O
And	O
the	O
color	O
transition	O
was	O
more	O
sensitive	O
in	O
the	O
microparticles	O
than	O
in	O
solutions	O
,	O
indicating	O
the	O
microparticles	O
are	O
more	O
applicable	O
for	O
visualized	O
determination	B-T059
.	O
Furthermore	O
,	O
Janus	O
microparticles	O
were	O
employed	B-T033
for	O
multitarget	O
sensing	O
in	O
the	O
two	O
hemespheres	O
,	O
and	O
glucose	B-T121
and	O
cholesterol	O
were	O
detected	B-T033
within	O
the	O
same	O
microparticles	O
without	O
obvious	O
interference	O
.	O
Besides	O
,	O
the	O
particles	O
could	O
be	O
manipulated	O
by	O
an	O
external	O
magnetic	O
field	O
.	O
The	O
glucose	O
and	O
cholesterol	O
levels	O
were	O
measured	O
in	O
human	O
serum	O
utilizing	O
the	O
microparticles	O
,	O
which	O
confirmed	B-T033
the	O
potential	O
application	O
of	O
the	O
microparticles	O
in	O
real	O
sample	O
detection	B-T061
.	O
      
Air	O
tamponade	O
of	O
the	O
heart	B-T023
Pneumopericardium	B-T047
is	O
a	O
rare	B-T047
disease	I-T047
defined	O
as	O
the	O
presence	B-T033
of	O
air	O
or	O
gas	O
in	O
the	O
pericardial	B-T023
sac	I-T023
.	O
Among	O
the	O
etiological	O
factors	O
,	O
the	O
following	O
stand	O
out	O
:	O
chest	O
trauma	O
,	O
barotrauma	O
,	O
air	O
-containing	O
fistulas	B-T190
between	O
the	O
pericardium	B-T023
and	O
the	O
surrounding	O
structures	O
,	O
secondary	O
gas	O
production	O
by	O
microorganisms	B-T001
growing	O
in	O
the	O
pericardial	B-T023
sac	I-T023
,	O
and	O
iatrogenic	O
factors	O
.	O
Until	O
now	O
,	O
spontaneous	O
pneumopericardium	B-T047
has	O
been	O
considered	O
a	O
harmless	O
and	O
temporary	O
state	O
,	O
but	O
a	O
review	O
of	O
clinical	O
cases	O
indicates	O
that	O
the	O
presence	B-T033
of	O
air	O
in	O
the	O
pericardium	B-T023
can	O
lead	O
to	O
cardiac	B-T047
tamponade	I-T047
and	O
life	B-T033
-	I-T033
threatening	I-T033
hemodynamic	O
disturbances	O
.	O
We	O
present	B-T033
the	O
case	O
of	O
an	O
80-	O
year	O
-	O
old	O
patient	O
with	O
a	O
chronic	O
bronchopericardial	B-T023
fistula	B-T190
,	O
who	O
suffered	O
from	O
a	O
cardiac	B-T047
arrest	I-T047
due	O
to	O
air	O
tamponade	O
of	O
the	O
heart	B-T023
.	O
      
Melatonin	B-T121
and	O
nitric	B-T121
oxide	I-T121
regulate	O
sunflower	O
seedling	O
growth	O
under	O
salt	O
stress	O
accompanying	O
differential	O
expression	O
of	O
Cu	O
/	O
Zn	O
SOD	O
and	O
Mn	O
SOD	O
Salinity	O
results	O
in	O
significant	O
reduction	O
in	O
sunflower	O
(	O
Helianthus	O
annuus	O
L.	O
)	O
seedling	O
growth	O
and	O
excessive	O
generation	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O
Present	O
work	O
highlights	O
the	O
possible	O
role	O
of	O
melatonin	B-T121
as	O
an	O
antioxidant	B-T121
through	O
its	O
interaction	O
with	O
nitric	B-T121
oxide	I-T121
(	O
NO	B-T121
)	O
,	O
and	O
as	O
an	O
early	O
and	O
long	O
distance	O
NaCl	O
-	O
stress	O
sensing	O
signaling	O
molecule	O
in	O
seedling	O
cotyledons	O
.	O
Exogenous	O
melatonin	B-T121
(	O
15µM)±	O
NaCl	B-T121
(	O
120mM	O
)	O
inhibit	O
seedling	O
growth	O
,	O
which	O
is	O
also	O
correlated	O
with	O
NO	B-T121
availability	O
,	O
accumulation	O
of	O
potential	O
superoxide	O
anion	O
(	O
O2(•-	O
)	O
)	O
and	O
peroxynitrite	O
anion	O
(	O
ONOO(-	O
)	O
)	O
,	O
extent	O
of	O
tyrosine	O
-	O
nitration	O
of	O
proteins	O
,	O
spatial	O
localization	O
and	O
activity	O
of	O
superoxide	O
dismutase	O
(	O
SOD	B-T121
)	O
isoforms	O
.	O
NO	B-T121
acts	O
as	O
a	O
positive	O
modulator	O
of	O
melatonin	B-T121
accumulation	O
in	O
seedling	O
cotyledons	O
as	O
a	O
long	O
-	O
distance	O
signaling	O
response	O
.	O
Modulation	O
of	O
superoxide	O
anion	O
and	O
peroxynitrite	O
anion	O
content	O
by	O
melatonin	B-T121
highlights	O
its	O
crucial	O
role	O
in	O
combating	O
deleterious	O
effects	O
of	O
ROS	O
and	O
reactive	O
nitrogen	O
species	O
(	O
RNS	O
)	O
.	O
Present	O
findings	O
provide	O
evidence	O
for	O
an	O
interaction	O
between	O
melatonin	B-T121
and	O
NO	B-T121
in	O
their	O
effect	O
on	O
seedling	O
growth	O
under	O
salt	O
stress	O
accompanying	O
differential	O
modulation	O
of	O
two	O
SOD	B-T121
isoforms	O
,	O
i.e.	O
Cu	O
/	O
Zn	O
SOD	O
and	O
Mn	O
SOD	O
.	O
      
Contralateral	O
Superior	O
Cerebellar	O
Artery	O
Syndrome	O
:	O
A	O
Consequence	O
of	O
Brain	B-T190
Herniation	I-T190
Vascular	B-T023
compromise	B-T033
is	O
a	O
well	O
-	O
known	O
consequence	O
of	O
brain	B-T190
herniation	I-T190
syndromes	B-T047
.	O
Transtentorial	O
brain	B-T190
herniation	I-T190
most	O
often	O
involves	O
posterior	B-T023
cerebral	I-T023
arteries	I-T023
.	O
However	O
,	O
isolated	O
involvement	O
of	O
contralateral	O
superior	B-T023
cerebellar	I-T023
artery	I-T023
(	O
SCA	B-T023
)	O
during	O
unilateral	O
impending	O
brain	B-T190
herniation	I-T190
is	O
reported	B-T058
only	O
once	O
and	O
we	O
present	O
another	O
case	O
of	O
this	O
exceedingly	O
rare	O
entity	O
.	O
A	O
24	O
-	O
year	O
-	O
old	O
man	O
was	O
referred	O
to	O
us	O
with	O
impending	O
herniation	B-T190
due	O
to	O
a	O
multiloculated	O
hydrocephalus	B-T047
,	O
and	O
during	O
the	O
course	O
of	O
illness	O
,	O
he	O
developed	O
an	O
isolated	O
SCA	B-T023
ischemia	O
in	O
the	O
opposite	O
side	O
of	O
the	O
most	O
dilated	B-T033
entrapped	O
horn	B-T023
.	O
In	O
the	O
current	O
article	O
we	O
discuss	O
the	O
probable	O
pathophysiologic	O
mechanisms	O
of	O
this	O
phenomenon	O
,	O
as	O
well	O
as	O
recommending	O
more	O
inclusive	O
brain	B-T023
studies	O
in	O
cases	O
suspected	O
of	O
Kernohan	O
-	O
Woltman	O
notch	O
phenomenon	O
in	O
unilateral	O
brain	B-T190
herniation	I-T190
.	O
The	O
rationale	O
for	O
this	O
commentary	O
is	O
that	O
contralateral	O
SCA	B-T023
transient	B-T047
ischemia	I-T047
or	O
infarct	O
might	O
be	O
the	O
underdiagnosed	B-T033
underlying	O
pathomechanism	O
of	O
ipsilateral	O
hemiparesis	B-T184
occurring	O
in	O
many	O
cases	O
of	O
this	O
somehow	O
vague	O
phenomenon	O
.	O
      
Vaccination	B-T061
of	O
piglets	O
at	O
2	O
and	O
3	O
weeks	O
of	O
age	O
with	O
Ingelvac	B-T121
PRRSFLEX	I-T121
®	I-T121
EU	I-T121
provides	O
protection	B-T033
against	O
heterologous	O
field	O
challenge	O
in	O
the	O
face	O
of	O
homologous	O
maternally	O
derived	O
antibodies	O
Due	O
to	O
difficulties	O
in	O
eradicating	B-T058
porcine	B-T047
reproductive	I-T047
and	I-T047
respiratory	I-T047
syndrome	I-T047
(	O
PRRS	B-T047
)	O
linked	O
to	O
biosecurity	O
challenges	O
,	O
transmission	O
of	O
the	O
virus	O
and	O
the	O
lack	O
of	O
efficient	O
DIVA	B-T121
vaccines	I-T121
,	O
successful	O
control	O
of	O
PRRS	B-T047
requires	O
a	O
combination	O
of	O
strict	O
management	B-T058
measures	I-T058
and	O
vaccination	B-T061
of	O
both	O
sows	O
and	O
piglets	O
.	O
The	O
present	O
study	O
aimed	O
to	O
assess	B-T058
the	O
efficacy	O
of	O
a	O
recently	O
developed	O
MLV	B-T121
vaccine	I-T121
(	O
Ingelvac	B-T121
PRRSFLEX	I-T121
®	I-T121
EU	I-T121
)	O
in	O
piglets	O
at	O
2	O
and	O
3	O
-	O
weeks	O
of	O
age	O
in	O
the	O
presence	B-T033
of	O
homologous	O
maternally	O
derived	O
antibodies	O
as	O
the	O
dams	O
were	O
vaccinated	B-T061
with	O
the	O
same	O
vaccine	B-T121
strain	I-T121
(	O
ReproCyc	B-T121
®	I-T121
PRRS	I-T121
EU	I-T121
)	O
.	O
The	O
study	O
was	O
carried	O
out	O
on	O
a	O
Hungarian	O
farrow	O
to	O
finish	O
farm	O
naturally	B-T033
infected	I-T033
with	O
PRRSv	B-T005
.	O
The	O
study	O
was	O
designed	O
as	O
a	O
blind	O
,	O
placebo	O
controlled	O
side	O
by	O
side	O
trial	O
.	O
ORF5	O
sequence	O
similarity	O
of	O
the	O
vaccine	B-T121
strain	I-T121
and	O
the	O
resident	O
field	O
strain	O
was	O
87.8	O
%	O
.	O
PRRS	B-T047
specific	O
real	O
-	O
time	O
quantitative	O
PCR	O
was	O
performed	O
from	O
serum	O
samples	O
to	O
measure	O
both	O
the	O
viral	B-T059
load	I-T059
and	O
the	O
frequency	O
of	O
virus	O
positive	O
animals	O
.	O
At	O
the	O
time	O
of	O
the	O
natural	O
infection	O
observed	O
in	O
the	O
control	O
group	O
at	O
10	O
-	O
12	O
weeks	O
of	O
age	O
,	O
the	O
number	O
of	O
viraemic	B-T033
animals	O
did	O
not	O
increase	O
significantly	O
in	O
the	O
vaccinated	B-T061
group	O
.	O
To	O
understand	O
the	O
infection	O
dynamics	O
,	O
positive	B-T033
PCR	O
samples	O
with	O
low	O
Ct	O
values	O
were	O
sequenced	O
(	O
ORF5	O
)	O
and	O
the	O
data	O
analysis	O
indicated	B-T033
the	O
circulation	B-T033
of	O
wild	O
type	O
virus	O
in	O
both	O
groups	O
,	O
however	O
wild	O
type	O
virus	B-T005
was	O
only	O
found	O
in	O
non	O
-	O
vaccinated	O
animals	O
.	O
Our	O
data	O
indicate	O
that	O
piglets	O
vaccinated	B-T061
at	O
as	O
early	O
as	O
2	O
weeks	O
of	O
age	O
with	O
Ingelvac	B-T121
PRRSFLEX	I-T121
®	I-T121
EU	I-T121
were	O
protected	O
both	O
in	O
terms	O
of	O
proportion	O
of	O
viraemic	B-T033
animals	O
and	O
viraemia	B-T047
levels	O
.	O
It	O
has	O
to	O
be	O
highlighted	O
that	O
these	O
results	O
were	O
achieved	O
in	O
piglets	O
with	O
high	O
levels	O
of	O
homologous	O
maternally	O
derived	O
antibodies	O
(	O
MDA	O
)	O
at	O
the	O
time	O
of	O
vaccination	B-T061
.	O
      
Effects	O
of	O
display	O
curvature	O
,	O
display	O
zone	O
,	O
and	O
task	O
duration	O
on	O
legibility	B-T033
and	O
visual	B-T047
fatigue	I-T047
during	O
visual	O
search	O
task	O
This	O
study	O
examined	O
the	O
effects	O
of	O
display	O
curvature	O
(	O
400	O
,	O
600	O
,	O
1200	O
mm	O
,	O
and	O
flat	O
)	O
,	O
display	O
zone	O
(	O
5	O
zones	O
)	O
,	O
and	O
task	O
duration	O
(	O
15	O
and	O
30	O
min	O
)	O
on	O
legibility	B-T033
and	O
visual	B-T047
fatigue	I-T047
.	O
Each	O
participant	O
completed	O
two	O
15	O
-	O
min	O
visual	O
search	O
task	O
sets	O
at	O
each	O
curvature	O
setting	O
.	O
The	O
600	O
-	O
mm	O
and	O
1200	O
-	O
mm	O
settings	O
yielded	O
better	O
results	O
than	O
the	O
flat	O
setting	O
in	O
terms	O
of	O
legibility	B-T033
and	O
perceived	O
visual	B-T047
fatigue	I-T047
.	O
Relative	O
to	O
the	O
corresponding	O
centre	O
zone	O
,	O
the	O
outermost	O
zones	O
of	O
the	O
1200	O
-	O
mm	O
and	O
flat	O
settings	O
showed	O
a	O
decrease	O
of	O
8%-37	O
%	O
in	O
legibility	B-T033
,	O
whereas	O
those	O
of	O
the	O
flat	O
setting	O
showed	O
an	O
increase	O
of	O
26%-45	O
%	O
in	O
perceived	O
visual	B-T047
fatigue	I-T047
.	O
Across	O
curvature	O
s	O
,	O
legibility	B-T033
decreased	O
by	O
2%-8	O
%	O
,	O
whereas	O
perceived	O
visual	B-T047
fatigue	I-T047
increased	O
by	O
22	O
%	O
during	O
the	O
second	O
task	O
set	O
.	O
The	O
two	O
task	O
sets	O
induced	O
an	O
increase	O
of	O
102	O
%	O
in	O
the	O
eye	O
complaint	O
score	O
and	O
a	O
decrease	O
of	O
0.3	O
Hz	O
in	O
the	O
critical	O
fusion	O
frequency	O
,	O
both	O
of	O
which	O
indicated	O
an	O
increase	O
in	O
visual	B-T047
fatigue	I-T047
.	O
In	O
summary	O
,	O
a	O
curvature	O
of	O
around	O
600	O
mm	O
,	O
central	O
display	O
zones	O
,	O
and	O
frequent	O
breaks	O
are	O
recommended	O
to	O
improve	B-T033
legibility	B-T033
and	O
reduce	O
visual	B-T047
fatigue	I-T047
.	O
      
Socioeconomic	O
Predictors	O
of	O
Adherence	B-T033
Behavior	I-T033
Among	O
HIV	O
-	O
Positive	O
Patients	O
Receiving	O
Antiretroviral	B-T061
Therapy	I-T061
in	O
Selangor	O
,	O
Malaysia	O
Medication	B-T033
adherence	I-T033
remains	O
a	O
critical	O
link	O
between	O
the	O
prescribed	B-T058
ART	B-T061
regimen	B-T061
and	O
treatment	O
outcome	O
.	O
Several	O
factors	O
may	O
influence	O
adherence	B-T033
behavior	I-T033
.	O
This	O
cross	O
-	O
sectional	O
study	O
aimed	O
to	O
highlight	O
socioeconomic	O
predictors	O
of	O
adherence	B-T033
behavior	I-T033
among	O
a	O
cohort	O
of	O
242	O
adult	O
Malaysian	O
patients	O
receiving	O
antiretroviral	B-T061
therapy	I-T061
in	O
Hospital	O
Sungai	O
Buloh	O
,	O
Malaysia	O
,	O
where	O
they	O
were	O
enrolled	O
in	O
a	O
parent	O
study	O
(	O
single	O
-	O
blinded	O
randomized	O
controlled	O
trial	O
)	O
between	O
January	O
and	O
December	O
2014	O
.	O
Statistical	O
analysis	O
of	O
secondary	O
data	O
on	O
adherence	B-T033
behavior	I-T033
and	O
sociodemographic	O
characteristics	O
of	O
the	O
patients	O
revealed	O
mean	B-T033
age	I-T033
of	O
33.4	O
years	O
and	O
ranged	O
from	O
18	O
to	O
64	O
years	O
;	O
88.8	O
%	O
were	O
males	O
.	O
A	O
total	O
of	O
224	O
(	O
93	O
%	O
)	O
patients	O
who	O
completed	O
6	O
months	O
'	O
adherence	B-T058
assessment	I-T058
were	O
included	O
in	O
the	O
model	O
.	O
Of	O
these	O
,	O
135	O
(	O
60.3	O
%	O
)	O
achieved	B-T033
optimal	O
adherence	O
.	O
Multivariate	O
binary	O
logistic	O
regression	O
analysis	O
revealed	O
that	O
patient	O
's	O
income	O
and	O
ethnicity	O
were	O
significant	O
predictors	O
of	O
adherence	B-T033
behavior	I-T033
.	O
This	O
may	O
be	O
valuable	O
for	O
targeted	O
programmatic	B-T061
interventions	I-T061
to	O
further	O
enhance	O
successful	O
treatment	O
outcomes	O
among	O
the	O
target	O
population	O
.	O
      
Structural	O
and	O
tribometric	O
characterization	O
of	O
biomimetically	O
inspired	O
synthetic	O
"	O
insect	O
adhesives	O
"	O
Background	O
:	O
Based	O
on	O
previous	O
chemical	B-T059
analyses	I-T059
of	O
insect	O
tarsal	B-T023
adhesives	O
,	O
we	O
prepared	O
12	O
heterogeneous	O
synthetic	O
emulsions	O
mimicking	O
the	O
polar	B-T033
/	I-T033
non	I-T033
-	I-T033
polar	I-T033
principle	I-T033
,	O
analysed	O
their	O
microscopical	O
structure	O
and	O
tested	O
their	O
adhesive	O
,	O
frictional	O
,	O
and	O
rheological	O
properties	O
.	O
Results	O
:	O
The	O
prepared	B-T033
emulsions	O
varied	O
in	O
their	O
consistency	O
from	O
solid	O
rubber	O
-	O
like	O
,	O
over	O
soft	O
elastic	O
,	O
to	O
fluid	O
(	O
watery	O
or	O
oily	O
)	O
.	O
With	O
droplet	O
sizes	O
>	O
100	O
nm	O
,	O
all	O
the	O
emulsions	O
belonged	O
to	O
the	O
common	O
type	O
of	O
macroemulsions	O
.	O
The	O
emulsions	O
of	O
the	O
first	O
generation	O
generally	O
showed	O
broader	O
droplet	O
-	O
size	O
ranges	O
compared	O
with	O
the	O
second	O
generation	O
,	O
especially	O
when	O
less	O
defined	O
components	O
such	O
as	O
petrolatum	B-T121
or	O
waxes	O
were	O
present	O
in	O
the	O
lipophilic	O
fraction	O
of	O
the	O
first	O
generation	O
of	O
emulsions	O
.	O
Some	O
of	O
the	O
prepared	B-T033
emulsions	O
showed	O
a	O
yield	B-T033
point	I-T033
and	O
were	O
Bingham	O
fluids	O
.	O
Tribometric	B-T059
adhesion	I-T059
was	O
tested	O
via	O
probe	B-T059
tack	I-T059
tests	I-T059
.	O
Compared	O
with	O
the	O
"	O
second	O
generation	O
"	O
(	O
containing	O
less	O
viscous	O
components	O
)	O
,	O
the	O
"	O
first	O
generation	O
"	O
emulsions	O
were	O
much	O
more	B-T033
adhesive	I-T033
(	O
31	O
-	O
93	O
mN	O
)	O
,	O
a	O
finding	O
attributable	O
to	O
their	O
highly	O
viscous	O
components	O
,	O
i.e.	O
,	O
wax	O
,	O
petrolatum	B-T121
,	O
gelatin	B-T121
and	O
poly(vinyl	O
alcohol	O
)	O
.	O
In	O
the	O
second	O
generation	O
emulsions	O
,	O
we	O
attained	O
much	O
lower	O
adhesivenesses	O
,	O
ranging	O
between	O
1	O
-	O
18	O
mN.	O
The	O
adhesive	O
performance	O
was	O
drastically	O
reduced	O
in	O
the	O
emulsions	O
that	O
contained	O
albumin	O
as	O
the	O
protein	O
component	O
or	O
that	O
lacked	O
protein	O
.	O
Tribometric	B-T059
shear	I-T059
tests	I-T059
were	O
performed	O
at	O
moderate	O
normal	O
loads	O
.	O
Our	O
measured	O
friction	O
forces	O
(	O
4	O
-	O
93	O
mN	O
in	O
the	O
first	O
and	O
0.1	O
-	O
5.8	O
mN	O
in	O
the	O
second	O
generation	O
emulsions	O
)	O
were	O
comparatively	O
low	O
.	O
Differences	O
in	O
shear	O
performance	O
were	O
related	O
to	O
the	O
chemical	O
composition	O
and	O
emulsion	O
structure	O
.	O
Conclusion	O
:	O
By	O
varying	O
their	O
chemical	O
composition	O
,	O
synthetic	O
heterogeneous	O
adhesive	O
emulsions	O
can	O
be	O
adjusted	O
to	O
have	O
diverse	O
consistencies	O
and	O
are	O
able	O
to	O
mimic	O
certain	O
rheological	O
and	O
tribological	O
properties	O
of	O
natural	O
tarsal	B-T023
insect	O
adhesives	O
.	O
      
Gelsolin	O
in	O
Onychophora	O
and	O
Tardigrada	O
with	O
notes	O
on	O
its	O
variability	O
in	O
the	O
Ecdysozoa	O
Rearrangements	O
of	O
the	O
filamentous	O
actin	O
network	O
involve	O
a	O
broad	O
range	O
of	O
actin	O
binding	O
proteins	O
.	O
Among	O
these	O
,	O
the	O
gelsolin	O
proteins	O
sever	O
actin	O
filaments	O
,	O
cap	O
their	O
fast	B-T033
growing	I-T033
end	O
and	O
nucleate	O
actin	O
assembly	O
in	O
a	O
calcium	B-T121
-	O
dependent	O
manner	O
.	O
Here	O
,	O
we	O
focus	O
on	O
the	O
gelsolin	O
of	O
the	O
onychophoran	O
Peripatoides	O
novaezealandiae	O
and	O
the	O
eutardigrade	O
Hypsibius	O
dujardini	O
.	O
From	O
the	O
cDNA	O
of	O
P.	O
novaezealandiae	O
we	O
obtained	O
the	O
complete	O
coding	O
sequence	O
with	O
an	O
open	O
reading	O
frame	O
of	O
2178	O
bp	O
.	O
It	O
encodes	O
a	O
protein	O
of	O
726	O
amino	B-T121
acids	I-T121
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
82,610.9Da	O
and	O
a	O
pI	O
of	O
5.57	O
.	O
This	O
sequence	O
is	O
comprised	O
of	O
six	O
segments	O
(	O
S1	O
-	O
S6	O
)	O
.	O
However	O
,	O
analysis	O
of	O
data	O
from	O
TardiBase	O
reveals	O
that	O
the	O
gelsolin	O
of	O
the	O
eutardigrade	O
Hypsibius	O
dujardini	O
has	O
only	O
three	O
segments	O
(	O
S1	O
-	O
S3	O
)	O
.	O
The	O
coding	O
sequence	O
consist	O
of	O
1119	O
bp	O
for	O
373	O
amino	B-T121
acids	I-T121
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
42,440.95Da	O
and	O
a	O
pI	O
of	O
6.17	O
.	O
The	O
Peripatoides	O
and	O
Hypsibius	O
gelsolin	O
revealed	O
both	O
conserved	O
binding	O
motifs	O
for	O
G	O
-	O
actin	O
,	O
F	O
-	O
actin	O
and	O
phosphatidylinositol	O
4,5	O
-	O
bisphosphate	O
(	O
PIP2	O
)	O
,	O
along	O
with	O
a	O
full	O
set	O
of	O
type-1	O
and	O
type-2	O
Ca(2	B-T121
+	I-T121
)	I-T121
-	O
binding	O
sites	O
which	O
could	O
result	O
in	O
the	O
binding	O
of	O
eight	O
and	O
four	O
calcium	B-T121
ions	I-T121
,	O
respectively	O
.	O
Both	O
gelsolin	O
proteins	O
lack	O
a	O
C	O
-	O
terminal	O
latch	O
-	O
helix	O
indicating	O
a	O
more	O
rapid	O
activation	O
in	O
the	O
submicromolar	O
Ca(2	B-T059
+	I-T059
)	I-T059
range	I-T059
.	O
We	O
suggest	O
that	O
a	O
gelsolin	O
with	O
three	O
segments	O
was	O
present	B-T033
in	O
the	O
last	O
common	O
ancestor	O
of	O
the	O
ecdysozoan	O
clade	O
Panarthropoda	O
(	O
Onychophora	O
,	O
Tardigrada	O
,	O
Arthropoda	O
)	O
,	O
primarily	O
because	O
the	O
gelsolin	O
of	O
all	O
non	O
-	O
Ecdysozoa	O
studied	O
so	O
far	O
(	O
except	O
Chordata	O
)	O
reveals	O
this	O
number	O
of	O
segments	O
.	O
Mapping	B-T059
of	O
our	O
molecular	O
data	O
onto	O
a	O
well	O
-	O
established	O
phylogeny	O
revealed	O
that	O
the	O
number	O
of	O
gelsolin	O
segments	O
does	O
not	O
correlate	O
with	O
the	O
phylogenetic	O
lineage	O
but	O
rather	O
with	O
particular	O
functional	O
demands	O
to	O
alter	O
the	O
kinetics	O
of	O
actin	O
polymerization	O
.	O
      
Zebrafish	O
akt2	O
is	O
essential	O
for	O
survival	O
,	O
growth	O
,	O
bone	O
development	O
,	O
and	O
glucose	O
homeostasis	O
As	O
one	O
of	O
three	O
akt	O
isoforms	O
,	O
akt2	O
plays	O
a	O
key	O
role	O
in	O
the	O
regulation	O
of	O
widely	O
divergent	O
cellular	O
processes	O
in	O
mammals	O
.	O
However	O
,	O
its	O
role	O
and	O
underlying	O
mechanisms	O
in	O
zebrafish	O
remain	O
largely	O
unknown	O
.	O
To	O
elucidate	O
the	O
function	O
of	O
akt2	O
in	O
zebrafish	O
,	O
we	O
generated	O
zebrafish	O
lacking	O
akt2	O
gene	O
via	O
CRISPR	O
/	O
Cas9	O
technology	O
.	O
Akt2	O
-	O
null	O
zebrafish	O
exhibit	O
partial	O
lethality	B-T033
and	O
severe	O
growth	O
deficiency	O
,	O
which	O
is	O
different	O
from	O
those	O
observed	O
in	O
akt2	O
-	O
null	O
mice	O
.	O
Furthermore	O
,	O
akt2	O
-	O
null	O
zebrafish	O
display	O
deficiency	O
in	O
fin	O
ray	O
development	O
,	O
but	O
their	O
cartilage	O
is	O
not	O
affected	O
.	O
Similar	O
to	O
observations	O
in	O
akt2	O
-	O
null	O
mice	O
,	O
akt2	O
-	O
null	O
zebrafish	O
display	O
impaired	O
glucose	O
homeostasis	O
.	O
However	O
,	O
in	O
contrast	O
to	O
that	O
in	O
akt2	O
-	O
null	O
mice	O
,	O
insulin	B-T059
level	I-T059
is	O
lower	O
in	O
akt2	O
-	O
null	O
zebrafish	O
,	O
implicating	O
the	O
symptoms	B-T184
of	O
type	B-T047
I	I-T047
diabetes	I-T047
exhibited	O
in	O
akt2	O
-	O
null	O
zebrafish	O
.	O
In	O
addition	O
,	O
transcriptome	B-T059
analysis	I-T059
reveals	O
that	O
the	O
genes	O
involved	O
in	O
metabolism	O
and	O
osteogenesis	O
are	O
disturbed	O
in	O
akt2	O
-	O
null	O
zebrafish	O
.	O
Taken	O
together	O
,	O
these	O
data	O
not	O
only	O
support	O
an	O
important	O
role	O
of	O
akt2	O
in	O
zebrafish	O
survival	O
,	O
growth	O
,	O
bone	O
development	O
and	O
glucose	O
homeostasis	O
,	O
but	O
also	O
suggest	O
that	O
akt2	O
has	O
divergent	O
functions	O
between	O
mice	O
and	O
zebrafish	O
,	O
even	O
though	O
they	O
are	O
evolutionarily	O
conserved	O
.	O
      
Quantitative	O
assessment	O
of	O
fluorescent	O
proteins	O
The	O
advent	O
of	O
fluorescent	O
proteins	O
(	O
FPs	O
)	O
for	O
genetic	O
labeling	O
of	O
molecules	O
and	O
cells	O
has	O
revolutionized	O
fluorescence	B-T059
microscopy	I-T059
.	O
Genetic	O
manipulations	O
have	O
created	O
a	O
vast	O
array	O
of	O
bright	O
and	O
stable	O
FPs	O
spanning	O
blue	O
to	O
red	O
spectral	O
regions	O
.	O
Common	O
to	O
autofluorescent	B-T059
FPs	O
is	O
their	O
tight	O
β	O
-	O
barrel	O
structure	O
,	O
which	O
provides	O
the	O
rigidity	O
and	O
chemical	O
environment	O
needed	O
for	O
effectual	O
fluorescence	O
.	O
Despite	O
the	O
common	O
structure	O
,	O
each	O
FP	O
has	O
unique	O
properties	O
.	O
Thus	O
,	O
there	O
is	O
no	O
single	O
'	O
best	O
'	O
FP	O
for	O
every	O
circumstance	O
,	O
and	O
each	O
FP	O
has	O
advantages	O
and	O
disadvantages	O
.	O
To	O
guide	O
decisions	O
about	O
which	O
FP	O
is	O
right	O
for	O
a	O
given	O
application	O
,	O
we	O
have	O
quantitatively	O
characterized	O
the	O
brightness	O
,	O
photostability	B-T033
,	O
pH	O
stability	O
and	O
monomeric	O
properties	O
of	O
more	O
than	O
40	O
FPs	O
to	O
enable	O
straightforward	O
and	O
direct	O
comparison	O
between	O
them	O
.	O
We	O
focus	O
on	O
popular	O
and/or	O
top	O
-	O
performing	O
FPs	O
in	O
each	O
spectral	O
region	O
.	O
      
Medial	B-T023
Patellofemoral	I-T023
Ligament	I-T023
Reconstruction	B-T061
Femoral	B-T023
Tunnel	O
Accuracy	O
:	O
Relationship	O
to	O
Disease	B-T047
-	O
Specific	O
Quality	O
of	O
Life	O
Medial	B-T023
patellofemoral	I-T023
ligament	I-T023
(	O
MPFL	B-T023
)	O
reconstruction	B-T061
is	O
a	O
procedure	O
aimed	O
to	O
reestablish	O
the	O
checkrein	O
to	O
lateral	O
patellar	O
translation	O
in	O
patients	O
with	O
symptomatic	O
patellofemoral	O
instability	O
.	O
Correct	O
femoral	B-T023
tunnel	O
position	O
is	O
thought	O
to	O
be	O
crucial	O
to	O
successful	O
MPFL	B-T023
reconstruction	B-T061
,	O
but	O
the	O
accuracy	O
of	O
this	O
statement	O
in	O
terms	O
of	O
patient	B-T058
outcomes	I-T058
has	O
not	O
been	O
tested	O
.	O
To	O
assess	O
the	O
accuracy	O
of	O
femoral	B-T023
tunnel	O
placement	B-T058
in	O
an	O
MPFL	B-T023
reconstruction	B-T061
cohort	O
and	O
to	O
determine	O
the	O
correlation	O
between	O
tunnel	O
accuracy	O
and	O
a	O
validated	O
disease	B-T047
-	O
specific	O
,	O
patient	O
-reported	O
quality	O
-	O
of	O
-	O
life	O
outcome	O
measure	O
.	O
Case	O
series	O
;	O
Level	O
of	O
evidence	O
,	O
4	O
.	O
Between	O
June	O
2008	O
and	O
February	O
2014	O
,	O
a	O
total	O
of	O
206	O
subjects	O
underwent	O
an	O
MPFL	B-T023
reconstruction	B-T061
.	O
Lateral	O
radiographs	B-T060
were	O
measured	O
to	O
determine	O
the	O
accuracy	O
of	O
the	O
femoral	B-T023
tunnel	O
by	O
measuring	O
the	O
distance	O
from	O
the	O
center	O
of	O
the	O
femoral	B-T023
tunnel	O
to	O
the	O
Schöttle	O
point	O
.	O
Banff	O
Patella	O
Instability	O
Instrument	O
(	O
BPII	O
)	O
scores	O
were	O
collected	O
a	O
mean	O
24	O
months	O
postoperatively	O
.	O
A	O
total	O
of	O
155	O
(	O
79.5	O
%	O
)	O
subjects	O
had	O
adequate	O
postoperative	O
lateral	O
radiographs	B-T060
and	O
complete	O
BPII	O
scores	O
.	O
The	O
mean	O
duration	O
of	O
follow	B-T058
-	I-T058
up	I-T058
(	O
±	O
SD	O
)	O
was	O
24.4	O
±	O
8.2	O
months	O
(	O
range	O
,	O
12	O
-	O
74	O
months	O
)	O
.	O
Measurement	O
from	O
the	O
center	O
of	O
the	O
femoral	B-T023
tunnel	O
to	O
the	O
Schöttle	O
point	O
resulted	O
in	O
143	O
(	O
92.3	O
%	O
)	O
tunnel	O
s	O
being	O
categorized	O
as	O
"	O
good	O
"	O
or	O
"	O
ideal	O
.	O
"	O
There	O
were	O
8	O
failures	O
in	O
the	O
cohort	O
,	O
none	O
of	O
which	O
occurred	O
in	O
malpositioned	O
tunnels	O
.	O
The	O
mean	O
distance	O
from	O
the	O
center	O
of	O
the	O
MPFL	B-T023
tunnel	O
to	O
the	O
center	O
of	O
the	O
Schöttle	O
point	O
was	O
5.9	O
±	O
4.2	O
mm	O
(	O
range	O
,	O
0.5	O
-	O
25.9	O
mm	O
)	O
.	O
The	O
mean	O
postoperative	O
BPII	O
score	O
was	O
65.2	O
±	O
22.5	O
(	O
range	O
,	O
9.2	O
-	O
100	O
)	O
.	O
Pearson	O
r	O
correlation	O
demonstrated	O
no	B-T033
statistically	I-T033
significant	I-T033
relationship	O
between	O
accuracy	O
of	O
femoral	B-T023
tunnel	O
position	O
and	O
BPII	O
score	O
(	O
r	O
=	O
-0.08	O
;	O
95	O
%	O
CI	O
,	O
-0.24	O
to	O
0.08	O
)	O
.	O
There	O
was	O
no	O
evidence	O
of	O
a	O
correlation	O
between	O
the	O
accuracy	O
of	O
MPFL	B-T023
reconstruction	B-T061
femoral	B-T023
tunnel	O
in	O
relation	O
to	O
the	O
Schöttle	O
point	O
and	O
disease	B-T047
-	O
specific	O
quality	O
-	O
of	O
-	O
life	O
scores	O
.	O
Graft	O
failure	O
was	O
not	O
related	O
to	O
femoral	B-T023
tunnel	O
placement	B-T058
.	O
The	O
patellofemoral	O
instability	O
population	O
is	O
complex	O
,	O
and	O
patients	O
present	O
with	O
multiple	O
risk	B-T033
factors	I-T033
that	O
,	O
in	O
addition	O
to	O
the	O
accuracy	O
of	O
femoral	O
tunnel	O
position	O
,	O
contribute	O
to	O
quality	O
of	O
life	O
and	O
warrant	O
further	O
investigation	B-T058
.	O
      
Evaluation	O
of	O
nutraceutical	B-T033
and	O
antinutritional	B-T033
properties	I-T033
in	O
barnyard	O
and	O
finger	O
millet	O
varieties	O
grown	O
in	O
Himalayan	O
region	O
Five	O
elite	O
varieties	O
of	O
barnyard	O
(	O
Echinochloa	O
frumentacea	O
)	O
and	O
finger	O
(	O
Eleusine	O
coracana	O
)	O
growing	O
at	O
northwestern	O
Himalaya	O
were	O
investigated	O
for	O
nutraceutical	B-T033
and	O
antinutritional	B-T033
properties	I-T033
.	O
Barnyard	O
millet	O
contained	O
higher	O
amount	O
of	O
crude	O
fiber	O
,	O
total	O
dietary	O
fiber	O
,	O
tryptophan	B-T121
content	O
,	O
total	B-T121
carotenoids	I-T121
,	O
α	B-T121
-	I-T121
tocopherol	I-T121
compared	O
to	O
the	O
finger	O
millet	O
whereas	O
the	O
finger	O
millet	O
contains	O
higher	O
amount	O
of	O
methionine	B-T121
and	O
ascorbic	B-T121
acid	I-T121
as	O
compared	O
to	O
the	O
barnyard	O
millet	O
.	O
The	O
secondary	O
metabolites	O
of	O
biological	O
functions	O
were	O
analyzed	O
and	O
found	O
that	O
barnyard	O
millet	O
contained	O
the	O
higher	O
amount	O
of	O
polyphenols	B-T121
,	O
tannins	B-T121
and	O
ortho	O
-	O
dihydroxy	O
phenol	O
content	O
compared	O
to	O
finger	O
millet	O
.	O
Among	O
antinutitional	O
compounds	O
barnyard	O
millet	O
contained	O
lower	O
phytic	B-T121
acid	I-T121
content	O
compare	O
to	O
finger	O
millet	O
whereas	O
no	B-T033
significant	I-T033
difference	I-T033
in	O
trypsin	O
inhibition	O
activity	O
of	O
barnyard	O
millet	O
and	O
finger	O
millet	O
varieties	O
were	O
found	O
.	O
Barnyard	O
millet	O
contained	O
higher	O
acid	O
phosphatase	O
,	O
α	O
-	O
galactosidase	O
and	O
α	O
-	O
amylase	O
inhibitor	O
activity	O
compared	O
to	O
finger	O
millet	O
.	O
Finger	O
millet	O
seeds	O
contained	O
about	O
10	O
-	O
13	O
folds	O
higher	O
calcium	B-T121
content	O
and	O
double	O
amount	O
of	O
manganese	O
content	O
in	O
comparison	O
to	O
barnyard	O
millet	O
seeds	O
.	O
Present	O
study	O
suggests	O
that	O
barnyard	O
millet	O
varieties	O
studied	O
under	O
present	O
investigation	O
were	O
found	O
nutritionally	O
superior	O
compared	O
to	O
finger	O
millet	O
varieties	O
.	O
      
Recovery	O
from	O
alcohol	B-T048
dependence	I-T048
:	O
Do	O
smoking	O
indicators	O
predict	O
abstinence	B-T061
?	O
There	O
is	O
inconsistent	O
evidence	O
about	O
the	O
potential	O
influence	O
of	O
smoking	O
on	O
recovery	O
from	O
alcohol	B-T048
dependence	I-T048
.	O
Our	O
study	B-T059
aimed	O
at	O
assessing	B-T058
the	O
impact	O
of	O
smoking	O
-	O
behavior	O
on	O
relapse	O
during	O
a	O
12	O
months	O
follow	B-T058
-	I-T058
up	I-T058
period	O
following	O
a	O
detoxification	B-T061
in	O
patients	O
with	O
Alcohol	B-T048
Use	I-T048
Disorder	I-T048
(	O
AUD	B-T048
)	O
.	O
Three	O
hundred	O
Patients	O
with	O
AUD	B-T048
(	O
74.9	O
%	O
smoking	O
)	O
were	O
recruited	O
from	O
two	O
inpatient	O
detoxification	O
units	O
in	O
psychiatric	O
hospitals	O
in	O
Germany	O
and	O
their	O
alcohol	O
consumption	O
was	O
prospectively	O
followed	O
for	O
1	O
year	O
.	O
Data	O
on	O
different	O
indicators	O
of	O
smoking	O
behavior	O
was	O
gathered	O
.	O
Cox	O
regression	O
model	O
was	O
used	O
to	O
evaluate	B-T058
potential	O
risk	B-T033
factors	I-T033
on	O
time	O
to	O
relapse	O
of	O
alcohol	O
consumption	O
.	O
Two	O
hundred	O
seventy	O
-	O
nine	O
participants	O
(	O
n	O
=	O
279	O
)	O
were	O
included	O
in	O
the	O
final	O
analysis	O
.	O
Smoking	O
increased	O
the	O
risk	O
for	O
alcohol	O
relapse	O
(	O
hazard	O
ratio	O
=	O
3.962	O
,	O
95	O
%	O
CI	O
1.582	O
-	O
9.921	O
)	O
.	O
However	O
,	O
this	O
increased	O
risk	O
is	O
slightly	O
reduced	O
with	O
higher	O
numbers	O
of	O
daily	O
consumed	B-T033
cigarettes	I-T033
(	O
hazard	O
ratio	O
per	O
cigarette	B-T033
=	O
.986	O
,	O
95	O
%	O
CI	O
.976-.995	O
)	O
.	O
Smoking	B-T033
reduced	I-T033
the	O
probability	O
of	O
maintaining	O
alcohol	B-T061
abstinence	I-T061
significantly	O
,	O
whereas	O
higher	O
number	O
of	O
cigarettes	B-T033
smoked	I-T033
daily	O
diminished	O
the	O
increased	O
risk	O
of	O
alcohol	O
relapse	O
in	O
alcohol	B-T048
-	I-T048
dependent	I-T048
patients	O
.	O
Coordinated	O
psychiatric	O
and	O
substance	B-T048
abuse	I-T048
interventions	B-T061
for	O
different	O
subgroups	O
of	O
patients	O
with	O
AUD	B-T048
in	O
the	O
post	O
-	O
acute	O
treatment	O
phase	O
are	O
necessary	O
.	O
Individualized	O
treatment	O
planning	O
is	O
especially	O
important	O
in	O
smoking	O
patients	O
with	O
AUD	B-T048
who	O
are	O
vulnerable	O
for	O
a	O
relapse	O
to	O
alcohol	O
drinking	O
and	O
for	O
somatic	O
complications	O
.	O
Our	O
findings	B-T033
might	O
support	O
individualized	O
treatment	O
plans	O
.(Am	O
J	O
Addict	O
2017;XX:1	O
-	O
8)	O
.	O
      
Potassium	B-T047
depletion	I-T047
stimulates	O
Na	O
-	O
Cl	O
cotransporter	O
via	O
phosphorylation	O
and	O
inactivation	O
of	O
the	O
ubiquitin	O
ligase	O
Kelch	O
-	O
like	O
3	O
Kelch	O
-	O
like	O
3	O
(	O
KLHL3	O
)	O
is	O
a	O
component	O
of	O
an	O
E3	O
ubiquitin	O
ligase	O
complex	O
that	O
regulates	O
blood	O
pressure	O
by	O
targeting	O
With	O
-	O
No	O
-	O
Lysine	O
(	O
WNK	O
)	O
kinases	O
for	O
degradation	O
.	O
Mutations	O
in	O
KLHL3	O
cause	O
constitutively	O
increased	B-T033
renal	I-T033
salt	I-T033
reabsorption	I-T033
and	O
impaired	O
K(+	O
)	O
secretion	O
,	O
resulting	O
in	O
hypertension	B-T047
and	O
hyperkalemia	B-T033
.	O
Although	O
clinical	O
studies	O
have	O
shown	O
that	O
dietary	O
K(+	O
)	O
intake	O
affects	O
blood	O
pressure	O
,	O
the	O
mechanisms	O
have	O
been	O
obscure	B-T033
.	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
KLHL3	O
ubiquitin	O
ligase	O
complex	O
is	O
involved	O
in	O
the	O
low-	O
K(+	O
)	O
-mediated	O
activation	O
of	O
Na	O
-	O
Cl	O
cotransporter	O
(	O
NCC	O
)	O
in	O
the	O
kidney	B-T023
.	O
In	O
the	O
distal	B-T023
convoluted	I-T023
tubules	I-T023
of	O
mice	O
eating	O
a	O
low	B-T061
-	I-T061
K(+	I-T061
)	I-T061
diet	I-T061
,	O
we	O
found	O
increased	O
KLHL3	O
phosphorylation	O
at	O
S433	O
(	O
KLHL3(S433	O
-	O
P	O
)	O
)	O
,	O
a	O
modification	B-T033
that	O
impairs	O
WNK	O
binding	O
,	O
and	O
also	O
reduced	O
total	O
KLHL3	O
levels	O
.	O
These	O
changes	O
are	O
accompanied	O
by	O
the	O
accumulation	B-T033
of	O
the	O
target	O
substrate	O
WNK4	O
,	O
and	O
activation	O
of	O
the	O
downstream	O
kinases	O
SPAK	O
(	O
STE20	O
/	O
SPS1	O
-related	O
proline	O
-	O
alanine	O
-	O
rich	O
protein	O
kinase	O
)	O
and	O
OSR1	O
(	O
oxidative	O
stress	O
-	O
responsive	O
1	O
)	O
,	O
resulting	O
in	O
NCC	O
phosphorylation	O
and	O
its	O
accumulation	B-T033
at	O
the	O
plasma	O
membrane	O
.	O
Increased	O
phosphorylation	O
of	O
S433	O
was	O
explained	O
by	O
increased	O
levels	O
of	O
active	O
,	O
phosphorylated	O
protein	O
kinase	O
C	O
(	O
but	O
not	O
protein	O
kinase	O
A	O
)	O
,	O
which	O
directly	O
phosphorylates	O
S433	O
.	O
Moreover	O
,	O
in	O
HEK	O
cells	O
expressing	O
KLHL3	O
and	O
WNK4	O
,	O
we	O
showed	O
that	O
the	O
activation	O
of	O
protein	O
kinase	O
C	O
by	O
phorbol	B-T121
12	I-T121
-	I-T121
myristate	I-T121
13	I-T121
-	I-T121
acetate	I-T121
induces	O
KLHL3(S433	O
-	O
P	O
)	O
and	O
increases	O
WNK4	O
levels	O
by	O
abrogating	O
its	O
ubiquitination	O
.	O
These	O
data	O
demonstrate	O
the	O
role	O
of	O
KLHL3	O
in	O
low-	O
K(+	O
)	O
-mediated	O
induction	O
of	O
NCC	O
;	O
this	O
physiologic	O
adaptation	O
reduces	O
distal	O
electrogenic	O
Na(+	O
)	O
reabsorption	O
,	O
preventing	O
further	O
renal	B-T023
K(+	O
)	O
loss	O
but	O
promoting	O
increased	O
blood	O
pressure	O
.	O
      
Predicting	O
changes	O
in	O
adaptive	O
functioning	O
and	O
behavioral	O
adjustment	O
following	O
treatment	B-T061
for	O
a	O
pediatric	B-T191
brain	I-T191
tumor	I-T191
:	O
A	O
report	O
from	O
the	O
Brain	B-T023
Radiation	O
Investigative	O
Study	O
Consortium	O
Children	O
are	O
at	O
risk	O
for	O
behavioral	O
and	O
adaptive	O
difficulties	O
following	O
pediatric	B-T191
brain	I-T191
tumor	I-T191
.	O
This	O
study	O
explored	O
whether	O
familial	O
/	O
demographic	O
,	O
developmental	O
,	O
diagnostic	O
,	O
or	O
treatment	B-T061
-related	O
variables	O
best	O
predict	O
posttreatment	O
behavioral	O
and	O
adaptive	O
functioning	O
.	O
Participants	O
included	O
40	O
children	O
(	O
mean	O
age	O
=	O
12.76	O
years	O
,	O
SD	O
=	O
4.01	O
)	O
posttreatment	O
(	O
mean	O
time	O
since	O
diagnosis	B-T033
=	O
1.99	O
years	O
,	O
SD	O
=	O
0.21	O
)	O
for	O
pediatric	B-T191
brain	I-T191
tumor	I-T191
.	O
Parents	O
rated	O
children	O
's	O
behavioral	O
adjustment	O
and	O
adaptive	O
functioning	O
and	O
provided	O
demographic	O
and	O
developmental	O
histories	B-T033
.	O
Diagnostic	B-T033
and	O
treatment	B-T061
-related	O
information	O
was	O
abstracted	O
from	O
medical	O
records	O
.	O
Ratings	O
of	O
adaptive	O
and	O
behavioral	O
functioning	O
approximately	O
2	O
years	O
postdiagnosis	B-T033
were	O
within	O
the	O
average	O
range	O
,	O
although	O
the	O
percentage	O
of	O
children	O
exceeding	O
clinical	O
cutoffs	O
for	O
impairment	O
in	O
adaptive	O
skills	O
exceeded	O
expectation	O
,	O
particularly	O
practical	O
skills	O
.	O
Premorbid	O
behavior	O
problems	O
and	O
tumor	O
size	O
predicted	O
posttreatment	O
adaptive	O
functioning	O
.	O
After	O
accounting	O
for	O
adaptive	O
functioning	O
near	O
diagnosis	B-T033
,	O
premorbid	O
behavior	O
problems	O
predicted	O
declines	O
in	O
adaptive	O
functioning	O
2	O
years	O
postdiagnosis	B-T033
.	O
After	O
accounting	O
for	O
adjustment	O
near	O
diagnosis	B-T033
,	O
no	O
variables	O
predicted	O
declines	O
in	O
behavioral	O
adjustment	O
.	O
Children	O
may	O
be	O
vulnerable	O
to	O
reduced	O
adaptive	O
functioning	O
following	O
pediatric	B-T191
brain	I-T191
tumor	I-T191
treatment	B-T061
,	O
especially	O
in	O
practical	O
skills	O
.	O
Assessing	O
prediagnosis	B-T033
functioning	O
and	O
diagnostic	B-T033
and	O
treatment	B-T061
-related	O
variables	O
may	O
improve	B-T033
our	O
ability	O
to	O
predict	O
those	O
at	O
greatest	O
risk	O
,	O
although	O
those	O
factors	O
may	O
be	O
less	O
helpful	O
in	O
identifying	O
children	O
likely	O
to	O
develop	O
behavioral	O
difficulties	O
.	O
Screening	B-T058
of	O
these	O
factors	O
in	O
tertiary	B-T058
care	I-T058
and	O
long	O
-	O
term	O
follow	B-T058
-	I-T058
up	I-T058
settings	O
may	O
improve	B-T033
identification	O
of	O
those	O
at	O
greatest	O
need	O
for	O
support	O
services	O
.	O
      
Interaction	O
of	O
lifestyle	O
,	O
behaviour	O
or	O
systemic	B-T047
diseases	I-T047
with	O
dental	B-T047
caries	I-T047
and	O
periodontal	B-T047
diseases	I-T047
:	O
consensus	O
report	O
of	O
group	O
2	O
of	O
the	O
joint	O
EFP	O
/	O
ORCA	O
workshop	O
on	O
the	O
boundaries	O
between	O
caries	B-T047
and	O
periodontal	B-T047
diseases	I-T047
Periodontal	B-T047
diseases	I-T047
and	O
dental	B-T047
caries	I-T047
are	O
the	O
most	O
common	B-T047
diseases	I-T047
of	O
humans	O
and	O
the	O
main	O
cause	O
of	O
tooth	B-T020
loss	I-T020
.	O
Both	O
diseases	B-T047
can	O
lead	O
to	O
nutritional	O
compromise	O
and	O
negative	O
impacts	O
upon	O
self	O
-	O
esteem	O
and	O
quality	O
of	O
life	O
.	O
As	O
complex	B-T047
chronic	I-T047
diseases	I-T047
,	O
they	O
share	O
common	B-T033
risk	I-T033
factors	I-T033
,	O
such	O
as	O
a	O
requirement	O
for	O
a	O
pathogenic	B-T001
plaque	I-T001
biofilm	I-T001
,	O
yet	O
they	O
exhibit	O
distinct	O
pathophysiologies	O
.	O
Multiple	O
exposures	O
contribute	O
to	O
their	O
causal	O
pathways	O
,	O
and	O
susceptibility	O
involves	O
risk	B-T033
factors	I-T033
that	O
are	O
inherited	O
(	O
e.g.	O
genetic	O
variants	O
)	O
,	O
and	O
those	O
that	O
are	O
acquired	O
(	O
e.g.	O
socio	O
-	O
economic	O
factors	O
,	O
biofilm	B-T007
load	O
or	O
composition	O
,	O
smoking	O
,	O
carbohydrate	O
intake	O
)	O
.	O
Identification	O
of	O
these	O
factors	O
is	O
crucial	O
in	O
the	O
prevention	B-T061
of	I-T061
both	I-T061
diseases	I-T061
as	O
well	O
as	O
in	O
their	B-T058
management	I-T058
.	O
To	O
systematically	O
appraise	O
the	O
scientific	O
literature	O
to	O
identify	O
potential	B-T033
risk	I-T033
factors	I-T033
for	O
caries	B-T047
and	O
periodontal	B-T047
diseases	I-T047
.	O
One	O
systematic	O
review	O
(	O
genetic	O
risk	O
factors	O
)	O
,	O
one	O
narrative	O
review	O
(	O
role	O
of	O
diet	O
and	O
nutrition	O
)	O
and	O
reference	O
documentation	O
for	O
modifiable	B-T033
acquired	I-T033
risk	I-T033
factors	I-T033
common	O
to	O
both	O
disease	O
groups	O
,	O
formed	O
the	O
basis	O
of	O
the	O
report	O
.	O
There	O
is	O
moderately	O
strong	O
evidence	O
for	O
a	O
genetic	B-T033
contribution	I-T033
to	O
periodontal	B-T047
diseases	I-T047
and	O
caries	O
susceptibility	O
,	O
with	O
an	O
attributable	O
risk	O
estimated	O
to	O
be	O
up	O
to	O
50	O
%	O
.	O
The	O
genetics	O
literature	O
for	O
periodontal	B-T047
disease	I-T047
is	O
more	O
substantial	O
than	O
for	O
caries	B-T047
and	O
genes	O
associated	O
with	O
chronic	B-T047
periodontitis	I-T047
are	O
the	O
vitamin	O
D	O
receptor	O
(	O
VDR	O
)	O
,	O
Fc	O
gamma	O
receptor	O
IIA	O
(	O
Fc	O
-	O
γRIIA	O
)	O
and	O
Interleukin	O
10	O
(	O
IL10	O
)	O
genes	O
.	O
For	O
caries	B-T047
,	O
genes	O
involved	O
in	O
enamel	B-T033
formation	I-T033
(	O
AMELX	O
,	O
AMBN	O
,	O
ENAM	O
,	O
TUFT	O
,	O
MMP20	O
,	O
and	O
KLK4	O
)	O
,	O
salivary	B-T033
characteristics	I-T033
(	O
AQP5	O
)	O
,	O
immune	O
regulation	O
and	O
dietary	O
preferences	O
had	O
the	O
largest	O
impact	O
.	O
No	O
common	O
genetic	O
variants	O
were	O
found	O
.	O
Fermentable	O
carbohydrates	O
(	O
sugars	O
and	O
starches	O
)	O
were	O
the	O
most	O
relevant	O
common	O
dietary	O
risk	B-T033
factor	I-T033
for	I-T033
both	I-T033
diseases	I-T033
,	O
but	O
associated	O
mechanisms	O
differed	O
.	O
In	O
caries	B-T047
,	O
the	O
fermentation	O
process	O
leads	O
to	O
acid	O
production	O
and	O
the	O
generation	O
of	O
biofilm	O
components	O
such	O
as	O
Glucans	B-T121
.	O
In	O
periodontitis	B-T047
,	O
glycaemia	B-T033
drives	I-T033
oxidative	O
stress	O
and	O
advanced	O
glycation	O
end	O
-	O
products	O
may	O
also	O
trigger	O
a	O
hyper	O
inflammatory	O
state	O
.	O
Micronutrient	O
deficiencies	O
,	O
such	O
as	O
for	O
vitamin	B-T121
C	I-T121
,	O
vitamin	B-T121
D	I-T121
or	O
vitamin	B-T121
B12	I-T121
,	O
may	O
be	O
related	O
to	O
the	O
onset	O
and	O
progression	O
of	O
both	O
diseases	O
.	O
Functional	O
foods	O
or	O
probiotics	B-T007
could	O
be	O
helpful	O
in	O
caries	B-T058
prevention	I-T058
and	O
periodontal	B-T047
disease	I-T047
management	B-T058
,	O
although	O
evidence	O
is	O
limited	O
and	O
biological	O
mechanisms	O
not	O
fully	O
elucidated	O
.	O
Hyposalivation	B-T033
,	O
rheumatoid	B-T047
arthritis	I-T047
,	O
smoking	B-T033
/	I-T033
tobacco	I-T033
use	I-T033
,	O
undiagnosed	B-T033
or	O
sub	B-T033
-	I-T033
optimally	I-T033
controlled	I-T033
diabetes	B-T047
and	O
obesity	B-T047
are	O
common	O
acquired	O
risk	B-T033
factors	I-T033
for	O
both	O
caries	B-T047
and	O
periodontal	B-T047
diseases	I-T047
.	O
      
Expressed	O
microRNA	O
associated	O
with	O
high	O
rate	O
of	O
egg	O
production	O
in	O
chicken	O
ovarian	B-T023
follicles	I-T023
MicroRNA	O
(	O
miRNA	O
)	O
is	O
a	O
highly	O
conserved	O
class	O
of	O
small	O
noncoding	O
RNA	O
about	O
19	O
-	O
24	O
nucleotides	O
in	O
length	O
that	O
function	O
in	O
a	O
specific	O
manner	O
to	O
post	O
-	O
transcriptionally	O
regulate	O
gene	O
expression	O
in	O
organisms	B-T001
.	O
Tissue	O
miRNA	O
expression	O
studies	O
have	O
discovered	O
a	O
myriad	O
of	O
functions	O
for	O
miRNAs	O
in	O
various	O
aspects	O
,	O
but	O
a	O
role	O
for	O
miRNAs	O
in	O
chicken	O
ovarian	O
tissue	O
at	O
300	O
days	O
of	O
age	O
has	O
not	O
hitherto	O
been	O
reported	O
.	O
In	O
this	O
study	O
,	O
we	O
performed	O
the	O
first	O
miRNA	O
analysis	O
of	O
ovarian	O
tissues	O
in	O
chickens	O
with	O
low	O
and	O
high	O
rates	O
of	O
egg	O
production	O
using	O
high	O
-	O
throughput	O
sequencing	O
.	O
By	O
comparing	O
low	O
rate	O
of	O
egg	O
production	O
chickens	O
with	O
high	O
rate	O
of	O
egg	O
production	O
chickens	O
,	O
17	O
significantly	O
differentially	O
expressed	O
miRNAs	O
were	O
found	O
(	O
P	O
<	O
0.05	O
)	O
,	O
including	O
11	O
known	O
and	O
six	O
novel	O
miRNAs	O
.	O
We	O
found	O
that	O
all	O
11	O
known	O
miRNAs	O
were	O
involved	O
mainly	O
in	O
pathways	O
of	O
reproduction	O
regulation	O
,	O
such	O
as	O
steroid	O
hormone	O
biosynthesis	O
and	O
dopaminergic	O
synapse	O
.	O
Additionally	O
,	O
expression	O
profiling	O
of	O
six	O
randomly	O
selected	O
differentially	O
regulated	O
miRNAs	O
were	O
validated	O
by	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
qPCR	O
)	O
.	O
Some	O
miRNAs	O
,	O
such	O
as	O
gga	O
-	O
miR-34b	O
,	O
gga	O
-	O
miR-34c	O
and	O
gga	O
-	O
miR-216b	O
,	O
were	O
reported	O
to	O
regulate	O
processes	O
such	O
as	O
proliferation	O
,	O
cell	O
cycle	O
,	O
apoptosis	O
and	O
metastasis	O
and	O
were	O
expressed	O
differentially	O
in	O
ovaries	B-T023
of	O
chickens	O
with	O
high	O
rates	O
of	O
egg	O
production	O
,	O
suggesting	O
that	O
these	O
miRNAs	O
have	O
an	O
important	O
role	O
in	O
ovary	B-T023
development	O
and	O
reproductive	O
management	O
of	O
chicken	O
.	O
Furthermore	O
,	O
we	O
uncovered	O
that	O
a	O
significantly	O
up	O
-	O
regulated	O
miRNA	O
-	O
gga	O
-	O
miR-200a-3p	O
-is	O
ubiquitous	O
in	O
reproduction	O
-	O
regulation	O
-related	O
pathways	O
.	O
This	O
miRNA	O
may	O
play	O
a	O
special	O
central	O
role	O
in	O
the	O
reproductive	O
management	O
of	O
chicken	O
,	O
and	O
needs	O
to	O
be	O
further	O
studied	O
for	O
confirmation	O
.	O
      
Consumption	O
of	O
fruits	O
and	O
vegetables	O
associated	O
with	O
other	O
risk	O
behaviors	O
among	O
adolescents	O
in	O
Northeast	O
Brazil	O
To	O
determine	O
the	O
prevalence	O
of	O
consumption	O
of	O
fruits	O
and	O
vegetables	O
and	O
identify	O
the	O
association	O
with	O
low	O
level	O
of	O
physical	O
activity	O
,	O
exposure	O
to	O
sedentary	B-T033
behavior	I-T033
,	O
consumption	O
of	O
soft	O
drinks	O
and	O
overweight	B-T184
/	O
obesity	B-T047
in	O
adolescents	O
.	O
This	O
is	O
a	O
cross	O
-	O
sectional	O
school	O
-	O
based	O
study	O
with	O
a	O
representative	O
sample	O
of	O
3992	O
students	O
aged	O
14	O
-	O
19	O
years	O
from	O
the	O
state	O
of	O
Sergipe	O
,	O
Brazil	O
.	O
The	O
outcome	O
was	O
low	O
consumption	O
of	O
fruits	O
and	O
vegetables	O
(	O
<	O
5	O
servings	O
/	O
day	O
)	O
.	O
Independent	O
variables	O
were	O
:	O
level	O
of	O
physical	O
activity	O
,	O
sedentary	B-T033
behavior	I-T033
,	O
consumption	O
of	O
soft	O
drinks	O
,	O
and	O
overweight	B-T184
/	O
obesity	B-T047
.	O
Global	O
Student	O
Health	O
Survey	O
questionnaire	O
and	O
body	B-T058
mass	I-T058
and	O
height	O
measurements	B-T058
were	O
used	O
,	O
as	O
well	O
as	O
chi	O
-	O
square	O
test	O
and	O
crude	O
and	O
adjusted	O
binary	O
logistic	O
regression	O
.	O
The	O
significance	O
level	O
adopted	O
was	O
5	O
%	O
.	O
The	O
prevalence	O
of	O
inadequate	O
consumption	O
of	O
fruits	O
and	O
vegetables	O
was	O
high	O
-	O
88.6	O
%	O
(	O
95	O
%	O
CI	O
=	O
87.6	O
-	O
89.5	O
)	O
.	O
Higher	O
likelihood	O
of	O
low	O
consumption	O
of	O
fruits	O
and	O
vegetables	O
was	O
verified	O
among	O
boys	O
who	O
were	O
exposed	O
to	O
sedentary	B-T033
behavior	I-T033
(	O
OR	O
=	O
1.63	O
;	O
95	O
%	O
CI	O
=	O
1.18	O
-	O
2.24	O
)	O
,	O
who	O
consumed	O
soft	O
drinks	O
(	O
OR	O
=	O
3.04	O
;	O
95	O
%	O
CI	O
=	O
2.10	O
-	O
4.40	O
)	O
,	O
with	O
insufficiently	O
physical	O
activity	O
(	O
OR	O
=	O
1.98	O
;	O
95	O
%	O
CI	O
=	O
1.43	O
-	O
2.73	O
)	O
and	O
girls	O
who	O
consumed	O
soft	O
drinks	O
(	O
OR	O
=	O
1.88	O
;	O
95	O
%	O
CI	O
=	O
1.43	O
-	O
2.47	O
)	O
and	O
those	O
with	O
overweight	B-T184
/	O
obesity	B-T047
(	O
OR	O
=	O
1.63	O
;	O
95	O
%	O
CI	O
=	O
1.19	O
-	O
2.23	O
)	O
.	O
There	O
is	O
a	O
need	O
of	O
public	O
policies	O
aimed	O
at	O
encouraging	O
the	O
consumption	O
of	O
healthy	O
foods	O
among	O
adolescents	O
.	O
      
The	O
emerging	O
contribution	O
of	O
social	O
wasps	O
to	O
grape	B-T047
rot	I-T047
disease	I-T047
ecology	O
Grape	B-T047
sour	I-T047
(	I-T047
bunch	I-T047
)	I-T047
rot	I-T047
is	O
a	O
polymicrobial	B-T047
disease	I-T047
of	O
vineyards	O
that	O
causes	O
millions	O
of	O
dollars	O
in	O
lost	O
revenue	O
per	O
year	O
due	O
to	O
decreased	O
quality	O
of	O
grapes	O
and	O
resultant	O
wine	O
.	O
The	O
disease	B-T047
is	O
associated	O
with	O
damaged	O
berries	O
infected	B-T033
with	O
a	O
community	O
of	O
acetic	B-T007
acid	I-T007
bacteria	I-T007
,	O
yeasts	O
,	O
and	O
filamentous	O
fungi	O
that	O
results	O
in	O
rotting	O
berries	O
with	O
high	O
amounts	O
of	O
undesirable	O
volatile	O
acidity	O
.	O
Many	O
insect	O
species	O
cause	O
the	O
initial	O
grape	O
berry	O
damage	O
that	O
can	O
lead	O
to	O
this	O
disease	B-T047
,	O
but	O
most	O
studies	O
have	O
focused	O
on	O
the	O
role	O
of	O
fruit	O
flies	O
in	O
facilitating	O
symptoms	B-T184
and	O
vectoring	O
the	O
microorganisms	B-T001
of	O
this	O
disease	B-T047
complex	O
.	O
Like	O
fruit	O
flies	O
,	O
social	O
wasps	O
are	O
abundant	O
in	O
vineyards	O
where	O
they	O
feed	O
on	O
ripe	O
berries	O
and	O
cause	O
significant	O
damage	O
,	O
while	O
also	O
dispersing	O
yeasts	O
involved	O
in	O
wine	O
fermentation	O
.	O
Despite	O
this	O
,	O
their	O
possible	O
role	O
in	O
disease	B-T047
facilitation	O
and	O
dispersal	B-T047
of	I-T047
grape	I-T047
rots	I-T047
has	O
not	O
been	O
explored	O
.	O
We	O
tested	O
the	O
hypothesis	O
that	O
the	O
paper	O
wasp	O
Polistes	O
dominulus	O
could	O
facilitate	O
grape	B-T047
sour	I-T047
rot	I-T047
in	O
the	O
absence	O
of	O
other	O
insect	O
vectors	O
.	O
Using	O
marker	B-T059
gene	I-T059
sequencing	I-T059
we	O
characterized	O
the	O
bacterial	B-T007
and	O
fungal	O
community	O
of	O
wild	O
-	O
caught	O
adults	O
.	O
We	O
used	O
a	O
sterilized	O
foraging	O
arena	O
to	O
determine	O
if	O
these	O
wasps	O
transfer	O
viable	O
microorganisms	B-T001
when	O
foraging	O
.	O
We	O
then	O
tested	O
if	O
wasps	O
harboring	O
their	O
native	O
microbial	B-T001
community	O
,	O
or	O
those	O
inoculated	B-T061
with	O
sour	B-T047
rot	I-T047
,	O
had	O
an	O
effect	O
on	O
grape	B-T047
sour	I-T047
rot	I-T047
incidence	O
and	O
severity	O
using	O
a	O
laboratory	O
foraging	O
arena	O
.	O
We	O
found	O
that	O
all	O
wasps	O
harbor	O
some	O
portion	O
of	O
the	O
sour	B-T047
rot	I-T047
microbial	B-T001
community	O
and	O
that	O
they	O
have	O
the	O
ability	O
to	O
transfer	O
viable	O
microorganisms	B-T001
when	O
foraging	O
.	O
Foraging	O
by	O
inoculated	B-T061
and	O
uninoculated	O
wasps	O
led	O
to	O
an	O
increase	O
in	O
berry	B-T047
rot	I-T047
disease	I-T047
symptom	B-T184
severity	O
and	O
incidence	O
.	O
Our	O
results	B-T033
indicate	O
that	O
paper	O
wasps	O
can	O
facilitate	O
sour	B-T047
rot	I-T047
diseases	I-T047
in	O
the	O
absence	O
of	O
other	O
vectors	O
and	O
that	O
the	O
mechanism	O
of	O
this	O
facilitation	O
may	O
include	O
both	O
increasing	O
host	B-T001
susceptibility	O
and	O
transmitting	O
these	O
microbial	B-T001
communities	O
to	O
the	O
grapes	O
.	O
Social	O
wasps	O
are	O
understudied	O
but	O
relevant	O
players	O
in	O
the	O
sour	B-T047
rot	I-T047
ecology	O
of	O
vineyards	O
.	O
      
Detection	B-T061
and	O
Characterization	O
of	O
Flat	B-T047
Aberrant	I-T047
Crypt	I-T047
Foci	I-T047
(	I-T047
Flat	I-T047
ACF	I-T047
)	I-T047
in	O
the	O
Novel	O
A	B-T050
/	I-T050
J	I-T050
Min/+	I-T050
Mouse	I-T050
Flat	B-T047
aberrant	I-T047
crypt	I-T047
foci	I-T047
(	O
flat	B-T047
ACF	I-T047
)	O
and	O
mucin	B-T047
-	I-T047
depleted	I-T047
foci	I-T047
(	O
MDF	B-T047
)	O
have	O
previously	O
been	O
described	O
as	O
preneoplastic	B-T047
colonic	I-T047
lesions	I-T047
.	O
We	O
used	O
the	O
novel	O
A	B-T050
/	I-T050
J	I-T050
Min/+	I-T050
mouse	I-T050
model	I-T050
,	O
that	O
demonstrates	O
extensive	O
spontaneous	O
colon	B-T191
carcinogenesis	I-T191
to	O
refine	O
the	O
method	O
of	O
detection	B-T061
of	O
flat	B-T047
ACF	I-T047
and	O
further	O
characterize	O
and	O
define	O
them	O
as	O
early	O
lesions	B-T033
by	O
histological	B-T059
examination	I-T059
and	O
comparison	O
with	O
MDF	B-T047
.	O
Colons	B-T023
were	O
stained	B-T059
with	I-T059
methylene	I-T059
blue	I-T059
(	O
MB	B-T121
)	O
for	O
flat	B-T047
ACF	I-T047
detection	B-T061
and	O
restained	B-T059
with	O
high	O
-	O
iron	O
diamine	O
-	O
alcian	O
blue	O
(	O
HID	O
-	O
AB	O
)	O
for	O
MDF	B-T047
detection	B-T061
.	O
Optimal	O
flat	B-T047
ACF	I-T047
recognition	O
required	O
at	O
least	O
24	O
h	O
of	O
storage	O
post-	O
MB	B-T059
staining	I-T059
and	O
adherence	O
to	O
a	O
set	O
of	O
characteristics	O
.	O
The	O
fraction	O
of	O
flat	B-T047
ACF	I-T047
corresponding	O
with	O
MDF	B-T047
was	O
93	O
%	O
.	O
Flat	B-T047
ACF	I-T047
/	O
MDF	B-T047
displayed	O
the	O
same	O
picture	O
of	O
severe	O
dysplasia	O
,	O
lack	O
of	O
mucus	O
and	O
goblet	O
cells	O
and	O
accumulation	B-T033
of	O
cytoplasmic	O
β	O
-	O
catenin	O
.	O
The	O
easily	O
detectable	O
flat	B-T047
ACF	I-T047
are	O
reliable	O
surface	O
biomarkers	O
of	O
Apc	O
-driven	O
colon	B-T191
carcinogenesis	I-T191
.	O
      
Assessment	B-T058
of	O
Vascular	O
Stent	O
Heating	O
with	O
Repetitive	B-T061
Transcranial	I-T061
Magnetic	I-T061
Stimulation	I-T061
A	O
high	O
proportion	O
of	O
patients	O
with	O
stroke	B-T047
do	O
not	O
qualify	O
for	O
repetitive	B-T061
transcranial	I-T061
magnetic	I-T061
stimulation	I-T061
(	O
rTMS	B-T061
)	O
clinical	O
studies	O
due	O
to	O
the	O
presence	O
of	O
metallic	O
stents	O
.	O
The	O
ultimate	O
concern	O
is	O
that	O
any	O
metal	O
could	O
become	O
heated	O
due	O
to	O
eddy	O
currents	O
.	O
However	O
,	O
to	O
date	O
,	O
no	O
clinical	O
safety	O
data	O
are	O
available	O
regarding	O
the	O
risk	O
of	O
metallic	O
stents	O
heating	O
with	O
rTMS	B-T061
.	O
We	O
tested	O
the	O
safety	O
of	O
common	O
rTMS	B-T061
protocols	O
(	O
1	O
Hz	O
and	O
10	O
Hz	O
)	O
with	O
stents	O
used	O
commonly	O
in	O
stroke	B-T047
,	O
nitinol	O
and	O
elgiloy	O
.	O
In	O
our	O
method	O
,	O
stents	O
were	O
tested	O
in	O
gelled	O
saline	O
at	O
2	O
different	O
locations	O
:	O
at	O
the	O
center	O
and	O
at	O
the	O
lobe	B-T023
of	O
the	O
coil	O
.	O
In	O
addition	O
,	O
at	O
each	O
location	O
,	O
stent	O
heating	O
was	O
evaluated	B-T058
in	O
3	O
different	O
orientations	O
:	O
parallel	O
to	O
the	O
long	O
axis	O
of	O
coil	O
,	O
parallel	O
to	O
the	O
short	O
axis	O
of	O
the	O
coil	O
,	O
and	O
perpendicular	O
to	O
the	O
plane	O
of	O
the	O
coil	O
.	O
We	O
found	O
that	O
stents	O
did	O
not	O
heat	O
to	O
more	O
than	O
1	O
°	O
C	O
with	O
either	O
1	O
Hz	O
rTMS	B-T061
or	O
10	O
Hz	O
rTMS	B-T061
in	O
any	O
configuration	O
or	O
orientation	O
.	O
Heating	O
in	O
general	O
was	O
greater	O
at	O
the	O
lobe	B-T023
when	O
the	O
stent	O
was	O
oriented	O
perpendicularly	O
.	O
Our	O
study	O
represents	O
a	O
new	O
method	O
for	O
ex	O
vivo	O
quantification	O
of	O
stent	O
heating	O
.	O
We	O
have	O
found	O
that	O
heating	O
of	O
stents	O
was	O
well	O
below	O
the	O
Food	O
and	O
Drug	O
Administration	O
standards	O
of	O
2	O
°	O
C	O
.	O
Thus	O
,	O
our	O
study	O
paves	O
the	O
way	O
for	O
in	O
vivo	O
testing	O
of	O
rTMS	B-T061
(	O
≤10	O
Hz	O
)	O
in	O
the	O
presence	O
of	O
implanted	O
magnetic	B-T060
resonance	I-T060
imaging	I-T060
-	O
compatible	O
stents	O
in	O
animal	O
studies	O
.	O
When	O
planning	O
human	O
safety	O
studies	O
though	O
,	O
geometry	O
,	O
orientation	O
,	O
and	O
location	O
relative	O
to	O
the	O
coil	O
would	O
be	O
important	O
to	O
consider	O
as	O
well	O
.	O
      
Primitive	B-T191
Neuroectodermal	I-T191
Tumors	I-T191
of	O
the	O
Female	B-T023
Genital	I-T023
Tract	I-T023
:	O
A	O
Morphologic	O
,	O
Immunohistochemical	B-T059
,	O
and	O
Molecular	O
Study	O
of	O
19	O
Cases	O
Primary	B-T191
primitive	I-T191
neuroectodermal	I-T191
tumor	I-T191
(	O
PNET	B-T191
)	O
of	O
the	O
female	B-T023
genital	I-T023
tract	I-T023
is	O
rare	O
,	O
and	O
its	O
proper	O
classification	O
remains	O
unclear	O
.	O
The	O
clinical	O
,	O
histologic	O
,	O
and	O
immunophenotypic	B-T059
features	O
as	O
well	O
as	O
EWSR1	O
rearrangement	O
status	O
of	O
19	O
gynecologic	O
PNETs	B-T191
,	O
including	O
10	O
ovarian	B-T023
,	O
8	O
uterine	B-T023
,	O
and	O
1	O
vulvar	B-T023
tumors	B-T191
,	O
are	O
herein	O
reported	O
.	O
Patient	O
age	O
ranged	O
from	O
12	O
to	O
68	O
years	O
,	O
with	O
a	O
median	O
age	O
of	O
20	O
and	O
51	O
years	O
among	O
those	O
with	O
ovarian	B-T023
and	O
uterine	B-T023
PNETs	B-T191
,	O
respectively	O
.	O
Morphologic	O
features	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
tumors	B-T191
were	O
seen	O
in	O
15	O
PNETs	B-T191
,	O
including	O
9	O
medulloblastomas	B-T191
,	O
3	O
ependymomas	B-T191
,	O
2	O
medulloepitheliomas	B-T191
,	O
and	O
1	O
glioblastoma	B-T191
,	O
consistent	O
with	O
central	B-T191
PNET	I-T191
.	O
The	O
remaining	O
4	O
PNETs	B-T191
were	O
composed	O
entirely	O
of	O
undifferentiated	O
small	O
round	O
blue	O
cells	O
and	O
were	O
classified	O
as	O
Ewing	B-T191
sarcoma	I-T191
/	I-T191
peripheral	I-T191
PNET	I-T191
.	O
Eight	O
PNETs	B-T191
were	O
associated	O
with	O
another	O
tumor	B-T191
type	O
,	O
including	O
5	O
ovarian	B-T023
mature	B-T191
cystic	I-T191
teratomas	I-T191
,	O
2	O
endometrial	O
low	O
-	O
grade	O
endometrioid	B-T191
carcinomas	I-T191
,	O
and	O
a	O
uterine	B-T191
carcinosarcoma	I-T191
.	O
By	O
immunohistochemistry	B-T060
,	O
17	O
PNETs	B-T191
expressed	O
at	O
least	O
1	O
marker	O
of	O
neuronal	B-T033
differentiation	I-T033
,	O
including	O
synaptophysin	O
,	O
NSE	O
,	O
CD56	O
,	O
S100	O
,	O
and	O
chromogranin	O
in	O
10	O
,	O
8	O
,	O
14	O
,	O
8	O
,	O
and	O
1	O
tumors	B-T191
,	O
respectively	O
.	O
GFAP	O
was	O
positive	O
in	O
4	O
PNETs	B-T191
,	O
all	O
of	O
which	O
were	O
of	O
central	O
type	O
.	O
Membranous	O
CD99	O
and	O
nuclear	O
Fli-1	O
staining	B-T059
was	O
seen	O
in	O
10	O
and	O
16	O
tumors	B-T191
,	O
respectively	O
,	O
and	O
concurrent	O
expression	O
of	O
both	O
markers	O
was	O
seen	O
in	O
both	O
central	B-T191
and	O
Ewing	B-T191
sarcoma	I-T191
/	I-T191
peripheral	I-T191
PNET	I-T191
s.	O
All	O
tumors	B-T191
expressed	O
vimentin	O
,	O
whereas	O
keratin	O
cocktail	O
(	O
CAM5.2	O
,	O
AE1	O
/	O
AE3	O
)	O
staining	B-T059
was	O
only	O
focally	O
present	O
in	O
4	O
PNETs	B-T191
.	O
Fluorescence	O
in	O
situ	O
hybridization	O
was	O
successful	O
in	O
all	O
cases	O
and	O
confirmed	O
EWSR1	O
rearrangement	O
in	O
2	O
of	O
4	O
tumors	B-T191
demonstrating	O
morphologic	O
features	O
of	O
Ewing	B-T191
sarcoma	I-T191
/	I-T191
peripheral	I-T191
PNET	I-T191
and	O
concurrent	O
CD99	O
and	O
Fli-1	O
expression	O
.	O
In	O
conclusion	O
,	O
central	B-T191
and	O
Ewing	B-T191
sarcoma	I-T191
/	I-T191
peripheral	I-T191
PNETs	I-T191
may	O
be	O
encountered	O
in	O
the	O
female	B-T023
genital	I-T023
tract	I-T023
with	O
central	B-T191
PNETs	I-T191
being	O
more	O
common	O
.	O
Central	B-T191
PNETs	I-T191
show	O
a	O
spectrum	O
of	O
morphologic	O
features	O
that	O
overlaps	O
with	O
CNS	O
tumors	B-T191
but	O
lack	O
EWSR1	O
rearrangement	O
s.	O
GFAP	O
expression	O
supports	O
a	O
morphologic	O
impression	O
of	O
central	B-T191
PNET	I-T191
and	O
is	O
absent	O
in	O
Ewing	O
sarcoma	B-T191
/	I-T191
peripheral	I-T191
PNET	I-T191
.	O
Ewing	B-T191
sarcoma	I-T191
/	I-T191
peripheral	I-T191
PNETs	I-T191
lack	O
morphologic	O
features	O
of	O
CNS	O
tumors	B-T191
.	O
      
Vascular	O
smooth	O
muscle	O
cell	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
γ	O
protects	O
against	O
endothelin-1	O
-	O
induced	O
oxidative	O
stress	O
and	O
inflammation	O
Peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
γ	O
(	O
PPARγ	O
)	O
agonists	B-T121
reduce	O
blood	O
pressure	O
and	O
vascular	O
injury	O
in	O
hypertensive	B-T033
rodents	O
.	O
Pparγ	O
inactivation	O
in	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMC	O
)	O
enhances	O
vascular	O
injury	O
.	O
Transgenic	O
mice	O
overexpressing	O
endothelin	O
(	O
ET)-1	O
selectively	O
in	O
the	O
endothelium	O
(	O
eET-1	O
)	O
exhibit	O
endothelial	B-T047
dysfunction	I-T047
,	O
increased	O
oxidative	O
stress	O
and	O
inflammation	O
.	O
We	O
hypothesized	O
that	O
inactivation	O
of	O
the	O
Pparγ	O
gene	O
in	O
VSMC	O
(	O
smPparγ	O
)	O
would	O
exaggerate	O
ET-1	O
-	O
induced	O
vascular	O
injury	O
.	O
eET-1	O
,	O
smPparγ	O
and	O
eET-1	O
/	O
smPparγ	O
mice	O
were	O
treated	B-T033
with	O
tamoxifen	B-T121
for	O
5	O
days	O
and	O
studied	O
4	O
weeks	O
later	O
.	O
SBP	O
was	O
higher	O
in	O
eET-1	O
and	O
unaffected	O
by	O
smPparγ	O
inactivation	O
.	O
Mesenteric	B-T023
artery	I-T023
vasodilatory	O
responses	O
to	O
acetylcholine	B-T121
were	O
impaired	O
only	O
in	O
smPparγ	O
.	O
N	O
-	O
Nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
abrogated	O
relaxation	O
responses	O
,	O
and	O
the	O
Ednra	O
/	O
Ednrb	O
mRNA	O
ratio	O
was	O
decreased	O
in	O
eET-1	O
/	O
smPparγ	O
,	O
which	O
could	O
indicate	O
that	O
nitric	B-T121
oxide	I-T121
production	O
was	O
enhanced	O
by	O
ET-1	O
stimulation	O
of	O
endothelin	O
type	O
B	O
receptors	O
.	O
Mesenteric	B-T023
artery	I-T023
media	O
/	O
lumen	O
was	O
greater	O
only	O
in	O
eET-1	O
/	O
smPparγ	O
.	O
Mesenteric	B-T023
artery	I-T023
reactive	O
oxygen	O
species	O
increased	O
in	O
smPparγ	O
and	O
were	O
further	O
enhanced	O
in	O
eET-1	O
/	O
smPparγ	O
.	O
Perivascular	O
fat	O
monocyte	O
/	O
macrophage	O
infiltration	O
was	O
higher	O
in	O
eET-1	O
and	O
smPparγ	O
and	O
increased	O
further	O
in	O
eET-1	O
/	O
smPparγ	O
.	O
Spleen	B-T023
CD11b	O
cells	O
were	O
increased	O
in	O
smPparγ	O
and	O
further	O
enhance	O
d	O
in	O
eET-1	O
/	O
smPparγ	O
,	O
whereas	O
Ly-6C	O
monocytes	O
increased	O
in	O
eET-1	O
and	O
smPparγ	O
but	O
not	O
in	O
eET-1	O
/	O
smPparγ	O
.	O
Spleen	B-T023
T	O
regulatory	O
lymphocytes	O
increased	O
in	O
smPparγ	O
and	O
decreased	O
in	O
eET-1	O
,	O
and	O
decreased	O
further	O
in	O
eET-1	O
/	O
smPparγ	O
.	O
VSMC	O
Pparγ	O
inactivation	O
exaggerates	O
ET-1	O
-	O
induced	O
vascular	O
injury	O
,	O
supporting	O
a	O
protective	O
role	O
for	O
PPARγ	O
in	O
hypertension	B-T047
through	O
modulation	O
of	O
pro	O
-	O
oxidant	O
and	O
proinflammatory	O
pathways	O
.	O
Paradoxically	O
,	O
ET-1	O
overexpression	O
preserved	O
endothelial	O
function	O
in	O
smPparγ	O
mice	O
,	O
presumably	O
by	O
enhancing	O
nitric	B-T121
oxide	I-T121
through	O
stimulation	O
of	O
endothelin	O
type	O
B	O
receptors	O
.	O
      
Endemic	O
hydrothermal	O
vent	O
species	O
identified	O
in	O
the	O
open	O
ocean	O
seed	O
bank	O
Hydrothermal	O
vent	O
systems	O
host	O
microbial	B-T001
communities	O
among	O
which	O
several	O
microorganisms	B-T001
have	O
been	O
considered	O
endemic	O
to	O
this	O
type	O
of	O
habitat	O
.	O
It	O
is	O
still	O
unclear	B-T033
how	O
these	O
organisms	B-T001
colonize	B-T033
geographically	O
distant	O
hydrothermal	O
environments	O
.	O
Based	O
on	O
16S	O
rRNA	O
gene	O
sequences	O
,	O
we	O
compare	O
the	O
bacterial	O
communities	O
of	O
sixteen	O
Atlantic	O
hydrothermal	O
vent	O
samples	O
with	O
our	O
own	O
and	O
publicly	O
available	O
global	O
open	O
ocean	O
samples	O
.	O
Analysing	O
sequences	O
obtained	O
from	O
63	O
million	O
16S	O
rRNA	O
genes	O
,	O
the	O
genera	O
we	O
could	O
identify	O
in	O
the	O
open	O
ocean	O
waters	O
contained	O
99.9	O
%	O
of	O
the	O
vent	O
reads	O
.	O
This	O
suggests	O
that	O
previously	O
observed	O
vent	O
exclusiveness	B-T033
is	O
,	O
in	O
most	O
cases	O
,	O
probably	O
an	O
artefact	B-T033
of	O
lower	O
sequencing	B-T059
depth	O
.	O
These	O
findings	B-T033
are	O
a	O
further	O
step	O
towards	O
elucidating	O
the	O
role	O
of	O
the	O
open	O
ocean	O
as	O
a	O
seed	O
bank	O
.	O
They	O
can	O
explain	O
the	O
predicament	B-T033
of	O
how	O
species	O
expected	O
to	O
be	O
endemic	O
to	O
vent	O
systems	O
are	O
able	B-T033
to	O
colonize	B-T033
geographically	O
distant	O
hydrothermal	O
habitats	O
and	O
contribute	O
to	O
our	O
understanding	O
of	O
whether	O
'	O
everything	O
is	O
really	O
everywhere	O
'	O
.	O
      
Evaluation	B-T058
of	O
the	O
VIDAS	B-T059
Anti	I-T059
-	I-T059
HCV	I-T059
Assay	I-T059
for	O
Detection	B-T061
of	O
Hepatitis	B-T047
C	I-T047
Virus	I-T047
Infection	I-T047
Anti	O
-	O
hepatitis	O
C	O
virus	O
antibody	O
(	O
anti	O
-	O
HCV	O
)	O
assays	B-T059
are	O
recommended	O
for	O
screening	B-T058
HCV	B-T005
-infected	O
persons	O
.	O
The	O
VIDAS	B-T059
Anti	I-T059
-	I-T059
HCV	I-T059
Assay	I-T059
(	O
bioMérieux	O
,	O
France	O
)	O
,	O
based	O
on	O
the	O
enzyme	B-T059
-	I-T059
linked	I-T059
fluorescence	I-T059
test	I-T059
principle	O
,	O
was	O
recently	O
introduced	O
in	O
Korea	O
.	O
We	O
evaluated	O
the	O
clinical	O
performance	O
of	O
the	O
VIDAS	B-T059
assay	I-T059
.	O
One	O
hundred	O
HCV	O
-	O
positive	O
and	O
1,002	O
HCV	O
-	O
negative	O
blood	O
samples	O
confirmed	O
by	O
Architect	B-T059
anti	I-T059
-	I-T059
HCV	I-T059
(	O
Abbott	O
Laboratories	O
,	O
USA	O
)	O
and	O
COBAS	O
TaqMan	O
HCV	O
real	O
-	O
time	O
PCR	O
(	O
Roche	O
Diagnostics	O
,	O
USA	O
)	O
or	O
the	O
Procleix	B-T059
Ultrio	I-T059
Plus	I-T059
Assay	I-T059
(	O
Gen	O
-	O
Probe	O
Incorporated	O
,	O
USA	O
)	O
were	O
obtained	O
from	O
the	O
Human	O
Serum	O
Bank	O
(	O
HSB	O
)	O
and	O
tested	O
by	O
VIDAS	B-T059
.	O
In	O
case	O
of	O
discrepant	B-T033
results	I-T033
,	O
we	O
conducted	O
a	O
recombinant	B-T059
immunoblot	I-T059
assay	I-T059
(	O
RIBA	B-T059
)	O
.	O
The	O
agreement	O
rates	O
for	O
known	O
HCV	O
-	O
positive	O
and	O
HCV	O
-	O
negative	O
samples	O
between	O
the	O
VIDAS	B-T059
assay	I-T059
and	O
the	O
HSB	O
testing	O
were	O
100	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
96.4	O
-	O
100	O
%	O
)	O
and	O
99.5	O
%	O
(	O
95	O
%	O
CI	O
:	O
98.8	O
-	O
99.8	O
%	O
)	O
,	O
respectively	O
.	O
One	O
of	O
the	O
five	O
discrepant	B-T033
samples	O
was	O
positive	B-T033
for	O
Core	O
2	O
+	O
and	O
NS3	O
-	O
2	O
2	O
+	O
reactivity	O
,	O
two	O
samples	O
were	O
negative	B-T033
,	O
and	O
the	O
other	O
two	O
were	O
indeterminate	O
regarding	O
NS4	O
2	O
+	O
reactivity	O
in	O
RIBA	B-T059
.	O
We	O
observed	O
a	O
significant	O
but	O
weak	O
positive	O
correlation	O
between	O
the	O
titers	O
of	O
VIDAS	B-T059
and	O
Architect	B-T059
assays	I-T059
(	O
r=0.315	O
,	O
P<0.001	O
)	O
.	O
The	O
VIDAS	B-T059
anti	I-T059
-	I-T059
HCV	I-T059
assay	I-T059
,	O
developed	O
on	O
the	O
VIDAS	B-T059
automated	B-T059
immunoassay	I-T059
platform	I-T059
based	O
on	O
the	O
ready	O
-	O
to	O
-	O
use	O
,	O
single	O
-	O
sample	O
test	O
concept	O
may	O
be	O
useful	O
in	O
small	O
-	O
to	O
-	O
medium	O
-	O
sized	O
laboratories	O
.	O
It	O
showed	O
good	O
agreement	O
with	O
Architect	B-T059
anti	I-T059
-	I-T059
HCV	I-T059
and	O
COBAS	O
PCR	O
assays	O
and	O
is	O
therefore	O
useful	O
for	O
detection	O
of	O
HCV	B-T047
infection	I-T047
.	O
Weakly	O
test	O
-	O
positive	O
(	O
ambiguous	O
)	O
samples	O
require	O
additional	O
testing	O
by	O
another	O
anti	O
-	O
HCV	O
,	O
RIBA	B-T059
,	O
or	O
HCV	B-T059
RNA	I-T059
assay	I-T059
.	O
      
Ultra	O
-	O
low	O
activities	O
of	O
a	O
common	O
radioisotope	O
for	O
permission	O
-free	O
tracking	O
of	O
a	O
drosophilid	O
fly	O
in	O
its	O
natural	O
habitat	O
Knowledge	O
of	O
a	O
species	O
'	O
ecology	O
,	O
including	O
its	O
movement	O
in	O
time	O
and	O
space	O
,	O
is	O
key	O
for	O
many	O
questions	O
in	O
biology	O
and	O
conservation	O
.	O
While	O
numerous	O
tools	O
for	O
tracking	O
larger	O
animals	O
are	O
available	O
,	O
millimetre	O
-	O
sized	O
insects	O
are	O
averse	O
to	O
standard	O
tracking	O
and	O
labelling	O
procedures	O
.	O
Here	O
,	O
we	O
evaluated	O
the	O
applicability	O
of	O
ultra	O
-	O
low	O
,	O
permission	O
-	O
exempt	O
activities	O
of	O
the	O
metastable	O
isomer	O
of	O
the	O
radionuclide	O
Technetium-99	O
for	O
labelling	O
and	O
field	B-T033
detection	I-T033
of	O
the	O
mountain	O
fly	O
Drosophila	O
nigrosparsa	O
.	O
We	O
demonstrate	O
that	O
an	O
activity	O
of	O
less	O
than	O
10	O
MBq	O
is	O
sufficient	O
to	O
label	O
dozens	O
of	O
flies	O
and	O
detect	B-T033
single	I-T033
individuals	I-T033
using	O
standard	O
radiation	B-T061
protection	I-T061
monitors	B-T059
.	O
The	O
methodology	O
presented	O
here	O
is	O
applicable	O
to	O
many	O
small	B-T033
-	I-T033
sized	I-T033
,	O
low	B-T033
-	I-T033
mobility	I-T033
animals	O
as	O
well	O
as	O
independent	O
from	O
light	O
and	O
weather	O
conditions	O
and	O
visual	B-T033
contact	I-T033
with	O
the	O
target	O
organism	B-T001
.	O
      
Risk	O
of	O
cancer	O
in	O
patients	O
with	O
heart	B-T047
failure	I-T047
who	O
use	O
digoxin	B-T121
:	O
a	O
10	O
-	O
year	O
follow	O
-	O
up	O
study	O
and	O
cell	O
-based	O
verification	O
Heart	B-T047
failure	I-T047
(	O
HF	B-T047
)	O
is	O
the	O
leading	O
cause	B-T033
of	I-T033
death	I-T033
in	O
the	O
world	O
and	O
digoxin	B-T121
remains	O
one	O
of	O
the	O
oldest	O
therapies	B-T061
for	O
HF	B-T047
.	O
However	O
,	O
its	O
safety	O
and	O
efficacy	O
have	O
been	O
controversial	O
since	O
its	O
initial	O
use	O
and	O
there	O
is	O
uncertainty	B-T033
about	O
its	O
long	O
-	O
term	O
efficacy	O
and	O
safety	O
.	O
Recently	O
,	O
the	O
repositioning	B-T061
of	O
cardiac	B-T121
glycosides	I-T121
is	O
to	O
function	O
in	O
anti	B-T061
-	I-T061
tumor	I-T061
activity	I-T061
via	O
multiple	O
working	O
pathways	O
.	O
It	O
is	O
interesting	O
to	O
compare	O
the	O
potential	O
effects	O
of	O
digoxin	B-T121
in	O
clinical	O
patients	O
and	O
cell	O
lines	O
.	O
First	O
,	O
we	O
analyze	O
patient	O
information	O
retrieved	O
from	O
the	O
National	O
Health	O
Insurance	O
Research	O
database	O
of	O
Taiwan	O
between	O
January	O
1	O
,	O
2000	O
and	O
December	O
31	O
,	O
2000	O
.	O
This	O
retrospective	O
study	O
included	O
a	O
study	O
cohort	O
(	O
1,219	O
patients	O
)	O
and	O
a	O
comparison	O
cohort	O
.	O
Our	O
analytical	O
data	O
suggested	O
that	O
patients	O
taking	O
digoxin	B-T121
are	O
at	O
an	O
increased	O
risk	O
of	O
cancers	O
,	O
including	O
breast	B-T191
,	O
liver	B-T191
,	O
and	O
lung	B-T191
cancers	I-T191
,	O
during	O
the	O
10	O
-	O
year	O
follow	B-T058
-	I-T058
up	I-T058
period	I-T058
.	O
In	O
contrast	O
to	O
the	O
anti	B-T061
-	I-T061
tumor	I-T061
function	I-T061
of	O
digoxin	B-T121
,	O
we	O
further	O
examined	O
the	O
potential	O
pathway	O
of	O
digoxin	B-T121
via	O
the	O
cell	O
-based	O
strategy	O
using	O
several	O
breast	B-T191
cancer	I-T191
cell	O
lines	O
,	O
including	O
MCF-7	O
,	O
BT-474	O
,	O
MAD	O
-	O
MB-231	O
,	O
and	O
ZR-75	O
-	O
1	O
.	O
Digoxin	B-T121
consistently	O
exerted	O
its	O
cytotoxicity	O
to	O
these	O
four	O
cell	O
lines	O
with	O
various	O
range	O
of	O
concentration	O
.	O
However	O
,	O
the	O
proliferation	O
of	O
ZR-75	O
-	O
1	O
cells	O
was	O
the	O
only	O
cell	O
lines	O
induced	O
by	O
digoxin	B-T121
and	O
the	O
others	O
were	O
dramatically	O
suppressed	O
by	O
digoxin	B-T121
.	O
The	O
responsiveness	O
of	O
SRSF3	O
to	O
digoxin	B-T121
might	O
be	O
involved	O
with	O
cell	O
-	O
type	O
differences	O
.	O
In	O
summary	O
,	O
we	O
combined	O
a	O
cohort	O
study	O
for	O
digoxin	B-T121
treatment	B-T061
for	O
HF	B-T047
patients	O
with	O
a	O
cell	O
-based	O
strategy	O
that	O
addresses	O
the	O
translation	O
issue	O
,	O
which	O
revealed	O
the	O
complexity	O
of	O
personalized	B-T061
medicine	I-T061
.	O
      
An	O
Analysis	O
of	O
Systematic	O
Elemental	O
Changes	O
in	O
Decomposing	B-T023
Bone	I-T023
The	O
aim	O
of	O
this	O
pilot	O
study	O
was	O
to	O
investigate	O
compositional	O
changes	O
in	O
bone	B-T023
during	O
decomposition	O
.	O
Elemental	O
concentrations	O
of	O
barium	O
,	O
calcium	B-T121
,	O
iron	B-T121
,	O
potassium	O
,	O
magnesium	O
,	O
zinc	B-T121
and	O
phosphorus	O
in	O
porcine	O
bone	B-T023
(	O
as	O
an	O
experimental	O
analog	O
for	O
human	O
bone	B-T023
)	O
were	O
analyzed	O
by	O
inductively	B-T059
coupled	I-T059
plasma	I-T059
optical	I-T059
emission	I-T059
spectroscopy	I-T059
(	O
ICP	B-T059
-	I-T059
OES	I-T059
)	O
.	O
The	O
samples	O
were	O
taken	O
from	O
porcine	O
bone	B-T023
subjected	O
to	O
shallow	O
burial	O
and	O
surface	O
depositions	O
at	O
28-	O
day	O
intervals	O
for	O
a	O
period	O
of	O
140	O
days	O
.	O
Results	B-T033
indicated	B-T033
that	O
ICP	B-T059
-	I-T059
OES	I-T059
elemental	O
profiling	O
has	O
potential	O
to	O
be	O
developed	O
as	O
a	O
forensic	B-T059
test	I-T059
for	O
determining	O
whether	O
a	O
bone	O
sample	O
originates	O
from	O
the	O
early	O
stages	O
of	O
soft	O
tissue	O
putrefaction	O
.	O
Significant	O
changes	O
in	O
iron	B-T121
,	O
sodium	O
and	O
potassium	O
concentrations	O
were	O
found	B-T033
over	O
140	O
days	O
.	O
These	O
elements	O
are	O
known	O
to	O
be	O
primarily	O
associated	O
with	O
proteins	O
and/or	O
tissue	O
fluids	O
within	O
the	O
bone	B-T023
.	O
Changes	O
in	O
their	O
respective	O
concentrations	O
may	O
therefore	O
be	O
linked	O
to	O
dehydration	B-T033
over	O
time	O
and	O
in	O
turn	O
may	O
be	O
indicative	O
of	O
time	O
since	O
deposition	O
.	O
      
Vitamin	O
D	O
Receptor	O
Activator	O
Use	O
and	O
Cause	O
-	O
specific	O
Death	O
among	O
dialysis	B-T061
Patients	O
:	O
a	O
Nationwide	O
Cohort	O
Study	O
using	O
Coarsened	O
Exact	O
Matching	O
Vitamin	O
D	O
receptor	O
activators	O
(	O
VDRA	O
)	O
may	O
exert	O
pleiotropic	O
effects	O
on	O
cardiovascular	B-T047
disease	I-T047
,	O
malignancy	B-T191
,	O
and	O
infections	O
among	O
dialysis	B-T061
patients	O
,	O
but	O
recent	O
studies	O
have	O
mainly	O
focused	O
on	O
cardiovascular	B-T033
outcomes	I-T033
.	O
Among	O
8,675	O
patients	O
who	O
started	O
dialysis	B-T061
in	O
2007	O
and	O
who	O
survived	O
until	O
January	O
1	O
,	O
2010	O
,	O
listed	O
in	O
the	O
Renal	O
Data	O
Registry	O
of	O
the	O
Japanese	O
Society	O
for	O
Dialysis	B-T061
Therapy	I-T061
,	O
5,365	O
VDRA	O
users	O
were	O
matched	O
to	O
3,203	O
non	O
-	O
users	O
based	O
on	O
clinically	O
relevant	O
variables	O
at	O
the	O
end	O
of	O
2009	O
using	O
the	O
coarsened	O
exact	O
matching	O
procedure	O
.	O
Until	O
December	O
31	O
,	O
2011	O
,	O
a	O
total	O
of	O
1,128	O
deaths	O
occurred	O
,	O
of	O
which	O
468	O
(	O
42	O
%	O
)	O
were	O
cardiovascular	O
deaths	O
,	O
229	O
(	O
20	O
%	O
)	O
were	O
infection	B-T033
-	I-T033
related	I-T033
deaths	I-T033
,	O
and	O
141	O
(	O
12	O
%	O
)	O
were	O
malignancy	O
-	O
related	O
deaths	O
.	O
Multivariable	O
survival	O
analyses	O
accounting	O
for	O
intra	O
-	O
region	O
correlation	O
revealed	O
that	O
VDRA	O
use	O
was	O
significantly	O
associated	O
with	O
lower	O
rates	O
of	O
infection	O
-	O
and	O
malignancy	B-T191
-related	O
deaths	O
[	O
subhazard	O
ratio	O
0.62	O
(	O
95	O
%	O
CI	O
,	O
0.52	O
-	O
0.73	O
)	O
and	O
0.70	O
(	O
95	O
%	O
CI	O
,	O
0.50	O
-	O
0.97	O
)	O
,	O
respectively	O
]	O
but	O
not	O
with	O
cardiovascular	O
death	O
[	O
subhazard	O
ratio	O
0.86	O
(	O
95	O
%	O
CI	O
,	O
0.72	O
-	O
1.04	O
)	O
]	O
.	O
Future	O
randomized	O
clinical	O
trials	O
with	O
a	O
sufficient	O
sample	O
size	O
and	O
an	O
adequate	O
follow	B-T058
-	I-T058
up	I-T058
period	O
are	O
warranted	O
to	O
test	O
the	O
clinical	O
effectiveness	O
of	O
VDRA	O
on	O
infection	O
and	O
malignancy	B-T191
,	O
rather	O
than	O
cardiovascular	B-T047
disease	I-T047
,	O
among	O
dialysis	B-T061
patients	O
.	O
      
Altered	O
pH	O
gradient	O
at	O
the	O
plasma	O
membrane	O
of	O
osteosarcoma	B-T191
cells	O
is	O
a	O
key	O
mechanism	O
of	O
drug	O
resistance	O
Current	O
therapy	B-T061
of	O
osteosarcoma	B-T191
(	O
OS	B-T191
)	O
,	O
the	O
most	O
common	O
primary	B-T191
bone	I-T191
malignancy	I-T191
,	O
is	O
based	O
on	O
a	O
combination	B-T061
of	I-T061
surgery	I-T061
and	I-T061
chemotherapy	I-T061
.	O
Multidrug	O
resistance	O
mediated	O
by	O
P	O
-	O
glycoprotein	O
(	O
P	O
-	O
gp	O
)	O
overexpression	O
has	O
been	O
previously	O
associated	O
with	O
treatment	B-T033
failure	I-T033
and	O
progression	O
of	O
OS	B-T191
,	O
although	O
other	O
mechanisms	O
may	O
also	O
play	O
a	O
role	O
.	O
We	O
considered	O
the	O
typical	O
acidic	O
extracellular	O
pH	O
(	O
pHe	O
)	O
of	O
sarcomas	B-T191
,	O
and	O
found	O
that	O
doxorubicin	B-T195
(	O
DXR	B-T195
)	O
cytotoxicity	O
is	O
reduced	O
in	O
P	O
-	O
gp	O
negative	O
OS	B-T191
cells	O
cultured	O
at	O
pHe	O
6.5	O
compared	O
to	O
standard	O
7.4	O
.	O
Short	O
-	O
time	O
(	O
24	O
-	O
48	O
hours	O
)	O
exposure	O
to	O
low	O
pHe	O
significantly	O
increased	O
the	O
number	O
and	O
acidity	O
of	O
lysosomes	O
,	O
and	O
the	O
combination	O
of	O
DXR	B-T195
with	O
omeprazole	B-T121
,	O
a	O
proton	B-T121
pump	I-T121
inhibitor	I-T121
targeting	O
lysosomal	O
acidity	O
,	O
significantly	O
enhanced	O
DXR	B-T195
cytotoxicity	O
.	O
In	O
OS	B-T191
xenografts	O
,	O
the	O
combination	B-T061
treatment	I-T061
of	O
DXR	B-T195
and	O
omeprazole	B-T121
significantly	O
reduced	O
tumor	O
volume	O
and	O
body	B-T033
weight	I-T033
loss	I-T033
.	O
The	O
impaired	O
toxicity	O
of	O
DXR	B-T195
at	O
low	O
pHe	O
was	O
not	O
associated	O
with	O
increased	O
autophagy	O
or	O
lysosomal	O
acidification	O
,	O
but	O
rather	O
,	O
as	O
shown	O
by	O
SNARF	O
staining	B-T059
,	O
with	O
a	O
reversal	O
of	O
the	O
pH	O
gradient	O
at	O
the	O
plasma	O
membrane	O
(	O
ΔpHcm	O
)	O
,	O
eventually	O
leading	O
to	O
a	O
reduced	O
DXR	B-T195
intracellular	O
accumulation	B-T033
.	O
Finally	O
,	O
the	O
reversal	O
of	O
ΔpHcm	O
in	O
OS	B-T191
cells	O
promoted	O
resistance	O
not	O
only	O
to	O
DXR	B-T195
,	O
but	O
also	O
to	O
cisplatin	B-T121
and	O
methotrexate	B-T121
,	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
to	O
vincristine	B-T121
.	O
Altogether	O
,	O
our	O
findings	O
show	O
that	O
,	O
in	O
OS	B-T191
cells	O
,	O
short	O
-	O
term	O
acidosis	O
induces	O
resistance	O
to	O
different	O
chemotherapeutic	B-T121
drugs	I-T121
by	O
a	O
reversal	O
of	O
ΔpHcm	O
,	O
suggesting	O
that	O
buffer	B-T121
therapies	B-T061
or	O
regimens	O
including	O
proton	B-T121
pump	I-T121
inhibitors	I-T121
in	O
combination	O
to	O
low	O
concentrations	O
of	O
conventional	O
anticancer	B-T121
agents	I-T121
may	O
offer	O
novel	O
solutions	O
to	O
overcome	O
drug	O
resistance	O
.	O
      
Consecutive	O
Endovascular	B-T061
Treatment	I-T061
of	O
20	O
Ruptured	O
Very	O
Small	O
(	O
<3	O
mm	O
)	O
Anterior	B-T047
Communicating	I-T047
Artery	I-T047
Aneurysms	I-T047
Small	O
aneurysms	B-T047
located	O
at	O
the	O
anterior	B-T023
communicating	I-T023
artery	I-T023
carry	O
significant	O
procedural	O
challenges	O
due	O
to	O
a	O
complex	O
anatomy	B-T017
.	O
Recent	O
advances	O
in	O
endovascular	B-T061
technologies	I-T061
have	O
expanded	O
the	O
use	O
of	O
coil	B-T061
embolization	I-T061
for	O
small	O
aneurysm	B-T047
treatment	O
.	O
However	O
,	O
limited	O
reports	O
describe	O
their	O
safety	O
and	O
efficacy	O
profiles	O
in	O
very	O
small	O
anterior	B-T047
communicating	I-T047
artery	I-T047
aneurysms	I-T047
.	O
We	O
sought	O
to	O
review	O
and	O
report	O
the	O
immediate	O
and	O
long	O
-	O
term	O
clinical	O
as	O
well	O
as	O
radiographic	O
outcomes	O
of	O
consecutive	O
patients	O
with	O
ruptured	O
very	O
small	O
anterior	B-T047
communicating	I-T047
artery	I-T047
aneurysms	I-T047
treated	O
with	O
current	O
endovascular	B-T061
coil	I-T061
embolization	I-T061
techniques	I-T061
.	O
A	O
prospectively	O
maintained	O
single	O
-	O
institution	O
neuroendovascular	O
database	O
was	O
accessed	O
to	O
identify	O
consecutive	O
cases	O
of	O
very	O
small	O
(	O
<3	O
mm	O
)	O
ruptured	O
anterior	B-T047
communicating	I-T047
artery	I-T047
aneurysms	I-T047
treated	O
endovascularly	O
between	O
2006	O
and	O
2013	O
.	O
A	O
total	O
of	O
20	O
patients	O
with	O
ruptured	O
very	O
small	O
(	O
<3	O
mm	O
)	O
anterior	B-T047
communicating	I-T047
artery	I-T047
aneurysms	I-T047
were	O
consecutively	O
treated	O
with	O
coil	B-T061
embolization	I-T061
.	O
The	O
average	O
maximum	O
diameter	O
was	O
2.66	O
±	O
0.41	O
mm	O
.	O
Complete	O
aneurysm	B-T061
occlusion	I-T061
was	O
achieved	O
for	O
17	O
(	O
85	O
%	O
)	O
aneurysms	B-T047
and	O
near	O
-	O
complete	O
aneurysm	B-T061
occlusion	I-T061
for	O
3	O
(	O
15	O
%	O
)	O
aneurysms	B-T047
.	O
Intraoperative	O
perforation	B-T033
was	O
seen	O
in	O
2	O
(	O
10	O
%	O
)	O
patients	O
without	O
any	O
clinical	O
worsening	O
or	O
need	O
for	O
an	O
external	B-T061
ventricular	I-T061
drain	I-T061
.	O
A	O
thromboembolic	O
event	O
occurred	O
in	O
1	O
(	O
5	O
%	O
)	O
patient	O
without	O
clinical	O
worsening	O
or	O
radiologic	O
infarct	O
.	O
Median	O
clinical	O
follow	B-T058
-	I-T058
up	I-T058
was	O
12	O
(	O
±14.1	O
)	O
months	O
and	O
median	O
imaging	O
follow	B-T058
-	I-T058
up	I-T058
was	O
12	O
(	O
±18.4	O
)	O
months	O
.	O
This	O
report	O
describes	O
the	O
largest	O
series	O
of	O
consecutive	O
endovascular	B-T061
treatments	I-T061
of	O
ruptured	O
very	O
small	O
anterior	B-T047
communicating	I-T047
artery	I-T047
aneurysms	I-T047
.	O
These	O
findings	O
suggest	O
that	O
coil	B-T061
embolization	I-T061
of	O
very	O
small	O
aneurysms	B-T047
in	O
this	O
location	O
can	O
be	O
performed	O
with	O
acceptable	O
rates	O
of	O
complications	O
and	O
recanalization	B-T061
.	O
      
Vestibular	O
-dependent	O
inter	O
-	O
stimulus	O
interval	O
effects	O
on	O
sound	O
evoked	O
potentials	O
of	O
central	O
origin	O
Todd	O
et	O
al	O
.	O
(	O
2014ab	O
)	O
have	O
recently	O
demonstrated	O
the	O
presence	B-T033
of	O
vestibular	O
-dependent	O
contributions	O
to	O
auditory	O
evoked	O
potentials	O
(	O
AEPs	O
)	O
when	O
passing	O
through	O
the	O
vestibular	O
threshold	O
as	O
determined	O
by	O
vestibular	O
evoked	O
myogenic	O
potentials	O
(	O
VEMPs	O
)	O
,	O
including	O
a	O
particular	O
deflection	O
labeled	O
as	O
an	O
N42	O
/	O
P52	O
prior	O
to	O
the	O
long	O
-	O
latency	O
AEPs	O
N1	O
and	O
P2	O
.	O
In	O
this	O
paper	O
we	O
report	B-T058
the	O
results	B-T033
of	O
an	O
experiment	O
to	O
determine	O
the	O
effect	O
of	O
inter	O
-	O
stimulus	O
interval	O
(	O
ISI	O
)	O
and	O
regularity	O
on	O
potentials	O
recorded	O
above	O
and	O
below	O
VEMP	O
threshold	O
.	O
Five	O
healthy	O
,	O
right	O
-	O
handed	O
subjects	O
were	O
recruited	O
and	O
evoked	O
potentials	O
were	O
recorded	O
to	O
binaurally	O
presented	O
sound	B-T061
stimulation	I-T061
,	O
above	O
and	O
below	O
vestibular	O
threshold	O
,	O
at	O
seven	O
stimulus	O
rates	O
with	O
ISIs	O
of	O
212	O
,	O
300	O
,	O
424	O
,	O
600	O
,	O
848	O
,	O
1200	O
and	O
1696	O
ms	O
.	O
The	O
inner	O
five	O
intervals	O
,	O
i.e.	O
300	O
,	O
424	O
,	O
600	O
,	O
848	O
,	O
1200	O
ms	O
,	O
were	O
presented	O
twice	O
in	O
both	O
regular	O
and	O
irregular	O
conditions	O
.	O
ANOVA	O
on	O
the	O
global	O
field	O
power	O
(	O
GFP	O
)	O
were	O
conducted	O
for	O
each	O
of	O
four	O
waves	O
,	O
N42	O
,	O
P52	O
,	O
N1	O
and	O
P2	O
with	O
factors	O
of	O
intensity	O
,	O
ISI	O
and	O
regularity	O
.	O
Both	O
N42	O
and	O
P52	O
waves	O
showed	O
significant	O
ANOVA	O
effects	O
of	O
intensity	O
but	O
no	O
other	O
main	O
effects	O
or	O
interactions	O
.	O
In	O
contrast	O
both	O
N1	O
and	O
P2	O
showed	O
additional	O
effects	O
of	O
ISI	O
,	O
as	O
well	O
as	O
intensity	O
,	O
and	O
evidence	O
of	O
non	O
-	O
linear	O
interactions	O
between	O
ISI	O
and	O
intensity	O
.	O
A	O
source	O
analysis	O
was	O
carried	O
out	O
consistent	O
with	O
prior	O
work	O
suggesting	O
that	O
when	O
above	O
vestibular	O
threshold	O
,	O
in	O
addition	O
to	O
bilateral	O
superior	O
temporal	B-T023
cortex	I-T023
,	O
ocular	B-T023
,	O
cerebellar	B-T023
and	O
cingulate	B-T023
sources	B-T033
are	O
recruited	O
.	O
Further	O
statistical	O
analysis	O
of	O
the	O
source	B-T033
currents	O
indicated	O
that	O
the	O
origin	O
of	O
the	O
interactions	O
with	O
intensity	O
may	O
be	O
the	O
ISI	O
sensitivity	O
of	O
the	O
vestibular	O
-dependent	O
sources	B-T033
.	O
This	O
in	O
turn	O
may	O
reflect	O
a	O
specific	O
vestibular	O
preference	O
for	O
stimulus	O
rates	O
associated	O
with	O
locomotion	O
,	O
i.e.	O
rates	O
close	O
to	O
2	O
Hz	O
,	O
or	O
ISIs	O
close	O
to	O
500	O
ms	O
,	O
where	O
saccular	O
afferents	O
show	O
increased	O
gain	O
and	O
the	O
corresponding	O
reflexes	O
are	O
most	O
sensitive	O
.	O
      
Mucosal	O
IgM	O
Antibody	O
with	O
d	B-T121
-	I-T121
Mannose	I-T121
Affinity	O
in	O
Fugu	O
Takifugu	O
rubripes	O
Is	O
Utilized	O
by	O
a	O
Monogenean	O
Parasite	O
Heterobothrium	O
okamotoi	O
for	O
Host	O
Recognition	O
How	O
parasites	O
recognize	O
their	O
definitive	O
hosts	B-T001
is	O
a	O
mystery	O
;	O
however	O
,	O
parasitism	O
is	O
reportedly	O
initiated	O
by	O
recognition	O
of	O
certain	O
molecules	O
on	O
host	O
surfaces	O
.	O
Fish	O
ectoparasites	O
make	O
initial	B-T033
contact	I-T033
with	O
their	O
hosts	B-T001
at	O
body	O
surfaces	O
,	O
such	O
as	O
skin	O
and	O
gills	B-T023
,	O
which	O
are	O
covered	O
with	O
mucosa	O
that	O
are	O
similar	O
to	O
those	O
of	O
mammalian	B-T023
guts	I-T023
.	O
Fish	O
are	O
among	O
the	O
most	O
primitive	O
vertebrates	O
with	O
immune	O
systems	O
that	O
are	O
equivalent	O
to	O
those	O
in	O
mammals	O
,	O
and	O
they	O
produce	O
and	O
secrete	O
IgM	O
into	O
mucus	O
.	O
In	O
this	O
study	O
,	O
we	O
showed	O
that	O
the	O
monogenean	O
parasite	O
Heterobothrium	O
okamotoi	O
utilizes	O
IgM	O
to	O
recognize	O
its	O
host	B-T001
,	O
fugu	O
Takifugu	O
rubripes	O
Oncomiracidia	O
are	O
infective	O
larvae	O
of	O
H.	O
okamotoi	O
that	O
shed	O
their	O
cilia	O
and	O
metamorphose	O
into	O
juveniles	O
when	O
exposed	O
to	O
purified	O
d	B-T121
-	I-T121
mannose	I-T121
-	O
binding	O
fractions	O
from	O
fugu	O
mucus	O
.	O
Using	O
liquid	B-T059
chromatography	I-T059
-	I-T059
tandem	I-T059
mass	I-T059
spectrometry	I-T059
analysis	I-T059
,	O
proteins	O
contained	O
in	O
the	O
fraction	O
were	O
identified	O
as	O
d	B-T121
-	I-T121
mannose	I-T121
-specific	O
IgM	O
with	O
two	O
d	B-T121
-	I-T121
mannose	I-T121
-binding	O
lectins	O
.	O
However	O
,	O
although	O
deciliation	O
was	O
significantly	O
induced	O
by	O
IgM	O
and	O
was	O
inhibited	O
by	O
d	B-T121
-	I-T121
mannose	I-T121
or	O
a	O
specific	O
Ab	O
against	O
fugu	O
IgM	O
,	O
other	O
lectins	O
had	O
no	O
effect	O
,	O
and	O
IgM	O
without	O
d	B-T121
-	I-T121
mannose	I-T121
affinity	O
induced	O
deciliation	O
to	O
a	O
limited	O
degree	O
.	O
Subsequent	O
immunofluorescent	B-T059
staining	I-T059
experiments	I-T059
showed	O
that	O
fugu	O
d	B-T121
-	I-T121
mannose	I-T121
-specific	O
IgM	O
binds	O
ciliated	O
epidermal	O
cells	O
of	O
oncomiracidium	O
.	O
These	O
observations	O
suggest	O
that	O
deciliation	O
is	O
triggered	O
by	O
binding	O
of	O
fugu	O
IgM	O
to	O
cell	O
surface	O
Ags	O
via	O
Ag	O
binding	O
sites	O
.	O
Moreover	O
,	O
concentrations	O
of	O
d	B-T121
-	I-T121
mannose	I-T121
-	O
binding	O
IgM	O
in	O
gill	O
mucus	O
were	O
sufficient	O
to	O
induce	O
deciliation	O
in	O
vitro	O
,	O
indicating	O
that	O
H.	O
okamotoi	O
parasites	O
initially	O
use	O
host	B-T001
Abs	O
to	O
colonize	B-T033
host	B-T001
gills	B-T023
.	O
      
Experience	O
is	O
Instrumental	O
in	O
Tuning	O
a	O
Link	O
Between	O
Language	O
and	O
Cognition	O
:	O
Evidence	O
from	O
6-	O
to	O
7-	O
Month	O
-	O
Old	O
Infants	O
'	O
Object	O
Categorization	O
At	O
birth	O
,	O
infants	O
not	O
only	O
prefer	O
listening	O
to	O
human	O
vocalizations	O
,	O
but	O
also	O
have	O
begun	O
to	O
link	O
these	O
vocalizations	O
to	O
cognition	O
:	O
For	O
infants	O
as	O
young	O
as	O
three	O
months	O
of	O
age	O
,	O
listening	O
to	O
human	O
language	O
supports	O
object	O
categorization	O
,	O
a	O
core	O
cognitive	O
capacity	O
.	O
This	O
precocious	O
link	O
is	O
initially	O
broad	O
:	O
At	O
3	O
and	O
4	O
months	O
,	O
vocalizations	O
of	O
both	O
humans	O
and	O
nonhuman	O
primates	O
support	O
categorization	O
.	O
But	O
by	O
6	O
months	O
,	O
infants	O
have	O
narrowed	O
the	O
link	O
:	O
Only	O
human	O
vocalizations	O
support	O
object	O
categorization	O
.	O
Here	O
we	O
ask	O
what	O
guides	O
infants	O
as	O
they	O
tune	O
their	O
initially	O
broad	O
link	O
to	O
a	O
more	O
precise	O
one	O
,	O
engaged	O
only	O
by	O
the	O
vocalizations	O
of	O
our	O
species	O
.	O
Across	O
three	O
studies	O
,	O
we	O
use	O
a	O
novel	O
exposure	O
paradigm	O
to	O
examine	O
the	O
effects	O
of	O
experience	O
.	O
We	O
document	O
that	O
merely	O
exposing	O
infants	O
to	O
nonhuman	O
primate	O
vocalizations	O
enables	O
infants	O
to	O
preserve	O
the	O
early	O
-	O
established	O
link	O
between	O
this	O
signal	O
and	O
categorization	O
.	O
In	O
contrast	O
,	O
exposing	O
infants	O
to	O
backward	O
speech	O
-	O
a	O
signal	O
that	O
fails	O
to	O
support	O
categorization	O
at	O
any	O
age	O
-	O
offers	O
no	O
such	O
advantage	O
.	O
Our	O
findings	B-T033
reveal	O
the	O
power	O
of	O
early	O
experience	O
as	O
infants	O
specify	O
which	O
signals	O
,	O
from	O
an	O
initially	O
broad	O
set	O
,	O
they	O
will	O
continue	O
to	O
link	O
to	O
cognition	O
.	O
      
The	O
influence	O
of	O
liposomal	O
formulation	O
on	O
the	O
incorporation	O
and	O
retention	O
of	O
PNA	O
oligomers	O
Liposomal	O
formulations	O
composed	O
of	O
phospholipids	O
with	O
different	O
unsaturation	O
degrees	O
,	O
head	O
groups	O
and	O
at	O
different	O
cholesterol	B-T059
content	I-T059
have	I-T059
been	I-T059
tested	I-T059
for	O
the	O
encapsulation	O
of	O
Peptide	O
Nucleic	O
Acid	O
(	O
PNA	O
)	O
oligomers	O
.	O
The	O
best	O
loading	O
capability	O
(	O
177μg	O
,	O
ER	O
%	O
=	O
87.2	O
)	O
was	O
obtained	O
for	O
pure	O
liposomes	O
of	O
phosphatidylglycerol	O
(	O
DOPG	O
)	O
with	O
negatively	O
charged	O
head	O
group	O
.	O
The	O
insertion	B-T058
of	O
a	O
10	O
-	O
20	O
%	O
of	O
cholesterol	O
in	O
DOPG	O
based	O
liposomes	O
provides	O
a	O
slight	O
decrease	O
(	O
∼160μg	O
)	O
of	O
the	O
PNA	O
loading	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
cholesterol	O
addition	O
(	O
20	O
-	O
30	O
%	O
)	O
slows	O
down	O
the	O
PNA	O
's	O
release	O
(	O
∼27	O
%	O
)	O
in	O
fetal	O
bovine	O
serum	O
from	O
the	O
liposomal	O
formulation	O
.	O
Based	O
on	O
the	O
encapsulation	O
and	O
the	O
release	O
properties	O
,	O
PEGylated	B-T121
DOPG	O
liposomes	O
with	O
a	O
percentage	O
of	O
cholesterol	O
of	O
10	O
-	O
20	O
%	O
are	O
the	O
optimal	O
formulation	O
for	O
the	O
loading	O
of	O
PNA	O
-	O
a210	O
.	O
      
The	O
Psychometric	B-T060
Costs	I-T060
of	O
Applicants	O
'	O
Faking	O
:	O
Examining	O
Measurement	O
Invariance	O
and	O
Retest	O
Correlations	O
Across	O
Response	O
Conditions	O
This	O
study	O
examines	O
the	O
stability	O
of	O
the	O
response	O
process	O
and	O
the	O
rank	O
-	O
order	O
of	O
respondents	O
responding	O
to	O
3	O
personality	O
scales	O
in	O
4	O
different	O
response	O
conditions	O
.	O
Applicants	O
to	O
the	O
University	O
College	O
of	O
Teacher	O
Education	O
Styria	O
(	O
N	O
=	O
243	O
)	O
completed	O
personality	O
scales	O
as	O
part	O
of	O
their	O
college	O
admission	O
process	O
.	O
Half	O
a	O
year	O
later	O
,	O
they	O
retook	O
the	O
same	O
personality	O
scales	O
in	O
1	O
of	O
3	O
randomly	O
assigned	O
experimental	O
response	O
conditions	O
:	O
honest	O
,	O
faking	O
-	O
good	O
,	O
or	O
reproduce	O
.	O
Longitudinal	O
means	O
and	O
covariance	O
structure	O
analyses	O
showed	O
that	O
applicants	O
'	O
response	O
processes	O
could	O
be	O
partially	O
reproduced	O
after	O
half	O
a	O
year	O
,	O
and	O
respondents	O
seemed	O
to	O
rely	O
on	O
an	O
honest	O
response	O
behavior	O
as	O
a	O
frame	O
of	O
reference	O
.	O
Additionally	O
,	O
applicants	O
'	O
faking	O
behavior	O
and	O
instructed	O
faking	O
(	O
faking	O
-	O
good	O
)	O
caused	O
differences	O
in	O
the	O
latent	O
retest	O
correlations	O
and	O
consistently	O
affected	O
measurement	O
properties	O
.	O
The	O
varying	O
latent	O
retest	O
correlations	O
indicated	B-T033
that	O
faking	O
can	O
distort	O
respondents	O
'	O
rank	O
-	O
order	O
and	O
thus	O
the	O
fairness	O
of	O
subsequent	O
selection	O
decisions	O
,	O
depending	O
on	O
the	O
kind	O
of	O
faking	O
behavior	O
.	O
Instructed	O
faking	O
(	O
faking	O
-	O
good	O
)	O
even	O
affected	O
weak	O
measurement	O
invariance	O
,	O
whereas	O
applicants	O
'	O
faking	O
behavior	O
did	O
not	O
.	O
Consequently	O
,	O
correlations	O
with	O
personality	O
scales	O
-which	O
can	O
be	O
utilized	O
for	O
predictive	O
validity	O
-may	O
be	O
readily	O
interpreted	O
for	O
applicants	O
.	O
Faking	O
behavior	O
also	O
introduced	O
a	O
uniform	O
bias	O
,	O
implying	O
that	O
the	O
classically	O
observed	O
mean	O
raw	O
score	O
differences	O
may	O
not	O
be	O
readily	O
interpreted	O
.	O
      
Dry	B-T184
skin	I-T184
conditions	O
are	O
related	O
to	O
the	O
recovery	O
rate	O
of	O
skin	O
temperature	O
after	O
cold	O
stress	O
rather	O
than	O
to	O
blood	O
flow	O
Cutaneous	O
blood	O
flow	O
plays	O
an	O
important	O
role	O
in	O
the	O
thermoregulation	O
,	O
oxygen	O
supply	O
,	O
and	O
nutritional	B-T061
support	I-T061
necessary	O
to	O
maintain	O
the	O
skin	O
.	O
However	O
,	O
there	O
is	O
little	O
evidence	O
for	O
a	O
link	O
between	O
blood	O
flow	O
and	O
skin	O
physiology	O
.	O
Therefore	O
,	O
we	O
conducted	O
surveys	O
of	O
healthy	O
volunteers	O
to	O
determine	O
the	O
relationship	O
(	O
s	O
)	O
between	O
dry	B-T184
skin	I-T184
properties	O
and	O
cutaneous	O
vascular	O
function	O
.	O
Water	O
content	O
of	O
the	O
stratum	O
corneum	O
,	O
transepidermal	B-T033
water	I-T033
loss	I-T033
,	O
and	O
visual	O
dryness	O
score	O
were	O
investigated	O
as	O
dry	B-T184
skin	I-T184
parameters	B-T033
.	O
Cutaneous	O
blood	O
flow	O
in	O
the	O
resting	B-T033
state	I-T033
,	O
the	O
recovery	O
rate	O
(	O
RR	O
)	O
of	O
skin	O
temperature	O
on	O
the	O
hand	B-T023
after	O
a	O
cold	B-T059
-	I-T059
stress	I-T059
test	I-T059
,	O
and	O
the	O
responsiveness	O
of	O
facial	B-T023
skin	I-T023
blood	O
flow	O
to	O
local	B-T061
cooling	I-T061
were	O
examined	B-T033
as	O
indices	O
of	O
cutaneous	O
vascular	O
functions	O
.	O
The	O
relationships	O
between	O
dry	B-T184
skin	I-T184
parameters	B-T033
and	O
cutaneous	O
vascular	O
functions	O
were	O
assessed	O
.	O
The	O
RR	O
correlated	O
negatively	O
with	O
the	O
visual	O
dryness	O
score	O
of	O
skin	O
on	O
the	O
leg	B-T023
but	O
correlated	O
positively	O
with	O
water	O
content	O
of	O
the	O
stratum	O
corneum	O
on	O
the	O
arm	O
.	O
No	O
significant	O
correlation	O
between	O
the	O
resting	B-T033
state	I-T033
of	O
blood	O
flow	O
and	O
dry	B-T184
skin	I-T184
parameters	B-T033
was	O
observed	O
.	O
In	O
both	O
the	O
face	O
and	O
the	O
body	O
,	O
deterioration	O
in	O
skin	B-T184
dryness	I-T184
from	O
summer	O
to	O
winter	O
was	O
significant	O
in	O
subjects	O
with	O
low	O
RR	O
.	O
The	O
RR	O
correlated	O
well	O
with	O
the	O
responsiveness	O
of	O
facial	B-T023
skin	I-T023
blood	O
flow	O
to	O
local	B-T061
cooling	I-T061
,	O
indicating	B-T033
that	O
the	O
RR	O
affects	O
systemic	O
dry	B-T184
skin	I-T184
conditions	O
.	O
These	O
results	O
suggest	O
that	O
the	O
RR	O
but	O
not	O
blood	O
flow	O
at	O
the	O
resting	B-T033
state	I-T033
is	O
associated	O
with	O
dry	B-T184
skin	I-T184
conditions	O
and	O
is	O
involved	O
in	O
skin	O
homeostasis	O
during	O
seasonal	O
environmental	B-T033
changes	I-T033
.	O
      
Optogenetic	O
Demonstration	O
of	O
Functional	O
Innervation	O
of	O
Mouse	O
Colon	B-T023
by	O
Neurons	O
Derived	O
From	O
Transplanted	O
Neural	O
Cells	O
Cell	B-T061
therapy	I-T061
offers	O
the	O
potential	O
to	O
treat	O
gastrointestinal	B-T047
motility	I-T047
disorders	I-T047
caused	O
by	O
diseased	O
or	O
absent	O
enteric	O
neurons	O
.	O
We	O
examined	O
whether	O
neurons	O
generated	O
from	O
transplanted	O
enteric	O
neural	O
cells	O
provide	O
a	O
functional	O
innervation	O
of	O
bowel	B-T023
smooth	O
muscle	O
in	O
mice	O
.	O
Enteric	O
neural	O
cells	O
expressing	O
the	O
light	O
-	O
sensitive	O
ion	O
channel	O
,	O
channelrhodopsin	O
,	O
were	O
isolated	O
from	O
the	O
fetal	O
or	O
postnatal	O
mouse	O
bowel	B-T023
and	O
transplanted	O
into	O
the	O
distal	O
colon	O
of	O
3-	O
to	O
4-	O
week	O
-old	O
wild	O
-	O
type	O
recipient	O
mice	O
.	O
Intracellular	O
electrophysiological	B-T059
recordings	I-T059
of	O
responses	O
to	O
light	O
stimulation	O
of	O
the	O
transplanted	O
cells	O
were	O
made	O
from	O
colonic	B-T023
smooth	O
muscle	O
cells	O
in	O
recipient	O
mice	O
.	O
Electrical	O
stimulation	O
of	O
endogenous	O
enteric	O
neurons	O
was	O
used	O
as	O
a	O
control	O
.	O
The	O
axons	O
of	O
graft	O
-derived	O
neurons	O
formed	O
a	O
plexus	B-T023
in	O
the	O
circular	B-T023
muscle	I-T023
layer	I-T023
.	O
Selective	O
stimulation	O
of	O
graft	O
-derived	O
cells	O
by	O
light	O
resulted	O
in	O
excitatory	O
and	O
inhibitory	O
junction	O
potentials	O
,	O
the	O
electrical	O
events	O
underlying	O
contraction	O
and	O
relaxation	O
,	O
respectively	O
,	O
in	O
colonic	B-T023
muscle	O
cells	O
.	O
Graft	O
-derived	O
excitatory	O
and	O
inhibitory	O
motor	O
neurons	O
released	O
the	O
same	O
neurotransmitters	O
as	O
endogenous	O
motor	O
neurons	O
-	O
acetylcholine	B-T121
and	O
a	O
combination	O
of	O
adenosine	B-T121
triphosphate	I-T121
and	O
nitric	B-T121
oxide	I-T121
,	O
respectively	O
.	O
Graft	O
-derived	O
neurons	O
also	O
included	O
interneurons	O
that	O
provided	O
synaptic	O
inputs	O
to	O
motor	O
neurons	O
,	O
but	O
the	O
pharmacologic	O
properties	O
of	O
interneurons	O
varied	O
with	O
the	O
age	O
of	O
the	O
donors	O
from	O
which	O
enteric	O
neural	O
cells	O
were	O
obtained	O
.	O
Enteric	O
neural	O
cells	O
transplanted	O
into	O
the	O
bowel	B-T023
give	O
rise	O
to	O
multiple	O
functional	O
types	O
of	O
neurons	O
that	O
integrate	O
and	O
provide	O
a	O
functional	O
innervation	O
of	O
the	O
smooth	O
muscle	O
of	O
the	O
bowel	B-T023
wall	I-T023
.	O
Circuits	O
composed	O
of	O
both	O
motor	O
neurons	O
and	O
interneurons	O
were	O
established	O
,	O
but	O
the	O
age	O
at	O
which	O
cells	O
are	O
isolated	O
influences	O
the	O
neurotransmitter	O
phenotype	O
of	O
interneurons	O
that	O
are	O
generated	O
.	O
      
Closing	O
the	O
Loop	O
in	O
Adults	O
,	O
Children	O
and	O
Adolescents	O
With	O
Suboptimally	B-T033
Controlled	I-T033
Type	I-T033
1	I-T033
Diabetes	I-T033
Under	O
Free	O
Living	O
Conditions	O
:	O
A	O
Psychosocial	O
Substudy	O
The	O
objective	O
was	O
to	O
explore	O
psychosocial	B-T033
experiences	I-T033
of	O
closed	O
loop	O
technology	O
for	O
adults	O
,	O
children	O
,	O
and	O
adolescents	O
with	O
type	B-T047
1	I-T047
diabetes	I-T047
and	O
their	O
parents	O
taking	O
part	O
in	O
two	O
multicenter	O
,	O
free	O
-	O
living	O
,	O
randomized	O
crossover	O
home	O
studies	O
.	O
Participants	O
using	O
insulin	O
pump	O
therapy	B-T061
were	O
randomized	O
to	O
either	O
12	O
weeks	O
of	O
automated	O
closed	O
-	O
loop	O
glucose	O
control	O
,	O
then	O
12	O
weeks	O
of	O
sensor	O
augmented	O
insulin	O
pump	O
therapy	B-T061
(	O
open	O
loop	O
)	O
,	O
or	O
vice	O
versa	O
.	O
Closed	O
loop	O
was	O
used	O
for	O
24	O
hours	O
by	O
adults	O
and	O
overnight	O
only	O
by	O
children	O
and	O
adolescents	O
.	O
Participants	O
completed	O
the	O
Diabetes	O
Technology	O
Questionnaire	O
(	O
DTQ	O
)	O
periodically	O
and	O
shared	O
their	O
views	O
in	O
semistructured	O
interviews	O
.	O
This	O
analysis	O
characterizes	O
the	O
impact	O
of	O
the	O
technology	O
,	O
positive	B-T033
and	O
negative	O
aspects	O
of	O
living	O
with	O
the	O
device	O
,	O
alongside	O
participants	O
'	O
expectations	O
,	O
hopes	O
,	O
and	O
anxieties	B-T033
.	O
Participants	O
were	O
32	O
adults	O
,	O
age	O
38.6	O
±	O
9.6	O
years	O
,	O
55	O
%	O
male	O
,	O
and	O
26	O
children	O
,	O
mean	O
age	O
12	O
years	O
(	O
range	O
6	O
-	O
18	O
years	O
)	O
,	O
54	O
%	O
male	O
.	O
DTQ	O
results	O
indicated	O
moderately	O
favorable	O
impact	O
of	O
,	O
and	O
satisfaction	O
with	O
,	O
both	O
open	O
and	O
closed	O
loop	O
interventions	B-T061
,	O
but	O
little	O
evidence	O
of	O
a	O
comparative	O
advantage	O
of	O
either	O
.	O
Key	O
positive	B-T033
themes	I-T033
included	O
perceived	O
improved	O
blood	O
glucose	O
control	O
,	O
improved	B-T033
general	I-T033
well	I-T033
-	I-T033
being	I-T033
,	O
particularly	O
on	O
waking	O
,	O
improved	O
sleep	O
,	O
reduced	O
burden	O
of	O
diabetes	B-T047
,	O
and	O
visibility	O
of	O
data	O
.	O
Key	O
negative	O
themes	O
included	O
having	O
to	O
carry	O
around	O
the	O
equipment	O
and	O
dislike	O
of	O
the	O
pump	O
and	O
second	O
cannula	O
(	O
ie	O
,	O
sensor	O
)	O
inserted	O
.	O
Overall	O
,	O
participants	O
reported	O
a	O
positive	B-T033
experience	O
of	O
the	O
closed	O
loop	O
technology	O
.	O
Results	O
are	O
consistent	O
with	O
previous	O
research	O
with	O
size	O
of	O
equipment	O
continuing	O
to	O
be	O
a	O
problem	B-T033
.	O
Progress	O
is	O
being	O
made	O
in	O
the	O
usability	O
of	O
the	O
closed	O
-	O
loop	O
system	O
.	O
      
DEPRESSION	B-T048
,	O
ANXIETY	B-T048
,	O
STRESS	B-T048
,	O
AND	O
THEIR	O
ASSOCIATED	O
FACTORS	O
AMONG	O
CORPS	O
MEMBERS	O
SERVING	O
IN	O
KEBBI	O
STATE	O
Depression	B-T048
,	O
anxiety	B-T048
and	O
stress	B-T048
,	O
are	O
not	O
only	O
health	B-T033
problems	I-T033
by	O
themselves	O
,	O
but	O
also	O
associated	O
with	O
other	O
negative	B-T033
health	O
consequences	O
.	O
The	O
national	O
youth	O
service	O
is	O
usually	O
characterized	O
by	O
a	O
number	O
of	O
new	O
challenges	O
and	O
experiences	O
which	O
may	O
require	O
life	O
style	O
adjustments	O
by	O
the	O
corps	O
member	O
.	O
However	O
,	O
no	O
previous	O
study	O
on	O
psychological	O
factors	O
has	O
been	O
conducted	O
among	O
corps	O
members	O
.	O
This	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
prevalence	O
of	O
depression	B-T048
,	O
anxiety	B-T048
and	O
,	O
stress	B-T048
and	O
their	O
associated	O
factors	O
among	O
corps	O
members	O
serving	O
in	O
Kebbi	O
state	O
.	O
A	O
cross	O
-	O
sectional	O
study	O
was	O
conducted	O
among	O
264	O
corps	O
members	O
from	O
four	O
local	O
government	O
areas	O
of	O
the	O
state	O
.	O
Selection	O
of	O
the	O
local	O
government	O
areas	O
and	O
the	O
individual	O
participants	O
was	O
by	O
simple	O
random	O
sampling	O
.	O
Data	O
was	O
collected	O
from	O
May	O
to	O
June	O
2014	O
using	O
a	O
self	O
-	O
administered	O
questionnaire	O
.	O
Data	O
analysis	O
used	O
chi	O
-	O
square	O
test	O
to	O
identify	O
the	O
relationship	O
between	O
categorical	O
variables	O
and	O
multivariate	O
logistic	O
regression	O
to	O
identify	O
the	O
independent	O
factors	O
for	O
depression	B-T048
,	O
anxiety	B-T048
and	O
stress	B-T048
each	O
.	O
The	O
response	O
rate	O
was	O
97	O
%	O
.	O
Most	O
of	O
the	O
respondents	O
were	O
males	O
(	O
63.6	O
%	O
)	O
,	O
single	O
(	O
85.5	O
%	O
)	O
,	O
and	O
above	O
20	O
years	O
of	O
age	O
(	O
71.6	O
%	O
)	O
.	O
The	O
overall	O
prevalences	O
of	O
depression	B-T048
,	O
anxiety	B-T048
and	O
stress	B-T048
among	O
the	O
respondents	O
were	O
36.4	O
%	O
,	O
54.5	O
%	O
and	O
18.2	O
%	O
respectively	O
.	O
The	O
independent	O
factors	O
for	O
depression	B-T048
were	O
;	O
being	O
from	O
the	O
North	O
central	O
(	O
OR	O
=	O
5.99	O
;	O
95	O
%	O
CI	O
:	O
2.194	O
-	O
16.354	O
)	O
or	O
South	O
-	O
south	O
;	O
and	O
the	O
perception	O
of	O
earning	O
enough	O
income	O
(	O
OR	O
=	O
2.987	O
;	O
95	O
%	O
CI	O
:	O
1.062	O
-	O
8.400	O
)	O
.	O
For	O
anxiety	B-T048
,	O
male	O
gender	O
(	O
OR	O
=	O
0.411	O
;	O
95	O
%	O
CI	O
:	O
0.169	O
-	O
0.999	O
)	O
;	O
and	O
being	O
from	O
the	O
North	O
central	O
were	O
significant	O
risk	B-T033
factors	I-T033
(	O
OR	O
=	O
3.731	O
;	O
95	O
%	O
CI	O
:	O
1.450	O
-	O
9.599	O
)	O
.	O
Being	O
above	O
26	O
years	O
of	O
age	O
was	O
an	O
independent	O
risk	B-T033
factor	I-T033
for	O
stress	B-T048
(	O
OR	O
=	O
0.083	O
;	O
95	O
%	O
CI	O
:	O
0.018	O
-	O
0.381	O
)	O
.	O
Also	O
,	O
those	O
who	O
had	O
ever	O
schooled	B-T033
outside	O
their	O
towns	O
of	O
residence	O
were	O
less	O
likely	O
to	O
be	O
stressed	O
compared	O
to	O
those	O
who	O
had	O
never	O
(	O
OR	O
=	O
0.30	O
;	O
95	O
%	O
CI	O
:	O
0.110	O
-	O
0.855	O
)	O
.	O
All	O
other	O
factors	O
did	O
not	O
show	O
any	O
significant	O
association	O
with	O
any	O
of	O
the	O
outcome	O
variables	O
in	O
multivariate	O
analysis	O
.	O
In	O
conclusion	O
,	O
the	O
prevalences	O
of	O
depression	B-T048
,	O
anxiety	B-T048
and	O
stress	B-T048
are	O
high	O
among	O
corps	O
members	O
serving	O
in	O
Kebbi	O
state	O
.	O
There	O
is	O
need	O
to	O
expand	O
the	O
scope	O
of	O
this	O
study	O
to	O
a	O
national	O
level	O
so	O
as	O
to	O
get	O
a	O
bigger	O
picture	O
of	O
the	O
problem	B-T033
.	O
      
Constructive	B-T033
and	I-T033
Unproductive	I-T033
Processing	I-T033
of	O
Traumatic	B-T048
Experiences	I-T048
in	O
Trauma	B-T061
-	I-T061
Focused	I-T061
Cognitive	I-T061
-	I-T061
Behavioral	I-T061
Therapy	I-T061
for	O
Youth	O
Although	O
there	O
is	O
substantial	O
evidence	O
to	O
support	O
the	O
efficacy	O
of	O
cognitive	B-T061
-	I-T061
behavioral	I-T061
treatments	I-T061
(	O
CBT	B-T061
)	O
for	O
posttraumatic	B-T048
stress	I-T048
disorder	I-T048
(	O
PTSD	B-T048
)	O
,	O
there	O
is	O
some	O
debate	O
about	O
how	O
these	O
treatments	B-T061
have	O
their	O
effects	O
.	O
Modern	O
learning	O
theory	O
and	O
cognitive	O
and	O
emotional	O
processing	O
theories	O
highlight	O
the	O
importance	O
of	O
reducing	O
avoidance	O
,	O
facilitating	O
the	O
constructive	B-T033
processing	I-T033
of	I-T033
feared	I-T033
experiences	I-T033
,	O
and	O
strengthening	O
new	O
inhibitory	O
learning	O
.	O
We	O
examined	O
variables	O
thought	O
to	O
be	O
associated	O
with	O
unproductive	B-T033
and	I-T033
constructive	I-T033
processing	I-T033
of	O
traumatic	B-T048
experiences	I-T048
in	O
a	O
sample	O
of	O
81	O
youth	O
with	O
elevated	O
PTSD	B-T048
symptoms	B-T184
,	O
who	O
received	O
Trauma	B-T061
-	I-T061
Focused	I-T061
Cognitive	I-T061
Behavioral	I-T061
Therapy	I-T061
(	O
TF	B-T061
-	I-T061
CBT	I-T061
)	O
for	O
abuse	B-T033
or	O
traumatic	B-T048
interpersonal	O
loss	O
.	O
Sessions	O
during	O
the	O
trauma	B-T061
narrative	I-T061
phase	I-T061
of	O
TF	B-T061
-	I-T061
CBT	I-T061
were	O
coded	O
for	O
indicators	O
of	O
unproductive	B-T033
processing	I-T033
(	O
overgeneralization	B-T033
,	O
rumination	B-T048
,	O
avoidance	O
)	O
and	O
constructive	B-T033
processing	I-T033
(	O
decentering	B-T033
,	O
accommodation	B-T033
of	I-T033
corrective	I-T033
information	I-T033
)	O
,	O
as	O
well	O
as	O
levels	B-T058
of	I-T058
negative	I-T058
emotion	I-T058
.	O
In	O
previous	O
analyses	O
of	O
this	O
trial	O
(	O
Ready	O
et	O
al	O
.	O
,	O
2015	O
)	O
,	O
more	O
overgeneralization	B-T033
during	O
the	O
narrative	B-T061
phase	I-T061
predicted	O
less	O
improvement	O
in	O
internalizing	B-T184
symptoms	I-T184
at	O
posttreatment	O
and	O
a	O
worsening	O
of	O
externalizing	B-T184
symptoms	I-T184
over	O
the	O
12	O
-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
.	O
In	O
contrast	O
,	O
more	O
accommodation	B-T033
predicted	I-T033
improvement	I-T033
in	O
internalizing	B-T184
symptoms	I-T184
and	O
also	O
moderated	O
the	O
negative	B-T033
effects	O
of	O
overgeneralization	B-T033
on	O
internalizing	B-T184
and	I-T184
externalizing	I-T184
symptoms	I-T184
.	O
The	O
current	O
study	O
examined	O
correlates	O
of	O
overgeneralization	B-T033
and	O
accommodation	B-T033
.	O
Overgeneralization	B-T033
was	O
associated	O
with	O
more	O
rumination	B-T048
,	O
less	O
decentering	O
,	O
and	O
more	O
negative	B-T058
emotion	I-T058
,	O
suggesting	O
immersion	B-T058
in	O
trauma	B-T048
-related	O
material	O
.	O
Accommodation	B-T033
was	O
associated	O
with	O
less	O
avoidance	O
and	O
more	O
decentering	B-T033
,	O
suggesting	O
a	O
healthy	O
distance	O
from	O
trauma	B-T048
-related	O
material	O
that	O
might	O
allow	O
for	O
processing	O
and	O
cognitive	B-T048
change	I-T048
.	O
Decentering	O
also	O
predicted	O
improvement	O
in	O
externalizing	B-T184
symptoms	I-T184
at	O
posttreatment	O
.	O
Rumination	B-T048
and	O
avoidance	O
showed	O
important	O
associations	O
with	O
overgeneralization	B-T033
and	O
accommodation	B-T033
,	O
respectively	O
,	O
but	O
did	O
not	O
predict	O
treatment	O
outcomes	O
.	O
This	O
study	O
identifies	O
correlates	O
of	O
overgeneralization	B-T033
and	O
accommodation	B-T033
that	O
might	O
shed	O
light	O
on	O
how	O
these	O
variables	O
relate	O
to	O
unproductive	B-T033
and	I-T033
constructive	I-T033
processing	I-T033
of	O
traumatic	B-T048
experiences	I-T048
.	O
      
Reduced	O
haemodynamic	O
coupling	O
and	O
exercise	O
are	O
associated	O
with	O
vascular	O
stiffening	O
in	O
pulmonary	B-T047
arterial	I-T047
hypertension	I-T047
Inadequate	O
right	B-T023
ventricular	I-T023
(	O
RV	B-T023
)	O
and	O
pulmonary	B-T023
arterial	I-T023
(	O
PA	B-T023
)	O
functional	O
responses	O
to	O
exercise	O
are	O
important	O
yet	O
poorly	O
understood	O
features	O
of	O
pulmonary	B-T047
arterial	I-T047
hypertension	I-T047
(	O
PAH	B-T047
)	O
.	O
This	O
study	O
combined	O
invasive	B-T061
catheterisation	B-T061
with	O
echocardiography	B-T060
to	O
assess	O
RV	B-T023
afterload	O
,	O
RV	O
function	O
and	O
ventricular	B-T023
-	O
vascular	B-T023
coupling	O
in	O
subjects	O
with	O
PAH	B-T047
.	O
Twenty	O
-	O
six	O
subjects	O
with	O
PAH	B-T047
were	O
prospectively	O
recruited	O
to	O
undergo	O
right	O
heart	O
catheterisation	B-T061
and	O
Doppler	B-T060
echocardiography	I-T060
at	O
rest	O
and	O
during	O
incremental	O
exercise	O
,	O
and	O
cardiac	B-T060
MRI	I-T060
at	O
rest	O
.	O
Measurements	O
at	O
rest	O
included	O
basic	O
haemodynamics	O
,	O
RV	O
function	O
and	O
coupling	O
efficiency	O
(	O
η	O
)	O
.	O
Measurements	O
during	O
incremental	O
exercise	O
included	O
pulmonary	B-T033
vascular	I-T033
resistance	I-T033
(	O
Z0	B-T033
)	O
,	O
characteristic	B-T060
impedance	I-T060
(	O
ZC	B-T060
,	O
a	O
measure	O
of	O
proximal	O
PA	B-T023
stiffness	O
)	O
and	O
proximal	O
and	O
distal	O
PA	O
compliance	O
(	O
CPA	O
)	O
.	O
In	O
patients	O
with	O
PAH	B-T047
,	O
the	O
proximal	O
PAs	B-T023
were	O
significantly	O
stiffer	B-T033
at	O
maximum	O
exercise	O
(	O
ZC	B-T060
=	O
2.31±0.38	O
vs	O
1.33±0.15	O
WU×m(2	O
)	O
at	O
rest	O
;	O
p=0.003	O
)	O
and	O
PA	O
compliance	O
was	O
decreased	O
(	O
CPA	O
=	O
0.88±0.10	O
vs	O
1.32±0.17	O
mL	O
/	O
mm	O
Hg	O
/	O
m(2	O
)	O
at	O
rest	O
;	O
p=0.0002	O
)	O
.	O
Z0	B-T033
did	O
not	O
change	O
with	O
exercise	O
.	O
As	O
a	O
result	O
,	O
the	O
resistance	O
-	O
compliance	O
(	O
RC	O
)	O
time	O
decreased	O
with	O
exercise	O
(	O
0.67±0.05	O
vs	O
1.00±0.07	O
s	O
at	O
rest	O
;	O
p<10(-6	O
)	O
)	O
.	O
When	O
patients	O
were	O
grouped	O
according	O
to	O
resting	O
coupling	O
efficiency	O
,	O
those	O
with	O
poorer	O
η	O
exhibited	O
stiffer	B-T033
proximal	O
PAs	B-T023
at	O
rest	O
,	O
a	O
lower	O
maximum	O
exercise	O
level	O
,	O
and	O
more	O
limited	O
CPA	O
reduction	O
at	O
maximum	O
exercise	O
.	O
In	O
PAH	B-T047
,	O
exercise	O
causes	O
proximal	O
and	O
distal	O
PA	B-T023
stiffening	O
,	O
which	O
combined	O
with	O
preserved	O
Z0	B-T033
results	O
in	O
decreased	O
RC	O
time	O
with	O
exercise	O
.	O
Stiff	B-T023
PAs	I-T023
at	O
rest	O
may	O
also	O
contribute	O
to	O
poor	O
haemodynamic	O
coupling	O
,	O
reflecting	O
reduced	O
pulmonary	B-T023
vascular	I-T023
reserve	O
that	O
contributes	O
to	O
limit	O
the	O
maximum	O
exercise	O
level	O
tolerated	O
.	O
      
A	O
standardized	O
approach	O
for	O
the	O
assessment	B-T058
and	O
treatment	B-T061
of	O
internationally	O
adopted	O
children	O
with	O
a	O
previously	O
repaired	O
anorectal	B-T190
malformation	I-T190
(	O
ARM	B-T190
)	O
A	O
significant	O
number	O
of	O
internationally	O
adopted	O
children	O
have	O
congenital	B-T019
birth	I-T019
defects	I-T019
.	O
As	O
a	O
specialist	O
center	O
for	O
colorectal	O
diagnoses	B-T060
,	O
we	O
evaluate	O
such	O
children	O
with	O
an	O
anorectal	B-T190
malformation	I-T190
(	O
ARM	B-T190
)	O
and	O
have	O
found	O
that	O
a	O
significant	O
number	O
need	O
a	O
reoperation	B-T061
.	O
Knowledge	B-T033
of	O
the	O
common	O
complications	O
following	O
ARM	B-T190
surgery	B-T061
has	O
led	O
us	O
to	O
develop	O
treatment	B-T061
algorithms	O
for	O
patients	O
with	O
unknown	O
past	B-T033
medical	I-T033
and	O
surgical	B-T033
history	I-T033
,	O
a	O
situation	O
typically	O
encountered	O
in	O
the	O
adopted	B-T033
population	O
.	O
The	O
results	O
of	O
investigations	B-T058
,	O
indications	O
,	O
and	O
rate	O
of	O
reoperation	B-T061
were	O
assessed	O
for	O
adopted	O
children	O
with	O
an	O
ARM	B-T190
evaluated	O
between	O
2014	O
and	O
2016	O
.	O
56	O
patients	O
(	O
28	O
males	O
)	O
were	O
identified	O
.	O
76.8	O
%	O
required	O
reoperative	B-T061
surgery	I-T061
.	O
Mislocation	O
of	O
the	O
anus	B-T023
outside	O
the	O
sphincter	B-T023
complex	O
was	O
seen	O
in	O
50	O
%	O
of	O
males	O
and	O
39.3	O
%	O
of	O
females	O
.	O
Anal	B-T019
stricture	I-T019
,	O
rectal	B-T047
prolapse	I-T047
,	O
retained	O
vaginal	B-T019
septum	I-T019
,	O
and	O
a	O
strictured	O
vaginal	O
introitus	O
were	O
also	O
common	O
.	O
The	O
reoperative	B-T061
surgery	I-T061
rate	O
in	O
the	O
internationally	O
adopted	O
child	O
with	O
an	O
ARM	B-T190
is	O
high	O
.	O
Complete	O
,	O
systematic	O
evaluation	O
of	O
these	O
children	O
is	O
required	O
to	O
identify	O
complications	O
following	O
initial	O
repair	B-T058
.	O
Development	O
of	O
mechanisms	O
to	O
improve	O
the	O
primary	O
surgical	B-T058
care	I-T058
these	O
children	O
receive	O
is	O
needed	O
.	O
      
Medulloblastoma	B-T191
:	O
molecular	O
pathways	O
and	O
histopathological	O
classification	O
Malignant	B-T191
brain	I-T191
tumors	I-T191
are	O
the	O
leading	O
cause	O
of	O
cancer	B-T191
death	B-T033
among	O
pediatric	O
patients	O
,	O
and	O
medulloblastoma	B-T191
constitutes	O
20	O
%	O
of	O
them	O
.	O
Currently	O
,	O
the	O
treatment	B-T061
is	O
risk	O
-	O
adapted	O
.	O
Maximum	O
surgical	B-T061
resection	I-T061
is	O
recommended	O
,	O
always	O
followed	O
by	O
chemotherapy	B-T061
and	O
neuroaxis	O
radiotherapy	B-T061
.	O
In	O
spite	O
of	O
the	O
improving	O
survival	O
rate	O
,	O
survivors	O
succumb	O
to	O
treatment	B-T061
-	O
induced	O
side	O
effects	O
.	O
To	O
reduce	O
toxic	O
effects	O
,	O
molecular	B-T061
-	I-T061
targeted	I-T061
treatment	I-T061
is	O
proposed	O
.	O
Medulloblastoma	B-T191
research	O
is	O
very	O
robust	O
,	O
and	O
new	O
articles	O
on	O
the	O
subject	O
are	O
published	O
daily	O
.	O
In	O
the	O
current	O
review	O
we	O
have	O
tried	O
to	O
bring	O
together	O
molecular	O
pathophysiology	O
of	O
the	O
neoplasm	B-T191
and	O
current	O
pathological	O
classification	O
,	O
thus	O
making	O
an	O
effort	O
to	O
relate	O
tumor	O
biology	O
and	O
the	O
histological	O
picture	O
.	O
      
Penetrating	O
Craniomaxillofacial	O
Injury	O
Caused	O
by	O
a	O
Pneumatic	O
Nail	O
Gun	O
Craniomaxillofacial	O
injuries	O
can	O
be	O
complex	O
,	O
requiring	O
a	O
multidisciplinary	O
approach	O
.	O
The	O
primary	O
survey	O
is	O
always	O
the	O
first	O
step	O
in	O
trauma	O
management	O
prior	O
to	O
proceeding	O
with	O
further	O
evaluation	O
and	O
treatment	O
.	O
A	O
26-	O
year	O
-old	O
man	O
presented	O
with	O
a	O
penetrating	O
nail	O
gun	O
injury	O
through	O
the	O
oral	O
and	O
nasal	O
cavities	O
.	O
He	O
did	O
not	O
present	O
in	O
extremis	O
but	O
required	O
elective	O
endotracheal	O
intubation	O
for	O
intraoperative	O
assessment	O
and	O
treatment	O
.	O
Airway	O
management	O
was	O
enhanced	O
by	O
the	O
use	O
of	O
lingual	B-T061
nerve	I-T061
and	O
inferior	B-T061
alveolar	I-T061
nerve	I-T061
blocks	I-T061
via	O
the	O
Vazirani	O
-	O
Akinosi	O
technique	O
to	O
maintain	O
spontaneous	B-T033
respiration	I-T033
while	O
the	O
tongue	B-T023
was	O
distracted	B-T033
from	O
the	O
palate	B-T023
.	O
The	O
nail	O
was	O
removed	O
and	O
rapid	O
sequence	O
induction	O
initiated	O
for	O
orotracheal	O
intubation	O
.	O
Local	O
nerve	O
blocks	O
can	O
be	O
an	O
effective	O
tool	O
in	O
the	O
armamentarium	O
of	O
the	O
craniomaxillofacial	O
trauma	O
surgeon	O
in	O
managing	O
blunt	O
and	O
penetrating	O
injuries	O
.	O
We	O
demonstrate	O
its	O
utility	O
in	O
airway	O
management	O
when	O
a	O
penetrating	O
foreign	O
body	O
in	O
the	O
upper	B-T023
airway	I-T023
precludes	O
orotracheal	O
or	O
nasotracheal	O
intubation	O
.	O
      
The	O
role	O
of	O
catheter	B-T061
ablation	I-T061
in	O
the	O
management	B-T058
of	O
atrial	B-T047
fibrillation	I-T047
Atrial	B-T047
fibrillation	I-T047
is	O
driven	O
by	O
spontaneous	O
electrical	O
activation	O
emerging	O
from	O
the	O
pulmonary	B-T023
veins	I-T023
.	O
Catheter	B-T061
ablation	I-T061
using	O
either	O
radiofrequency	B-T061
or	O
cryothermal	B-T061
energy	I-T061
electrically	O
isolates	O
these	O
veins	B-T023
from	O
the	O
left	B-T023
atrium	I-T023
,	O
both	O
reducing	O
the	O
burden	O
of	O
atrial	B-T047
fibrillation	I-T047
episodes	O
and	O
improving	O
the	O
patient	O
's	O
symptoms	B-T184
.	O
Catheter	B-T061
ablation	I-T061
is	O
superior	O
to	O
antiarryhthmic	B-T121
drugs	I-T121
when	O
patients	O
are	O
carefully	O
selected	O
.	O
Underlying	O
medical	O
problems	O
-	O
including	O
obesity	B-T047
,	O
hypertension	B-T047
and	O
obstructive	B-T047
sleep	I-T047
apnoea	I-T047
-	O
should	O
be	O
optimally	O
treated	O
before	O
considering	O
ablation	B-T061
.	O
Although	O
this	O
treatment	B-T061
has	O
the	O
potential	O
to	O
cure	O
patients	O
of	O
their	O
symptoms	B-T184
,	O
they	O
should	O
be	O
aware	O
of	O
the	O
important	O
associated	O
procedural	B-T033
complications	I-T033
.	O
      
Promoting	O
Healthy	O
Growth	O
or	O
Feeding	O
Obesity	B-T047
?	O
The	O
Need	O
for	O
Evidence	O
-Based	O
Oversight	O
of	O
Infant	O
Nutritional	O
Supplement	O
Claims	O
The	O
Developmental	O
Origins	O
of	O
Health	O
and	O
Disease	O
(	O
DOHaD	O
)	O
model	O
recognizes	O
growth	O
in	O
infancy	O
and	O
childhood	O
as	O
a	O
fundamental	O
determinant	O
of	O
lifespan	O
health	O
.	O
Evidence	O
of	O
long	O
-	O
term	O
health	O
risks	O
among	O
small	O
neonates	O
who	O
subsequently	O
grow	O
rapidly	O
poses	O
a	O
challenge	O
for	O
interventions	B-T058
aiming	O
to	O
support	O
healthy	O
growth	O
,	O
not	O
merely	O
drive	O
weight	B-T033
gain	I-T033
.	O
Defining	O
healthy	O
growth	O
beyond	O
"	O
getting	O
bigger	O
"	O
is	O
essential	O
as	O
infant	O
and	O
young	O
child	O
feeding	O
industries	O
expand	O
.	O
Liquid	O
-based	O
nutritional	O
supplements	O
,	O
originally	O
formulated	O
for	O
undernourished	B-T047
children	O
,	O
are	O
increasingly	O
marketed	O
for	O
and	O
consumed	O
by	O
children	O
generally	O
.	O
Clarifying	O
the	O
nature	O
of	O
the	O
evidentiary	O
base	O
on	O
which	O
structure	O
/	O
function	O
claims	O
promoting	O
"	O
healthy	O
growth	O
"	O
are	O
constructed	O
is	O
important	O
to	O
curb	O
invalid	O
generalizations	O
.	O
Evidence	O
points	O
to	O
changing	O
social	O
beliefs	O
and	O
cultural	O
practices	O
surrounding	O
supplementary	B-T061
feeding	I-T061
,	O
raising	O
specific	O
concerns	O
about	O
the	O
long	O
-	O
term	O
health	O
consequences	O
of	O
an	O
associated	O
altered	O
feeding	O
culture	O
,	O
including	O
reduced	O
dietary	O
variety	O
and	O
weight	B-T033
gain	I-T033
.	O
Reassessing	O
the	O
evidence	O
for	O
and	O
relevance	O
of	O
dietary	O
supplements	O
'	O
"	O
promoting	O
healthy	O
growth	O
"	O
claims	O
for	O
otherwise	O
healthy	O
children	O
is	O
both	O
needed	O
in	O
a	O
time	O
of	O
global	O
obesity	B-T047
and	O
an	O
opportunity	O
to	O
refine	O
intervention	B-T061
approaches	I-T061
among	O
small	O
children	O
for	O
whom	O
rapid	O
subsequent	O
growth	O
in	O
early	O
life	O
augments	O
risk	O
for	O
chronic	B-T047
disease	I-T047
.	O
Scientific	O
and	O
health	B-T058
care	I-T058
partnerships	O
are	O
needed	O
to	O
consider	O
current	O
governmental	O
oversight	O
shortfalls	O
in	O
protecting	O
vulnerable	O
populations	O
from	O
overconsumption	O
.	O
This	O
is	O
important	O
because	O
we	O
may	O
be	O
doing	O
more	O
harm	O
than	O
good	O
.	O
      
Silk	B-T121
I	I-T121
and	O
Silk	B-T121
II	I-T121
studied	O
by	O
fast	B-T059
scanning	I-T059
calorimetry	I-T059
Using	O
fast	B-T059
scanning	I-T059
calorimetry	I-T059
(	O
FSC	B-T059
)	O
,	O
we	O
investigated	O
the	O
glass	O
transition	O
and	O
crystal	O
melting	O
of	O
samples	O
of	O
B.	O
mori	O
silk	O
fibroin	O
containing	O
Silk	B-T121
I	I-T121
and/or	O
Silk	B-T121
II	I-T121
crystal	O
s.	O
Due	O
to	O
the	O
very	O
short	O
residence	O
times	O
at	O
high	O
temperatures	O
during	O
such	O
measurements	O
,	O
thermal	O
decomposition	O
of	O
silk	B-T121
protein	I-T121
can	O
be	O
significantly	O
suppressed	O
.	O
FSC	B-T059
was	O
performed	O
at	O
2000K	O
/	O
s	O
using	O
the	O
Mettler	B-T059
Flash	I-T059
DSC1	I-T059
on	O
fibroin	O
films	O
with	O
masses	O
around	O
130	O
-	O
270ng	O
.	O
Films	O
were	O
prepared	O
with	O
different	O
crystalline	O
fractions	O
(	O
ranging	O
from	O
0.26	O
to	O
0.50	O
)	O
and	O
with	O
different	O
crystal	O
structures	O
(	O
Silk	B-T121
I	I-T121
,	O
Silk	B-T121
II	I-T121
,	O
or	O
mixed	O
)	O
by	O
varying	O
the	O
processing	O
conditions	O
.	O
These	O
included	O
water	B-T121
annealing	B-T061
at	O
different	O
temperatures	O
,	O
exposure	O
to	O
50	O
%	O
MeOH	O
in	O
water	B-T121
,	O
or	O
autoclaving	O
.	O
The	O
resulting	O
crystal	O
structure	O
was	O
examined	O
using	O
wide	O
angle	O
X	B-T060
-	I-T060
ray	I-T060
scattering	I-T060
.	O
Degree	O
of	O
crystallinity	O
was	O
evaluated	B-T033
from	O
Fourier	O
transform	O
infrared	O
(	O
FTIR	O
)	O
spectroscopy	O
and	O
from	O
analysis	O
of	O
the	O
heat	O
capacity	O
increment	O
at	O
the	O
glass	O
transition	O
temperature	O
.	O
Silk	O
fibroin	O
films	O
prepared	O
by	O
water	B-T121
annealing	B-T061
at	O
25	O
°	O
C	O
were	O
the	O
least	O
crystalline	O
and	O
had	O
Silk	B-T121
I	I-T121
structure	O
.	O
FTIR	O
and	O
FSC	B-T059
studies	O
showed	O
that	O
films	O
prepared	O
by	O
autoclaving	O
or	O
50	O
%	O
MeOH	O
exposure	O
were	O
the	O
most	O
crystalline	O
and	O
had	O
Silk	B-T121
II	I-T121
structure	O
.	O
Intermediate	O
crystalline	O
fraction	O
and	O
mixed	O
Silk	B-T121
I	I-T121
/	O
Silk	B-T121
II	I-T121
structure	O
s	O
were	O
found	O
in	O
films	O
prepared	O
by	O
water	B-T121
annealing	B-T061
at	O
37	O
°	O
C	O
.	O
FSC	B-T059
results	B-T033
indicate	O
that	O
Silk	B-T121
I	I-T121
Silk	B-T121
I	I-T121
I	I-T121
crystals	O
exhibit	O
endotherms	O
of	O
narrower	O
width	O
and	O
have	O
higher	O
mean	O
melting	O
temperature	O
Tm(II)=351±2.6	O
°	O
C	O
,	O
compared	O
to	O
Silk	B-T121
I	I-T121
crystals	O
which	O
melt	O
at	O
Tm(I)=292±3.8	O
°	O
C	O
.	O
Films	O
containing	O
mixed	O
Silk	B-T121
I	I-T121
/	O
Silk	B-T121
II	I-T121
structure	O
showed	O
two	O
clearly	O
separated	O
endothermic	O
peaks	O
.	O
Evidence	O
suggests	O
that	O
the	O
two	O
types	O
of	O
crystal	O
s	O
melt	O
separately	O
and	O
do	O
not	O
thermal	O
ly	O
interconvert	O
on	O
the	O
extremely	O
short	O
time	O
scale	O
(	O
0.065s	O
between	O
onset	O
and	O
end	O
of	O
melting	O
)	O
of	O
the	O
FSC	B-T059
experiment	I-T059
.	O
Silkworm	O
silk	B-T121
is	O
a	O
naturally	O
occurring	O
biomaterial	O
.	O
The	O
fibroin	O
component	O
of	O
silk	B-T121
forms	I-T121
two	O
types	O
of	O
crystals	O
.	O
Silk	B-T121
properties	O
depend	O
upon	O
the	O
amount	O
and	O
type	O
of	O
crystals	O
,	O
and	O
their	O
stability	O
.	O
One	O
measure	O
of	O
stability	O
is	O
crystal	O
melting	O
temperature	O
.	O
Crystal	O
s	O
which	O
are	O
more	O
stable	O
have	O
a	O
higher	O
melting	O
temperature	O
.	O
Until	O
now	O
,	O
it	O
has	O
been	O
challenging	O
to	O
study	O
thermal	O
behavior	O
of	O
silk	B-T121
crystal	O
s	O
because	O
they	O
degrade	O
at	O
high	O
temperature	O
.	O
To	O
avoid	O
degradation	O
,	O
and	O
study	O
the	O
melting	O
properties	O
of	O
silk	B-T121
biomaterial	O
,	O
we	O
heated	O
silk	B-T121
at	O
a	O
very	O
fast	O
rate	O
of	O
2000K	O
/	O
s	O
using	O
a	O
special	O
calorimeter	O
.	O
We	O
have	O
shown	O
that	O
the	O
two	O
crystal	O
types	O
have	O
very	O
different	O
melting	O
temperature	O
s	O
,	O
indicating	O
that	O
one	O
crystal	O
type	O
is	O
much	O
more	O
stable	O
than	O
the	O
other	O
.	O
      
Comparison	O
of	O
methods	O
for	O
isolating	B-T059
primary	O
hepatocytes	O
from	O
mini	O
pigs	O
Successful	O
porcine	O
hepatocyte	O
isolation	B-T059
is	O
crucial	O
for	O
the	O
development	O
of	O
bioartificial	O
liver	O
devices	O
and	O
hepatocyte	B-T061
transplantation	I-T061
.	O
Serva	B-T121
collagenase	I-T121
NB	I-T121
grades	I-T121
are	O
formulated	O
collagenases	B-T121
that	O
are	O
suitable	O
for	O
various	O
tissue	O
isolation	B-T059
applications	O
.	O
N	B-T121
-	I-T121
acetylcysteine	I-T121
(	O
NAC	B-T121
)	O
can	O
improve	O
the	O
viability	O
of	O
human	O
hepatocytes	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effectiveness	O
of	O
two	O
collagenases	B-T121
and	O
effect	O
of	O
NAC	B-T121
on	O
hepatocyte	O
isolation	B-T059
from	O
porcine	O
liver	B-T023
tissue	I-T023
.	O
Porcine	O
hepatocytes	O
were	O
isolated	B-T059
using	O
the	O
perfusion	B-T061
method	I-T061
from	O
Bama	O
mini	O
pigs	O
assigned	O
to	O
the	O
Serva	B-T121
NB	I-T121
4	I-T121
group	O
(	O
n=6	O
)	O
,	O
the	O
Serva	B-T121
NB	I-T121
8	I-T121
group	O
(	O
n=6	O
)	O
,	O
or	O
the	O
NB	B-T121
8	I-T121
+	O
NAC	B-T121
group	O
(	O
n=6	O
)	O
.	O
Viability	O
and	O
yield	O
were	O
defined	O
as	O
fresh	O
hepatocytes	O
and	O
their	O
spheroids	B-T033
formation	I-T033
after	O
24	O
-	O
hour	O
rocker	B-T059
culture	I-T059
in	O
serum	O
-	O
free	O
medium	O
.	O
Metabolic	O
function	O
was	O
assessed	O
by	O
gene	O
expression	O
,	O
albumin	O
,	O
and	O
urea	B-T121
synthesis	O
.	O
All	O
procedures	O
resulted	O
in	O
successful	O
hepatocyte	O
isolation	B-T059
.	O
Cells	O
from	O
the	O
NB	B-T121
8	I-T121
+	O
NAC	B-T121
group	O
had	O
(	O
97.8±1.9)%	O
viability	O
,	O
which	O
was	O
higher	O
than	O
the	O
NB	B-T121
8	I-T121
group	O
with	O
(	O
94.4±2.4)%	O
and	O
the	O
NB	B-T121
4	I-T121
group	O
with	O
(	O
94.5±3.2)%	O
(	O
P<.001	O
)	O
.	O
The	O
final	O
cell	O
yield	O
reached	O
(	O
11.8±1.0)×10(9	O
)	O
cells	O
in	O
the	O
NB	B-T121
8	I-T121
+	O
NAC	B-T121
group	O
,	O
compared	O
to	O
(	O
9.5±2.1)×10(9	O
)	O
cells	O
in	O
the	O
NB	B-T121
8	I-T121
group	O
(	O
P<.01	O
)	O
and	O
(	O
9.1±1.1	O
)	O
×10(9	O
)	O
cells	O
in	O
the	O
NB	B-T121
4	I-T121
group	O
(	O
P<.001	O
)	O
.	O
The	O
secretion	O
of	O
albumin	O
was	O
superior	O
in	O
the	O
NB	B-T121
8	I-T121
+	O
NAC	B-T121
group	O
at	O
a	O
concentration	O
of	O
(	O
425.8±35.3	O
)	O
ng	O
/	O
mL	O
compared	O
to	O
the	O
NB	B-T121
8	I-T121
group	O
(	O
339.1±32.6	O
)	O
ng	O
/	O
mL	O
(	O
P	O
<	O
.001	O
)	O
and	O
NB	B-T121
4	I-T121
group	O
(	O
293.6±43.3	O
)	O
ng	O
/	O
mL	O
(	O
P	O
<	O
.01	O
)	O
.	O
The	O
injury	O
of	O
hepatocytes	O
also	O
decreased	O
in	O
the	O
NB	B-T121
8	I-T121
+	O
NAC	B-T121
group	O
(	O
P<.01	O
)	O
.	O
The	O
data	O
are	O
presented	O
as	O
means	O
±	O
SD	O
.	O
Formulated	O
collagenase	B-T121
Serva	I-T121
NB	I-T121
8	I-T121
and	O
NAC	B-T121
could	O
improve	O
the	O
porcine	O
hepatocyte	O
isolation	B-T059
,	O
resulting	O
in	O
higher	O
yields	O
of	O
viable	O
cells	O
.	O
      
Loss	O
of	O
Snf5	O
Induces	O
Formation	O
of	O
an	O
Aberrant	O
SWI	O
/	O
SNF	O
Complex	O
The	O
SWI	O
/	O
SNF	O
chromatin	O
remodeling	O
complex	O
is	O
highly	O
conserved	O
from	O
yeast	O
to	O
human	O
,	O
and	O
aberrant	O
SWI	O
/	O
SNF	O
complexes	O
contribute	O
to	O
human	O
disease	B-T047
.	O
The	O
Snf5	O
/	O
SMARCB1	O
/	O
INI1	O
subunit	O
of	O
SWI	O
/	O
SNF	O
is	O
a	O
tumor	O
suppressor	O
frequently	O
lost	O
in	O
pediatric	O
rhabdoid	B-T191
cancers	I-T191
.	O
We	O
examined	O
the	O
effects	O
of	O
Snf5	O
loss	O
on	O
the	O
composition	B-T033
,	O
nucleosome	O
binding	O
,	O
recruitment	O
,	O
and	O
remodeling	O
activities	O
of	O
yeast	O
SWI	O
/	O
SNF	O
.	O
The	O
Snf5	O
subunit	O
is	O
shown	O
by	O
crosslinking	B-T059
-	I-T059
mass	I-T059
spectrometry	I-T059
(	O
CX	B-T059
-	I-T059
MS	I-T059
)	O
and	O
subunit	O
deletion	B-T059
analysis	I-T059
to	O
interact	O
with	O
the	O
ATPase	O
domain	O
of	O
Snf2	O
and	O
to	O
form	O
a	O
submodule	O
consisting	O
of	O
Snf5	O
,	O
Swp82	O
,	O
and	O
Taf14	O
.	O
Snf5	O
promotes	O
binding	O
of	O
the	O
Snf2	O
ATPase	O
domain	O
to	O
nucleosomal	O
DNA	O
and	O
enhances	O
the	O
catalytic	O
and	O
nucleosome	O
remodeling	O
activities	O
of	O
SWI	O
/	O
SNF	O
.	O
Snf5	O
is	O
also	O
required	O
for	O
SWI	O
/	O
SNF	O
recruitment	O
by	O
acidic	O
transcription	O
factors	O
.	O
RNA	B-T059
-	I-T059
seq	I-T059
analysis	I-T059
suggests	O
that	O
both	O
the	O
recruitment	O
and	O
remodeling	O
functions	O
of	O
Snf5	O
are	O
required	O
in	O
vivo	O
for	O
SWI	O
/	O
SNF	O
regulation	O
of	O
gene	O
expression	O
.	O
Thus	O
,	O
loss	O
of	O
SNF5	O
alters	O
the	O
structure	O
and	O
function	O
of	O
SWI	O
/	O
SNF	O
.	O
      
Folate	B-T121
-	O
conjugated	O
gene	O
-	O
carrying	O
microbubbles	O
with	O
focused	B-T061
ultrasound	I-T061
for	O
concurrent	O
blood	B-T023
-	I-T023
brain	I-T023
barrier	I-T023
opening	O
and	O
local	O
gene	O
delivery	O
Previous	O
studies	O
have	O
demonstrated	O
that	O
circulating	O
DNA	O
-	O
encapsulated	O
microbubbles	O
(	O
MBs	O
)	O
combined	O
with	O
focused	B-T061
ultrasound	I-T061
(	O
FUS	B-T061
)	O
can	O
be	O
used	O
for	O
local	O
blood	B-T023
-	I-T023
brain	I-T023
barrier	I-T023
(	O
BBB	B-T023
)	O
opening	O
and	O
gene	O
delivery	O
.	O
However	O
,	O
few	O
studies	O
focused	O
on	O
how	O
to	O
increase	O
the	O
efficiency	O
of	O
gene	O
delivery	O
to	O
brain	B-T191
tumors	I-T191
after	O
the	O
released	O
gene	O
penetrating	O
the	O
BBB	B-T023
.	O
Here	O
,	O
we	O
proposed	O
the	O
use	O
of	O
folate	B-T121
-	O
conjugated	O
DNA	O
-	O
loaded	O
cationic	O
MBs	O
(	O
FCMBs	O
)	O
.	O
When	O
combined	O
with	O
FUS	B-T061
as	O
a	O
trigger	O
for	O
BBB	B-T023
opening	O
,	O
FCMBs	O
were	O
converted	O
into	O
nanometer	O
-	O
sized	O
vesicles	O
that	O
were	O
transported	O
to	O
the	O
brain	B-T023
parenchyma	B-T023
.	O
The	O
FCMBs	O
can	O
selectively	O
aggregate	O
around	O
tumor	O
cells	O
that	O
overexpressed	O
the	O
folate	O
receptor	O
,	O
thus	O
enhancing	O
gene	O
delivery	O
via	O
folate	O
-	O
stimulated	O
endocytosis	O
.	O
Our	O
results	O
confirmed	O
that	O
FCMBs	O
can	O
carry	O
DNA	O
on	O
the	O
surface	O
of	O
the	O
MB	O
shell	O
and	O
have	O
good	O
targeting	O
ability	O
on	O
C6	O
glioma	O
cells	O
.	O
In	O
addition	O
,	O
the	O
optimized	O
FUS	B-T061
parameters	O
for	O
FCMBs	O
-	O
enhanced	O
gene	O
delivery	O
were	O
confirmed	O
by	O
cell	O
experiments	O
(	O
center	O
frequency	O
=	O
1	O
MHz	O
;	O
acoustic	O
pressure	O
=	O
700	O
kPa	O
;	O
pulse	O
repetition	O
frequency	O
=	O
5	O
Hz	O
;	O
cycle	O
number	O
=	O
10000	O
;	O
exposure	O
time	O
=	O
1	O
min	O
;	O
FCMBs	O
concentration	O
=	O
4	O
×	O
10(7	O
)	O
MB	O
/	O
mL	O
)	O
.	O
In	O
vivo	O
data	O
also	O
indicated	B-T033
that	O
FCMBs	O
show	O
better	O
gene	O
transfection	O
efficiency	O
than	O
MBs	O
without	O
folate	O
conjugation	O
and	O
the	O
traditional	O
approach	O
of	O
directly	O
injecting	B-T061
the	O
gene	O
.	O
This	O
study	O
described	O
our	O
novel	O
development	O
of	O
multifunctional	O
MBs	O
for	O
FUS	B-T061
-	O
triggered	O
gene	O
delivery	O
/	O
therapy	B-T061
.	O
      
A	O
fast	O
small	O
-	O
sample	O
kernel	O
independence	O
test	O
for	O
microbiome	B-T001
community	O
-	O
level	O
association	O
analysis	O
To	O
fully	O
understand	O
the	O
role	O
of	O
microbiome	B-T001
in	O
human	O
health	O
and	O
diseases	B-T047
,	O
researchers	O
are	O
increasingly	O
interested	O
in	O
assessing	O
the	O
relationship	O
between	O
microbiome	B-T001
composition	I-T001
and	O
host	B-T001
genomic	O
data	O
.	O
The	O
dimensionality	O
of	O
the	O
data	O
as	O
well	O
as	O
complex	O
relationships	O
between	O
microbiota	B-T001
and	O
host	B-T001
genomics	O
pose	O
considerable	O
challenges	B-T058
for	O
analysis	O
.	O
In	O
this	O
article	O
,	O
we	O
apply	O
a	O
kernel	O
RV	O
coefficient	O
(	O
KRV	O
)	O
test	O
to	O
evaluate	O
the	O
overall	O
association	O
between	O
host	B-T001
gene	O
expression	O
and	O
microbiome	B-T001
composition	I-T001
.	O
The	O
KRV	O
statistic	O
can	O
capture	O
nonlinear	O
correlations	O
and	O
complex	O
relationships	O
among	O
the	O
individual	O
data	O
types	O
and	O
between	O
gene	O
expression	O
and	O
microbiome	B-T001
composition	I-T001
through	O
measuring	O
general	O
dependency	O
.	O
Testing	O
proceeds	O
via	O
a	O
similar	O
route	O
as	O
existing	O
tests	O
of	O
the	O
generalized	O
RV	O
coefficients	O
and	O
allows	O
for	O
rapid	O
p	O
-	O
value	O
calculation	O
.	O
Strategies	O
to	O
allow	O
adjustment	O
for	O
confounding	O
effects	O
,	O
which	O
is	O
crucial	O
for	O
avoiding	O
misleading	O
results	O
,	O
and	O
to	O
alleviate	O
the	O
problem	B-T033
of	O
selecting	O
the	O
most	O
favorable	O
kernel	O
are	O
considered	O
.	O
Simulation	O
studies	O
show	O
that	O
KRV	O
is	O
useful	O
in	O
testing	O
statistical	O
independence	O
with	O
finite	O
samples	O
given	O
the	O
kernels	O
are	O
appropriately	O
chosen	O
,	O
and	O
can	O
powerfully	O
identify	O
existing	O
associations	O
between	O
microbiome	B-T001
composition	I-T001
and	O
host	B-T001
genomic	O
data	O
while	O
protecting	O
type	O
I	O
error	O
.	O
We	O
apply	O
the	O
KRV	O
to	O
a	O
microbiome	B-T001
study	O
examining	O
the	O
relationship	O
between	O
host	B-T001
transcriptome	O
and	O
microbiome	B-T001
composition	I-T001
within	O
the	O
context	O
of	O
inflammatory	B-T047
bowel	I-T047
disease	I-T047
and	O
are	O
able	O
to	O
derive	O
new	O
biological	O
insights	O
and	O
provide	O
formal	O
inference	O
on	O
prior	O
qualitative	O
observations	O
.	O
      
Basal	O
ryanodine	O
receptor	O
activity	O
suppresses	O
autophagic	O
flux	O
The	O
inositol	O
1,4,5	O
-	O
trisphosphate	O
receptors	O
(	O
IP3Rs	O
)	O
and	O
intracellular	O
Ca(2	O
+	O
)	O
signaling	O
are	O
critically	O
involved	O
in	O
regulating	O
different	O
steps	O
of	O
autophagy	O
,	O
a	O
lysosomal	O
degradation	O
pathway	O
.	O
The	O
ryanodine	O
receptors	O
(	O
RyR	O
)	O
,	O
intracellular	O
Ca(2+)-release	O
channels	O
mainly	O
expressed	O
in	O
excitable	B-T033
cell	O
types	O
including	O
muscle	O
and	O
neurons	O
,	O
have	O
however	O
not	O
yet	O
been	O
extensively	O
studied	O
in	O
relation	O
to	O
autophagy	O
.	O
Yet	O
,	O
aberrant	O
expression	O
and	O
excessive	O
activity	O
of	O
RyRs	O
in	O
these	O
tissues	O
has	O
been	O
implicated	B-T033
in	O
the	O
onset	O
of	O
several	O
diseases	B-T047
including	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
,	O
where	O
impaired	O
autophagy	O
regulation	O
contributes	O
to	O
the	O
pathology	O
.	O
In	O
this	O
study	O
,	O
we	O
determined	B-T059
whether	O
pharmacological	O
RyR	O
inhibition	O
could	O
modulate	O
autophagic	O
flux	O
in	O
ectopic	O
RyR	O
-	O
expressing	O
models	O
,	O
like	O
HEK293	O
cells	O
and	O
in	O
cell	O
types	O
that	O
endogenously	O
express	O
RyR	O
s	O
,	O
like	O
C2C12	O
myoblasts	O
and	O
primary	O
hippocampal	B-T023
neurons	O
.	O
Importantly	O
,	O
RyR3	O
overexpression	O
in	O
HEK293	O
cells	O
impaired	O
the	O
autophagic	O
flux	O
.	O
Conversely	O
,	O
in	O
all	O
cell	O
models	O
tested	O
,	O
pharmacological	O
inhibition	O
of	O
endogenous	O
or	O
ectopically	O
expressed	O
RyRs	O
,	O
using	O
dantrolene	B-T121
or	O
ryanodine	B-T121
,	O
augmented	O
autophagic	O
flux	O
by	O
increasing	O
lysosomal	O
turn	O
-	O
over	O
(	O
number	O
of	O
autophagosomes	O
and	O
autolysosomes	O
measured	O
as	O
mCherry	O
-	O
LC3	O
punctae	O
/	O
cell	O
increased	O
from	O
70.37±7.81	O
in	O
control	O
HEK	O
RyR3	O
cells	O
to	O
111.18±7.72	O
and	O
98.14±7.31	O
after	O
dantrolene	B-T121
and	O
ryanodine	B-T121
treatments	B-T061
,	O
respectively	O
)	O
.	O
Moreover	O
,	O
in	O
differentiated	O
C2C12	O
cells	O
,	O
transmission	B-T059
electron	I-T059
microscopy	I-T059
demonstrated	O
that	O
dantrolene	B-T121
treatment	B-T061
decreased	O
the	O
number	O
of	O
early	O
autophagic	O
vacuoles	O
from	O
5.9±2.97	O
to	O
1.8±1.03	O
per	O
cellular	O
cross	O
section	O
.	O
The	O
modulation	O
of	O
the	O
autophagic	O
flux	O
could	O
be	O
linked	O
to	O
the	O
functional	O
inhibition	O
of	O
RyR	O
channels	O
as	O
both	O
RyR	O
inhibitors	O
efficiently	O
diminished	O
the	O
number	O
of	O
cells	O
showing	O
spontaneous	O
RyR3	O
activity	O
in	O
the	O
HEK293	O
cell	O
model	O
(	O
from	O
41.14%±2.12	O
in	O
control	O
cells	O
to	O
18.70%±2.25	O
and	O
9.74%±2.67	O
after	O
dantrolene	B-T121
and	O
ryanodine	B-T121
treatments	B-T061
,	O
respectively	O
)	O
.	O
In	O
conclusion	O
,	O
basal	O
RyR	O
-mediated	O
Ca(2+)-release	O
events	O
suppress	O
autophagic	O
flux	O
at	O
the	O
level	O
of	O
the	O
lysosomes	O
.	O
      
High	B-T060
-	I-T060
Throughput	I-T060
Analysis	I-T060
of	O
the	O
IgG	O
N	O
-	O
Glycome	O
by	O
UPLC	B-T059
-	O
FLR	O
As	O
biological	O
and	O
clinical	O
relevance	O
of	O
glycosylation	O
is	O
becoming	O
more	O
apparent	O
,	O
interest	O
in	O
large	O
scale	O
studies	O
of	O
the	O
glycome	O
is	O
growing	O
.	O
Glycans	B-T121
attached	O
to	O
immunoglobulin	B-T121
G	I-T121
(	O
IgG	B-T121
)	O
were	O
shown	O
to	O
be	O
essential	O
for	O
its	O
function	O
and	O
IgG	B-T121
glycosylation	O
was	O
shown	O
to	O
change	O
with	O
various	O
processes	O
,	O
making	O
IgG	B-T121
one	O
of	O
the	O
most	O
studied	O
glycoproteins	O
.	O
Many	O
approaches	O
including	O
liquid	B-T059
chromatography	I-T059
,	O
capillary	B-T059
gel	I-T059
electrophoresis	I-T059
,	O
and	O
mass	B-T059
spectrometry	I-T059
were	O
developed	O
to	O
study	O
IgG	B-T121
glycosylation	O
.	O
Generation	O
of	O
high	O
-	O
quality	O
glycomics	O
data	O
in	O
a	O
high	O
-	O
throughput	O
fashion	O
requires	O
reproducible	O
and	O
robust	O
sample	B-T059
preparation	I-T059
and	O
accurate	O
and	O
reliable	O
quantitative	O
analysis	O
.	O
This	O
chapter	O
presents	O
a	O
protocol	O
for	O
an	O
optimized	O
and	O
high	O
-	O
throughput	O
IgG	O
N	O
-	O
glycan	O
release	O
,	O
fluorescent	B-T059
labeling	I-T059
and	O
cleanup	O
,	O
and	O
analysis	O
of	O
fluorescently	O
labeled	O
IgG	O
N	O
-	O
glycans	O
by	O
hydrophilic	B-T059
interaction	I-T059
liquid	I-T059
chromatography	I-T059
(	O
HILIC	B-T059
)	O
on	O
an	O
ultra	B-T059
performance	I-T059
liquid	I-T059
chromatography	I-T059
(	O
UPLC	B-T059
)	O
system	O
with	O
fluorescence	O
(	O
FLR	O
)	O
detection	B-T061
.	O
      
A	O
comparison	O
of	O
outcomes	O
in	O
morbidly	B-T047
obese	I-T047
,	O
obese	B-T047
and	O
non	O
-	O
obese	O
patients	O
undergoing	O
primary	B-T061
total	I-T061
knee	I-T061
and	O
total	B-T061
hip	I-T061
arthroplasty	I-T061
Obesity	B-T047
is	O
a	O
growing	O
public	O
health	B-T033
issue	I-T033
with	O
the	O
prevalence	O
of	O
morbid	B-T033
obesity	I-T033
,	I-T033
(	I-T033
Body	I-T033
Mass	I-T033
Index	I-T033
(	I-T033
BMI	I-T033
)	I-T033
≥	I-T033
40	I-T033
kg	I-T033
/	I-T033
m(2	I-T033
)	I-T033
)	I-T033
increasing	O
.	O
There	O
is	O
some	O
evidence	O
these	O
patients	O
have	O
more	O
peri-	B-T047
and	I-T047
post	I-T047
-	I-T047
operative	I-T047
complications	I-T047
and	O
poorer	O
outcomes	O
when	O
undergoing	O
arthroplasty	B-T061
procedures	I-T061
.	O
This	O
audit	O
aimed	O
to	O
determine	O
and	O
compare	O
the	O
outcomes	O
of	O
non	O
-	O
obese	O
,	O
obese	B-T047
and	O
morbidly	B-T047
obese	I-T047
patients	O
undergoing	O
arthroplasty	B-T061
at	O
our	O
institution	O
.	O
This	O
was	O
a	O
retrospective	B-T058
audit	I-T058
of	O
patients	O
from	O
our	O
institution	O
who	O
had	O
undergone	O
total	B-T061
knee	I-T061
(	O
TKA	B-T061
)	O
or	O
total	B-T061
hip	I-T061
arthroplasty	I-T061
(	O
THA	B-T061
)	O
in	O
2009	O
.	O
Data	O
collected	O
were	O
:	O
age	O
,	O
gender	O
,	O
BMI	O
,	O
length	O
of	O
stay	O
(	O
LOS	O
)	O
,	O
Oxford	O
knee	O
or	O
hip	O
score	O
(	O
OKS	O
/	O
OHS	O
)	O
,	O
satisfaction	B-T033
and	O
complications	O
up	O
to	O
two	O
years	O
post	B-T061
operation	I-T061
.	O
Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
BMI	B-T033
<	I-T033
30	I-T033
,	O
BMI	O
30	O
-	O
40	O
and	O
BMI	B-T033
>	I-T033
40	I-T033
.	O
Outcomes	O
for	O
each	O
BMI	O
group	O
were	O
compared	O
.	O
1014	O
TKA	B-T061
and	O
906	O
THA	B-T061
operations	B-T061
were	O
included	O
.	O
When	O
compared	O
to	O
obese	B-T047
and	O
non	O
-	O
obese	O
patients	O
,	O
morbidly	B-T047
obese	I-T047
patients	O
undergoing	O
TKA	B-T061
had	O
a	O
mean	O
LOS	O
one	O
day	O
longer	O
,	O
a	O
mean	O
OKS	O
four	O
points	O
lower	O
and	O
higher	O
rates	O
of	O
postoperative	O
problems	O
,	O
37	O
%	O
vs.	O
21	O
%	O
.	O
For	O
THA	B-T061
patients	O
there	O
was	O
no	B-T033
difference	I-T033
in	O
LOS	O
,	O
OHS	O
score	O
was	O
two	O
points	O
lower	O
for	O
each	O
increasing	O
BMI	O
category	O
and	O
postoperative	O
problems	O
increase	O
from	O
25	O
%	O
for	O
non	O
-	O
obese	O
to	O
31	O
%	O
for	O
obese	B-T047
and	O
38	O
%	O
for	O
morbidly	B-T047
obese	I-T047
patients	O
.	O
These	O
results	O
will	O
be	O
useful	O
in	O
informing	O
obese	B-T047
patients	O
of	O
their	O
potential	O
outcomes	O
following	O
TKA	B-T061
or	O
THA	B-T061
.	O
These	O
patients	O
can	O
then	O
make	O
a	O
more	O
informed	O
choice	O
before	O
proceeding	O
with	O
arthroplasty	B-T061
.	O
      
Design	O
of	O
a	O
candidate	O
vibrational	O
signal	O
for	O
mating	O
disruption	O
against	O
the	O
glassy	O
-	O
winged	O
sharpshooter	O
,	O
Homalodisca	O
vitripennis	O
The	O
glassy	O
-	O
winged	O
sharpshooter	O
(	O
GWSS	O
)	O
,	O
Homalodisca	O
vitripennis	O
,	O
is	O
an	O
important	O
pest	O
of	O
grapevines	O
due	O
to	O
its	O
ability	O
to	O
transmit	O
Xylella	B-T007
fastidiosa	I-T007
,	O
the	O
causal	B-T001
agent	I-T001
of	O
Pierce	B-T047
's	I-T047
disease	I-T047
.	O
GWSS	O
mating	O
communication	O
is	O
based	O
on	O
vibrational	O
signals	O
;	O
therefore	O
,	O
vibrational	O
mating	O
disruption	O
could	O
be	O
an	O
alternative	O
to	O
insecticides	O
for	O
suppression	O
of	O
GWSS	O
population	O
.	O
Our	O
objectives	O
were	O
to	O
identify	O
spectral	O
features	O
of	O
female	O
signal	O
that	O
elicit	O
male	O
signaling	O
,	O
design	O
disruptive	O
signals	O
able	O
to	O
alter	O
male	O
perception	O
and	O
acceptance	O
of	O
a	O
female	O
,	O
and	O
determine	O
the	O
signal	O
intensity	O
required	O
for	O
future	O
field	O
applications	O
.	O
Results	B-T033
showed	O
that	O
male	O
responses	O
to	O
playback	O
of	O
modified	O
female	O
signals	O
were	O
significantly	O
reduced	O
by	O
60	O
-	O
75%when	O
part	O
of	O
the	O
female	O
signal	O
spectral	O
components	O
above	O
or	O
below	O
400	O
Hz	O
were	O
deleted	O
.	O
Playback	O
bioassays	B-T059
showed	O
that	O
transmission	O
of	O
an	O
80	O
Hz	O
pure	O
frequency	O
tone	O
to	O
plants	O
completely	O
suppressed	O
male	O
signaling	O
to	O
female	O
signal	O
playback	O
,	O
even	O
if	O
the	O
disruptive	O
signal	O
amplitude	O
was	O
10	O
dB	O
lower	O
than	O
the	O
female	O
signal	O
playback	O
.	O
Although	O
the	O
mechanism	O
underlying	O
cessation	O
of	O
male	O
signaling	O
activity	O
in	O
the	O
presence	B-T033
of	O
disruption	O
is	O
not	O
yet	O
understood	O
,	O
results	B-T033
suggest	O
that	O
an	O
80	O
Hz	O
vibrational	O
signal	O
should	O
be	O
tested	O
in	O
laboratory	O
and	O
field	O
experiments	O
to	O
assess	O
its	O
efficacy	O
in	O
disrupting	O
mating	O
of	O
GWSS	O
.	O
      
Increased	O
acute	O
mortality	O
with	O
chemoradiotherapy	B-T061
for	O
locally	B-T191
advanced	I-T191
head	I-T191
and	I-T191
neck	I-T191
cancer	I-T191
in	O
patients	O
≥70	O
years	O
Concurrent	B-T061
chemoradiotherapy	I-T061
(	O
CRT	B-T061
)	O
is	O
the	O
standard	B-T061
of	I-T061
care	I-T061
for	O
many	O
sites	O
of	O
locally	B-T191
advanced	I-T191
head	I-T191
and	I-T191
neck	I-T191
squamous	I-T191
cell	I-T191
carcinomas	I-T191
(	O
LAHNC	B-T191
)	O
.	O
However	O
,	O
on	O
meta	O
-	O
analysis	O
,	O
the	O
addition	O
of	O
chemotherapy	B-T061
did	O
not	O
improve	O
survival	O
for	O
patients	O
>	O
70	O
years	O
.	O
We	O
hypothesized	O
that	O
elderly	O
patients	O
treated	O
with	O
CRT	B-T061
would	O
have	O
increased	O
toxicity	O
without	O
similar	O
improvements	O
in	O
survival	O
.	O
A	O
single	O
-	O
institution	O
,	O
IRB	O
-	O
approved	O
retrospective	O
study	O
took	O
place	O
from	O
2005	O
to	O
2012	O
including	O
369	O
patients	O
treated	O
with	O
CRT	B-T061
for	O
LAHNC	B-T191
.	O
Multivariate	O
models	O
for	O
death	B-T033
at	O
3	O
months	O
and	O
death	B-T033
over	O
time	O
were	O
developed	O
using	O
logistic	O
regression	O
and	O
Cox	O
modeling	O
,	O
respectively	O
.	O
Patients	O
≥70	O
years	O
were	O
treated	O
less	O
often	O
with	O
concurrent	O
cisplatin	B-T121
dosed	O
every	O
3	O
weeks	O
(	O
25.5	O
%	O
vs.	O
71.4	O
%	O
,	O
respectively	O
)	O
and	O
more	O
often	O
with	O
weekly	O
carboplatin	B-T121
(	O
31.9	O
%	O
vs.	O
3.4	O
%	O
)	O
than	O
patients	O
<	O
70	O
years	O
(	O
n=322	O
;	O
p<0.001	O
)	O
.	O
Patients	O
≥70	O
years	O
experienced	O
increased	O
toxicity	O
during	O
treatment	B-T061
with	O
more	O
frequently	O
hospitalizations	B-T058
(	O
36.2	O
%	O
vs.	O
21.1	O
%	O
;	O
p=0.02	O
)	O
and	O
a	O
lower	O
rate	O
of	O
PEG	B-T061
removal	I-T061
at	O
last	O
follow	B-T058
-	I-T058
up	I-T058
or	O
death	B-T033
(	O
77.1	O
%	O
vs.	O
92.9	O
%	O
;	O
p=0.004	O
)	O
.	O
A	O
higher	O
proportion	O
of	O
patients	O
≥70	O
years	O
died	O
within	O
3	O
months	O
(	O
12.8	O
%	O
vs.	O
2.8	O
%	O
;	O
p=0.001	O
)	O
following	O
CRT	B-T061
.	O
Patients	O
≥70	O
had	O
an	O
increased	O
risk	O
of	O
death	B-T033
at	O
3	O
months	O
following	O
CRT	B-T061
(	O
odds	O
ratio	O
5.19	O
,	O
95	O
%	O
CI	O
1.64	O
-	O
16.41	O
;	O
p=0.005	O
)	O
and	O
worse	O
survival	O
over	O
time	O
(	O
hazard	O
ratio	O
2.30	O
,	O
95	O
%	O
CI	O
1.34	O
-	O
3.93	O
;	O
p=0.002	O
)	O
.	O
Patients	O
≥70	O
years	O
were	O
more	O
often	O
treated	O
with	O
less	O
toxic	O
chemotherapy	B-T061
,	O
yet	O
experienced	O
higher	O
rates	O
of	O
hospitalization	B-T058
during	O
treatment	B-T061
and	O
increased	O
rates	O
of	O
acute	O
mortality	O
following	O
CRT	B-T061
.	O
The	O
efficacy	O
of	O
chemoradiotherapy	B-T061
for	O
elderly	O
patients	O
should	O
be	O
evaluated	O
in	O
a	O
prospective	O
setting	O
.	O
      
Entrapment	B-T047
of	O
the	O
posterior	B-T023
femoral	I-T023
cutaneous	I-T023
nerve	I-T023
and	O
its	O
inferior	B-T023
cluneal	I-T023
branches	I-T023
:	O
anatomical	O
basis	O
of	O
surgery	O
for	O
inferior	B-T184
cluneal	I-T184
neuralgia	I-T184
The	O
apparent	O
failure	O
of	O
pudendal	B-T023
nerve	I-T023
surgery	O
in	O
some	O
patients	O
has	O
led	O
us	O
to	O
suggest	O
the	O
possibility	O
of	O
entrapment	B-T047
of	O
other	O
adjacent	O
nerve	O
structures	O
,	O
leading	O
to	O
the	O
concept	O
of	O
inferior	B-T184
cluneal	I-T184
neuralgia	I-T184
.	O
Via	O
its	O
numerous	O
collateral	B-T023
branches	I-T023
,	O
the	O
posterior	B-T023
femoral	I-T023
cutaneous	I-T023
nerve	I-T023
innervates	O
a	O
very	O
extensive	O
territory	O
including	O
the	O
posterior	O
surface	O
of	O
the	O
thigh	O
,	O
the	O
infragluteal	B-T023
fold	I-T023
,	O
the	O
skin	O
over	O
the	O
ischial	B-T023
tuberosity	I-T023
,	O
but	O
also	O
the	O
lateral	O
anal	O
region	O
,	O
scrotum	B-T023
or	O
labium	B-T023
majus	I-T023
via	O
its	O
perineal	B-T023
branch	I-T023
.	O
We	O
described	O
the	O
pathophysiological	O
features	O
of	O
cluneal	B-T184
neuralgia	I-T184
,	O
the	O
surgical	B-T060
technique	I-T060
and	O
our	O
preliminary	O
results	O
.	O
We	O
performed	O
a	O
transmuscular	B-T061
approach	I-T061
leading	O
to	O
the	O
fat	B-T023
of	O
the	O
deep	O
gluteal	O
region	O
.	O
Exploration	B-T061
was	O
continued	O
cranially	O
underneath	O
the	O
piriformis	B-T023
,	O
looking	O
for	O
potential	O
entrapments	B-T047
affecting	O
the	O
posterior	B-T023
femoral	I-T023
cutaneous	I-T023
nerve	I-T023
and	O
the	O
sciatic	B-T023
nerve	I-T023
.	O
Nerve	B-T061
decompression	I-T061
on	O
the	O
lateral	O
surface	O
of	O
the	O
ischial	B-T023
tuberosity	I-T023
was	O
then	O
performed	O
.	O
A	O
constant	O
anatomical	O
finding	O
must	O
be	O
highlighted	O
:	O
the	O
presence	O
of	O
a	O
lateral	O
fibrous	O
expansion	B-T061
from	O
the	O
ischium	B-T023
passing	O
behind	O
the	O
nerves	O
and	O
vessels	B-T023
,	O
especially	O
the	O
posterior	B-T023
femoral	I-T023
cutaneous	I-T023
nerve	I-T023
and	O
its	O
perineal	B-T023
branches	I-T023
.	O
In	O
our	O
patients	O
,	O
release	O
of	O
this	O
expansion	B-T061
allowed	O
decompression	B-T061
of	O
the	O
nerve	B-T047
trapped	I-T047
by	O
this	O
expansion	B-T061
.	O
Cluneal	B-T184
neuralgia	I-T184
constitutes	O
a	O
distinct	O
entity	O
of	O
perineal	B-T184
pain	I-T184
,	O
which	O
must	O
be	O
identified	O
and	O
distinguished	O
from	O
pudendal	B-T047
neuralgia	I-T047
.	O
Surgery	O
should	O
be	O
performed	O
via	O
a	O
transgluteal	O
approach	O
.	O
A	O
lateral	B-T023
ischial	I-T023
obstacle	O
must	O
be	O
investigated	O
,	O
in	O
the	O
form	O
of	O
a	O
constant	O
fibrous	O
expansion	B-T061
,	O
which	O
,	O
like	O
a	O
retinaculum	B-T023
,	O
can	O
cause	O
nerve	B-T047
entrapment	I-T047
.	O
      
The	O
lost	O
art	O
of	O
the	O
splenorrhaphy	B-T061
In	O
the	O
case	O
of	O
the	O
hemodynamically	B-T047
unstable	I-T047
child	O
,	O
splenorrhaphy	B-T061
is	O
preferred	O
to	O
splenectomy	B-T061
to	O
avert	O
postsplenectomy	O
sepsis	B-T047
.	O
However	O
,	O
successful	O
splenorrhaphy	B-T061
requires	O
familiarity	O
with	O
the	O
procedure	B-T061
.	O
We	O
sought	O
to	O
determine	O
how	O
many	O
splenectomies	B-T061
or	O
splenorrhaphies	B-T061
for	O
trauma	O
the	O
average	O
pediatric	O
surgeon	O
can	O
be	O
expected	O
to	O
perform	O
during	O
their	O
career	O
.	O
The	O
Pediatric	O
Health	O
Information	O
System	O
(	O
PHIS	O
)	O
Database	O
was	O
queried	O
for	O
patients	O
≤18	O
years	O
coded	O
with	O
an	O
International	O
Classification	O
of	O
Diseases	O
9th	O
Edition	O
diagnosis	O
code	O
of	O
a	O
splenic	O
injury	O
from	O
2004	O
to	O
2013	O
.	O
Age	O
,	O
gender	O
,	O
grade	O
of	O
splenic	O
injury	O
,	O
and	O
operations	B-T061
performed	O
were	O
extracted	O
.	O
Numbers	O
of	O
pediatric	O
surgeons	O
per	O
hospital	O
were	O
obtained	O
.	O
9567	O
children	O
were	O
identified	O
.	O
2.1	O
%	O
underwent	O
a	O
splenectomy	B-T061
and	O
0.8	O
%	O
underwent	O
a	O
splenorrhaphy	B-T061
.	O
The	O
average	O
surgeon	O
performed	O
0.6	O
(	O
SD=0.6	O
)	O
splenectomies	B-T061
and	O
0.2	O
(	O
SD=0.4	O
)	O
splenorrhaphies	B-T061
for	O
trauma	O
.	O
If	O
these	O
rates	O
remain	O
constant	O
over	O
time	O
,	O
the	O
average	O
surgeon	O
would	O
perform	O
1.8	O
(	O
SD	O
=	O
1.7	O
)	O
splenectomies	B-T061
and	O
0.6	O
(	O
SD	O
=	O
1.1	O
)	O
splenorrhaphies	B-T061
for	O
trauma	O
over	O
a	O
30-	O
year	O
surgical	O
career	O
.	O
Nonoperative	B-T061
management	I-T061
is	O
associated	O
with	O
a	O
host	O
of	O
benefits	O
,	O
but	O
has	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
experience	O
level	O
of	O
the	O
pediatric	O
surgeons	O
expected	O
to	O
perform	O
an	O
emergency	O
splenectomy	B-T061
or	O
splenorrhaphy	B-T061
when	O
the	O
unusual	O
occasion	O
arises	O
.	O
      
Correlation	O
between	O
preoperative	O
physical	B-T033
signs	I-T033
and	O
functional	O
outcomes	O
after	O
laminoplasty	B-T061
for	O
ossification	O
of	O
the	O
posterior	O
longitudinal	O
ligament	O
Ossification	O
of	O
the	O
posterior	O
longitudinal	O
ligament	O
(	O
OPLL	O
)	O
can	O
cause	O
myelopathy	B-T047
that	O
is	O
often	O
managed	B-T058
surgically	B-T061
.	O
Knowledge	O
of	O
predictors	O
of	O
surgical	B-T061
outcomes	O
can	O
provide	O
decision	O
support	O
to	O
surgeons	O
.	O
The	O
aims	O
of	O
this	O
study	O
were	O
to	O
investigate	O
the	O
relationships	O
between	O
preoperative	O
physical	B-T033
signs	I-T033
and	O
postoperative	O
functional	O
outcomes	O
in	O
patients	O
with	O
OPLL	O
and	O
to	O
clarify	O
whether	O
physical	B-T033
signs	I-T033
could	O
predict	O
functional	O
outcomes	O
.	O
Fifty	O
-	O
five	O
patients	O
with	O
OPLL	O
who	O
had	O
undergone	O
cervical	B-T061
laminoplasty	I-T061
were	O
included	O
in	O
this	O
study	O
.	O
Six	O
physical	B-T033
signs	I-T033
including	O
hyperreflexia	B-T033
,	O
Babinski	B-T033
sign	I-T033
,	O
sensory	B-T047
disturbance	I-T047
,	O
grip	O
strength	O
,	O
10	B-T060
-	I-T060
s	I-T060
grip	I-T060
and	I-T060
release	I-T060
test	I-T060
,	O
and	O
bladder	O
dysfunction	O
,	O
and	O
four	O
other	O
factors	O
including	O
age	O
,	O
duration	O
of	O
symptoms	O
,	O
history	O
of	O
minor	O
trauma	O
and	O
preoperative	O
Japanese	O
Orthopaedic	O
Association	O
(	O
JOA	O
)	O
score	O
were	O
investigated	O
as	O
potential	O
predictive	O
prognostic	O
factors	O
using	O
both	O
univariate	O
and	O
multivariate	O
analyses	O
.	O
The	O
mean	O
recovery	O
rate	O
of	O
JOA	O
score	O
was	O
62.5	O
±	O
32.5	O
%	O
.	O
The	O
neurological	O
recovery	O
rate	O
was	O
negatively	B-T033
associated	O
with	O
age	O
(	O
P	O
=	O
0.002	O
)	O
,	O
the	O
duration	O
of	O
symptoms	O
(	O
P	O
=	O
0.002	O
)	O
and	O
Babinski	B-T033
sign	I-T033
(	O
P	O
=	O
0.007	O
)	O
,	O
whereas	O
it	O
was	O
positively	B-T033
correlated	O
with	O
grip	O
strength	O
(	O
P	O
=	O
0.011	O
)	O
.	O
Multiple	O
logistic	O
regression	O
analyses	O
revealed	O
that	O
age	O
(	O
Odds	O
ratio	O
:	O
0.89	O
,	O
95	O
%	O
CI	O
:	O
0.81	O
-	O
0.99	O
)	O
and	O
Babinski	B-T033
sign	I-T033
(	O
Odds	O
ratio	O
:	O
0.18	O
,	O
95	O
%	O
CI	O
:	O
0.04	O
-	O
0.89	O
)	O
were	O
factors	O
associated	O
with	O
functional	O
outcomes	O
.	O
Satisfactory	O
functional	O
outcomes	O
could	O
be	O
expected	O
for	O
patients	O
who	O
are	O
young	O
and	O
do	O
not	O
exhibit	O
the	O
Babinski	B-T033
sign	I-T033
,	O
showing	O
that	O
the	O
Babinski	B-T033
sign	I-T033
could	O
be	O
useful	O
as	O
an	O
indicator	O
of	O
the	O
window	O
of	O
opportunity	O
for	O
achieving	O
satisfactory	O
functional	O
outcomes	O
.	O
      
Decreased	O
Frequencies	O
of	O
Peripheral	O
Blood	O
CD4+CD25+CD127	O
-	O
Foxp3	O
+	O
in	O
Patients	O
with	O
Graves	B-T047
'	I-T047
Disease	I-T047
and	O
Graves	B-T047
'	I-T047
Orbitopathy	I-T047
:	O
Enhancing	O
Effect	O
of	O
Insulin	O
Growth	O
Factor-1	O
on	O
Treg	O
Cells	O
Graves	B-T047
'	I-T047
orbitopathy	I-T047
(	O
GO	B-T047
)	O
is	O
characterized	O
by	O
orbital	O
T	O
cell	O
infiltration	O
.	O
We	O
evaluated	B-T058
the	O
regulatory	O
T	O
(	O
Treg	O
)	O
cell	O
fractions	O
induced	O
with	O
IGF-1	O
in	O
Graves	B-T047
'	I-T047
disease	I-T047
(	O
GD	B-T047
)	O
with	O
and	O
without	O
GO	B-T047
.	O
Peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
were	O
obtained	O
from	O
13	O
patients	O
with	O
GD	B-T047
without	O
eye	B-T184
manifestations	I-T184
;	O
10	O
patients	O
with	O
active	O
GO	B-T047
;	O
and	O
12	O
patients	O
with	O
nodular	B-T047
goiter	I-T047
(	O
NG	B-T047
)	O
.	O
All	O
the	O
patients	O
from	O
GD	B-T047
,	O
GO	B-T047
,	O
and	O
NG	B-T047
were	O
subclinical	O
hyperthyroid	O
.	O
We	O
analyzed	O
the	O
expression	B-T059
of	I-T059
Treg	I-T059
cell	I-T059
markers	I-T059
(	O
CD4	O
,	O
CD25	O
,	O
CD127(-	O
)	O
,	O
Foxp3	O
)	O
on	O
T	O
cells	O
and	O
their	O
ability	O
to	O
respond	O
to	O
IGF-1	O
stimulation	O
.	O
In	O
patients	O
with	O
GD	B-T047
without	O
GO	B-T047
,	O
we	O
found	O
lowered	O
percentages	O
of	O
CD4(+	O
)	O
Foxp3(+	O
)	O
cells	O
,	O
as	O
compared	O
to	O
nodular	B-T047
goiter	I-T047
1.77	O
vs.	O
5.42	O
%	O
(	O
p=0.0276	O
)	O
.	O
Similarly	O
,	O
significantly	O
reduced	O
frequencies	O
of	O
CD4(+)CD25(+)CD127(-)Foxp3(+	O
)	O
and	O
CD4(+)CD25(+)CD127(-	O
)	O
cells	O
were	O
observed	O
in	O
GD	B-T047
patients	O
as	O
compared	O
to	O
nodular	B-T047
goiter	I-T047
patients	O
with	O
hyperthyreosis	B-T047
,	O
(	O
0.7	O
vs.	O
1.48	O
%	O
)	O
(	O
p=0.0071	O
)	O
and	O
(	O
14.5	O
vs.	O
37.2	O
%	O
)	O
(	O
p=0.0051	O
)	O
,	O
respectively	O
.	O
In	O
GO	B-T047
with	O
active	O
GO	B-T047
,	O
only	O
the	O
percentage	O
of	O
CD4(+)CD25(+)CD127(-	O
)	O
cells	O
was	O
found	O
to	O
be	O
decreased	O
versus	O
nodular	B-T047
goiter	I-T047
(	O
9.35	O
vs.	O
37.2	O
)	O
(	O
p=0.0275	O
)	O
.	O
Stimulation	O
of	O
PBMC	O
derived	O
from	O
GO	B-T047
patients	O
with	O
IGF-1	O
resulted	O
in	O
significant	O
increase	O
of	O
frequency	O
of	O
both	O
CD4(+	O
)	O
Foxp3(+	O
)	O
and	O
CD4(+)CD25(+)CD127(-	O
)	O
Foxp3	O
cells	O
.	O
Decreased	O
frequencies	O
of	O
peripheral	O
blood	O
CD4(+)CD25(+)CD127(-)Foxp3(+	O
)	O
in	O
patients	O
with	O
GD	B-T047
and	O
GO	B-T047
could	O
be	O
an	O
useful	O
marker	O
of	O
autoimmune	O
process	O
and	O
perhaps	O
a	O
possible	O
target	O
for	O
future	O
therapies	O
.	O
This	O
is	O
the	O
first	O
study	O
demonstrating	O
Treg	O
-	O
enhancing	O
effects	O
of	O
IGF-1	O
.	O
Thus	O
IGF-1	O
can	O
be	O
accounted	O
for	O
modulating	O
Treg	O
cell	O
-related	O
action	O
in	O
GO	B-T047
.	O
      
Twisting	O
method	O
for	O
reducing	O
friction	O
during	O
insertion	B-T061
of	O
a	O
sheath	O
introducer	O
and	O
a	O
sheathless	O
guiding	O
catheter	O
A	O
sheathless	O
system	O
that	O
inserts	B-T058
a	O
catheter	O
directly	O
into	O
the	O
artery	B-T023
can	O
reduce	O
puncture	O
site	O
-related	O
complications	O
through	O
a	O
2	O
-	O
Fr	O
reduction	O
of	O
the	O
outer	O
diameter	O
.	O
However	O
,	O
the	O
gap	O
between	O
the	O
dilator	O
and	O
the	O
guiding	O
catheter	O
of	O
the	O
sheathless	O
system	O
is	O
larger	O
than	O
the	O
gap	O
between	O
the	O
dilator	O
and	O
sheath	O
of	O
the	O
introducer	O
system	O
,	O
resulting	O
in	O
stronger	O
insertion	B-T061
resistance	O
.	O
A	O
twisting	O
method	O
with	O
rapid	O
alternating	O
rotation	O
of	O
a	O
device	O
to	O
the	O
left	O
and	O
right	O
during	O
insertion	B-T061
insertion	B-T061
can	O
reduce	O
the	O
insertion	B-T061
resistance	O
.	O
This	O
method	O
can	O
be	O
effective	O
with	O
the	O
sheathless	O
system	O
which	O
has	O
a	O
larger	O
gap	O
.	O
To	O
examine	O
the	O
effect	O
of	O
size	O
reduction	O
on	O
the	O
sheathless	O
system	O
and	O
the	O
effect	O
of	O
insertion	B-T061
resistance	O
reduction	O
using	O
the	O
twisting	O
method	O
,	O
we	O
developed	O
an	O
insertion	B-T061
simulator	O
and	O
compared	O
insertion	B-T061
resistance	O
to	O
a	O
5	O
-	O
Fr	O
sheath	O
introducer	O
and	O
a	O
5	O
-	O
Fr	O
sheathless	O
system	O
,	O
with	O
and	O
without	O
the	O
twisting	O
method	O
.	O
The	O
insertion	B-T061
simulator	O
pushed	O
a	O
sheath	O
introducer	O
or	O
a	O
sheathless	O
system	O
toward	O
a	O
mock	B-T033
artery	B-T023
consisted	O
with	O
a	O
5	O
-	O
mm	O
urethane	O
and	O
a	O
1	O
-	O
mm	O
rubber	O
sheet	O
by	O
an	O
electrical	O
motor	O
with	O
or	O
without	O
twisting	O
motion	O
generated	O
by	O
a	O
crank	O
shaft	O
.	O
Insertion	B-T061
resistance	O
during	O
the	O
penetration	O
was	O
measured	O
by	O
a	O
tension	O
meter	O
.	O
The	O
insertion	B-T061
resistance	O
was	O
less	O
with	O
the	O
5	O
-	O
Fr	O
sheathless	O
system	O
than	O
with	O
the	O
5	O
-	O
Fr	O
sheath	O
introducer	O
.	O
The	O
resistance	O
reduced	O
further	O
with	O
use	O
of	O
twisting	O
for	O
both	O
the	O
sheathed	O
and	O
sheathless	O
catheters	O
.	O
In	O
conclusion	O
,	O
the	O
experiment	O
suggests	O
the	O
benefits	O
of	O
twisting	O
insertion	B-T061
of	O
a	O
sheathless	O
guiding	O
catheter	O
for	O
reduction	O
of	O
puncture	O
site	O
-related	O
complications	O
.	O
      
Physicochemical	O
characterization	O
of	O
chitosan	B-T121
-	O
hyaluronan	B-T121
-coated	O
solid	O
lipid	O
nanoparticles	O
for	O
the	O
targeted	O
delivery	B-T061
of	O
paclitaxel	B-T121
:	O
a	O
proof	O
-	O
of	O
-	O
concept	O
study	O
in	O
breast	O
cancer	O
cells	O
To	O
investigate	O
the	O
potential	O
of	O
modified	O
solid	O
lipid	O
nanoparticles	O
(	O
SLN	O
)	O
for	O
the	O
delivery	O
of	O
paclitaxel	B-T121
(	O
PAX	B-T121
)	O
.	O
SLN	B-T121
loaded	I-T121
with	I-T121
PAX	I-T121
were	O
prepared	O
via	O
modified	O
high	B-T059
-	I-T059
pressure	I-T059
hot	I-T059
homogenization	I-T059
.	O
Formulation	O
parameters	O
were	O
optimized	O
to	O
obtain	O
a	O
high	O
-	O
quality	O
delivery	O
system	O
.	O
SLN	O
cores	O
were	O
coated	O
,	O
layer	O
-	O
by	O
-	O
layer	O
,	O
with	O
a	O
chitosan	B-T121
and	O
hyaluronan	B-T121
(	O
HA	B-T121
)	O
shell	O
.	O
Selectivity	O
toward	O
HA	B-T121
receptors	O
was	O
tested	O
in	O
a	O
breast	O
cancer	O
cell	O
line	O
,	O
MCF-7	O
.	O
Stable	O
and	O
reproducible	O
nano	O
-	O
sized	O
and	O
negatively	O
charged	O
nanoparticles	O
resulted	O
.	O
Findings	O
reveal	O
that	O
chitosan	B-T121
-	O
HA	B-T121
-coated	O
SLN	O
facilitated	O
the	O
targeting	O
,	O
cellular	O
uptake	O
and	O
the	O
time-/dose	O
-	O
controlled	O
delivery	O
and	O
release	O
of	O
PAX	B-T121
,	O
enhancing	O
intrinsic	B-T061
chemotherapeutic	I-T061
activities	I-T061
.	O
SLN	O
are	O
suitable	O
carrier	O
candidates	O
for	O
nano	O
-	O
oncology	O
given	O
their	O
localized	O
,	O
and	O
potent	O
cytotoxic	B-T121
potential	I-T121
overcoming	B-T033
multidrug	O
-	O
resistant	O
cancer	O
cells	O
.	O
      
Risk	B-T033
Factors	I-T033
for	O
Infection	O
After	O
Knee	B-T060
Arthroscopy	I-T060
:	O
Analysis	O
of	O
595,083	O
Cases	O
From	O
3	O
United	O
States	O
Databases	O
To	O
identify	O
and	O
quantify	O
patient-	B-T033
and	O
procedure	B-T033
-	I-T033
related	I-T033
risk	I-T033
factors	I-T033
for	O
post	O
-	O
arthroscopic	O
knee	B-T047
infections	I-T047
using	O
a	O
large	O
dataset	O
.	O
An	O
administrative	O
health	O
care	O
database	O
including	O
8	O
years	O
of	O
records	O
from	O
2	O
large	O
commercial	O
insurers	O
and	O
Medicare	O
(	O
a	O
5	O
%	O
random	O
sample	O
)	O
was	O
queried	O
to	O
identify	O
all	O
knee	B-T060
arthroscopies	I-T060
performed	O
on	O
patients	O
aged	O
at	O
least	O
15	O
years	O
using	O
Current	O
Procedural	O
Terminology	O
(	O
CPT	O
)	O
codes	O
.	O
Each	O
CPT	O
code	O
was	O
designated	O
as	O
a	O
high-	B-T058
or	O
low	B-T058
-	I-T058
complexity	I-T058
procedure	I-T058
,	O
with	O
the	O
former	O
typically	O
requiring	O
accessory	O
incisions	B-T061
or	O
increased	O
operative	O
time	O
.	O
Deep	O
infections	O
were	O
identified	O
by	O
a	O
CPT	O
code	O
for	O
incision	B-T061
and	O
drainage	B-T061
within	O
90	O
days	O
of	O
surgery	O
.	O
Superficial	O
infections	O
were	O
identified	O
by	O
International	O
Classification	O
of	O
Diseases	O
,	O
Ninth	O
Revision	O
infection	O
codes	O
without	O
any	O
record	O
of	O
incision	B-T061
and	O
drainage	B-T061
.	O
Patients	O
were	O
compared	O
based	O
on	O
age	O
,	O
sex	O
,	O
body	O
mass	O
index	O
,	O
tobacco	O
use	O
,	O
presence	O
of	O
diabetes	B-T047
,	O
and	O
Charlson	O
Comorbidity	O
Index	O
.	O
A	O
total	O
of	O
526,537	O
patients	O
underwent	O
595,083	O
arthroscopic	B-T060
knee	I-T060
procedures	I-T060
.	O
Deep	O
postoperative	O
infections	O
occurred	O
at	O
a	O
rate	O
of	O
0.22	O
%	O
.	O
Superficial	O
infections	O
occurred	O
at	O
a	O
rate	O
of	O
0.29	O
%	O
.	O
Tobacco	O
use	O
and	O
morbid	B-T047
obesity	I-T047
were	O
the	O
largest	O
risk	B-T033
factors	I-T033
for	O
deep	O
and	O
superficial	O
infections	O
,	O
respectively	O
(	O
P	O
<	O
.001	O
;	O
relative	O
risk	O
of	O
1.90	O
and	O
2.19	O
,	O
respectively	O
)	O
.	O
There	O
were	O
also	O
higher	O
infection	O
rates	O
among	O
patients	O
undergoing	O
relatively	O
high	B-T060
-	I-T060
complexity	I-T060
arthroscopies	I-T060
,	O
men	O
,	O
obese	B-T047
patients	O
,	O
diabetic	B-T047
patients	O
,	O
and	O
younger	O
patients	O
(	O
in	O
order	O
of	O
decreasing	O
relative	O
risk	O
)	O
.	O
Increased	O
Charlson	O
Comorbidity	O
Index	O
was	O
associated	O
with	O
superficial	O
and	O
total	O
infections	O
(	O
P	O
<	O
.001	O
)	O
.	O
Post	O
-	O
arthroscopic	O
knee	B-T047
infections	I-T047
were	O
more	O
frequent	O
among	O
morbidly	B-T047
obese	I-T047
patients	O
,	O
tobacco	B-T033
users	I-T033
,	O
patients	O
undergoing	O
relatively	O
complex	B-T058
procedures	I-T058
,	O
men	O
,	O
obese	O
patients	O
,	O
diabetic	O
patients	O
,	O
relatively	O
young	O
patients	O
,	O
and	O
patients	O
with	O
increased	O
comorbidity	O
burdens	O
in	O
this	O
study	O
population	O
.	O
This	O
knowledge	O
may	O
allow	O
more	O
informed	O
preoperative	B-T058
counseling	I-T058
,	O
aid	O
surgeons	O
in	O
patient	O
selection	O
,	O
and	O
facilitate	O
infection	B-T061
prevention	I-T061
by	O
targeting	O
individuals	O
with	O
higher	O
inherent	O
risk	O
.	O
Level	O
IV	O
,	O
cross	O
-	O
sectional	O
study	O
.	O
      
Fibrinogen	B-T121
:	O
A	O
Marker	O
in	O
Predicting	O
Diabetic	B-T047
Foot	I-T047
Ulcer	I-T047
Severity	O
Aims	O
.	O
To	O
examine	B-T058
whether	O
fibrinogen	O
levels	O
are	O
a	O
valuable	O
biomarker	O
for	O
assessing	B-T058
disease	O
severity	O
and	O
monitoring	B-T058
disease	O
progression	O
in	O
patients	O
with	O
diabetic	B-T047
foot	I-T047
ulcer	I-T047
(	O
DFU	B-T047
)	O
.	O
Methods	O
.	O
A	O
retrospective	O
study	O
was	O
designed	O
to	O
examine	O
the	O
utility	O
of	O
fibrinogen	B-T121
in	O
estimating	O
disease	O
severity	O
in	O
patients	O
with	O
DFU	B-T047
admitted	B-T058
to	O
our	O
hospital	O
between	O
January	O
2015	O
and	O
January	O
2016	O
.	O
In	O
total	O
,	O
152	O
patients	O
with	O
DFU	B-T047
were	O
enrolled	O
in	O
the	O
study	O
group	O
,	O
and	O
52	O
age	O
and	O
gender	O
matched	O
people	O
with	O
diabetes	B-T047
but	O
no	O
DFU	B-T047
were	O
included	O
as	O
the	O
control	O
group	O
.	O
DFU	B-T047
severity	O
was	O
assessed	O
using	O
Wagner	O
criteria	O
.	O
Results	O
.	O
Patients	O
with	O
DFU	B-T047
were	O
divided	O
into	O
2	O
subgroups	O
based	O
on	O
the	O
Wagner	O
criteria	O
.	O
Mean	O
fibrinogen	O
values	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
DFU	B-T047
grade	O
≧	O
3	O
compared	O
to	O
those	O
with	O
DFU	B-T047
grades	O
1	O
-	O
2	O
(	O
5.23	O
±	O
1.37	O
g	O
/	O
L	O
versus	O
3.61	O
±	O
1.04	O
g	O
/	O
L	O
)	O
.	O
Using	O
ROC	O
statistic	O
,	O
a	O
cut	O
-	O
off	O
value	O
of	O
5.13	O
g	O
/	O
L	O
indicated	O
the	O
possible	O
amputation	B-T061
with	O
a	O
sensitivity	O
of	O
81.8	O
%	O
and	O
a	O
specificity	O
of	O
78.9	O
%	O
(	O
positive	O
predictive	O
value	O
[	O
PPV	O
]	O
78.6	O
%	O
,	O
negative	O
predictive	O
value	O
[	O
89.0	O
%	O
]	O
)	O
.	O
Fibrinogen	O
values	O
were	O
found	O
to	O
be	O
correlated	O
with	O
CRP	O
levels	O
,	O
neutrophil	B-T059
,	O
and	O
WBC	B-T059
count	I-T059
.	O
Conclusions	O
.	O
Fibrinogen	O
levels	O
might	O
be	O
a	O
valuable	O
tool	O
for	O
assessing	B-T058
the	O
disease	O
severity	O
and	O
monitoring	B-T058
the	O
disease	O
progression	O
in	O
patients	O
with	O
DFU	B-T047
.	O
      
Evaluation	B-T058
and	O
Treatment	O
of	O
Anemia	B-T047
in	O
Premature	B-T047
Infants	I-T047
Anemia	B-T047
in	O
preterm	O
infants	O
is	O
the	O
pathophysiological	O
process	O
with	O
greater	O
and	O
more	O
rapid	O
decline	O
in	O
hemoglobin	O
compared	O
to	O
the	O
physiological	O
anemia	B-T047
in	O
infants	O
.	O
There	O
is	O
a	O
need	O
for	O
transfusions	B-T061
and	O
administration	B-T061
of	O
human	B-T121
recombinant	I-T121
erythropoietin	I-T121
.	O
To	O
determine	O
the	O
frequency	O
of	O
anemia	B-T047
in	O
premature	B-T047
infants	I-T047
at	O
the	O
Pediatric	O
Clinic	O
,	O
University	O
Clinical	O
Center	O
Sarajevo	O
,	O
as	O
well	O
as	O
parameter	O
values	O
in	O
the	O
blood	B-T059
count	I-T059
of	O
premature	B-T047
infants	I-T047
and	O
to	O
explore	O
a	O
relationship	O
between	O
blood	B-T061
transfusions	I-T061
with	O
the	O
advent	O
of	O
intraventricular	O
hemorrhage	O
(	O
determine	O
treatment	O
outcome	O
in	O
preterm	O
infants	O
)	O
.	O
Research	O
is	O
retrospective	O
study	O
and	O
it	O
included	O
the	O
period	O
of	O
six	O
months	O
in	O
year	O
2014	O
.	O
Research	O
included	O
100	O
patients	O
,	O
gestational	O
age	O
<	O
37	O
weeks	O
(	O
premature	B-T047
infants	I-T047
)	O
.	O
Data	O
were	O
collected	O
by	O
examining	B-T033
the	O
medical	O
records	O
of	O
patients	O
at	O
the	O
Pediatric	O
Clinic	O
,	O
UCCS	O
.	O
The	O
first	O
group	O
of	O
patients	O
were	O
premature	B-T047
infants	I-T047
of	O
gestational	O
age	O
≤	O
32	O
weeks	O
(	O
62/100	O
)	O
and	O
the	O
second	O
group	O
were	O
premature	B-T047
infants	I-T047
of	O
gestational	O
age	O
33	O
-	O
37	O
weeks	O
(	O
38/100	O
)	O
.	O
Among	O
the	O
patients	O
,	O
5	O
%	O
were	O
boys	O
and	O
46	O
%	O
girls	O
.	O
There	O
was	O
significant	O
difference	O
in	O
birth	O
weight	O
and	O
APGAR	O
score	O
among	O
the	O
groups	O
.	O
In	O
the	O
first	O
group	O
,	O
there	O
were	O
27.42	O
%	O
of	O
deaths	B-T033
,	O
while	O
in	O
the	O
second	O
group	O
,	O
there	O
were	O
only	O
10.53	O
%	O
of	O
deaths	B-T033
.	O
There	O
was	O
a	O
significant	O
difference	O
in	O
the	O
length	O
of	O
treatment	O
.	O
There	O
was	O
a	O
statistically	O
significant	O
difference	O
in	O
the	O
need	O
for	O
transfusion	B-T061
among	O
the	O
groups	O
.	O
18	O
patients	O
in	O
the	O
first	O
group	O
required	O
a	O
transfusion	B-T061
,	O
while	O
in	O
the	O
second	O
group	O
only	O
3	O
patients	O
.	O
Preterm	O
infants	O
of	O
gestational	O
age	O
≤	O
32	O
weeks	O
are	O
likely	O
candidates	O
for	O
blood	B-T061
transfusion	I-T061
during	O
treatment	O
.	O
Preterm	O
infants	O
of	O
gestational	O
age	O
≤	O
32	O
weeks	O
have	O
the	O
risk	O
of	O
intracranial	B-T047
bleeding	I-T047
associated	O
with	O
the	O
application	B-T058
of	O
blood	B-T061
transfusion	I-T061
in	O
the	O
first	O
week	O
of	O
life	O
.	O
      
A	O
Window	O
on	O
the	O
Study	B-T061
of	I-T061
Aversive	I-T061
Instrumental	O
Learning	O
:	O
Strains	B-T001
,	O
Performance	O
,	O
Neuroendocrine	O
,	O
and	O
Immunologic	O
Systems	O
The	O
avoidance	O
response	O
is	O
present	O
in	O
pathological	O
anxiety	B-T033
and	O
interferes	O
with	O
normal	O
daily	O
functions	O
.	O
The	O
aim	O
of	O
this	O
article	O
is	O
to	O
shed	O
light	O
on	O
performance	O
markers	O
of	O
active	O
avoidance	O
(	O
AA	O
)	O
using	O
two	O
different	O
rat	O
strains	O
,	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
and	O
Wistar	O
.	O
Specifically	O
,	O
good	O
and	O
poor	O
performers	O
were	O
evaluated	B-T058
regarding	O
anxiety	B-T033
traits	O
exhibited	O
in	O
the	O
elevated	O
plus	O
maze	O
(	O
EPM	O
)	O
and	O
corticosterone	B-T059
levels	I-T059
and	O
motor	O
activity	O
in	O
the	O
open	B-T059
field	I-T059
test	I-T059
.	O
In	O
addition	O
,	O
the	O
plasma	B-T059
levels	I-T059
of	O
Interleukin-6	O
(	O
IL-6	O
)	O
,	O
Interleukin-1Beta	O
(	O
IL-1beta	O
)	O
,	O
Nerve	O
Growth	O
Factor	O
Beta	O
(	O
NGF	O
-	O
beta	O
)	O
,	O
Tumor	O
Necrosis	O
Factor	O
-	O
Alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
1	O
(	O
CINC-1	O
)	O
were	O
compared	O
in	O
the	O
good	O
and	O
poor	O
performers	O
to	O
better	O
understand	O
the	O
role	O
of	O
the	O
immunologic	O
system	O
in	O
aversive	B-T061
learning	I-T061
.	O
Behavioral	O
criteria	O
were	O
employed	O
to	O
identify	O
subpopulations	O
of	O
SD	O
and	O
Wistar	O
rats	O
based	O
on	O
their	O
behavioral	O
scores	O
during	O
a	O
two	O
-	O
way	O
AA	O
test	O
.	O
The	O
animals	O
were	O
tested	O
for	O
anxiety	B-T033
-like	O
behavior	O
in	O
the	O
EPM	O
and	O
motor	O
activity	O
in	O
the	O
open	B-T059
-	I-T059
field	I-T059
test	I-T059
.	O
Plasma	B-T059
corticosterone	I-T059
levels	I-T059
were	O
measured	O
at	O
the	O
end	O
of	O
the	O
avoidance	O
test	O
.	O
Cytokine	B-T059
levels	I-T059
of	O
IL-6	O
,	O
IL-1beta	O
,	O
NGF	O
-	O
beta	O
,	O
TNF	O
-	O
alpha	O
,	O
and	O
CINC-1	O
were	O
measured	O
in	O
the	O
plasma	O
of	O
the	O
Wistar	O
rats	O
.	O
Sixty	O
-	O
six	O
percent	O
of	O
the	O
Wistar	O
rats	O
and	O
35	O
%	O
of	O
the	O
SD	O
rats	O
exhibited	O
a	O
poor	O
performance	O
.	O
This	O
feature	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
anxiety	B-T033
-like	O
behavior	O
in	O
the	O
EPM	O
.	O
The	O
poor	O
and	O
good	O
performers	O
exhibited	O
lower	O
levels	B-T059
of	I-T059
corticosterone	I-T059
compared	O
with	O
the	O
control	O
animals	O
,	O
which	O
suggests	O
that	O
training	O
alters	O
corticosterone	B-T059
levels	I-T059
,	O
thereby	O
leading	O
to	O
hypocortisolism	B-T047
,	O
independent	O
of	O
the	O
performance	O
.	O
The	O
CINC-1	O
levels	O
were	O
increased	O
in	O
the	O
poor	O
performers	O
,	O
which	O
reinforces	O
the	O
role	O
of	O
immunologic	O
system	O
activation	O
in	O
learning	B-T048
deficits	I-T048
.	O
Our	O
study	O
provides	O
a	O
better	O
understanding	O
of	O
the	O
complex	O
interactions	O
that	O
underlie	O
neuroimmune	O
consequences	O
and	O
their	O
implications	O
for	O
performance	O
.	O
      
Assessment	B-T058
and	O
classification	O
of	O
protocol	B-T033
deviations	I-T033
Deviations	B-T033
from	O
the	O
approved	O
trial	O
protocol	O
are	O
common	O
during	O
clinical	O
trials	O
.	O
They	O
have	O
been	O
conventionally	O
classified	O
as	O
deviations	B-T033
or	O
violations	O
,	O
depending	O
on	O
their	O
impact	O
on	O
the	O
trial	O
.	O
A	O
new	O
method	O
has	O
been	O
proposed	O
by	O
which	O
deviations	B-T033
are	O
classified	O
in	O
five	O
grades	O
from	O
1	O
to	O
5	O
.	O
A	O
deviation	B-T033
of	O
Grade	B-T033
1	I-T033
has	O
no	B-T033
impact	O
on	O
the	O
subjects	O
'	O
well	B-T033
-	I-T033
being	I-T033
or	O
on	O
the	O
quality	O
of	O
data	O
.	O
At	O
the	O
maximum	O
,	O
a	O
deviation	B-T033
Grade	O
5	O
leads	O
to	O
the	O
death	B-T033
of	O
the	O
subject	O
.	O
This	O
method	O
of	O
classification	O
was	O
applied	O
to	O
deviations	B-T033
noted	O
in	O
the	O
center	O
over	O
the	O
last	O
3	O
years	O
.	O
It	O
was	O
observed	O
that	O
most	O
deviations	B-T033
were	O
of	O
Grades	O
1	O
and	O
2	O
,	O
with	O
fewer	O
falling	O
in	O
Grades	O
3	O
and	O
4	O
.	O
There	O
were	O
no	O
deviations	B-T033
that	O
led	O
to	O
the	O
death	B-T033
of	I-T033
the	I-T033
subject	I-T033
(	O
Grade	O
5	O
)	O
.	O
This	O
method	O
of	O
classification	O
would	O
help	O
trial	O
managers	O
decide	O
on	O
the	O
action	O
to	O
be	O
taken	O
on	O
the	O
occurrence	O
of	O
deviations	B-T033
,	O
which	O
would	O
be	O
based	O
on	O
their	O
impact	O
.	O
      
A	O
Wnt	O
Pathway	O
Activator	B-T121
Induces	O
Apoptosis	O
and	O
Cell	O
Death	O
in	O
Mouse	B-T191
Monocytic	I-T191
Leukemia	I-T191
Cells	O
A	O
Wnt	B-T121
agonist	I-T121
,	I-T121
2	B-T121
-	I-T121
amino-4-[3,4-(methylenedioxy)benzylamino]-6-(3	I-T121
-	I-T121
methoxyphenyl	I-T121
)	I-T121
pyrimidine	I-T121
,	O
is	O
a	O
cell	O
-	O
permeable	O
pyrimidine	B-T121
compound	I-T121
that	O
has	O
been	O
shown	O
to	O
mimic	O
the	O
effect	O
of	O
Wnt	O
.	O
In	O
this	O
study	O
,	O
leukemic	O
mouse	O
cell	O
lines	O
,	O
RAW	O
264.7	O
and	O
J774.1	O
,	O
were	O
incubated	O
with	O
the	O
Wnt	B-T121
agonist	I-T121
.	O
The	O
Wnt	B-T121
agonist	I-T121
showed	O
cell	O
death	O
in	O
the	O
concentration	O
of	O
1	O
-	O
10	O
μM.	O
The	O
Wnt	B-T121
agonist	I-T121
did	O
not	O
show	O
inhibition	O
of	O
GSK-3β	O
activity	O
but	O
induced	O
β	O
-	O
catenin	O
accumulation	O
in	O
the	O
nucleus	O
.	O
The	O
Wnt	B-T121
agonist	I-T121
showed	O
caspase	O
-	O
independent	O
cell	O
death	O
,	O
but	O
no	O
further	O
involvement	O
in	O
cell	O
death	O
ER	O
stress	O
signaling	O
.	O
Here	O
we	O
discuss	O
the	O
possible	O
mechanism	O
of	O
Wnt	B-T121
agonist	I-T121
-	O
induced	O
apoptotic	O
cell	O
death	O
in	O
RAW	O
264.7	O
cells	O
.	O
      
Tyrphostin	B-T121
AG	I-T121
-	I-T121
related	I-T121
compounds	I-T121
attenuate	O
H2O2	B-T121
-	O
induced	O
TRPM2	O
-	O
dependent	O
and	O
-	O
independent	O
cellular	O
responses	O
TRPM2	O
is	O
a	O
Ca(2+)-permeable	O
channel	O
that	O
is	O
activated	O
by	O
H2O2	B-T121
.	O
TRPM2	O
-mediated	O
Ca(2	O
+	O
)	O
signaling	O
has	O
been	O
implicated	O
in	O
the	O
aggravation	B-T033
of	O
inflammatory	B-T047
diseases	I-T047
.	O
Therefore	O
,	O
the	O
development	O
of	O
TRPM2	O
inhibitors	B-T121
to	O
prevent	O
the	O
aggravation	B-T033
of	O
these	O
diseases	B-T047
is	O
expected	O
.	O
We	O
recently	O
reported	O
that	O
some	O
Tyrphostin	B-T121
AG	I-T121
-	I-T121
related	I-T121
compounds	I-T121
inhibited	O
the	O
H2O2	B-T121
-	O
induced	O
activation	O
of	O
TRPM2	O
by	O
scavenging	O
the	O
intracellular	O
hydroxyl	O
radical	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
effects	O
of	O
AG	B-T121
-	I-T121
related	I-T121
compounds	I-T121
on	O
H2O2	B-T121
-	O
induced	O
cellular	O
responses	O
in	O
human	O
monocytic	O
U937	O
cells	O
,	O
which	O
functionally	O
express	O
TRPM2	O
.	O
The	O
effects	O
of	O
AG	B-T121
-	I-T121
related	I-T121
compounds	I-T121
on	O
H2O2	B-T121
-	O
induced	O
changes	O
in	O
intracellular	O
Ca(2	B-T121
+	I-T121
)	I-T121
concentrations	O
,	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
activation	O
,	O
and	O
CXCL8	O
secretion	O
were	O
assessed	O
using	O
U937	O
cells	O
.	O
Ca(2	O
+	O
)	O
influxes	O
via	O
TRPM2	O
in	O
response	O
to	O
H2O2	B-T121
were	O
blocked	O
by	O
AG	B-T121
-	I-T121
related	I-T121
compounds	I-T121
.	O
AG	B-T121
-	I-T121
related	I-T121
compounds	I-T121
also	O
inhibited	O
the	O
H2O2	B-T121
-	O
induced	O
activation	O
of	O
ERK	O
,	O
and	O
subsequent	O
secretion	O
of	O
CXCL8	O
mediated	O
by	O
TRPM2	O
-	O
dependent	O
and	O
-	O
independent	O
mechanisms	O
.	O
Our	O
results	O
show	O
that	O
AG	B-T121
-	I-T121
related	I-T121
compounds	I-T121
inhibit	O
H2O2	B-T121
-	O
induced	O
CXCL8	O
secretion	O
following	O
ERK	O
activation	O
,	O
which	O
is	O
mediated	O
by	O
TRPM2	O
-	O
dependent	O
and	O
-	O
independent	O
mechanisms	O
in	O
U937	O
cells	O
.	O
We	O
previously	O
reported	O
that	O
AG	B-T121
-	I-T121
related	I-T121
compounds	I-T121
blocked	O
H2O2	B-T121
-	O
induced	O
TRPM2	O
activation	O
by	O
scavenging	O
the	O
hydroxyl	O
radical	O
.	O
The	O
inhibitory	O
effects	O
of	O
AG	B-T121
-	I-T121
related	I-T121
compounds	I-T121
on	O
TRPM2	O
-	O
independent	O
responses	O
may	O
be	O
due	O
to	O
scavenging	O
of	O
the	O
hydroxyl	O
radical	O
.	O
      
Effect	O
of	O
magnesium	B-T061
supplementation	I-T061
on	O
depression	B-T048
status	B-T033
in	O
depressed	B-T048
patients	O
with	O
magnesium	B-T047
deficiency	I-T047
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
magnesium	B-T061
supplementation	I-T061
on	O
the	O
depression	B-T048
status	B-T033
of	O
depressed	B-T048
patients	O
suffering	B-T033
from	O
magnesium	B-T047
deficiency	I-T047
.	O
Sixty	B-T033
depressed	I-T033
people	I-T033
suffering	B-T033
from	O
hypomagnesemia	B-T033
participated	O
in	O
this	O
trial	O
.	O
The	O
individuals	O
were	O
randomly	O
categorized	O
into	O
two	O
groups	O
of	O
30	O
members	O
;	O
one	O
receiving	O
two	O
250	O
-	O
mg	O
tablets	B-T121
of	I-T121
magnesium	I-T121
oxide	I-T121
(	O
MG	B-T121
)	O
daily	O
and	O
the	O
other	O
receiving	O
placebo	O
(	O
PG	O
)	O
for	O
8	O
wk	O
.	O
The	O
Beck	B-T060
Depression	I-T060
Inventory	I-T060
-	I-T060
II	I-T060
was	O
conducted	O
and	O
the	O
concentration	O
of	O
serum	B-T059
magnesium	I-T059
was	I-T059
measured	I-T059
.	O
At	O
the	O
end	O
of	O
intervention	O
,	O
88.5	O
%	O
of	O
the	O
MG	B-T121
and	O
48.1	O
%	O
of	O
the	O
PG	O
(	O
P	O
=	O
0.002	O
)	O
had	O
a	O
normal	O
level	O
of	O
magnesium	O
.	O
The	O
mean	O
changes	B-T033
of	I-T033
serum	I-T033
magnesium	I-T033
were	O
significantly	O
different	O
across	O
the	O
two	O
groups	O
.	O
After	O
the	O
intervention	O
,	O
the	O
mean	O
Beck	O
score	O
significantly	O
declined	O
.	O
However	O
,	O
in	O
the	O
MG	B-T121
,	O
this	O
reduction	O
was	O
more	O
significant	O
than	O
in	O
the	O
PG	O
(	O
P	O
=	O
0.02	O
)	O
,	O
so	O
that	O
the	O
mean	O
changes	O
in	O
this	O
group	O
experienced	O
15.65	O
±	O
8.9	O
reduction	O
,	O
but	O
in	O
the	O
PG	O
,	O
it	O
declined	O
by	O
10.40	O
±	O
7.9	O
.	O
Daily	O
consumption	O
of	O
500	O
mg	O
magnesium	B-T121
oxide	I-T121
tablets	I-T121
for	O
≥8	O
wk	O
by	O
depressed	B-T048
patients	O
suffering	B-T033
from	O
magnesium	B-T047
deficiency	I-T047
leads	O
to	O
improvements	O
in	O
depression	B-T048
status	B-T033
and	O
magnesium	O
levels	O
.	O
Therefore	O
,	O
assessment	B-T059
of	I-T059
the	I-T059
magnesium	I-T059
serum	I-T059
and	O
resolving	O
this	O
deficiency	B-T047
positively	O
influence	O
the	O
treatment	B-T061
of	O
depressed	B-T048
patients	O
.	O
      
Resistance	O
Exercise	O
in	O
Pregnancy	O
and	O
Outcome	B-T033
As	O
the	O
health	O
benefits	O
of	O
exercise	O
are	O
increasingly	O
recognized	O
,	O
the	O
traditional	B-T058
advice	I-T058
to	O
rest	O
during	O
pregnancy	O
has	O
changed	O
toward	O
a	O
more	O
healthy	O
and	O
active	O
pregnancy	O
,	O
therefore	O
different	O
forms	O
of	O
exercise	O
have	O
been	O
integrated	O
into	O
the	O
life	O
of	O
the	O
pregnant	O
woman	O
.	O
Although	O
the	O
benefits	O
of	O
using	O
a	O
combination	O
of	O
resistance	O
and	O
aerobic	B-T061
exercises	I-T061
are	O
not	O
yet	O
determined	O
,	O
studies	O
about	O
resistance	O
and	O
strengthen	O
training	O
programs	O
are	O
few	O
although	O
no	B-T184
adverse	I-T184
outcomes	B-T033
were	O
reported	O
.	O
      
Biochemical	O
characteristics	O
of	O
AtFAR2	O
,	O
a	O
fatty	O
acid	O
reductase	O
from	O
Arabidopsis	O
thaliana	O
that	O
reduces	O
fatty	O
acyl	O
-	O
CoA	O
and	O
-	O
ACP	O
substrates	O
into	O
fatty	O
alcohols	O
Fatty	O
alcohols	O
and	O
derivatives	O
are	O
important	O
for	O
proper	O
deposition	O
of	O
a	O
functional	O
pollen	O
wall	O
.	O
Mutations	O
in	O
specific	O
genes	O
encoding	O
fatty	O
acid	O
reductases	O
(	O
FAR	O
)	O
responsible	O
for	O
fatty	O
alcohol	O
production	O
cause	O
abnormal	B-T033
development	O
of	O
pollen	O
.	O
A	O
disrupted	O
AtFAR2	O
(	O
MS2	O
)	O
gene	O
in	O
Arabidopsis	O
thaliana	O
results	O
in	O
pollen	O
developing	O
an	O
abnormal	B-T033
exine	O
layer	O
and	O
a	O
reduced	B-T033
fertility	I-T033
phenotype	O
.	O
AtFAR2	O
has	O
been	O
shown	O
to	O
be	O
targeted	O
to	O
chloroplasts	O
and	O
in	O
a	O
purified	O
form	O
to	O
be	O
specific	O
for	O
acyl	O
-	O
ACP	O
substrates	O
.	O
Here	O
,	O
we	O
present	O
data	O
on	O
the	O
in	O
vitro	O
and	O
in	O
planta	O
characterizations	O
of	O
AtFAR2	O
from	O
A.	O
thaliana	O
and	O
show	O
that	O
this	O
enzyme	O
has	O
the	O
ability	O
to	O
use	O
both	O
,	O
C16:0	O
-	O
ACP	O
and	O
C16:0	O
-	O
CoA	O
,	O
as	O
substrates	O
to	O
produce	O
C16:0	O
-	O
alcohol	O
.	O
Our	O
results	O
further	O
show	O
that	O
AtFAR2	O
is	O
highly	O
similar	O
in	O
properties	O
and	O
substrate	O
specificity	O
to	O
AtFAR6	O
for	O
which	O
in	O
vitro	O
data	O
has	O
been	O
published	O
,	O
and	O
which	O
is	O
also	O
a	O
chloroplast	O
localized	O
enzyme	O
.	O
This	O
suggests	O
that	O
although	O
AtFAR2	O
is	O
the	O
major	O
enzyme	O
responsible	O
for	O
exine	O
layer	O
functionality	O
,	O
AtFAR6	O
might	O
provide	O
functional	O
redundancy	O
to	O
AtFAR2	O
.	O
      
The	O
Use	O
of	O
a	O
Software	O
-	O
Assisted	O
Method	O
to	O
Estimate	O
Fetal	O
Weight	O
at	O
and	O
Near	O
Term	O
Using	O
Magnetic	B-T060
Resonance	I-T060
Imaging	I-T060
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
apply	O
a	O
semi	O
-	O
automated	O
calculation	O
method	O
of	O
fetal	B-T018
body	O
volume	O
and	O
,	O
thus	O
,	O
of	O
magnetic	O
resonance	O
-	O
estimated	O
fetal	O
weight	O
(	O
MR	O
-	O
EFW	O
)	O
prior	O
to	O
planned	O
delivery	O
and	O
to	O
evaluate	B-T058
whether	O
the	O
technique	O
of	O
measurement	O
could	O
be	O
simplified	O
while	O
remaining	O
accurate	O
.	O
MR	O
-	O
EFW	O
was	O
calculated	O
using	O
a	O
semi	O
-	O
automated	O
method	O
at	O
38.6	O
weeks	O
of	O
gestation	O
in	O
36	O
patients	O
and	O
compared	O
to	O
the	O
picture	O
archiving	O
and	O
communication	O
system	O
(	O
PACS	O
)	O
.	O
Per	O
patient	O
,	O
8	O
sequences	O
were	O
acquired	O
with	O
a	O
slice	O
thickness	O
of	O
4	O
-	O
8	O
mm	O
and	O
an	O
intersection	O
gap	O
of	O
0	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
16	O
,	O
or	O
20	O
mm	O
.	O
The	O
median	O
absolute	O
relative	O
errors	O
for	O
MR	O
-	O
EFW	O
and	O
the	O
time	O
of	O
planimetric	O
measurements	O
were	O
calculated	O
for	O
all	O
8	O
sequences	O
and	O
for	O
each	O
method	O
(	O
assisted	O
vs.	O
PACS	O
)	O
,	O
and	O
the	O
difference	O
between	O
the	O
methods	O
was	O
calculated	O
.	O
The	O
median	O
delivery	O
weight	O
was	O
3,280	O
g.	O
The	O
overall	O
median	O
relative	O
error	O
for	O
all	O
288	O
MR	O
-	O
EFW	O
calculations	O
was	O
2.4	O
%	O
using	O
the	O
semi	O
-	O
automated	O
method	O
and	O
2.2	O
%	O
for	O
the	O
PACS	O
method	O
.	O
Measurements	O
did	O
not	O
differ	O
between	O
the	O
8	O
sequences	O
using	O
the	O
assisted	O
method	O
(	O
p	O
=	O
0.313	O
)	O
or	O
the	O
PACS	O
(	O
p	O
=	O
0.118	O
)	O
,	O
while	O
the	O
time	O
of	O
planimetric	O
measurement	O
decreased	O
significantly	O
with	O
a	O
larger	O
gap	O
(	O
p	O
<	O
0.001	O
)	O
and	O
in	O
the	O
assisted	O
method	O
compared	O
to	O
the	O
PACS	O
method	O
(	O
p	O
<	O
0.01	O
)	O
.	O
Our	O
simplified	O
MR	O
-	O
EFW	O
measurement	O
showed	O
a	O
dramatic	O
decrease	O
in	O
time	O
of	O
planimetric	O
measurement	O
without	O
a	O
decrease	O
in	O
the	O
accuracy	O
of	O
weight	O
estimates	O
.	O
      
Multisensory	O
Integration	O
in	O
the	O
Virtual	B-T048
Hand	I-T048
Illusion	I-T048
with	O
Active	O
Movement	O
Improving	O
the	O
sense	B-T033
of	I-T033
immersion	I-T033
is	O
one	O
of	O
the	O
core	O
issues	O
in	O
virtual	O
reality	O
.	O
Perceptual	B-T048
illusions	I-T048
of	O
ownership	O
can	O
be	O
perceived	O
over	O
a	O
virtual	O
body	O
in	O
a	O
multisensory	B-T061
virtual	O
reality	O
environment	O
.	O
Rubber	O
Hand	O
and	O
Virtual	B-T048
Hand	I-T048
Illusions	I-T048
showed	O
that	O
body	O
ownership	O
can	O
be	O
manipulated	O
by	O
applying	O
suitable	O
visual	B-T061
and	O
tactile	B-T061
stimulation	I-T061
.	O
In	O
this	O
study	O
,	O
we	O
investigate	O
the	O
effects	O
of	O
multisensory	O
integration	O
in	O
the	O
Virtual	B-T048
Hand	I-T048
Illusion	I-T048
with	O
active	O
movement	O
.	O
A	O
virtual	O
xylophone	O
playing	O
system	O
which	O
can	O
interactively	O
provide	O
synchronous	O
visual	B-T061
,	O
tactile	B-T061
,	O
and	O
auditory	B-T061
stimulation	I-T061
was	O
constructed	O
.	O
We	O
conducted	O
two	O
experiments	O
regarding	O
different	O
movement	O
conditions	O
and	O
different	O
sensory	B-T061
stimulations	I-T061
.	O
Our	O
results	O
demonstrate	O
that	O
multisensory	O
integration	O
with	O
free	O
active	O
movement	O
can	O
improve	O
the	O
sense	O
of	O
immersion	O
in	O
virtual	O
reality	O
.	O
      
Genotyping	B-T059
of	O
German	O
and	O
Austrian	O
Taylorella	B-T007
equigenitalis	I-T007
isolates	O
using	O
repetitive	O
extragenic	O
palindromic	O
(	O
REP	O
)	O
PCR	O
and	O
pulsed	B-T059
-	I-T059
field	I-T059
gel	I-T059
electrophoresis	I-T059
(	O
PFGE	B-T059
)	O
A	O
total	O
of	O
124	O
Taylorella	B-T007
(	I-T007
T.	I-T007
)	I-T007
equigenitalis	I-T007
and	O
five	O
T.	B-T007
asinigenitalis	I-T007
field	O
isolates	O
collected	O
between	O
2002	O
and	O
2014	O
were	O
available	O
for	O
genotyping	B-T059
using	O
REP-	O
(	O
repetitive	O
extragenic	O
palindromic	O
)	O
PCR	O
and	O
PFGE	B-T059
(	O
pulsed	B-T059
-	I-T059
field	I-T059
gel	I-T059
electrophoresis	I-T059
)	O
.	O
The	O
study	O
comprised	O
79	O
T.	B-T007
equigenitalis	I-T007
field	O
isolates	O
originating	O
from	O
ten	O
defined	O
breeds	O
of	O
German	O
horses	O
and	O
revealed	O
a	O
spectrum	O
of	O
five	O
REP	O
(	O
rep	O
-	O
E1	O
-	O
E4	O
,	O
rep	O
-	O
E3a	O
)	O
and	O
15	O
PFGE	B-T059
(	O
TE	O
-	O
A1	O
-	O
A9	O
,	O
TE	O
-	O
B1	O
-	O
B3	O
,	O
TE	O
-	O
C	O
,	O
TE	O
-	O
E1	O
,	O
and	O
TE	O
-	O
E2	O
)	O
genotypes	O
.	O
T.	B-T007
equigenitalis	I-T007
field	O
isolates	O
(	O
n=40	O
)	O
obtained	O
from	O
Austrian	O
Lipizzaner	O
horses	O
were	O
differentiated	O
into	O
three	O
REP	O
(	O
rep	O
-	O
E1	O
,	O
rep	O
-	O
E3a	O
,	O
and	O
rep	O
-	O
E4	O
)	O
and	O
three	O
PFGE	B-T059
genotypes	O
(	O
TE	O
-	O
A2	O
,	O
TE	O
-	O
A5	O
,	O
and	O
TE	O
-	O
D	O
)	O
;	O
those	O
isolated	O
from	O
four	O
Austrian	O
Trotters	O
belonged	O
to	O
the	O
REP	O
/	O
PFGE	B-T059
genotype	O
rep	O
-	O
E2	O
/	O
TE	O
-	O
A1	O
.	O
Interestingly	O
,	O
a	O
T.	B-T007
equigenitalis	I-T007
isolate	O
recovered	O
from	O
a	O
Holsteiner	O
stallion	O
living	O
in	O
South	O
Africa	O
revealed	O
the	O
REP	O
/	O
PFGE	B-T059
genotype	O
rep	O
-	O
E1	O
/	O
TE	O
-	O
A5	O
which	O
was	O
otherwise	O
exclusively	O
present	B-T033
in	O
the	O
majority	O
of	O
Austrian	O
Lipizzaner	O
horses	O
in	O
our	O
study	O
.	O
The	O
type	O
strain	B-T001
included	O
in	O
this	O
study	O
revealed	O
the	O
genotype	O
REP	O
/	O
PFGE	B-T059
rep	O
-	O
E1	O
/	O
TE	O
-	O
F.	O
Six	O
strains	B-T001
of	O
T.	B-T007
asinigenitalis	I-T007
including	O
the	O
type	O
strain	B-T001
were	O
separated	O
into	O
three	O
REP	O
(	O
rep	O
-	O
A1	O
-	O
A3	O
)	O
and	O
six	O
PFGE	B-T059
genotypes	O
(	O
TA	O
-	O
A1	O
,	O
TA	O
-	O
A2	O
,	O
TA	O
-	O
A3	O
,	O
TA	O
-	O
B	O
,	O
TA	O
-	O
C	O
,	O
TA	O
-	O
D	O
)	O
.	O
Overall	O
,	O
the	O
generated	O
REP	O
and	O
PFGE	B-T059
genotypes	O
showed	O
a	O
good	O
correlation	O
,	O
whereas	O
REP	O
-	O
PCR	O
proved	O
to	O
be	O
a	O
suitable	B-T059
method	I-T059
for	O
molecular	B-T059
epidemiological	I-T059
screening	I-T059
of	O
T.	B-T007
equigenitalis	I-T007
and	O
T.	B-T007
asinigenitalis	I-T007
isolates	O
that	O
should	O
be	O
differentiated	O
in	O
detail	O
by	O
genotyping	B-T059
using	O
PFGE	B-T059
.	O
      
The	O
impact	O
on	O
productivity	O
of	O
a	O
hypothetical	O
tax	O
on	O
sugar	O
-	O
sweetened	O
beverages	O
To	O
quantify	O
the	O
potential	O
impact	O
of	O
an	O
additional	O
20	O
%	O
tax	O
on	O
sugar	O
-	O
sweetened	O
beverages	O
(	O
SSBs	O
)	O
on	O
productivity	O
in	O
Australia	O
.	O
We	O
used	O
a	O
multi	O
-	O
state	O
lifetable	O
Markov	O
model	O
to	O
examine	B-T033
the	O
potential	O
impact	O
of	O
an	O
additional	O
20	O
%	O
tax	O
on	O
SSBs	O
on	O
total	O
lifetime	O
productivity	O
in	O
the	O
paid	O
and	O
unpaid	O
sectors	O
of	O
the	O
economy	O
.	O
The	O
study	O
population	O
consisted	O
of	O
Australians	O
aged	O
20	O
years	O
or	O
older	O
in	O
2010	O
,	O
whose	O
health	O
and	O
other	O
relevant	O
outcomes	O
were	O
modelled	O
over	O
their	O
remaining	O
lifetime	O
.	O
The	O
SSBs	O
tax	O
was	O
estimated	O
to	O
reduce	O
the	O
number	O
of	O
people	O
with	O
obesity	B-T047
by	O
1.96	O
%	O
of	O
the	O
entire	O
population	O
(	O
437,000	O
fewer	O
persons	O
with	O
obesity	B-T047
)	O
,	O
and	O
reduce	O
the	O
number	O
of	O
employees	O
with	O
obesity	B-T047
by	O
317,000	O
persons	O
.	O
These	O
effects	O
translated	O
into	O
productivity	O
gains	O
in	O
the	O
paid	O
sector	O
of	O
AU$751	O
million	O
for	O
the	O
working	O
-	O
age	O
population	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
AU$565	O
million	O
to	O
AU$954	O
million	O
)	O
,	O
using	O
the	O
human	O
capital	O
approach	O
.	O
In	O
the	O
unpaid	O
sector	O
,	O
the	O
potential	O
productivity	O
gains	O
amounted	O
to	O
AU$1172	O
million	O
(	O
AU$929	O
million	O
to	O
AU$1435	O
million	O
)	O
using	O
the	O
replacement	O
cost	O
method	O
.	O
These	O
productivity	O
benefits	O
are	O
in	O
addition	O
to	O
the	O
health	O
benefits	O
of	O
35,000	O
life	O
years	O
gained	O
and	O
a	O
reduction	O
in	O
healthcare	O
costs	O
of	O
AU$425	O
million	O
.	O
An	O
additional	O
20	O
%	O
tax	O
on	O
SSBs	O
not	O
only	O
improves	B-T033
health	O
outcomes	O
and	O
reduces	O
healthcare	O
costs	O
,	O
but	O
provides	O
productivity	O
gains	O
in	O
both	O
the	O
paid	O
and	O
unpaid	O
sectors	O
of	O
the	O
economy	O
.	O
      
Tooth	O
wear	O
as	O
a	O
means	O
to	O
quantify	O
intra	O
-	O
specific	O
variations	O
in	O
diet	O
and	O
chewing	O
movements	O
In	O
mammals	O
,	O
tooth	B-T023
function	O
,	O
and	O
its	O
efficiency	O
,	O
depends	O
both	O
on	O
the	O
mechanical	O
properties	O
of	O
the	O
food	O
and	O
on	O
chewing	O
dynamics	O
.	O
These	O
aspects	O
have	O
rarely	O
been	O
studied	O
in	O
combination	O
and/or	O
at	O
the	O
intra	O
-	O
specific	O
level	O
.	O
Here	O
we	O
applied	O
3D	O
dental	B-T023
surface	O
texture	O
analysis	O
to	O
a	O
sample	O
of	O
field	O
voles	O
(	O
Microtus	O
agrestis	O
)	O
trapped	O
from	O
Finnish	O
Lapland	O
at	O
different	O
seasons	O
and	O
localities	O
to	O
test	O
for	O
inter	O
-	O
population	O
variations	O
.	O
We	O
also	O
explored	O
intra	O
-	O
individual	O
variation	O
in	O
chewing	O
dynamics	O
by	O
analysing	O
two	O
facets	O
on	O
the	O
second	B-T023
upper	I-T023
molars	I-T023
.	O
Our	O
results	B-T033
confirm	O
that	O
the	O
two	O
localities	O
have	O
similar	O
environments	O
and	O
that	O
the	O
voles	O
feed	O
on	O
the	O
same	O
items	O
there	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
texture	O
data	O
suggest	O
that	O
diets	O
are	O
seasonally	O
variable	O
,	O
probably	O
due	O
to	O
varying	O
concentrations	O
of	O
abrasives	O
.	O
Lastly	O
,	O
the	O
textures	O
on	O
the	O
buccal	O
facets	O
are	O
more	O
isotropic	O
and	O
their	O
direction	O
deviates	O
more	O
from	O
the	O
mesial	O
chewing	O
direction	O
than	O
the	O
lingual	B-T023
facets	O
.	O
We	O
interpret	O
these	O
results	B-T033
as	O
reflecting	O
food	O
,	O
rather	O
than	O
chewing	O
,	O
movements	O
,	O
where	O
food	O
particles	O
are	O
more	O
guided	O
on	O
the	O
lingual	B-T023
side	O
of	O
the	O
molars	B-T023
.	O
This	O
has	O
implications	O
for	O
the	O
application	O
of	O
dental	O
microwear	O
analysis	O
to	O
fossils	O
:	O
only	O
homologous	O
facets	O
can	O
be	O
compared	O
,	O
even	O
when	O
the	O
molar	B-T023
row	O
seems	O
to	O
constitute	O
a	O
functional	O
unit	O
.	O
      
Physical	O
activity	O
limits	O
the	O
effects	O
of	O
age	O
and	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
on	O
postural	O
control	O
The	O
aim	O
was	O
to	O
study	O
the	O
possible	O
influence	O
of	O
physical	O
activity	O
on	O
the	O
postural	O
performance	O
of	O
subjects	O
with	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
(	O
AD	B-T047
)	O
.	O
The	O
postural	O
performance	O
(	O
i.e.	O
surface	O
area	O
of	O
the	O
center	O
of	O
foot	O
pressure	O
displacement	O
)	O
of	O
3	O
groups	O
was	O
compared	O
:	O
Alzheimer	O
active	O
group	O
(	O
AA	O
)	O
,	O
Alzheimer	O
non	O
-	O
active	O
group	O
(	O
ANA	O
)	O
and	O
healthy	O
non	O
-	O
active	O
group	O
(	O
HNA	O
)	O
.	O
The	O
AA	O
group	O
's	O
postural	O
performance	O
was	O
superior	O
to	O
that	O
of	O
the	O
ANA	O
and	O
HNA	O
groups	O
.	O
AD	B-T047
disturbed	O
postural	O
performance	O
but	O
participation	O
in	O
regular	O
physical	O
activity	O
made	O
it	O
possible	O
to	O
limit	O
the	O
disturbing	O
effects	O
of	O
AD	B-T047
to	O
a	O
surprising	O
extent	O
,	O
since	O
the	O
postural	O
performance	O
of	O
active	O
AD	O
subjects	O
was	O
also	O
superior	O
to	O
that	O
of	O
healthy	O
subjects	O
.	O
      
Bacteria	B-T007
from	O
Wheat	O
and	O
Cucurbit	O
Plant	O
Roots	O
Metabolize	O
PAHs	O
and	O
Aromatic	O
Root	O
Exudates	O
:	O
Implications	O
for	O
Rhizodegradation	O
The	O
chemical	O
interaction	O
between	O
plants	O
and	O
bacteria	B-T007
in	O
the	O
root	O
zone	O
can	O
lead	O
to	O
soil	O
decontamination	O
.	O
Bacteria	B-T007
which	O
degrade	O
PAHs	O
have	O
been	O
isolated	O
from	O
the	O
rhizospheres	O
of	O
plant	O
species	O
with	O
varied	O
biological	O
traits	O
,	O
however	O
,	O
it	O
is	O
not	O
known	O
what	O
phytochemicals	O
promote	O
contaminant	O
degradation	O
.	O
One	O
monocot	O
and	O
two	O
dicotyledon	O
plants	O
were	O
grown	O
in	O
PAH	O
-	O
contaminated	O
soil	O
from	O
a	O
manufactured	O
gas	O
plant	O
(	O
MGP	O
)	O
site	O
.	O
A	O
phytotoxicity	B-T059
assay	I-T059
confirmed	O
greater	O
soil	O
decontamination	O
in	O
rhizospheres	O
when	O
compared	O
to	O
bulk	O
soil	O
controls	O
.	O
Bacteria	B-T007
were	O
isolated	O
from	O
plant	O
roots	O
(	O
rhizobacteria	B-T007
)	O
and	O
selected	O
for	O
growth	O
on	O
anthracene	O
and	O
chrysene	O
on	O
PAH	O
-	O
amended	O
plates	O
.	O
Rhizosphere	O
isolates	O
metabolized	O
3-	O
and	O
4	O
-	O
ring	O
PAHs	O
and	O
PAH	O
catabolic	O
intermediates	O
in	O
liquid	B-T059
incubations	I-T059
.	O
Aromatic	O
root	O
exudate	O
compounds	O
,	O
namely	O
flavonoids	O
and	O
simple	B-T121
phenols	I-T121
,	O
were	O
also	O
substrates	O
for	O
isolated	O
rhizobacteria	B-T007
.	O
In	O
particular	O
,	O
the	O
phenolic	B-T121
compounds	I-T121
-	O
morin	B-T121
,	O
caffeic	B-T121
acid	I-T121
,	O
and	O
protocatechuic	B-T121
acid	I-T121
-	O
appear	O
to	O
be	O
linked	O
to	O
bacterial	B-T007
degradation	O
of	O
3-	O
and	O
4-	O
ring	O
PAHs	O
in	O
the	O
rhizosphere	O
.	O
      
Mismatch	O
Repair	O
Incompatibilities	O
in	O
Diverse	O
Yeast	O
Populations	O
An	O
elevated	O
mutation	O
rate	O
can	O
provide	O
cells	O
with	O
a	O
source	B-T033
of	O
mutations	O
to	O
adapt	O
to	O
changing	O
environments	O
.	O
We	O
identified	O
a	O
negative	B-T033
epistatic	O
interaction	O
involving	O
naturally	O
occurring	O
variants	O
in	O
the	O
MLH1	O
and	O
PMS1	O
mismatch	O
repair	O
(	O
MMR	O
)	O
genes	O
of	O
Saccharomyces	O
cerevisiae	O
We	O
hypothesized	O
that	O
this	O
MMR	O
incompatibility	O
,	O
created	O
through	O
mating	O
between	O
divergent	O
S.	O
cerevisiae	O
,	O
yields	O
mutator	O
progeny	O
that	O
can	O
rapidly	O
but	O
transiently	O
adapt	O
to	O
an	O
environmental	O
stress	O
.	O
Here	O
we	O
analyzed	O
the	O
MLH1	O
and	O
PMS1	O
genes	O
across	O
1010	O
S.	O
cerevisiae	O
natural	O
isolates	O
spanning	O
a	O
wide	O
range	O
of	O
ecological	O
sources	B-T033
(	O
tree	O
exudates	O
,	O
Drosophila	O
,	O
fruits	O
,	O
and	O
various	O
fermentation	O
and	O
clinical	O
isolates	O
)	O
and	O
geographical	O
sources	B-T033
(	O
Europe	O
,	O
America	O
,	O
Africa	O
,	O
and	O
Asia	O
)	O
.	O
We	O
identified	O
one	O
homozygous	O
clinical	O
isolate	O
and	O
18	O
heterozygous	O
isolates	O
containing	O
the	O
incompatible	O
MMR	O
genotype	O
.	O
The	O
MLH1	O
-	O
PMS1	O
gene	O
combination	O
isolated	O
from	O
the	O
homozygous	O
clinical	O
isolate	O
conferred	O
a	O
mutator	O
phenotype	O
when	O
expressed	O
in	O
the	O
S288c	O
laboratory	O
background	O
.	O
Using	O
a	O
novel	O
reporter	O
to	O
measure	O
mutation	O
rates	O
,	O
we	O
showed	O
that	O
the	O
overall	O
mutation	O
rate	O
in	O
the	O
homozygous	O
incompatible	O
background	O
was	O
similar	O
to	O
that	O
seen	O
in	O
compatible	O
strains	B-T001
,	O
indicating	O
the	O
presence	O
of	O
suppressor	O
mutations	O
in	O
the	O
clinical	O
isolate	O
that	O
lowered	O
its	O
mutation	O
rate	O
.	O
This	O
observation	O
and	O
the	O
identification	O
of	O
18	O
heterozygous	O
isolates	O
,	O
which	O
can	O
lead	O
to	O
MMR	O
incompatible	O
genotypes	O
in	O
the	O
offspring	O
,	O
are	O
consistent	O
with	O
an	O
elevated	O
mutation	O
rate	O
rapidly	O
but	O
transiently	O
facilitating	O
adaptation	O
.	O
To	O
avoid	O
long	O
-	O
term	O
fitness	O
costs	O
,	O
the	O
incompatibility	O
is	O
apparently	O
buffered	B-T121
by	O
mating	O
or	O
by	O
acquiring	O
suppressors	O
.	O
These	O
observations	O
highlight	O
effective	O
strategies	O
in	O
eukaryotes	O
to	O
avoid	O
long	O
-	O
term	O
fitness	O
costs	O
associated	O
with	O
elevated	O
mutation	O
rates	O
.	O
      
Fluoride	B-T121
concentration	O
in	O
saliva	O
and	O
biofilm	B-T007
fluid	I-T007
following	O
the	O
application	B-T058
of	O
three	O
fluoride	O
varnishes	O
Most	O
of	O
the	O
commercially	O
available	O
fluoride	O
varnishes	O
(	O
FV	O
)	O
have	O
not	O
been	O
evaluated	B-T058
for	O
their	O
cariostatic	O
properties	O
.	O
Consequently	B-T033
,	O
the	O
aim	O
of	O
this	O
in	O
vivo	O
study	O
was	O
to	O
investigate	B-T058
intra	O
-	O
oral	O
fluoride	B-T121
retention	O
and	O
clearance	B-T033
patterns	I-T033
from	O
three	O
different	O
FV	O
.	O
Eighteen	O
subjects	O
(	O
7	O
-	O
11	O
years	O
)	O
participated	O
in	O
a	O
laboratory	O
analyst	O
-	O
blinded	O
,	O
randomized	O
,	O
crossover	O
study	O
comparing	O
the	O
ability	O
of	O
5	O
%	O
sodium	O
fluoride	O
varnishes	O
(	O
CavityShield	O
-	O
CS	O
,	O
Enamel	O
Pro	O
-	O
EP	O
,	O
Vanish	O
-	O
V	O
)	O
to	O
enhance	O
fluoride	B-T121
concentrations	O
in	O
biofilm	B-T007
fluid	I-T007
,	O
centrifuged	O
and	O
whole	O
saliva	O
over	O
a	O
period	O
of	O
48h	O
after	O
a	O
single	O
FV	O
application	O
.	O
Similar	O
fluoride	B-T121
concentration	O
×	O
time	O
patterns	O
were	O
noted	O
for	O
all	O
investigated	O
FV	O
and	O
studied	O
variables	O
,	O
with	O
the	O
highest	O
fluoride	B-T121
concentrations	O
observed	O
for	O
the	O
first	O
biological	O
sample	O
collected	O
after	O
FV	O
application	O
(	O
30min	O
)	O
.	O
Mean±SE	O
(	O
area	O
under	O
fluoride	O
clearance	O
curve	O
)	O
values	O
were	O
(	O
μg	O
F	O
/	O
g	O
or	O
ml×min	O
):	O
biofilm	B-T007
fluid	I-T007
-	O
CS	O
(	O
472±191	O
)	O
,	O
EP	O
(	O
423±75	O
)	O
,	O
V	O
(	O
1264±279	O
)	O
;	O
centrifuged	O
saliva	O
-	O
CS	O
(	O
42±7	O
)	O
,	O
EP	O
(	O
19±3	O
)	O
,	O
V	O
(	O
41±8	O
)	O
;	O
whole	O
saliva	O
-	O
CS	O
(	O
68±11	O
)	O
,	O
EP	O
(	O
64±10	O
)	O
,	O
V	O
(	O
60±7	O
)	O
.	O
V	O
delivered	O
more	O
fluoride	B-T121
to	O
biofilm	B-T007
fluid	I-T007
than	O
CS	O
(	O
p=0.0116	O
)	O
and	O
EP	O
(	O
p=0.0065	O
)	O
,	O
which	O
did	O
not	O
differ	O
(	O
p=0.27	O
)	O
.	O
For	O
centrifuged	O
saliva	O
,	O
CS	O
and	O
V	O
were	O
not	O
significantly	O
different	O
(	O
p=0.86	O
)	O
,	O
but	O
resulted	O
in	O
higher	O
fluoride	B-T121
retention	O
than	O
EP	O
(	O
p<0.0008	O
)	O
.	O
No	O
significant	O
differences	O
among	O
FV	O
were	O
observed	O
for	O
whole	O
saliva	O
(	O
p=0.79	O
)	O
.	O
The	O
present	B-T033
study	O
has	O
shown	O
that	O
FV	O
vary	O
in	O
their	O
ability	O
to	O
deliver	O
fluoride	B-T121
intra	O
-	O
orally	O
potentially	O
related	O
to	O
formulation	O
differences	O
.	O
To	O
what	O
extent	O
the	O
present	B-T033
findings	B-T033
relate	O
to	O
clinical	O
efficacy	O
remains	O
,	O
however	O
,	O
to	O
be	O
determined	B-T059
.	O
Clinical	O
research	O
that	O
investigates	B-T058
fluoride	B-T121
release	O
patterns	O
into	O
saliva	O
and	O
biofilm	B-T007
fluid	I-T007
from	O
different	O
FV	O
products	O
is	O
insufficient	O
.	O
More	O
research	O
is	O
needed	O
to	O
investigate	B-T058
different	O
FV	O
formulations	O
for	O
their	O
efficacy	O
in	O
order	O
to	O
help	O
clinicians	O
make	O
better	O
evidence	O
based	O
treatment	O
choices	O
.	O
      
CDF	O
-	O
quantile	O
distributions	O
for	O
modelling	O
random	O
variables	O
on	O
the	O
unit	O
interval	O
This	O
paper	O
introduces	O
a	O
two	O
-	O
parameter	O
family	O
of	O
distributions	O
for	O
modelling	O
random	O
variables	O
on	O
the	O
(	O
0,1	O
)	O
interval	O
by	O
applying	O
the	O
cumulative	O
distribution	O
function	O
of	O
one	O
'	O
parent	O
'	O
distribution	O
to	O
the	O
quantile	O
function	O
of	O
another	O
.	O
Family	O
members	O
have	O
explicit	O
probability	O
density	O
functions	O
,	O
cumulative	O
distribution	O
functions	O
and	O
quantile	O
s	O
in	O
a	O
location	O
parameter	O
and	O
a	O
dispersion	O
parameter	O
.	O
They	O
capture	O
a	O
wide	O
variety	O
of	O
shapes	O
that	O
the	O
beta	O
and	O
Kumaraswamy	O
distributions	O
can	B-T033
not	I-T033
.	O
They	O
are	O
amenable	O
to	O
likelihood	O
inference	O
,	O
and	O
enable	O
a	O
wide	O
variety	O
of	O
quantile	O
regression	O
models	O
,	O
with	O
predictors	O
for	O
both	O
the	O
location	O
and	O
dispersion	O
parameters	O
.	O
We	O
demonstrate	O
their	O
applicability	O
to	O
psychological	O
research	O
problems	O
and	O
their	O
utility	O
in	O
modelling	O
real	O
data	O
.	O
      
Hemodynamic	O
correlates	O
of	O
transient	B-T048
cognitive	I-T048
impairment	I-T048
after	O
transient	B-T047
ischemic	I-T047
attack	I-T047
and	O
minor	B-T047
stroke	I-T047
:	O
A	O
transcranial	B-T060
Doppler	I-T060
study	I-T060
Transient	B-T048
cognitive	I-T048
impairment	I-T048
(	O
TCI	B-T048
)	O
on	O
the	O
Mini	B-T060
Mental	I-T060
State	I-T060
Evaluation	I-T060
score	O
is	O
common	O
after	O
transient	B-T047
ischemic	I-T047
attack	I-T047
/	O
minor	B-T047
stroke	I-T047
and	O
might	O
identify	O
patients	O
at	O
increased	O
risk	O
of	O
dementia	B-T048
.	O
We	O
aimed	O
to	O
replicate	O
TCI	B-T048
using	O
the	O
Montreal	O
Cognitive	O
Assessment	O
(	O
MoCA	O
)	O
,	O
compare	O
it	O
with	O
persistent	B-T048
Mild	I-T048
Cognitive	I-T048
Impairment	I-T048
(	O
PMCI	B-T048
)	O
,	O
and	O
to	O
determine	O
whether	O
global	O
cerebral	B-T023
hemodynamic	O
changes	O
could	O
explain	O
transient	O
impairment	O
.	O
Consecutive	O
patients	O
with	O
transient	B-T047
ischemic	I-T047
attack	I-T047
/	O
minor	B-T047
stroke	I-T047
(	O
NIHSS	O
≤	O
3	O
)	O
were	O
assessed	O
with	O
the	O
MoCA	O
and	O
transcranial	B-T060
Doppler	I-T060
ultrasound	I-T060
acutely	O
and	O
at	O
1	O
month	O
.	O
We	O
compared	O
patients	O
with	O
TCI	B-T048
(	O
baseline	O
MoCA	O
<	O
26	O
with	O
≥	O
2	O
points	O
increase	O
at	O
1	O
month	O
)	O
,	O
PMCI	B-T048
(	O
MoCA	O
<	O
26	O
with	O
<	O
2	O
points	O
increase	O
)	O
,	O
and	O
no	B-T033
cognitive	I-T033
impairment	I-T033
(	O
NCI	B-T033
;	O
MoCA	O
≥	O
26	O
)	O
.	O
Of	O
326	O
patients	O
,	O
46	O
(	O
14.1	O
%	O
)	O
had	O
PMCI	B-T048
,	O
98	O
(	O
30.1	O
%	O
)	O
TCI	B-T048
,	O
and	O
182	O
(	O
55.8	O
%	O
)	O
NCI	B-T033
.	O
At	O
baseline	O
,	O
TCI	B-T048
patients	O
had	O
higher	B-T033
systolic	I-T033
blood	I-T033
pressure	I-T033
(	O
150.95	O
±	O
21.52	O
vs	O
144.86	O
±	O
22.44	O
mmHg	O
,	O
p	O
=	O
0.02	O
)	O
and	O
lower	O
cerebral	O
blood	O
flow	O
velocities	O
,	O
particularly	O
end	O
-	O
diastolic	O
velocity	O
(	O
30.16	O
±	O
9.63	O
vs	O
35.02	O
±	O
9.01	O
cm	O
/	O
s	O
,	O
p	O
<	O
0.001	O
)	O
and	O
mean	B-T033
flow	I-T033
velocity	I-T033
(	O
48.95	O
±	O
12.72	O
vs	O
54	O
±	O
12.46	O
cm	O
/	O
s	O
,	O
p	O
=	O
0.001	O
)	O
than	O
those	O
with	O
NCI	B-T033
,	O
but	O
similar	O
clinical	O
and	O
hemodynamic	O
profiles	B-T059
to	O
those	O
with	O
PMCI	B-T048
.	O
Systolic	B-T033
BP	I-T033
fell	I-T033
between	O
baseline	O
and	O
1	O
month	O
(	O
mean	O
reduction	B-T061
=	O
14.01	O
±	O
21.26	O
mmHg	O
)	O
and	O
end	O
-	O
diastolic	O
velocity	O
and	O
mean	B-T033
flow	I-T033
velocity	I-T033
increased	O
(	O
mean	O
increase	O
=	O
+	O
2.42	O
±	O
6.41	O
and	O
1.89	O
±	O
8.77	O
cm	O
/	O
s	O
,	O
respectively	O
)	O
,	O
but	O
these	O
changes	O
did	O
not	B-T033
differ	I-T033
between	O
patients	O
with	O
TCI	B-T048
,	O
PMCI	B-T048
,	O
and	O
NCI	B-T033
.	O
TCI	B-T048
is	O
detectable	O
with	O
the	O
MoCA	O
after	O
transient	B-T047
ischemic	I-T047
attack	I-T047
and	O
minor	B-T047
stroke	I-T047
and	O
has	O
similar	O
clinical	O
and	O
hemodynamic	O
profile	B-T059
to	O
PMCI	B-T048
.	O
However	O
,	O
TCI	B-T048
does	O
not	O
appear	O
to	O
be	O
due	O
to	O
exaggerated	O
acute	O
reversible	O
global	O
hemodynamic	O
changes	O
.	O
      
Direct	O
anterior	O
approach	O
for	O
total	B-T061
hip	I-T061
arthroplasty	I-T061
with	O
a	O
novel	O
mobile	O
traction	O
table	O
-a	O
prospective	O
cohort	O
study	O
The	O
purpose	O
of	O
this	O
prospective	O
cohort	O
study	O
was	O
to	O
clarify	O
the	O
safety	O
and	O
efficacy	O
of	O
total	B-T061
hip	I-T061
arthroplasty	I-T061
via	O
the	O
direct	O
anterior	O
approach	O
in	O
the	O
supine	O
position	O
with	O
a	O
novel	O
mobile	O
traction	O
table	O
.	O
The	O
first	O
experience	O
of	O
consecutive	B-T061
surgeries	I-T061
by	O
a	O
single	O
surgeon	O
using	O
the	O
direct	O
anterior	O
approach	O
with	O
a	O
traction	O
table	O
is	O
described	O
with	O
a	O
two	O
-	O
year	O
follow	B-T058
-	I-T058
up	I-T058
period	O
.	O
Of	O
121	O
patients	O
,	O
100	O
patients	O
without	O
previous	B-T033
hip	I-T033
surgeries	I-T033
,	O
severe	B-T190
deformity	I-T190
,	O
or	O
cemented	B-T061
implants	I-T061
were	O
divided	O
into	O
two	O
groups	O
comprising	O
the	O
first	O
50	O
patients	O
and	O
the	O
second	O
50	O
patients	O
.	O
The	O
implant	O
survival	O
rate	O
was	O
99	O
%	O
at	O
the	O
two	O
-	O
year	O
follow	B-T058
-	I-T058
up	I-T058
.	O
Revision	B-T061
surgery	I-T061
was	O
required	O
for	O
periprosthetic	O
femoral	O
fracture	O
in	O
one	O
patient	O
.	O
The	O
complication	O
rate	O
possibly	O
related	O
to	O
the	O
traction	O
table	O
was	O
5	O
%	O
(	O
5	O
patients	O
):	O
three	O
anterior	O
dislocations	O
,	O
one	O
periprosthetic	O
femoral	O
fracture	O
,	O
and	O
one	O
intraoperative	B-T058
perforation	I-T058
caused	O
by	O
femoral	O
rasping	O
.	O
The	O
complication	O
rate	O
tended	O
to	O
decrease	O
in	O
the	O
second	O
group	O
compared	O
to	O
the	O
first	O
group	O
(	O
4	O
%	O
versus	O
6	O
%	O
)	O
.	O
Mean	O
surgical	O
time	O
(	O
72.0	O
minutes	O
versus	O
82.5	O
min	O
,	O
p	O
=	O
0.027	O
)	O
,	O
rate	O
of	O
allogeneic	B-T061
blood	I-T061
transfusion	I-T061
(	O
2	O
%	O
versus	O
24	O
%	O
,	O
p	O
=	O
0.001	O
)	O
,	O
and	O
cup	B-T033
alignment	I-T033
in	O
the	O
safe	O
zone	O
(	O
100	O
%	O
versus	O
88	O
%	O
,	O
p	O
=	O
0.027	O
)	O
were	O
significantly	O
improved	O
in	O
the	O
second	O
group	O
compared	O
to	O
the	O
first	O
group	O
.	O
The	O
direct	O
anterior	O
approach	O
with	O
a	O
novel	O
mobile	O
traction	O
table	O
showed	O
a	O
positive	B-T033
learning	I-T033
curve	I-T033
for	O
surgical	O
time	O
,	O
rate	O
of	O
allogeneic	B-T061
blood	I-T061
transfusion	I-T061
,	O
and	O
cup	B-T033
alignment	I-T033
in	O
the	O
safe	O
zone	O
.	O
      
PROTECTIVE	O
EFFECTS	O
OF	O
DIPEPTIDYL	B-T121
PEPTIDASE-4	I-T121
INHIBITORS	I-T121
ON	O
PROGRESSION	O
OF	O
DIABETIC	B-T047
RETINOPATHY	I-T047
IN	O
PATIENTS	O
WITH	O
TYPE	B-T047
2	I-T047
DIABETES	I-T047
To	O
investigate	O
the	O
effects	O
of	O
dipeptidyl	B-T121
peptidase-4	I-T121
inhibitors	I-T121
(	O
DPP4	B-T121
)	O
on	O
the	O
progression	O
of	O
diabetic	B-T047
retinopathy	I-T047
(	O
DR	B-T047
)	O
in	O
patients	O
with	O
Type	B-T047
2	I-T047
diabetes	I-T047
based	O
on	O
the	O
DR	B-T047
severity	O
scale	O
.	O
The	O
medical	O
records	O
of	O
82	O
patients	O
with	O
Type	B-T047
2	I-T047
diabetes	I-T047
enrolled	O
from	O
2005	O
to	O
2015	O
were	O
retrospectively	O
reviewed	O
.	O
Fundus	B-T060
photographs	I-T060
were	O
graded	O
using	O
Early	O
Treatment	O
Diabetic	O
Retinopathy	O
Study	O
methods	O
.	O
The	O
associations	O
between	O
baseline	O
risk	B-T033
factors	I-T033
and	O
progression	O
of	O
DR	B-T047
were	O
investigated	O
.	O
Seven	O
of	O
28	O
patients	O
treated	O
with	O
DPP4	B-T121
inhibitors	I-T121
and	O
26	O
of	O
54	O
treated	O
with	O
other	O
hypoglycemic	B-T121
agents	I-T121
showed	O
progression	O
of	O
retinopathy	B-T047
,	O
defined	O
as	O
one	O
or	O
more	O
steps	O
on	O
the	O
Early	O
Treatment	O
Diabetic	O
Retinopathy	O
Study	O
scale	O
(	O
P	O
=	O
0.043	O
)	O
.	O
Only	O
treatment	O
with	O
DPP4	B-T121
inhibitors	I-T121
significantly	O
reduced	O
the	O
progression	O
of	O
DR	B-T047
in	O
patients	O
after	O
propensity	O
score	O
matching	O
(	O
P	O
=	O
0.009	O
)	O
.	O
Treatment	O
with	O
DPP4	B-T121
inhibitors	I-T121
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
DR	B-T047
progression	O
(	O
P	O
=	O
0.011	O
)	O
.	O
Treatment	O
with	O
DPP4	B-T121
inhibitors	I-T121
was	O
the	O
independent	O
protective	O
factor	O
against	O
the	O
progression	O
of	O
DR	B-T047
,	O
aside	O
from	O
improving	B-T033
glycemic	I-T033
control	I-T033
.	O
This	O
is	O
the	O
first	O
study	O
to	O
show	O
the	O
benefits	O
of	O
DPP4	B-T121
inhibitors	I-T121
in	O
reducing	O
DR	B-T047
progression	O
,	O
and	O
provides	O
encouraging	O
preliminary	O
data	O
for	O
further	O
evaluation	B-T058
of	O
DPP4	B-T121
inhibitors	I-T121
in	O
the	O
progression	O
of	O
DR	B-T047
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O
      
Bone	B-T047
Degeneration	I-T047
and	O
Its	O
Recovery	O
in	O
SMP30	O
/	O
GNL	O
-	O
Knockout	O
Mice	O
Senescence	O
marker	O
protein-30	O
(	O
SMP30	O
)	O
decreases	O
androgen	B-T121
-independently	O
with	O
aging	O
and	O
is	O
a	O
lactone	O
-	O
hydrolyzing	O
enzyme	O
gluconolactonase	O
(	O
GNL	O
)	O
that	O
is	O
involved	O
in	O
vitamin	B-T121
C	I-T121
biosynthesis	O
.	O
In	O
the	O
present	O
study	O
,	O
bone	B-T023
properties	O
of	O
SMP30	O
/	O
GNL	O
knockout	O
(	O
KO	O
)	O
mice	O
with	O
deficiency	O
in	O
vitamin	B-T121
C	I-T121
synthesis	O
were	O
investigated	O
to	O
reveal	O
the	O
effects	O
of	O
SMP30	O
/	O
GNL	O
and	O
exogenous	O
vitamin	B-T121
C	I-T121
supplementation	B-T121
on	O
bone	O
formation	O
.	O
Mineral	O
content	O
(	O
BMC	O
)	O
and	O
mineral	O
density	O
(	O
BMD	O
)	O
of	O
the	O
mandible	B-T023
and	O
femur	B-T023
of	O
SMP30	O
/	O
GNL	O
KO	O
and	O
wild	O
-	O
type	O
mice	O
at	O
2	O
and	O
3	O
months	O
of	O
age	O
with	O
or	O
without	O
vitamin	B-T121
C	I-T121
supplementation	B-T121
were	O
measured	O
by	O
dual	B-T060
-	I-T060
energy	I-T060
X	I-T060
-	I-T060
ray	I-T060
absorptiometry	I-T060
.	O
Body	O
and	O
bone	B-T023
weight	O
of	O
both	O
age	O
groups	O
decreased	O
and	O
became	O
significantly	O
lower	O
than	O
those	O
of	O
wild	O
-	O
type	O
mice	O
.	O
The	O
bones	B-T023
of	O
SMP30	O
/	O
GNL	O
KO	O
mice	O
were	O
rough	O
and	O
porous	O
,	O
with	O
BMC	O
and	O
BMD	O
significantly	O
below	O
wild	O
-	O
type	O
.	O
Oral	O
supplementation	B-T121
with	O
vitamin	B-T121
C	I-T121
eliminated	O
differences	O
in	O
body	O
weight	O
,	O
bone	B-T023
weight	O
,	O
BMC	O
,	O
and	O
BMD	O
between	O
SMP30	O
/	O
GNL	O
KO	O
and	O
wild	O
-	O
type	O
mice	O
at	O
each	O
age	O
.	O
These	O
results	O
indicate	O
that	O
bone	B-T047
degeneration	I-T047
in	O
SMP30	O
/	O
GNL	O
KO	O
mice	O
was	O
caused	O
by	O
lack	O
of	O
vitamin	B-T121
C	I-T121
,	O
and	O
that	O
this	O
mouse	O
strain	O
is	O
an	O
appropriate	O
model	O
for	O
bone	O
metabolism	O
in	O
humans	O
,	O
which	O
have	O
no	O
ability	O
to	O
synthesize	O
vitamin	B-T121
C	I-T121
C.	O
      
Association	O
of	O
kidney	B-T047
disease	I-T047
with	O
obstructive	B-T047
sleep	I-T047
apnea	I-T047
in	O
a	O
population	O
study	O
of	O
men	O
To	O
determine	B-T059
the	O
relationship	O
between	O
obstructive	B-T047
sleep	I-T047
apnea	I-T047
(	O
OSA	B-T047
)	O
and	O
chronic	B-T047
kidney	I-T047
disease	I-T047
(	O
CKD	B-T047
)	O
.	O
Previous	O
population	O
studies	O
of	O
the	O
association	O
are	O
sparse	O
,	O
conflicting	B-T033
and	O
confined	O
largely	O
to	O
studies	O
of	O
administrative	B-T033
data	O
.	O
Cross	O
-	O
sectional	O
analysis	O
in	O
unselected	O
participants	O
of	O
the	O
Men	O
Androgens	O
Inflammation	O
Lifestyle	O
Environment	O
and	O
Stress	O
(	O
MAILES	O
)	O
study	O
,	O
aged	O
>	O
40	O
y.	O
Renal	B-T023
data	O
were	O
available	O
on	O
812	O
men	O
without	O
a	O
prior	O
OSA	B-T047
diagnosis	B-T033
who	O
underwent	O
full	O
in	O
-	O
home	O
polysomnography	B-T060
(	O
Embletta	O
X100	O
)	O
in	O
2010	O
-	O
2011	O
.	O
CKD	B-T047
was	O
defined	O
as	O
an	O
estimated	B-T059
glomerular	I-T059
filtration	I-T059
rate	I-T059
(	O
eGFR	B-T059
)	O
<	O
60	O
mL	O
/	O
min/1.73m2	O
or	O
eGFR	B-T059
≥60	O
and	O
albuminuria	B-T033
(	O
albumin	B-T059
creatinine	I-T059
ratio	I-T059
≥3.0	O
mg	O
/	O
mmol	O
)	O
.	O
CKD	B-T047
[	O
10.5	O
%	O
,	O
n=85	O
(	O
Stage	O
1	O
-	O
3	O
,	O
9.7	O
%	O
;	O
Stage	O
4	O
-	O
5	O
,	O
0.7	O
%	O
)	O
]	O
of	O
predominantly	O
mild	B-T033
severity	I-T033
showed	O
significant	O
association	O
s	O
with	O
OSA	B-T047
(	O
AHI≥10	O
):	O
odds	O
ratio	O
(	O
OR)=1.9	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI):1.02	O
-	O
3.5	O
,	O
severe	O
OSA	B-T047
(	O
AHI	O
≥30	O
/	O
h	O
):	O
OR	O
=	O
2.6	O
,	O
95	O
%	O
CI:1.1	O
-	O
6.2	O
,	O
and	O
respiratory	O
related	O
arousal	O
index	O
:	O
≥7.6	O
/	O
h	O
OR	O
=	O
2.3	O
,	O
95%CI	O
:	O
1.1	O
-	O
4.7	O
,	O
but	O
not	O
measures	O
of	O
hypoxemia	B-T033
after	O
adjustment	O
for	O
age	O
,	O
hypertension	B-T047
,	O
diabetes	B-T047
,	O
smoking	O
,	O
obesity	B-T047
,	O
and	O
NSAID	B-T121
use	O
.	O
There	O
was	O
no	O
association	O
of	O
CKD	B-T047
with	O
daytime	B-T033
sleepiness	I-T033
.	O
In	O
men	O
with	O
CKD	B-T047
,	O
those	O
with	O
OSA	B-T047
were	O
not	B-T033
significantly	I-T033
more	O
likely	O
to	O
report	B-T058
symptoms	B-T184
(	O
sleepiness	B-T033
,	O
snoring	B-T184
,	O
apneas	O
)	O
or	O
be	O
identified	O
with	O
the	O
STOP	O
OSA	O
screening	O
questionnaire	O
,	O
compared	O
to	O
men	O
without	O
OSA	B-T047
.	O
Predominantly	O
mild	O
CKD	B-T047
is	O
associated	O
with	O
severe	O
OSA	B-T047
and	O
arousals	O
.	O
Further	O
population	O
studies	O
examining	B-T033
the	O
longitudinal	O
relationship	O
between	O
CKD	B-T047
and	O
OSA	B-T047
are	O
warranted	O
.	O
Better	O
methods	O
are	O
needed	O
to	O
identify	O
OSA	B-T047
in	O
CKD	B-T047
which	O
may	O
have	O
few	O
symptoms	B-T184
.	O
      
Is	O
UV	O
-	O
Induced	O
Electron	O
-	O
Driven	O
Proton	O
Transfer	O
Active	O
in	O
a	O
Chemically	O
Modified	O
A	O
·	O
T	O
DNA	O
Base	O
Pair	O
?	O
Transient	B-T059
electronic	I-T059
and	I-T059
vibrational	I-T059
absorption	I-T059
spectroscopies	I-T059
have	O
been	O
used	O
to	O
investigate	O
whether	O
UV	O
-	O
induced	O
electron	O
-	O
driven	O
proton	O
transfer	O
(	O
EDPT	O
)	O
mechanisms	O
are	O
active	O
in	O
a	O
chemically	O
modified	O
adenine	O
-	O
thymine	O
(	O
A	O
·	O
T	O
)	O
DNA	O
base	O
pair	O
.	O
To	O
enhance	O
the	O
fraction	O
of	O
biologically	O
relevant	O
Watson	O
-	O
Crick	O
(	O
WC	O
)	O
hydrogen	O
-	O
bonding	O
motifs	O
and	O
eliminate	O
undesired	O
Hoogsteen	O
structures	O
,	O
a	O
chemically	O
modified	O
derivative	O
of	O
A	O
was	O
synthesized	O
,	O
8-(tert	O
-	O
butyl)-9	O
-	O
ethyladenine	O
(	O
8tBA	O
)	O
.	O
Equimolar	O
solutions	O
of	O
8tBA	O
and	O
silyl	O
-	O
protected	O
T	O
nucleosides	O
in	O
chloroform	O
yield	O
a	O
mixture	O
of	O
WC	O
pairs	O
,	O
reverse	O
WC	O
pairs	O
,	O
and	O
residual	O
monomers	O
.	O
Unlike	O
previous	O
transient	B-T059
absorption	I-T059
studies	I-T059
of	O
WC	O
guanine	O
-	O
cytosin	O
e	O
(	O
G	O
·	O
C	O
)	O
pairs	O
,	O
no	O
clear	O
spectroscopic	O
or	O
kinetic	O
evidence	O
was	O
identified	O
for	O
the	O
participation	O
of	O
EDPT	O
in	O
the	O
excited	O
-	O
state	O
relaxation	O
dynamics	O
of	O
8tBA	O
·	O
T	O
pairs	O
,	O
although	O
ultrafast	O
(	O
sub-100	O
fs	O
)	O
EDPT	O
can	O
not	O
be	O
discounted	O
.	O
Monomer	O
-	O
like	O
dynamics	O
are	O
proposed	O
to	O
dominate	O
in	O
8tBA	O
·	O
T.	O
      
Gene	O
-based	O
genome	O
-	O
wide	O
association	O
study	O
identified	O
19p13.3	O
for	O
lean	O
body	O
mass	O
Lean	O
body	O
mass	O
(	O
LBM	O
)	O
is	O
a	O
complex	O
trait	O
for	O
human	O
health	O
.	O
To	O
identify	O
genomic	O
loci	O
underlying	O
LBM	O
,	O
we	O
performed	O
a	O
gene	O
-based	O
genome	O
-	O
wide	O
association	O
study	O
of	O
lean	O
mass	O
index	O
(	O
LMI	O
)	O
in	O
1000	O
unrelated	B-T033
Caucasian	O
subjects	O
,	O
and	O
replicated	O
in	O
2283	O
unrelated	B-T033
Caucasians	O
subjects	O
.	O
Gene	O
-based	O
association	O
analyses	O
highlighted	O
the	O
significant	O
associations	O
of	O
three	O
genes	O
UQCR	O
,	O
TCF3	O
and	O
MBD3	O
in	O
one	O
single	O
locus	O
19p13.3	O
(	O
discovery	O
p	O
=	O
6.10	O
×	O
10(-5	O
)	O
,	O
1.65	O
×	O
10(-4	O
)	O
and	O
1.10	O
×	O
10(-4	O
)	O
;	O
replication	O
p	O
=	O
2.21	O
×	O
10(-3	O
)	O
,	O
1.84	O
×	O
10(-3	O
)	O
and	O
6.95	O
×	O
10(-3	O
)	O
;	O
combined	O
p	O
=	O
2.26	O
×	O
10(-6	O
)	O
,	O
4.86	O
×	O
10(-6	O
)	O
and	O
1.15	O
×	O
10(-5	O
)	O
,	O
respectively	O
)	O
.	O
These	O
results	O
,	O
together	O
with	O
the	O
known	O
functional	O
relevance	O
of	O
the	O
three	O
genes	O
to	O
LMI	O
,	O
suggested	O
that	O
the	O
19p13.3	O
region	O
containing	O
UQCR	O
,	O
TCF3	O
and	O
MBD3	O
genes	O
was	O
a	O
novel	O
locus	O
underlying	O
lean	O
mass	O
variation	O
.	O
      
Anatomic	O
assessment	B-T058
of	O
the	O
left	O
main	O
bifurcation	O
and	O
dynamic	O
bifurcation	O
angles	O
using	O
computed	B-T060
tomography	I-T060
angiography	I-T060
An	O
understanding	O
of	O
the	O
left	B-T023
main	I-T023
coronary	I-T023
artery	I-T023
(	O
LMCA	B-T023
)	O
anatomy	B-T017
is	O
important	O
for	O
accurate	O
diagnosis	O
and	O
therapeutic	B-T061
.	O
We	O
aimed	O
to	O
investigate	O
LMCA	B-T023
anatomy	B-T017
via	O
128	B-T060
-	I-T060
multisliced	I-T060
coronary	I-T060
computed	I-T060
-	I-T060
tomography	I-T060
-	I-T060
angiography	I-T060
(	O
CCTA	B-T060
)	O
in	O
patients	O
with	O
normal	O
LMCA	B-T023
.	O
A	O
total	O
of	O
201	O
CCTA	B-T060
studies	O
were	O
included	O
in	O
this	O
study	O
.	O
Anatomical	B-T017
features	I-T017
of	O
LMCA	B-T023
including	O
cross	O
-	O
sectional	O
areas	O
of	O
the	O
LMCA	B-T023
ostial	O
,	O
LMCA	B-T023
distal	O
,	O
LAD	B-T023
ostial	I-T023
and	O
LCX	B-T023
ostial	O
,	O
and	O
degree	O
of	O
tapering	O
and	O
LMCA	B-T023
bifurcation	O
angles	O
(	O
BA	O
)	O
in	O
the	O
form	O
of	O
LMCA	B-T023
-	O
LCX	B-T023
BA	O
,	O
LMCA	B-T023
-	O
LAD	B-T023
BA	O
,	O
LAD	B-T023
-	O
LCX	B-T023
BA	O
at	O
end	O
-	O
diastole	O
and	O
end	O
-	O
systole	O
.	O
The	O
mean	O
age	O
was	O
55	O
±	O
11	O
with	O
55.7	O
%	O
males	O
.	O
RCA	B-T023
was	O
dominant	O
in	O
173	O
(	O
86.1	O
%	O
)	O
patients	O
.	O
Mean	O
LMCA	B-T023
length	O
was	O
10.0±4.5	O
mm	O
.	O
The	O
mean	O
values	O
of	O
LMCA	B-T023
ostial	O
,	O
LMCA	B-T023
distal	O
,	O
LAD	B-T023
ostial	I-T023
and	O
LCX	B-T023
ostial	O
areas	O
were	O
18.2±5.1	O
mm²	O
,	O
13.2±4.0	O
,	O
9.0±3.2	O
mm²	O
and	O
7.6±2.8	O
mm²	O
,	O
respectively	O
.	O
LMCA	B-T023
ostial	O
-	O
distal	O
area	O
,	O
LMCA	B-T023
distal	O
-	O
LAD	B-T023
ostial	I-T023
area	O
and	O
LMCA	B-T023
distal	O
-	O
LCX	B-T023
ostial	O
area	O
ratios	O
were	O
≥1.44	O
-	O
<	O
1.69	O
in	O
47	O
(	O
23.4	O
%	O
)	O
,	O
53	O
(	O
26.4	O
%	O
)	O
,	O
47	O
(	O
23.4	O
%	O
)	O
patients	O
,	O
respectively	O
,	O
and	O
were	O
≥1.69-<1.96	O
in	O
19	O
(	O
9.5	O
%	O
)	O
,	O
24(11.9	O
%	O
)	O
,	O
40(19.9	O
%	O
)	O
patients	O
respectively	O
.	O
Systolic	O
motion	O
modifies	O
LMCA	B-T023
BAs	O
;	O
systolic	O
motion	O
begets	O
an	O
increment	O
of	O
LMCA	B-T023
-	O
LAD	B-T023
angle	O
in	O
72.6	O
%	O
of	O
patients	O
and	O
decrement	O
of	O
LAD	B-T023
-	O
LCX	B-T023
angle	O
in	O
75.6	O
%	O
of	O
the	O
patients	O
.	O
Patients	O
with	O
T	O
-	O
shaped	O
LAD	B-T023
-	O
LCX	B-T023
BA	O
was	O
shown	O
to	O
have	O
significantly	O
longer	O
LMCA	B-T023
,	O
larger	O
LAD	B-T023
ostial	I-T023
area	O
,	O
larger	O
LCX	B-T023
ostial	O
area	O
and	O
higher	O
diastolic	O
-	O
to	O
-	O
systolic	O
range	O
(	O
DSR	O
)	O
of	O
LAD	B-T023
-	O
LCX	B-T023
BA	O
compared	O
to	O
patients	O
with	O
Y	O
-	O
shaped	O
LAD	B-T023
-	O
LCX	B-T023
BA	O
.	O
LMCA	B-T023
with	O
T	O
-	O
shaped	O
distal	O
BA	O
was	O
found	O
to	O
have	O
significantly	O
longer	O
LMCA	B-T023
,	O
larger	O
LAD	B-T023
ostial	I-T023
area	O
,	O
larger	O
LCX	B-T023
ostial	O
area	O
and	O
higher	O
DSR	O
of	O
distal	O
BA	O
compared	O
to	O
patients	O
with	O
Y	O
-	O
shaped	O
distal	O
BA	O
.	O
These	O
findings	B-T033
may	O
provide	O
useful	O
information	O
for	O
LMCA	B-T023
bifurcation	B-T061
stenting	I-T061
or	O
designing	O
dedicated	O
stents	O
for	O
LMCA	B-T023
.	O
      
Fully	O
Endoscope	O
-	O
Controlled	O
Clipping	B-T061
Bilateral	B-T047
Middle	I-T047
Cerebral	I-T047
Artery	I-T047
Aneurysm	I-T047
Via	O
Unilateral	B-T061
Supraorbital	I-T061
Keyhole	I-T061
Approach	I-T061
Clipping	B-T061
bilateral	B-T047
middle	I-T047
cerebral	I-T047
artery	I-T047
(	I-T047
bMCA	I-T047
)	I-T047
aneurysms	I-T047
via	O
unilateral	B-T061
approach	I-T061
in	O
a	O
single	B-T061
-	I-T061
stage	I-T061
operation	I-T061
is	O
considered	O
as	O
a	O
challenge	O
procedure	O
.	O
To	O
our	O
knowledge	O
,	O
there	O
is	O
no	O
study	O
in	O
surgical	B-T058
management	I-T058
of	O
patients	O
with	O
bMCA	B-T047
aneurysms	I-T047
by	O
fully	O
endoscope	O
-	O
controlled	O
techniques	O
.	O
The	O
author	O
reported	O
a	O
patient	O
with	O
bMCA	B-T047
aneurysms	I-T047
who	O
underwent	O
aneurysms	B-T061
clipping	I-T061
via	O
a	O
unilateral	B-T061
supraorbital	I-T061
keyhole	I-T061
approach	I-T061
by	O
endoscope	O
-	O
controlled	O
microneurosurgery	B-T061
,	O
and	O
the	O
patient	O
had	O
an	O
uneventful	O
postoperative	O
course	O
without	O
neurologic	O
impairment	O
and	O
complication	O
.	O
Furthermore	O
,	O
the	O
author	O
discussed	O
the	O
advantages	O
and	O
adaptation	O
of	O
endoscope	O
-	O
controlled	O
clipping	B-T061
bMCA	B-T047
aneurysms	I-T047
via	O
unilateral	B-T061
supraorbital	I-T061
keyhole	I-T061
approach	I-T061
.	O
      
Ankaflavin	O
and	O
Monascin	O
Induce	O
Apoptosis	O
in	O
Activated	O
Hepatic	O
Stellate	O
Cells	O
through	O
Suppression	O
of	O
the	O
Akt	O
/	O
NF	O
-	O
κB	O
/	O
p38	O
Signaling	O
Pathway	O
The	O
increased	O
proliferation	O
of	O
activated	O
hepatic	O
stellate	O
cells	O
(	O
HSCs	O
)	O
is	O
associated	O
with	O
hepatic	B-T047
fibrosis	I-T047
and	O
excessive	O
extracellular	O
matrix	O
(	O
ECM)-	O
protein	O
production	O
.	O
We	O
examined	O
the	O
inhibitory	O
effects	O
of	O
the	O
Monascus	O
purpureus	O
-fermented	O
metabolites	O
,	O
ankaflavin	O
and	O
monascin	O
(	O
15	O
and	O
30	O
μM	O
)	O
,	O
on	O
the	O
Akt	O
/	O
nuclear	O
factor	O
(	O
NF)-κB	O
and	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
pathways	O
in	O
HSC	O
-	O
T6	O
(	O
activated	O
hepatic	O
stellate	O
cell	O
line	O
)	O
.	O
Ankaflavin	O
and	O
monascin	O
(	O
30	O
μM	O
)	O
induced	O
apoptosis	O
and	O
significantly	O
inhibited	O
cell	O
growth	O
(	O
cell	O
viabilities	O
:	O
80.2	O
±	O
5.43	O
%	O
and	O
62.8	O
±	O
8.20	O
%	O
,	O
respectively	O
,	O
versus	O
control	O
cells	O
;	O
P	O
<	O
0.05	O
)	O
.	O
Apoptosis	O
and	O
G1	O
phase	O
arrest	O
(	O
G1	O
phase	O
percentages	O
:	O
76.1	O
±	O
2.85	O
%	O
and	O
79.9	O
±	O
1.80	O
%	O
,	O
respectively	O
,	O
versus	O
control	O
cells	O
65.9	O
±	O
4.94	O
%	O
;	O
P	O
<	O
0.05	O
)	O
correlated	O
with	O
increased	O
p53	O
and	O
p21	O
levels	O
and	O
caspase	O
3	O
activity	O
and	O
decreased	O
cyclin	O
D1	O
and	O
Bcl-2	O
-	O
family	O
protein	O
levels	O
(	O
P	O
<	O
0.05	O
,	O
all	O
cases	O
)	O
.	O
The	O
apoptotic	O
effects	O
of	O
ankaflavin	O
and	O
monascin	O
were	O
HSC	O
-	O
T6	O
-	O
specific	O
,	O
suggesting	O
their	O
potential	O
in	O
treating	O
liver	B-T047
fibrosis	I-T047
.	O
      
Effects	O
of	O
Transplanted	B-T061
Human	O
Cord	O
Blood	O
-	O
Mononuclear	O
Cells	O
on	O
Pulmonary	O
Hypertension	O
in	O
Immunodeficient	O
Mice	O
and	O
Their	O
Distribution	O
To	O
investigate	B-T058
the	O
effects	O
of	O
human	O
umbilical	O
cord	O
blood	O
-derived	O
mononuclear	O
cell	O
(	O
hUCB	O
-	O
MNC	O
)	O
transplantation	B-T061
on	O
pulmonary	O
hypertension	O
(	O
PH	O
)	O
induced	O
by	O
monocrotaline	O
(	O
MCT	O
)	O
in	O
immunodeficient	O
mice	O
and	O
their	O
distribution	O
.	O
MCT	O
was	O
administered	O
to	O
BALB	O
/	O
c	O
Slc	O
-	O
nu	O
/	O
nu	O
mice	O
,	O
and	O
PH	O
was	O
induced	O
in	O
mice	O
4	O
weeks	O
later	O
.	O
Fresh	O
hUCB	O
-	O
MNCs	O
harvested	B-T061
from	O
a	O
human	O
donor	O
after	O
her	O
delivery	O
were	O
injected	O
intravenously	O
into	O
those	O
PH	O
mice	O
.	O
The	O
medial	O
thickness	O
of	O
pulmonary	B-T023
arterioles	I-T023
,	O
ratio	O
of	O
right	B-T023
ventricular	I-T023
to	O
septum	B-T023
plus	O
left	B-T023
ventricular	I-T023
weight	O
(	O
RV	B-T023
/	O
S	B-T023
+	O
LV	B-T023
)	O
,	O
and	O
ratio	O
of	O
acceleration	O
time	O
to	O
ejection	O
time	O
of	O
pulmonary	O
blood	O
flow	O
waveform	O
(	O
AT	O
/	O
ET	O
)	O
were	O
determined	O
4	O
weeks	O
after	O
hUCB	O
-	O
MNC	O
transplantation	B-T061
.	O
To	O
reveal	O
the	O
incorporation	O
into	O
the	O
lung	B-T023
,	O
CMTMR	B-T121
-	O
labeled	O
hUCB	O
-	O
MNCs	O
were	O
observed	O
in	O
the	O
lung	B-T023
by	O
fluorescent	B-T059
microscopy	I-T059
.	O
DiR	O
-	O
labeled	O
hUCB	O
-	O
MNCs	O
were	O
detected	B-T033
in	O
the	O
lung	B-T023
and	O
other	O
organs	B-T023
by	O
bioluminescence	O
images	O
.	O
Medial	O
thickness	O
,	O
RV	B-T023
/	O
S	B-T023
+	O
LV	B-T023
and	O
AT	O
/	O
ET	O
were	O
significantly	O
improved	B-T033
4	O
weeks	O
after	O
hUCB	O
-	O
MNC	O
transplantation	B-T061
compared	O
with	O
those	O
in	O
mice	O
without	O
hUCB	O
-	O
MNC	O
transplantation	B-T061
.	O
CMTMR	B-T121
-	O
positive	B-T033
hUCB	O
-	O
MNCs	O
were	O
observed	O
in	O
the	O
lung	B-T023
3	O
hours	O
after	O
transplantation	B-T061
.	O
Bioluminescence	O
signals	O
were	O
detected	B-T033
more	O
strongly	O
in	O
the	O
lung	B-T023
than	O
in	O
other	O
organs	B-T023
for	O
24	O
hours	O
after	O
transplantation	B-T061
.	O
The	O
results	B-T033
indicate	B-T033
that	O
hUCB	O
-	O
MNCs	O
are	O
incorporated	O
into	O
the	O
lung	B-T023
early	O
after	O
hUCB	O
-	O
MNC	O
transplantation	B-T061
and	O
improve	B-T033
MCT	O
-	O
induced	O
PH	O
.	O
J.	O
Med	O
.	O
Invest	O
.	O
64	O
:	O
43	O
-	O
49	O
,	O
February	O
,	O
2017	O
.	O
      
Characterization	O
of	O
Phytochrome	O
Interacting	O
Factors	O
from	O
the	O
Moss	O
Physcomitrella	O
patens	O
Illustrates	O
Conservation	O
of	O
Phytochrome	O
Signaling	O
Modules	O
in	O
Land	O
Plants	O
Across	O
the	O
plant	O
kingdom	O
,	O
phytochrome	O
(	O
PHY	O
)	O
photoreceptors	O
play	O
an	O
important	O
role	O
during	O
adaptive	O
and	O
developmental	O
responses	O
to	O
light	O
.	O
In	O
Arabidopsis	O
thaliana	O
,	O
light	O
-	O
activated	O
PHYs	O
accumulate	O
in	O
the	O
nucleus	O
,	O
where	O
they	O
regulate	O
downstream	O
signaling	O
components	O
,	O
such	O
as	O
phytochrome	O
interacting	O
factors	O
(	O
PIFs	O
)	O
.	O
PIFs	O
are	O
transcription	O
factors	O
that	O
act	O
as	O
repressors	O
of	O
photomorphogenesis	O
;	O
their	O
inhibition	O
by	O
PHYs	O
leads	O
to	O
substantial	O
changes	O
in	O
gene	O
expression	O
.	O
The	O
nuclear	O
function	O
of	O
PHYs	O
,	O
however	O
,	O
has	O
so	O
far	O
been	O
investigated	O
in	O
only	O
a	O
few	O
non	O
-	O
seed	O
plants	O
.	O
Here	O
,	O
we	O
identified	O
putative	O
target	O
genes	O
of	O
PHY	O
signaling	O
in	O
the	O
moss	O
Physcomitrella	O
patens	O
and	O
found	O
light	O
-	O
regulated	O
genes	O
that	O
are	O
putative	O
orthologs	O
of	O
PIF	O
-	O
controlled	O
genes	O
in	O
Arabidopsis	O
.	O
Phylogenetic	O
analyses	O
revealed	O
that	O
an	O
ancestral	O
PIF	O
-	O
like	O
gene	O
was	O
already	O
present	O
in	O
streptophyte	O
algae	O
,	O
i.e.	O
,	O
before	O
the	O
water	O
-	O
to	O
-	O
land	O
transition	O
of	O
plants	O
.	O
The	O
PIF	O
homologs	O
in	O
the	O
genome	O
of	O
P.	O
patens	O
resemble	O
Arabidopsis	O
PIFs	O
in	O
their	O
protein	O
domain	O
structure	O
,	O
molecular	O
properties	O
,	O
and	O
physiological	O
effects	O
,	O
albeit	O
with	O
notable	O
differences	O
in	O
the	O
motif	O
-	O
dependent	O
PHY	O
interaction	O
.	O
Our	O
results	O
suggest	O
that	O
P.	O
patens	O
PIFs	O
are	O
involved	O
in	O
PHY	O
signaling	O
.	O
The	O
PHY	O
-	O
PIF	O
signaling	O
node	O
that	O
relays	O
light	O
signals	O
to	O
target	O
genes	O
has	O
been	O
largely	O
conserved	O
during	O
land	O
plant	O
evolution	O
,	O
with	O
evidence	O
of	O
lineage	O
-	O
specific	O
diversification	O
.	O
      
Surface	O
mediated	O
cooperative	O
interactions	O
of	O
drugs	O
enhance	O
mechanical	O
forces	O
for	O
antibiotic	B-T195
action	O
The	O
alarming	O
increase	O
of	O
pathogenic	B-T001
bacteria	I-T001
that	O
are	O
resistant	O
to	O
multiple	O
antibiotics	O
is	O
now	O
recognized	O
as	O
a	O
major	B-T033
health	I-T033
issue	I-T033
fuelling	O
demand	B-T061
for	O
new	O
drugs	B-T121
.	O
Bacterial	O
resistance	O
is	O
often	O
caused	O
by	O
molecular	B-T033
changes	I-T033
at	O
the	O
bacterial	O
surface	O
,	O
which	O
alter	O
the	O
nature	O
of	O
specific	O
drug	O
-	O
target	O
interactions	O
.	O
Here	O
,	O
we	O
identify	O
a	O
novel	O
mechanism	O
by	O
which	O
drug	O
-	O
target	O
interactions	O
in	O
resistant	B-T007
bacteria	I-T007
can	O
be	O
enhanced	O
.	O
We	O
examined	O
the	O
surface	O
forces	O
generated	O
by	O
four	O
antibiotics	B-T195
;	O
vancomycin	B-T195
,	O
ristomycin	B-T195
,	O
chloroeremomycin	B-T121
and	O
oritavancin	B-T121
against	O
drug	O
-	O
susceptible	O
and	O
drug	B-T007
-	I-T007
resistant	I-T007
targets	I-T007
on	O
a	O
cantilever	O
and	O
demonstrated	O
significant	O
differences	O
in	O
mechanical	O
response	O
when	O
drug	B-T007
-	I-T007
resistant	I-T007
targets	I-T007
are	O
challenged	O
with	O
different	O
antibiotics	B-T195
although	O
no	O
significant	O
differences	O
were	O
observed	O
when	O
using	O
susceptible	O
targets	O
.	O
Remarkably	O
,	O
the	O
binding	O
affinity	O
for	O
oritavancin	B-T121
against	O
drug	B-T007
-	I-T007
resistant	I-T007
targets	I-T007
(	O
70	O
nM	O
)	O
was	O
found	O
to	O
be	O
11,000	O
times	O
stronger	O
than	O
for	O
vancomycin	B-T195
(	O
800	O
μM	O
)	O
,	O
a	O
powerful	O
antibiotic	B-T195
used	O
as	O
the	O
last	O
resort	B-T061
treatment	I-T061
for	O
streptococcal	B-T007
and	O
staphylococcal	B-T007
bacteria	I-T007
including	O
methicillin	B-T007
-	I-T007
resistant	I-T007
Staphylococcus	I-T007
aureus	I-T007
(	O
MRSA	B-T007
)	O
.	O
Using	O
an	O
exactly	O
solvable	O
model	O
,	O
which	O
takes	O
into	O
account	O
the	O
solvent	O
and	O
membrane	O
effects	O
,	O
we	O
demonstrate	O
that	O
drug	O
-	O
target	O
interactions	O
are	O
strengthened	O
by	O
pronounced	O
polyvalent	O
interactions	O
catalyzed	O
by	O
the	O
surface	O
itself	O
.	O
These	O
findings	O
further	O
enhance	O
our	O
understanding	O
of	O
antibiotic	O
mode	O
of	O
action	O
and	O
will	O
enable	O
development	O
of	O
more	O
effective	O
therapies	B-T061
.	O
      
A	O
pilot	O
study	O
of	O
intraocular	B-T061
lens	I-T061
explantation	I-T061
in	O
69	O
eyes	B-T023
in	O
Chinese	O
patients	O
To	O
study	O
the	O
effects	O
of	O
intraocular	B-T061
lens	I-T061
(	I-T061
IOL	I-T061
)	I-T061
explantation	I-T061
and	O
demographic	O
characteristics	O
.	O
Retrospective	O
non	O
-	O
comparative	O
case	O
series	O
.	O
Clinical	O
data	O
recorded	O
from	O
patient	O
charts	O
included	O
the	O
following	O
:	O
demographic	O
,	O
preoperative	B-T058
and	O
postoperative	O
characteristics	O
;	O
complications	O
;	O
surgical	O
methods	O
,	O
and	O
changes	O
in	O
visual	B-T060
acuity	I-T060
.	O
A	O
total	O
of	O
69	O
eyes	B-T023
in	O
67	O
Chinese	O
patients	O
who	O
received	O
IOL	B-T061
explants	I-T061
were	O
studied	O
.	O
The	O
patients	O
'	O
mean	O
age	O
at	O
the	O
time	O
of	O
explantation	O
was	O
46.1	O
years	O
old	O
[	O
SD	O
22.5	O
(	O
6	O
-	O
85	O
)	O
]	O
,	O
and	O
37	O
patients	O
were	O
female	O
(	O
55.2	O
%	O
)	O
.	O
Regarding	O
employment	O
,	O
47.8	O
%	O
were	O
farmers	O
,	O
23.9	O
%	O
were	O
retired	O
,	O
16.4	O
%	O
were	O
students	O
,	O
4.5	O
%	O
were	O
unemployed	B-T033
,	O
3	O
%	O
were	O
workers	O
,	O
and	O
4.5	O
%	O
were	O
other	O
(	O
including	O
staff	O
members	O
,	O
teachers	O
and	O
officers	O
)	O
.	O
The	O
main	O
reasons	O
for	O
explantation	B-T061
were	O
dislocation	O
/	O
decentration	B-T033
in	O
41	O
cases	O
(	O
59.4	O
%	O
)	O
and	O
retinal	B-T047
detachment	I-T047
in	O
10	O
cases	O
(	O
14.5	O
%	O
)	O
.	O
The	O
third	O
most	O
prevalent	O
cause	O
was	O
incorrect	B-T033
lens	I-T033
power	I-T033
in	O
7	O
eyes	B-T023
(	O
10.1	O
%	O
)	O
.	O
The	O
remaining	O
reasons	O
were	O
endophthalmitis	B-T047
in	O
6	O
cases	O
(	O
8.7	O
%	O
)	O
,	O
posterior	B-T047
capsular	I-T047
opacity	I-T047
in	O
3	O
eyes	B-T023
(	O
4.3	O
%	O
)	O
,	O
and	O
impacting	O
retinal	B-T061
surgery	I-T061
operation	I-T061
in	O
2	O
cases	O
(	O
2.9	O
%	O
)	O
.	O
The	O
main	O
comorbidities	O
were	O
high	B-T047
myopia	I-T047
in	O
18	O
eyes	B-T023
(	O
26.1	O
%	O
)	O
,	O
trauma	O
in	O
8	O
eyes	B-T023
(	O
11.6	O
%	O
)	O
,	O
retinal	B-T047
detachment	I-T047
in	O
6	O
eyes	B-T023
(	O
8.7	O
%	O
)	O
,	O
congenital	B-T019
cataracts	I-T019
in	O
8	O
eyes	B-T023
(	O
11.6	O
%	O
)	O
,	O
and	O
Marfan	B-T047
's	I-T047
syndrome	I-T047
in	O
2	O
eyes	B-T023
(	O
2.9	O
%	O
)	O
.	O
The	O
mean	O
time	O
from	O
implantation	O
to	O
explantation	O
was	O
4.0y	O
[	O
SD	O
4.2	O
(	O
0.005	O
-	O
15	O
)	O
]	O
.	O
Treatment	B-T058
after	I-T058
explantation	I-T058
included	O
posterior	B-T061
chamber	I-T061
IOL	I-T061
implantation	I-T061
in	O
44	O
eyes	B-T023
(	O
63.8	O
%	O
)	O
and	O
aphakia	B-T190
in	O
25	O
eyes	B-T023
(	O
36.2	O
%	O
)	O
.	O
After	B-T033
surgery	I-T033
,	O
the	O
best	B-T033
corrected	I-T033
visual	I-T033
ability	I-T033
(	O
BCVA	B-T033
)	O
was	O
improved	O
in	O
50	O
cases	O
(	O
72.5	O
%	O
)	O
,	O
including	O
28	O
patients	O
(	O
40.6	O
%	O
)	O
in	O
whom	O
visual	O
ability	O
was	O
improved	O
by	O
more	O
than	O
two	O
lines	O
.	O
Dislocation	O
/	O
decentration	B-T033
is	O
the	O
main	O
cause	O
for	O
explantation	B-T061
,	O
and	O
high	B-T047
myopia	I-T047
is	O
a	O
main	B-T033
risk	I-T033
factor	I-T033
.	O
Posterior	B-T061
chamber	I-T061
IOL	I-T061
implantation	I-T061
remains	O
the	O
most	O
elected	O
treatment	B-T058
after	I-T058
explantation	I-T058
.	O
      
Whole	B-T061
-	I-T061
body	I-T061
strength	I-T061
training	I-T061
with	O
Huber	O
Motion	O
Lab	O
and	O
traditional	B-T061
strength	I-T061
training	I-T061
in	O
cardiac	B-T061
rehabilitation	I-T061
:	O
A	O
randomized	O
controlled	O
study	O
Isometric	B-T061
strengthening	I-T061
has	O
been	O
rarely	O
studied	O
in	O
patients	O
with	O
coronary	B-T047
heart	I-T047
disease	I-T047
(	O
CHD	B-T047
)	O
,	O
mainly	O
because	O
of	O
possible	O
potential	O
side	O
effects	O
and	O
lack	O
of	O
appropriate	O
and	O
reliable	O
devices	O
.	O
We	O
aimed	O
to	O
compare	O
2	O
different	O
modes	O
of	O
resistance	B-T061
training	I-T061
,	O
an	O
isometric	O
mode	O
with	O
the	O
Huber	O
Motion	O
Lab	O
(	O
HML	O
)	O
and	O
traditional	B-T061
strength	I-T061
training	I-T061
(	O
TST	B-T061
)	O
,	O
in	O
CHD	B-T047
patients	O
undergoing	O
a	O
cardiac	B-T061
rehabilitation	I-T061
program	O
.	O
We	O
randomly	O
assigned	O
50	O
patients	O
to	O
HML	O
or	O
TST	B-T061
.	O
Patients	O
underwent	O
complete	O
blinded	O
evaluation	B-T058
before	O
and	O
after	O
the	O
rehabilitation	B-T061
program	I-T061
,	O
including	O
testing	B-T060
for	I-T060
cardiopulmonary	I-T060
exercise	I-T060
,	O
maximal	B-T060
isometric	I-T060
voluntary	I-T060
contraction	I-T060
,	O
endothelial	O
function	O
and	O
body	O
composition	O
.	O
After	O
4	O
weeks	O
of	O
training	O
(	O
16	O
sessions	O
)	O
,	O
the	O
groups	O
did	O
not	O
differ	O
in	O
body	O
composition	O
,	O
anthropometric	O
characteristics	O
,	O
or	O
endothelial	O
function	O
.	O
With	O
HML	O
,	O
peak	O
power	O
output	O
(	O
P=0.035	O
)	O
,	O
maximal	O
heart	O
rate	O
(	O
P<0.01	O
)	O
and	O
gain	O
of	O
force	O
measured	O
in	O
the	O
chest	O
press	O
position	O
(	O
P<0.02	O
)	O
were	O
greater	O
after	O
versus	O
before	O
training	O
.	O
Both	O
protocols	O
appeared	O
to	O
be	O
well	O
tolerated	O
,	O
safe	O
and	O
feasible	O
for	O
these	O
CHD	B-T047
patients	O
.	O
A	O
training	O
protocol	O
involving	O
6s	O
phases	O
of	O
isometric	O
contractions	O
with	O
10s	O
of	O
passive	O
recovery	O
on	O
an	O
HML	O
device	O
could	O
be	O
safely	O
implemented	O
in	O
rehabilitation	B-T061
programs	I-T061
for	O
patients	O
with	O
CHD	B-T047
and	O
improve	O
functional	O
outcomes	O
.	O
      
Adequacy	O
criteria	O
for	O
thyroid	B-T060
FNA	I-T060
evaluated	B-T058
by	O
ThinPrep	B-T060
slides	I-T060
only	O
Adequacy	O
criteria	O
for	O
thyroid	B-T060
fine	I-T060
-	I-T060
needle	I-T060
aspiration	I-T060
(	O
FNA	B-T060
)	O
recommended	O
by	O
The	O
Bethesda	B-T059
System	I-T059
for	I-T059
Reporting	I-T059
Thyroid	I-T059
Cytopathology	I-T059
(	O
TBS	B-T059
)	O
were	O
developed	O
with	O
smears	B-T060
,	O
but	O
they	O
are	O
commonly	O
applied	O
to	O
ThinPreps	B-T060
(	O
TPs	B-T060
)	O
.	O
This	O
study	O
evaluated	B-T058
adequacy	O
in	O
TPs	B-T060
at	O
different	O
diagnostic	O
thresholds	O
.	O
All	O
FNA	B-T060
procedures	I-T060
performed	O
between	O
2010	O
and	O
2015	O
with	O
matched	O
surgical	O
specimens	O
were	O
analyzed	O
.	O
Cell	B-T059
counts	I-T059
and	O
cytological	O
features	O
were	O
evaluated	B-T058
in	O
all	O
initially	O
nondiagnostic	B-T033
(	O
ND	B-T033
)	O
cases	O
.	O
ND	B-T033
cases	O
were	O
reclassified	O
into	O
TBS	B-T059
categories	O
by	O
2	O
pathologists	O
,	O
and	O
the	O
results	O
were	O
compared	O
with	O
surgical	O
outcomes	O
.	O
One	O
hundred	O
forty	O
-	O
six	O
of	O
the	O
151	O
cases	O
initially	O
classified	O
as	O
ND	B-T033
were	O
available	O
for	O
review	O
,	O
and	O
they	O
had	O
a	O
mean	O
cell	B-T059
count	I-T059
of	O
60.5	O
(	O
standard	O
deviation	O
,	O
71.4	O
)	O
.	O
Interobserver	O
agreement	O
on	O
the	O
reclassification	O
of	O
ND	B-T033
cases	O
was	O
moderate	O
(	O
k	O
=	O
0.57	O
)	O
,	O
and	O
consensus	O
yielded	O
48	O
ND	B-T033
cases	O
(	O
33	O
%	O
)	O
,	O
72	O
benign	O
cases	O
(	O
49	O
%	O
)	O
,	O
24	O
cases	O
of	O
atypia	B-T033
of	O
undetermined	B-T033
significance	I-T033
(	O
16	O
%	O
)	O
,	O
and	O
2	O
cases	O
suspicious	B-T033
for	I-T033
malignancy	I-T033
(	O
1	O
%	O
)	O
.	O
Lowering	O
the	O
diagnostic	O
threshold	O
to	O
any	O
follicular	B-T023
cells	O
yielded	O
a	O
sensitivity	O
of	O
92	O
%	O
,	O
a	O
specificity	O
of	O
60	O
%	O
,	O
a	O
positive	O
predictive	O
value	O
of	O
59	O
%	O
,	O
a	O
negative	O
predictive	O
value	O
of	O
92	O
%	O
,	O
and	O
a	O
false	O
-	O
negative	O
rate	O
of	O
7.7	O
%	O
,	O
whereas	O
the	O
values	O
for	O
the	O
initially	O
diagnostic	O
cases	O
were	O
93	O
%	O
,	O
58	O
%	O
,	O
59	O
%	O
,	O
93	O
%	O
,	O
and	O
7.7	O
%	O
,	O
respectively	O
.	O
Including	O
cases	O
with	O
>	O
60	O
cells	O
but	O
lacking	O
6	O
groups	O
containing	O
at	O
least	O
10	O
cells	O
did	O
not	O
affect	O
test	B-T060
performance	I-T060
.	O
Nuclear	O
enlargement	O
,	O
pallor	B-T033
,	O
grooves	O
,	O
and	O
the	O
presence	B-T033
of	O
histiocytoid	O
cells	O
in	O
initially	O
ND	B-T033
FNA	B-T060
correlated	O
with	O
malignancy	B-T191
.	O
In	O
thyroid	B-T060
FNA	I-T060
examined	B-T033
with	O
TP	B-T060
only	O
,	O
lowering	O
the	O
adequacy	O
threshold	O
and	O
eliminating	O
the	O
requirement	O
of	O
6	O
groups	O
of	O
at	O
least	O
10	O
cells	O
did	O
not	O
significantly	O
affect	O
test	B-T060
performance	I-T060
if	O
cytological	O
features	O
associated	O
with	O
malignancy	B-T191
were	O
absent	O
.	O
Cancer	O
Cytopathol	O
2017	O
.	O
©	O
2017	O
American	O
Cancer	O
Society	O
.	O
      
Collecting	O
and	O
Reporting	O
Safety	O
Data	O
and	O
Monitoring	O
Trial	O
Conduct	O
In	O
Pragmatic	O
Trials	O
Pragmatic	O
trials	O
offer	O
the	O
opportunity	O
to	O
obtain	O
real	O
-	O
life	O
data	O
on	O
the	O
relative	O
effectiveness	O
and	O
safety	O
of	O
a	O
treatment	B-T061
before	O
or	O
after	O
market	O
authorisation	O
.	O
This	O
is	O
the	O
penultimate	O
paper	O
in	O
a	O
series	O
of	O
eight	O
,	O
describing	O
the	O
impact	O
of	O
design	O
choices	O
on	O
the	O
practical	O
implementation	O
of	O
pragmatic	O
trials	O
.	O
This	O
paper	O
focuses	O
on	O
the	O
practical	O
challenges	O
of	O
collecting	O
and	O
reporting	O
safety	O
data	O
and	O
of	O
monitoring	O
trial	O
conduct	O
while	O
maintaining	O
routine	O
clinical	B-T061
care	I-T061
practice	I-T061
.	O
Current	O
ICH	O
guidance	O
recommends	O
that	O
,	O
all	O
serious	B-T033
adverse	I-T033
events	I-T033
(	O
SAEs	B-T033
)	O
and	O
all	O
drug	B-T121
-related	O
events	O
must	O
be	O
reported	O
in	O
an	O
interventional	B-T061
trial	O
.	O
In	O
line	O
with	O
current	O
guidance	O
,	O
we	O
propose	O
a	O
risk	O
based	O
approach	O
to	O
the	O
collection	O
of	O
non	B-T033
-	O
drug	B-T121
related	O
non	B-T033
-	I-T033
serious	I-T033
AEs	I-T033
,	O
and	O
even	O
serious	O
events	O
not	O
related	O
to	O
treatment	B-T061
based	O
on	O
the	O
risk	O
profile	O
of	O
the	O
medicine	B-T121
/class	O
in	O
the	O
patient	O
population	O
of	O
interest	O
.	O
Different	O
options	O
available	O
to	O
support	O
the	O
collection	O
and	O
reporting	O
of	O
safety	O
data	O
whilst	O
minimizing	O
study	O
-related	O
follow	B-T058
-	I-T058
up	I-T058
visits	I-T058
are	O
discussed	O
.	O
A	O
risk	O
-based	O
approach	O
to	O
monitoring	O
trial	O
conduct	O
is	O
also	O
discussed	O
,	O
highlighting	O
the	O
difference	O
in	O
the	O
balance	O
of	O
risks	O
likely	O
to	O
occur	O
in	O
a	O
pragmatic	O
trial	O
compared	O
to	O
traditional	O
clinical	O
trials	O
,	O
and	O
the	O
careful	O
consideration	O
that	O
must	O
be	O
given	O
to	O
the	O
mitigation	O
and	O
management	B-T058
of	I-T058
these	I-T058
risks	I-T058
in	O
order	O
to	O
maintain	O
routine	O
care	O
.	O
      
Improvement	O
of	O
older	O
-	O
person	O
-	O
specific	O
QOL	O
after	O
hearing	O
aid	O
fitting	B-T061
and	O
its	O
relation	O
to	O
social	B-T033
interaction	I-T033
This	O
study	O
aimed	O
to	O
investigate	O
whether	O
hearing	O
aids	O
use	O
is	O
associated	O
with	O
improvement	O
of	O
older	O
-	O
person	O
-	O
specific	O
QOL	O
and	O
whether	O
social	B-T033
interactions	I-T033
modify	O
the	O
association	O
.	O
The	O
WHOQOL	O
-	O
OLD	O
questionnaire	O
was	O
answered	O
by	O
105	O
older	O
adults	O
aged	O
60	O
to	O
90	O
years	O
who	O
were	O
newly	O
fitted	B-T061
hearing	O
aids	O
on	O
the	O
day	O
of	O
fitting	B-T061
and	O
at	O
2	O
-	O
6	O
months	O
afterward	O
.	O
The	O
associations	O
between	O
the	O
daily	O
hours	O
of	O
hearing	O
aid	O
usage	O
and	O
social	O
relations	O
with	O
changes	O
in	O
the	O
WHOQOL	O
-	O
OLD	O
total	O
score	O
after	O
hearing	O
aids	O
fitting	B-T061
were	O
estimated	O
adjusting	B-T061
for	O
possible	B-T033
confounders	O
.	O
Older	O
persons	O
with	O
hearing	B-T033
loss	I-T033
experienced	O
significant	O
increases	O
in	O
WHOQOL	O
-	O
OLD	O
total	O
score	O
after	O
hearing	O
aid	O
fitting	B-T061
.	O
Regular	O
use	O
of	O
hearing	O
aid	O
was	O
associated	O
with	O
a	O
greater	O
increase	O
in	O
the	O
total	O
score	O
.	O
The	O
combined	O
categorical	O
variable	O
of	O
social	O
relations	O
and	O
hearing	O
aid	O
usage	O
revealed	O
no	O
separate	O
effects	O
of	O
these	O
two	O
variables	O
,	O
but	O
a	O
combined	O
effect	O
;	O
only	O
those	O
with	O
frequent	O
social	B-T033
interactions	I-T033
who	O
used	O
their	O
hearing	O
aid	O
regularly	O
had	O
a	O
significantly	O
greater	O
increase	O
in	O
WHOQOL	O
-	O
OLD	O
total	O
score	O
.	O
This	O
study	O
's	O
findings	O
indicate	O
that	O
hearing	O
aid	O
fitting	B-T061
may	O
be	O
associated	O
with	O
a	O
subsequent	O
improvement	O
in	O
older	O
-	O
person	O
-	O
specific	O
QOL	O
by	O
improvements	O
in	O
hearing	O
due	O
to	O
the	O
hearing	O
aid	O
,	O
and	O
possibly	B-T033
enhanced	O
communication	O
opportunities	O
.	O
      
Effects	O
of	O
Environmental	O
Factors	O
and	O
Metallic	O
Electrodes	O
on	O
AC	O
Electrical	O
Conduction	O
Through	O
DNA	O
Molecule	O
Deoxyribonucleic	O
acid	O
(	O
DNA	O
)	O
is	O
one	O
of	O
the	O
best	O
candidate	O
materials	O
for	O
various	O
device	O
applications	O
such	O
as	O
in	O
electrodes	O
for	O
rechargeable	O
batteries	O
,	O
biosensors	O
,	O
molecular	O
electronics	O
,	O
medical	O
-	O
and	O
biomedical	O
-	O
applications	O
etc	O
.	O
Hence	O
,	O
it	O
is	O
worthwhile	O
to	O
examine	O
the	O
mechanism	O
of	O
charge	O
transport	O
in	O
the	O
DNA	O
molecule	O
,	O
however	O
,	O
still	O
a	O
question	O
without	O
a	O
clear	O
answer	O
is	O
DNA	O
a	O
molecular	O
conducting	O
material	O
(	O
wire	O
)	O
,	O
semiconductor	O
,	O
or	O
insulator	O
?	O
The	O
answer	O
,	O
after	O
the	O
published	O
data	O
,	O
is	O
still	O
ambiguous	O
without	O
any	O
confirmed	O
and	O
clear	O
scientific	O
answer	O
.	O
DNA	O
is	O
found	O
to	O
be	O
always	O
surrounded	O
with	O
different	O
electric	O
charges	O
,	O
ions	O
,	O
and	O
dipoles	O
.	O
These	O
surrounding	O
charges	O
and	O
electric	O
barrier(s	O
)	O
due	O
to	O
metallic	O
electrodes	O
(	O
as	O
environmental	O
factors	O
(	O
EFs	O
)	O
)	O
play	O
a	O
substantial	O
role	O
when	O
measuring	O
the	O
electrical	O
conductivity	O
through	O
λ	O
-	O
double	O
helix	O
(	O
DNA	O
)	O
molecule	O
suspended	O
between	O
metallic	O
electrodes	O
.	O
We	O
found	O
that	O
strong	O
frequency	O
dependence	O
of	O
AC	O
-	O
complex	O
conductivity	O
comes	O
from	O
the	O
electrical	O
conduction	O
of	O
EFs	O
.	O
This	O
leads	O
to	O
superimposing	O
serious	O
incorrect	O
experimental	O
data	O
to	O
measured	O
ones	O
.	O
At	O
1	O
MHz	O
,	O
we	O
carried	O
out	O
a	O
first	O
control	O
experiment	O
on	O
electrical	O
conductivity	O
with	O
and	O
without	O
the	O
presence	O
of	O
DNA	O
molecule	O
.	O
If	O
there	O
are	O
possible	O
electrical	O
conduction	O
due	O
to	O
stray	O
ions	O
and	O
contribution	O
of	O
substrate	O
,	O
we	O
will	O
detected	O
them	O
.	O
This	O
control	O
experiment	O
revealed	O
that	O
there	O
is	O
an	O
important	O
role	O
played	O
by	O
the	O
environmental	O
-	O
charges	O
around	O
DNA	O
molecule	O
and	O
any	O
experiment	O
should	O
consider	O
this	O
role	O
.	O
We	O
have	O
succeeded	O
to	O
measure	O
both	O
electrical	O
conductivity	O
due	O
to	O
EFs	O
(	O
σ	O
ENV	O
)	O
and	O
electrical	O
conductivity	O
due	O
to	O
DNA	O
molecule	O
(	O
σ	O
DNA	O
)	O
independently	O
by	O
carrying	O
the	O
measurements	O
at	O
different	O
DNA	O
-	O
lengths	O
and	O
subtracting	O
the	O
data	O
.	O
We	O
carried	O
out	O
measurements	O
as	O
a	O
function	O
of	O
frequency	O
(	O
f	O
)	O
and	O
temperature	O
(	O
T	O
)	O
in	O
the	O
ranges	O
0.1	O
Hz	O
<	O
f	O
<	O
1	O
MHz	O
and	O
288	O
K	O
<	O
T	O
<	O
343	O
K.	O
The	O
measured	O
conductivity	O
(	O
σ	O
MES	O
)	O
portrays	O
a	O
metal	O
-like	O
behavior	O
at	O
high	O
frequencies	O
near	O
1	O
MHz	O
.	O
However	O
,	O
we	O
found	O
that	O
σ	O
DNA	O
was	O
far	O
from	O
this	O
behavior	O
because	O
the	O
conduction	O
due	O
to	O
EFs	O
superimposes	O
σ	O
DNA	O
,	O
in	O
particular	O
at	O
low	O
frequencies	O
.	O
By	O
measuring	O
the	O
electrical	O
conductivity	O
at	O
different	O
lengths	O
:	O
40	O
,	O
60	O
,	O
80	O
,	O
and	O
100	O
nm	O
,	O
we	O
have	O
succeeded	O
not	O
only	O
to	O
separate	O
the	O
electrical	O
conduction	O
of	O
the	O
DNA	O
molecule	O
from	O
all	O
EFs	O
effects	O
that	O
surround	O
the	O
molecule	O
,	O
but	O
also	O
to	O
present	O
accurate	O
values	O
of	O
σ	O
DNA	O
and	O
the	O
dielectric	O
constant	O
of	O
the	O
molecule	O
ε'DNA	O
as	O
a	O
function	O
of	O
temperature	O
and	O
frequency	O
.	O
Furthermore	O
,	O
in	O
order	O
to	O
explain	O
these	O
data	O
,	O
we	O
present	O
a	O
model	O
describing	O
the	O
electrical	O
conduction	O
through	O
DNA	O
molecule	O
:	O
DNA	O
is	O
a	O
classical	O
semiconductor	O
with	O
charges	O
,	O
dipoles	O
and	O
ions	O
that	O
result	O
in	O
creation	O
of	O
localized	O
energy	O
-	O
states	O
(	O
LESs	O
)	O
in	O
the	O
extended	O
bands	O
and	O
in	O
the	O
energy	O
gap	O
of	O
the	O
DNA	O
molecule	O
.	O
This	O
model	O
explains	O
clearly	O
the	O
mechanism	O
of	O
charge	O
transfer	O
mechanism	O
in	O
the	O
DNA	O
,	O
and	O
it	O
sheds	O
light	O
on	O
why	O
the	O
charge	O
transfer	O
through	O
the	O
DNA	O
can	O
lead	O
to	O
insulating	O
,	O
semiconducting	O
,	O
or	O
metallic	O
behavior	O
on	O
the	O
same	O
time	O
.	O
The	O
model	O
considers	O
charges	O
on	O
DNA	O
,	O
in	O
the	O
extended	O
bands	O
,	O
either	O
could	O
be	O
free	O
to	O
move	O
under	O
electric	O
field	O
or	O
localized	O
in	O
potential	O
wells	O
/	O
hills	O
.	O
Localization	O
of	O
charges	O
in	O
DNA	O
is	O
an	O
intrinsic	O
structural	O
-	O
property	O
of	O
this	O
solitaire	O
molecule	O
.	O
At	O
all	O
temperatures	O
,	O
the	O
expected	O
increase	O
in	O
thermal	O
-	O
induced	O
charge	O
is	O
attributed	O
to	O
the	O
delocalization	O
of	O
holes	O
(	O
or	O
/	O
and	O
electrons	O
)	O
in	O
potential	O
hills	O
(	O
or	O
/	O
and	O
potential	O
wells	O
)	O
which	O
accurately	O
accounts	O
for	O
the	O
total	O
electric	O
and	O
dielectric	O
behavior	O
through	O
DNA	O
molecule	O
.	O
We	O
succeeded	O
to	O
fit	O
the	O
experiment	O
al	O
data	O
to	O
the	O
proposed	O
model	O
with	O
reasonable	O
magnitudes	O
of	O
potential	O
hills	O
/	O
wells	O
that	O
are	O
in	O
the	O
energy	O
range	O
from	O
0.068	O
eV.	O
      
Cross	O
-	O
Species	O
Rhesus	O
Cytomegalovirus	B-T047
Infection	I-T047
of	O
Cynomolgus	O
Macaques	O
Cytomegaloviruses	B-T005
(	O
CMV	B-T005
)	O
are	O
highly	O
species	O
-	O
specific	O
due	O
to	O
millennia	O
of	O
co	O
-	O
evolution	O
and	O
adaptation	O
to	O
their	O
host	B-T001
,	O
with	O
no	O
successful	O
experimental	O
cross-	O
species	O
infection	O
in	O
primates	O
reported	O
to	O
date	O
.	O
Accordingly	O
,	O
full	O
genome	O
phylogenetic	O
analysis	O
of	O
multiple	O
new	O
CMV	B-T005
field	O
isolates	O
derived	O
from	O
two	O
closely	O
related	O
nonhuman	O
primate	O
species	O
,	O
Indian	B-T033
-	I-T033
origin	I-T033
rhesus	O
macaques	O
(	O
RM	O
)	O
and	O
Mauritian	O
-origin	O
cynomolgus	O
macaques	O
(	O
MCM	O
)	O
,	O
revealed	O
distinct	O
and	O
tight	O
lineage	O
clustering	O
according	O
to	O
the	O
species	B-T033
of	I-T033
origin	I-T033
,	O
with	O
MCM	O
CMV	B-T005
isolates	O
mirroring	O
the	O
limited	O
genetic	O
diversity	O
of	O
their	O
primate	O
host	B-T001
that	O
underwent	O
a	O
population	O
bottleneck	O
400	O
years	O
ago	O
.	O
Despite	O
the	O
ability	O
of	O
Rhesus	O
CMV	B-T005
(	O
RhCMV	B-T005
)	O
laboratory	O
strain	O
68	O
-	O
1	O
to	O
replicate	O
efficiently	O
in	O
MCM	O
fibroblasts	O
and	O
potently	O
inhibit	O
antigen	O
presentation	O
to	O
MCM	O
T	O
cells	O
in	O
vitro	O
,	O
RhCMV	B-T005
68	O
-	O
1	O
failed	O
to	O
productively	O
infect	O
MCM	O
in	O
vivo	O
,	O
even	O
in	O
the	O
absence	O
of	O
host	B-T001
CD8	O
+	O
T	O
and	O
NK	O
cells	O
.	O
In	O
contrast	O
,	O
RhCMV	B-T005
clone	O
68	O
-	O
1.2	O
,	O
genetically	O
repaired	B-T058
to	O
express	O
the	O
homologues	O
of	O
the	O
HCMV	B-T005
anti	O
-	O
apoptosis	O
gene	O
UL36	O
and	O
epithelial	O
cell	O
tropism	O
genes	O
UL128	O
and	O
UL130	O
absent	O
in	O
68	O
-	O
1	O
,	O
efficiently	O
infected	O
MCM	O
as	O
evidenced	O
by	O
the	O
induction	O
of	O
transgene	O
-specific	O
T	O
cells	O
and	O
virus	O
shedding	O
.	O
Recombinant	O
variants	O
of	O
RhCMV	B-T005
68	O
-	O
1	O
and	O
68	O
-	O
1.2	O
revealed	O
that	O
expression	O
of	O
either	O
UL36	O
or	O
UL128	O
together	O
with	O
UL130	O
enabled	O
productive	O
MCM	O
infection	O
,	O
indicating	O
that	O
multiple	O
layers	O
of	O
cross-	O
species	O
restriction	O
operate	O
even	O
between	O
closely	O
related	O
hosts	B-T001
.	O
Cumulatively	O
,	O
these	O
results	O
implicate	O
cell	O
tropism	O
and	O
evasion	O
of	O
apoptosis	O
as	O
critical	O
determinants	O
of	O
CMV	B-T005
transmission	O
across	O
primate	O
species	O
barriers	O
,	O
and	O
extend	O
the	O
macaque	O
model	O
of	O
human	O
CMV	B-T005
infection	O
and	O
immunology	O
to	O
MCM	O
,	O
a	O
nonhuman	O
primate	O
species	O
with	O
uniquely	O
simplified	O
host	B-T001
immunogenetics	O
.	O
      
In	O
Vivo	O
3	O
-	O
Dimensional	O
Strain	O
Mapping	O
Confirms	O
Large	O
Optic	B-T023
Nerve	I-T023
Head	I-T023
Deformations	B-T190
Following	O
Horizontal	O
Eye	O
Movements	O
To	O
measure	O
lamina	B-T023
cribrosa	I-T023
(	O
LC	B-T023
)	O
strains	B-T190
(	O
deformations	B-T190
)	O
following	O
abduction	O
and	O
adduction	O
in	O
healthy	O
subjects	O
and	O
to	O
compare	O
them	O
with	O
those	O
resulting	O
from	O
a	O
relatively	O
high	O
acute	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
elevation	O
.	O
A	O
total	O
of	O
16	O
eyes	B-T023
from	O
8	O
healthy	O
subjects	O
were	O
included	O
.	O
Among	O
the	O
16	O
eyes	B-T023
,	O
11	O
had	O
peripapillary	B-T033
atrophy	I-T033
(	O
PPA	B-T033
)	O
.	O
For	O
each	O
subject	O
,	O
both	O
optic	B-T023
nerve	I-T023
heads	I-T023
(	O
ONHs	B-T023
)	O
were	O
imaged	O
using	O
optical	B-T060
coherence	I-T060
tomography	I-T060
(	O
OCT	B-T060
)	O
at	O
baseline	O
(	O
twice	O
)	O
,	O
in	O
different	O
gaze	O
positions	O
(	O
adduction	O
and	O
abduction	O
of	O
20	O
°	O
)	O
and	O
following	O
an	O
acute	O
IOP	O
elevation	O
of	O
approximately	O
20	O
mm	O
Hg	O
from	O
baseline	O
(	O
via	O
ophthalmodynamometry	B-T060
)	O
.	O
Strains	B-T190
of	O
LC	B-T023
for	O
all	O
loading	O
scenarios	O
were	O
mapped	O
using	O
a	O
three	O
-	O
dimensional	O
tracking	O
algorithm	O
.	O
In	O
all	O
16	O
eyes	B-T023
,	O
LC	B-T023
strains	B-T190
induced	O
by	O
adduction	O
and	O
abduction	O
were	O
5.83	O
%	O
±	O
3.78	O
%	O
and	O
3.93	O
%	O
±	O
2.57	O
%	O
,	O
respectively	O
,	O
and	O
both	O
significantly	O
higher	O
than	O
the	O
control	O
strains	B-T190
measured	O
from	O
the	O
repeated	O
baseline	O
acquisitions	O
(	O
P	O
<	O
0.01	O
)	O
.	O
Strains	B-T190
of	O
LC	B-T023
in	O
adduction	O
were	O
on	O
average	O
higher	O
than	O
those	O
in	O
abduction	O
,	O
but	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
P	O
=	O
0.07	O
)	O
.	O
Strains	B-T190
of	O
LC	B-T023
induced	O
by	O
IOP	O
elevations	O
(	O
on	O
average	O
21.13	O
±	O
7.61	O
mm	O
Hg	O
)	O
were	O
6.41	O
%	O
±	O
3.21	O
%	O
and	O
significantly	O
higher	O
than	O
the	O
control	O
strains	B-T190
(	O
P	O
<	O
0.0005	O
)	O
.	O
Gaze	O
-	O
induced	O
LC	B-T023
strains	B-T190
in	O
the	O
PPA	B-T033
group	O
were	O
on	O
average	O
larger	O
than	O
those	O
in	O
the	O
non	O
-	O
PPA	O
group	O
;	O
however	O
,	O
the	O
relationship	O
was	O
not	O
statistically	O
significant	O
.	O
Our	O
results	B-T033
confirm	O
that	O
horizontal	O
eye	O
movements	O
generate	O
significant	O
ONH	B-T023
strains	B-T190
,	O
which	O
is	O
consistent	O
with	O
our	O
previous	O
estimations	O
using	O
finite	O
element	O
analysis	O
.	O
Further	O
studies	O
are	O
needed	O
to	O
explore	O
a	O
possible	B-T033
link	O
between	O
ONH	B-T023
strains	B-T190
induced	O
by	O
eye	O
movements	O
and	O
axonal	B-T033
loss	I-T033
in	O
optic	B-T047
neuropathies	I-T047
.	O
      
Heterogeneous	O
depression	B-T048
trajectories	O
in	O
multiple	B-T047
sclerosis	I-T047
patients	O
Trajectories	O
of	O
depression	B-T048
over	O
time	O
may	O
be	O
heterogeneous	O
in	O
Multiple	B-T047
Sclerosis	I-T047
(	O
MS	B-T047
)	O
patients	O
.	O
Describing	O
these	O
trajectories	O
will	O
help	O
clinicians	O
understand	O
better	O
the	O
progression	O
of	O
depression	B-T048
in	O
MS	B-T047
patients	O
to	O
aid	O
in	O
patient	O
care	O
decisions	O
.	O
Latent	O
class	O
growth	O
analysis	O
(	O
LCGA	O
)	O
was	O
applied	O
to	O
3507	O
MS	B-T047
patients	O
using	O
an	O
electronic	O
health	O
records	O
(	O
EHR	O
)	O
data	O
base	O
to	O
identify	O
subgroups	O
of	O
MS	B-T047
patients	O
based	O
on	O
self	O
-	O
reported	O
depression	B-T061
screening	I-T061
(	O
PHQ-9	O
)	O
.	O
Latent	O
trajectory	O
classes	O
were	O
used	O
for	O
group	O
comparisons	O
based	O
on	O
baseline	O
clinical	O
characteristics	O
.	O
Three	O
subgroups	O
were	O
found	O
characterized	O
by	O
high	O
(	O
10.0	O
%	O
[	O
of	O
participants	O
]	O
)	O
,	O
wavering	O
above	O
and	O
below	O
moderate	O
(	O
26.2	O
%	O
)	O
and	O
low	O
and	O
variable	O
(	O
63.8	O
%	O
)	O
depression	B-T033
level	I-T033
trajectories	O
.	O
The	O
subpopulation	O
trajectories	O
,	O
respectively	O
,	O
were	O
also	O
characterized	O
by	O
high	O
,	O
moderate	O
and	O
low	O
MS	B-T047
disability	B-T033
at	O
baseline	O
.	O
In	O
contrast	O
,	O
the	O
overall	O
average	O
trajectory	O
was	O
slightly	O
declining	O
and	O
below	O
the	O
moderate	O
depression	B-T048
threshold	O
.	O
The	O
LCGA	O
approach	O
described	O
in	O
this	O
paper	O
and	O
applied	O
to	O
MS	B-T047
patients	O
provides	O
a	O
template	O
for	O
improved	O
use	O
of	O
an	O
EHR	O
data	O
base	O
for	O
understanding	O
heterogeneous	O
depression	B-T061
screening	I-T061
trajectories	O
.	O
Clinicians	O
may	O
use	O
such	O
information	O
to	O
more	O
closely	O
monitor	B-T058
patients	I-T058
that	O
are	O
expected	O
to	O
maintain	O
high	O
or	O
unstable	B-T033
depression	B-T033
levels	I-T033
.	O
      
The	O
PLA2	O
gene	O
mediates	O
the	O
humoral	O
immune	O
responses	O
in	O
Bactrocera	O
dorsalis	O
(	O
Hendel	O
)	O
The	O
phospholipase	O
A2	O
(	O
PLA2	O
)	O
gene	O
encodes	O
the	O
enzyme	O
that	O
catalyzes	O
the	O
hydrolysis	O
of	O
phospholipids	O
(	O
PLs	O
)	O
from	O
the	O
sn-2	O
position	O
.	O
However	O
,	O
little	O
is	O
known	O
about	O
its	O
role	O
in	O
humoral	O
immune	O
responses	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
expression	O
profile	O
of	O
PLA2	O
in	O
different	O
tissues	O
and	O
developmental	O
stages	O
in	O
Bactrocera	O
dorsalis	O
(	O
Hendel	O
)	O
,	O
and	O
the	O
results	O
showed	O
that	O
the	O
transcriptional	O
level	O
of	O
PLA2	O
was	O
high	O
in	O
the	O
egg	O
and	O
mature	O
stage	O
and	O
in	O
the	O
testis	B-T023
tissue	O
.	O
Bacterial	B-T047
infection	I-T047
increased	O
the	O
expression	O
of	O
PLA2	O
,	O
and	O
the	O
highest	O
degree	O
of	O
up	O
-	O
regulation	O
appeared	O
in	O
the	O
fat	B-T023
body	I-T023
.	O
Silencing	O
PLA2	O
influenced	O
the	O
expression	O
of	O
immune	O
-	O
related	O
genes	O
,	O
including	O
MyD88	O
and	O
defensin	B-T121
in	O
the	O
Toll	O
pathway	O
and	O
relish	O
and	O
diptericin	O
in	O
the	O
Imd	O
pathway	O
.	O
Moreover	O
,	O
the	O
expression	O
of	O
MyD88	O
and	O
defensin	B-T121
was	O
down	O
-	O
regulated	O
significantly	O
in	O
the	O
ds	O
-	O
PLA2	O
group	O
compared	O
with	O
those	O
in	O
the	O
ds	O
-	O
egfp	O
group	O
when	O
B.	O
dorsalis	O
was	O
infected	B-T033
with	O
L.	B-T007
monocytogenes	I-T007
and	O
S.	B-T007
aureus	I-T007
,	O
indicating	O
that	O
PLA2	O
was	O
involved	O
in	O
the	O
activation	O
of	O
the	O
Toll	O
pathway	O
.	O
Meanwhile	O
,	O
infection	O
with	O
L.	B-T007
monocytogenes	I-T007
and	O
E.	B-T007
coli	I-T007
,	O
which	O
activate	O
the	O
Imd	O
pathway	O
,	O
does	O
not	O
increase	O
the	O
mRNA	O
levels	O
of	O
relish	O
and	O
diptericin	O
in	O
the	O
ds	O
-	O
PLA2	O
group	O
as	O
severely	O
as	O
it	O
increases	O
those	O
in	O
the	O
ds	O
-	O
egfp	O
group	O
,	O
indicating	O
that	O
the	O
Imd	O
pathway	O
was	O
also	O
repressed	O
after	O
silencing	O
PLA2	O
.	O
Notably	O
,	O
the	O
development	O
of	O
lipid	O
droplets	O
in	O
fat	B-T023
body	I-T023
cells	O
was	O
influenced	O
by	O
silencing	O
PLA2	O
,	O
implying	O
that	O
PLA2	O
affects	O
the	O
function	O
of	O
fat	B-T023
body	I-T023
tissue	O
.	O
These	O
results	O
suggest	O
that	O
the	O
PLA2	O
gene	O
may	O
mediate	O
humoral	O
immune	O
responses	O
by	O
reducing	O
lipid	O
storage	O
in	O
fat	B-T023
body	I-T023
cells	O
in	O
B.	O
dorsalis	O
.	O
      
Feasibility	O
of	O
a	O
transition	O
intervention	B-T061
aimed	O
at	O
adolescents	O
with	O
chronic	B-T047
illness	I-T047
International	O
guidelines	O
recommend	O
planned	O
and	O
structured	O
transition	O
programmes	B-T058
for	O
adolescents	O
with	O
chronic	B-T047
illness	I-T047
because	O
inadequate	O
transition	O
may	O
lead	O
to	O
poor	B-T033
disease	I-T033
control	I-T033
and	O
risk	O
of	O
lacking	O
outpatient	B-T058
follow	I-T058
-	I-T058
up	I-T058
.	O
To	O
investigate	O
the	O
feasibility	O
of	O
a	O
transition	O
intervention	B-T061
aimed	O
at	O
adolescents	O
with	O
chronic	B-T047
illness	I-T047
focusing	O
on	O
declines	O
,	O
drop	O
-	O
outs	O
,	O
no	O
-	O
shows	O
and	O
advantages	O
and	O
disadvantages	O
of	O
participating	O
.	O
We	O
invited	O
236	O
adolescents	O
(	O
12	O
-	O
20	O
years	O
)	O
with	O
juvenile	B-T047
idiopathic	I-T047
arthritis	I-T047
(	O
JIA	B-T047
)	O
to	O
participate	O
in	O
a	O
randomised	O
controlled	O
trial	O
(	O
RCT	O
)	O
transition	O
intervention	B-T061
.	O
Reasons	O
for	O
decline	O
and	O
drop	O
-	O
outs	O
were	O
calculated	O
.	O
Adolescents	O
'	O
experiences	O
of	O
advantages	O
and	O
disadvantages	O
of	O
participating	O
and	O
reasons	O
for	O
no	O
-	O
shows	O
were	O
investigated	O
through	O
focus	O
groups	O
and	O
telephone	O
interviews	O
,	O
which	O
were	O
analysed	O
using	O
thematic	O
analysis	O
.	O
One	O
hundred	O
and	O
twenty	O
of	O
the	O
236	O
eligible	O
patients	O
declined	O
to	O
participate	O
in	O
the	O
intervention	B-T061
and	O
20	O
%	O
dropped	O
out	O
during	O
the	O
intervention	B-T061
.	O
Unspecified	O
declines	O
and	O
practical	B-T033
issues	I-T033
were	O
the	O
most	O
common	O
reason	O
to	O
decline	O
,	O
and	O
'	O
do	O
not	O
wish	O
to	O
continue	O
'	O
was	O
the	O
most	O
common	O
reason	O
to	O
drop	O
-	O
out	O
.	O
Reasons	O
for	O
no	O
-	O
shows	O
were	O
forgetting	B-T048
and	O
being	O
too	O
busy	O
.	O
Advantages	O
of	O
participating	O
were	O
stated	O
as	O
'	O
participating	O
without	O
parents	O
'	O
,	O
'	O
trust	O
and	O
confidentiality	O
'	O
,	O
'	O
being	O
able	O
to	O
set	O
the	O
agenda	O
'	O
and	O
'	O
responsiveness	O
'	O
.	O
Disadvantages	O
were	O
'	O
unclear	B-T033
aim	O
of	O
the	O
study	O
'	O
,	O
'	O
meeting	O
others	O
with	O
JIA	B-T047
'	O
,	O
'	O
too	O
few	O
conversations	O
'	O
and	O
'	O
transport	O
issues	B-T033
'	O
.	O
Many	O
adolescents	O
had	O
difficulties	B-T033
understanding	O
the	O
aim	O
of	O
the	O
intervention	B-T061
.	O
However	O
,	O
most	O
participants	O
appreciated	O
the	O
conversations	O
about	O
identity	O
as	O
well	O
as	O
the	O
trust	O
and	O
confidentiality	O
in	O
the	O
communication	O
.	O
In	O
the	O
future	O
,	O
adolescents	O
should	O
be	O
offered	O
more	O
individually	O
organised	O
programmes	B-T058
according	O
to	O
their	O
preferences	O
and	O
needs	O
in	O
cooperation	O
with	O
parents	O
and	O
health	O
care	O
providers	O
.	O
      
Emergency	O
department	O
use	O
and	O
barriers	O
to	O
wellness	O
:	O
a	O
survey	O
of	O
emergency	O
department	O
frequent	O
users	O
There	O
is	O
no	O
common	O
understanding	O
of	O
how	O
needs	O
of	O
emergency	O
department	O
(	O
ED	O
)	O
frequent	O
users	O
differ	O
from	O
other	O
patients	O
.	O
This	O
study	O
sought	O
to	O
examine	O
how	O
to	O
best	O
serve	O
this	O
population	O
.	O
Examinations	B-T058
of	O
why	O
ED	O
frequent	O
users	O
present	B-T033
to	O
the	O
ED	O
,	O
what	O
barriers	O
to	O
care	B-T058
exist	O
,	O
and	O
what	O
service	O
offerings	O
may	O
help	O
these	O
patients	O
achieve	O
an	O
optimal	O
level	O
of	O
health	O
were	O
conducted	O
.	O
We	O
performed	O
a	O
prospective	O
study	O
of	O
frequent	O
ED	O
users	O
in	O
an	O
adult	O
only	O
,	O
level	O
1	O
trauma	O
center	O
with	O
approximately	O
90,000	O
visits	B-T058
per	O
year	O
.	O
Frequent	O
ED	O
users	O
were	O
defined	O
as	O
those	O
who	O
make	O
four	O
or	O
more	O
ED	B-T058
visits	I-T058
in	O
a	O
12	O
month	O
period	O
.	O
Participants	O
were	O
administered	O
a	O
piloted	O
structured	O
interview	O
by	O
a	O
trained	O
researcher	O
querying	O
demographics	O
,	O
ED	O
usage	O
,	O
perceived	O
barriers	O
to	O
care	B-T058
,	O
and	O
potential	O
aids	O
to	O
maintaining	O
health	O
.	O
Of	O
1,523	O
screened	B-T058
patients	O
,	O
297	O
were	O
identified	O
as	O
frequent	O
ED	O
users	O
.	O
One	O
hundred	O
frequent	O
ED	O
users	O
were	O
enrolled	O
.	O
The	O
mean	O
age	O
was	O
48	O
years	O
(	O
95	O
%	O
CI	O
45	O
-	O
51	O
)	O
.	O
The	O
majority	O
of	O
subjects	O
were	O
female	O
(	O
64	O
%	O
,	O
64/100	O
,	O
95	O
%	O
CI	O
55	O
-	O
73	O
%	O
)	O
,	O
white	O
(	O
61	O
%	O
,	O
60/98	O
,	O
95	O
%	O
CI	O
52	O
-	O
71	O
%	O
)	O
and	O
insured	O
by	O
Medicaid	O
(	O
55	O
%	O
,	O
47/86	O
,	O
95	O
%	O
CI	O
44	O
-	O
65	O
%	O
)	O
or	O
Medicare	O
(	O
23	O
%	O
,	O
20/86	O
,	O
95	O
%	O
CI	O
14	O
-	O
32	O
%	O
)	O
.	O
Subjects	O
had	O
a	O
median	O
of	O
6	O
ED	B-T058
visits	I-T058
,	O
and	O
2	O
inpatient	O
admissions	O
in	O
the	O
past	O
12	O
months	O
at	O
this	O
hospital	O
.	O
Most	O
frequent	O
ED	O
users	O
(	O
61	O
%	O
,	O
59/96	O
,	O
95	O
%	O
CI	O
52	O
-	O
71	O
%	O
)	O
stated	O
the	O
primary	O
reason	O
for	O
their	O
visit	B-T058
was	O
that	O
they	O
felt	O
that	O
their	O
health	B-T033
problem	I-T033
could	O
only	O
be	O
treated	O
in	O
an	O
ED	O
.	O
Transportation	O
presented	O
as	O
a	O
major	O
barrier	O
to	O
few	O
patients	O
(	O
7	O
%	O
,	O
7/95	O
,	O
95	O
%	O
CI	O
3	O
-	O
14	O
%	O
)	O
.	O
Subjects	O
stated	O
that	O
"	O
after	B-T058
-	I-T058
hours	I-T058
options	I-T058
,	O
besides	O
the	O
ED	O
for	O
minor	O
health	O
issues	O
"	O
(	O
63	O
%	O
,	O
60/95	O
,	O
95	O
%	O
CI	O
53	O
-	O
73	O
%	O
)	O
and	O
having	O
"	O
a	O
nurse	O
to	O
work	O
with	O
you	O
one	B-T061
-	I-T061
on	I-T061
-	I-T061
one	I-T061
to	O
help	O
manage	B-T058
health	B-T058
care	I-T058
needs	O
"	O
(	O
53	O
%	O
,	O
50/95	O
,	O
95	O
%	O
CI	O
43	O
-	O
63	O
%	O
)	O
would	O
be	O
most	O
helpful	O
in	O
achieving	O
optimal	O
health	O
.	O
This	O
study	O
characterized	O
ED	O
frequent	O
users	O
and	O
identified	O
several	O
opportunities	O
to	O
better	O
serve	O
this	O
population	O
.	O
By	O
understanding	O
barriers	O
to	O
care	B-T058
from	O
the	O
patient	O
perspective	O
,	O
health	O
systems	O
can	O
potentially	O
address	O
unmet	O
needs	O
that	O
prevent	O
wellness	O
in	O
this	O
population	O
.	O
      
Neurological	B-T033
Decline	I-T033
in	O
an	O
Elderly	O
with	O
Repaired	O
Myelomeningocele	B-T019
Complicated	O
with	O
Lumbar	B-T047
Canal	I-T047
Stenosis	I-T047
:	O
a	O
case	O
report	O
Tethered	B-T047
cord	I-T047
syndrome	I-T047
is	O
a	O
well	O
-	O
known	O
complication	O
after	O
myelomeningocele	B-T019
(	O
MMC	B-T019
)	O
repair	B-T058
in	O
childhood	O
.	O
However	O
,	O
late	O
complications	O
in	O
adults	O
with	O
a	O
repaired	O
MMC	B-T019
are	O
not	O
well	O
understood	O
.	O
In	O
particular	O
,	O
the	O
influence	O
of	O
a	O
degenerative	B-T190
spinal	I-T190
deformity	I-T190
on	O
a	O
sustained	O
tethered	B-T033
cord	I-T033
is	O
still	O
unclear	O
.	O
A	O
63	O
-	O
year	O
-	O
old	O
man	O
with	O
a	O
repaired	O
MMC	B-T019
presented	O
with	O
a	O
progressive	B-T033
gait	I-T033
disturbance	I-T033
and	O
numbness	B-T184
in	O
both	O
lower	B-T023
limbs	I-T023
.	O
Magnetic	O
resonance	O
images	O
demonstrated	O
that	O
the	O
tethered	B-T033
spinal	I-T033
cord	I-T033
was	O
compressed	O
by	O
severe	O
canal	B-T047
stenosis	I-T047
along	O
the	O
entire	O
lumbar	O
spine	O
.	O
After	O
a	O
multi	B-T061
-	I-T061
level	I-T061
lumbar	I-T061
decompression	I-T061
surgery	B-T061
,	O
the	O
patient	O
recovered	O
to	O
baseline	O
neurological	O
status	O
.	O
In	O
adults	O
with	O
a	O
repaired	O
MMC	B-T019
,	O
lumbar	B-T047
canal	I-T047
stenosis	I-T047
should	O
be	O
investigated	O
as	O
a	O
possible	O
cause	O
of	O
late	O
neurological	B-T033
decline	I-T033
.	O
Clinical	O
manifestations	O
may	O
be	O
complicated	O
by	O
the	O
coexistence	O
of	O
both	O
the	O
original	O
and	O
subsequent	O
neurological	B-T047
disorders	I-T047
.	O
Because	O
these	O
additional	O
disorders	B-T047
result	O
from	O
compressive	B-T047
myelopathy	I-T047
,	O
early	O
surgical	B-T061
decompression	I-T061
is	O
indicated	O
to	O
avoid	O
irreversible	O
spinal	B-T047
cord	I-T047
dysfunction	I-T047
.	O
      
Description	O
of	O
the	O
first	O
species	O
of	O
Fiorianteon	O
Olmi	O
(	O
Hymenoptera	O
,	O
Dryinidae	O
)	O
from	O
the	O
Afrotropical	O
region	O
Fiorianteon	O
sulcatumsp	O
.	O
n.	O
is	O
described	O
from	O
Fianarantsoa	O
Province	O
(	O
Madagascar	O
)	O
.	O
It	O
is	O
the	O
first	O
species	O
of	O
Fiorianteon	O
found	O
in	O
the	O
Afrotropical	O
region	O
.	O
The	O
genus	O
Fiorianteon	O
can	O
be	O
distinguished	O
from	O
the	O
closely	O
related	O
genus	O
Conganteon	O
by	O
the	O
distal	O
part	O
of	O
the	O
stigmal	B-T023
vein	I-T023
,	O
which	O
is	O
as	O
long	O
as	O
,	O
or	O
shorter	B-T033
than	O
the	O
proximal	O
part	O
of	O
the	O
stigmal	B-T023
vein	I-T023
(	O
longer	O
than	O
the	O
proximal	O
part	O
of	O
the	O
vein	B-T023
in	O
Conganteon	O
)	O
.	O
      
Polymeric	O
Nanostructure	O
Compiled	O
with	O
Multifunctional	O
Components	O
To	O
Exert	O
Tumor	B-T191
-	O
Targeted	O
Delivery	O
of	O
Antiangiogenic	O
Gene	O
for	O
Tumor	B-T191
Growth	I-T191
Suppression	O
Nucleic	O
acid	O
-	O
based	O
therapy	B-T061
has	O
emerged	O
as	O
a	O
revolutionary	O
methodology	O
for	O
treatment	O
of	O
the	O
diseases	B-T047
related	O
to	O
protein	O
dysfunction	O
;	O
however	O
,	O
lack	O
of	O
systemically	O
applicable	O
synthetic	O
delivery	O
systems	O
limits	O
its	O
current	O
usage	O
in	O
local	O
applications	O
,	O
particularly	O
for	O
DNA	O
-	O
based	O
therapy	B-T061
with	O
regard	O
to	O
the	O
poor	O
bioavailability	O
in	O
the	O
systemic	O
administrations	O
.	O
To	O
overcome	O
this	O
obstacle	O
,	O
we	O
compiled	O
multiple	O
chemistry	B-T059
-	I-T059
based	I-T059
strategies	I-T059
into	O
the	O
manufacture	O
of	O
the	O
gene	O
delivery	O
formulations	O
to	O
pursue	O
improved	B-T033
tolerability	O
of	O
DNA	O
to	O
the	O
enzymatic	O
degradation	O
in	O
the	O
biological	O
milieu	O
and	O
prolonged	O
retention	O
in	O
the	O
systemic	O
circulation	O
.	O
Here	O
,	O
we	O
constructed	O
a	O
distinctive	O
multilayered	O
functional	O
architecture	O
:	O
plasmid	O
DNA	O
(	O
pDNA	O
)	O
was	O
electrostatically	O
complexed	O
with	O
cationic	O
poly(lysine	O
)	O
(	O
polyplex	O
)	O
as	O
the	O
interior	O
pDNA	O
reservoir	O
,	O
which	O
was	O
further	O
cross	O
-	O
linked	O
by	O
redox	O
-	O
responsive	O
disulfide	O
cross	O
-	O
linking	O
to	O
minimize	O
the	O
occurrence	O
of	O
polyplex	O
disassembly	O
through	O
exchange	O
reaction	O
with	O
the	O
biological	O
charged	O
components	O
.	O
Still	O
,	O
the	O
pDNA	O
reservoir	O
was	O
spatially	O
protected	O
by	O
a	O
sequential	O
thermoresponsive	O
poly(N	O
-	O
isopropylacrylamide	O
)	O
palisade	B-T033
as	O
the	O
intermediate	B-T033
barrier	I-T033
and	O
a	O
biocompatible	O
hydrophilic	O
poly(ethylene	B-T121
glycol	I-T121
)	I-T121
(	O
PEG	B-T121
)	O
shell	O
with	O
the	O
aim	O
of	O
preventing	O
the	O
accessibility	O
of	O
the	O
biological	O
species	O
,	O
particularly	O
the	O
nuclease	O
degradation	O
to	O
the	O
pDNA	O
payload	O
.	O
Subsequent	O
investigations	B-T058
validated	O
the	O
utilities	O
of	O
these	O
strategies	O
in	O
accomplishing	O
prolonged	O
blood	O
retention	O
.	O
In	O
an	O
attempt	O
to	O
apply	O
this	O
method	O
for	O
tumor	O
therapy	B-T061
,	O
ligand	O
cyclic	O
(	O
Arg	O
-	O
Gly	O
-	O
Asp	O
)	O
peptide	O
was	O
attached	O
at	O
the	O
distal	O
end	O
of	O
PEG	B-T121
,	O
validating	O
prompted	O
tumor	B-T191
-	O
targeted	O
delivery	O
and	O
gene	O
expression	O
of	O
the	O
loaded	O
antiangiogenic	O
gene	O
at	O
the	O
targeted	O
tumor	O
cells	O
and	O
accordingly	O
exerting	O
antiangiogenesis	O
of	O
the	O
tumors	B-T191
for	O
abrogation	O
of	O
tumor	B-T191
growth	I-T191
.	O
Together	O
with	O
its	O
excellent	O
safe	O
profile	O
,	O
the	O
proposed	O
formulation	O
suggests	O
potential	O
utility	O
as	O
a	O
practical	O
gene	O
delivery	O
system	O
for	O
treatment	O
of	O
intractable	O
diseases	B-T047
.	O
      
Renieramycin	O
M	O
Attenuates	O
Cancer	O
Stem	O
Cell	O
-like	O
Phenotypes	O
in	O
H460	O
Lung	B-T023
Cancer	O
Cells	O
Cancer	O
stem	O
cells	O
(	O
CSCs	O
)	O
are	O
a	O
subpopulation	O
of	O
cancer	O
cells	O
that	O
possess	O
self	O
-	O
renewal	O
and	O
differentiation	O
capacities	O
.	O
CSCs	O
contribute	O
to	O
drug	O
-	O
resistance	O
,	O
cancer	B-T191
recurrence	I-T191
and	O
metastasis	O
,	O
thus	O
development	O
of	O
CSC	O
-targeted	O
therapeutic	B-T061
strategies	I-T061
has	O
recently	O
received	O
significant	O
attention	O
in	O
cancer	O
research	O
.	O
In	O
this	O
study	O
,	O
the	O
potential	O
efficacy	O
of	O
renieramycin	O
M	O
(	O
RM	O
)	O
isolated	O
from	O
the	O
sponge	O
Xestospongia	O
species	O
,	O
was	O
examined	B-T033
against	O
lung	B-T023
CSCs	O
.	O
Colony	B-T059
and	I-T059
spheroid	I-T059
formation	I-T059
assays	I-T059
,	O
as	O
well	O
as	O
western	B-T059
blotting	I-T059
analysis	I-T059
of	O
lung	B-T023
CSC	O
protein	O
markers	O
were	O
employed	O
to	O
determine	O
the	O
CSC	O
-like	O
phenotypes	O
of	O
H460	O
lung	B-T023
cancer	O
cells	O
after	O
treatment	B-T061
with	O
RM	O
at	O
non	O
-	O
toxic	O
concentrations	O
.	O
RM	O
treatment	B-T061
reduced	O
significantly	O
colony	B-T059
and	I-T059
spheroid	I-T059
formation	I-T059
of	O
H460	O
cells	O
.	O
Moreover	O
,	O
the	O
CSC	O
markers	O
CD133	O
,	O
CD44	O
and	O
ALDH1A1	O
of	O
CSC	O
-enriched	O
H460	O
cells	O
were	O
reduced	O
significantly	O
following	O
RM	O
treatment	B-T061
.	O
RM	O
could	O
be	O
a	O
potent	O
anti	B-T121
-	I-T121
metastatic	I-T121
agent	I-T121
by	O
suppressing	O
lung	B-T023
CSC	O
-like	O
phenotypes	O
in	O
H460	O
cells	O
.	O
      
Spine	O
fracture	O
prevalence	O
in	O
a	O
nationally	O
representative	O
sample	O
of	O
US	O
women	O
and	O
men	O
aged	O
≥40	O
years	O
:	O
results	O
from	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
NHANES	O
)	O
2013	O
-	O
2014	O
Spine	O
fracture	O
prevalence	O
is	O
similar	O
in	O
men	O
and	O
women	O
,	O
increasing	O
from	O
<	O
5	O
%	O
in	O
those	O
<	O
60	O
to	O
11	O
%	O
in	O
those	O
70	O
-	O
79	O
and	O
18	O
%	O
in	O
those	O
≥80	O
years	O
.	O
Prevalence	O
was	O
higher	O
with	O
age	O
,	O
lower	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
,	O
and	O
in	O
those	O
meeting	O
criteria	O
for	O
spine	B-T060
imaging	I-T060
.	O
Most	O
subjects	O
with	O
spine	O
fractures	O
were	O
unaware	B-T033
of	O
them	O
.	O
Spine	O
fractures	O
have	O
substantial	O
medical	O
significance	O
but	O
are	O
seldom	O
recognized	O
.	O
This	O
study	O
collected	O
contemporary	O
nationally	O
representative	O
spine	O
fracture	O
prevalence	O
data	O
.	O
Cross	O
-	O
sectional	O
analysis	O
of	O
3330	O
US	O
adults	O
aged	O
≥40	O
years	O
participating	O
in	O
NHANES	O
2013	O
-	O
2014	O
with	O
evaluable	O
Vertebral	O
Fracture	O
Assessment	O
(	O
VFA	B-T060
)	O
.	O
VFA	B-T060
was	O
graded	O
by	O
semiquantitative	O
measurement	O
.	O
BMD	O
and	O
an	O
osteoporosis	B-T047
questionnaire	O
were	O
collected	O
.	O
Overall	O
spine	O
fracture	O
prevalence	O
was	O
5.4	O
%	O
and	O
similar	O
in	O
men	O
and	O
women	O
.	O
Prevalence	O
increased	O
with	O
age	O
from	O
<	O
5	O
%	O
in	O
those	O
<	O
60	O
to	O
11	O
%	O
in	O
those	O
70	O
-	O
79	O
and	O
18	O
%	O
in	O
those	O
≥80	O
years	O
.	O
Fractures	O
were	O
more	O
common	O
in	O
non	O
-	O
Hispanic	O
whites	O
and	O
in	O
people	O
with	O
lower	O
body	O
mass	O
index	O
and	O
BMD	O
.	O
Among	O
subjects	O
with	O
spine	O
fracture	O
,	O
26	O
%	O
met	O
BMD	O
criteria	O
for	O
osteoporosis	B-T047
.	O
Prevalence	O
was	O
higher	O
in	O
subjects	O
who	O
met	O
National	O
Osteoporosis	O
Foundation	O
(	O
NOF	O
)	O
criteria	O
for	O
spine	B-T060
imaging	I-T060
(	O
14	O
vs	O
4.7	O
%	O
,	O
P	O
<	O
0.001	O
)	O
.	O
Only	O
8	O
%	O
of	O
people	O
with	O
a	O
spine	O
fracture	O
diagnosed	B-T033
by	O
VFA	B-T060
had	O
a	O
self	O
-	O
reported	O
fracture	O
,	O
and	O
among	O
those	O
who	O
self	O
-	O
reported	O
a	O
spine	O
fracture	O
,	O
only	O
21	O
%	O
were	O
diagnosed	B-T033
with	O
fracture	O
by	O
VFA	B-T060
.	O
Spine	O
fracture	O
prevalence	O
is	O
similar	O
in	O
women	O
and	O
men	O
and	O
increases	O
with	O
age	O
and	O
lower	O
BMD	O
,	O
although	O
most	O
subjects	O
with	O
spine	O
fracture	O
do	O
not	O
meet	O
BMD	O
criteria	O
for	O
osteoporosis	B-T047
.	O
Since	O
most	O
(	O
>	O
90	O
%	O
)	O
individuals	O
were	O
unaware	B-T033
of	O
their	O
spine	O
fractures	O
,	O
lateral	O
spine	B-T060
imaging	I-T060
is	O
needed	O
to	O
identify	O
these	O
women	O
and	O
men	O
.	O
Spine	O
fracture	O
prevalence	O
was	O
threefold	O
higher	O
in	O
individuals	O
meeting	O
NOF	O
criteria	O
for	O
spine	B-T060
imaging	I-T060
(	O
∼1	O
in	O
7	O
undergoing	O
VFA	B-T060
)	O
.	O
Identifying	O
spine	O
fractures	O
as	O
part	O
of	O
comprehensive	O
risk	B-T058
assessment	I-T058
may	O
improve	B-T033
clinical	B-T060
decision	I-T060
making	I-T060
.	O
      
Successful	O
Fetal	B-T060
Tele	I-T060
-	I-T060
Echo	I-T060
at	O
a	O
Small	O
Regional	O
Hospital	O
Prenatal	B-T060
diagnosis	I-T060
of	O
complex	O
congenital	B-T019
heart	I-T019
disease	I-T019
(	O
CHD	B-T019
)	O
has	O
been	O
shown	O
to	O
improve	B-T033
newborn	B-T033
outcomes	O
.	O
The	O
rate	O
of	O
prenatal	B-T060
diagnosis	I-T060
and	O
access	O
to	O
fetal	B-T060
echocardiography	I-T060
vary	O
widely	O
across	O
the	O
United	O
States	O
.	O
A	O
clinical	B-T060
fetal	I-T060
tele	I-T060
-	I-T060
echo	I-T060
service	O
was	O
established	O
at	O
King	O
's	O
Daughters	O
Medical	O
Center	O
(	O
KDMC	O
)	O
in	O
Ashland	O
,	O
KY	O
,	O
a	O
region	O
in	O
eastern	O
Kentucky	O
that	O
is	O
3	O
h	O
from	O
the	O
nearest	O
congenital	O
heart	O
surgeon	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
fetal	B-T060
tele	I-T060
-	I-T060
echo	I-T060
utilizing	O
local	O
sonographers	O
at	O
a	O
small	O
regional	O
hospital	O
can	O
accurately	O
and	O
efficiently	O
identify	O
fetuses	B-T018
with	O
complex	O
CHD	B-T019
.	O
Medical	O
records	O
were	O
reviewed	O
for	O
all	O
mother	B-T058
-	I-T058
infant	I-T058
pairs	I-T058
who	O
had	O
fetal	B-T060
tele	I-T060
-	I-T060
echoes	I-T060
performed	O
at	O
KDMC	O
and	O
interpreted	O
by	O
University	O
of	O
Louisville	O
pediatric	O
cardiology	O
between	O
March	O
2011	O
and	O
December	O
2013	O
.	O
Findings	B-T033
on	O
fetal	B-T060
tele	I-T060
-	I-T060
echo	I-T060
were	O
compared	O
to	O
newborn	O
echo	B-T060
and	O
clinical	O
course	O
,	O
and	O
divided	O
into	O
four	O
groups	O
:	O
(	O
1	O
)	O
Correct	O
-	O
no	B-T033
difference	I-T033
between	O
fetal	B-T060
tele	I-T060
-	I-T060
echo	I-T060
and	O
newborn	O
echo	B-T060
,	O
(	O
2	O
)	O
Likely	O
Correct	O
-	O
normal	O
fetal	B-T060
tele	I-T060
-	I-T060
echo	I-T060
and	O
benign	O
newborn	O
course	O
,	O
(	O
3	O
)	O
Major	O
Difference	O
-one	O
that	O
affected	O
newborn	B-T033
clinical	O
course	O
,	O
and	O
(	O
4	O
)	O
Minor	O
Difference	O
-did	O
not	O
affect	O
clinical	O
course	O
.	O
Seventy	O
-	O
five	O
mother	B-T058
-	I-T058
infant	I-T058
pairs	I-T058
were	O
analyzed	O
.	O
Fetal	B-T060
tele	I-T060
-	I-T060
echoes	I-T060
were	O
Correct	O
in	O
21	O
%	O
,	O
Likely	O
Correct	O
in	O
56	O
%	O
,	O
showed	O
Major	O
Differences	O
in	O
0	O
%	O
,	O
and	O
showed	O
Minor	O
Differences	O
in	O
23	O
%	O
.	O
For	O
identifying	O
complex	O
CHD	B-T019
,	O
fetal	B-T060
tele	I-T060
-	I-T060
echo	I-T060
had	O
a	O
sensitivity	O
and	O
specificity	O
of	O
100	O
%	O
.	O
The	O
average	O
number	O
of	O
fetal	B-T060
echocardiograms	I-T060
per	O
mother	B-T058
-	I-T058
infant	I-T058
pair	I-T058
was	O
1.1	O
.	O
Fetal	B-T060
tele	I-T060
-	I-T060
echocardiography	I-T060
performed	O
by	O
local	O
sonographers	O
at	O
a	O
small	O
regional	O
hospital	O
can	O
accurately	O
and	O
efficiently	O
identify	O
fetuses	B-T018
with	O
complex	O
CHD	B-T019
.	O
      
Determination	B-T058
of	O
volatile	O
organic	O
compounds	O
exhaled	O
by	O
cell	O
lines	O
derived	O
from	O
hematological	B-T191
malignancies	I-T191
Background	O
:	O
The	O
gas	O
human	O
exhaled	O
contains	O
many	O
volatile	O
organic	O
compounds	O
(	O
VOCs	O
)	O
,	O
which	O
is	O
related	O
to	O
the	O
health	O
status	O
of	O
body	O
.	O
Analysis	O
of	O
VOCs	O
has	O
been	O
proposed	O
as	O
a	O
noninvasive	O
diagnostic	B-T060
tool	I-T060
for	O
certain	O
cancers	B-T191
.	O
Detailed	O
research	O
on	O
the	O
VOCs	O
in	O
gas	O
exhaled	O
by	O
cell	O
can	O
characterize	O
cell	O
type	O
specific	O
metabolites	O
and	O
may	O
be	O
helpful	O
to	O
detect	O
the	O
cancer	O
markers	O
in	O
clinical	O
practice	O
.	O
Methods	O
:	O
Solid	B-T059
phase	I-T059
microextraction	I-T059
-	O
gas	B-T059
chromatography	I-T059
-	O
mass	B-T059
spectrometry	I-T059
was	O
used	O
to	O
detect	O
VOCs	O
in	O
the	O
headspace	O
of	O
tissue	O
culture	O
flask	O
in	O
non	B-T191
-	I-T191
Hodgkin	I-T191
's	I-T191
lymphoma	I-T191
cell	O
line	O
JEKO	O
and	O
acute	B-T191
mononuclear	I-T191
leukemia	I-T191
cell	O
line	O
SHI-1	O
,	O
to	O
elaborate	O
the	O
characteristic	O
gaseous	O
biomarkers	O
of	O
hematological	B-T191
malignancies	I-T191
.	O
While	O
macrophage	O
cells	O
and	O
lymphocytic	O
cells	O
were	O
acted	O
as	O
control	O
.	O
The	O
blank	O
group	O
was	O
only	O
the	O
RPMI	O
1640	O
medium	O
containing	O
10	O
%	O
fetal	O
calf	O
serum	O
that	O
without	O
cells	O
.	O
Results	O
:	O
Comparing	O
to	O
control	O
group	O
,	O
the	O
concentration	O
of	O
dimethyl	O
sulphide	O
,	O
2,4	O
-	O
dimethyl	O
-	O
heptane	O
,	O
methylbenzene	O
,	O
o	O
-	O
xylene	O
,	O
dodecane	B-T121
and	O
1,3	O
-	O
ditert	O
-	O
butylbenzene	O
in	O
JEKO	O
cells	O
were	O
relatively	O
higher	O
,	O
while	O
the	O
concentration	O
of	O
ethanol	B-T121
,	O
hexanal	O
and	O
benzaldehyde	O
was	O
lower	O
.	O
In	O
SHI-1	O
cells	O
,	O
the	O
levels	O
of	O
2,4	O
-	O
dimethyl	O
-	O
heptane	O
,	O
benzene	O
,	O
4	O
-	O
methyldecane	O
,	O
chloroform	O
,	O
3,7	O
-	O
dimethyl	O
dodecane	O
and	O
hexadecane	O
were	O
significantly	O
elevated	O
,	O
but	O
the	O
levels	O
of	O
hexanol	O
and	O
cyclohexanol	B-T121
were	O
distinctly	O
reduced	O
.	O
Conclusions	O
:	O
This	O
pilot	O
study	O
revealed	O
that	O
the	O
malignant	B-T191
hematological	I-T191
cells	O
could	O
change	O
the	O
components	O
of	O
VOCs	O
in	O
the	O
cell	B-T059
culture	I-T059
flask	I-T059
in	O
a	O
cell	O
type	O
specific	O
pattern	O
.	O
The	O
traits	O
of	O
VOCs	O
in	O
our	O
setting	O
offered	O
new	O
strategy	O
for	O
hematological	B-T191
malignancies	I-T191
tracing	O
,	O
and	O
would	O
act	O
as	O
potential	O
biomarkers	O
in	O
diagnosis	B-T033
of	O
malignant	O
hematological	B-T047
diseases	I-T047
.	O
      
Differential	O
regulation	O
of	O
spontaneous	O
and	O
evoked	O
inhibitory	O
synaptic	O
transmission	O
in	O
somatosensory	B-T023
cortex	I-T023
by	O
retinoic	B-T121
acid	I-T121
Retinoic	B-T121
acid	I-T121
(	O
RA	B-T121
)	O
,	O
a	O
developmental	O
morphogen	B-T121
,	O
has	O
emerged	O
in	O
recent	O
studies	O
as	O
a	O
novel	O
synaptic	O
signaling	O
molecule	O
that	O
acts	O
in	O
mature	O
hippocampal	B-T023
neurons	O
to	O
modulate	O
excitatory	O
and	O
inhibitory	O
synaptic	O
transmission	O
in	O
the	O
context	O
of	O
homeostatic	O
synaptic	O
plasticity	O
.	O
However	O
,	O
it	O
is	O
unclear	O
whether	O
RA	B-T121
is	O
capable	O
of	O
modulating	O
neural	O
circuits	O
outside	O
of	O
the	O
hippocampus	B-T023
,	O
and	O
if	O
so	O
,	O
whether	O
the	O
mode	O
of	O
RA	O
's	O
action	O
at	O
synapses	O
is	O
similar	O
to	O
that	O
within	O
the	O
hippocampal	B-T023
network	O
.	O
Here	O
we	O
explore	O
for	O
the	O
first	O
time	O
RA	B-T121
's	O
synaptic	O
function	O
outside	O
the	O
hippocampus	B-T023
and	O
uncover	O
a	O
novel	O
function	O
of	O
all	B-T121
-	I-T121
trans	I-T121
retinoic	I-T121
acid	I-T121
at	O
inhibitory	O
synapses	O
.	O
Acute	O
RA	B-T121
treatment	O
increases	O
spontaneous	O
inhibitory	O
synaptic	O
transmission	O
in	O
L2/3	O
pyramidal	O
neurons	O
of	O
the	O
somatosensory	B-T023
cortex	I-T023
,	O
and	O
this	O
effect	O
requires	O
expression	O
of	O
RA	O
's	O
receptor	O
RARα	O
both	O
pre-	O
and	O
post	O
-	O
synaptically	O
.	O
Intriguingly	O
,	O
RA	B-T121
does	O
not	O
seem	O
to	O
affect	O
evoked	O
inhibitory	O
transmission	O
assayed	O
with	O
either	O
extracellular	O
stimulation	O
or	O
direct	O
activation	O
of	O
action	O
potentials	O
in	O
presynaptic	O
interneurons	O
at	O
connected	O
pairs	O
of	O
interneurons	O
and	O
pyramidal	O
neurons	O
.	O
Taken	O
together	O
,	O
these	O
results	B-T033
suggest	O
that	O
RA	B-T121
's	I-T121
action	O
at	O
synapses	O
is	O
not	O
monotonous	O
,	O
but	O
is	O
diverse	O
depending	O
on	O
the	O
type	O
of	O
synaptic	O
connection	O
(	O
excitatory	O
versus	O
inhibitory	O
)	O
and	O
circuit	O
(	O
hippocampal	B-T023
versus	O
cortical	B-T023
)	I-T023
.	O
Thus	O
,	O
synaptic	O
signaling	O
of	O
RA	B-T121
may	O
mediate	O
multi	O
-	O
faceted	O
regulation	O
of	O
synaptic	O
plasticity	O
.	O
In	O
addition	O
to	O
its	O
classic	O
roles	O
in	O
brain	O
development	O
,	O
retinoic	B-T121
acid	I-T121
(	O
RA	B-T121
)	O
has	O
recently	O
been	O
shown	O
to	O
regulate	O
excitatory	O
and	O
inhibitory	O
transmission	O
in	O
the	O
adult	O
brain	B-T023
.	O
Here	O
,	O
the	O
authors	O
show	O
that	O
in	O
layer	B-T023
2/3	I-T023
(	O
L2/3	B-T023
)	O
of	O
the	O
somatosensory	B-T023
cortex	I-T023
(	O
S1	B-T023
)	O
,	O
acute	O
RA	B-T121
induces	O
increases	O
in	O
spontaneous	O
but	O
not	O
action	O
-	O
potential	O
evoked	O
transmission	O
,	O
and	O
that	O
this	O
requires	O
retinoic	O
acid	O
receptor	O
(	O
RARα	O
)	O
both	O
in	O
presynaptic	O
PV	O
-positive	O
interneurons	O
and	O
postsynaptic	O
pyramidal	O
(	O
PN	O
)	O
neurons	O
.	O
      
Midodrine	B-T121
and	O
tolvaptan	B-T121
in	O
patients	O
with	O
cirrhosis	B-T047
and	O
refractory	B-T033
or	O
recurrent	O
ascites	O
:	O
a	O
randomised	O
pilot	O
study	O
Splanchnic	O
arterial	O
vasodilatation	O
and	O
subsequent	O
sodium	B-T047
and	O
water	B-T033
retention	I-T033
play	O
an	O
important	O
role	O
in	O
cirrhotic	B-T047
ascites	I-T047
.	O
Midodrine	B-T121
and	O
tolvaptan	B-T121
have	O
been	O
used	O
separately	O
in	O
these	O
patients	O
.	O
However	O
,	O
there	O
are	O
no	O
reports	O
on	O
the	O
use	O
of	O
combination	B-T061
of	O
midodrine	B-T121
and	O
tolvaptan	B-T121
in	O
the	O
control	O
of	O
ascites	B-T047
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	B-T058
the	O
safety	O
and	O
efficacy	O
of	O
midodrine	B-T121
,	O
tolvaptan	B-T121
and	O
their	O
combination	B-T061
in	O
control	O
of	O
refractory	B-T033
or	O
recurrent	O
ascites	O
in	O
cirrhotics	B-T047
.	O
Fifty	O
cirrhotic	O
patients	O
with	O
refractory	B-T033
or	O
recurrent	O
ascites	O
were	O
randomised	O
to	O
receive	O
midodrine	B-T121
(	O
n=13	O
)	O
,	O
tolvaptan	B-T121
(	O
n=12	O
)	O
or	O
both	O
(	O
n=13	O
)	O
plus	O
standard	O
medical	B-T061
therapy	I-T061
(	O
SMT	B-T061
)	O
or	O
SMT	B-T061
alone	O
(	O
n=12	O
)	O
.	O
A	O
significant	B-T033
increase	I-T033
in	I-T033
urinary	I-T033
volume	I-T033
and	O
urinary	B-T047
sodium	I-T047
at	O
1	O
and	O
3	O
months	O
(	O
P<.05	O
)	O
was	O
observed	O
in	O
all	O
groups	O
except	O
SMT	B-T061
.	O
There	O
was	O
no	O
worsening	O
of	O
renal	B-T033
or	O
hepatic	O
function	O
in	O
any	O
group	O
.	O
There	O
was	O
deterioration	O
of	O
model	O
for	O
end	O
-	O
stage	O
liver	O
disease	O
(	O
MELD	O
)	O
in	O
SMT	O
.	O
Midodrine	B-T121
as	O
well	O
as	O
combination	B-T061
of	O
midodrine	B-T121
and	O
tolvaptan	B-T121
but	O
not	O
tolvaptan	B-T121
alone	O
was	O
superior	O
to	O
SMT	B-T061
in	O
control	O
of	O
ascites	B-T047
at	O
3	O
months	O
(	O
P<.05	O
)	O
.	O
The	O
combination	B-T061
therapy	I-T061
was	O
also	O
superior	O
to	O
midodrine	B-T121
in	O
the	O
control	O
of	O
ascites	B-T047
at	O
1	O
month	O
.	O
The	O
morbidity	O
and	O
mortality	O
were	O
similar	O
in	O
all	O
the	O
groups	O
except	O
SMT	B-T061
.	O
The	O
results	O
of	O
this	O
pilot	O
study	O
suggest	O
that	O
midodrine	B-T121
and	O
combination	B-T061
with	O
tolvaptan	B-T121
better	O
controls	O
ascites	B-T047
without	O
any	O
renal	B-T047
or	O
hepatic	O
dysfunction	O
.	O
The	O
combination	B-T061
therapy	I-T061
rapidly	O
controls	O
ascites	B-T047
as	O
compared	O
to	O
midodrine	B-T121
or	O
tolvaptan	B-T121
alone	O
.	O
      
Omega	B-T121
3	I-T121
Fatty	I-T121
Acids	I-T121
Reduce	O
Bone	O
Resorption	O
While	O
Promoting	O
Bone	O
Generation	O
in	O
Rat	O
Apical	B-T047
Periodontitis	I-T047
This	O
study	O
evaluated	B-T058
the	O
effects	O
of	O
the	O
dietary	O
supplement	O
omega	B-T121
3	I-T121
polyunsaturated	I-T121
fatty	I-T121
acids	I-T121
(	O
ω-3	B-T121
PUFAs	I-T121
)	O
on	O
pulp	B-T047
exposure	I-T047
-induced	O
apical	B-T047
periodontitis	I-T047
(	O
AP	B-T047
)	O
in	O
rats	O
.	O
Twenty	O
-	O
eight	O
male	O
rats	O
were	O
divided	O
into	O
groups	O
:	O
control	O
untreated	B-T033
rats	O
(	O
C	O
)	O
,	O
control	O
rats	O
treated	O
with	O
ω-3	B-T121
PUFAs	I-T121
alone	O
(	O
C	O
-	O
O	O
)	O
,	O
rats	O
with	O
pulp	B-T047
exposure	I-T047
-induced	O
AP	B-T047
,	O
and	O
rats	O
with	O
pulp	B-T047
exposure	I-T047
-induced	O
AP	B-T047
treated	O
with	O
ω-3	B-T121
PUFAs	I-T121
(	O
AP	B-T047
-O	O
)	O
.	O
The	O
ω-3	B-T121
PUFAs	I-T121
were	O
administered	B-T061
orally	I-T061
,	O
once	O
a	O
day	O
,	O
for	O
15	O
days	O
before	O
pulp	B-T047
exposure	I-T047
and	O
,	O
subsequently	O
,	O
30	O
days	O
after	O
pulp	B-T047
exposure	I-T047
.	O
Rats	O
were	O
killed	O
30	O
days	O
after	O
pulp	B-T047
exposure	I-T047
,	O
and	O
jaws	B-T023
were	O
subjected	O
to	O
histologic	O
and	O
immunohistochemical	B-T059
analyses	O
.	O
Immunohistochemical	B-T059
analyses	O
were	O
performed	O
to	O
detect	O
tartrate	O
-	O
resistant	O
acid	O
phosphatase	O
-	O
positive	B-T033
osteoclasts	O
and	O
osteocalcin	O
-	O
positive	B-T033
osteoblasts	O
on	O
the	O
bone	O
surface	O
of	O
periapical	O
area	O
.	O
Results	O
were	O
statistically	O
evaluated	B-T058
by	O
using	O
analysis	O
of	O
variance	O
and	O
Tukey	O
honestly	O
significant	O
difference	O
,	O
and	O
P	O
<	O
.05	O
was	O
considered	O
statistically	O
significant	O
.	O
The	O
bone	O
resorption	O
lesion	B-T033
was	O
significantly	O
larger	O
in	O
the	O
AP	B-T047
group	O
compared	O
with	O
AP	B-T047
-O	O
,	O
C	O
,	O
and	O
C	O
-	O
O	O
groups	O
(	O
P	O
<	O
.05	O
)	O
.	O
The	O
level	O
of	O
inflammatory	O
cell	O
infiltration	O
was	O
significantly	O
elevated	O
,	O
and	O
the	O
number	O
of	O
tartrate	O
-	O
resistant	O
acid	O
phosphatase	O
-	O
positive	B-T033
osteoclasts	O
was	O
significantly	O
higher	O
in	O
the	O
periapical	O
lesions	B-T033
of	O
the	O
AP	B-T047
group	O
compared	O
with	O
AP	B-T047
-O	O
,	O
C	O
,	O
and	O
C	O
-	O
O	O
groups	O
(	O
P	O
<	O
.05	O
)	O
.	O
The	O
number	O
of	O
osteocalcin	O
-	O
positive	B-T033
osteoblasts	O
was	O
significantly	O
increased	O
in	O
the	O
AP	B-T047
-O	O
group	O
compared	O
with	O
the	O
AP	B-T047
group	O
(	O
P	O
>	O
.05	O
)	O
.	O
Supplementation	B-T061
with	O
ω-3	B-T121
PUFAs	I-T121
not	O
only	O
suppresses	O
bone	O
resorption	O
but	O
also	O
promotes	O
new	O
bone	O
formation	O
in	O
the	O
periapical	O
area	O
of	O
rats	O
with	O
AP	B-T047
in	O
conjunction	O
with	O
downregulation	O
of	O
inflammatory	O
cell	O
infiltration	O
into	O
the	O
lesion	B-T033
.	O
      
Early	O
hippocampal	B-T023
volume	B-T033
loss	I-T033
as	O
a	O
marker	O
of	O
eventual	O
memory	B-T048
deficits	I-T048
caused	O
by	O
repeated	B-T033
stress	I-T033
Exposure	O
to	O
severe	O
and	O
prolonged	O
stress	B-T033
has	O
detrimental	B-T033
effects	I-T033
on	O
the	O
hippocampus	B-T023
.	O
However	O
,	O
relatively	O
little	O
is	O
known	O
about	O
the	O
gradual	O
changes	O
in	O
hippocampal	B-T023
structure	I-T023
,	O
and	O
its	O
behavioral	O
consequences	O
,	O
over	O
the	O
course	O
of	O
repeated	B-T033
stress	I-T033
.	O
Behavioral	B-T058
analyses	I-T058
during	O
10	O
days	O
of	O
chronic	O
stress	O
pointed	O
to	O
a	O
delayed	O
decline	O
in	O
spatial	O
memory	O
,	O
the	O
full	O
impact	O
of	O
which	O
is	O
evident	O
only	O
after	O
the	O
end	O
of	O
stress	B-T033
.	O
In	O
contrast	O
,	O
concurrent	O
volumetric	O
measurements	O
in	O
the	O
same	O
animals	O
revealed	O
significant	O
reduction	O
in	O
hippocampal	B-T023
volumes	O
in	O
stressed	B-T033
animals	O
relative	O
to	O
their	O
unstressed	B-T033
counterparts	I-T033
,	O
as	O
early	O
as	O
the	O
third	O
day	O
of	O
stress	B-T033
.	O
Notably	O
,	O
animals	O
that	O
were	O
behaviorally	O
the	O
worst	O
affected	O
at	O
the	O
end	O
of	O
chronic	O
stress	O
suffered	B-T048
the	O
most	O
pronounced	O
early	B-T033
loss	I-T033
in	I-T033
hippocampal	I-T033
volume	I-T033
.	O
Together	O
,	O
these	O
findings	O
support	O
the	O
view	O
that	O
not	O
only	O
is	O
smaller	O
hippocampal	B-T023
volume	O
linked	O
to	O
stress	B-T033
-	O
induced	O
memory	B-T048
deficits	I-T048
,	O
but	O
it	O
may	O
also	O
act	O
as	O
an	O
early	O
risk	B-T033
factor	I-T033
for	O
the	O
eventual	O
development	O
of	O
cognitive	B-T048
impairments	I-T048
seen	O
in	O
stress	B-T048
-	I-T048
related	I-T048
psychiatric	I-T048
disorders	I-T048
.	O
      
De	O
Ritis	O
Ratio	O
(	O
AST	O
/	O
ALT	O
)	O
as	O
a	O
Significant	O
Prognostic	O
Factor	O
in	O
Patients	O
With	O
Upper	B-T191
Tract	I-T191
Urothelial	I-T191
Cancer	I-T191
Treated	O
With	O
Surgery	O
We	O
investigated	O
the	O
clinical	O
prognostic	O
value	O
of	O
preoperative	O
De	O
Ritis	O
ratio	O
(	O
aspartate	O
aminotransferase	O
[	O
AST]/alanine	O
aminotransferase	O
[	O
ALT	O
]	O
)	O
on	O
postsurgical	B-T033
survival	O
outcomes	O
in	O
patients	O
with	O
upper	B-T191
tract	I-T191
urothelial	I-T191
cancer	I-T191
(	O
UTUC	B-T191
)	O
.	O
We	O
retrospectively	O
analyzed	O
the	O
data	O
of	O
623	O
patients	O
who	O
underwent	O
radical	B-T061
nephrouretectomy	I-T061
for	O
UTUC	B-T191
.	O
Multivariate	O
regression	O
tests	O
were	O
performed	O
to	O
identify	O
possible	O
associations	O
between	O
adverse	O
pathologic	O
events	O
and	O
AST	O
/	O
ALT	O
.	O
The	O
risk	O
of	O
postoperative	O
progression	O
and	O
survival	O
were	O
tested	O
using	O
Kaplan	O
-	O
Meier	O
analyses	O
and	O
Cox	O
proportional	O
hazards	O
models	O
.	O
According	O
to	O
the	O
receiver	O
operator	O
characteristic	O
curve	O
of	O
AST	O
/	O
ALT	O
for	O
cancer	O
-	O
specific	O
mortality	O
,	O
patients	O
with	O
AST	O
/	O
ALT	O
value	O
≥1.5	O
were	O
regarded	O
as	O
the	O
high	O
AST	O
/	O
ALT	O
group	O
,	O
and	O
the	O
remaining	O
patients	O
formed	O
the	O
low	O
AST	O
/	O
ALT	O
group	O
.	O
In	O
Kaplan	O
-	O
Meier	O
analyses	O
,	O
the	O
high	O
AST	O
/	O
ALT	O
group	O
showed	O
worse	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
,	O
cancer	O
-	O
specific	O
survival	O
(	O
CSS	O
)	O
,	O
and	O
overall	O
survival	O
(	O
all	O
P	O
<	O
.001	O
)	O
.	O
Elevated	O
AST	O
/	O
ALT	O
was	O
associated	O
with	O
higher	O
T	O
stage	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
1.577	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.077	O
-	O
2.311	O
;	O
P	O
=	O
.033	O
)	O
and	O
higher	O
cellular	O
grade	O
(	O
HR	O
,	O
1.538	O
;	O
95	O
%	O
CI	O
,	O
1.034	O
-	O
2.287	O
;	O
P	O
=	O
.041	O
)	O
in	O
multivariate	O
regression	O
tests	O
.	O
In	O
multivariate	O
Cox	O
analyses	O
,	O
high	O
AST	O
/	O
ALT	O
was	O
revealed	O
as	O
an	O
independent	O
predictor	O
of	O
PFS	O
(	O
HR	O
,	O
2.335	O
;	O
95	O
%	O
CI	O
,	O
1.633	O
-	O
3.340	O
;	O
P	O
<	O
.001	O
)	O
,	O
CSS	O
(	O
HR	O
,	O
2.550	O
;	O
1.689	O
-	O
3.851	O
;	O
P	O
<	O
.001	O
)	O
,	O
and	O
overall	O
survival	O
(	O
HR	O
,	O
2.069	O
;	O
95	O
%	O
CI	O
,	O
1.409	O
-	O
3.038	O
;	O
P	O
<	O
.001	O
)	O
.	O
Elevated	O
preoperative	O
AST	O
/	O
ALT	O
was	O
a	O
significant	O
predictor	O
of	O
worse	B-T033
postoperative	O
survival	O
in	O
patients	O
surgically	B-T061
treated	I-T061
for	O
UTUC	B-T191
.	O
Further	O
large	O
prospective	O
studies	O
are	O
needed	O
for	O
better	O
understanding	O
of	O
the	O
prognostic	O
value	O
of	O
preoperative	O
AST	O
/	O
ALT	O
.	O
      
Neonatal	B-T047
infections	I-T047
:	O
Case	O
definition	O
and	O
guidelines	O
for	O
data	O
collection	O
,	O
analysis	O
,	O
and	O
presentation	O
of	O
immunisation	B-T061
safety	O
data	O
Maternal	B-T033
vaccination	B-T061
is	O
an	O
important	O
area	O
of	O
research	O
and	O
requires	O
appropriate	O
and	O
internationally	O
comparable	O
definitions	O
and	O
safety	O
standards	O
.	O
The	O
GAIA	O
group	O
,	O
part	O
of	O
the	O
Brighton	O
Collaboration	O
was	O
created	O
with	O
the	O
mandate	O
of	O
proposing	O
standardised	O
definitions	O
applicable	O
to	O
maternal	B-T033
vaccine	B-T121
research	O
.	O
This	O
study	O
proposes	O
international	O
definitions	O
for	O
neonatal	B-T047
infections	I-T047
.	O
The	O
neonatal	B-T047
infections	I-T047
GAIA	O
working	O
group	O
performed	O
a	O
literature	O
review	O
using	O
Medline	O
,	O
EMBASE	O
and	O
the	O
Cochrane	O
collaboration	O
and	O
collected	O
definitions	O
in	O
use	O
in	O
neonatal	O
and	O
public	O
health	O
networks	O
.	O
The	O
common	O
criteria	O
derived	O
from	O
the	O
extensive	O
search	O
formed	O
the	O
basis	O
for	O
a	O
consensus	O
process	O
that	O
resulted	O
in	O
three	O
separate	O
definitions	O
for	O
neonatal	O
blood	O
stream	O
infections	O
(	O
BSI	O
)	O
,	O
meningitis	B-T047
and	O
lower	B-T047
respiratory	I-T047
tract	I-T047
infections	I-T047
(	O
LRTI	B-T047
)	O
.	O
For	O
each	O
definition	O
three	O
levels	O
of	O
evidence	O
are	O
proposed	O
to	O
ensure	O
the	O
applicability	O
of	O
the	O
definitions	O
to	O
different	O
settings	O
.	O
Recommendations	O
about	O
data	O
collection	O
,	O
analysis	O
and	O
presentation	O
are	O
presented	O
and	O
harmonized	O
with	O
the	O
Brighton	O
Collaboration	O
and	O
GAIA	O
format	O
and	O
other	O
existing	O
international	O
standards	O
for	O
study	O
reporting	O
.	O
      
Vestibular	B-T047
disorders	I-T047
and	O
nausea	B-T184
during	O
head	B-T191
and	O
neck	B-T191
intensity	B-T061
-	I-T061
modulated	I-T061
radiation	I-T061
therapy	I-T061
We	O
studied	O
whether	O
there	O
is	O
a	O
relationship	O
between	O
nausea	B-T184
and	O
vestibular	B-T047
disorders	I-T047
in	O
patients	O
treated	B-T061
with	I-T061
intensity	B-T061
modulated	I-T061
radiation	I-T061
therapy	I-T061
(	O
IMRT	B-T061
)	O
for	O
head	B-T191
and	O
neck	B-T191
cancer	I-T191
.	O
We	O
performed	O
a	O
prospective	O
single	O
-	O
centre	O
study	O
that	O
enrolled	B-T058
31	O
patients	O
.	O
A	O
videonystagmography	B-T061
was	O
carried	O
out	O
before	O
and	O
within	O
15	O
days	O
after	O
radiation	B-T061
therapy	I-T061
for	O
each	O
patient	O
.	O
Nausea	B-T184
was	O
assessed	O
at	O
baseline	O
,	O
every	O
week	O
,	O
and	O
at	O
the	O
post	B-T061
-	I-T061
radiotherapy	I-T061
videonystagmography	B-T061
visit	O
.	O
Twenty	O
-	O
six	O
patients	O
had	O
benefited	O
from	O
a	O
complete	O
interpretable	O
videonystagmography	B-T061
.	O
For	O
14	O
of	O
these	O
patients	O
vestibular	B-T033
damage	I-T033
was	O
diagnosed	B-T033
post	B-T061
-	I-T061
radiotherapy	I-T061
.	O
During	O
irradiation	O
,	O
six	O
patients	O
felt	O
nauseous	B-T184
,	O
but	O
without	O
dizziness	B-T184
.	O
In	O
univariate	O
analysis	O
,	O
we	O
found	O
a	O
relationship	O
statistically	O
significant	O
between	O
the	O
average	O
dose	O
received	O
by	O
the	O
vestibules	O
and	O
vestibular	B-T047
disorder	I-T047
videonystagmography	B-T061
(	O
P=0.001	O
,	O
odds	O
ratio	O
[	O
OR	O
]	O
:	O
1.08	O
[	O
1.025-.138	O
]	O
)	O
,	O
but	O
there	O
was	O
no	B-T033
relationship	O
between	O
vestibular	B-T047
disorder	I-T047
videonystagmography	B-T061
and	O
nausea	B-T184
(	O
P=0.701	O
)	O
.	O
Irradiation	O
of	O
the	O
vestibular	O
system	O
during	O
IMRT	B-T061
does	O
not	O
seem	O
to	O
explain	O
the	O
nausea	B-T184
.	O
      
The	O
Chinese	O
Herbal	O
Mixture	O
Tien	B-T121
-	I-T121
Hsien	I-T121
Liquid	I-T121
Augments	O
the	O
Anticancer	O
Immunity	O
in	O
Tumor	O
Cell	O
-	O
Vaccinated	B-T033
Mice	O
Background	O
The	O
Chinese	O
herbal	O
mixture	O
,	O
Tien	B-T121
-	I-T121
Hsien	I-T121
liquid	I-T121
(	O
THL	B-T121
)	O
,	O
has	O
been	O
used	O
as	O
an	O
anticancer	O
dietary	O
supplement	O
for	O
more	O
than	O
20	O
years	O
.	O
Our	O
previous	O
studies	O
have	O
shown	O
that	O
THL	B-T121
can	O
modulate	O
immune	O
response	O
and	O
inhibit	O
tumor	B-T191
growth	I-T191
.	O
In	O
this	O
study	O
,	O
we	O
further	O
evaluated	B-T058
the	O
effect	O
of	O
THL	B-T121
on	O
anticancer	O
immune	O
response	O
in	O
mice	O
vaccinated	B-T033
with	O
γ	O
-	O
ray	O
-	O
irradiated	O
tumor	O
cells	O
.	O
Methods	O
The	O
antitumor	O
effect	O
of	O
THL	B-T121
was	O
determined	O
in	O
mice	O
vaccinated	B-T033
with	O
low	O
-	O
tumorigenic	O
CT-26	O
-	O
low	O
colon	O
cancer	O
cells	O
or	O
γ	B-T061
-	I-T061
ray	I-T061
-	I-T061
irradiated	I-T061
high	O
-	O
tumorigenic	O
CT-26	O
-	O
high	O
colon	O
cancer	O
cells	O
.	O
The	O
number	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
and	O
T	O
lymphocytes	O
in	O
the	O
spleen	B-T023
was	O
analyzed	O
by	O
flow	B-T059
cytometry	I-T059
.	O
The	O
tumor	B-T191
-	O
killing	O
activities	O
of	O
NK	O
cells	O
and	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
were	O
analyzed	O
by	O
flow	B-T059
cytometry	I-T059
using	O
YAC-1	O
and	O
CT-26	O
-	O
high	O
cells	O
,	O
respectively	O
,	O
as	O
target	O
cells	O
.	O
The	O
levels	O
of	O
IFN	B-T121
-	I-T121
γ	I-T121
,	O
IL-2	O
,	O
and	O
TNF	O
-	O
α	O
were	O
determined	O
by	O
ELISA	B-T059
.	O
Results	O
THL	B-T121
suppressed	O
the	O
growth	O
of	O
CT-26	O
-	O
high	O
tumor	O
in	O
mice	O
previously	O
vaccinated	B-T033
with	O
low	O
-	O
tumorigenic	O
CT-26	O
-	O
low	O
cells	O
or	O
γ	B-T061
-	I-T061
irradiated	I-T061
CT-26	O
-	O
high	O
cells	O
.	O
THL	B-T121
increased	O
the	O
populations	O
of	O
NK	O
cells	O
and	O
CD4	O
+	O
T	O
lymphocytes	O
in	O
the	O
spleen	B-T023
and	O
enhanced	O
the	O
tumor	B-T191
-	O
killing	O
activities	O
of	O
NK	O
cells	O
and	O
CTL	O
in	O
mice	O
vaccinated	B-T033
with	O
γ	B-T061
-	I-T061
irradiated	I-T061
CT-26	O
-	O
high	O
cells	O
.	O
THL	B-T121
increased	O
the	O
production	O
of	O
IFN	B-T121
-	I-T121
γ	I-T121
,	O
IL-2	O
,	O
and	O
TNF	O
-	O
α	O
in	O
mice	O
vaccinated	B-T033
with	O
γ	B-T061
-	I-T061
irradiated	I-T061
CT-26	O
-	O
high	O
cells	O
.	O
Conclusion	O
THL	B-T121
can	O
enhance	O
the	O
antitumor	O
immune	O
responses	O
in	O
mice	O
vaccinated	B-T033
with	O
killed	O
tumor	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
THL	B-T121
may	O
be	O
used	O
as	O
a	O
complementary	O
medicine	O
for	O
cancer	B-T191
patients	O
previously	O
treated	O
with	O
killed	B-T121
tumor	I-T121
cell	I-T121
vaccines	I-T121
,	O
radiotherapy	B-T061
,	O
or	O
chemotherapy	B-T061
.	O
      
Maf1	O
-mediated	O
regulation	O
of	O
yeast	O
RNA	O
polymerase	O
III	O
is	O
correlated	O
with	O
CCA	O
addition	O
at	O
the	O
3	O
'	O
end	O
of	O
tRNA	O
precursors	O
In	O
eukaryotic	O
cells	O
tRNA	O
synthesis	O
is	O
negatively	B-T033
regulated	O
by	O
the	O
protein	O
Maf1	O
,	O
conserved	O
from	O
yeast	O
to	O
humans	O
.	O
Maf1	O
from	O
yeast	O
Saccharomyces	O
cerevisiae	O
mediates	O
repression	O
of	O
trna	O
transcription	O
when	O
cells	O
are	O
transferred	O
from	O
medium	O
with	O
glucose	B-T121
to	O
medium	O
with	O
glycerol	B-T121
,	O
a	O
non	O
-	O
fermentable	O
carbon	O
source	B-T033
.	O
The	O
strain	B-T001
with	O
deleted	B-T033
gene	O
encoding	O
Maf1	O
(	O
maf1Δ	O
)	O
is	O
viable	O
but	O
accumulates	O
tRNA	O
precursors	O
.	O
In	O
this	O
study	O
tRNA	O
precursors	O
were	O
analysed	O
by	O
RNA	B-T059
-	I-T059
Seq	I-T059
and	O
Northern	B-T059
hybridization	I-T059
in	O
wild	O
type	O
strain	B-T001
and	O
maf1Δ	O
mutant	O
grown	O
in	O
glucose	B-T121
medium	O
or	O
upon	O
shift	O
to	O
repressive	O
conditions	O
.	O
A	O
negative	B-T033
effect	O
of	O
maf1Δ	O
mutant	O
on	O
the	O
addition	O
of	O
the	O
auxiliary	O
CCA	O
nucleotides	O
to	O
the	O
3	O
'	O
end	O
of	O
pre	O
-	O
tRNAs	O
was	O
observed	O
in	O
cells	O
shifted	O
to	O
unfavourable	O
growth	O
conditions	O
.	O
This	O
effect	O
was	O
reduced	O
by	O
overexpression	O
of	O
the	O
yeast	O
CCA1	O
gene	O
encoding	O
ATP(CTP):tRNA	O
nucleotidyltransferase	O
.	O
The	O
CCA	O
sequence	O
at	O
the	O
3	O
'	O
end	O
is	O
important	O
for	O
export	O
of	O
tRNA	O
precursors	O
from	O
the	O
nucleus	O
and	O
essential	O
for	O
tRNA	O
charging	O
with	O
amino	B-T121
acids	I-T121
.	O
Data	O
presented	O
here	O
indicate	O
that	O
CCA	O
-	O
addition	O
to	O
intron	O
-containing	O
end	O
-	O
processed	O
tRNA	O
precursors	O
is	O
a	O
limiting	O
step	O
in	O
tRNA	O
maturation	O
when	O
there	O
is	O
no	O
Maf1	O
mediated	O
RNA	O
polymerase	O
III	O
(	O
Pol	O
III	O
)	O
repression	O
.	O
The	O
correlation	O
between	O
CCA	O
synthesis	O
and	O
Pol	O
III	O
regulation	O
by	O
Maf1	O
could	O
be	O
important	O
in	O
coordination	O
of	O
tRNA	O
transcription	O
,	O
processing	O
and	O
regulation	O
of	O
translation	O
.	O
      
MESOTHELIAL	O
CELL	O
ADHERENCE	O
TO	O
VASCULAR	O
PROSTHESES	O
AND	O
THEIR	O
SUBSEQUENT	O
GROWTH	O
IN	O
VITRO	O
Cell	O
seeding	B-T059
may	O
decrease	O
the	O
thrombogenicity	O
of	O
implanted	O
vascular	O
grafts	O
,	O
but	O
its	O
application	O
is	O
hampered	O
by	O
the	O
limited	O
availability	O
of	O
autologous	O
endothelial	O
cells	O
.	O
Human	O
peritoneal	O
mesothelial	O
cells	O
have	O
blood	O
flow	O
supporting	O
qualities	O
and	O
are	O
readily	O
available	O
.	O
This	O
study	O
investigated	O
the	O
adherence	O
of	O
mesothelial	O
cells	O
to	O
vascular	O
prostheses	O
and	O
their	O
subsequent	O
growth	O
in	O
vitro	O
.	O
Circular	O
pieces	O
of	O
various	O
vascular	O
prosthetic	O
materials	O
were	O
seeded	B-T059
with	O
51Chromium	B-T121
-	I-T121
labeled	I-T121
mesothelial	O
and	O
endothelial	O
cells	O
and	O
left	O
for	O
either	O
5	O
,	O
15	O
,	O
30	O
,	O
60	O
,	O
and	O
120	O
minutes	O
.	O
The	O
unattached	B-T033
cells	O
were	O
removed	O
and	O
the	O
degree	O
of	O
cell	O
attachment	O
was	O
measured	O
.	O
The	O
number	O
of	O
mesothelial	O
cells	O
to	O
Dacron	O
increased	O
during	O
the	O
first	O
60	O
min	O
up	O
to	O
35.2	O
%	O
of	O
the	O
seeded	B-T059
inoculum	O
where	O
after	O
a	O
plateau	O
was	O
reached	B-T033
.	O
Scanning	B-T059
electron	I-T059
microscopy	I-T059
showed	O
spreaded	O
mesothelial	O
cells	O
adherent	O
to	O
the	O
Dacron	O
fibers	O
.	O
A	O
significant	O
increase	O
in	O
adherence	O
was	O
observed	O
after	O
preincubation	B-T059
of	O
Dacron	O
with	O
10	O
μg	O
/	O
mL	O
fibronectin	O
,	O
but	O
no	B-T033
improvement	I-T033
was	O
found	B-T033
after	O
preincubation	B-T059
with	O
human	O
serum	O
albumin	O
or	O
gelatin	B-T121
.	O
Mesothelial	O
cells	O
adhered	O
better	O
to	O
Gelcoated	O
than	O
to	O
Gelsealed	O
or	O
plain	O
Dacron	O
.	O
The	O
adherence	O
of	O
mesothelial	O
cells	O
to	O
ePTFE	O
(	O
Teflon	O
)	O
was	O
significantly	O
poorer	O
.	O
No	B-T033
significant	I-T033
differences	O
in	O
adherence	O
were	O
found	B-T033
between	O
mesothelial	O
and	O
endothelial	O
cells	O
.	O
Mesothelial	O
cell	O
growth	O
on	O
Dacron	O
resulted	O
in	O
a	O
modest	O
increase	O
in	O
the	O
number	O
of	O
viable	O
cells	O
during	O
27	O
days	O
,	O
which	O
implies	O
biocompatibility	O
of	O
Dacron	O
and	O
mesothelial	O
cells	O
in	O
vitro	O
.	O
      
Clinical	B-T058
Observation	I-T058
of	O
Treatment	O
of	O
Chronic	O
Subdural	O
Hematoma	O
With	O
Novel	O
Double	O
Needle	O
Minimally	O
Invasive	O
Aspiration	O
Technology	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
explore	O
the	O
clinical	O
effects	O
,	O
including	O
the	O
prevention	O
of	O
complications	O
,	O
of	O
the	O
treatment	O
of	O
chronic	O
subdural	O
hematoma	O
with	O
double	O
needle	O
aspiration	O
.	O
The	O
clinical	O
data	O
of	O
31	O
patients	O
with	O
chronic	O
subdural	O
hematoma	O
treated	O
by	O
double	O
YL-1	O
needle	O
double	O
skull	B-T061
drilling	I-T061
and	O
31	O
controls	O
treated	O
by	O
traditional	O
drilling	B-T061
and	O
drainage	B-T061
were	O
analyzed	O
retrospectively	O
.	O
In	O
the	O
YL-1	O
needle	O
group	O
,	O
only	O
1	O
patient	O
was	O
with	O
hematoma	O
recurrence	O
,	O
1	O
patient	O
was	O
with	O
intracranial	B-T047
pneumocephalus	I-T047
,	O
and	O
the	O
remaining	O
patients	O
who	O
were	O
followed	O
up	O
for	O
3	O
months	O
achieved	O
a	O
clinical	B-T033
cure	I-T033
.	O
In	O
the	O
traditional	B-T061
drilling	I-T061
and	O
drainage	B-T061
group	O
,	O
13	O
patients	O
were	O
with	O
hematoma	O
recurrence	O
within	O
3	O
months	O
after	O
the	O
operation	B-T061
and	O
7	O
patients	O
were	O
with	O
postoperative	O
intracranial	B-T047
pneumocephalus	I-T047
.	O
The	O
method	O
of	O
double	O
YL-1	O
needle	O
is	O
better	O
than	O
the	O
traditional	B-T061
drilling	I-T061
and	O
drainage	B-T061
method	I-T061
for	O
the	O
treatment	O
of	O
chronic	O
subdural	O
hematoma	O
because	O
it	O
reduces	O
the	O
postoperative	O
recurrence	O
rate	O
and	O
complications	O
.	O
      
Reimbursement	O
Based	O
on	O
Value	O
in	O
Knee	B-T061
Surgery	I-T061
:	O
What	O
You	O
Need	O
to	O
Know	O
about	O
the	O
Medicare	O
Access	O
and	O
Children	O
's	O
Health	O
Insurance	O
Program	O
Reauthorization	O
Act	O
of	O
2015	O
Health	O
care	O
cost	O
is	O
consuming	O
a	O
large	O
portion	O
of	O
the	O
nation	O
's	O
gross	O
domestic	O
product	O
while	O
placing	O
added	O
economic	O
burdens	O
on	O
physicians	O
and	O
their	O
patients	O
.	O
With	O
total	B-T061
joint	I-T061
replacement	I-T061
being	O
one	O
of	O
the	O
early	O
-	O
targeted	O
procedures	B-T061
in	O
the	O
evolving	O
health	O
care	O
environment	O
,	O
knee	O
surgeons	O
will	O
benefit	O
from	O
developing	O
a	O
critical	O
knowledge	O
on	O
health	O
care	O
reforms	O
and	O
their	O
financial	O
implications	O
.	O
The	O
Medicare	O
Access	O
and	O
Children	O
's	O
Health	O
Insurance	O
Program	O
Reauthorization	O
Act	O
represents	O
a	O
cohesive	O
movement	O
toward	O
value	O
-	O
based	O
payment	O
reform	O
and	O
contains	O
several	O
unchartered	O
rulings	O
that	O
require	O
detailed	O
attention	O
by	O
knee	O
surgeons	O
.	O
In	O
this	O
article	O
,	O
we	O
provide	O
a	O
contextual	O
framework	O
of	O
health	O
care	O
legislation	O
that	O
has	O
led	O
to	O
the	O
formation	O
of	O
the	O
current	O
health	O
policy	O
,	O
and	O
present	O
a	O
comprehensive	O
summary	O
and	O
update	O
on	O
the	O
Merit	O
-	O
Based	O
Incentive	O
Payment	O
Systems	O
and	O
Alternative	O
Payment	O
Models	O
reimbursement	O
models	O
.	O
      
Comparison	O
between	O
magnetic	B-T060
resonance	I-T060
imaging	I-T060
and	O
B	B-T060
-	I-T060
mode	I-T060
ultrasound	I-T060
in	O
detecting	B-T033
and	O
estimating	O
the	O
extent	O
of	O
human	O
carotid	B-T047
atherosclerosis	I-T047
In	O
MRI	B-T060
studies	I-T060
of	O
carotid	B-T020
plaques	I-T020
,	O
ultrasound	B-T060
is	O
used	O
to	O
find	B-T033
plaques	B-T033
,	O
which	O
are	O
later	O
imaged	O
using	O
MRI	B-T060
.	O
The	O
performance	O
in	O
plaque	B-T033
detection	B-T033
has	O
not	O
been	O
compared	O
between	O
the	O
modalities	O
.	O
The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
compare	O
the	O
performance	O
of	O
MRI	B-T060
and	O
ultrasound	B-T060
in	O
detecting	B-T033
carotid	B-T020
artery	I-T020
plaques	I-T020
and	O
measuring	O
extent	O
of	O
atherosclerosis	B-T047
.	O
Subjects	O
with	O
at	O
least	O
one	O
plaque	B-T033
(	O
height	O
≥2·5	O
mm	O
)	O
on	O
ultrasound	B-T060
were	O
imaged	O
using	O
MRI	B-T060
.	O
The	O
number	O
of	O
plaques	B-T033
and	O
their	O
height	O
was	O
measured	O
in	O
both	O
modalities	O
;	O
plaque	B-T033
area	O
and	O
volume	O
were	O
analysed	O
on	O
ultrasound	B-T060
and	O
MRI	B-T060
,	O
respectively	O
.	O
Thirty	O
-	O
eight	O
subjects	O
were	O
included	O
.	O
MRI	B-T060
detected	B-T033
plaques	B-T033
in	O
95	O
%	O
of	O
carotid	B-T023
arteries	I-T023
with	O
a	O
plaque	B-T033
height	O
of	O
≥2·5	O
mm	O
on	O
ultrasound	B-T060
and	O
in	O
all	O
carotid	B-T023
arteries	I-T023
with	O
a	O
plaque	B-T033
exceeding	O
2·5	O
mm	O
.	O
MRI	B-T060
detected	B-T033
53	O
%	O
of	O
the	O
plaques	B-T033
with	O
a	O
height	O
below	O
2·5	O
mm	O
.	O
The	O
plaque	B-T033
height	O
measured	O
with	O
both	O
techniques	O
correlated	O
significantly	O
,	O
0·59	O
,	O
P<0·0001	O
.	O
Ultrasound	B-T060
-derived	O
plaque	B-T033
height	O
and	O
plaque	B-T033
area	O
correlated	O
similarly	O
to	O
MRI	B-T060
-derived	O
plaque	B-T033
volume	O
,	O
r	O
=	O
0·52	O
;	O
P<0·0001	O
and	O
r	O
=	O
0·47	O
;	O
P	O
=	O
0·001	O
,	O
respectively	O
.	O
We	O
conclude	O
that	O
MRI	B-T060
has	O
a	O
similar	O
sensitivity	O
to	O
ultrasound	B-T060
in	O
finding	B-T033
carotid	B-T020
artery	I-T020
plaques	I-T020
that	O
are	O
2·5	O
mm	O
or	O
higher	O
.	O
In	O
smaller	O
plaques	B-T033
,	O
MRI	B-T060
detects	B-T033
fewer	O
plaques	B-T033
.	O
Multiple	B-T020
carotid	I-T020
plaques	I-T020
seen	O
on	O
ultrasound	B-T060
most	O
often	O
are	O
a	O
misinterpretation	O
of	O
the	O
anatomy	O
and	O
correspond	O
to	O
a	O
single	B-T033
plaque	I-T033
.	O
Plaque	B-T033
height	O
on	O
ultrasound	B-T060
is	O
comparable	O
to	O
plaque	B-T033
height	O
on	O
MRI	B-T060
and	O
correlates	O
fairly	O
well	O
with	O
plaque	B-T033
volume	O
on	O
MRI	B-T060
making	O
it	O
an	O
interesting	O
proxy	O
for	O
plaque	B-T033
burden	O
.	O
      
Preliminary	O
Randomized	O
Controlled	O
Trial	O
of	O
Habit	B-T061
Reversal	I-T061
Training	I-T061
for	O
Treatment	B-T061
of	O
Hair	B-T048
Pulling	I-T048
in	O
Youth	O
This	O
study	O
evaluated	B-T058
the	O
treatment	B-T061
efficacy	O
of	O
habit	B-T061
reversal	I-T061
training	I-T061
(	O
HRT	B-T061
)	O
relative	O
to	O
treatment	O
as	O
usual	O
(	O
TAU	O
)	O
for	O
children	O
and	O
adolescents	O
aged	O
7	O
-	O
17	O
years	O
with	O
a	O
primary	O
diagnosis	O
of	O
trichotillomania	B-T048
(	O
TTM	B-T048
)	O
.	O
An	O
initial	O
assessment	B-T058
consisting	O
of	O
semistructured	O
interviews	O
and	O
rating	O
scales	O
was	O
conducted	O
.	O
Participants	O
(	O
N	O
=	O
40	O
,	O
85	O
%	O
female	O
)	O
meeting	O
diagnostic	O
criteria	O
for	O
TTM	B-T048
were	O
randomized	O
to	O
either	O
8	O
weekly	O
sessions	O
of	O
HRT	B-T061
by	O
trained	O
therapists	O
or	O
8	O
weeks	O
of	O
TAU	O
.	O
One	O
week	O
after	O
the	O
final	O
HRT	B-T061
session	O
or	O
final	O
TAU	O
week	O
,	O
patients	O
completed	O
a	O
posttreatment	B-T058
assessment	I-T058
,	O
followed	O
by	O
1-	O
and	O
3-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
assessments	B-T058
.	O
All	O
assessments	B-T058
were	O
conducted	O
by	O
a	O
trained	O
rater	O
who	O
was	O
blinded	O
to	O
treatment	B-T061
condition	O
.	O
The	O
group	O
by	O
time	O
analysis	O
of	O
variance	O
yielded	O
a	O
significant	O
interaction	O
on	O
the	O
National	O
Institute	O
of	O
Mental	O
Health	O
-	O
Trichotillomania	O
Severity	O
Scale	O
Total	O
Score	O
(	O
F1,38	O
=	O
16.47	O
,	O
p	O
<	O
0.001	O
,	O
η(2)p	O
=	O
0.30	O
)	O
.	O
The	O
mean	B-T033
score	I-T033
decreased	O
from	O
12.67	O
±	O
4.60	O
at	O
baseline	O
to	O
5.62	O
±	O
4.38	O
at	O
posttreatment	B-T058
in	O
the	O
HRT	B-T061
group	O
(	O
t20	O
=	O
5.99	O
,	O
p	O
<	O
0.001	O
,	O
d	O
=	O
1.31	O
)	O
,	O
whereas	O
the	O
TAU	O
group	O
changed	O
from	O
10.42	O
±	O
4.35	O
to	O
9.32	O
±	O
4.11	O
(	O
t18	O
=	O
1.34	O
,	O
p	O
=	O
0.20	O
,	O
d	O
=	O
0.31	O
)	O
.	O
The	O
Massachusetts	O
General	O
Hospital	O
-	O
Hair	O
Pulling	O
Scale	O
Total	O
Score	O
decreased	O
from	O
15.14	O
±	O
3.86	O
at	O
baseline	O
to	O
7.14	O
±	O
5.54	O
at	O
posttreatment	B-T058
in	O
the	O
HRT	B-T061
group	O
(	O
t20	O
=	O
6.16	O
,	O
p	O
<	O
0.001	O
,	O
d	O
=	O
1.34	O
)	O
;	O
the	O
TAU	O
group	O
changed	O
from	O
14.16	O
±	O
4.51	O
to	O
12.26	O
±	O
4.34	O
(	O
t18	O
=	O
1.50	O
,	O
p	O
=	O
0.15	O
,	O
d	O
=	O
0.34	O
)	O
.	O
On	O
the	O
Clinical	O
Global	O
Impressions	O
-	O
Improvement	O
,	O
16/21	O
participants	O
(	O
76	O
%	O
)	O
were	O
rated	O
as	O
treatment	B-T061
responders	O
in	O
the	O
HRT	B-T061
group	O
versus	O
4/19	O
(	O
21	O
%	O
)	O
in	O
the	O
TAU	O
group	O
(	O
χ(2	O
)	O
=	O
12.13	O
,	O
p	O
<	O
0.001	O
,	O
V	O
=	O
0.55	O
)	O
.	O
At	O
1-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
,	O
10	O
-	O
12	O
treatment	B-T061
responders	O
who	O
completed	O
the	O
assessment	B-T058
maintained	O
improvement	O
.	O
At	O
3-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
,	O
six	O
of	O
eight	O
maintained	O
improvement	O
.	O
HRT	B-T061
can	O
be	O
an	O
effective	O
treatment	B-T061
for	O
TTM	B-T048
in	O
youth	O
.	O
      
Cobalamin	O
Protection	B-T033
against	O
Oxidative	O
Stress	O
in	O
the	O
Acidophilic	O
Iron	B-T007
-	I-T007
oxidizing	I-T007
Bacterium	I-T007
Leptospirillum	B-T007
Group	I-T007
II	I-T007
CF-1	I-T007
Members	O
of	O
the	O
genus	O
Leptospirillum	B-T007
are	O
aerobic	O
iron	B-T007
-	I-T007
oxidizing	I-T007
bacteria	I-T007
belonging	O
to	O
the	O
phylum	B-T007
Nitrospira	I-T007
.	O
They	O
are	O
important	O
members	O
of	O
microbial	B-T001
communities	O
that	O
catalyze	O
the	O
biomining	O
of	O
sulfidic	O
ores	O
,	O
thereby	O
solubilizing	O
metal	O
ions	O
.	O
These	O
microorganisms	B-T001
live	O
under	O
extremely	O
acidic	O
and	O
metal	O
-loaded	O
environments	O
and	O
thus	O
must	O
tolerate	O
high	O
concentrations	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O
Cobalamin	O
(	O
vitamin	B-T121
B12	I-T121
)	O
is	O
a	O
cobalt	O
-containing	O
tetrapyrrole	O
cofactor	O
involved	O
in	O
intramolecular	O
rearrangement	O
reactions	O
and	O
has	O
recently	O
been	O
suggested	O
to	O
be	O
an	O
intracellular	O
antioxidant	B-T121
.	O
In	O
this	O
work	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
the	O
exogenous	O
addition	O
of	O
cobalamin	O
on	O
oxidative	O
stress	O
parameters	O
in	O
Leptospirillum	B-T007
group	I-T007
II	I-T007
strain	I-T007
CF-1	I-T007
.	O
Our	O
results	O
revealed	O
that	O
the	O
external	O
supplementation	O
of	O
cobalamin	O
reduces	O
the	O
levels	O
of	O
intracellular	O
ROSs	O
and	O
the	O
damage	O
to	O
biomolecules	O
,	O
and	O
also	O
stimulates	O
the	O
growth	O
and	O
survival	O
of	O
cells	O
exposed	O
to	O
oxidative	O
stress	O
exerted	O
by	O
ferric	O
ion	O
,	O
hydrogen	B-T121
peroxide	I-T121
,	O
chromate	O
and	O
diamide	B-T121
.	O
Furthermore	O
,	O
exposure	O
of	O
strain	B-T007
CF-1	I-T007
to	O
oxidative	O
stress	O
elicitors	O
resulted	O
in	O
the	O
transcriptional	O
activation	O
of	O
the	O
cbiA	O
gene	O
encoding	O
CbiA	O
of	O
the	O
cobalamin	O
biosynthetic	O
pathway	O
.	O
Altogether	O
,	O
these	O
data	O
suggest	O
that	O
cobalamin	O
plays	O
an	O
important	O
role	O
in	O
redox	O
protection	B-T033
of	O
Leptospirillum	B-T007
strain	I-T007
CF-1	I-T007
,	O
supporting	O
survival	O
of	O
this	O
microorganism	B-T001
under	O
extremely	O
oxidative	O
environmental	O
conditions	O
.	O
Understanding	O
the	O
mechanisms	O
underlying	O
the	O
protective	B-T033
effect	O
of	O
cobalamin	O
against	O
oxidative	O
stress	O
may	O
help	O
to	O
develop	O
strategies	O
to	O
make	O
biomining	O
processes	O
more	O
effective	O
.	O
      
Temporal	O
and	O
Spatial	O
Variability	O
of	O
Fungal	B-T017
Structures	I-T017
and	O
Host	O
Responses	O
in	O
an	O
Incompatible	O
Rust	O
-	O
Wheat	O
Interaction	O
Information	O
about	O
temporal	O
and	O
spatial	O
variability	O
of	O
fungal	B-T017
structures	I-T017
and	O
host	O
responses	O
is	O
scarce	O
in	O
comparison	O
to	O
the	O
vast	O
amount	O
of	O
genetic	O
,	O
biochemical	O
,	O
and	O
physiological	O
studies	O
of	O
host	O
-	O
pathogen	O
interactions	O
.	O
In	O
this	O
study	O
,	O
we	O
used	O
avirulent	O
wild	O
type	O
and	O
virulent	O
mutant	O
isolates	O
of	O
Puccinia	O
striiformis	O
to	O
characterize	O
the	O
interactions	O
in	O
wheat	O
carrying	O
yellow	O
rust	O
Yr2	O
resistance	O
.	O
Both	O
conventional	O
and	O
advanced	O
microscopic	O
techniques	O
were	O
used	O
for	O
a	O
detailed	O
study	O
of	O
morphology	O
and	O
growth	O
of	O
fungal	O
colonies	O
and	O
associated	O
host	O
cell	O
responses	O
.	O
The	O
growth	O
of	O
the	O
wild	O
type	O
isolates	O
was	O
highly	O
restricted	O
due	O
to	O
hypersensitive	O
response	O
(	O
HR	O
,	O
plant	O
cell	O
death	O
)	O
indicated	B-T033
by	O
autofluorescence	B-T059
and	O
change	O
in	O
the	O
shape	O
of	O
the	O
affected	O
plant	O
cells	O
.	O
The	O
host	O
response	O
appeared	O
post	O
-	O
haustorial	B-T017
,	O
but	O
large	O
variation	O
in	O
the	O
time	O
and	O
stage	O
of	O
arrest	O
was	O
observed	O
for	O
individual	O
fungal	O
colonies	O
,	O
probably	O
due	O
to	O
a	O
delay	O
between	O
detection	B-T061
and	O
response	O
.	O
Some	O
colonies	O
were	O
stopped	O
right	O
after	O
the	O
formation	O
of	O
the	O
primary	B-T047
infection	I-T047
hyphae	O
whereas	O
others	O
formed	O
highly	O
branched	O
mycelia	O
.	O
HR	O
was	O
first	O
observed	O
in	O
host	O
cells	O
in	O
direct	O
contact	O
with	O
fungal	B-T017
structures	I-T017
,	O
after	O
which	O
the	O
defense	O
responses	O
spread	O
to	O
adjacent	O
host	O
cells	O
,	O
and	O
eventually	O
led	O
to	O
encasement	O
of	O
the	O
fungal	O
colony	O
.	O
Several	O
cells	O
with	O
HR	O
contained	O
haustoria	B-T017
,	O
which	O
were	O
small	O
and	O
underdeveloped	O
,	O
but	O
some	O
cells	O
contained	O
normal	O
sized	O
haustoria	B-T017
without	O
signs	B-T184
of	O
hypersensitivity	O
.	O
The	O
growth	O
of	O
the	O
virulent	O
mutants	O
in	O
the	O
resistant	O
plants	O
was	O
similar	O
to	O
the	O
growth	O
in	O
plants	O
without	O
Yr2	O
resistance	O
,	O
which	O
is	O
a	O
strong	O
indication	O
that	O
the	O
incompatible	O
phenotype	O
was	O
associated	O
with	O
Yr2	O
.	O
The	O
interaction	O
between	O
P.	O
striiformis	O
and	O
wheat	O
with	O
Yr2	O
resistance	O
was	O
highly	O
variable	O
in	O
time	O
and	O
space	O
,	O
which	O
demonstrate	O
that	O
histological	O
studies	O
are	O
important	O
for	O
a	O
deeper	O
understanding	O
of	O
host	O
-	O
pathogen	O
interactions	O
and	O
plant	O
defense	O
mechanisms	O
in	O
general	O
.	O
      
Comparison	O
of	O
Occlusive	O
and	O
Open	O
Application	O
in	O
a	O
Psoriasis	O
Plaque	O
Test	O
Design	O
,	O
Exemplarily	O
Using	O
Investigations	O
of	O
Mapracorat	B-T121
0.1	O
%	O
Ointment	O
versus	O
Vehicle	O
and	O
Reference	O
Drugs	B-T121
Psoriasis	O
plaque	O
tests	O
(	O
PPTs	O
)	O
are	O
important	O
tools	O
in	O
the	O
early	O
phases	O
of	O
antipsoriatic	B-T121
drug	O
development	O
.	O
Two	O
distinct	O
PPT	O
design	O
variants	O
(	O
open	O
vs.	O
occluded	O
drug	O
application	O
)	O
are	O
commonly	O
used	O
,	O
but	O
no	O
previous	O
work	O
has	O
aimed	O
to	O
directly	O
compare	O
and	O
contrast	O
their	O
performance	O
.	O
We	O
compared	O
the	O
antipsoriatic	B-T121
efficacy	O
of	O
mapracorat	B-T121
0.1	O
%	O
ointment	O
and	O
reference	O
drugs	B-T121
reported	O
in	O
2	O
separate	O
studies	O
,	O
representing	O
open	O
and	O
occluded	O
PPT	O
designs	O
.	O
The	O
drug	O
effect	O
size	O
was	O
measured	O
by	O
sonography	B-T060
(	O
mean	O
change	O
in	O
echo	O
-	O
poor	O
band	O
thickness	O
)	O
,	O
chromametry	B-T059
,	O
and	O
standardized	O
clinical	B-T033
assessment	I-T033
.	O
Antipsoriatic	B-T121
effects	O
were	O
detectable	O
for	O
the	O
study	O
drugs	B-T121
in	O
both	O
occluded	O
and	O
open	O
PPTs	O
.	O
Differences	O
between	O
the	O
potency	O
of	O
antipsoriatic	B-T121
drugs	I-T121
and	O
vehicle	O
were	O
observable	O
.	O
The	O
total	O
antipsoriatic	B-T121
effect	O
size	O
appeared	O
to	O
be	O
higher	O
in	O
the	O
occluded	O
PPT	O
than	O
the	O
open	O
PPT	O
,	O
despite	O
the	O
shorter	O
treatment	O
duration	O
(	O
2	O
vs.	O
4	O
weeks	O
)	O
.	O
Effect	O
dynamics	O
over	O
time	O
revealed	O
greater	O
differences	O
between	O
some	O
study	O
drugs	B-T121
in	O
the	O
open	O
PPT	O
compared	O
to	O
the	O
occluded	O
PPT	O
.	O
Taking	O
the	O
higher	O
technical	O
challenges	O
for	O
the	O
open	O
PPT	O
into	O
account	O
,	O
we	O
recommend	O
the	O
occluded	O
PPT	O
as	O
a	O
standard	O
screening	O
setting	O
in	O
early	O
drug	O
development	O
.	O
In	O
special	O
cases	O
,	O
considering	O
certain	O
drug	B-T121
aspects	O
or	O
study	O
objectives	O
that	O
would	O
require	O
procedural	O
adaptations	O
,	O
an	O
open	O
PPT	O
could	O
be	O
the	O
better	O
-	O
suited	O
design	O
.	O
Finally	O
,	O
both	O
PPT	O
models	O
show	O
clear	O
advantages	O
:	O
classification	O
as	O
phase	O
I	O
studies	O
,	O
small	O
number	O
of	O
psoriatic	O
subjects	O
,	O
relatively	O
short	O
study	O
duration	O
,	O
excellent	O
discrimination	O
between	O
compounds	O
and	O
concentrations	O
,	O
parallel	O
measurement	O
of	O
treatment	O
response	O
,	O
and	O
go	O
/	O
no	O
go	O
decisions	O
very	O
early	O
in	O
clinical	O
development	O
.	O
      
The	O
Experience	O
of	O
Women	O
Veterans	O
Coming	O
Back	O
from	O
War	O
Issues	B-T048
surrounding	I-T048
mental	I-T048
health	I-T048
are	O
common	O
for	O
women	O
veterans	O
who	O
have	O
served	O
in	O
Iraq	O
and	O
Afghanistan	O
wars	O
.	O
The	O
goal	O
of	O
this	O
phenomenological	O
study	O
was	O
to	O
document	O
themes	O
in	O
the	O
stories	O
gathered	O
from	O
eight	O
women	O
veterans	O
who	O
had	O
come	O
back	O
from	O
war	O
.	O
Themes	O
in	O
the	O
stories	O
were	O
:	O
arriving	O
with	O
mixed	O
sentiments	O
;	O
evolving	O
to	O
a	O
changed	O
view	O
of	O
self	O
;	O
permeating	B-T033
aggravation	I-T033
;	O
confounding	O
broken	O
relationships	O
,	O
frequent	B-T033
deployments	I-T033
,	O
and	O
change	B-T033
in	I-T033
military	I-T033
status	I-T033
;	O
remembering	O
war	O
experiences	O
;	O
and	O
seeking	B-T033
opportunity	I-T033
for	I-T033
what	I-T033
is	I-T033
possible	I-T033
.	O
Mental	B-T048
health	I-T048
issues	I-T048
can	O
be	O
observed	O
in	O
the	O
themes	O
.	O
Including	O
story	O
as	O
part	O
of	O
the	O
mental	O
health	O
visit	O
with	O
veterans	O
may	O
be	O
beneficial	O
to	O
veterans	O
as	O
they	O
deal	O
with	O
the	O
transition	O
of	O
coming	O
back	O
.	O
      
The	O
clinical	B-T033
prognosis	I-T033
of	O
implants	O
that	O
are	O
placed	O
against	O
super	B-T047
-	I-T047
erupted	I-T047
opposing	O
dentition	B-T023
If	O
teeth	B-T023
are	O
missing	B-T020
,	O
super	B-T047
-	I-T047
eruption	I-T047
of	I-T047
teeth	I-T047
in	O
the	O
opposing	O
arch	O
can	O
occur	O
in	O
the	O
area	O
and	O
can	O
change	O
the	O
occlusal	O
plane	O
.	O
When	O
missing	B-T020
teeth	I-T020
are	O
replaced	O
with	O
implants	O
,	O
the	O
oral	O
surgeon	O
must	O
determine	O
whether	O
or	O
not	O
the	O
super	B-T023
-	I-T023
erupted	I-T023
teeth	I-T023
need	O
to	O
be	O
treated	O
in	O
order	O
to	O
normalize	O
the	O
occlusal	O
plane	O
.	O
In	O
this	O
study	O
,	O
we	O
evaluated	B-T058
the	O
clinical	B-T033
prognosis	I-T033
of	O
dentition	B-T023
after	O
implant	B-T061
placement	I-T061
and	O
prosthetic	B-T061
treatment	I-T061
were	O
completed	O
in	O
an	O
occlusal	O
plane	O
altered	O
by	O
super	B-T023
-	I-T023
erupted	I-T023
teeth	I-T023
in	O
the	O
opposing	O
arch	O
without	O
additional	O
treatment	O
of	O
the	O
super	B-T023
-	I-T023
erupted	I-T023
teeth	I-T023
.	O
Twenty	O
-	O
two	O
patients	O
(	O
9	O
males	O
,	O
13	O
females	O
)	O
were	O
treated	O
with	O
implants	O
and	O
prosthetics	O
without	O
addressing	O
the	O
super	B-T047
-	I-T047
erupted	I-T047
opposing	O
dentition	B-T023
from	O
April	O
2004	O
to	O
August	O
2012	O
at	O
Seoul	O
National	O
University	O
Bundang	O
Hospital	O
.	O
A	O
total	O
of	O
33	O
implants	O
were	O
placed	O
.	O
Values	O
of	O
crestal	B-T047
bone	I-T047
loss	I-T047
,	O
survival	O
rates	O
,	O
and	O
surgical	O
and	O
prosthetic	O
complications	O
for	O
an	O
average	O
of	O
29.6	O
months	O
after	O
prosthetic	B-T061
loading	I-T061
were	O
recorded	O
.	O
In	O
one	O
case	O
,	O
the	O
cover	O
screw	O
was	O
exposed	O
after	O
implant	B-T061
surgery	I-T061
.	O
The	O
mean	O
crestal	B-T047
bone	I-T047
loss	I-T047
was	O
0.09±0.30	O
mm	O
.	O
Of	O
the	O
33	O
implants	O
,	O
31	O
survived	O
,	O
a	O
survival	O
rate	O
of	O
93.94	O
%	O
.	O
A	O
prosthetic	O
complication	O
occurred	O
in	O
one	O
case	O
but	O
functioned	O
well	O
after	O
correction	O
.	O
Favorable	O
clinical	O
results	O
from	O
prosthetic	O
complications	O
,	O
crestal	B-T047
bone	I-T047
loss	I-T047
,	O
and	O
implant	O
survival	O
rates	O
were	O
exhibited	O
in	O
implants	O
next	O
to	O
a	O
super	B-T023
-	I-T023
erupted	I-T023
opposing	I-T023
tooth	I-T023
.	O
      
Monitoring	B-T058
proteolytic	O
processing	O
events	O
by	O
quantitative	B-T059
mass	I-T059
spectrometry	I-T059
Protease	O
activity	O
plays	O
a	O
key	O
role	O
in	O
a	O
wide	O
variety	O
of	O
biological	O
processes	O
including	O
gene	O
expression	O
,	O
protein	O
turnover	O
and	O
development	O
.	O
misregulation	B-T033
of	O
these	O
proteins	O
has	O
been	O
associated	O
with	O
many	O
cancer	B-T033
types	I-T033
such	O
as	O
prostate	B-T191
,	O
breast	B-T191
,	O
and	O
skin	B-T191
cancer	I-T191
.	O
thus	O
,	O
the	O
identification	O
of	O
protease	O
substrates	O
will	O
provide	O
key	O
information	O
to	O
understand	O
proteolysis	O
-related	O
pathologies	O
.	O
Areas	O
covered	O
:	O
Proteomics	O
-based	O
methods	O
to	O
investigate	O
proteolysis	O
activity	O
,	O
focusing	O
on	O
substrate	O
identification	O
,	O
protease	O
specificity	O
and	O
their	O
applications	B-T061
in	O
systems	O
biology	O
are	O
reviewed	O
.	O
Their	O
quantification	O
strategies	O
,	O
challenges	B-T058
and	O
pitfalls	O
are	O
underlined	O
and	O
the	O
biological	O
implications	O
of	O
protease	O
malfunction	O
are	O
highlighted	O
.	O
Expert	O
commentary	O
:	O
Dysregulated	B-T033
protease	O
activity	O
is	O
a	O
hallmark	O
for	O
some	O
disease	B-T047
pathologies	O
such	O
as	O
cancer	B-T191
.	O
Current	O
biochemical	O
approaches	O
are	O
low	O
throughput	O
and	O
some	O
are	O
limited	O
by	O
the	O
amount	O
of	O
sample	O
required	O
to	O
obtain	O
reliable	O
results	O
.	O
Mass	B-T059
spectrometry	I-T059
based	O
proteomics	O
provides	O
a	O
suitable	O
platform	O
to	O
investigate	O
protease	O
activity	O
,	O
providing	O
information	O
about	O
substrate	O
specificity	O
and	O
mapping	B-T059
cleavage	O
sites	O
.	O
      
Clinical	O
Features	O
of	O
Smokers	B-T033
With	O
Radiological	B-T060
Emphysema	B-T047
But	O
Without	O
Airway	B-T023
Limitation	O
The	O
clinical	O
characteristics	O
of	O
patients	O
with	O
emphysema	B-T047
but	O
without	O
airway	B-T023
limitations	O
remain	O
unknown	O
.	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
clinical	O
features	O
of	O
current	B-T033
and	O
former	B-T033
smokers	I-T033
without	O
airflow	O
limitation	O
who	O
have	O
radiologic	B-T060
emphysema	B-T047
on	O
chest	B-T060
CT	I-T060
scans	I-T060
vs	O
a	O
control	O
group	O
of	O
current	B-T033
and	O
ex	B-T033
-	I-T033
smokers	I-T033
without	O
emphysema	B-T047
.	O
Subjects	O
enrolled	O
had	O
anthropometric	B-T060
characteristics	I-T060
recorded	O
,	O
provided	O
a	O
medical	B-T033
history	I-T033
,	O
and	O
underwent	O
low	O
-	O
dose	O
chest	B-T060
CT	I-T060
scanning	I-T060
.	O
The	O
following	O
parameters	B-T033
were	O
also	O
evaluated	O
:	O
pulmonary	B-T060
function	I-T060
tests	I-T060
including	O
diffusion	B-T060
capacity	I-T060
for	I-T060
carbon	I-T060
monoxide	I-T060
(	O
Dlco	B-T060
)	O
,	O
the	O
modified	O
Medical	O
Research	O
Council	O
dyspnea	O
score	O
,	O
COPD	O
assessment	O
test	O
(	O
CAT	O
)	O
,	O
and	O
6	B-T060
-	I-T060
min	I-T060
walk	I-T060
test	I-T060
(	O
6MWT	B-T060
)	O
.	O
A	O
comparison	O
was	O
conducted	O
between	O
those	O
with	O
and	O
without	O
CT	B-T060
-	O
confirmed	B-T033
emphysema	B-T047
.	O
Of	O
the	O
203	O
subjects	O
,	O
154	O
had	O
emphysema	B-T047
,	O
and	O
49	O
did	O
not	O
.	O
Adjusted	O
group	O
comparisons	O
revealed	O
that	O
a	O
higher	O
proportion	O
of	O
patients	O
with	O
emphysema	B-T047
according	O
to	O
low	O
-	O
dose	O
chest	B-T060
CT	I-T060
scanning	I-T060
had	O
an	O
abnormal	B-T033
Dlco	I-T033
value	O
(	O
<	O
80	O
%	O
)	O
(	O
46	O
%	O
vs	O
19	O
%	O
;	O
P	O
=	O
.02	O
)	O
,	O
a	O
decrease	O
in	O
percentage	O
of	O
oxygen	O
saturation	O
>	O
4	O
%	O
during	O
the	O
6MWT	B-T060
(	O
8.5	O
%	O
vs	O
0	O
;	O
P	O
=	O
.04	O
)	O
,	O
and	O
an	O
altered	O
quality	O
of	O
life	O
(	O
CAT	O
score	O
≥	O
10	O
)	O
(	O
32	O
%	O
vs	O
14	O
%	O
;	O
P	O
=	O
.01	O
)	O
.	O
A	O
detailed	O
analysis	O
of	O
the	O
CAT	O
questionnaire	O
items	O
revealed	O
that	O
more	O
patients	O
with	O
emphysema	B-T047
had	O
a	O
score	O
≥	O
1	O
in	O
the	O
"	O
chest	B-T184
tightness	I-T184
"	O
(	O
P	O
=	O
.05	O
)	O
and	O
"	O
limitation	O
when	O
doing	O
activities	O
at	O
home	O
"	O
(	O
P	O
<	O
.01	O
)	O
items	O
compared	O
with	O
those	O
with	O
no	B-T033
emphysema	I-T033
.	O
They	O
also	O
experienced	O
significantly	O
more	O
exacerbations	B-T033
in	O
the	O
previous	O
year	O
(	O
0.19	O
vs	O
0.04	O
;	O
P	O
=	O
.02	O
)	O
.	O
A	O
significant	O
proportion	O
of	O
smokers	B-T033
with	O
emphysema	B-T047
according	O
to	O
low	O
-	O
dose	O
chest	B-T060
CT	I-T060
scanning	I-T060
but	O
without	O
airway	B-T023
limitation	O
had	O
alterations	O
in	O
their	O
quality	O
of	O
life	O
,	O
number	O
of	O
exacerbations	B-T033
,	O
Dlco	B-T060
values	O
,	O
and	O
oxygen	O
saturation	O
during	O
the	O
6MWT	B-T060
test	I-T060
.	O
      
Comparison	O
and	O
Outcome	O
Analysis	B-T058
of	I-T058
Patients	I-T058
with	O
Takotsubo	B-T047
Cardiomyopathy	I-T047
Triggered	O
by	O
Emotional	B-T048
Stress	I-T048
or	O
Physical	O
Stress	O
Background	O
:	O
Previous	O
studies	O
revealed	O
that	O
takotsubo	B-T047
cardiomyopathy	I-T047
(	O
TTC	B-T047
)	O
is	O
triggered	O
by	O
physical	O
and	O
emotional	B-T048
stresses	I-T048
.	O
This	O
study	O
was	O
performed	O
to	O
determine	O
the	O
short-	O
and	O
long	O
-	O
term	O
prognostic	O
impact	O
of	O
emotional-	B-T048
and	O
physical	O
stress	O
associated	O
with	O
TTC	B-T047
.	O
Methods	O
and	O
results	O
:	O
Our	O
institutional	O
database	O
constituted	O
a	O
collective	O
of	O
84	O
patients	O
diagnosed	B-T033
with	O
TTC	B-T047
between	O
2003	O
and	O
2015	O
.	O
The	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
as	O
per	O
the	O
presence	O
of	O
emotional	B-T048
stress	I-T048
(	O
n	O
=	O
24	O
,	O
21	O
%	O
)	O
or	O
physical	O
stress	O
(	O
n	O
=	O
60	O
,	O
52.6	O
%	O
)	O
.	O
The	O
endpoint	O
was	O
a	O
composite	O
of	O
in	B-T033
-	I-T033
hospital	I-T033
events	I-T033
(	O
thromboembolic	O
events	O
and	O
life	B-T033
-	I-T033
threatening	I-T033
arrhythmias	B-T033
)	O
,	O
myocardial	B-T047
infarction	I-T047
,	O
all-	O
cause	B-T033
of	I-T033
mortality	I-T033
,	O
re	B-T058
-	I-T058
hospitalization	I-T058
due	O
to	O
heart	B-T047
failure	I-T047
,	O
stroke	B-T047
,	O
and	O
recurrence	O
of	O
TTC	B-T047
.	O
A	O
Kaplan	O
-	O
Meier	O
analysis	O
indicated	O
a	O
significantly	O
lower	O
event	O
-	O
free	O
survival	O
rate	O
over	O
a	O
mean	O
follow	B-T058
-	I-T058
up	I-T058
of	O
5	O
years	O
in	O
the	O
emotional	B-T048
group	O
than	O
the	O
physical	O
stress	O
group	O
(	O
log	O
-	O
rank	O
,	O
p	O
<	O
0.01	O
)	O
.	O
Multivariate	O
Cox	O
regression	O
analysis	O
revealed	O
only	O
emotional	B-T048
stress	I-T048
(	O
HR	O
0.4	O
,	O
95	O
%	O
CI	O
:	O
0.2	O
-	O
0.9	O
,	O
p	O
<	O
0.05	O
)	O
as	O
a	O
negative	B-T033
independent	I-T033
predictor	I-T033
of	O
the	O
primary	O
endpoint	O
.	O
Conclusion	O
:	O
Rates	O
of	O
in	B-T033
-	I-T033
hospital	I-T033
events	I-T033
and	O
short-	O
as	O
well	O
as	O
long	O
-	O
term	O
events	O
were	O
significantly	O
lower	O
in	O
TTC	B-T047
patients	O
suffering	B-T048
from	O
emotional	B-T048
stress	I-T048
as	O
compared	O
to	O
patients	O
with	O
physical	O
stress	O
.	O
      
CHOROIDAL	O
VASCULARITY	O
INDEX	O
:	O
A	O
Novel	O
Optical	B-T060
Coherence	I-T060
Tomography	I-T060
Based	O
Parameter	O
in	O
Patients	O
With	O
Exudative	B-T047
Age	I-T047
-	I-T047
Related	I-T047
Macular	I-T047
Degeneration	I-T047
To	O
evaluate	O
choroidal	B-T023
structural	O
changes	O
in	O
exudative	B-T047
age	I-T047
-	I-T047
related	I-T047
macular	I-T047
degeneration	I-T047
(	O
AMD	B-T047
)	O
using	O
choroidal	O
vascularity	O
index	O
computed	O
from	O
image	O
binarization	O
on	O
spectral	B-T060
domain	I-T060
optical	I-T060
coherence	I-T060
tomography	I-T060
with	O
enhanced	O
depth	B-T060
imaging	I-T060
.	O
This	O
prospective	O
case	O
series	O
included	O
42	O
consecutive	O
patients	O
with	O
unilateral	O
exudative	B-T047
AMD	I-T047
.	O
Choroidal	B-T023
images	B-T060
were	O
segmented	O
into	O
luminal	O
area	O
and	O
stromal	O
area	O
.	O
Choroidal	O
vascularity	O
index	O
was	O
defined	O
as	O
the	O
ratio	O
of	O
luminal	O
area	O
to	O
total	O
choroid	O
area	O
.	O
Mean	O
choroidal	O
vascularity	O
index	O
and	O
mean	O
choroidal	O
thickness	O
between	O
study	O
and	O
fellow	O
eyes	B-T023
of	O
the	O
same	O
patient	O
with	O
dry	O
AMD	B-T047
were	O
compared	O
using	O
Student	O
's	O
t	O
-	O
test	O
.	O
There	O
was	O
a	O
significantly	O
lower	O
choroidal	O
vascularity	O
index	O
in	O
eyes	B-T023
with	O
exudative	B-T047
AMD	I-T047
(	O
60.14	O
±	O
4.55	O
vs.	O
62.75	O
±	O
4.82	O
,	O
P	O
<	O
0.01	O
)	O
.	O
Luminal	O
area	O
(	O
P	O
<	O
0.01	O
)	O
was	O
decreased	O
in	O
eyes	B-T023
with	O
exudative	B-T047
AMD	I-T047
but	O
there	O
was	O
no	B-T033
significant	I-T033
difference	I-T033
in	O
total	O
choroid	O
area	O
(	O
P	O
=	O
0.05	O
)	O
and	O
choroidal	O
thickness	O
(	O
P	O
=	O
0.93	O
)	O
between	O
study	O
and	O
fellow	O
eyes	B-T023
.	O
Eyes	B-T023
with	O
exudative	B-T047
AMD	I-T047
demonstrated	O
reduced	O
choroidal	O
vascularity	O
index	O
but	O
insignificant	O
differences	O
in	O
choroidal	O
thickness	O
compared	O
with	O
their	O
fellow	O
eyes	B-T023
.	O
Choroidal	O
vascularity	O
index	O
may	O
be	O
a	O
potential	O
noninvasive	B-T033
tool	I-T033
for	O
studying	O
structural	O
changes	O
in	O
choroid	B-T023
and	O
monitoring	O
choroidal	B-T047
disease	I-T047
in	O
exudative	B-T047
AMD	I-T047
.	O
      
Human	B-T121
cathelicidin	I-T121
LL-37	I-T121
enhance	O
the	O
antibiofilm	B-T033
effect	I-T033
of	O
EGCG	B-T121
on	O
Streptococcus	B-T007
mutans	I-T007
Streptococcus	B-T007
mutans	I-T007
forms	O
biofilms	B-T007
as	O
a	O
resistance	O
mechanism	O
against	O
antimicrobial	B-T121
agents	I-T121
in	O
the	O
human	O
oral	O
cavity	O
.	O
We	O
recently	O
showed	O
that	O
human	B-T121
cathelicidin	I-T121
LL-37	I-T121
exhibits	O
inhibitory	O
effects	O
on	O
biofilm	O
formation	O
of	O
S.	B-T007
mutans	I-T007
through	O
interaction	O
with	O
lipoteichoic	O
acid	O
(	O
LTA	O
)	O
,	O
but	O
without	O
antibacterial	B-T033
or	O
biofilm	B-T007
dispersal	O
abilities	O
.	O
(	B-T121
-)-Epigallocatechin	I-T121
gallate	I-T121
(	O
EGCG	B-T121
)	O
is	O
the	O
most	O
abundant	O
constituent	O
of	O
tea	O
catechins	B-T121
that	O
has	O
the	O
greatest	O
anti	B-T033
-	I-T033
infective	I-T033
potential	I-T033
to	O
inhibit	O
the	O
growth	O
of	O
various	O
microorganisms	B-T001
and	O
biofilm	O
formation	O
.	O
Therefore	O
,	O
in	O
this	O
study	O
,	O
we	O
evaluated	B-T058
whether	O
LL-37	B-T121
interacts	O
with	O
EGCG	B-T121
to	O
enhance	O
the	O
antibiofilm	B-T033
effect	I-T033
of	O
EGCG	B-T121
on	O
S.	B-T007
mutans	I-T007
biofilm	O
formation	O
.	O
Clinical	O
S.	B-T007
mutans	I-T007
strains	B-T001
(	O
n	O
=	O
10	O
)	O
isolated	O
from	O
children	O
's	O
saliva	O
were	O
tested	O
in	O
a	O
biofilm	O
formation	O
assay	B-T059
.	O
The	O
antibiofilm	B-T033
effect	I-T033
of	O
EGCG	B-T121
with	O
and	O
without	O
LL-37	B-T121
was	O
analyzed	O
by	O
the	O
minimum	O
biofilm	B-T007
eradication	O
concentration	O
assay	B-T059
and	O
confirmed	O
using	O
field	O
emission	B-T059
-	I-T059
scanning	I-T059
electron	I-T059
microscopy	I-T059
.	O
In	O
addition	O
,	O
the	O
interaction	O
among	O
EGCG	B-T121
,	O
LL-37	B-T121
,	O
and	O
LTA	O
of	O
S.	B-T007
mutans	I-T007
was	O
determined	O
using	O
quartz	O
crystal	O
microbalance	O
analysis	O
.	O
EGCG	B-T121
killed	O
100	O
%	O
of	O
planktonic	B-T007
S.	B-T007
mutans	I-T007
within	O
5	O
h	O
,	O
inhibited	O
biofilm	O
formation	O
within	O
24	O
h	O
,	O
and	O
reduced	O
bacteria	B-T007
cells	I-T007
in	O
preformed	O
biofilms	B-T007
within	O
3	O
h	O
at	O
a	O
concentration	O
of	O
0.2	O
mg	O
/	O
mL.	O
However	O
,	O
EGCG	B-T121
did	O
not	O
appear	O
to	O
interact	O
with	O
LTA	O
.	O
LL-37	B-T121
effectively	O
enhanced	O
the	O
bactericidal	O
activity	O
of	O
EGCG	B-T121
against	O
biofilm	O
formation	O
and	O
preformed	O
biofilms	B-T007
as	O
determined	O
by	O
quantitative	O
crystal	B-T121
violet	I-T121
staining	B-T059
and	O
field	O
emission	B-T059
-	I-T059
scanning	I-T059
electron	I-T059
microscopy	I-T059
.	O
In	O
addition	O
,	O
quartz	O
crystal	O
microbalance	O
analysis	O
revealed	O
that	O
LL-37	B-T121
interacted	O
with	O
EGCG	B-T121
and	O
promoted	O
binding	O
between	O
EGCG	B-T121
and	O
LTA	O
of	O
S.	B-T007
mutans	I-T007
.	O
We	O
show	O
that	O
LL-37	B-T121
enhances	O
the	O
antibiofilm	B-T033
effect	I-T033
of	O
EGCG	B-T121
on	O
S.	B-T007
mutans	I-T007
.	O
This	O
finding	O
provides	O
new	O
knowledge	O
for	O
dental	B-T061
treatment	I-T061
by	O
using	O
LL-37	B-T121
as	O
a	O
potential	O
antibiofilm	B-T121
compound	I-T121
.	O
      
Efficient	O
genome	O
editing	O
of	O
differentiated	O
renal	B-T023
epithelial	O
cells	O
Recent	O
advances	O
in	O
genome	O
editing	O
technologies	O
have	O
enabled	O
the	O
rapid	O
and	O
precise	O
manipulation	O
of	O
genomes	O
,	O
including	O
the	O
targeted	O
introduction	O
,	O
alteration	O
,	O
and	O
removal	O
of	O
genomic	O
sequences	O
.	O
However	O
,	O
respective	O
methods	O
have	O
been	O
described	O
mainly	O
in	O
non	O
-	O
differentiated	O
or	O
haploid	O
cell	O
types	O
.	O
Genome	O
editing	O
of	O
well	O
-	O
differentiated	O
renal	B-T023
epithelial	O
cells	O
has	O
been	O
hampered	O
by	O
a	O
range	O
of	O
technological	B-T033
issues	I-T033
,	O
including	O
optimal	O
design	O
,	O
efficient	O
expression	O
of	O
multiple	O
genome	O
editing	O
constructs	O
,	O
attainable	O
mutation	O
rates	O
,	O
and	O
best	O
screening	O
strategies	O
.	O
Here	O
,	O
we	O
present	O
an	O
easily	O
implementable	O
workflow	O
for	O
the	O
rapid	O
generation	O
of	O
targeted	O
heterozygous	O
and	O
homozygous	O
genomic	O
sequence	O
alterations	O
in	O
renal	B-T023
cells	O
using	O
transcription	O
activator	O
-	O
like	O
effector	O
nucleases	O
(	O
TALENs	O
)	O
and	O
the	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeat	O
(	O
CRISPR	O
)	O
system	O
.	O
We	O
demonstrate	O
the	O
versatility	O
of	O
established	O
protocols	O
by	O
generating	O
novel	O
cellular	O
models	O
for	O
studying	O
autosomal	B-T019
dominant	I-T019
polycystic	I-T019
kidney	I-T019
disease	I-T019
(	O
ADPKD	B-T019
)	O
.	O
Furthermore	O
,	O
we	O
show	O
that	O
cell	O
culture	O
-	O
validated	O
genetic	O
modifications	O
can	O
be	O
readily	O
applied	O
to	O
mouse	O
embryonic	O
stem	O
cells	O
(	O
mESCs	O
)	O
for	O
the	O
generation	O
of	O
corresponding	O
mouse	O
models	O
.	O
The	O
described	O
procedure	O
for	O
efficient	O
genome	O
editing	O
can	O
be	O
applied	O
to	O
any	O
cell	O
type	O
to	O
study	O
physiological	O
and	O
pathophysiological	O
functions	O
in	O
the	O
context	O
of	O
precisely	O
engineered	O
genotypes	O
.	O
      
Recombinant	B-T001
MHC	O
Tetramers	O
for	O
Isolation	B-T061
of	O
Virus	B-T005
-	O
Specific	O
CD8(+	O
)	O
Cells	O
from	O
Healthy	O
Donors	O
:	O
Potential	O
Approach	O
for	O
Cell	B-T061
Therapy	I-T061
of	O
Posttransplant	B-T047
Cytomegalovirus	I-T047
Infection	I-T047
Patients	O
undergoing	O
allogeneic	O
hematopoietic	B-T061
stem	I-T061
cell	I-T061
transplantation	I-T061
have	O
a	O
high	O
risk	O
of	O
cytomegalovirus	B-T047
reactivation	I-T047
,	O
which	O
in	O
the	O
absence	O
of	O
T	O
-	O
cell	O
immunity	O
can	O
result	O
in	O
the	O
development	O
of	O
an	O
acute	B-T033
inflammatory	I-T033
reaction	I-T033
and	O
damage	O
of	O
internal	O
organs	O
.	O
Transfusion	B-T061
of	O
the	O
virus	O
-	O
specific	O
donor	O
T	O
-	O
lymphocytes	O
represents	O
an	O
alternative	O
to	O
a	O
highly	O
toxic	O
and	O
often	O
ineffective	O
antiviral	B-T061
therapy	I-T061
.	O
Potentially	O
promising	O
cell	B-T061
therapy	I-T061
approach	O
comprises	O
transfusion	B-T061
of	O
cytotoxic	O
T	O
-	O
lymphocytes	O
,	O
specific	O
to	O
the	O
viral	O
antigens	O
,	O
immediately	O
after	O
their	O
isolation	B-T061
from	O
the	O
donor	O
's	O
blood	O
circulation	O
without	O
any	O
in	O
vitro	O
expansion	O
.	O
Specific	O
T	O
-	O
cells	O
could	O
be	O
separated	O
from	O
potentially	O
alloreactive	O
lymphocytes	O
using	O
recombinant	B-T001
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
multimers	O
,	O
carrying	O
synthetic	O
viral	O
peptides	O
.	O
Rapid	O
transfusion	B-T061
of	O
virus	B-T005
-	O
specific	O
T	O
-	O
cells	O
to	O
patients	O
has	O
several	O
crucial	O
advantages	O
in	O
comparison	O
with	O
methods	O
based	O
on	O
the	O
in	O
vitro	O
expansion	O
of	O
the	O
cells	O
.	O
About	O
30	O
%	O
of	O
hematopoietic	O
stem	O
cell	O
donors	O
and	O
46	O
%	O
of	O
transplant	O
recipients	O
at	O
the	O
National	O
Research	O
Center	O
for	O
Hematology	O
were	O
carriers	O
of	O
the	O
HLA	O
-	O
A*02	O
allele	O
.	O
Moreover	O
,	O
94	O
%	O
of	O
Russian	O
donors	O
have	O
an	O
immune	O
response	O
against	O
the	O
cytomegalovirus	B-T005
(	O
CMV	B-T005
)	O
.	O
Using	O
recombinant	B-T001
HLA	O
-	O
A*02	O
multimers	O
carrying	O
an	O
immunodominant	O
cytomegalovirus	O
peptide	O
(	O
NLV	O
)	O
,	O
we	O
have	O
shown	O
that	O
the	O
majority	O
of	O
healthy	O
donors	O
have	O
pronounced	O
T	O
-	O
cell	O
immunity	O
against	O
this	O
antigen	O
,	O
whereas	O
shortly	O
after	O
the	O
transplantation	B-T061
the	O
patients	O
do	O
not	O
have	O
specific	O
T	O
-	O
lymphocytes	O
.	O
The	O
donor	O
cells	O
have	O
the	O
immune	O
phenotype	O
of	O
memory	O
cells	O
and	O
can	O
be	O
activated	O
and	O
proliferate	O
after	O
stimulation	O
with	O
the	O
specific	O
antigen	O
.	O
Donor	B-T033
lymphocytes	I-T033
can	O
be	O
substantially	O
enriched	O
to	O
significant	O
purity	O
by	O
magnetic	B-T059
separation	I-T059
with	O
recombinant	B-T001
MHC	O
multimers	O
and	O
are	O
not	O
activated	O
upon	O
cocultivation	B-T059
with	O
the	O
antigen	O
-presenting	O
cells	O
from	O
HLA	O
-	O
incompatible	O
donors	O
without	O
addition	O
of	O
the	O
specific	O
antigen	O
.	O
This	O
study	O
demonstrated	O
that	O
strong	O
immune	O
response	O
to	O
CMV	B-T005
of	O
healthy	O
donors	O
and	O
prevalence	O
of	O
HLA	O
-	O
A*02	O
allele	O
in	O
the	O
Russian	O
population	O
make	O
it	O
possible	O
to	O
isolate	O
a	O
significant	O
number	O
of	O
virus	O
-	O
specific	O
cells	O
using	O
HLA	O
-	O
A*02	O
-	O
NLV	O
multimers	O
.	O
After	O
the	O
transfusion	B-T061
,	O
these	O
cells	O
should	O
protect	O
patients	O
from	O
CMV	B-T005
without	O
development	O
of	O
allogeneic	O
immune	O
response	O
.	O
      
A	O
prime	O
a	O
day	O
keeps	O
calories	O
away	O
:	O
The	O
effects	O
of	O
supraliminal	O
priming	O
on	O
food	O
consumption	O
and	O
the	O
moderating	O
role	O
of	O
gender	O
and	O
eating	O
restraint	O
The	O
link	O
between	O
intentions	O
and	O
action	O
in	O
weight	B-T061
control	I-T061
is	O
weaker	O
than	O
previously	O
thought	O
,	O
so	O
recent	O
research	O
has	O
called	O
for	O
further	O
investigation	O
of	O
ways	O
to	O
improve	O
weight	B-T061
control	I-T061
that	O
bypass	O
conscious	O
intentions	O
.	O
Priming	O
has	O
been	O
shown	O
to	O
have	O
effects	O
on	O
individual	O
behavior	O
in	O
a	O
variety	O
of	O
contexts	O
by	O
influencing	O
subconscious	O
cognition	O
.	O
This	O
paper	O
investigates	O
the	O
effects	O
of	O
semantic	O
priming	O
using	O
healthy	O
body	O
image	O
,	O
goal	O
-	O
oriented	O
words	O
on	O
food	O
consumption	O
.	O
The	O
moderating	O
role	O
of	O
both	O
restrained	O
eating	O
and	O
gender	O
is	O
investigated	O
.	O
161	O
participants	O
were	O
involved	O
in	O
an	O
experiment	O
using	O
a	O
novel	O
version	O
of	O
a	O
scrambled	O
sentence	O
priming	O
game	O
.	O
The	O
outcome	O
measure	O
was	O
the	O
number	O
of	O
kilocalories	O
consumed	B-T061
,	O
examined	O
using	O
a	O
between	O
subjects	O
ANCOVA	O
with	O
priming	O
,	O
gender	O
,	O
restrained	O
eating	O
index	O
,	O
self	O
-	O
reported	O
BMI	O
,	O
and	O
two	O
interaction	O
terms	O
(	O
priming	O
x	O
gender	O
,	O
and	O
priming	O
x	O
restrained	O
eating	O
index	O
)	O
.	O
There	O
was	O
no	O
main	O
effect	O
of	O
priming	O
but	O
there	O
was	O
an	O
interaction	O
of	O
priming	O
with	O
gender	O
.	O
Females	O
consumed	O
significantly	O
fewer	O
kilocalories	O
after	O
being	O
exposed	O
to	O
priming	O
words	O
related	O
to	O
a	O
healthy	O
body	O
image	O
(	O
i.e.	O
"	O
slim	O
"	O
,	O
"	O
fit	O
,	O
"	O
)	O
compared	O
to	O
females	O
receiving	O
the	O
neutral	O
prime	O
,	O
with	O
a	O
medium	O
effect	O
size	O
(	O
d	O
=	O
0.58	O
)	O
.	O
The	O
body	O
image	O
prime	O
did	O
not	O
significantly	O
affect	O
food	O
intake	O
for	O
males	O
,	O
nor	O
did	O
it	O
have	O
a	O
differential	O
effect	O
on	O
restrained	O
eaters	O
.	O
This	O
study	O
shows	O
that	O
priming	O
can	O
be	O
an	O
effective	O
method	O
for	O
influencing	O
females	O
to	O
reduce	O
food	O
intake	O
,	O
regardless	O
of	O
whether	O
they	O
are	O
restrained	O
or	O
unrestrained	O
eaters	O
.	O
Future	O
studies	O
could	O
investigate	O
whether	O
different	O
priming	O
words	O
related	O
to	O
a	O
male	O
's	O
healthy	O
body	O
image	O
goal	O
(	O
i.e.	O
"	O
buff	O
,	O
"	O
"	O
muscles	O
,	O
"	O
etc	O
.	O
)	O
would	O
similarly	O
reduce	O
food	O
intake	O
for	O
males	O
.	O
      
Demonstration	O
and	O
validation	O
of	O
a	O
new	O
pressure	O
-based	O
MRI	O
-safe	O
pain	B-T033
tolerance	I-T033
device	O
One	O
of	O
the	O
barriers	O
to	O
studying	O
the	O
behavioral	O
and	O
emotional	O
effects	O
of	O
pain	B-T184
using	O
functional	B-T060
Magnetic	I-T060
Resonance	I-T060
Imaging	I-T060
(	O
fMRI	B-T060
)	O
is	O
the	O
absence	O
of	O
a	O
commercially	O
available	O
,	O
MRI	O
-	O
compatible	O
,	O
pressure	O
-based	O
algometer	O
to	O
elicit	O
pain	B-T184
.	O
The	O
present	O
study	O
sought	O
to	O
address	O
this	O
barrier	O
through	O
creation	O
and	O
validation	O
of	O
a	O
novel	O
MRI	O
-safe	O
apparatus	O
capable	O
of	O
delivering	O
incremental	O
,	O
measurable	O
amounts	O
of	O
pressure	O
inside	O
a	O
scanning	O
bore	O
.	O
We	O
introduced	O
an	O
MR	O
-	O
safe	O
device	O
used	O
to	O
administer	O
pressure	O
-based	O
pain	B-T184
.	O
To	O
test	B-T059
against	O
a	O
commercially	O
available	O
,	O
MRI	O
-	O
incompatible	O
algometer	O
(	O
AlgoMed	O
)	O
,	O
199	O
participants	O
reported	O
their	O
pain	B-T033
tolerance	I-T033
for	O
both	O
devices	O
.	O
A	O
second	O
experiment	O
tested	B-T059
the	O
validity	O
of	O
pressure	O
-based	O
pain	B-T184
in	O
an	O
MRI	O
environment	O
by	O
comparing	O
brain	B-T023
activation	O
with	O
established	O
neural	B-T023
networks	I-T023
for	O
pain	B-T184
.	O
10	O
participants	O
performed	O
an	O
identical	O
procedure	O
to	O
test	B-T059
for	O
pain	B-T184
tolerance	O
while	O
being	O
scanned	B-T060
in	O
a	O
7	O
T	O
MRI	O
scanner	O
.	O
Results	O
support	O
the	O
validity	O
and	O
reliability	O
of	O
our	O
novel	O
device	O
.	O
In	O
Study	O
1	O
,	O
pain	B-T033
tolerance	I-T033
with	O
this	O
device	O
was	O
strongly	O
correlated	O
with	O
pain	B-T033
tolerance	I-T033
as	O
measured	O
by	O
a	O
commercially	O
available	O
algometer	O
(	O
r=0.78	O
)	O
.	O
In	O
Study	O
2	O
,	O
this	O
device	O
yielded	O
BOLD	O
activation	O
within	O
the	O
insula	B-T023
(	O
BA	B-T023
13	I-T023
)	O
and	O
anterior	B-T023
cingulate	I-T023
gyrus	I-T023
(	O
BA	O
24	O
)	O
;	O
as	O
pressure	O
increased	O
,	O
activation	O
in	O
these	O
areas	O
parametrically	O
increased	O
.	O
These	O
findings	O
correspond	O
to	O
other	O
studies	O
using	O
thermal	B-T061
,	O
electrical	B-T061
,	O
or	O
mechanical	B-T061
pain	B-T184
applications	I-T184
.	O
Behavioral	O
and	O
functional	O
data	O
demonstrate	O
that	O
this	O
new	O
device	O
is	O
a	O
valid	O
method	O
of	O
administering	B-T061
pressure	O
-related	O
pain	B-T184
in	O
MRI	O
environments	O
.	O
Our	O
novel	O
MRI	O
-safe	O
device	O
is	O
a	O
valid	O
instrument	O
to	O
measure	O
and	O
administer	O
pressure	O
-based	O
pain	B-T184
.	O
      
Famous	O
faces	O
and	O
voices	O
:	O
Differential	O
profiles	O
in	O
early	O
right	B-T023
and	O
left	B-T023
semantic	B-T048
dementia	I-T048
and	O
in	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
Famous	O
face	O
and	O
voice	O
recognition	O
is	O
reported	O
to	O
be	O
impaired	O
both	O
in	O
semantic	B-T048
dementia	I-T048
(	O
SD	B-T048
)	O
and	O
in	O
Alzheimer	B-T047
's	I-T047
Disease	I-T047
(	O
AD	B-T047
)	O
,	O
although	O
more	O
severely	O
in	O
the	O
former	O
.	O
In	O
AD	B-T047
a	O
coexistence	O
of	O
perceptual	O
impairment	O
in	O
face	O
and	O
voice	O
processing	O
has	O
also	O
been	O
reported	O
and	O
this	O
could	O
contribute	O
to	O
the	O
altered	O
performance	O
in	O
complex	O
semantic	O
tasks	O
.	O
On	O
the	O
other	O
hand	O
,	O
in	O
SD	B-T048
both	O
face	O
and	O
voice	O
recognition	O
disorders	B-T047
could	O
be	O
related	O
to	O
the	O
prevalence	O
of	O
atrophy	O
in	O
the	O
right	B-T023
temporal	I-T023
lobe	I-T023
(	O
RTL	B-T023
)	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
twofold	O
:	O
(	O
1	O
)	O
to	O
investigate	O
famous	O
faces	O
and	O
voices	O
recognition	O
in	O
SD	B-T048
and	O
AD	B-T047
to	O
verify	O
if	O
the	O
two	O
diseases	B-T047
show	O
a	O
differential	O
pattern	O
of	O
impairment	O
,	O
resulting	O
from	O
disruption	O
of	O
different	O
cognitive	O
mechanisms	O
;	O
(	O
2	O
)	O
to	O
check	O
if	O
face	O
and	O
voice	O
recognition	O
disorders	B-T047
prevail	O
in	O
patients	O
with	O
atrophy	O
mainly	O
affecting	O
the	O
RTL	B-T023
.	O
To	O
avoid	O
the	O
potential	O
influence	O
of	O
primary	O
perceptual	O
problems	B-T033
in	O
face	O
and	O
voice	O
recognition	O
,	O
a	O
pool	O
of	O
patients	O
suffering	O
from	O
early	O
SD	B-T048
and	O
AD	B-T047
were	O
administered	O
a	O
detailed	O
set	O
of	O
tests	B-T058
exploring	O
face	O
and	O
voice	O
perception	O
.	O
Thirteen	O
SD	B-T048
(	O
8	O
with	O
prevalence	O
of	O
right	B-T023
and	O
5	O
with	O
prevalence	O
of	O
left	B-T023
temporal	I-T023
atrophy	O
)	O
and	O
25	O
CE	O
patients	O
,	O
who	O
did	O
not	O
show	O
visual	O
and	O
auditory	O
perceptual	O
impairment	O
,	O
were	O
finally	O
selected	O
and	O
were	O
administered	O
an	O
experimental	O
battery	O
exploring	O
famous	O
face	O
and	O
voice	O
recognition	O
and	O
naming	O
.	O
Twelve	O
SD	B-T048
patients	O
underwent	O
cerebral	B-T023
PET	B-T060
imaging	I-T060
and	O
were	O
classified	O
in	O
right	B-T023
and	O
left	B-T023
SD	B-T048
according	O
to	O
the	O
onset	O
modality	O
and	O
to	O
the	O
prevalent	O
decrease	O
in	O
FDG	O
uptake	O
in	O
right	B-T023
or	O
left	B-T023
temporal	I-T023
lobe	I-T023
respectively	O
.	O
Correlation	O
of	O
PET	B-T060
imaging	I-T060
and	O
famous	O
face	O
and	O
voice	O
recognition	O
was	O
performed	O
.	O
Results	O
showed	O
a	O
differential	O
performance	O
profile	O
in	O
the	O
two	O
diseases	B-T047
,	O
because	O
AD	B-T047
patients	O
were	O
significantly	O
impaired	O
in	O
the	O
naming	O
tests	O
,	O
but	O
showed	O
preserved	O
recognition	O
,	O
whereas	O
SD	B-T048
patients	O
were	O
profoundly	O
impaired	O
both	O
in	O
naming	O
and	O
in	O
recognition	O
of	O
famous	O
faces	O
and	O
voices	O
.	O
Furthermore	O
,	O
face	O
and	O
voice	O
recognition	O
disorders	B-T047
prevailed	O
in	O
SD	B-T048
patients	O
with	O
RTL	B-T023
atrophy	O
,	O
who	O
also	O
showed	O
a	O
conceptual	O
impairment	O
on	O
the	O
Pyramids	O
and	O
Palm	O
Trees	O
test	O
more	O
important	O
in	O
the	O
pictorial	O
than	O
in	O
the	O
verbal	O
modality	O
.	O
Finally	O
,	O
in	O
12	O
SD	B-T048
patients	O
in	O
whom	O
PET	B-T060
was	O
available	O
,	O
a	O
strong	O
correlation	O
between	O
FDG	O
uptake	O
and	O
face	O
-	O
to	O
-	O
name	O
and	O
voice	O
-	O
to	O
-	O
name	O
matching	O
data	O
was	O
found	O
in	O
the	O
right	B-T023
but	O
not	O
in	O
the	O
left	B-T023
temporal	I-T023
lobe	I-T023
.	O
The	O
data	O
support	O
the	O
hypothesis	O
of	O
a	O
different	O
cognitive	O
basis	O
for	O
impairment	O
of	O
face	O
and	O
voice	O
recognition	O
in	O
the	O
two	O
dementias	B-T048
and	O
suggest	O
that	O
the	O
pattern	O
of	O
impairment	O
in	O
SD	B-T048
may	O
be	O
due	O
to	O
a	O
loss	O
of	O
semantic	O
representations	O
,	O
while	O
a	O
defect	O
of	O
semantic	O
control	O
,	O
with	O
impaired	O
naming	O
and	O
preserved	O
recognition	O
might	O
be	O
hypothesized	O
in	O
AD	B-T047
.	O
Furthermore	O
,	O
the	O
correlation	O
between	O
face	O
and	O
voice	O
recognition	O
disorders	B-T047
and	O
RTL	B-T023
damage	O
are	O
consistent	O
with	O
the	O
hypothesis	O
assuming	O
that	O
in	O
the	O
RTL	B-T023
person	O
-specific	O
knowledge	O
may	O
be	O
mainly	O
based	O
upon	O
non	O
-	O
verbal	O
representations	O
.	O
      
Well	O
,	O
I	O
Would	O
n't	O
be	O
Any	O
Worse	O
Off	O
,	O
Would	O
I	O
,	O
Than	O
I	O
am	O
Now	O
?	O
A	O
Qualitative	O
Study	O
of	O
Decision	O
-	O
Making	O
,	O
Hopes	O
,	O
and	O
Realities	O
of	O
Adults	O
With	O
Type	B-T047
1	I-T047
Diabetes	I-T047
Undergoing	O
Islet	B-T061
Cell	I-T061
Transplantation	I-T061
For	O
selected	O
individuals	O
with	O
type	B-T047
1	I-T047
diabetes	I-T047
,	O
pancreatic	B-T061
islet	I-T061
transplantation	I-T061
(	O
IT	B-T061
)	O
prevents	O
recurrent	O
severe	O
hypoglycemia	B-T047
and	O
optimizes	B-T061
glycemia	I-T061
,	O
although	O
ongoing	O
systemic	B-T061
immunosuppression	I-T061
is	O
needed	O
.	O
Our	O
aim	O
was	O
to	O
explore	O
candidates	O
and	O
recipients	O
'	O
expectations	O
of	O
transplantation	B-T061
,	O
their	O
experience	O
of	O
being	O
on	O
the	O
waiting	B-T033
list	I-T033
,	O
and	O
(	O
for	O
recipients	O
)	O
the	O
procedure	O
and	O
life	O
posttransplant	O
.	O
Cross	O
-	O
sectional	O
qualitative	O
research	O
design	O
using	O
semistructured	O
interviews	B-T058
with	O
16	O
adults	O
(	O
8	O
pretransplant	O
,	O
8	O
posttransplant	O
;	O
from	O
4	O
UK	O
centers	O
(	O
n	O
=	O
13	O
)	O
and	O
1	O
Canadian	O
center	O
(	O
n	O
=	O
3	O
)	O
)	O
.	O
Interviews	B-T058
were	O
audio	B-T058
-	I-T058
recorded	I-T058
,	O
transcribed	O
,	O
and	O
underwent	O
inductive	O
thematic	O
analysis	O
.	O
Interviewees	O
were	O
aged	O
(	O
mean	O
±	O
SD	O
)	O
52	O
±	O
10	O
years	O
(	O
range	O
,	O
30	O
-	O
64	O
)	O
;	O
duration	O
of	O
diabetes	B-T047
,	O
36	O
±	O
9	O
years	O
(	O
range	O
,	O
21	O
-	O
56	O
)	O
;	O
12	O
(	O
75	O
%	O
)	O
were	O
women	O
.	O
Narrative	O
accounts	O
centered	O
on	O
expectations	O
,	O
hopes	O
,	O
and	O
realities	O
;	O
decision	O
-	O
making	O
;	O
waiting	O
and	O
uncertainty	O
;	O
the	O
procedure	O
,	O
hospital	O
stay	O
,	O
and	O
follow	B-T058
-	I-T058
up	I-T058
.	O
Expected	O
benefits	O
included	O
fewer	O
severe	O
hypoglycemic	B-T047
episodes	I-T047
,	O
reduced	O
need	O
for	O
insulin	B-T121
,	O
preventing	O
onset	O
/	O
progression	O
of	O
complications	O
and	O
improved	O
psychological	B-T033
well	I-T033
-	I-T033
being	I-T033
.	O
These	O
were	O
realized	O
for	O
most	O
,	O
at	O
least	O
in	O
the	O
short	O
term	O
.	O
Most	O
interviewees	O
described	O
well	O
-	O
informed	O
,	O
shared	O
decision	O
-	O
making	O
with	O
clinicians	O
and	O
family	O
,	O
and	O
managing	O
their	O
expectations	O
.	O
Although	O
life	O
"	O
on	O
the	O
list	O
"	O
could	O
be	O
stressful	O
,	O
and	O
immunosuppressant	B-T121
side	O
effects	O
were	O
severe	O
,	O
interviewees	O
reported	O
"	O
no	B-T033
regrets	O
.	O
"	O
Posttransplant	O
,	O
interviewees	O
experienced	O
increased	O
confidence	O
,	O
through	O
freedom	B-T033
from	I-T033
hypoglycemia	I-T033
and	O
regained	O
glycemic	B-T061
control	I-T061
,	O
which	O
tempered	O
any	O
disappointment	O
about	O
continued	O
reliance	O
on	O
insulin	B-T121
.	O
Most	O
viewed	O
their	O
transplant	B-T061
as	O
a	O
success	O
,	O
though	O
several	O
reflected	O
upon	O
setbacks	O
and	O
hidden	O
hopes	O
for	O
becoming	O
"	O
insulin	B-T033
-	I-T033
free	I-T033
.	O
"	O
Independently	O
undertaken	O
interviews	B-T058
demonstrated	O
realistic	O
and	O
balanced	O
expectations	O
of	O
IT	B-T061
and	O
indicate	O
how	O
to	O
optimize	O
the	O
process	O
and	O
support	O
for	O
future	O
IT	B-T061
candidates	O
.	O
      
Clinicopathological	O
relevance	O
of	O
kinesin	O
family	O
member	O
18A	O
expression	O
in	O
invasive	B-T191
breast	I-T191
cancer	I-T191
Recently	O
,	O
kinesin	O
motor	O
proteins	O
have	O
been	O
focused	O
on	O
as	O
targets	O
for	O
cancer	B-T061
therapy	I-T061
.	O
Kinesins	O
are	O
microtubule	O
-based	O
motor	O
proteins	O
that	O
mediate	O
diverse	O
functions	O
within	O
the	O
cell	O
,	O
including	O
the	O
transport	O
of	O
vesicles	O
,	O
organelles	O
,	O
chromosomes	O
and	O
protein	O
complexes	O
,	O
as	O
well	O
as	O
the	O
movement	O
of	O
microtubules	O
.	O
In	O
the	O
current	O
study	O
,	O
the	O
expression	O
of	O
kinesin	O
family	O
member	O
18A	O
(	O
KIF18A	O
)	O
,	O
a	O
member	O
of	O
kinesin	O
superfamily	O
,	O
was	O
investigated	O
in	O
breast	B-T191
cancer	I-T191
using	O
immunohistochemistry	B-T060
,	O
and	O
its	O
effect	O
on	O
breast	B-T191
cancer	I-T191
prognosis	O
was	O
examined	O
.	O
KIF18A	O
expression	O
level	O
was	O
significantly	O
associated	O
with	O
lymph	B-T191
node	I-T191
metastasis	I-T191
(	O
P=0.047	O
)	O
.	O
In	O
patients	O
with	O
high	O
levels	O
of	O
KIF18A	O
expression	O
,	O
survival	O
was	O
significantly	O
poorer	O
compared	O
to	O
patients	O
with	O
low	O
levels	O
of	O
KIF18A	O
expression	O
(	O
disease	O
-	O
free	O
survival	O
,	O
P=0.030	O
)	O
.	O
Multivariate	O
analysis	O
revealed	O
that	O
venous	B-T033
invasion	I-T033
(	O
hazard	O
ratio	O
,	O
9.22	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
3.90	O
-	O
23.66	O
;	O
P<0.001	O
)	O
and	O
KIF18A	O
expression	O
(	O
hazard	O
ratio	O
,	O
3.20	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.34	O
-	O
6.09	O
;	O
P=0.010	O
)	O
were	O
independent	O
predictive	O
factors	O
for	O
lymph	B-T191
node	I-T191
metastasis	I-T191
.	O
KIF18A	O
may	O
be	O
a	O
useful	O
predictive	O
marker	O
for	O
lymph	B-T191
node	I-T191
metastasis	I-T191
in	O
breast	B-T191
cancer	I-T191
,	O
which	O
could	O
facilitate	O
curative	B-T033
adjuvant	I-T033
treatment	B-T061
.	O
      
Encaged	O
Chironomus	O
riparius	O
larvae	O
in	O
assessment	O
of	O
trace	B-T121
metal	I-T121
bioavailability	O
and	O
transfer	O
in	O
a	O
landfill	O
leachate	O
collection	O
pond	O
Household	O
wastes	O
may	O
constitute	O
a	O
vector	O
of	O
environmental	O
contamination	O
when	O
buried	O
,	O
in	O
particular	O
through	O
degradation	O
and	O
production	O
of	O
leachates	O
containing	O
significant	O
trace	B-T121
metal	I-T121
(	O
TM	B-T121
)	O
concentrations	O
that	O
may	O
constitute	O
a	O
serious	O
risk	O
to	O
biota	O
.	O
The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
assess	O
the	O
bioavailability	O
and	O
transfer	O
potential	O
of	O
various	O
TMs	B-T121
present	B-T033
in	O
water	B-T121
and	O
sediments	O
in	O
a	O
reservoir	O
receiving	O
landfill	O
leachates	O
.	O
An	O
active	O
biomonitoring	O
approach	O
was	O
adopted	O
consisting	O
of	O
exposing	O
naive	O
laboratory	B-T001
organisms	I-T001
in	O
cages	O
deployed	O
in	O
the	O
field	O
.	O
Aquatic	B-T001
insects	I-T001
such	O
as	O
Chironomus	O
riparius	O
larvae	O
are	O
good	O
candidates	O
since	O
they	O
represent	O
key	O
organisms	B-T001
in	O
the	O
trophic	O
functioning	O
of	O
aquatic	O
ecosystems	O
.	O
The	O
results	B-T033
show	O
that	O
water	B-T121
,	O
suspended	O
particles	O
,	O
and	O
sediments	O
were	O
significant	O
ly	O
contaminated	O
by	O
various	O
TMs	B-T121
(	O
As	B-T121
,	O
Cd	O
,	O
Cu	B-T121
,	O
Ni	O
,	O
Pb	O
,	O
and	O
Zn	B-T121
)	O
.	O
Their	O
contribution	O
to	O
the	O
transfer	O
of	O
TMs	B-T121
depends	O
,	O
however	O
,	O
on	O
the	O
specific	O
element	O
considered	O
,	O
e.g.	O
,	O
Cd	O
in	O
sediments	O
or	O
Pb	O
in	O
both	O
suspended	O
particles	O
and	O
sediments	O
.	O
The	O
internal	O
fate	O
of	O
TMs	B-T121
was	O
investigated	O
according	O
to	O
their	O
fractionation	B-T059
between	O
an	O
insoluble	O
and	O
a	O
cytosolic	O
fraction	O
.	O
This	O
approach	O
revealed	O
different	O
detoxification	B-T061
strategies	O
capable	O
of	O
preventing	O
the	O
induction	O
of	O
deleterious	O
effects	O
at	O
the	O
individual	O
scale	O
.	O
However	O
,	O
the	O
accumulation	B-T033
of	O
several	O
TMs	B-T121
in	O
C.	O
riparius	O
larvae	O
tissues	O
may	O
also	O
represent	O
a	O
significant	O
load	O
potentially	O
transferable	O
to	O
higher	O
trophic	O
levels	O
.	O
      
γ	O
-	O
Butenolide	O
and	O
furanone	O
derivatives	O
from	O
the	O
soil	O
-derived	O
fungus	O
Aspergillus	O
sclerotiorum	O
PSU	O
-	O
RSPG178	O
Chromatographic	B-T059
separation	I-T059
of	O
the	O
broth	O
extract	O
of	O
the	O
soil	O
-derived	O
fungus	O
Aspergillus	O
sclerotiorum	O
PSU	O
-	O
RSPG178	O
resulted	O
in	O
isolation	O
of	O
four	O
γ	O
-	O
butenolide	O
-	O
furanone	O
dimers	O
,	O
aspersclerotiorones	O
A	O
-	O
D	O
,	O
a	O
furanone	O
derivative	O
,	O
aspersclerotiorone	O
E	O
,	O
and	O
two	O
γ	O
-	O
butenolide	O
derivatives	O
,	O
aspersclerotiorones	O
F	O
and	O
G	O
,	O
together	O
with	O
six	O
known	O
compounds	O
,	O
penicillic	B-T195
acid	I-T195
,	O
dihydropenicillic	O
acid	O
,	O
5,6	O
-	O
dihydro-6	O
-	O
hydroxypenicillic	O
acid	O
,	O
6	O
-	O
methoxy-5,6	O
-	O
dihydropenicillic	O
acid	O
,	O
coculnol	O
and	O
(	O
4R,5R)-4,5	O
-	O
dihydroxy-3	O
-	O
methoxy-5	O
-	O
methylcyclohex-2	O
-	O
en-1	O
-	O
one	O
.	O
Their	O
structures	O
were	O
determined	O
by	O
spectroscopic	B-T059
evidence	I-T059
.	O
For	O
aspersclerotiorones	O
A	O
and	O
B	O
,	O
the	O
structures	O
were	O
confirmed	O
by	O
single	B-T059
-	I-T059
crystal	I-T059
X	I-T059
-	I-T059
ray	I-T059
diffraction	I-T059
crystallography	I-T059
.	O
Penicillic	O
acid	O
displayed	O
weak	O
antibacterial	O
activity	O
against	O
Staphylococcus	B-T007
aureus	I-T007
and	O
Escherichia	B-T007
coli	I-T007
with	O
equal	O
MIC	O
values	O
of	O
128	O
μg	O
/	O
mL	O
,	O
and	O
it	O
was	O
noncytotoxic	O
towards	O
African	O
green	O
monkey	O
kidney	B-T023
fibroblast	O
cells	O
.	O
      
Comparative	O
kinematic	B-T060
gait	I-T060
analysis	I-T060
in	O
young	O
and	O
old	O
Beagle	O
dogs	O
Age	O
-	O
related	O
involution	O
in	O
dogs	O
involves	O
loss	B-T033
of	I-T033
muscle	I-T033
mass	I-T033
and	O
changes	O
in	O
connective	O
tissue	O
and	O
articular	O
cartilage	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	B-T033
whether	O
an	O
age	O
-	O
related	O
influence	O
on	O
joint	B-T033
mobility	I-T033
can	O
be	O
detected	B-T033
in	O
the	O
absence	O
of	O
diseases	B-T047
.	O
Five	O
young	O
(	O
Ø	O
2.0	O
years	O
)	O
and	O
five	O
old	O
(	O
Ø	O
10.4	O
years	O
)	O
healthy	O
and	O
sound	O
Beagle	O
dogs	O
were	O
measured	O
during	O
locomotion	O
on	O
a	O
treadmill	O
by	O
computer	B-T059
-	I-T059
assisted	I-T059
gait	B-T060
analysis	I-T060
.	O
Angles	O
of	O
the	O
shoulder	O
,	O
elbow	O
,	O
carpal	O
,	O
hip	O
,	O
stifle	O
and	O
tarsal	O
joints	O
were	O
analyzed	O
,	O
including	O
joint	O
angle	O
progression	O
curves	O
,	O
minimum	O
and	O
maximum	O
joint	O
angles	O
and	O
range	O
of	O
motion	O
(	O
ROM	O
)	O
.	O
The	O
old	O
group	O
showed	O
a	O
smaller	O
maximum	O
joint	O
angle	O
(	O
p	O
=	O
0.037	O
)	O
and	O
ROM	O
(	O
p	O
=	O
0.037	O
)	O
of	O
the	O
carpal	O
joint	O
and	O
similar	O
tendencies	O
in	O
the	O
shoulder	O
,	O
elbow	O
and	O
carpal	O
joint	O
.	O
The	O
descriptive	O
analysis	O
of	O
the	O
progression	O
curves	O
revealed	O
less	B-T033
flexion	I-T033
and	O
extension	O
of	O
the	O
joints	O
of	O
the	O
forelimb	O
.	O
This	O
indicates	O
restricted	O
joint	B-T033
mobility	I-T033
of	O
the	O
forelimb	O
but	O
primarily	O
of	O
the	O
carpal	O
joint	O
.	O
Findings	O
in	O
the	O
joints	O
of	O
the	O
hindlimb	B-T023
were	O
not	O
consistent	O
;	O
contrasting	O
alterations	O
may	O
be	O
due	O
to	O
a	O
compensatory	O
mechanism	O
.	O
As	O
most	O
alterations	O
were	O
found	B-T033
in	O
the	O
distal	O
joints	O
,	O
these	O
should	O
receive	O
particular	O
attention	O
when	O
examining	O
elderly	O
dogs	O
.	O
      
Improving	O
the	O
Sexual	O
Health	O
of	O
Young	O
People	O
With	O
Mobility	B-T033
Impairments	I-T033
:	O
Challenges	B-T058
and	O
Recommendations	O
This	O
mixed	O
-	O
method	O
study	O
(	O
a	O
)	O
describes	O
challenges	B-T058
to	O
providing	O
sexual	O
health	O
services	B-T058
to	O
youth	O
with	O
mobility	B-T033
impairments	I-T033
from	O
the	O
perspective	O
of	O
health	O
care	O
providers	O
and	O
experts	O
and	O
(	O
b	O
)	O
describes	O
and	O
compares	O
sexual	O
health	O
-related	O
experiences	O
of	O
youth	O
with	O
mobility	B-T033
impairments	I-T033
.	O
Secondary	O
data	O
analysis	O
of	O
My	O
Path	O
,	O
a	O
study	O
focused	O
on	O
the	O
transition	O
to	O
adulthood	O
for	O
youth	O
with	O
mobility	B-T033
impairments	I-T033
.	O
Using	O
an	O
exploratory	O
sequential	O
design	O
,	O
qualitative	O
data	O
(	O
n	O
=	O
10	O
)	O
were	O
analyzed	O
using	O
systematic	O
content	O
analysis	O
followed	O
by	O
quantitative	O
analysis	O
of	O
survey	O
data	O
(	O
N	O
=	O
337	O
)	O
.	O
Challenges	B-T058
included	O
not	O
talking	O
about	O
sex	O
,	O
managing	O
sexual	O
development	O
,	O
adaptation	O
and	O
instruction	O
,	O
parent	O
roles	O
,	O
and	O
safety	O
.	O
Survey	O
data	O
showed	O
that	O
youth	O
with	O
mobility	B-T033
impairments	I-T033
are	O
diverse	O
in	O
their	O
experiences	O
with	O
sexual	O
behavior	O
and	O
sources	B-T033
of	O
sexual	O
health	O
information	O
.	O
Although	O
connected	O
with	O
primary	O
care	O
providers	O
,	O
few	O
received	O
information	O
about	O
sexual	O
health	O
.	O
Interventions	B-T058
to	O
improve	B-T033
youths	O
'	O
well	O
-	O
being	O
should	O
include	O
comprehensive	B-T058
care	I-T058
and	O
education	O
that	O
promotes	O
and	O
supports	O
healthy	O
sexual	O
development	O
.	O
      
Co	O
-	O
delivery	O
of	O
pemetrexed	B-T121
and	O
miR-21	O
antisense	O
oligonucleotide	O
by	O
lipid	O
-	O
polymer	O
hybrid	O
nanoparticles	O
and	O
effects	O
on	O
glioblastoma	B-T191
cells	O
Combination	B-T061
therapy	I-T061
using	O
anticancer	B-T121
drugs	I-T121
and	O
nucleic	O
acid	O
is	O
a	O
more	O
promising	O
strategy	O
to	O
overcome	O
multidrug	O
resistance	O
in	O
cancer	B-T191
and	O
to	O
enhance	O
apoptosis	O
.	O
In	O
this	O
study	O
,	O
lipid	O
-	O
polymer	O
hybrid	O
nanoparticles	O
(	O
LPNs	O
)	O
,	O
which	O
contain	O
both	O
pemetrexed	B-T121
and	O
miR-21	O
antisense	O
oligonucleotide	O
(	O
anti	O
-	O
miR-21	O
)	O
,	O
have	O
been	O
developed	O
for	O
treatment	O
of	O
glioblastoma	B-T191
,	O
the	O
most	O
aggressive	B-T191
type	O
of	O
brain	B-T191
tumor	I-T191
.	O
Prepared	O
LPNs	O
have	O
been	O
well	O
characterized	O
by	O
particle	O
size	O
distribution	O
and	O
zeta	O
potential	O
measurements	O
,	O
determination	O
of	O
encapsulation	O
efficiency	O
,	O
and	O
in	O
vitro	O
release	O
experiments	O
.	O
Morphology	O
of	O
LPNs	O
was	O
determined	O
by	O
transmission	B-T059
electron	I-T059
microscopy	I-T059
.	O
LPNs	O
had	O
a	O
hydrodynamic	O
size	O
below	O
100	O
nm	O
and	O
exhibited	O
sustained	O
release	O
of	O
pemetrexed	B-T121
up	O
to	O
10	O
h.	O
Encapsulation	O
of	O
pemetrexed	B-T121
in	O
LPNs	O
increased	O
cellular	O
uptake	O
from	O
6	O
%	O
to	O
78	O
%	O
.	O
Results	O
of	O
confocal	B-T059
microscopy	I-T059
analysis	I-T059
have	O
shown	O
that	O
co	O
-	O
delivery	O
of	O
anti	O
-	O
miR-21	O
significantly	O
improved	O
accumulation	B-T033
of	O
LPNs	O
in	O
the	O
nucleus	O
of	O
U87MG	O
cells	O
.	O
Nevertheless	O
,	O
more	O
effective	O
cytotoxicity	O
results	O
could	O
not	O
be	O
obtained	O
due	O
to	O
low	O
concentration	O
of	O
anti	O
-	O
miR-21	O
,	O
loaded	O
in	O
LPNs	O
.	O
We	O
expect	O
that	O
the	O
effective	O
drug	O
delivery	O
systems	O
can	O
be	O
obtained	O
with	O
higher	O
concentration	O
of	O
anti	O
-	O
miR-21	O
for	O
the	O
treatment	B-T061
of	O
glioblastoma	B-T191
.	O
      
MiR-424	O
-	O
5p	O
participates	O
in	O
esophageal	B-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
invasion	O
and	O
metastasis	B-T191
via	O
SMAD7	O
pathway	O
mediated	O
EMT	O
ESCC	B-T191
is	O
a	O
life	B-T033
-	I-T033
threatening	I-T033
disease	B-T047
due	O
to	O
invasion	O
and	O
metastasis	B-T191
in	O
the	O
early	O
stage	O
.	O
Great	O
efforts	O
had	O
been	O
made	O
to	O
detect	B-T033
the	O
molecular	O
mechanisms	O
which	O
led	O
to	O
the	O
invasion	O
and	O
metastasis	B-T191
in	O
ESCC	B-T191
.	O
Recent	O
evidence	O
had	O
suggested	O
that	O
deregulation	O
of	O
miR-424	O
-	O
5p	O
took	O
an	O
important	O
role	O
in	O
cancers	B-T191
.	O
However	O
,	O
its	O
role	O
and	O
functional	O
mechanism	O
in	O
ESCC	B-T191
had	O
seldom	O
been	O
elucidated	O
.	O
The	O
expression	O
levels	O
of	O
miR-424	O
-	O
5p	O
were	O
detected	B-T033
in	O
ESCC	B-T191
tissues	O
and	O
cell	O
lines	O
by	O
real	O
-	O
time	O
PCR	O
methods	O
.	O
Then	O
,	O
the	O
invasion	O
,	O
metastasis	B-T191
and	O
proliferation	O
ability	O
of	O
ESCC	B-T191
cell	O
lines	O
transfected	O
with	O
miR-424	O
-	O
5p	O
mimics	O
were	O
analyzed	O
separately	O
by	O
transwell	B-T059
invasion	I-T059
assay	I-T059
,	O
wound	B-T059
healing	I-T059
assay	I-T059
and	O
cell	O
proliferation	O
assay	O
.	O
Finally	O
,	O
the	O
target	O
gene	O
of	O
miR-424	O
-	O
5p	O
was	O
studied	O
and	O
verified	O
by	O
luciferase	B-T059
activity	I-T059
assay	I-T059
.	O
And	O
the	O
role	O
of	O
miR-424	O
-	O
5p	O
in	O
EMT	O
was	O
also	O
investigated	O
by	O
real	O
-	O
time	O
PCR	O
and	O
western	B-T059
blot	I-T059
assay	I-T059
.	O
We	O
showed	O
that	O
the	O
expression	O
levels	O
of	O
miR-424	O
-	O
5p	O
were	O
decreased	O
both	O
in	O
ESCC	B-T191
tissues	O
and	O
cell	O
lines	O
.	O
Furthermore	O
,	O
the	O
expression	O
levels	O
of	O
miR-424	O
-	O
5p	O
were	O
negatively	O
linked	O
to	O
lymph	B-T023
node	I-T023
metastasis	B-T191
in	O
ESCC	B-T191
tissues	O
.	O
Restoration	O
of	O
miR-424	O
-	O
5p	O
in	O
EC-1	O
cells	O
by	O
using	O
miR-424	O
-	O
5p	O
mimics	O
could	O
decrease	O
the	O
invasion	O
,	O
metastasis	B-T191
and	O
proliferation	O
of	O
EC-1	O
cells	O
,	O
indicating	O
its	O
role	O
in	O
inhibition	O
on	O
the	O
invasion	O
and	O
metastasis	B-T191
ability	O
of	O
ESCC	B-T191
cells	O
and	O
tissues	O
.	O
In	O
addition	O
,	O
we	O
demonstrated	O
that	O
SMAD7	O
was	O
a	O
specific	O
target	O
gene	O
for	O
miR-424	O
-	O
5p	O
by	O
luciferase	B-T059
activity	I-T059
assay	I-T059
and	O
miR-424	O
-	O
5p	O
could	O
not	O
only	O
negatively	B-T033
regulate	O
SMAD7	O
expression	O
but	O
also	O
participate	O
in	O
EMT	O
via	O
SMAD7	O
,	O
because	O
overexpression	O
of	O
SMAD7	O
could	O
partly	O
enhance	O
the	O
miR-424	O
-	O
5p	O
anti	B-T033
-	I-T033
EMT	I-T033
function	O
.	O
Our	O
results	O
described	O
that	O
miR-424	O
-	O
5p	O
-	O
SMAD7	O
pathway	O
contributed	O
to	O
ESCC	B-T191
invasion	O
and	O
metastasis	B-T191
and	O
up	O
-	O
regulation	O
of	O
miR-424	O
-	O
5p	O
perhaps	O
provided	O
a	O
strategy	O
for	O
preventing	O
tumor	B-T033
invasion	I-T033
,	O
metastasis	B-T191
.	O
      
Insurance	O
Coverage	O
and	O
Utilization	O
at	O
a	O
Sexually	O
Transmitted	O
Disease	O
Clinic	O
in	O
a	O
Medicaid	O
Expansion	O
State	O
In	O
Rhode	O
Island	O
,	O
the	O
Patient	O
Protection	O
and	O
Affordable	O
Care	O
Act	O
has	O
led	O
to	O
over	O
95	O
%	O
of	O
the	O
state	O
's	O
population	O
being	O
insured	O
.	O
We	O
evaluated	B-T058
insurance	O
coverage	O
and	O
barriers	B-T033
to	O
insurance	B-T058
use	O
among	O
patients	O
presenting	O
for	O
services	B-T058
at	O
the	O
Rhode	O
Island	O
sexually	O
transmitted	O
disease	O
(	O
STD	O
)	O
clinic	O
.	O
We	O
analyzed	O
factors	O
associated	O
with	O
insurance	O
coverage	O
and	O
utilization	O
among	O
patients	O
presenting	O
for	O
STD	B-T047
services	B-T058
between	O
July	O
and	O
December	O
2015	O
.	O
A	O
total	O
of	O
692	O
patients	O
had	O
insurance	O
information	O
available	O
;	O
of	O
those	O
,	O
40	O
%	O
were	O
uninsured	O
.	O
Patients	O
without	O
insurance	O
were	O
more	O
likely	O
than	O
those	O
with	O
insurance	B-T058
to	O
be	O
nonwhite	O
(	O
50	O
%	O
among	O
uninsured	O
,	O
compared	O
with	O
40	O
%	O
among	O
insured	O
;	O
P	O
=	O
0.014	O
)	O
and	O
Hispanic	O
or	O
Latino	O
/	O
a	O
(	O
25	O
%	O
,	O
compared	O
with	O
16	O
%	O
;	O
P	O
=	O
0.006	O
)	O
,	O
and	O
less	O
likely	O
to	O
be	O
men	O
who	O
have	O
sex	O
with	O
men	O
(	O
27	O
%	O
,	O
compared	O
with	O
39	O
%	O
;	O
P	O
=	O
0.001	O
)	O
.	O
Of	O
those	O
with	O
health	B-T058
insurance	I-T058
,	O
26	O
%	O
obtained	O
coverage	O
as	O
a	O
result	O
of	O
the	O
Affordable	O
Care	O
Act	O
,	O
and	O
56	O
%	O
of	O
those	O
were	O
previously	O
uninsured	O
.	O
Among	O
uninsured	O
individuals	O
,	O
barriers	B-T033
to	O
obtaining	O
health	B-T058
insurance	I-T058
included	O
cost	O
and	O
unemployment	B-T033
.	O
Among	O
those	O
with	O
insurance	O
,	O
43	O
%	O
reported	O
willingness	B-T033
to	O
use	O
insurance	B-T058
for	O
STD	B-T047
services	B-T058
.	O
Barriers	B-T033
to	O
insurance	B-T058
use	O
included	O
concerns	O
about	O
anonymity	O
and	O
out	O
-	O
of	O
-	O
pocket	O
costs	O
.	O
Despite	O
expanded	O
insurance	B-T058
access	O
,	O
many	O
individuals	O
presenting	O
to	O
the	O
Rhode	O
Island	O
STD	O
Clinic	O
were	O
uninsured	O
.	O
Among	O
those	O
who	O
were	O
insured	O
,	O
significant	O
barriers	B-T033
still	O
existed	O
to	O
using	O
insurance	B-T058
.	O
STD	O
clinics	O
continue	O
to	O
play	O
an	O
important	O
role	O
in	O
providing	O
safety	B-T058
-	I-T058
net	I-T058
STD	B-T047
services	B-T058
in	O
states	O
with	O
low	O
uninsured	O
rates	O
.	O
Both	O
public	O
and	O
private	O
insurers	O
are	O
needed	O
to	O
address	O
financial	B-T033
barriers	I-T033
and	O
optimize	O
payment	O
structures	O
for	O
services	B-T058
.	O
      
Crocetin	B-T121
improves	B-T033
the	O
quality	O
of	O
in	O
vitro	O
-	O
produced	O
bovine	O
embryos	B-T018
:	O
Implications	O
for	O
blastocyst	O
development	O
,	O
cryotolerance	O
,	O
and	O
apoptosis	O
The	O
aim	O
of	O
this	O
work	O
was	O
to	O
assess	B-T058
the	O
effect	O
of	O
supplementation	B-T061
of	O
bovine	O
culture	O
medium	O
with	O
the	O
natural	B-T121
antioxidant	I-T121
crocetin	B-T121
on	O
in	O
vitro	O
blastocyst	O
development	O
and	O
quality	O
.	O
This	O
was	O
evaluated	B-T058
as	O
cryotolerance	O
,	O
apoptosis	O
index	O
,	O
and	O
total	B-T059
cells	I-T059
number	I-T059
and	O
allocation	O
.	O
Abattoir	O
-derived	O
oocytes	O
were	O
matured	O
and	O
fertilized	O
in	O
vitro	O
according	O
to	O
standard	O
procedure	O
.	O
Twenty	O
hours	O
after	O
IVF	B-T061
,	O
presumptive	O
zygotes	B-T018
were	O
cultured	B-T059
in	O
synthetic	B-T023
oviduct	I-T023
fluid	O
medium	O
,	O
supplemented	O
with	O
0	O
,	O
1	O
,	O
2.5	O
,	O
and	O
5	O
μM	O
crocetin	B-T121
(	O
experiment	O
1	O
)	O
at	O
39	O
°	O
C	O
under	O
humidified	B-T061
air	I-T061
with	O
5	O
%	O
CO2	O
,	O
7	O
%	O
O2	B-T121
,	O
and	O
88	O
%	O
N2	O
.	O
On	O
Day	O
7	O
,	O
embryo	O
yields	O
were	O
assessed	O
and	O
the	O
blastocysts	B-T018
were	O
vitrified	O
by	O
Cryotop	O
method	O
in	O
16.5	O
%	O
ethylene	O
glycol	O
,	O
16.5	O
%	O
DMSO	B-T121
,	O
and	O
0.5	O
M	O
sucrose	B-T121
.	O
Finally	O
,	O
blastocysts	B-T018
produced	O
on	O
Day	O
8	O
in	O
the	O
absence	O
(	O
control	O
)	O
and	O
presence	B-T033
of	O
1	O
μM	O
crocetin	B-T121
were	O
used	O
for	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	O
nick	O
end	O
labelling	O
and	O
differential	B-T059
staining	I-T059
to	O
evaluate	B-T058
,	O
respectively	O
,	O
the	O
apoptotic	O
rate	O
and	O
the	O
allocation	O
of	O
cells	O
into	O
inner	B-T018
cell	I-T018
mass	I-T018
(	O
ICM	B-T018
)	O
and	O
trophectoderm	B-T018
(	O
TE	B-T018
)	O
lineages	O
(	O
experiment	O
2	O
)	O
.	O
Embryo	O
development	O
was	O
higher	O
in	O
the	O
1	O
μM	O
crocetin	O
group	O
compared	O
to	O
the	O
control	O
,	O
both	O
in	O
terms	O
of	O
total	O
embryo	B-T018
output	B-T033
(	O
37.7	O
±	O
4.2	O
%	O
,	O
52.9	O
±	O
6.3	O
%	O
,	O
40.9	O
±	O
7.6	O
%	O
,	O
and	O
42.4	O
±	O
8.7	O
%	O
,	O
respectively	O
,	O
with	O
0	O
,	O
1	O
,	O
2.5	O
,	O
and	O
5	O
μM	O
;	O
P	O
<	O
0.01	O
)	O
and	O
grade	O
1	O
and	O
2	O
blastocysts	B-T018
(	O
33.6	O
±	O
4.9	O
%	O
,	O
46.1	O
±	O
7.3	O
%	O
,	O
37.8	O
±	O
7.9	O
%	O
,	O
and	O
39.4	O
±	O
7.9	O
%	O
,	O
respectively	O
,	O
with	O
0	O
,	O
1	O
,	O
2.5	O
,	O
and	O
5	O
μM	O
;	O
P	O
<	O
0.05	O
)	O
.	O
Moreover	O
,	O
the	O
percentage	O
of	O
fast	O
-	O
developing	O
embryos	O
increased	O
in	O
1	O
μM	O
crocetin	O
group	O
compared	O
to	O
the	O
control	O
(	O
23.4	O
±	O
4.7	O
%	O
,	O
32.7	O
±	O
6.6	O
%	O
,	O
27.2	O
±	O
6.6	O
%	O
,	O
and	O
30.1	O
±	O
7.2	O
%	O
,	O
respectively	O
,	O
with	O
0	O
,	O
1	O
,	O
2.5	O
,	O
and	O
5	O
μM	O
;	O
P	O
<	O
0.05	O
)	O
.	O
In	O
addition	O
,	O
the	O
enrichment	O
of	O
culture	O
medium	O
with	O
1	O
μM	O
crocetin	B-T121
improved	B-T033
embryo	B-T018
cryotolerance	O
compared	O
to	O
the	O
control	O
,	O
as	O
indicated	O
by	O
higher	O
hatching	O
rates	O
recorded	O
after	O
48	O
hours	O
postwarming	O
culture	O
(	O
46.5	O
%	O
vs.	O
60.4	O
%	O
;	O
P	O
<	O
0.05	O
)	O
.	O
Furthermore	O
,	O
1	O
μM	O
crocetin	B-T121
decreased	O
both	O
the	O
average	O
number	O
(	O
9.9	O
±	O
0.4	O
vs.	O
7.1	O
±	O
0.3	O
)	O
and	O
the	O
percentage	O
of	O
apoptotic	O
cells	O
(	O
7.1	O
±	O
0.4	O
vs.	O
4.2	O
±	O
0.2	O
)	O
in	O
blastocysts	B-T018
compared	O
to	O
the	O
control	O
(	O
P	O
<	O
0.01	O
)	O
.	O
However	O
,	O
no	O
differences	O
were	O
recorded	O
in	O
the	O
average	O
number	O
of	O
ICM	B-T018
,	O
TE	B-T018
,	O
and	O
total	O
cells	O
between	O
1	O
μM	O
crocetin	B-T121
and	O
control	O
groups	O
.	O
In	O
conclusion	O
,	O
the	O
enrichment	O
of	O
bovine	O
culture	O
medium	O
with	O
1	O
μM	O
crocetin	B-T121
increased	O
both	O
blastocyst	O
yield	O
and	O
quality	O
,	O
as	O
indicated	O
by	O
the	O
improved	B-T033
chronology	O
of	O
embryo	O
development	O
,	O
increased	O
resistance	O
to	O
cryopreservation	B-T059
,	O
and	O
reduced	O
incidence	O
of	O
apoptosis	O
.	O
      
Addressing	O
holistic	O
health	O
and	O
work	O
empowerment	O
through	O
a	O
body	B-T058
-	I-T058
mind	I-T058
-	I-T058
spirit	I-T058
intervention	I-T058
program	I-T058
among	O
helping	O
professionals	O
in	O
continuous	O
education	O
:	O
A	O
pilot	O
study	O
To	O
examine	O
the	O
effectiveness	O
of	O
a	O
body	B-T058
-	I-T058
mind	I-T058
-	I-T058
spirit	I-T058
(	I-T058
BMS	I-T058
)	I-T058
intervention	I-T058
program	I-T058
in	O
improving	O
the	O
holistic	O
well	O
-	O
being	O
and	O
work	O
empowerment	O
among	O
helping	O
professionals	O
in	O
continuous	O
education	O
.	O
Forty	O
-	O
four	O
helping	O
professionals	O
,	O
who	O
were	O
in	O
their	O
first	O
-	O
year	O
part	O
-	O
time	O
postgraduate	O
study	O
,	O
participated	O
in	O
the	O
present	O
study	O
.	O
All	O
participants	O
attended	O
a	O
3	O
-	O
day	O
BMS	B-T058
intervention	I-T058
program	I-T058
which	O
emphasized	O
a	O
holistic	O
approach	O
to	O
health	O
and	O
well	O
-	O
being	O
.	O
Ratings	O
on	O
their	O
levels	O
of	O
physical	B-T033
distress	I-T033
,	O
daily	O
functioning	O
,	O
affect	O
,	O
spirituality	O
,	O
and	O
psychologica	O
l	O
empowerment	O
at	O
work	O
were	O
compared	O
before	O
and	O
immediately	O
after	O
the	O
intervention	B-T058
.	O
Participants	O
reported	O
significantly	O
lower	O
levels	O
of	O
negative	B-T033
affect	I-T033
and	O
physical	B-T033
distress	I-T033
,	O
and	O
were	O
less	O
spiritually	B-T033
disoriented	I-T033
after	O
the	O
intervention	B-T058
.	O
Enhanced	O
levels	O
of	O
daily	O
functioning	O
,	O
positive	O
affect	O
,	O
spiritual	O
resilience	O
,	O
and	O
tranquility	O
were	O
also	O
reported	O
.	O
Results	O
also	O
suggested	O
that	O
participants	O
were	O
empowered	O
at	O
work	O
,	O
and	O
specifically	O
felt	O
more	O
able	O
to	O
make	O
an	O
impact	O
on	O
work	O
outcomes	O
.	O
The	O
3	O
-	O
day	O
BMS	B-T058
intervention	I-T058
program	I-T058
produced	O
a	O
positive	B-T033
and	O
measurable	O
effec	O
t	O
on	O
participants	O
'	O
holistic	O
well	O
-	O
being	O
and	O
empowerment	O
at	O
work	O
.	O
Educators	O
in	O
related	O
fields	O
could	O
incorporate	O
holistic	O
practices	O
into	O
the	O
curriculum	O
to	O
better	O
prepare	O
the	O
future	O
practitioners	O
,	O
leading	O
to	O
better	O
outcomes	O
both	O
to	O
the	O
professionals	O
themselves	O
and	O
their	O
clients	O
or	O
patients	O
.	O
      
Similar	O
patterns	O
of	O
neural	O
activity	O
predict	O
memory	O
function	O
during	O
encoding	O
and	O
retrieval	O
Neural	B-T023
networks	I-T023
that	O
span	O
the	O
medial	B-T023
temporal	I-T023
lobe	I-T023
(	O
MTL	B-T023
)	O
,	O
prefrontal	B-T023
cortex	I-T023
,	O
and	O
posterior	B-T023
cortical	I-T023
regions	I-T023
are	O
essential	O
to	O
episodic	O
memory	O
function	O
in	O
humans	O
.	O
Encoding	O
and	O
retrieval	O
are	O
supported	O
by	O
the	O
engagement	O
of	O
both	O
distinct	O
neural	B-T023
pathways	I-T023
across	O
the	O
cortex	B-T023
and	O
common	O
structures	O
within	O
the	O
medial	B-T023
temporal	I-T023
lobes	I-T023
.	O
However	O
,	O
the	O
degree	O
to	O
which	O
memory	O
performance	O
can	O
be	O
determined	O
by	O
neural	O
processing	O
that	O
is	O
common	O
to	O
encoding	O
and	O
retrieval	O
remains	O
to	O
be	O
determined	O
.	O
To	O
identify	O
neural	O
signatures	O
of	O
successful	O
memory	O
function	O
,	O
we	O
administered	O
a	O
delayed	O
free	O
-	O
recall	O
task	O
to	O
187	O
neurosurgical	B-T061
patients	O
implanted	B-T061
with	O
subdural	O
or	O
intraparenchymal	B-T023
depth	O
electrodes	O
.	O
We	O
developed	O
multivariate	O
classifiers	O
to	O
identify	O
patterns	O
of	O
spectral	O
power	O
across	O
the	O
brain	B-T023
that	O
independently	O
predicted	O
successful	O
episodic	O
encoding	O
and	O
retrieval	O
.	O
During	O
encoding	O
and	O
retrieval	O
,	O
patterns	O
of	O
increased	O
high	O
frequency	O
activity	O
in	O
prefrontal	B-T023
,	O
MTL	B-T023
,	O
and	O
inferior	B-T023
parietal	I-T023
cortices	I-T023
,	O
accompanied	O
by	O
widespread	O
decreases	O
in	O
low	O
frequency	O
power	O
across	O
the	O
brain	B-T023
predicted	O
successful	O
memory	O
function	O
.	O
Using	O
a	O
cross	O
-	O
decoding	O
approach	O
,	O
we	O
demonstrate	O
the	O
ability	O
to	O
predict	O
memory	O
function	O
across	O
distinct	O
phases	O
of	O
the	O
free	O
-	O
recall	O
task	O
.	O
Furthermore	O
,	O
we	O
demonstrate	O
that	O
classifiers	O
that	O
combine	O
information	O
from	O
both	O
encoding	O
and	O
retrieval	O
states	O
can	O
outperform	O
task	O
-	O
independent	O
models	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
engagement	O
of	O
a	O
core	O
memory	O
network	O
during	O
either	O
encoding	O
or	O
retrieval	O
shapes	O
the	O
ability	B-T033
to	I-T033
remember	I-T033
the	I-T033
past	I-T033
,	O
despite	O
distinct	O
neural	O
interactions	O
that	O
facilitate	O
encoding	O
and	O
retrieval	O
.	O
      
Beyond	O
neutral	O
and	O
forbidden	O
links	O
:	O
morphological	O
matches	O
and	O
the	O
assembly	O
of	O
mutualistic	O
hawkmoth	O
-	O
plant	O
networks	O
A	O
major	O
challenge	O
in	O
evolutionary	O
ecology	O
is	O
to	O
understand	O
how	O
co	O
-	O
evolutionary	O
processes	O
shape	O
patterns	O
of	O
interactions	O
between	O
species	O
at	O
community	O
level	O
.	O
Pollination	O
of	O
flowers	O
with	O
long	O
corolla	O
tubes	O
by	O
long	O
-	O
tongued	O
hawkmoths	O
has	O
been	O
invoked	O
as	O
a	O
showcase	O
model	O
of	O
co	O
-	O
evolution	O
.	O
Recently	O
,	O
optimal	O
foraging	O
models	O
have	O
predicted	O
that	O
there	O
might	O
be	O
a	O
close	O
association	O
between	O
mouthparts	O
'	O
length	O
and	O
the	O
corolla	O
depth	O
of	O
the	O
visited	O
flowers	O
,	O
thus	O
favouring	O
trait	O
convergence	O
and	O
specialization	O
at	O
community	O
level	O
.	O
Here	O
,	O
we	O
assessed	O
whether	O
hawkmoths	O
more	O
frequently	O
pollinate	O
plants	O
with	O
floral	O
tube	O
lengths	O
similar	O
to	O
their	O
proboscis	O
lengths	O
(	O
morphological	O
match	O
hypothesis	O
)	O
against	O
abundance	O
-based	O
processes	O
(	O
neutral	O
hypothesis	O
)	O
and	O
ecological	O
trait	O
mismatches	O
constraints	O
(	O
forbidden	O
links	O
hypothesis	O
)	O
,	O
and	O
how	O
these	O
processes	O
structure	O
hawkmoth	O
-	O
plant	O
mutualistic	O
networks	O
from	O
five	O
communities	O
in	O
four	O
biogeographical	O
regions	O
of	O
South	O
America	O
.	O
We	O
found	O
convergence	O
in	O
morphological	O
traits	O
across	O
the	O
five	O
communities	O
and	O
that	O
the	O
distribution	O
of	O
morphological	O
differences	O
between	O
hawkmoths	O
and	O
plants	O
is	O
consistent	O
with	O
expectations	O
under	O
the	O
morphological	O
match	O
hypothesis	O
in	O
three	O
of	O
the	O
five	O
communities	O
.	O
In	O
the	O
two	O
remaining	O
communities	O
,	O
which	O
are	O
ecotones	O
between	O
two	O
distinct	O
biogeographical	O
areas	O
,	O
interactions	O
are	O
better	O
predicted	O
by	O
the	O
neutral	O
hypothesis	O
.	O
Our	O
findings	O
are	O
consistent	O
with	O
the	O
idea	O
that	O
diffuse	O
co	O
-	O
evolution	O
drives	O
the	O
evolution	O
of	O
extremely	O
long	O
proboscises	O
and	O
flower	O
tubes	O
,	O
and	O
highlight	O
the	O
importance	O
of	O
morphological	O
traits	O
,	O
beyond	O
the	O
forbidden	O
links	O
hypothesis	O
,	O
in	O
structuring	O
interactions	O
between	O
mutualistic	O
partners	O
,	O
revealing	O
that	O
the	O
role	O
of	O
niche	O
-	O
based	O
processes	O
can	O
be	O
much	O
more	O
complex	O
than	O
previously	O
known	O
.	O
      
Central	O
Corneal	O
Thickness	O
Reproducibility	O
among	O
Ten	O
Different	O
Instruments	O
To	O
assess	B-T058
agreement	O
between	O
one	O
ultrasonic	O
(	O
US	O
)	O
and	O
nine	O
optical	O
instruments	O
for	O
the	O
measurement	O
of	O
central	O
corneal	O
thickness	O
(	O
CCT	O
)	O
,	O
and	O
to	O
evaluate	B-T058
intra-	O
and	O
inter	O
-	O
operator	O
reproducibility	O
.	O
In	O
this	O
observational	O
cross	O
-	O
sectional	O
study	O
,	O
two	O
masked	O
operators	O
measured	O
CCT	O
thickness	O
twice	O
in	O
28	O
healthy	O
eyes	B-T023
.	O
We	O
used	O
seven	O
spectral	O
-	O
domain	O
optical	O
coherence	O
tomography	O
(	O
SD	O
-	O
OCT	O
)	O
devices	O
,	O
one	O
time	O
-	O
domain	O
OCT	O
,	O
one	O
Scheimpflug	O
camera	O
,	O
and	O
one	O
US	O
-	O
based	O
instrument	O
.	O
Inter-	O
and	O
intra	O
-	O
operator	O
reproducibility	O
was	O
evaluated	B-T058
by	O
intraclass	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
,	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
,	O
and	O
Bland	O
-	O
Altman	O
test	O
analysis	O
.	O
Instrument	O
-to-	O
instrument	O
reproducibility	O
was	O
determined	O
by	O
ANOVA	O
for	O
repeated	O
measurements	O
.	O
We	O
also	O
tested	O
how	O
the	O
devices	O
disagreed	O
regarding	O
systemic	O
bias	O
and	O
random	O
error	O
using	O
a	O
structural	O
equation	O
model	O
.	O
Mean	O
CCT	O
of	O
all	O
instruments	O
ranged	O
from	O
536	O
±	O
42	O
μm	O
to	O
577	O
±	O
40	O
μm	O
.	O
An	O
instrument	O
-to-	O
instrument	O
correlation	O
test	O
showed	O
high	O
values	O
among	O
the	O
10	O
investigated	O
devices	O
(	O
correlation	O
coefficient	O
range	O
0.852	O
-	O
0.995	O
;	O
p	O
values	O
<	O
0.0001	O
in	O
all	O
cases	O
)	O
.	O
The	O
highest	O
correlation	O
coefficient	O
values	O
were	O
registered	O
between	O
3D	O
OCT-2000	O
Topcon	O
-	O
Spectral	O
OCT	O
/	O
SLO	O
Opko	O
(	O
0.995	O
)	O
and	O
Cirrus	O
HD	O
-	O
OCT	O
Zeiss	O
-	O
RS-3000	O
Nidek	O
(	O
0.995	O
)	O
,	O
whereas	O
the	O
lowest	O
were	O
seen	O
between	O
SS-1000	O
CASIA	O
and	O
Spectral	O
OCT	O
/	O
SLO	O
Opko	O
(	O
0.852	O
)	O
.	O
ICC	O
and	O
CV	O
showed	O
excellent	O
inter-	O
and	O
intra	O
-	O
operator	O
reproducibility	O
for	O
all	O
optic	O
-based	O
devices	O
,	O
except	O
for	O
the	O
US	O
-based	O
device	O
.	O
Bland	O
-	O
Altman	O
analysis	O
demonstrated	O
low	O
mean	O
biases	O
between	O
operators	O
.	O
Despite	O
highlighting	O
good	O
intra-	O
and	O
inter	O
-	O
operator	O
reproducibility	O
,	O
we	O
found	O
that	O
a	O
scale	O
bias	O
between	O
instruments	O
might	O
interfere	O
with	O
thorough	O
CCT	O
monitoring	B-T058
.	O
We	O
suggest	O
that	O
optimal	O
monitoring	B-T058
is	O
achieved	O
with	O
the	O
same	O
operator	O
and	O
the	O
same	O
device	O
.	O
      
Medicare	O
claims	O
indicators	O
of	O
healthcare	B-T058
utilization	O
differences	O
after	O
hospitalization	B-T058
for	O
ischemic	B-T047
stroke	I-T047
:	O
Race	O
,	O
gender	O
,	O
and	O
caregiving	O
effects	O
Background	O
Differences	O
in	O
healthcare	B-T058
utilization	O
after	O
stroke	B-T047
may	O
partly	O
explain	O
race	O
or	O
gender	O
differences	O
in	O
stroke	B-T047
outcomes	O
and	O
identify	O
factors	O
that	O
might	O
reduce	O
post	O
-	O
acute	B-T047
stroke	I-T047
care	O
costs	O
.	O
Aim	O
To	O
examine	O
systematic	O
differences	O
in	O
Medicare	O
claims	O
for	O
healthcare	B-T058
utilization	O
after	O
hospitalization	B-T058
for	O
ischemic	B-T047
stroke	I-T047
in	O
a	O
US	O
population	O
-based	O
sample	O
.	O
Methods	O
Claims	O
were	O
examined	B-T033
over	O
a	O
six	O
-	O
month	O
period	O
after	O
hospitalization	B-T058
for	O
279	O
ischemic	B-T047
stroke	I-T047
survivors	O
65	O
years	O
or	O
older	O
from	O
the	O
REasons	O
for	O
Geographic	O
And	O
Racial	B-T033
Differences	I-T033
in	O
Stroke	B-T047
(	O
REGARDS	B-T047
)	O
study	O
.	O
Statistical	O
analyses	O
examined	B-T033
differences	O
in	O
post	O
-	O
acute	B-T058
healthcare	I-T058
utilization	O
,	O
adjusted	O
for	O
pre	O
-	O
stroke	B-T047
utilization	O
,	O
as	O
a	O
function	O
of	O
race	O
(	O
African	O
-	O
American	O
vs.	O
White	O
)	O
,	O
gender	O
,	O
age	O
,	O
stroke	O
belt	O
residence	O
,	O
income	O
,	O
Medicaid	O
dual	O
-	O
eligibility	O
,	O
Charlson	O
comorbidity	O
index	O
,	O
and	O
whether	O
the	O
person	O
lived	O
with	O
an	O
available	O
caregiver	O
.	O
Results	O
After	O
adjusting	O
for	O
covariates	O
,	O
women	O
were	O
more	O
likely	O
than	O
men	O
to	O
receive	O
home	B-T058
health	I-T058
care	I-T058
and	O
to	O
use	O
emergency	B-T058
department	I-T058
services	I-T058
during	O
the	O
post	O
-	O
acute	B-T058
care	I-T058
period	O
.	O
These	O
effects	O
were	O
maintained	O
even	O
after	O
further	O
adjustment	O
for	O
acute	B-T047
stroke	I-T047
severity	O
.	O
African	O
-	O
Americans	O
had	O
more	O
home	B-T058
health	I-T058
care	I-T058
visits	B-T058
than	O
Whites	O
among	O
patients	O
who	O
received	O
some	O
home	B-T058
health	I-T058
care	I-T058
.	O
Having	O
a	O
co	O
-	O
residing	O
caregiver	O
was	O
associated	O
with	O
reduced	O
acute	B-T058
hospitalization	I-T058
length	O
of	O
stay	O
and	O
fewer	O
post	O
-	O
acute	B-T058
emergency	I-T058
department	I-T058
and	O
primary	B-T058
care	I-T058
physician	I-T058
visits	I-T058
.	O
Conclusions	O
Underutilization	O
of	O
healthcare	O
after	O
stroke	B-T047
does	O
not	O
appear	O
to	O
explain	O
poorer	O
long	O
-	O
term	O
stroke	B-T047
outcomes	O
for	O
women	O
and	O
African	O
-	O
Americans	O
in	O
this	O
epidemiologically	O
-derived	O
sample	O
.	O
Caregiver	O
availability	O
may	O
contribute	O
to	O
reduced	O
formal	O
care	O
and	O
cost	O
during	O
the	O
post	O
-	O
acute	B-T058
period	O
.	O
      
Comparative	O
proteomic	B-T059
analysis	I-T059
reveals	O
alterations	O
in	O
development	O
and	O
photosynthesis	O
-related	O
proteins	O
in	O
diploid	O
and	O
triploid	O
rice	O
Polyploidy	O
has	O
pivotal	O
influences	O
on	O
rice	O
(	O
Oryza	O
sativa	O
L.	O
)	O
morphology	O
and	O
physiology	O
,	O
and	O
is	O
very	O
important	O
for	O
understanding	O
rice	O
domestication	O
and	O
improving	O
agricultural	O
traits	O
.	O
Diploid	O
(	O
DP	O
)	O
and	O
triploid	O
(	O
TP	O
)	O
rice	O
shows	O
differences	O
in	O
morphological	O
parameters	B-T033
,	O
such	O
as	O
plant	O
height	O
,	O
leaf	O
length	O
,	O
leaf	O
width	O
and	O
the	O
physiological	O
index	O
of	O
chlorophyll	O
content	O
.	O
However	O
,	O
the	O
underlying	O
mechanisms	O
determining	O
these	O
morphological	O
differences	O
are	O
remain	O
to	O
be	O
defined	O
.	O
To	O
better	O
understand	O
the	O
proteomic	O
changes	O
between	O
DP	O
and	O
TP	O
,	O
tandem	B-T059
mass	I-T059
tags	I-T059
(	I-T059
TMT	I-T059
)	I-T059
mass	I-T059
spectrometry	I-T059
(	I-T059
MS	I-T059
)	I-T059
/	O
MS	B-T059
was	O
used	O
to	O
detect	O
the	O
significant	O
changes	O
to	O
protein	O
expression	O
between	O
DP	O
and	O
TP	O
.	O
Results	O
indicated	O
that	O
both	O
photosynthesis	O
and	O
metabolic	O
pathways	O
were	O
highly	O
significantly	O
associated	O
with	O
proteomic	O
alteration	O
between	O
DP	O
and	O
TP	O
based	O
on	O
biological	O
process	O
and	O
pathway	B-T059
enrichment	I-T059
analysis	I-T059
,	O
and	O
13	O
higher	O
abundance	O
chloroplast	O
proteins	O
involving	O
in	O
these	O
two	O
pathways	O
were	O
identified	O
in	O
TP	O
.	O
Quantitative	O
real	O
-	O
time	O
PCR	O
analysis	O
demonstrated	O
that	O
5	O
of	O
the	O
13	O
chloroplast	O
proteins	O
ATPF	O
,	O
PSAA	O
,	O
PSAB	O
,	O
PSBB	O
and	O
RBL	O
in	O
TP	O
were	O
higher	O
abundance	O
compared	O
with	O
those	O
in	O
DP	O
.	O
This	O
study	O
integrates	O
morphology	O
,	O
physiology	O
and	O
proteomic	B-T059
profiling	I-T059
alteration	O
of	O
DP	O
and	O
TP	O
to	O
address	O
their	O
underlying	O
different	O
molecular	O
mechanisms	O
.	O
Our	O
finding	O
revealed	O
that	O
ATPF	O
,	O
PSAA	O
,	O
PSAB	O
,	O
PSBB	O
and	O
RBL	O
can	O
induce	O
considerable	O
expression	O
changes	O
in	O
TP	O
and	O
may	O
affect	O
the	O
development	O
and	O
growth	O
of	O
rice	O
through	O
photosynthesis	O
and	O
metabolic	O
pathways	O
.	O
      
Placental	B-T018
Pathologic	O
Associations	O
with	O
Morbidly	O
Adherent	O
Placenta	O
:	O
Potential	O
insights	O
into	O
Pathogenesis	O
The	O
pathology	O
that	O
underlies	O
morbidly	O
adherent	O
placenta	O
(	O
MAP	O
)	O
is	O
poorly	O
understood	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
placental	B-T018
pathology	O
,	O
especially	O
implantation	O
site	O
pathology	O
,	O
associated	O
with	O
MAP	O
.	O
This	O
was	O
a	O
single	O
institution	O
,	O
retrospective	O
case	O
-	O
control	O
study	O
design	O
examining	O
placentas	B-T018
of	O
patients	O
who	O
delivered	B-T033
between	O
January	O
2008	O
and	O
September	O
2013	O
.	O
MAP	O
cases	O
were	O
defined	O
by	O
the	O
need	O
for	O
clinical	O
intervention	B-T058
at	O
delivery	B-T061
beyond	O
spontaneous	O
placental	B-T061
delivery	I-T061
or	O
simple	O
manual	B-T061
extraction	I-T061
of	O
the	O
placenta	B-T018
.	O
Controls	O
consisted	O
of	O
patients	O
with	O
placentas	B-T018
sent	O
for	O
examination	B-T058
due	O
to	O
a	O
history	B-T033
of	O
maternal	O
malignancy	B-T191
with	O
no	B-T033
clinical	O
suspicion	O
of	O
accreta	O
.	O
Placental	B-T018
pathologic	B-T033
findings	I-T033
of	O
maternal	B-T047
vascular	I-T047
underperfusion	I-T047
(	O
MVU	B-T047
)	O
,	O
acute	B-T033
inflammation	I-T033
,	O
chronic	O
inflammation	O
,	O
fetal	B-T018
vascular	B-T047
obstruction	I-T047
and	O
hemorrhage	O
were	O
recorded	O
and	O
compared	O
using	O
bivariable	O
and	O
multivariable	O
analyses	O
.	O
Three	O
categories	O
of	O
pathologic	O
changes	O
were	O
seen	O
more	O
commonly	O
in	O
MAP	O
placentas	B-T018
(	O
N=101	O
)	O
than	O
control	O
placentas	B-T018
(	O
N=110	O
):	O
chronic	O
basal	O
inflammation	O
,	O
villous	O
changes	O
of	O
MVU	B-T047
and	O
retromembranous	O
and	O
retromembranous	O
/	O
intervillous	O
hemorrhage	O
.	O
In	O
multivariable	O
analyses	O
adjusted	O
for	O
confounders	O
,	O
chronic	B-T047
basal	I-T047
villitis	I-T047
(	O
aOR	O
5.6	O
,	O
1.73	O
-	O
18.18	O
)	O
,	O
plasma	B-T033
cell	I-T033
deciduitis	I-T033
(	O
aOR	O
2.63	O
,	O
1.08	O
-	O
6.39	O
)	O
,	O
increased	B-T033
syncytial	I-T033
knots	I-T033
(	O
aOR	O
3.92	O
,	O
1.57	O
-	O
9.75	O
)	O
,	O
villous	O
agglutination	O
(	O
aOR	O
24.85	O
,	O
2.78	O
-	O
221.75	O
)	O
,	O
increased	B-T033
perivillous	I-T033
fibrin	I-T033
(	O
aOR	O
5.08	O
,	O
1.49	O
-	O
17.34	O
)	O
,	O
and	O
the	O
presence	O
of	O
subchorionic	O
/	O
intervillous	B-T033
thrombi	I-T033
(	O
aOR	O
4.01	O
,	O
1.63	O
-	O
9.86	O
)	O
remained	O
associated	O
with	O
MAP	O
.	O
MAP	O
is	O
highly	O
associated	O
with	O
evidence	O
of	O
intraparenchymal	O
placental	O
hemorrhage	O
villous	O
changes	O
of	O
MVU	B-T047
,	O
and	O
a	O
lymphoplasmacytic	B-T033
infiltrate	I-T033
at	O
the	O
implantation	O
site	O
.	O
The	O
contribution	O
of	O
this	O
basal	B-T033
chronic	I-T033
inflammatory	I-T033
infiltrate	I-T033
to	O
MAP	O
requires	O
further	O
investigation	O
.	O
      
Effects	O
of	O
high	O
-	O
intensity	O
training	O
on	O
cardiovascular	B-T047
risk	I-T047
factors	I-T047
in	O
premenopausal	B-T033
and	O
postmenopausal	B-T033
women	O
Menopause	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
cardiovascular	B-T047
disease	I-T047
and	O
the	O
causal	O
factors	O
have	O
been	O
proposed	O
to	O
be	O
the	O
loss	O
of	O
estrogen	B-T121
and	O
the	O
subsequent	O
alterations	O
of	O
the	O
hormonal	O
milieu	O
.	O
However	O
,	O
which	O
factors	O
contribute	O
to	O
the	O
deterioration	O
of	O
cardiometabolic	O
health	O
in	O
postmenopausal	B-T033
women	O
is	O
debated	O
as	O
the	O
menopausal	O
transition	O
is	O
also	O
associated	O
with	O
increased	O
age	O
and	O
fat	O
mass	O
.	O
Furthermore	O
,	O
indications	O
of	O
reduced	O
cardiometabolic	O
adaptations	O
to	O
exercise	O
in	O
postmenopausal	B-T033
women	O
add	O
to	O
the	O
adverse	O
health	O
profile	O
.	O
We	O
sought	O
to	O
evaluate	B-T058
risk	B-T033
factors	I-T033
for	O
type	B-T047
2	I-T047
diabetes	I-T047
and	O
cardiovascular	B-T047
disease	I-T047
in	O
late	O
premenopausal	B-T033
and	O
early	O
postmenopausal	B-T033
women	O
,	O
matched	O
by	O
age	O
and	O
body	O
composition	O
,	O
and	O
investigate	O
the	O
effect	O
of	O
high	O
-	O
intensity	O
training	O
.	O
A	O
3	O
-	O
month	O
high	O
-	O
intensity	O
aerobic	O
training	O
intervention	B-T061
,	O
involving	O
healthy	O
,	O
nonobese	B-T033
,	O
late	O
premenopausal	B-T033
(	O
n	O
=	O
40	O
)	O
and	O
early	O
postmenopausal	B-T033
(	O
n	O
=	O
39	O
)	O
women	O
was	O
conducted	O
and	O
anthropometrics	O
,	O
body	O
composition	O
,	O
blood	O
pressure	O
,	O
lipid	B-T059
profile	I-T059
,	O
glucose	O
tolerance	O
,	O
and	O
maximal	O
oxygen	O
consumption	O
were	O
determined	O
at	O
baseline	O
and	O
after	O
the	O
intervention	B-T061
.	O
At	O
baseline	O
,	O
the	O
groups	O
matched	O
in	O
anthropometrics	O
and	O
body	O
composition	O
,	O
and	O
only	O
differed	O
by	O
4.2	O
years	O
in	O
age	O
(	O
mean	O
[	O
95	O
%	O
confidence	O
limits	O
]	O
49.2	O
[	O
48.5	O
-	O
49.9	O
]	O
vs	O
53.4	O
[	O
52.4	O
-	O
54.4	O
]	O
years	O
)	O
.	O
Time	O
since	O
last	O
menstrual	O
period	O
for	O
the	O
postmenopausal	B-T033
women	O
was	O
(	O
mean	O
[	O
95	O
%	O
confidecnce	O
limits	O
]	O
3.1	O
[	O
2.6	O
-	O
3.7	O
]	O
years	O
)	O
.	O
Hormonal	O
levels	O
(	O
estrogen	B-T121
,	O
follicle	B-T121
stimulation	I-T121
hormone	I-T121
,	O
luteinizing	B-T121
hormone	I-T121
)	O
confirmed	O
menopausal	O
status	O
.	O
At	O
baseline	O
the	O
postmenopausal	B-T033
women	O
had	O
higher	O
total	O
cholesterol	O
(	O
P	O
<	O
.001	O
)	O
,	O
low	O
-	O
density	O
lipoprotein	O
-	O
cholesterol	O
(	O
P	O
<	O
.05	O
)	O
,	O
and	O
high	O
-	O
density	O
lipoprotein	O
-	O
cholesterol	O
(	O
P	O
<	O
.001	O
)	O
than	O
the	O
premenopausal	B-T033
women	O
.	O
The	O
training	O
intervention	B-T061
reduced	O
body	O
weight	O
(	O
P	O
<	O
.01	O
)	O
,	O
waist	O
circumference	O
(	O
P	O
<	O
.01	O
)	O
,	O
and	O
improved	B-T033
body	O
composition	O
by	O
increasing	O
lean	O
body	O
mass	O
(	O
P	O
<	O
.001	O
)	O
and	O
decreasing	B-T033
fat	O
mass	O
(	O
P	O
<	O
.001	O
)	O
similarly	O
in	O
both	O
groups	O
.	O
Moreover	O
,	O
training	O
resulted	O
in	O
lower	B-T033
diastolic	I-T033
blood	I-T033
pressure	I-T033
(	O
P	O
<	O
.05	O
)	O
,	O
resting	B-T033
heart	I-T033
rate	I-T033
(	O
P	O
<	O
.001	O
)	O
,	O
total	O
cholesterol	O
(	O
P	O
<	O
.01	O
)	O
,	O
low	O
-	O
density	O
lipoprotein	O
-	O
cholesterol	O
(	O
P	O
<	O
.01	O
)	O
,	O
total	O
cholesterol	O
/	O
high	O
-	O
density	O
lipoprotein	O
-	O
cholesterol	O
index	O
(	O
P	O
<	O
.01	O
)	O
,	O
and	O
improved	B-T033
plasma	B-T059
insulin	I-T059
concentration	I-T059
during	O
the	O
oral	B-T060
glucose	I-T060
tolerance	I-T060
test	I-T060
(	O
P	O
<	O
.05	O
)	O
in	O
both	O
groups	O
.	O
Cardiovascular	B-T047
risk	I-T047
factors	I-T047
are	O
similar	O
in	O
late	O
premenopausal	B-T033
and	O
early	O
postmenopausal	B-T033
women	O
,	O
matched	O
by	O
age	O
and	O
body	O
composition	O
,	O
with	O
the	O
exception	O
that	O
postmenopausal	B-T033
women	O
have	O
higher	O
high-	B-T059
and	O
low	B-T059
-	I-T059
density	I-T059
lipoprotein	I-T059
-	I-T059
cholesterol	I-T059
levels	I-T059
.	O
A	O
3	O
-	O
month	O
intervention	B-T061
of	O
high	O
-	O
intensity	O
aerobic	O
training	O
reduces	O
risk	B-T033
factors	I-T033
for	O
type	B-T047
2	I-T047
.diabetes	I-T047
and	O
cardiovascular	B-T047
disease	I-T047
to	O
a	O
similar	O
extent	O
in	O
late	O
premenopausal	B-T033
and	O
early	O
postmenopausal	B-T033
women	O
.	O
      
Clinical	O
characteristics	O
of	O
genital	B-T047
chlamydia	I-T047
infection	I-T047
in	O
pelvic	B-T047
inflammatory	I-T047
disease	I-T047
Chlamydia	B-T047
infection	I-T047
in	O
acute	B-T047
pelvic	I-T047
inflammatory	I-T047
disease	I-T047
(	O
PID	B-T047
)	O
is	O
associated	O
with	O
serious	O
complications	O
including	O
ectopic	O
pregnancy	O
,	O
tubal	B-T047
infertility	I-T047
,	O
Fitz	B-T047
-	I-T047
Hugh	I-T047
-	I-T047
Curtis	I-T047
syndrome	I-T047
and	O
tubo	B-T047
-	I-T047
ovarian	I-T047
abscess	I-T047
(	O
TOA	B-T047
)	O
.	O
This	O
study	O
compared	O
clinical	O
and	O
laboratory	O
data	O
between	O
PID	B-T047
with	O
and	O
without	O
chlamydia	B-T047
infection	I-T047
.	O
The	O
medical	O
records	O
of	O
497	O
women	O
who	O
were	O
admitted	O
with	O
PID	B-T047
between	O
2002	O
and	O
2011	O
were	O
reviewed	O
.	O
The	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
(	O
PID	B-T047
with	O
and	O
without	O
chlamydia	B-T047
infection	I-T047
)	O
,	O
which	O
were	O
compared	O
in	O
terms	O
of	O
the	O
patients	O
'	O
characteristics	O
,	O
clinical	O
presentation	O
,	O
and	O
laboratory	O
findings	O
,	O
including	O
inflammatory	O
markers	O
.	O
The	O
chlamydia	O
and	O
non	O
-	O
chlamydia	O
groups	O
comprised	O
175	O
and	O
322	O
women	O
,	O
respectively	O
.	O
The	O
patients	O
in	O
the	O
chlamydia	O
group	O
were	O
younger	O
and	O
had	O
a	O
higher	O
rate	O
of	O
TOA	B-T047
,	O
a	O
longer	O
mean	O
hospital	O
stay	O
,	O
and	O
had	O
undergone	O
more	O
surgeries	B-T061
than	O
the	O
patients	O
in	O
the	O
non-	O
chlamydia	O
group	O
.	O
The	O
erythrocyte	O
sedimentation	O
rate	O
(	O
ESR	O
)	O
,	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
,	O
and	O
CA-125	O
level	O
were	O
higher	O
in	O
the	O
chlamydia	O
group	O
than	O
in	O
the	O
non	O
-	O
chlamydia	O
group	O
,	O
but	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
white	B-T033
blood	I-T033
cell	I-T033
count	I-T033
between	O
the	O
two	O
groups	O
.	O
The	O
CA-125	O
level	O
was	O
the	O
strongest	O
predictor	O
of	O
chlamydia	B-T047
infection	I-T047
,	O
followed	O
by	O
the	O
ESR	O
and	O
CRP	O
level	O
.	O
The	O
area	O
under	O
the	O
receiving	O
operating	O
curve	O
for	O
CA-125	O
,	O
ESR	O
,	O
and	O
CRP	O
was	O
0.804	O
,	O
0.755	O
,	O
and	O
0.663	O
,	O
respectively	O
.	O
Chlamydia	B-T047
infection	I-T047
in	O
acute	B-T047
PID	I-T047
is	O
associated	O
with	O
increased	O
level	O
of	O
inflammatory	O
markers	O
,	O
such	O
as	O
CA-125	O
,	O
ESR	O
and	O
CRP	O
,	O
incidence	O
of	O
TOA	B-T047
,	O
operation	B-T061
risk	O
,	O
and	O
longer	O
hospitalization	B-T058
.	O
      
Glycated	O
Hemoglobin	O
(	O
HbA1c	O
)	O
Correlation	O
with	O
Severity	O
of	O
Coronary	B-T047
Artery	I-T047
Disease	I-T047
in	O
Non	B-T033
-	I-T033
diabetic	I-T033
Patients	O
-	O
A	O
Hospital	O
based	O
Study	O
from	O
North	O
-	O
Eastern	O
India	O
Glycated	O
Hemoglobin	O
(	O
HbA1c	O
)	O
levels	O
are	O
predictive	O
of	O
cardiovascular	B-T047
disease	I-T047
and	O
mortality	O
in	O
patients	O
with	O
diabetes	B-T047
mellitus	I-T047
,	O
however	O
,	O
association	O
of	O
HbA1c	O
with	O
Coronary	B-T047
Artery	I-T047
Disease	I-T047
(	O
CAD	B-T047
)	O
in	O
non	B-T033
-	I-T033
diabetics	I-T033
is	O
inconsistent	O
.	O
To	O
evaluate	B-T058
the	O
correlation	O
between	O
HbA1c	O
level	O
and	O
severity	O
of	O
CAD	B-T047
in	O
non	O
-	O
diabetic	O
patients	O
using	O
SYNTAX	O
score	O
in	O
a	O
cohort	O
of	O
proven	O
CAD	B-T047
on	O
angiography	B-T060
at	O
Gauhati	O
Medical	O
College	O
,	O
Guwahati	O
,	O
Assam	O
,	O
India	O
,	O
which	O
is	O
a	O
major	O
tertiary	O
care	O
hospital	O
of	O
North	O
-	O
Eastern	O
India	O
.	O
We	O
prospectively	O
collected	O
data	O
of	O
non	O
-	O
diabetic	O
patients	O
with	O
proven	O
CAD	B-T047
on	O
angiography	B-T060
from	O
June	O
2014	O
to	O
June	O
2015	O
.	O
Patients	O
were	O
divided	O
into	O
four	O
groups	O
(	O
interquartiles	O
)	O
according	O
to	O
HbA1c	O
levels	O
,	O
less	O
than	O
4.8	O
%	O
,	O
4.8	O
%	O
to	O
5.1	O
%	O
,	O
5.1	O
%	O
to	O
5.6	O
%	O
,	O
and	O
5.6	O
%	O
to	O
6.5	O
%	O
.	O
Severity	O
of	O
CAD	B-T047
was	O
assessed	O
using	O
SYNTAX	O
score	O
and	O
the	O
number	O
of	O
coronary	O
vessels	O
diseased	O
.	O
We	O
compared	O
different	O
quartiles	O
of	O
HbA1c	O
with	O
regard	O
to	O
SYNTAX	O
score	O
and	O
number	O
of	O
diseased	O
vessels	O
.	O
A	O
total	O
of	O
346	O
patients	O
were	O
included	O
in	O
the	O
study	O
.	O
Mean	O
age	O
was	O
58.1±10.4	O
years	O
.	O
Of	O
the	O
total	O
91.9	O
%	O
(	O
318	O
)	O
were	O
males	O
,	O
44.8	O
%	O
(	O
155	O
)	O
were	O
hypertensives	B-T033
,	O
29.2	O
%	O
(	O
101	O
)	O
were	O
smokers	B-T033
and	O
34.7	O
%	O
(	O
120	O
)	O
were	O
dyslipidemic	B-T033
.	O
We	O
found	O
that	O
CAD	B-T047
severity	O
by	O
SYNTAX	O
score	O
as	O
well	O
as	O
number	O
of	O
vessels	B-T023
involved	O
was	O
significantly	O
different	O
among	O
quartiles	O
(	O
p	O
-	O
values	O
<	O
0.001	O
and	O
<	O
0.001	O
respectively	O
)	O
.	O
Increase	O
in	O
HbA1c	O
level	O
was	O
strongly	O
correlated	O
with	O
disease	O
severity	O
and	O
higher	O
SYNTAX	O
score	O
.	O
A	O
significant	O
increase	O
was	O
noted	O
in	O
the	O
mean	O
number	O
of	O
diseased	O
vessels	O
(	O
p	O
-	O
value	O
<	O
0.001	O
)	O
as	O
HbA1c	O
level	O
increases	O
.	O
Age	O
,	O
gender	O
,	O
hypertension	B-T047
and	O
dyslipidemia	B-T047
did	O
not	O
show	O
significant	O
difference	O
among	O
quartiles	O
however	O
smoking	O
was	O
found	O
to	O
be	O
an	O
independent	O
predictor	O
of	O
severity	O
of	O
CAD	B-T047
by	O
SYNTAX	O
score	O
(	O
p	O
<	O
0.05	O
)	O
.	O
From	O
this	O
clinical	O
study	O
,	O
we	O
can	O
conclude	O
that	O
a	O
significant	O
correlation	O
exists	O
between	O
HbA1c	O
and	O
severity	O
of	O
CAD	B-T047
by	O
SYNTAX	O
score	O
as	O
well	O
as	O
number	O
of	O
vessels	B-T023
involved	O
in	O
non-	B-T033
diabetes	I-T033
.	O
      
Integrating	O
Palliative	O
Care	O
in	O
Pediatric	O
Oncology	O
:	O
Evidence	O
for	O
an	O
Evolving	O
Paradigm	O
for	O
Comprehensive	B-T058
Cancer	B-T061
Care	I-T061
The	O
demonstrated	O
benefit	O
of	O
integrating	O
palliative	O
care	O
(	O
PC	O
)	O
into	O
cancer	B-T061
treatment	I-T061
has	O
triggered	O
an	O
increased	O
need	O
for	O
PC	O
services	O
.	O
The	O
trajectory	O
of	O
integrating	O
PC	O
in	O
comprehensive	B-T058
cancer	O
centers	O
,	O
particularly	O
pediatric	O
centers	O
,	O
is	O
unknown	O
.	O
We	O
describe	O
our	O
8-	O
year	O
experience	O
of	O
initiating	O
and	O
establishing	O
PC	O
with	O
the	O
Quality	B-T058
of	I-T058
Life	I-T058
Service	I-T058
(	O
QoLS	B-T058
)	O
at	O
St.	O
Jude	O
Children	O
's	O
Research	O
Hospital	O
.	O
We	O
retrospectively	O
reviewed	O
records	O
of	O
patients	O
seen	O
by	O
the	O
QoLS	B-T058
(	O
n=615	O
)	O
from	O
March	O
2007	O
to	O
December	O
2014	O
.	O
Variables	O
analyzed	O
for	O
each	O
year	O
,	O
using	O
descriptive	O
statistics	O
,	O
included	O
diagnostic	O
groups	O
,	O
QoLS	B-T058
encounters	B-T058
,	O
goals	B-T058
of	I-T058
care	I-T058
,	O
duration	O
of	O
survival	O
,	O
and	O
location	O
of	O
death	O
.	O
Total	O
QoLS	B-T058
patient	O
encounters	B-T058
increased	O
from	O
58	O
(	O
2007	O
)	O
to	O
1,297	O
(	O
2014	O
)	O
,	O
new	O
consults	B-T058
increased	O
from	O
17	O
(	O
2007	O
)	O
to	O
115	O
(	O
2014	O
)	O
,	O
and	O
mean	O
encounters	B-T058
per	O
patient	O
increased	O
from	O
5.06	O
(	O
2007	O
)	O
to	O
16.11	O
(	O
2014	O
)	O
.	O
Goal	B-T058
of	I-T058
care	I-T058
at	O
initial	B-T058
consultation	I-T058
shifted	O
from	O
primarily	O
comfort	O
to	O
an	O
increasing	O
goal	O
of	O
cure	O
.	O
The	O
median	O
number	O
of	O
days	O
from	O
initial	B-T058
consult	I-T058
to	O
death	B-T033
increased	O
from	O
52	O
days	O
(	O
2008	O
)	O
to	O
223	O
days	O
(	O
2014	O
)	O
.	O
A	O
trend	O
toward	O
increased	O
outpatient	O
location	O
of	O
death	O
was	O
noted	O
with	O
42	O
%	O
outpatient	O
deaths	B-T033
in	O
2007	O
,	O
increasing	O
to	O
a	O
majority	O
in	O
each	O
subsequent	O
year	O
(	O
range	O
,	O
51%-74	O
%	O
)	O
.	O
Hospital	O
-	O
wide	O
,	O
patients	O
receiving	O
PC	O
services	O
before	O
death	B-T033
increased	O
from	O
approximately	O
50	O
%	O
to	O
nearly	O
100	O
%	O
.	O
Since	O
its	O
inception	O
,	O
the	O
QoLS	B-T058
experienced	O
a	O
dramatic	O
increase	O
in	O
referrals	B-T058
and	O
encounters	B-T058
per	O
patient	O
,	O
increased	O
use	O
by	O
all	O
clinical	B-T058
services	I-T058
,	O
a	O
trend	O
toward	O
earlier	O
consultation	B-T058
and	O
longer	O
term	O
follow	B-T058
-	I-T058
up	I-T058
,	O
increasing	O
outpatient	O
location	O
of	O
death	O
,	O
and	O
near-	O
universal	O
PC	O
involvement	O
at	O
the	O
end	B-T058
-	I-T058
of	I-T058
-	I-T058
life	I-T058
.	O
The	O
successful	O
integration	O
of	O
PC	O
in	O
a	O
comprehensive	B-T058
cancer	O
center	O
,	O
and	O
the	O
resulting	O
potential	O
for	O
improved	O
care	B-T058
provision	I-T058
over	O
time	O
,	O
can	O
serve	O
as	O
a	O
model	O
for	O
other	O
programs	B-T058
on	O
a	O
broad	O
scale	O
.	O
      
Validating	O
Signs	B-T184
and	I-T184
Symptoms	I-T184
From	O
An	O
Actual	O
Mass	O
Casualty	O
Incident	O
to	O
Characterize	O
An	O
Irritant	O
Gas	O
Syndrome	O
Agent	O
(	O
IGSA	O
)	O
Exposure	O
:	O
A	O
First	O
Step	O
in	O
The	O
Development	O
of	O
a	O
Novel	O
IGSA	O
Triage	B-T061
Algorithm	O
Chemical	B-T033
exposures	I-T033
can	O
pose	O
a	O
significant	O
threat	O
to	O
life	O
.	O
Rapid	O
assessment	B-T058
by	O
first	O
responders	O
/	O
emergency	O
nurses	O
is	O
required	O
to	O
reduce	O
death	O
and	O
disability	B-T033
.	O
Currently	O
,	O
no	O
informatics	O
tools	O
for	O
irritant	O
gas	O
syndrome	O
agent	O
s	O
(	O
IGSA	O
)	O
exposures	O
exist	O
to	O
process	O
victims	O
efficiently	O
,	O
continuously	O
monitor	B-T058
for	O
latent	O
signs	B-T184
/	I-T184
symptoms	I-T184
,	O
or	O
make	O
triage	B-T061
recommendations	O
.	O
This	O
study	O
describes	O
the	O
first	O
step	O
in	O
developing	O
ED	O
informatics	O
tools	O
for	O
chemical	O
incidents	O
:	O
validation	O
of	O
signs	B-T184
/	I-T184
symptoms	I-T184
that	O
characterize	O
an	O
IGSA	O
syndrome	B-T047
.	O
Data	O
abstracted	O
from	O
146	O
patients	O
treated	B-T061
for	O
chlorine	B-T033
exposure	I-T033
in	O
one	O
emergency	O
department	O
during	O
a	O
2005	O
train	O
derailment	O
and	O
152	O
patients	O
not	O
exposed	B-T033
to	I-T033
chlorine	I-T033
(	O
a	O
comparison	O
group	O
)	O
were	O
mapped	O
to	O
93	O
possible	O
signs	B-T184
/	I-T184
symptoms	I-T184
within	O
2	O
tools	O
(	O
WISER	O
and	O
CHEMM	O
-	O
IST	O
)	O
designed	O
to	O
assist	O
emergency	O
responders	O
/	O
emergency	O
nurses	O
with	O
managing	O
hazardous	O
material	O
exposures	O
.	O
Inferential	O
statistics	O
(	O
χ(2)/	O
Fisher	O
's	O
exact	O
test	O
)	O
and	O
diagnostics	B-T060
tests	I-T060
were	O
used	O
to	O
examine	O
mapped	O
signs	B-T184
/	I-T184
symptoms	I-T184
of	O
persons	O
who	O
were	O
and	O
were	O
not	O
exposed	B-T033
to	I-T033
chlorine	I-T033
.	O
Three	O
clusters	O
of	O
signs	B-T184
/	I-T184
symptoms	I-T184
are	O
statistically	O
associated	O
with	O
an	O
IGSA	O
syndrome	B-T047
(	O
P	O
<	O
.01	O
):	O
respiratory	O
(	O
shortness	B-T184
of	I-T184
breath	I-T184
,	O
wheezing	B-T184
,	O
coughing	B-T184
,	O
and	O
choking	O
)	O
;	O
chest	B-T184
discomfort	I-T184
(	O
tightness	B-T184
,	O
pain	B-T184
,	O
and	O
burning	B-T184
)	O
,	O
and	O
eye	B-T023
,	O
nose	B-T023
and/or	O
throat	B-T023
(	O
pain	B-T184
,	O
irritation	O
,	O
and	O
burning	B-T184
)	O
.	O
The	O
syndrome	B-T047
requires	O
the	O
presence	B-T033
of	O
signs	B-T184
/	I-T184
symptoms	I-T184
from	O
at	O
least	O
2	O
of	O
these	O
clusters	O
.	O
The	O
latency	O
period	O
must	O
also	O
be	O
considered	O
for	O
exposed	O
/	O
potentially	O
exposed	O
persons	O
.	O
This	O
study	O
uses	O
actual	O
patient	O
data	O
from	O
a	O
chemical	O
incident	O
to	O
characterize	O
and	O
validate	O
signs	B-T184
/	I-T184
symptoms	I-T184
of	O
an	O
IGSA	O
syndrome	B-T047
.	O
Validating	O
signs	B-T184
/	I-T184
symptoms	I-T184
is	O
the	O
first	O
step	O
in	O
developing	O
new	O
ED	O
informatics	O
tools	O
with	O
the	O
potential	O
to	O
revolutionize	O
the	O
process	O
by	O
which	O
emergency	O
nurses	O
manage	O
triage	B-T061
victims	O
of	O
chemical	O
incidents	O
.	O
      
Low	O
-	O
Volume	O
vs	O
High	O
-	O
Volume	O
Centers	O
and	O
Management	B-T058
of	I-T058
Fournier	I-T058
's	I-T058
Gangrene	I-T058
Fournier	B-T047
's	I-T047
Gangrene	I-T047
in	O
Washington	O
State	O
Fournier	B-T047
's	I-T047
gangrene	I-T047
(	O
FG	B-T047
)	O
is	O
a	O
life	B-T033
-	I-T033
threatening	I-T033
infection	I-T033
affecting	O
the	O
perineum	O
and	O
genitals	B-T023
.	O
Complex	O
patient	B-T058
management	I-T058
often	O
necessitates	O
transfer	O
to	O
tertiary	O
centers	O
.	O
We	O
aimed	O
to	O
characterize	O
hospital	B-T058
transfer	I-T058
patterns	O
and	O
assess	O
morbidity	O
among	O
patients	O
with	O
FG	B-T047
in	O
Washington	O
State	O
.	O
The	O
Washington	O
State	O
Comprehensive	O
Hospital	O
Abstract	O
Reporting	O
System	O
includes	O
claims	O
from	O
all	O
hospital	O
discharges	O
in	O
Washington	O
.	O
We	O
identified	O
patients	O
with	O
FG	B-T047
between	O
2007	O
and	O
2013	O
,	O
based	O
on	O
diagnosis	O
and	O
treatment	O
codes	O
.	O
Analyses	O
were	O
stratified	O
by	O
center	O
volume	O
(	O
low	O
-	O
volume	O
centers	O
[	O
LVCs	O
]	O
or	O
high	O
-	O
volume	O
centers	O
[	O
HVCs	O
]	O
)	O
,	O
and	O
transfer	B-T033
status	I-T033
.	O
Variables	O
of	O
interest	O
included	O
number	O
of	O
debridements	B-T061
,	O
septic	O
shock	O
,	O
acute	B-T047
renal	I-T047
failure	I-T047
,	O
acute	B-T047
respiratory	I-T047
failure	I-T047
,	O
length	B-T058
of	I-T058
hospitalization	I-T058
,	O
and	O
death	B-T033
.	O
We	O
identified	O
165	O
FG	B-T047
patients	O
.	O
Only	O
1	O
HVC	O
treated	O
more	O
than	O
2	O
FG	B-T047
patients	O
per	O
year	O
.	O
Overall	O
mortality	O
was	O
6.7	O
%	O
.	O
Most	O
patients	O
(	O
57	O
%	O
)	O
were	O
treated	O
entirely	O
at	O
LVCs	O
;	O
87	O
%	O
of	O
patients	O
treated	O
at	O
the	O
HVC	O
were	O
transferred	O
from	O
an	O
LVC	O
.	O
High	O
-	O
volume	O
center	O
-treated	O
patients	O
had	O
similar	O
baseline	O
comorbidities	O
(	O
p	O
=	O
0.77	O
)	O
and	O
similar	O
mortality	O
(	O
p	O
=	O
0.87	O
)	O
,	O
despite	O
higher	O
rates	O
of	O
septic	O
shock	O
(	O
p	O
<	O
0.01	O
)	O
and	O
respiratory	B-T047
failure	I-T047
(	O
p	O
=	O
0.01	O
)	O
compared	O
with	O
LVC	O
patients	O
.	O
Among	O
HVC	O
-	O
transferred	B-T058
patients	I-T058
,	O
immediate	O
compared	O
with	O
delayed	O
transfer	O
was	O
associated	O
with	O
fewer	O
debridements	B-T061
(	O
p	O
<	O
0.01	O
)	O
,	O
lower	O
rates	O
of	O
septic	O
shock	O
(	O
p	O
=	O
0.05	O
)	O
,	O
and	O
acute	B-T047
renal	I-T047
failure	I-T047
(	O
p	O
=	O
0.04	O
)	O
.	O
Patients	O
treated	O
at	O
the	O
HVC	O
were	O
more	O
acutely	B-T033
ill	I-T033
,	O
yet	O
mortality	O
was	O
similar	O
compared	O
with	O
patients	O
treated	O
solely	O
at	O
LVCs	O
,	O
suggesting	O
a	O
benefit	O
to	O
transfer	O
of	O
high	O
acuity	O
patients	O
.	O
Immediate	O
vs	O
delayed	O
transfer	O
may	O
benefit	O
FG	B-T047
health	O
outcomes	O
;	O
however	O
,	O
this	O
may	O
also	O
reflect	O
greater	O
disease	B-T047
acuity	O
of	O
patients	O
with	O
delayed	O
transfer	B-T033
status	I-T033
.	O
      
Cobalt-60	O
Machines	O
and	O
Medical	O
Linear	O
Accelerators	O
:	O
Competing	O
Technologies	O
for	O
External	B-T061
Beam	I-T061
Radiotherapy	I-T061
Medical	O
linear	O
accelerators	O
(	O
linacs	O
)	O
and	O
cobalt-60	O
machines	O
are	O
both	O
mature	O
technologies	O
for	O
external	B-T061
beam	I-T061
radiotherapy	I-T061
.	O
A	O
comparison	O
is	O
made	O
between	O
these	O
two	O
technologies	O
in	O
terms	O
of	O
infrastructure	O
and	O
maintenance	O
,	O
dosimetry	B-T059
,	O
shielding	B-T033
requirements	O
,	O
staffing	O
,	O
costs	O
,	O
security	O
,	O
patient	O
throughput	O
and	O
clinical	O
use	O
.	O
Infrastructure	O
and	O
maintenance	O
are	O
more	O
demanding	O
for	O
linacs	O
due	O
to	O
the	O
complex	O
electric	O
componentry	O
.	O
In	O
dosimetry	B-T059
,	O
a	O
higher	O
beam	O
energy	O
,	O
modulated	O
dose	O
rate	O
and	O
smaller	O
focal	O
spot	O
size	O
mean	O
that	O
it	O
is	O
easier	B-T033
to	O
create	O
an	O
optimised	O
treatment	B-T061
with	O
a	O
linac	O
for	O
conformal	O
dose	O
coverage	O
of	O
the	O
tumour	B-T191
while	O
sparing	O
healthy	B-T023
organs	I-T023
at	O
risk	O
.	O
In	O
shielding	B-T033
,	O
the	O
requirements	O
for	O
a	O
concrete	O
bunker	O
are	O
similar	O
for	O
cobalt-60	O
machines	O
and	O
linacs	O
but	O
extra	O
shielding	B-T033
and	O
protection	B-T033
from	O
neutrons	O
are	O
required	O
for	O
linacs	O
.	O
Staffing	B-T033
levels	I-T033
can	O
be	O
higher	O
for	O
linacs	O
and	O
more	O
staff	O
training	O
is	O
required	O
for	O
linacs	O
.	O
Life	O
cycle	O
costs	O
are	O
higher	O
for	O
linacs	O
,	O
especially	O
multi	O
-	O
energy	O
linacs	O
.	O
Security	O
is	O
more	O
complex	O
for	O
cobalt-60	O
machines	O
because	O
of	O
the	O
high	O
activity	O
radioactive	O
source	O
.	O
Patient	O
throughput	O
can	O
be	O
affected	O
by	O
source	B-T033
decay	O
for	O
cobalt-60	O
machines	O
but	O
poor	O
maintenance	O
and	O
breakdowns	O
can	O
severely	O
affect	O
patient	O
throughput	O
for	O
linacs	O
.	O
In	O
clinical	O
use	O
,	O
more	O
complex	O
treatment	B-T061
techniques	O
are	O
easier	B-T033
to	O
achieve	O
with	O
linacs	O
,	O
and	O
the	O
availability	O
of	O
electron	O
beams	O
on	O
high	O
-	O
energy	O
linacs	O
can	O
be	O
useful	O
for	O
certain	O
treatments	B-T061
.	O
In	O
summary	O
,	O
there	O
is	O
no	O
simple	O
answer	O
to	O
the	O
question	O
of	O
the	O
choice	O
of	O
either	O
cobalt-60	O
machines	O
or	O
linacs	O
for	O
radiotherapy	B-T061
in	O
low-	B-T033
and	O
middle	O
-	O
income	O
countries	O
.	O
In	O
fact	O
a	O
radiotherapy	O
department	O
with	O
a	O
combination	O
of	O
technologies	O
,	O
including	O
orthovoltage	O
X	O
-	O
ray	O
units	O
,	O
may	O
be	O
an	O
option	O
.	O
Local	O
needs	O
,	O
conditions	O
and	O
resources	O
will	O
have	O
to	O
be	O
factored	O
into	O
any	O
decision	O
on	O
technology	O
taking	O
into	O
account	O
the	O
characteristics	O
of	O
both	O
forms	O
of	O
teletherapy	B-T061
,	O
with	O
the	O
primary	O
goal	O
being	O
the	O
sustainability	O
of	O
the	O
radiotherapy	O
service	O
over	O
the	O
useful	O
lifetime	O
of	O
the	O
equipment	O
.	O
      
Ontology	O
-Based	O
High	O
-	O
Level	O
Context	O
Inference	O
for	O
Human	O
Behavior	O
Identification	O
Recent	O
years	O
have	O
witnessed	O
a	O
huge	O
progress	O
in	O
the	O
automatic	O
identification	O
of	O
individual	O
primitives	O
of	O
human	O
behavior	O
,	O
such	O
as	O
activities	O
or	O
locations	O
.	O
However	O
,	O
the	O
complex	O
nature	O
of	O
human	O
behavior	O
demands	O
more	O
abstract	O
contextual	O
information	O
for	O
its	O
analysis	O
.	O
This	O
work	O
presents	O
an	O
ontology	O
-based	O
method	O
that	O
combines	O
low	O
-	O
level	O
primitives	O
of	O
behavior	O
,	O
namely	O
activity	O
,	O
locations	O
and	O
emotions	O
,	O
unprecedented	O
to	O
date	O
,	O
to	O
intelligently	O
derive	O
more	O
meaningful	O
high	O
-	O
level	O
context	O
information	O
.	O
The	O
paper	O
contributes	O
with	O
a	O
new	O
open	O
ontology	O
describing	O
both	O
low	O
-	O
level	O
and	O
high	O
-	O
level	O
context	O
information	O
,	O
as	O
well	O
as	O
their	O
relationships	O
.	O
Furthermore	O
,	O
a	O
framework	O
building	O
on	O
the	O
developed	O
ontology	O
and	O
reasoning	O
models	O
is	O
presented	O
and	O
evaluated	O
.	O
The	O
proposed	O
method	O
proves	O
to	O
be	O
robust	O
while	O
identifying	O
high	O
-	O
level	O
contexts	O
even	O
in	O
the	O
event	O
of	O
erroneously	O
-	O
detected	B-T033
low	O
-l	O
evel	O
context	O
s.	O
Despite	O
reasonable	O
inference	O
times	O
being	O
obtained	O
for	O
a	O
relevant	O
set	O
of	O
users	O
and	O
instances	O
,	O
additional	O
work	O
is	O
required	O
to	O
scale	O
to	O
long	O
-	O
term	O
scenarios	O
with	O
a	O
large	O
number	O
of	O
users	O
.	O
      
A	O
Systematic	O
Review	O
of	O
the	O
Diagnostic	O
and	O
Prognostic	O
Value	O
of	O
Urinary	O
Protein	O
Biomarkers	O
in	O
Urothelial	B-T191
Bladder	I-T191
Cancer	I-T191
For	O
over	O
80	O
years	O
,	O
cystoscopy	B-T060
has	O
remained	O
the	O
gold	O
-	O
standard	O
for	O
detecting	B-T033
tumours	B-T191
of	O
the	O
urinary	B-T023
bladder	I-T023
.	O
Since	O
bladder	B-T191
tumours	I-T191
have	O
a	O
tendency	O
to	O
recur	O
and	O
progress	O
,	O
many	O
patients	O
are	O
subjected	O
to	O
repeated	O
cystoscopies	B-T060
during	O
long	O
-	O
term	O
surveillance	B-T058
,	O
with	O
the	O
procedure	B-T061
being	O
both	O
unpleasant	O
for	O
the	O
patient	O
and	O
expensive	O
for	O
healthcare	O
providers	O
.	O
The	O
identification	O
and	O
validation	O
of	O
bladder	B-T191
tumour	I-T191
specific	O
molecular	O
markers	O
in	O
urine	O
could	O
enable	O
tumour	B-T191
detection	B-T033
and	O
reduce	O
reliance	O
on	O
cystoscopy	B-T060
,	O
and	O
numerous	O
classes	O
of	O
biomarkers	O
have	O
been	O
studied	O
.	O
Proteins	O
represent	O
the	O
most	O
intensively	O
studied	O
class	O
of	O
biomolecule	O
in	O
this	O
setting	O
.	O
As	O
an	O
aid	O
to	O
researchers	O
searching	O
for	O
better	O
urinary	O
biomarkers	O
,	O
we	O
report	O
a	O
comprehensive	O
systematic	O
review	O
of	O
the	O
literature	O
and	O
a	O
searchable	O
database	O
of	O
proteins	O
that	O
have	O
been	O
investigated	B-T058
to	O
date	O
.	O
Our	O
objective	O
was	O
to	O
classify	O
these	O
proteins	O
as	O
:	O
1	O
)	O
those	O
with	O
robustly	O
characterised	O
sensitivity	O
and	O
specificity	O
for	O
bladder	B-T191
cancer	I-T191
detection	B-T033
;	O
2	O
)	O
those	O
that	O
show	O
potential	O
but	O
further	O
investigation	B-T058
is	O
required	O
;	O
3	O
)	O
those	O
unlikely	O
to	O
warrant	O
further	O
investigation	B-T058
;	O
and	O
4	O
)	O
those	O
investigated	B-T058
as	O
prognostic	O
markers	O
.	O
This	O
work	O
should	O
help	O
to	O
prioritise	O
certain	O
biomarkers	O
for	O
rigorous	O
validation	O
,	O
whilst	O
preventing	O
wasted	O
effort	O
on	O
proteins	O
that	O
have	O
shown	O
no	O
association	O
whatsoever	O
with	O
the	O
disease	B-T047
,	O
or	O
only	O
modest	O
biomarker	O
performance	O
despite	O
large	O
-	O
scale	O
efforts	O
at	O
validation	O
.	O
      
Anterior	O
single	O
implants	O
with	O
different	O
neck	O
designs	O
:	O
5	O
Year	O
results	O
of	O
a	O
randomized	O
clinical	O
trial	O
The	O
design	O
of	O
the	O
implant	O
neck	O
might	O
be	O
significant	O
for	O
preservation	B-T059
of	O
marginal	O
bone	O
.	O
To	O
compare	O
the	O
5	O
-	O
year	O
radiographic	O
and	O
clinical	O
outcome	O
of	O
single	O
anterior	O
implants	O
provided	O
with	O
a	O
smooth	O
neck	O
,	O
a	O
rough	O
neck	O
or	O
a	O
scalloped	O
rough	O
neck	O
.	O
93	O
Patients	O
with	O
a	O
missing	O
anterior	O
tooth	B-T023
in	O
the	O
maxilla	B-T023
were	O
included	O
.	O
At	O
random	O
,	O
patients	O
received	O
an	O
implant	O
with	O
a	O
1.5	O
mm	O
smooth	O
neck	O
(	O
"	O
smooth	O
group	O
"	O
)	O
,	O
a	O
rough	O
neck	O
with	O
grooves	O
(	O
"	O
rough	O
group	O
"	O
)	O
or	O
a	O
scalloped	O
rough	O
neck	O
with	O
grooves	O
(	O
"	O
scalloped	O
group	O
"	O
)	O
.	O
Implants	O
were	O
installed	O
in	O
healed	O
sites	O
.	O
Follow	B-T058
-	I-T058
up	I-T058
visits	I-T058
were	O
conducted	O
after	O
final	O
crown	O
delivery	O
and	O
1	O
year	O
and	O
5	O
years	O
later	O
.	O
Scalloped	O
implants	O
showed	O
significantly	O
more	O
initial	O
marginal	O
bone	O
resorption	O
.	O
The	O
total	O
amount	O
of	O
bone	O
loss	O
was	O
1.26	O
±	O
0.90	O
mm	O
in	O
the	O
smooth	O
group	O
,	O
1.20	O
±	O
1.1	O
mm	O
in	O
the	O
rough	O
group	O
and	O
2.28	O
±	O
0.97	O
mm	O
in	O
the	O
scalloped	O
group	O
(	O
P	O
<	O
.05	O
)	O
.	O
Survival	O
rates	O
were	O
96.2	O
%	O
for	O
the	O
smooth	O
and	O
scalloped	O
group	O
and	O
100	O
%	O
for	O
the	O
rough	O
group	O
.	O
Scalloped	O
implants	O
showed	O
deeper	O
pocket	O
depths	O
,	O
more	O
bleeding	O
and	O
more	O
technical	O
complications	O
.	O
There	O
were	O
no	O
differences	O
in	O
esthetic	O
outcome	O
nor	O
in	O
patient	O
satisfaction	O
.	O
For	O
anterior	O
single	O
tooth	O
replacements	O
,	O
scalloped	O
implants	O
show	O
less	O
favorable	O
radiographic	O
and	O
clinical	O
outcome	O
compared	O
to	O
regular	O
implants	O
with	O
a	O
smooth	O
neck	O
or	O
rough	O
neck	O
.	O
      
The	O
relationships	O
between	O
rugby	O
players	O
'	O
tackle	O
training	O
attitudes	O
and	O
behaviour	O
and	O
their	O
match	O
tackle	O
attitudes	O
and	O
behaviour	O
The	O
tackle	O
event	O
in	O
rugby	O
is	O
a	O
technical	O
and	O
physical	O
contest	O
between	O
opposing	O
players	O
.	O
A	O
player	O
's	O
ability	O
to	O
tolerate	O
and	O
contest	O
during	O
a	O
tackle	O
is	O
a	O
prerequisite	O
for	O
safe	O
participation	O
and	O
success	O
in	O
rugby	O
.	O
Little	O
is	O
known	O
about	O
the	O
relationship	O
between	O
tackle	O
training	O
and	O
tackling	O
in	O
matches	O
in	O
rugby	O
union	O
.	O
Therefore	O
,	O
we	O
investigated	O
the	O
relationships	O
between	O
players	O
'	O
training	O
attitudes	O
and	O
behaviour	O
and	O
their	O
match	O
attitudes	O
and	O
behaviour	O
for	O
tackling	O
in	O
rugby	O
union	O
.	O
A	O
questionnaire	O
was	O
designed	O
to	O
assess	B-T058
attitude	O
(	O
importance	O
)	O
and	O
behaviours	O
(	O
frequency	O
and	O
quantity	O
)	O
among	O
junior	O
(	O
under	O
19	O
)	O
players	O
on	O
a	O
5	O
-	O
point	O
Likert	O
Scale	O
.	O
Questionnaires	O
were	O
handed	O
out	O
to	O
220	O
players	O
(	O
10	O
schools	O
)	O
at	O
a	O
tournament	O
and	O
75	O
%	O
(	O
9	O
schools	O
,	O
n=164	O
)	O
were	O
returned	O
for	O
analysis	O
.	O
Associations	O
between	O
training	O
attitudes	O
and	O
behaviours	O
were	O
tested	O
using	O
the	O
χ(2	O
)	O
test	O
,	O
Cramer	O
's	O
V	O
and	O
τ	O
-	O
b.	O
The	O
more	O
time	O
spent	O
on	O
emphasising	O
proper	O
technique	O
to	O
prevent	O
injuries	O
in	O
training	O
,	O
the	O
more	O
important	O
players	O
rated	O
'	O
own	O
safety	O
'	O
(	O
τ	O
-	O
b=0.21	O
,	O
moderate	O
,	O
z=3.1	O
,	O
p<0.01	O
)	O
,	O
'	O
going	O
for	O
the	O
ball	O
only	O
'	O
(	O
τ	O
-	O
b=0.27	O
,	O
moderate	O
,	O
z=4.6	O
,	O
p<0.001	O
)	O
and	O
'	O
staying	O
on	O
feet	O
'	O
(	O
τ	O
-	O
b=0.23	O
,	O
moderate	O
,	O
z=3.6	O
,	O
p<0.001	O
)	O
in	O
match	O
play	O
.	O
The	O
more	O
time	O
spent	O
on	O
emphasising	O
proper	O
technique	O
to	O
improve	B-T033
performance	O
in	O
training	O
,	O
the	O
more	O
important	O
players	O
rated	O
actions	O
'	O
going	O
for	O
ball	O
only	O
'	O
(	O
τ	O
-	O
b=0.23	O
,	O
moderate	O
,	O
z=3.7	O
,	O
p<0.001	O
)	O
and	O
'	O
preventing	O
the	O
ball	O
carrier	O
from	O
retaining	O
position	O
'	O
(	O
τ	O
-	O
b=0.20	O
,	O
moderate	O
,	O
z=3.1	O
,	O
p<0.01	O
)	O
in	O
match	O
play	O
.	O
This	O
is	O
the	O
first	O
study	O
to	O
report	O
on	O
the	O
relationships	O
between	O
players	O
'	O
training	O
attitudes	O
and	O
behaviour	O
and	O
their	O
match	O
attitudes	O
and	O
behaviour	O
s	O
for	O
tackling	O
in	O
rugby	O
union	O
.	O
The	O
importance	O
of	O
tackle	O
training	O
to	O
prevent	O
injury	O
,	O
and	O
the	O
amount	O
of	O
time	O
spent	O
on	O
technique	O
to	O
prevent	O
injuries	O
,	O
was	O
associated	O
with	O
behaviours	O
that	O
reduce	O
the	O
risk	B-T033
of	I-T033
injury	I-T033
in	O
matches	O
.	O
      
Exposure	B-T033
to	I-T033
suicidal	I-T033
behaviors	I-T033
:	O
A	O
common	O
suicide	B-T033
risk	B-T033
factor	I-T033
or	O
a	O
personal	O
negative	B-T033
life	I-T033
event	I-T033
?	O
Numerous	O
suicide	B-T033
risk	B-T033
factors	I-T033
have	O
been	O
proposed	O
but	O
not	O
adequately	O
validated	O
for	O
epidemiology	O
,	O
treatment	B-T061
and	O
prevention	O
efforts	O
.	O
Exposures	B-T033
to	I-T033
suicidal	I-T033
behaviors	I-T033
(	O
ESB	B-T033
)	O
,	O
from	O
family	O
and	O
friend	O
suicide	B-T033
attempts	I-T033
and	O
completions	B-T033
,	O
were	O
tested	O
for	O
validity	O
as	O
a	O
suicidal	B-T033
risk	B-T033
factor	I-T033
and	O
also	O
for	O
measurement	O
and	O
construct	O
adequacy	O
.	O
An	O
anonymous	O
online	O
survey	O
yielded	O
713	O
participants	O
(	O
aged	O
18	O
-	O
71	O
)	O
,	O
who	O
reported	O
ESB	B-T033
,	O
completed	O
the	O
Suicidal	O
Affect	O
-	O
Behavior	O
-	O
Cognition	O
Scale	O
(	O
SABCS	O
)	O
,	O
and	O
comprised	O
a	O
broad	O
spectrum	O
on	O
those	O
variables	O
.	O
Tests	O
of	O
dimensionality	O
and	O
internal	O
consistency	O
showed	O
the	O
four	O
ESB	B-T033
variables	O
(	O
attempts	B-T033
/	O
completions	B-T033
through	O
family	O
/	O
friends	O
)	O
were	O
independent	O
and	O
did	O
not	O
form	O
a	O
common	O
factor	O
or	O
an	O
identifiable	O
ESB	B-T033
latent	O
trait	O
.	O
ESB	B-T033
variables	O
were	O
,	O
however	O
,	O
associated	O
with	O
demographic	B-T033
and	O
psychiatric	B-T033
histories	I-T033
.	O
A	O
battery	O
of	O
tests	O
revealed	O
no	O
meaningful	O
associations	O
between	O
ESB	B-T033
and	O
total	O
suicidality	O
or	O
suicide	B-T033
risk	B-T033
factors	I-T033
(	O
social	O
support	O
,	O
depression	B-T048
,	O
anxiety	B-T033
,	O
stress	B-T033
,	O
satisfaction	O
with	O
life	O
and	O
emotional	O
stability	O
)	O
.	O
In	O
addition	O
,	O
in	O
contrast	O
to	O
previous	O
reports	O
,	O
young	O
adults	O
(	O
n	O
=	O
200	O
;	O
aged	O
18	O
-	O
20	O
)	O
showed	O
no	O
increased	O
suicidality	O
due	O
to	O
ESB	B-T033
.	O
Results	O
showed	O
no	O
validity	O
for	O
ESB	B-T033
as	O
a	O
common	O
risk	B-T033
factor	I-T033
for	O
suicidality	O
or	O
other	O
psychopathology	O
,	O
or	O
as	O
a	O
latent	O
trait	O
.	O
ESB	B-T033
showed	O
evidence	O
as	O
a	O
personal	O
negative	B-T033
life	I-T033
event	I-T033
with	O
individual	O
effects	O
and	O
interpretations	O
.	O
      
Comparative	O
Epidemiologic	O
Characteristics	O
of	O
Pertussis	B-T047
in	O
10	O
Central	O
and	O
Eastern	O
European	O
Countries	O
,	O
2000	O
-	O
2013	O
We	O
undertook	O
an	O
epidemiological	O
survey	O
of	O
the	O
annual	O
incidence	O
of	O
pertussis	B-T047
reported	B-T058
from	O
2000	O
to	O
2013	O
in	O
ten	O
Central	O
and	O
Eastern	O
European	O
countries	O
to	O
ascertain	O
whether	O
increased	O
pertussis	B-T047
reports	O
in	O
some	O
countries	O
share	O
common	O
underlying	O
drivers	O
or	O
whether	O
there	O
are	O
specific	O
features	O
in	O
each	O
country	O
.	O
The	O
annual	O
incidence	O
of	O
pertussis	B-T047
in	O
the	O
participating	O
countries	O
was	O
obtained	O
from	O
relevant	O
government	O
institutions	O
and/or	O
national	O
surveillance	O
systems	O
.	O
We	O
reviewed	O
the	O
changes	O
in	O
the	O
pertussis	B-T047
incidence	O
rates	O
in	O
each	O
country	O
to	O
explore	O
differences	O
and/or	O
similarities	O
between	O
countries	O
in	O
relation	O
to	O
pertussis	B-T047
surveillance	O
;	O
case	O
definitions	O
for	O
detection	B-T033
and	O
confirmation	O
of	O
pertussis	B-T047
;	O
incidence	O
and	O
number	O
of	O
cases	O
of	O
pertussis	B-T047
by	O
year	O
,	O
overall	O
and	O
by	O
age	O
group	O
;	O
population	O
by	O
year	O
,	O
overall	O
and	O
by	O
age	O
group	O
;	O
pertussis	B-T047
immunization	B-T061
schedule	I-T061
and	O
coverage	O
,	O
and	O
switch	O
from	O
whole	B-T121
-	I-T121
cell	I-T121
pertussis	I-T121
vaccines	I-T121
(	O
wP	B-T121
)	O
to	O
acellular	B-T121
pertussis	I-T121
vaccines	I-T121
(	O
aP	B-T121
)	O
.	O
There	O
was	O
heterogeneity	O
in	O
the	O
reported	B-T058
annual	O
incidence	O
rates	O
and	O
trends	O
observed	O
across	O
countries	O
.	O
Reported	B-T058
pertussis	B-T047
incidence	O
rates	O
varied	O
considerably	O
,	O
ranging	O
from	O
0.01	O
to	O
96	O
per	O
100,000	O
population	O
,	O
with	O
the	O
highest	O
rates	O
generally	O
reported	B-T058
in	O
Estonia	O
and	O
the	O
lowest	O
in	O
Hungary	O
and	O
Serbia	O
.	O
The	O
greatest	O
burden	O
appears	O
for	O
the	O
most	O
part	O
in	O
infants	O
(	O
<	O
1	O
year	O
)	O
in	O
Bulgaria	O
,	O
Hungary	O
,	O
Latvia	O
,	O
Romania	O
,	O
and	O
Serbia	O
,	O
but	O
not	O
in	O
the	O
other	O
participating	O
countries	O
where	O
the	O
burden	O
may	O
have	O
shifted	O
to	O
older	O
children	O
,	O
though	O
surveillance	O
of	O
adults	O
may	O
be	O
inappropriate	O
.	O
There	O
was	O
no	O
consistent	O
pattern	O
associated	O
with	O
the	O
switch	O
from	O
wP	B-T121
to	O
aP	B-T121
vaccines	I-T121
on	O
reported	B-T058
pertussis	B-T047
incidence	O
rates	O
.	O
The	O
heterogeneity	O
in	O
reported	B-T058
data	O
may	O
be	O
related	O
to	O
a	O
number	O
of	O
factors	O
including	O
surveillance	O
system	O
characteristics	O
or	O
capabilities	O
,	O
different	O
case	O
definitions	O
,	O
type	O
of	O
pertussis	B-T047
confirmation	B-T059
tests	I-T059
used	O
,	O
public	O
awareness	B-T033
of	O
the	O
disease	B-T047
,	O
as	O
well	O
as	O
real	O
differences	O
in	O
the	O
magnitude	O
of	O
the	O
disease	B-T047
,	O
or	O
a	O
combination	O
of	O
these	O
factors	O
.	O
Our	O
study	O
highlights	O
the	O
need	O
to	O
standardize	O
pertussis	B-T047
detection	B-T033
and	O
confirmation	O
in	O
surveillance	O
programs	O
across	O
Europe	O
,	O
complemented	O
with	O
carefully	O
-	O
designed	O
seroprevalence	O
studies	O
using	O
the	O
same	O
protocols	O
and	O
methodologies	O
.	O
      
Neuro	B-T047
-	I-T047
Behcet	I-T047
disease	I-T047
presenting	O
as	O
a	O
solitary	O
cerebellar	O
hemorrhagic	O
lesion	B-T033
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
Behcet	B-T047
's	I-T047
disease	I-T047
is	O
a	O
heterogeneous	B-T033
,	O
multisystem	B-T047
,	O
inflammatory	B-T047
disorder	I-T047
of	O
unknown	B-T033
etiology	I-T033
.	O
The	O
classic	O
triad	O
of	O
oral	B-T047
and	O
genital	B-T047
ulcerations	I-T047
in	O
conjunction	O
with	O
uveitis	B-T047
was	O
originally	O
described	O
by	O
the	O
Turkish	O
dermatologist	O
Hulusi	O
Behcet	O
in	O
1937	O
,	O
but	O
associated	B-T184
symptoms	I-T184
of	O
the	O
cardiovascular	O
,	O
central	O
nervous	O
,	O
pulmonary	O
,	O
and	O
gastrointestinal	O
systems	O
were	O
later	O
identified	O
.	O
In	O
fact	O
,	O
Behcet	B-T047
's	I-T047
disease	I-T047
with	O
neurological	B-T047
involvement	I-T047
(	O
neuro	B-T047
-	I-T047
Behcet	I-T047
's	I-T047
disease	I-T047
)	O
is	O
not	O
uncommon	O
.	O
Patients	O
with	O
neuro	B-T047
-	I-T047
Behcet	I-T047
's	I-T047
disease	I-T047
typically	O
exhibit	O
a	O
diverse	O
array	O
of	O
symptoms	B-T184
,	O
most	O
commonly	O
in	O
the	O
brainstem	B-T023
and	O
diencephalic	B-T023
regions	O
.	O
Herein	O
,	O
we	O
report	O
an	O
unusual	O
case	O
of	O
neuro	B-T047
-	I-T047
Behcet	I-T047
's	I-T047
disease	I-T047
in	O
a	O
patient	O
who	O
presented	O
with	O
a	O
solitary	O
cerebellar	O
hemorrhage	O
.	O
A	O
39	O
-	O
year	O
-	O
old	O
Asian	O
woman	O
was	O
admitted	B-T058
to	O
our	O
hospital	O
with	O
complaints	B-T033
of	O
a	O
sudden	O
speech	B-T033
difficulty	I-T033
that	O
had	O
manifested	O
the	O
same	O
morning	O
,	O
and	O
dizziness	B-T184
and	O
mild	O
vomiting	B-T184
experienced	O
over	O
the	O
previous	O
3	O
days	O
.	O
Magnetic	O
resonance	O
images	O
revealed	O
target	O
-	O
like	O
hemorrhagic	O
lesions	B-T033
in	O
the	O
right	B-T023
hemisphere	I-T023
of	I-T023
the	I-T023
cerebellum	I-T023
.	O
Risk	B-T033
factors	I-T033
that	O
may	O
result	O
in	O
cerebellar	O
hemorrhage	O
,	O
such	O
as	O
high	B-T047
blood	I-T047
pressure	I-T047
or	O
bleeding	O
diathesis	O
,	O
were	O
ruled	B-T033
out	I-T033
,	O
and	O
subsequent	O
brain	B-T023
angiograms	B-T060
were	O
normal	O
.	O
These	O
findings	B-T033
suggest	O
that	O
the	O
patient	O
's	O
cerebellar	O
hemorrhage	O
could	O
have	O
been	O
due	O
to	O
intracranial	O
vasculitis	B-T047
in	O
a	O
rare	O
,	O
if	O
not	O
unique	O
,	O
complication	O
of	O
neuro	B-T047
-	I-T047
Behcet	I-T047
's	I-T047
disease	I-T047
.	O
      
Mechanisms	O
of	O
ear	B-T023
trauma	O
and	O
reconstructive	B-T061
techniques	O
in	O
105	O
consecutive	O
patients	O
Acquired	O
auricular	B-T023
deformities	B-T190
may	O
diminish	O
facial	O
esthetics	O
and	O
cause	O
psychological	B-T048
distress	I-T048
.	O
The	O
aim	O
of	O
this	O
article	O
is	O
to	O
provide	O
an	O
overview	O
of	O
the	O
type	O
of	O
injuries	O
and	O
applied	B-T061
reconstructive	I-T061
techniques	O
in	O
a	O
large	O
academic	O
hospital	O
in	O
The	O
Netherlands	O
.	O
A	O
retrospective	O
chart	O
review	O
was	O
conducted	O
for	O
the	O
last	O
105	O
patients	O
who	O
underwent	O
auricular	B-T023
reconstruction	B-T061
for	O
an	O
acquired	B-T020
deformity	I-T020
.	O
Data	O
concerning	O
gender	O
,	O
affected	B-T033
side	I-T033
,	O
cause	B-T033
of	I-T033
injury	I-T033
,	O
anatomical	O
region	O
,	O
the	O
previous	O
and	O
further	O
surgeries	B-T061
,	O
type	O
of	O
cartilage	O
,	O
and	O
skin	O
cover	O
used	O
were	O
collected	O
and	O
analyzed	O
.	O
105	O
patients	O
were	O
included	O
.	O
Acquired	O
auricular	B-T023
deformities	B-T190
were	O
mainly	O
caused	O
by	O
bite	O
injuries	O
(	O
22	O
%	O
)	O
,	O
traffic	O
accidents	O
(	O
17	O
%	O
)	O
,	O
burns	O
(	O
9.5	O
%	O
)	O
,	O
and	O
post	B-T061
-	I-T061
otoplasty	I-T061
complications	O
(	O
9.5	O
%	O
)	O
.	O
The	O
upper	B-T023
third	I-T023
of	I-T023
the	I-T023
auricle	I-T023
was	O
most	O
often	O
injured	O
(	O
41	O
%	O
)	O
,	O
followed	O
by	O
the	O
entire	B-T023
auricle	I-T023
(	O
19	O
%	O
)	O
.	O
70	O
%	O
of	O
cases	O
required	O
reconstruction	B-T061
with	O
costal	O
cartilage	O
.	O
The	O
most	O
common	O
form	O
of	O
cutaneous	O
cover	O
was	O
a	O
postauricular	B-T061
skin	I-T061
flap	I-T061
(	O
40	O
%	O
of	O
cases	O
)	O
.	O
This	O
study	O
gives	O
a	O
complete	O
overview	O
of	O
causes	O
and	O
treatment	O
of	O
acquired	O
auricular	B-T023
deformities	B-T190
.	O
The	O
results	O
are	O
comparable	O
with	O
the	O
results	O
of	O
similar	O
studies	O
found	O
in	O
literature	O
.	O
Bite	O
wounds	O
are	O
the	O
leading	O
cause	O
of	O
acquired	O
auricular	B-T023
injuries	O
.	O
The	O
upper	B-T023
third	I-T023
is	O
most	O
commonly	O
affected	O
.	O
In	O
the	O
largest	O
percentage	O
of	O
reconstructions	B-T061
,	O
costal	O
cartilage	O
and	O
a	O
postauricular	B-T023
flap	I-T023
were	O
used	O
to	O
correct	O
the	O
deformity	B-T190
.	O
      
Absorption	O
Characteristics	O
of	O
Vertebrate	O
Non	O
-	O
Visual	O
Opsin	O
,	O
Opn3	O
Most	O
animals	O
possess	O
multiple	O
opsins	O
which	O
sense	O
light	O
for	O
visual	O
and	O
non	O
-	O
visual	O
functions	O
.	O
Here	O
,	O
we	O
show	O
spectral	O
characteristics	O
of	O
non	O
-	O
visual	O
opsins	O
,	O
vertebrate	O
Opn3s	O
,	O
which	O
are	O
widely	O
distributed	O
among	O
vertebrates	O
.	O
We	O
successfully	O
expressed	O
zebrafish	O
Opn3	O
in	O
mammalian	O
cultured	O
cells	O
and	O
measured	O
its	O
absorption	B-T059
spectrum	I-T059
spectroscopically	I-T059
.	O
When	O
incubated	B-T059
with	O
11	O
-	O
cis	O
retinal	O
,	O
zebrafish	O
Opn3	O
formed	O
a	O
blue	O
-	O
sensitive	O
photopigment	O
with	O
an	O
absorption	O
maximum	O
around	O
465	O
nm	O
.	O
The	O
Opn3	O
converts	O
to	O
an	O
all	B-T121
-	I-T121
trans	I-T121
retinal	I-T121
-	I-T121
bearing	I-T121
photoproduct	O
with	O
an	O
absorption	B-T059
spectrum	I-T059
similar	O
to	O
the	O
dark	O
state	O
following	O
brief	O
blue	O
-	O
light	O
irradiation	O
.	O
The	O
photoproduct	O
experienced	O
a	O
remarkable	O
blue	O
-	O
shift	O
,	O
with	O
changes	O
in	O
position	O
of	O
the	O
isosbestic	O
point	O
,	O
during	O
further	O
irradiation	O
.	O
We	O
then	O
used	O
a	O
cAMP	B-T121
-	O
dependent	O
luciferase	O
reporter	O
assay	B-T059
to	O
investigate	O
light	O
-	O
dependent	O
cAMP	B-T121
responses	O
in	O
cultured	O
cells	O
expressing	O
zebrafish	O
,	O
pufferfish	O
,	O
anole	O
and	O
chicken	O
Opn3	O
.	O
The	O
wild	O
type	O
opsins	O
did	O
not	O
produce	O
responses	O
,	O
but	O
cells	O
expressing	O
chimera	B-T001
mutants	O
(	O
WT	O
Opn3s	O
in	O
which	O
the	O
third	O
intracellular	O
loops	O
were	O
replaced	O
with	O
the	O
third	O
intracellular	O
loop	O
of	O
a	O
Gs	O
-	O
coupled	O
jellyfish	O
opsin	O
)	O
displayed	O
light	O
-	O
dependent	O
changes	O
in	O
cAMP	B-T121
.	O
The	O
results	O
suggest	O
that	O
Opn3	O
is	O
capable	O
of	O
activating	O
G	O
protein(s	O
)	O
in	O
a	O
light	O
-	O
dependent	O
manner	O
.	O
Finally	O
,	O
we	O
used	O
this	O
assay	B-T059
to	O
measure	O
the	O
relative	O
wavelength	O
-	O
dependent	O
response	O
of	O
cells	O
expressing	O
Opn3	O
chimeras	B-T001
to	O
multiple	O
quantally	O
-	O
matched	O
stimuli	O
.	O
The	O
inferred	O
spectral	O
sensitivity	O
curve	O
of	O
zebrafish	O
Opn3	O
accurately	O
matched	O
the	O
measured	O
absorption	B-T059
spectrum	I-T059
.	O
We	O
were	O
unable	O
to	O
estimate	O
the	O
spectral	O
sensitivity	O
curve	O
of	O
mouse	O
or	O
anole	O
Opn3	O
,	O
but	O
,	O
like	O
zebrafish	O
Opn3	O
,	O
the	O
chicken	O
and	O
pufferfish	O
Opn3	O
-	O
JiL3	O
chimeras	B-T001
also	O
formed	O
blue	O
-	O
sensitive	O
pigments	O
.	O
These	O
findings	O
suggest	O
that	O
vertebrate	O
Opn3s	O
may	O
form	O
blue	O
-	O
sensitive	O
G	O
protein	O
-	O
coupled	O
pigments	O
.	O
Further	O
,	O
we	O
suggest	O
that	O
the	O
method	O
described	O
here	O
,	O
combining	O
a	O
cAMP	B-T121
-	O
dependent	O
luciferase	O
reporter	O
assay	B-T059
with	O
chimeric	B-T001
opsins	O
possessing	O
the	O
third	O
intracellular	O
loop	O
of	O
jellyfish	O
opsin	O
,	O
is	O
a	O
versatile	O
approach	O
for	O
estimating	O
absorption	B-T059
spectra	I-T059
of	O
opsins	O
with	O
unknown	O
signaling	O
cascades	O
or	O
for	O
which	O
absorption	B-T059
spectra	I-T059
are	O
difficult	O
to	O
obtain	O
.	O
      
Passive	O
case	O
detection	O
of	O
malaria	B-T047
in	O
Ratanakiri	O
Province	O
(	O
Cambodia	O
)	O
to	O
detect	B-T033
villages	O
at	B-T033
higher	I-T033
risk	I-T033
for	O
malaria	B-T047
Cambodia	O
reduced	O
malaria	B-T047
incidence	O
by	O
more	O
than	O
75	O
%	O
between	O
2000	O
and	O
2015	O
,	O
a	O
target	O
of	O
the	O
Millennium	O
Development	O
Goal	O
6	O
.	O
The	O
Cambodian	O
Government	O
aims	O
to	O
eliminate	O
all	O
forms	O
of	O
malaria	B-T047
by	O
2025	O
.	O
The	O
country	O
's	O
malaria	B-T047
incidence	O
is	O
highly	O
variable	O
at	O
provincial	O
level	O
,	O
but	O
less	O
is	O
known	O
at	O
village	O
level	O
.	O
This	O
study	O
used	O
passive	O
case	O
detection	O
(	O
PCD	O
)	O
data	O
at	O
village	O
level	O
in	O
Ratanakiri	O
Province	O
from	O
2010	O
to	O
2014	O
to	O
describe	O
incidence	O
trends	O
and	O
identify	O
high	B-T033
-	I-T033
risk	I-T033
areas	I-T033
of	I-T033
malaria	B-T047
to	O
be	O
primarily	O
targeted	O
towards	O
malaria	B-T047
elimination	O
.	O
In	O
2010	O
,	O
the	O
Cambodian	O
malaria	B-T047
programme	O
created	O
a	O
Malaria	O
Information	O
System	O
(	O
MIS	O
)	O
to	O
capture	O
malaria	B-T047
information	O
at	O
village	O
level	O
through	O
PCD	O
by	O
village	O
malaria	O
workers	O
and	O
health	O
facilities	O
.	O
The	O
MIS	O
data	O
of	O
Ratanakiri	O
Province	O
2010	O
-	O
2014	O
were	O
used	O
to	O
calculate	O
annual	O
incidence	O
rates	O
by	O
Plasmodium	O
species	O
at	O
province	O
and	O
commune	O
levels	O
.	O
For	O
estimating	O
the	O
trend	O
at	O
provincial	O
level	O
only	O
villages	O
reporting	B-T058
each	O
year	O
were	O
selected	O
.	O
The	O
communal	O
incidences	O
and	O
the	O
number	O
of	O
cases	O
per	O
village	O
were	O
visualized	O
on	O
a	O
map	O
per	O
Plasmodium	O
species	O
and	O
per	O
year	O
.	O
Analysis	O
of	O
spatial	O
clustering	O
of	O
village	O
malaria	B-T047
cases	O
by	O
Plasmodium	O
species	O
was	O
performed	O
by	O
year	O
.	O
Overall	O
,	O
malaria	B-T047
annual	O
incidence	O
rates	O
per	O
1000	O
inhabitants	O
decreased	O
from	O
86	O
(	O
2010	O
)	O
to	O
30	O
(	O
2014	O
)	O
.	O
Falciparum	O
incidence	O
decreased	O
(	O
by	O
79	O
%	O
in	O
2014	O
compared	O
to	O
2010	O
;	O
CI	O
95	O
%	O
76	O
-	O
82	O
%	O
)	O
more	O
rapidly	O
than	O
vivax	O
incidence	O
(	O
by	O
19	O
%	O
in	O
2014	O
compared	O
to	O
2010	O
;	O
CI	O
95	O
%	O
5	O
-	O
32	O
%	O
)	O
.	O
There	O
were	O
ten	O
to	O
16	O
significant	O
spatial	O
clusters	O
each	O
year	O
.	O
Big	O
clusters	O
tended	O
to	O
extend	O
along	O
the	O
Cambodian	O
-	O
Vietnamese	O
border	O
and	O
along	O
the	O
Sesan	O
River	O
.	O
Three	O
clusters	O
appeared	O
throughout	O
all	O
years	O
(	O
2010	O
-	O
2014	O
):	O
one	O
with	O
21	O
villages	O
appeared	O
each	O
year	O
,	O
the	O
second	O
shrunk	O
progressively	O
from	O
2012	O
to	O
2014	O
and	O
the	O
third	O
was	O
split	O
into	O
two	O
smaller	O
clusters	O
in	O
2013	O
and	O
2014	O
.	O
The	O
decline	O
of	O
malaria	B-T047
burden	O
can	O
be	O
attributed	O
to	O
intensive	O
malaria	O
control	O
activities	O
implemented	O
in	O
the	O
areas	O
:	O
distribution	O
of	O
a	O
long	O
-	O
lasting	O
insecticidal	O
net	O
per	O
person	O
and	O
early	B-T060
diagnosis	I-T060
and	O
prompt	O
treatment	O
.	O
Dihydro	B-T121
-	I-T121
artemisinin	I-T121
piperaquine	B-T121
was	O
the	O
only	O
first	B-T061
-	I-T061
line	I-T061
treatment	I-T061
for	O
all	O
malaria	B-T047
cases	O
.	O
No	O
radical	O
treatment	O
with	O
primaquine	B-T121
was	O
provided	O
for	O
Plasmodium	O
vivax	O
cases	O
,	O
which	O
could	O
explain	O
the	O
slow	O
decrease	O
of	O
P.	O
vivax	O
due	O
to	O
relapses	O
.	O
To	O
achieve	O
malaria	B-T047
elimination	O
by	O
2025	O
,	O
priority	O
should	O
be	O
given	O
to	O
the	O
control	O
of	O
stable	O
malaria	O
clusters	O
appearing	O
over	O
time	O
.	O
      
Parental	O
perceptions	O
of	O
children´s	O
agency	O
:	O
Parental	O
warmth	O
,	O
school	O
achievement	O
and	O
adjustment	O
The	O
present	O
study	O
examined	O
Swedish	O
mothers	O
'	O
and	O
fathers	O
'	O
warmth	O
towards	O
their	O
children	O
in	O
relation	O
to	O
their	O
children´s	O
agency	O
.	O
It	O
also	O
examined	O
the	O
longitudinal	O
relation	O
between	O
agency	O
and	O
children	O
's	O
externalizing	O
,	O
internalizing	O
,	O
and	O
school	O
achievement	O
.	O
Swedish	O
children	O
's	O
mothers	O
and	O
fathers	O
(	O
N	O
=	O
103	O
)	O
were	O
interviewed	O
at	O
three	O
time	O
points	O
(	O
when	O
children	O
were	O
8	O
,	O
9	O
,	O
and	O
10	O
years	O
old	O
)	O
about	O
their	O
warmth	O
towards	O
their	O
children	O
,	O
children	O
's	O
agency	O
,	O
and	O
children	O
's	O
externalizing	O
and	O
internalizing	O
behaviors	O
and	O
school	O
achievement	O
.	O
Parental	O
warmth	O
at	O
Time	O
1	O
was	O
significantly	O
correlated	O
with	O
child	O
agency	O
at	O
Time	O
2	O
,	O
which	O
was	O
significantly	O
correlated	O
with	O
child	O
externalizing	O
and	O
internalizing	O
behaviors	O
and	O
academic	O
achievement	O
at	O
Time	O
3	O
.	O
There	O
were	O
no	O
differences	O
between	O
girls	O
and	O
boys	O
.	O
Results	O
from	O
this	O
study	O
indicate	O
that	O
Swedish	O
parents	O
'	O
warmth	O
is	O
directly	O
related	O
to	O
subsequent	O
perceptions	O
of	O
children	O
's	O
agency	O
,	O
which	O
in	O
turn	O
are	O
related	O
to	O
subsequently	O
lower	O
child	O
externalizing	O
and	O
internalizing	O
problems	B-T033
and	O
higher	O
academic	O
achievement	O
.	O
These	O
findings	B-T033
held	O
in	O
the	O
context	O
of	O
a	O
three-	O
year	O
longitudinal	O
study	O
and	O
for	O
both	O
boys	O
and	O
girls	O
,	O
suggesting	O
the	O
importance	O
of	O
child	O
agency	O
in	O
the	O
link	O
between	O
parental	O
warmth	O
and	O
children	O
's	O
adjustment	O
.	O
      
Effects	O
of	O
obesity	B-T047
on	O
IL-33	O
/	O
ST2	O
system	O
in	O
heart	B-T023
,	O
adipose	O
tissue	O
and	O
liver	B-T023
:	O
study	O
in	O
the	O
experimental	O
model	O
of	O
Zucker	O
rats	O
Suppression	O
of	O
tumorigenicity	O
2	O
(	O
ST2	O
)	O
mediates	O
the	O
effect	O
of	O
Interleukin-33	O
(	O
IL-33	O
)	O
.	O
Few	O
data	O
are	O
reported	O
on	O
the	O
relationship	O
between	O
IL-33	O
/	O
ST2	O
and	O
obesity	B-T047
.	O
We	O
aimed	O
to	O
investigate	O
effects	O
of	O
obesity	B-T047
on	O
IL-33	O
/	O
ST2	O
system	O
in	O
heart	B-T023
,	O
adipose	O
tissue	O
and	O
liver	B-T023
in	O
a	O
rodent	B-T050
model	I-T050
of	O
obesity	B-T047
.	O
The	O
relationship	O
of	O
cardiac	O
expression	O
of	O
IL-33	O
/	O
ST2	O
system	O
with	O
natriuretic	B-T121
peptides	I-T121
(	O
NPs	B-T121
)	O
system	O
and	O
inflammatory	O
mediators	O
was	O
also	O
studied	O
.	O
mRNA	O
expression	O
of	O
IL-33	O
/	O
ST2	O
system	O
was	O
evaluated	O
in	O
cardiac	B-T060
,	O
adipose	O
and	O
hepatic	B-T060
biopsies	I-T060
from	O
obese	O
Zucker	O
rats	O
(	O
O	O
)	O
and	O
controls	O
(	O
CO	O
)	O
.	O
Expression	O
levels	O
of	O
sST2	O
was	O
significantly	O
lower	O
in	O
O	O
rats	O
compared	O
with	O
CO	O
(	O
p<0.05	O
)	O
in	O
all	O
tissues	O
.	O
Besides	O
,	O
the	O
mRNA	O
levels	O
of	O
IL-33	O
decreased	O
significant	O
in	O
fat	O
of	O
O	O
respect	O
to	O
CO	O
,	O
while	O
,	O
expression	O
levels	O
of	O
ST2L	O
was	O
significantly	O
higher	O
in	O
liver	B-T023
of	O
CO	O
than	O
in	O
O.	O
A	O
strong	O
relationship	O
of	O
IL-33	O
/	O
ST2	O
with	O
NPs	B-T121
and	O
classical	O
inflammatory	O
mediators	O
was	O
observed	O
in	O
cardiac	O
tissue	O
.	O
Expression	O
of	O
sST2	O
in	O
cardiac	O
,	O
adipose	O
and	O
liver	B-T023
tissue	I-T023
decreased	O
in	O
O	O
compared	O
with	O
controls	O
,	O
suggesting	O
an	O
involvement	O
for	O
IL-33	O
/	O
ST2	O
system	O
in	O
molecular	O
mechanisms	O
of	O
obesity	B-T047
.	O
The	O
strong	O
relationships	O
with	O
NP	B-T121
systems	O
and	O
inflammatory	O
mediators	O
could	O
suggest	O
an	O
involvement	O
for	O
IL-33	O
/	O
ST2	O
in	O
molecular	O
pathways	O
leading	O
to	O
cardiac	B-T033
dysfunction	I-T033
and	O
inflammation	O
associated	O
with	O
obesity	B-T047
.	O
      
The	O
Multi	O
-	O
center	O
Evaluation	O
of	O
the	O
Accuracy	O
of	O
the	O
Contrast	O
MEdium	O
INduced	O
Pd	O
/	O
Pa	O
RaTiO	O
in	O
Predicting	O
FFR	O
(	O
MEMENTO	O
-	O
FFR	O
)	O
Study	O
Adenosine	B-T121
administration	B-T061
is	O
needed	O
for	O
the	O
achievement	O
of	O
maximal	O
hyperaemia	B-T047
fractional	O
flow	O
reserve	O
(	O
FFR	O
)	O
assessment	B-T058
.	O
The	O
objective	O
was	O
to	O
test	O
the	O
accuracy	O
of	O
Pd	O
/	O
Pa	O
ratio	O
registered	O
during	O
submaximal	O
hyperaemia	B-T047
induced	O
by	O
non	O
-	O
ionic	O
contrast	O
medium	O
(	O
contrast	O
FFR	O
[	O
cFFR	O
]	O
)	O
in	O
predicting	O
FFR	O
and	O
comparing	O
it	O
to	O
the	O
performance	O
of	O
resting	B-T033
Pd	O
/	O
Pa	O
in	O
a	O
collaborative	O
registry	O
of	O
926	O
patients	O
enrolled	O
in	O
10	O
hospitals	O
from	O
four	O
European	O
countries	O
(	O
Italy	O
,	O
Spain	O
,	O
France	O
and	O
Portugal	O
)	O
.	O
Resting	B-T033
Pd	O
/	O
Pa	O
,	O
cFFR	O
and	O
FFR	O
were	O
measured	O
in	O
1,026	O
coronary	B-T047
stenoses	I-T047
functionally	O
evaluated	O
using	O
commercially	O
available	O
pressure	O
wires	O
.	O
cFFR	O
was	O
obtained	O
after	O
intracoronary	O
injection	O
of	O
contrast	O
medium	O
,	O
while	O
FFR	O
was	O
measured	O
after	O
administration	B-T061
of	O
adenosine	B-T121
.	O
Resting	B-T033
Pd	O
/	O
Pa	O
and	O
cFFR	O
were	O
significantly	O
higher	O
than	O
FFR	O
(	O
0.93±0.05	O
vs.	O
0.87±0.08	O
vs.	O
0.84±0.08	O
,	O
p<0.001	O
)	O
.	O
A	O
strong	O
correlation	O
and	O
a	O
close	O
agreement	O
at	O
Bland	O
-	O
Altman	O
analysis	O
between	O
cFFR	O
and	O
FFR	O
were	O
observed	O
(	O
r=0.90	O
,	O
p<0.001	O
and	O
95	O
%	O
CI	O
of	O
disagreement	O
:	O
from	O
-0.042	O
to	O
0.11	O
)	O
.	O
ROC	O
curve	O
analysis	O
showed	O
an	O
excellent	O
accuracy	O
(	O
89	O
%	O
)	O
of	O
the	O
cFFR	O
cut	O
-	O
off	O
of	O
≤0.85	O
in	O
predicting	O
an	O
FFR	O
value	O
≤0.80	O
(	O
AUC	O
0.95	O
[	O
95	O
%	O
CI	O
:	O
0.94	O
-	O
0.96	O
]	O
)	O
,	O
significantly	O
better	O
than	O
that	O
observed	O
using	O
resting	B-T033
Pd	O
/	O
Pa	O
(	O
AUC	O
:	O
0.90	O
,	O
95	O
%	O
CI	O
:	O
0.88	O
-	O
0.91	O
;	O
p<0.001	O
)	O
.	O
A	O
cFFR	O
/	O
FFR	O
hybrid	O
approach	O
showed	O
a	O
significantly	O
lower	O
number	O
of	O
lesions	B-T033
requiring	O
adenosine	B-T121
than	O
a	O
resting	B-T033
Pd	O
/	O
Pa	O
/	O
FFR	O
hybrid	O
approach	O
(	O
22	O
%	O
vs.	O
44	O
%	O
,	O
p<0.0001	O
)	O
.	O
cFFR	O
is	O
accurate	O
in	O
predicting	O
the	O
functional	O
significance	O
of	O
coronary	B-T047
stenosis	I-T047
.	O
This	O
could	O
allow	O
limiting	O
the	O
use	O
of	O
adenosine	B-T121
to	O
obtain	O
FFR	O
to	O
a	O
minority	O
of	O
stenoses	O
with	O
considerable	O
savings	O
of	O
time	O
and	O
costs	O
.	O
      
The	O
Effects	O
of	O
Messages	O
about	O
the	O
Causes	O
of	O
Obesity	B-T047
on	O
Disciplinary	O
Action	O
Decisions	O
for	O
Overweight	B-T047
Employees	O
We	O
investigated	O
the	O
impact	O
of	O
messages	O
about	O
the	O
causes	O
of	O
obesity	B-T047
(	O
controllable	B-T033
or	O
uncontrollable	O
)	O
on	O
the	O
disciplinary	O
action	O
consequences	O
selected	O
for	O
obese	B-T047
employees	O
in	O
response	O
to	O
a	O
work	B-T033
-	I-T033
related	I-T033
mistake	O
.	O
Participants	O
read	O
about	O
either	O
the	O
controllable	B-T033
or	O
uncontrollable	O
causes	O
of	O
obesity	B-T047
before	O
reviewing	O
an	O
ostensible	O
employee	O
file	O
that	O
included	O
a	O
description	O
of	O
an	O
employee	O
mistake	O
.	O
Depending	O
on	O
condition	O
,	O
the	O
file	O
contained	O
a	O
photo	O
of	O
the	O
employee	O
that	O
either	O
depicted	O
them	O
as	O
obese	B-T047
or	O
average	O
weight	O
.	O
Participants	O
were	O
more	O
willing	O
to	O
withhold	O
a	O
raise	O
or	O
promotion	O
from	O
an	O
obese	B-T047
employee	O
than	O
from	O
an	O
average	O
-	O
weight	O
employee	O
.	O
Further	O
,	O
there	O
was	O
little	O
evidence	O
that	O
the	O
messages	O
about	O
the	O
causes	O
of	O
obesity	B-T047
affected	O
participants	O
'	O
perceived	B-T033
control	I-T033
and	O
self	O
-	O
efficacy	O
for	O
healthy	O
behaviors	O
.	O
      
AMPK	O
-	O
autophagy	O
inhibition	O
sensitizes	O
icaritin	O
-	O
induced	O
anti	B-T033
-	I-T033
colorectal	I-T033
cancer	I-T033
cell	O
activity	O
The	O
current	O
research	O
studied	O
the	O
potential	O
effect	O
of	O
autophagy	O
on	O
icaritin	O
-	O
induced	O
anti	B-T033
-	I-T033
colorectal	I-T033
cancer	I-T033
(	O
CRC	B-T191
)	O
cell	O
activity	O
.	O
Treatment	O
of	O
icaritin	O
in	O
both	O
primary	O
and	O
established	O
(	O
HT-29	O
)	O
CRC	B-T191
cells	O
induced	O
feedback	O
activation	O
of	O
autophagy	O
,	O
evidenced	O
by	O
p62	O
degradation	O
,	O
Beclin-1	O
and	O
autophagy	O
-	O
related	O
gene-5	O
(	O
ATG-5	O
)	O
upregulation	O
,	O
as	O
well	O
as	O
light	O
chain	O
3B	O
(	O
LC3B)-	O
GFP	O
puncta	O
formation	O
.	O
Pharmacological	O
inhibiting	O
of	O
autophagy	O
dramatically	O
potentiated	O
icaritin	O
-	O
induced	O
CRC	B-T191
cell	O
death	O
and	O
apoptosis	O
.	O
Meanwhile	O
,	O
shRNA	O
-mediated	O
knockdown	O
of	O
Beclin-1	O
or	O
ATG-5	O
also	O
sensitized	O
icaritin	O
-	O
induced	O
CRC	B-T191
cell	O
death	O
and	O
apoptosis	O
.	O
Icaritin	O
activated	O
AMP	O
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
signaling	O
in	O
CRC	B-T191
cells	O
,	O
functioning	O
as	O
the	O
upstream	O
signaling	O
for	O
autophagy	O
activation	O
.	O
shRNA	O
/	O
siRNA	O
-mediated	O
knockdown	O
of	O
AMPKα1	O
inhibited	O
icaritin	O
-	O
induced	O
autophagy	O
activation	O
,	O
but	O
exacerbated	O
CRC	B-T191
cell	O
death	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
AMPK	O
activator	O
compound	B-T121
13	I-T121
(	O
C13	B-T121
)	O
or	O
the	O
autophagy	O
activator	O
MHY1485	B-T121
attenuated	O
icaritin	O
-	O
induced	O
cytotoxicity	O
.	O
In	O
nude	O
mice	O
,	O
icaritin	O
(	O
oral	B-T061
administration	I-T061
administration)-	O
induced	O
HT-29	O
tumor	B-T191
growth	I-T191
inhibition	O
was	O
potentiated	O
when	O
combined	O
with	O
AMPKα1	O
shRNA	O
knockdown	O
in	O
tumors	B-T191
.	O
We	O
conclude	O
that	O
feedback	O
activation	O
of	O
AMPK	O
-	O
autophagy	O
pathway	O
could	O
be	O
a	O
primary	O
resistance	O
factor	O
of	O
icaritin	O
.	O
      
A	O
miniature	O
bird	O
-borne	O
passive	O
air	O
sampler	O
for	O
monitoring	B-T058
halogenated	O
flame	O
retardants	O
Birds	O
have	O
been	O
used	O
intensively	O
as	O
biomonitors	O
of	O
halogenated	O
flame	O
retardants	O
(	O
HFRs	O
)	O
,	O
and	O
several	O
studies	O
have	O
reported	O
elevated	O
tissue	O
concentrations	O
and	O
inter-	O
individual	O
variability	O
for	O
these	O
contaminants	O
.	O
While	O
diet	O
is	O
known	O
to	O
be	O
an	O
important	O
exposure	O
pathway	O
for	O
HFRs	O
in	O
birds	O
,	O
it	O
has	O
been	O
suggested	O
that	O
exposure	O
through	O
air	O
may	O
represent	O
an	O
underestimated	O
source	B-T033
of	O
HFRs	O
for	O
certain	O
species	O
.	O
However	O
,	O
a	O
method	O
was	O
not	O
available	O
for	O
measuring	O
the	O
atmospheric	O
exposure	O
of	O
individual	O
birds	O
to	O
HFRs	O
or	O
other	O
semi	O
-	O
volatile	O
contaminants	O
.	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
bird	O
-borne	O
passive	O
air	O
sampler	O
(	O
PAS	O
)	O
enabling	O
the	O
determination	B-T059
of	O
individual	O
atmospheric	O
exposure	O
to	O
gas	O
-	O
and	O
particle	O
-	O
phase	O
HFRs	O
using	O
the	O
ring	O
-	O
billed	O
gull	O
(	O
Larus	O
delawarensis	O
)	O
nesting	O
in	O
the	O
Montreal	O
area	O
(	O
QC	O
,	O
Canada	O
)	O
.	O
The	O
new	O
miniaturized	O
elliptical	O
-	O
shaped	O
PAS	O
(	O
mean	O
weight	O
:	O
2.72	O
g	O
)	O
was	O
tested	O
using	O
two	B-T059
sorbent	I-T059
types	I-T059
during	O
three	O
exposure	O
periods	O
(	O
one	O
,	O
two	O
and	O
three	O
weeks	O
)	O
.	O
Results	O
showed	O
that	O
PAS	O
using	O
polyurethane	O
foam	O
(	O
PUF	O
)	O
combined	O
with	O
a	O
glass	O
fiber	O
filter	O
collected	O
all	O
major	O
polybrominated	O
diphenyl	O
ethers	O
(	O
PBDEs	O
)	O
and	O
exhibited	O
better	O
performance	O
for	O
collecting	O
highly	O
hydrophobic	O
DecaBDE	O
mixture	O
congeners	O
compared	O
to	O
the	O
PAS	O
using	O
polydimethylsiloxane	O
(	O
PDMS	O
)	O
.	O
Emerging	O
HFRs	O
including	O
hexabromobenzene	O
,	O
Dechlorane	O
604	O
Component	O
B	O
,	O
and	O
Dechlorane	O
plus	O
(	O
DP	O
)	O
isomers	O
also	O
were	O
sampled	B-T060
by	O
the	O
PUF	O
-based	O
PAS	O
.	O
Sampling	B-T060
rates	O
for	O
most	O
HFRs	O
were	O
comparable	O
between	O
the	O
three	O
exposure	O
periods	O
.	O
This	O
novel	O
bird	O
-borne	O
PAS	O
provides	O
valuable	O
information	O
on	O
the	O
non	O
-	O
dietary	O
exposure	O
of	O
free	B-T033
-	I-T033
ranging	I-T033
birds	O
to	O
HFRs	O
.	O
      
The	O
use	O
of	O
Oxford	O
Nanopore	O
native	O
barcoding	O
for	O
complete	O
genome	O
assembly	O
The	O
Oxford	O
Nanopore	O
Technologies	O
MinION(TM	O
)	O
is	O
a	O
mobile	O
DNA	O
sequencer	O
that	O
can	O
produce	O
long	O
read	O
sequences	O
with	O
a	O
short	O
turn	O
-	O
around	O
time	O
.	O
Here	O
we	O
report	O
the	O
first	O
demonstration	O
of	O
single	O
contig	O
genome	O
assembly	O
using	O
Oxford	O
Nanopore	O
native	O
barcoding	O
when	O
applied	O
to	O
a	O
multiplexed	O
library	O
of	O
12	O
samples	O
and	O
combined	O
with	O
existing	O
Illumina	O
short	O
-	O
read	O
data	O
.	O
This	O
paves	O
the	O
way	O
for	O
the	O
closure	O
of	O
multiple	O
bacterial	O
genomes	O
from	O
a	O
single	O
MinION(TM	O
)	O
sequencing	O
run	O
,	O
given	O
the	O
availability	O
of	O
existing	O
short	O
-	O
read	O
data	O
.	O
The	O
strain	B-T001
we	O
used	O
,	O
MHO_001	B-T001
,	O
represents	O
the	O
important	O
community	O
-	O
acquired	O
methicillin	O
resistant	O
Staphylococcus	B-T007
aureus	I-T007
lineage	O
USA300	B-T001
.	O
Using	O
a	O
hybrid	O
assembly	O
of	O
existing	O
short	O
read	O
and	O
barcoded	O
long	O
read	O
sequences	O
from	O
multiplexed	O
data	O
,	O
we	O
completed	O
a	O
genome	O
of	O
the	O
S.	B-T007
aureus	I-T007
USA300	B-T001
strain	I-T001
MHO_001	I-T001
.	O
The	O
long	O
-	O
read	O
data	O
represented	O
only	O
~5	O
-	O
10	O
%	O
of	O
an	O
average	O
MinION(TM	O
)	O
run	O
(	O
~7x	O
genomic	O
coverage	O
)	O
,	O
but	O
,	O
using	O
standard	O
tools	O
,	O
this	O
was	O
sufficient	O
to	O
complete	O
the	O
circular	O
chromosome	O
of	O
S.	B-T007
aureus	I-T007
strain	B-T001
MHO_001	I-T001
(	O
2.86	O
Mb	O
)	O
and	O
two	O
complete	O
plasmids	O
(	O
27	O
Kb	O
and	O
3	O
Kb	O
)	O
.	O
Minor	O
differences	O
were	O
noted	O
when	O
compared	O
to	O
USA300	B-T001
reference	O
genome	O
,	O
USA300_FPR3757	O
,	O
including	O
the	O
translocation	O
,	O
loss	O
and	O
gain	O
of	O
mobile	O
genetic	O
elements	O
.	O
Here	O
we	O
demonstrate	O
that	O
MinION(TM	O
)	O
reads	O
,	O
multiplexed	O
using	O
native	O
barcoding	O
,	O
can	O
be	O
used	O
in	O
combination	O
with	O
short	O
-	O
read	O
data	O
,	O
to	O
fully	O
complete	O
a	O
bacterial	O
genome	O
.	O
The	O
ability	O
to	O
complete	O
multiple	O
genomes	O
,	O
for	O
which	O
short	O
-	O
read	O
data	O
is	O
already	O
available	B-T033
,	O
from	O
a	O
single	O
MinION(TM	O
)	O
run	O
is	O
set	O
to	O
impact	O
on	O
our	O
understanding	O
of	O
accessory	O
genome	O
content	O
,	O
plasmid	O
diversity	O
and	O
genome	O
rearrangements	O
.	O
      
Risk	B-T033
factors	I-T033
for	O
hepatitis	B-T047
C	I-T047
virus	I-T047
infection	I-T047
in	O
the	O
Colombian	O
Caribbean	O
coast	O
:	O
A	O
case	O
-	O
control	O
study	O
An	O
estimated	O
6.8	O
-	O
8.9	O
million	O
people	O
are	O
infected	B-T033
with	O
hepatitis	B-T005
C	I-T005
virus	I-T005
in	O
Latin	O
America	O
,	O
of	O
which	O
less	O
than	O
1	O
%	O
receives	O
antiviral	B-T061
treatment	I-T061
.	O
Studies	O
so	O
far	O
in	O
Colombia	O
have	O
attempted	O
to	O
determine	O
the	O
prevalence	O
of	O
the	O
disease	B-T047
in	O
some	O
risk	O
groups	O
,	O
thus	O
preventing	O
the	O
identification	O
of	O
other	O
factors	O
potentially	O
involved	O
in	O
the	O
spread	O
of	O
the	O
infection	O
.	O
To	O
identify	O
traditional	O
and	O
non	O
-	O
traditional	O
risk	B-T033
factors	I-T033
for	O
chronic	B-T047
hepatitis	I-T047
C	I-T047
in	O
the	O
Colombian	O
Caribbean	O
coast	O
.	O
This	O
was	O
a	O
case	O
-	O
control	O
study	O
(	O
1:3	O
)	O
matched	O
by	O
health	O
care	O
provider	O
and	O
age	O
(	O
±	O
10	O
years	O
)	O
conducted	O
at	O
the	O
primary	B-T058
care	I-T058
level	I-T058
of	O
gastroenterology	O
and	O
hepatology	O
outpatient	B-T058
services	I-T058
.	O
All	O
patients	O
with	O
a	O
positive	B-T033
ELISA	B-T059
underwent	O
a	O
confirmatory	O
viral	B-T059
load	I-T059
test	I-T059
.	O
A	O
multivariate	O
logistic	O
regression	O
analysis	O
identified	O
the	O
independent	O
predictors	O
of	O
infection	O
.	O
Blood	B-T061
transfusion	I-T061
(	O
OR	O
=	O
159.2	O
;	O
95	O
%	O
CI	O
:	O
35.4	O
-	O
715	O
;	O
p<0.001	O
)	O
and	O
history	O
of	O
hospitalization	O
before	O
1994	O
(	O
OR	O
=	O
4.7	O
;	O
95	O
%	O
CI	O
:	O
1.3	O
-	O
17.1	O
;	O
p=0.018	O
)	O
were	O
identified	O
as	O
the	O
only	O
two	O
independent	O
predictors	O
of	O
infection	O
.	O
It	O
is	O
necessary	O
to	O
check	O
the	O
reproducibility	O
of	O
these	O
results	O
and	O
to	O
conduct	O
cost	O
-	O
effectiveness	O
studies	O
before	O
recommending	O
their	O
use	O
in	O
the	O
design	O
of	O
new	O
screening	O
strategies	O
.	O
      
Acute	O
Kidney	O
Injury	O
Severity	O
and	O
Long	O
-	O
Term	O
Readmission	B-T058
and	O
Mortality	O
After	O
Cardiac	B-T061
Surgery	I-T061
Acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
is	O
a	O
common	O
complication	O
after	O
cardiac	B-T061
surgery	I-T061
.	O
While	O
AKI	O
severity	O
is	O
known	O
to	O
be	O
associated	O
with	O
increased	O
risk	O
of	O
short	O
-	O
term	O
outcomes	O
,	O
its	O
long	O
-	O
term	O
impact	O
is	O
less	O
well	O
understood	O
.	O
Adult	O
patients	O
undergoing	O
isolated	O
coronary	B-T061
artery	I-T061
bypass	I-T061
graft	I-T061
surgery	I-T061
at	O
eight	O
centers	O
were	O
enrolled	O
into	O
the	O
Northern	O
New	O
England	O
biomarker	O
registry	O
(	O
n	O
=	O
1,610	O
)	O
.	O
Patients	O
were	O
excluded	O
if	O
they	O
had	O
renal	B-T047
failure	I-T047
(	O
n	O
=	O
15	O
)	O
or	O
died	B-T033
during	O
index	B-T058
admission	I-T058
(	O
n	O
=	O
38	O
)	O
.	O
Severity	O
of	O
AKI	O
was	O
defined	O
using	O
the	O
Acute	O
Kidney	O
Injury	O
Network	O
(	O
AKIN	O
)	O
.	O
We	O
linked	O
our	O
cohort	O
to	O
national	O
Medicare	O
and	O
state	O
all	O
-	O
payer	O
claims	O
to	O
ascertain	O
readmissions	B-T058
and	O
to	O
the	O
National	O
Death	O
Index	O
to	O
ascertain	O
survival	O
.	O
Kaplan	O
-	O
Meier	O
and	O
multivariate	O
Cox	O
proportional	O
hazards	O
modeling	O
was	O
conducted	O
for	O
time	O
to	O
readmission	B-T058
and	O
death	B-T033
over	O
5	O
years	O
.	O
Within	O
5	O
years	O
,	O
513	O
patients	O
(	O
33.8	O
%	O
)	O
had	O
AKI	O
with	O
AKIN	O
stage	O
1	O
(	O
29.9	O
%	O
)	O
and	O
stage	O
2	O
to	O
3	O
(	O
3.9	O
%	O
)	O
.	O
There	O
were	O
620	O
readmissions	B-T058
(	O
39.9	O
%	O
)	O
and	O
370	O
deaths	B-T033
(	O
23.8	O
%	O
)	O
.	O
After	O
adjustment	O
,	O
stage	O
1	O
AKI	O
patients	O
had	O
a	O
31	O
%	O
increased	O
risk	O
of	O
readmission	B-T058
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
1.10	O
to	O
1.57	O
)	O
,	O
whereas	O
stage	O
2	O
or	O
3	O
patients	O
had	O
a	O
98	O
%	O
increased	O
risk	O
(	O
95	O
%	O
CI	O
:	O
1.41	O
to	O
2.78	O
)	O
compared	O
with	O
patients	O
having	O
no	B-T033
AKI	O
.	O
Relative	O
to	O
patients	O
without	O
AKI	O
,	O
stage	O
1	O
patients	O
had	O
a	O
56	O
%	O
increased	O
risk	O
of	O
mortality	O
(	O
95	O
%	O
CI	O
:	O
1.14	O
to	O
2.13	O
)	O
,	O
whereas	O
stage	O
2	O
or	O
3	O
patients	O
had	O
a	O
3.5	O
times	O
higher	O
risk	O
(	O
95	O
%	O
CI	O
:	O
2.16	O
to	O
5.60	O
)	O
.	O
Severity	O
of	O
AKI	O
using	O
the	O
AKIN	O
stage	O
criteria	O
is	O
associated	O
with	O
a	O
significantly	O
increased	O
risk	O
of	O
5	O
-	O
year	O
readmission	B-T058
and	O
mortality	O
.	O
Our	O
findings	O
suggest	O
that	O
efforts	O
to	O
reduce	O
AKI	O
in	O
the	O
perioperative	O
period	O
may	O
have	O
a	O
significant	O
long	O
-	O
term	O
impact	O
on	O
patients	O
and	O
payers	O
in	O
reducing	O
mortality	O
and	O
health	B-T058
care	I-T058
utilization	I-T058
.	O
      
Punch	B-T048
injury	O
self	O
-	O
harm	O
in	O
young	O
people	O
Punch	B-T048
injuries	O
are	O
a	O
form	O
of	O
self	O
-	O
harm	O
characterised	O
by	O
the	O
intentional	O
act	O
of	O
striking	O
an	O
object	O
with	O
a	O
closed	O
fist	O
.	O
We	O
aimed	O
to	O
describe	O
the	O
characteristics	O
and	O
trends	O
in	O
young	O
people	O
presenting	O
with	O
injuries	O
sustained	O
via	O
the	O
punch	B-T048
mechanism	O
.	O
A	O
comprehensive	O
retrospective	O
review	O
of	O
medical	O
records	O
was	O
completed	O
of	O
all	O
young	O
people	O
aged	O
10	O
-	O
18	O
years	O
presenting	O
to	O
our	O
Central	O
London	O
Emergency	O
Department	O
over	O
a	O
12	O
-	O
month	O
period	O
.	O
A	O
subset	O
of	O
the	O
total	O
group	O
was	O
identified	O
as	O
the	O
punch	B-T048
injury	O
subgroup	O
.	O
A	O
total	O
of	O
78	O
punch	B-T048
injury	O
presentations	O
were	O
identified	O
.	O
In	O
this	O
subgroup	O
,	O
the	O
male	O
:	O
female	O
ratio	O
is	O
4.57:1	O
;	O
37.18	O
%	O
of	O
presentations	O
were	O
associated	O
with	O
a	O
fracture	O
(	O
n	O
=	O
29	O
)	O
and	O
35.90	O
%	O
(	O
n	O
=	O
28	O
)	O
of	O
patients	O
re	O
-	O
presented	O
following	O
another	O
punch	B-T048
injury	O
,	O
as	O
a	O
victim	B-T033
of	I-T033
violence	I-T033
,	O
or	O
by	O
other	O
psychiatric	O
presentation	O
.	O
In	O
conclusion	O
,	O
a	O
male	B-T033
preponderance	I-T033
was	O
observed	O
,	O
with	O
frequent	O
re	O
-	O
presentations	O
,	O
often	O
in	O
high	B-T033
-	I-T033
risk	I-T033
circumstances	O
.	O
An	O
opportunity	O
for	O
screening	B-T058
,	O
including	O
mental	O
health	O
,	O
social	O
and	O
substance	B-T033
misuse	I-T033
,	O
was	O
identified	O
.	O
Further	O
research	O
is	O
needed	O
to	O
enable	O
targeted	O
effective	O
interventions	B-T058
in	O
this	O
group	O
.	O
      
Measure	B-T058
Up	I-T058
Pressure	I-T058
Down	I-T058
:	I-T058
Provider	I-T058
Toolkit	I-T058
to	O
Improve	O
Hypertension	B-T047
Control	O
Hypertension	B-T047
is	O
one	O
of	O
the	O
most	O
important	O
risk	B-T033
factors	I-T033
for	O
heart	B-T047
disease	I-T047
,	O
stroke	B-T047
,	O
kidney	B-T047
failure	I-T047
,	O
and	O
diabetes	B-T047
complications	I-T047
.	O
Nearly	O
one	O
in	O
three	O
Americans	O
adults	O
has	O
high	B-T047
blood	I-T047
pressure	I-T047
,	O
and	O
the	O
cost	O
associated	O
with	O
treating	B-T061
this	O
condition	B-T047
is	O
staggering	O
.	O
The	O
Measure	B-T058
Up	I-T058
Pressure	I-T058
Down	I-T058
:	I-T058
Provider	I-T058
Toolkit	I-T058
to	O
Improve	O
Hypertension	B-T047
Control	O
is	O
a	O
resource	O
developed	O
by	O
the	O
American	O
Medical	O
Group	O
Foundation	O
in	O
partnership	O
with	O
the	O
American	O
Medical	O
Group	O
Association	O
.	O
The	O
goal	O
of	O
this	O
toolkit	O
is	O
to	O
mobilize	O
health	O
care	O
practitioners	O
to	O
work	O
together	O
through	O
team	O
-based	O
approaches	O
to	O
achieve	O
an	O
80	O
%	O
control	O
rate	O
of	O
high	B-T047
blood	I-T047
pressure	I-T047
among	O
their	O
patient	O
population	O
.	O
The	O
toolkit	O
can	O
be	O
used	O
by	O
health	O
educators	O
,	O
clinic	O
administrators	O
,	O
physicians	O
,	O
students	O
,	O
and	O
other	O
clinic	O
staff	O
as	O
a	O
step	O
-	O
by	O
-	O
step	O
resource	O
for	O
developing	O
the	O
infrastructure	O
needed	O
to	O
better	O
identify	O
and	O
treat	B-T061
individuals	O
with	O
high	B-T047
blood	I-T047
pressure	I-T047
or	O
other	O
chronic	B-T047
conditions	I-T047
.	I-T047
      
Leonurine	O
Attenuates	O
Hyperalgesia	B-T184
in	O
Mice	O
with	O
Induced	O
Adenomyosis	B-T047
BACKGROUND	O
Adenomyosis	B-T047
,	O
defined	O
as	O
the	O
invasion	O
of	O
endometrial	B-T023
glands	I-T023
and	O
stroma	B-T023
into	O
the	O
myometrium	B-T023
,	O
is	O
a	O
common	O
gynecological	B-T047
disorder	I-T047
.	O
In	O
the	O
present	O
study	O
we	O
report	O
on	O
the	O
effect	O
of	O
leonurine	O
on	O
ICR	O
mice	O
with	O
adenomyosis	B-T047
induced	O
by	O
neonatal	O
tamoxifen	B-T121
.	O
MATERIAL	O
AND	O
METHODS	O
After	O
being	O
treated	O
with	O
tamoxifen	B-T121
for	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
,	O
we	O
assessed	O
body	O
weight	O
and	O
pain	B-T184
modulation	O
in	O
mice	O
in	O
hotplate	O
tests	B-T059
.	O
The	O
mice	O
were	O
divided	O
into	O
5	O
groups	O
:	O
a	O
low	O
-	O
dose	O
leonurine	O
treatment	B-T061
group	O
,	O
a	O
high	O
-	O
dose	O
leonurine	O
treatment	B-T061
group	O
,	O
a	O
valproic	B-T121
acid	I-T121
(	O
VPA	B-T121
)	O
treatment	B-T061
group	O
,	O
a	O
vehicle	O
only	O
treatment	B-T061
group	O
,	O
and	O
a	O
blank	B-T033
control	O
group	O
.	O
We	O
evaluated	B-T058
body	O
weight	O
,	O
pain	O
modulation	O
in	O
hotplate	O
tests	B-T059
,	O
and	O
the	O
depth	O
of	O
myometrial	O
infiltration	O
.	O
Immunoreactivity	O
staining	B-T059
of	O
progesterone	O
receptor	O
(	O
PR	O
)	O
,	O
nuclear	O
factor	O
-	O
κB	O
phosphorylated	O
-	O
p65	O
(	O
p	O
-	O
p65	O
)	O
,	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
,	O
and	O
oxytocin	O
receptor	O
(	O
OTR	O
)	O
was	O
evaluated	B-T058
by	O
immunohistochemistry	B-T060
.	O
RESULTS	O
The	O
measurement	O
of	O
the	O
body	O
weight	O
,	O
myometrial	O
infiltration	O
,	O
and	O
pain	O
modulation	O
showed	O
that	O
neonatal	O
tamoxifen	B-T121
treatment	B-T061
led	O
to	O
adenomyosis	B-T047
.	O
Leonurine	O
treatment	B-T061
appeared	O
to	O
decrease	O
hyperalgesia	B-T184
and	O
myometrial	O
infiltration	O
.	O
Immunoreactivity	O
staining	B-T059
showed	O
decreased	O
p	O
-	O
p65	O
,	O
COX-2	O
,	O
and	O
OTR	O
protein	O
expressions	O
.	O
CONCLUSIONS	O
Our	O
results	O
indicate	O
that	O
leonurine	O
attenuates	O
hyperalgesia	B-T184
in	O
mice	O
with	O
induced	O
adenomyosis	B-T047
via	O
down	O
-	O
regulating	O
expressions	O
of	O
p	O
-	O
P65	O
,	O
COX-2	O
,	O
and	O
OTR	O
,	O
and	O
could	O
be	O
beneficial	O
for	O
treating	O
adenomyosis	B-T047
.	O
      
Zebrafish	O
adult	O
pigment	O
stem	O
cells	O
are	O
multipotent	O
and	O
form	O
pigment	O
cells	O
by	O
a	O
progressive	O
fate	O
restriction	O
process	O
:	O
Clonal	B-T060
analysis	I-T060
identifies	O
shared	O
origin	O
of	O
all	O
pigment	O
cell	O
types	O
Skin	B-T033
pigment	I-T033
pattern	O
formation	O
is	O
a	O
paradigmatic	B-T061
example	O
of	O
pattern	O
formation	O
.	O
In	O
zebrafish	O
,	O
the	O
adult	O
body	B-T023
stripes	I-T023
are	O
generated	O
by	O
coordinated	O
rearrangement	O
of	O
three	O
distinct	O
pigment	O
cell	O
-	O
types	O
,	O
black	O
melanocytes	O
,	O
shiny	O
iridophores	O
and	O
yellow	O
xanthophores	O
.	O
A	O
stem	O
cell	O
origin	O
of	O
melanocytes	O
and	O
iridophores	O
has	O
been	O
proposed	O
although	O
the	O
potency	O
of	O
those	O
stem	O
cells	O
has	O
remained	O
unclear	B-T033
.	O
Xanthophores	O
,	O
however	O
,	O
seemed	O
to	O
originate	O
predominantly	O
from	O
proliferation	O
of	O
embryonic	B-T018
xanthophores	O
.	O
Now	O
,	O
data	O
from	O
Singh	O
et	O
al	O
.	O
shows	O
that	O
all	O
three	O
cell	O
-	O
types	O
derive	O
from	O
shared	O
stem	O
cells	O
,	O
and	O
that	O
these	O
cells	O
generate	O
peripheral	O
neural	O
cell	O
-	O
types	O
too	O
.	O
Furthermore	O
,	O
clonal	O
compositions	O
are	O
best	O
explained	O
by	O
a	O
progressive	O
fate	O
restriction	O
model	O
generating	O
the	O
individual	O
cell	O
-	O
types	O
.	O
The	O
numbers	O
of	O
adult	O
pigment	O
stem	O
cells	O
associated	O
with	O
the	O
dorsal	B-T023
root	I-T023
ganglia	I-T023
remain	B-T033
low	O
,	O
but	O
progenitor	O
numbers	O
increase	O
significantly	O
during	O
larval	O
development	O
up	O
to	O
metamorphosis	O
,	O
likely	O
via	O
production	O
of	O
partially	O
restricted	O
progenitors	O
on	O
the	O
spinal	B-T023
nerves	I-T023
.	O
      
Trump	O
's	O
got	O
the	O
right	O
idea	O
I	O
am	O
a	O
US	O
nursing	O
student	O
and	O
feel	O
that	O
Obamacare	O
is	O
a	O
bad	O
idea	O
.	O
I	O
'm	O
disappointed	O
that	O
President	O
Trump	O
was	O
not	B-T033
able	I-T033
to	I-T033
get	I-T033
rid	I-T033
of	I-T033
it	O
last	O
month	O
.	O
      
Evidence	O
that	O
vitronectin	O
is	O
a	O
potent	O
migration	O
-	O
enhancing	O
factor	O
for	O
cancer	O
cells	O
chaperoned	O
by	O
fibrinogen	B-T121
:	O
a	O
novel	O
view	O
of	O
the	O
metastasis	O
of	O
cancer	O
cells	O
to	O
low-	O
fibrinogen	B-T121
lymphatics	O
and	O
body	O
cavities	O
Diluted	O
(	O
1	O
%	O
)	O
plasma	O
induces	O
migration	O
of	O
malignant	O
cell	O
lines	O
much	O
more	O
strongly	O
than	O
potent	O
pro	O
-	O
metastatic	O
factors	O
.	O
To	O
characterize	O
the	O
factor(s	O
)	O
present	O
in	O
diluted	O
plasma	O
responsible	O
for	O
this	O
phenomenon	O
we	O
performed	O
i	O
)	O
heat	O
inactivation	O
,	O
ii	O
)	O
dialysis	O
,	O
iii	O
)	O
proteinase	O
K	O
treatment	O
,	O
and	O
iv	O
)	O
molecular	O
size	O
filtration	O
studies	O
.	O
We	O
found	O
that	O
this	O
remarkable	O
pro	O
-	O
migratory	O
activity	O
of	O
diluted	O
normal	O
plasma	O
is	O
associated	O
with	O
a	O
~50	O
-	O
100	O
-	O
kD	O
protein	O
that	O
interacts	O
with	O
GαI	O
protein	O
-	O
coupled	O
receptors	O
and	O
activates	O
p42/44	O
MAPK	O
and	O
AKT	O
signaling	O
in	O
target	O
cells	O
.	O
Since	O
this	O
pro	O
-	O
migratory	O
activity	O
of	O
1	O
%	O
plasma	O
decreases	O
at	O
higher	O
plasma	O
concentrations	O
(	O
>	O
20	O
%	O
)	O
,	O
but	O
is	O
retained	O
in	O
serum	O
,	O
we	O
hypothesized	O
that	O
fibrinogen	B-T121
may	O
be	O
involved	O
as	O
a	O
chaperone	O
of	O
the	O
protein(s	O
)	O
.	O
To	O
identify	O
the	O
pro	O
-	O
migratory	O
protein(s	O
)	O
present	O
in	O
diluted	O
plasma	O
and	O
fibrinogen	B-T121
-depleted	O
serum	O
,	O
we	O
performed	O
gel	B-T059
filtration	I-T059
and	O
hydrophobic	B-T059
interaction	I-T059
chromatography	I-T059
followed	O
by	O
mass	B-T059
spectrometry	I-T059
analysis	I-T059
.	O
We	O
identified	O
several	O
putative	O
protein	O
candidates	O
that	O
were	O
further	O
tested	O
in	O
in	O
vitro	O
experiments	O
.	O
We	O
found	O
that	O
this	O
pro	O
-	O
migratory	O
factor	O
chaperoned	O
by	O
fibrinogen	B-T121
is	O
vitronectin	O
,	O
which	O
activates	O
uPAR	O
,	O
and	O
that	O
this	O
effect	O
can	O
be	O
inhibited	O
by	O
fibrinogen	B-T121
.	O
These	O
results	O
provide	O
a	O
novel	O
mechanism	O
for	O
the	O
metastasis	O
of	O
cancer	O
cells	O
to	O
lymphatics	O
and	O
body	O
cavities	O
,	O
in	O
which	O
the	O
concentration	O
of	O
fibrinogen	B-T121
is	O
low	O
,	O
and	O
thus	O
suggests	O
that	O
free	O
vitronectin	O
stimulates	O
migration	O
of	O
tumor	O
cells	O
.	O
      
Methylation	O
Analysis	O
of	O
BRCA1	O
and	O
APC	O
in	O
Breast	B-T191
Cancer	I-T191
and	O
It	O
's	O
Relationship	O
to	O
Clinicopathological	O
Features	O
Promoter	O
methylation	O
of	O
tumor	O
suppressor	O
genes	O
is	O
an	O
important	O
epigenetic	O
alteration	O
that	O
occurs	O
in	O
the	O
primary	O
stages	O
of	O
human	O
tumors	B-T191
,	O
including	O
breast	B-T191
cancer	I-T191
.	O
Identification	O
of	O
methylated	O
genes	O
and	O
their	O
relationship	O
to	O
clinical	O
features	O
can	O
contribute	O
to	O
the	O
prognosis	B-T058
and	O
early	B-T060
detection	I-T060
of	O
tumors	B-T191
.	O
In	O
this	O
study	O
,	O
we	O
explored	O
the	O
methylation	O
status	O
of	O
APC	O
and	O
BRCA1	O
genes	O
and	O
their	O
relationship	O
to	O
clinical	O
factors	O
in	O
breast	B-T191
cancer	I-T191
patients	O
.	O
BRCA1	O
and	O
APC	O
promoter	O
methylation	O
was	O
examined	O
by	O
methylation	O
-	O
specific	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MS	O
-	O
MLPA	O
)	O
assay	B-T059
in	O
formalin	O
-	O
fixed	O
paraffin	O
embedded	O
(	O
FFPE	O
)	O
breast	O
tissue	O
from	O
75	O
patients	O
.	O
APC	O
promoter	O
methylation	O
was	O
detected	B-T033
in	O
30.67	O
%	O
breast	B-T191
cancer	I-T191
tissues	O
and	O
BRCA1	O
was	O
methylated	O
in	O
9.33	O
%	O
of	O
breast	B-T191
tumors	I-T191
.	O
Methylation	O
of	O
APC	O
was	O
associated	O
with	O
low	O
histological	O
grade	O
(	O
p	O
=	O
0.006	O
)	O
and	O
methylation	O
of	O
BRCA1	O
was	O
related	O
with	O
lymph	B-T023
node	I-T023
metastasis	O
(	O
p	O
=	O
0.017	O
)	O
.	O
These	O
findings	B-T033
suggest	O
that	O
the	O
methylation	O
status	O
of	O
APC	O
and	O
BRCA1	O
can	O
be	O
a	O
predictive	O
marker	O
for	O
early	B-T060
detection	I-T060
and	O
better	O
management	B-T058
of	O
breast	B-T191
cancer	I-T191
patients	O
.	O
      
Next	O
-	O
Generation	O
Sequencing	O
Approaches	O
to	O
Define	O
the	O
Role	O
of	O
the	O
Autophagy	O
Lysosomal	O
Pathway	O
in	O
Human	O
Disease	B-T047
:	O
The	O
Example	O
of	O
LysoPlex	O
Next	O
-	O
Generation	O
Sequencing	O
(	O
NGS	O
)	O
technologies	O
have	O
deeply	O
changed	O
the	O
throughput	O
of	O
genetic	B-T059
testing	I-T059
allowing	O
analyzing	O
millions	O
of	O
DNA	O
fragments	O
in	O
parallel	O
.	O
One	O
key	O
application	O
is	O
the	O
understanding	O
of	O
genetically	O
heterogeneous	B-T033
and	O
complex	B-T047
diseases	I-T047
where	O
50	O
-	O
100	O
different	O
genes	O
may	O
converge	O
to	O
control	O
the	O
same	O
pathways	O
.	O
These	O
disorders	B-T047
can	O
not	O
be	O
studied	O
using	O
traditional	O
approaches	O
,	O
based	O
on	O
gene	O
-	O
by	O
-	O
gene	O
Sanger	O
sequencing	O
.	O
We	O
have	O
set	O
up	O
an	O
NGS	O
protocol	O
based	O
on	O
a	O
specific	O
selection	O
of	O
DNA	O
regions	O
belonging	O
to	O
about	O
900	O
genes	O
of	O
the	O
autophagy	O
-	O
lysosomal	O
(	O
ALP	O
)	O
pathway	O
.	O
We	O
here	O
specify	O
all	O
the	O
technical	O
steps	O
and	O
challenges	B-T058
of	O
our	O
protocol	O
,	O
named	O
LysoPlex	O
.	O
This	O
is	O
based	O
on	O
the	O
Haloplex	O
technology	O
and	O
together	O
with	O
high	O
-	O
coverage	O
sequencing	O
empowers	O
a	O
high	O
and	O
uniform	O
coverage	O
of	O
ALP	O
genes	O
.	O
LysoPlex	O
outplays	O
other	O
NGS	O
applications	O
in	O
sensitivity	O
and	O
specificity	O
,	O
providing	O
an	O
accurate	O
picture	O
of	O
all	O
variations	O
in	O
ALP	O
genes	O
.	O
      
Joint	O
model	O
imputation	O
to	O
estimate	O
the	O
treatment	B-T033
effect	I-T033
on	O
long	O
-	O
term	O
survival	O
using	O
auxiliary	O
events	O
Clinical	O
trial	O
duration	O
may	O
be	O
a	O
concern	O
in	O
clinical	O
research	O
,	O
especially	O
in	O
cancer	O
trials	O
where	O
the	O
endpoint	O
is	O
overall	O
survival	O
.	O
A	O
surrogate	O
endpoint	O
can	O
be	O
used	O
as	O
an	O
auxiliary	O
variable	O
to	O
analyze	O
the	O
treatment	B-T033
effect	I-T033
earlier	O
.	O
At	O
an	O
early	O
time	O
point	O
,	O
the	O
high	O
number	O
of	O
censored	O
observations	O
can	O
be	O
compensated	O
by	O
the	O
imputation	O
of	O
the	O
unobserved	B-T033
deaths	B-T033
times	O
.	O
We	O
propose	O
to	O
use	O
predictions	O
of	O
the	O
risk	O
of	O
death	O
from	O
a	O
joint	O
model	O
for	O
a	O
recurrent	O
event	O
and	O
a	O
terminal	O
event	O
,	O
which	O
account	O
for	O
disease	B-T047
relapse	I-T047
information	O
.	O
Two	O
imputation	O
methods	O
were	O
compared	O
:	O
sampling	O
from	O
the	O
estimated	O
parametric	O
distribution	O
of	O
the	O
survival	O
time	O
and	O
sampling	O
using	O
its	O
nonparametric	O
estimation	O
.	O
The	O
treatment	B-T033
effect	I-T033
and	O
its	O
standard	O
error	O
were	O
estimated	O
via	O
multiple	O
imputations	O
.	O
The	O
performances	O
of	O
the	O
two	O
methods	O
were	O
compared	O
in	O
terms	O
of	O
bias	O
in	O
the	O
estimates	O
,	O
standard	O
errors	O
,	O
and	O
coverage	O
probability	O
.	O
Both	O
methods	O
were	O
then	O
retrospectively	O
applied	O
to	O
two	O
randomized	O
clinical	O
trials	O
studying	O
the	O
effect	O
of	O
adjuvant	O
chemotherapy	B-T061
in	O
breast	B-T191
cancer	I-T191
patients	O
.	O
      
Quantifying	O
Nonlinear	O
Contributions	O
to	O
Cortical	B-T059
Responses	I-T059
Evoked	I-T059
by	O
Continuous	B-T061
Wrist	I-T061
Manipulation	I-T061
Cortical	B-T059
responses	I-T059
to	O
continuous	O
stimuli	O
as	O
recorded	O
using	O
either	O
magneto-	B-T060
or	O
electroencephalography	B-T060
(	O
EEG	B-T060
)	O
have	O
shown	O
power	O
at	O
harmonics	O
of	O
the	O
stimulated	O
frequency	O
,	O
indicating	O
nonlinear	O
behavior	O
.	O
Even	O
though	O
the	O
selection	O
of	O
analysis	O
techniques	O
depends	O
on	O
the	O
linearity	O
of	O
the	O
system	O
under	O
study	O
,	O
the	O
importance	O
of	O
nonlinear	O
contributions	O
to	O
cortical	B-T059
responses	I-T059
has	O
not	O
been	O
formally	O
addressed	O
.	O
The	O
goal	O
of	O
this	O
paper	O
is	O
to	O
quantify	O
the	O
nonlinear	O
contributions	O
to	O
the	O
cortical	B-T059
response	I-T059
obtained	O
from	O
continuous	O
sensory	B-T061
stimulation	I-T061
.	O
EEG	B-T060
was	O
used	O
to	O
record	O
the	O
cortical	B-T059
response	I-T059
evoked	I-T059
by	O
continuous	B-T033
movement	I-T033
of	I-T033
the	I-T033
wrist	I-T033
joint	I-T033
of	O
healthy	O
subjects	O
applied	O
with	O
a	O
robotic	O
manipulator	O
.	O
Multisine	O
stimulus	O
signals	O
(	O
i.e.	O
,	O
the	O
sum	O
of	O
several	O
sinusoids	O
)	O
elicit	O
a	O
periodic	O
cortical	B-T059
response	I-T059
and	O
allow	O
to	O
assess	O
the	O
nonlinear	O
contributions	O
to	O
the	O
response	O
.	O
Wrist	B-T061
dynamics	I-T061
(	O
relation	O
between	O
joint	O
angle	O
and	O
torque	O
)	O
were	O
successfully	O
linearized	O
,	O
explaining	O
99	O
%	O
of	O
the	O
response	O
.	O
In	O
contrast	O
,	O
the	O
cortical	B-T059
response	I-T059
revealed	O
a	O
highly	O
nonlinear	O
relation	O
;	O
where	O
most	O
power	O
(	O
∼	O
80	O
%	O
)	O
occurred	O
at	O
non	O
-	O
stimulated	O
frequencies	O
.	O
Moreover	O
,	O
only	O
10	O
%	O
of	O
the	O
response	O
could	O
be	O
explained	O
using	O
a	O
nonparametric	O
linear	O
model	O
.	O
These	O
results	B-T033
indicate	O
that	O
the	O
recorded	O
evoked	B-T059
cortical	I-T059
responses	I-T059
are	O
governed	O
by	O
nonlinearities	O
and	O
that	O
linear	O
methods	O
do	O
not	O
suffice	O
when	O
describing	O
the	O
relation	O
between	O
mechanical	O
stimulus	O
and	O
cortical	B-T033
response	I-T033
.	O
      
Worldwide	O
Occurrence	O
of	O
Mycotoxins	O
in	O
Cereals	O
and	O
Cereal	O
-	O
Derived	O
Food	O
Products	O
:	O
Public	O
Health	O
Perspectives	O
of	O
Their	O
Co	O
-	O
occurrence	O
Cereal	O
grains	O
and	O
their	O
processed	O
food	O
products	O
are	O
frequently	O
contaminated	O
with	O
mycotoxins	O
.	O
Among	O
many	O
,	O
five	O
major	O
mycotoxins	O
of	O
aflatoxins	O
,	O
ochratoxins	O
,	O
fumonisins	O
,	O
deoxynivalenol	O
,	O
and	O
zearalenone	O
are	O
of	O
significant	O
public	O
health	O
concern	O
as	O
they	O
can	O
cause	O
adverse	O
effects	O
in	O
humans	O
.	O
Being	O
airborne	O
or	O
soilborne	O
,	O
the	O
cosmopolitan	O
nature	O
of	O
mycotoxigenic	O
fungi	O
contribute	O
to	O
the	O
worldwide	O
occurrence	O
of	O
mycotoxins	O
.	O
On	O
the	O
basis	O
of	O
the	O
global	O
occurrence	O
data	O
reported	B-T058
during	O
the	O
past	O
10	O
years	O
,	O
the	O
incidences	O
and	O
maximum	O
levels	O
in	O
raw	O
cereal	O
grains	O
were	O
55	O
%	O
and	O
1642	O
μg	O
/	O
kg	O
for	O
aflatoxins	O
,	O
29	O
%	O
and	O
1164	O
μg	O
/	O
kg	O
for	O
ochratoxin	B-T121
A	I-T121
,	O
61	O
%	O
and	O
71,121	O
μg	O
/	O
kg	O
for	O
fumonisins	O
,	O
58	O
%	O
and	O
41,157	O
μg	O
/	O
kg	O
,	O
for	O
deoxynivalenol	O
,	O
and	O
46	O
%	O
and	O
3049	O
μg	O
/	O
kg	O
for	O
zearalenone	O
.	O
The	O
concentrations	O
of	O
mycotoxins	O
tend	O
to	O
be	O
lower	O
in	O
processed	O
food	O
products	O
;	O
the	O
incidences	O
varied	O
depending	O
on	O
the	O
individual	O
mycotoxins	O
,	O
possibly	O
due	O
to	O
the	O
varying	O
stability	O
during	O
processing	O
and	O
distribution	O
of	O
mycotoxins	O
.	O
It	O
should	O
be	O
noted	O
that	O
more	O
than	O
one	O
mycotoxin	O
,	O
produced	O
by	O
a	O
single	O
or	O
several	O
fungal	O
species	O
,	O
may	O
occur	O
in	O
various	O
combinations	O
in	O
a	O
given	O
sample	O
or	O
food	O
.	O
Most	O
studies	O
reported	B-T058
additive	O
or	O
synergistic	O
effects	O
,	O
suggesting	O
that	O
these	O
mixtures	O
may	O
pose	O
a	O
significant	O
threat	O
to	O
public	O
health	O
,	O
particularly	O
to	O
infants	O
and	O
young	O
children	O
.	O
Therefore	O
,	O
information	O
on	O
the	O
co	O
-	O
occurrence	O
of	O
mycotoxins	O
and	O
their	O
interactive	O
toxicity	O
is	O
summarized	O
in	O
this	O
paper	O
.	O
      
A	O
primer	O
on	O
intraosseous	O
access	O
:	O
History	B-T033
,	O
clinical	B-T033
considerations	I-T033
,	O
and	O
current	O
devices	O
Intraosseous	O
(	O
IO	O
)	O
access	O
is	O
a	O
method	O
recommended	O
by	O
the	O
American	O
Heart	O
Association	O
and	O
the	O
European	O
Resuscitation	O
Council	O
to	O
administer	O
resuscitative	B-T121
drugs	I-T121
and	O
fluids	O
when	O
intravenous	O
(	O
IV	O
)	O
access	O
can	O
not	O
be	O
rapidly	O
or	O
easily	O
obtained	O
.	O
Many	O
clinicians	O
have	O
limited	O
knowledge	O
or	O
experience	O
with	O
the	O
IO	O
route	O
.	O
The	O
purpose	O
of	O
this	O
review	O
was	O
to	O
provide	O
the	O
reader	O
with	O
a	O
succinct	O
review	O
of	O
the	O
history	B-T033
,	O
clinical	B-T033
considerations	I-T033
,	O
and	O
devices	O
associated	O
with	O
IO	O
access	O
.	O
Narrative	O
review	O
.	O
University	O
-	O
based	O
academic	O
research	O
cell	O
.	O
Not	O
applicable	O
.	O
Not	O
applicable	O
.	O
IO	O
access	O
is	O
a	O
lifesaving	O
bridge	O
to	O
definitive	O
vascular	O
access	O
that	O
may	O
be	O
considered	O
when	O
an	O
IV	O
can	O
not	O
be	O
rapidly	O
attained	O
and	O
the	O
patient	O
's	O
outcome	O
may	O
be	O
negatively	B-T033
affected	I-T033
without	O
prompt	O
circulatory	O
access	O
.	O
The	O
IO	O
route	O
has	O
few	O
contraindications	O
for	O
use	O
and	O
a	O
low	O
rate	O
of	O
serious	O
complications	O
.	O
Multiple	O
manual	O
and	O
powered	O
devices	O
that	O
may	O
be	O
placed	O
in	O
several	O
anatomic	O
sites	O
are	O
commercially	O
available	O
.	O
All	O
clinicians	O
who	O
provide	O
acute	B-T058
care	I-T058
or	O
respond	O
to	O
cardiovascular	O
emergencies	O
should	O
obtain	O
training	O
and	O
maintain	O
proficiency	O
in	O
placing	O
and	O
using	O
IO	O
devices	O
as	O
the	O
IO	O
route	O
is	O
recommended	O
by	O
the	O
major	O
resuscitation	O
organizations	O
as	O
the	O
preferred	O
route	O
of	O
infusion	O
when	O
rapid	O
,	O
reliable	O
IV	O
access	O
is	O
unavailable	O
.	O
      
Us3	O
and	O
Us9	O
proteins	O
contribute	O
to	O
the	O
stromal	B-T033
invasion	I-T033
of	O
bovine	B-T005
herpesvirus	I-T005
1	I-T005
in	O
the	O
respiratory	O
mucosa	O
Bovine	B-T047
herpesvirus	I-T047
1	I-T047
(	I-T047
BHV-1	I-T047
)	I-T047
infection	I-T047
may	O
lead	O
to	O
conjunctivitis	B-T047
,	O
upper	B-T023
respiratory	I-T023
tract	I-T023
problems	B-T033
,	O
pneumonia	B-T047
,	O
genital	B-T047
disorders	I-T047
and	O
abortion	B-T033
.	O
BHV-1	B-T005
is	O
able	O
to	O
spread	O
quickly	O
in	O
a	O
plaque	B-T033
-wise	O
manner	O
and	O
invade	O
by	O
breaching	O
the	O
basement	O
membrane	O
(	O
BM	O
)	O
barrier	O
in	O
the	O
respiratory	O
mucosa	O
.	O
BHV-1	B-T005
Us3	O
,	O
a	O
serine	O
/	O
threonine	O
kinase	O
,	O
induces	O
a	O
dramatic	O
cytoskeletal	O
reorganization	O
and	O
BHV-1	B-T005
Us9	O
,	O
a	O
tail	O
-	O
anchored	O
membrane	O
protein	O
,	O
is	O
required	O
for	O
axonal	O
transport	O
of	O
viruses	B-T005
in	O
neurons	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
Us3	O
and	O
Us9	O
during	O
BHV-1	B-T047
infection	I-T047
in	O
the	O
respiratory	O
mucosa	O
.	O
First	O
,	O
we	O
constructed	O
and	O
characterized	O
BHV-1	B-T005
Us3	O
null	B-T005
,	O
Us9	O
null	B-T005
and	O
revertant	B-T005
viruses	I-T005
.	O
Then	O
,	O
we	O
analysed	O
the	O
viral	O
replication	O
and	O
plaque	B-T033
size	O
(	O
latitude	O
)	O
in	O
Madin	O
-	O
Darby	O
bovine	O
kidney	O
(	O
MDBK	O
)	O
cells	O
and	O
the	O
respiratory	O
mucosa	O
as	O
well	O
as	O
viral	O
penetration	O
depth	O
underneath	O
the	O
BM	O
of	O
the	O
respiratory	O
mucosa	O
when	O
inoculated	B-T061
with	O
these	O
recombinant	B-T005
viruses	I-T005
.	O
Knockout	B-T050
of	O
Us3	O
resulted	O
in	O
a	O
1	O
log10	O
reduction	O
in	O
viral	O
titre	O
and	O
plaque	B-T033
size	O
(	O
latitude	O
)	O
in	O
MDBK	O
cells	O
and	O
the	O
trachea	B-T023
mucosa	I-T023
.	O
There	O
were	O
no	B-T033
defects	O
in	O
the	O
cell	O
-	O
to	O
-	O
cell	O
spread	O
observed	O
for	O
BHV-1	B-T005
Us9	O
null	B-T005
virus	I-T005
.	O
Both	O
BHV-1	B-T005
Us3	O
null	B-T005
and	O
Us9	O
null	B-T005
viruses	I-T005
showed	O
a	O
significant	O
reduction	O
of	O
plaque	B-T033
penetration	O
underneath	O
the	O
BM	O
;	O
however	O
,	O
penetration	O
was	O
not	O
completely	O
inhibited	O
.	O
In	O
conclusion	O
,	O
the	O
current	O
findings	O
demonstrated	O
that	O
Us3	O
and	O
Us9	O
play	O
an	O
important	O
role	O
in	O
the	O
invasion	B-T033
of	O
BHV-1	B-T005
through	O
the	O
BM	O
of	O
the	O
respiratory	O
mucosa	O
,	O
which	O
shows	O
the	O
way	O
forward	O
for	O
research	O
-based	O
attenuation	O
of	O
viruses	B-T005
in	O
order	O
to	O
make	O
safer	O
and	O
better	O
-	O
performing	O
vaccines	B-T121
.	O
      
Determination	O
of	O
the	O
Mutant	B-T061
Prevention	I-T061
Concentration	I-T061
and	O
the	O
Mutant	O
Selection	O
Window	O
of	O
Topical	B-T121
Antimicrobial	I-T121
Agents	I-T121
against	O
Propionibacterium	B-T007
acnes	I-T007
Determination	O
of	O
the	O
mutant	B-T061
prevention	I-T061
concentration	I-T061
(	O
MPC	B-T061
)	O
and	O
the	O
mutant	O
selection	O
window	O
(	O
MSW	O
)	O
of	O
antimicrobial	B-T121
agents	I-T121
used	O
to	O
treat	O
pathogenic	B-T001
bacteria	B-T007
is	O
important	O
in	O
order	O
to	O
apply	O
effective	O
antimicrobial	B-T121
therapies	B-T061
.	O
Here	O
,	O
we	O
determined	O
the	O
MPCs	B-T061
of	O
the	O
major	O
topical	B-T121
antimicrobial	I-T121
agents	I-T121
against	O
Propionibacterium	B-T007
acnes	I-T007
and	O
Staphylococcus	B-T007
aureus	I-T007
which	O
cause	O
skin	B-T047
infections	I-T047
and	O
compared	O
their	O
MSWs	O
.	O
Among	O
the	O
MPCs	B-T061
of	O
nadifloxacin	B-T195
and	O
clindamycin	B-T195
,	O
the	O
clindamycin	B-T195
MPC	B-T061
was	O
determined	O
to	O
be	O
the	O
lowest	O
against	O
P.	B-T007
acnes	I-T007
.	O
In	O
contrast	O
,	O
the	O
nadifloxacin	B-T195
MPC	B-T061
was	O
the	O
lowest	O
against	O
S.	B-T007
aureus	I-T007
.	O
Calculations	O
based	O
on	O
the	O
minimum	O
inhibitory	O
concentrations	O
and	O
MPCs	B-T061
showed	O
that	O
clindamycin	B-T195
has	O
the	O
lowest	O
MSW	O
against	O
both	O
P.	B-T007
acnes	I-T007
and	O
S.	B-T007
aureus	I-T007
.	O
Nadifloxacin	B-T195
MSWs	O
were	O
4	O
-	O
fold	O
higher	O
against	O
P.	B-T007
acnes	I-T007
than	O
against	O
S.	B-T007
aureus	I-T007
.	O
It	O
is	O
more	O
likely	O
for	O
P.	B-T007
acnes	I-T007
to	O
acquire	O
resistance	O
to	O
fluoroquinolones	B-T121
than	O
S.	B-T007
aureus	I-T007
.	O
Therefore	O
,	O
topical	B-T061
application	I-T061
of	O
clindamycin	B-T195
contributes	O
very	O
little	O
to	O
the	O
emergence	O
of	O
resistant	O
P.	B-T007
acnes	I-T007
and	O
S.	B-T007
aureus	I-T007
strains	O
.	O
      
Altered	O
interregional	O
correlations	O
between	O
serotonin	O
transporter	O
availability	O
and	O
cerebral	B-T121
glucose	I-T121
metabolism	O
in	O
schizophrenia	B-T048
:	O
A	O
high	B-T060
-	I-T060
resolution	I-T060
PET	I-T060
study	O
using	O
[	O
(	O
11)C]DASB	O
and	O
[	O
(	O
18)F]FDG	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
patterns	O
of	O
interregional	O
correlations	O
of	O
serotonin	O
transporter	O
(	O
SERT	O
)	O
availability	O
with	O
glucose	O
metabolism	O
using	O
7	B-T060
-	I-T060
Tesla	I-T060
magnetic	I-T060
resonance	I-T060
imaging	I-T060
(	O
MRI	B-T060
)	O
and	O
high	B-T060
-	I-T060
resolution	I-T060
positron	I-T060
emission	I-T060
tomography	I-T060
(	O
PET	B-T060
)	O
with	O
(	O
11)C-3	O
-	O
amino-4-(2	O
-	O
dimethylaminomethylphenylthio)benzonitrile	O
(	O
[	O
(	O
11)C]DASB	O
)	O
and	O
[	O
(	O
18)F]fluorodeoxyglucose	O
(	O
[	O
(	O
18)F]FDG	O
)	O
in	O
antipsychotic	O
-	O
free	O
patients	O
with	O
schizophrenia	B-T048
in	O
order	O
to	O
shed	O
new	O
light	O
on	O
the	O
disrupted	O
functional	O
connectivity	O
in	O
schizophrenia	B-T048
.	O
Nineteen	O
patients	O
with	O
schizophrenia	B-T048
and	O
18	O
healthy	O
controls	O
underwent	O
high	B-T060
-	I-T060
resolution	I-T060
PET	I-T060
and	O
MRI	B-T060
.	O
The	O
binding	O
potential	O
(	O
BPND	O
)	O
of	O
[	O
(	O
11)C]DASB	O
and	O
standardized	O
uptake	O
value	O
ratio	O
(	O
SUVR	O
)	O
of	O
[	O
(	O
18)F]FDG	O
were	O
obtained	O
.	O
In	O
SERT	O
availability	O
,	O
the	O
region	O
of	O
interest	O
(	O
ROI)-based	O
analyses	O
showed	O
no	O
significant	O
group	O
differences	O
in	O
any	O
region	O
,	O
except	O
for	O
the	O
anterior	O
hippocampus	B-T023
where	O
the	O
SERT	O
availability	O
was	O
lower	O
in	O
patients	O
with	O
schizophrenia	B-T048
than	O
in	O
controls	O
.	O
The	O
ROI	O
-	O
and	O
voxel	O
-based	O
analyses	O
revealed	O
that	O
the	O
[	O
(	O
18)F]FDG	O
SUVR	O
values	O
were	O
significantly	O
lower	O
in	O
patients	O
than	O
in	O
controls	O
in	O
the	O
right	B-T023
superior	I-T023
frontal	I-T023
gyrus	I-T023
and	O
medial	O
part	O
of	O
the	O
left	B-T023
superior	I-T023
frontal	I-T023
gyrus	I-T023
.	O
Regarding	O
the	O
interregional	O
correlations	O
of	O
[	O
(	O
11)C]DASB	O
BPND	O
with	O
[	O
(	O
18)F]FDG	O
SUVR	O
,	O
more	O
widespread	O
positive	B-T033
correlations	O
across	O
the	O
brain	O
regions	O
were	O
observed	O
in	O
control	O
subjects	O
than	O
in	O
patients	O
with	O
schizophrenia	B-T048
.	O
Notably	O
,	O
the	O
patients	O
and	O
control	O
subjects	O
showed	O
statistically	O
significant	O
differences	O
in	O
correlations	O
between	O
the	O
SERT	O
availability	O
in	O
the	O
parietal	B-T023
and	O
temporal	B-T023
cortices	I-T023
and	O
the	O
glucose	O
metabolism	O
in	O
the	O
posterior	B-T023
cingulate	I-T023
cortex	I-T023
.	O
These	O
results	O
suggest	O
abnormal	B-T033
functional	O
connectivity	O
between	O
the	O
higher	O
-	O
order	O
cortical	O
regions	O
in	O
schizophrenia	B-T048
and	O
a	O
possible	O
important	O
role	O
of	O
the	O
posterior	B-T023
cingulate	I-T023
gyrus	I-T023
and	O
its	O
related	O
circuitry	O
in	O
the	O
pathophysiology	O
of	O
schizophrenia	B-T048
.	O
      
Surviving	O
moment	O
to	O
moment	O
:	O
The	O
experience	O
of	O
living	O
in	O
a	O
state	B-T033
of	O
ambivalence	O
for	O
those	O
with	O
recurrent	O
suicide	B-T033
attempts	I-T033
This	O
qualitative	O
study	O
aimed	O
to	O
capture	O
the	O
experience	O
of	O
living	O
in	O
the	O
ambivalent	O
space	O
between	O
life	O
and	O
death	O
for	O
adults	O
with	O
recurrent	O
suicide	B-T033
attempts	I-T033
(	O
RSA	B-T033
)	O
.	O
It	O
sought	O
to	O
expand	O
upon	O
an	O
earlier	O
study	O
that	O
explored	O
the	O
processes	O
involved	O
in	O
transitioning	O
away	O
from	O
RSA	B-T033
among	O
adults	O
,	O
which	O
revealed	O
that	O
occupying	O
this	O
ambivalent	O
space	O
is	O
a	O
crucial	O
part	O
of	O
this	O
process	O
.	O
Interpretive	O
phenomenological	O
analysis	O
(	O
IPA	O
)	O
was	O
used	O
.	O
This	O
methodology	O
was	O
designed	O
to	O
explore	O
the	O
lived	O
experiences	O
and	O
meaning	O
making	O
and	O
enabled	O
interpretation	O
of	O
the	O
multidimensional	O
subjective	O
experiences	O
of	O
RSA	B-T033
participants	O
.	O
In	O
-	O
depth	O
semi	O
-	O
structured	O
interviews	O
were	O
conducted	O
with	O
eight	O
adult	O
women	O
with	O
a	O
history	O
of	O
RSA	B-T033
who	O
had	O
participated	O
in	O
a	O
therapeutic	B-T061
intervention	I-T061
at	O
the	O
research	O
site	O
(	O
Skills	O
for	O
Safer	O
Living	O
:	O
A	O
Psychosocial	O
/	O
Psychoeducational	O
Intervention	O
for	O
People	O
with	O
Recurrent	O
Suicide	B-T033
Attempts	I-T033
[	O
SfSL	O
/	O
PISA	B-T033
]	O
)	O
.	O
The	O
six	O
stages	O
of	O
IPA	O
were	O
followed	O
to	O
analyse	O
the	O
interview	B-T058
data	O
.	O
Analysis	O
revealed	O
the	O
superordinate	O
theme	O
,	O
'	O
surviving	O
moment	O
to	O
moment	O
'	O
,	O
which	O
refers	O
to	O
a	O
precarious	B-T033
state	I-T033
of	O
making	O
decisions	O
about	O
one	O
's	O
life	O
and	O
destiny	O
on	O
a	O
moment	O
-to-	O
moment	O
basis	O
without	O
clear	O
commitment	O
to	O
either	O
life	O
or	O
death	O
.	O
Two	O
subordinate	O
themes	O
were	O
identified	O
:	O
'	O
deciding	O
not	O
to	O
die	B-T033
in	O
the	O
moment	O
'	O
when	O
the	O
participants	O
were	O
more	O
invested	O
in	O
dying	B-T033
than	O
living	O
and	O
'	O
deciding	O
to	O
live	O
in	O
the	O
moment	O
'	O
when	O
they	O
were	O
more	O
invested	O
in	O
living	O
than	O
dying	B-T033
.	O
The	O
study	O
illuminated	O
the	O
complex	O
process	O
of	O
making	O
decisions	O
about	O
ones	O
'	O
destiny	O
on	O
a	O
moment	O
-to-	O
moment	O
basis	O
.	O
It	O
revealed	O
the	O
torment	O
experienced	O
when	O
occupying	O
this	O
state	B-T033
,	O
while	O
paradoxically	O
,	O
also	O
revealing	O
how	O
indecision	B-T033
about	O
life	O
and	O
death	O
provided	O
a	O
lifeline	O
opportunity	O
for	O
those	O
with	O
RSA	B-T033
.	O
Clinicians	O
who	O
recognize	O
the	O
subtle	O
distinctions	O
associated	O
with	O
this	O
in	O
-	O
between	O
state	B-T033
can	O
tailor	O
their	O
interventions	B-T061
accordingly	O
.	O
Surviving	O
moment	O
to	O
moment	O
is	O
characterized	O
by	O
a	O
state	B-T033
of	O
emotional	B-T033
flux	I-T033
and	O
uncertainty	B-T033
about	O
one	O
's	O
destiny	O
,	O
where	O
the	O
person	O
has	O
not	O
fully	O
committed	O
to	O
either	O
life	O
or	O
death	O
.	O
Within	O
this	O
state	B-T033
,	O
there	O
are	O
two	O
interlinked	O
subprocesses	O
,	O
whereby	O
the	O
person	O
is	O
leaning	O
more	O
towards	O
death	O
or	O
life	O
.	O
A	O
critical	O
feature	O
in	O
working	O
with	O
this	O
client	O
group	O
is	O
to	O
recognize	O
their	O
ambiguity	O
and	O
the	O
fragility	B-T033
and	O
temporality	O
of	O
their	O
decisions	O
about	O
their	O
destiny	O
.	O
The	O
practitioner	O
has	O
an	O
opportunity	O
to	O
be	O
a	O
catalyst	O
in	O
the	O
momentum	O
towards	O
life	O
by	O
demonstrating	O
understanding	O
of	O
this	O
survival	O
struggle	B-T033
and	O
tailoring	B-T061
intervention	I-T061
to	O
fit	O
with	O
the	O
nuanced	O
processes	O
within	O
this	O
state	B-T033
.	O
      
Committee	O
Opinion	O
No	O
.	O
701	O
Summary	O
:	O
Choosing	O
The	O
Route	O
Of	O
Hysterectomy	B-T061
For	O
Benign	O
Disease	B-T047
Hysterectomy	B-T061
is	O
one	O
of	O
the	O
most	O
frequently	O
performed	O
surgical	B-T061
procedures	I-T061
in	O
the	O
United	O
States	O
.	O
Selection	O
of	O
the	O
route	O
of	O
hysterectomy	B-T061
for	O
benign	O
causes	O
can	O
be	O
influenced	O
by	O
the	O
size	O
and	O
shape	O
of	O
the	O
vagina	B-T023
and	O
uterus	B-T023
;	O
accessibility	O
to	O
the	O
uterus	B-T023
;	O
extent	O
of	O
extrauterine	B-T047
disease	I-T047
;	O
the	O
need	O
for	O
concurrent	O
procedures	O
;	O
surgeon	O
training	O
and	O
experience	O
;	O
average	O
case	O
volume	O
;	O
available	O
hospital	O
technology	B-T058
,	O
devices	O
,	O
and	O
support	O
;	O
whether	O
the	O
case	O
is	O
emergent	O
or	O
scheduled	O
;	O
and	O
preference	O
of	O
the	O
informed	O
patient	O
.	O
Vaginal	B-T061
and	O
laparoscopic	B-T061
procedures	I-T061
are	O
considered	O
"	O
minimally	O
invasive	O
"	O
surgical	O
approaches	O
because	O
they	O
do	O
not	O
require	O
a	O
large	O
abdominal	B-T061
incision	I-T061
and	O
,	O
thus	O
,	O
typically	O
are	O
associated	O
with	O
shortened	O
hospitalization	B-T058
and	O
postoperative	B-T033
recovery	I-T033
times	I-T033
compared	O
with	O
open	O
abdominal	B-T061
hysterectomy	I-T061
.	O
Minimally	O
invasive	O
approaches	O
to	O
hysterectomy	B-T061
should	O
be	O
performed	O
,	O
whenever	O
feasible	O
,	O
based	O
on	O
their	O
well	O
-	O
documented	O
advantages	O
over	O
abdominal	B-T061
hysterectomy	I-T061
.	O
The	O
vaginal	O
approach	O
is	O
preferred	O
among	O
the	O
minimally	O
invasive	O
approaches	O
.	O
Laparoscopic	B-T061
hysterectomy	I-T061
is	O
a	O
preferable	O
alternative	O
to	O
open	O
abdominal	B-T061
hysterectomy	I-T061
for	O
those	O
patients	O
in	O
whom	O
a	O
vaginal	B-T061
hysterectomy	I-T061
is	O
not	O
indicated	O
or	O
feasible	O
.	O
Although	O
minimally	O
invasive	O
approaches	O
to	O
hysterectomy	B-T061
are	O
the	O
preferred	O
route	O
,	O
open	B-T061
abdominal	B-T061
hysterectomy	I-T061
remains	O
an	O
important	O
surgical	O
option	O
for	O
some	O
patients	O
.	O
The	O
obstetrician	O
-	O
gynecologist	O
should	O
discuss	O
the	O
options	O
with	O
patients	O
and	O
make	O
clear	O
recommendations	O
on	O
which	O
route	O
of	O
hysterectomy	B-T061
will	O
maximize	O
benefits	O
and	O
minimize	O
risks	O
given	O
the	O
specific	O
clinical	O
situation	O
.	O
The	O
relative	O
advantages	O
and	O
disadvantages	O
of	O
the	O
approaches	O
to	O
hysterectomy	B-T061
should	O
be	O
discussed	O
in	O
the	O
context	O
of	O
the	O
patient	O
's	O
values	O
and	O
preferences	O
,	O
and	O
the	O
patient	O
and	O
health	O
care	O
provider	O
should	O
together	O
determine	O
the	O
best	O
course	O
of	O
action	O
after	O
this	O
discussion	O
.	O
      
Psychogenic	B-T048
non	I-T048
-	I-T048
epileptic	I-T048
seizure	I-T048
in	O
patients	O
with	O
intellectual	B-T048
disability	I-T048
with	O
special	O
focus	O
on	O
choice	O
of	O
therapeutic	B-T061
intervention	I-T061
There	O
have	O
been	O
a	O
number	O
of	O
studies	O
exploring	O
treatments	B-T061
for	O
psychogenic	B-T048
non	I-T048
-	I-T048
epileptic	I-T048
seizure	I-T048
(	O
PNES	B-T048
)	O
but	O
largely	O
neglecting	B-T033
the	O
sizable	O
subgroup	O
of	O
patients	O
with	O
intellectual	B-T048
disability	I-T048
(	O
ID	B-T048
)	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
attempted	O
to	O
demonstrate	O
effects	O
and	O
preferred	O
modes	O
of	O
therapeutic	B-T061
intervention	I-T061
in	O
PNES	B-T048
patients	O
with	O
ID	B-T048
being	O
treated	O
at	O
a	O
Japanese	O
municipal	O
center	O
with	O
a	O
short	O
referral	B-T058
chain	I-T058
.	O
We	O
examined	B-T033
46	O
PNES	B-T048
patients	O
with	O
ID	B-T048
(	O
ID	B-T048
group	O
)	O
and	O
106	O
PNES	B-T048
patients	O
without	O
ID	B-T048
(	O
non	B-T033
-	I-T033
ID	I-T033
group	O
)	O
retrospectively	O
in	O
case	O
charts	O
.	O
In	O
addition	O
to	O
examining	B-T033
basic	O
demographic	O
and	O
clinical	O
data	O
,	O
effects	O
of	O
different	O
therapeutic	B-T061
intervention	I-T061
were	O
examined	B-T033
as	O
a	O
function	O
of	O
decrease	O
or	O
disappearance	O
of	O
PNES	B-T048
attacks	O
in	O
the	O
ID	B-T048
group	O
.	O
Age	O
at	O
the	O
first	O
visit	B-T058
as	O
well	O
as	O
PNES	B-T048
onset	O
was	O
younger	O
in	O
the	O
ID	B-T048
than	O
in	O
the	O
non	B-T033
-	I-T033
ID	I-T033
group	O
(	O
t=2.651	O
,	O
p=0.009	O
;	O
t=3.528	O
,	O
p=0.001	O
,	O
respectively	O
)	O
.	O
PNES	B-T048
-free	O
ratio	O
at	O
the	O
last	O
visit	B-T058
tended	O
to	O
be	O
higher	O
in	O
the	O
non	B-T033
-	I-T033
ID	I-T033
group	O
(	O
chi	O
square	O
=	O
3.455	O
;	O
p=0.063	O
)	O
.	O
Psychosis	B-T048
was	O
more	O
often	O
encountered	O
in	O
the	O
ID	B-T048
group	O
(	O
chi	O
square	O
=	O
13.443	O
;	O
p=0.001	O
)	O
.	O
Although	O
cognitive	B-T061
therapy	I-T061
and	O
pharmaco	B-T061
-	I-T061
therapeutic	I-T061
approaches	O
were	O
quite	O
similarly	O
distributed	O
in	O
both	O
groups	O
,	O
environmental	O
adjustment	O
was	O
often	O
introduced	O
in	O
the	O
ID	B-T048
group	O
(	O
44	O
%	O
)	O
as	O
compared	O
to	O
the	O
non	B-T033
-	I-T033
ID	I-T033
group	O
(	O
15	O
%	O
)	O
(	O
chi	O
square	O
=	O
14.299	O
;	O
p=0.001	O
)	O
.	O
Brief	O
weekly	O
visit	B-T058
service	I-T058
is	O
also	O
more	O
often	O
utilized	O
by	O
the	O
patients	O
with	O
ID	B-T048
(	O
54	O
%	O
)	O
than	O
by	O
those	O
without	O
ID	B-T048
(	O
35	O
%	O
)	O
(	O
chi	O
square	O
=	O
5.021	O
,	O
p=0.025	O
)	O
.	O
Optimal	O
treatment	B-T061
approaches	O
in	O
this	O
sizable	O
patient	O
subgroup	O
should	O
be	O
the	O
subject	O
of	O
future	O
prospective	O
studies	O
.	O
      
Hypovitaminosis	B-T047
D	I-T047
and	O
Associated	O
Cardiometabolic	O
Risk	O
in	O
Women	O
with	O
PCOS	B-T047
Women	O
with	O
Polycystic	B-T047
Ovary	I-T047
Syndrome	I-T047
(	O
PCOS	B-T047
)	O
frequently	O
suffer	O
from	O
metabolic	B-T047
disturbances	I-T047
like	O
insulin	O
resistance	O
,	O
hypertension	B-T047
and	O
atherogenic	B-T047
dyslipidemia	I-T047
.	O
Accumulating	B-T033
evidences	O
suggest	O
that	O
Vitamin	B-T047
D	I-T047
deficiency	I-T047
is	O
common	O
in	O
PCOS	B-T047
and	O
may	O
be	O
associated	O
with	O
metabolic	B-T047
and	O
endocrinal	B-T047
dysfunctions	I-T047
in	O
PCOS	B-T047
.	O
Thus	O
women	O
with	O
PCOS	B-T047
may	O
be	O
at	O
elevated	O
risk	O
of	O
cardiovascular	B-T047
disease	I-T047
.	O
Present	O
study	O
aims	O
to	O
evaluate	O
Vitamin	B-T121
D	I-T121
status	O
and	O
to	O
assess	O
its	O
association	O
with	O
metabolic	B-T047
and	O
endocrinal	B-T047
dysregulations	I-T047
in	O
women	O
with	O
PCOS	B-T047
,	O
which	O
might	O
help	O
in	O
early	B-T061
identification	I-T061
and	O
prevention	B-T061
of	O
future	O
symptomatic	O
cardiac	B-T047
disease	I-T047
.	O
A	O
total	O
of	O
44	O
women	O
with	O
PCOS	B-T047
,	O
diagnosed	O
by	O
Rotterdam	O
criteria	O
and	O
45	O
healthy	O
control	O
without	O
PCOS	B-T047
,	O
were	O
evaluated	O
for	O
Vitamin	B-T121
D	I-T121
and	O
cardiometabolic	B-T033
risk	I-T033
factors	I-T033
,	O
including	O
fasting	O
plasma	O
glucose	O
,	O
insulin	O
resistance	O
,	O
dyslipidemia	B-T047
,	O
hs	B-T033
-	I-T033
CRP	I-T033
.	O
That	O
apart	O
,	O
several	O
endocrinal	O
parameters	O
of	O
hyperandrogenism	B-T047
were	O
also	O
examined	O
.	O
Several	O
correlation	O
studies	O
were	O
determined	O
to	O
establish	O
the	O
role	O
of	O
Vitamin	B-T121
D	I-T121
as	O
a	O
cardiometabolic	B-T033
risk	I-T033
factor	I-T033
in	O
PCOS	B-T047
.	O
Results	O
were	O
expressed	O
as	O
mean±SD	O
and	O
were	O
statistically	O
analysed	O
using	O
SPSS	O
software	O
version	O
16	O
,	O
unpaired	O
student	O
's	O
t	O
-	O
test	O
and	O
Pearson	O
's	O
correlation	O
coefficient	O
.	O
We	O
found	O
lower	O
levels	O
of	O
Vitamin	B-T121
D	I-T121
,	O
which	O
was	O
statistically	O
significant	O
as	O
compared	O
to	O
healthy	O
controls	O
.	O
Hyperinsulinemia	B-T047
,	O
rise	O
in	O
insulin	O
resistance	O
and	O
marked	O
dyslipidemia	B-T047
was	O
observed	O
in	O
the	O
present	O
study	O
.	O
Another	O
relevant	O
finding	O
was	O
significant	O
correlation	O
of	O
Vitamin	B-T121
D	I-T121
with	O
insulin	B-T121
and	O
Homeostatic	B-T059
Model	I-T059
of	I-T059
Assessment-	I-T059
Insulin	I-T059
Resistance	I-T059
Index	I-T059
(	O
HOMA	B-T059
-	I-T059
IR	I-T059
)	O
.	O
Hypovitaminosis	B-T047
D	I-T047
was	O
prevalent	O
in	O
PCOS	B-T047
.	O
This	O
was	O
related	O
to	O
metabolic	B-T047
and	O
hormonal	B-T033
disorders	I-T033
in	O
PCOS	B-T047
.	O
Possibly	O
this	O
combined	O
with	O
impaired	B-T033
fasting	I-T033
glucose	I-T033
,	O
IR	O
and	O
dyslipidemia	B-T047
,	O
could	O
account	O
for	O
Cardio	O
vascular	O
risks	O
in	O
PCOS	B-T047
.	O
Further	O
prospective	O
observational	O
studies	O
and	O
randomized	O
control	O
trials	O
are	O
required	O
to	O
explore	O
the	O
above	O
hypothesis	O
.	O
      
Development	O
of	O
the	O
four	O
-	O
item	O
Letter	O
and	O
Shape	O
Drawing	O
test	O
(	O
LSD-4	O
):	O
A	O
brief	O
bedside	B-T060
test	I-T060
of	O
visuospatial	O
function	O
Conventional	O
bedside	B-T060
tests	I-T060
of	O
visuospatial	O
function	O
such	O
as	O
the	O
Clock	O
Drawing	O
(	O
CDT	O
)	O
and	O
Intersecting	O
Pentagons	O
(	O
IPT	O
)	O
lack	O
consistency	O
in	O
delivery	O
and	O
interpretation	B-T033
.	O
We	O
compared	O
performance	O
on	O
a	O
novel	O
test	O
of	O
visuospatial	O
ability	O
-	O
the	O
LSD	O
-	O
with	O
the	O
IPT	O
,	O
CDT	O
and	O
MMSE	B-T060
in	O
180	O
acute	O
elderly	O
medical	O
inpatients	O
[	O
mean	O
age	O
79.7±7.1	O
(	O
range	O
62	O
-	O
96	O
)	O
;	O
91	O
females	O
(	O
50.6	O
%	O
)	O
]	O
.	O
124	O
(	O
69	O
%	O
)	O
scored	O
≤23	O
on	O
the	O
MMSE	B-T060
;	O
60	O
with	O
mild	O
(	O
score	O
18	O
-	O
23	O
)	O
and	O
64	O
with	O
severe	O
(	O
score	O
≤17	O
)	O
impairment	O
.	O
78	O
(	O
43	O
%	O
)	O
scored	O
≥6	O
on	O
the	O
CDT	O
,	O
while	O
for	O
the	O
IPT	O
,	O
87	O
(	O
47	O
%	O
)	O
scored	O
≥4	O
.	O
The	O
CDT	O
and	O
IPT	O
agreed	B-T033
on	O
the	O
classification	O
of	O
138	O
patients	O
(	O
77	O
%	O
)	O
with	O
modest-	O
strong	O
agreement	O
with	O
the	O
MMSE	B-T060
categories	O
.	O
Correlation	O
between	O
the	O
LSD	O
and	O
visuospatial	O
tests	O
was	O
high	O
.	O
A	O
four	O
-	O
item	O
version	O
of	O
the	O
LSD	O
incorporating	O
items	O
1,10,12,15	O
had	O
high	O
correlation	O
with	O
the	O
LSD-15	O
and	O
strong	O
association	O
with	O
MMSE	B-T060
categories	O
.	O
The	O
LSD-4	O
provides	O
a	O
brief	O
and	O
easily	B-T033
interpreted	O
bedside	B-T060
test	I-T060
of	O
visuospatial	O
function	O
that	O
has	O
high	O
coverage	O
of	O
elderly	O
patients	O
with	O
neurocognitive	B-T048
impairment	I-T048
,	O
good	O
agreement	O
with	O
conventional	O
tests	O
of	O
visuospatial	O
ability	O
and	O
favourable	O
ability	O
to	O
identify	O
significant	O
cognitive	B-T048
impairment	I-T048
.	O
[	O
181	O
words	O
]	O
.	O
      
High	O
-	O
density	O
lipoprotein	O
-associated	O
sphingosine-1	O
-	O
phosphate	O
activity	O
in	O
heterozygous	B-T047
familial	I-T047
hypercholesterolaemia	I-T047
Patients	O
with	O
heterozygous	B-T047
familial	I-T047
hypercholesterolaemia	I-T047
(	O
FH	B-T047
)	O
suffer	B-T184
from	O
high	B-T033
plasma	I-T033
cholesterol	I-T033
and	O
an	O
environment	O
of	O
increased	O
oxidative	O
stress	O
.	O
We	O
examined	O
its	O
potential	O
effects	O
on	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL)-associated	O
sphingosine-1	O
-	O
phosphate	O
(	O
S1P	O
)	O
content	O
(	O
HDL	O
-	O
S1P	O
)	O
and	O
HDL	O
-mediated	O
protection	O
against	O
oxidative	O
stress	O
,	O
both	O
with	O
and	O
without	O
statin	B-T058
treatment	I-T058
.	O
In	O
a	O
case	O
-	O
control	O
study	O
,	O
HDL	O
was	O
isolated	O
from	O
12	O
FH	B-T047
patients	O
with	O
and	O
without	O
statin	B-T058
treatment	I-T058
and	O
from	O
12	O
healthy	O
controls	O
.	O
The	O
HDL	O
-	O
S1P	O
content	O
and	O
the	O
capacity	O
of	O
HDL	O
to	O
protect	B-T033
cardiomyocytes	O
against	O
oxidative	O
stress	O
in	O
vitro	O
were	O
measured	O
.	O
HDL	O
-associated	O
S1P	O
was	O
significantly	O
correlated	O
with	O
cell	O
protection	O
,	O
but	O
not	O
with	O
HDL	O
-	O
cholesterol	O
or	O
apolipoprotein	O
AI	O
.	O
The	O
latter	O
did	O
not	O
correlate	O
with	O
HDL	O
-mediated	O
cell	O
protection	O
.	O
Neither	O
the	O
HDL	O
-	O
S1P	O
content	O
nor	O
HDL	O
protective	O
capacity	O
differed	O
between	O
nontreated	O
FH	B-T047
patients	O
and	O
controls	O
.	O
The	O
relative	O
amounts	O
of	O
apolipoprotein	O
AI	O
and	O
apolipoprotein	O
M	O
were	O
similar	O
between	O
controls	O
and	O
FH	B-T047
patients	O
.	O
Statin	B-T058
treatment	I-T058
had	O
no	O
effect	O
on	O
any	O
of	O
these	O
measures	O
.	O
The	O
FH	B-T047
environment	O
is	O
not	O
detrimental	O
to	O
HDL	O
-	O
S1P	O
content	O
or	O
HDL	O
-	O
S1P	O
-mediated	O
cell	O
protection	O
.	O
Statin	B-T058
treatment	I-T058
does	O
not	O
modulate	O
HDL	O
function	O
in	O
this	O
regard	O
.	O
      
Simvastatin	B-T121
Promotes	O
Hematoma	O
Absorption	O
and	O
Reduces	O
Hydrocephalus	B-T047
Following	O
Intraventricular	O
Hemorrhage	O
in	O
Part	O
by	O
Upregulating	O
CD36	O
We	O
previously	O
found	O
that	O
hematoma	O
worsens	B-T033
hydrocephalus	B-T047
after	O
intraventricular	O
hemorrhage	O
(	O
IVH	O
)	O
via	O
increasing	O
iron	O
deposition	O
and	O
aggravating	O
ependymal	O
cilia	O
injury	O
;	O
therefore	O
,	O
promoting	O
hematoma	O
absorption	O
may	O
be	O
a	O
promising	O
strategy	O
for	O
IVH	O
.	O
Recently	O
,	O
some	O
investigations	O
imply	O
that	O
simvastatin	B-T121
has	O
the	O
ability	O
of	O
accelerating	O
hematoma	O
absorption	O
.	O
Thus	O
,	O
this	O
study	O
was	O
designed	O
to	O
examine	O
the	O
efficacy	O
of	O
simvastatin	B-T121
for	O
IVH	O
in	O
rats	O
.	O
Intracerebral	O
hemorrhage	O
with	O
ventricular	O
extension	O
was	O
induced	O
in	O
adult	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
after	O
autologous	B-T061
blood	I-T061
injection	I-T061
.	O
Simvastatin	B-T121
or	O
vehicle	O
was	O
administered	B-T061
orally	I-T061
at	O
1	O
day	O
after	O
IVH	O
and	O
then	O
daily	O
for	O
1	O
week	O
.	O
MRI	B-T060
studies	I-T060
were	O
performed	O
to	O
measure	O
the	O
volumes	B-T059
of	O
intracranial	O
hematoma	O
and	O
lateral	O
ventricle	O
at	O
days	O
1	O
,	O
3	O
,	O
7	O
,	O
14	O
,	O
and	O
28	O
after	O
IVH	O
.	O
Motor	O
and	O
neurocognitive	O
functions	O
were	O
assessed	O
at	O
days	O
1	O
to	O
7	O
and	O
23	O
to	O
28	O
,	O
respectively	O
.	O
Iron	O
deposition	O
,	O
iron	B-T121
-related	O
protein	O
expression	O
,	O
ependymal	B-T033
damage	I-T033
,	O
and	O
histology	O
were	O
detected	B-T033
at	O
day	O
28	O
.	O
Expression	O
of	O
CD36	O
scavenger	O
receptor	O
(	O
facilitating	O
phagocytosis	O
)	O
was	O
examined	B-T033
at	O
day	O
3	O
after	O
IVH	O
using	O
western	B-T059
blotting	I-T059
and	O
immunofluorescence	B-T059
.	O
Simvastatin	B-T121
significantly	O
increased	O
hematoma	O
absorption	O
ratio	O
,	O
reduced	O
ventricular	O
volume	O
,	O
and	O
attenuated	B-T033
neurological	I-T033
dysfunction	I-T033
post-	O
IVH	O
.	O
In	O
addition	O
,	O
less	B-T033
iron	I-T033
accumulation	I-T033
and	O
more	O
cilia	O
survival	O
was	O
observed	O
in	O
the	O
simvastatin	B-T121
group	O
when	O
compared	O
with	O
the	O
control	O
.	O
What	O
's	O
more	O
,	O
higher	O
expression	O
of	O
CD36	O
was	O
detected	B-T033
around	O
the	O
hematoma	O
after	O
simvastatin	B-T121
administration	B-T061
.	O
Simvastatin	B-T121
significantly	O
enhanced	O
brain	B-T023
hematoma	O
absorption	O
,	O
alleviated	B-T047
hydrocephalus	I-T047
,	O
and	O
improved	B-T033
neurological	O
recovery	O
after	O
experimental	O
IVH	O
,	O
which	O
may	O
in	O
part	O
by	O
upregulating	O
CD36	O
expression	O
.	O
Our	O
data	O
suggest	O
that	O
early	O
simvastatin	B-T121
use	O
may	O
be	O
a	O
novel	O
therapy	B-T061
for	O
IVH	O
patients	O
.	O
      
The	O
correlation	O
of	O
the	O
results	O
of	O
the	O
survey	O
SNOT-20	O
of	O
objective	O
studies	O
of	O
nasal	B-T033
obstruction	I-T033
and	O
the	O
geometry	O
of	O
the	O
nasal	O
cavities	O
In	O
this	O
paper	O
were	O
verified	O
the	O
correlation	O
between	O
the	O
results	O
of	O
the	O
survey	O
SNOT-20	O
and	O
the	O
results	B-T033
of	I-T033
the	I-T033
objective	I-T033
tests	I-T033
of	O
nasal	B-T033
obstruction	I-T033
which	O
are	O
rhinomanometry	B-T060
and	O
acoustic	B-T060
rhinometry	I-T060
before	O
and	O
after	O
surgical	B-T061
treatment	I-T061
,	O
such	O
as	O
septoplasty	B-T061
,	O
septoconchoplasty	B-T060
,	O
ethmoidectomy	B-T061
and	O
septoethmoidectomy	B-T060
.	O
The	O
material	O
used	O
in	O
this	O
study	O
was	O
233	O
patients	O
diagnosed	B-T033
routinely	O
in	O
the	O
Rhinomanometry	B-T060
Laboratory	O
of	O
the	O
Department	O
of	O
Otolaryngology	O
at	O
the	O
Medical	O
University	O
of	O
Warsaw	O
,	O
reporting	O
rhinological	B-T047
problems	I-T047
.	O
Data	O
were	O
obtained	O
from	O
70	O
women	O
(	O
31,4	O
%	O
)	O
ranging	O
in	O
ages	O
from	O
18	O
to	O
81	O
years	O
of	O
age	O
and	O
153	O
men	O
(	O
68,6	O
%	O
)	O
ranging	O
in	O
ages	O
from	O
16	O
to	O
81	O
years	O
of	O
age	O
.	O
The	O
researches	O
presented	O
in	O
the	O
study	O
were	O
made	O
using	O
the	O
device	O
RhinoMetrics	O
SRE	O
2100	O
which	O
combines	O
the	O
Rhinomanometer	O
(	O
RhinoStream	O
)	O
and	O
Acoustic	O
Rhinometer	O
(	O
RhinoScan	O
)	O
Interacoustics	O
AS	O
(	O
Denmark	O
)	O
.	O
Survey	O
SNOT-20	O
(	O
Sino	O
-	O
Nasal	O
Outcome	O
Test-20	O
)	O
in	O
Polish	O
was	O
completed	O
by	O
patients	O
before	O
surgery	O
and	O
during	O
the	O
postoperative	O
control	O
visits	O
.	O
The	O
calculated	O
correlations	O
between	O
the	O
objective	B-T033
parameter	I-T033
,	O
which	O
was	O
the	O
resistance	O
to	O
the	O
flow	B-T033
of	I-T033
air	I-T033
through	I-T033
the	I-T033
nasal	I-T033
cavity	I-T033
,	O
and	O
the	O
subjective	B-T033
feelings	I-T033
of	I-T033
respondents	I-T033
expressed	O
in	O
the	O
survey	O
SNOT-20	O
were	O
generally	O
weak	O
,	O
and	O
statistical	O
significance	O
was	O
achieved	O
with	O
respect	O
to	O
the	O
first	O
question	O
survey	O
(	O
the	O
severity	B-T033
of	I-T033
the	I-T033
nose	I-T033
obstruction	I-T033
)	O
for	O
all	O
components	O
of	O
resistance	O
flow	O
.	O
The	O
feeling	O
of	O
nasal	B-T033
obstruction	I-T033
is	O
the	O
most	O
reproducible	O
and	O
reliable	O
complaint	O
reported	O
by	O
the	O
patient	O
with	O
rhinological	B-T047
problems	I-T047
.	O
      
Novel	O
and	O
Lost	O
Forests	O
in	O
the	O
Upper	O
Midwestern	O
United	O
States	O
,	O
from	O
New	O
Estimates	O
of	O
Settlement	O
-	O
Era	O
Composition	O
,	O
Stem	O
Density	O
,	O
and	O
Biomass	O
EuroAmerican	O
land	O
-	O
use	O
and	O
its	O
legacies	O
have	O
transformed	O
forest	O
structure	O
and	O
composition	O
across	O
the	O
United	O
States	O
(	O
US	O
)	O
.	O
More	O
accurate	O
reconstructions	O
of	O
historical	O
states	O
are	O
critical	O
to	O
understanding	O
the	O
processes	O
governing	O
past	O
,	O
current	O
,	O
and	O
future	O
forest	O
dynamics	O
.	O
Here	O
we	O
present	O
new	O
gridded	O
(	O
8x8	O
km	O
)	O
reconstructions	O
of	O
pre	O
-	O
settlement	O
(	O
1800s	O
)	O
forest	O
composition	O
and	O
structure	O
from	O
the	O
upper	O
Midwestern	O
US	O
(	O
Minnesota	O
,	O
Wisconsin	O
,	O
and	O
most	O
of	O
Michigan	O
)	O
,	O
using	O
19th	O
Century	O
Public	O
Land	O
Survey	O
System	O
(	O
PLSS	O
)	O
,	O
with	O
estimates	O
of	O
relative	O
composition	O
,	O
above	O
-	O
ground	O
biomass	O
,	O
stem	O
density	O
,	O
and	O
basal	O
area	O
for	O
28	O
tree	O
types	O
.	O
This	O
mapping	O
is	O
more	O
robust	O
than	O
past	O
efforts	O
,	O
using	O
spatially	O
varying	O
correction	O
factors	O
to	O
accommodate	O
sampling	O
design	O
,	O
azimuthal	O
censoring	O
,	O
and	O
biases	O
in	O
tree	O
selection	O
.	O
We	O
compare	O
pre	O
-	O
settlement	O
to	O
modern	O
forests	O
using	O
US	O
Forest	O
Service	O
Forest	O
Inventory	O
and	O
Analysis	O
(	O
FIA	O
)	O
data	O
to	O
show	O
the	O
prevalence	O
of	O
lost	O
forests	O
(	O
pre	O
-	O
settlement	O
forests	O
with	O
no	O
current	O
analog	O
)	O
,	O
and	O
novel	O
forests	O
(	O
modern	O
forests	O
with	O
no	O
past	O
analogs	O
)	O
.	O
Differences	O
between	O
pre	O
-	O
settlement	O
and	O
modern	O
forests	O
are	O
spatially	O
structured	O
owing	O
to	O
differences	O
in	O
land	O
-	O
use	O
impacts	O
and	O
accompanying	O
ecological	O
responses	O
.	O
Modern	O
forests	O
are	O
more	O
homogeneous	O
,	O
and	O
ecotonal	O
gradients	O
are	O
more	O
diffuse	O
today	O
than	O
in	O
the	O
past	O
.	O
Novel	O
forest	O
assemblages	O
represent	O
28	O
%	O
of	O
all	O
FIA	O
cells	O
,	O
and	O
28	O
%	O
of	O
pre	O
-	O
settlement	O
forests	O
no	B-T033
longer	I-T033
exist	O
in	O
a	O
modern	O
context	O
.	O
Lost	O
forests	O
include	O
tamarack	O
forests	O
in	O
northeastern	O
Minnesota	O
,	O
hemlock	O
and	O
cedar	O
dominated	O
forests	O
in	O
north	O
-	O
central	O
Wisconsin	O
and	O
along	O
the	O
Upper	O
Peninsula	O
of	O
Michigan	O
,	O
and	O
elm	O
,	O
oak	O
,	O
basswood	O
and	O
ironwood	O
forests	O
along	O
the	O
forest	O
-	O
prairie	O
boundary	O
in	O
south	O
central	O
Minnesota	O
and	O
eastern	O
Wisconsin	O
.	O
Novel	O
FIA	O
forest	O
assemblages	O
are	O
distributed	O
evenly	O
across	O
the	O
region	O
,	O
but	O
novelty	O
shows	O
a	O
strong	O
relationship	O
to	O
spatial	O
distance	O
from	O
remnant	O
forests	O
in	O
the	O
upper	O
Midwest	O
,	O
with	O
novelty	O
predicted	O
at	O
between	O
20	O
to	O
60	O
km	O
from	O
remnants	O
,	O
depending	O
on	O
historical	O
forest	O
type	O
.	O
The	O
spatial	O
relationships	O
between	O
remnant	O
and	O
novel	O
forests	O
,	O
shifts	O
in	O
ecotone	O
structure	O
and	O
the	O
loss	O
of	O
historic	O
forest	O
types	O
point	O
to	O
significant	O
challenges	O
for	O
land	O
managers	O
if	O
landscape	O
restoration	O
is	O
a	O
priority	O
.	O
The	O
spatial	O
signals	O
of	O
novelty	O
and	O
ecological	O
change	O
also	O
point	O
to	O
potential	O
challenges	O
in	O
using	O
modern	O
spatial	O
distributions	O
of	O
species	O
and	O
communities	O
and	O
their	O
relationship	O
to	O
underlying	O
geophysical	O
and	O
climatic	O
attributes	O
in	O
understanding	O
potential	O
responses	O
to	O
changing	O
climate	O
.	O
The	O
signal	O
of	O
human	O
settlement	O
on	O
modern	O
forests	O
is	O
broad	O
,	O
spatially	O
varying	O
and	O
acts	O
to	O
homogenize	O
modern	O
forests	O
relative	O
to	O
their	O
historic	O
counterparts	O
,	O
with	O
significant	O
implications	O
for	O
future	O
management	O
.	O
      
Investigation	O
on	O
evaluation	B-T058
criteria	O
of	O
backwashing	O
effects	O
for	O
a	O
pilot	O
-	O
scale	O
BAF	O
treating	O
petrochemical	O
wastewater	O
Parameters	O
for	O
evaluation	B-T058
criteria	O
of	O
air	O
-	O
water	B-T121
backwashing	O
effect	O
s	O
of	O
a	O
pilot	O
-	O
scale	O
biological	O
aerated	O
filter	O
(	O
BAF	O
)	O
treating	O
petrochemical	O
wastewater	O
were	O
investigated	O
.	O
The	O
parameters	O
included	O
the	O
suspended	O
solids	O
(	O
SS	O
)	O
and	O
specific	B-T033
oxygen	I-T033
uptake	I-T033
rate	I-T033
(	O
SOUR	B-T033
)	O
of	O
the	O
backwashing	O
effluent	O
,	O
recovery	O
of	O
the	O
BAF	O
after	O
backwashing	O
,	O
and	O
the	O
removal	O
of	O
the	O
biomass	O
/	O
bioactivity	O
attached	O
on	O
the	O
filter	O
media	O
after	O
backwashing	O
.	O
Results	O
showed	O
that	O
the	O
weight	O
of	O
the	O
total	O
sludge	O
produced	O
in	O
the	O
backwashing	O
effluent	O
increased	O
with	O
the	O
increase	O
in	O
water	B-T121
-	O
backwashing	O
intensity	O
,	O
while	O
the	O
total	O
SOUR	B-T033
of	O
backwashing	O
effluent	O
rose	O
notably	O
with	O
the	O
increase	O
of	O
air	O
-	O
backwashing	O
intensity	O
.	O
The	O
optimal	O
backwashing	O
intensity	O
of	O
14	O
L/(m(2)·s	O
)	O
for	O
air	O
and	O
4	O
L/(m(2)·s	O
)	O
for	O
water	B-T121
were	O
obtained	O
.	O
When	O
the	O
BAF	O
was	O
backwashed	O
on	O
this	O
condition	O
,	O
the	O
BAF	O
recovered	O
with	O
high	O
average	O
removal	O
of	O
chemical	O
oxygen	O
demand	O
(	O
COD	O
)	O
and	O
ammonia	O
nitrogen	O
[	O
Formula	O
:	O
see	O
text	O
]	O
of	O
14.3	O
%	O
and	O
50.3	O
%	O
,	O
respectively	O
.	O
High	O
amount	O
of	O
biomass	O
removal	O
at	O
15.8	O
%	O
and	O
low	O
level	O
of	O
bioactivity	O
removal	O
at	O
8.8	O
%	O
attached	O
on	O
the	O
filter	O
media	O
were	O
also	O
found	O
.	O
Concentrations	O
of	O
the	O
benzene	O
,	O
toluene	O
,	O
ethylbenzene	O
and	O
(	O
o-	O
,	O
m-	O
,	O
p-	O
)	O
xylenes	O
(	O
BTEX	O
)	O
and	O
phenol	B-T121
in	O
the	O
backwashed	O
sludge	O
were	O
analyzed	O
,	O
showing	O
that	O
the	O
backwashing	O
was	O
essential	O
to	O
remove	O
some	O
aromatic	O
compounds	O
adsorbed	B-T059
in	O
the	O
microorganisms	B-T001
.	O
      
Zika	B-T005
Virus	I-T005
Disrupts	O
Phospho	O
-	O
TBK1	O
Localization	O
and	O
Mitosis	O
in	O
Human	O
Neuroepithelial	O
Stem	O
Cells	O
and	O
Radial	O
Glia	O
The	O
mechanisms	O
underlying	O
Zika	B-T005
virus	I-T005
ZIKV	B-T005
(	O
ZIKV)-related	O
microcephaly	B-T019
and	O
other	O
neurodevelopment	O
defects	O
remain	O
poorly	O
understood	O
.	O
Here	O
,	O
we	O
describe	O
the	O
derivation	O
and	O
characterization	O
,	O
including	O
single	O
-	O
cell	O
RNA	O
-	O
seq	O
,	O
of	O
neocortical	B-T023
and	O
spinal	B-T023
cord	I-T023
neuroepithelial	O
stem	O
(	O
NES	O
)	O
cells	O
to	O
model	O
early	O
human	O
neurodevelopment	O
and	O
ZIKV	B-T005
-related	O
neuropathogenesis	B-T047
.	O
By	O
analyzing	O
human	O
NES	O
cells	O
,	O
organotypic	O
fetal	B-T018
brain	B-T023
slices	O
,	O
and	O
a	O
ZIKV	B-T005
-	O
infected	B-T033
micrencephalic	B-T019
brain	B-T023
,	O
we	O
show	O
that	O
ZIKV	B-T005
infects	B-T033
both	O
neocortical	B-T023
and	O
spinal	B-T023
NES	O
cells	O
as	O
well	O
as	O
their	O
fetal	B-T018
homolog	O
,	O
radial	O
glial	O
cells	O
(	O
RGCs	O
)	O
,	O
causing	O
disrupted	O
mitoses	O
,	O
supernumerary	O
centrosomes	O
,	O
structural	O
disorganization	B-T033
,	O
and	O
cell	O
death	O
.	O
ZIKV	B-T047
infection	I-T047
of	O
NES	O
cells	O
and	O
RGCs	O
causes	O
centrosomal	O
depletion	O
and	O
mitochondrial	O
sequestration	O
of	O
phospho	O
-	O
TBK1	O
during	O
mitosis	O
.	O
We	O
also	O
found	O
that	O
nucleoside	B-T121
analogs	I-T121
inhibit	O
ZIKV	B-T005
replication	O
in	O
NES	O
cells	O
,	O
protecting	O
them	O
from	O
ZIKV	B-T005
-	O
induced	O
pTBK1	O
relocalization	O
and	O
cell	O
death	O
.	O
We	O
established	O
a	O
model	O
system	O
of	O
human	O
neural	O
stem	O
cells	O
to	O
reveal	O
cellular	O
and	O
molecular	O
mechanisms	O
underlying	O
neurodevelopmental	O
defects	O
associated	O
with	O
ZIKV	B-T047
infection	I-T047
and	O
its	O
potential	O
treatment	B-T061
.	O
      
Assessment	O
of	O
genetic	O
relationship	O
among	O
Rhododendron	O
cultivars	O
using	O
amplified	O
fragment	O
length	O
polymorphism	O
and	O
inter	O
-	O
simple	O
sequence	O
repeat	O
markers	O
Genetic	O
relationships	O
of	O
17	O
Rhododendron	O
cultivars	O
,	O
China	O
,	O
were	O
assessed	O
using	O
inter	O
-	O
simple	O
sequence	O
repeat	O
(	O
ISSR	O
)	O
and	O
amplified	O
fragment	O
length	O
polymorphism	O
(	O
AFLP	O
)	O
markers	O
.	O
A	O
total	O
of	O
133	O
bands	O
were	O
obtained	O
using	O
nine	O
selected	O
ISSR	O
primers	O
,	O
129	O
(	O
96.99	O
%	O
)	O
of	O
which	O
were	O
polymorphic	O
;	O
267	O
bands	O
were	O
amplified	O
by	O
four	O
AFLP	O
primer	O
pairs	O
,	O
251	O
(	O
94.01	O
%	O
)	O
of	O
which	O
exhibited	O
polymorphism	O
.	O
Based	O
on	O
these	O
polymorphic	O
products	O
,	O
a	O
cluster	O
analysis	O
revealed	O
similarities	O
between	O
the	O
results	O
of	O
the	O
ISSR	O
and	O
AFLP	O
.	O
All	O
of	O
the	O
cultivars	O
were	O
clustered	O
into	O
two	O
major	O
branches	O
;	O
one	O
branch	O
contained	O
the	O
same	O
four	O
cultivars	O
,	O
and	O
the	O
other	O
cultivars	O
were	O
separated	O
into	O
different	O
groups	O
in	O
the	O
other	O
branch	O
.	O
The	O
cluster	O
results	O
showed	O
that	O
the	O
genetic	O
relationships	O
of	O
the	O
17	O
cultivars	O
were	O
partly	O
related	O
to	O
their	O
morphological	O
characteristics	O
,	O
particularly	O
the	O
flowering	O
phase	O
.	O
Therefore	O
,	O
the	O
results	O
of	O
this	O
study	O
support	O
the	O
classification	O
of	O
Rhododendron	O
cultivars	O
according	O
to	O
flowering	O
phase	O
.	O
In	O
addition	O
,	O
the	O
cluster	O
results	O
can	O
be	O
used	O
to	O
select	O
suitable	O
parents	O
for	O
breeding	O
.	O
      
Recombinant	O
fibrinogen	B-T121
reveals	O
the	O
differential	O
roles	O
of	O
α-	O
and	O
γ	O
-	O
chain	O
cross	O
-	O
linking	O
and	O
molecular	O
heterogeneity	O
in	O
fibrin	O
clot	O
strain	O
-	O
stiffening	O
Essentials	O
Fibrinogen	B-T121
circulates	O
in	O
human	O
plasma	O
as	O
a	O
complex	O
mixture	O
of	O
heterogeneous	O
molecular	O
variants	O
.	O
We	O
measured	O
strain	O
-	O
stiffening	O
of	O
recombinantly	O
produced	O
fibrinogen	B-T121
upon	O
clotting	O
.	O
Factor	B-T121
XIII	I-T121
and	O
molecular	O
heterogeneity	O
alter	O
clot	O
elasticity	O
at	O
the	O
protofibril	B-T121
and	O
fiber	O
level	O
.	O
This	O
highlights	O
the	O
hitherto	O
unknown	O
role	O
of	O
molecular	O
composition	O
in	O
fibrin	O
clot	O
mechanics	O
.	O
Background	O
Fibrin	B-T121
plays	O
a	O
crucial	O
role	O
in	O
haemostasis	O
and	O
wound	O
healing	O
by	O
forming	O
strain	O
-	O
stiffening	O
fibrous	O
networks	O
that	O
reinforce	O
blood	O
clots	O
.	O
The	O
molecular	O
origin	O
of	O
fibrin	B-T121
's	I-T121
strain	O
-	O
stiffening	O
behavior	O
remains	O
poorly	O
understood	O
,	O
primarily	O
because	O
plasma	O
fibrinogen	B-T121
is	O
a	O
complex	O
mixture	O
of	O
heterogeneous	O
molecular	O
variants	O
and	O
is	O
often	O
contaminated	O
by	O
plasma	O
factors	O
that	O
affect	O
clot	O
properties	O
.	O
Objectives	O
and	O
methods	O
To	O
facilitate	O
mechanistic	O
dissection	O
of	O
fibrin	B-T121
nonlinear	O
elasticity	O
,	O
we	O
produced	O
a	O
homogeneous	O
recombinant	O
fibrinogen	B-T121
corresponding	O
to	O
the	O
main	O
variant	O
in	O
human	O
plasma	O
,	O
termed	O
rFib610	B-T121
.	O
We	O
characterized	O
the	O
structure	O
of	O
rFib610	B-T121
clots	O
using	O
turbidimetry	B-T059
,	O
microscopy	B-T059
and	O
X	B-T059
-	I-T059
ray	I-T059
scattering	I-T059
.	O
We	O
used	O
rheology	B-T059
to	O
measure	O
the	O
strain	O
-	O
stiffening	O
behavior	O
of	O
the	O
clots	O
and	O
determined	O
the	O
fiber	O
properties	O
by	O
modeling	O
the	O
clots	O
as	O
semi	O
-	O
flexible	O
polymer	O
networks	O
.	O
Results	O
We	O
show	O
that	O
addition	O
of	O
FXIII	B-T121
to	O
rFib610	B-T121
clots	O
causes	O
a	O
dose	O
-	O
dependent	O
stiffness	O
increase	O
at	O
small	O
deformations	O
and	O
renders	O
the	O
strain	O
-	O
stiffening	O
response	O
reversible	O
.	O
We	O
find	O
that	O
γ	O
-	O
chain	O
cross	O
-	O
linking	O
contributes	O
to	O
clot	O
elasticity	O
by	O
changing	O
the	O
force	O
-	O
extension	O
behavior	O
of	O
the	O
protofibrils	B-T121
,	O
whereas	O
α	O
-	O
chain	O
cross	O
-	O
linking	O
stiffens	O
the	O
fibers	O
,	O
as	O
a	O
consequence	O
of	O
tighter	O
coupling	O
between	O
the	O
constituent	O
protofibrils	B-T121
.	O
Interestingly	O
,	O
rFib610	B-T121
protofibrils	B-T121
have	O
a	O
25	O
%	O
larger	O
bending	O
rigidity	O
than	O
plasma	O
-purified	O
fibrin	B-T121
protofibrils	B-T121
and	O
a	O
delayed	O
strain	O
-	O
stiffening	O
,	O
indicating	O
that	O
molecular	O
heterogeneity	O
influences	O
clot	O
mechanics	O
at	O
the	O
protofibril	B-T121
scale	I-T121
.	O
Conclusions	O
Fibrinogen	B-T121
molecular	O
heterogeneity	O
and	O
FXIII	B-T121
affect	O
the	O
mechanical	O
function	O
of	O
fibrin	O
clots	O
by	O
altering	O
the	O
nonlinear	O
viscoelastic	O
properties	O
at	O
the	O
protofibril	O
and	O
fiber	O
scale	O
.	O
This	O
work	O
provides	O
a	O
starting	O
point	O
to	O
investigate	O
the	O
role	O
of	O
molecular	O
heterogeneity	O
of	O
plasma	O
fibrinogen	B-T121
in	O
fibrin	O
clot	O
mechanics	O
and	O
haemostasis	O
.	O
      
Low	O
intensity	O
sprint	B-T061
training	I-T061
with	O
blood	O
flow	O
restriction	O
improves	O
100	O
m	O
dash	O
We	O
investigated	O
the	O
effects	O
of	O
practical	O
blood	O
flow	O
restriction	O
(	O
pBFR	O
)	O
of	O
leg	B-T023
muscles	I-T023
during	O
sprint	B-T061
training	I-T061
on	O
the	O
100	O
m	O
dash	O
time	O
in	O
well	O
-	O
trained	O
sport	O
students	O
.	O
Participants	O
performed	O
6x100	O
m	O
sprints	O
at	O
60	O
-	O
70	O
%	O
of	O
their	O
maximal	O
100	O
m	O
sprinting	O
speed	O
twice	O
a	O
week	O
for	O
6	O
weeks	O
,	O
either	O
with	O
(	O
IG	O
;	O
n=12	O
)	O
or	O
without	O
pBFR	O
(	O
CG	O
;	O
n=12	O
)	O
.	O
The	O
100	O
m	O
dash	O
time	O
significantly	O
decreased	O
more	O
in	O
the	O
IG	O
(	O
-0.38±0.24	O
s	O
)	O
than	O
in	O
the	O
CG	O
(	O
-0.16±0.17	O
s	O
)	O
.	O
The	O
muscle	O
thickness	O
of	O
the	O
rectus	B-T023
femoris	I-T023
increased	O
only	O
in	O
the	O
IG	O
,	O
while	O
no	O
group	O
by	O
time	O
interactions	O
were	O
found	O
for	O
the	O
muscle	O
thickness	O
of	O
the	O
biceps	B-T023
femoris	I-T023
and	O
the	O
biceps	B-T023
brachii	I-T023
.	O
The	O
maximal	O
isometric	O
force	O
,	O
measured	O
using	O
a	O
leg	O
press	O
,	O
did	O
not	B-T033
change	I-T033
in	O
either	O
group	O
.	O
However	O
,	O
the	O
rate	O
of	O
force	O
development	O
improved	O
in	O
the	O
IG	O
.	O
Growth	B-T121
hormone	I-T121
,	O
testosterone	B-T121
,	O
insulin	O
-	O
like	O
growth	O
factor	O
1	O
,	O
and	O
cortisol	B-T121
concentrations	O
did	O
not	B-T033
significantly	I-T033
differ	I-T033
between	O
both	O
groups	O
at	O
any	O
measurement	O
time	O
point	O
(	O
pre	O
,	O
1	O
min	O
,	O
20	O
min	O
,	O
120	O
min	O
,	O
and	O
24	O
h	O
after	O
the	O
six	O
all	O
-	O
out	O
sprints	O
of	O
the	O
first	O
training	O
session	O
)	O
.	O
The	O
muscle	B-T020
damage	I-T020
marker	O
h	O
-	O
FABP	O
increased	O
significantly	O
more	O
in	O
the	O
CG	O
than	O
in	O
the	O
IG	O
.	O
The	O
pBFR	O
improved	O
the	O
100	O
m	O
dash	O
time	O
significantly	O
more	O
than	O
low	O
-	O
intensity	O
sprint	B-T061
interval	I-T061
training	I-T061
alone	O
.	O
Other	O
noted	O
benefits	O
of	O
training	O
with	O
pBFR	O
were	O
a	O
decreased	O
level	O
of	O
muscle	B-T020
damage	I-T020
,	O
a	O
greater	O
increase	O
of	O
the	O
rectus	B-T023
femoris	I-T023
muscle	I-T023
thickness	O
,	O
and	O
a	O
higher	O
rate	O
of	O
force	O
development	O
.	O
However	O
,	O
the	O
tested	O
hormones	O
were	O
unable	O
to	O
explain	O
the	O
additional	O
beneficial	O
effects	O
.	O
      
Acute	O
kidney	O
injury	O
and	O
fluid	B-T047
overload	I-T047
in	O
infants	O
and	O
children	O
after	O
cardiac	B-T061
surgery	I-T061
Acute	O
kidney	O
injury	O
is	O
a	O
common	O
and	O
serious	O
complication	O
after	O
congenital	B-T061
heart	I-T061
surgery	I-T061
,	O
particularly	O
among	O
infants	O
.	O
This	O
comorbidity	O
has	O
been	O
independently	O
associated	O
with	O
adverse	O
outcomes	O
including	O
an	O
increase	O
in	O
mortality	O
.	O
Postoperative	O
acute	O
kidney	O
injury	O
has	O
a	O
complex	O
pathophysiology	O
with	O
many	O
risk	B-T033
factors	I-T033
,	O
and	O
therefore	O
no	B-T033
single	I-T033
medication	I-T033
or	O
therapy	B-T033
has	O
been	O
demonstrated	O
to	O
be	O
effective	O
for	O
treatment	B-T061
or	O
prevention	O
.	O
However	O
,	O
it	O
has	O
been	O
established	O
that	O
the	O
associated	O
fluid	B-T047
overload	I-T047
is	O
one	O
of	O
the	O
major	O
determinants	O
of	O
morbidity	O
,	O
particularly	O
in	O
infants	O
after	O
cardiac	B-T061
surgery	I-T061
.	O
Therefore	O
,	O
in	O
the	O
absence	O
of	O
an	O
intervention	B-T061
to	O
prevent	O
acute	O
kidney	O
injury	O
,	O
much	O
of	O
the	O
effort	O
to	O
improve	O
outcomes	O
has	O
focused	O
on	O
treating	O
and	O
preventing	O
fluid	B-T047
overload	I-T047
.	O
Early	O
renal	B-T061
replacement	I-T061
therapy	I-T061
,	O
often	O
in	O
the	O
form	O
of	O
peritoneal	B-T061
dialysis	I-T061
,	O
has	O
been	O
shown	O
to	O
be	O
safe	O
and	O
beneficial	O
in	O
infants	O
with	O
oliguria	B-T047
after	O
heart	B-T061
surgery	I-T061
.	O
As	O
understanding	O
of	O
the	O
pathophysiology	O
of	O
acute	O
kidney	O
injury	O
and	O
the	O
ability	O
to	O
confidently	O
diagnose	B-T033
it	O
earlier	O
continues	O
to	O
evolve	O
,	O
it	O
is	O
likely	O
that	O
novel	O
preventative	O
and	O
therapeutic	B-T061
interventions	I-T061
will	O
be	O
available	O
in	O
the	O
future	O
.	O
      
Tailor	O
-	O
made	O
drug	O
carrier	O
:	O
Comparison	O
of	O
formation	O
-	O
dependent	O
physicochemical	O
properties	O
within	O
self	O
-	O
assembled	O
aggregates	O
for	O
an	O
optimal	O
drug	O
carrier	O
Self	O
-	O
assembled	O
surfactant	O
aggregates	O
,	O
such	O
as	O
micelles	O
and	O
vesicles	O
,	O
have	O
been	O
investigated	O
for	O
their	O
application	O
as	O
drug	O
carriers	O
in	O
the	O
treatment	B-T061
of	O
various	O
diseases	B-T047
.	O
However	O
,	O
the	O
characteristics	O
that	O
decide	O
which	O
aggregate	O
is	O
the	O
best	O
drug	O
carrier	O
for	O
each	O
disease	B-T047
have	O
not	O
yet	O
been	O
clarified	O
.	O
In	O
order	O
to	O
design	O
an	O
optimal	O
drug	O
carrier	O
for	O
each	O
disease	B-T047
,	O
various	O
kinds	O
of	O
self	O
-	O
assembled	O
aggregates	O
,	O
such	O
as	O
spherical	O
micelles	O
,	O
lens	O
-	O
like	O
vesicles	O
,	O
and	O
tube	O
-	O
like	O
vesicles	O
,	O
were	O
evaluated	O
by	O
"	O
multiple	O
techniques	O
"	O
including	O
dynamic	B-T059
light	I-T059
scattering	I-T059
,	O
differential	B-T059
scanning	I-T059
calorimetry	I-T059
,	O
nuclear	B-T060
magnetic	I-T060
resonance	I-T060
spectroscopy	I-T060
,	O
and	O
fluorescence	B-T059
measurement	I-T059
using	O
the	O
Laurdan	O
probe	O
.	O
These	O
studies	O
led	O
to	O
the	O
compilation	O
of	O
a	O
database	O
on	O
the	O
formation	O
-	O
dependent	O
properties	O
of	O
self	O
-	O
assembled	O
aggregates	O
.	O
As	O
the	O
relationship	O
between	O
physicochemical	O
properties	O
of	O
self	O
-	O
assembled	O
aggregates	O
and	O
their	O
functions	O
as	O
drug	O
carriers	O
have	O
been	O
extensively	O
reported	O
,	O
this	O
database	O
can	O
be	O
utilized	O
for	O
designing	O
an	O
optimal	O
drug	O
carrier	O
,	O
i.e.	O
,	O
a	O
tailor	O
-	O
made	O
drug	O
carrier	O
.	O
      
Effects	O
of	O
heat	O
treatment	O
on	O
conformation	O
and	O
cell	O
growth	O
activity	O
of	O
alpha-	O
lactalbumin	O
and	O
beta	O
-	O
lactoglobulin	O
from	O
market	O
milk	O
Heat	O
processes	O
,	O
low	O
temperature	O
for	O
long	O
time	O
(	O
LTLT	O
)	O
pasteurization	O
and	O
ultra	B-T061
-	I-T061
heat	I-T061
treatment	I-T061
(	I-T061
UHT	I-T061
)	I-T061
sterilization	I-T061
,	O
are	O
essential	O
for	O
commercial	O
market	O
milk	O
to	O
improve	O
the	O
shelf	O
life	O
of	O
raw	O
milk	O
and	O
ensure	O
microbial	B-T001
safety	O
.	O
We	O
evaluated	O
the	O
effects	O
of	O
heat	O
experience	O
on	O
the	O
molecular	O
properties	O
of	O
α	O
-	O
lactalbumin	O
(	O
α	O
-	O
LA	O
)	O
and	O
β	O
-	O
lactoglobulin	O
(	O
β	O
-	O
LG	O
)	O
isolated	O
from	O
four	O
types	O
of	O
market	O
milk	O
such	O
as	O
LTLT	O
-	O
A	O
(	O
66	O
°	O
C	O
for	O
30	O
min	O
)	O
,	O
LTLT	O
-	O
B	O
(	O
65	O
°	O
C	O
for	O
30	O
min	O
)	O
,	O
UHT	B-T061
-	I-T061
I	I-T061
(	O
130	O
°	O
C	O
for	O
2	O
s	O
,	O
indirect	O
heating	O
)	O
and	O
UHT	B-T061
-	I-T061
D	I-T061
(	O
135	O
°	O
C	O
for	O
2	O
s	O
,	O
direct	O
heating	O
)	O
samples	O
.	O
We	O
examined	O
molecular	O
conformations	O
using	O
circular	B-T059
dichroism	I-T059
spectrum	I-T059
measurement	I-T059
and	O
cell	O
growth	O
activity	O
using	O
the	O
WST-1	O
method	O
for	O
the	O
proteins	O
.	O
α	O
-	O
LA	O
isolated	O
from	O
each	O
of	O
these	O
four	O
types	O
of	O
market	O
milk	O
displayed	O
no	B-T033
significant	I-T033
structural	O
difference	O
as	O
compared	O
to	O
raw	O
milk	O
α	O
-	O
LA	O
,	O
while	O
α	O
-	O
LA	O
of	O
UHT	B-T061
-	I-T061
I	I-T061
only	O
inhibited	O
cell	O
growth	O
of	O
an	O
intestinal	B-T023
epithelial	O
cell	O
line	O
more	O
potently	O
than	O
raw	O
milk	O
α	O
-	O
LA	O
.	O
In	O
the	O
case	O
of	O
β	O
-	O
LG	O
,	O
only	O
the	O
UHT	B-T061
-	I-T061
I	I-T061
sample	O
demonstrated	O
a	O
drastic	O
change	O
in	O
structure	O
,	O
while	O
it	O
did	B-T033
not	I-T033
exhibit	I-T033
any	O
cytotoxicity	O
.	O
We	O
found	O
that	O
cell	O
viability	O
effects	O
of	O
α	O
-	O
LA	O
and	O
β	O
-	O
LG	O
are	O
attributable	O
to	O
the	O
type	O
of	O
UHT	B-T061
;	O
indirect	O
and	O
direct	O
.	O
These	O
findings	B-T033
indicate	O
that	O
the	O
effect	O
of	O
heat	O
treatment	O
on	O
whey	O
proteins	O
should	O
carefully	O
be	O
investigated	O
further	O
.	O
      
Expressions	O
of	O
CD8	O
+	O
TILs	O
,	O
PD	O
-	O
L1	O
and	O
Foxp3	O
+	O
TILs	O
in	O
stage	B-T191
I	I-T191
NSCLC	I-T191
guiding	O
adjuvant	B-T061
chemotherapy	I-T061
decisions	O
Currently	O
,	O
adjuvant	B-T061
chemotherapy	I-T061
is	O
recommended	O
for	O
patients	O
with	O
high	B-T033
risk	I-T033
stage	B-T191
I	I-T191
non	I-T191
-	I-T191
small	I-T191
cell	I-T191
lung	I-T191
cancer	I-T191
(	O
NSCLC	B-T191
)	O
.	O
However	O
,	O
identifying	O
high	B-T033
risk	I-T033
patients	O
remains	O
a	O
challenge	O
.	O
This	O
study	O
aims	O
to	O
identify	O
the	O
patient	O
cohorts	O
more	O
likely	O
to	O
benefit	O
from	O
adjuvant	B-T061
chemotherapy	I-T061
based	O
on	O
the	O
tumor	B-T191
micro	O
-	O
immune	O
environment	O
.	O
CD8	O
+	O
TILs	O
significantly	O
associated	O
with	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survial	O
(	O
OS	O
)	O
(	O
p=0.002	O
;	O
0.040	O
)	O
.	O
Patients	O
with	O
high	B-T033
risk	I-T033
factors	I-T033
may	O
also	O
predict	O
shorter	O
DFS	O
(	O
P=0.056	O
)	O
.	O
When	O
compared	O
together	O
,	O
patients	O
with	O
high	O
-	O
CD8	O
+	O
TILs	O
showed	O
better	O
DFS	O
than	O
patients	O
with	O
low	O
-	O
CD8	O
+	O
TILs	O
,	O
no	O
matter	O
their	O
risk	B-T033
factors	I-T033
status	O
.	O
There	O
's	O
no	B-T033
correlation	I-T033
between	O
PD	O
-	O
L1	O
expressions	O
and	O
survival	O
.	O
PD	O
-	O
L1	O
was	O
highly	O
expressed	O
in	O
men	O
,	O
squamous	O
and	O
well	O
differentiated	O
carcinoma	B-T191
.	O
In	O
addition	O
,	O
Foxp3	O
+	O
TILs	O
alone	O
did	O
n't	O
show	O
any	O
prognostic	O
effects	O
,	O
but	O
low	O
-	O
Foxp3	O
/	O
high	O
-	O
CD8	O
+	O
TILs	O
were	O
associated	O
with	O
prolonged	O
DFS	O
(	O
p=0.031	O
)	O
.	O
A	O
total	O
of	O
126	O
patients	O
with	O
surgically	O
resected	O
stage	B-T191
I	I-T191
NSCLC	I-T191
were	O
included	O
to	O
perform	O
immunohistochemistry	B-T060
of	O
CD8	O
+	O
tumor	O
infiltrating	O
lymphocytes	O
(	O
TILs	O
)	O
,	O
programmed	O
death	O
ligand-1	O
(	O
PD	O
-	O
L1	O
)	O
and	O
forkhead	O
box	O
P3	O
(	O
Foxp3)+	O
TILs	O
.	O
CD8	O
+	O
TILs	O
are	O
effective	O
prognostic	O
predictors	O
.	O
Patients	O
with	O
surgically	O
resected	O
stage	B-T191
I	I-T191
NSCLC	I-T191
showing	O
low	O
CD8	O
+	O
TILs	O
could	O
be	O
considered	O
for	O
adjuvant	B-T061
chemotherapy	I-T061
,	O
even	O
if	O
they	O
have	O
no	O
high	B-T033
risk	I-T033
features	O
.	O
      
Synchronous	O
vitellogenin	O
expression	O
and	O
sexual	O
maturation	O
during	O
migration	O
are	O
negatively	B-T033
correlated	O
with	O
juvenile	O
hormone	O
levels	O
in	O
Mythimna	O
separata	O
Annual	O
migration	O
of	O
pests	O
between	O
different	O
seasonal	O
habitats	O
can	O
lead	O
to	O
serious	O
crop	O
damage	O
.	O
Reproductive	O
immaturity	O
is	O
generally	O
associated	O
with	O
the	O
migratory	O
process	O
(	O
oogenesis	O
-	O
flight	B-T047
syndrome	I-T047
)	O
,	O
but	O
the	O
mechanism	O
of	O
reproductive	O
development	O
during	O
migration	O
varies	O
unpredictably	B-T033
.	O
Here	O
,	O
the	O
vitellogenin	O
gene	O
(	O
MsVg	O
)	O
and	O
three	O
key	O
regulatory	O
enzyme	O
genes	O
(	O
MsJhamt	O
,	O
MsJheh	O
and	O
MsJhe	O
)	O
related	O
to	O
juvenile	O
hormone	O
(	O
JH	O
)	O
synthesis	O
and	O
degradation	O
were	O
identified	O
and	O
characterized	O
in	O
Mythimna	O
separata	O
.	O
The	O
relative	O
expression	O
of	O
MsVg	O
varied	O
significantly	O
in	O
response	O
to	O
seasonal	O
changes	O
and	O
was	O
significantly	O
correlated	O
with	O
stages	O
of	O
ovarian	O
development	O
.	O
The	O
relatively	O
low	O
levels	O
of	O
JH	O
titer	O
did	O
not	B-T033
differ	I-T033
significantly	O
in	O
male	O
moths	O
but	O
slightly	O
increased	O
in	O
female	O
adults	O
during	O
the	O
migratory	O
season	O
,	O
which	O
was	O
consistent	O
with	O
changes	O
in	O
mRNA	O
levels	O
for	O
MsJhamt	O
,	O
MsJheh	O
and	O
MsJhe	O
.	O
JH	O
titer	O
was	O
negatively	B-T033
associated	O
with	O
relative	O
seasonal	O
levels	O
of	O
vitellogenin	O
mRNA	O
transcripts	O
and	O
with	O
ovarian	O
development	O
in	O
migrating	O
M.	O
separata	O
.	O
The	O
synchrony	O
of	O
MsVg	O
expression	O
with	O
sexual	O
maturation	O
highlighted	O
the	O
potential	O
of	O
MsVg	O
transcript	O
levels	O
to	O
serve	O
as	O
an	O
index	O
to	O
monitor	O
the	O
adult	O
reproductive	O
status	O
.	O
In	O
addition	O
,	O
the	O
level	O
of	O
JH	O
and	O
sexual	O
maturity	O
were	O
correlated	O
with	O
the	O
extent	O
of	O
JH	O
in	O
regulating	O
the	O
MsVg	O
expression	O
and	O
reproduction	O
during	O
seasonal	O
northern	O
and	O
southern	O
migration	O
.	O
      
Surgical	B-T061
Excision	I-T061
of	O
Heterotopic	O
Ossification	O
Leads	O
to	O
Re	O
-	O
Emergence	O
of	O
Mesenchymal	O
Stem	O
Cell	O
Populations	O
Responsible	O
for	O
Recurrence	O
Trauma	O
-	O
induced	O
heterotopic	O
ossification	O
(	O
HO	O
)	O
occurs	O
after	O
severe	O
musculoskeletal	O
injuries	O
and	O
burns	O
,	O
and	O
presents	O
a	O
significant	O
barrier	O
to	O
patient	O
rehabilitation	B-T061
.	O
Interestingly	O
,	O
the	O
incidence	O
of	O
HO	O
significantly	O
increases	O
with	O
repeated	B-T061
operations	I-T061
and	O
after	O
resection	B-T061
of	O
previous	O
HO	O
.	O
Treatment	B-T061
of	O
established	O
heterotopic	O
ossification	O
is	O
challenging	O
because	O
surgical	B-T061
excision	I-T061
is	O
often	O
incomplete	O
,	O
with	O
evidence	O
of	O
persistent	O
heterotopic	B-T033
bone	I-T033
.	O
As	O
a	O
result	O
,	O
patients	O
may	O
continue	O
to	O
report	O
the	O
signs	B-T033
or	I-T033
symptoms	I-T033
of	O
HO	O
,	O
including	O
chronic	B-T184
pain	I-T184
,	O
nonhealing	B-T033
wounds	O
,	O
and	O
joint	B-T033
restriction	I-T033
.	O
In	O
this	O
study	O
,	O
we	O
designed	O
a	O
model	B-T050
of	O
recurrent	O
HO	O
that	O
occurs	O
after	O
surgical	B-T061
excision	I-T061
of	O
mature	O
HO	O
in	O
a	O
mouse	B-T050
model	I-T050
of	O
hind	B-T023
-	I-T023
limb	I-T023
Achilles	I-T023
'	I-T023
tendon	I-T023
transection	B-T061
with	O
dorsal	O
burn	O
injury	O
.	O
We	O
first	O
demonstrated	O
that	O
key	O
signaling	O
mediators	O
of	O
HO	O
,	O
including	O
bone	O
morphogenetic	O
protein	O
signaling	O
,	O
are	O
diminished	O
in	O
mature	O
bone	O
.	O
However	O
,	O
upon	O
surgical	B-T061
excision	I-T061
,	O
we	O
have	O
noted	O
upregulation	O
of	O
downstream	O
mediators	O
of	O
osteogenic	B-T121
differentiation	O
,	O
including	O
pSMAD	O
1	O
/	O
5	O
.	O
Additionally	O
,	O
surgical	B-T061
excision	I-T061
resulted	O
in	O
re	O
-	O
emergence	O
of	O
a	O
mesenchymal	O
cell	O
population	O
marked	O
by	O
expression	O
of	O
platelet	O
-	O
derived	O
growth	O
factor	O
receptor	O
-	O
α	O
(	O
PDGFRα	O
)	O
and	O
present	B-T033
in	O
the	O
initial	O
developing	O
HO	O
lesion	B-T033
but	O
absent	O
in	O
mature	O
HO	O
.	O
In	O
the	O
recurrent	O
lesion	B-T033
,	O
these	O
PDGFRα	O
+	O
mesenchymal	O
cells	O
are	O
also	O
highly	O
proliferative	O
,	O
similar	O
to	O
the	O
initial	O
developing	O
HO	O
lesion	B-T033
.	O
These	O
findings	O
indicate	O
that	O
surgical	B-T061
excision	I-T061
of	O
HO	O
results	B-T033
in	O
recurrence	O
through	O
similar	O
mesenchymal	O
cell	O
populations	O
and	O
signaling	O
mechanisms	O
that	O
are	O
present	B-T033
in	O
the	O
initial	O
developing	O
HO	O
lesion	B-T033
.	O
These	O
results	B-T033
are	O
consistent	O
with	O
findings	B-T033
in	O
patients	O
that	O
new	O
foci	O
of	O
ectopic	O
bone	O
can	O
develop	O
in	O
excision	B-T061
sites	O
and	O
are	O
likely	O
related	O
to	O
de	O
novo	O
formation	O
rather	O
than	O
extension	O
of	O
unresected	O
bone	O
.	O
Stem	O
Cells	O
Translational	O
Medicine	O
2017;6:799	O
-	O
806	O
.	O
      
A	O
novel	O
quantitative	O
PCR	O
detects	O
Babesia	O
infection	O
in	O
patients	O
not	O
identified	O
by	O
currently	O
available	O
non	B-T059
-	I-T059
nucleic	I-T059
acid	I-T059
amplification	I-T059
tests	I-T059
Ticks	O
transmit	O
Babesia	O
microti	O
,	O
the	O
causative	B-T033
agents	I-T033
of	O
babesiosis	B-T047
in	O
North	O
America	O
and	O
Europe	O
.	O
Babesiosis	B-T047
is	O
now	O
endemic	B-T047
in	O
Northeastern	O
USA	O
and	O
affects	O
people	O
of	O
all	O
ages	O
.	O
Babesia	O
species	O
infect	O
erythrocytes	O
and	O
can	O
be	O
transmitted	O
through	O
blood	B-T061
transfusion	I-T061
.	O
Whole	O
blood	O
and	O
blood	B-T121
products	I-T121
,	O
which	O
are	O
not	O
tested	O
for	O
Babesia	O
,	O
can	O
cause	O
transfusion	B-T061
-	O
transmitted	O
babesiosis	B-T047
(	O
TTB	B-T047
)	O
resulting	O
in	O
severe	O
consequences	O
in	O
the	O
immuno	B-T033
-	I-T033
compromised	I-T033
patients	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
epidemiological	O
evaluation	O
of	O
babesiosis	B-T047
in	O
a	O
tick	B-T047
-	I-T047
infested	I-T047
state	I-T047
.	O
We	O
examined	B-T033
blood	O
samples	O
from	O
192	O
patients	O
who	O
visited	O
clinics	O
during	O
the	O
active	O
tick	B-T047
-	I-T047
borne	I-T047
diseases	I-T047
season	O
,	O
using	O
a	O
newly	O
developed	O
qPCR	O
assay	O
that	O
uses	O
the	O
specific	O
molecular	O
beacon	O
probe	O
.	O
Due	O
to	O
the	O
absence	O
of	O
clear	O
symptomology	B-T184
,	O
clinical	O
laboratories	O
did	O
not	O
test	O
131	O
samples	O
by	O
IFA	B-T059
,	O
FISH	O
or	O
microscopic	B-T059
examination	I-T059
of	O
Giemsa	O
-	O
stained	O
blood	B-T059
smears	I-T059
.	O
Babesia	O
infection	O
was	O
detected	O
in	O
all	O
age	O
groups	O
by	O
FISH	O
and	O
microscopy	B-T059
;	O
notably	O
patients	O
>	O
40	O
years	O
of	O
age	O
represented	O
64	O
%	O
of	O
tested	O
samples	O
and	O
13	O
%	O
were	O
younger	O
patients	O
.	O
We	O
tested	O
all	O
samples	O
using	O
qPCR	O
and	O
found	O
that	O
38	O
%	O
were	O
positive	B-T033
for	O
Babesia	O
.	O
Of	O
28	O
samples	O
that	O
were	O
positive	B-T033
by	O
FISH	O
,	O
27	O
(	O
96	O
%	O
)	O
were	O
also	O
positive	B-T033
by	O
qPCR	O
indicating	O
high	O
congruency	O
between	O
nucleic	B-T059
acid	I-T059
based	I-T059
tests	I-T059
.	O
Interestingly	O
,	O
of	O
78	O
asymptomatic	B-T033
samples	O
not	O
tested	O
by	O
FISH	O
,	O
22	O
were	O
positive	B-T033
by	O
our	O
qPCR	O
.	O
Direct	O
detection	B-T061
of	O
Babesia	O
relies	O
upon	O
microscopic	B-T059
examination	I-T059
of	O
patient	O
blood	B-T059
smears	I-T059
,	O
which	O
is	O
labor	O
intensive	O
,	O
difficult	O
to	O
scale	O
up	O
,	O
requires	O
specific	O
expertise	O
and	O
is	O
hence	O
,	O
often	O
not	O
performed	O
.	O
In	O
fact	O
,	O
a	O
clinical	O
laboratory	O
examined	B-T033
only	O
23	O
of	O
86	O
blood	O
samples	O
obtained	O
from	O
two	O
different	O
counties	O
by	O
microscopy	B-T059
.	O
By	O
considering	O
individuals	O
positive	B-T033
for	O
Babesia	O
infection	O
when	O
results	O
from	O
currently	O
available	O
microscopy	B-T059
,	O
FISH	O
or	O
serological	B-T059
tests	I-T059
were	O
positive	B-T033
,	O
we	O
found	O
that	O
our	O
qPCR	O
is	O
highly	O
sensitive	O
(	O
96.2	O
%	O
)	O
and	O
showed	O
a	O
specificity	O
of	O
70.5	O
%	O
for	O
Babesia	O
.	O
Robust	O
qPCR	O
using	O
specific	O
probes	O
can	O
be	O
highly	O
useful	O
for	O
efficient	O
and	O
appropriate	O
diagnosis	O
of	O
babesiosis	B-T047
in	O
patients	O
in	O
conjunction	O
with	O
conventional	O
diagnostics	O
,	O
or	O
as	O
a	O
stand	O
-	O
alone	O
test	O
,	O
especially	O
for	O
donated	O
blood	B-T059
screening	I-T059
.	O
The	O
use	O
of	O
a	O
nucleic	B-T059
acid	I-T059
amplification	I-T059
test	I-T059
based	O
screening	B-T059
of	I-T059
blood	I-T059
and	O
blood	B-T121
products	I-T121
could	O
prevent	O
TTB	B-T047
.	O
      
Bi	O
-	O
layered	O
constructs	O
of	O
poly(glycerol	O
-	O
sebacate	O
)	O
-	O
β	O
-	O
tricalcium	O
phosphate	O
for	O
bone	O
-	O
soft	O
tissue	O
interface	O
applications	O
This	O
study	O
aims	O
to	O
establish	O
a	O
facile	O
protocol	O
for	O
the	O
preparation	O
of	O
a	O
bi	O
-	O
layered	O
poly(glycerol	O
-	O
sebacate	O
)	O
(	O
PGS)/	O
β	O
-	O
tricalcium	O
phosphate	O
(	O
β	O
-	O
TCP	O
)	O
construct	O
and	O
to	O
investigate	O
its	O
potential	O
for	O
bone	O
-	O
soft	O
tissue	O
engineering	B-T061
applications	O
.	O
The	O
layered	O
structure	O
was	O
prepared	O
by	O
distributing	O
the	O
ceramic	O
particles	O
within	O
a	O
prepolymer	O
synthesized	O
in	O
a	O
microwave	O
reactor	O
followed	O
by	O
a	O
cross	O
-	O
linking	O
of	O
the	O
final	O
construct	O
in	O
vacuum	O
(	O
<	O
10	O
mbar	O
)	O
.	O
The	O
vacuum	O
stage	O
led	O
to	O
the	O
separation	O
of	O
cross	O
-	O
linked	O
elastomer	O
(	O
top	O
)	O
and	O
ceramic	O
(	O
bottom	O
)	O
phases	O
.	O
Results	O
showed	O
that	O
addition	O
of	O
β	O
-	O
TCP	O
particles	O
to	O
the	O
elastomer	O
matrix	O
after	O
the	O
polymerization	O
led	O
to	O
an	O
increase	O
in	O
compression	O
strength	O
(	O
up	O
to	O
14±2.3MPa	O
)	O
.	O
Tensile	O
strength	O
(	O
σ	O
)	O
,	O
Young	O
's	O
modulus	O
(	O
E	O
)	O
,	O
and	O
elongation	O
at	O
break	O
(	O
%	O
)	O
values	O
were	O
calculated	O
as	O
0.29±0.03MPa	O
and	O
0.21±0.03	O
;	O
0.38±0.02	O
and	O
1.95±0.4	O
;	O
and	O
240±50	O
%	O
and	O
24±2	O
%	O
for	O
PGS	O
and	O
PGS	O
/	O
β	O
-	O
TCP	O
bi	O
-	O
layered	O
constructs	O
,	O
respectively	O
.	O
Morphology	O
was	O
characterized	O
by	O
using	O
Scanning	B-T059
Electron	I-T059
Microscopy	I-T059
(	O
SEM	B-T059
)	O
and	O
micro	B-T060
-	I-T060
computed	I-T060
tomography	I-T060
(	O
μ	B-T060
-	I-T060
CT	I-T060
)	O
.	O
Tomography	B-T060
data	O
revealed	O
an	O
open	O
porosity	O
of	O
35	O
%	O
for	O
the	O
construct	O
,	O
mostly	O
contributed	O
from	O
the	O
ceramic	O
phase	O
since	O
the	O
elastomer	O
side	O
has	O
no	O
pore	O
.	O
Homogeneous	O
β	O
-	O
TCP	O
distribution	O
within	O
the	O
elastomeric	O
structure	O
was	O
observed	O
.	O
Cell	O
culture	O
studies	O
confirmed	O
biocompatibility	O
with	O
poor	O
elastomer	O
-	O
side	O
and	O
good	O
bone	O
-	O
side	O
cell	O
attachment	O
.	O
In	O
a	O
further	O
study	O
to	O
investigate	O
the	O
osteogenic	O
properties	O
,	O
the	O
construct	O
were	O
loaded	O
with	O
BMP-2	O
and/or	O
TGF	B-T121
-	I-T121
β1	I-T121
.	O
The	O
PGS	O
/	O
β	O
-	O
TCP	O
bi	O
-	O
layered	O
constructs	O
with	O
improved	O
mechanical	O
and	O
biological	O
properties	O
have	O
the	O
potential	O
to	O
be	O
used	O
in	O
bone	O
-	O
soft	O
tissue	O
interface	O
applications	O
where	O
soft	O
tissue	O
penetration	O
is	O
a	O
problem	B-T033
.	O
      
Air	O
pollution	O
,	O
neighbourhood	O
and	O
maternal	B-T033
-	O
level	O
factors	O
modify	O
the	O
effect	O
of	O
smoking	O
on	O
birth	O
weight	O
:	O
a	O
multilevel	O
analysis	O
in	O
British	O
Columbia	O
,	O
Canada	O
Maternal	B-T033
smoking	O
during	O
pregnancy	O
negatively	B-T033
impacts	O
fetal	O
growth	O
,	O
but	O
the	O
effect	O
is	O
not	O
homogenous	O
across	O
the	O
population	O
.	O
We	O
sought	O
to	O
determine	O
how	O
the	O
relationship	O
between	O
cigarette	O
use	O
and	O
fetal	O
growth	O
is	O
modified	B-T033
by	O
the	O
social	O
and	O
physical	O
environment	O
.	O
Birth	O
records	O
with	O
covariates	O
were	O
obtained	O
from	O
the	O
BC	O
Perinatal	O
Database	O
Registry	O
(	O
N	O
=	O
232,291	O
)	O
.	O
Maternal	B-T033
smoking	O
status	O
was	O
self	O
-	O
reported	O
as	O
the	O
number	O
of	O
cigarettes	O
smoked	O
per	O
day	O
usually	O
at	O
the	O
first	B-T061
prenatal	I-T061
care	I-T061
visit	I-T061
.	O
Census	O
dissemination	O
areas	O
(	O
DAs	O
)	O
were	O
used	O
as	O
neighbourhood	O
-	O
level	O
units	O
and	O
linked	O
to	O
individual	O
births	O
using	O
residential	O
postal	O
codes	O
to	O
assign	O
exposure	O
to	O
particulate	O
air	O
pollution	O
(	O
PM2.5	O
)	O
and	O
neighbourhood	O
-	O
level	O
attributes	O
such	O
as	O
socioeconomic	O
status	O
(	O
SES	O
)	O
,	O
proportion	O
of	O
post	O
-	O
secondary	O
education	O
,	O
immigrant	O
density	O
and	O
living	O
in	O
a	O
rural	O
place	O
.	O
Random	O
coefficient	O
models	O
were	O
used	O
with	O
cigarettes	O
/day	O
modeled	O
with	O
a	O
random	O
slope	O
to	O
estimate	O
its	O
between-	O
DA	O
variability	O
and	O
test	O
cross	O
-	O
level	O
interactions	O
with	O
the	O
neighbourhood	O
-	O
level	O
variables	O
on	O
continuous	O
birth	O
weight	O
.	O
A	O
significant	O
negative	B-T033
and	O
non	O
-	O
linear	O
association	O
was	O
found	O
between	O
maternal	B-T033
smoking	O
and	O
birth	O
weight	O
.	O
There	O
was	O
significant	O
between-	O
DA	O
intercept	O
variability	O
in	O
birth	O
weight	O
as	O
well	O
as	O
between-	O
DA	O
slope	O
variability	O
of	O
maternal	B-T033
smoking	O
on	O
birth	O
weight	O
of	O
which	O
68	O
and	O
30	O
%	O
respectively	O
was	O
explained	O
with	O
the	O
inclusion	O
of	O
DA	O
-	O
level	O
variables	O
and	O
their	O
cross	O
-	O
level	O
interactions	O
.	O
High	O
DA	O
-	O
level	O
SES	O
had	O
a	O
strong	O
positive	B-T033
association	O
with	O
birth	O
weight	O
but	O
the	O
effect	O
was	O
moderated	O
with	O
increased	O
cigarettes	O
/day	O
.	O
Conversely	O
,	O
heavy	B-T033
smokers	I-T033
showed	O
the	O
largest	O
increases	O
in	O
birth	O
weight	O
with	O
rising	O
neighbourhood	O
education	B-T033
levels	I-T033
.	O
Increased	O
levels	O
of	O
PM2.5	O
and	O
immigrant	O
density	O
were	O
negatively	B-T033
associated	O
with	O
birth	O
weight	O
,	O
but	O
showed	O
positive	B-T033
interactions	O
with	O
increased	O
levels	O
of	O
smoking	O
.	O
Older	O
maternal	O
age	O
and	O
suspected	O
drug	B-T048
or	O
alcohol	O
use	O
both	O
had	O
negative	B-T033
interactions	O
with	O
increased	O
levels	O
of	O
maternal	B-T033
smoking	O
.	O
Maternal	B-T033
smoking	O
had	O
a	O
negative	B-T033
and	O
non	O
-	O
linear	O
dose	O
-	O
response	O
association	O
with	O
birth	O
weight	O
which	O
was	O
highly	O
variable	O
between	O
neighbourhood	O
s	O
and	O
evidence	O
of	O
effect	O
modification	B-T033
with	O
neighbourhood	O
-	O
level	O
factors	O
.	O
These	O
results	O
suggest	O
that	O
focusing	O
exclusively	O
on	O
individual	O
behaviours	O
may	O
have	O
limited	O
success	O
in	O
improving	O
outcomes	O
without	O
addressing	O
the	O
contextual	O
influences	O
at	O
the	O
neighbourhood	O
-	O
level	O
.	O
Further	O
studies	O
are	O
needed	O
to	O
corroborate	O
our	O
findings	B-T033
and	O
to	O
understand	O
how	O
neighbourhood	O
-	O
level	O
attributes	O
interact	O
with	O
smoking	O
to	O
affect	O
birth	O
outcomes	O
.	O
      
Differing	O
rates	O
of	O
antibody	O
acquisition	O
to	O
merozoite	O
antigens	O
in	O
malaria	B-T047
:	O
implications	O
for	O
immunity	O
and	O
surveillance	B-T058
Antibodies	O
play	O
a	O
key	O
role	O
in	O
acquired	O
human	O
immunity	O
to	O
Plasmodium	B-T047
falciparum	I-T047
(	I-T047
Pf	I-T047
)	I-T047
malaria	I-T047
and	O
target	O
merozoites	O
to	O
reduce	O
or	O
prevent	O
blood	O
-stage	O
replication	O
and	O
the	O
development	O
of	O
disease	B-T047
.	O
Merozoites	O
present	O
a	O
complex	O
array	O
of	O
antigens	O
to	O
the	O
immune	O
system	O
,	O
and	O
currently	O
,	O
there	O
is	O
only	O
a	O
partial	O
understanding	O
of	O
the	O
targets	O
of	O
protective	O
antibodies	O
and	O
how	O
responses	O
to	O
different	O
antigens	O
are	O
acquired	O
and	O
boosted	O
.	O
We	O
hypothesized	O
that	O
there	O
would	O
be	O
differences	O
in	O
the	O
rate	O
of	O
acquisition	O
of	O
antibodies	O
to	O
different	O
antigens	O
and	O
how	O
well	O
they	O
are	O
boosted	O
by	O
infection	O
,	O
which	O
impacts	O
the	O
acquisition	O
of	O
immunity	O
.	O
We	O
examined	O
responses	O
to	O
a	O
range	O
of	O
merozoite	O
antigens	O
in	O
2	O
different	O
cohorts	O
of	O
children	O
and	O
adults	O
with	O
different	O
age	O
structures	O
and	O
levels	O
of	O
malaria	B-T047
exposure	O
.	O
Overall	O
,	O
antibodies	O
were	O
associated	O
with	O
age	O
,	O
exposure	O
,	O
and	O
active	O
infection	O
,	O
and	O
the	O
repertoire	O
of	O
responses	O
increased	O
with	O
age	O
and	O
active	O
infection	O
.	O
However	O
,	O
rates	O
of	O
antibody	O
acquisition	O
varied	O
between	O
antigens	O
and	O
different	O
regions	O
within	O
an	O
antigen	O
following	O
exposure	O
to	O
malaria	B-T047
,	O
supporting	O
our	O
hypothesis	O
.	O
Antigen	O
-specific	O
responses	O
could	O
be	O
broadly	O
classified	O
into	O
early	O
response	O
types	O
in	O
which	O
antibodies	O
were	O
acquired	O
early	O
in	O
childhood	O
exposure	O
and	O
late	O
response	O
types	O
that	O
appear	O
to	O
require	O
substantially	O
more	O
exposure	O
for	O
the	O
development	O
of	O
substantial	O
levels	O
.	O
We	O
identified	O
antigen	O
-specific	O
responses	O
that	O
were	O
effectively	O
boosted	O
after	O
recent	O
infection	O
,	O
whereas	O
other	O
responses	O
were	O
not	O
.	O
These	O
findings	O
advance	O
our	O
understanding	O
of	O
the	O
acquisition	O
of	O
human	O
immunity	O
to	O
malaria	B-T047
and	O
are	O
relevant	O
to	O
the	O
development	O
of	O
malaria	B-T121
vaccines	I-T121
targeting	O
merozoite	O
antigens	O
and	O
the	O
selection	O
of	O
antigens	O
for	O
use	O
in	O
malaria	B-T047
surveillance	B-T058
.	O
      
MiR	O
221	O
/	O
222	O
as	O
new	O
players	O
in	O
tamoxifen	B-T121
resistance	O
Breast	B-T191
cancer	I-T191
is	O
the	O
most	O
frequent	O
cancer	B-T191
in	O
women	O
.	O
Despite	O
advances	O
in	O
early	B-T060
detection	I-T060
and	O
treatment	B-T061
,	O
it	O
has	O
the	O
second	O
highest	O
mortality	O
rate	O
after	O
lung	B-T191
cancer	I-T191
.	O
Around	O
85	O
%	O
of	O
breast	B-T191
carcinomas	I-T191
are	O
ER+	B-T033
;	O
thus	O
,	O
antiestrogens	B-T121
like	O
tamoxifen	B-T121
are	O
beneficial	O
.	O
Although	O
,	O
tamoxifen	B-T121
is	O
useful	O
for	O
many	O
patients	O
,	O
plenty	O
of	O
patients	O
respond	B-T033
poorly	I-T033
to	O
initial	O
therapy	B-T061
or	O
recurrence	O
occurs	O
in	O
about	O
30	O
%	O
of	O
cases	O
,	O
because	O
tamoxifen	B-T121
resistance	O
happens	O
.	O
Drug	O
resistance	O
remains	O
a	O
major	O
clinical	O
obstacle	O
to	O
successful	O
treatment	O
of	O
breast	B-T191
cancer	I-T191
and	O
more	O
than	O
90	O
%	O
of	O
unsuccessful	B-T033
treatments	I-T033
are	O
because	O
of	O
acquired	O
resistance	O
and	O
MultiDrug	O
Resistance	O
(	O
MDR	O
)	O
is	O
a	O
major	O
contributor	O
.	O
MicroRNAs	O
are	O
members	O
of	O
a	O
novel	O
class	O
of	O
short	O
noncoding	O
RNAs	O
.	O
Besides	O
to	O
their	O
various	O
roles	O
in	O
gene	O
expression	O
,	O
miRNAs	O
are	O
considered	O
as	O
important	O
cancer	B-T191
therapeutic	O
targets	O
and	O
biomarkers	O
.	O
Since	O
2005	O
,	O
when	O
miRNA	O
deregulation	O
was	O
first	O
reported	O
in	O
breast	B-T191
cancer	I-T191
,	O
more	O
than	O
1000	O
reports	O
have	O
been	O
published	O
about	O
miRNAs	O
.	O
Increasing	O
number	O
of	O
studies	O
showed	O
the	O
importance	O
of	O
miRNAs	O
in	O
antiestrogen	B-T061
therapy	I-T061
,	O
especially	O
on	O
tamoxifen	B-T121
;	O
thus	O
,	O
it	O
is	O
not	O
surprising	O
that	O
these	O
tiny	O
molecules	O
are	O
involved	O
in	O
drug	O
resistance	O
.	O
Due	O
to	O
the	O
pivotal	O
role	O
of	O
these	O
known	O
RNA	O
molecules	O
,	O
in	O
this	O
review	O
,	O
we	O
tried	O
to	O
illustrate	O
the	O
importance	O
of	O
the	O
miRNAs	O
as	O
a	O
new	O
player	O
in	O
breast	B-T191
cancer	I-T191
pathogenesis	O
.	O
We	O
have	O
also	O
focused	O
on	O
cancer	B-T191
drug	O
resistance	O
mechanisms	O
highlighting	O
the	O
role	O
of	O
important	O
oncomirs	O
,	O
miR	O
221	O
/	O
222	O
,	O
involved	O
in	O
cell	O
cycle	O
deregulation	O
in	O
breast	B-T191
cancer	I-T191
.	O
The	O
relationship	O
between	O
these	O
oncomiRs	O
with	O
resistance	O
to	O
tamoxifen	B-T121
is	O
also	O
emphasized	O
.	O
      
Neospora	O
caninum	O
in	O
Axis	O
Deer	O
(	O
Axis	O
axis	O
)	O
and	O
Fallow	O
Deer	O
(	O
Dama	O
dama	O
)	O
in	O
Northern	O
Mexico	O
Serum	O
samples	O
from	O
18	O
axis	O
deer	O
(	O
Axis	O
axis	O
)	O
and	O
19	O
fallow	O
deer	O
(	O
Dama	O
dama	O
)	O
were	O
analyzed	O
with	O
an	O
enzyme	B-T059
-	I-T059
linked	I-T059
immunosorbent	I-T059
assay	I-T059
for	O
Neospora	O
caninum	O
antibodies	O
.	O
Two	O
axis	O
(	O
11	O
%	O
)	O
and	O
two	O
fallow	O
deer	O
(	O
11	O
%	O
)	O
were	O
positive	B-T033
for	O
N.	O
caninum	O
antibodies	O
.	O
      
Quality	O
Improvement	O
of	O
Liver	B-T023
Ultrasound	B-T060
Images	O
Using	O
Fuzzy	O
Techniques	O
Liver	B-T023
ultrasound	B-T060
images	O
are	O
so	O
common	O
and	O
are	O
applied	O
so	O
often	O
to	O
diagnose	B-T033
diffuse	B-T047
liver	I-T047
diseases	I-T047
like	O
fatty	B-T047
liver	I-T047
.	O
However	O
,	O
the	O
low	O
quality	O
of	O
such	O
images	O
makes	O
it	O
difficult	O
to	O
analyze	O
them	O
and	O
diagnose	B-T033
diseases	B-T047
.	O
The	O
purpose	O
of	O
this	O
study	O
,	O
therefore	O
,	O
is	O
to	O
improve	O
the	O
contrast	O
and	O
quality	O
of	O
liver	B-T023
ultrasound	B-T060
images	O
.	O
In	O
this	O
study	O
,	O
a	O
number	O
of	O
image	O
contrast	O
enhancement	O
algorithms	O
which	O
are	O
based	O
on	O
fuzzy	O
logic	O
were	O
applied	O
to	O
liver	B-T023
ultrasound	B-T060
images	O
-	O
in	O
which	O
the	O
view	O
of	O
kidney	B-T023
is	O
observable	O
-	O
using	O
Matlab2013b	O
to	O
improve	O
the	O
image	O
contrast	O
and	O
quality	O
which	O
has	O
a	O
fuzzy	O
definition	O
;	O
just	O
like	O
image	O
contrast	O
improvement	O
algorithms	O
using	O
a	O
fuzzy	O
intensification	O
operator	O
,	O
contrast	O
improvement	O
algorithms	O
applying	O
fuzzy	O
image	O
histogram	O
hyperbolization	O
,	O
and	O
contrast	O
improvement	O
algorithms	O
by	O
fuzzy	O
IF	O
-	O
THEN	O
rules	O
.	O
With	O
the	O
measurement	O
of	O
Mean	O
Squared	O
Error	O
and	O
Peak	O
Signal	O
to	O
Noise	O
Ratio	O
obtained	O
from	O
different	O
images	O
,	O
fuzzy	O
methods	O
provided	O
better	O
results	O
,	O
and	O
their	O
implementation	O
-	O
compared	O
with	O
histogram	O
equalization	O
method	O
-	O
led	O
both	O
to	O
the	O
improvement	O
of	O
contrast	O
and	O
visual	B-T033
quality	I-T033
of	O
images	O
and	O
to	O
the	O
improvement	O
of	O
liver	B-T023
segmentation	O
algorithms	O
results	O
in	O
images	O
.	O
Comparison	O
of	O
the	O
four	O
algorithms	O
revealed	O
the	O
power	O
of	O
fuzzy	O
logic	O
in	O
improving	O
image	O
contrast	O
compared	O
with	O
traditional	O
image	O
processing	O
algorithms	O
.	O
Moreover	O
,	O
contrast	O
improvement	O
algorithm	O
based	O
on	O
a	O
fuzzy	O
intensification	O
operator	O
was	O
selected	O
as	O
the	O
strongest	O
algorithm	O
considering	O
the	O
measured	O
indicators	O
.	O
This	O
method	O
can	O
also	O
be	O
used	O
in	O
future	O
studies	O
on	O
other	O
ultrasound	B-T060
images	O
for	O
quality	O
improvement	O
and	O
other	O
image	O
processing	O
and	O
analysis	O
applications	O
.	O
      
Developing	O
understanding	O
of	O
object	O
fall	B-T033
:	O
Going	O
beyond	O
inhibitory	O
processes	O
A	O
study	O
is	O
reported	O
where	O
118	O
participants	O
aged	O
between	O
10	O
years	O
and	O
early	O
20s	O
drew	O
the	O
trajectories	O
they	O
expected	O
objects	O
to	O
follow	O
as	O
they	O
fell	B-T033
.	O
The	O
younger	O
participants	O
typically	O
anticipated	B-T033
backward	O
trajectories	O
during	O
fall	B-T033
from	O
moving	O
carriers	O
while	O
forward	O
but	O
non	O
-	O
parabolic	O
trajectories	O
were	O
relatively	O
more	O
frequent	O
amongst	O
the	O
older	O
participants	O
.	O
Both	O
patterns	O
suggest	O
strong	O
sociocultural	O
influences	O
,	O
with	O
implications	O
for	O
models	O
that	O
regard	O
development	O
in	O
this	O
area	O
as	O
purely	O
the	O
inhibition	O
of	O
principles	O
established	O
in	O
infancy	O
.	O
Statement	O
of	O
contribution	O
What	O
is	O
already	O
known	O
on	O
this	O
subject	O
?	O
Research	O
with	O
infants	O
demonstrates	O
an	O
early	O
-	O
established	O
belief	O
that	O
dropped	O
objects	O
fall	B-T033
straight	O
down	O
.	O
The	O
erroneous	O
expectations	O
that	O
pre	O
-	O
schoolers	O
hold	O
about	O
object	O
fall	B-T033
are	O
consistent	O
with	O
failure	O
to	O
inhibit	O
the	O
presumption	O
of	O
straight	O
-	O
down	O
fall	B-T033
,	O
in	O
contexts	O
where	O
it	O
is	O
inappropriate	O
.	O
What	O
does	O
this	O
study	O
add	O
?	O
The	O
research	O
replicates	O
and	O
extends	O
research	O
with	O
older	O
participants	O
,	O
which	O
indicates	O
errors	O
that	O
can	O
not	O
be	O
explained	B-T058
via	O
failed	O
inhibition	O
of	O
straight	O
-	O
down	O
fall	B-T033
.	O
It	O
is	O
the	O
first	O
study	O
to	O
trace	O
patterns	O
of	O
errors	O
across	O
late	O
childhood	O
,	O
adolescence	O
and	O
early	O
adulthood	O
.	O
A	O
consequence	O
of	O
the	O
findings	B-T033
is	O
that	O
adequate	O
modelling	O
in	O
developmental	O
psychology	O
must	O
consider	O
multilayered	O
interactions	O
between	O
prior	O
representations	O
and	O
sociocultural	O
experiences	O
.	O
      
Dental	O
enamel	B-T033
defects	I-T033
in	O
German	O
medieval	O
and	O
early	O
-	O
modern	O
-	O
age	O
populations	O
Aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
frequency	O
and	O
type	O
of	O
developmental	B-T033
defects	I-T033
of	I-T033
enamel	I-T033
(	O
DDE	B-T033
)	O
in	O
a	O
medieval	O
and	O
an	O
early	O
-	O
modern	O
-	O
age	O
population	O
from	O
Thuringia	O
,	O
Germany	O
.	O
Sixty	O
-	O
six	O
skeletons	O
subdivided	O
into	O
31	O
single	O
burials	O
(	O
12(th)/13(th	O
)	O
c.	O
)	O
and	O
35	O
individuals	O
buried	O
in	O
groups	O
(	O
15(th)/16(th	O
)	O
c.	O
)	O
were	O
examined	B-T033
.	O
DDE	B-T033
were	O
classified	O
on	O
1,246	O
teeth	B-T023
according	O
to	O
the	O
DDE	B-T033
index	O
.	O
Molar	B-T047
-	I-T047
incisor	I-T047
-	I-T047
hypomineralisation	I-T047
(	O
MIH	B-T047
)	O
,	O
a	O
special	O
type	O
of	O
DDE	B-T033
,	O
was	O
recorded	O
according	O
to	O
the	O
European	O
Academy	O
of	O
Paediatric	O
Dentistry	O
(	O
EAPD	O
)	O
criteria	O
.	O
DDE	B-T033
was	O
found	O
in	O
89.4	O
%	O
of	O
the	O
individuals	O
(	O
single	O
burials	O
90.3	O
%	O
and	O
group	O
burials	O
88.6	O
%	O
)	O
.	O
Hypoplastic	O
pits	B-T033
were	O
the	O
most	O
frequent	O
defect	O
in	O
primary	B-T023
teeth	I-T023
and	O
linear	B-T047
enamel	I-T047
hypoplasia	I-T047
(	O
LEH	B-T047
)	O
in	O
permanent	B-T023
teeth	I-T023
.	O
13	O
individuals	O
(	O
24.1	O
%	O
)	O
showed	O
at	O
least	O
one	O
hypomineralised	B-T047
permanent	B-T023
tooth	I-T023
,	O
12.2	O
%	O
had	O
MIH	B-T047
on	O
at	O
least	O
one	O
first	O
permanent	B-T023
molar	I-T023
and	O
10.0	O
%	O
in	O
permanent	B-T023
incisors	I-T023
.	O
Second	B-T023
primary	I-T023
molars	I-T023
were	O
affected	O
in	O
8.0	O
%	O
of	O
the	O
children	O
and	O
juveniles	O
.	O
No	O
individual	O
suffered	O
from	O
affected	O
molars	B-T023
and	O
incisors	B-T023
in	O
combination	O
.	O
Endogenous	O
factors	O
like	O
nutritional	B-T047
deficiencies	I-T047
and	O
health	B-T033
problems	I-T033
in	O
early	O
childhood	O
could	O
have	O
been	O
aetiological	O
reasons	O
of	O
DDE	B-T033
and	O
MIH	B-T047
.	O
The	O
frequency	O
of	O
DDE	B-T033
and	O
MIH	B-T047
might	O
have	O
been	O
masked	O
by	O
extended	O
carious	B-T047
lesions	I-T047
,	O
dental	O
wear	O
and	O
ante	B-T033
-	I-T033
mortem	I-T033
tooth	B-T020
loss	I-T020
.	O
      
The	O
consummatory	O
and	O
motivational	O
behaviors	O
for	O
natural	O
rewards	O
following	O
long	O
-	O
term	O
withdrawal	B-T061
from	O
morphine	B-T121
:	O
no	O
anhedonia	B-T048
but	O
persistent	O
maladaptive	B-T033
behaviors	I-T033
for	O
high	O
-	O
value	O
rewards	O
The	O
negative	O
affective	O
state	O
,	O
e.g.	O
,	O
anhedonia	B-T048
,	O
emerges	O
after	O
abstinence	B-T061
from	O
abused	O
drugs	O
may	O
be	O
linked	O
to	O
the	O
motivational	O
processes	O
of	O
drug	B-T033
craving	I-T033
and	O
relapse	O
.	O
Although	O
anhedonia	B-T048
diminishes	O
over	O
time	O
with	O
drug	O
abstinence	O
,	O
it	O
is	O
not	O
yet	O
rather	O
explicit	O
whether	O
anhedonia	B-T048
exists	O
or	O
not	O
following	O
protracted	O
withdrawal	B-T061
.	O
The	O
behavioral	O
responses	O
to	O
natural	O
rewards	O
were	O
examined	O
after	O
2	O
to	O
3	O
weeks	O
withdrawal	B-T061
from	O
morphine	B-T121
.	O
Male	O
rats	O
were	O
pretreated	O
with	O
either	O
a	O
binge	O
-	O
like	O
morphine	B-T121
paradigm	O
or	O
daily	O
saline	B-T061
injection	I-T061
for	O
5	O
days	O
.	O
The	O
consummatory	O
and	O
motivational	O
behaviors	O
for	O
three	O
natural	O
rewards	O
(	O
sucrose	B-T121
solutions	I-T121
4	O
,	O
15	O
,	O
and	O
60	O
%	O
,	O
social	O
stimulus	O
:	O
male	O
rat	O
,	O
and	O
sexual	O
stimulus	O
:	O
estrous	O
female	O
rat	O
)	O
were	O
examined	O
under	O
varied	O
testing	O
conditions	O
.	O
The	O
morphine	B-T121
-	O
withdrawn	B-T061
rats	O
significantly	O
increased	O
their	O
intake	O
of	O
15	O
%	O
sucrose	B-T121
solution	I-T121
during	O
the	O
1	O
-	O
h	O
consumption	B-T060
test	I-T060
and	O
their	O
operant	O
responding	O
for	O
15	O
%	O
sucrose	B-T121
solution	I-T121
under	O
a	O
progressive	O
ratio	O
(	O
PR	O
)	O
schedule	O
of	O
reinforcement	O
.	O
When	O
obtaining	O
a	O
reinforcer	O
was	O
associated	O
with	O
a	O
0.5	O
mA	O
foot	B-T023
shock	B-T061
under	O
a	O
PR	O
-	O
punishment	O
schedule	O
,	O
the	O
morphine	B-T121
-	O
withdrawn	B-T061
rats	O
showed	O
a	O
higher	O
performance	O
for	O
60	O
%	O
sucrose	B-T121
solution	I-T121
.	O
Meanwhile	O
,	O
the	O
morphine	B-T121
-	O
withdrawn	B-T061
rats	O
displayed	O
a	O
higher	O
motivation	O
to	O
sexual	O
stimulus	O
during	O
the	O
free	B-T060
-	I-T060
approach	I-T060
test	I-T060
and	O
more	O
approaching	O
behaviors	O
towards	O
sexual	O
stimulus	O
in	O
a	O
conflict	B-T060
-	I-T060
based	I-T060
approach	I-T060
test	I-T060
(	O
concurrent	O
presence	O
of	O
reward	O
and	O
aversive	O
stimulus	O
)	O
.	O
No	B-T033
anhedonia	B-T048
-like	O
behavior	O
but	O
sensitized	O
behaviors	O
for	O
natural	O
rewards	O
were	O
found	O
after	O
long	O
-	O
term	O
morphine	B-T121
withdrawal	B-T061
.	O
Notably	O
,	O
the	O
morphine	B-T121
-	O
withdrawn	B-T061
rats	O
displayed	O
persistent	O
motivated	O
behaviors	O
for	O
high	O
-	O
value	O
rewards	O
(	O
60	O
%	O
sucrose	B-T121
and	O
sexual	O
stimulus	O
)	O
in	O
the	O
conflict	B-T060
tests	I-T060
suggesting	O
impairments	O
in	O
inhibitory	O
control	O
in	O
morphine	B-T121
-	O
treated	O
rats	O
.	O
      
Selection	O
of	O
an	O
Artificial	O
Diet	O
for	O
Laboratory	O
Rearing	B-T059
of	O
Opogona	O
sacchari	O
(	O
Lepidoptera	O
:	O
Tineidae	O
)	O
(	O
Bojer	O
,	O
1856	O
)	O
The	O
banana	O
moth	O
Opogona	O
sacchari	O
(	O
Bojer	O
)	O
(	O
Lepidoptera	O
:	O
Tineidae	O
)	O
is	O
a	O
polyphagous	O
pest	O
that	O
can	O
cause	O
serious	O
damage	O
,	O
in	O
particular	O
to	O
banana	O
crops	O
in	O
southern	O
Brazil	O
.	O
The	O
insect	O
is	O
a	O
quarantine	O
pest	O
in	O
several	O
countries	O
,	O
including	O
Argentina	O
,	O
the	O
main	O
consumer	O
market	O
for	O
bananas	O
from	O
southern	O
Brazil	O
.	O
Little	O
information	O
is	O
available	O
about	O
the	O
biology	O
and	O
ecology	O
of	O
this	O
moth	O
,	O
such	O
as	O
a	O
suitable	O
diet	O
for	O
laboratory	O
rearing	B-T059
.	O
In	O
order	O
to	O
provide	O
support	O
for	O
integrated	O
pest	O
management	O
of	O
the	O
pest	O
,	O
this	O
study	O
furnished	O
data	O
for	O
selecting	O
two	O
diets	O
suitable	O
for	O
continuous	O
laboratory	O
rearing	B-T059
of	O
O.	O
sacchari	O
,	O
one	O
based	O
on	O
dried	O
beans	O
,	O
wheat	O
germ	O
,	O
soy	O
bran	O
,	O
brewer	O
's	O
yeast	O
,	O
and	O
casein	B-T121
and	O
another	O
diet	O
with	O
wheat	O
germ	O
and	O
casein	B-T121
as	O
protein	O
sources	B-T033
.	O
With	O
both	O
diets	O
,	O
the	O
viability	O
of	O
the	O
egg	O
-	O
adult	O
period	O
exceeded	O
68	O
%	O
,	O
with	O
fertility	O
over	O
338	O
eggs	O
per	O
female	O
.	O
A	O
corrected	O
biotic	O
potential	O
analysis	O
gave	O
similar	O
values	O
for	O
the	O
two	O
diets	O
.	O
      
Implementation	O
of	O
infrared	B-T059
and	O
Raman	B-T059
modalities	O
for	O
glycosaminoglycan	B-T121
characterization	O
in	O
complex	O
systems	O
Glycosaminoglycans	B-T121
(	O
GAGs	B-T121
)	O
are	O
natural	O
,	O
linear	O
and	O
negatively	O
charged	O
heteropolysaccharides	B-T121
which	O
are	O
incident	O
in	O
every	O
mammalian	O
tissue	O
.	O
They	O
consist	O
of	O
repeating	O
disaccharide	O
units	O
,	O
which	O
are	O
composed	O
of	O
either	O
sulfated	O
or	O
non	O
-	O
sulfated	O
monosaccharides	O
.	O
Depending	O
on	O
tissue	O
types	O
,	O
GAGs	B-T121
exhibit	O
structural	O
heterogeneity	O
such	O
as	O
the	O
position	O
and	O
degree	O
of	O
sulfation	O
or	O
within	O
their	O
disaccharide	O
units	O
composition	O
being	O
heparin	B-T121
,	O
heparan	O
sulfate	O
,	O
chondroitine	B-T121
sulfate	I-T121
,	O
dermatan	O
sulfate	O
,	O
keratan	O
sulfate	O
,	O
and	O
hyaluronic	B-T121
acid	I-T121
.	O
They	O
are	O
covalently	O
linked	O
to	O
a	O
core	O
protein	O
(	O
proteoglycans	O
)	O
or	O
as	O
free	O
chains	O
(	O
hyaluronan	B-T121
)	O
.	O
GAGs	B-T121
affect	O
cell	O
properties	O
and	O
functions	O
either	O
by	O
direct	O
interaction	O
with	O
cell	O
receptors	O
or	O
by	O
sequestration	O
of	O
growth	O
factors	O
.	O
These	O
evidences	O
of	O
divert	O
biological	O
roles	O
of	O
GAGs	B-T121
make	O
their	O
characterization	O
at	O
cell	O
and	O
tissue	O
levels	O
of	O
importance	O
.	O
Thus	O
,	O
non	O
-	O
invasive	O
techniques	O
are	O
interesting	O
to	O
investigate	O
,	O
to	O
qualitatively	O
and	O
quantitatively	O
characterize	O
GAGs	B-T121
in	O
vitro	O
in	O
order	O
to	O
use	O
them	O
as	O
diagnostic	O
biomarkers	O
and/or	O
as	O
therapeutic	O
targets	O
in	O
several	O
human	O
diseases	B-T047
including	O
cancer	B-T191
.	O
Infrared	B-T059
and	O
Raman	B-T059
microspectroscopies	I-T059
and	O
imaging	B-T060
are	O
sensitive	O
enough	O
to	O
differentiate	O
and	O
classify	O
GAG	B-T121
types	O
and	O
subtypes	O
in	O
spite	O
of	O
their	O
close	O
molecular	O
structures	O
.	O
Spectroscopic	B-T059
markers	O
characteristic	O
of	O
reference	O
GAG	B-T121
molecules	O
were	O
identified	O
.	O
Beyond	O
these	O
investigations	B-T058
of	O
the	O
standard	O
GAG	B-T121
spectral	O
signature	O
,	O
infrared	B-T059
and	O
Raman	B-T059
spectral	O
signatures	O
of	O
GAG	B-T121
were	O
searched	O
in	O
complex	O
biological	O
systems	O
like	O
cells	O
.	O
The	O
aim	O
of	O
the	O
present	O
review	O
is	O
to	O
describe	O
the	O
implementation	O
of	O
these	O
complementary	O
vibrational	B-T059
spectroscopy	I-T059
techniques	I-T059
,	O
and	O
to	O
discuss	O
their	O
potentials	O
,	O
advantages	O
and	O
disadvantages	O
for	O
GAG	B-T121
analysis	B-T059
.	O
In	O
addition	O
,	O
this	O
review	O
presents	O
new	O
data	O
as	O
we	O
show	O
for	O
the	O
first	O
time	O
GAG	B-T121
infrared	B-T059
and	O
Raman	B-T059
spectral	O
signatures	O
from	O
conditioned	O
media	O
and	O
live	O
cells	O
,	O
respectively	O
.	O
      
Homocysteine	O
as	O
a	O
peripheral	O
biomarker	O
in	O
bipolar	B-T048
disorder	I-T048
:	O
A	O
meta	O
-	O
analysis	O
Bipolar	B-T048
disorder	I-T048
(	O
BD	B-T048
)	O
is	O
a	O
psychiatric	B-T048
disorder	I-T048
with	O
an	O
uncertain	B-T033
aetiology	O
.	O
Recently	O
,	O
special	O
attention	O
has	O
been	O
given	O
to	O
homocysteine	O
(	O
Hcy	O
)	O
,	O
as	O
it	O
has	O
been	O
suggested	O
that	O
alterations	O
in	O
1	O
-	O
carbon	O
metabolism	O
might	O
be	O
implicated	O
in	O
diverse	O
psychiatric	B-T048
disorders	I-T048
.	O
However	O
,	O
there	O
is	O
uncertainty	B-T033
regarding	O
possible	O
alterations	O
in	O
peripheral	O
Hcy	O
levels	O
in	O
BD	B-T048
.	O
This	O
study	O
comprises	O
a	O
meta	O
-	O
analysis	O
comparing	O
serum	B-T059
and	O
plasma	B-T059
Hcy	I-T059
levels	I-T059
in	O
persons	O
with	O
BD	B-T048
and	O
healthy	O
controls	O
.	O
We	O
conducted	O
a	O
systematic	O
search	O
for	O
all	O
eligible	O
English	O
and	O
non	O
-	O
English	O
peer	O
-	O
reviewed	O
articles	O
.	O
Nine	O
cross	O
-	O
sectional	O
studies	O
were	O
included	O
in	O
the	O
meta	O
-	O
analyses	O
,	O
providing	O
data	O
on	O
1547	O
participants	O
.	O
Random	O
-	O
effects	O
meta	O
-	O
analysis	O
showed	O
that	O
serum	B-T059
and	O
plasma	B-T059
levels	I-T059
of	I-T059
Hcy	I-T059
were	O
increased	O
in	O
subjects	O
with	O
BD	B-T048
in	O
either	O
mania	B-T048
or	O
euthymia	B-T048
when	O
compared	O
to	O
healthy	O
controls	O
,	O
with	O
a	O
large	O
effect	O
size	O
in	O
the	O
mania	B-T048
group	O
(	O
g=0.98	O
,	O
95	O
%	O
CI	O
:	O
0.8	O
-	O
1.17	O
,	O
P<0.001	O
,	O
n=495	O
)	O
and	O
a	O
small	O
effect	O
in	O
the	O
euthymia	B-T048
group	O
(	O
g=0.3	O
,	O
95	O
%	O
CI	O
:	O
0.11	O
-	O
0.48	O
,	O
P=0.002	O
,	O
n=1052	O
)	O
.	O
Our	O
meta	O
-	O
analysis	O
provides	O
evidence	O
that	O
Hcy	B-T033
levels	I-T033
are	I-T033
elevated	I-T033
in	O
persons	O
with	O
BD	B-T048
during	O
mania	B-T048
and	O
euthymia	B-T048
.	O
Peripheral	O
Hcy	O
could	O
be	O
considered	O
as	O
a	O
potential	O
biomarker	O
in	O
BD	B-T048
,	O
both	O
of	O
trait	O
(	O
since	O
it	O
is	O
increased	O
in	O
euthymia	B-T048
)	O
,	O
and	O
also	O
of	O
state	O
(	O
since	O
its	O
increase	O
is	O
more	O
accentuated	O
in	O
mania	B-T048
)	O
.	O
Longitudinal	O
studies	O
are	O
needed	O
to	O
clarify	O
the	O
relationship	O
between	O
bipolar	B-T048
disorder	I-T048
and	O
Hcy	O
,	O
as	O
well	O
as	O
the	O
usefulness	O
of	O
peripheral	O
Hcy	O
as	O
both	O
a	O
trait	O
and	O
state	O
biomarker	O
in	O
BD	B-T048
.	O
      
Commissioning	O
through	O
competition	O
and	O
cooperation	O
in	O
the	O
English	O
NHS	B-T058
under	O
the	O
Health	B-T058
and	I-T058
Social	I-T058
Care	I-T058
Act	I-T058
2012	I-T058
:	O
evidence	O
from	O
a	O
qualitative	O
study	O
of	O
four	O
clinical	O
commissioning	O
groups	O
The	O
Health	B-T058
and	I-T058
Social	I-T058
Care	I-T058
Act	I-T058
2012	I-T058
(	O
'	O
HSCA	B-T058
2012	I-T058
'	O
)	O
introduced	O
a	O
new	O
,	O
statutory	O
,	O
form	O
of	O
regulation	O
of	O
competition	O
into	O
the	O
National	B-T058
Health	I-T058
Service	I-T058
(	O
NHS	B-T058
)	O
,	O
while	O
at	O
the	O
same	O
time	O
recognising	O
that	O
cooperation	O
was	O
necessary	O
.	O
NHS	B-T058
England	O
's	O
policy	O
document	O
,	O
The	O
Five	O
Year	O
Forward	O
View	O
(	O
'	O
5YFV	O
'	O
)	O
of	O
2014	O
placed	O
less	O
emphasis	O
on	O
competition	O
without	O
altering	O
the	O
legislation	O
.	O
We	O
explored	O
how	O
commissioners	O
and	O
providers	O
understand	O
the	O
complex	O
regulatory	O
framework	O
,	O
and	O
how	O
they	O
behave	O
in	O
relation	O
to	O
competition	O
and	O
cooperation	O
.	O
We	O
carried	O
out	O
detailed	O
case	O
studies	O
in	O
four	O
clinical	O
commissioning	O
groups	O
,	O
using	O
interviews	O
and	O
documentary	O
analysis	O
to	O
explore	O
the	O
commissioners	O
'	O
and	O
providers	O
'	O
understanding	O
and	O
experience	O
of	O
competition	O
and	O
cooperation	O
.	O
We	O
conducted	O
42	O
interviews	O
with	O
senior	O
managers	O
in	O
commissioning	O
organisations	O
and	O
senior	O
managers	O
in	O
NHS	B-T058
and	O
independent	O
provider	O
organisations	O
(	O
acute	O
and	O
community	O
services	O
)	O
.	O
Neither	O
commissioners	O
nor	O
providers	O
fully	O
understand	O
the	O
regulatory	O
regime	O
in	O
respect	O
of	O
competition	O
in	O
the	O
NHS	B-T058
,	O
and	O
have	O
not	O
found	O
that	O
the	O
regulatory	O
authorities	O
have	O
provided	O
adequate	O
guidance	O
.	O
Despite	O
the	O
HSCA	B-T058
2012	I-T058
promoting	O
competition	O
,	O
commissioners	O
chose	O
mainly	O
to	O
use	O
collaborative	O
strategies	O
to	O
effect	O
major	O
service	O
reconfigurations	O
,	O
which	O
is	O
endorsed	O
as	O
a	O
suitable	O
approach	O
by	O
providers	O
.	O
Nevertheless	O
,	O
commissioners	O
are	O
using	O
competitive	O
tendering	O
in	O
respect	O
of	O
more	O
peripheral	O
services	O
in	O
order	O
to	O
improve	O
quality	B-T058
of	I-T058
care	I-T058
and	O
value	O
for	O
money	O
.	O
Commissioners	O
regard	O
the	O
use	O
of	O
competition	O
and	O
cooperation	O
as	O
appropriate	O
in	O
the	O
NHS	B-T058
currently	O
,	O
although	O
collaborative	O
strategies	O
appear	O
more	O
helpful	O
in	O
respect	O
of	O
large	O
-	O
scale	O
changes	O
.	O
However	O
,	O
the	O
current	O
regulatory	O
framework	O
contained	O
in	O
the	O
HSCA	B-T058
2012	I-T058
,	O
particularly	O
since	O
the	O
publication	O
of	O
the	O
5YFV	O
,	O
is	O
not	O
clear	O
.	O
Better	O
guidance	O
should	O
be	O
issued	O
by	O
the	O
regulatory	O
authorities	O
.	O
      
Characterization	O
of	O
exposure	O
in	O
epidemiological	O
studies	O
on	O
air	O
pollution	O
from	O
biodegradable	O
wastes	O
:	O
Misclassification	O
and	O
comparison	O
of	O
exposure	O
assessment	B-T058
strategies	O
The	O
assignment	O
of	O
exposure	O
is	O
one	O
of	O
the	O
main	O
challenges	O
faced	O
by	O
environmental	O
epidemiologists	O
.	O
However	O
,	O
misclassification	O
of	O
exposures	O
has	O
not	O
been	O
explored	O
in	O
population	O
epidemiological	O
studies	O
on	O
air	O
pollution	O
from	O
biodegradable	O
wastes	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
use	O
of	O
different	O
approaches	O
for	O
assessing	O
exposure	O
to	O
air	O
pollution	O
from	O
biodegradable	O
wastes	O
by	O
analyzing	O
(	O
1	O
)	O
the	O
misclassification	O
of	O
exposure	O
that	O
is	O
committed	O
by	O
using	O
these	O
surrogates	O
,	O
(	O
2	O
)	O
the	O
existence	O
of	O
differentia	O
l	O
misclassification	O
(	O
3	O
)	O
the	O
effects	O
that	O
misclassification	O
may	O
have	O
on	O
health	O
effect	O
estimates	O
and	O
the	O
interpretation	O
of	O
epidemiological	O
results	B-T033
,	O
and	O
(	O
4	O
)	O
the	O
ability	O
of	O
the	O
exposure	O
measures	O
to	O
predict	O
health	O
outcomes	O
using	O
10	O
-	O
fold	O
cross	O
validation	O
.	O
Four	O
different	O
exposure	O
assessment	B-T058
approaches	O
were	O
studied	O
:	O
ammonia	B-T121
concentrations	O
at	O
the	O
residence	O
(	O
Metric	O
I	O
)	O
,	O
distance	O
to	O
the	O
closest	O
source	B-T033
(	O
Metric	O
II	O
)	O
,	O
number	O
of	O
sources	B-T033
within	O
certain	O
distances	O
from	O
the	O
residence	O
(	O
Metric	O
IIIa	O
,	O
b	O
)	O
and	O
location	O
in	O
a	O
specific	O
region	O
(	O
Metric	O
IV	O
)	O
.	O
Exposure	O
-	O
response	O
models	O
based	O
on	O
Metric	O
I	O
provided	O
the	O
highest	O
predictive	O
ability	O
(	O
72.3	O
%	O
)	O
and	O
goodness	O
-	O
of	O
-	O
fit	O
,	O
followed	O
by	O
IV	O
,	O
III	O
and	O
II	O
.	O
When	O
compared	O
to	O
Metric	O
I	O
,	O
Metric	O
IV	O
yielded	O
the	O
best	O
results	B-T033
for	O
exposure	O
misclassification	O
analysis	O
and	O
interpretation	O
of	O
health	O
effect	O
estimates	O
,	O
followed	O
by	O
Metric	O
IIIb	O
,	O
IIIa	O
and	O
II	O
.	O
The	O
study	O
showed	O
that	O
modelled	O
NH3	B-T121
concentrations	O
provide	O
more	O
accurate	O
estimations	O
of	O
true	O
exposure	O
than	O
distances	O
-	O
based	O
surrogates	O
,	O
and	O
that	O
distance	O
-	O
based	O
surrogates	O
(	O
especially	O
those	O
based	O
on	O
distance	O
to	O
the	O
closest	O
point	O
source	B-T033
)	O
are	O
imprecise	O
methods	O
to	O
identify	O
exposed	O
populations	O
,	O
although	O
they	O
may	O
be	O
useful	O
for	O
initial	O
studies	O
.	O
      
Lycopene	B-T121
and	O
risk	O
of	O
cardiovascular	B-T047
diseases	I-T047
:	O
A	O
meta	O
-	O
analysis	O
of	O
observational	B-T033
studies	I-T033
The	O
aim	O
of	O
current	O
meta	O
-	O
analysis	O
was	O
to	O
investigate	O
the	O
relation	O
between	O
lycopene	B-T121
and	O
risk	O
of	O
cardiovascular	B-T047
diseases	I-T047
(	O
CVD	B-T047
)	O
.	O
Studies	O
concerning	O
about	O
the	O
association	O
between	O
lycopene	B-T121
and	O
risk	O
of	O
CVD	B-T047
were	O
searched	O
on	O
Pubmed	O
,	O
Embase	O
,	O
and	O
Web	O
of	O
Science	O
from	O
inception	O
to	O
October	O
2016	O
.	O
A	O
total	O
of	O
14	O
eligible	O
studies	O
were	O
identified	O
.	O
A	O
significantly	O
inverse	O
association	O
with	O
a	O
pooled	O
risk	O
ratio	O
(	O
RR	O
)	O
of	O
0.83	O
(	O
95	O
%	O
CI	O
:	O
0.76	O
-	O
0.90	O
)	O
was	O
shown	O
between	O
lycopene	B-T121
exposure	O
and	O
risk	O
of	O
CVD	B-T047
.	O
Findings	B-T033
were	O
similar	O
restricting	O
to	O
dietary	O
studies	O
(	O
RR	O
=	O
0.87	O
,	O
95	O
%	O
CI	O
=	O
0.79	O
-	O
0.96	O
)	O
and	O
biomarker	O
studies	O
(	O
RR	O
=	O
0.74	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
62	O
-	O
0.87	O
)	O
.	O
Dietary	O
lycopene	B-T121
intake	O
was	O
statistically	O
significant	O
for	O
coronary	B-T047
heart	I-T047
disease	I-T047
(	O
CHD	B-T047
)	O
(	O
RR	O
:	O
0.87	O
;	O
95	O
%	O
CI	O
:	O
0.76	O
-	O
0.98	O
)	O
and	O
stroke	B-T047
(	O
RR	O
:	O
0.83	O
;	O
95	O
%	O
CI	O
:	O
0.69	O
-	O
0.96).The	O
pooled	O
risk	O
estimate	O
was	O
generally	O
similar	O
for	O
lycopene	B-T121
biomarker	O
concentrations	O
,	O
but	O
the	O
association	O
was	O
only	O
statistically	O
significant	O
for	O
stroke	B-T047
(	O
RR	O
:	O
0.65	O
;	O
95	O
%	O
CI	O
:	O
0.42	O
-	O
0.87	O
)	O
.	O
Subgroup	O
analyses	O
showed	O
that	O
retrospective	O
and	O
low	O
quality	O
studies	O
were	O
statistically	O
significant	O
sources	O
of	O
heterogeneity	O
.	O
Higher	O
lycopene	B-T121
exposure	O
is	O
inversely	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
CVD	B-T047
.	O
Further	O
well	O
-	O
designed	O
randomized	O
clinical	O
trials	O
are	O
required	O
to	O
assess	O
the	O
role	O
of	O
lycopene	B-T121
on	O
CVD	B-T047
.	O
      
The	O
Abundance	O
of	O
Endofungal	B-T007
Bacterium	I-T007
Rhizobium	B-T007
radiobacter	I-T007
(	O
syn	O
.	O
Agrobacterium	B-T007
tumefaciens	I-T007
)	O
Increases	O
in	O
Its	O
Fungal	O
Host	B-T001
Piriformospora	O
indica	O
during	O
the	O
Tripartite	O
Sebacinalean	O
Symbiosis	O
with	O
Higher	O
Plants	O
Rhizobium	B-T007
radiobacter	I-T007
(	O
syn	O
.	O
Agrobacterium	B-T007
tumefaciens	I-T007
,	O
syn	O
.	O
"	O
Agrobacterium	B-T007
fabrum	I-T007
"	O
)	O
is	O
an	O
endofungal	B-T007
bacterium	I-T007
of	O
the	O
fungal	O
mutualist	O
Piriformospora	O
(	O
syn	O
.	O
Serendipita	O
)	O
indica	O
(	O
Basidiomycota	O
)	O
,	O
which	O
together	O
form	O
a	O
tripartite	O
Sebacinalean	O
symbiosis	O
with	O
a	O
broad	O
range	O
of	O
plants	O
.	O
R.	B-T007
radiobacter	I-T007
strain	B-T001
F4	I-T001
(	O
RrF4	B-T001
)	O
,	O
isolated	O
from	O
P.	O
indica	O
DSM	O
11827	O
,	O
induces	O
growth	O
promotion	O
and	O
systemic	O
resistance	O
in	O
cereal	O
crops	O
,	O
including	O
barley	O
and	O
wheat	O
,	O
suggesting	O
that	O
R.	B-T007
radiobacter	I-T007
contributes	O
to	O
a	O
successful	O
symbiosis	O
.	O
Here	O
,	O
we	O
studied	O
the	O
impact	O
of	O
endobacteria	B-T007
on	O
the	O
morphology	O
and	O
the	O
beneficial	O
activity	O
of	O
P.	O
indica	O
during	O
interactions	O
with	O
plants	O
.	O
Low	O
numbers	O
of	O
endobacteria	B-T007
were	O
detected	B-T033
in	O
the	O
axenically	B-T059
grown	I-T059
P.	O
indica	O
(	O
long	O
term	O
lab	B-T059
-	I-T059
cultured	I-T059
,	O
lcPiri	O
)	O
whereas	O
mycelia	O
colonizing	B-T033
the	O
plant	O
root	O
contained	O
increased	O
numbers	O
of	O
bacteria	B-T007
.	O
Higher	O
numbers	O
of	O
endobacteria	B-T007
were	O
also	O
found	O
in	O
axenic	B-T059
cultures	I-T059
of	O
P.	O
indica	O
that	O
was	O
freshly	O
re	O
-	O
isolated	O
(	O
riPiri	O
)	O
from	O
plant	O
roots	O
,	O
though	O
numbers	O
dropped	O
during	O
repeated	O
axenic	B-T059
re	I-T059
-	I-T059
cultivation	I-T059
.	O
Prolonged	O
treatments	B-T061
of	O
P.	O
indica	O
cultures	B-T059
with	O
various	O
antibiotics	B-T195
could	O
not	O
completely	O
eliminate	O
the	O
bacterium	B-T007
,	O
though	O
the	O
number	O
of	O
detectable	O
endobacteria	B-T007
decreased	O
significantly	O
,	O
resulting	O
in	O
partial	B-T033
-	I-T033
cured	I-T033
P.	O
indica	O
(	O
pcPiri	O
)	O
.	O
pcPiri	O
showed	O
reduced	O
growth	O
in	O
axenic	B-T059
cultures	I-T059
and	O
poor	O
sporulation	O
.	O
Consistent	O
with	O
this	O
,	O
pcPiri	O
also	O
showed	O
reduced	O
plant	O
growth	O
promotion	O
and	O
reduced	O
systemic	O
resistanc	O
e	O
against	O
powdery	O
mildew	O
infection	O
as	O
compared	O
with	O
riPiri	O
and	O
lcPiri	O
.	O
These	O
results	O
are	O
consistent	O
with	O
the	O
assumption	O
that	O
the	O
endobacterium	B-T007
R.	B-T007
radiobacter	I-T007
improves	B-T033
P.	O
indica	O
's	O
fitness	O
and	O
thus	O
contributes	O
to	O
the	O
success	O
of	O
the	O
tripartite	O
Sebacinalean	O
symbiosis	O
.	O
      
The	O
bachelorette	O
:	O
Female	O
Siamese	O
fighting	O
fish	O
avoid	O
males	O
exposed	O
to	O
an	O
estrogen	B-T121
mimic	O
Due	O
to	O
improper	O
disposal	O
and	O
a	O
lack	O
of	O
removal	O
during	O
the	O
wastewater	O
treatment	O
process	O
,	O
endocrine	O
disrupting	O
chemicals	O
enter	O
aquatic	O
ecosystems	O
where	O
they	O
exert	O
detrimental	O
effects	O
on	O
fish	O
behavior	O
and	O
physiology	O
.	O
Perhaps	O
the	O
most	O
well	O
-	O
studied	O
and	O
prevalent	O
EDC	O
is	O
17α	B-T121
-	I-T121
ethinylestradiol	I-T121
(	O
EE2	B-T121
)	O
,	O
an	O
active	O
ingredient	O
in	O
oral	B-T121
contraceptives	I-T121
,	O
which	O
is	O
known	O
to	O
cause	O
dramatic	O
reductions	O
in	O
male	O
-typical	O
behaviors	O
.	O
While	O
it	O
is	O
likely	O
that	O
alterations	O
in	O
male	O
courtship	O
behavior	O
decrease	O
reproductive	O
fitness	O
,	O
this	O
is	O
rarely	O
explicitly	O
examined	O
.	O
To	O
this	O
end	O
,	O
whether	O
EE2	B-T121
exposure	O
reduces	O
male	O
attractiveness	O
to	O
female	O
Siamese	O
fighting	O
fish	O
,	O
Betta	O
splendens	O
,	O
was	O
investigated	O
by	O
showing	O
females	O
video	O
images	O
of	O
exposed	O
and	O
unexposed	O
males	O
.	O
Females	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
exposure	O
conditions	O
(	O
exposed	O
to	O
EE2	B-T121
,	O
control	O
)	O
and	O
each	O
subject	O
then	O
viewed	O
four	O
different	O
video	O
combinations	O
of	O
male	O
conspecifics	O
(	O
courting	O
exposed	O
+	O
exposed	O
;	O
courting	O
unexposed	O
+	O
unexposed	O
;	O
courting	O
unexposed	O
+	O
exposed	O
;	O
swimming	O
unexposed	O
+	O
exposed	O
)	O
.	O
Females	O
,	O
regardless	O
of	O
whether	O
or	O
not	O
they	O
were	O
exposed	O
to	O
EE2	B-T121
,	O
directed	O
markedly	O
less	O
behavior	O
towards	O
exposed	O
males	O
,	O
especially	O
when	O
they	O
viewed	O
an	O
exposed	O
male	O
and	O
an	O
unexposed	O
male	O
simultaneously	O
.	O
These	O
findings	O
demonstrate	O
that	O
EE2	B-T121
can	O
have	O
significant	O
individual	O
-	O
and	O
population	O
-	O
level	O
consequences	O
on	O
fitness	O
by	O
disrupting	O
sexual	O
selection	O
and	O
,	O
ultimately	O
,	O
the	O
success	O
of	O
exposed	O
males	O
.	O
      
Thaw	B-T059
-and	O
-	O
use	O
target	O
cells	O
pre	O
-	O
labeled	O
with	O
calcein	O
AM	O
for	O
antibody	B-T059
-	I-T059
dependent	I-T059
cell	I-T059
-	I-T059
mediated	I-T059
cytotoxicity	I-T059
assays	I-T059
In	O
vitro	O
antibody	B-T059
-	I-T059
dependent	I-T059
cell	I-T059
-	I-T059
mediated	I-T059
cytotoxicity	I-T059
(	I-T059
ADCC	I-T059
)	I-T059
assays	I-T059
are	O
routinely	O
performed	O
to	O
support	O
the	O
research	O
and	O
development	O
of	O
therapeutic	O
antibodies	O
.	O
In	O
ADCC	B-T059
assays	I-T059
,	O
target	O
cells	O
bound	O
by	O
the	O
antibodies	O
are	O
lysed	O
by	O
activated	O
effector	O
cells	O
following	O
interactions	O
between	O
the	O
Fc	O
region	O
of	O
the	O
bound	O
antibody	O
and	O
Fcγ	O
receptors	O
on	O
effector	O
cells	O
.	O
Target	O
cell	O
lysis	O
is	O
typically	O
measured	O
by	O
quantification	O
of	O
released	O
endogenous	O
enzymes	O
,	O
e.g.	O
,	O
lactate	O
dehydrogenase	O
,	O
or	O
measurement	O
of	O
released	O
exogenous	O
labels	O
,	O
e.g.	O
,	O
(	B-T121
51)Cr	I-T121
,	O
europium	O
or	O
calcein	O
.	O
ADCC	B-T059
assays	I-T059
based	O
on	O
the	O
detection	O
of	O
exogenous	O
labels	O
released	O
from	O
lysed	O
target	O
cells	O
generally	O
show	O
higher	O
sensitivity	O
and	O
require	O
shorter	O
incubation	B-T033
times	I-T033
.	O
However	O
,	O
target	O
cells	O
are	O
usually	O
labeled	O
immediately	O
prior	O
to	O
assay	B-T059
,	O
which	O
inadvertently	O
introduces	O
additional	O
assay	B-T059
variations	O
due	O
to	O
differences	O
in	O
target	O
cell	O
conditions	O
and	O
labeling	B-T059
/	O
handling	B-T059
processes	I-T059
.	O
In	O
this	O
report	O
,	O
we	O
describe	O
the	O
use	O
of	O
thaw	B-T059
-and	O
-	O
use	O
pre	O
-	O
labeled	O
target	O
cells	O
for	O
ADCC	B-T059
assays	I-T059
.	O
Thaw	B-T059
-and	O
-	O
use	O
target	O
cells	O
in	O
our	O
experiments	O
were	O
pre	O
-	O
labeled	O
with	O
the	O
fluorescent	O
dye	O
calcein	O
AM	O
,	O
cryopreserved	B-T059
in	O
single	O
-	O
use	O
aliquots	O
and	O
used	O
directly	O
in	O
assays	B-T059
after	O
thawing	B-T059
.	O
Upon	O
thaw	B-T059
,	O
the	O
pre	O
-	O
labeled	O
cells	O
displayed	O
viability	O
and	O
label	O
retention	O
comparable	O
to	O
freshly	O
labeled	O
cells	O
,	O
responded	O
to	O
ADCC	O
mediated	O
by	O
both	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
engineered	O
natural	O
killer	O
cells	O
,	O
performed	O
stably	O
for	O
at	O
least	O
3	O
years	O
and	O
provided	O
favorable	O
precision	O
and	O
accuracy	O
to	O
ADCC	B-T059
assays	I-T059
.	O
Implementation	O
of	O
thaw	B-T059
-and	O
-	O
use	O
pre	O
-	O
labeled	O
target	O
cells	O
in	O
ADCC	B-T059
assays	I-T059
can	O
help	O
to	O
alleviate	O
both	O
cell	B-T059
culture	I-T059
and	O
dye	B-T059
labeling	I-T059
derived	O
variability	O
,	O
increase	O
the	O
flexibility	O
of	O
assay	B-T059
scheduling	O
and	O
improve	O
assay	O
consistency	O
and	O
robustness	O
.	O
      
Effectiveness	O
of	O
offloading	B-T061
methods	B-T061
in	O
preventing	B-T061
primary	O
diabetic	B-T047
foot	I-T047
ulcers	I-T047
in	O
adults	O
with	O
diabetes	B-T047
:	O
a	O
systematic	O
review	O
The	O
incidence	O
of	O
foot	B-T047
ulceration	I-T047
related	O
to	O
diabetes	B-T047
is	O
increasing	O
.	O
Many	O
foot	B-T061
care	I-T061
professionals	O
recommend	O
offloading	B-T061
measures	O
as	O
part	O
of	O
management	B-T058
strategies	I-T058
for	O
modulating	O
excess	O
pressure	O
to	O
prevent	B-T061
development	O
of	O
diabetic	B-T047
foot	I-T047
ulcers	I-T047
(	O
DFUs	B-T047
)	O
.	O
These	O
measures	O
may	O
include	O
padding	B-T061
,	O
insoles	O
/	O
orthotic	O
devices	O
and	O
footwear	O
.	O
There	O
is	O
a	O
lack	O
of	O
evidence	O
-based	O
guidance	O
on	O
the	O
effectiveness	O
of	O
the	O
different	O
offloading	B-T061
options	O
for	O
preventing	B-T061
primary	O
ulceration	B-T047
in	O
those	O
with	O
diabetes	B-T047
.	O
To	O
identify	O
,	O
critically	O
appraise	O
and	O
synthesize	O
the	O
best	O
available	O
evidence	O
on	O
methods	B-T061
of	O
offloading	B-T061
to	O
prevent	B-T061
the	O
development	O
,	O
and	O
reduce	O
the	O
risk	O
,	O
of	O
primary	O
foot	B-T047
ulceration	I-T047
in	O
adults	O
with	O
diabetes	B-T047
.The	O
question	O
addressed	O
by	O
the	O
review	O
was	O
:	O
what	O
is	O
the	O
effectiveness	O
of	O
methods	B-T061
of	O
offloading	B-T061
in	O
preventing	B-T061
primary	O
DFUs	B-T047
in	O
adults	O
with	O
diabetes	B-T047
?	O
Adults	O
18	O
years	O
and	O
older	O
with	O
diabetes	B-T047
mellitus	I-T047
,	O
regardless	O
of	O
age	O
,	O
gender	O
,	O
ethnicity	O
,	O
duration	O
or	O
type	O
of	O
diabetes	B-T047
,	O
with	O
no	O
history	B-T033
of	O
DFUs	B-T047
and	O
in	O
any	O
clinical	O
setting	O
will	O
be	O
included	O
.	O
Interventions	B-T061
will	O
include	O
all	O
external	O
methods	B-T061
of	O
offloading	B-T061
.	O
All	O
comparators	O
will	O
be	O
considered	O
.	O
Studies	O
that	O
utilize	O
interventions	B-T061
not	O
considered	O
usual	O
practice	B-T061
in	O
the	O
prevention	B-T061
of	O
DFUs	B-T047
will	O
be	O
excluded	O
.	O
The	O
primary	O
outcome	O
will	O
be	O
primary	O
foot	B-T047
ulceration	I-T047
.	O
The	O
secondary	O
outcome	O
will	O
be	O
indications	O
of	O
changes	O
in	O
plantar	O
pressure	O
.	O
This	O
review	O
will	O
consider	O
all	O
quantitative	O
study	O
designs	O
.	O
A	O
three	O
-	O
step	O
strategy	O
for	O
published	O
and	O
unpublished	O
literature	O
will	O
be	O
used	O
.	O
Fourteen	O
databases	O
will	O
be	O
searched	O
for	O
studies	O
in	O
English	O
up	O
to	O
November	O
2013	O
.	O
The	O
JBI	O
-	O
MAStARI	O
extraction	O
tool	O
was	O
used	O
to	O
extract	O
relevant	O
data	O
.	O
Results	O
were	O
summarized	O
using	O
narrative	O
and	O
tables	O
.	O
Three	O
studies	O
which	O
examined	O
the	O
effectiveness	O
of	O
four	O
different	O
offloading	B-T061
interventions	B-T061
met	O
the	O
inclusion	O
criteria	O
.	O
There	O
is	O
limited	O
evidence	O
that	O
use	O
of	O
a	O
footwear	O
system	O
(	O
prototype	O
shoe	O
plus	O
polyurethane	O
or	O
cork	O
insole	O
)	O
may	O
prevent	B-T061
a	O
break	O
in	O
the	O
skin	O
;	O
use	O
of	O
customized	O
rigid	O
orthotic	O
devices	O
may	O
contribute	O
to	O
a	O
reduction	O
in	O
the	O
grade	O
and	O
number	O
of	O
calluses	B-T020
;	O
and	O
a	O
manufactured	O
shoe	O
plus	O
customized	O
insole	O
may	O
reduce	O
plantar	O
pressure	O
and	O
therefore	O
reduce	O
the	O
potential	O
risk	O
of	O
skin	B-T047
ulceration	I-T047
.	O
There	O
is	O
limited	O
and	O
low	O
-	O
quality	O
evidence	O
that	O
in	O
a	O
population	O
of	O
adults	O
with	O
diabetes	B-T047
with	O
no	O
history	B-T033
of	O
DFU	B-T047
,	O
the	O
use	O
of	O
footwear	O
with	O
customized	O
or	O
prefabricated	O
orthotic	O
devices	O
may	O
provide	O
some	O
reduction	O
in	O
plantar	O
pressure	O
and	O
therefore	O
help	O
to	O
prevent	B-T061
a	O
primary	O
DFU	B-T047
.	O
There	O
is	O
a	O
lack	O
of	O
evidence	O
on	O
the	O
relative	O
effectiveness	O
of	O
different	O
offloading	B-T061
options	O
.	O
      
Scutellaria	O
barbata	O
D.	O
Don	O
extract	O
inhibits	O
the	O
tumor	B-T191
growth	I-T191
through	O
down	O
-	O
regulating	O
of	O
Treg	O
cells	O
and	O
manipulating	O
Th1	O
/	O
Th17	O
immune	O
response	O
in	O
hepatoma	O
H22	O
-bearing	O
mice	O
Previous	O
studies	O
showed	O
Scutellaria	O
barbata	O
D.	O
Don	O
extract	O
(	O
SBE	O
)	O
is	O
a	O
potent	O
inhibitor	B-T121
in	O
hepatoma	B-T191
and	O
could	O
improve	O
immune	O
function	O
of	O
hepatoma	O
H22	O
-bearing	O
mice	O
.	O
However	O
,	O
the	O
immunomodulatory	O
function	O
of	O
SBE	O
on	O
the	O
tumor	B-T191
growth	I-T191
of	O
hepatoma	B-T191
remains	O
unclear	B-T033
.	O
This	O
study	O
aimed	O
to	O
investigate	O
the	O
anti	O
-	O
tumor	O
effects	O
of	O
SBE	O
on	O
hepatoma	O
H22	O
-bearing	O
mice	O
and	O
explore	O
the	O
underlying	O
immunomodulatory	O
function	O
.	O
The	O
hepatoma	O
H22	O
-bearing	O
mice	O
were	O
treated	O
by	O
SBE	O
for	O
30	O
days	O
.	O
The	O
effect	O
of	O
SBE	O
on	O
the	O
proliferation	O
of	O
HepG2	O
cells	O
in	O
vitro	O
,	O
the	O
growth	B-T191
of	I-T191
transplanted	I-T191
tumor	I-T191
,	O
the	O
cytotoxicity	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
in	O
spleen	B-T023
,	O
the	O
amount	O
of	O
CD4(+)CD25(+)Foxp3(+	B-T121
)	I-T121
Treg	I-T121
cells	I-T121
and	O
Th17	O
cells	O
in	O
tumor	O
tissue	O
,	O
and	O
the	O
levels	O
of	O
IL-10	O
,	O
TGF	O
-	O
β	O
,	O
IL-17A	O
,	O
IL-2	O
,	O
and	O
IFN	O
-	O
γ	O
in	O
serum	O
of	O
the	O
hepatoma	O
H22	O
-bearing	O
mice	O
was	O
observered	O
.	O
IL-17A	O
was	O
injected	O
to	O
the	O
SBE	O
treated	O
mice	O
from	O
day	O
9	O
post	O
H22	O
inoculation	B-T061
to	O
examine	O
its	O
effect	O
on	O
tumor	B-T191
growth	I-T191
.	O
SBE	O
treatment	O
inhibited	O
the	O
proliferation	O
of	O
HepG2	O
cells	O
in	O
vitro	O
with	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
significantly	O
suppressed	O
the	O
tumor	B-T191
growth	I-T191
of	O
hepatoma	O
H22	O
-bearing	O
mice	O
.	O
Meanwhile	O
,	O
it	O
increased	O
NK	O
cells	O
'	O
cytotoxicity	O
in	O
spleen	B-T023
,	O
down	O
-	O
regulated	O
the	O
amount	O
of	O
CD4(+)CD25(+)Foxp3(+	B-T121
)	I-T121
Treg	I-T121
cells	I-T121
and	O
Th17	O
cells	O
in	O
tumor	O
tissue	O
,	O
and	O
decreased	O
IL-10	O
,	O
TGF	O
-	O
β	O
,	O
and	O
IL-17A	O
levels	O
(	O
P	O
<	O
0.01	O
)	O
whereas	O
increased	O
IL-2	O
and	O
IFN	O
-	O
γ	O
levels	O
(	O
P	O
<	O
0.01	O
)	O
in	O
the	O
serum	O
of	O
hepatoma	O
H22	O
-bearing	O
mice	O
.	O
Moreover	O
,	O
administration	O
of	O
recombinant	O
mouse	O
IL-17A	O
reversed	O
the	O
anti	O
-	O
tumor	O
effects	O
of	O
SBE	O
.	O
SBE	O
could	O
inhibit	O
the	O
proliferation	O
of	O
HepG2	O
cells	O
in	O
vitro	O
.	O
Meanwhile	O
,	O
SBE	O
also	O
could	O
inhibit	O
the	O
growth	O
of	O
H22	O
implanted	B-T191
tumor	I-T191
in	O
hepatoma	O
H22	O
-bearing	O
mice	O
,	O
and	O
this	O
function	O
might	O
be	O
associated	O
with	O
immunomodulatory	O
activity	O
through	O
down	O
-	O
regulating	O
of	O
Treg	O
cells	O
and	O
manipulating	O
Th1	O
/	O
Th17	O
immune	O
response	O
.	O
      
Assessing	O
the	O
benefits	O
of	O
targeted	O
drug	O
delivery	O
by	O
nanocarriers	O
:	O
A	O
partico	O
/	O
pharmacokinetic	O
framework	O
An	O
in	O
vivo	O
kinetic	O
framework	O
is	O
introduced	O
to	O
analyze	O
and	O
predict	O
the	O
quantitative	O
advantage	O
of	O
using	O
nanocarriers	O
to	O
deliver	O
drugs	O
,	O
especially	O
anticancer	B-T121
agents	I-T121
,	O
compared	O
to	O
administering	B-T061
the	O
same	O
drugs	B-T121
in	O
their	O
free	O
form	O
.	O
This	O
framework	O
recognizes	O
three	O
levels	O
of	O
kinetics	O
.	O
First	O
is	O
the	O
particokinetics	O
associated	O
with	O
deposition	O
of	O
nanocarriers	O
into	O
tissues	O
associated	O
with	O
drug	O
effect	O
and	O
toxicity	O
,	O
their	O
residence	O
inside	O
those	O
tissues	O
,	O
and	O
elimination	O
of	O
the	O
nanocarriers	O
from	O
the	O
body	O
.	O
Second	O
is	O
the	O
release	B-T033
pattern	I-T033
in	O
time	O
of	O
free	O
drug	O
from	O
the	O
nanocarriers	O
.	O
Third	O
is	O
the	O
pharmacokinetics	O
of	O
free	O
drug	O
,	O
as	O
it	O
relates	O
to	O
deposition	O
and	O
elimination	O
processes	O
in	O
the	O
target	O
and	O
toxicity	O
associated	O
tissues	O
,	O
and	O
total	O
body	O
clearance	O
.	O
A	O
figure	O
of	O
merit	O
,	O
the	O
drug	O
targeting	O
index	O
(	O
DTI	O
)	O
,	O
is	O
used	O
to	O
quantitate	O
the	O
benefit	O
of	O
nanocarrier	O
based	O
drug	O
delivery	O
by	O
considering	O
the	O
effects	O
of	O
preferential	O
deposition	O
of	O
nanoparticles	O
into	O
target	O
tissues	O
and	O
relative	O
avoidance	O
of	O
tissues	O
associated	O
with	O
drug	O
toxicity	O
,	O
compared	O
to	O
drug	B-T121
that	O
is	O
administered	B-T061
in	O
its	O
free	O
form	O
.	O
General	O
methods	O
are	O
derived	O
for	O
calculating	O
DTI	O
when	O
appropriate	O
particokinetic	O
,	O
pharmacokinetic	O
,	O
and	O
drug	O
release	O
rate	O
information	O
is	O
available	O
,	O
and	O
it	O
is	O
shown	O
that	O
relatively	O
simple	O
algebraic	O
forms	O
result	O
when	O
some	O
common	O
assumptions	O
are	O
made	O
.	O
This	O
approach	O
may	O
find	O
use	O
in	O
developing	O
and	O
selecting	O
nanocarrier	O
formulations	O
,	O
either	O
for	O
populations	O
or	O
for	O
individuals	O
.	O
      
Aquaporin-2	O
excretion	O
in	O
hospitalized	O
patients	O
with	O
cirrhosis	B-T047
:	O
Relation	O
to	O
development	O
of	O
renal	B-T047
insufficiency	I-T047
and	O
mortality	O
Urinary	O
aquaporin-2	O
(	O
AQP2	O
)	O
is	O
a	O
parameter	O
of	O
water	O
transport	O
in	O
the	O
principal	O
cells	O
in	O
the	O
distal	O
part	O
of	O
the	O
nephron	B-T023
and	O
involved	O
in	O
water	O
retention	O
in	O
cirrhosis	B-T047
and	O
may	O
be	O
a	O
marker	O
of	O
renal	O
function	O
.	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
AQP2	O
as	O
a	O
predictor	O
of	O
renal	B-T047
insufficiency	I-T047
and	O
death	O
in	O
patients	O
with	O
cirrhosis	B-T047
.	O
Urine	O
samples	O
from	O
199	O
patients	O
(	O
90	O
patients	O
without	O
organ	B-T184
failure	I-T184
[	O
Group	O
1	O
]	O
,	O
58	O
patients	O
with	O
organ	B-T184
failure	I-T184
excluding	O
renal	B-T047
failure	I-T047
[	O
Group	O
2	O
]	O
,	O
and	O
51	O
patients	O
with	O
organ	B-T184
failure	I-T184
including	O
renal	B-T047
failure	I-T047
[	O
Group	O
3	O
]	O
)	O
from	O
the	O
CANONIC	O
study	O
were	O
analyzed	O
for	O
urine	O
AQP2	O
and	O
urine	O
osmolality	O
.	O
There	O
was	O
no	B-T033
difference	I-T033
in	O
AQP2	O
between	O
the	O
three	O
groups	O
.	O
Urine	O
osmolality	O
was	O
significantly	O
lower	O
in	O
patients	O
in	O
Group	O
3	O
versus	O
Group	O
1	O
and	O
Group	O
2	O
(	O
P	O
=	O
0.0004	O
)	O
.	O
No	B-T033
relation	I-T033
was	O
found	O
between	O
AQP2	O
and	O
glomerular	B-T060
filtration	I-T060
rate	I-T060
or	O
creatinine	O
;	O
however	O
,	O
AQP2	O
was	O
a	O
significant	O
predictor	O
of	O
the	O
development	O
of	O
renal	B-T047
insufficiency	I-T047
(	O
P	O
=	O
0.0485	O
)	O
.	O
In	O
a	O
univariate	O
analysis	O
,	O
AQP2	O
was	O
a	O
significant	O
predictor	O
of	O
14	O
and	O
28	O
-	O
day	O
survival	O
,	O
but	O
this	O
was	O
not	O
confirmed	O
in	O
multivariate	O
analysis	O
.	O
Aquaporin-2	O
was	O
not	O
associated	O
with	O
disease	O
severity	O
or	O
markers	O
of	O
renal	O
function	O
but	O
was	O
a	O
predictor	O
for	O
the	O
development	O
of	O
renal	B-T047
insufficiency	I-T047
and	O
death	O
.	O
Therefore	O
,	O
its	O
future	O
use	O
as	O
marker	O
of	O
renal	B-T047
insufficiency	I-T047
could	O
be	O
promising	O
,	O
but	O
further	O
research	O
is	O
needed	O
before	O
it	O
can	O
be	O
considered	O
a	O
clinical	O
useful	O
tool	O
.	O
      
The	O
Complete	O
Chloroplast	O
Genome	O
Sequence	O
of	O
the	O
Medicinal	O
Plant	O
Swertia	O
mussotii	O
Using	O
the	O
PacBio	O
RS	O
II	O
Platform	O
Swertia	O
mussotii	O
is	O
an	O
important	O
medicinal	O
plant	O
that	O
has	O
great	O
economic	O
and	O
medicinal	B-T121
value	I-T121
and	O
is	O
found	O
on	O
the	O
Qinghai	O
Tibetan	O
Plateau	O
.	O
The	O
complete	O
chloroplast	O
(	O
cp	O
)	O
genome	O
of	O
S.	O
mussotii	O
is	O
153,431	O
bp	O
in	O
size	O
,	O
with	O
a	O
pair	O
of	O
inverted	O
repeat	O
(	O
IR	O
)	O
regions	O
of	O
25,761	O
bp	O
each	O
that	O
separate	O
an	O
large	O
single	O
-	O
copy	O
(	O
LSC	O
)	O
region	O
of	O
83,567	O
bp	O
and	O
an	O
a	O
small	O
single	O
-	O
copy	O
(	O
SSC	O
)	O
region	O
of	O
18,342	O
bp	O
.	O
The	O
S.	O
mussotii	O
cp	O
genome	O
encodes	O
84	O
protein	O
-	O
coding	O
genes	O
,	O
37	O
transfer	O
RNA	O
(	O
tRNA	O
)	O
genes	O
,	O
and	O
eight	O
ribosomal	O
RNA	O
(	O
rRNA	O
)	O
genes	O
.	O
The	O
identity	O
,	O
number	O
,	O
and	O
GC	O
content	O
of	O
S.	O
mussotii	O
cp	O
genes	O
were	O
similar	O
to	O
those	O
in	O
the	O
genomes	O
of	O
other	O
Gentianales	O
species	O
.	O
Via	O
analysis	O
of	O
the	O
repeat	O
structure	O
,	O
11	O
forward	O
repeats	O
,	O
eight	O
palindromic	O
repeats	O
,	O
and	O
one	O
reverse	O
repeat	O
were	O
detected	B-T033
in	O
the	O
S.	O
mussotii	O
cp	O
genome	O
.	O
There	O
are	O
45	O
SSRs	O
in	O
the	O
S.	O
mussotii	O
cp	O
genome	O
,	O
the	O
majority	O
of	O
which	O
are	O
mononucleotides	O
found	O
in	O
all	O
other	O
Gentianales	O
species	O
.	O
An	O
entire	O
cp	O
genome	O
comparison	O
study	O
of	O
S.	O
mussotii	O
and	O
two	O
other	O
species	O
in	O
Gentianaceae	O
was	O
conducted	O
.	O
The	O
complete	O
cp	O
genome	O
sequence	O
provides	O
intragenic	O
information	O
for	O
the	O
cp	O
genetic	O
engineering	O
of	O
this	O
medicinal	O
plant	O
.	O
      
Design	O
and	O
characteristics	O
of	O
cytotoxic	O
fibroblast	O
growth	O
factor	O
1	O
conjugate	B-T121
for	O
fibroblast	O
growth	O
factor	O
receptor	O
-	O
targeted	B-T061
cancer	I-T061
therapy	I-T061
Fibroblast	O
growth	O
factor	O
receptors	O
(	O
FGFRs	O
)	O
are	O
attractive	O
candidate	O
cancer	B-T061
therapy	I-T061
targets	O
as	O
they	O
are	O
overexpressed	O
in	O
multiple	O
types	O
of	O
tumors	B-T191
,	O
such	O
as	O
breast	B-T191
,	O
prostate	B-T191
,	O
bladder	B-T191
,	O
and	O
lung	B-T191
cancer	I-T191
.	O
In	O
this	O
study	O
,	O
a	O
natural	O
ligand	O
of	O
FGFR	O
,	O
an	O
engineered	O
variant	O
of	O
fibroblast	O
growth	O
factor	O
1	O
(	O
FGF1V	O
)	O
,	O
was	O
conjugated	O
to	O
a	O
potent	B-T121
cytotoxic	I-T121
drug	I-T121
,	O
monomethyl	B-T121
auristatin	I-T121
E	I-T121
(	O
MMAE	B-T121
)	O
,	O
and	O
used	O
as	O
a	O
targeting	O
agent	O
for	O
cancer	O
cells	O
overexpressing	O
FGFRs	O
,	O
similar	O
to	O
antibodies	O
in	O
antibody	B-T061
-	I-T061
drug	I-T061
conjugates	I-T061
.	O
The	O
FGF1V	B-T121
-	I-T121
valine	I-T121
-	I-T121
citrulline	I-T121
-	I-T121
MMAE	I-T121
conjugate	I-T121
showed	O
a	O
favorable	O
stability	O
profile	O
,	O
bound	O
FGFRs	O
on	O
the	O
cell	O
surface	O
specifically	O
,	O
and	O
efficiently	O
released	O
the	O
drug	B-T121
(	I-T121
MMAE	I-T121
)	I-T121
upon	O
cleavage	O
by	O
the	O
lysosomal	O
protease	O
cathepsin	O
B.	O
Importantly	O
,	O
the	O
conjugate	B-T121
showed	O
a	O
prominent	O
cytotoxic	O
effect	O
toward	O
cell	O
lines	O
expressing	O
FGFR	O
.	O
FGF1V	B-T121
-	I-T121
vcMMAE	I-T121
was	O
highly	O
cytotoxic	O
at	O
concentrations	O
even	O
an	O
order	O
of	O
magnitude	O
lower	O
than	O
those	O
found	O
for	O
free	O
MMAE	B-T121
.	O
This	O
effect	O
was	O
FGFR	O
-specific	O
as	O
cells	O
lacking	O
FGFR	O
did	B-T033
not	I-T033
show	I-T033
any	O
increased	O
mortality	O
.	O
      
The	O
influence	O
of	O
cognitive	O
load	O
on	O
metabolic	O
cost	O
of	O
transport	O
during	O
overground	O
walking	O
in	O
healthy	O
,	O
young	O
adults	O
Our	O
aim	O
was	O
to	O
examine	O
whether	O
cognitive	O
processing	O
during	O
walking	O
increases	O
the	O
metabolic	O
cost	O
of	O
transport	O
in	O
healthy	O
young	O
adults	O
.	O
Twenty	O
healthy	O
,	O
young	O
adults	O
completed	O
five	O
conditions	O
:	O
(	O
1	O
)	O
walking	O
at	O
a	O
self	O
-	O
selected	O
speed	O
(	O
spontaneous	O
single	O
-	O
task	O
)	O
,	O
(	O
2	O
)	O
seated	B-T033
resting	O
(	O
baseline	O
)	O
,	O
(	O
3	O
)	O
performing	O
cognitive	O
task	O
while	O
seated	B-T033
(	O
cognitive	O
single	O
-	O
task	O
)	O
,	O
(	O
4	O
)	O
walking	O
while	O
simultaneously	O
performing	O
the	O
cognitive	O
task	O
(	O
dual	O
-	O
task	O
)	O
,	O
and	O
(	O
5	O
)	O
single	O
-	O
task	O
walking	O
at	O
a	O
speed	O
that	O
matched	O
the	O
participant	O
's	O
dual	O
-	O
task	O
gait	O
speed	O
(	O
matched	O
single	O
-	O
task	O
)	O
.	O
Rate	O
of	O
oxygen	O
consumption	O
(	O
V̇O2	O
)	O
was	O
recorded	O
during	O
all	O
conditions	O
.	O
Gait	O
speed	O
and	O
cost	O
of	O
walking	O
(	O
Cw	O
;	O
oxygen	O
consumed	O
per	O
distance	O
traveled	O
)	O
were	O
recorded	O
during	O
all	O
walking	O
conditions	O
.	O
Reaction	O
time	O
and	O
accuracy	O
of	O
responses	O
in	O
the	O
cognitive	O
task	O
were	O
recorded	O
during	O
all	O
cognitive	O
task	O
conditions	O
.	O
Data	O
from	O
the	O
fifth	O
minute	O
of	O
each	O
5-	O
min	O
condition	O
were	O
analyzed	O
.	O
There	O
was	O
no	O
difference	O
in	O
V̇O2	O
between	O
the	O
dual	O
-	O
task	O
and	O
matched	O
single	O
-	O
task	O
walking	O
conditions	O
.	O
V̇O2	O
in	O
the	O
seated	B-T033
cognitive	O
condition	O
was	O
significantly	O
smaller	O
than	O
both	O
walking	O
conditions	O
,	O
but	O
was	O
not	O
significantly	O
different	O
than	O
zero	O
.	O
Cw	O
was	O
significantly	O
greater	O
during	O
the	O
matched	O
single	O
-	O
task	O
walking	O
condition	O
than	O
during	O
the	O
dual	O
-	O
task	O
walking	O
condition	O
.	O
However	O
,	O
the	O
difference	O
in	O
Cw	O
was	O
so	O
small	O
that	O
it	O
is	O
unlikely	O
to	O
be	O
clinically	O
significant	O
(	O
0.008	O
mLO2	O
/	O
kg	O
/	O
m	O
,	O
95	O
%	O
CI	O
0.002	O
-	O
0.014	O
)	O
.	O
Cognitive	O
processing	O
while	O
walking	O
may	O
not	O
increase	O
energy	O
demands	O
of	O
walking	O
in	O
healthy	O
young	O
adults	O
.	O
Maintaining	O
non	O
-	O
preferred	O
gait	O
speed	O
(	O
matched	O
speed	O
)	O
overground	O
continuously	O
for	O
5	O
min	O
may	O
require	O
attentional	O
resources	O
,	O
and	O
thereby	O
increase	O
metabolic	O
costs	O
relative	O
to	O
walking	O
at	O
habitual	O
speed	O
.	O
      
Biomimetic	O
whitlockite	O
inorganic	O
nanoparticles	O
-mediated	O
in	O
situ	O
remodeling	O
and	O
rapid	O
bone	O
regeneration	O
Bone	O
remodeling	O
process	O
relies	O
on	O
complex	O
signaling	O
pathway	O
between	O
osteoblasts	O
and	O
osteoclasts	O
and	O
control	O
mechanisms	O
to	O
achieve	O
homeostasis	O
of	O
their	O
growth	O
and	O
differentiation	O
.	O
Despite	O
previous	O
achievements	O
in	O
understanding	O
complicated	O
signaling	O
pathways	O
between	O
cells	O
and	O
bone	B-T023
extracellular	O
matrices	O
during	O
bone	O
remodeling	O
process	O
,	O
a	O
role	O
of	O
local	O
ionic	O
concentration	O
remains	O
to	O
be	O
elucidated	O
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
synthetic	O
whitlockite	O
(	O
WH	O
:	O
Ca18Mg2(HPO4)2(PO4)12	O
)	O
nanoparticles	O
can	O
recapitulate	O
early	O
-	O
stage	O
of	O
bone	O
regeneration	O
through	O
stimulating	O
osteogenic	O
differentiation	O
,	O
prohibiting	O
osteoclastic	O
activity	O
,	O
and	O
transforming	O
into	O
mechanically	O
enhanced	O
hydroxyapatite	O
(	O
HAP)-	O
neo	O
bone	O
tissues	O
by	O
continuous	O
supply	O
of	O
PO4(3-	B-T121
)	I-T121
and	O
Mg(2	B-T121
+	I-T121
)	I-T121
under	O
physiological	O
conditions	O
.	O
In	O
addition	O
,	O
based	O
on	O
their	O
structural	O
analysis	O
,	O
the	O
dynamic	O
phase	O
transformation	O
from	O
WH	O
into	O
HAP	O
contributed	O
as	O
a	O
key	O
factor	O
for	O
rapid	O
bone	O
regeneration	O
with	O
denser	O
hierarchical	O
neo	B-T023
-	I-T023
bone	I-T023
structure	O
.	O
Our	O
findings	B-T033
suggest	O
a	O
groundbreaking	O
concept	O
of	O
'	O
living	O
bone	B-T023
minerals	O
'	O
that	O
actively	O
communicate	O
with	O
the	O
surrounding	O
system	O
to	O
induce	O
self	O
-	O
healing	O
,	O
while	O
previous	O
notions	O
about	O
bone	B-T023
minerals	O
have	O
been	O
limited	O
to	O
passive	O
products	O
of	O
cellular	O
mineralization	O
.	O
      
Novel	O
biomarkers	O
for	O
patients	O
with	O
idiopathic	O
acute	B-T047
anterior	I-T047
uveitis	I-T047
:	O
neutrophil	O
to	O
lymphocyte	O
ratio	O
and	O
platelet	O
to	O
lymphocyte	O
ratio	O
To	O
assess	O
the	O
levels	O
of	O
the	O
neutrophil	O
to	O
lymphocyte	O
ratio	O
(	O
N	O
/	O
L	O
)	O
and	O
the	O
platelet	O
to	O
lymphocyte	O
ratio	O
(	O
P	O
/	O
L	O
)	O
in	O
patients	O
with	O
idiopathic	O
acute	B-T047
anterior	I-T047
uveitis	I-T047
(	O
AAU	B-T047
)	O
and	O
to	O
compare	O
with	O
healthy	O
controls	O
.	O
Thirty	O
-	O
six	O
male	O
patients	O
with	O
idiopathic	O
AAU	B-T047
and	O
36	O
male	O
healthy	O
subjects	O
were	O
enrolled	O
in	O
this	O
retrospective	O
study	O
.	O
Complete	O
ophthalmological	B-T061
examination	I-T061
and	O
complete	O
blood	B-T059
count	I-T059
measurements	I-T059
results	B-T033
of	O
all	O
subjects	O
were	O
evaluated	B-T058
.	O
There	O
was	O
a	O
significant	O
difference	O
in	O
N	O
/	O
L	O
and	O
P	O
/	O
L	O
between	O
idiopathic	O
AAU	B-T047
and	O
control	O
groups	O
(	O
P=0.006	O
,	O
P=0.022	O
)	O
.	O
Also	O
,	O
correlation	O
analysis	O
revealed	O
a	O
significant	O
correlation	O
between	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
and	O
N	O
/	O
L	O
(	O
P=0.002	O
;	O
r=0.461	O
)	O
.	O
Our	O
study	O
for	O
the	O
first	O
time	O
provides	O
evidence	O
of	O
N	O
/	O
L	O
and	O
P	O
/	O
L	O
may	O
be	O
useful	O
biomarkers	O
in	O
patients	O
with	O
idiopathic	O
AAU	B-T047
.	O
N	O
/	O
L	O
is	O
correlated	O
with	O
CRP	O
,	O
so	O
it	O
can	O
be	O
a	O
useful	O
biomarker	O
to	O
predict	O
the	O
prognosis	B-T058
in	O
idiopathic	O
AAU	B-T047
.	O
      
Structured	O
Instruction	O
With	O
Modified	O
Storybooks	O
to	O
Teach	O
Morphosyntax	O
and	O
Vocabulary	O
to	O
Preschoolers	O
Who	O
are	O
Deaf	O
/	O
Hard	O
of	O
Hearing	O
Children	O
who	O
are	O
deaf	O
/	O
hard	O
of	O
hearing	O
(	O
D	O
/	O
HH	O
)	O
are	O
at	O
risk	O
for	O
diminished	O
morphosyntactical	O
and	O
vocabulary	O
development	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
repeated	O
reading	O
combined	O
with	O
structured	O
instruction	O
.	O
Targets	O
were	O
a	O
morphosyntactical	O
form	O
and	O
novel	O
vocabulary	O
words	O
.	O
Participants	O
were	O
3	O
preschoolers	O
who	O
are	O
D	O
/	O
HH	O
who	O
were	O
receiving	O
instruction	O
with	O
an	O
oral	O
approach	O
.	O
Data	O
from	O
a	O
multiple	O
baseline	O
design	O
indicated	O
that	O
all	O
children	O
acquired	O
the	O
targeted	O
skills	O
and	O
demonstrated	O
high	O
levels	O
of	O
generalization	O
of	O
these	O
skills	O
to	O
untrained	B-T033
context	O
.	O
Implications	O
for	O
teaching	O
young	O
children	O
who	O
are	O
D	O
/	O
HH	O
using	O
repeated	O
storybook	O
reading	O
are	O
discussed	O
.	O
      
Altered	O
expression	O
of	O
the	O
Olr59	O
,	O
Ethe1	O
,	O
and	O
Slc10a2	O
genes	O
in	O
the	O
liver	B-T023
of	O
F344	O
rats	O
by	O
neonatal	O
thyroid	O
hormone	O
disruption	O
Many	O
concerns	O
have	O
been	O
expressed	O
regarding	O
the	O
possible	O
adverse	O
effects	O
of	O
thyroid	O
hormone	O
-	O
disrupting	O
chemicals	O
in	O
the	O
environment	O
.	O
The	O
disruption	O
of	O
thyroid	O
hormones	O
in	O
the	O
neonatal	O
period	O
may	O
lead	O
to	O
permanent	O
effects	O
on	O
thyroid	O
hormone	O
homeostasis	O
as	O
well	O
as	O
related	O
developmental	B-T048
disorders	I-T048
,	O
as	O
thyroid	O
hormones	O
are	O
essential	O
for	O
regulating	O
the	O
growth	O
and	O
differentiation	B-T033
of	I-T033
many	I-T033
tissues	I-T033
.	O
To	O
understand	O
the	O
long	O
-	O
term	O
alteration	O
in	O
gene	O
expressions	O
by	O
neonatal	O
administration	B-T061
of	I-T061
thyroid	I-T061
hormone	I-T061
-like	O
chemicals	O
in	O
general	O
,	O
we	O
identified	O
genes	O
whose	O
expression	O
was	O
altered	O
in	O
the	O
liver	B-T023
,	O
an	O
important	O
component	O
of	O
the	O
thyroid	O
hormone	O
axis	O
,	O
by	O
neonatal	O
exposure	O
to	O
triiodothyronine	B-T121
(	O
T3	B-T121
)	O
.	O
T3	B-T121
was	O
administered	B-T061
to	O
male	O
F344	O
rats	O
on	O
postnatal	O
days	O
1	O
,	O
3	O
,	O
and	O
5	O
(	O
week	O
0	O
)	O
.	O
At	O
8	O
weeks	O
of	O
age	O
,	O
cDNA	O
microarray	O
analysis	O
was	O
used	O
to	O
identify	O
hepatic	O
genes	O
whose	O
expression	O
was	O
altered	O
by	O
neonatal	O
exposure	O
to	O
T3	B-T121
.	O
Among	O
the	O
up	O
-	O
regulated	O
genes	O
that	O
were	O
identified	O
,	O
the	O
expression	O
of	O
Olr59	O
,	O
Ethe1	O
,	O
and	O
Slc10a2	O
increased	O
specifically	O
in	O
rats	O
neonatally	O
exposed	O
to	O
T3	B-T121
.	O
Interestingly	O
,	O
altered	O
hepatic	O
expression	O
of	O
these	O
genes	O
indeed	O
increased	O
when	O
a	O
hydroxylated	O
polybrominated	O
diphenyl	O
ether	O
(	O
PBDE	O
)	O
,	O
OH	O
-	O
BDE42	O
,	O
which	O
is	O
capable	O
of	O
binding	O
to	O
the	O
TR	O
,	O
was	O
given	O
neonatally	O
.	O
Our	O
data	O
demonstrated	O
that	O
neonatal	O
exposure	O
to	O
thyroid	O
hormones	O
could	O
affect	O
the	O
long	O
-	O
term	O
expression	O
of	O
the	O
genes	O
,	O
which	O
could	O
be	O
useful	O
markers	O
for	O
neonatal	B-T047
effects	I-T047
by	O
thyroid	O
hormone	O
-	O
disrupting	O
chemicals	O
.	O
Copyright	O
©	O
2017	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O
      
Historical	O
relationships	O
of	O
three	O
enigmatic	O
phasianid	O
genera	O
(	O
Aves	O
:	O
Galliformes	O
)	O
inferred	O
using	O
phylogenomic	O
and	O
mitogenomic	O
data	O
The	O
phylogeny	O
of	O
the	O
Phasianidae	O
(	O
pheasants	O
,	O
partridges	O
,	O
and	O
allies	O
)	O
has	O
been	O
studied	O
extensively	O
.	O
However	O
,	O
these	O
studies	O
have	O
largely	O
ignored	O
three	O
enigmatic	O
genera	O
because	O
of	O
scarce	O
DNA	O
source	B-T033
material	I-T033
and	O
limited	O
overlapping	O
phylogenetic	O
data	O
:	O
blood	O
pheasants	O
(	O
Ithaginis	O
)	O
,	O
snow	O
partridges	O
(	O
Lerwa	O
)	O
,	O
and	O
long	O
-	O
billed	O
partridges	O
(	O
Rhizothera	O
)	O
.	O
Thus	O
,	O
phylogenetic	O
positions	O
of	O
these	O
three	O
genera	O
remain	O
uncertain	O
in	O
what	O
is	O
otherwise	O
a	O
well	O
-	O
resolved	O
phylogeny	O
.	O
Previous	O
studies	O
using	O
different	O
data	O
types	O
place	O
Lerwa	O
and	O
Ithaginis	O
in	O
similar	O
positions	O
,	O
but	O
the	O
absence	O
of	O
overlapping	O
data	O
means	O
the	O
relationship	O
between	O
them	O
could	O
not	O
be	O
inferred	O
.	O
Rhizothera	O
was	O
originally	O
described	O
in	O
the	O
genus	O
Perdix	O
(	O
true	O
partridges	O
)	O
,	O
although	O
a	O
partial	O
cytochrome	O
b	O
(	O
CYB	O
)	O
sequence	O
suggests	O
it	O
is	O
sister	O
to	O
Pucrasia	O
(	O
koklass	O
pheasant	O
)	O
.	O
To	O
identify	O
robust	O
relationships	O
among	O
Ithaginis	O
,	O
Lerwa	O
,	O
Rhizothera	O
,	O
and	O
their	O
phasianid	O
relatives	O
,	O
we	O
used	O
3692	O
ultra	O
-	O
conserved	O
element	O
(	O
UCE	O
)	O
loci	O
and	O
complete	O
mitogenomes	O
from	O
19	O
species	O
including	O
previously	O
hypothesized	O
relatives	O
of	O
the	O
three	O
focal	O
genera	O
and	O
representatives	O
from	O
all	O
major	O
phasianid	O
clades	O
.	O
We	O
used	O
DNA	O
extracted	O
from	O
historical	O
specimen	B-T033
toepads	I-T033
for	O
species	O
that	O
lacked	O
fresh	O
tissue	O
in	O
museum	B-T059
collections	I-T059
.	O
Maximum	O
likelihood	O
and	O
multispecies	O
coalescent	O
UCE	O
analyses	O
strongly	O
supported	O
Lerwa	O
sister	O
to	O
a	O
large	O
clade	O
which	O
included	O
Ithaginis	O
at	O
its	O
base	O
,	O
and	O
also	O
including	O
turkey	O
,	O
grouse	O
,	O
typical	O
pheasants	O
,	O
tragopans	O
,	O
Pucrasia	O
,	O
and	O
Perdix	O
.	O
Rhizothera	O
was	O
also	O
in	O
this	O
clade	O
,	O
sister	O
to	O
a	O
diverse	O
group	O
comprising	O
Perdix	O
,	O
typical	O
pheasants	O
,	O
Pucrasia	O
,	O
turkey	O
and	O
grouse	O
.	O
Mitogenomic	O
genealogies	O
differed	O
from	O
UCEs	O
topologies	O
,	O
supporting	O
a	O
sister	O
relationship	O
between	O
Ithaginis	O
and	O
Lerwa	O
rather	O
than	O
a	O
grade	O
.	O
The	O
position	O
of	O
Rhizothera	O
using	O
mitogenomes	O
depended	O
on	O
analytical	O
choices	O
.	O
Unpartitioned	O
and	O
codon	B-T059
-	I-T059
based	I-T059
analyses	I-T059
placed	O
Rhizothera	O
sister	O
to	O
a	O
tragopan	O
clade	O
,	O
whereas	O
a	O
partitioned	O
DNA	O
model	O
of	O
the	O
mitogenome	O
was	O
congruent	O
with	O
UCE	B-T033
results	I-T033
.	O
In	O
all	O
mitogenome	B-T059
analyses	I-T059
,	O
Pucrasia	O
was	O
sister	O
to	O
a	O
clade	O
including	O
Perdix	O
and	O
the	O
typical	O
pheasants	O
with	O
high	O
support	O
,	O
in	O
contrast	O
to	O
UCEs	O
and	O
published	O
nuclear	O
intron	O
data	O
.	O
Due	O
to	O
the	O
strong	O
support	O
and	O
consistent	O
topology	O
provided	O
by	O
all	O
UCE	O
analyses	O
,	O
we	O
have	O
identified	O
phylogenetic	O
relationships	O
of	O
these	O
three	O
enigmatic	O
,	O
poorly	O
-	O
studied	O
,	O
phasianid	O
taxa	O
.	O
      
Hif-1α	O
Overexpression	O
Improves	B-T033
Transplanted	B-T061
Bone	I-T061
Mesenchymal	I-T061
Stem	I-T061
Cells	I-T061
Survival	O
in	O
Rat	B-T050
MCAO	I-T050
Stroke	I-T050
Model	I-T050
Bone	O
mesenchymal	O
stem	O
cells	O
(	O
BMSCs	O
)	O
death	O
after	O
transplantation	B-T061
is	O
a	O
serious	O
obstacle	O
impacting	O
on	O
the	O
outcome	O
of	O
cell	B-T061
therapy	I-T061
for	O
cerebral	B-T047
infarction	I-T047
.	O
This	O
study	O
was	O
aimed	O
to	O
investigate	O
whether	O
modification	O
of	O
BMSCs	O
with	O
hypoxia	O
-	O
inducible	O
factor	O
1α	O
(	O
Hif-1α	O
)	O
could	O
enhance	O
the	O
survival	O
of	O
the	O
implanted	B-T061
BMSCs	I-T061
.	O
BMSCs	O
were	O
isolated	B-T059
from	O
Wistar	O
rats	O
,	O
and	O
were	O
infected	O
with	O
Hif-1α	B-T121
-	I-T121
GFP	I-T121
lentiviral	I-T121
vector	I-T121
or	O
Hif-1α	O
siRNA	O
.	O
The	O
modified	O
BMSCs	O
were	O
exposed	O
to	O
oxygen	O
-	O
glucose	O
deprivation	O
(	O
OGD	O
)	O
condition	O
,	O
cellular	O
viability	O
and	O
apoptosis	O
were	O
then	O
assessed	O
.	O
An	O
inhibitor	B-T121
of	O
AMPK	O
(	O
compound	B-T121
C	I-T121
)	O
was	O
used	O
to	O
detect	B-T061
whether	O
AMPK	O
and	O
mTOR	O
were	O
implicated	O
in	O
the	O
functions	O
of	O
Hif-1α	O
on	O
BMSCs	O
survival	O
.	O
Besides	O
,	O
ultrastructure	O
of	O
BMSCs	O
was	O
observed	O
and	O
the	O
expression	O
of	O
autophagy	O
markers	O
was	O
measured	O
.	O
The	O
modified	O
BMSCs	O
were	O
transplanted	B-T061
into	O
middle	B-T020
cerebral	I-T020
artery	I-T020
occlusion	I-T020
(	O
MCAO	B-T020
)	O
model	B-T050
of	I-T050
rats	I-T050
,	O
and	O
the	O
cerebral	B-T047
infarction	I-T047
volume	O
and	O
neurological	O
function	O
was	O
assessed	O
.	O
The	O
results	O
indicated	O
that	O
Hif-1α	O
overexpression	O
protected	O
OGD	O
induced	O
injury	O
by	O
promoting	O
cellular	O
viability	O
and	O
inhibiting	O
apoptosis	O
.	O
AMPK	O
was	O
activated	O
while	O
mTOR	O
was	O
inactivated	O
by	O
Hif-1α	O
overexpression	O
,	O
and	O
that	O
might	O
be	O
through	O
which	O
Hif-1α	O
functioned	O
BMSCs	O
survival	O
.	O
Hif-1α	O
overexpression	O
promoted	O
autophagy	O
;	O
more	O
important	O
,	O
compound	B-T121
C	I-T121
abolished	O
the	O
induction	O
of	O
Hif-1α	O
on	O
autophagy	O
.	O
Transplantation	B-T061
of	I-T061
the	I-T061
overexpressed	I-T061
Hif-1α	I-T061
of	I-T061
BMSCs	I-T061
into	O
the	O
MCAO	B-T050
rats	I-T050
reduced	O
brain	B-T047
infarct	I-T047
volume	O
and	O
improved	B-T033
neurobehavioral	O
outcome	O
;	O
besides	O
,	O
it	O
inhibited	O
pro	O
-	O
inflammatory	O
cytokines	O
generation	O
while	O
promoted	O
neurotrophin	O
secretion	O
.	O
In	O
conclusion	O
,	O
Hif-1α	O
might	O
be	O
contributed	O
in	O
the	O
survival	O
of	O
BMSCs	O
by	O
regulating	O
the	O
activation	O
of	O
AMPK	O
and	O
mTOR	O
,	O
as	O
well	O
as	O
by	O
promoting	O
autophagy	O
.	O
      
The	O
antineoplastic	B-T121
drug	I-T121
,	O
trastuzumab	B-T121
,	O
dysregulates	B-T033
metabolism	O
in	O
iPSC	O
-derived	O
cardiomyocytes	O
The	O
targeted	B-T061
ERBB2	I-T061
therapy	I-T061
,	O
trastuzumab	B-T121
,	O
has	O
had	O
a	O
tremendous	O
impact	O
on	O
management	B-T058
of	O
patients	O
with	O
HER2	B-T191
+	I-T191
breast	I-T191
cancer	I-T191
,	O
leading	O
to	O
development	O
and	O
increased	O
use	O
of	O
further	O
HER2	O
targeted	B-T061
therapies	I-T061
.	O
The	O
major	O
clinical	O
side	O
effect	O
is	O
cardiotoxicity	O
but	O
the	O
mechanism	O
is	O
largely	O
unknown	O
.	O
On	O
the	O
basis	O
that	O
gene	O
expression	O
is	O
known	O
to	O
be	O
altered	O
in	O
multiple	O
models	O
of	O
heart	B-T047
failure	I-T047
,	O
we	O
examined	O
differential	O
gene	O
expression	O
of	O
iPSC	O
-derived	O
cardiomyocytes	O
treated	O
at	O
day	O
11	O
with	O
the	O
ERBB2	O
targeted	O
monoclonal	O
antibody	O
,	O
trastuzumab	B-T121
for	O
48	O
h	O
and	O
the	O
small	B-T121
molecule	I-T121
tyrosine	I-T121
kinase	I-T121
inhibitor	I-T121
of	O
EGFR	O
and	O
ERBB2	O
.	O
Transcriptome	B-T059
sequencing	I-T059
was	O
performed	O
on	O
four	O
replicates	O
from	O
each	O
group	O
(	O
48	O
h	O
untreated	O
,	O
48	O
h	O
trastuzumab	B-T121
and	O
48	O
h	O
lapatinib	B-T121
)	O
and	O
differential	O
gene	O
expression	O
analyses	O
were	O
performed	O
on	O
each	O
treatment	O
group	O
relative	O
to	O
untreated	O
cardiomyocytes	O
.	O
517	O
and	O
1358	O
genes	O
were	O
differentially	O
expressed	O
,	O
p	O
<	O
0.05	O
,	O
respectively	O
in	O
cardiomyocytes	O
treated	O
with	O
trastuzumab	B-T121
and	O
lapatinib	B-T121
.	O
Gene	O
ontology	O
analyses	O
revealed	O
in	O
cardiomyocytes	O
treated	O
with	O
trastuzumab	B-T121
,	O
significant	O
down	O
-	O
regulation	O
of	O
genes	O
involved	O
in	O
small	O
molecule	O
metabolism	O
(	O
p	O
=	O
3.22	O
�	O
—	O
10(-9	O
)	O
)	O
and	O
cholesterol	O
(	O
p	O
=	O
0.01	O
)	O
and	O
sterol	O
(	O
p	O
=	O
0.03	O
)	O
processing	O
.	O
We	O
next	O
measured	O
glucose	O
uptake	O
and	O
lactate	B-T121
production	O
in	O
iPSC	O
-derived	O
cardiomyocytes	O
13	O
days	O
post	O
-	O
plating	O
,	O
treated	O
with	O
trastuzumab	B-T121
up	O
to	O
96	O
h.	O
We	O
observed	O
significantly	O
decreased	O
glucose	O
uptake	O
from	O
the	O
media	O
of	O
iPSC	O
-derived	O
cardiomyocytes	O
treated	O
with	O
trastuzumab	B-T121
as	O
early	O
as	O
24	O
h	O
(	O
p	O
=	O
0.001	O
)	O
and	O
consistently	O
up	O
to	O
96	O
h	O
(	O
p	O
=	O
0.03	O
)	O
.	O
Our	O
study	O
suggests	O
dysregulation	B-T033
of	O
cardiac	B-T023
gene	O
expression	O
and	O
metabolism	O
as	O
key	O
elements	O
of	O
ERBB2	O
signaling	O
that	O
could	O
potentially	O
be	O
early	O
biomarkers	O
of	O
cardiotoxicity	O
.	O
      
Incidence	O
and	O
effect	O
of	O
variant	O
histology	O
on	O
oncological	O
outcomes	O
in	O
patients	O
with	O
bladder	B-T191
cancer	I-T191
treated	O
with	O
radical	B-T061
cystectomy	I-T061
We	O
sought	O
to	O
describe	O
incidence	O
of	O
histological	O
variants	O
after	O
radical	B-T061
cystectomy	I-T061
(	O
RC	B-T061
)	O
due	O
to	O
bladder	B-T191
cancer	I-T191
(	O
BCa	B-T191
)	O
.	O
Moreover	O
,	O
we	O
investigated	O
survival	O
outcomes	O
accounting	O
for	O
this	O
parameter	O
.	O
We	O
retrospectively	O
evaluated	B-T058
data	O
from	O
1,067	O
patients	O
with	O
BCa	B-T191
treated	O
with	O
RC	B-T061
between	O
1990	O
and	O
2013	O
at	O
a	O
single	O
tertiary	O
care	O
referral	O
center	O
.	O
All	O
specimen	O
were	O
evaluated	B-T058
by	O
dedicated	O
uropathologists	O
.	O
Univariable	O
and	O
multivariable	O
Cox	O
regression	O
analyses	O
tested	O
the	O
effect	O
of	O
different	O
histopathological	O
variant	O
on	O
recurrence	O
,	O
cancer	O
-	O
specific	O
mortality	O
(	O
CSM	O
)	O
,	O
and	O
overall	O
mortality	O
(	O
OM	O
)	O
after	O
accounting	O
for	O
all	O
available	O
confounders	O
.	O
Of	O
1,067	O
patients	O
,	O
729	O
(	O
68.3	O
%	O
)	O
harbored	O
pure	B-T191
urothelial	I-T191
BCa	I-T191
while	O
338	O
(	O
31.7	O
%	O
)	O
were	O
found	O
to	O
have	O
a	O
variant	O
.	O
Considering	O
uncommon	O
variants	O
,	O
21	O
(	O
2.0	O
%	O
)	O
were	O
sarcomatoid	B-T191
,	O
10	O
(	O
0.9	O
%	O
)	O
lymphoepitelial	B-T191
,	O
19	O
(	O
1.8	O
%	O
)	O
small	B-T191
cell	I-T191
,	O
109	O
(	O
10.2	O
%	O
)	O
squamous	B-T191
,	O
89	O
(	O
8.3	O
%	O
)	O
micropapillary	B-T191
,	O
23	O
(	O
2.2	O
%	O
)	O
glandular	B-T191
,	O
34	O
(	O
3.2	O
%	O
)	O
mixed	O
variants	O
,	O
and	O
33	O
(	O
3.1	O
%	O
)	O
were	O
found	O
with	O
other	O
types	O
of	O
variants	O
.	O
With	O
a	O
median	O
follow	B-T058
-	I-T058
up	I-T058
of	O
6.2	O
years	O
,	O
343	O
recurrence	O
,	O
365	O
CSM	O
,	O
and	O
451	O
OM	O
were	O
recorded	O
,	O
respectively	O
.	O
At	O
multivariable	O
Cox	O
regression	O
analyses	O
,	O
the	O
presence	O
of	O
small	B-T191
cell	I-T191
variant	I-T191
was	O
associated	O
with	O
higher	O
recurrence	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
=	O
3.47	O
,	O
P<0.001	O
)	O
,	O
CSM	O
(	O
HR	O
=	O
3.30	O
,	O
P<0.04	O
)	O
,	O
and	O
OM	O
(	O
HR	O
=	O
2.97	O
,	O
P<0.003	O
)	O
as	O
compared	O
with	O
pure	O
urothelial	B-T191
cancer	I-T191
.	O
Conversely	O
,	O
no	B-T033
survival	I-T033
differences	I-T033
were	O
recorded	O
considering	O
other	O
histological	O
variants	O
(	O
all	O
P	O
>	O
0.1	O
)	O
.	O
Our	O
study	O
confirms	O
that	O
histological	O
variant	O
is	O
not	O
an	O
infrequent	O
event	O
at	O
RC	B-T061
specimen	O
.	O
However	O
,	O
in	O
our	O
single	O
-	O
center	O
series	O
,	O
only	O
patients	O
found	O
with	O
small	B-T191
cell	I-T191
variant	I-T191
were	O
associated	O
with	O
a	O
negative	B-T033
effect	O
on	O
survival	O
after	O
RC	B-T061
.	O
      
Does	O
a	O
policy	O
of	O
earlier	B-T061
induction	I-T061
affect	O
labour	O
outcomes	O
in	O
women	O
induced	O
for	O
postmaturity	B-T047
?	O
A	O
retrospective	O
analysis	O
in	O
a	O
tertiary	O
hospital	O
in	O
the	O
North	O
of	O
England	O
to	O
investigate	O
whether	O
a	O
change	O
in	O
the	O
management	O
of	O
postmature	O
pregnancy	O
to	O
earlier	B-T061
induction	I-T061
affects	O
the	O
length	O
of	O
labour	O
and	O
the	O
induction	B-T061
process	I-T061
.	O
Secondly	O
,	O
to	O
assess	O
the	O
feasibility	O
of	O
the	O
research	O
process	O
to	O
inform	O
a	O
future	O
larger	O
study	O
.	O
a	O
change	O
in	O
management	O
of	O
postmature	O
pregnancy	O
in	O
an	O
NHS	B-T058
hospital	O
in	O
October	O
2013	O
,	O
from	O
induction	B-T061
at	O
42	O
weeks	O
gestation	O
to	O
induction	B-T061
between	O
41	O
-	O
42	O
weeks	O
,	O
provided	O
an	O
opportunity	O
to	O
conduct	O
a	O
retrospective	O
analysis	O
.	O
Pre	O
-	O
existing	O
data	O
from	O
the	O
maternity	O
database	O
and	O
casenotes	O
were	O
collected	O
and	O
primary	O
outcomes	O
analysed	O
using	O
the	O
Mann	O
-	O
Whitney	O
test	O
and	O
the	O
Hodges	O
-	O
Lehman	O
confidence	O
interval	O
for	O
differences	O
in	O
medians	O
.	O
a	O
large	O
city	O
based	O
tertiary	O
referral	O
hospital	O
in	O
the	O
North	O
of	O
England	O
.	O
125	O
women	O
induced	O
before	O
the	O
change	O
in	O
policy	O
were	O
compared	O
with	O
309	O
women	O
induced	O
after	O
the	O
change	O
.	O
primary	O
outcomes	O
were	O
length	O
of	O
1st	O
and	O
2nd	O
stage	O
of	O
labour	O
,	O
overall	O
length	O
of	O
labour	O
,	O
length	O
of	O
induction	B-T061
to	O
established	O
labour	O
and	O
length	O
of	O
induction	B-T061
to	O
birth	O
.	O
the	O
median	O
overall	O
length	O
of	O
labour	O
for	O
women	O
induced	O
at	O
42	O
weeks	O
was	O
6.5	O
hours	O
,	O
while	O
for	O
women	O
induced	O
at	O
41	O
-	O
42	O
weeks	O
this	O
was	O
5.2	O
hours	O
.	O
The	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
p=0.15	O
,	O
95	O
%	O
CI	O
for	O
median	O
difference	O
-0.27	O
to	O
1.93	O
hours	O
)	O
with	O
a	O
small	O
effect	O
size	O
(	O
Pearson	O
's	O
r=-0.08	O
)	O
.	O
The	O
median	O
length	O
of	O
induction	B-T061
to	O
birth	O
was	O
13.6	O
hours	O
for	O
women	O
induced	O
at	O
42	O
weeks	O
and	O
16.5	O
hours	O
for	O
women	O
induced	O
at	O
41	O
-	O
42	O
weeks	O
.	O
This	O
difference	O
was	O
also	O
not	O
statistically	O
significant	O
(	O
p=0.14	O
,	O
95	O
%	O
CI	O
for	O
median	O
difference	O
-7.25	O
to	O
1.20	O
hours	O
)	O
with	O
a	O
small	O
effect	O
size	O
(	O
Pearson	O
's	O
r=-0.13	O
)	O
.	O
This	O
study	O
demonstrated	O
no	O
statistically	O
significant	O
difference	O
s	O
in	O
length	O
of	O
labour	O
and	O
induction	B-T061
following	O
a	O
change	O
in	O
the	O
management	O
of	O
postmature	O
pregnancy	O
to	O
earlier	B-T061
induction	I-T061
.	O
A	O
large	O
study	O
is	O
needed	O
to	O
establish	O
definitively	O
the	O
effects	O
of	O
earlier	B-T061
induction	I-T061
on	O
labour	O
outcomes	O
.	O
      
Interleukin-1β	O
induced	O
Stress	O
Granules	O
Sequester	O
COX-2	O
mRNA	O
and	O
Regulates	O
its	O
Stability	O
and	O
Translation	O
in	O
Human	O
OA	B-T047
Chondrocytes	O
Enhanced	O
and	O
immediate	O
expression	O
of	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
mRNA	O
is	O
observed	O
in	O
IL-1β	O
-	O
stimulated	B-T061
OA	B-T047
chondrocytes	O
but	O
the	O
synthesis	O
of	O
protein	O
found	O
significantly	O
delayed	O
.	O
Here	O
we	O
investigated	O
the	O
role	O
of	O
stress	O
granules	O
(	O
SGs	O
)	O
,	O
ribonucleoprotein	O
complexes	O
that	O
regulate	O
mRNA	O
translation	O
,	O
in	O
the	O
delayed	O
translation	O
of	O
COX-2	O
mRNAs	O
in	O
IL-1β	O
-	O
stimulated	B-T061
OA	B-T047
chondrocytes	O
.	O
Stimulation	B-T061
of	O
human	O
chondrocytes	O
with	O
IL-1β	O
activated	O
the	O
stress	O
response	O
genes	O
and	O
the	O
phosphorylation	O
of	O
eIF2α	O
that	O
triggered	O
the	O
assembly	O
of	O
SGs	O
.	O
Using	O
combined	O
immunofluorescence	B-T059
staining	I-T059
of	O
SGs	O
markers	O
and	O
COX-2	O
protein	O
,	O
RNA	O
fluorescence	O
in	O
situ	O
hybridization	O
and	O
RNA	O
immunoprecipitation	B-T059
,	O
the	O
COX-2	O
mRNAs	O
were	O
found	O
sequestered	O
in	O
SGs	O
in	O
IL-1β	O
-	O
stimulated	B-T061
OA	B-T047
chondrocytes	O
.	O
No	B-T033
increase	O
in	O
COX-2	O
protein	O
expression	O
was	O
observed	O
during	O
the	O
persistence	O
of	O
SGs	O
but	O
enhanced	O
expression	O
of	O
COX-2	O
protein	O
was	O
noted	O
upon	O
clearance	O
of	O
the	O
SGs	O
.	O
Inhibition	O
of	O
SGs	O
clearance	O
blocked	O
COX-2	O
mRNA	O
translation	O
whereas	O
blocking	O
the	O
assembly	O
of	O
SGs	O
by	O
TIA-1	O
depletion	O
resulted	O
in	O
rapid	O
and	O
increased	O
production	O
of	O
COX-2	O
and	O
PGE2	B-T121
.	O
Our	O
findings	O
show	O
for	O
the	O
first	O
time	O
assembly	O
of	O
SGs	O
and	O
sequestration	O
of	O
COX-2	O
mRNAs	O
in	O
human	O
OA	B-T047
chondrocytes	O
under	O
pathological	B-T184
conditions	I-T184
.	O
Post	O
-	O
transcriptional	O
regulation	O
of	O
COX-2	O
mRNAs	O
translation	O
by	O
SGs	O
indicates	O
a	O
role	O
in	O
IL-1β	O
-mediated	O
catabolic	O
response	O
that	O
could	O
be	O
therapeutically	B-T061
targeted	O
in	O
OA	B-T047
.	O
      
Structural	B-T061
Modification	I-T061
of	O
Lipopolysaccharide	O
Conferred	O
by	O
mcr-1	O
in	O
Gram	B-T007
-	I-T007
Negative	I-T007
ESKAPE	I-T007
Pathogens	B-T001
mcr-1	O
was	O
initially	O
reported	O
as	O
the	O
first	O
plasmid	O
-mediated	O
colistin	B-T195
resistance	O
gene	O
in	O
clinical	O
isolates	O
of	O
Escherichia	B-T007
coli	I-T007
and	O
Klebsiella	B-T007
pneumoniae	I-T007
in	O
China	O
and	O
has	O
subsequently	O
been	O
identified	O
worldwide	O
in	O
various	O
species	O
of	O
the	O
family	B-T007
Enterobacteriaceae	I-T007
mcr-1	O
encodes	O
a	O
phosphoethanolamine	O
transferase	O
,	O
and	O
its	O
expression	O
has	O
been	O
shown	O
to	O
generate	O
phosphoethanolamine	O
-modified	O
bis	O
-	O
phosphorylated	O
hexa	O
-	O
acylated	O
lipid	O
A	O
in	O
E.	B-T007
coli	I-T007
Here	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
mcr-1	O
on	O
colistin	B-T195
susceptibility	B-T033
and	O
on	O
lipopolysaccharide	O
structures	O
in	O
laboratory	O
and	O
clinical	O
strains	O
of	O
the	O
Gram	B-T007
-	I-T007
negative	I-T007
ESKAPE	I-T007
(	O
Enterococcus	B-T007
faecium	I-T007
,	O
Staphylococcus	B-T007
aureus	I-T007
,	O
K.	B-T007
pneumoniae	I-T007
K.	B-T007
pneumoniae	I-T007
,	O
Acinetobacter	B-T007
baumannii	I-T007
,	O
Pseudomonas	B-T007
aeruginosa	I-T007
,	O
and	O
Enterobacter	B-T007
species	I-T007
)	O
pathogens	B-T001
,	O
which	O
are	O
often	O
treated	O
clinically	O
by	O
colistin	B-T195
.	O
The	O
effects	O
of	O
mcr-1	O
on	O
colistin	B-T195
resistance	O
were	O
determined	O
using	O
MIC	B-T059
assays	I-T059
of	O
laboratory	O
and	O
clinical	O
strains	O
of	O
E.	B-T007
coli	I-T007
,	O
K.	B-T007
pneumoniae	I-T007
,	O
A.	B-T007
baumannii	I-T007
,	O
and	O
P.	B-T007
aeruginosa	I-T007
Lipid	O
A	O
structural	O
changes	O
resulting	O
from	O
MCR-1	O
were	O
analyzed	O
by	O
mass	B-T059
spectrometry	I-T059
.	O
The	O
introduction	O
of	O
mcr-1	O
led	O
to	O
colistin	B-T195
resistance	O
in	O
E.	B-T007
coli	I-T007
,	O
K.	B-T007
pneumoniae	I-T007
,	O
and	O
A.	B-T007
baumannii	I-T007
but	O
only	O
moderately	O
reduced	O
susceptibility	B-T033
in	O
P.	B-T007
aeruginosa	I-T007
Phosphoethanolamine	O
modification	B-T033
of	O
lipid	O
A	O
was	O
observed	O
consistently	O
for	O
all	O
four	O
species	O
.	O
These	O
findings	O
highlight	O
the	O
risk	O
of	O
colistin	B-T195
resistance	O
as	O
a	O
consequence	O
of	O
mcr-1	O
expression	O
among	O
ESKAPE	B-T007
pathogens	B-T001
,	O
especially	O
in	O
K.	B-T007
pneumoniae	I-T007
and	O
A.	B-T007
baumannii	I-T007
Furthermore	O
,	O
the	O
observation	O
that	O
lipid	O
A	O
structures	O
were	O
modified	O
despite	O
only	O
modest	O
increases	O
in	O
colistin	B-T195
MICs	B-T059
in	O
some	O
instances	O
suggests	O
more	O
sophisticated	O
surveillance	O
methods	O
may	O
need	O
to	O
be	O
developed	O
to	O
track	O
the	O
dissemination	O
of	O
mcr-1	O
or	O
plasmid	O
-mediated	O
phosphoethanolamine	O
transferases	O
in	O
general	O
.	O
      
CS	B-T121
-	O
PEG	B-T121
decorated	O
PLGA	O
nano	O
-	O
prototype	O
for	O
delivery	O
of	O
bioactive	O
compounds	O
:	O
A	O
novel	O
approach	O
for	O
induction	O
of	O
apoptosis	O
in	O
HepG2	O
cell	O
line	O
Polymer	O
-	O
based	O
nanoparticles	O
are	O
used	O
as	O
vectors	O
for	O
cancer	B-T191
drug	O
delivery	O
.	O
The	O
bioactive	O
compounds	O
(	O
quercetin	B-T121
,	O
ellagic	B-T121
acid	I-T121
and	O
gallic	O
acid	O
)	O
are	O
well	O
known	O
to	O
be	O
not	O
only	O
antioxidants	B-T121
but	O
also	O
chemopreventive	B-T121
candidates	I-T121
against	O
various	O
types	O
of	O
cancers	B-T191
.	O
To	O
circumvent	O
the	O
low	O
bioavailability	O
and	O
the	O
short	O
half	O
-	O
life	O
time	O
obstacles	O
,	O
we	O
hypothesized	O
a	O
novel	O
PLGA	O
nano	O
-	O
platform	O
functionalized	O
with	O
CS	B-T121
and	O
PEG	B-T121
to	O
encapsulate	O
these	O
phytochemicals	O
.	O
This	O
encapsulation	O
will	O
protect	B-T033
the	O
compounds	B-T121
from	O
the	O
phagocytic	O
uptake	O
and	O
deliver	O
PLGA	B-T121
-	I-T121
CS	I-T121
-	I-T121
PEG	I-T121
nano	I-T121
-	I-T121
prototype	I-T121
with	O
high	O
biodegradability	O
and	O
biosafety	O
.	O
Three	O
consequent	O
types	O
of	O
PLGA	B-T121
-	I-T121
based	I-T121
nanocomposites	I-T121
were	O
prepared	O
and	O
characterized	O
.	O
Furthermore	O
,	O
we	O
investigated	O
the	O
newly	O
synthesized	O
nano	O
-	O
formulations	O
against	O
human	O
hepatocellular	B-T191
carcinoma	I-T191
(	O
HepG2	O
)	O
and	O
colorectal	B-T191
cancer	I-T191
(	O
HCT	O
116	O
)	O
cell	O
lines	O
using	O
cell	O
growth	O
inhibition	O
assays	B-T059
,	O
followed	O
by	O
apoptosis	O
and	O
necrosis	O
assays	B-T059
using	O
flow	B-T059
cytometry	I-T059
to	O
detect	B-T059
the	O
underlying	O
mechanism	O
of	O
HepG2	O
cell	O
death	O
.	O
Through	O
Malvern	O
Zeta	O
Sizer	O
,	O
we	O
recorded	O
that	O
the	O
average	O
diameters	O
of	O
the	O
nano	O
-	O
prototypes	O
ranged	O
from	O
150	O
to	O
300	O
nm	O
.	O
The	O
cytotoxic	B-T059
activity	I-T059
of	O
quercetin	B-T121
,	O
ellagic	B-T121
acid	I-T121
,	O
and	O
gallic	O
acid	O
-	O
encapsulated	O
PLGA	O
,	O
PLGA	B-T121
-	I-T121
CS	I-T121
,	O
and	O
PLGA	B-T121
-	I-T121
CS	I-T121
-	I-T121
PEG	I-T121
nano	I-T121
-	I-T121
prototypes	I-T121
it	O
has	O
been	O
found	B-T033
that	O
they	O
reduce	O
the	O
IC50s	O
of	O
the	O
HepG2	O
cells	O
values	O
by	O
2.2	O
,	O
2.9	O
,	O
2.8-	O
folds	O
,	O
1	O
,	O
1.5	O
,	O
2.7-	O
folds	O
,	O
and	O
0.9	O
,	O
0.7	O
,	O
1.5-	O
folds	O
,	O
respectively	O
.	O
Mechanistically	O
,	O
the	O
nano	O
-	O
platforms	O
of	O
quercetin	B-T121
seem	O
to	O
be	O
dependent	O
on	O
both	O
apoptosis	O
and	O
necrosis	O
,	O
while	O
those	O
of	O
ellagic	B-T121
acid	I-T121
and	O
gallic	O
acid	O
are	O
mainly	O
dependent	O
on	O
apoptosis	O
.	O
CS	B-T121
-	O
PEG	B-T121
-blended	O
PLGA	O
nano	O
-	O
delivery	O
system	O
of	O
quercetin	B-T121
,	O
ellagic	B-T121
acid	I-T121
and	O
gallic	O
acid	O
can	O
potentiate	O
apoptosis	O
-	O
mediated	O
cell	O
death	O
in	O
HepG2	O
cell	O
line	O
.	O
      
Fragment	O
-Based	O
Discovery	O
of	O
5	B-T121
-	I-T121
Arylisatin	I-T121
-Based	O
Inhibitors	B-T121
of	O
Matrix	O
Metalloproteinases	O
2	O
and	O
13	O
Matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
are	O
well	O
-	O
established	O
targets	O
for	O
several	O
pathologies	O
.	O
In	O
particular	O
,	O
MMP-2	O
and	O
MMP-13	O
play	O
a	O
prominent	O
role	O
in	O
cancer	O
progression	O
.	O
In	O
this	O
study	O
,	O
a	O
structure	B-T058
-	I-T058
based	I-T058
screening	I-T058
campaign	O
was	O
applied	O
to	O
prioritize	O
metalloproteinase	O
-oriented	O
fragments	O
.	O
This	O
computational	O
model	O
was	O
applied	O
to	O
a	O
representative	O
fragment	O
set	O
from	O
the	O
publically	O
available	O
EDASA	O
Scientific	O
compound	O
library	O
.	O
These	O
fragments	O
were	O
prioritized	O
,	O
and	O
the	O
top	O
-	O
ranking	O
hits	O
were	O
tested	O
in	O
a	O
biological	B-T059
assay	I-T059
to	O
validate	O
the	O
model	O
.	O
Two	O
scaffolds	O
showed	O
consistent	O
activity	O
in	O
the	O
assay	B-T059
,	O
and	O
the	O
isatin	B-T121
-	I-T121
based	I-T121
compounds	I-T121
were	O
the	O
most	O
interesting	O
.	O
These	O
latter	O
fragments	O
have	O
significant	O
potential	O
as	O
tools	O
for	O
the	O
design	O
and	O
realization	O
of	O
novel	O
MMP	B-T121
inhibitors	I-T121
.	O
In	O
addition	O
to	O
their	O
micromolar	O
activity	O
,	O
the	O
chemical	O
synthesis	O
affords	O
flexible	O
and	O
creative	O
access	O
to	O
their	O
analogues	O
.	O
      
Transfusion	O
medicine	O
in	O
medical	O
education	O
:	O
an	O
analysis	O
of	O
curricular	O
grids	O
in	O
Brazil	O
and	O
a	O
review	O
of	O
the	O
current	O
literature	O
Blood	B-T061
transfusions	I-T061
are	O
one	O
of	O
the	O
most	O
performed	O
medical	B-T058
procedures	I-T058
in	O
the	O
world	O
.	O
Thus	O
,	O
as	O
education	O
in	O
transfusion	O
medicine	O
is	O
vital	O
to	O
medical	B-T033
care	I-T033
,	O
it	O
should	O
aim	O
to	O
promote	O
a	O
responsible	O
practice	O
with	O
the	O
rational	O
use	O
of	O
blood	O
by	O
doctors	O
.	O
This	O
study	O
aims	O
to	O
investigate	O
the	O
situation	O
of	O
the	O
teaching	O
of	O
transfusion	O
medicine	O
in	O
medical	O
schools	O
in	O
Brazil	O
.	O
The	O
websites	O
of	O
the	O
249	O
Brazilian	O
medical	O
schools	O
in	O
operation	O
in	O
June	O
2015	O
were	O
visited	O
and	O
the	O
curricula	O
of	O
the	O
medical	O
courses	O
were	O
investigated	O
in	O
respect	O
to	O
the	O
presence	O
or	O
absence	O
of	O
a	O
transfusion	O
medicine	O
discipline	O
.	O
When	O
available	O
,	O
the	O
subject	O
grids	O
were	O
analyzed	O
to	O
verify	O
whether	O
a	O
description	O
of	O
content	O
regarding	O
transfusion	O
medicine	O
was	O
given	O
within	O
other	O
disciplines	O
.	O
Of	O
the	O
249	O
medical	O
school	O
sites	O
visited	O
,	O
information	O
on	O
the	O
curriculum	O
was	O
obtained	O
from	O
178	O
.	O
Of	O
the	O
medical	O
schools	O
that	O
published	O
their	O
curriculum	O
,	O
132	O
(	O
74.1	O
%	O
)	O
did	O
not	O
have	O
disciplines	O
of	O
transfusion	O
medicine	O
or	O
hematology	O
and	O
only	O
seven	O
(	O
3.9	O
%	O
)	O
had	O
a	O
discipline	O
of	O
transfusion	O
medicine	O
in	O
the	O
curricular	O
grid	O
.	O
Education	O
on	O
transfusion	O
medicine	O
is	O
of	O
fundamental	O
importance	O
for	O
safe	B-T061
and	I-T061
efficient	I-T061
transfusion	I-T061
practices	I-T061
.	O
Deficiencies	O
in	O
medical	O
knowledge	O
of	O
this	O
subject	O
have	O
been	O
found	O
worldwide	O
.	O
The	O
results	O
of	O
this	O
study	O
indicate	O
a	O
possible	O
deficiency	O
in	O
teaching	O
the	O
basics	O
of	O
this	O
specialty	O
.	O
Thus	O
,	O
additional	O
prospective	O
studies	O
to	O
assess	B-T058
the	O
knowledge	O
and	O
practice	O
of	O
transfusion	O
medicine	O
in	O
Brazilian	O
medical	O
schools	O
are	O
warranted	O
,	O
which	O
could	O
prompt	O
a	O
discussion	O
on	O
the	O
importance	O
of	O
offering	O
training	O
in	O
transfusion	O
medicine	O
to	O
medical	O
students	O
.	O
      
Progressive	O
Occlusion	O
and	O
Recanalization	B-T061
after	O
Endovascular	B-T061
Treatment	I-T061
for	O
287	O
Unruptured	B-T047
Small	I-T047
Aneurysms	I-T047
(	O
<	O
5	O
mm	O
):	O
A	O
Single	O
-	O
Center	O
6	O
-	O
Year	O
Experience	O
We	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
coiling	O
for	O
small	O
unruptured	B-T047
intracranial	I-T047
aneurysms	I-T047
UIAs	B-T047
(	O
UIAs)﹤5	O
mm	O
)	O
on	O
progressive	O
occlusio	O
n	O
and	O
recanalization	B-T061
,	O
and	O
the	O
dubious	O
factors	O
related	O
to	O
progressive	O
occlusion	O
and	O
recanalization	B-T061
among	O
UIAs	B-T047
without	O
complete	O
occlusion	O
.	O
A	O
total	O
of	O
264	O
patients	O
with	O
287	O
small	O
UIAs	B-T047
were	O
coiled	O
in	O
our	O
institute	O
between	O
June	O
2009	O
and	O
December	O
2014	O
.	O
All	O
UIAs	B-T047
enrolled	O
were	O
divided	O
into	O
small	O
(	O
3	O
-	O
5	O
mm	O
)	O
and	O
very	O
small	O
(	O
<3	O
mm	O
)	O
group	O
s	O
,	O
and	O
UIAs	B-T047
without	O
initial	O
complete	O
occlusion	O
were	O
divided	O
into	O
progressive	O
,	O
stable	O
and	O
recanalization	B-T061
groups	O
.	O
Baseline	O
characteristics	O
,	O
procedure	B-T061
-related	O
complications	O
,	O
angiographic	B-T060
follow	B-T058
-	I-T058
up	I-T058
results	I-T058
,	O
and	O
clinical	O
outcomes	O
were	O
statistically	O
analyzed	O
.	O
Among	O
287	O
aneurysms	B-T047
,	O
211	O
aneurysms	B-T047
(	O
73.5	O
%	O
)	O
were	O
completely	O
coiled	O
,	O
three	O
(	O
1.2	O
%	O
)	O
intraoperative	O
ruptures	O
and	O
12	O
(	O
4.2	O
%	O
)	O
perioperative	O
thromboembolic	O
events	O
occurred	O
.	O
Angiographic	B-T060
follow	B-T058
-	I-T058
up	I-T058
was	O
available	O
for	O
174	O
patients	O
(	O
65.9	O
%	O
)	O
,	O
the	O
incidence	O
of	O
recanalization	B-T061
was	O
5.7	O
%	O
.	O
Among	O
56	O
aneurysms	B-T047
without	O
complete	O
occlusion	O
,	O
43	O
(	O
76.8	O
%	O
)	O
had	O
progressive	O
occlusion	O
and	O
6(10.7	O
%	O
)	O
had	O
recanalization	B-T061
.	O
Anatomic	B-T033
results	I-T033
of	O
initial	O
and	O
follow	B-T058
-	I-T058
up	I-T058
between	O
small	O
and	O
very	O
small	O
groups	O
were	O
similar	O
in	O
both	O
groups	O
.	O
On	O
logistic	O
regression	O
analysis	O
,	O
smaller	O
size	O
(	O
<3	O
mm	O
)	O
without	O
complete	O
occlusion	O
related	O
to	O
recanalization	B-T061
(	O
OR	O
,	O
8.0	O
,	O
95	O
%	O
CI	O
,	O
1.3	O
-	O
50.0	O
,	O
P=0.026	O
)	O
.	O
Our	O
study	O
suggested	O
that	O
coil	B-T061
embolization	I-T061
of	O
small	O
UIAs	B-T047
can	O
achieve	O
a	O
high	O
rate	O
of	O
progressive	O
occlusion	O
and	O
low	O
rate	O
of	O
recanalization	B-T061
during	O
follow	B-T058
-	I-T058
up	I-T058
.	O
Anatomic	B-T033
results	I-T033
of	O
initial	O
and	O
follow	B-T058
-	I-T058
up	I-T058
between	O
small	O
(	O
3	O
-	O
5	O
mm	O
)	O
and	O
very	O
small	O
(	O
<3	O
mm	O
)	O
groups	O
were	O
similar	O
in	O
both	O
groups	O
.	O
What	O
's	O
more	O
,	O
smaller	O
size	O
(	O
<3	O
mm	O
)	O
without	O
complete	O
occlusion	O
may	O
relate	O
to	O
recanalization	B-T061
.	O
      
Metacarpophalangeal	B-T061
Joint	I-T061
Arthrodesis	I-T061
of	O
the	O
Thumb	B-T023
-	O
Minimum	O
of	O
Eight	O
Months	O
Follow	B-T058
-	I-T058
up	I-T058
Disorders	B-T047
of	O
the	O
thumb	O
metacarpophalangeal	O
(	O
MCP	O
)	O
joint	O
can	O
lead	O
to	O
significant	O
loss	O
of	O
function	O
and	O
pain	B-T184
.	O
Thumb	O
MCP	O
arthrodesis	B-T061
following	O
traumatic	O
injuries	O
is	O
inadequately	O
described	O
and	O
recent	O
studies	O
have	O
questioned	O
the	O
outcome	O
of	O
this	O
treatment	B-T061
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
report	B-T058
outcome	O
and	O
disability	B-T033
following	O
thumb	O
MCP	O
joint	O
arthrodesis	B-T061
in	O
the	O
treatment	B-T061
of	O
chronic	O
instability	O
after	O
traumatic	O
injuries	O
.	O
A	O
retrospective	O
review	B-T061
of	O
26	O
patients	O
operated	B-T061
on	O
with	O
MCP	O
joint	O
arthrodesis	B-T061
,	O
median	O
follow	B-T058
-	I-T058
up	I-T058
42	O
months	O
(	O
8	O
-	O
104	O
months	O
)	O
.	O
Subjective	O
outcome	O
was	O
assessed	O
using	O
the	O
disabilities	O
of	O
the	O
Arm	O
,	O
Shoulder	O
,	O
and	O
Hand	O
-	O
questionnaire	O
(	O
DASH	O
)	O
.	O
In	O
addition	O
,	O
patient	O
satisfaction	O
,	O
pain	B-T184
,	O
stiffness	B-T184
,	O
and	O
impairment	O
of	O
activities	O
of	O
daily	O
living	O
were	O
assessed	O
on	O
a	O
Visual	B-T060
Analogue	I-T060
Scale	I-T060
(	O
VAS	B-T060
)	O
followed	O
by	O
a	O
question	O
stating	O
whether	O
they	O
would	O
undergo	O
the	O
same	O
procedure	O
again	O
.	O
Two	O
patients	O
(	O
7.7	O
%	O
)	O
needed	O
re	B-T061
-	I-T061
operation	I-T061
due	O
to	O
nonunion	B-T033
.	O
Four	O
patients	O
(	O
15.4	O
%	O
)	O
needed	O
hardware	B-T061
removal	I-T061
.	O
Median	O
DASH	O
-	O
score	O
was	O
18	O
(	O
25	O
-	O
75	O
%	O
range	O
6	O
-	O
47	O
)	O
,	O
with	O
lower	O
DASH	O
score	O
s	O
being	O
better	O
.	O
Score	O
s	O
were	O
significantly	O
worse	O
in	O
gender	O
and	O
age	O
matched	O
individuals	O
(	O
p<0.05	O
)	O
.	O
Median	O
VAS	B-T060
for	O
pain	B-T184
was	O
3.7	O
(	O
range	O
0	O
-	O
8)	O
.	O
More	O
than	O
50	O
%	O
of	O
patients	O
reported	O
mild	B-T033
,	O
moderate	B-T184
or	O
severe	B-T033
pain	I-T033
,	O
but	O
all	O
patients	O
reported	O
that	O
they	O
were	O
willing	O
to	O
undergo	O
the	O
same	O
procedure	O
again	O
.	O
Our	O
data	O
suggest	O
,	O
that	O
patients	O
with	O
post	O
-	O
traumatic	O
thumb	O
injuries	O
managed	O
with	O
thumb	O
MCP	O
joint	O
arthrodesis	B-T061
perform	O
worse	O
than	O
gender	O
and	O
age	O
matched	O
individuals	O
.	O
Many	O
lived	O
with	O
pain	B-T184
,	O
but	O
all	O
reported	O
that	O
they	O
were	O
willing	O
to	O
undergo	O
the	O
same	O
procedure	O
again	O
.	O
We	O
suggest	O
that	O
the	O
disability	O
scale	O
by	O
the	O
National	O
Board	O
of	O
Industrial	O
Injuries	O
should	O
be	O
reconsidered	O
for	O
patients	O
operated	B-T061
on	O
with	O
thumb	O
MCP	O
arthrodesis	B-T061
.	O
      
Epidemiology	O
and	O
risk	B-T033
factors	I-T033
associated	O
with	O
surgical	O
site	O
infection	O
after	O
different	O
types	O
of	O
hepatobiliary	O
and	O
pancreatic	O
surgery	O
Surgical	O
site	O
infection	O
(	O
SSI	O
)	O
is	O
one	O
of	O
the	O
most	O
common	O
healthcare	O
-	O
associated	O
infections	O
(	O
HAIs	O
)	O
;	O
however	O
,	O
SSI	O
after	O
hepatobiliary	O
and	O
pancreatic	O
surgery	O
(	O
HBPS	O
)	O
has	O
not	O
been	O
well	O
investigated	O
in	O
a	O
large	O
cohort	O
of	O
patients	O
.	O
This	O
study	O
analyzed	O
the	O
factors	O
associated	O
with	O
SSI	O
following	O
HBPS	O
in	O
Japan	O
,	O
using	O
a	O
Japanese	O
national	O
database	O
.	O
Data	O
on	O
HBPS	O
performed	O
between	O
2012	O
and	O
2014	O
were	O
extracted	O
from	O
a	O
national	O
monitoring	O
system	O
for	O
HAI	O
:	O
The	O
Japan	B-T061
Nosocomial	I-T061
Infections	I-T061
Surveillance	I-T061
.	O
Using	O
multivariate	O
logistic	O
regression	O
,	O
I	O
assessed	O
the	O
factors	O
associated	O
with	O
SSI	O
.	O
The	O
cumulative	O
incidence	O
of	O
SSI	O
following	O
HBPS	O
was	O
15.6	O
%	O
(	O
2873/18,398	O
)	O
.	O
The	O
incidence	O
of	O
SSI	O
after	O
pancreatoduodenectomy	B-T061
was	O
28.0	O
%	O
,	O
which	O
was	O
significantly	O
higher	O
than	O
that	O
after	O
liver	B-T061
resection	I-T061
and	O
other	O
types	O
of	O
HBPS	O
(	O
8.8	O
and	O
15.5	O
%	O
,	O
respectively	O
)	O
.	O
Among	O
the	O
four	O
traditional	O
risk	B-T033
factors	I-T033
,	O
the	O
American	O
Society	O
of	O
Anesthesiologists	O
score	O
was	O
ineffective	O
for	O
predicting	O
SSI	O
in	O
the	O
final	O
model	O
of	O
all	O
three	O
types	O
of	O
surgery	B-T061
.	O
Additional	O
risk	B-T033
factors	I-T033
were	O
identified	O
,	O
including	O
age	O
and	O
male	O
gender	O
.	O
The	O
incidence	O
of	O
and	O
factors	O
associated	O
with	O
SSI	O
after	O
the	O
three	O
types	O
of	O
HBPS	O
analyzed	O
differed	O
significantly	O
.	O
To	O
accurately	O
compare	O
hospital	O
performance	O
in	O
relation	O
to	O
SSI	O
following	O
HBPS	O
,	O
the	O
operative	B-T061
procedure	I-T061
category	O
in	O
the	O
surveillance	B-T058
system	I-T058
must	O
be	O
divided	O
into	O
three	O
types	O
.	O
      
Shared	O
decision	O
making	O
in	O
the	O
UK	O
:	O
Moving	O
towards	O
wider	O
uptake	O
Shared	O
decision	O
making	O
(	O
SDM	O
)	O
is	O
firmly	O
on	O
the	O
policy	O
agenda	O
in	O
the	O
UK	O
and	O
a	O
recent	O
legal	O
ruling	O
has	O
confirmed	O
its	O
importance	O
.	O
Policymakers	O
,	O
ethicists	O
,	O
professional	O
regulators	O
and	O
societies	O
,	O
patient	O
organisations	O
and	O
now	O
the	O
courts	O
are	O
committed	O
to	O
ensuring	O
that	O
SDM	O
becomes	O
the	O
norm	O
throughout	O
the	O
NHS	B-T058
,	O
but	O
an	O
unfavourable	O
economic	O
climate	O
makes	O
this	O
especially	O
challenging	O
.	O
Considerable	O
progress	O
has	O
been	O
made	O
over	O
the	O
last	O
few	O
years	O
,	O
with	O
new	O
learning	O
from	O
demonstration	O
sites	O
,	O
various	O
initiatives	O
in	O
capacity	B-T058
building	I-T058
and	O
training	O
,	O
wider	O
availability	O
of	O
patient	O
decision	O
aids	O
,	O
and	O
important	O
leadership	O
initiatives	O
.	O
Enthusiasm	O
for	O
this	O
way	O
of	O
working	O
is	O
growing	O
among	O
clinicians	O
,	O
patients	O
and	O
managers	O
,	O
but	O
it	O
could	O
be	O
undermined	O
if	O
SDM	O
comes	O
to	O
be	O
seen	O
primarily	O
as	O
a	O
means	O
of	O
cost	O
control	O
.	O
      
The	O
Silorane	O
-	O
based	O
Resin	O
Composites	O
:	O
A	O
Review	O
This	O
article	O
aims	O
to	O
review	O
the	O
research	O
done	O
on	O
the	O
silorane	O
-	O
based	O
resin	O
composites	O
(	O
SBRC	O
)	O
regarding	O
polymerization	O
shrinkage	O
and	O
contraction	O
stresses	O
and	O
their	O
ability	O
to	O
improve	O
the	O
shortcomings	O
of	O
the	O
methacrylate	O
-	O
based	O
resin	O
composites	O
(	O
MRBC	O
)	O
.	O
Special	O
attention	O
is	O
given	O
to	O
their	O
physical	O
and	O
mechanical	O
properties	O
,	O
bond	O
strength	O
,	O
marginal	B-T061
adaptation	I-T061
,	O
and	O
cusp	O
deflection	O
.	O
The	O
clinical	B-T033
significance	I-T033
of	O
this	O
material	O
is	O
critically	O
appraised	O
with	O
a	O
focus	O
on	O
the	O
ability	O
of	O
SBRC	O
to	O
strengthen	O
the	O
tooth	B-T023
structure	I-T023
as	O
a	O
direct	O
restorative	O
material	O
.	O
A	O
search	O
of	O
English	O
peer	O
-	O
reviewed	O
dental	O
literature	O
(	O
2003	O
-	O
2015	O
)	O
from	O
PubMed	O
and	O
MEDLINE	O
databases	O
was	O
conducted	O
with	O
the	O
terms	O
"	O
low	O
shrinkage	O
"	O
and	O
"	O
silorane	O
composites	O
.	O
"	O
The	O
list	O
was	O
screened	O
,	O
and	O
70	O
articles	O
that	O
were	O
relevant	O
to	O
the	O
objectives	O
of	O
this	O
work	O
were	O
included	O
.	O
      
Modulation	O
of	O
Interleukins	O
in	O
Sepsis	B-T047
-	O
Associated	O
Clotting	B-T047
Disorders	I-T047
:	O
Interplay	O
With	O
Hemostatic	B-T047
Derangement	I-T047
Interleukins	O
play	O
a	O
central	O
role	O
in	O
the	O
immune	O
system	O
and	O
are	O
involved	O
in	O
a	O
variety	O
of	O
immunological	B-T047
,	O
inflammatory	B-T047
,	O
and	O
infectious	B-T047
disease	I-T047
states	O
including	O
sepsis	B-T047
syndrome	I-T047
.	O
Levels	O
of	O
interleukins	O
may	O
correlate	O
with	O
overall	O
survival	O
and	O
may	O
directly	O
or	O
indirectly	O
affect	O
some	O
of	O
the	O
regulators	B-T121
of	O
coagulation	O
and	O
fibrinolysis	O
,	O
thereby	O
disrupting	O
hemostasis	O
and	O
thrombosis	O
.	O
Our	O
hypothesis	O
is	O
that	O
in	O
sepsis	B-T047
-	I-T047
associated	I-T047
coagulopathies	I-T047
(	O
SACs	B-T047
)	O
,	O
interleukins	O
may	O
be	O
upregulated	O
,	O
leading	O
to	O
hemostatic	B-T047
imbalance	I-T047
by	O
generating	O
thrombogenic	O
mediators	O
.	O
We	O
profiled	O
the	O
levels	O
of	O
interleukins	O
IL-1α	O
,	O
IL-1β	O
,	O
IL-2	O
,	O
IL-4	O
,	O
IL-6	O
,	O
IL-8	O
,	O
and	O
IL-10	O
in	O
addition	O
to	O
d	O
-	O
dimer	O
(	O
DD	O
)	O
in	O
patients	O
with	O
SAC	B-T047
and	O
in	O
normal	O
donors	O
.	O
We	O
observed	O
the	O
highest	O
increase	O
in	O
interleukins	O
IL-6	O
(	O
322	O
-	O
fold	O
)	O
,	O
IL-8	O
(	O
48	O
-	O
fold	O
)	O
,	O
IL-10	O
(	O
72	O
-	O
fold	O
)	O
,	O
and	O
DD	O
(	O
18	O
-	O
fold	O
)	O
.	O
This	O
suggests	O
that	O
interleukins	O
such	O
as	O
IL-6	O
and	O
IL-10	O
have	O
a	O
close	O
association	O
with	O
coagulopathy	B-T047
and	O
fibrinolytic	O
dysregulation	O
in	O
sepsis	B-T047
and	O
can	O
be	O
considered	O
as	O
candidates	O
for	O
potential	O
therapeutic	O
targets	O
in	O
SAC	B-T047
.	O
      
Transcriptome	O
and	O
Metabolome	O
Analyses	O
of	O
Glucosinolates	O
in	O
Two	O
Broccoli	O
Cultivars	O
Following	O
Jasmonate	O
Treatment	O
for	O
the	O
Induction	O
of	O
Glucosinolate	O
Defense	O
to	O
Trichoplusia	O
ni	O
(	O
Hübner	O
)	O
Lepidopteran	O
larvae	O
growth	O
is	O
influenced	O
by	O
host	B-T001
plant	O
glucosinolate	O
(	O
GS	O
)	O
concentrations	O
,	O
which	O
are	O
,	O
in	O
turn	O
,	O
influenced	O
by	O
the	O
phytohormone	O
jasmonate	O
(	O
JA	O
)	O
.	O
In	O
order	O
to	O
elucidate	O
insect	O
resistance	O
biomarkers	O
to	O
lepidopteran	O
pests	O
,	O
transcriptome	O
and	O
metabolome	O
analyses	O
following	O
JA	O
treatments	O
were	O
conducted	O
with	O
two	O
broccoli	O
cultivars	O
,	O
Green	O
Magic	O
and	O
VI-158	O
,	O
which	O
have	O
differentially	O
induced	O
indole	O
GSs	O
,	O
neoglucobrassicin	O
and	O
glucobrassicin	O
,	O
respectively	O
.	O
To	O
test	O
these	O
two	O
inducible	O
GSs	O
on	O
growth	O
of	O
cabbage	O
looper	O
(	O
Trichoplusia	O
ni	O
)	O
,	O
eight	O
neonate	O
cabbage	O
looper	O
larvae	O
were	O
placed	O
onto	O
each	O
of	O
three	O
plants	O
per	O
JA	O
treatments	O
(	O
0	O
,	O
100	O
,	O
200	O
,	O
400	O
µM	O
)	O
three	O
days	O
after	O
treatment	O
.	O
After	O
five	O
days	O
of	O
feeding	O
,	O
weight	O
of	O
larvae	O
and	O
their	O
survival	O
rate	O
was	O
found	O
to	O
decrease	O
with	O
increasing	O
JA	O
concentrations	O
in	O
both	O
broccoli	O
cultivars	O
.	O
JA	O
-	O
inducible	O
GSs	O
were	O
measured	O
by	O
high	B-T059
performance	I-T059
liquid	I-T059
chromatography	I-T059
.	O
Neoglucobrassicin	O
in	O
Green	O
Magic	O
and	O
glucobrassicin	O
in	O
VI-158	O
leaves	O
were	O
increased	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
One	O
or	O
both	O
of	O
these	O
glucosinolates	O
and/or	O
their	O
hydrolysis	O
products	O
showed	O
significant	O
inverse	O
correlations	O
with	O
larval	O
weight	O
and	O
survival	O
(	O
five	O
days	O
after	O
treatment	O
)	O
while	O
being	O
positively	B-T033
correlated	O
with	O
the	O
number	O
of	O
days	O
to	O
pupation	O
.	O
This	O
implies	O
that	O
these	O
two	O
JA	O
-	O
inducible	O
glucosinolates	O
can	O
influence	O
the	O
growth	O
and	O
survival	O
of	O
cabbage	O
looper	O
larvae	O
.	O
Transcriptome	B-T059
profiling	I-T059
supported	O
the	O
observed	O
changes	O
in	O
glucosinolate	O
and	O
their	O
hydrolysis	O
product	O
concentrations	O
following	O
JA	O
treatments	O
.	O
Several	O
genes	O
related	O
to	O
GS	O
metabolism	O
differentiate	O
the	O
two	O
broccoli	O
cultivars	O
in	O
their	O
pattern	O
of	O
transcriptional	O
response	O
to	O
JA	O
treatments	O
.	O
Indicative	O
of	O
the	O
corresponding	O
change	O
in	O
indole	O
GS	O
concentrations	O
,	O
transcripts	O
of	O
the	O
transcription	O
factor	O
MYB122	O
,	O
core	O
structure	O
biosynthesis	O
genes	O
(	O
CYP79B2	O
,	O
UGT74B1	O
,	O
SUR1	O
,	O
SOT16	O
,	O
SOT17	O
,	O
and	O
SOT18	O
)	O
,	O
an	O
indole	O
glucosinolate	O
side	O
chain	O
modification	B-T033
gene	O
(	O
IGMT1	O
)	O
,	O
and	O
several	O
glucosinolate	O
hydrolysis	O
genes	O
(	O
TGG1	O
,	O
TGG2	O
,	O
and	O
ESM1	O
)	O
were	O
significantly	O
increased	O
in	O
Green	O
Magic	O
(	O
statistically	O
significant	O
in	O
most	O
cases	O
at	O
400	O
µM	O
)	O
while	O
UGT74B1	O
and	O
MYB122	O
were	O
significantly	O
increased	O
in	O
VI-158	O
.	O
Therefore	O
,	O
these	O
metabolite	O
and	O
transcript	O
biomarker	O
results	O
indicate	O
that	O
transcriptome	B-T059
profiling	I-T059
can	O
identify	O
genes	O
associated	O
with	O
the	O
formation	O
of	O
two	O
different	O
indole	O
GS	O
and	O
their	O
hydrolysis	O
products	O
.	O
Therefore	O
,	O
these	O
metabolite	O
and	O
transcript	O
biomarkers	O
could	O
be	O
useful	O
in	O
an	O
effective	O
marker	O
-	O
assisted	O
breeding	O
strategy	O
for	O
resistance	O
to	O
generalist	O
lepidopteran	O
pests	O
in	O
broccoli	O
and	O
potentially	O
other	O
Brassica	O
vegetables	O
.	O
      
Association	O
of	O
prenatal	O
and	O
early	O
life	O
exposure	O
to	O
tetrachloroethylene	O
(	O
PCE	O
)	O
with	O
polycystic	B-T047
ovary	I-T047
syndrome	I-T047
and	O
other	O
reproductive	B-T047
disorders	I-T047
in	O
the	O
cape	O
cod	O
health	O
study	O
:	O
A	O
retrospective	O
cohort	O
study	O
Tetrachloroethylene	O
(	O
PCE	O
)	O
is	O
an	O
organic	O
lipophilic	O
solvent	O
with	O
possible	O
neuroendocrine	O
toxicity	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
association	O
of	O
prenatal	O
and	O
early	O
childhood	O
exposure	O
to	O
PCE	O
-	O
contaminated	O
drinking	O
water	O
and	O
development	O
of	O
adult	B-T033
-	I-T033
onset	I-T033
Polycystic	B-T047
Ovary	I-T047
Syndrome	I-T047
(	O
PCOS	B-T047
)	O
,	O
endometriosis	B-T047
,	O
difficulty	B-T033
conceiving	I-T033
and	O
miscarriage	O
.	O
Five	O
-	O
hundred	O
exposed	O
and	O
331	O
unexposed	O
female	O
participants	O
born	O
between	O
1969	O
and	O
1983	O
completed	O
questionnaires	O
on	O
demographic	O
and	O
lifestyle	O
characteristics	O
,	O
and	O
reproductive	B-T047
disorders	I-T047
.	O
Residential	O
locations	O
from	O
the	O
prenatal	O
period	O
through	O
five	O
years	O
of	O
age	O
were	O
used	O
to	O
estimate	O
early	O
life	O
PCE	O
exposure	O
with	O
water	O
modeling	O
software	O
.	O
For	O
any	O
early	O
life	O
exposure	O
to	O
PCE	O
,	O
the	O
adjusted	O
risk	O
ratio	O
for	O
PCOS	B-T047
was	O
0.9	O
(	O
95	O
%	O
CI	O
:	O
0.5	O
-	O
1.6	O
)	O
.	O
No	O
statistically	O
significan	O
t	O
associations	O
were	O
observed	O
for	O
increasing	O
levels	O
of	O
exposure	O
with	O
PCOS	B-T047
or	O
the	O
other	O
reproductive	B-T047
disorders	I-T047
.	O
No	O
meaningful	O
associations	O
were	O
found	B-T033
among	O
adult	O
women	O
with	O
early	O
life	O
exposure	O
to	O
PCE	O
-	O
contaminated	O
drinking	O
water	O
and	O
adult	B-T033
-	I-T033
onset	I-T033
reproductive	B-T047
disorders	I-T047
.	O
      
Association	O
of	O
abdominal	O
fat	O
with	O
serum	O
amylase	B-T121
in	O
an	O
older	O
cohort	O
:	O
The	O
Baltimore	O
Longitudinal	O
Study	O
of	O
Aging	O
Abdominal	O
fat	O
is	O
a	O
major	O
determinant	O
of	O
metabolic	B-T047
diseases	I-T047
in	O
older	O
individuals	O
.	O
Obesity	B-T047
and	O
diabetes	B-T047
are	O
associated	O
with	O
low	O
serum	B-T033
amylase	I-T033
(	I-T033
SA	I-T033
)	I-T033
levels	I-T033
,	O
but	O
the	O
association	O
between	O
SA	B-T033
and	O
metabolic	B-T047
disease	I-T047
is	O
poorly	O
understood	O
.	O
We	O
investigated	O
the	O
association	O
of	O
low	O
SA	B-T033
with	O
diabetes	B-T047
and	O
sex	O
-	O
specific	O
associations	O
of	O
serum	O
amylase	B-T121
with	O
abdominal	O
fat	O
in	O
older	O
adults	O
.	O
In	O
community	O
-	O
dwelling	O
volunteers	O
from	O
the	O
Baltimore	O
Longitudinal	O
Study	O
of	O
Aging	O
(	O
778	O
participants	O
,	O
age	O
66.8±13.6	O
years	O
)	O
,	O
we	O
assessed	O
abdominal	O
fat	O
by	O
computed	B-T060
tomography	I-T060
and	O
diabetes	B-T033
status	I-T033
using	O
the	O
American	O
Diabetes	O
Association	O
criteria	O
.	O
Linear	O
regression	O
analyses	O
assessed	O
the	O
cross	O
-	O
sectional	O
associations	O
between	O
abdominal	O
fat	O
and	O
SA	B-T033
,	O
and	O
logistic	O
regression	O
assessed	O
the	O
odds	O
of	O
diabetes	B-T047
,	O
given	O
low	O
SA	B-T033
.	O
In	O
unadjusted	O
analyses	O
,	O
individuals	O
in	O
the	O
lowest	O
SA	B-T033
quartile	O
(	O
<	O
48μ	O
/	O
L	O
)	O
had	O
1.97	O
greater	O
odds	O
of	O
diabetes	B-T047
,	O
(	O
95	O
%	O
CI	O
,	O
1.01	O
-	O
3.83	O
)	O
than	O
those	O
in	O
the	O
highest	O
quartile	O
(	O
⩾80μ	O
/	O
L	O
)	O
.	O
This	O
association	O
was	O
no	O
longer	O
significant	O
after	O
adjusting	O
for	O
visceral	O
adipose	O
tissue	O
area	O
(	O
VAT	O
,	O
dm(2	O
)	O
)	O
,	O
abdominal	O
subcutaneous	O
adipose	O
tissue	O
(	O
SAT	O
,	O
dm(2	O
)	O
)	O
or	O
BMI	O
.	O
In	O
adjusted	O
analyses	O
,	O
VAT	O
and	O
SAT	O
were	O
significantly	O
associated	O
with	O
SA	B-T033
in	O
both	O
sexes	O
.	O
Among	O
women	O
,	O
SA	B-T033
was	O
more	O
strongly	O
associated	O
with	O
VAT	O
than	O
with	O
SAT	O
or	O
BMI	O
;	O
VAT	O
(	O
β=-0.117±0.048	O
,	O
P<0.001	O
)	O
,	O
SAT	O
(	O
β=-0.023±0.025	O
,	O
P=0.346	O
)	O
and	O
BMI	O
(	O
β=-0.0052±0.075	O
,	O
P=0.49	O
)	O
.	O
The	O
association	O
between	O
SA	B-T121
and	O
diabetes	B-T047
was	O
explained	O
mainly	O
by	O
abdominal	O
visceral	O
fat	O
.	O
In	O
women	O
,	O
SA	B-T121
was	O
more	O
strongly	O
associated	O
with	O
VAT	O
than	O
with	O
BMI	O
or	O
SAT	O
.	O
These	O
findings	O
provide	O
motivation	O
for	O
future	O
mechanistic	O
studies	O
on	O
SA	B-T121
's	I-T121
role	O
in	O
metabolic	B-T047
diseases	I-T047
.	O
      
Modified	O
frailty	O
index	O
predicts	O
postoperative	B-T033
outcomes	O
in	O
older	O
gastrointestinal	B-T191
cancer	I-T191
patients	O
Frailty	B-T033
disproportionately	O
impacts	O
older	O
patients	O
with	O
gastrointestinal	B-T191
cancer	I-T191
,	O
rendering	O
them	O
at	O
increased	B-T033
risk	I-T033
for	I-T033
poor	I-T033
outcomes	I-T033
.	O
A	O
frailty	O
index	O
may	O
aid	O
in	O
preoperative	O
risk	O
stratification	O
.	O
We	O
hypothesized	O
that	O
high	O
modified	B-T033
frailty	I-T033
index	I-T033
(	I-T033
mFI	I-T033
)	I-T033
scores	I-T033
are	O
associated	O
with	O
adverse	B-T033
outcomes	I-T033
after	O
tumor	B-T191
resection	B-T061
in	O
older	O
,	O
gastrointestinal	B-T191
cancer	I-T191
patients	O
.	O
Patients	O
(	O
60	O
-	O
90	O
years	O
old	O
)	O
who	O
underwent	O
gastrointestinal	O
tumor	O
resection	O
were	O
identified	O
in	O
the	O
2005	O
-	O
2012	O
NSQIP	B-T033
Participant	O
Use	O
File	O
.	O
mFI	B-T033
was	O
defined	O
by	O
11	O
previously	O
described	O
,	O
preoperative	O
variables	O
.	O
Frailty	B-T033
was	O
defined	O
by	O
an	O
mFI	B-T033
score	I-T033
>	O
0.27	O
.	O
The	O
postoperative	B-T058
course	I-T058
was	O
evaluated	B-T058
using	O
univariate	O
and	O
multivariate	O
analysis	O
.	O
41	O
455	O
patients	O
(	O
mean	O
age	O
72.4	O
years	O
,	O
47.4	O
%	O
female	O
)	O
were	O
identified	O
.	O
The	O
most	O
prevalent	O
form	O
of	O
cancer	B-T191
was	O
colorectal	B-T191
(	O
69.3	O
%	O
,	O
n	O
=	O
28	O
708	O
)	O
and	O
2.8	O
%	O
of	O
patients	O
were	O
frail	B-T033
(	O
n	O
=	O
1,164	O
)	O
.	O
Frail	B-T033
patients	O
were	O
significantly	O
more	O
likely	O
to	O
have	O
increased	O
length	O
of	O
stay	O
(	O
11.7	O
vs	O
9.0	O
days	O
)	O
,	O
major	O
complications	O
(	O
29.1	O
%	O
vs	O
17.9	O
%	O
)	O
,	O
and	O
30	O
-	O
day	O
mortality	O
(	O
5.6	O
%	O
vs	O
2.5	O
%	O
)	O
,	O
(	O
all	O
P	O
<	O
0.001	O
)	O
.	O
Multivariate	O
analysis	O
identified	O
mFI	B-T033
as	O
an	O
independent	O
predictor	O
of	O
major	O
complications	O
(	O
OR	O
1.52	O
,	O
95%CI	O
1.39	O
-	O
1.65	O
,	O
P	O
<	O
0.001	O
)	O
and	O
30	O
-	O
day	O
mortality	O
(	O
OR	O
1.48	O
,	O
95%CI	O
1.24	O
-	O
1.75	O
,	O
P	O
<	O
0.001	O
)	O
.	O
mFI	B-T033
was	O
associated	O
with	O
the	O
incidence	O
of	O
postoperative	B-T033
complications	O
and	O
mortality	O
in	O
older	O
surgical	O
patients	O
with	O
gastrointestinal	B-T191
cancer	I-T191
.	O
      
A	O
Novel	O
Insulin	O
/	O
Glucose	O
Model	O
after	O
a	O
Mixed	B-T059
-	I-T059
Meal	I-T059
Test	I-T059
in	O
Patients	O
with	O
Type	B-T047
1	I-T047
Diabetes	I-T047
on	O
Insulin	O
Pump	O
Therapy	B-T061
Current	O
closed	O
-	O
loop	O
insulin	O
delivery	O
methods	O
stem	O
from	O
sophisticated	O
models	O
of	O
the	O
glucose	O
-	O
insulin	O
(	O
G	O
/	O
I	O
)	O
system	O
,	O
mostly	O
based	O
on	O
complex	O
studies	O
employing	B-T033
glucose	O
tracer	O
technology	O
.	O
We	O
tested	O
the	O
performance	O
of	O
a	O
new	O
minimal	O
model	O
(	O
GLUKINSLOOP	O
2.0	O
)	O
of	O
the	O
G	O
/	O
I	O
system	O
to	O
characterize	O
the	O
glucose	O
and	O
insulin	O
dynamics	O
during	O
multiple	O
mixed	B-T059
meal	I-T059
tests	I-T059
(	O
MMT	B-T059
)	O
of	O
different	O
sizes	O
in	O
patients	O
with	O
type	B-T047
1	I-T047
diabetes	I-T047
(	O
T1D	B-T047
)	O
on	O
insulin	O
pump	O
therapy	B-T061
(	O
continuous	B-T061
subcutaneous	I-T061
insulin	I-T061
infusion	I-T061
,	O
CSII	B-T061
)	O
.	O
The	O
GLUKINSLOOP	O
2.0	O
identified	O
the	O
G	O
/	O
I	O
system	O
,	O
provided	O
a	O
close	O
fit	O
of	O
the	O
G	O
/	O
I	O
time	O
-	O
courses	O
and	O
showed	O
acceptable	O
reproducibility	O
of	O
the	O
G	O
/	O
I	O
system	O
parameters	B-T033
in	O
repeated	O
studies	O
of	O
identical	O
and	O
double	O
-	O
sized	O
MMTs	B-T059
.	O
This	O
model	O
can	O
provide	O
a	O
fairly	O
good	O
and	O
reproducible	O
description	O
of	O
the	O
G	O
/	O
I	O
system	O
in	O
T1D	B-T047
patients	O
on	O
CSII	B-T061
,	O
and	O
it	O
may	O
be	O
applied	O
to	O
create	O
a	O
bank	O
of	O
"	B-T058
virtual	I-T058
"	I-T058
patients	I-T058
.	O
Our	O
results	O
might	O
be	O
relevant	O
at	O
improving	O
the	O
architecture	O
of	O
upcoming	O
closed	O
-	O
loop	O
CSII	B-T061
systems	O
.	O
      
A	O
Tractable	O
Method	O
for	O
Measuring	O
Nanomaterial	O
Risk	O
Using	O
Bayesian	O
Networks	O
While	O
control	O
banding	B-T061
has	O
been	O
identified	O
as	O
a	O
suitable	O
framework	O
for	O
the	O
evaluation	O
and	O
the	O
determination	O
of	O
potential	O
human	O
health	B-T061
risks	I-T061
associated	O
with	O
exposure	O
to	O
nanomaterials	O
(	O
NMs	O
)	O
,	O
the	O
approach	O
currently	O
lacks	O
any	O
implementation	O
that	O
enjoys	O
widespread	O
support	O
.	O
Large	O
inconsistencies	O
in	O
characterisation	O
data	O
,	O
toxicological	O
measurements	O
and	O
exposure	O
scenarios	O
make	O
it	O
difficult	O
to	O
map	O
and	O
compare	O
the	O
risk	O
associated	O
with	O
NMs	O
based	O
on	O
physicochemical	O
data	O
,	O
concentration	O
and	O
exposure	O
route	O
.	O
Here	O
we	O
demonstrate	O
the	O
use	O
of	O
Bayesian	O
networks	O
as	O
a	O
reliable	O
tool	O
for	O
NM	O
risk	O
estimation	O
.	O
This	O
tool	O
is	O
tractable	O
,	O
accessible	O
and	O
scalable	O
.	O
Most	O
importantly	O
,	O
it	O
captures	O
a	O
broad	O
span	O
of	O
data	O
types	O
,	O
from	O
complete	O
,	O
high	O
quality	O
data	O
sets	O
through	O
to	O
data	O
sets	O
with	O
missing	O
data	O
and/or	O
values	O
with	O
a	O
relatively	O
high	O
spread	O
of	O
probability	O
distribution	O
.	O
The	O
tool	O
is	O
able	O
to	O
learn	O
iteratively	O
in	O
order	O
to	O
further	O
refine	O
forecasts	O
as	O
the	O
quality	O
of	O
data	O
available	O
improves	O
.	O
We	O
demonstrate	O
how	O
this	O
risk	O
measurement	O
approach	O
works	O
on	O
NMs	O
with	O
varying	O
degrees	O
of	O
risk	O
potential	O
,	O
namely	O
,	O
carbon	O
nanotubes	O
,	O
silver	O
and	O
titanium	B-T121
dioxide	I-T121
.	O
The	O
results	O
afford	O
even	O
non	O
-	O
experts	O
an	O
accurate	O
picture	O
of	O
the	O
occupational	O
risk	O
probabilities	O
associated	O
with	O
these	O
NMs	O
and	O
,	O
in	O
doing	O
so	O
,	O
demonstrated	O
how	O
NM	O
risk	O
can	O
be	O
evaluated	O
into	O
a	O
tractable	O
,	O
quantitative	O
risk	O
comparator	O
.	O
      
Synchronisms	O
between	O
bud	O
and	O
cambium	B-T023
phenology	O
in	O
black	O
spruce	O
:	O
early	O
-	O
flushing	O
provenances	O
exhibit	O
early	O
xylem	O
formation	O
Bud	O
and	O
cambial	B-T023
phenology	O
represent	O
the	O
adaptation	O
of	O
species	O
to	O
the	O
local	O
environment	O
that	O
allows	O
the	O
growing	O
season	O
to	O
be	O
maximized	O
while	O
minimizing	O
the	O
risk	O
of	O
frost	O
for	O
the	O
developing	O
tissues	O
.	O
The	O
temporal	O
relationship	O
between	O
the	O
apical	O
and	O
radial	O
meristems	O
can	O
help	O
in	O
the	O
understanding	O
of	O
tree	O
growth	O
as	O
a	O
whole	O
process	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
cambial	B-T023
phenology	O
in	O
black	O
spruce	O
(	O
Picea	O
mariana	O
(	O
Mill	O
.	O
)	O
B.S.P.	O
)	O
provenances	O
classified	O
as	O
early	O
and	O
late	O
bud	O
flushing	O
.	O
The	O
different	O
phases	O
of	O
cambial	B-T023
phenology	O
were	O
assessed	O
on	O
wood	O
microcores	O
sampled	O
weekly	O
from	O
April	O
to	O
October	O
in	O
2014	O
and	O
2015	O
from	O
61	O
trees	O
growing	O
in	O
a	O
provenance	O
trial	O
in	O
Quebec	O
,	O
Canada	O
.	O
Trees	O
showing	O
an	O
early	O
bud	O
flush	O
also	O
exhibited	O
early	O
reactivation	O
of	O
xylem	O
differentiation	O
,	O
although	O
an	O
average	O
difference	O
of	O
12	O
days	O
for	O
buds	O
corresponded	O
to	O
small	O
although	O
significant	O
differences	O
of	O
4	O
days	O
for	O
xylem	O
.	O
Provenances	O
with	O
early	O
bud	O
flush	O
had	O
an	O
early	O
bud	O
set	O
and	O
completed	O
xylem	O
formation	O
earlier	O
than	O
late	O
bud	O
flush	O
provenances	O
.	O
No	B-T033
significant	I-T033
difference	O
in	O
the	O
period	O
of	O
xylem	O
formation	O
and	O
total	O
growth	O
was	O
observed	O
between	O
the	O
flushing	O
classes	O
.	O
Our	O
results	B-T033
demonstrate	O
that	O
the	O
ecotype	O
differentiation	O
of	O
black	O
spruce	O
provenances	O
represented	O
by	O
the	O
phenological	O
adaptation	O
of	O
buds	O
to	O
the	O
local	O
climate	O
corresponds	O
to	O
specific	O
growth	O
dynamics	O
of	O
the	O
xylem	O
.	O
      
Avulsions	O
of	O
Triceps	B-T023
Brachii	I-T023
:	O
associated	O
injuries	O
and	O
surgical	B-T061
treatment	I-T061
;	O
a	O
case	O
series	O
This	O
study	O
reports	O
the	O
clinical	O
presentations	O
,	O
intra	O
-operative	O
findings	B-T033
,	O
type	O
of	O
the	O
treatments	B-T061
,	O
outcome	O
of	O
the	O
treatment	B-T061
and	O
specially	O
associated	O
injuries	O
in	O
patients	O
with	O
the	O
avulsion	O
of	O
the	O
distal	O
end	O
of	O
the	O
triceps	B-T023
brachii	I-T023
(	I-T023
TB	I-T023
)	I-T023
tendon	I-T023
.	O
We	O
studied	O
6	O
patients	O
with	O
rupture	O
or	O
avulsion	O
of	O
the	O
distal	O
end	O
of	O
the	O
TB	B-T023
tendon	I-T023
.	O
The	O
medical	O
records	O
,	O
imaging	O
files	O
,	O
clinical	O
outcomes	O
at	O
the	O
final	O
follow	B-T058
up	I-T058
visit	I-T058
were	O
reviewed	O
.	O
The	O
clinical	O
outcomes	O
were	O
assessed	O
by	O
Mayo	O
Elbow	O
Score	O
at	O
the	O
final	O
follow	B-T058
-	I-T058
up	I-T058
visit	I-T058
.	O
All	O
patients	O
were	O
male	O
,	O
4	O
of	O
them	O
having	O
injury	O
in	O
the	O
left	B-T023
hand	I-T023
as	O
the	O
non	O
-	O
dominant	O
hand	B-T023
.	O
Mean	O
age	O
of	O
them	O
was	O
34.5	O
years	O
.	O
All	O
cases	O
had	O
small	O
bony	O
fleck	O
in	O
the	O
posterior	O
of	O
elbow	O
in	O
lateral	B-T060
radiograph	I-T060
.	O
Three	O
patients	O
had	O
associated	O
injuries	O
-including	O
intra	O
-	O
articular	O
fractures	O
and	O
medial	O
collateral	O
ligament	O
rupture	O
.	O
In	O
one	O
case	O
V	B-T061
-	I-T061
Y	I-T061
plasty	I-T061
of	O
the	O
distal	O
TB	B-T023
was	O
done	O
.	O
In	O
4	O
patients	O
the	O
results	O
of	O
surgery	B-T061
were	O
excellent	O
,	O
one	O
was	O
good	O
and	O
one	O
was	O
fair	O
.	O
Although	O
TB	B-T023
tendon	I-T023
rupture	O
is	O
rare	O
,	O
it	O
should	O
be	O
-considered	O
in	O
differential	O
diagnosis	O
of	O
the	O
upper	O
-extremity	O
trauma	O
and	O
its	O
associated	O
injuries	O
should	O
be	O
addressed	O
properly	O
.	O
      
Serum	O
levels	O
of	O
genomic	O
DNA	O
of	O
α1(I	O
)	O
collagen	O
are	O
elevated	O
in	O
scleroderma	B-T047
patients	O
Recent	O
studies	O
have	O
indicated	O
that	O
various	O
nucleic	O
acids	O
are	O
present	O
in	O
human	O
sera	O
,	O
and	O
attracted	O
attention	O
for	O
their	O
potential	O
as	O
novel	O
disease	O
markers	O
in	O
many	O
human	O
diseases	B-T047
.	O
In	O
this	O
study	O
,	O
we	O
tried	O
to	O
evaluate	O
the	O
possibility	O
that	O
DNA	O
and	O
RNA	O
of	O
collagens	O
exist	O
in	O
human	O
sera	O
,	O
and	O
determined	O
whether	O
their	O
serum	O
levels	O
can	O
be	O
useful	O
biomarkers	O
in	O
scleroderma	B-T047
patients	O
.	O
The	O
RNA	O
or	O
DNA	O
of	O
collagens	O
were	O
purified	O
from	O
sera	O
,	O
and	O
detected	B-T033
by	O
polymerase	O
chain	O
reaction	O
or	O
quantitated	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
.	O
Among	O
approximately	O
18	O
360	O
bases	O
of	O
full	O
-	O
length	O
α1(I	O
)	O
collagen	O
DNA	O
,	O
various	O
regions	O
were	O
detected	B-T033
by	O
polymerase	O
chain	O
reaction	O
in	O
human	O
sera	O
.	O
However	O
,	O
α2(I	O
)	O
collagen	O
DNA	O
,	O
α1(I	O
)	O
collagen	O
RNA	O
or	O
α2(I	O
)	O
collagen	O
RNA	O
were	O
not	B-T033
detectable	I-T033
.	O
α1(I	O
)	O
Collagen	O
DNA	O
in	O
sera	O
was	O
quantitative	O
using	O
our	O
method	O
.	O
The	O
levels	O
of	O
serum	O
α1(I	O
)	O
collagen	O
DNA	O
were	O
significantly	O
increased	O
in	O
scleroderma	B-T047
patients	O
compared	O
with	O
healthy	O
control	O
subjects	O
or	O
systemic	B-T047
lupus	I-T047
erythematosus	I-T047
patients	O
.	O
According	O
to	O
the	O
receiver	O
-	O
operator	O
curve	O
analysis	O
,	O
serum	O
α1(I	O
)	O
collagen	O
DNA	O
levels	O
were	O
shown	O
to	O
be	O
effective	O
as	O
a	O
diagnostic	O
marker	O
of	O
scleroderma	B-T047
.	O
Furthermore	O
,	O
when	O
we	O
determined	O
the	O
association	O
of	O
serum	O
α1(I	O
)	O
collagen	O
DNA	O
levels	O
with	O
clinical	O
/	O
laboratory	O
features	O
in	O
scleroderma	B-T047
patients	O
,	O
those	O
with	O
elevated	O
α1(I	O
)	O
collagen	O
DNA	O
levels	O
showed	O
significantly	O
higher	O
prevalence	O
of	O
pitting	B-T047
scars	I-T047
/	O
ulcers	B-T047
.	O
In	O
summary	O
,	O
elevation	O
of	O
serum	O
α1(I	O
)	O
collagen	O
DNA	O
levels	O
in	O
scleroderma	B-T047
patients	O
may	O
be	O
useful	O
as	O
the	O
diagnostic	O
marker	O
,	O
reflecting	O
the	O
presence	O
of	O
vasculopathy	B-T047
.	O
Jou	O
rna	O
      
Intrinsic	O
rifamycin	B-T195
resistance	O
of	O
Mycobacterium	B-T007
abscessus	I-T007
is	O
mediated	O
by	O
ADP	O
-	O
ribosyltransferase	O
MAB_0591	O
Rifampicin	B-T195
,	O
a	O
potent	O
first	O
-	O
line	O
TB	B-T121
drug	I-T121
of	O
the	O
rifamycin	B-T195
group	I-T195
,	O
shows	O
only	O
little	O
activity	O
against	O
the	O
emerging	O
pathogen	B-T001
Mycobacterium	B-T007
abscessus	I-T007
.	O
Reportedly	O
,	O
bacterial	O
resistance	O
to	O
rifampicin	B-T195
is	O
associated	O
with	O
polymorphisms	O
in	O
the	O
target	O
gene	O
rpoB	O
or	O
the	O
presence	O
of	O
enzymes	O
that	O
modify	O
and	O
thereby	O
inactivate	O
rifampicin	B-T195
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
the	O
MAB_0591	O
(	O
arrMab)-encoded	O
rifampicin	B-T195
ADP	O
-	O
ribosyltransferase	O
(	O
Arr_Mab	O
)	O
in	O
innate	O
high	O
-	O
level	O
rifampicin	B-T195
resistance	O
in	O
M.	B-T007
abscessus	I-T007
.	O
Recombinant	B-T001
Escherichia	B-T007
coli	I-T007
and	O
Mycobacterium	B-T007
tuberculosis	I-T007
strains	B-T001
expressing	O
MAB_0591	O
were	O
generated	O
,	O
as	O
was	O
an	O
M.	B-T007
abscessus	I-T007
deletion	O
mutant	O
deficient	O
for	O
MAB_0591	O
.	O
MIC	B-T059
assays	I-T059
were	O
used	O
to	O
study	O
susceptibility	O
to	O
rifampicin	B-T195
and	O
C25	O
carbamate	O
-modified	O
rifamycin	B-T195
derivatives	I-T195
.	O
Heterologous	O
expression	O
of	O
MAB_0591	O
conferred	O
rifampicin	B-T195
resistance	O
to	O
E.	B-T007
coli	I-T007
and	O
M.	B-T007
tuberculosis	I-T007
Rifamycin	B-T195
MIC	O
values	O
were	O
consistently	O
lower	O
for	O
the	O
M.	B-T007
abscessus	I-T007
ΔarrMab	O
mutant	O
as	O
compared	O
with	O
the	O
M.	B-T007
abscessus	I-T007
ATCC	I-T007
19977	I-T007
parental	B-T001
type	I-T001
strain	I-T001
.	O
The	O
rifamycin	B-T195
WT	O
phenotype	O
was	O
restored	O
after	O
complementation	O
of	O
the	O
M.	B-T007
abscessus	I-T007
ΔarrMab	O
mutant	O
with	O
arrMab	O
Further	O
MIC	O
data	O
demonstrated	O
that	O
a	O
C25	O
modification	B-T033
increases	O
rifamycin	B-T195
activity	O
in	O
WT	O
M.	B-T007
abscessus	I-T007
However	O
,	O
MIC	O
studies	O
in	O
the	O
M.	B-T007
abscessus	I-T007
ΔarrMab	O
mutant	O
suggest	O
that	O
C25	O
modified	O
rifamycins	B-T195
are	O
still	O
subject	O
to	O
modification	B-T033
by	O
Arr_Mab	O
CONCLUSIONS	O
:	O
Our	O
findings	O
identify	O
Arr_Mab	O
as	O
the	O
major	O
innate	O
rifamycin	B-T195
resistance	O
determinant	O
of	O
M.	B-T007
abscessus	I-T007
.	O
Our	O
data	O
also	O
indicate	O
that	O
Arr_Mab	O
-mediated	O
rifamycin	B-T195
resistance	O
in	O
M.	B-T007
abscessus	I-T007
can	O
only	O
in	O
part	O
be	O
overcome	O
by	O
C25	O
carbamate	O
modification	B-T033
.	O
      
Development	O
of	O
a	O
novel	O
near	O
-	O
infrared	O
fluorescent	O
theranostic	O
combretastain	B-T121
A-4	I-T121
analogue	O
,	O
YK-5	B-T121
-	I-T121
252	I-T121
,	O
to	O
target	O
triple	B-T191
negative	I-T191
breast	I-T191
cancer	I-T191
The	O
treatment	B-T061
of	O
triple	B-T191
negative	I-T191
breast	I-T191
cancer	I-T191
(	O
TNBC	B-T191
)	O
is	O
a	O
significant	O
challenge	O
to	O
cancer	O
research	O
.	O
The	O
lack	O
of	O
hormone	O
receptors	O
limits	O
the	O
treatment	B-T061
options	O
available	O
to	O
patients	O
with	O
this	O
diagnosis	B-T033
,	O
forcing	O
them	O
to	O
endure	O
prolonged	O
radiation	B-T061
and	O
chemotherapy	B-T061
.	O
Anti	B-T061
-	I-T061
angiogenesis	I-T061
is	O
a	O
chemotherapeutic	O
strategy	O
that	O
targets	O
the	O
vasculature	B-T017
of	O
tumors	B-T191
.	O
Combretastatin	B-T121
A-4	I-T121
(	O
CA-4	B-T121
)	O
is	O
a	O
well	O
-	O
known	O
vasculature	B-T017
-	O
disrupting	O
agent	O
,	O
which	O
has	O
been	O
shown	O
to	O
effectively	O
kill	O
a	O
variety	O
of	O
cancers	B-T191
through	O
inhibition	O
of	O
tubulin	O
polymerization	O
.	O
Due	O
to	O
its	O
toxicity	O
,	O
small	O
molecule	O
analogues	O
of	O
CA-4	B-T121
have	O
been	O
sought	O
out	O
.	O
We	O
have	O
designed	O
a	O
novel	O
dual	O
action	O
CA-4	B-T121
prodrug	O
,	O
YK-5	B-T121
-	I-T121
252	I-T121
,	O
which	O
releases	O
the	O
drug	B-T121
through	O
a	O
disulfide	O
bond	O
cleavage	O
mechanism	O
and	O
contains	O
a	O
near	O
-	O
infrared	O
(	O
NIR	O
)	O
fluorophore	B-T121
,	O
which	O
allows	O
fluorescence	O
monitoring	O
of	O
cleavage	O
.	O
This	O
disulfide	O
linkage	O
causes	O
CA-4	B-T121
to	O
become	O
effective	O
only	O
when	O
released	O
by	O
glutathione	O
(	O
GSH	O
)	O
reducing	O
the	O
toxicity	O
of	O
the	O
drug	B-T121
while	O
simultaneously	O
releasing	O
the	O
NIR	O
fluorophore	B-T121
.	O
Therefore	O
the	O
prodrug	O
,	O
YK-5	B-T121
-	I-T121
252	I-T121
,	O
represents	O
a	O
novel	O
CA-4	B-T121
analogue	O
which	O
has	O
reduced	O
toxicity	O
and	O
can	O
be	O
used	O
for	O
theranostics	O
imaging	B-T060
.	O
      
MagR	O
Alone	O
Is	O
Insufficient	O
to	O
Confer	O
Cellular	O
Calcium	O
Responses	O
to	O
Magnetic	O
Stimulation	B-T061
Magnetic	O
manipulation	B-T061
of	O
cell	O
activity	O
offers	O
advantages	O
over	O
optical	B-T061
manipulation	I-T061
but	O
an	O
ideal	O
tool	O
remains	O
elusive	O
.	O
The	O
MagR	O
protein	O
was	O
found	O
through	O
its	O
interaction	O
with	O
cryptochrome	O
(	O
Cry	O
)	O
and	O
the	O
protein	O
in	O
solution	O
appeared	O
to	O
respond	O
to	O
magnetic	O
stimulation	B-T061
(	O
MS	B-T061
)	O
.	O
After	O
we	O
initiated	O
an	O
investigation	B-T058
on	O
the	O
specific	O
role	O
of	O
MagR	O
in	O
cellular	O
response	O
to	O
MS	B-T061
,	O
a	O
subsequent	O
study	O
claimed	O
that	O
MagR	O
expression	O
alone	O
could	O
achieve	O
cellular	O
activation	O
by	O
MS	B-T061
.	O
Here	O
we	O
report	O
that	O
despite	O
systematically	O
testing	O
different	O
ways	O
of	O
measuring	O
intracellular	O
calcium	B-T121
and	O
different	O
MS	B-T061
protocols	O
,	O
it	O
was	O
not	O
possible	O
to	O
detect	B-T033
any	O
cellular	O
or	O
neuronal	O
responses	O
to	O
MS	B-T061
in	O
MagR	O
-	O
expressing	O
HEK	O
cells	O
or	O
primary	O
neurons	O
from	O
the	O
dorsal	O
root	B-T023
ganglion	I-T023
and	O
the	O
hippocampus	B-T023
.	O
By	O
contrast	O
,	O
in	O
neurons	O
co	O
-	O
expressing	O
MagR	O
and	O
channelrhodopin	O
,	O
optical	B-T061
but	O
not	O
MS	B-T061
increased	O
calcium	O
influx	O
in	O
hippocampal	B-T023
neurons	O
.	O
Our	O
results	O
indicate	O
that	O
MagR	O
alone	O
is	O
not	O
sufficient	O
to	O
confer	O
cellular	O
magnetic	O
responses	O
.	O
      
Pulmonary	O
function	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
1-	O
year	O
follow	B-T058
up	I-T058
after	O
cardiac	B-T061
surgery	I-T061
Pulmonary	O
function	O
is	O
severely	O
reduced	O
in	O
the	O
early	O
period	O
after	O
cardiac	B-T061
surgery	I-T061
,	O
and	O
impairments	O
have	O
been	O
described	O
up	O
to	O
4	O
-	O
6	O
months	O
after	O
surgery	O
.	O
Evaluation	B-T058
of	O
pulmonary	O
function	O
in	O
a	O
longer	O
perspective	O
is	O
lacking	O
.	O
In	O
this	O
prospective	O
study	O
pulmonary	O
function	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
were	O
investigated	O
1	O
year	O
after	O
cardiac	B-T061
surgery	I-T061
.	O
Pulmonary	O
function	O
measurements	O
,	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
SF-36	O
)	O
,	O
dyspnoea	B-T184
,	O
subjective	O
breathing	O
and	O
coughing	B-T184
ability	O
and	O
pain	B-T184
were	O
evaluated	B-T058
before	O
and	O
1	O
year	O
after	O
surgery	O
in	O
150	O
patients	O
undergoing	O
coronary	B-T061
artery	I-T061
bypass	I-T061
grafting	I-T061
,	O
valve	B-T061
surgery	I-T061
or	O
combined	O
surgery	B-T061
.	O
One	O
year	O
after	O
surgery	O
the	O
forced	O
vital	O
capacity	O
and	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
were	O
significantly	O
decreased	O
(	O
by	O
4	O
-	O
5	O
%	O
)	O
compared	O
to	O
preoperative	O
values	O
(	O
p	O
<	O
0.05	O
)	O
.	O
Saturation	O
of	O
peripheral	O
oxygen	O
was	O
unchanged	B-T033
1	O
year	O
postoperatively	O
compared	O
to	O
baseline	O
.	O
A	O
significantly	O
improved	B-T033
health	O
-	O
related	O
quality	O
of	O
life	O
was	O
found	O
1	O
year	O
after	O
surgery	O
,	O
with	O
improvements	O
in	O
all	O
eight	O
aspects	O
of	O
SF-36	O
(	O
p	O
<	O
0.001	O
)	O
.	O
Sternotomy	B-T061
-related	O
pain	B-T184
was	O
low	O
1	O
year	O
postoperatively	O
at	O
rest	O
(	O
median	O
0	O
[	O
min	O
-	O
max	O
;	O
0	O
-	O
7	O
]	O
)	O
,	O
while	O
taking	O
a	O
deep	B-T184
breath	I-T184
(	O
0	O
[	O
0	O
-	O
4	O
]	O
)	O
and	O
while	O
coughing	B-T184
(	O
0	O
[	O
0	O
-	O
8	O
]	O
)	O
.	O
A	O
more	O
pronounced	O
decrease	O
in	O
pulmonary	O
function	O
was	O
associated	O
with	O
dyspnoea	B-T184
limitations	O
and	O
impaired	O
subjective	O
breathing	O
and	O
coughing	B-T184
ability	O
.	O
One	O
year	O
after	O
cardiac	B-T061
surgery	I-T061
static	O
and	O
dynamic	O
lung	B-T060
function	I-T060
measurements	I-T060
were	O
slightly	O
decreased	O
,	O
while	O
health	O
-	O
related	O
quality	O
of	O
life	O
was	O
improved	B-T033
in	O
comparison	O
to	O
preoperative	O
values	O
.	O
Measured	O
levels	O
of	O
pain	B-T184
were	O
low	O
and	O
saturation	O
of	O
peripheral	O
oxygen	O
was	O
same	O
as	O
preoperatively	O
.	O
      
A	O
systematic	O
review	O
investigating	O
psychosocial	O
aspects	O
of	O
egg	B-T061
sharing	I-T061
in	O
the	O
United	O
Kingdom	O
and	O
their	O
potential	O
effects	O
on	O
egg	B-T061
donation	I-T061
numbers	O
This	O
review	O
aims	O
to	O
provide	O
an	O
up	O
-	O
to	O
-	O
date	O
knowledge	O
of	O
the	O
psychosocial	O
aspects	O
of	O
egg	B-T061
donation	I-T061
from	O
the	O
perspectives	O
of	O
the	O
egg	O
share	O
donor	O
and	O
their	O
recipient	O
.	O
It	O
explores	O
the	O
motives	O
,	O
experiences	O
and	O
attitudes	O
of	O
egg	O
sharers	O
and	O
their	O
views	O
towards	O
donor	O
anonymity	O
and	O
disclosure	O
.	O
Conclusions	O
are	O
made	O
on	O
how	O
these	O
findings	B-T033
can	O
guide	O
clinical	O
practice	O
and	O
improve	O
egg	B-T061
sharing	I-T061
numbers	O
.	O
A	O
systematic	O
search	O
of	O
peer	O
-	O
reviewed	O
journals	O
of	O
four	O
computerized	O
databases	O
was	O
undertaken	O
.	O
Eleven	O
studies	O
were	O
included	O
in	O
the	O
review	O
.	O
Psychosocial	O
aspects	O
towards	O
donation	B-T061
were	O
positive	B-T033
from	O
the	O
egg	O
share	O
donor	O
and	O
recipient	O
.	O
Concerns	O
raised	O
were	O
whether	O
participating	O
in	O
the	O
egg	B-T061
sharing	I-T061
scheme	O
would	O
impact	O
on	O
their	O
success	O
rates	O
,	O
as	O
well	O
as	O
frustration	O
expressed	O
by	O
a	O
minority	O
regarding	O
the	O
lack	B-T033
of	I-T033
knowledge	I-T033
of	O
egg	B-T061
sharing	I-T061
outside	O
of	O
fertility	O
clinics	O
.	O
The	O
2005	O
legislative	O
changes	O
in	O
the	O
UK	O
have	O
not	O
caused	O
the	O
anticipated	O
dramatic	O
decrease	O
in	O
egg	B-T061
donation	I-T061
;	O
however	O
,	O
oocyte	B-T061
donation	I-T061
still	O
falls	O
short	O
of	O
demand	B-T061
.	O
Egg	B-T061
sharing	I-T061
provides	O
a	O
practical	O
option	O
for	O
more	O
patients	O
to	O
access	O
IVF	B-T061
,	O
whilst	O
also	O
providing	O
more	O
donor	O
oocytes	O
.	O
Improved	O
information	O
provision	O
will	O
result	O
in	O
greater	O
awareness	O
of	O
egg	B-T061
sharing	I-T061
,	O
with	O
the	O
potential	O
to	O
recruit	O
more	O
donors	O
and	O
meet	O
the	O
needs	O
of	O
recipients	O
currently	O
on	O
long	O
waiting	O
lists	O
.	O
      
Incontinence	B-T047
-associated	O
dermatitis	B-T047
:	O
reducing	O
adverse	O
events	O
Incontinence	B-T047
-associated	O
dermatitis	B-T047
(	O
IAD	B-T047
)	O
is	O
a	O
common	O
problem	B-T033
in	O
patients	O
with	O
faecal	B-T047
and/or	O
urinary	O
incontinence	O
.	O
Urine	O
alters	O
the	O
normal	O
skin	O
flora	B-T033
and	O
increases	O
permeability	O
of	O
the	O
stratum	O
corneum	O
and	O
faecal	O
enzymes	O
on	O
the	O
skin	O
contribute	O
to	O
skin	B-T184
damage	I-T184
.	O
Faecal	O
bacteria	B-T007
can	O
then	O
penetrate	O
the	O
skin	O
,	O
increasing	O
the	O
risk	O
of	O
secondary	B-T047
infection	I-T047
.	O
However	O
,	O
IAD	B-T047
can	O
be	O
prevented	B-T061
and	O
healed	O
with	O
timely	O
and	O
appropriate	O
skin	B-T061
cleansing	I-T061
and	O
skin	O
protection	O
.	O
This	O
includes	O
appropriate	O
use	O
of	O
containment	O
devices	O
.	O
This	O
article	O
also	O
looks	O
at	O
HARTMANN	O
incontinence	O
pads	O
that	O
have	O
been	O
developed	O
to	O
absorb	O
the	O
fluids	O
that	O
cause	O
IAD	B-T047
and	O
maintain	O
the	O
skin	O
's	O
acidic	O
pH.	O
The	O
acidic	O
pH	O
of	O
the	O
skin	O
contributes	O
to	O
its	O
barrier	O
function	O
and	O
defence	O
against	O
infection	O
.	O
Therefore	O
,	O
maintaining	O
an	O
acidic	O
pH	O
will	O
help	O
protect	O
the	O
skin	O
from	O
damage	O
.	O
      
Physiological	O
Properties	O
and	O
Behavioral	O
Correlates	O
of	O
Hippocampal	B-T023
Granule	O
Cells	O
and	O
Mossy	O
Cells	O
The	O
hippocampal	B-T023
dentate	B-T023
gyrus	I-T023
is	O
often	O
viewed	O
as	O
a	O
segregator	O
of	O
upstream	O
information	O
.	O
Physiological	O
support	O
for	O
such	O
function	O
has	O
been	O
hampered	O
by	O
a	O
lack	O
of	O
well	O
-	O
defined	O
characteristics	O
that	O
can	O
identify	O
granule	O
cells	O
and	O
mossy	O
cells	O
.	O
We	O
developed	O
an	O
electrophysiology	O
-based	O
classification	O
of	O
dentate	B-T023
granule	O
cells	O
and	O
mossy	O
cells	O
in	O
mice	O
that	O
we	O
validated	O
by	O
optogenetic	O
tagging	O
of	O
mossy	O
cells	O
.	O
Granule	O
cells	O
exhibited	O
sparse	O
firing	O
,	O
had	O
a	O
single	O
place	O
field	O
,	O
and	O
showed	O
only	O
modest	O
changes	O
when	O
the	O
mouse	O
was	O
tested	O
in	O
different	O
mazes	O
in	O
the	O
same	O
room	O
.	O
In	O
contrast	O
,	O
mossy	O
cells	O
were	O
more	O
active	O
,	O
had	O
multiple	O
place	O
fields	O
and	O
showed	O
stronger	O
remapping	O
of	O
place	O
fields	O
under	O
the	O
same	O
conditions	O
.	O
Although	O
the	O
granule	O
cell	O
-	O
mossy	O
cell	O
synapse	O
was	O
strong	O
and	O
facilitating	O
,	O
mossy	O
cells	O
rarely	O
"	O
inherited	O
"	O
place	O
fields	O
from	O
single	O
granule	O
cells	O
.	O
Our	O
findings	O
suggest	O
that	O
the	O
granule	O
cells	O
and	O
mossy	O
cells	O
could	O
be	O
modulated	O
separately	O
and	O
their	O
joint	O
action	O
may	O
be	O
critical	O
for	O
pattern	O
separation	O
.	O
      
The	O
2016	O
Infusion	B-T061
Therapy	I-T061
Standards	O
of	O
Practice	O
Approximately	O
every	O
5	O
years	O
,	O
the	O
Infusion	O
Nurses	O
Society	O
publishes	O
evidence	O
-	O
based	O
practice	O
standards	O
.	O
This	O
article	O
provides	O
an	O
overview	O
of	O
the	O
process	O
used	O
in	O
standards	O
development	O
,	O
describes	O
the	O
format	O
of	O
the	O
standards	O
,	O
and	O
provides	O
a	O
short	O
summary	O
of	O
selected	O
standards	O
as	O
applied	O
to	O
home	B-T058
care	I-T058
.	O
The	O
Standards	O
are	O
an	O
important	O
document	O
that	O
should	O
be	O
available	O
to	O
every	O
home	B-T058
care	I-T058
organization	O
that	O
provides	O
home	B-T061
infusion	I-T061
therapy	I-T061
.	O
      
Executive	O
functions	O
deficits	O
impair	O
extinction	O
of	O
generalization	O
of	O
fear	O
of	O
movement	B-T033
-	I-T033
related	I-T033
pain	I-T033
Generalization	O
of	O
fear	O
of	O
movement	B-T033
-	I-T033
related	I-T033
pain	I-T033
across	O
novel	O
but	O
similar	O
movements	O
can	O
lead	O
to	O
fear	O
responses	O
to	O
movements	O
that	O
are	O
actually	O
not	O
associated	O
with	O
pain	B-T184
.	O
The	O
peak	O
-	O
shift	O
effect	O
describes	O
a	O
phenomenon	O
whereby	O
particular	O
novel	O
movements	O
elicit	O
even	O
greater	O
fear	O
responses	O
than	O
the	O
original	O
pain	B-T184
-	I-T184
provoking	I-T184
movement	O
(	O
CS+	O
)	O
,	O
because	O
they	O
represent	O
a	O
more	O
extreme	O
version	O
of	O
the	O
CS+	O
.	O
There	O
is	O
great	O
variance	O
in	O
the	O
propensity	O
to	O
generalize	O
as	O
well	O
as	O
the	O
speed	O
of	O
extinction	O
learning	O
when	O
these	O
novel	O
movements	O
are	O
not	O
followed	O
by	O
pain	B-T184
.	O
It	O
can	O
be	O
argued	O
that	O
this	O
variance	O
may	O
be	O
associated	O
with	O
executive	O
function	O
capacity	O
,	O
as	O
individuals	O
may	O
be	O
unable	O
to	O
intentionally	O
inhibit	O
fear	O
responses	O
.	O
This	O
study	O
examined	B-T033
whether	O
executive	O
function	O
capacity	O
contributes	O
to	O
generalization	O
and	O
extinction	O
of	O
generalization	O
as	O
well	O
as	O
peak	O
-	O
shift	O
of	O
conditioned	O
fear	O
of	O
movement	B-T033
-	I-T033
related	I-T033
pain	I-T033
and	O
expectancy	O
.	O
Healthy	O
participants	O
performed	O
a	O
proprioceptive	O
fear	O
conditioning	O
task	O
.	O
Executive	O
function	O
tests	O
assessing	O
updating	O
,	O
switching	O
,	O
and	O
inhibition	O
were	O
used	O
to	O
predict	O
changes	O
in	O
(	O
extinction	O
of	O
)	O
fear	O
of	O
movement	B-T033
-	I-T033
related	I-T033
pain	I-T033
and	O
pain	B-T184
expectancy	O
generalization	O
.	O
Low	O
inhibitory	O
capacity	O
was	O
associated	O
with	O
slower	O
extinction	O
of	O
generalized	O
fear	O
of	O
movement	B-T033
-	I-T033
related	I-T033
pain	I-T033
and	O
pain	B-T184
expectancy	O
.	O
Evidence	O
was	O
found	O
in	O
favor	O
of	O
an	O
area	O
-	O
shift	O
,	O
rather	O
than	O
a	O
peak	O
-	O
shift	O
effect	O
,	O
which	O
implies	O
that	O
the	O
peak	O
conditioned	O
fear	O
response	O
extended	O
to	O
,	O
but	O
did	O
not	O
shift	O
to	O
a	O
novel	O
stimulus	O
.	O
Participants	O
with	O
low	O
inhibitory	O
capacity	O
may	O
have	O
difficulties	O
withholding	O
fear	O
responses	O
,	O
leading	O
to	O
a	O
slower	O
decrease	O
of	O
generalized	O
fear	O
over	O
time	O
.	O
The	O
findings	B-T033
may	O
be	O
relevant	O
to	O
inform	O
treatments	O
.	O
Low	O
inhibitory	O
capacity	O
is	O
not	O
associated	O
with	O
slower	O
generalization	O
,	O
but	O
extinction	O
of	O
fear	O
generalization	O
.	O
Fear	O
elicited	O
by	O
a	O
novel	O
safe	O
movement	O
,	O
situated	O
outside	O
the	O
CS+/-	O
continuum	O
on	O
the	O
CS+	O
side	O
,	O
can	O
be	O
as	O
strong	O
as	O
to	O
the	O
original	O
stimulus	O
predicting	O
the	O
pain	B-T033
-	I-T033
onset	I-T033
.	O
      
Chronic	B-T033
exposure	I-T033
to	I-T033
haloperidol	B-T121
and	O
olanzapine	B-T121
leads	O
to	O
common	O
and	O
divergent	O
shape	B-T033
changes	I-T033
in	O
the	O
rat	O
hippocampus	B-T023
in	O
the	O
absence	O
of	O
grey	O
-	O
matter	O
volume	O
loss	O
One	O
of	O
the	O
most	O
consistently	O
reported	O
brain	B-T190
abnormalities	I-T190
in	O
schizophrenia	B-T048
(	O
SCZ	B-T048
)	O
is	O
decreased	O
volume	B-T033
and	I-T033
shape	I-T033
deformation	I-T033
of	O
the	O
hippocampus	B-T023
.	O
However	O
,	O
the	O
potential	O
contribution	O
of	O
chronic	B-T121
antipsychotic	I-T121
medication	I-T121
exposure	B-T033
to	O
these	O
phenomena	O
remains	O
unclear	O
.	O
We	O
examined	O
the	O
effect	O
of	O
chronic	B-T033
exposure	I-T033
(	O
8	O
weeks	O
)	O
to	O
clinically	O
relevant	O
doses	O
of	O
either	O
haloperidol	B-T121
(	O
HAL	B-T121
)	O
or	O
olanzapine	B-T121
(	O
OLZ	B-T121
)	O
on	O
adult	O
rat	O
hippocampal	O
volume	B-T033
and	I-T033
shape	I-T033
using	O
ex	O
vivo	O
structural	B-T060
MRI	I-T060
with	O
the	O
brain	B-T023
retained	I-T023
inside	I-T023
the	I-T023
cranium	I-T023
to	O
prevent	O
distortions	B-T190
due	O
to	O
dissection	B-T061
,	O
followed	O
by	O
tensor	B-T059
-	I-T059
based	I-T059
morphometry	I-T059
(	O
TBM	B-T059
)	O
and	O
elastic	O
surface	O
-	O
based	O
shape	O
deformation	O
analysis	O
.	O
The	O
volume	O
of	O
the	O
hippocampus	B-T023
was	O
also	O
measured	O
post	B-T060
-	I-T060
mortem	I-T060
from	O
brain	B-T023
tissue	I-T023
sections	O
in	O
each	O
group	O
.	O
Chronic	B-T033
exposure	I-T033
to	O
either	O
HAL	B-T121
or	O
OLZ	B-T121
had	O
no	O
effect	O
on	O
the	O
volume	O
of	O
the	O
hippocampus	B-T023
,	O
even	O
at	O
exploratory	B-T060
thresholds	I-T060
,	O
which	O
was	O
confirmed	O
post	B-T060
-	I-T060
mortem	I-T060
.	O
In	O
contrast	O
,	O
shape	O
deformation	O
analysis	O
revealed	O
that	O
chronic	O
HAL	B-T121
and	O
OLZ	B-T121
exposure	B-T033
lead	O
to	O
both	O
common	O
and	O
divergent	B-T033
shape	I-T033
deformations	I-T033
(	O
q	O
=	O
0.05	O
,	O
FDR	O
-	O
corrected	O
)	O
in	O
the	O
rat	O
hippocampus	B-T023
.	O
In	O
particular	O
,	O
in	O
the	O
dorsal	B-T023
hippocampus	I-T023
,	O
HAL	B-T121
exposure	B-T033
led	O
to	O
inward	B-T033
shape	I-T033
deformation	I-T033
,	O
whereas	O
OLZ	B-T121
exposure	B-T033
led	O
to	O
outward	B-T033
shape	I-T033
deformation	I-T033
.	O
Interestingly	O
,	O
outward	B-T033
shape	I-T033
deformations	I-T033
that	O
were	O
common	O
to	O
both	O
drugs	B-T121
occurred	O
in	O
the	O
ventral	B-T023
hippocampus	I-T023
.	O
These	O
effects	O
remained	O
significant	O
after	O
controlling	O
for	O
hippocampal	B-T023
volume	O
suggesting	O
true	O
shape	B-T033
changes	I-T033
.	O
Chronic	B-T033
exposure	I-T033
to	O
either	O
HAL	B-T121
or	O
OLZ	B-T121
leads	O
to	O
both	O
common	O
and	O
divergent	O
effects	O
on	O
rat	O
hippocampal	B-T023
shape	I-T023
in	O
the	O
absence	O
of	O
volume	O
change	O
.	O
The	O
implications	O
of	O
these	O
findings	O
for	O
the	O
clinic	O
are	O
discussed	O
.	O
      
Short	O
-	O
term	O
Variability	O
of	O
Vitamin	B-T121
D	I-T121
-Related	O
Biomarkers	O
Quantifying	O
the	O
variability	O
of	O
biomarkers	O
is	O
important	O
,	O
as	O
high	O
within	O
-	O
person	O
variability	O
can	O
lead	O
to	O
misclassification	O
of	O
individuals	O
.	O
Short	O
-	O
term	O
variability	O
of	O
important	O
markers	O
of	O
vitamin	O
D	O
metabolism	O
is	O
relatively	O
unknown	O
.	O
A	O
repeatability	O
study	O
was	O
conducted	O
in	O
160	O
Atherosclerosis	B-T047
Risk	O
in	O
Communities	O
study	O
participants	O
(	O
60	O
%	O
female	O
,	O
28	O
%	O
black	O
,	O
mean	O
age	O
76	O
years	O
)	O
.	O
Fasting	B-T033
serum	O
was	O
drawn	O
at	O
2	O
time	O
points	O
,	O
a	O
median	O
of	O
6	O
(	O
range	O
3	O
-	O
13	O
)	O
weeks	O
apart	O
.	O
Vitamin	O
D	O
binding	O
protein	O
(	O
VDBP	O
)	O
and	O
25	O
-	O
hydroxyvitamin	O
D	O
[	O
25(OH)D	O
]	O
were	O
measured	O
by	O
LC	B-T059
-	I-T059
MS	I-T059
,	O
fibroblast	O
growth	O
factor	O
(	O
FGF23	O
)	O
and	O
parathyroid	B-T121
hormone	I-T121
(	O
PTH	B-T121
)	O
by	O
enzyme	B-T059
-	I-T059
linked	I-T059
immunoassay	I-T059
,	O
and	O
calcium	B-T121
and	O
phosphorus	O
by	O
Roche	B-T059
Cobas	I-T059
6000	I-T059
.	O
Free	O
and	O
bioavailable	O
25(OH)D	O
were	O
calculated	O
.	O
We	O
calculated	O
the	O
within	O
-	O
person	O
CV	O
(	O
CVW	O
)	O
,	O
intraclass	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
,	O
Spearman	O
rank	O
correlation	O
coefficient	O
(	O
r	O
)	O
,	O
and	O
percent	O
reclassified	O
.	O
The	O
CVW	O
was	O
lowest	O
for	O
calcium	B-T121
(	O
2.0	O
%	O
)	O
,	O
albumin	O
(	O
3.6	O
%	O
)	O
,	O
25(OH)D	O
(	O
6.9	O
%	O
)	O
,	O
VDBP	O
(	O
7.0	O
%	O
)	O
and	O
phosphorus	O
(	O
7.6	O
%	O
)	O
;	O
intermediate	O
for	O
free	O
25(OH)D	O
(	O
9.0	O
%	O
)	O
and	O
bioavailable	O
25(OH)D	O
(	O
9.9	O
%	O
)	O
;	O
and	O
highest	O
for	O
PTH	B-T121
(	O
16.7	O
%	O
)	O
and	O
FGF23	O
(	O
17.8	O
%	O
)	O
.	O
Reclassification	O
was	O
highest	O
for	O
PTH	B-T121
,	O
VDBP	O
,	O
and	O
phosphorus	O
(	O
all	O
7.5	O
%	O
)	O
.	O
The	O
ICC	O
and	O
r	O
were	O
highest	O
(	O
≥0.80	O
)	O
for	O
25(OH)D	O
,	O
free	O
25(OH)D	O
,	O
bioavailable	O
25(OH)D	O
and	O
PTH	B-T121
,	O
but	O
somewhat	O
lower	O
(	O
approximately	O
0.60	O
-	O
0.75	O
)	O
for	O
the	O
other	O
biomarkers	O
.	O
Six-	O
week	O
short	O
-	O
term	O
variability	O
,	O
as	O
assessed	O
by	O
CVW	O
,	O
was	O
quite	O
low	O
for	O
VDBP	O
,	O
calcium	B-T121
and	O
phosphorus	O
,	O
but	O
fairly	O
high	O
for	O
FGF23	O
and	O
PTH	B-T121
.	O
As	O
such	O
,	O
multiple	O
measurements	O
of	O
FGF23	O
and	O
PTH	B-T121
may	O
be	O
needed	O
to	O
minimize	O
misclassification	O
.	O
These	O
results	O
provide	O
insight	O
into	O
the	O
extent	O
of	O
potential	O
misclassification	O
of	O
vitamin	B-T121
D	I-T121
markers	O
in	O
research	O
and	O
clinical	O
settings	O
.	O
      
Sepsis	B-T047
Clinical	O
Criteria	O
in	O
Emergency	O
Department	O
Patients	O
Admitted	B-T058
to	O
an	O
Intensive	O
Care	O
Unit	O
:	O
An	O
External	O
Validation	O
Study	O
of	O
Quick	B-T033
Sequential	I-T033
Organ	I-T033
Failure	I-T033
Assessment	I-T033
Quick	B-T033
Sequential	I-T033
Organ	I-T033
Failure	I-T033
Assessment	I-T033
(	O
qSOFA	B-T033
)	O
is	O
a	O
prognostic	O
score	O
for	O
patients	O
with	O
sepsis	B-T047
.	O
Our	O
aim	O
was	O
to	O
compare	O
the	O
area	O
under	O
the	O
receiver	O
operating	O
curve	O
(	O
AUROC	O
)	O
,	O
sensitivity	O
,	O
specificity	O
,	O
and	O
likelihood	O
ratios	O
of	O
qSOFA	B-T033
vs.	O
systemic	B-T047
inflammation	I-T047
response	I-T047
syndrome	I-T047
(	O
SIRS	B-T047
)	O
in	O
predicting	O
in	O
-	O
hospital	O
mortality	O
among	O
emergency	O
department	O
(	O
ED	O
)	O
patients	O
with	O
suspected	O
infection	O
admitted	B-T058
to	O
intensive	O
care	O
units	O
(	O
ICUs	O
)	O
.	O
We	O
conducted	O
a	O
retrospective	O
cohort	O
chart	O
review	O
study	O
of	O
ED	O
patients	O
admitted	B-T058
to	O
an	O
ICU	O
with	O
suspected	O
infection	O
from	O
August	O
1	O
,	O
2012	O
to	O
February	O
28	O
,	O
2015	O
.	O
We	O
included	O
all	O
patients	O
with	O
body	O
fluid	O
cultures	O
sampled	O
either	O
during	O
their	O
ED	O
stay	O
without	O
antibiotic	B-T061
administration	I-T061
or	O
within	O
24	O
h	O
of	O
antibiotics	B-T061
administered	I-T061
in	O
the	O
ED	O
.	O
Trained	O
chart	O
abstractors	O
blinded	O
to	O
the	O
study	O
hypothesis	O
double	O
-	O
entered	O
data	O
from	O
each	O
patient	O
's	O
electronic	O
medical	O
record	O
including	O
demographic	O
characteristics	O
,	O
vital	O
signs	O
,	O
laboratory	B-T059
study	I-T059
results	I-T059
,	O
physical	B-T058
examination	I-T058
findings	B-T033
,	O
and	O
in	O
-	O
hospital	O
mortality	O
.	O
We	O
then	O
calculated	O
the	O
AUROC	O
,	O
sensitivity	O
,	O
specificity	O
,	O
and	O
likelihood	O
ratios	O
for	O
qSOFA	B-T033
and	O
SIRS	B-T047
for	O
predicting	O
in	O
-	O
hospital	O
mortality	O
.	O
Of	O
214	O
patients	O
admitted	B-T058
to	O
an	O
ICU	O
with	O
presumed	B-T047
sepsis	I-T047
,	O
39	O
(	O
18.2	O
%	O
)	O
died	B-T033
during	I-T033
hospitalization	I-T033
.	O
The	O
AUROC	O
value	O
was	O
0.65	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
0.56	O
-	O
0.74	O
)	O
for	O
SIRS	B-T047
vs.	O
0.66	O
(	O
95	O
%	O
CI	O
0.57	O
-	O
0.76	O
)	O
for	O
qSOFA	B-T033
;	O
2	O
+	O
qSOFA	B-T033
criteria	O
predicted	O
in	O
-	O
hospital	O
mortality	O
with	O
89.7	O
%	O
sensitivity	O
,	O
27.4	O
%	O
specificity	O
,	O
1.2	O
positive	O
likelihood	O
ratio	O
,	O
and	O
0.4	O
negative	O
likelihood	O
ratio	O
.	O
Among	O
ED	O
patients	O
admitted	B-T058
to	O
an	O
ICU	O
,	O
the	O
SIRS	B-T047
and	O
qSOFA	B-T033
criteria	O
had	O
comparable	O
prognostic	O
value	O
for	O
predicting	O
in	O
-	O
hospital	O
mortality	O
.	O
These	O
prognostic	O
values	O
are	O
similar	O
to	O
those	O
reported	O
by	O
the	O
Sepsis-3	O
guidelines	O
for	O
ICU	O
encounters	O
.	O
      
The	O
nanocomposite	O
nature	O
of	O
bone	B-T023
drives	O
its	O
strength	O
and	O
damage	O
resistance	O
In	O
human	B-T023
bone	I-T023
,	O
an	O
amorphous	O
mineral	O
serves	O
as	O
a	O
precursor	O
to	O
the	O
formation	O
of	O
a	O
highly	O
substituted	O
nanocrystalline	O
apatite	O
.	O
However	O
,	O
the	O
precise	O
role	O
of	O
this	O
amorphous	O
mineral	O
remains	O
unknown	O
.	O
Here	O
,	O
we	O
show	O
by	O
using	O
transmission	B-T059
electron	I-T059
microscopy	I-T059
that	O
100	O
-	O
300	O
nm	O
amorphous	O
calcium	B-T121
phosphate	I-T121
regions	O
are	O
present	O
in	O
the	O
disordered	O
phase	O
of	O
trabecular	O
bone	O
.	O
Nanomechanical	O
experiments	O
on	O
cylindrical	O
samples	O
,	O
with	O
diameters	O
between	O
250	O
nm	O
and	O
3,000	O
nm	O
,	O
of	O
the	O
bone	B-T023
's	I-T023
ordered	O
and	O
disordered	O
phases	O
revealed	O
a	O
transition	O
from	O
plastic	O
deformation	B-T033
to	O
brittle	B-T033
failure	O
and	O
at	O
least	O
a	O
factor	O
-	O
of-2	O
higher	O
strength	O
in	O
the	O
smaller	O
samples	O
.	O
We	O
postulate	O
that	O
this	O
transition	O
in	O
failure	O
mechanism	O
is	O
caused	O
by	O
the	O
suppression	O
of	O
extrafibrillar	O
shearing	B-T061
in	O
the	O
smaller	O
samples	O
,	O
and	O
that	O
the	O
emergent	O
smaller	O
-is-	O
stronger	O
size	O
effect	O
is	O
related	O
to	O
the	O
sample	O
-	O
size	O
scaling	O
of	O
the	O
distribution	O
of	O
flaws	O
.	O
Our	O
findings	B-T033
should	O
help	O
in	O
the	O
understanding	O
of	O
the	O
multi	O
-	O
scale	O
nature	O
of	O
bone	B-T023
and	O
provide	O
insights	O
into	O
the	O
biomineralization	O
process	O
.	O
      
Adverse	O
outcomes	O
in	O
older	O
adults	O
attending	O
emergency	O
departments	O
:	O
a	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
of	O
the	O
Identification	O
of	O
Seniors	O
At	O
Risk	O
(	O
ISAR	O
)	O
screening	O
tool	O
older	O
adults	O
are	O
frequent	O
users	O
of	O
emergency	B-T058
services	I-T058
and	O
demonstrate	O
high	O
rates	O
of	O
adverse	O
outcomes	O
following	O
emergency	B-T061
care	I-T061
.	O
to	O
perform	O
a	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
of	O
the	O
Identification	O
of	O
Seniors	O
At	O
Risk	O
(	O
ISAR	O
)	O
screening	O
tool	O
,	O
to	O
determine	O
its	O
predictive	O
value	O
in	O
identifying	O
adults	O
≥65	O
years	O
at	O
risk	O
of	O
functional	B-T033
decline	I-T033
,	O
unplanned	O
emergency	B-T058
department	I-T058
(	I-T058
ED	I-T058
)	I-T058
readmission	I-T058
,	O
emergency	O
hospitalisation	B-T058
or	O
death	B-T033
within	O
180	O
days	O
after	O
index	O
ED	B-T058
visit	I-T058
/	O
hospitalisation	B-T058
.	O
a	O
systematic	O
literature	O
search	O
was	O
conducted	O
in	O
PubMed	O
,	O
EMBASE	O
,	O
CINAHL	O
,	O
EBSCO	O
and	O
the	O
Cochrane	O
Library	O
to	O
identify	O
validation	O
and	O
impact	O
analysis	O
studies	O
of	O
the	O
ISAR	O
tool	O
.	O
A	O
pre	O
-	O
specified	O
ISAR	O
score	O
of	O
≥2	O
(	O
maximum	O
score	O
6	O
points	O
)	O
was	O
used	O
to	O
identify	O
patients	O
at	O
high	B-T033
risk	I-T033
of	I-T033
adverse	O
outcomes	O
.	O
A	O
bivariate	O
random	O
effects	O
model	O
generated	O
pooled	O
estimates	O
of	O
sensitivity	O
and	O
specificity	O
.	O
Statistical	O
heterogeneity	O
was	O
explored	O
and	O
methodological	O
quality	O
was	O
assessed	O
using	O
validated	O
criteria	O
.	O
thirty	O
-	O
two	O
validation	O
studies	O
(	O
n	O
=	O
12,939	O
)	O
are	O
included	O
.	O
At	O
≥2	O
,	O
the	O
pooled	O
sensitivity	O
of	O
the	O
ISAR	O
for	O
predicting	O
ED	O
return	O
,	O
emergency	O
hospitalisation	B-T058
and	O
mortality	O
at	O
6	O
months	O
is	O
0.80	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.70	O
-	O
0.87	O
)	O
,	O
0.82	O
(	O
95	O
%	O
CI	O
0.74	O
-	O
0.88	O
)	O
and	O
0.87	O
(	O
95	O
%	O
CI	O
0.75	O
-	O
0.94	O
)	O
,	O
respectively	O
,	O
with	O
a	O
pooled	O
specificity	O
of	O
0.31	O
(	O
95	O
%	O
CI	O
0.24	O
-	O
0.38	O
)	O
,	O
0.32	O
(	O
95	O
%	O
CI	O
0.24	O
-	O
0.41	O
)	O
and	O
0.35	O
(	O
95	O
%	O
CI	O
0.26	O
-	O
0.44	O
)	O
.	O
Similar	O
values	O
are	O
demonstrated	O
at	O
30	O
and	O
90	O
days	O
.	O
Three	O
heterogeneous	O
impact	O
analysis	O
studies	O
examined	B-T033
the	O
clinical	O
implementation	O
of	O
the	O
ISAR	O
and	O
reported	O
mixed	O
findings	O
across	O
patient	O
and	O
process	O
outcomes	O
.	O
the	O
ISAR	O
has	O
modest	O
predictive	O
accuracy	O
and	O
may	O
serve	O
as	O
a	O
decision	O
-	O
making	O
adjunct	O
when	O
determining	O
which	O
older	O
adults	O
can	O
be	O
safely	O
discharged	B-T058
.	O
      
Defining	B-T058
,	O
Describing	O
,	O
and	O
Categorizing	O
Public	B-T058
Health	I-T058
Infrastructure	I-T058
Priorities	O
for	O
Tropical	O
Cyclone	O
,	O
Flood	O
,	O
Storm	O
,	O
Tornado	O
,	O
and	O
Tsunami	O
-	O
Related	O
Disasters	O
The	O
study	O
aim	O
was	O
to	O
undertake	O
a	O
qualitative	O
research	O
literature	O
review	O
to	O
analyze	O
available	O
databases	O
to	O
define	B-T058
,	O
describe	O
,	O
and	O
categorize	O
public	B-T058
health	I-T058
infrastructure	I-T058
(	O
PHI	B-T058
)	O
priorities	O
for	O
tropical	O
cyclone	O
,	O
flood	O
,	O
storm	O
,	O
tornado	O
,	O
and	O
tsunami	O
-	O
related	O
disasters	O
.	O
Five	O
electronic	O
publication	O
databases	O
were	O
searched	O
to	O
define	B-T058
,	O
describe	O
,	O
or	O
categorize	O
PHI	B-T058
and	O
discuss	O
tropical	O
cyclone	O
,	O
flood	O
,	O
storm	O
,	O
tornado	O
,	O
and	O
tsunami	O
-	O
related	O
disasters	O
and	O
their	O
impact	O
on	O
PHI	B-T058
.	O
The	O
data	O
were	O
analyzed	O
through	O
aggregation	O
of	O
individual	O
articles	O
to	O
create	O
an	O
overall	O
data	O
description	O
.	O
The	O
data	O
were	O
grouped	O
into	O
PHI	B-T058
themes	O
,	O
which	O
were	O
then	O
prioritized	O
on	O
the	O
basis	O
of	O
degree	O
of	O
interdependency	O
.	O
Sixty	O
-	O
seven	O
relevant	O
articles	O
were	O
identified	O
.	O
PHI	B-T058
was	O
categorized	O
into	O
13	O
themes	O
with	O
a	O
total	O
of	O
158	O
descriptors	O
.	O
The	O
highest	O
priority	O
PHI	B-T058
identified	O
was	O
workforce	O
.	O
This	O
was	O
followed	O
by	O
water	O
,	O
sanitation	O
,	O
equipment	O
,	O
communication	O
,	O
physical	O
structure	O
,	O
power	O
,	O
governance	O
,	O
prevention	O
,	O
supplies	O
,	O
service	O
,	O
transport	O
,	O
and	O
surveillance	O
.	O
This	O
review	O
identified	O
workforce	O
as	O
the	O
most	O
important	O
of	O
the	O
13	O
thematic	O
areas	O
related	O
to	O
PHI	B-T058
and	O
disasters	O
.	O
If	O
its	O
functionality	O
fails	O
,	O
workforce	O
has	O
the	O
greatest	O
impact	O
on	O
the	O
performance	O
of	O
health	B-T058
services	I-T058
.	O
If	O
addressed	O
post	O
-	O
disaster	O
,	O
the	O
remaining	O
forms	O
of	O
PHI	B-T058
will	O
then	O
be	O
progressively	O
addressed	O
.	O
These	O
findings	O
are	O
a	O
step	O
toward	O
providing	O
an	O
evidence	O
base	O
to	O
inform	O
PHI	B-T058
priorities	O
in	O
the	O
disaster	O
setting	O
.	O
(	O
Disaster	O
Med	O
Public	O
Health	O
Preparedness	O
.	O
2016;10:598	O
-	O
610	O
)	O
.	O
      
Endothermal	B-T061
venous	I-T061
ablation	I-T061
of	O
the	O
saphenous	B-T023
vein	I-T023
on	O
patients	O
who	O
are	O
on	O
anticoagulation	B-T061
therapy	I-T061
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
risks	O
of	O
bleeding	O
,	O
deep	B-T047
venous	I-T047
thrombosis	I-T047
(	O
DVT	B-T047
)	O
,	O
endovenous	O
heat	O
induced	O
thrombosis	O
(	O
EHIT	O
)	O
and	O
failure	O
of	O
ablation	B-T061
on	O
patients	O
who	O
undergo	O
ablation	B-T061
while	O
on	O
oral	B-T061
anticoagulation	I-T061
.	O
We	O
compared	O
378	O
(	O
3.4	O
%	O
)	O
out	O
of	O
11252	O
patients	O
(	O
group	O
A	O
)	O
who	O
had	O
undergone	O
724	O
endovenous	B-T061
ablation	I-T061
of	O
the	O
saphenous	B-T023
veins	I-T023
from	O
January	O
1	O
,	O
2011	O
to	O
September	O
30	O
,	O
2014	O
while	O
on	O
oral	B-T061
anticoagulation	I-T061
to	O
a	O
randomly	O
selected	O
375	O
patients	O
(	O
group	O
B	O
)	O
who	O
underwent	O
641	O
endovenous	B-T061
ablation	I-T061
in	O
the	O
same	O
time	O
period	O
but	O
were	O
not	O
on	O
anticoagulation	B-T061
.	O
The	O
demographic	O
data	O
,	O
history	B-T033
of	I-T033
DVT	B-T047
,	O
the	O
Clinical	O
,	O
Etiologic	O
,	O
Anatomic	O
,	O
Pathologic	O
(	O
CEAP	O
)	O
classification	O
and	O
the	O
VCSS	O
(	O
Venous	O
Clinical	O
Severity	O
Score	O
)	O
scores	O
were	O
analyzed	O
.	O
The	O
indications	O
for	O
anticoagulation	B-T061
,	O
the	O
anticoagulants	B-T121
used	O
were	O
recorded	O
.	O
The	O
primary	O
endpoints	O
were	O
bleeding	O
,	O
development	O
of	O
DVT	B-T047
or	O
EHIT	O
,	O
and	O
failure	O
of	O
ablation	B-T061
.	O
Patients	O
in	O
group	O
A	O
were	O
older	O
,	O
had	O
more	O
men	O
,	O
more	O
history	O
of	O
DVT	B-T047
and	O
PE	B-T047
,	O
had	O
higher	O
CEAP	O
and	O
VCSS	O
scores	O
compared	O
to	O
group	O
B.	O
The	O
type	O
of	O
anticoagulation	B-T061
used	O
was	O
warfarin	B-T121
in	O
77.2	O
%	O
direct	B-T121
oral	I-T121
inhibitors	I-T121
(	O
DOIs	B-T121
)	O
in	O
22.8	O
%	O
.	O
The	O
rate	O
of	O
failure	O
of	O
ablation	B-T061
at	O
3	O
days	O
was	O
39	O
(	O
5.6	O
%	O
)	O
for	O
Group	O
A	O
and	O
3	O
(	O
0.5	O
%	O
)	O
for	O
Group	O
B	O
(	O
P<0.0001	O
)	O
and	O
at	O
one	O
month	O
it	O
was	O
46	O
(	O
10.1	O
%	O
)	O
vs.	O
27	O
(	O
6.7	O
%	O
)	O
(	O
P=0.086	O
)	O
.	O
The	O
number	O
of	O
EHIT	O
cases	O
in	O
group	O
A	O
at	O
3	O
days	O
was	O
2	O
(	O
0.3	O
%	O
)	O
,	O
compared	O
to	O
6	O
(	O
0.9	O
%	O
)	O
in	O
group	O
B	O
(	O
P=0.016	O
)	O
and	O
at	O
1	O
month	O
it	O
was	O
0	O
compared	O
to	O
4	O
(	O
1.0	O
%	O
)	O
(	O
P=0.0483	O
)	O
.	O
The	O
DVT	B-T047
,	O
SVT	B-T047
,	O
hematoma	O
and	O
wound	O
infection	O
rates	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O
Ablation	B-T061
of	O
the	O
saphenous	B-T023
veins	I-T023
in	O
patients	O
who	O
are	O
on	O
oral	B-T061
anticoagulation	I-T061
is	O
safe	O
and	O
does	O
not	O
increase	O
the	O
risk	O
of	O
bleeding	O
or	O
hematoma	O
,	O
but	O
it	O
may	O
slightly	O
lower	O
the	O
incidence	O
of	O
EHIT	O
and	O
increase	O
the	O
incidence	O
of	O
failure	O
of	O
ablation	B-T061
.	O
      
Stalk	B-T017
versus	O
base	B-T017
invasion	B-T033
in	O
pT1	B-T033
papillary	B-T191
cancers	I-T191
of	I-T191
the	I-T191
bladder	I-T191
:	O
improved	O
substaging	O
system	O
predicting	O
risk	O
of	O
progression	O
Pathologic	B-T033
stage	I-T033
T1	I-T033
(	O
pT1	B-T033
)	O
bladder	B-T191
cancers	I-T191
are	O
a	O
clinically	O
heterogeneous	O
group	O
.	O
However	O
,	O
current	O
staging	O
guidelines	O
for	O
superficially	O
invasive	B-T191
cancers	I-T191
do	O
not	O
acknowledge	O
the	O
variability	O
in	O
type	O
and	O
extent	O
of	O
lamina	B-T033
propria	I-T033
invasion	I-T033
in	O
papillary	B-T191
urothelial	I-T191
carcinomas	I-T191
(	O
PUC	B-T191
)	O
,	O
and	O
historically	O
proposed	O
substaging	O
systems	O
showed	O
either	O
high	O
inter	O
-	O
observer	O
variation	O
or	O
limited	O
value	O
in	O
predicting	O
patient	B-T058
outcomes	I-T058
.	O
Herein	O
we	O
reappraise	B-T058
pT1	B-T033
PUC	B-T191
substaging	O
,	O
aiming	O
to	O
identify	O
a	O
novel	O
scheme	O
which	O
is	O
reproducible	O
and	O
prognostically	O
meaningful	O
.	O
Stage	B-T033
pT1	I-T033
PUC	B-T191
diagnosed	B-T033
during	O
years	O
1999	O
-	O
2015	O
were	O
retrospectively	O
reviewed	O
and	O
characterized	O
as	O
focal	O
invasion	O
confined	O
to	O
papillary	B-T017
stalk	I-T017
,	O
focal	O
invasion	B-T033
of	O
tumor	B-T191
base	B-T017
,	O
or	O
extensive	O
invasion	B-T033
of	O
tumor	B-T191
base	B-T017
.	O
Cases	O
with	O
concurrent	O
flat	B-T033
carcinoma	I-T033
in	I-T033
-	I-T033
situ	I-T033
,	O
angiolymphatic	B-T033
invasion	I-T033
,	O
absent	O
muscularis	O
propria	O
,	O
or	O
clinically	O
advanced	O
disease	O
were	O
excluded	O
.	O
We	O
calculated	O
cumulative	O
incidence	O
of	O
recurrence	B-T033
,	O
progression	O
,	O
and	O
death	O
by	O
tumor	O
subtype	O
and	O
evaluated	B-T058
differential	B-T033
risks	I-T033
using	O
log	O
-	O
rank	O
tests	O
and	O
Kaplan	O
-	O
Meier	O
curves	O
stratified	O
by	O
type	O
and	O
extent	O
of	O
invasion	O
.	O
Among	O
62	O
patients	O
satisfying	O
inclusion	O
criteria	O
,	O
22	O
of	O
29	O
patients	O
with	O
base	B-T017
extensive	O
invasion	B-T033
progressed	O
while	O
4	O
of	O
13	O
with	O
base	B-T017
focal	O
and	O
0	O
of	O
20	O
with	O
stalk	B-T017
only	O
invasion	B-T033
progressed	O
.	O
There	O
was	O
strong	O
evidence	O
that	O
base	B-T017
extensive	O
patients	O
had	O
higher	O
risk	O
of	O
progression	O
and	O
death	O
due	O
to	O
bladder	B-T191
cancer	I-T191
than	O
base	B-T017
focal	O
or	O
stalk	B-T017
only	O
counterparts	O
(	O
P<0.0001	O
)	O
.	O
However	O
,	O
tumor	O
subtype	O
was	O
not	O
significantly	O
associated	O
with	O
risk	O
of	O
recurrence	B-T033
(	O
P=0.21	O
)	O
.	O
We	O
propose	O
an	O
innovative	O
substaging	O
approach	O
for	O
reporting	O
site	O
and	O
extent	O
of	O
lamina	B-T033
propria	I-T033
invasion	I-T033
in	O
patients	O
with	O
pT1	B-T033
PUC	B-T191
allowing	O
patient	O
stratification	O
for	O
risk	O
of	O
progression	O
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O
      
Evaluation	B-T058
of	O
the	O
Effects	O
of	O
Intravenous	O
and	O
Percutaneous	O
Low	B-T061
Level	I-T061
Laser	I-T061
Therapy	I-T061
in	O
the	O
Management	B-T061
of	O
Shoulder	O
Myofascial	B-T047
Pain	I-T047
Syndrome	I-T047
Myofascial	B-T047
pain	I-T047
syndrome	I-T047
(	O
MPS	B-T047
)	O
treatment	B-T061
is	O
challenging	O
with	O
a	O
high	O
recurrence	O
rate	O
and	O
still	O
lacks	O
a	O
clear	O
treatment	B-T061
frame	I-T061
.	O
Therefore	O
research	O
on	O
new	O
,	O
more	O
efficient	O
and	O
long	O
lasting	O
effect	O
treatment	B-T061
modalities	O
is	O
necessary	O
.	O
This	O
study	O
looked	O
at	O
the	O
effects	O
of	O
intravenous	O
laser	B-T061
therapy	I-T061
(	O
IVL	B-T061
)	O
and	O
percutaneous	O
low	B-T061
level	I-T061
laser	I-T061
(	O
PLLL	B-T061
)	O
in	O
the	O
management	B-T061
of	O
shoulder	O
MPS	B-T047
.	O
In	O
this	O
randomized	O
controlled	O
trial	O
,	O
30	O
patients	O
fulfilling	O
inclusion	O
criteria	O
were	O
randomly	O
equally	O
allocated	O
to	O
3	O
groups	O
,	O
control	O
,	O
IVL	O
and	O
PLLL	O
.	O
Control	O
group	O
received	O
12	O
sessions	O
of	O
placebo	O
low	B-T061
level	I-T061
laser	I-T061
,	O
IVL	O
group	O
received	O
12	O
sessions	O
of	O
IVL	B-T061
therapy	I-T061
,	O
and	O
PLLL	O
group	O
received	O
12	O
sessions	O
of	O
PLLL	B-T061
therapy	I-T061
.	O
All	O
patients	O
were	O
trained	O
for	O
better	O
body	O
posture	O
,	O
body	O
mechanics	O
,	O
gentle	B-T061
massage	I-T061
of	O
trigger	O
points	O
,	O
stretching	B-T061
exercises	I-T061
of	O
affected	O
muscle	O
(	O
trapezius	B-T023
)	O
,	O
and	O
received	O
10	O
mg	O
of	O
oral	O
nortriptyline	B-T121
regimen	B-T061
every	O
night	O
for	O
3	O
months	O
.	O
Outcomes	O
included	O
pain	O
severity	O
,	O
functional	B-T033
disability	I-T033
,	O
and	O
quality	O
of	O
life	O
.	O
Patients	O
were	O
assessed	O
using	O
Numeric	O
Rating	O
Scale	O
(	O
NRS	O
)	O
,	O
Pain	O
Disability	O
Index	O
(	O
PDI	O
)	O
,	O
and	O
Short	O
Form	O
Health	O
Survey	O
(	O
SF-12	O
)	O
.	O
Data	B-T033
collected	I-T033
were	O
analyzed	O
using	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
,	O
Mann	O
-	O
Whitney	O
and	O
t	O
tests	O
.	O
The	O
mean	O
of	O
PDI	O
and	O
maximum	O
pain	O
intensity	O
during	O
day	O
and	O
night	O
significantly	O
reduced	O
in	O
both	O
PLLL	O
and	O
IVL	O
groups	O
compared	O
to	O
control	O
group	O
.	O
Although	O
pain	O
severity	O
and	O
PDI	O
reduction	O
was	O
more	O
pronounced	O
in	O
IVL	O
group	O
compared	O
to	O
PLLL	O
group	O
,	O
the	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O
Also	O
,	O
quality	O
of	O
life	O
statistically	O
significantly	O
improved	O
in	O
both	O
IVL	O
and	O
PLLL	O
groups	O
compared	O
to	O
control	O
group	O
was	O
more	O
,	O
and	O
although	O
higher	O
in	O
IVL	O
group	O
,	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
when	O
compared	O
to	O
PLLL	O
group	O
.	O
No	B-T033
side	I-T033
effects	I-T033
were	O
observed	O
in	O
the	O
intervention	O
groups	O
.	O
Intravenous	O
laser	B-T061
and	O
PLLL	B-T061
therapy	I-T061
had	O
a	O
positive	O
effect	O
on	O
pain	O
severity	O
and	O
PDI	O
reduction	O
,	O
and	O
quality	O
of	O
life	O
in	O
this	O
study	O
.	O
Also	O
no	B-T033
adverse	I-T033
event	I-T033
was	O
recorded	O
.	O
Thus	O
,	O
intravenous	O
lasers	B-T061
and	O
PLLL	B-T061
therapy	I-T061
seem	O
to	O
be	O
effective	O
complementary	O
modalities	O
in	O
managing	B-T061
patients	O
with	O
shoulder	O
MPS	B-T047
.	O
      
Quantitative	O
regulation	O
of	O
histone	O
variant	O
H2A.Z	O
during	O
cell	O
cycle	O
by	O
ubiquitin	O
proteasome	O
system	O
and	O
SUMO	O
-	O
targeted	O
ubiquitin	O
ligases	O
Quantitative	O
control	O
of	O
histones	O
and	O
histone	O
variants	O
during	O
cell	O
cycle	O
is	O
relevant	O
to	O
their	O
epigenetic	O
functions	O
.	O
We	O
found	O
that	O
the	O
level	O
of	O
yeast	O
histone	O
variant	O
H2A.Z	O
in	O
the	O
G2	O
/	O
M	O
-	O
phase	O
is	O
actively	O
kept	O
low	O
by	O
the	O
ubiquitin	O
proteasome	O
system	O
and	O
SUMO	O
-	O
targeted	O
ubiquitin	O
ligases	O
.	O
Overexpression	O
of	O
H2A.Z	O
induced	O
defects	O
in	O
mitotic	O
progression	O
,	O
suggesting	O
functional	O
importance	O
of	O
this	O
quantitative	O
control	O
.	O
      
Identifying	O
research	O
priorities	O
with	O
nurses	O
at	O
a	O
tertiary	O
children	O
's	O
hospital	O
in	O
the	O
United	O
Kingdom	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
undertake	O
a	O
research	O
priority	O
setting	O
exercise	O
with	O
the	O
aim	O
of	O
maximizing	O
efficiency	O
and	O
impact	O
in	O
research	O
activity	O
undertaken	O
by	O
nurses	O
at	O
one	O
children	O
's	O
tertiary	O
healthcare	O
institution	O
by	O
ensuring	O
the	O
clinical	O
staff	O
directly	O
shaped	O
a	O
coherent	B-T033
,	O
transparent	O
and	O
consensus	O
driven	O
nurse	O
-	O
led	O
research	O
agenda	O
.	O
In	O
Round	O
1	O
,	O
the	O
research	O
topics	O
of	O
147	O
nurses	O
were	O
elicited	O
using	O
a	O
modified	O
nominal	O
group	O
technique	O
as	O
the	O
consensus	O
method	O
.	O
The	O
number	O
of	O
participants	O
in	O
the	O
24	O
separate	O
discussions	O
ranged	O
from	O
3	O
to	O
21	O
,	O
generating	O
lists	O
of	O
between	O
6	O
and	O
23	O
topics	O
.	O
In	O
Round	O
2	O
,	O
nurses	O
from	O
the	O
clinical	O
areas	O
ranked	O
topics	O
of	O
importance	O
resulting	O
in	O
a	O
set	O
of	O
four	O
to	O
five	O
priorities	O
.	O
In	O
Round	O
3	O
,	O
the	O
divisional	O
heads	O
of	O
nursing	O
consulted	O
with	O
staff	O
in	O
all	O
of	O
their	O
clinical	O
areas	O
to	O
each	O
finalize	O
their	O
five	O
divisional	O
priorities	O
.	O
The	O
Nursing	O
Research	O
Working	O
Group	O
discussed	O
and	O
refined	O
the	O
divisions	O
'	O
priorities	O
and	O
voted	O
on	O
the	O
final	O
list	O
to	O
agree	O
the	O
top	O
five	O
research	O
priorities	O
for	O
the	O
organization	O
.	O
A	O
total	O
of	O
269	O
research	O
topics	O
were	O
initially	O
generated	O
.	O
Following	O
three	O
rounds	O
of	O
ranking	O
and	O
prioritizing	O
,	O
five	O
priorities	O
were	O
agreed	O
at	O
Divisional	O
level	O
,	O
and	O
from	O
these	O
,	O
the	O
five	O
top	O
organizational	O
priorities	O
were	O
selected	O
.	O
These	O
were	O
(	O
i	O
)	O
understanding	O
and	O
improving	O
all	O
aspects	O
of	O
the	O
patient	O
journey	O
through	O
the	O
hospital	O
system	O
;	O
(	O
ii	O
)	O
play	O
;	O
(	O
iii	O
)	O
staff	O
wellbeing	O
,	O
patient	B-T058
care	I-T058
and	O
productivity	O
;	O
(	O
iv	O
)	O
team	O
work	O
-	O
linking	O
to	O
a	O
more	O
efficient	O
service	O
;	O
and	O
(	O
v	O
)	O
supporting	O
parents	O
/	O
parent	O
pathway	O
.	O
Divisional	O
priorities	O
have	O
been	O
disseminated	O
widely	O
to	O
clinical	B-T058
teams	I-T058
to	O
inform	O
a	O
patient	O
-	O
specific	O
nurse	O
-	O
led	O
research	O
agenda	O
.	O
Organizational	O
priorities	O
agreed	O
upon	O
have	O
been	O
disseminated	O
through	O
management	O
structures	O
and	O
processes	O
to	O
ensure	O
engagement	O
at	O
all	O
levels	O
.	O
A	O
subgroup	O
of	O
the	O
Nursing	O
Research	O
Working	O
Group	O
has	O
been	O
delegated	O
to	O
take	O
this	O
work	O
forward	O
so	O
that	O
the	O
agreed	O
priorities	O
continue	O
to	O
contribute	O
towards	O
shaping	O
nurse	O
-	O
led	O
research	O
activity	O
,	O
thereby	O
going	O
some	O
way	O
to	O
inform	O
and	O
embed	O
an	O
evidence	O
-	O
based	O
culture	O
of	O
inquiry	O
.	O
      
ITPR3	O
gene	O
haplotype	O
is	O
associated	O
with	O
cervical	B-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
risk	O
in	O
Taiwanese	O
women	O
Host	O
immunogenetic	O
background	O
plays	O
an	O
important	O
role	O
in	O
human	B-T047
papillomavirus	I-T047
(	I-T047
HPV	I-T047
)	I-T047
infection	I-T047
and	O
cervical	B-T191
cancer	I-T191
development	I-T191
.	O
Inositol	O
1,4,5	O
-	O
triphosphate	O
receptor	O
type	O
3	O
(	O
ITPR3	O
)	O
is	O
essential	O
for	O
both	O
immune	O
activation	O
and	O
cancer	B-T191
pathogenesis	O
.	O
We	O
aim	O
to	O
investigate	O
if	O
ITPR3	O
genetic	O
polymorphisms	O
are	O
associated	O
with	O
the	O
risk	O
of	O
cervical	O
cancer	O
in	O
Taiwanese	O
women	O
.	O
ITPR3	O
rs3748079	O
A	O
/	O
G	O
and	O
rs2229634	O
C	O
/	O
T	O
polymorphisms	O
were	O
genotyped	O
in	O
a	O
hospital	O
-	O
based	O
study	O
of	O
462	O
women	O
with	O
cervical	B-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
(	O
CSCC	B-T191
)	O
and	O
921	O
age	O
-	O
matched	O
healthy	O
control	O
women	O
.	O
The	O
presence	O
and	O
genotypes	O
of	O
HPV	B-T005
in	O
CSCC	B-T191
was	O
determined	O
.	O
No	O
significant	O
association	O
of	O
individual	O
ITPR3	O
variants	O
were	O
found	O
among	O
controls	O
,	O
CSCC	B-T191
,	O
and	O
HPV-16	O
positive	O
CSCC	B-T191
.	O
However	O
,	O
we	O
found	O
a	O
significant	O
association	O
of	O
haplotype	O
AT	O
between	O
CSCC	B-T191
and	O
controls	O
(	O
OR	O
=	O
2.28	O
,	O
95	O
%	O
CI	O
1.31	O
-	O
3.97	O
,	O
P	O
=	O
2.83	O
×	O
10	O
-	O
3	O
)	O
and	O
the	O
OR	O
increased	O
further	O
in	O
CSCC	B-T191
patients	O
infected	O
with	O
HPV-16	B-T005
(	O
OR	O
=	O
2.89	O
,	O
95	O
%	O
CI	O
1.55	O
-	O
5.37	O
,	O
P	O
=	O
4.54	O
×	O
10	O
-	O
4	O
)	O
.	O
The	O
linkage	O
disequilibrium	O
analysis	O
demonstrated	O
that	O
ITPR3	O
association	O
with	O
CSCC	B-T191
was	O
independent	O
of	O
HLA	O
-	O
DRB1	O
alleles	O
.	O
In	O
conclusion	O
,	O
these	O
findings	O
suggest	O
that	O
AT	O
haplotype	O
in	O
the	O
ITPR3	O
gene	O
may	O
serve	O
as	O
a	O
potential	O
marker	O
for	O
genetic	O
susceptibility	O
to	O
CSCC	B-T191
.	O
      
Remote	O
Ischemic	B-T061
Conditioning	I-T061
and	O
Renal	B-T023
Protection	B-T033
Over	O
the	O
course	O
of	O
the	O
last	O
2	O
decades	O
,	O
the	O
concept	O
of	O
remote	O
ischemic	B-T061
conditioning	I-T061
(	O
RIC	B-T061
)	O
has	O
attracted	O
considerable	O
research	O
interest	O
,	O
because	O
RIC	B-T061
,	O
in	O
most	O
of	O
its	O
embodiments	O
offers	O
an	O
inexpensive	O
way	O
of	O
protecting	B-T033
tissues	O
against	O
ischemic	O
damage	O
inflicted	O
by	O
a	O
number	O
of	O
medical	O
conditions	O
or	O
procedures	B-T058
.	O
Acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
is	O
a	O
common	O
side	O
effect	O
in	O
the	O
context	O
of	O
various	O
medical	B-T058
procedures	I-T058
,	O
and	O
RIC	B-T061
has	O
been	O
suggested	O
as	O
a	O
means	O
of	O
reducing	O
its	O
incidence	O
.	O
Outcomes	O
regarding	O
kidney	O
function	O
have	O
been	O
reported	O
in	O
numerous	O
studies	O
that	O
evaluated	O
the	O
effects	O
of	O
RIC	B-T061
in	O
a	O
variety	O
of	O
settings	O
(	O
eg	O
,	O
cardiac	B-T061
surgery	I-T061
,	O
interventions	B-T061
requiring	O
intravenous	O
administration	O
of	O
contrast	O
media	O
)	O
.	O
Although	O
several	O
individual	O
studies	O
have	O
implied	O
a	O
beneficial	O
effect	O
of	O
RIC	B-T061
in	O
preserving	O
kidney	O
function	O
,	O
3	O
recently	O
published	O
randomized	O
controlled	O
trials	O
evaluating	O
more	O
than	O
1000	O
patients	O
each	O
(	O
Effect	O
of	O
Remote	B-T061
Ischemic	I-T061
Preconditioning	I-T061
in	O
the	O
Cardiac	B-T061
Surgery	I-T061
,	O
Remote	B-T061
Ischaemic	I-T061
Preconditioning	I-T061
for	O
Heart	B-T061
Surgery	I-T061
,	O
and	O
E	B-T061
RIC	I-T061
CA	I-T061
RIC	B-T061
)	O
were	O
negative	B-T033
.	O
However	O
,	O
AKI	O
or	O
any	O
other	O
index	O
of	O
renal	O
function	O
was	O
not	O
a	O
stand	O
-	O
alone	O
primary	O
end	O
point	O
in	O
any	O
of	O
these	O
trials	O
.	O
On	O
the	O
other	O
hand	O
,	O
a	O
range	O
of	O
meta	O
-	O
analyses	O
(	O
each	O
including	O
thousands	O
of	O
participants	O
)	O
have	O
reported	O
mixed	O
results	O
,	O
with	O
the	O
most	O
recent	O
among	O
them	O
showing	O
benefit	O
from	O
RIC	B-T061
,	O
pinpointing	O
at	O
the	O
same	O
time	O
a	O
number	O
of	O
shortcomings	O
in	O
published	O
studies	O
,	O
adversely	O
affecting	O
the	O
quality	O
of	O
available	O
data	O
.	O
The	O
present	O
review	O
provides	O
a	O
critical	O
appraisal	O
of	O
the	O
current	O
state	O
of	O
this	O
field	O
of	O
research	O
.	O
It	O
is	O
the	O
opinion	O
of	O
the	O
authors	O
of	O
this	O
review	O
that	O
there	O
is	O
a	O
clear	O
need	O
for	O
a	O
common	O
clinical	O
trial	O
framework	O
for	O
ischemic	B-T061
conditioning	I-T061
studies	O
.	O
If	O
the	O
current	O
babel	O
of	O
definitions	O
,	O
procedures	O
,	O
outcomes	O
,	O
and	O
goals	O
persists	O
,	O
it	O
is	O
most	O
likely	O
that	O
soon	O
ischemic	B-T061
conditioning	I-T061
will	O
be	O
"	O
yesterday	O
's	O
news	O
"	O
with	O
no	O
definitive	O
conclusions	O
having	O
been	O
reached	O
in	O
terms	O
of	O
its	O
real	O
clinical	B-T061
utility	I-T061
.	O
      
An	O
influenza	B-T005
A	I-T005
virus	I-T005
(	I-T005
H7N9	I-T005
)	I-T005
anti	B-T033
-	I-T033
neuraminidase	I-T033
monoclonal	O
antibody	O
with	O
prophylactic	B-T061
and	I-T061
therapeutic	I-T061
activity	I-T061
in	O
vivo	O
Zoonotic	B-T047
A(H7N9	B-T005
)	I-T005
avian	I-T005
influenza	I-T005
viruses	I-T005
emerged	O
in	O
China	O
in	O
2013	O
and	O
continue	O
to	O
be	O
a	O
threat	O
to	O
human	O
public	B-T058
health	I-T058
,	O
having	O
infected	B-T033
over	O
800	O
individuals	O
with	O
a	O
mortality	O
rate	O
approaching	O
40	O
%	O
.	O
Treatment	B-T061
options	I-T061
for	O
people	O
infected	B-T033
with	O
A(H7N9	B-T005
)	I-T005
include	O
the	O
use	O
of	O
neuraminidase	B-T121
(	I-T121
NA	I-T121
)	I-T121
inhibitors	I-T121
.	O
However	O
,	O
like	O
other	O
influenza	B-T005
viruses	I-T005
,	O
A(H7N9	B-T005
)	I-T005
can	O
become	O
resistant	O
to	O
these	O
drugs	B-T121
.	O
The	O
use	O
of	O
monoclonal	O
antibodies	O
is	O
a	O
rapidly	O
developing	O
strategy	O
for	O
controlling	O
influenza	B-T005
virus	I-T005
infection	O
.	O
Here	O
we	O
generated	O
a	O
murine	O
monoclonal	O
antibody	O
(	O
3c10	O
-	O
3	O
)	O
directed	O
against	O
the	O
NA	O
of	O
A(H7N9	B-T005
)	I-T005
and	O
show	O
that	O
prophylactic	O
systemic	O
administration	O
of	O
3c10	O
-	O
3	O
fully	O
protected	O
mice	O
from	O
lethal	O
challenge	O
with	O
wild	O
-	O
type	O
A	B-T005
/	I-T005
Anhui/1/2013	I-T005
(	O
H7N9	B-T005
)	O
.	O
Further	O
,	O
post-	O
infection	O
treatment	B-T061
with	O
a	O
single	O
systemic	O
dose	O
of	O
3c10	O
-	O
3	O
at	O
either	O
24	O
,	O
48	O
or	O
72	O
h	O
post	O
A(H7N9	B-T005
)	I-T005
challenge	O
resulted	O
in	O
both	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
protection	B-T033
of	O
up	O
to	O
100	O
%	O
of	O
mice	O
,	O
demonstrating	O
therapeutic	O
potential	O
for	O
3c10	O
-	O
3	O
.	O
Epitope	B-T059
mapping	I-T059
revealed	O
that	O
3c10	O
-	O
3	O
binds	O
near	O
the	O
enzyme	O
active	O
site	O
of	O
NA	O
,	O
and	O
functional	O
characterization	O
showed	O
that	O
3c10	O
-	O
3	O
inhibits	O
the	O
enzyme	O
activity	O
of	O
NA	O
and	O
restricts	O
the	O
cell	O
-to-	O
cell	O
spread	O
of	O
the	O
virus	B-T005
in	O
cultured	O
cells	O
.	O
Affinity	O
analysis	O
also	O
revealed	O
that	O
3c10	O
-	O
3	O
binds	O
equally	O
well	O
to	O
recombinant	O
NA	O
of	O
wild	O
-	O
type	O
A	B-T005
/	I-T005
Anhui/1/2013	I-T005
and	O
to	O
a	O
variant	O
NA	O
carrying	O
a	O
R289	O
K	O
mutation	O
known	O
to	O
infer	O
NAI	B-T121
resistance	O
.	O
These	O
results	O
suggest	O
that	O
3c10	O
-	O
3	O
has	O
the	O
potential	O
to	O
be	O
used	O
as	O
a	O
therapeutic	O
to	O
treat	O
A(H7N9	B-T005
)	I-T005
infections	O
either	O
as	O
an	O
alternative	O
to	O
,	O
or	O
in	O
combination	O
with	O
,	O
current	O
NA	O
antiviral	B-T121
inhibitors	I-T121
.	O
      
A	O
three	O
perspective	O
study	O
of	O
the	O
sense	O
of	O
home	O
of	O
nursing	O
home	O
residents	O
:	O
the	O
views	O
of	O
residents	O
,	O
care	O
professionals	O
and	O
relatives	O
The	O
sense	O
of	O
home	O
of	O
nursing	O
home	O
residents	O
is	O
a	O
multifactorial	B-T033
phenomenon	O
which	O
is	O
important	O
for	O
the	O
quality	O
of	O
living	O
.	O
The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
factors	O
influencing	O
the	O
sense	O
of	O
home	O
of	O
older	O
adults	O
residing	O
in	O
the	O
nursing	O
home	O
from	O
the	O
perspective	O
of	O
residents	O
,	O
relatives	O
and	O
care	O
professionals	O
.	O
A	O
total	O
of	O
78	O
participants	O
(	O
n	O
=	O
24	O
residents	O
,	O
n	O
=	O
18	O
relatives	O
and	O
n	O
=	O
26	O
care	O
professionals	O
)	O
from	O
4	O
nursing	O
homes	O
in	O
the	O
Netherlands	O
engaged	O
in	O
a	O
qualitative	O
study	O
,	O
in	O
which	O
photography	O
was	O
as	O
a	O
supportive	O
tool	O
for	O
subsequent	O
interviews	O
and	O
focus	O
groups	O
.	O
The	O
data	O
were	O
analyzed	O
based	O
on	O
open	O
ended	O
coding	O
,	O
axial	O
coding	O
and	O
selective	O
coding	O
.	O
The	O
sense	O
of	O
home	O
of	O
nursing	O
home	O
residents	O
is	O
influenced	O
by	O
a	O
number	O
of	O
jointly	O
identified	O
factors	O
,	O
including	O
the	O
building	O
and	O
interior	O
design	O
;	O
eating	O
and	O
drinking	O
;	O
autonomy	O
and	O
control	O
;	O
involvement	O
of	O
relatives	O
;	O
engagement	O
with	O
others	O
and	O
activities	O
;	O
quality	B-T058
of	I-T058
care	I-T058
are	O
shared	O
themes	O
.	O
Residents	O
and	O
relatives	O
stressed	O
the	O
importance	O
of	O
having	O
a	O
connection	O
with	O
nature	O
and	O
the	O
outdoors	O
,	O
as	O
well	O
as	O
coping	O
strategies	O
.	O
Relatives	O
and	O
care	O
professionals	O
emphasized	O
the	O
role	O
the	O
organization	O
of	O
facilitation	B-T058
of	O
care	O
played	O
,	O
as	O
well	O
as	O
making	O
residents	O
feel	O
like	O
they	O
still	O
matter	O
.	O
The	O
sense	O
of	O
home	O
of	O
nursing	O
home	O
residents	O
is	O
influenced	O
by	O
a	O
multitude	O
of	O
factors	O
related	O
to	O
the	O
psychology	O
of	O
the	O
residents	O
,	O
and	O
the	O
social	O
and	O
built	O
environmental	O
contexts	O
.	O
A	O
holistic	O
understanding	O
of	O
which	O
factors	O
influence	O
the	O
sense	O
of	O
home	O
of	O
residents	O
can	O
lead	O
to	O
strategies	O
to	O
optimize	O
this	O
sense	O
of	O
home	O
.	O
This	O
study	O
also	O
indicated	O
that	O
the	O
nursing	O
home	O
has	O
a	O
dual	O
nature	O
as	O
a	O
place	O
of	O
residence	O
and	O
a	O
place	O
where	O
people	O
are	O
supported	O
through	O
numerous	O
care	O
strategies	O
.	O
      
Primary	O
Management	B-T058
and	O
Outcome	O
-	O
Open	O
Laryngotracheal	O
Trauma	O
Acute	O
external	O
injury	O
to	O
the	O
larynx	B-T023
is	O
both	O
life	B-T033
threatening	I-T033
and	O
a	O
potential	O
long	O
term	O
management	O
challenge	O
.	O
As	O
Otorhinolaryngologist	O
we	O
must	O
be	O
prepared	O
and	O
well	O
versed	O
to	O
manage	O
these	O
patients	O
.	O
In	O
our	O
study	O
seven	O
patients	O
of	O
open	O
laryngeal	O
traumas	O
were	O
managed	O
by	O
primary	B-T061
closure	I-T061
.	O
In	O
five	O
patients	O
nature	O
of	O
injury	O
was	O
known	O
in	O
other	O
two	O
patients	O
exact	O
nature	O
of	O
injury	O
was	O
not	O
known	O
.	O
After	O
primary	B-T061
closure	I-T061
five	O
patients	O
with	O
known	O
injury	O
survived	O
and	O
two	O
patients	O
with	O
unknown	O
injury	O
died	O
.	O
As	O
per	O
our	O
experience	B-T033
,	O
we	O
recommend	O
primary	B-T061
closure	I-T061
,	O
if	O
the	O
exact	O
nature	O
of	O
injury	O
is	O
known	O
as	O
the	O
outcome	O
is	O
definitely	O
favourable	B-T033
.	O
      
Persistent	O
Organic	O
Pollutants	O
(	O
POPs	O
)	O
in	O
the	O
atmosphere	O
of	O
three	O
Chilean	O
cities	O
using	O
passive	O
air	O
samplers	O
In	O
this	O
study	O
passive	O
air	O
samplers	O
containing	O
polyurethane	O
foam	O
(	O
PUF	O
)	O
disks	O
were	O
deployed	O
in	O
three	O
cities	O
across	O
Chile	O
;	O
Santiago	O
(	O
STG	O
)	O
(	O
n=5	O
,	O
sampling	O
sites	O
)	O
,	O
Concepciόn	O
(	O
CON	O
)	O
(	O
n=6	O
)	O
and	O
Temuco	O
(	O
TEM	O
)	O
(	O
n=6	O
)	O
from	O
2008	O
to	O
2009	O
.	O
Polychlorinated	O
biphenyls	O
(	O
PCBs	O
)	O
(	O
7	O
indicator	O
congeners	O
)	O
,	O
chlorinated	O
pesticides	O
hexachlorocyclohexanes	B-T121
(	O
HCHs	B-T121
)	O
,	O
dichlorodiphenyl	O
trichloroethanes	O
(	O
DDTs	O
)	O
and	O
flame	O
retardants	O
such	O
as	O
polybrominated	O
diphenyl	O
ethers	O
(	O
PBDEs	O
)	O
were	O
determined	O
by	O
gas	B-T059
chromatography	I-T059
coupled	I-T059
mass	I-T059
spectrometry	I-T059
(	O
GC	B-T059
/	I-T059
MS	I-T059
)	O
.	O
A	O
sampling	O
rate	O
(	O
R	O
)	O
typical	O
of	O
urban	O
sites	O
(	O
4m(3)/day	O
)	O
was	O
used	O
to	O
estimate	O
the	O
atmospheric	O
concentrations	O
of	O
individual	O
compounds	O
.	O
PCB	O
concentrations	O
in	O
the	O
air	O
(	O
pg	O
/	O
m(3	O
)	O
)	O
ranged	O
from	O
~1	O
-	O
10	O
(	O
TEM	O
)	O
,	O
~1	O
-	O
40	O
(	O
STG	O
)	O
and	O
4	O
-	O
30	O
(	O
CON	O
)	O
.	O
Higher	O
molecular	O
weight	O
PCBs	O
(	O
PCB	O
-153	O
,	O
-180	O
)	O
were	O
detected	B-T033
at	O
industrial	O
sites	O
(	O
in	O
Concepción	O
)	O
.	O
The	O
HCHs	B-T121
showed	O
a	O
prevalence	O
of	O
γ	B-T121
-	I-T121
HCH	I-T121
across	O
all	O
sites	O
,	O
indicative	O
of	O
inputs	O
from	O
the	O
use	O
of	O
lindane	B-T121
but	O
a	O
limited	O
use	O
of	O
technical	O
HCHs	B-T121
in	O
Chile	O
.	O
DDTs	O
were	O
detected	B-T033
with	O
a	O
prevalence	O
of	O
p	O
,	O
p'-DDE	O
accounting	O
for	O
~50	O
%	O
of	O
the	O
total	O
DDTs	O
.	O
PBDE	O
concentrations	O
in	O
air	O
(	O
pg	O
/	O
m(3	O
)	O
)	O
ranged	O
from	O
1	O
to	O
55	O
(	O
STG	O
)	O
,	O
0.5	O
to	O
20	O
(	O
CON	O
)	O
and	O
from	O
0.4	O
to	O
10	O
(	O
TEM	O
)	O
,	O
and	O
were	O
generally	O
similar	O
to	O
those	O
reported	O
for	O
many	O
other	O
urban	O
areas	O
globally	O
.	O
The	O
pattern	O
of	O
PBDEs	O
was	O
different	O
among	O
the	O
three	O
cities	O
;	O
however	O
,	O
PBDE	O
-209	O
was	O
dominant	O
at	O
most	O
of	O
the	O
sites	O
.	O
These	O
results	B-T033
represent	O
one	O
of	O
the	O
few	O
assessments	B-T058
of	O
air	O
concentrations	O
of	O
POPs	O
across	O
different	O
urban	O
areas	O
within	O
the	O
same	O
country	O
.	O
These	O
data	O
will	O
support	O
Chilean	O
commitments	O
as	O
a	O
signatory	O
to	O
the	O
Stockholm	O
Convention	O
on	O
POPs	O
and	O
for	O
reporting	O
as	O
a	O
member	O
country	O
of	O
the	O
Group	O
of	O
Latin	O
America	O
and	O
Caribbean	O
Countries	O
(	O
GRULAC	O
)	O
region	O
.	O
      
Comparison	O
of	O
270	B-T200
Versus	O
320	B-T200
mg	I-T200
I	I-T200
/	I-T200
mL	I-T200
of	I-T200
Iodixanol	I-T200
in	O
1	O
Image	B-T058
Assessment	I-T058
of	O
Both	O
Renal	B-T023
Arteries	I-T023
and	O
Veins	B-T023
With	O
Dual	B-T060
-	I-T060
Energy	I-T060
Spectral	I-T060
CT	I-T060
Imaging	I-T060
in	O
Late	O
Arterial	O
Phase	O
and	O
Their	O
Influence	O
on	O
Renal	O
Function	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
image	O
quality	O
of	O
renal	B-T023
arteries	I-T023
and	O
veins	B-T023
with	O
dual	B-T060
-	I-T060
energy	I-T060
spectral	I-T060
computed	I-T060
tomography	I-T060
(	I-T060
CT	I-T060
)	I-T060
imaging	I-T060
in	O
late	O
arterial	O
phase	O
using	O
270	B-T200
and	O
320	B-T200
mg	I-T200
I	I-T200
/	I-T200
mL	I-T200
of	I-T200
iodixanol	I-T200
and	O
their	O
influence	O
on	O
renal	O
function	O
.	O
A	O
total	O
of	O
1062	O
patients	O
underwent	O
renal	B-T060
CT	I-T060
angiography	I-T060
with	O
270	B-T200
or	O
320	B-T200
mg	I-T200
I	I-T200
/	I-T200
mL	I-T200
of	I-T200
iodixanol	I-T200
with	O
dual	B-T060
-	I-T060
energy	I-T060
spectral	I-T060
CT	I-T060
imaging	I-T060
in	O
late	O
arterial	O
phase	O
.	O
Image	O
quality	O
and	O
their	O
influence	O
on	O
renal	O
function	O
were	O
compared	O
.	O
There	O
were	O
no	O
significant	O
differences	O
of	O
CT	O
value	O
,	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
,	O
contrast	O
-	O
to	O
-	O
noise	O
ratio	O
,	O
and	O
subjective	O
score	O
of	O
renal	B-T023
vessels	I-T023
between	O
2	O
groups	O
(	O
all	O
P	O
>	O
0.05	O
)	O
.	O
The	O
incidence	O
of	O
contrast	B-T047
-	I-T047
induced	I-T047
nephropathy	I-T047
in	O
patients	O
with	O
abnormal	O
renal	O
function	O
using	O
320	B-T200
mg	I-T200
I	I-T200
/	I-T200
mL	I-T200
of	I-T200
iodixanol	I-T200
was	O
significantly	O
higher	O
than	O
using	O
270	B-T200
mg	I-T200
I	I-T200
/	I-T200
mL	I-T200
of	I-T200
iodixanol	I-T200
(	O
P	O
=	O
0.043	O
)	O
.	O
The	O
renal	B-T023
arteries	I-T023
and	O
veins	B-T023
can	O
be	O
fully	O
assessed	O
in	O
late	O
arterial	O
phase	O
with	O
270	B-T200
mg	I-T200
I	I-T200
/	I-T200
mL	I-T200
of	I-T200
iodixanol	I-T200
using	O
dual	B-T060
-	I-T060
energy	I-T060
spectral	I-T060
CT	I-T060
scan	I-T060
with	O
better	O
preserved	O
renal	O
function	O
.	O
      
Inhibitory	O
effects	O
of	O
Lactobacillus	B-T007
rhamnosus	I-T007
and	O
Lactobacillus	B-T007
casei	I-T007
on	O
Candida	O
biofilm	B-T007
of	O
denture	B-T033
surface	I-T033
Candida	O
albicans	O
biofilm	B-T007
is	O
associated	O
with	O
denture	B-T047
-	I-T047
related	I-T047
stomatitis	I-T047
and	O
oral	B-T047
candidiasis	I-T047
of	O
elderly	O
.	O
Probiotics	B-T007
are	O
beneficial	O
bacteria	B-T007
and	O
have	O
antibacterial	B-T033
activity	I-T033
against	O
pathogenic	B-T007
bacteria	I-T007
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
antifungal	B-T033
activity	I-T033
of	O
various	O
probiotics	B-T007
against	O
C.	O
albicans	O
and	O
the	O
inhibitory	O
effects	O
of	O
probiotics	B-T007
on	O
Candida	O
biofilm	B-T007
on	O
the	O
denture	B-T033
surface	I-T033
.	O
The	O
spent	O
culture	O
media	O
of	O
various	O
probiotics	B-T007
were	O
investigated	O
the	O
antifungal	O
efficacy	O
against	O
C.	O
albicans	O
.	O
Candida	O
biofilm	B-T007
was	O
formed	O
on	O
a	O
denture	O
base	O
resin	O
and	O
was	O
then	O
treated	O
with	O
Lactobacillus	B-T007
rhamnosus	I-T007
and	O
Lactobacillus	B-T007
casei	I-T007
.	O
Also	O
,	O
the	O
biofilm	B-T007
s	O
of	O
L.	B-T007
rhamnosus	I-T007
and	O
L.	B-T007
casei	I-T007
were	O
formed	O
and	O
were	O
sequentially	O
treated	O
with	O
C.	O
albicans	O
.	O
Colony	O
-	O
forming	O
units	O
of	O
C.	O
albicans	O
on	O
the	O
denture	B-T033
surface	I-T033
were	O
counted	O
after	O
spreading	O
on	O
agar	B-T121
plate	O
.	O
The	O
denture	O
base	O
resin	O
was	O
treated	O
with	O
the	O
spent	O
culture	O
media	O
for	O
30	O
days	O
,	O
after	O
which	O
the	O
denture	B-T033
surface	I-T033
roughness	B-T033
was	O
analyzed	O
with	O
an	O
atomic	B-T059
force	I-T059
microscope	I-T059
.	O
L.	B-T007
rhamnosus	I-T007
and	O
L.	B-T007
casei	I-T007
exhibited	O
stronger	O
antifungal	B-T033
activity	I-T033
than	O
other	O
probiotics	B-T007
.	O
The	O
spent	O
culture	O
medium	O
of	O
L.	B-T007
rhamnosus	I-T007
and	O
L.	B-T007
casei	I-T007
exhibited	O
the	O
antifungal	B-T033
activity	I-T033
against	O
blastoconidia	O
and	O
biofilm	B-T007
of	O
C.	O
albicans	O
.	O
L.	B-T007
rhamnosus	I-T007
and	O
L.	B-T007
casei	I-T007
showed	O
the	O
antifungal	B-T033
activity	I-T033
against	O
Candida	O
biofilm	B-T007
,	O
and	O
the	O
biofilm	B-T007
of	O
L.	B-T007
rhamnosus	I-T007
and	O
L.	B-T007
casei	I-T007
inhibited	O
formation	O
of	O
Candida	O
biofilm	B-T007
on	O
denture	B-T033
surface	I-T033
.	O
Neither	O
of	O
the	O
probiotics	B-T007
affected	O
the	O
surface	B-T033
roughness	I-T033
of	O
the	O
denture	O
base	O
resin	O
.	O
L.	B-T007
rhamnosus	I-T007
and	O
L.	B-T007
casei	I-T007
may	O
be	O
the	O
ideal	O
probiotics	B-T007
for	O
the	O
prevention	O
and	O
treatment	O
of	O
denture	B-T047
-	I-T047
related	I-T047
stomatitis	I-T047
.	O
      
Giant	O
Antrochoanal	B-T191
Polyp	I-T191
-A	O
Rare	O
Presentation	O
Antrochoanal	B-T191
polyp	I-T191
(	O
ACP	B-T191
)	O
,	O
also	O
called	O
as	O
Killian	B-T191
polyp	I-T191
,	O
is	O
an	O
infrequent	O
,	O
benign	B-T033
lesion	I-T033
of	O
maxillary	B-T023
origin	O
in	O
non	O
-	O
atopic	O
patients	O
.	O
The	O
antrochoanal	B-T191
polyp	I-T191
is	O
shaped	O
according	O
to	O
the	O
anatomical	O
constraints	O
of	O
the	O
lateral	O
nasal	O
wall	O
,	O
particularly	O
the	O
middle	B-T023
meatus	I-T023
and	O
antrum	B-T023
,	O
resembling	O
typically	O
a	O
dumbbell	O
.	O
Here	O
presenting	O
a	O
common	O
problem	B-T033
with	O
unusual	O
presentation	O
.	O
      
Forensic	O
characteristics	O
and	O
phylogenetic	O
analyses	O
of	O
the	O
Chinese	O
Yi	O
population	O
via	O
19	O
X	O
-	O
chromosomal	O
STR	O
loci	O
The	O
demographic	O
characteristics	O
and	O
genetic	O
polymorphism	O
data	O
of	O
56	O
Chinese	O
nationalities	O
or	O
31	O
administrative	O
divisions	O
in	O
Chinese	O
mainland	O
have	O
repeatedly	O
been	O
the	O
genetic	O
research	O
hotspots	O
.	O
While	O
most	O
genetic	O
studies	O
focused	O
on	O
some	O
particular	O
Chinese	O
populations	O
based	O
on	O
autosomal	O
or	O
Y	O
-	O
chromosomal	O
genetic	O
markers	O
,	O
the	O
forensic	O
characteristics	O
and	O
phylogenetic	O
analyses	O
of	O
the	O
seventh	O
largest	O
Chinese	O
population	O
(	O
Yi	O
ethnicity	O
)	O
on	O
the	O
X	O
-	O
chromosomal	O
genetic	O
markers	O
are	O
scarce	O
.	O
Here	O
,	O
allele	O
frequencies	O
and	O
forensic	B-T033
statistical	I-T033
parameters	I-T033
for	O
19	O
X	O
-	O
chromosomal	O
short	O
tandem	O
repeat	O
loci	O
(	O
DXS7424	O
-	O
DXS101	O
,	O
DXS6789	O
-	O
DXS6809	O
,	O
DXS7423	O
-	O
DXS10134	O
,	O
DXS10103	O
-	O
HPRTB	O
-	O
DXS10101	O
,	O
DXS10159	O
-	O
DXS10162	O
-	O
DXS10164	O
,	O
DXS10148	O
-	O
DXS10135	O
-	O
DXS8378	O
,	O
and	O
DXS7132	O
-	O
DXS10079	O
-	O
DXS10074	O
-	O
DXS10075	O
)	O
of	O
331	O
Chinese	O
Yi	O
individuals	O
were	O
obtained	O
.	O
All	O
19	O
X	O
-	O
chromosomal	O
short	O
tandem	O
repeat	O
(	O
STR	O
)	O
loci	O
in	O
females	O
were	O
consistent	O
with	O
the	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
test	O
.	O
A	O
total	O
of	O
214	O
alleles	O
were	O
identified	O
with	O
the	O
corresponding	O
allele	O
frequencies	O
spanned	O
from	O
0.0019	O
to	O
0.6106	O
.	O
The	O
combined	O
PE	O
,	O
PDF	O
,	O
and	O
PDM	O
were	O
0.9999999214	O
,	O
0.9999999999999999999993	O
,	O
and	O
0.9999999999998	O
,	O
respectively	O
.	O
The	O
high	O
combined	O
MECKrüger	O
,	O
MECKishida	O
,	O
MECDesmarais	O
,	O
and	O
MECDesmarais	O
Duo	O
were	O
achieved	O
as	O
0.9999999617638	O
,	O
0.9999999999971	O
,	O
0.9999999999971	O
,	O
and	O
0.9999999931538	O
,	O
respectively	O
.	O
The	O
findings	B-T033
suggested	O
that	O
the	O
panel	O
of	O
19	O
X	O
-	O
STR	O
loci	O
is	O
highly	O
polymorphic	O
and	O
informative	O
in	O
the	O
Yi	O
ethnic	O
population	O
and	O
can	O
be	O
considered	O
to	O
be	O
a	O
powerful	O
tool	O
in	O
forensic	O
complex	O
kinship	O
identification	O
.	O
Population	O
differentiation	O
analyses	O
among	O
12	O
populations	O
indicated	O
that	O
significant	O
differences	O
in	O
genetic	O
structure	O
were	O
observed	O
in	O
between	O
the	O
Yi	O
ethnicity	O
and	O
the	O
Chinese	O
Uyghur	O
as	O
well	O
as	O
Kazakh	O
,	O
and	O
genetic	O
homogeneity	O
existed	O
in	O
similar	O
ethno	O
-	O
origin	O
or	O
geographic	O
origin	O
populations	O
.	O
      
Association	O
of	O
CKIP-1	O
P21A	O
polymorphism	O
with	O
risk	O
of	O
chronic	B-T047
heart	I-T047
failure	I-T047
in	O
a	O
Chinese	O
population	O
Pathological	O
cardiac	O
hypertrophy	O
is	O
an	O
independent	O
risk	B-T033
factor	I-T033
for	O
chronic	B-T047
heart	I-T047
failure	I-T047
.	O
Casein	O
kinase-2	O
interacting	O
protein-1	O
(	O
CKIP-1	O
)	O
can	O
inhibit	O
pathological	O
cardiac	O
hypertrophy	O
.	O
Therefore	O
,	O
we	O
investigated	O
whether	O
CKIP-1	O
nonsynonymous	O
polymorphism	O
rs2306235	O
(	O
Pro21Ala	O
)	O
contributes	O
to	O
risk	O
and	O
prognosis	B-T058
of	O
chronic	B-T047
heart	I-T047
failure	I-T047
in	O
a	O
Chinese	O
population	O
.	O
A	O
total	O
of	O
923	O
adult	O
patients	O
with	O
chronic	B-T047
heart	I-T047
failure	I-T047
and	O
1020	O
age	O
-	O
and	O
gender	O
-matched	O
healthy	O
controls	O
were	O
recruited	O
.	O
CKIP-1	O
rs2306235	O
polymorphism	O
was	O
genotyped	B-T059
using	O
PCR	O
-	O
restriction	B-T059
fragment	I-T059
length	I-T059
polymorphism	I-T059
.	O
Additional	O
follow	B-T058
-	I-T058
up	I-T058
data	O
for	O
140	O
chronic	B-T047
heart	I-T047
failure	I-T047
patients	O
was	O
evaluated	B-T058
.	O
The	O
rs2306235	O
G	O
allele	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
chronic	B-T047
heart	I-T047
failure	I-T047
(	O
OR	O
=	O
1.38	O
,	O
95	O
%	O
CI	O
=	O
1.09	O
-	O
1.75	O
,	O
p	O
=	O
0.007	O
)	O
,	O
especially	O
in	O
patients	O
with	O
hypertension	B-T047
(	O
OR	O
=	O
1.45	O
,	O
95	O
%	O
CI	O
=	O
1.09	O
-	O
1.75	O
,	O
p	O
=	O
0.006	O
)	O
and	O
coronary	B-T047
heart	I-T047
disease	I-T047
(	O
OR	O
=	O
1.41	O
,	O
95	O
%	O
CI	O
=	O
1.09	O
-	O
1.83	O
,	O
p	O
=	O
0.010	O
)	O
after	O
adjustment	O
for	O
multiple	B-T033
cardiovascular	I-T033
risk	B-T033
factors	I-T033
.	O
However	O
,	O
rs2306235	O
polymorphism	O
was	O
not	O
associated	O
with	O
cardiovascular	O
mortality	O
in	O
chronic	B-T047
heart	I-T047
failure	I-T047
(	O
p	O
=	O
0.875	O
)	O
.	O
CKIP-1	O
rs2306235	O
polymorphism	O
may	O
be	O
a	O
risk	B-T033
factor	I-T033
for	O
chronic	B-T047
heart	I-T047
failure	I-T047
in	O
a	O
Chinese	O
Han	O
population	O
.	O
      
Isolation	B-T059
and	O
prebiotic	O
activity	O
of	O
water	O
-	O
soluble	O
polysaccharides	B-T121
fractions	O
from	O
the	O
bamboo	O
shoots	O
(	O
Phyllostachys	O
praecox	O
)	O
The	O
water	O
-	O
soluble	O
polysaccharides	B-T121
from	O
bamboo	O
shoots	O
(	O
Phyllostachys	O
praecox	O
)	O
(	O
WBP	B-T121
)	O
were	O
isolated	O
,	O
and	O
the	O
characterizations	O
as	O
well	O
as	O
prebiotic	O
activities	O
were	O
investigated	O
.	O
The	O
yield	O
of	O
WBP	B-T121
was	O
7.58±0.31	O
%	O
under	O
optimal	O
hot	O
-	O
water	O
extraction	B-T059
conditions	O
.	O
Two	O
fractions	O
,	O
i.e.	O
,	O
WBP-1	B-T121
and	O
WBP-2	B-T121
with	O
molecular	O
weight	O
of	O
83.50kDa	O
and	O
80.08kDa	O
,	O
respectively	O
,	O
were	O
purified	O
by	O
chromatography	B-T059
.	O
Both	O
the	O
polysaccharides	B-T121
fractions	O
were	O
identified	O
as	O
heteropolysaccharides	O
-	O
protein	O
complexes	O
composed	O
of	O
15	O
kinds	O
of	O
common	O
amino	B-T121
acids	I-T121
in	O
protein	O
part	O
and	O
rhamnose	O
,	O
arabinose	O
,	O
xylose	O
,	O
mannose	B-T121
,	O
glucose	B-T121
and	O
galactose	O
in	O
different	O
molar	O
ratios	O
in	O
polysaccharide	B-T121
part	O
.	O
The	O
existence	O
of	O
α-	O
and	O
β	O
-	O
glycosidic	O
linkages	O
between	O
the	O
sugar	O
units	O
was	O
confirmed	O
by	O
FTIR	O
and	O
NMR	B-T060
spectra	I-T060
.	O
Compared	O
with	O
the	O
blank	O
control	O
and	O
the	O
reference	O
of	O
FOS	O
,	O
WBP-1	B-T121
and	O
WBP-2	B-T121
significantly	O
increased	O
the	O
numbers	O
of	O
Bifidobacterium	B-T007
adolescentis	I-T007
and	O
Bifidobacterium	B-T007
bifidum	I-T007
(	O
P<0.05	O
)	O
,	O
which	O
contributed	O
to	O
the	O
production	O
of	O
organic	O
acids	O
,	O
suggesting	O
that	O
the	O
polysaccharides	B-T121
have	O
potential	O
prebiotic	O
properties	O
.	O
      
Impact	O
of	O
Soil	O
Salinity	O
on	O
the	O
Structure	O
of	O
the	O
Bacterial	B-T007
Endophytic	O
Community	O
Identified	O
from	O
the	O
Roots	O
of	O
Caliph	O
Medic	O
(	O
Medicago	O
truncatula	O
)	O
In	O
addition	O
to	O
being	O
a	O
forage	O
crop	O
,	O
Caliph	O
medic	O
(	O
Medicago	O
truncatula	O
)	O
is	O
also	O
a	O
model	O
legume	O
plant	O
and	O
is	O
used	O
for	O
research	O
focusing	O
on	O
the	O
molecular	O
characterization	O
of	O
the	O
interaction	O
between	O
rhizobia	B-T007
and	O
plants	O
.	O
However	O
,	O
the	O
endophytic	B-T001
microbiome	I-T001
in	O
this	O
plant	O
is	O
poorly	O
defined	O
.	O
Endophytic	O
bacteria	B-T007
play	O
a	O
role	O
in	O
supplying	O
plants	O
with	O
the	O
basic	O
requirements	O
necessary	O
for	O
growth	O
and	O
development	O
.	O
Moreover	O
,	O
these	O
bacteria	B-T007
also	O
play	O
a	O
role	O
in	O
the	O
mechanism	O
of	O
salinity	O
stress	O
adaptation	O
in	O
plants	O
.	O
As	O
a	O
prelude	O
to	O
the	O
isolation	B-T059
and	O
utilization	O
of	O
these	O
bacteria	B-T007
in	O
Caliph	O
medic	O
farming	O
,	O
41	O
bacterial	B-T007
OTUs	O
were	O
identified	O
in	O
this	O
project	O
from	O
within	O
the	O
interior	O
of	O
the	O
roots	O
of	O
this	O
plant	O
by	O
pyrosequencing	B-T059
of	O
the	O
small	O
ribosomal	O
subunit	O
gene	O
(	O
16S	O
rDNA	O
)	O
using	O
a	O
cultivation	B-T059
-	I-T059
independent	I-T059
approach	I-T059
.	O
In	O
addition	O
,	O
the	O
differential	O
abundance	O
of	O
these	O
bacteria	B-T007
was	O
studied	O
following	O
exposure	O
of	O
the	O
plants	O
to	O
salinity	O
stress	O
.	O
About	O
29,064	O
high	O
-	O
quality	O
reads	O
were	O
obtained	O
from	O
the	O
sequencing	B-T059
of	O
six	O
libraries	O
prepared	O
from	O
control	O
and	O
salinity	O
-	O
treated	O
tissues	O
.	O
Statistical	O
analysis	O
revealed	O
that	O
the	O
abundance	O
of	O
~70	O
%	O
of	O
the	O
OTUs	O
was	O
significantly	O
(	O
p	O
≤	O
0.05	O
)	O
altered	O
in	O
roots	O
that	O
were	O
exposed	O
to	O
salinity	O
stress	O
.	O
Sequence	B-T059
analysis	I-T059
showed	O
a	O
similarity	O
between	O
some	O
of	O
the	O
identified	O
species	O
and	O
other	O
,	O
known	O
,	O
growth	B-T007
-	I-T007
promoting	I-T007
bacteria	I-T007
,	O
marine	B-T001
and	O
salt	B-T007
-	I-T007
stressed	I-T007
soil	I-T007
-	I-T007
borne	I-T007
bacteria	I-T007
,	O
and	O
nitrogen	B-T007
-	I-T007
fixing	I-T007
bacterial	I-T007
isolates	O
.	O
Determination	O
of	O
the	O
amendments	O
to	O
the	O
bacteria	B-T007
l	O
community	O
due	O
to	O
salinity	O
stress	O
in	O
Caliph	O
medic	O
provides	O
a	O
crucial	O
step	O
toward	O
developing	O
an	O
understanding	O
of	O
the	O
association	O
of	O
these	O
endophytes	O
,	O
under	O
salt	O
stress	O
conditions	O
,	O
in	O
this	O
model	O
plant	O
.	O
To	O
provide	O
direct	O
evidence	O
regarding	O
their	O
growth	O
promoting	O
activity	O
,	O
a	O
group	O
of	O
endophytic	O
bacteria	B-T007
were	O
isolated	O
from	O
inside	O
of	O
plant	O
roots	O
using	O
a	O
cultivation	B-T059
-	I-T059
dependent	I-T059
approach	I-T059
.	O
Several	O
of	O
these	O
isolates	O
were	O
able	O
to	O
produce	O
ACC	O
-	O
deaminase	O
,	O
ammonia	B-T121
and	O
IAA	O
;	O
and	O
to	O
solubilize	O
Zn+2	B-T121
and	O
PO4	B-T121
-	I-T121
3	I-T121
.	O
This	O
data	O
is	O
consistent	O
with	O
the	O
predicted	O
occurrence	O
(	O
based	O
on	O
cultivation	B-T059
-	I-T059
independent	I-T059
techniques	I-T059
)	O
of	O
these	O
bacteria	B-T007
and	O
provides	O
some	O
insight	O
into	O
the	O
importance	O
of	O
the	O
endophytic	O
bacteria	B-T007
in	O
Caliph	O
medic	O
when	O
grown	O
under	O
normal	O
and	O
saline	O
conditions	O
.	O
      
Bilirubin	O
and	O
atherosclerotic	B-T047
diseases	B-T047
Bilirubin	O
is	O
the	O
final	O
product	O
of	O
heme	O
catabolism	O
in	O
the	O
systemic	O
circulation	O
.	O
For	O
decades	O
,	O
increased	O
serum	O
/	O
plasma	O
bilirubin	O
levels	O
were	O
considered	O
an	O
ominous	O
sign	B-T033
of	O
an	O
underlying	O
liver	B-T047
disease	I-T047
.	O
However	O
,	O
data	O
from	O
recent	O
years	O
convincingly	O
suggest	O
that	O
mildly	O
elevated	O
bilirubin	O
concentrations	O
are	O
associated	O
with	O
protection	B-T033
against	O
various	O
oxidative	O
stress	O
-mediated	O
diseases	B-T047
diseases	B-T047
,	O
atherosclerotic	B-T047
conditions	O
being	O
the	O
most	O
clinically	O
relevant	O
.	O
Although	O
scarce	O
data	O
on	O
beneficial	O
effects	O
of	O
bilirubin	O
had	O
been	O
published	O
also	O
in	O
the	O
past	O
,	O
it	O
took	O
until	O
1994	O
when	O
the	O
first	O
clinical	O
study	O
demonstrated	O
an	O
increased	O
risk	O
of	O
coronary	B-T047
heart	I-T047
disease	I-T047
in	O
subjects	O
with	O
low	O
serum	O
bilirubin	O
levels	O
,	O
and	O
bilirubin	O
was	O
found	O
to	O
be	O
a	O
risk	B-T033
factor	I-T033
for	O
atherosclerotic	B-T047
diseases	B-T047
independent	O
of	O
standard	O
risk	B-T033
factors	I-T033
.	O
Consistent	O
with	O
these	O
results	O
,	O
we	O
proved	O
in	O
our	O
own	O
studies	O
,	O
that	O
subjects	O
with	O
mild	O
elevation	O
of	O
serum	O
levels	O
of	O
unconjugated	O
bilirubin	O
(	O
benign	O
hyperbilirubinemia	B-T047
,	O
Gilbert	B-T047
syndrome	I-T047
)	O
have	O
much	O
lower	O
prevalence	O
/	O
incidence	O
of	O
coronary	B-T047
heart	I-T047
as	O
well	O
as	O
peripheral	B-T047
vascular	I-T047
disease	I-T047
.	O
We	O
have	O
also	O
demonstrated	O
that	O
this	O
association	O
is	O
even	O
more	O
general	O
,	O
with	O
serum	O
bilirubin	O
being	O
a	O
biomarker	O
of	O
numerous	O
other	O
diseases	B-T047
diseases	B-T047
,	O
often	O
associated	O
with	O
increased	O
risk	O
of	O
atherosclerosis	B-T047
.	O
In	O
addition	O
,	O
very	O
recent	O
data	O
have	O
demonstrated	O
biological	O
pathways	O
modulated	O
by	O
bilirubin	O
,	O
which	O
are	O
responsible	O
for	O
observed	O
strong	O
clinical	O
associations	O
.	O
      
Visual	O
outcome	O
,	O
endocrine	O
function	O
and	O
tumor	B-T191
control	O
after	O
fractionated	B-T061
stereotactic	I-T061
radiation	I-T061
therapy	I-T061
of	O
craniopharyngiomas	B-T191
in	I-T191
adults	I-T191
:	O
findings	O
in	O
a	O
prospective	O
cohort	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	B-T058
visual	O
outcome	O
,	O
endocrine	O
function	O
and	O
tumor	B-T191
control	O
in	O
a	O
prospective	O
cohort	O
of	O
craniopharyngioma	B-T191
patients	O
,	O
treated	B-T061
with	I-T061
fractionated	B-T061
stereotactic	I-T061
radiation	I-T061
therapy	I-T061
(	O
FSRT	B-T061
)	O
.	O
Sixteen	O
adult	O
patients	O
with	O
craniopharyngiomas	B-T191
were	O
eligible	O
for	O
analysis	O
.	O
They	O
were	O
treated	B-T061
with	I-T061
linear	O
accelerator	O
-	O
based	O
FSRT	B-T061
during	O
1999	O
-	O
2015	O
.	O
In	O
all	O
cases	O
,	O
diagnosis	O
was	O
confirmed	O
by	O
histological	O
analysis	O
.	O
The	O
prescription	B-T058
dose	O
to	O
the	O
tumor	B-T191
was	O
54	O
Gy	O
(	O
median	O
,	O
range	O
48	O
-	O
54	O
)	O
in	O
1.8	O
or	O
2.0	O
Gy	O
per	O
fraction	O
,	O
and	O
the	O
maximum	O
radiation	O
dose	O
to	O
the	O
optic	B-T023
nerves	I-T023
and	O
chiasm	B-T023
was	O
54.2	O
Gy	O
(	O
median	O
,	O
range	O
48.6	O
-	O
60.0	O
)	O
for	O
the	O
cohort	O
.	O
Serial	O
ophthalmological	B-T061
and	O
endocrine	B-T058
evaluations	I-T058
and	O
magnetic	B-T060
resonance	I-T060
imaging	I-T060
(	O
MRI	B-T060
)	O
scans	B-T060
were	O
performed	O
at	O
regular	O
intervals	O
.	O
Median	O
follow	B-T058
-	I-T058
up	I-T058
was	O
3.3	O
years	O
(	O
range	O
1.1	O
-	O
14.1	O
)	O
,	O
3.7	O
years	O
(	O
range	O
0.8	O
-	O
15.2	O
)	O
,	O
and	O
3.6	O
years	O
(	O
range	O
0.7	O
-	O
13.1	O
)	O
for	O
visual	O
outcome	O
,	O
endocrine	O
function	O
,	O
and	O
tumor	B-T191
control	O
,	O
respectively	O
.	O
Visual	O
acuity	O
impairment	O
was	O
present	O
in	O
10	O
patients	O
(	O
62.5	O
%	O
)	O
and	O
visual	B-T033
field	I-T033
defects	I-T033
were	O
present	O
in	O
12	O
patients	O
(	O
75	O
%	O
)	O
before	O
FSRT	B-T061
.	O
One	O
patient	O
developed	O
radiation	B-T047
-	I-T047
induced	I-T047
optic	I-T047
neuropathy	I-T047
at	O
seven	O
years	O
after	O
FSRT	B-T061
.	O
Thirteen	O
of	O
16	O
patients	O
(	O
81.3	O
%	O
)	O
had	O
pituitary	B-T047
deficiency	I-T047
before	O
FSRT	B-T061
,	O
and	O
did	O
not	O
develop	O
further	O
pituitary	B-T047
deficiency	I-T047
after	O
FSRT	B-T061
.	O
Mean	O
tumor	O
volume	O
pre-	O
FSRT	B-T061
was	O
2.72	O
cm(3	O
)	O
(	O
range	O
0.20	O
-	O
9.90	O
)	O
and	O
post-	O
FSRT	B-T061
1.2	O
cm(3	O
)	O
(	O
range	O
0.00	O
-	O
13.10	O
)	O
.	O
Tumor	B-T191
control	O
rate	O
was	O
81.3	O
%	O
at	O
two	O
,	O
five	O
,	O
and	O
10	O
years	O
after	O
FSRT	B-T061
.	O
FSRT	B-T061
was	O
relatively	O
safe	O
in	O
this	O
prospective	O
cohort	O
of	O
craniopharyngiomas	B-T191
,	O
with	O
only	O
one	O
case	O
of	O
radiation	B-T047
-	I-T047
induced	I-T047
optic	I-T047
neuropathy	I-T047
and	O
no	O
case	O
of	O
new	O
endocrinopathy	B-T047
.	O
Tumor	B-T191
control	O
rate	O
was	O
acceptable	O
.	O
      
TLR9	O
Deficiency	O
Leads	O
to	O
Accelerated	O
Renal	B-T047
Disease	I-T047
and	O
Myeloid	O
Lineage	O
Abnormalities	B-T033
in	O
Pristane	B-T121
-Induced	O
Murine	O
Lupus	B-T047
Systemic	B-T047
lupus	I-T047
erythematosus	I-T047
(	O
SLE	B-T047
)	I-T047
is	O
a	O
chronic	O
,	O
life	B-T033
-	I-T033
threatening	I-T033
autoimmune	B-T047
disorder	I-T047
,	O
leading	O
to	O
multiple	O
organ	B-T023
pathologies	O
and	O
kidney	B-T023
destruction	O
.	O
Analyses	O
of	O
numerous	O
murine	O
models	B-T050
of	O
spontaneous	O
SLE	B-T047
have	O
revealed	O
a	O
critical	O
role	O
for	O
endosomal	O
TLRs	O
in	O
the	O
production	O
of	O
autoantibodies	O
and	O
development	O
of	O
other	O
clinical	O
disease	B-T047
manifestations	O
.	O
Nevertheless	O
,	O
the	O
corresponding	O
TLR9	O
-	O
deficient	O
autoimmune	O
-prone	O
strains	B-T001
consistently	O
develop	O
more	O
severe	O
disease	B-T047
pathology	O
.	O
Injection	B-T061
of	O
BALB	O
/	O
c	O
mice	O
with	O
2,6,10,14	B-T121
-	I-T121
tetramethylpentadecane	I-T121
(	O
TMPD	B-T121
)	O
,	O
commonly	O
known	O
as	O
pristane	B-T121
,	O
also	O
results	O
in	O
the	O
development	O
of	O
SLE	B-T047
-	I-T047
like	I-T047
disease	I-T047
.	O
We	O
now	O
show	O
that	O
Tlr9(-/-	O
)	O
BALB	O
/	O
c	O
mice	O
injected	B-T061
i.p	I-T061
.	I-T061
with	O
TMPD	B-T121
develop	O
more	O
severe	O
autoimmunity	O
than	O
do	O
their	O
TLR	O
-sufficient	O
cohorts	O
.	O
Early	O
indications	O
include	O
an	O
increased	O
accumulation	B-T033
of	O
TLR7	O
-	O
expressing	O
Ly6C(hi	O
)	O
inflammatory	O
monocytes	O
at	O
the	O
site	O
of	O
injection	O
,	O
upregulation	O
of	O
IFN	B-T121
-regulated	O
gene	O
expression	O
in	O
the	O
peritoneal	O
cavity	O
,	O
and	O
an	O
increased	O
production	O
of	O
myeloid	O
lineage	O
precursors	O
(	O
common	O
myeloid	O
progenitors	O
and	O
granulocyte	O
myeloid	O
precursors	O
)	O
in	O
the	O
bone	O
marrow	O
.	O
TMPD	B-T121
-	O
injected	B-T061
Tlr9(-/-	O
)	O
BALB	O
/	O
c	O
mice	O
develop	O
higher	O
autoantibody	O
titers	O
against	O
RNA	O
,	O
neutrophil	O
cytoplasmic	O
Ags	O
,	O
and	O
myeloperoxidase	O
than	O
do	O
TMPD	B-T121
-	O
injected	B-T061
wild	O
-	O
type	O
BALB	O
/	O
c	O
mice	O
.	O
The	O
TMP	B-T121
-	O
injected	B-T061
Tlr9(-/-	O
)	O
mice	O
,	O
and	O
not	O
the	O
wild	O
-	O
type	O
mice	O
,	O
also	O
develop	O
a	O
marked	O
increase	O
in	O
glomerular	B-T121
IgG	I-T121
deposition	O
and	O
infiltrating	O
granulocytes	O
,	O
much	O
more	O
severe	O
glomerulonephritis	B-T047
,	O
and	O
a	O
reduced	O
lifespan	O
.	O
Collectively	O
,	O
the	O
data	O
point	O
to	O
a	O
major	O
role	O
for	O
TLR7	O
in	O
the	O
response	O
to	O
self	O
-	O
antigens	O
in	O
this	O
model	B-T050
of	O
experimental	O
autoimmunity	O
.	O
Therefore	O
,	O
the	O
BALB	O
/	O
c	O
pristane	B-T121
model	B-T050
recapitulates	O
other	O
TLR7	O
-driven	O
spontaneous	O
models	B-T050
of	O
SLE	B-T047
and	O
is	O
negatively	B-T033
regulated	O
by	O
TLR9	O
.	O
      
Interobserver	O
and	O
Intraobserver	O
Reliability	O
of	O
Clinical	B-T033
Assessments	I-T033
in	O
Knee	B-T047
Osteoarthritis	I-T047
Clinical	B-T033
examination	I-T033
of	O
the	O
knee	B-T023
is	O
subject	O
to	O
measurement	O
error	O
.	O
The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
determine	O
interobserver	O
and	O
intraobserver	O
reliability	O
of	O
commonly	O
used	O
clinical	O
tests	O
in	O
patients	O
with	O
knee	B-T047
osteoarthritis	I-T047
(	O
OA	B-T047
)	O
.	O
We	O
studied	O
subjects	O
with	O
symptomatic	O
knee	B-T047
OA	I-T047
who	O
were	O
participants	O
in	O
an	O
open	O
-	O
label	O
clinical	O
trial	O
of	O
intraarticular	B-T061
steroid	I-T061
therapy	I-T061
.	O
Following	O
standardization	O
of	O
the	O
clinical	B-T059
test	I-T059
procedures	I-T059
,	O
2	O
clinicians	O
assessed	B-T058
25	O
subjects	O
independently	O
at	O
the	O
same	O
visit	B-T058
,	O
and	O
the	O
same	O
clinician	O
assessed	B-T058
88	O
subjects	O
over	O
an	O
interval	O
period	O
of	O
2	O
-	O
10	O
weeks	O
;	O
in	O
both	O
cases	O
prior	O
to	O
the	O
steroid	B-T061
intervention	B-T061
.	O
Clinical	B-T033
examination	I-T033
included	O
assessment	B-T058
of	O
bony	O
enlargement	O
,	O
crepitus	O
,	O
quadriceps	B-T033
wasting	I-T033
,	O
knee	B-T033
effusion	I-T033
,	O
joint	O
-	O
line	O
and	O
anserine	B-T023
tenderness	B-T184
,	O
and	O
knee	B-T033
range	I-T033
of	I-T033
movement	I-T033
(	O
ROM	B-T033
)	O
.	O
Intraclass	O
correlation	O
coefficients	O
(	O
ICC	O
)	O
,	O
estimated	O
kappa	O
(	O
κ	O
)	O
,	O
weighted	O
kappa	O
(	O
κω	O
)	O
,	O
and	O
Bland	O
-	O
Altman	O
plots	O
were	O
used	O
to	O
determine	O
interobserver	O
and	O
intraobserver	O
levels	O
of	O
agreement	O
.	O
Using	O
Landis	O
and	O
Koch	O
criteria	O
,	O
interobserver	O
κ	O
scores	O
were	O
moderate	O
for	O
patellofemoral	O
joint	O
(	O
κ	O
=	O
0.53	O
)	O
and	O
anserine	B-T023
tenderness	B-T184
(	O
κ	O
=	O
0.48	O
)	O
;	O
good	O
for	O
bony	O
enlargement	O
(	O
κ	O
=	O
0.66	O
)	O
,	O
quadriceps	B-T033
wasting	I-T033
(	O
κ	O
=	O
0.78	O
)	O
,	O
crepitus	O
(	O
κ	O
=	O
0.78	O
)	O
,	O
medial	O
tibiofemoral	O
joint	O
tenderness	B-T184
(	O
κ	O
=	O
0.76	O
)	O
,	O
and	O
effusion	B-T033
assessed	O
by	O
ballottement	B-T184
(	O
κ	O
=	O
0.73	O
)	O
and	O
bulge	B-T060
sign	I-T060
(	O
κω	O
=	O
0.78	O
)	O
;	O
and	O
excellent	O
for	O
lateral	O
tibiofemoral	O
joint	O
tenderness	B-T184
(	O
κ	O
=	O
1.00	O
)	O
,	O
flexion	O
(	O
ICC	O
=	O
0.97	O
)	O
,	O
and	O
extension	O
(	O
ICC	O
=	O
0.87	O
)	O
ROM	B-T033
.	O
Intraobserver	O
κ	O
scores	O
were	O
moderate	O
for	O
lateral	O
tibiofemoral	O
joint	O
tenderness	B-T184
(	O
κ	O
=	O
0.60	O
)	O
;	O
good	O
for	O
crepitus	O
(	O
κ	O
=	O
0.78	O
)	O
,	O
effusion	B-T033
assessed	O
by	O
ballottement	B-T184
test	I-T184
(	O
κ	O
=	O
0.77	O
)	O
,	O
patellofemoral	O
joint	O
(	O
κ	O
=	O
0.66	O
)	O
,	O
medial	O
tibiofemoral	O
joint	O
(	O
κ	O
=	O
0.64	O
)	O
,	O
and	O
anserine	B-T023
tenderness	B-T184
(	O
κ	O
=	O
0.73	O
)	O
;	O
and	O
excellent	O
for	O
effusion	B-T033
assessed	O
by	O
bulge	B-T060
sign	I-T060
(	O
κω	O
=	O
0.83	O
)	O
,	O
bony	O
enlargement	O
(	O
κ	O
=	O
0.98	O
)	O
,	O
quadriceps	B-T033
wasting	I-T033
(	O
κ	O
=	O
0.83	O
)	O
,	O
flexion	O
(	O
ICC	O
=	O
0.99	O
)	O
,	O
and	O
extension	O
(	O
ICC	O
=	O
0.96	O
)	O
ROM	B-T033
.	O
Among	O
individuals	O
with	O
symptomatic	O
knee	B-T047
OA	I-T047
,	O
the	O
reliability	O
of	O
clinical	B-T033
examination	I-T033
of	O
the	O
knee	B-T023
was	O
at	O
least	O
good	O
for	O
the	O
majority	O
of	O
clinical	B-T033
signs	I-T033
of	O
knee	B-T047
OA	I-T047
.	O
      
Effects	O
of	O
a	O
novel	O
phosphodiesterase	B-T121
10A	I-T121
inhibitor	I-T121
in	O
non	O
-	O
human	O
primates	O
:	O
A	O
therapeutic	O
approach	O
for	O
schizophrenia	B-T048
with	O
improved	O
side	O
effect	O
profile	O
Schizophrenia	B-T048
symptoms	B-T184
are	O
associated	O
with	O
alterations	B-T047
in	I-T047
basal	I-T047
ganglia	I-T047
-	I-T047
cortical	I-T047
networks	I-T047
that	O
include	O
the	O
cyclic	O
nucleotides	O
(	O
cAMP	B-T121
/	O
cGMP	O
)	O
signaling	O
pathways	O
.	O
Phosphodiesterase	B-T121
10A	I-T121
(	I-T121
PDE10A	I-T121
)	I-T121
inhibitors	I-T121
have	O
been	O
considered	O
as	O
therapeutic	B-T121
agents	I-T121
for	O
schizophrenia	B-T048
because	O
the	O
regulation	O
of	O
cAMP	O
and	O
cGMP	O
in	O
the	O
striatum	B-T023
by	O
PDE10A	O
plays	O
an	O
important	O
role	O
in	O
the	O
signaling	O
mechanisms	O
of	O
the	O
striatal	O
-	O
cortical	O
network	O
,	O
and	O
thereby	O
in	O
cognitive	O
function	O
.	O
In	O
the	O
present	O
study	O
we	O
assessed	O
in	O
non	O
-	O
human	O
primates	O
(	O
NHPs	O
)	O
the	O
effects	O
of	O
a	O
novel	O
PDE10A	B-T121
inhibitor	I-T121
(	O
FRM-6308	B-T121
)	O
that	O
has	O
demonstrated	O
high	B-T121
potency	I-T121
and	O
selectivity	O
for	O
human	O
recombinant	O
PDE10A	O
in	O
vitro	O
.	O
The	O
behavioral	B-T033
effects	I-T033
of	O
FRM-6308	B-T121
in	O
a	O
dose	O
range	O
were	O
determined	O
in	O
rhesus	O
monkeys	O
using	O
a	O
standardized	B-T033
motor	I-T033
disability	I-T033
scale	I-T033
for	O
primates	O
,	O
motor	B-T061
tasks	I-T061
,	O
and	O
the	O
"	O
drug	O
effects	O
on	O
the	O
nervous	O
system	O
"	O
(	O
DENS	O
)	O
scale	O
.	O
The	O
neuronal	O
metabolic	O
effects	O
of	O
FRM-6308	B-T121
were	O
determined	O
with	O
[	B-T060
(	I-T060
18)F]-fluorodeoxyglucose	I-T060
PET	I-T060
imaging	I-T060
.	O
Results	O
showed	O
that	O
FRM-6308	B-T121
did	O
not	O
have	O
any	O
specific	O
effects	O
on	O
the	O
motor	O
system	O
at	O
s.c	O
.	O
doses	O
up	O
to	O
0.32	O
mg	O
/	O
kg	O
in	O
NHPs	O
,	O
which	O
induced	O
a	O
significant	O
increase	O
in	O
the	O
FDG	O
-	O
SUV	O
in	O
striatum	B-T023
(	O
F	O
16.069	O
,	O
p	O
<	O
0.05	O
)	O
and	O
cortical	O
(	O
F	O
15.181	O
,	O
p	O
<	O
0.05	O
)	O
regions	O
.	O
Higher	O
doses	O
induced	O
sedation	B-T033
and	O
occasional	B-T184
involuntary	I-T184
movements	I-T184
with	O
clear	O
development	O
of	O
tolerance	B-T033
after	I-T033
repeated	I-T033
exposures	I-T033
.	O
These	O
findings	O
suggest	O
that	O
FRM-6308	B-T121
has	O
the	O
adequate	B-T061
pharmacological	I-T061
profile	I-T061
to	O
advance	O
testing	O
in	O
clinical	O
trials	O
and	O
demonstrate	O
antipsychotic	O
efficacy	O
of	O
PDE10A	O
inhibition	O
for	O
the	O
treatment	O
of	O
schizophrenia	B-T048
patients	O
.	O
      
Shear	O
and	O
extensional	O
properties	O
of	O
kefiran	B-T121
Kefiran	B-T121
is	O
a	O
neutral	B-T121
polysaccharide	I-T121
constituted	O
by	O
glucose	B-T121
and	O
galactose	O
produced	O
by	O
Lactobacillus	B-T007
kefiranofaciens	I-T007
.	O
It	O
is	O
included	O
into	O
kefir	O
grains	O
and	O
has	O
several	O
health	O
promoting	O
properties	O
.	O
In	O
the	O
present	O
work	O
,	O
shear	O
and	O
extensional	O
properties	O
of	O
different	O
kefiran	B-T121
aqueous	O
dispersions	O
(	O
0.5	O
,	O
1	O
and	O
2	O
%	O
wt	O
.	O
)	O
were	O
assessed	O
and	O
compared	O
to	O
other	O
neutral	O
gums	O
commonly	O
used	O
in	O
food	O
,	O
cosmetic	O
and	O
pharmaceutics	O
industries	O
(	O
methylcellulose	B-T121
,	O
locust	B-T200
bean	I-T200
gum	I-T200
and	O
guar	B-T121
gum	I-T121
)	O
.	O
Kefiran	B-T121
showed	O
shear	O
flow	O
characteristics	O
similar	O
to	O
that	O
displayed	O
by	O
other	O
representative	O
neutral	O
gums	O
,	O
although	O
it	O
always	O
yielded	O
lower	O
viscosities	O
at	O
a	O
given	O
concentration	O
.	O
For	O
each	O
gum	O
system	O
it	O
was	O
possible	O
to	O
find	O
a	O
correlation	O
between	O
dynamic	O
and	O
steady	O
shear	O
properties	O
by	O
a	O
master	O
curve	O
including	O
both	O
the	O
apparent	O
and	O
complex	O
viscosities	O
.	O
When	O
studying	O
extensional	O
properties	O
of	O
selected	O
gums	O
at	O
2	O
%	O
wt	O
.	O
by	O
means	O
of	O
a	O
capillary	O
break	O
-	O
up	O
rheometer	O
,	O
kefiran	B-T121
solutions	O
did	O
not	O
show	O
important	O
extensional	O
properties	O
,	O
displaying	O
a	O
behaviour	O
close	O
the	O
Newtonian	O
.	O
      
Blood	O
Pressure	O
and	O
All	B-T033
-	I-T033
Cause	I-T033
Mortality	I-T033
by	O
Level	O
of	O
Cognitive	O
Function	O
in	O
the	O
Elderly	O
:	O
Results	B-T033
From	O
a	O
Population	O
-	O
Based	O
Study	O
in	O
Rural	O
Greece	O
This	O
study	O
aimed	O
to	O
investigate	O
whether	O
the	O
effect	O
of	O
blood	O
pressure	O
(	O
BP	O
)	O
on	O
mortality	B-T033
differs	O
by	O
levels	O
of	O
cognitive	O
function	O
.	O
The	O
associations	O
of	O
brachial	O
systolic	O
BP	O
,	O
diastolic	O
BP	O
,	O
mean	B-T033
arterial	I-T033
pressure	I-T033
(	O
MAP	B-T033
)	O
,	O
and	O
pulse	O
pressure	O
with	O
all	B-T033
-	I-T033
cause	I-T033
mortality	I-T033
were	O
prospectively	B-T033
explored	I-T033
(	O
follow	B-T058
-	I-T058
up	I-T058
7.0±2.2	O
years	O
)	O
in	O
660	O
community	O
-	O
dwelling	O
individuals	O
(	O
≥60	B-T033
years	I-T033
)	O
using	O
adjusted	O
Cox	O
models	O
,	O
stratified	O
by	O
cognitive	B-T048
impairment	I-T048
(	O
Mini	B-T060
-	I-T060
Mental	I-T060
State	I-T060
Examination	I-T060
[	O
MMSE	B-T060
]	O
<	O
24	O
)	O
.	O
No	O
association	O
between	O
brachial	O
BP	O
variables	O
and	O
mortality	B-T033
was	O
shown	O
for	O
the	O
total	O
sample	O
in	O
quartiles	O
analysis	O
;	O
however	O
,	O
MAP	B-T033
in	O
the	O
highest	O
quartile	O
,	O
compared	O
with	O
the	O
second	O
,	O
was	O
associated	O
with	O
mortality	B-T033
(	O
hazard	O
ratio	O
,	O
1.85	O
;	O
95	O
%	O
confidence	O
intervals	O
,	O
1.09	O
-	O
3.12	O
)	O
among	O
cognitively	B-T048
impaired	I-T048
individuals	O
.	O
The	O
fractional	O
-	O
polynomials	O
approach	O
for	O
BP	O
confirmed	B-T033
this	O
finding	B-T033
and	O
further	O
showed	O
,	O
solely	O
in	O
the	O
MMSE	B-T060
<	O
24	O
subcohort	O
,	O
U	O
-	O
shaped	O
trends	O
of	O
MAP	B-T033
and	O
systolic	O
BP	O
,	O
with	O
increased	O
mortality	O
risk	O
in	O
extremely	O
low	O
or	O
high	O
values	O
;	O
no	O
such	O
pattern	O
was	O
evident	O
for	O
patients	O
with	O
MMSE	B-T060
≥24	O
.	O
Elderly	O
individuals	O
with	O
cognitive	B-T048
impairment	I-T048
might	O
be	O
more	O
susceptible	O
to	O
the	O
detrimental	O
effects	O
of	O
low	O
and	O
elevated	O
MAP	B-T033
and	O
systolic	O
BP	O
.	O
      
Chronic	B-T061
Enzyme	I-T061
Replacement	I-T061
to	O
the	O
Brain	B-T023
of	O
a	O
Late	B-T047
Infantile	I-T047
Neuronal	I-T047
Ceroid	I-T047
Lipofuscinosis	I-T047
Mouse	O
Has	O
Differential	O
Effects	O
on	O
Phenotypes	O
of	O
Disease	B-T047
Late	B-T047
infantile	I-T047
neuronal	I-T047
ceroid	I-T047
lipofuscinosis	I-T047
(	O
LINCL	B-T047
)	O
is	O
a	O
fatal	O
inherited	O
neurodegenerative	B-T047
disease	I-T047
caused	O
by	O
loss	O
of	O
lysosomal	O
protease	O
tripeptidyl	O
peptidase	O
1	O
(	O
TPP1	O
)	O
.	O
We	O
have	O
investigated	O
the	O
effects	O
of	O
chronic	O
intrathecal	O
(	O
IT	O
)	O
administration	O
using	O
enzyme	B-T061
replacement	I-T061
therapy	I-T061
(	O
ERT	B-T061
)	O
to	O
the	O
brain	B-T023
of	O
an	O
LINCL	B-T047
mouse	B-T050
model	I-T050
,	O
in	O
which	O
locomotor	O
function	O
declines	O
dramatically	O
prior	O
to	O
early	B-T033
death	I-T033
.	O
Median	O
lifespan	O
was	O
significantly	O
extended	O
from	O
126	O
days	O
to	O
>	O
259	O
days	O
when	O
chronic	B-T061
IT	I-T061
treatment	I-T061
was	O
initiated	O
before	O
the	O
onset	O
of	O
disease	B-T047
.	O
While	O
treated	O
animals	O
lived	O
longer	O
and	O
showed	O
little	O
sign	O
of	O
locomotor	B-T033
dysfunction	I-T033
as	O
measured	O
by	O
stride	O
length	O
,	O
some	O
or	O
all	O
(	O
depending	O
on	O
regimen	O
)	O
still	O
died	O
prematurely	O
.	O
One	O
explanation	O
is	O
that	O
cerebrospinal	O
fluid	O
(	O
CSF)-mediated	O
delivery	O
may	O
not	O
deliver	O
TPP1	O
to	O
all	O
brain	O
regions	O
.	O
Morphological	O
studies	O
support	O
this	O
,	O
showing	O
delivery	O
of	O
TPP1	O
to	O
ventral	O
,	O
but	O
not	O
deeper	O
and	O
dorsal	O
regions	O
.	O
When	O
IT	B-T061
treatment	I-T061
is	O
initiated	O
in	O
severely	O
affected	O
LINCL	B-T047
mice	O
,	O
lifespan	O
was	O
extended	O
modestly	O
in	O
most	O
but	O
dramatically	O
extended	O
in	O
approximately	O
one	O
-	O
third	O
of	O
the	O
cohort	O
.	O
Treatment	O
improved	O
locomotor	O
function	O
in	O
these	O
severely	O
compromised	O
animals	O
after	O
it	O
had	O
declined	O
to	O
the	O
point	O
at	O
which	O
animals	O
normally	O
die	O
.	O
This	O
indicates	O
that	O
some	O
pathology	O
in	O
LINCL	B-T047
is	O
reversible	O
and	O
does	O
not	O
simply	O
reflect	O
neuronal	O
death	O
.	O
      
Laparoscopic	B-T060
Approach	I-T060
for	O
Thermoablation	B-T061
Microwave	I-T061
in	O
the	O
Treatment	B-T061
of	O
Hepatocellular	B-T191
Carcinoma	I-T191
:	O
A	O
Single	O
Center	O
Experience	O
The	O
surgical	B-T061
therapy	I-T061
of	O
choice	O
for	O
hepatocellular	B-T191
carcinoma	I-T191
(	O
HCC	B-T191
)	O
is	O
liver	B-T061
transplantation	I-T061
(	O
LT	B-T061
)	O
or	O
hepatic	B-T061
resection	I-T061
,	O
although	O
only	O
a	O
small	O
percentage	O
of	O
patients	O
can	O
undergo	O
these	O
procedures	O
.	O
Microwave	B-T061
thermal	I-T061
ablation	I-T061
(	O
MWTA	B-T061
)	O
can	O
be	O
an	O
effective	O
alternative	O
treatment	B-T061
for	O
HCC	B-T191
that	O
complicates	O
a	O
cirrhotic	B-T047
liver	I-T047
disease	I-T047
,	O
either	O
as	O
a	O
final	O
procedure	O
or	O
for	O
downstaging	B-T060
patients	O
on	O
the	O
waiting	O
list	O
for	O
LT	B-T061
,	O
or	O
in	O
combination	O
with	O
resective	B-T061
surgery	B-T061
to	O
achieve	O
oncological	B-T191
radicality	O
.	O
The	O
purpose	O
of	O
this	O
retrospective	O
study	O
was	O
to	O
evaluate	B-T058
experience	O
with	O
the	O
laparoscopic	B-T060
approach	I-T060
of	O
MWTA	B-T061
at	O
our	O
center	O
.	O
In	O
a	O
cohort	O
of	O
35	O
consecutive	O
patients	O
undergoing	O
MWTA	B-T061
with	O
laparoscopic	B-T060
approach	I-T060
between	O
January	O
,	O
2013	O
and	O
May	O
,	O
2016	O
,	O
we	O
reviewed	O
the	O
demographic	O
data	O
,	O
the	O
Barcelona	O
clinic	O
liver	O
cancer	O
stage	O
,	O
the	O
severity	O
of	O
cirrhotic	B-T047
liver	I-T047
disease	I-T047
,	O
the	O
size	O
of	O
the	O
ablated	B-T061
lesion	B-T033
,	O
the	O
duration	O
of	O
the	O
procedure	O
,	O
and	O
complications	O
occurring	O
within	O
90	O
days	O
of	O
surgery	B-T061
.	O
MWTA	B-T061
was	O
performed	O
by	O
applying	O
one	O
to	O
three	O
hepatic	O
parenchymal	O
insertions	B-T058
(	O
mean	O
1.8	O
)	O
per	O
patient	O
.	O
The	O
mean	O
duration	O
of	O
surgery	B-T061
was	O
163	O
±	O
18	O
minutes	O
.	O
There	O
was	O
no	O
blood	B-T033
loss	I-T033
in	O
any	O
of	O
the	O
procedures	O
.	O
Complete	O
necrosis	O
on	O
CT	B-T060
scan	I-T060
was	O
achieved	O
in	O
26/35	O
patients	O
(	O
75	O
%	O
)	O
.	O
The	O
mean	O
hospital	O
stay	O
was	O
4.6	O
(	O
range	O
2	O
-	O
7	O
)	O
days	O
;	O
major	O
complications	O
were	O
postablation	O
syndrome	B-T047
in	O
2/35	O
(	O
5.7	O
%	O
)	O
,	O
peritoneal	O
fluid	O
in	O
4/35	O
(	O
11.4	O
%	O
)	O
,	O
and	O
transient	O
jaundice	B-T047
in	O
1/35	O
(	O
2.8	O
%	O
)	O
patients	O
.	O
There	O
was	O
no	B-T033
mortality	I-T033
.	O
Laparoscopic	B-T060
MWTA	B-T061
is	O
a	O
safe	O
and	O
effective	O
treatment	B-T061
for	O
unresectable	O
HCC	B-T191
and	O
when	O
a	O
percutaneous	O
procedure	O
is	O
not	O
feasible	O
.	O
      
Lung	B-T033
nodule	I-T033
in	O
French	O
Guiana	O
in	O
a	O
immunocompetent	O
patient	O
We	O
report	O
the	O
case	O
of	O
an	O
immunocompetent	O
French	O
soldier	O
stationed	O
in	O
French	O
Guiana	O
,	O
who	O
developed	O
symptomatic	O
pulmonary	B-T047
histoplasmosis	I-T047
.	O
      
Typical	O
Skin	O
Injuries	O
in	O
Children	O
With	O
Autism	B-T048
Spectrum	I-T048
Disorder	I-T048
Pediatric	O
skin	O
injuries	O
have	O
primarily	O
been	O
described	O
in	O
typically	O
developing	O
children	O
.	O
Our	O
objectives	O
were	O
to	O
describe	O
the	O
prevalence	O
and	O
pattern	O
of	O
skin	O
injuries	O
of	O
children	O
with	O
autism	B-T048
spectrum	I-T048
disorder	I-T048
(	O
ASD	B-T048
)	O
,	O
to	O
describe	O
how	O
this	O
compared	O
with	O
previously	O
demonstrated	O
skin	O
injury	O
locations	B-T033
in	O
typically	O
developing	O
children	O
,	O
and	O
to	O
identify	O
differences	O
in	O
skin	O
injury	O
frequency	O
and	O
locations	B-T033
between	O
autistic	O
children	O
with	O
and	O
without	O
self	O
-	O
injurious	O
behaviors	O
(	O
SIBs	O
)	O
.	O
Children	O
with	O
ASD	B-T048
were	O
recruited	O
between	O
September	O
of	O
2011	O
and	O
September	O
of	O
2014	O
.	O
Demographic	O
information	O
was	O
obtained	O
from	O
the	O
caregiver	O
.	O
All	O
skin	O
injuries	O
and	O
their	O
locations	B-T033
were	O
documented	B-T058
.	O
Of	O
the	O
41	O
children	O
enrolled	O
,	O
half	O
were	O
reported	O
to	O
have	O
SIBs	O
.	O
The	O
most	O
identified	O
skin	O
injury	O
locations	B-T033
were	O
the	O
legs	B-T023
,	O
knees	B-T023
,	O
and	O
back	O
.	O
Children	O
with	O
autism	B-T048
(	O
1	O
)	O
obtain	O
skin	O
injuries	O
frequently	O
and	O
in	O
similar	O
locations	B-T033
as	O
typically	O
developing	O
children	O
and	O
(	O
2	O
)	O
rarely	O
obtain	O
skin	O
injuries	O
to	O
locations	B-T033
that	O
are	O
considered	O
uncommon	O
for	O
accidental	O
injuries	O
despite	O
reports	O
of	O
SIBs	O
.	O
      
Assembly	O
of	O
the	O
outermost	O
spore	O
layer	O
:	O
pieces	O
of	O
the	O
puzzle	O
are	O
coming	O
together	O
Certain	O
endospore	B-T007
-	I-T007
forming	I-T007
soil	I-T007
dwelling	I-T007
bacteria	I-T007
are	O
important	O
human	O
,	O
animal	O
or	O
insect	O
pathogens	B-T001
.	O
These	O
organisms	B-T001
produce	O
spores	B-T001
containing	O
an	O
outer	O
layer	O
,	O
the	O
exosporium	O
.	O
The	O
exosporium	O
is	O
the	O
site	O
of	O
interactions	O
between	O
the	O
spore	B-T001
and	O
the	O
soil	O
environment	O
and	O
between	O
the	O
spore	B-T001
and	O
the	O
infected	B-T033
host	B-T001
during	O
the	O
initial	O
stages	O
of	O
infection	O
.	O
The	O
composition	O
and	O
assembly	O
process	O
of	O
the	O
exosporium	O
are	O
poorly	O
understood	O
.	O
This	O
is	O
partly	O
due	O
to	O
the	O
extreme	O
stability	O
of	O
the	O
exosporium	O
that	O
has	O
proven	O
to	O
be	O
refractive	O
to	O
existing	O
methods	O
to	O
deconstruct	O
the	O
intact	O
structure	O
into	O
its	O
component	O
parts	O
.	O
Although	O
more	O
than	O
20	O
proteins	O
have	O
been	O
identified	O
as	O
exosporium	O
-	O
associated	O
,	O
their	O
abundance	O
,	O
relationship	O
to	O
other	O
proteins	O
and	O
the	O
processes	O
by	O
which	O
they	O
are	O
assembled	O
to	O
create	O
the	O
exosporium	O
are	O
largely	O
unknown	O
.	O
In	O
this	O
issue	O
of	O
Molecular	O
Microbiology	O
,	O
Terry	O
,	O
Jiang	O
,	O
and	O
colleagues	O
in	O
Per	O
Bullough	O
's	O
laboratory	O
show	O
that	O
the	O
ExsY	O
protein	O
is	O
a	O
major	O
structural	O
protein	O
of	O
the	O
exosporium	O
basal	O
layer	O
of	O
B.	B-T007
cereus	I-T007
family	I-T007
spores	B-T001
and	O
that	O
it	O
can	O
self	O
-	O
assemble	O
into	O
complex	O
structures	O
that	O
possess	O
many	O
of	O
the	O
structural	O
features	O
characteristic	O
of	O
the	O
exosporium	O
basal	O
layer	O
.	O
The	O
authors	O
refined	O
a	O
model	O
for	O
exosporium	O
assembly	O
.	O
Their	O
findings	B-T033
may	O
have	O
implications	O
for	O
exosporium	O
formation	O
in	O
other	O
spore	B-T007
forming	I-T007
bacteria	I-T007
,	O
including	O
Clostridium	B-T007
species	I-T007
.	O
      
Pancreatic	B-T191
Cancer	I-T191
:	O
A	O
Survival	O
Analysis	O
Study	O
in	O
Oklahoma	O
Pancreatic	B-T191
cancer	I-T191
is	O
among	O
the	O
most	O
deadly	B-T191
cancers	I-T191
.	O
Risk	B-T033
factors	I-T033
associated	O
with	O
the	O
disease	B-T047
include	O
age	O
,	O
race	O
,	O
sex	O
,	O
smoking	O
status	O
,	O
and	O
diabetes	B-T033
status	I-T033
.	O
We	O
conducted	O
a	O
prospective	O
analysis	O
of	O
risk	B-T033
factors	I-T033
and	O
length	O
of	O
survival	O
among	O
pancreatic	O
cancer	O
patients	O
living	O
in	O
Oklahoma	O
between	O
1997	O
and	O
2012	O
(	O
n=6,291	O
)	O
.	O
Kaplan	O
-	O
Meier	O
survival	O
curves	O
were	O
created	O
followed	O
by	O
the	O
log	O
-	O
rank	O
test	O
to	O
compare	O
difference	O
in	O
the	O
survival	O
time	O
.	O
Cox	O
proportional	O
hazard	O
regression	O
models	O
were	O
used	O
to	O
examine	O
the	O
strength	O
of	O
association	O
through	O
the	O
estimated	O
hazard	O
ratios	O
.	O
The	O
median	O
survival	O
time	O
of	O
the	O
cohort	O
was	O
three	O
months	O
.	O
Significant	O
risk	B-T033
factors	I-T033
for	O
reduced	O
survival	O
times	O
included	O
age	O
,	O
stage	O
at	O
diagnosis	O
,	O
and	O
year	O
of	O
diagnosis	O
.	O
Results	O
are	O
in	O
agreement	O
with	O
previous	O
research	B-T033
findings	I-T033
.	O
There	O
have	O
been	O
small	O
but	O
noteworthy	O
improvements	O
in	O
survival	O
times	O
for	O
pancreatic	O
cancer	O
patients	O
in	O
Oklahoma	O
.	O
Length	O
of	O
survival	O
during	O
the	O
study	O
period	O
was	O
significantly	O
associated	O
with	O
known	O
risk	B-T033
factors	I-T033
such	O
as	O
age	O
and	O
stage	O
of	O
diagnosis	O
.	O
      
Improving	O
protein	O
complex	O
prediction	O
by	O
reconstructing	O
a	O
high	O
-	O
confidence	O
protein	O
-	O
protein	O
interaction	O
network	O
of	O
Escherichia	B-T007
coli	I-T007
from	O
different	O
physical	O
interaction	O
data	O
sources	O
Although	O
different	O
protein	O
-	O
protein	O
physical	O
interaction	O
(	O
PPI	O
)	O
datasets	O
exist	O
for	O
Escherichia	B-T007
coli	I-T007
,	O
no	O
common	O
methodology	O
exists	O
to	O
integrate	O
these	O
datasets	O
and	O
extract	O
reliable	O
modules	O
reflecting	O
the	O
existing	O
biological	O
process	O
and	O
protein	O
complexes	O
.	O
Naïve	O
Bayesian	O
formula	O
is	O
the	O
highly	O
accepted	O
method	O
to	O
integrate	O
different	O
PPI	O
datasets	O
into	O
a	O
single	O
weighted	O
PPI	O
network	O
,	O
but	O
detecting	O
proper	O
weights	O
in	O
such	O
network	O
is	O
still	O
a	O
major	O
problem	O
.	O
In	O
this	O
paper	O
,	O
we	O
proposed	O
a	O
new	O
methodology	O
to	O
integrate	O
various	O
physical	O
PPI	O
datasets	O
into	O
a	O
single	O
weighted	O
PPI	O
network	O
in	O
a	O
way	O
that	O
the	O
detected	B-T033
modules	O
in	O
PPI	O
network	O
exhibit	O
the	O
highest	O
similarity	O
to	O
available	O
functional	O
modules	O
.	O
We	O
used	O
the	O
co	B-T061
-	I-T061
expression	I-T061
modules	O
as	O
functional	O
modules	O
,	O
and	O
we	O
shown	O
that	O
direct	O
functional	O
modules	O
detected	B-T033
from	O
Gene	O
Ontology	O
terms	O
could	O
be	O
used	O
as	O
an	O
alternative	O
dataset	O
.	O
After	O
running	O
this	O
integrating	O
methodology	O
over	O
six	O
different	O
physical	O
PPI	O
datasets	O
,	O
orthologous	O
high	O
-	O
confidence	O
interactions	O
from	O
a	O
related	O
organism	B-T001
and	O
two	O
AP	B-T059
-	I-T059
MS	I-T059
PPI	O
datasets	O
gained	B-T033
high	I-T033
weights	I-T033
in	O
the	O
integrated	O
networks	O
,	O
while	O
the	O
weights	O
for	O
one	O
AP	B-T059
-	I-T059
MS	I-T059
PPI	O
dataset	O
and	O
two	O
other	O
datasets	O
derived	O
from	O
public	O
databases	O
have	O
converged	O
to	O
zero	O
.	O
The	O
majority	O
of	O
detected	B-T033
modules	O
shaped	O
around	O
one	O
or	O
few	O
hub	O
protein(s	O
)	O
.	O
Still	O
,	O
a	O
large	O
number	O
of	O
highly	O
interacting	O
protein	O
modules	O
were	O
detected	B-T033
which	O
are	O
functionally	O
relevant	O
and	O
are	O
likely	O
to	O
construct	O
protein	O
complexes	O
.	O
We	O
provided	O
a	O
new	O
high	O
confidence	O
protein	O
complex	O
prediction	O
method	O
supported	O
by	O
functional	O
studies	O
and	O
literature	O
mining	O
.	O
      
A	O
longitudinal	O
study	O
assessing	O
childcare	O
services	O
'	O
adoption	O
of	O
obesity	B-T047
prevention	B-T058
policies	I-T058
and	I-T058
practices	I-T058
Despite	O
ongoing	O
investments	O
to	O
improve	O
the	O
obesogenic	B-T047
environments	O
of	O
childcare	O
settings	O
,	O
little	O
is	O
known	O
regarding	O
how	O
these	O
services	O
have	O
changed	O
their	O
physical	O
activity	O
and	O
nutrition	O
-	O
promoting	O
practices	O
.	O
This	O
study	O
aims	O
to	O
describe	O
changes	O
in	O
the	O
proportion	O
of	O
Australian	O
childcare	O
services	O
that	O
have	O
adopted	O
best	B-T058
-	I-T058
practice	I-T058
healthy	B-T061
eating	I-T061
and	O
physical	O
activity	O
practices	B-T058
between	O
2006	O
and	O
2013	O
and	O
to	O
assess	O
whether	O
adoption	O
varied	O
by	O
socio	O
-	O
economic	O
status	O
and	O
locality	O
.	O
A	O
randomly	O
selected	O
sample	O
of	O
nominated	O
supervisors	O
(	O
n	O
=	O
358	O
)	O
from	O
childcare	O
services	O
located	O
in	O
New	O
South	O
Wales	O
,	O
Australia	O
,	O
participated	O
in	O
a	O
telephone	O
survey	O
in	O
2006	O
,	O
2009	O
,	O
2010	O
and	O
2013	O
.	O
Supervisors	O
reported	O
on	O
their	O
service	O
's	O
adoption	O
of	O
six	O
practices	B-T058
:	O
(	O
i	O
)	O
having	O
written	O
nutrition	O
and	O
physical	O
activity	O
policies	O
;	O
(	O
ii	O
)	O
staff	O
trained	O
in	O
physical	O
activity	O
and	O
nutrition	O
in	O
the	O
past	O
year	O
;	O
(	O
iii	O
)	O
scheduled	O
time	O
for	O
fundamental	O
movement	O
skills	O
and	O
(	O
iv	O
)	O
outdoor	O
play	O
;	O
(	O
v	O
)	O
weekly	O
or	O
less	O
screen	B-T033
time	I-T033
opportunitie	I-T033
s	O
;	O
and	O
(	O
vi	O
)	O
serving	O
only	O
non	O
-	O
sweetened	O
beverages	O
.	O
A	O
significant	O
increase	O
in	O
the	O
prevalence	O
of	O
services	O
adopting	O
all	O
but	O
one	O
practice	B-T058
,	O
between	O
2006	O
and	O
2013	O
was	O
identified	O
.	O
Ninety	O
one	O
percent	O
of	O
services	O
adopted	O
four	O
or	O
more	O
practices	B-T058
,	O
a	O
significant	O
increase	O
from	O
38	O
%	O
in	O
2006	O
.	O
There	O
were	O
no	O
differences	O
in	O
the	O
proportion	O
of	O
services	O
adopting	O
each	O
practice	B-T058
by	O
locality	O
and	O
socio	O
-	O
economic	O
status	O
.	O
Government	O
investment	O
in	O
obesity	B-T047
prevention	B-T058
programmes	I-T058
can	O
equitably	O
improve	O
childcare	O
service	O
's	O
adoption	O
of	O
healthy	B-T061
eating	I-T061
and	O
physical	O
activity	O
promoting	O
practices	B-T058
on	O
a	O
jurisdiction	O
-wide	O
basis	O
.	O
The	O
establishment	O
of	O
a	O
routine	O
system	O
to	O
monitor	O
adoption	O
of	O
a	O
broader	O
range	O
of	O
practices	B-T058
by	O
childcare	O
services	O
is	O
warranted	O
.	O
      
Moberg	B-T059
Picking	I-T059
-	I-T059
Up	I-T059
Test	I-T059
in	O
patients	O
with	O
hand	B-T047
osteoarthritis	I-T047
Clinical	B-T058
measurement	I-T058
.	O
The	O
Moberg	B-T059
Pick	I-T059
-	I-T059
up	I-T059
Test	I-T059
(	O
MPUT	B-T059
)	O
was	O
previously	O
used	O
to	O
evaluate	O
functional	B-T033
performance	I-T033
in	O
patients	O
with	O
hand	B-T023
inflammatory	B-T047
disease	I-T047
.	O
This	O
is	O
the	O
first	O
study	O
using	O
the	O
MPUT	B-T059
in	O
hand	B-T047
osteoarthritis	I-T047
(	O
OA	B-T047
)	O
.	O
Compare	O
the	O
functional	B-T033
performance	I-T033
(	O
MPUT	B-T059
)	O
in	O
hand	B-T047
OA	I-T047
patients	O
and	O
healthy	O
controls	O
.	O
Fifty	O
hand	B-T047
OA	I-T047
patients	O
and	O
50	O
controls	O
were	O
assessed	O
using	O
the	O
MPUT	B-T059
,	O
AUSCAN	O
and	O
Cochin	O
questionnaires	O
,	O
grip	B-T033
and	O
pinch	B-T060
strength	I-T060
,	O
pain	B-T184
using	O
a	O
visual	B-T060
analog	I-T060
scale	I-T060
and	O
a	O
Likert	O
scale	O
regarding	O
difficulty	O
to	O
perform	O
MPUT	B-T059
.	O
In	O
the	O
MPUT	B-T059
evaluation	B-T058
,	O
the	O
OA	B-T047
group	O
presented	O
a	O
statistically	O
significant	O
difference	O
from	O
the	O
control	O
group	O
.	O
The	O
OA	B-T047
group	O
spent	O
more	O
time	O
executing	O
test	O
.	O
The	O
grip	B-T033
and	O
pinch	B-T060
strength	I-T060
measurements	I-T060
showed	O
higher	O
values	O
for	O
the	O
control	O
group	O
.	O
The	O
OA	B-T047
group	O
reported	O
a	O
greater	O
difficulty	O
than	O
the	O
control	O
group	O
in	O
performing	O
the	O
test	O
.	O
The	O
MPUT	B-T059
is	O
a	O
short	O
and	O
easy	O
to	O
apply	O
test	O
,	O
which	O
can	O
be	O
safely	O
used	O
to	O
assess	O
the	O
functional	B-T033
performance	I-T033
of	O
the	O
hand	B-T047
OA	I-T047
.	O
II	O
.	O
      
Panitumumab	B-T121
-Associated	O
Encephalopathy	B-T047
after	O
Accidental	O
Intra	O
-	O
arterial	O
Application	B-T058
through	O
Dislocated	O
Central	O
Venous	O
Access	O
Device	O
Acute	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
toxicity	O
and	O
immune	O
-related	O
side	O
effects	O
are	O
increasingly	O
recognized	O
with	O
the	O
use	O
of	O
monoclonal	O
antibodies	O
for	O
cancer	B-T061
therapy	I-T061
.	O
Here	O
,	O
we	O
report	O
a	O
patient	O
who	O
developed	O
of	O
acute	B-T033
-	I-T033
onset	I-T033
encephalopathy	I-T033
and	O
coma	B-T047
,	O
which	O
began	O
shortly	O
after	O
administration	O
of	O
panitumumab	B-T121
for	O
the	O
treatment	B-T061
of	O
metastatic	B-T191
colorectal	I-T191
cancer	I-T191
.	O
Echocardiography	B-T060
revealed	O
that	O
the	O
drug	B-T121
had	O
been	O
infused	O
into	O
the	O
left	B-T023
cardiac	I-T023
ventricle	I-T023
via	O
a	O
dislocated	O
central	O
venous	O
line	O
.	O
Diffusion	B-T060
-	I-T060
weighted	I-T060
magnetic	I-T060
resonance	I-T060
imaging	I-T060
disclosed	O
multiple	O
cortical	B-T033
hyperintensities	I-T033
,	O
which	O
were	O
preferentially	O
located	O
in	O
the	O
frontal	B-T023
lobes	I-T023
.	O
While	O
the	O
neurological	B-T047
condition	I-T047
improved	O
within	O
a	O
few	O
days	O
,	O
the	O
patient	O
died	O
4	O
weeks	O
later	O
.	O
It	O
seems	O
likely	O
that	O
the	O
administration	O
of	O
the	O
antibody	O
via	O
the	O
intra	O
-	O
arterial	O
route	O
contributed	O
to	O
the	O
development	O
of	O
this	O
condition	B-T047
.	O
Toxic	O
encephalopathy	O
may	O
be	O
a	O
hitherto	O
unrecognized	O
complication	O
of	O
panitumumab	B-T121
treatment	B-T061
and	O
should	O
be	O
taken	O
into	O
consideration	O
in	O
patients	O
developing	O
CNS	O
symptoms	B-T184
undergoing	O
this	O
therapy	B-T061
.	O
      
Comparative	B-T058
evaluation	I-T058
of	O
iodine-131	B-T121
metaiodobenzylguanidine	I-T121
and	O
18	O
-	O
fluorodeoxyglucose	O
positron	B-T060
emission	I-T060
tomography	I-T060
in	O
assessing	O
neural	B-T047
crest	I-T047
tumors	I-T047
:	O
Will	O
they	O
play	O
a	O
complementary	O
role	O
?	O
18	O
-	O
Fluorodeoxyglucose	O
positron	B-T060
emission	I-T060
tomography	I-T060
(	O
FDG	B-T060
-	I-T060
PET	I-T060
)	O
has	O
established	O
a	O
role	O
in	O
the	O
evaluation	O
of	O
several	O
malignancies	B-T191
.	O
However	O
,	O
its	O
precise	O
clinical	O
role	O
in	O
the	O
neural	B-T047
crest	I-T047
cell	I-T047
tumors	I-T047
continues	O
to	O
evolve	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
iodine-131	B-T121
metaiodobenzylguanidine	I-T121
(	O
(	B-T121
131)I	I-T121
-	I-T121
MIBG	I-T121
)	O
and	O
FDG	B-T060
-	I-T060
PET	I-T060
of	O
head	O
to	O
head	O
in	O
patients	O
with	O
neural	B-T047
crest	I-T047
tumors	I-T047
both	O
qualitatively	O
and	O
semiquantitatively	O
and	O
to	O
determine	O
their	O
clinical	B-T033
utility	I-T033
in	O
disease	B-T033
status	I-T033
evaluation	I-T033
and	O
further	B-T058
management	I-T058
.	O
A	O
total	O
of	O
32	O
patients	O
who	O
had	O
undergone	O
(	B-T121
131)I	I-T121
-	I-T121
MIBG	I-T121
and	O
FDG	B-T060
-	I-T060
PET	I-T060
prospectively	O
were	O
evaluated	O
and	O
clinicopathologically	O
grouped	O
into	O
three	O
categories	O
:	O
neuroblastoma	B-T191
,	O
pheochromocytoma	B-T191
,	O
and	O
medullary	B-T191
carcinoma	I-T191
thyroid	I-T191
.	O
In	O
18	O
patients	O
of	O
neuroblastoma	B-T191
,	O
FDG	B-T060
PET	I-T060
and	O
(	B-T121
131)I	I-T121
-	I-T121
MIBG	I-T121
showed	O
patient	B-T033
-	I-T033
specific	I-T033
sensitivity	I-T033
of	O
84	O
%	O
and	O
72	O
%	O
,	O
respectively	O
.	O
The	O
mean	O
maximum	O
standardized	O
uptake	O
value	O
(	O
SUVmax	O
)	O
of	O
primary	B-T047
lesions	I-T047
in	O
patients	O
with	O
unfavorable	O
histology	O
was	O
found	O
to	O
be	O
relatively	O
higher	O
than	O
those	O
with	O
favorable	O
histology	O
(	O
5.18	O
±	O
2.38	O
vs.	O
3.21	O
±	O
1.69	O
)	O
.	O
The	O
mean	O
SUVmax	O
of	O
two	O
common	O
sites	O
(	O
posterior	B-T023
superior	I-T023
iliac	I-T023
spine	I-T023
[	O
PSIS	B-T023
]	O
and	O
greater	B-T023
trochanter	I-T023
)	O
was	O
higher	O
in	O
patients	O
with	O
involved	O
marrow	B-T023
than	O
those	O
with	O
uninvolved	O
one	O
(	O
2.36	O
and	O
2.75	O
vs.	O
1.26	O
and	O
1.34	O
,	O
respectively	O
)	O
.	O
The	O
ratio	O
of	O
SUVmax	O
of	O
the	O
involved/	O
contralateral	O
normal	O
sites	O
was	O
2.16	O
±	O
1.9	O
.	O
In	O
equivocal	O
bone	O
marrow	O
results	O
,	O
the	O
uptake	O
pattern	O
with	O
SUV	O
estimation	O
can	O
depict	O
metastatic	O
involvement	O
and	O
help	O
in	O
redirecting	O
the	O
biopsy	O
site	O
.	O
Among	O
seven	O
patients	O
of	O
pheochromocytoma	B-T191
,	O
FDG	B-T060
-	I-T060
PET	I-T060
revealed	O
100	O
%	O
patient	B-T033
-	I-T033
specific	I-T033
sensitivity	I-T033
.	O
FDG	B-T060
-	I-T060
PET	I-T060
detected	O
more	O
metastatic	O
foci	O
than	O
(	B-T121
131)I	I-T121
-	I-T121
MIBG	I-T121
(	O
18	O
vs.	O
13	O
sites	O
)	O
.	O
In	O
seven	O
patients	O
of	O
medullary	B-T191
carcinoma	I-T191
thyroid	I-T191
,	O
FDG	B-T060
-	I-T060
PET	I-T060
localized	O
residual	O
,	O
recurrent	B-T047
,	O
or	O
metastatic	B-T191
disease	I-T191
with	O
much	O
higher	O
sensitivity	O
(	O
32	O
metastatic	O
foci	O
with	O
72	O
%	O
patient	B-T033
specific	I-T033
sensitivity	I-T033
)	O
than	O
(	B-T121
131)I	I-T121
-	I-T121
MIBG	I-T121
,	O
trending	O
along	O
the	O
higher	B-T059
serum	I-T059
calcitonin	I-T059
levels	I-T059
.	O
FDG	B-T060
-	I-T060
PET	I-T060
is	O
not	O
only	O
a	O
good	O
complementary	O
modality	O
in	O
the	O
management	O
of	O
neural	B-T047
crest	I-T047
cell	I-T047
tumors	I-T047
but	O
also	O
it	O
can	O
even	O
be	O
superior	O
,	O
especially	O
in	O
cases	O
of	O
(	B-T121
131)I	I-T121
-	I-T121
MIBG	I-T121
nonavid	B-T191
tumors	I-T191
.	O
      
Forest	O
protected	O
areas	O
governance	O
in	O
Zimbabwe	O
:	O
Shift	O
needed	O
away	O
from	O
a	O
long	B-T033
history	I-T033
of	O
local	O
community	O
exclusion	O
In	O
this	O
literature	O
review	O
based	O
paper	O
we	O
explored	O
the	O
concept	O
of	O
exclusion	O
of	O
local	O
communities	O
from	O
accessing	O
resources	O
in	O
forest	O
protected	O
areas	O
(	O
FPAs	O
)	O
in	O
Zimbabwe	O
.	O
We	O
discussed	O
the	O
colonial	O
and	O
post	O
-	O
colonial	O
forms	O
,	O
causes	O
and	O
mechanisms	O
of	O
exclusion	O
and	O
their	O
social	O
,	O
economic	O
and	O
ecological	O
outcomes	O
.	O
We	O
examined	B-T033
the	O
range	O
of	O
powers	O
embodied	O
in	O
and	O
exercised	O
through	O
various	O
mechanisms	O
,	O
processes	O
and	O
social	O
relations	O
and	O
their	O
impact	O
on	O
local	O
communities	O
'	O
access	O
to	O
FPA	O
resources	O
and	O
associated	O
benefits	O
along	O
the	O
historical	O
trajectory	O
of	O
forest	O
governance	O
in	O
Zimbabwe	O
.	O
Results	O
showed	O
that	O
the	O
forms	O
and	O
extent	O
of	O
exclusion	O
changed	O
over	O
time	O
in	O
tandem	O
with	O
the	O
shifting	O
political	O
and	O
economic	O
landscape	O
.	O
During	O
the	O
colonial	O
period	O
,	O
it	O
was	O
total	O
exclusion	O
whereby	O
people	O
were	O
evicted	O
from	O
forest	O
land	O
as	O
well	O
as	O
being	O
denied	O
access	O
to	O
basic	O
resources	O
for	O
their	O
livelihoods	O
.	O
Local	O
communities	O
'	O
access	O
to	O
low	O
value	O
FPA	O
resources	O
improved	B-T033
during	O
the	O
post	O
-	O
colonial	O
period	O
but	O
access	O
to	O
high	O
value	O
resources	O
like	O
commercial	O
timber	O
as	O
well	O
as	O
sharing	O
income	O
benefits	O
derived	O
from	O
FPA	O
commercial	O
activities	O
remained	O
a	O
pipe	O
dream	O
.	O
Regulation	O
,	O
legitimation	O
,	O
force	O
and	O
markets	O
constituted	O
the	O
mixture	O
of	O
the	O
power	O
elements	O
that	O
FPA	O
governing	O
authorities	O
used	O
to	O
exclude	O
local	O
communities	O
.	O
These	O
powers	O
remained	O
intact	O
despite	O
attempts	O
at	O
collaborative	O
governance	O
in	O
the	O
1990s	O
.	O
However	O
,	O
from	O
the	O
year	O
2000	O
,	O
local	O
communities	O
expressed	O
their	O
dissatisfaction	O
with	O
the	O
centralised	O
exclusionary	O
governance	O
system	O
by	O
invading	O
the	O
FPAs	O
rendering	O
them	O
ungovernable	B-T033
.	O
There	O
is	O
therefore	O
a	O
need	O
for	O
policy	O
reform	O
within	O
the	O
FPA	O
sector	O
to	O
improve	B-T033
the	O
current	O
dire	O
situation	O
.	O
      
Bayesian	O
and	O
Phylogenic	O
Approaches	O
for	O
Studying	O
Relationships	O
among	O
Table	O
Olive	O
Cultivars	O
To	O
enhance	O
table	O
olive	O
tree	O
authentication	O
,	O
relationship	O
,	O
and	O
productivity	O
,	O
we	O
consider	O
the	O
analysis	O
of	O
18	O
worldwide	O
table	O
olive	O
cultivars	O
(	O
Olea	O
europaea	O
L.	O
)	O
based	O
on	O
morphological	O
,	O
biological	O
,	O
and	O
physicochemical	O
markers	O
analyzed	O
by	O
bioinformatic	O
and	O
biostatistic	O
tools	O
.	O
Accordingly	O
,	O
we	O
assess	O
the	O
relationships	O
between	O
the	O
studied	O
varieties	O
,	O
on	O
the	O
one	O
hand	O
,	O
and	O
the	O
potential	O
productivity	O
-	O
quantitative	O
parameter	O
links	O
on	O
the	O
other	O
hand	O
.	O
The	O
bioinformatic	O
analysis	O
based	O
on	O
the	O
graphical	O
representation	O
of	O
the	O
matrix	O
of	O
Euclidean	O
distances	O
,	O
the	O
principal	O
components	O
analysis	O
,	O
unweighted	O
pair	O
group	O
method	O
with	O
arithmetic	O
mean	O
,	O
and	O
principal	O
coordinate	O
analysis	O
(	O
PCoA	O
)	O
revealed	O
three	O
major	O
clusters	O
which	O
were	O
not	O
correlated	O
with	O
the	O
geographic	O
origin	B-T033
.	O
The	O
statistical	O
analysis	O
based	O
on	O
Kendall	O
's	O
and	O
Spearman	O
correlation	O
coefficients	O
suggests	O
two	O
highly	O
significant	O
associations	O
with	O
both	O
fruit	O
color	O
and	O
pollinization	O
and	O
the	O
productivity	O
character	O
.	O
These	O
results	O
are	O
confirmed	O
by	O
the	O
multiple	O
linear	O
regression	O
prediction	O
models	O
.	O
In	O
fact	O
,	O
based	O
on	O
the	O
coefficient	O
of	O
determination	O
(	O
R	O
(	O
2	O
)	O
)	O
value	O
,	O
the	O
best	O
model	O
demonstrated	O
the	O
power	O
of	O
the	O
pollinization	O
on	O
the	O
tree	O
productivity	O
(	O
R	O
(	O
2	O
)	O
=	O
0.846	O
)	O
.	O
Moreover	O
,	O
the	O
derived	O
directed	O
acyclic	O
graph	O
showed	O
that	O
only	O
two	O
direct	O
influences	O
are	O
detected	B-T033
:	O
effect	O
of	O
tolerance	O
on	O
fruit	O
and	O
stone	O
symmetry	O
on	O
side	O
and	O
effect	O
of	O
tolerance	O
on	O
stone	O
form	O
and	O
oil	O
content	O
on	O
the	O
other	O
side	O
.	O
This	O
work	O
provides	O
better	O
understanding	O
of	O
the	O
diversity	O
available	O
in	O
worldwide	O
table	O
olive	O
cultivars	O
and	O
supplies	O
an	O
important	O
contribution	O
for	O
olive	O
breeding	O
and	O
authenticity	O
.	O
      
Cerebral	B-T047
toxoplasmosis	I-T047
in	O
patients	O
with	O
acquired	B-T047
immune	I-T047
deficiency	I-T047
syndrome	I-T047
in	O
the	O
neurological	O
emergency	O
department	O
of	O
a	O
tertiary	O
hospital	O
Cerebral	B-T047
toxoplasmosis	I-T047
is	O
the	O
most	O
common	O
cause	O
of	O
space	O
occupying	O
brain	B-T047
lesion	I-T047
in	O
patients	O
with	O
HIV	B-T047
/	I-T047
AIDS	I-T047
in	O
Brazil	O
.	O
In	O
the	O
post	O
-	O
HAART	O
era	O
,	O
it	O
is	O
responsible	O
for	O
high	O
rates	O
of	O
morbidity	O
and	O
mortality	O
worldwide	O
.	O
This	O
study	O
consists	O
of	O
a	O
case	O
series	O
of	O
56	O
patients	O
diagnosed	B-T033
with	O
cerebral	B-T047
toxoplasmosis	I-T047
whose	O
clinical	O
features	O
,	O
brain	B-T060
imaging	I-T060
and	O
cerebrospinal	O
fluid	O
aspects	O
were	O
analyzed	O
.	O
Cerebral	B-T047
toxoplasmosis	I-T047
led	O
to	O
the	O
diagnosis	B-T033
of	O
infection	O
by	O
the	O
human	B-T005
immunodeficiency	I-T005
virus	I-T005
(	O
HIV	B-T005
)	O
in	O
27	O
(	O
48.2	O
%	O
)	O
of	O
the	O
patients	O
,	O
while	O
29	O
(	O
51.2	O
%	O
)	O
others	O
already	O
knew	O
to	O
be	O
HIV	O
seropositive	O
.	O
However	O
,	O
at	O
the	O
time	O
of	O
diagnosis	B-T033
of	O
cerebral	B-T047
toxoplasmosis	I-T047
,	O
only	O
9	O
(	O
16.6	O
%	O
)	O
reported	B-T058
being	O
under	O
antiretroviral	B-T061
therapy	I-T061
and	O
5	O
(	O
8.9	O
%	O
)	O
were	O
receiving	O
primary	O
prophylaxis	B-T061
for	O
toxoplasmosis	B-T047
.	O
Headache	B-T184
,	O
strength	B-T184
deficit	I-T184
and	O
fever	B-T184
were	O
the	O
most	O
frequent	O
signs	B-T184
and	I-T184
symptoms	I-T184
throughout	O
the	O
study	O
.	O
Fifty	O
-	O
three	O
patients	O
showed	O
changes	O
consistent	O
with	O
toxoplasmosis	B-T047
in	O
CT	B-T060
or	O
MRI	B-T060
.	O
Thirty	O
-	O
four	O
(	O
60.7	O
%	O
)	O
CSF	O
samples	O
were	O
positive	B-T033
in	O
the	O
indirect	B-T059
haemagglutination	I-T059
test	I-T059
and	O
for	O
the	O
reaction	O
of	O
Toxoplasma	O
gondii	O
IgG	O
ELISA	B-T059
,	O
while	O
31	O
(	O
55.4	O
%	O
)	O
were	O
positive	B-T033
in	O
the	O
direct	B-T059
haemagglutination	I-T059
test	I-T059
.	O
Fifty	O
(	O
89.3	O
%	O
)	O
patients	O
underwent	O
first	B-T061
-	I-T061
line	I-T061
treatment	I-T061
for	O
toxoplasmosis	B-T047
.	O
Cerebral	B-T047
toxoplasmosis	I-T047
is	O
still	O
a	O
very	O
relevant	O
neurological	B-T047
disease	I-T047
in	O
individuals	O
with	O
AIDS	B-T047
admitted	B-T058
to	O
neurology	O
emergency	O
departments	O
.	O
Early	B-T060
diagnosis	I-T060
and	O
initiation	O
of	O
empiric	B-T033
treatment	I-T033
and	O
antiretroviral	B-T061
therapy	I-T061
are	O
important	O
for	O
good	O
prognosis	B-T058
.	O
      
Data	O
set	O
of	O
interactomes	O
and	O
metabolic	O
pathways	O
of	O
proteins	O
differentially	O
expressed	O
in	O
brains	B-T023
with	O
Alzheimer׳s	B-T047
disease	I-T047
Alzheimer׳s	B-T047
disease	I-T047
is	O
one	O
of	O
the	O
main	O
causes	O
of	O
dementia	B-T048
in	O
the	O
elderly	O
and	O
its	O
frequency	O
is	O
on	O
the	O
rise	O
worldwide	O
.	O
It	O
is	O
considered	O
the	O
result	O
of	O
complex	O
interactions	O
between	O
genetic	O
and	O
environmental	O
factors	O
,	O
being	O
many	O
of	O
them	O
unknown	O
.	O
Therefore	O
,	O
there	O
is	O
a	O
dire	O
necessity	O
for	O
the	O
identification	O
of	O
novel	O
molecular	O
players	O
for	O
the	O
understanding	O
of	O
this	O
disease	B-T047
.	O
In	O
this	O
data	O
article	O
we	O
determined	O
the	O
protein	O
expression	O
profiles	O
of	O
whole	O
protein	O
extracts	O
from	O
cortex	O
regions	O
of	O
brains	O
from	O
patients	O
with	O
Alzheimer׳s	B-T047
disease	I-T047
in	O
comparison	O
to	O
a	O
normal	B-T023
brain	I-T023
.	O
We	O
identified	O
721	O
iTRAQ	O
-	O
labeled	O
polypeptides	O
with	O
more	O
than	O
95	O
%	O
in	O
confidence	O
.	O
We	O
analyzed	O
all	O
proteins	O
that	O
changed	O
in	O
their	O
expression	O
level	O
and	O
located	O
them	O
in	O
the	O
KEGG	O
metabolic	O
pathways	O
,	O
as	O
well	O
as	O
in	O
the	O
mitochondrial	O
complexes	O
of	O
the	O
electron	O
transport	O
chain	O
and	O
ATP	O
synthase	O
.	O
In	O
addition	O
,	O
we	O
analyzed	O
the	O
over-	O
and	O
sub	O
-	O
expressed	O
polypeptides	O
through	O
IPA	O
software	O
,	O
specifically	O
Core	O
I	O
and	O
Biomarkers	O
I	O
modules	O
.	O
Data	O
in	O
this	O
article	O
is	O
related	O
to	O
the	O
research	O
article	O
"	O
Identification	O
of	O
proteins	O
that	O
are	O
differentially	O
expressed	O
in	O
brains	B-T023
with	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
using	O
iTRAQ	B-T059
labeling	I-T059
and	O
tandem	O
mass	O
spectrometry	O
"	O
(	O
Minjarez	O
et	O
al	O
.	O
,	O
2016	O
)	O
[	O
1	O
]	O
.	O
      
Prevalence	O
of	O
HPV	B-T005
genotypes	O
in	O
cervical	B-T191
adenocarcinoma	I-T191
:	O
a	O
study	O
in	O
Greek	O
women	O
To	O
study	O
the	O
prevalence	O
of	O
human	B-T005
papillomavirus	I-T005
(	O
HPV	B-T005
)	O
genotypes	O
among	O
cervical	B-T191
adenocarcinomas	I-T191
in	O
Greek	O
women	O
.	O
The	O
study	O
group	O
comprised	O
78	O
adenocarcinoma	B-T191
cases	O
(	O
20	O
in	B-T191
situ	I-T191
and	O
58	O
invasive	B-T191
)	O
.	O
HPV	O
DNA	O
was	O
amplified	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
HPV	B-T005
genotypes	O
were	O
identified	O
by	O
reverse	O
hybridization	O
.	O
There	O
was	O
a	O
high	O
prevalence	O
of	O
HPV	B-T047
infection	I-T047
both	O
for	O
in	B-T191
situ	I-T191
(	O
95	O
%	O
)	O
or	O
invasive	B-T191
(	I-T191
94.83	I-T191
%	I-T191
)	I-T191
adenocarcinomas	I-T191
,	O
comprising	O
also	O
cancers	B-T191
of	O
unusual	O
morphology	O
.	O
HPV	B-T005
16	I-T005
was	O
the	O
commonest	O
strain	B-T001
(	O
N=57	O
,	O
73.08	O
%	O
)	O
followed	O
by	O
HPV	B-T005
18	I-T005
(	O
N=28	O
,	O
35.90	O
%	O
)	O
.	O
Interestingly	O
,	O
13	O
cases	O
(	O
16.67	O
%	O
)	O
were	O
also	O
HPV	B-T005
52	I-T005
positive	I-T005
(	O
as	O
co	B-T047
-	I-T047
infection	I-T047
with	O
HPV	B-T005
16	I-T005
or	O
18	B-T005
)	O
.	O
All	O
other	O
strains	B-T001
with	O
the	O
exception	O
of	O
HPV	B-T005
66	I-T005
were	O
found	O
only	O
as	O
co	B-T047
-	I-T047
infections	I-T047
.	O
No	O
significant	O
age	O
difference	O
was	O
noted	O
in	O
terms	O
of	O
any	O
HPV	B-T005
strain	B-T001
positivity	B-T033
.	O
HPV	O
DNA	O
was	O
found	O
in	O
the	O
large	O
majority	O
of	O
cervical	B-T191
adenocarcinomas	I-T191
.	O
As	O
opposed	O
to	O
other	O
studies	O
,	O
HPV	B-T005
52	I-T005
was	O
the	O
third	O
most	O
commonly	O
encountered	B-T058
strain	B-T001
after	O
HPV	B-T005
16	I-T005
and	O
HPV	B-T005
18	I-T005
.	O
The	O
above	O
findings	O
would	O
probably	O
be	O
of	O
help	O
in	O
decision	O
making	O
concerning	O
vaccination	B-T061
policy	O
for	O
the	O
prevention	O
of	O
HPV	B-T047
infection	I-T047
in	O
Greece	O
.	O
      
Fluorescence-	B-T059
and	O
magnetic	B-T059
-	I-T059
activated	I-T059
cell	I-T059
sorting	I-T059
strategies	O
to	O
separate	O
spermatozoa	O
involving	O
plural	O
contributors	O
from	O
biological	O
mixtures	O
for	O
human	B-T060
identification	I-T060
No	O
effective	O
method	O
has	O
been	O
developed	O
to	O
distinguish	O
sperm	O
cells	O
originating	O
from	O
different	O
men	O
in	O
multi	O
-	O
suspect	O
sexual	B-T048
assault	I-T048
cases	O
.	O
Here	O
we	O
combined	O
MACS	B-T059
and	O
FACS	B-T059
to	O
isolate	B-T059
single	O
donor	O
sperm	O
cells	O
from	O
forensic	O
mixture	O
samples	O
including	O
female	O
vaginal	B-T023
epithelial	O
cells	O
and	O
sperm	O
cells	O
from	O
multiple	O
contributors	O
.	O
Sperms	O
from	O
vaginal	O
swab	O
were	O
isolated	O
by	O
MACS	B-T059
using	O
FITC	O
-conjugated	O
A	O
kinase	O
anchor	O
protein	O
3	O
(	O
AKAP3	O
)	O
antibody	O
;	O
target	O
individual	O
sperm	O
cells	O
involving	O
two	O
or	O
three	O
donors	O
were	O
separated	O
by	O
FACS	B-T059
using	O
FITC	O
-labeled	O
blood	O
group	O
A	O
/	O
B	O
antigen	O
antibody	O
.	O
This	O
procedure	O
was	O
further	O
tested	O
in	O
two	O
mock	B-T033
multi	O
-	O
suspect	O
sexual	B-T048
assault	I-T048
samples	O
and	O
one	O
practical	O
casework	O
sample	O
.	O
Our	O
results	O
showed	O
that	O
complete	O
single	O
donor	O
STR	O
profiles	O
could	O
be	O
successfully	O
obtained	O
from	O
sperm	O
/	O
epithelial	O
cell	O
and	O
sperm	O
mixtures	O
from	O
two	O
contributors	O
.	O
For	O
unbalanced	O
sperm	O
/	O
epithelial	O
cells	O
and	O
sperm	O
cells	O
mixtures	O
,	O
sensitivity	O
results	O
revealed	O
that	O
target	O
cells	O
could	O
be	O
detected	B-T033
at	O
as	O
low	O
as	O
1:32	O
and	O
1:8	O
mixed	O
ratios	O
,	O
respectively	O
.	O
Although	O
highly	O
relies	O
on	O
cell	B-T059
number	I-T059
and	O
blood	O
types	O
or	O
secretor	O
status	O
of	O
the	O
individuals	O
,	O
this	O
procedure	O
would	O
still	O
be	O
useful	O
tools	O
for	O
forensic	B-T059
DNA	I-T059
analysis	I-T059
of	O
multi	O
-	O
suspect	O
sexual	B-T048
assault	I-T048
cases	O
by	O
the	O
combined	O
use	O
of	O
FACS	B-T059
and	O
MACS	B-T059
based	O
on	O
sperm	O
-specific	O
AKAP3	O
antigen	O
and	O
human	O
blood	O
type	O
antigen	O
.	O
      
Trajectories	O
of	O
Health	O
and	O
Behavioral	B-T058
Health	I-T058
Services	I-T058
Use	O
among	O
Community	O
Corrections	O
-Involved	O
Rural	B-T033
Adults	O
This	O
article	O
seeks	O
to	O
establish	O
time	O
-	O
based	O
trajectories	O
of	O
health	O
and	O
behavioral	B-T058
health	I-T058
services	I-T058
utilization	O
for	O
community	O
corrections	O
-	O
involved	O
(	O
CCI	O
)	O
adults	O
and	O
to	O
examine	O
demographic	O
and	O
clinical	O
correlates	O
associated	O
with	O
these	O
trajectories	O
.	O
To	O
accomplish	O
this	O
aim	O
,	O
the	O
authors	O
applied	O
a	O
latent	O
class	O
growth	O
analysis	O
(	O
LCGA	O
)	O
to	O
services	B-T058
use	O
data	O
from	O
a	O
sample	O
of	O
rural	B-T033
CCI	O
adults	O
who	O
reported	O
their	O
medical	O
,	O
mental	O
health	O
,	O
and	O
substance	O
use	O
treatment	O
utilization	O
behavior	O
every	O
60	O
days	O
for	O
1.5	O
years	O
.	O
LCGA	O
established	O
1.5	O
-	O
year	O
trajectories	O
and	O
demographic	O
correlates	O
of	O
health	B-T058
services	I-T058
among	O
rural	B-T033
CCI	O
adults	O
.	O
For	O
medical	B-T058
services	I-T058
,	O
three	O
classes	O
emerged	O
(	O
stable	O
-	O
low	O
users	O
,	O
13	O
%	O
;	O
stable	O
-	O
intermediate	O
users	O
,	O
40	O
%	O
;	O
and	O
stable	O
-	O
high	O
users	O
,	O
47	O
%	O
)	O
.	O
For	O
mental	O
health	O
and	O
substance	O
use	O
services	B-T058
,	O
three	O
classes	O
emerged	O
(	O
stable	O
-	O
low	O
,	O
69	O
%	O
and	O
61	O
%	O
,	O
respectively	O
;	O
low	O
-	O
baseline	O
-	O
increase	O
,	O
10	O
%	O
and	O
12	O
%	O
,	O
respectively	O
;	O
high	O
-	O
baseline	O
decline	O
,	O
21	O
%	O
and	O
28	O
%	O
,	O
respectively	O
)	O
.	O
Employment	O
,	O
gender	O
,	O
medication	B-T033
usage	I-T033
,	O
and	O
depression	B-T048
severity	O
predicted	O
membership	O
across	O
all	O
services	B-T058
.	O
Results	O
underscore	O
the	O
importance	O
of	O
social	O
workers	O
and	O
other	O
community	B-T058
services	I-T058
providers	O
aligning	O
health	B-T058
services	I-T058
access	O
with	O
the	O
needs	O
of	O
the	O
CCI	O
population	O
,	O
and	O
highlight	O
CCI	O
adults	O
as	O
being	O
at	O
risk	O
of	O
underservice	O
in	O
critical	O
prevention	B-T061
and	O
intervention	B-T061
domains	I-T061
.	O
      
Grasping	O
At	O
The	O
Moon	O
:	O
Enhancing	O
Access	O
To	O
Careers	O
In	O
The	O
Health	O
Professions	O
A	O
former	O
HHS	O
secretary	O
reflects	O
on	O
what	O
's	O
needed	O
to	O
enable	O
more	O
minorities	O
to	O
become	O
doctors	O
and	O
other	O
health	O
professionals	O
.	O
      
Metabolomics	O
,	O
Nutrition	B-T033
,	O
and	O
Potential	O
Biomarkers	O
of	O
Food	O
Quality	O
,	O
Intake	O
,	O
and	O
Health	O
Status	O
Diet	O
,	O
dietary	O
patterns	O
,	O
and	O
other	O
environmental	O
factors	O
such	O
as	O
exposure	O
to	O
toxins	O
are	O
playing	O
an	O
important	O
role	O
in	O
the	O
prevention	O
/	O
development	O
of	O
many	O
diseases	B-T047
,	O
like	O
obesity	B-T047
,	O
type	B-T047
2	I-T047
diabetes	I-T047
,	O
and	O
consequently	O
on	O
the	O
health	O
status	O
of	O
individuals	O
.	O
A	O
major	O
challenge	O
nowadays	O
is	O
to	O
identify	O
novel	O
biomarkers	O
to	O
detect	B-T033
as	O
early	O
as	O
possible	O
metabolic	O
dysfunction	O
and	O
to	O
predict	O
evolution	O
of	O
health	O
status	O
in	O
order	O
to	O
refine	O
nutritional	B-T061
advices	I-T061
to	O
specific	O
population	O
groups	O
.	O
Omics	O
technologies	O
such	O
as	O
genomics	O
,	O
transcriptomics	O
,	O
proteomics	O
,	O
and	O
metabolomics	O
coupled	O
with	O
statistical	O
and	O
bioinformatics	O
tools	O
have	O
already	O
shown	O
great	O
potential	O
in	O
this	O
research	O
field	O
even	O
if	O
so	O
far	O
only	O
few	O
biomarkers	O
have	O
been	O
validated	O
.	O
For	O
the	O
past	O
two	O
decades	O
,	O
important	O
analytical	B-T059
techniques	I-T059
have	O
been	O
developed	O
to	O
detect	B-T033
as	O
many	O
metabolites	O
as	O
possible	O
in	O
human	O
biofluids	O
such	O
as	O
urine	O
,	O
blood	O
,	O
and	O
saliva	O
.	O
In	O
the	O
field	O
of	O
food	O
science	O
and	O
nutrition	O
,	O
many	O
studies	O
have	O
been	O
carried	O
out	O
for	O
food	O
authenticity	O
,	O
quality	O
,	O
and	O
safety	O
,	O
as	O
well	O
as	O
for	O
food	O
processing	O
.	O
Furthermore	O
,	O
metabolomic	O
investigations	O
have	O
been	O
carried	O
out	O
to	O
discover	O
new	O
early	O
biomarkers	O
of	O
metabolic	O
dysfunction	O
and	O
predictive	O
biomarkers	O
of	O
developing	O
pathologies	O
(	O
obesity	B-T047
,	O
metabolic	B-T047
syndrome	I-T047
,	O
type-2	B-T047
diabetes	I-T047
,	O
etc	O
.	O
)	O
.	O
Great	O
emphasis	O
is	O
also	O
placed	O
in	O
the	O
development	O
of	O
methodologies	O
to	O
identify	O
and	O
validate	O
biomarkers	O
of	O
nutrients	O
exposure	O
.	O
      
Transition	O
From	O
Hospital	O
to	O
Home	O
in	O
Preterm	O
Infants	O
and	O
Their	O
Families	O
When	O
the	O
day	O
of	O
discharge	B-T058
from	O
a	O
neonatal	O
intensive	O
care	O
unit	O
(	O
NICU	O
)	O
comes	O
for	O
the	O
parents	O
of	O
newborn	O
infants	O
,	O
they	O
are	O
filled	O
with	O
long	O
-	O
awaited	O
joy	O
and	O
happiness	O
.	O
They	O
go	O
home	O
feeling	O
as	O
parents	O
,	O
away	O
from	O
scheduled	O
routines	O
of	O
the	O
hospital	O
,	O
monitor	B-T033
alarms	I-T033
,	O
clinical	B-T033
rounds	I-T033
,	O
numerous	O
tests	B-T059
,	O
and	O
so	O
on	O
.	O
What	O
do	O
we	O
know	O
about	O
what	O
happens	O
after	O
these	O
little	O
patients	O
and	O
their	O
families	O
leave	O
the	O
NICU	O
?	O
What	O
happens	O
from	O
the	O
point	O
of	O
leaving	O
the	O
hospital	O
until	O
when	O
things	O
get	O
settled	O
and	O
life	O
becomes	O
perceived	O
as	O
normal	O
?	O
This	O
article	O
presents	O
a	O
short	O
summary	O
of	O
research	O
conducted	O
with	O
the	O
vulnerable	O
population	O
of	O
high	B-T033
-	I-T033
risk	I-T033
and	O
preterm	O
infants	O
and	O
their	O
families	O
postdischarge	B-T058
.	O
Available	O
evidence	O
suggests	O
that	O
transition	O
to	O
home	O
after	O
hospital	B-T058
discharge	I-T058
,	O
a	O
phenomenon	O
that	O
many	O
families	O
experience	O
,	O
is	O
challenging	O
and	O
requires	O
attention	B-T058
from	O
clinicians	O
and	O
researchers	O
if	O
we	O
are	O
to	O
provide	O
effective	O
,	O
efficient	O
,	O
and	O
high	B-T058
-	I-T058
quality	I-T058
care	I-T058
.	O
      
Basal	O
and	O
maximal	O
metabolic	O
rates	O
differ	O
in	O
their	O
response	O
to	O
rapid	O
temperature	O
change	O
among	O
avian	O
species	O
In	O
birds	O
,	O
acclimation	O
and	O
acclimatization	O
to	O
temperature	O
are	O
associated	O
with	O
changes	O
in	O
basal	O
(	O
BMR	O
)	O
,	O
summit	O
(	O
Msum	O
)	O
and	O
maximal	O
(	O
MMR	O
)	O
metabolic	O
rates	O
but	O
little	O
is	O
known	O
about	O
the	O
rate	O
at	O
which	O
species	O
adjust	O
their	O
phenotype	O
to	O
short	O
-	O
term	O
temperature	O
variations	O
.	O
Our	O
aims	O
were	O
(	O
1	O
)	O
to	O
determine	O
the	O
pattern	O
of	O
metabolic	O
adjustments	O
following	O
a	O
rapid	O
temperature	O
change	O
,	O
(	O
2	O
)	O
to	O
determine	O
whether	O
performance	O
varies	O
at	O
similar	O
rates	O
during	O
exposure	O
to	O
warm	O
or	O
cold	O
environments	O
,	O
and	O
(	O
3	O
)	O
to	O
determine	O
if	O
BMR	O
,	O
Msum	O
and	O
MMR	O
change	O
at	O
comparable	O
rates	O
during	O
thermal	O
acclimation	O
.	O
We	O
measured	O
these	O
parameters	O
in	O
white	O
-	O
throated	O
sparrows	O
(	O
Zonotrichia	O
albicollis	O
)	O
,	O
black	O
-	O
capped	O
chickadees	O
(	O
Poecile	O
atricapillus	O
)	O
,	O
and	O
snow	O
buntings	O
(	O
Plectrophenax	O
nivalis	O
)	O
after	O
acclimation	O
to	O
10	O
°	O
C	O
(	O
day	O
0	O
)	O
and	O
on	O
the	O
4th	O
and	O
8th	O
days	O
of	O
acclimation	O
to	O
either	O
-5	O
or	O
28	O
°	O
C	O
.	O
Birds	O
changed	O
their	O
metabolic	O
phenotype	O
within	O
8	O
days	O
with	O
patterns	O
differing	O
among	O
species	O
.	O
Sparrows	O
expressed	O
the	O
expected	O
metabolic	O
increases	O
in	O
the	O
cold	O
and	O
decreases	O
at	O
thermoneutrality	O
while	O
performance	O
in	O
chickadees	O
and	O
buntings	O
was	O
not	O
influenced	O
by	O
temperature	O
but	O
changed	O
over	O
time	O
with	O
inverse	O
patterns	O
.	O
Our	O
results	B-T033
suggest	O
that	O
BMR	O
varies	O
at	O
comparable	O
rates	O
in	O
warm	O
and	O
cold	O
environments	O
but	O
changes	O
faster	O
than	O
Msum	O
and	O
MMR	O
,	O
likely	O
due	O
to	O
limitations	O
in	O
the	O
rate	O
of	O
change	O
in	O
organ	O
size	O
and	O
function	O
.	O
They	O
also	O
suggest	O
that	O
maximal	O
metabolic	O
capacity	O
is	O
lost	O
faster	O
in	O
a	O
warm	O
environment	O
than	O
it	O
is	O
gained	O
in	O
a	O
cold	O
environment	O
.	O
With	O
the	O
expected	O
increase	O
in	O
temperature	O
stochasticity	O
at	O
northern	O
latitudes	O
,	O
a	O
loss	O
of	O
thermogenic	O
capacity	O
during	O
warm	O
winter	O
days	O
could	O
,	O
therefore	O
,	O
be	O
detrimental	O
if	O
birds	O
are	O
slow	O
to	O
readjust	O
their	O
phenotype	O
with	O
the	O
return	O
of	O
cold	O
days	O
.	O
      
Covalent	B-T121
Modulators	I-T121
of	O
the	O
Vacuolar	O
ATPase	O
The	O
vacuolar	O
H(+	O
)	O
ATPase	O
(	O
V	O
-	O
ATPase	O
)	O
is	O
a	O
complex	O
multisubunit	O
machine	O
that	O
regulates	O
important	O
cellular	O
processes	O
through	O
controlling	O
acidity	O
of	O
intracellular	O
compartments	B-T017
in	O
eukaryotes	O
.	O
Existing	O
small	O
-	O
molecule	O
modulators	B-T121
of	O
V	O
-	O
ATPase	O
either	O
are	O
restricted	O
to	O
targeting	O
one	O
membranous	O
subunit	O
of	O
V	O
-	O
ATPase	O
or	O
have	O
poorly	O
understood	O
mechanisms	O
of	O
action	O
.	O
Small	O
molecules	O
with	O
novel	O
and	O
defined	O
mechanisms	O
of	O
inhibition	O
are	O
thus	O
needed	O
to	O
functionally	O
characterize	O
V	O
-	O
ATPase	O
and	O
to	O
fully	O
evaluate	O
the	O
therapeutic	O
relevance	O
of	O
V	O
-	O
ATPase	O
in	O
human	O
diseases	B-T047
.	O
We	O
have	O
discovered	O
electrophilic	O
quinazolines	O
that	O
covalently	O
modify	O
a	O
soluble	O
catalytic	O
subunit	O
of	O
V	O
-	O
ATPase	O
with	O
high	O
potency	O
and	O
exquisite	O
proteomic	O
selectivity	O
as	O
revealed	O
by	O
fluorescence	B-T060
imaging	I-T060
and	O
chemical	B-T059
proteomic	I-T059
activity	I-T059
-	I-T059
based	I-T059
profiling	I-T059
.	O
The	O
site	O
of	O
covalent	O
modification	O
was	O
mapped	O
to	O
a	O
cysteine	O
residue	O
located	O
in	O
a	O
region	O
of	O
V	O
-	O
ATPase	O
subunit	O
A	O
that	O
is	O
thought	O
to	O
regulate	O
the	O
dissociation	O
of	O
V	O
-	O
ATPase	O
.	O
We	O
further	O
demonstrate	O
that	O
a	O
previously	O
reported	O
V	B-T121
-	I-T121
ATPase	I-T121
inhibitor	I-T121
,	O
3	O
-	O
bromopyruvate	O
,	O
also	O
targets	O
the	O
same	O
cysteine	O
residue	O
and	O
that	O
our	O
electrophilic	O
quinazolines	O
modulate	O
the	O
function	O
of	O
V	O
-	O
ATPase	O
in	O
cells	O
.	O
With	O
their	O
well	O
-	O
defined	O
mechanism	O
of	O
action	O
and	O
high	O
proteomic	O
specificity	O
,	O
the	O
described	O
quinazolines	O
offer	O
a	O
powerful	O
set	O
of	O
chemical	O
probes	O
to	O
investigate	O
the	O
physiological	O
and	O
pathological	O
roles	O
of	O
V	O
-	O
ATPase	O
.	O
      
Effects	O
of	O
regular	O
water	O
-	O
and	O
land	O
-	O
based	O
exercise	O
on	O
physical	B-T033
function	I-T033
after	O
5	O
years	O
:	O
A	O
long	O
-	O
term	O
study	O
on	O
the	O
well	O
-	O
being	O
of	O
older	O
Japanese	O
adults	O
To	O
investigate	O
the	O
effects	O
of	O
5	O
years	O
of	O
physical	O
exercise	O
on	O
functional	O
parameters	O
among	O
older	O
Japanese	O
adults	O
who	O
carried	O
out	O
water	O
-	O
or	O
land	O
-	O
based	O
exercise	O
.	O
We	O
retrospectively	O
investigated	O
data	O
from	O
5707	O
medical	B-T058
examinations	I-T058
and	O
enrolled	B-T058
77	O
older	O
adults	O
into	O
the	O
study	O
.	O
Eligible	O
participants	O
had	O
to	O
be	O
aged	O
≥60	O
years	O
,	O
and	O
engaged	O
in	O
water	O
-	O
based	O
exercise	O
(	O
n	O
=	O
38	O
)	O
or	O
a	O
combination	O
of	O
water	O
-	O
and	O
land	O
-	O
based	O
exercise	O
(	O
n	O
=	O
39	O
)	O
for	O
at	O
least	O
80	O
%	O
of	O
their	O
total	O
exercise	O
time	O
for	O
over	O
5	O
years	O
at	O
our	O
fitness	O
center	O
.	O
In	O
statistical	O
analysis	O
,	O
a	O
two	O
-	O
way	O
repeated	O
-	O
measures	O
analysis	O
of	O
variance	O
was	O
carried	O
out	O
to	O
examine	B-T033
the	O
effects	O
over	O
time	O
and	O
by	O
exercise	B-T033
type	I-T033
,	O
and	O
the	O
changes	O
in	O
each	O
parameter	O
over	O
5	O
years	O
were	O
also	O
compared	O
between	O
the	O
two	O
groups	O
.	O
We	O
found	B-T033
significant	O
main	O
effects	O
and	O
an	O
interaction	O
between	O
time	O
and	O
exercise	B-T033
type	I-T033
for	O
gait	O
speed	O
,	O
with	O
an	O
early	O
decline	O
in	O
the	O
combined	O
exercise	O
group	O
,	O
as	O
well	O
as	O
significant	O
main	O
effects	O
of	O
time	O
,	O
showing	O
a	O
functional	B-T033
decline	I-T033
in	O
grip	O
strength	O
,	O
one	O
-	O
leg	O
standing	O
time	O
and	O
step	B-T033
/	I-T033
height	I-T033
ratio	O
in	O
both	O
exercise	B-T033
types	I-T033
at	O
the	O
5-	O
year	O
follow	B-T058
up	I-T058
.	O
The	O
5-	O
year	O
changes	O
in	O
each	O
parameter	O
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
despite	O
the	O
frequency	B-T033
of	I-T033
exercise	I-T033
,	O
even	O
though	O
we	O
found	B-T033
a	O
negative	B-T033
correlation	O
between	O
changes	O
in	O
one	O
-	O
leg	O
standing	O
time	O
and	O
total	O
amount	O
of	O
water	O
-	O
based	O
exercise	O
.	O
Contrary	O
to	O
expectations	O
,	O
these	O
results	O
suggest	O
that	O
regular	O
engagement	O
in	O
water	O
-	O
based	O
exercise	O
,	O
even	O
combined	O
with	O
land	O
-	O
based	O
exercise	O
,	O
might	O
have	O
poor	O
long	O
-	O
term	O
benefits	O
for	O
maintaining	O
physical	O
performance	O
in	O
older	O
adults	O
.	O
Geriatr	O
Gerontol	O
Int	O
2017	O
;	O
••	O
:	O
••-••.	O
      
Cdc45	O
-	O
induced	O
loading	O
of	O
human	O
RPA	O
onto	O
single	O
-	O
stranded	O
DNA	O
Cell	O
division	O
cycle	O
protein	O
45	O
(	O
Cdc45	O
)	O
is	O
an	O
essential	O
component	O
of	O
the	O
eukaryotic	O
replicative	O
DNA	O
helicase	O
.	O
We	O
found	O
that	O
human	O
Cdc45	O
forms	O
a	O
complex	O
with	O
the	O
single	O
-	O
stranded	O
DNA	O
(	O
ssDNA	O
)	O
binding	O
protein	O
RPA	O
.	O
Moreover	O
,	O
it	O
actively	O
loads	O
RPA	O
onto	O
nascent	O
ssDNA	O
.	O
Pull	B-T059
-	I-T059
down	I-T059
assays	I-T059
and	O
surface	O
plasmon	O
resonance	O
studies	O
revealed	O
that	O
Cdc45	O
-	O
bound	O
RPA	O
complexed	O
with	O
ssDNA	O
in	O
the	O
8	O
-	O
10	O
nucleotide	O
binding	O
mode	O
,	O
but	O
dissociated	O
when	O
RPA	O
covered	O
a	O
30	O
-	O
mer	O
.	O
Real	B-T059
-	I-T059
time	I-T059
analysis	I-T059
of	O
RPA	O
-	O
ssDNA	O
binding	O
demonstrated	O
that	O
Cdc45	O
catalytically	O
loaded	O
RPA	O
onto	O
ssDNA	O
.	O
This	O
placement	O
reaction	O
required	O
physical	O
contacts	O
of	O
Cdc45	O
with	O
the	O
RPA70A	O
subdomain	O
.	O
Our	O
results	O
imply	O
that	O
Cdc45	O
controlled	O
stabilization	B-T061
of	O
the	O
8-	O
nt	O
RPA	O
binding	O
mode	O
,	O
the	O
subsequent	O
RPA	O
transition	O
into	O
30	O
-	O
mer	O
mode	O
and	O
facilitated	O
an	O
ordered	O
binding	O
to	O
ssDNA	O
.	O
We	O
propose	O
that	O
a	O
Cdc45	O
-mediated	O
loading	O
guarantees	O
a	O
seamless	O
deposition	O
of	O
RPA	O
on	O
newly	O
emerging	O
ssDNA	O
at	O
the	O
nascent	O
replication	O
fork	O
.	O
      
Utility	O
of	O
Post	B-T060
-	I-T060
Mortem	I-T060
Genetic	O
Testing	O
in	O
Cases	O
of	O
Sudden	B-T047
Arrhythmic	I-T047
Death	I-T047
Syndrome	I-T047
Sudden	B-T047
arrhythmic	I-T047
death	I-T047
syndrome	I-T047
(	O
SADS	B-T047
)	O
describes	O
a	O
sudden	O
death	O
with	O
negative	O
autopsy	B-T060
and	O
toxicological	O
analysis	O
.	O
Cardiac	B-T047
genetic	I-T047
disease	I-T047
is	O
a	O
likely	O
etiology	O
.	O
This	O
study	O
investigated	O
the	O
clinical	O
utility	O
and	O
combined	O
yield	O
of	O
post	B-T060
-	I-T060
mortem	I-T060
genetic	O
testing	O
(	O
molecular	B-T060
autopsy	I-T060
)	O
in	O
cases	O
of	O
SADS	B-T047
and	O
comprehensive	O
clinical	B-T058
evaluation	I-T058
of	O
surviving	O
relatives	O
.	O
We	O
evaluated	B-T058
302	O
expertly	O
validated	O
SADS	B-T047
cases	O
with	O
suitable	O
DNA	O
(	O
median	O
age	O
:	O
24	O
years	O
;	O
65	O
%	O
males	O
)	O
who	O
underwent	O
next	O
-	O
generation	O
sequencing	B-T059
using	O
an	O
extended	O
panel	O
of	O
77	O
primary	O
electrical	O
disorder	O
and	O
cardiomyopathy	O
genes	O
.	O
Pathogenic	B-T033
and	O
likely	O
pathogenic	O
variants	O
were	O
classified	O
using	O
American	O
College	O
of	O
Medical	O
Genetics	O
(	O
ACMG	O
)	O
consensus	O
guidelines	O
.	O
The	O
yield	O
of	O
combined	O
molecular	B-T060
autopsy	I-T060
and	O
clinical	B-T058
evaluation	I-T058
in	O
82	O
surviving	O
families	O
was	O
evaluated	B-T058
.	O
A	O
gene	O
-	O
level	O
rare	O
variant	O
association	O
analysis	O
was	O
conducted	O
in	O
SADS	B-T047
cases	O
versus	O
controls	O
.	O
A	O
clinically	O
actionable	O
pathogenic	B-T033
or	O
likely	O
pathogenic	O
variant	O
was	O
identified	O
in	O
40	O
of	O
302	O
cases	O
(	O
13	O
%	O
)	O
.	O
The	O
main	O
etiologies	O
established	O
were	O
catecholaminergic	B-T047
polymorphic	I-T047
ventricular	I-T047
tachycardia	I-T047
and	O
long	B-T047
QT	I-T047
syndrome	I-T047
(	O
17	O
[	O
6	O
%	O
]	O
and	O
11	O
[	O
4	O
%	O
]	O
,	O
respectively	O
)	O
.	O
Gene	O
-	O
based	O
rare	O
variants	O
association	O
analysis	O
showed	O
enrichment	O
of	O
rare	O
predicted	O
deleterious	O
variants	O
in	O
RYR2	O
(	O
p	O
=	O
5	O
×	O
10(-5	O
)	O
)	O
.	O
Combining	O
molecular	B-T060
autopsy	I-T060
with	O
clinical	B-T058
evaluation	I-T058
in	O
surviving	O
families	O
increased	O
diagnostic	O
yield	O
from	O
26	O
%	O
to	O
39	O
%	O
.	O
Molecular	B-T060
autopsy	I-T060
for	O
electrical	O
disorder	O
and	O
cardiomyopathy	O
genes	O
,	O
using	O
ACMG	O
guidelines	O
for	O
variant	O
classification	O
,	O
identified	O
a	O
modest	O
but	O
realistic	O
yield	O
in	O
SADS	B-T047
.	O
Our	O
data	O
highlighted	O
the	O
predominant	O
role	O
of	O
catecholaminergic	B-T047
polymorphic	I-T047
ventricular	I-T047
tachycardia	I-T047
and	O
long	B-T047
QT	I-T047
syndrome	I-T047
,	O
especially	O
the	O
RYR2	O
gene	O
,	O
as	O
well	O
as	O
the	O
minimal	O
yield	O
from	O
other	O
genes	O
.	O
Furthermore	O
,	O
we	O
showed	O
the	O
enhanced	O
utility	O
of	O
combined	O
clinical	B-T058
and	O
genetic	B-T058
evaluation	I-T058
.	O
      
Quantitative	O
determination	B-T059
of	O
five	O
metabolites	O
of	O
aspirin	B-T121
by	O
UHPLC	B-T059
-	I-T059
MS	I-T059
/	O
MS	B-T059
coupled	O
with	O
enzymatic	O
reaction	O
and	O
its	O
application	O
to	O
evaluate	O
the	O
effects	O
of	O
aspirin	B-T121
dosage	O
on	O
the	O
metabolic	O
profile	O
Acetylsalicylic	B-T121
acid	I-T121
(	O
Aspirin	B-T121
,	O
ASA	B-T121
)	O
is	O
a	O
famous	O
drug	B-T121
for	O
cardiovascular	B-T047
diseases	I-T047
in	O
recent	O
years	O
.	O
Effects	O
of	O
ASA	B-T121
dosage	O
on	O
the	O
metabolic	O
profile	O
have	O
not	O
been	O
fully	O
understood	O
.	O
The	O
purpose	O
of	O
our	O
study	O
is	O
to	O
establish	O
a	O
rapid	O
and	O
reliable	O
method	B-T059
to	O
quantify	O
ASA	B-T121
metabolites	O
in	O
biological	O
matrices	O
,	O
especially	O
for	O
glucuronide	O
metabolites	O
whose	O
standards	O
are	O
not	O
commercially	O
available	O
.	O
Then	O
we	O
applied	O
this	O
method	B-T059
to	O
evaluate	O
the	O
effects	O
of	O
ASA	B-T121
dosage	O
on	O
the	O
metabolic	O
and	O
excretion	O
profile	O
of	O
ASA	B-T121
metabolites	O
in	O
rat	O
urine	O
.	O
Salicylic	B-T121
acid	I-T121
(	O
SA	B-T121
)	O
,	O
gentisic	B-T121
acid	I-T121
(	O
GA	B-T121
)	O
and	O
salicyluric	O
acid	O
(	O
SUA	O
)	O
were	O
determined	O
directly	O
by	O
UHPLC	B-T059
-	I-T059
MS	I-T059
/	O
MS	B-T059
,	O
while	O
salicyl	O
phenolic	O
glucuronide	O
(	O
SAPG	O
)	O
and	O
salicyluric	O
acid	O
phenolic	O
glucuronide	O
(	O
SUAPG	O
)	O
were	O
quantified	O
indirectly	O
by	O
measuring	O
the	O
released	O
SA	B-T121
and	O
SUA	O
from	O
SAPG	O
and	O
SUAPG	O
after	O
β	O
-	O
glucuronidase	O
digestion	O
.	O
SUA	O
and	O
SUAPG	O
were	O
the	O
major	O
metabolites	O
of	O
ASA	B-T121
in	O
rat	O
urine	O
24	O
h	O
after	O
ASA	B-T121
administration	O
,	O
which	O
accounted	O
for	O
50	O
%	O
(	O
SUA	O
)	O
and	O
26	O
%	O
(	O
SUAPG	O
)	O
.	O
When	O
ASA	B-T121
dosage	O
was	O
increased	O
,	O
the	O
contributions	O
dropped	O
to	O
32	O
%	O
and	O
18	O
%	O
,	O
respectively	O
.	O
The	O
excretion	O
of	O
other	O
three	O
metabolites	O
(	O
GA	B-T121
,	O
SA	B-T121
and	O
SAPG	O
)	O
however	O
showed	O
remarkable	O
increases	O
by	O
16	O
%	O
,	O
6	O
%	O
and	O
4	O
%	O
,	O
respectively	O
.	O
In	O
addition	O
,	O
SUA	O
and	O
SUAPG	O
were	O
mainly	O
excreted	O
in	O
the	O
time	O
period	O
of	O
12	O
-	O
24	O
h	O
,	O
while	O
GA	B-T121
was	O
excreted	O
in	O
the	O
earlier	O
time	O
periods	O
(	O
0	O
-	O
4	O
h	O
and	O
4	O
-	O
8	O
h	O
)	O
.	O
SA	B-T121
was	O
mainly	O
excreted	O
in	O
the	O
time	O
period	O
of	O
0	O
-	O
4	O
h	O
and	O
12	O
-	O
24	O
h.	O
And	O
the	O
excretion	O
of	O
SAPG	O
was	O
equally	O
distributed	O
in	O
the	O
four	O
time	O
periods	O
.	O
We	O
went	O
further	O
to	O
show	O
that	O
the	O
excretion	O
of	O
five	O
metabolites	O
in	O
rat	O
urine	O
was	O
delayed	O
when	O
ASA	B-T121
dosage	O
was	O
increased	O
.	O
In	O
conclusion	O
,	O
we	O
have	O
developed	O
a	O
rapid	O
and	O
sensitive	O
method	B-T059
to	O
determine	O
the	O
five	O
ASA	B-T121
metabolites	O
(	O
SA	B-T121
,	O
GA	B-T121
,	O
SUA	O
,	O
SAPG	O
and	O
SUAPG	O
)	O
in	O
rat	O
urine	O
.	O
We	O
showed	O
that	O
ASA	B-T121
dosage	O
could	O
significantly	O
influence	O
the	O
metabolic	O
and	O
excretion	O
profile	O
of	O
ASA	B-T121
metabolites	O
in	O
rat	O
urine	O
.	O
      
Gold	B-T121
-	O
Nanosponge	O
-Based	O
Multistimuli	O
-	O
Responsive	O
Drug	O
Vehicles	O
for	O
Targeted	O
Chemo	B-T061
-	I-T061
Photothermal	I-T061
Therapy	I-T061
Gold	B-T121
-	O
nanosponge	O
-based	O
multistimuli	O
-	O
responsive	O
drug	O
vehicles	O
are	O
constructed	O
for	O
combined	O
chemo	B-T061
-	I-T061
photothermal	I-T061
therapy	I-T061
with	O
pinpointed	O
drug	B-T121
delivery	O
and	O
release	O
capabilities	O
and	O
minimized	O
nonspecific	O
systemic	O
spread	O
of	O
drugs	B-T121
,	O
remarkably	O
enhancing	O
the	O
therapeutic	O
efficiency	O
while	O
minimizing	O
acute	O
side	O
effects	O
.	O
      
Geolocalization	O
of	O
Influenza	B-T047
Outbreak	O
Within	O
an	O
Acute	B-T058
Care	I-T058
Population	O
:	O
A	O
Layered	O
-	O
Surveillance	O
Approach	O
We	O
seek	O
to	O
use	O
a	O
novel	O
layered	O
-	O
surveillance	O
approach	O
to	O
localize	O
influenza	B-T047
clusters	O
within	O
an	O
acute	B-T058
care	I-T058
population	O
.	O
The	O
first	O
layer	O
of	O
this	O
system	O
is	O
a	O
syndromic	B-T047
surveillance	B-T058
screen	I-T058
to	O
guide	O
rapid	B-T059
polymerase	I-T059
chain	I-T059
reaction	I-T059
testing	I-T059
.	O
The	O
second	O
layer	O
is	O
geolocalization	O
and	O
cluster	O
analysis	O
of	O
these	O
patients	O
.	O
We	O
posit	O
that	O
any	O
identified	O
clusters	O
could	O
represent	O
at	O
-	O
risk	O
populations	O
who	O
could	O
serve	O
as	O
high	O
-	O
yield	O
targets	O
for	O
preventive	B-T061
medical	I-T061
interventions	I-T061
.	O
This	O
was	O
a	O
prospective	O
observational	O
surveillance	O
study	O
.	O
Patients	O
were	O
screened	B-T058
with	O
a	O
previously	O
derived	O
clinical	O
decision	O
guideline	O
that	O
has	O
a	O
90	O
%	O
sensitivity	O
and	O
30	O
%	O
specificity	O
for	O
influenza	B-T047
.	O
Patients	O
received	O
points	O
for	O
the	O
following	O
signs	B-T184
and	I-T184
symptoms	I-T184
within	O
the	O
past	O
7	O
days	O
:	O
cough	B-T184
(	O
2	O
points	O
)	O
,	O
headache	B-T184
(	O
1	O
point	O
)	O
,	O
subjective	O
fever	O
(	O
1	O
point	O
)	O
,	O
and	O
documented	B-T184
fever	I-T184
at	O
triage	B-T061
(	O
temperature	O
>	O
38	O
°	O
C	O
[	O
100.4	O
°	O
F	O
]	O
)	O
(	O
1	O
point	O
)	O
.	O
Patients	O
scoring	O
3	O
points	O
or	O
higher	O
were	O
indicated	B-T033
for	O
influenza	B-T047
testing	O
.	O
Patients	O
were	O
tested	O
with	O
Xpert	B-T059
Flu	I-T059
(	O
Cepheid	O
,	O
Sunnyvale	O
,	O
CA	O
)	O
,	O
a	O
rapid	B-T059
polymerase	I-T059
chain	I-T059
reaction	I-T059
test	I-T059
.	O
Positive	B-T033
results	O
were	O
mapped	O
with	O
ArcGIS	O
(	O
ESRI	O
,	O
Redlands	O
,	O
CA	O
)	O
and	O
analyzed	O
with	O
kernel	O
density	O
estimation	O
to	O
create	O
heat	O
maps	O
.	O
There	O
were	O
1,360	O
patients	O
tested	O
with	O
Xpert	B-T059
Flu	I-T059
with	O
retrievable	O
addresses	O
within	O
the	O
greater	O
Phoenix	O
metro	O
area	O
.	O
One	O
hundred	O
sixty	O
-	O
seven	O
(	O
12	O
%	O
)	O
of	O
them	O
tested	O
positive	O
for	O
influenza	O
A	O
and	O
23	O
(	O
2	O
%	O
)	O
tested	O
positive	O
for	O
influenza	O
B.	O
The	O
influenza	B-T005
A	I-T005
virus	I-T005
exhibited	O
a	O
clear	O
cluster	O
pattern	O
within	O
this	O
patient	O
population	O
.	O
The	O
densest	O
cluster	O
was	O
located	O
in	O
an	O
approximately	O
1-	O
square	O
-	O
mile	O
region	O
southeast	O
of	O
our	O
hospital	O
.	O
Our	O
layered	O
-	O
surveillance	O
approach	O
was	O
effective	O
in	O
localizing	O
a	O
cluster	O
of	O
influenza	B-T047
A	I-T047
outbreak	O
.	O
This	O
region	O
may	O
house	O
a	O
high	O
-	O
yield	O
target	O
population	O
for	O
public	B-T058
health	I-T058
intervention	I-T058
.	O
Further	O
collaborative	O
efforts	O
will	O
be	O
made	O
between	O
our	O
hospital	O
and	O
the	O
Maricopa	O
County	O
Department	O
of	O
Public	O
Health	O
to	O
perform	O
a	O
series	O
of	O
community	O
vaccination	B-T061
events	O
before	O
the	O
next	O
influenza	B-T047
season	O
.	O
We	O
hope	O
these	O
efforts	O
will	O
ultimately	O
serve	O
to	O
reduce	O
the	O
burden	O
of	O
this	O
disease	B-T047
on	O
our	O
patient	O
population	O
,	O
and	O
that	O
this	O
system	O
will	O
serve	O
as	O
a	O
framework	O
for	O
future	O
investigations	B-T058
locating	O
at	O
-	O
risk	O
populations	O
.	O
      
Non	O
-	O
pharmacological	O
treatments	B-T061
for	O
pain	B-T061
relief	I-T061
:	O
TENS	B-T061
and	O
acupuncture	B-T061
Acupuncture	B-T061
and	O
transcutaneous	B-T061
electrical	I-T061
nerve	I-T061
stimulation	I-T061
(	O
TENS	B-T061
)	O
are	O
non	O
-	O
pharmacological	O
methods	O
that	O
have	O
been	O
used	O
for	O
millennia	O
to	O
relieve	B-T061
pain	I-T061
.	O
As	O
with	O
all	O
complementary	B-T061
treatments	I-T061
,	O
efficacy	O
evaluations	B-T058
face	O
two	O
hurdles	O
:	O
the	O
non	O
-	O
feasibility	O
of	O
double	O
-	O
blinding	O
and	O
the	O
difficulty	O
in	O
identifying	O
the	O
optimal	O
control	O
population	O
or	O
treatment	B-T061
.	O
Nevertheless	O
,	O
recent	O
studies	O
of	O
good	O
methodological	O
quality	O
have	O
demonstrated	O
benefits	O
in	O
many	O
types	O
of	O
pain	B-T184
compared	O
to	O
conventional	O
treatment	B-T061
.	O
The	O
mechanisms	O
of	O
action	O
of	O
acupuncture	B-T061
and	O
TENS	B-T061
,	O
which	O
are	O
increasingly	O
well	O
understood	O
,	O
involve	O
endogenous	O
pain	B-T061
control	I-T061
systems	I-T061
,	O
cerebral	O
plasticity	O
,	O
and	O
nonspecific	O
effects	O
(	O
e.g.	O
,	O
expectations	O
and	O
placebo	O
effect	O
)	O
.	O
No	O
serious	O
adverse	O
effects	O
have	O
been	O
reported	O
.	O
These	O
data	O
support	O
the	O
more	O
widespread	O
use	O
of	O
non	O
-	O
pharmacological	O
pain	B-T061
management	I-T061
,	O
most	O
notably	O
in	O
patients	O
with	O
chronic	B-T184
pain	I-T184
inadequately	O
relieved	O
by	O
medications	B-T121
alone	O
.	O
      
Does	O
Video	O
Laryngoscopy	O
Offer	O
Advantages	O
over	O
Direct	B-T060
Laryngoscopy	I-T060
during	O
Cardiopulmonary	B-T061
Resuscitation	I-T061
?	O
Interruption	O
of	O
chest	B-T058
compressions	I-T058
should	O
be	O
minimized	O
because	O
of	O
its	O
negative	B-T033
effects	O
on	O
survival	O
.	O
This	O
randomized	O
,	O
controlled	O
,	O
cross	O
-	O
over	O
study	O
aimed	O
to	O
analyze	O
the	O
effectiveness	O
of	O
Macintosh	O
,	O
Miller	O
,	O
McCoy	O
and	O
McGrath	O
laryngoscopes	O
during	O
with	O
or	O
without	O
chest	B-T058
compressions	I-T058
in	O
the	O
scope	O
of	O
a	O
simulated	O
cardiopulmonary	B-T061
resuscitation	I-T061
scenario	O
.	O
The	O
time	O
required	O
for	O
successful	O
tracheal	B-T061
intubation	I-T061
,	O
number	O
of	O
attempts	O
,	O
dental	O
trauma	O
severity	O
and	O
the	O
need	O
for	O
optimization	O
manoeuvres	O
were	O
recorded	B-T033
during	O
cardiopulmonary	B-T061
resuscitation	I-T061
with	O
and	O
without	O
chest	B-T058
compressions	I-T058
.	O
The	O
experience	O
with	O
computer	O
games	O
during	O
the	O
last	O
10	O
years	O
were	O
asked	O
to	O
the	O
participants	O
and	O
recorded	B-T033
.	O
McCoy	O
laryngoscope	O
yielded	O
the	O
shortest	O
time	O
for	O
successful	O
tracheal	B-T061
intubation	I-T061
both	O
in	O
the	O
presence	B-T033
of	O
and	O
without	O
chest	B-T058
compressions	I-T058
.	O
During	O
the	O
use	O
of	O
McCoy	O
laryngoscopes	O
,	O
fewer	O
tracheal	B-T061
intubation	I-T061
attempts	O
,	O
lower	O
incidence	O
of	O
dental	O
trauma	O
and	O
lower	O
visual	O
analogue	O
scale	O
scores	O
on	O
the	O
ease	O
of	O
intubation	B-T061
were	O
recorded	B-T033
.	O
Participants	O
who	O
are	O
experienced	O
computer	O
game	O
players	O
using	O
Macintosh	O
,	O
McCoy	O
and	O
McGrath	O
achieved	B-T033
successful	O
tracheal	B-T061
intubation	I-T061
in	O
a	O
significantly	O
shorter	O
time	O
during	O
resuscitation	B-T061
without	O
chest	B-T058
compressions	I-T058
.	O
Dental	O
trauma	O
incidence	O
and	O
number	O
of	O
tracheal	B-T061
intubation	I-T061
attempts	O
did	O
not	O
show	O
any	O
significant	O
difference	O
between	O
the	O
four	O
laryngoscopes	O
being	O
related	O
to	O
the	O
rate	O
of	O
playing	O
computer	O
games	O
.	O
McGrath	O
video	O
laryngoscopes	O
do	O
not	O
appear	O
to	O
have	O
advantages	O
over	O
direct	B-T060
laryngoscopes	I-T060
for	O
securing	O
a	O
smooth	O
and	O
successful	O
tracheal	B-T061
intubation	I-T061
during	O
rhythmic	B-T058
chest	I-T058
compressions	I-T058
.	O
We	O
believe	O
that	O
as	O
McCoy	O
laryngoscope	O
provided	O
tracheal	B-T061
intubation	I-T061
in	O
a	O
shorter	O
time	O
and	O
with	O
fewer	O
attempts	O
,	O
this	O
laryngoscope	O
may	O
increase	O
the	O
success	O
rate	O
of	O
resuscitation	B-T061
.	O
      
Economic	O
Burden	O
of	O
Illness	B-T184
Among	O
Patients	O
with	O
Severe	B-T033
Asthma	I-T033
in	O
a	O
Managed	O
Care	O
Setting	O
Despite	O
intensive	O
pharmacotherapy	B-T061
,	O
a	O
considerable	O
number	O
of	O
patients	O
with	O
severe	B-T033
asthma	I-T033
have	O
inadequate	O
disease	B-T047
control	O
.	O
Patients	O
with	O
severe	B-T033
asthma	I-T033
who	O
experience	O
exacerbations	B-T033
consume	O
significant	O
health	O
care	O
resources	O
.	O
To	O
assess	O
health	O
care	O
resource	O
utilization	O
and	O
associated	O
costs	O
among	O
patients	O
with	O
persistent	O
severe	B-T033
asthma	I-T033
who	O
experienced	O
exacerbations	B-T033
compared	O
with	O
patients	O
with	O
persistent	O
but	O
nonsevere	O
asthma	B-T047
.	O
This	O
retrospective	O
analysis	O
of	O
a	O
national	O
administrative	O
claims	O
database	O
identified	O
patients	O
aged	O
≥	O
12	O
years	O
who	O
had	O
at	O
least	O
1	O
medical	O
claim	O
with	O
an	O
asthma	B-T047
diagnosis	B-T033
in	O
2012	O
and	O
had	O
continuous	O
medical	B-T033
and	O
pharmacy	B-T033
coverage	I-T033
under	O
a	O
commercial	O
or	O
Medicare	O
Advantage	O
plan	O
from	O
January	O
1	O
,	O
2012	O
,	O
to	O
December	O
31	O
,	O
2013	O
.	O
Patients	O
were	O
assigned	O
to	O
1	O
of	O
2	O
mutually	O
exclusive	O
cohorts	O
-	O
persistent	B-T047
asthma	I-T047
(	O
PA	B-T047
)	O
or	O
severe	B-T033
asthma	I-T033
SA	B-T033
(	O
SA)-according	O
to	O
an	O
established	O
algorithm	O
based	O
on	O
asthma	B-T047
-related	O
health	O
care	O
resource	O
use	O
and	O
pharmacy	B-T033
claims	I-T033
for	O
controller	B-T121
medication	I-T121
.	O
SA	B-T033
patients	O
were	O
required	O
to	O
meet	O
PA	B-T047
criteria	O
and	O
also	O
have	O
evidence	O
of	O
≥2	O
asthma	B-T033
exacerbations	I-T033
in	O
2012	O
.	O
Asthma	B-T047
-related	O
health	O
care	O
resource	O
utilization	O
and	O
costs	O
were	O
computed	O
from	O
asthma	B-T047
medication	B-T058
use	O
(	O
rescue	O
and	O
controller	O
therapy	O
)	O
and	O
medical	O
claims	O
with	O
an	O
asthma	B-T047
diagnosis	B-T033
in	O
the	O
primary	O
position	O
in	O
2012	O
and	O
2013	O
.	O
Adherence	O
to	O
controller	O
therapy	O
was	O
assessed	O
over	O
365	O
days	O
by	O
using	O
the	O
proportion	O
of	O
days	O
covered	O
(	O
PDC	O
)	O
,	O
starting	O
with	O
the	O
first	O
claim	O
for	O
controller	O
therapy	O
in	O
2012	O
.	O
Differences	O
between	O
the	O
PA	B-T047
and	O
SA	B-T033
cohorts	O
were	O
analyzed	O
by	O
t	O
-	O
test	O
for	O
continuous	O
variables	O
and	O
chi	O
-	O
square	O
test	O
for	O
categorical	O
variables	O
.	O
Asthma	B-T047
-related	O
costs	O
in	O
2013	O
were	O
also	O
analyzed	O
using	O
a	O
generalized	O
linear	O
model	O
with	O
a	O
gamma	O
distribution	O
and	O
log	O
link	O
,	O
adjusted	O
for	O
patient	O
demographics	O
(	O
age	O
,	O
gender	O
,	O
region	O
,	O
and	O
insurance	O
type	O
)	O
and	O
Quan	O
-	O
Charlson	O
comorbidity	O
score	O
.	O
A	O
total	O
of	O
65,359	O
patients	O
were	O
included	O
:	O
63,597	O
(	O
97.3	O
%	O
)	O
PA	B-T047
patients	O
and	O
1,762	O
SA	B-T033
patients	O
(	O
2.7	O
%	O
)	O
.	O
Compared	O
with	O
the	O
PA	B-T047
cohort	O
,	O
the	O
SA	B-T033
cohort	O
was	O
older	O
(	O
mean	O
age	O
=	O
50.8	O
years	O
vs.	O
46.5	O
years	O
,	O
P	O
<	O
0.001	O
)	O
and	O
had	O
higher	O
mean	O
comorbidity	O
score	O
(	O
1.47	O
vs.	O
1.31	O
,	O
P	O
<	O
0.001	O
)	O
.	O
The	O
mean	O
count	O
of	O
all	O
asthma	B-T047
medications	B-T058
fills	O
was	O
2.2	O
-	O
fold	O
(	O
2012	O
)	O
and	O
2.1	O
-	O
fold	O
(	O
2013	O
)	O
higher	O
in	O
the	O
SA	B-T033
cohort	O
,	O
compared	O
with	O
the	O
PA	B-T047
cohort	O
(	O
P	O
<	O
0.001	O
)	O
.	O
Mean	O
PDC	O
for	O
all	O
oral	O
and	O
inhaled	O
controller	B-T061
therapy	I-T061
was	O
also	O
higher	O
in	O
the	O
SA	B-T033
cohort	O
compared	O
with	O
the	O
PA	B-T047
cohort	O
(	O
0.80	O
vs.	O
0.65	O
,	O
P	O
<	O
0.001	O
)	O
.	O
SA	B-T033
patients	O
had	O
a	O
significantly	O
greater	O
mean	O
count	O
of	O
asthma	B-T047
-related	O
hospitalizations	B-T058
,	O
emergency	B-T058
room	I-T058
visits	I-T058
,	O
and	O
ambulatory	B-T033
visits	I-T033
in	O
2012	O
and	O
2013	O
(	O
P	O
<	O
0.001	O
)	O
.	O
Unadjusted	O
mean	O
annual	O
asthma	B-T047
-related	O
costs	O
in	O
the	O
SA	B-T033
versus	O
PA	B-T047
cohorts	O
were	O
$	O
6,496	O
versus	O
$	O
2,739	O
(	O
P	O
<	O
0.001	O
)	O
in	O
2012	O
and	O
$	O
5,174	O
versus	O
$	O
1,775	O
(	O
P	O
<	O
0.001	O
)	O
in	O
2013	O
.	O
Higher	O
asthma	B-T047
-related	O
costs	O
were	O
driven	O
by	O
greater	O
mean	O
annual	O
asthma	B-T047
medication	B-T058
costs	O
in	O
2012	O
(	O
$	O
4,545	O
vs.	O
$	O
1,738	O
,	O
P	O
<	O
0.001	O
)	O
and	O
2013	O
(	O
$	O
4,068	O
vs.	O
$	O
1,348	O
,	O
P	O
<	O
0.001	O
)	O
.	O
Adjusted	O
mean	O
annual	O
asthma	B-T047
-related	O
costs	O
in	O
2013	O
were	O
$	O
3,336	O
greater	O
(	O
cost	O
ratio	O
=	O
2.878	O
,	O
P	O
<	O
0.001	O
)	O
in	O
the	O
SA	B-T033
cohort	O
,	O
and	O
adjusted	O
mean	O
annual	O
asthma	B-T047
medication	B-T058
costs	O
were	O
$	O
2,672	O
higher	O
(	O
cost	O
ratio=2.982	O
,	O
P	O
<	O
0.001	O
)	O
in	O
the	O
SA	B-T033
cohort	O
.	O
Patients	O
with	O
SA	B-T033
who	O
experienced	O
2	O
or	O
more	O
exacerbations	B-T033
had	O
2.1	O
-	O
fold	O
greater	O
use	O
of	O
controller	B-T061
medications	I-T061
across	O
both	O
study	O
years	O
and	O
were	O
more	O
adherent	O
to	O
controller	O
therapy	O
than	O
patients	O
with	O
PA	B-T047
.	O
Despite	O
more	O
intensive	O
pharmacotherapy	B-T061
,	O
SA	B-T033
patients	O
incurred	O
2.9	O
-	O
fold	O
higher	O
adjusted	O
asthma	B-T047
-related	O
costs	O
and	O
3	O
-	O
fold	O
higher	O
adjusted	O
asthma	B-T047
medication	B-T058
costs	O
than	O
PA	B-T047
patients	O
.	O
Patients	O
with	O
SA	B-T033
consistently	O
demonstrated	O
a	O
higher	O
rate	O
of	O
health	B-T058
care	I-T058
utilization	O
.	O
Funding	O
for	O
this	O
study	O
(	O
HO-14	O
-	O
14443	O
)	O
was	O
provided	O
by	O
GlaxoSmithKline	O
(	O
GSK	O
)	O
.	O
All	O
listed	O
authors	O
meet	O
the	O
criteria	O
for	O
authorship	O
set	O
forth	O
by	O
the	O
International	O
Committee	O
for	O
Medical	O
Journal	O
Editors	O
.	O
Albers	O
,	O
Forshag	O
,	O
and	O
Yancey	O
are	O
employees	O
of	O
GSK	O
and	O
hold	O
stock	O
in	O
GSK	O
.	O
Dalal	O
,	O
Nagar	O
,	O
and	O
Ortega	O
were	O
employees	O
of	O
GSK	O
at	O
the	O
time	O
this	O
research	O
was	O
conducted	O
.	O
Chastek	O
and	O
Korrer	O
are	O
employees	O
of	O
Optum	O
,	O
which	O
received	O
consulting	O
fees	O
from	O
GSK	O
for	O
research	O
related	O
to	O
this	O
study	O
.	O
Study	O
concept	O
and	O
design	O
were	O
contributed	O
by	O
Chastek	O
,	O
Nagar	O
,	O
and	O
Dalal	O
.	O
Korrer	O
took	O
the	O
lead	O
in	O
data	O
collection	O
,	O
along	O
with	O
Chastek	O
,	O
and	O
data	O
interpretation	O
was	O
performed	O
by	O
Chastek	O
,	O
Ortega	O
,	O
Forshag	O
,	O
and	O
Dalal	O
.	O
The	O
manuscript	O
was	O
written	O
by	O
Chastek	O
and	O
Dalal	O
and	O
revised	O
by	O
Albers	O
and	O
Yancy	O
,	O
assisted	O
by	O
the	O
other	O
authors	O
.	O
      
Genital	B-T047
and	O
Extragenital	B-T047
Gonorrhea	I-T047
and	O
Chlamydia	B-T047
in	O
Children	O
and	O
Adolescents	O
Evaluated	B-T058
for	O
Sexual	O
Abuse	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
use	O
of	O
a	O
nucleic	B-T059
acid	I-T059
amplification	I-T059
test	I-T059
in	O
detecting	B-T061
genital	B-T007
and	O
extragenital	B-T007
Neisseria	I-T007
gonorrhoeae	I-T007
(	O
NG	B-T007
)	O
and	O
Chlamydia	B-T007
trachomatis	I-T007
(	O
CT	B-T007
)	O
in	O
children	O
and	O
adolescents	O
assessed	B-T058
for	O
sexual	O
abuse	O
/	O
assault	B-T048
.	O
The	O
charts	O
of	O
children	O
aged	O
0	O
to	O
17	O
years	O
,	O
consecutively	O
evaluated	B-T058
for	O
sexual	O
victimization	O
,	O
in	O
emergency	O
department	O
and	O
outpatient	O
settings	O
were	O
reviewed	O
.	O
Data	O
extracted	O
included	O
age	O
,	O
sex	O
,	O
type	O
of	O
sexual	B-T033
contact	I-T033
,	O
anogenital	O
findings	B-T033
,	O
previous	O
sexual	B-T033
contact	I-T033
,	O
toxicology	B-T033
results	I-T033
,	O
and	O
sites	O
tested	B-T059
for	O
NG	B-T007
and	O
CT	B-T007
.	O
Of	O
the	O
1319	O
patients	O
who	O
were	O
tested	B-T059
,	O
579	O
were	O
tested	B-T059
at	O
more	O
than	O
1	O
site	O
,	O
and	O
120	O
had	O
at	O
least	O
1	O
infected	B-T033
site	O
.	O
Chlamydia	B-T007
trachomatis	I-T007
was	O
identified	O
in	O
104	O
patients	O
,	O
and	O
NG	B-T007
was	O
found	O
in	O
33	O
.	O
In	O
bivariate	O
analysis	O
,	O
a	O
positive	O
test	O
was	O
associated	O
with	O
female	O
sex	O
,	O
age	O
older	O
than	O
11	O
years	O
,	O
previous	O
sexual	B-T033
contact	I-T033
,	O
acute	O
or	O
healed	O
genital	O
injury	O
,	O
drug	B-T033
/	I-T033
alcohol	I-T033
intoxication	I-T033
,	O
and	O
examination	B-T058
within	O
72	O
hours	O
of	O
sexual	B-T033
contact	I-T033
.	O
Fifty	O
-	O
one	O
patients	O
had	O
positive	B-T033
anal	B-T023
tests	B-T059
,	O
and	O
24	O
had	O
positive	B-T033
oral	O
tests	B-T059
.	O
More	O
than	O
75	O
%	O
of	O
patients	O
with	O
positive	B-T033
extragenital	B-T059
tests	I-T059
had	O
additional	O
positive	B-T033
tests	B-T059
or	O
anogenital	O
injury	O
.	O
Most	O
with	O
a	O
positive	B-T033
anal	B-T023
(	O
59	O
%	O
)	O
or	O
oral	O
(	O
77	O
%	O
)	O
test	B-T059
did	O
not	O
report	O
that	O
the	O
assailant	O
's	O
genitals	B-T023
came	O
into	O
contact	O
with	O
that	O
site	O
.	O
Positive	B-T033
tests	B-T059
for	O
NG	B-T007
and	O
CT	B-T007
in	O
patients	O
evaluated	B-T058
for	O
sexual	O
victimization	O
may	O
represent	O
infection	O
from	O
sexual	B-T033
contact	I-T033
,	O
contiguous	O
spread	O
of	O
infection	O
,	O
or	O
the	O
presence	O
of	O
infected	O
assailant	O
secretions	O
.	O
Relying	O
on	O
patient	O
reports	O
of	O
symptoms	B-T184
,	O
or	O
types	O
of	O
sexual	B-T033
contact	I-T033
,	O
to	O
determine	O
need	O
for	O
testing	O
may	O
miss	O
NG	B-T047
and	O
CT	B-T047
infections	I-T047
in	O
patients	O
evaluated	B-T058
for	O
sexual	O
victimization	O
.	O
      
Repetitive	O
and	O
Prolonged	O
Omega-3	B-T121
Fatty	I-T121
Acid	I-T121
Treatment	B-T061
After	O
Traumatic	O
Brain	O
Injury	O
Enhances	O
Long	O
-	O
Term	O
Tissue	O
Restoration	B-T061
and	O
Cognitive	B-T061
Recovery	I-T061
Traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
is	O
one	O
of	O
the	O
most	O
disabling	B-T033
clinical	I-T033
conditions	I-T033
that	O
could	O
lead	O
to	O
neurocognitive	B-T048
disorders	I-T048
in	O
survivors	O
.	O
Our	O
group	O
and	O
others	O
previously	O
reported	O
that	O
prophylactic	B-T061
enrichment	I-T061
of	O
dietary	O
omega-3	B-T121
polyunsaturated	I-T121
fatty	I-T121
acids	I-T121
(	O
n-3	B-T121
PUFAs	I-T121
)	O
markedly	O
ameliorate	O
cognitive	B-T048
deficits	I-T048
after	O
TBI	O
.	O
However	O
,	O
it	O
remains	O
unclear	B-T033
whether	O
a	O
clinically	O
relevant	O
therapeutic	B-T061
regimen	I-T061
with	O
n-3	B-T121
PUFAs	I-T121
administered	O
after	O
TBI	O
would	O
still	O
offer	O
significant	O
improvement	O
of	O
long	O
-	O
term	O
cognitive	B-T061
recovery	I-T061
.	O
In	O
the	O
present	O
study	O
,	O
we	O
employed	O
the	O
decline	O
of	O
spatial	O
cognitive	B-T048
function	I-T048
as	O
a	O
main	O
outcome	O
after	O
TBI	O
to	O
investigate	O
the	O
therapeutic	O
efficacy	O
of	O
post	O
-	O
TBI	O
n-3	B-T121
PUFA	I-T121
treatment	B-T061
and	O
the	O
underlying	O
mechanisms	O
.	O
Mice	O
were	O
subjected	O
to	O
sham	B-T061
operation	I-T061
or	O
controlled	O
cortical	B-T023
impact	O
,	O
followed	O
by	O
random	O
assignment	O
to	O
receive	O
the	O
following	O
four	O
treatments	B-T061
:	O
(	O
1	O
)	O
vehicle	O
control	O
;	O
(	O
2	O
)	O
daily	O
intraperitoneal	B-T061
injections	I-T061
of	O
n-3	B-T121
PUFAs	I-T121
for	O
2	O
weeks	O
,	O
beginning	O
2	O
h	O
after	O
TBI	O
;	O
(	O
3	O
)	O
fish	O
oil	O
dietary	O
supplementation	B-T061
throughout	O
the	O
study	O
,	O
beginning	O
1	O
day	O
after	O
TBI	O
;	O
or	O
(	O
4	O
)	O
combination	O
of	O
treatments	B-T061
(	O
2	O
)	O
and	O
(	O
3	O
)	O
.	O
Spatial	O
cognitive	O
deficits	O
and	O
chronic	O
brain	B-T023
tissue	I-T023
loss	O
,	O
as	O
well	O
as	O
endogenous	O
brain	B-T061
repair	I-T061
processes	I-T061
such	O
as	O
neurogenesis	O
,	O
angiogenesis	O
,	O
and	O
oligodendrogenesis	O
,	O
were	O
evaluated	O
up	O
to	O
35	O
days	O
after	O
TBI	O
.	O
The	O
results	O
revealed	O
prominent	O
spatial	O
cognitive	B-T048
deficits	I-T048
and	O
massive	O
tissue	B-T023
loss	O
caused	O
by	O
TBI	O
.	O
Among	O
all	O
mice	O
receiving	O
post	O
-	O
TBI	O
n-3	B-T121
PUFA	I-T121
treatments	B-T061
,	O
the	O
combined	O
treatment	B-T061
of	O
fish	O
oil	O
dietary	O
supplement	O
and	O
n-3	B-T121
PUFA	I-T121
injections	O
demonstrated	O
a	O
reproducible	O
beneficial	O
effect	O
in	O
attenuating	O
cognitive	B-T048
deficits	I-T048
although	O
without	O
reducing	O
gross	O
tissue	B-T023
loss	O
.	O
Mechanistically	O
,	O
the	O
combined	O
treatment	B-T061
promoted	O
post	O
-	O
TBI	O
restorative	B-T061
processes	I-T061
in	O
the	O
brain	B-T023
,	O
including	O
generation	O
of	O
immature	O
neurons	O
,	O
microvessels	B-T023
,	O
and	O
oligodendrocytes	O
,	O
each	O
of	O
which	O
was	O
significantly	O
correlated	O
with	O
the	O
improved	B-T033
cognitive	O
recovery	O
.	O
These	O
results	O
indicated	B-T033
that	O
repetitive	O
and	O
prolonged	O
n-3	B-T121
PUFA	I-T121
treatments	B-T061
after	O
TBI	O
are	O
capable	O
of	O
enhancing	O
brain	B-T023
remodeling	O
and	O
could	O
be	O
developed	O
as	O
a	O
potential	O
therapy	B-T061
to	O
treat	O
TBI	O
victims	O
in	O
the	O
clinic	O
.	O
      
The	O
relationship	O
between	O
thoracic	O
configuration	O
and	O
changes	O
in	O
volumes	O
of	O
hemithoraces	O
in	O
upright	B-T033
sitting	I-T033
[	O
Purpose	O
]	O
Some	O
patients	O
with	O
respiratory	B-T047
disease	I-T047
exhibit	O
asymmetrical	B-T033
movement	I-T033
of	I-T033
the	I-T033
thorax	I-T033
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
relationship	O
of	O
thoracic	O
configuration	O
with	O
changes	O
in	O
thoracic	O
volume	O
in	O
13	O
sedentary	O
healthy	O
men	O
.	O
[	O
Subjects	O
and	O
Methods	O
]	O
In	O
upright	B-T033
sitting	I-T033
,	O
84	O
reflective	O
markers	O
were	O
placed	O
on	O
the	O
anterior	O
and	O
posterior	O
aspects	O
of	O
the	O
trunk	O
to	O
record	O
thoracic	O
volume	O
during	O
quiet	O
and	O
volitional	O
deep	B-T033
breathing	I-T033
.	O
Using	O
a	O
three	O
-	O
dimensional	O
motion	O
analyzer	O
,	O
the	O
difference	O
in	O
volume	O
within	O
the	O
upper	O
and	O
lower	O
hemithoraces	O
was	O
measured	O
.	O
For	O
calculation	O
of	O
the	O
thoracic	O
volume	O
six	O
imaginary	O
hexahedra	O
were	O
visualized	O
for	O
the	O
upper	O
and	O
lower	O
thorax	O
using	O
four	O
reflective	O
markers	O
for	O
each	O
on	O
the	O
anterior	O
and	O
posterior	O
aspects	O
of	O
the	O
thorax	O
.	O
Each	O
hexahedron	O
was	O
then	O
divided	O
into	O
three	O
imaginary	O
triangular	O
pyramids	O
to	O
calculate	O
positional	B-T033
vectors	O
.	O
Finally	O
,	O
the	O
volume	O
for	O
both	O
the	O
hexahedra	O
and	O
triangular	O
pyramids	O
was	O
calculated	O
.	O
Four	O
thoracic	O
volumes	O
were	O
obtained	O
.	O
[	O
Results	O
]	O
The	O
findings	O
showed	O
that	O
the	O
left	O
upper	O
and	O
right	O
lower	O
hemithorax	O
yielded	O
significantly	O
larger	O
thoracic	O
volumes	O
.	O
[	O
Conclusion	O
]	O
In	O
conclusion	O
the	O
left	O
upper	O
and	O
right	O
lower	O
hemithoraces	O
were	O
found	O
to	O
expand	O
more	O
than	O
their	O
corresponding	O
sides	O
.	O
Understanding	O
the	O
characteristics	O
of	O
thoracic	O
excursion	B-T184
during	O
quiet	O
and	O
volitional	O
deep	B-T033
breathing	I-T033
could	O
be	O
of	O
value	O
in	O
assessment	B-T058
and	O
instruction	O
of	O
breathing	O
techniques	O
to	O
patients	O
.	O
      
Extracellular	O
Self	O
-	O
Assembly	O
of	O
Functional	O
and	O
Tunable	O
Protein	O
Conjugates	O
from	O
Bacillus	B-T007
subtilis	I-T007
The	O
ability	O
to	O
stably	O
and	O
specifically	O
conjugate	O
recombinant	O
proteins	O
to	O
one	O
another	O
is	O
a	O
powerful	O
approach	O
for	O
engineering	O
multifunctional	O
enzymes	O
,	O
protein	B-T121
therapeutics	I-T121
,	O
and	O
novel	O
biological	O
materials	O
.	O
While	O
many	O
of	O
these	O
applications	O
have	O
been	O
illustrated	O
through	O
in	O
vitro	O
and	O
in	O
vivo	O
intracellular	O
protein	O
conjugation	O
methods	O
,	O
extracellular	O
self	O
-	O
assembly	O
of	O
protein	O
conjugates	O
offers	O
unique	O
advantages	O
:	O
simplifying	O
purification	B-T059
,	O
reducing	O
toxicity	O
and	O
burden	O
,	O
and	O
enabling	O
tunability	O
.	O
Exploiting	O
the	O
recently	O
described	O
SpyTag	B-T059
-	I-T059
SpyCatcher	I-T059
system	I-T059
,	O
we	O
describe	O
here	O
how	O
enzymes	O
and	O
structural	O
proteins	O
can	O
be	O
genetically	O
encoded	O
to	O
covalently	O
conjugate	O
in	O
culture	O
media	O
following	O
programmable	O
secretion	O
from	O
Bacillus	B-T007
subtilis	I-T007
.	O
Using	O
this	O
approach	O
,	O
we	O
demonstrate	O
how	O
self	O
-	O
conjugation	O
of	O
a	O
secreted	O
industrial	O
enzyme	O
,	O
XynA	O
,	O
dramatically	O
increases	O
its	O
resilience	B-T033
to	O
boiling	O
,	O
and	O
we	O
show	O
that	O
cellular	O
consortia	O
can	O
be	O
engineered	O
to	O
self	O
-	O
assemble	O
functional	O
protein	O
-	O
protein	O
conjugates	O
with	O
tunable	O
composition	O
.	O
This	O
novel	O
genetically	O
encoded	O
modular	O
system	O
provides	O
a	O
flexible	O
strategy	O
for	O
protein	O
conjugation	O
harnessing	O
the	O
substantial	O
advantages	O
of	O
extracellular	O
self	O
-	O
assembly	O
.	O
      
A	O
closer	O
look	O
at	O
school	O
bonding	O
among	O
African	O
American	O
adolescents	O
in	O
low	O
-	O
income	O
communities	O
:	O
A	O
latent	O
class	O
analysis	O
Positive	B-T033
school	O
bonding	O
is	O
a	O
significant	O
precursor	O
to	O
students	O
'	O
school	O
success	O
.	O
However	O
,	O
African	O
American	O
youth	O
report	O
lower	O
school	O
success	O
compared	O
with	O
their	O
White	O
counterparts	O
.	O
This	O
study	O
examined	O
correlates	O
of	O
school	O
bonding	O
among	O
633	O
African	O
American	O
youth	O
who	O
were	O
recruited	O
from	O
community	O
settings	O
in	O
Chicago	O
.	O
Major	O
findings	B-T033
indicated	O
that	O
negative	B-T033
peer	I-T033
norms	I-T033
,	O
exposure	O
to	O
community	B-T033
violence	I-T033
,	O
and	O
poor	O
mental	O
health	O
were	O
negatively	B-T033
correlated	O
with	O
school	O
bonding	O
,	O
while	O
parental	O
monitoring	O
,	O
positive	B-T033
self	I-T033
-	I-T033
regard	I-T033
,	O
and	O
future	O
orientation	O
were	O
correlated	O
with	O
higher	O
school	O
motivation	O
.	O
Students	O
classified	O
as	O
having	O
high	O
or	O
moderate	O
school	O
bonding	O
were	O
more	O
likely	O
to	O
live	O
with	O
both	O
parents	O
,	O
experience	O
higher	O
levels	O
of	O
parental	O
monitoring	O
,	O
and	O
exhibit	B-T033
positive	I-T033
self	I-T033
-	I-T033
regard	I-T033
.	O
Implications	O
are	O
discussed	O
in	O
view	O
of	O
these	O
findings	B-T033
.	O
      
Structure	O
of	O
the	O
bacterial	O
plant	O
-	O
ferredoxin	O
receptor	O
FusA	O
Iron	B-T121
is	O
a	O
limiting	O
nutrient	O
in	O
bacterial	B-T047
infection	I-T047
putting	O
it	O
at	O
the	O
centre	O
of	O
an	O
evolutionary	O
arms	O
race	O
between	O
host	B-T001
and	O
pathogen	B-T001
.	O
Gram	B-T007
-	I-T007
negative	I-T007
bacteria	I-T007
utilize	O
TonB	O
-dependent	O
outer	O
membrane	O
receptors	O
to	O
obtain	O
iron	B-T121
during	O
infection	O
.	O
These	O
receptors	O
acquire	O
iron	B-T121
either	O
in	O
concert	O
with	O
soluble	O
iron	O
-	O
scavenging	O
siderophores	O
or	O
through	O
direct	O
interaction	O
and	O
extraction	B-T061
from	O
host	B-T001
proteins	O
.	O
Characterization	O
of	O
these	O
receptors	O
provides	O
invaluable	O
insight	O
into	O
pathogenesis	O
.	O
However	O
,	O
only	O
a	O
subset	O
of	O
virulence	O
-related	O
TonB	O
-dependent	O
receptors	O
have	O
been	O
currently	O
described	O
.	O
Here	O
we	O
report	O
the	O
discovery	O
of	O
FusA	O
,	O
a	O
new	O
class	O
of	O
TonB	O
-dependent	O
receptor	O
,	O
which	O
is	O
utilized	O
by	O
phytopathogenic	B-T007
Pectobacterium	I-T007
spp	I-T007
.	I-T007
to	O
obtain	O
iron	B-T121
from	O
plant	O
ferredoxin	O
.	O
Through	O
the	O
crystal	O
structure	O
of	O
FusA	O
we	O
show	O
that	O
binding	O
of	O
ferredoxin	O
occurs	O
through	O
specialized	O
extracellular	O
loops	O
that	O
form	O
extensive	O
interactions	O
with	O
ferredoxin	O
.	O
The	O
function	O
of	O
FusA	O
and	O
the	O
presence	O
of	O
homologues	O
in	O
clinically	O
important	O
pathogens	B-T001
suggests	O
that	O
small	O
iron	O
-	O
containing	O
proteins	O
represent	O
an	O
iron	B-T121
source	B-T033
for	O
bacterial	O
pathogens	B-T001
.	O
      
Towards	O
culturally	B-T058
competent	I-T058
paediatric	I-T058
oncology	I-T058
care	I-T058
.	O
A	O
qualitative	O
study	O
from	O
the	O
perspective	O
of	O
care	O
providers	O
In	O
order	O
to	O
gain	O
more	O
insight	O
on	O
the	O
influence	O
of	O
ethnic	B-T033
diversity	O
in	O
paediatric	O
cancer	B-T061
care	I-T061
,	O
the	O
perspectives	O
of	O
care	O
providers	O
were	O
explored	O
.	O
Semi	B-T058
-	I-T058
structured	I-T058
interviews	I-T058
were	O
conducted	O
among	O
12	O
paediatric	O
oncologists	O
and	O
13	O
nurses	O
of	O
two	O
different	O
paediatric	O
oncology	O
wards	O
and	O
were	O
analysed	O
using	O
a	O
framework	O
method	O
.	O
We	O
found	O
that	O
care	O
providers	O
described	O
the	O
contact	O
with	O
Turkish	O
and	O
Moroccan	O
parents	O
as	O
more	O
difficult	O
.	O
They	O
offered	O
two	O
reasons	O
for	O
this	O
:	O
(	O
1	O
)	O
language	B-T033
barriers	I-T033
between	O
care	O
provider	O
and	O
parents	O
hindered	O
the	O
exchange	O
of	O
information	O
;	O
(	O
2	O
)	O
cultural	B-T058
barriers	I-T058
between	O
care	O
provider	O
and	O
parents	O
about	O
sharing	O
the	O
diagnosis	B-T033
and	O
palliative	O
perspective	O
hindered	O
communication	O
.	O
Care	O
providers	O
reported	O
different	O
solutions	O
to	O
deal	O
with	O
these	O
barriers	O
,	O
such	O
as	O
using	O
an	O
interpreter	O
and	O
improving	O
their	O
cultural	O
knowledge	O
about	O
their	O
patients	O
.	O
They	O
,	O
however	O
,	O
were	O
not	O
using	O
interpreters	O
sufficiently	O
and	O
were	O
unaware	O
of	O
the	O
importance	O
of	O
eliciting	B-T048
parents	O
'	O
perspectives	O
.	O
Communication	O
techniques	O
to	O
overcome	O
dilemmas	O
between	O
parents	O
and	O
care	O
providers	O
were	O
not	O
used	O
and	O
care	O
providers	O
were	O
unaware	O
of	O
stereotypes	O
and	O
prejudice	O
.	O
Care	O
providers	O
should	O
be	O
offered	O
insight	O
in	O
cultural	B-T058
barriers	I-T058
they	O
are	O
unaware	O
of	O
.	O
Training	O
in	O
cultural	O
competence	O
might	O
be	O
a	O
possibility	O
to	O
overcome	O
manifest	O
barriers	O
.	O
      
Lactate	O
induces	O
osteoblast	O
differentiation	O
by	O
stabilization	O
of	O
HIF1α	O
Aerobic	O
glycolysis	O
is	O
involved	O
in	O
osteoblast	O
differentiation	O
induced	O
by	O
Wnt	O
signaling	O
or	O
PTH	B-T121
treatment	O
.	O
However	O
,	O
it	O
is	O
still	O
unclear	O
whether	O
lactate	O
,	O
the	O
end	O
product	O
of	O
aerobic	O
glycolysis	O
,	O
plays	O
any	O
role	O
in	O
osteoblast	O
differentiation	O
.	O
Herein	O
we	O
report	O
that	O
in	O
cultures	B-T059
of	O
osteoblast	O
-	O
lineage	O
cells	O
,	O
lactate	O
promoted	O
alkaline	O
phosphatase	O
-positive	O
cell	O
formation	O
,	O
increased	O
the	O
activity	O
of	O
alkaline	O
phosphatase	O
,	O
and	O
induced	O
the	O
expression	O
of	O
osteocalcin	O
.	O
This	O
osteoblast	O
differentiation	O
-inducing	O
effect	O
of	O
lactate	O
can	O
be	O
inhibited	O
by	O
blocking	O
its	O
entry	O
into	O
cells	O
with	O
MCT1	O
siRNA	O
or	O
inhibitors	B-T121
,	O
and	O
by	O
interfering	O
with	O
its	O
metabolism	O
by	O
using	O
specific	O
siRNAs	O
for	O
LDHB	O
and	O
PDH	O
.	O
Moreover	O
,	O
lactate	O
stabilized	O
HIF1α	O
expression	O
and	O
inhibited	O
HIF1α	O
activity	O
,	O
with	O
BAY87	B-T121
-	I-T121
2243	I-T121
lowering	O
the	O
osteoblast	O
differentiation	O
-inducing	O
effect	O
of	O
lactate	O
.	O
Thus	O
,	O
these	O
findings	B-T033
reveal	O
an	O
unrecognized	O
role	O
for	O
aerobic	O
glycolysis	O
in	O
osteoblast	O
differentiation	O
via	O
its	O
end	O
product	O
,	O
lactate	O
.	O
      
1	O
in	O
100	O
babies	O
:	O
the	O
fetal	B-T019
alcohol	I-T019
spectrum	I-T019
disorder	I-T019
pathway	O
Alcohol	O
consumed	O
during	O
pregnancy	O
is	O
the	O
nation	O
's	O
leading	O
preventable	O
cause	O
of	O
developmental	B-T048
disabilities	I-T048
and	O
birth	B-T019
defects	I-T019
.	O
One	O
in	O
100	O
babies	O
is	O
estimated	O
to	O
be	O
born	O
with	O
alcohol	B-T047
-	I-T047
related	I-T047
damage	I-T047
,	O
according	O
to	O
the	O
World	O
Health	O
Organization	O
.	O
Fetal	B-T019
alcohol	I-T019
spectrum	I-T019
disorders	I-T019
(	O
FASDs	B-T019
)	O
are	O
more	O
common	O
than	O
autism	B-T048
but	O
are	O
under-	O
diagnosed	B-T033
.	O
      
The	O
use	O
of	O
Ocimum	O
americanum	O
essential	O
oil	O
against	O
the	O
pathogens	B-T001
Aeromonas	B-T007
hydrophila	I-T007
and	O
Gyrodactylus	O
sp	O
.	O
in	O
silver	O
catfish	O
(	O
Rhamdia	O
quelen	O
)	O
The	O
bactericidal	O
activity	O
(	O
MIC	B-T059
-	I-T059
test	I-T059
)	O
of	O
Ocimum	O
americanum	O
(	O
inflorescences	O
)	O
essential	O
oil	O
(	O
OAEO	O
)	O
against	O
Aeromonas	B-T007
hydrophila	I-T007
was	O
determined	O
in	O
this	O
study	O
.	O
It	O
was	O
also	O
investigated	O
the	O
potential	O
of	O
OAEO	O
and	O
the	O
main	O
compound	O
found	O
in	O
the	O
oil	O
(	O
linalool	B-T121
)	O
at	O
subinhibitory	O
concentrations	O
to	O
be	O
inhibitors	O
of	O
hemolysis	O
caused	O
by	O
Aer	B-T007
.	I-T007
hydrophila	I-T007
in	O
fish	O
erythrocytes	O
.	O
An	O
in	O
vivo	O
experiment	O
was	O
conducted	O
to	O
evaluate	O
survival	O
of	O
fish	O
(	O
Rhamdia	O
quelen	O
)	O
experimentally	O
infected	B-T033
with	O
Aer	B-T007
.	I-T007
hydrophila	I-T007
and	O
exposed	O
to	O
OAEO	O
.	O
A	O
second	O
experiment	O
was	O
conducted	O
to	O
evaluate	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
activity	O
of	O
OAEO	O
(	O
mix	O
from	O
inflorescences	O
and	O
leaves	O
)	O
against	O
the	O
parasite	O
Gyrodactylus	O
sp	O
.	O
The	O
OAEO	O
showed	O
weak	O
in	O
vitro	O
activity	O
against	O
Aer	B-T007
.	I-T007
hydrophila	I-T007
(	O
6400	O
μg	O
ml(-1	O
)	O
)	O
.	O
At	O
subinhibitory	O
concentrations	O
OAEO	O
(	O
100	O
μg	O
ml(-1	O
)	O
)	O
inhibited	O
hemolysis	O
(	O
90	O
%	O
)	O
caused	O
by	O
Aer	B-T007
.	I-T007
hydrophila	I-T007
in	O
fish	O
erythrocytes	O
,	O
however	O
,	O
linalool	B-T121
did	O
not	O
present	O
hemolysis	O
inhibition	O
activity	O
.	O
At	O
low	O
concentrations	O
(	O
10	O
and	O
20	O
mg	O
l(-1	O
)	O
)	O
added	O
to	O
the	O
water	B-T121
OAEO	O
promoted	O
survival	O
of	O
experimentally	O
infected	B-T033
fish	O
with	O
Aer	B-T007
.	I-T007
hydrophila	I-T007
.	O
Lastly	O
,	O
OAEO	O
-mix	O
(	O
50	O
mg	O
l(-1	O
)	O
)	O
was	O
effective	O
against	O
Gyrodactylus	O
sp	O
.	O
significantly	O
reducing	O
(	O
60	O
%	O
)	O
the	O
number	O
of	O
parasites	O
in	O
the	O
fish	O
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O
      
Propensity	O
Score	O
Matched	O
Comparison	O
of	O
Partial	O
to	O
Whole	O
Gland	B-T023
Cryotherapy	B-T061
for	O
Intermediate	B-T033
-	I-T033
Risk	I-T033
Prostate	B-T191
Cancer	I-T191
:	O
An	O
analysis	O
of	O
the	O
COLD	O
registry	O
data	O
To	O
compare	O
the	O
oncological	B-T191
and	O
functional	O
outcomes	O
of	O
partial	O
versus	O
whole	O
-	O
gland	B-T023
cryotherapy	B-T061
for	O
men	O
with	O
intermediate	B-T033
-	I-T033
risk	I-T033
prostate	B-T191
cancer	I-T191
.	O
Men	O
with	O
intermediate	B-T033
-	I-T033
risk	I-T033
prostate	B-T191
cancer	I-T191
treated	B-T061
with	I-T061
primary	O
prostate	B-T061
cryotherapy	I-T061
from	O
1993	O
-	O
2013	O
were	O
selected	O
from	O
the	O
Cryo	O
On	O
-	O
Line	O
Data	O
Registry	O
for	O
a	O
1:1	O
matched	O
comparison	O
between	O
those	O
undergoing	O
whole	O
-	O
gland	B-T023
and	O
partial	O
prostate	B-T061
cryotherapy	I-T061
(	O
targeted	B-T061
-	I-T061
ablation	I-T061
,	O
unilateral	B-T061
/	I-T061
bilateral	I-T061
nerve	I-T061
-	I-T061
sparing	I-T061
ablations	I-T061
)	O
.	O
A	O
propensity	O
score	O
was	O
developed	O
based	O
on	O
age	O
,	O
pre	O
-	O
biopsy	O
serum	O
PSA	O
,	O
biopsy	B-T033
Gleason	I-T033
score	I-T033
,	O
clinical	O
stage	O
,	O
prostate	O
volume	O
,	O
neoadjuvant	B-T061
androgen	I-T061
deprivation	I-T061
status	O
,	O
year	O
of	O
surgery	B-T061
and	O
pre	O
-	O
treatment	O
potency	O
.	O
Outcomes	O
were	O
biochemical	O
progression	O
-	O
free	O
survival	O
(	O
BPFS	O
)	O
using	O
ASTRO	O
and	O
Phoenix	O
criteria	O
,	O
12	O
-	O
month	O
continence	O
(	O
strictly	O
pad	O
-	O
free	O
)	O
and	O
sexual	O
function	O
(	O
potency	O
sufficient	O
for	O
sexual	O
intercourse	O
)	O
.	O
After	O
propensity	O
score	O
-	O
matching	O
,	O
BPFS	O
was	O
compared	O
using	O
Kaplan	O
-	O
Meier	O
analysis	O
and	O
functional	O
outcomes	O
using	O
chi	O
-	O
square	O
tests	O
.	O
In	O
all	O
,	O
897	O
men	O
were	O
identified	O
(	O
731	O
whole	O
-	O
gland	B-T023
and	O
166	O
partial	O
)	O
.	O
Post	O
-	O
matching	O
,	O
166	O
pairs	O
of	O
men	O
were	O
analysed	O
(	O
mean	O
follow	B-T058
-	I-T058
up	I-T058
31	O
months	O
)	O
.	O
The	O
2/5	O
year	O
BPFS	O
rate	O
was	O
87.2%/76.4	O
%	O
for	O
whole	O
-	O
gland	B-T023
vs.	O
80.7%/70.0	O
%	O
for	O
partial	O
ablation	B-T061
using	O
Phoenix	O
(	O
p=0.26	O
)	O
and	O
72.3%/69.6	O
%	O
for	O
whole	O
gland	B-T023
vs.	O
82.1%/75.0	O
%	O
for	O
partial	O
ablation	B-T061
using	O
ASTRO	O
criteria	O
(	O
p=0.10	O
)	O
.	O
Of	O
164	O
pairs	O
,	O
the	O
12	O
-	O
month	O
continence	O
rate	O
was	O
similar	O
94.1	O
%	O
vs.	O
95.1	O
%	O
(	O
p=0.803	O
)	O
.	O
Of	O
139	O
pairs	O
,	O
the	O
12	O
-	O
month	O
rate	O
of	O
successful	O
intercourse	O
was	O
29.5	O
%	O
for	O
whole	O
-	O
gland	B-T023
and	O
46.8	O
%	O
for	O
partial	O
ablation	B-T061
(	O
OR	O
2.1	O
,	O
p=0.003	O
)	O
.	O
The	O
incidence	O
of	O
post	O
-	O
treatment	O
urinary	B-T033
retention	I-T033
was	O
6.0	O
%	O
and	O
6.6	O
%	O
(	O
p=0.88	O
)	O
following	O
whole	O
-	O
gland	B-T023
and	O
partial	O
ablation	B-T061
respectively	O
and	O
that	O
of	O
rectourethral	B-T047
fistula	I-T047
was	O
1.2	O
%	O
and	O
0	O
%	O
(	O
p=0.50	O
)	O
Conclusion	O
:	O
Partial	O
ablation	B-T061
results	B-T033
in	O
better	O
post	O
-	O
treatment	O
sexual	O
function	O
compared	O
to	O
whole	O
-	O
gland	B-T023
ablation	B-T061
in	O
men	O
with	O
intermediate	B-T033
-	I-T033
risk	I-T033
prostate	B-T191
cancer	I-T191
.	O
We	O
did	O
not	O
observe	O
a	O
difference	O
in	O
early	O
BPFS	O
between	O
the	O
two	O
groups	O
.	O
      
E3	O
Ligase	O
RNF126	O
Directly	O
Ubiquitinates	O
Frataxin	O
,	O
Promoting	O
Its	O
Degradation	O
:	O
Identification	O
of	O
a	O
Potential	O
Therapeutic	O
Target	O
for	O
Friedreich	B-T047
Ataxia	I-T047
Friedreich	B-T047
ataxia	I-T047
(	O
FRDA	B-T047
)	O
is	O
a	O
severe	O
genetic	O
neurodegenerative	B-T047
disease	I-T047
caused	O
by	O
reduced	O
expression	O
of	O
the	O
mitochondrial	O
protein	O
frataxin	O
.	O
To	O
date	O
,	O
there	O
is	O
no	O
therapy	O
to	O
treat	B-T061
this	O
condition	O
.	O
The	O
amount	O
of	O
residual	O
frataxin	O
critically	O
affects	O
the	O
severity	O
of	O
the	O
disease	B-T047
;	O
thus	O
,	O
attempts	O
to	O
restore	O
physiological	O
frataxin	O
levels	O
are	O
considered	O
therapeutically	O
relevant	O
.	O
Frataxin	O
levels	O
are	O
controlled	O
by	O
the	O
ubiquitin	O
-	O
proteasome	O
system	O
;	O
therefore	O
,	O
inhibition	O
of	O
the	O
frataxin	O
E3	O
ligase	O
may	O
represent	O
a	O
strategy	O
to	O
achieve	O
an	O
increase	O
in	O
frataxin	O
levels	O
.	O
Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
the	O
RING	O
E3	O
ligase	O
RNF126	O
as	O
the	O
enzyme	O
that	O
specifically	O
mediates	O
frataxin	O
ubiquitination	O
and	O
targets	O
it	O
for	O
degradation	O
.	O
RNF126	O
interacts	O
with	O
frataxin	O
and	O
promotes	O
its	O
ubiquitination	O
in	O
a	O
catalytic	O
activity	O
-	O
dependent	O
manner	O
,	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
Most	O
importantly	O
,	O
RNF126	O
depletion	O
results	O
in	O
frataxin	O
accumulation	B-T033
in	O
cells	O
derived	O
from	O
FRDA	B-T047
patients	O
,	O
highlighting	O
the	O
relevance	O
of	O
RNF126	O
as	O
a	O
new	O
therapeutic	O
target	O
for	O
Friedreich	B-T047
ataxia	I-T047
.	O
      
An	O
ion	O
-	O
gating	O
multinanochannel	O
system	O
based	O
on	O
a	O
copper	B-T121
-	O
responsive	O
self	O
-	O
cleaving	O
DNAzyme	O
We	O
developed	O
an	O
ion	O
-	O
gating	O
nanochannel	O
composite	O
system	O
by	O
immobilizing	O
a	O
Cu(2	B-T121
+	I-T121
)	I-T121
-	O
responsive	O
self	O
-	O
cleaving	O
DNAzyme	O
into	O
PET	O
conical	O
multinanochannels	O
,	O
which	O
could	O
control	O
the	O
ion	O
transport	O
by	O
regulating	O
the	O
surface	O
charge	O
density	O
of	O
the	O
channels	O
.	O
      
Mechanisms	O
of	O
compensation	B-T058
in	O
the	O
gait	B-T033
of	O
patients	O
with	O
drop	B-T047
foot	I-T047
Drop	B-T047
foot	I-T047
is	O
a	O
complex	O
syndrome	B-T047
,	O
with	O
multiple	O
interactions	O
between	O
joints	O
and	O
muscles	O
.	O
Abnormalities	B-T033
in	O
movement	B-T033
patterns	I-T033
can	O
be	O
measured	O
using	O
motion	B-T058
capture	I-T058
techniques	I-T058
,	O
but	O
identifying	O
compensation	B-T058
mechanisms	O
remains	O
challenging	O
.	O
In	O
order	O
to	O
identify	O
compensatory	O
mechanisms	O
in	O
patients	O
with	O
drop	B-T047
foot	I-T047
,	O
this	O
study	O
evaluated	O
a	O
sample	O
of	O
15	O
such	O
patients	O
using	O
a	O
computerized	O
gait	O
analysis	O
system	O
,	O
as	O
compared	O
to	O
a	O
group	O
of	O
15	O
healthy	O
subjects	O
.	O
Four	O
classes	O
of	O
parameters	O
were	O
distinguished	O
,	O
falling	B-T033
in	O
differing	O
intervals	O
of	O
percentage	O
differences	O
between	O
the	O
groups	O
in	O
the	O
study	O
.	O
The	O
first	O
class	O
comprised	O
two	O
kinematic	O
parameters	O
for	O
which	O
the	O
values	O
of	O
percentage	O
differences	O
in	O
the	O
control	O
group	O
were	O
more	O
than	O
100	O
%	O
greater	O
than	O
for	O
the	O
patient	O
group	O
.	O
The	O
second	O
class	O
comprised	O
two	O
kinetic	O
parameters	O
falling	B-T033
in	O
the	O
interval	O
of	O
100	O
-	O
49	O
%	O
.	O
In	O
the	O
third	O
class	O
,	O
in	O
the	O
49	O
-	O
20	O
%	O
interval	O
the	O
main	O
differences	O
were	O
observed	O
for	O
spatiotemporal	O
parameters	O
,	O
whereas	O
in	O
the	O
20	O
-	O
4	O
%	O
interval	O
the	O
differences	O
were	O
distributed	O
similarly	O
for	O
kinematic	O
,	O
kinetic	O
and	O
spatiotemporal	O
parameters	O
.	O
These	O
differences	O
in	O
gait	B-T033
pattern	I-T033
between	O
the	O
groups	O
may	O
be	O
related	O
to	O
both	O
primary	O
motor	B-T033
deficits	I-T033
and	O
secondary	O
compensatory	O
mechanisms	O
.	O
Generally	O
,	O
we	O
conclude	O
that	O
drop	B-T047
foot	I-T047
affects	O
the	O
patients	O
'	O
overall	O
kinematic	O
and	O
kinetic	O
gait	B-T033
parameters	O
,	O
with	O
compensation	B-T058
seen	O
as	O
a	O
chain	O
originating	O
from	O
a	O
change	O
of	O
movement	O
within	O
the	O
ankle	O
joint	O
.	O
      
Targeting	O
brain	B-T023
and	O
peripheral	O
plasticity	O
of	O
the	O
lipidome	O
in	O
acute	O
kainic	B-T121
acid	I-T121
-	O
induced	O
epileptic	B-T047
seizures	I-T047
in	O
mice	O
via	O
quantitative	B-T059
mass	I-T059
spectrometry	I-T059
Epilepsy	B-T047
is	O
a	O
highly	O
common	O
chronic	B-T047
neurological	I-T047
disorder	I-T047
,	O
manifested	O
in	O
many	O
different	O
types	O
,	O
affecting	O
~1	O
%	O
of	O
the	O
worldwide	O
human	O
population	O
.	O
The	O
molecular	O
mechanisms	O
of	O
epileptogenesis	B-T047
have	O
not	O
yet	O
been	O
clarified	O
,	O
and	O
pharmacoresistance	B-T047
exhibited	O
by	O
30	O
-	O
40	O
%	O
of	O
epilepsy	B-T047
patients	O
remains	O
a	O
major	O
obstacle	O
in	O
medical	O
care	B-T058
.	O
Growing	O
evidence	O
indicates	O
a	O
role	O
of	O
lipid	O
signalling	O
pathways	O
in	O
epileptogenesis	B-T047
,	O
thus	O
lipid	O
signals	O
emerge	O
as	O
potential	O
biomarkers	O
for	O
the	O
onset	O
and	O
evolving	O
course	O
of	O
the	O
epileptic	B-T047
disorder	I-T047
,	O
as	O
well	O
as	O
potential	O
therapeutic	B-T121
agents	I-T121
and	O
targets	O
.	O
For	O
this	O
purpose	O
,	O
we	O
applied	O
a	O
lipidomic	O
strategy	O
to	O
unravel	O
lipid	O
alterations	O
in	O
brain	O
regions	O
,	O
periphery	O
tissues	O
and	O
plasma	O
that	O
are	O
specific	O
for	O
acute	O
epileptic	B-T047
seizures	I-T047
in	O
mice	O
at	O
1h	O
after	O
seizure	B-T047
induction	O
by	O
systemic	O
kainic	B-T121
acid	I-T121
injection	O
as	O
compared	O
to	O
vehicle	O
controls	O
.	O
Specifically	O
,	O
levels	O
of	O
(	O
i	O
)	O
selected	O
phospholipids	O
and	O
sphingomyelins	O
,	O
(	O
ii	O
)	O
the	O
endocannabinoids	O
anandamide	O
(	O
AEA	O
)	O
and	O
2	B-T121
-	I-T121
arachidonoyl	I-T121
glycerol	I-T121
(	O
2	B-T121
-	I-T121
AG	I-T121
)	O
,	O
and	O
the	O
endocannabinoid	O
-related	O
compounds	O
oleoylethanolamide	O
(	O
OEA	O
)	O
and	O
palmitoylethanolamide	B-T121
(	O
PEA	B-T121
)	O
,	O
(	O
iii	O
)	O
arachidonic	O
acid	O
(	O
AA	O
)	O
,	O
(	O
iv	O
)	O
selected	O
eicosanoids	O
,	O
and	O
(	O
v	O
)	O
fatty	O
acyl	O
content	O
of	O
lipidome	O
were	O
determined	O
in	O
pulverized	O
tissues	B-T023
from	O
six	O
brain	O
regions	O
of	O
kainic	B-T121
acid	I-T121
induced	O
epileptic	B-T047
seizure	I-T047
models	O
and	O
vehicle	O
controls	O
:	O
hypothalamus	B-T023
,	O
hippocampus	B-T023
,	O
thalamus	B-T023
,	O
striatum	B-T023
,	O
cerebellum	B-T023
and	O
cerebral	B-T023
cortex	I-T023
,	O
and	O
from	O
peripheral	O
organs	B-T023
,	O
such	O
as	O
heart	B-T023
and	O
lungs	B-T023
,	O
and	O
in	O
plasma	O
.	O
Alterations	O
in	O
lipid	O
levels	O
after	O
acute	O
epileptic	B-T047
seizures	I-T047
as	O
compared	O
to	O
non	O
-	O
seizure	O
controls	O
were	O
found	O
to	O
be	O
brain	O
region	O
-	O
and	O
periphery	O
tissue	O
-	O
specific	O
,	O
including	O
specific	O
plasma	O
lipid	O
correlates	O
,	O
highlighting	O
their	O
value	O
as	O
marker	O
candidates	O
in	O
translational	O
research	O
studies	O
,	O
and/or	O
drug	O
discovery	O
and	O
response	B-T058
monitoring	I-T058
.	O
      
BALB	O
/	O
c	O
mice	O
immunized	B-T061
with	O
a	O
combination	O
of	O
virus	O
-	O
like	O
particles	O
incorporating	O
Kaposi	B-T005
sarcoma	I-T005
-	I-T005
associated	I-T005
herpesvirus	I-T005
(	O
KSHV	B-T005
)	O
envelope	O
glycoproteins	O
gpK8.1	O
,	O
gB	O
,	O
and	O
gH	O
/	O
gL	O
induced	O
comparable	O
serum	O
neutralizing	O
antibody	O
activity	O
to	O
UV	O
-	O
inactivated	O
KSHV	B-T005
Infection	O
with	O
Kaposi	B-T005
sarcoma	I-T005
-	I-T005
associated	I-T005
herpesvirus	I-T005
(	O
KSHV	B-T005
)	O
is	O
estimated	O
to	O
account	O
for	O
over	O
44,000	O
new	O
cases	O
of	O
Kaposi	B-T191
sarcoma	I-T191
annually	O
,	O
with	O
84	O
%	O
occurring	O
in	O
Africa	O
,	O
where	O
the	O
virus	B-T005
is	O
endemic	O
.	O
To	O
date	O
,	O
there	O
is	O
no	O
prophylactic	B-T121
vaccine	I-T121
against	O
KSHV	B-T005
.	O
KSHV	B-T005
gpK8.1	O
,	O
gB	O
,	O
and	O
gH	O
/	O
gL	O
glycoproteins	O
,	O
implicated	O
in	O
the	O
virus	B-T005
entry	O
into	O
host	O
cells	O
,	O
are	O
attractive	O
vaccine	B-T121
targets	O
for	O
eliciting	O
potent	O
neutralizing	O
antibodies	O
(	O
nAbs	O
)	O
against	O
virus	B-T047
infection	I-T047
.	O
We	O
incorporated	O
gpK8.1	O
,	O
gB	O
,	O
or	O
gH	O
/	O
gL	O
on	O
the	O
surface	O
of	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
and	O
characterized	O
these	O
VLPs	O
for	O
their	O
composition	O
,	O
size	O
,	O
and	O
functionality	O
.	O
To	O
determine	O
which	O
viral	O
glycoprotein(s	O
)	O
elicit	O
the	O
most	O
effective	O
serum	O
-	O
nAbs	O
,	O
we	O
immunized	B-T061
BALB	O
/	O
c	O
mice	O
with	O
gpK8.1	O
,	O
gB	O
,	O
or	O
gH	O
/	O
gL	O
VLPs	O
individually	O
or	O
in	O
combination	O
.	O
Neutralizing	O
antibody	O
assay	O
revealed	O
that	O
sera	O
from	O
mice	O
immunized	B-T061
with	O
the	O
VLPs	O
inhibited	O
KSHV	B-T005
infection	B-T047
of	O
HEK-293	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
As	O
a	O
single	O
immunogen	O
,	O
gpK8.1	O
VLPs	O
stimulated	O
comparable	O
nAb	O
activity	O
to	O
that	O
of	O
UV	O
-	O
inactivated	O
KSHV	B-T005
(	O
UV	B-T005
-	I-T005
KSHV	I-T005
)	O
.	O
In	O
contrast	O
,	O
UV	B-T005
-	I-T005
KSHV	I-T005
stimulated	O
higher	O
titers	O
of	O
nAb	O
compared	O
to	O
gB	O
(	O
p	O
=	O
0.0316	O
)	O
or	O
gH	O
/	O
gL	O
(	O
p	O
=	O
0.0486	O
)	O
.	O
Mice	O
immunized	B-T061
with	O
the	O
combination	O
of	O
gB	O
and	O
gH	O
/	O
gL	O
VLPs	O
had	O
a	O
better	O
nAb	O
response	O
than	O
those	O
immunized	B-T061
with	O
either	O
gB	O
(	O
p	O
=	O
0.0268	O
)	O
,	O
or	O
gH	O
/gL	O
(	O
p	O
=	O
0.0397	O
)	O
as	O
single	O
VLP	O
immunogens	O
.	O
Immunization	B-T061
with	O
any	O
VLP	O
combination	O
stimulated	O
comparable	O
nAb	O
activity	O
to	O
UV	B-T005
-	I-T005
KSHV	I-T005
serum	O
.	O
Our	O
data	O
provide	O
the	O
first	O
evidence	O
that	O
KSHV	B-T005
gpK8.1	O
,	O
gB	O
,	O
and	O
gH	O
/	O
gL	O
glycoproteins	O
can	O
be	O
incorporated	O
onto	O
the	O
surface	O
of	O
VLPs	O
and	O
used	O
as	O
prophylactic	B-T121
vaccine	I-T121
candidates	O
,	O
with	O
potential	O
to	O
prevent	O
KSHV	B-T005
infection	B-T047
.	O
      
Diagnostic	O
utility	O
of	O
additional	O
conventional	O
techniques	B-T060
after	O
endobronchial	B-T060
ultrasonography	I-T060
guidance	B-T058
during	O
transbronchial	B-T060
biopsy	I-T060
Endobronchial	B-T060
ultrasonography	I-T060
with	O
a	O
guide	O
sheath	O
transbronchial	B-T060
biopsy	I-T060
(	O
EBUS	B-T060
-	O
GS	O
TBB	B-T060
)	O
has	O
been	O
used	O
to	O
diagnose	B-T033
peripheral	B-T033
pulmonary	I-T033
lesions	I-T033
(	O
PPLs	B-T033
)	O
.	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
diagnostic	O
utility	O
of	O
conventional	O
TBB	B-T060
after	O
EBUS	B-T060
-	O
GS	O
TBB	B-T060
.	O
A	O
retrospective	O
analysis	O
of	O
patients	O
who	O
underwent	O
conventional	O
TBB	B-T060
after	O
EBUS	B-T060
-	O
GS	O
TBB	B-T060
for	O
PPL	B-T033
between	O
August	O
1	O
,	O
2012	O
and	O
December	O
31	O
,	O
2014	O
.	O
We	O
performed	O
multivariate	O
analysis	O
to	O
examine	O
the	O
association	O
of	O
various	O
clinical	O
factors	O
,	O
including	O
EBUS	B-T060
probe	O
distance	O
and	O
sample	O
size	O
area	O
,	O
with	O
diagnostic	O
yield	O
.	O
Of	O
88	O
eligible	O
patients	O
,	O
57	O
(	O
65	O
%	O
)	O
were	O
successfully	O
diagnosed	B-T033
by	O
EBUS	B-T060
-	O
GS	O
TBB	B-T060
.	O
In	O
31	O
patients	O
not	O
diagnosed	B-T033
by	O
EBUS	B-T060
-	O
GS	O
TBB	B-T060
,	O
15	O
(	O
48	O
%	O
)	O
were	O
successfully	O
diagnosed	B-T033
by	O
additional	O
conventional	O
TBB	B-T060
.	O
Ground	B-T033
glass	I-T033
opacity	I-T033
(	O
GGO	B-T033
)	O
was	O
a	O
significant	O
factor	O
associated	O
with	O
the	O
diagnostic	O
yield	O
of	O
additional	O
conventional	O
TBB	B-T060
following	O
EBUS	B-T060
-	O
GS	O
TBB	B-T060
.	O
Multivariate	O
analysis	O
and	O
receiver	O
operator	O
curves	O
revealed	O
that	O
distance	O
between	O
the	O
PPL	B-T033
and	O
the	O
EBUS	B-T060
probe	O
of	O
less	O
than	O
2.55	O
mm	O
favored	O
the	O
utility	O
of	O
conventional	O
TBB	B-T060
.	O
Additional	O
conventional	O
TBB	B-T060
after	O
EBUS	B-T060
-	O
GS	O
TBB	B-T060
could	O
be	O
a	O
useful	O
procedure	B-T060
for	O
the	O
diagnosis	B-T033
of	O
ground	B-T033
glass	I-T033
opacity	I-T033
PPLs	B-T033
and	O
in	O
cases	O
of	O
a	O
distance	O
of	O
less	O
than	O
2.55	O
mm	O
between	O
the	O
EBUS	B-T060
probe	O
and	O
the	O
lesion	B-T033
.	O
      
Prevalence	O
of	O
high	B-T033
-	I-T033
risk	I-T033
human	B-T047
papillomavirus	I-T047
infection	I-T047
among	O
women	O
in	O
Shaanxi	O
province	O
of	O
China	O
:	O
A	O
hospital	O
-based	O
investigation	B-T058
This	O
study	O
aimed	O
to	O
investigate	O
the	O
characteristics	O
of	O
female	O
high	B-T047
-	I-T047
risk	I-T047
human	I-T047
papillomavirus	I-T047
(	I-T047
HR	I-T047
-	I-T047
HPV	I-T047
)	I-T047
infection	I-T047
in	O
Shaanxi	O
province	O
of	O
China	O
.	O
A	O
total	O
of	O
14	O
111	O
women	O
were	O
enrolled	O
for	O
HPV	B-T005
genotyping	B-T059
test	I-T059
,	O
and	O
a	O
cytology	B-T059
,	O
and/or	O
cervix	B-T060
biopsy	I-T060
were	O
performed	O
in	O
partial	O
women	O
.	O
Of	O
these	O
women	O
,	O
the	O
HPV	B-T047
infection	I-T047
rate	O
was	O
30.21	O
%	O
,	O
and	O
26.73	O
%	O
were	O
caused	O
by	O
HR	B-T005
-	I-T005
HPV	I-T005
.	O
The	O
most	O
common	O
HR	B-T005
-	I-T005
HPV	I-T005
genotypes	O
were	O
HPV-16	B-T005
,	O
HPV-58	B-T005
,	O
HPV-52	B-T005
,	O
HPV-18	B-T005
,	O
and	O
HPV-31	B-T005
.	O
The	O
prevalence	O
of	O
HR	B-T005
-	I-T005
HPV	I-T005
among	O
women	O
older	O
than	O
50	O
years	O
was	O
significantly	O
higher	O
than	O
the	O
other	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O
The	O
main	O
carcinogenic	O
genotypes	O
were	O
HPV-16	B-T005
,	O
HPV-18	B-T005
,	O
HPV-58	B-T005
,	O
HPV-52	B-T005
,	O
and	O
HPV-31	B-T005
.	O
HPV-16	B-T005
and	O
HPV-18	B-T005
combined	O
caused	O
80.79	O
%	O
of	O
cervical	B-T191
cancer	I-T191
cases	O
.	O
The	O
infection	O
with	O
multiple	O
HR	B-T005
-	I-T005
HPVs	I-T005
was	O
not	B-T033
a	O
risk	B-T033
factor	I-T033
for	O
cervical	O
lesions	O
.	O
In	O
conclusion	O
,	O
HPV	B-T047
infection	I-T047
was	O
common	O
among	O
women	O
in	O
Shaanxi	O
province	O
.	O
Women	O
older	O
than	O
50	O
years	O
were	O
a	O
high	O
-	O
risk	O
group	O
for	O
HR	B-T047
-	I-T047
HPV	I-T047
infection	I-T047
and	O
cervical	B-T191
cancer	I-T191
.	O
HPV-16	B-T005
and	O
HPV-18	B-T005
were	O
the	O
main	O
carcinogenic	O
genotypes	O
in	O
this	O
region	O
.	O
      
Muscle	O
synergies	O
after	O
stroke	B-T047
are	O
correlated	O
with	O
perilesional	O
high	O
gamma	O
Movements	B-T033
can	O
be	O
factored	O
into	O
modules	O
termed	O
"	O
muscle	O
synergies	O
"	O
.	O
After	O
stroke	B-T047
,	O
abnormal	B-T033
synergies	O
are	O
linked	O
to	O
impaired	O
movements	B-T033
;	O
however	O
,	O
their	O
neural	O
basis	O
is	O
not	O
understood	O
.	O
In	O
a	O
single	O
subject	O
,	O
we	O
examined	O
how	O
electrocorticography	B-T060
signals	I-T060
from	O
the	O
perilesional	O
cortex	B-T023
were	O
associated	O
with	O
synergies	O
.	O
The	O
measured	O
synergies	O
contained	O
a	O
mix	O
of	O
both	O
normal	O
and	O
abnormal	B-T033
patterns	O
and	O
were	O
remarkably	O
similar	O
to	O
those	O
described	O
in	O
past	O
work	O
.	O
Interestingly	O
,	O
we	O
found	O
that	O
both	O
normal	O
and	O
abnormal	B-T033
synergies	O
were	O
correlated	O
with	O
perilesional	O
high	O
gamma	O
.	O
Given	O
the	O
link	O
between	O
high	O
gamma	O
and	O
cortical	B-T033
spiking	I-T033
,	O
our	O
results	O
suggest	O
that	O
perilesional	B-T033
spiking	I-T033
may	O
organize	O
synergies	O
after	O
stroke	B-T047
.	O
      
Pembrolizumab	B-T121
for	O
the	O
treatment	B-T061
of	O
non	B-T191
-	I-T191
small	I-T191
cell	I-T191
lung	I-T191
cancer	I-T191
In	O
the	O
last	O
years	O
,	O
a	O
spectacular	O
development	O
of	O
immunotherapeutic	B-T121
agents	I-T121
aimed	O
at	O
the	O
PD-1	O
/	O
PD	O
-	O
L1	O
axis	O
has	O
taken	O
place	O
.	O
This	O
development	O
of	O
these	O
checkpoint	O
inhibitors	O
has	O
greatly	O
influenced	O
our	O
approach	O
to	O
the	O
treatment	B-T061
of	O
lung	B-T191
cancer	I-T191
in	O
first	B-T061
and	O
second	B-T061
line	I-T061
.	O
The	O
limited	O
toxicity	O
profile	O
and	O
the	O
ability	O
to	O
treat	B-T061
for	O
prolonged	O
periods	O
,	O
even	O
in	O
smokers	B-T033
,	O
is	O
a	O
welcome	O
expansion	O
of	O
the	O
therapeutic	O
arsenal	O
of	O
the	O
oncologist	O
.	O
Areas	O
covered	O
:	O
This	O
review	O
highlights	O
the	O
results	O
of	O
recent	O
clinical	O
trials	O
on	O
pembrolizumab	B-T121
for	O
the	O
treatment	B-T061
of	O
non	B-T191
-	I-T191
small	I-T191
cell	I-T191
lung	I-T191
cancer	I-T191
.	O
The	O
authors	O
discuss	O
both	O
first	B-T061
and	O
second	B-T061
line	I-T061
treatment	I-T061
with	O
pembrolizumab	B-T121
as	O
monotherapy	B-T061
and	O
in	O
combination	B-T061
therapies	I-T061
.	O
Additionally	O
,	O
implications	O
of	O
the	O
PD	O
-	O
L1	O
immunohistochemistry	B-T059
assay	I-T059
with	O
the	O
22C3	O
antibody	O
and	O
its	O
use	O
in	O
clinical	O
practice	O
and	O
trials	O
is	O
discussed	O
.	O
Expert	O
commentary	O
:	O
A	O
higher	O
overall	B-T033
response	I-T033
,	O
overall	O
survival	O
and	O
a	O
moderate	O
toxicity	O
profile	O
is	O
observed	O
with	O
the	O
use	O
of	O
pembrolizumab	B-T121
,	O
compared	O
to	O
chemotherapy	B-T061
,	O
in	O
both	O
first	B-T061
and	O
second	B-T061
line	I-T061
.	O
These	O
promising	O
results	O
have	O
already	O
translated	O
into	O
the	O
registration	B-T058
of	O
pembrolizumab	B-T121
in	O
first	B-T061
and	O
second	B-T061
line	I-T061
in	O
patients	O
with	O
a	O
high	O
expression	O
of	O
PD	O
-	O
L1	O
.	O
However	O
,	O
as	O
PD	O
-	O
L1	O
staining	B-T059
does	O
not	O
sufficiently	O
discriminate	O
responders	B-T033
from	O
non	B-T033
-	I-T033
responders	I-T033
for	O
all	O
checkpoint	O
inhibitors	O
,	O
there	O
still	O
is	O
a	O
need	O
for	O
a	O
better	O
predictive	O
biomarker	O
.	O
      
Intracameral	O
cefuroxime	B-T195
in	O
the	O
prevention	B-T061
of	O
postoperative	B-T047
endophthalmitis	I-T047
:	O
an	O
experience	O
from	O
Hong	O
Kong	O
The	O
purpose	O
was	O
to	O
study	O
the	O
effect	O
of	O
introducing	O
intracameral	O
cefuroxime	B-T195
,	O
which	O
was	O
compounded	B-T058
by	O
a	O
hospital	O
pharmacy	O
,	O
on	O
postoperative	B-T047
endophthalmitis	I-T047
in	O
a	O
tertiary	O
eye	O
centre	O
in	O
Hong	O
Kong	O
.	O
All	O
cases	O
that	O
underwent	O
cataract	B-T061
surgeries	I-T061
over	O
a	O
12	O
-	O
year	O
period	O
(	O
January	O
2004	O
to	O
December	O
2015	O
)	O
were	O
included	O
.	O
The	O
routine	O
use	O
of	O
intracameral	O
cefuroxime	B-T195
at	O
the	O
end	O
of	O
cataract	B-T061
surgery	I-T061
was	O
introduced	O
at	O
our	O
centre	O
after	O
April	O
2010	O
.	O
All	O
cefuroxime	B-T195
aliquots	O
were	O
prepared	O
by	O
the	O
hospital	O
pharmacy	O
using	O
an	O
aseptic	B-T058
compounding	I-T058
technique	O
.	O
The	O
rates	O
of	O
postoperative	B-T047
endophthalmitis	I-T047
before	O
April	O
2010	O
(	O
Group	O
1	O
,	O
no	O
intracameral	O
cefuroxime	B-T195
)	O
and	O
after	O
April	O
2010	O
(	O
Group	O
2	O
,	O
routine	O
use	O
of	O
intracameral	O
cefuroxime	B-T195
)	O
were	O
compared	O
.	O
A	O
total	O
of	O
30,428	O
eyes	B-T023
(	O
7,332	O
in	O
Group	O
1	O
and	O
23,096	O
in	O
Group	O
2	O
)	O
were	O
studied	O
.	O
Eight	O
cases	O
developed	O
postoperative	B-T047
endophthalmitis	I-T047
(	O
1.09	O
in	O
1000	O
;	O
0.11	O
%	O
)	O
in	O
Group	O
1	O
whereas	O
no	O
cases	O
developed	O
endophthalmitis	B-T047
(	O
0	O
%	O
)	O
in	O
Group	O
2	O
.	O
The	O
rate	O
of	O
reduction	O
was	O
statistically	O
significant	O
(	O
p	O
<	O
0.0001	O
)	O
.	O
Seven	O
out	O
of	O
eight	O
cases	O
of	O
endophthalmitis	B-T047
were	O
confirmed	O
by	O
positive	B-T033
culture	I-T033
.	O
Organisms	B-T001
identified	O
were	O
Group	B-T007
G	I-T007
Streptococcus	I-T007
(	O
two	O
cases	O
)	O
,	O
Group	B-T007
B	I-T007
Streptococcus	I-T007
,	O
Staphylococcus	B-T007
aureus	I-T007
,	O
Serratia	B-T007
marcescens	I-T007
,	O
and	O
coagulase	B-T007
-	I-T007
negative	I-T007
Staphylococcus	I-T007
(	O
two	O
cases	O
)	O
.	O
Antibiotic	B-T033
susceptibility	I-T033
testing	O
results	O
were	O
available	O
in	O
six	O
cases	O
.	O
Four	O
out	O
of	O
six	O
organisms	B-T001
were	O
susceptible	O
to	O
the	O
penicillin	B-T195
group	I-T195
.	O
No	B-T033
adverse	I-T033
events	I-T033
related	O
to	O
the	O
use	O
of	O
intracameral	O
cefuroxime	B-T195
were	O
encountered	O
.	O
The	O
use	O
of	O
intracameral	O
cefuroxime	B-T195
could	O
significantly	O
reduce	O
the	O
rate	O
of	O
postoperative	B-T047
endophthalmitis	I-T047
in	O
a	O
tertiary	O
centre	O
in	O
Hong	O
Kong	O
.	O
The	O
use	O
of	O
aseptic	B-T058
compounding	I-T058
to	O
prepare	O
cefuroxime	B-T195
aliquots	O
by	O
hospital	O
pharmacy	O
appeared	O
to	O
be	O
safe	O
and	O
efficacious	O
.	O
      
Design	O
,	O
Synthesis	O
,	O
and	O
Cytotoxic	O
Evaluation	B-T058
of	O
Certain	O
7	O
-	O
Chloro-4-(piperazin-1	O
-	O
yl)quinoline	O
Derivatives	O
as	O
VEGFR	O
-	O
II	O
Inhibitors	O
Signaling	O
pathway	O
inhibition	O
of	O
VEGFR	O
-	O
II	O
is	O
visualized	O
as	O
valuable	O
tool	O
in	O
cancer	B-T191
management	B-T058
.	O
In	O
the	O
current	O
study	O
,	O
the	O
synthesis	O
of	O
novel	O
1	O
-	O
4-(7	O
-	O
chloroquinolin-4	O
-	O
yl)piperazin-1	O
-	O
yl)-2-(N	O
-	O
substituted	O
-	O
amino)-ethanone	O
derivatives	O
(	O
4a	O
-	O
t	O
)	O
was	O
achieved	O
through	O
the	O
amination	O
of	O
2	O
-	O
chloro-1-(4-(7	O
-	O
chloroquinolin-4	O
-	O
yl)piperazin-1	O
-	O
yl)ethanone	O
(	O
3	O
)	O
with	O
different	O
secondary	O
amines	O
.	O
The	O
structures	O
of	O
the	O
target	O
compounds	O
were	O
confirmed	O
by	O
IR	B-T059
,	O
(	B-T060
1	I-T060
)	I-T060
H	I-T060
-	I-T060
NMR	I-T060
,	O
(	B-T060
13	I-T060
)	I-T060
C	I-T060
-	I-T060
NMR	I-T060
,	O
HRMS	B-T059
,	O
and	O
microanalysis	B-T059
.	O
Compounds	O
4a	O
-	O
t	O
were	O
subjected	O
to	O
in	O
vitro	O
anticancer	B-T061
screening	B-T058
against	O
human	B-T191
breast	I-T191
cancer	I-T191
(	O
MCF-7	O
)	O
and	O
prostate	B-T191
cancer	I-T191
(	O
PC3	O
)	O
cell	O
lines	O
.	O
The	O
highest	O
cytotoxicty	O
against	O
both	O
cell	O
lines	O
was	O
displayed	O
by	O
2-(4-(4	O
-	O
bromobenzyl)piperazin-1	O
-	O
yl)-1-(4-(7	O
-	O
chloroquinolin-4	O
-	O
yl)piperazin-1	O
-	O
yl)ethanone	O
(	O
4q	O
)	O
,	O
with	O
IC50	O
values	O
of	O
6.502	O
and	O
11.751	O
μM	O
against	O
MCF-7	O
and	O
PC3	O
cells	O
,	O
respectively	O
,	O
compared	O
with	O
the	O
standard	O
drug	O
doxorubicin	B-T195
(	O
MCF-7	O
:	O
6.774	O
μM	O
,	O
PC3	O
:	O
7.7316	O
μM	O
)	O
.	O
Due	O
to	O
its	O
notable	O
activity	O
toward	O
MCF-7	O
cells	O
,	O
4q	O
was	O
further	O
evaluated	O
as	O
VEGFR	O
-	O
II	O
inhibitor	O
,	O
showing	O
an	O
IC50	O
of	O
1.38	O
μM	O
compared	O
to	O
sorafenib	B-T121
(	O
0.33	O
μM	O
)	O
.	O
The	O
docking	O
study	O
proved	O
that	O
4q	O
has	O
a	O
binding	O
mode	O
akin	O
to	O
that	O
of	O
VEGFR	O
-	O
II	O
inhibitors	O
.	O
      
Intrapartum	O
Cervical	O
Laceration	O
and	O
Subsequent	O
Pregnancy	B-T033
Outcomes	I-T033
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
describe	O
pregnancy	B-T033
outcomes	I-T033
,	O
including	O
cervical	B-T047
insufficiency	I-T047
and	O
preterm	B-T033
birth	I-T033
,	O
in	O
the	O
subsequent	O
pregnancy	O
following	O
an	O
intrapartum	O
cervical	O
laceration	O
.	O
Retrospective	O
cohort	O
of	O
women	O
with	O
their	O
first	O
two	O
consecutive	O
singleton	O
pregnancies	O
carried	O
to	O
≥	O
20(0/7	O
)	O
weeks	O
'	O
gestation	O
within	O
a	O
tertiary	O
health	O
care	O
system	O
from	O
2002	O
to	O
2012	O
.	O
Cervical	O
laceration	O
cases	O
were	O
identified	O
by	O
ICD9	O
codes	O
and	O
included	O
if	O
suture	B-T061
repair	I-T061
was	O
required	O
.	O
In	O
this	O
study	O
,	O
55	O
women	O
were	O
confirmed	B-T033
to	O
have	O
a	O
cervical	O
laceration	O
in	O
the	O
first	O
delivery	O
;	O
43	O
lacerations	O
after	O
vaginal	B-T061
delivery	I-T061
(	B-T061
VD	I-T061
)	I-T061
and	O
12	O
after	O
cesarean	B-T061
delivery	I-T061
(	B-T061
CD	I-T061
)	I-T061
.	O
The	O
median	O
gestational	O
age	O
of	O
the	O
first	O
delivery	O
was	O
40(0/7	O
)	O
weeks	O
and	O
the	O
median	O
birth	O
weight	O
3,545	O
g	O
;	O
these	O
did	O
not	O
differ	O
between	O
VD	B-T061
and	O
CD	B-T061
.	O
In	O
the	O
second	O
pregnancy	O
,	O
2	O
of	O
55	O
women	O
(	O
4.6	O
%	O
)	O
had	O
a	O
prophylactic	O
cerclage	B-T061
placed	O
;	O
1	O
carried	O
to	O
term	O
and	O
the	O
other	O
delivered	B-T033
at	O
35(6/7	O
)	O
weeks	O
.	O
In	O
total	O
,	O
four	O
women	O
(	O
9.3	O
%	O
)	O
delivered	B-T033
the	O
second	O
pregnancy	O
<	O
37	O
weeks	O
:	O
three	O
had	O
a	O
prior	O
term	O
VD	B-T061
and	O
one	O
had	O
a	O
prior	O
34	O
weeks	O
VD	B-T061
.	O
There	O
was	O
only	O
one	O
case	O
of	O
recurrent	O
cervical	O
laceration	O
,	O
occurring	O
in	O
the	O
setting	O
of	O
vaginal	B-T061
deliveries	I-T061
.	O
Obstetric	O
cervical	O
lacerations	O
are	O
uncommon	O
.	O
Complications	O
in	O
the	O
following	O
pregnancy	O
were	O
low	O
,	O
despite	O
lack	O
of	O
additional	O
prophylactic	O
cerclage	B-T061
use	O
.	O
      
The	O
Bindex	O
(	O
®	O
)	O
ultrasound	O
device	O
:	O
reliability	O
of	O
cortical	B-T023
bone	I-T023
thickness	O
measures	O
and	O
their	O
relationship	O
to	O
regional	O
bone	O
mineral	O
density	O
The	O
Bindex	O
(	O
®	O
)	O
quantitative	O
ultrasound	O
(	O
QUS	O
)	O
device	O
is	O
currently	O
available	O
and	O
this	O
study	O
analyzed	O
(	O
I	O
)	O
its	O
relative	O
and	O
absolute	O
intra-	O
and	O
inter	O
-	O
session	O
reliability	O
and	O
(	O
II	O
)	O
the	O
relationship	O
between	O
the	O
data	O
provided	O
by	O
Bindex(	O
®	O
)-QUS	O
and	O
the	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
measured	O
by	O
dual	B-T060
-	I-T060
energy	I-T060
x	I-T060
-	I-T060
ray	I-T060
absorptiometry	I-T060
at	O
corresponding	O
skeletal	O
sites	O
in	O
young	O
and	O
healthy	O
subjects	O
(	O
age	O
:	O
25.0	O
±	O
3.6	O
years	O
)	O
.	O
Bindex(	O
®	O
)-QUS	O
calculates	O
a	O
density	O
index	O
on	O
the	O
basis	O
of	O
the	O
thickness	O
of	O
cortical	B-T023
bone	I-T023
measured	O
at	O
the	O
distal	B-T023
radius	I-T023
and	O
the	O
distal	B-T023
plus	O
proximal	B-T023
tibia	I-T023
.	O
The	O
data	O
show	O
a	O
very	O
good	O
relative	O
and	O
absolute	O
intra-	O
(	O
ICC	O
=	O
0.977	O
,	O
CV	O
=	O
1.5	O
%	O
)	O
and	O
inter	O
-	O
session	O
reliability	O
(	O
ICC	O
=	O
0.978	O
,	O
CV	O
=	O
1.4	O
%	O
)	O
for	O
the	O
density	O
index	O
.	O
The	O
highest	O
positive	B-T033
correlations	O
were	O
found	O
between	O
cortical	B-T023
thickness	O
and	O
BMD	O
for	O
the	O
distal	B-T023
radius	I-T023
and	O
distal	B-T023
tibia	I-T023
(	O
r	O
⩾	O
0.71	O
,	O
p	O
<	O
0.001	O
)	O
.	O
The	O
data	O
indicate	O
that	O
the	O
Bindex(	O
®	O
)-QUS	O
parameters	B-T033
are	O
repeatable	O
within	O
and	O
between	O
measurement	O
sessions	O
.	O
Furthermore	O
,	O
the	O
measurements	O
reflect	O
the	O
BMD	O
at	O
specific	O
skeletal	O
sites	O
.	O
Bindex(	O
®	O
)-QUS	O
might	O
be	O
a	O
useful	O
tool	O
for	O
the	O
measurement	O
of	O
skeletal	O
adaptations	O
.	O
      
Correlation	O
of	O
cardiopulmonary	B-T060
exercise	I-T060
testing	I-T060
parameters	O
with	O
quality	O
of	O
life	O
in	O
stable	B-T033
COPD	B-T047
patients	O
The	O
precise	O
head	O
to	O
head	O
relationships	O
between	O
Cardio	B-T060
-	I-T060
pulmonary	I-T060
exercise	I-T060
testing	I-T060
(	O
CPET	B-T060
)	O
parameters	O
and	O
patients	O
'	O
daily	B-T033
symptoms	I-T033
/	O
activities	O
and	O
the	O
disease	B-T047
social	O
/	O
emotional	O
impact	O
are	O
less	O
well	O
defined	O
.	O
In	O
this	O
study	O
,	O
the	O
correlation	O
of	O
COPD	B-T047
daily	B-T033
symptoms	I-T033
and	O
quality	O
of	O
life	O
[	O
assessed	O
by	O
St.	O
George	O
's	O
Respiratory	O
Questionnaire	O
(	O
SGRQ	O
)	O
]	O
and	O
COPD	B-T047
severity	O
index	O
(	O
BODE	O
-	O
index	O
)	O
with	O
CPET	B-T060
parameters	O
were	O
investigated	O
.	O
Symptom	B-T184
-limited	O
CPET	B-T060
was	O
performed	O
in	O
37	O
consecutive	O
COPD	B-T047
(	O
GOLD	B-T060
I	I-T060
-	I-T060
III	I-T060
)	O
subjects	O
during	O
non-	O
exacerbation	B-T047
phase	O
.	O
The	O
SGRQ	O
was	O
also	O
completed	O
by	O
each	O
patient	O
.	O
SGRQ	O
-	O
score	O
correlated	O
negatively	B-T033
with	O
FEV1	B-T060
(	O
r=-0.49	O
,	O
P<0.01	O
)	O
,	O
predicted	O
maximal	B-T033
work	I-T033
-	I-T033
rate	I-T033
(	O
%	B-T033
WR	I-T033
-	I-T033
max	I-T033
)	O
(	O
r=-0.44	O
,	O
P<0.01	O
)	O
,	O
V'O2	B-T033
/	O
WR	O
(	O
r=-0.52	O
,	O
P<0.01	O
)	O
and	O
breathing	O
reserve	O
(	O
r=-0.50	O
,	O
P<0.01	O
)	O
.	O
However	O
it	O
did	B-T033
not	I-T033
correlate	I-T033
with	O
Peak	B-T033
-	I-T033
V'O2	I-T033
%	O
predicted	O
(	O
r=-0.27	O
,	O
P=0.10	O
)	O
.	O
In	O
20	O
(	O
54.1	O
%	O
)	O
subjects	O
in	O
which	O
leg	B-T033
fatigue	I-T033
was	I-T033
the	I-T033
main	I-T033
cause	I-T033
for	I-T033
stopping	I-T033
the	I-T033
test	I-T033
,	O
Peak	B-T033
-	I-T033
V'O2	I-T033
,	O
%	B-T033
WR	I-T033
-	I-T033
max	I-T033
,	O
HR	O
-	O
Reserve	O
and	O
Breathing	O
reserve	O
were	O
higher	O
(	O
P=0.04	O
,	O
<	O
0.01	O
,	O
0.04	O
and	O
<	O
0.01	O
respectively	O
)	O
than	O
the	O
others	O
.	O
There	O
was	O
also	O
a	O
significant	O
correlation	O
between	O
BODE	O
-	O
index	O
and	O
∆VO2	B-T033
/	O
∆WR	O
(	O
r=-0.64	O
,	O
P<0.001	O
)	O
and	O
breathing	O
-	O
reserve	O
(	O
r=-0.38	O
,	O
P=0.018	O
)	O
.	O
The	O
observed	O
relationships	O
between	O
CPET	B-T060
parameter	O
and	O
daily	O
subjective	O
complaints	O
in	O
COPD	B-T047
were	O
not	O
strong	O
.	O
Those	O
who	O
discontinued	O
the	O
CPET	B-T060
because	B-T033
of	I-T033
leg	I-T033
fatigue	I-T033
were	O
in	O
the	O
earlier	O
stages	O
of	O
COPD	B-T047
.	O
Significant	O
negative	B-T033
correlation	O
between	O
∆VO2	B-T033
/	O
∆WR	O
and	O
BODE	O
-	O
index	O
suggests	O
that	O
along	O
with	O
COPD	B-T047
progression	O
,	O
regardless	O
of	O
negative	B-T033
past	I-T033
history	I-T033
,	O
other	O
comorbidities	O
such	O
as	O
cardiac	B-T033
/	O
musculoskeletal	B-T033
problems	I-T033
should	O
be	O
sought	O
.	O
      
Acoustic	O
startle	O
response	O
in	O
rats	O
predicts	O
inter	O
-	O
individual	O
variation	O
in	O
fear	O
extinction	O
Although	O
a	O
large	O
portion	O
of	O
the	O
population	O
is	O
exposed	O
to	O
a	O
traumatic	O
event	O
at	O
some	O
point	O
,	O
only	O
a	O
small	O
percentage	O
of	O
the	O
population	O
develops	O
post	B-T048
-	I-T048
traumatic	I-T048
stress	I-T048
disorder	I-T048
(	O
PTSD	B-T048
)	O
,	O
suggesting	O
the	O
presence	O
of	O
predisposing	O
factors	O
.	O
Abnormal	B-T033
acoustic	O
startle	O
response	O
(	O
ASR	O
)	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
PTSD	B-T048
,	O
implicating	O
it	O
as	O
a	O
potential	O
predictor	O
of	O
the	O
development	O
of	O
PTSD	B-T048
-like	O
behavior	O
.	O
Since	O
poor	O
extinction	O
and	O
retention	O
of	O
extinction	O
learning	O
are	O
characteristic	O
of	O
PTSD	B-T048
patients	O
,	O
it	O
is	O
of	O
interest	O
to	O
determine	O
if	O
abnormal	B-T033
ASR	O
is	O
predictive	O
of	O
development	O
of	O
such	O
deficits	O
.	O
To	O
determine	O
whether	O
baseline	O
ASR	O
has	O
utility	O
in	O
predicting	O
the	O
development	O
of	O
PTSD	B-T048
-like	O
behavior	O
,	O
the	O
relationship	O
between	O
baseline	O
ASR	O
and	O
freezing	O
behavior	O
following	O
Pavlovian	O
fear	O
conditioning	O
was	O
examined	O
in	O
a	O
group	O
of	O
adult	O
,	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
.	O
Baseline	O
acoustic	O
startle	O
response	O
(	O
ASR	O
)	O
was	O
assessed	O
preceding	O
exposure	O
to	O
a	O
Pavlovian	O
fear	O
conditioning	O
paradigm	O
where	O
freezing	O
behavior	O
was	O
measured	O
during	O
fear	O
conditioning	O
,	O
extinction	O
training	O
,	O
and	O
extinction	O
testing	O
.	O
Although	O
there	O
was	O
no	O
relationship	O
between	O
baseline	O
ASR	O
and	O
fear	O
memory	O
following	O
conditioning	O
,	O
rats	O
with	O
low	O
baseline	O
ASR	O
had	O
significantly	O
lower	O
magnitude	O
of	O
retention	O
of	O
the	O
extinction	O
memory	O
than	O
rats	O
with	O
high	O
baseline	O
ASR	O
.	O
The	O
results	O
suggest	O
that	O
baseline	O
ASR	O
has	O
value	O
as	O
a	O
predictive	O
index	O
of	O
the	O
development	O
of	O
a	O
PTSD	B-T048
-like	O
phenotype	O
.	O
      
The	O
impact	O
of	O
adjunctive	B-T061
guanfacine	B-T121
extended	O
release	O
on	O
stimulant	B-T121
adherence	O
in	O
children	O
/	O
adolescents	O
with	O
attention	B-T048
-	I-T048
deficit	I-T048
/	O
hyperactivity	B-T048
disorder	I-T048
To	O
assess	O
stimulant	B-T121
adherence	O
among	O
children	O
/	O
adolescents	O
with	O
attention	B-T048
-	I-T048
deficit	I-T048
/	O
hyperactivity	B-T048
disorder	I-T048
(	O
ADHD	B-T048
)	O
augmenting	O
stimulants	B-T121
with	O
guanfacine	O
extended	O
-	O
release	O
(	O
GXR	O
)	O
.	O
Inclusion	O
criteria	O
:	O
6	O
-	O
17	O
years	O
,	O
≥1	O
ADHD	B-T048
diagnosis	B-T033
,	O
≥1	O
long	B-T121
-	I-T121
acting	I-T121
and/or	O
short	B-T121
-	I-T121
acting	I-T121
stimulant	I-T121
with	O
GXR	O
augmentation	B-T061
.	O
Modified	O
medication	O
possession	O
ratio	O
(	O
mMPR	O
;	O
days	O
medication	B-T058
available	O
/	O
days	O
in	O
period	O
,	O
excluding	O
medication	B-T058
holidays	O
)	O
was	O
assessed	O
;	O
mMPR	O
<	O
0.80	O
nonadherent	B-T033
.	O
Regression	O
models	O
assessed	B-T058
change	O
in	O
mMPR	O
adjusting	O
for	O
demographic	O
and	O
clinical	O
characteristics	O
.	O
Among	O
patients	O
nonadherent	B-T033
to	O
stimulants	B-T121
pre	O
-	O
augmentation	B-T061
(	O
n	O
=	O
165	O
)	O
,	O
unadjusted	O
mean	O
(	O
SD	O
)	O
pre	O
-	O
and	O
post	O
-	O
stimulant	B-T121
mMPRs	O
were	O
0.68	O
(	O
0.11	O
)	O
and	O
0.87	O
(	O
0.16	O
)	O
.	O
Adjusted	O
mean	O
change	O
in	O
mMPR	O
was	O
0.20	O
for	O
long	B-T121
-	I-T121
acting	I-T121
versus	O
0.18	O
for	O
short	B-T121
-	I-T121
acting	I-T121
stimulants	I-T121
(	O
p	O
=	O
0.34	O
)	O
.	O
Among	O
patients	O
nonadherent	B-T033
to	O
stimulants	B-T121
,	O
GXR	O
augmentation	B-T061
was	O
associated	O
with	O
increased	O
stimulant	B-T121
adherence	O
.	O
      
Protein	O
Design	O
for	O
Nanostructural	B-T059
Engineering	I-T059
:	O
Concluding	O
Remarks	O
and	O
Future	O
Directions	O
This	O
final	O
chapter	O
aims	O
to	O
summarize	O
the	O
main	O
conclusions	O
of	O
the	O
book	O
and	O
to	O
point	O
to	O
possible	O
directions	O
for	O
further	O
research	O
in	O
the	O
field	O
of	O
protein	O
design	O
for	O
nanostructural	B-T059
engineering	I-T059
.	O
Even	O
though	O
this	O
research	O
field	O
is	O
still	O
at	O
its	O
infancy	O
,	O
multidisciplinary	O
research	O
efforts	O
in	O
the	O
design	O
of	O
synthetic	O
protein	O
-based	O
nanostructures	O
and	O
functional	O
materials	O
have	O
resulted	O
in	O
significant	O
progress	O
.	O
The	O
chapters	O
in	O
this	O
book	O
cover	O
several	O
selected	O
examples	O
of	O
the	O
most	O
recent	O
advances	O
concerning	O
the	O
use	O
of	O
proteins	O
and	O
peptides	O
as	O
building	O
blocks	O
for	O
the	O
fabrication	O
of	O
architectures	O
and	O
functional	O
nanostructures	O
,	O
assemblies	O
,	O
and	O
materials	O
.	O
Here	O
,	O
we	O
provide	O
a	O
general	O
overview	O
of	O
the	O
strategies	O
that	O
can	O
be	O
employed	O
to	O
prepare	O
functional	O
protein	O
-based	O
nanostructures	O
,	O
and	O
nanostructured	O
materials	O
and	O
devices	O
.	O
Finally	O
,	O
we	O
highlight	O
some	O
of	O
the	O
main	O
aspects	O
to	O
be	O
considered	O
by	O
the	O
research	O
community	O
to	O
set	O
the	O
path	O
for	O
the	O
near	O
future	O
developments	O
.	O
      
Direct	O
contact	O
with	O
perivascular	B-T023
tumor	O
cells	O
enhances	O
integrin	O
αvβ3	O
signaling	O
and	O
migration	O
of	O
endothelial	O
cells	O
The	O
secretion	O
of	O
soluble	O
pro	O
-	O
angiogenic	O
factors	O
by	O
tumor	O
cells	O
and	O
stromal	O
cells	O
in	O
the	O
perivascular	B-T023
niche	O
promotes	O
the	O
aggressive	B-T191
angiogenesis	I-T191
that	O
is	O
typical	O
of	O
glioblastoma	B-T191
(	O
GBM	B-T191
)	O
.	O
Here	O
,	O
we	O
show	O
that	O
angiogenesis	B-T191
also	O
can	O
be	O
promoted	O
by	O
a	O
direct	O
interaction	O
between	O
brain	B-T023
tumor	O
cells	O
,	O
including	O
tumor	O
cells	O
with	O
cancer	O
stem	O
-like	O
properties	O
(	O
CSCs	O
)	O
,	O
and	O
endothelial	O
cells	O
(	O
ECs	O
)	O
.	O
As	O
shown	O
in	O
vitro	O
,	O
this	O
direct	O
interaction	O
is	O
mediated	O
by	O
binding	O
of	O
integrin	O
αvβ3	O
expressed	O
on	O
ECs	O
to	O
the	O
RGD	O
-	O
peptide	O
in	O
L1CAM	O
expressed	O
on	O
CSCs	O
.	O
It	O
promotes	O
both	O
EC	O
network	O
formation	O
and	O
enhances	O
directed	O
migration	O
toward	O
basic	O
fibroblast	O
growth	O
factor	O
.	O
Activation	O
of	O
αvβ3	O
and	O
bone	O
marrow	O
tyrosine	O
kinase	O
on	O
chromosome	O
X	O
(	O
BMX	O
)	O
is	O
required	O
for	O
migration	O
stimulated	O
by	O
direct	O
binding	O
but	O
not	O
for	O
migration	O
stimulated	O
by	O
soluble	O
factors	O
.	O
RGD	O
-	O
peptide	O
treatment	O
of	O
mice	O
with	O
established	O
intracerebral	O
GBM	B-T191
xenografts	O
significantly	O
reduced	O
the	O
percentage	O
of	O
Sox2	O
-positive	O
tumor	O
cells	O
and	O
CSCs	O
in	O
close	O
proximity	O
to	O
ECs	O
,	O
decreased	O
integrin	O
αvβ3	O
and	O
BMX	O
activation	O
and	O
p130CAS	O
phosphorylation	O
in	O
the	O
ECs	O
,	O
and	O
reduced	O
the	O
vessel	B-T023
surface	O
area	O
.	O
These	O
results	O
reveal	O
a	O
previously	O
unrecognized	O
aspect	O
of	O
the	O
regulation	O
of	O
angiogenesis	B-T191
in	O
GBM	B-T191
that	O
can	O
impact	O
therapeutic	O
anti	B-T121
-	I-T121
angiogenic	I-T121
targeting	O
.	O
      
Targeted	B-T061
therapy	I-T061
in	O
gastric	B-T191
cancer	I-T191
Gastric	B-T191
cancer	I-T191
is	O
the	O
fourth	O
most	O
common	O
cancer	B-T191
worldwide	O
.	O
Surgery	B-T061
in	O
combination	O
with	O
multimodal	B-T061
therapy	I-T061
provides	O
the	O
only	O
curative	B-T033
therapy	I-T033
until	O
now	O
.	O
The	O
importance	O
of	O
targeted	B-T061
therapy	I-T061
became	O
clear	O
over	O
the	O
last	O
few	O
years	O
.	O
Due	O
to	O
the	O
implication	O
of	O
HER2	O
and	O
angiogenesis	O
-directed	O
targeted	B-T061
therapies	I-T061
major	O
advances	O
in	O
the	O
treatment	B-T061
of	O
gastric	B-T191
cancer	I-T191
could	O
be	O
reached	O
.	O
Nevertheless	O
,	O
benefits	O
in	O
survival	O
remain	O
unsatisfactory	O
and	O
the	O
development	O
of	O
resistance	O
to	O
monoclonal	O
antibodies	O
is	O
arising	O
.	O
A	O
comprehensive	O
and	O
comparative	O
literature	O
research	O
was	O
performed	O
to	O
evaluate	B-T058
the	O
status	O
of	O
HER2	O
and	O
angiogenesis	O
-directed	O
targeted	B-T061
therapy	I-T061
in	O
gastric	B-T191
cancer	I-T191
.	O
Up	O
to	O
now	O
,	O
trastuzumab	B-T121
and	O
ramucirumab	O
are	O
the	O
only	O
agents	B-T121
showing	O
remarkable	O
benefits	O
in	O
the	O
therapy	B-T061
for	O
the	O
patients	O
suffering	O
from	O
gastric	B-T191
cancer	I-T191
.	O
The	O
limitations	O
of	O
targeted	B-T061
therapies	I-T061
in	O
gastric	B-T191
cancer	I-T191
are	O
mainly	O
associated	O
with	O
the	O
development	O
of	O
secondary	O
resistance	O
.	O
Addition	O
of	O
targeted	B-T061
therapy	I-T061
in	O
second	B-T061
-	I-T061
line	I-T061
treatment	I-T061
is	O
beneficial	O
when	O
compared	O
with	O
chemotherapy	B-T061
alone	O
.	O
Nevertheless	O
,	O
results	B-T033
in	O
first	B-T061
-	I-T061
line	I-T061
treatment	I-T061
remain	O
modest	O
.	O
Therefore	O
,	O
new	O
therapeutic	B-T121
agents	I-T121
and	O
combinations	B-T121
in	O
the	O
first	B-T061
-	I-T061
line	I-T061
treatment	I-T061
of	O
gastric	B-T191
cancer	I-T191
are	O
urgently	O
needed	O
and	O
remain	O
to	O
be	O
validated	O
in	O
clinical	O
trials	O
.	O
      
Role	O
of	O
agonistic	O
autoantibodies	O
against	O
type-1	O
angiotensin	O
II	O
receptor	O
in	O
the	O
pathogenesis	O
of	O
retinopathy	B-T047
in	O
preeclampsia	O
To	O
investigate	O
the	O
mechanism	O
underlying	O
AT1	O
-	O
AA	O
-induced	O
retinopathy	B-T047
in	O
severe	O
preeclampsia	O
by	O
measuring	O
the	O
positive	O
rate	O
and	O
titer	O
of	O
AT1	O
-	O
AA	O
in	O
plasma	O
from	O
women	O
with	O
severe	O
preeclampsia	O
and	O
normal	O
pregnant	O
women	O
to	O
see	O
whether	O
AT1	O
-	O
AA	O
titer	O
was	O
correlated	O
with	O
the	O
grade	O
of	O
retinopathy	B-T047
.	O
A	O
preeclampsia	O
rat	O
model	O
was	O
also	O
established	O
by	O
intravenous	O
injection	O
of	O
AT1	O
-	O
AA	O
extracted	O
from	O
the	O
plasma	O
of	O
patient	O
suffering	O
from	O
severe	O
preeclampsia	O
.	O
The	O
results	O
showed	O
that	O
the	O
plasma	O
titer	O
and	O
positive	O
rate	O
of	O
AT1	O
-	O
AA	O
were	O
significantly	O
higher	O
in	O
women	O
with	O
severe	O
preeclampsia	O
than	O
normal	O
pregnant	O
women	O
.	O
The	O
antibody	O
titer	O
in	O
cases	O
of	O
severe	O
preeclampsia	O
was	O
associated	O
with	O
the	O
grade	O
of	O
retinopathy	B-T047
,	O
and	O
positively	O
correlated	O
with	O
the	O
level	O
of	O
TNF	O
-	O
α	O
and	O
VEGF	O
.	O
The	O
animal	O
experiment	O
results	O
showed	O
that	O
the	O
modeled	O
rats	O
presented	O
symptoms	B-T184
very	O
similar	O
to	O
symptoms	B-T184
of	O
human	O
preeclampsia	O
,	O
including	O
retinopathy	B-T047
.	O
Ocular	B-T023
fundus	I-T023
examination	B-T058
showed	O
retinal	B-T033
microvascular	I-T033
abnormalities	I-T033
,	O
hemorrhaging	O
and	O
leakage	B-T033
in	O
the	O
severe	O
preeclampsia	O
.	O
Morphological	O
changes	O
included	O
edema	B-T184
,	O
thickening	B-T033
of	O
the	O
INL	B-T023
and	O
ONL	B-T023
,	O
and	O
pigment	B-T033
atrophy	I-T033
.	O
TNF	O
-	O
α	O
and	O
VEGF	O
levels	O
were	O
increased	O
in	O
the	O
vitreous	O
humor	O
and	O
retina	B-T023
of	O
the	O
model	O
rats	O
.	O
Our	O
studies	O
results	O
suggest	O
that	O
abnormal	O
expression	O
of	O
AT1	O
-	O
AA	O
could	O
induce	O
damage	O
to	O
retinal	O
capillary	O
endothelial	O
cells	O
and	O
increase	O
vascular	O
permeability	O
,	O
resulting	O
in	O
retinopathy	B-T047
.	O
      
miR-27b	O
inhibits	O
gastric	B-T191
cancer	I-T191
metastasis	B-T191
by	O
targeting	O
NR2F2	O
Increasing	O
attention	O
is	O
focused	O
on	O
the	O
down	O
-	O
regulation	O
of	O
miRNAs	O
in	O
cancer	B-T191
process	I-T191
.	O
Nuclear	O
receptor	O
subfamily	O
2	O
(	O
NR2F2	O
,	O
also	O
known	O
as	O
COUP	O
-	O
TFII	O
)	O
is	O
involved	O
in	O
the	O
development	O
of	O
many	O
types	O
of	O
cancers	B-T191
,	O
but	O
its	O
role	O
in	O
gastric	B-T191
cancer	I-T191
remains	O
elusive	O
.	O
In	O
this	O
experiment	O
,	O
oncomine	O
and	O
Kaplan	O
-	O
meier	O
database	O
revealed	O
that	O
NR2F2	O
was	O
up	O
-	O
regulated	O
in	O
gastric	B-T191
cancer	I-T191
and	O
that	O
the	O
high	O
NR2F2	O
expression	O
contributed	O
to	O
poor	O
survival	O
.	O
MicroRNA-27b	O
was	O
targeted	O
and	O
down	O
-	O
regulated	O
by	O
NR2F2	O
in	O
human	O
gastric	B-T191
cancer	I-T191
tissues	O
and	O
cells	O
.	O
The	O
ectopic	O
expression	O
of	O
miR-27b	O
inhibited	O
gastric	B-T191
cancer	I-T191
cell	O
proliferation	O
and	O
tumor	B-T191
growth	I-T191
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Assays	B-T059
suggested	O
that	O
the	O
overexpression	O
of	O
miR-27b	O
could	O
promote	O
MGC-803	O
cells	O
'	O
migration	O
and	O
invasion	O
and	O
retard	O
their	O
metastasis	B-T191
to	O
the	O
liver	B-T023
.	O
In	O
addition	O
,	O
down	O
-	O
regulation	O
of	O
miR-27b	O
enhanced	O
GES-1	O
cells	O
'	O
proliferation	O
and	O
metastasis	B-T191
in	O
vitro	O
.	O
These	O
findings	B-T033
reveal	O
that	O
miR-27b	O
is	O
a	O
tumor	O
suppressor	O
in	O
gastric	B-T191
cancer	I-T191
and	O
a	O
biomarker	O
for	O
improving	O
patients	O
'	O
survival	O
.	O
      
Vasopressin	B-T121
regulates	O
the	O
growth	O
of	O
the	O
biliary	O
epithelium	O
in	O
polycystic	B-T019
liver	I-T019
disease	I-T019
The	O
neurohypophysial	B-T121
hormone	I-T121
arginine	B-T121
vasopressin	I-T121
(	O
AVP	B-T121
)	O
acts	O
by	O
three	O
distinct	O
receptor	O
subtypes	O
:	O
V1a	O
,	O
V1b	O
,	O
and	O
V2	O
.	O
In	O
the	O
liver	B-T023
,	O
AVP	B-T121
is	O
involved	O
in	O
ureogenesis	O
,	O
glycogenolysis	O
,	O
neoglucogenesis	O
and	O
regeneration	O
.	O
No	O
data	O
exist	O
about	O
the	O
presence	B-T033
of	O
AVP	B-T121
in	O
the	O
biliary	O
epithelium	O
.	O
Cholangiocytes	O
are	O
the	O
target	O
cells	O
in	O
a	O
number	O
of	O
animal	B-T050
models	I-T050
of	O
cholestasis	B-T047
,	O
including	O
bile	B-T023
duct	I-T023
ligation	B-T061
(	O
BDL	B-T061
)	O
,	O
and	O
in	O
several	O
human	O
pathologies	O
,	O
such	O
as	O
polycystic	B-T019
liver	I-T019
disease	I-T019
characterized	O
by	O
the	O
presence	B-T033
of	O
cysts	B-T047
that	O
bud	O
from	O
the	O
biliary	O
epithelium	O
.	O
In	O
vivo	O
,	O
liver	B-T023
fragments	O
from	O
normal	O
and	O
BDL	B-T061
mice	O
and	O
rats	O
as	O
well	O
as	O
liver	O
samples	O
from	O
normal	O
and	O
ADPKD	B-T019
patients	O
were	O
collected	O
to	O
evaluate	O
:	O
(	O
i	O
)	O
intrahepatic	O
bile	B-T023
duct	I-T023
mass	B-T033
by	O
immunohistochemistry	B-T060
for	O
cytokeratin-19	O
;	O
and	O
(	O
ii	O
)	O
expression	O
of	O
V1a	O
,	O
V1b	O
and	O
V2	O
by	O
immunohistochemistry	B-T060
,	O
immunofluorescence	B-T059
and	O
real	O
-	O
time	O
PCR	O
.	O
In	O
vitro	O
,	O
small	O
and	O
large	O
mouse	O
cholangiocytes	O
,	O
H69	O
(	O
non	O
-	O
malignant	O
human	O
cholangiocytes	O
)	O
and	O
LCDE	O
(	O
human	O
cholangiocytes	O
from	O
the	O
cystic	B-T190
epithelium	I-T190
)	O
were	O
stimulated	O
with	O
vasopressin	B-T121
in	O
the	O
absence/	O
presence	B-T033
of	O
AVP	B-T121
antagonists	I-T121
such	O
as	O
OPC-31260	B-T121
and	O
Tolvaptan	B-T121
,	O
before	O
assessing	O
cellular	O
growth	O
by	O
MTT	B-T059
assay	I-T059
and	O
cAMP	B-T121
levels	O
.	O
Cholangiocytes	O
express	O
V2	O
receptor	O
that	O
was	O
upregulated	O
following	O
BDL	B-T061
and	O
in	O
ADPKD	B-T019
liver	O
samples	O
.	O
Administration	B-T061
of	O
AVP	B-T121
increased	O
proliferation	O
and	O
cAMP	B-T121
levels	O
of	O
small	O
cholangiocytes	O
and	O
LCDE	O
cells	O
.	O
We	O
found	O
no	O
effect	O
in	O
the	O
proliferation	O
of	O
large	O
mouse	O
cholangiocytes	O
and	O
H69	O
cells	O
.	O
Increases	O
were	O
blocked	O
by	O
preincubation	B-T059
with	O
the	O
AVP	B-T121
antagonists	I-T121
.	O
These	O
results	O
showed	O
that	O
AVP	B-T121
and	O
its	O
receptors	O
may	O
be	O
important	O
in	O
the	O
modulation	O
of	O
the	O
proliferation	O
rate	O
of	O
the	O
biliary	O
epithelium	O
.	O
      
HOST	B-T001
IMMUNE	O
RECOGNITION	O
OF	O
THE	O
EPIDEMIC	O
CYSTIC	B-T047
FIBROSIS	I-T047
PATHOGEN	B-T001
BURKHOLDERIA	B-T007
DOLOSA	I-T007
Burkholderia	B-T007
dolosa	I-T007
caused	O
an	O
outbreak	O
in	O
the	O
cystic	B-T047
fibrosis	I-T047
(	O
CF	B-T047
)	O
clinic	O
at	O
Boston	O
Children	O
's	O
Hospital	O
from	O
1998	O
to	O
2005	O
and	O
led	O
to	O
the	O
infection	O
of	O
over	O
40	O
patients	O
,	O
many	O
of	O
whom	O
died	O
due	O
to	O
complications	O
from	O
infection	O
by	O
this	O
organism	B-T007
.	O
To	O
assess	O
whether	O
B.	B-T007
dolosa	I-T007
significantly	O
contributes	O
to	O
disease	B-T047
or	O
is	O
recognized	O
by	O
the	O
host	B-T001
immune	O
response	O
,	O
mice	O
were	O
infected	B-T033
with	O
a	O
sequenced	O
outbreak	O
B.	B-T007
dolosa	I-T007
strain	I-T007
,	O
AU0158	B-T007
,	O
and	O
responses	O
compared	O
to	O
the	O
well	O
-	O
studied	O
CF	B-T047
pathogen	B-T001
,	O
Pseudomonas	B-T007
aeruginosa	I-T007
In	O
parallel	O
,	O
mice	O
were	O
also	O
infected	B-T033
with	O
a	O
polar	O
flagellin	O
mutant	O
of	O
B.	B-T007
dolosa	I-T007
to	O
examine	O
the	O
role	O
of	O
flagella	O
in	O
B.	B-T007
dolosa	I-T007
lung	B-T023
colonization	B-T033
.	O
The	O
results	O
showed	O
a	O
higher	O
persistence	O
in	O
the	O
host	B-T001
by	O
B.	B-T007
dolosa	I-T007
strains	I-T007
and	O
yet	O
neutrophil	O
recruitment	O
and	O
cytokine	O
production	O
were	O
lower	O
compared	O
to	O
P.	B-T007
aeruginosa	I-T007
The	O
ability	O
of	O
host	B-T001
immune	O
cells	O
to	O
recognize	O
B.	B-T007
dolosa	I-T007
was	O
then	O
assessed	O
and	O
B.	B-T007
dolosa	I-T007
induced	O
a	O
robust	O
cytokine	O
response	O
in	O
cultured	O
cells	O
and	O
this	O
effect	O
was	O
dependent	O
on	O
the	O
flagella	O
only	O
when	O
bacteria	B-T007
were	O
dead	O
.	O
Together	O
,	O
these	O
results	O
suggest	O
that	O
B.	B-T007
dolosa	I-T007
can	O
be	O
recognized	O
by	O
host	O
cells	O
in	O
vitro	O
but	O
may	O
avoid	O
or	O
suppress	O
the	O
host	B-T001
immune	O
response	O
in	O
vivo	O
through	O
unknown	O
mechanisms	O
.	O
B.	B-T007
dolosa	I-T007
was	O
then	O
compared	O
to	O
other	O
Burkholderia	B-T007
species	I-T007
and	O
found	O
to	O
induce	O
similar	O
levels	O
of	O
cytokine	O
production	O
despite	O
being	O
internalized	O
by	O
macrophages	O
more	O
than	O
B.	B-T007
cenocepacia	I-T007
strains	I-T007
.	O
These	O
data	O
suggest	O
that	O
B.	B-T007
dolosa	I-T007
AU0158	I-T007
may	O
act	O
differently	O
with	O
host	O
cells	O
and	O
is	O
it	O
recognized	O
differently	O
by	O
immune	O
systems	O
compared	O
other	O
Burkholderia	B-T007
strains	I-T007
or	O
species	O
.	O
      
Crude	O
4	O
-	O
methylcyclohexanemethanol	O
(	O
MCHM	O
)	O
did	O
not	O
cause	O
skin	B-T033
irritation	I-T033
in	O
humans	O
in	O
48	O
-	O
h	O
patch	B-T060
test	I-T060
Crude	O
4	O
-	O
methylcyclohexanemethanol	O
(	O
MCHM	O
)	O
is	O
an	O
industrial	O
chemical	O
used	O
to	O
wash	O
and	O
clean	O
coal	O
.	O
On	O
January	O
9th	O
,	O
2014	O
approximately	O
10,000	O
gallons	O
of	O
a	O
mixture	O
containing	O
crude	O
MCHM	O
were	O
released	O
into	O
the	O
Elk	O
River	O
near	O
Charleston	O
,	O
West	O
Virginia	O
,	O
contaminating	O
the	O
local	O
water	O
supply	O
.	O
Following	O
the	O
spill	O
,	O
residents	O
reported	B-T058
numerous	O
health	B-T184
complaints	I-T184
,	O
and	O
sought	O
medical	B-T033
attention	I-T033
for	O
ailments	B-T184
including	O
rashes	B-T184
and	O
itching	B-T184
.	O
The	O
relationship	O
between	O
the	O
complaints	B-T184
and	O
the	O
spill	O
were	O
unknown	O
,	O
as	O
such	O
symptoms	B-T184
are	O
reported	B-T058
frequently	O
in	O
the	O
background	O
.	O
In	O
this	O
study	O
,	O
the	O
primary	O
irritation	B-T033
potential	O
of	O
crude	O
MCHM	O
was	O
evaluated	O
in	O
206	O
individuals	O
who	O
underwent	O
48	O
hour	O
semi	O
-	O
occluded	O
patch	B-T060
testing	I-T060
.	O
MCHM	O
concentrations	O
assessed	O
in	O
this	O
study	O
were	O
1	O
,	O
5	O
,	O
15	O
,	O
and	O
100	O
ppm	O
.	O
No	O
appreciable	O
skin	O
reactions	O
were	O
observed	O
in	O
individuals	O
at	O
any	O
concentration	O
.	O
Three	O
of	O
the	O
five	O
concentrations	O
evaluated	O
were	O
above	O
the	O
highest	O
measured	O
concentration	O
of	O
MCHM	O
in	O
the	O
tap	B-T121
water	I-T121
of	O
residents	O
in	O
West	O
Virginia	O
(	O
3.7	O
ppm	O
)	O
.	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
crude	O
MCHM	O
would	O
not	O
be	O
a	O
dermal	O
irritant	O
for	O
the	O
vast	O
majority	O
,	O
if	O
not	O
all	O
,	O
potentially	O
exposed	O
persons	O
at	O
the	O
concentrations	O
in	O
the	O
water	B-T121
reported	B-T058
after	O
the	O
spill	O
.	O
      
Renal	B-T047
arterial	I-T047
mycotic	I-T047
aneurysm	I-T047
after	O
kidney	B-T061
transplantation	I-T061
Mycotic	B-T047
aneurysm	I-T047
is	O
a	O
rare	O
condition	O
mostly	O
attributable	O
to	O
Candida	O
or	O
Aspergillus	O
species	O
.	O
About	O
20	O
cases	O
of	O
Candida	O
-related	O
arteritis	O
have	O
been	O
reported	O
in	O
kidney	B-T061
transplant	I-T061
patients	O
.	O
Herein	O
,	O
we	O
report	O
the	O
case	O
of	O
a	O
40	O
-	O
year-	O
old	O
man	O
who	O
received	O
a	O
kidney	B-T023
from	O
a	O
deceased	O
donor	O
in	O
whom	O
an	O
accidental	O
digestive	O
wound	O
was	O
made	O
during	O
organ	B-T058
retrieval	I-T058
.	O
He	O
presented	O
with	O
sudden	O
anuria	B-T047
47	O
days	O
after	O
renal	B-T061
transplantation	I-T061
revealing	O
a	O
large	O
mycotic	B-T047
aneurysm	I-T047
of	O
the	O
kidney	O
graft	O
renal	B-T023
artery	I-T023
.	O
Organs	B-T023
derived	O
from	O
donors	O
in	O
whom	O
a	O
digestive	O
breach	O
is	O
noticed	O
should	O
be	O
used	O
with	O
caution	O
.	O
      
Bone	O
extracellular	O
matrix	O
hydrogel	O
enhances	O
osteogenic	O
differentiation	O
of	O
C2C12	O
myoblasts	O
and	O
mouse	O
primary	O
calvarial	B-T023
cells	O
Hydrogel	O
scaffolds	O
derived	O
from	O
the	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
of	O
mammalian	O
tissues	O
have	O
been	O
successfully	O
used	O
to	O
promote	O
tissue	O
repair	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
osteogenic	O
potential	O
of	O
ECM	O
hydrogels	O
prepared	O
from	O
demineralized	O
and	O
decellularized	O
bovine	O
bone	O
in	O
the	O
presence	O
and	O
absence	O
of	O
osteogenic	O
medium	O
.	O
Culture	B-T059
of	O
C2C12	O
and	O
mouse	O
primary	O
calvarial	B-T023
cells	O
(	O
mPCs	O
)	O
on	O
decellularized	O
bone	O
ECM	O
(	O
bECM	O
)	O
and	O
demineralized	O
bone	O
matrix	O
(	O
DBM	O
)	O
gels	O
resulted	O
in	O
increased	O
expression	B-T059
of	O
osteogenic	O
gene	O
markers	O
,	O
including	O
a	O
3.6-	O
and	O
13.4	O
-	O
fold	O
increase	O
in	O
osteopontin	O
and	O
15.7-	O
and	O
27.1	O
-	O
fold	O
increase	O
in	O
osteocalcin	O
when	O
mPCs	O
were	O
cultured	B-T059
upon	O
bECM	O
with	O
basal	O
and	O
osteogenic	O
media	O
,	O
respectively	O
.	O
bECM	O
hydrogels	O
stimulated	O
the	O
osteogenic	O
differentiation	O
of	O
C2C12	O
and	O
mPCs	O
even	O
in	O
the	O
absence	O
of	O
osteogenic	O
medium	O
.	O
These	O
results	O
suggest	O
that	O
bECM	O
hydrogel	O
scaffolds	O
may	O
have	O
great	O
utility	O
in	O
future	O
clinical	O
applications	O
for	O
bone	O
tissue	B-T061
engineering	I-T061
.	O
©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc.	O
J	O
Biomed	O
Mater	O
Res	O
Part	O
B	O
:	O
Appl	O
Biomater	O
,	O
2017	O
.	O
      
Social	O
capital	O
and	O
healthy	O
ageing	O
in	O
Indonesia	O
A	O
large	O
international	O
literature	O
has	O
found	O
a	O
positive	B-T033
association	O
between	O
social	O
capital	O
and	O
measures	O
of	O
physical	B-T033
and	O
mental	O
health	O
.	O
However	O
,	O
there	O
is	O
a	O
paucity	O
of	O
research	O
on	O
the	O
links	O
between	O
social	O
capital	O
and	O
healthy	O
ageing	O
in	O
a	O
developing	O
country	O
environment	O
,	O
where	O
universal	O
social	O
security	O
coverage	O
is	O
absent	O
and	O
health	O
infrastructure	O
is	O
poor	O
.	O
In	O
this	O
paper	O
,	O
we	O
develop	O
and	O
empirically	O
test	O
a	O
model	O
of	O
the	O
linkages	O
between	O
social	O
capital	O
and	O
the	O
health	O
outcomes	O
for	O
older	O
adults	O
in	O
Indonesia	O
,	O
using	O
data	O
from	O
the	O
Indonesian	O
Family	O
Life	O
Survey	O
-	O
East	O
(	O
IFLS	O
-	O
East	O
)	O
,	O
conducted	O
in	O
2012	O
.	O
Using	O
multivariate	O
regression	O
analysis	O
,	O
we	O
examine	O
whether	O
social	O
capital	O
plays	O
a	O
role	O
in	O
mitigating	O
poor	B-T033
health	I-T033
among	O
older	O
individuals	O
aged	O
50	O
years	O
and	O
above	O
in	O
Indonesia	O
's	O
most	O
vulnerable	O
provinces	O
.	O
We	O
test	O
the	O
robustness	O
of	O
these	O
social	O
capital	O
variables	O
across	O
different	O
health	O
measures	O
(	O
self	O
-	O
assessed	O
health	O
,	O
Activities	O
of	O
Daily	O
Living	O
(	O
ADL	O
)	O
,	O
measures	O
of	O
chronic	B-T047
illness	I-T047
and	O
mental	O
health	O
measures	O
)	O
,	O
as	O
well	O
as	O
across	O
different	O
demographic	O
groups	O
,	O
after	O
controlling	O
for	O
an	O
array	O
of	O
socio	O
-	O
economic	O
,	O
demographic	O
and	O
geographic	O
characteristics	O
.	O
Our	O
findings	B-T033
show	O
that	O
access	O
to	O
better	O
social	O
capital	O
(	O
using	O
measures	O
of	O
neighbourhood	O
trust	O
and	O
community	O
participation	O
)	O
is	O
associated	O
with	O
a	O
higher	O
degree	O
of	O
physical	O
mobility	O
,	O
independence	O
,	O
and	O
mental	O
well	O
-	O
being	O
among	O
older	O
individuals	O
but	O
has	O
no	O
influence	O
on	O
chronic	B-T047
illnesses	I-T047
.	O
These	O
results	O
are	O
consistent	O
when	O
we	O
estimate	O
samples	O
disaggregated	O
by	O
gender	O
,	O
rural	B-T033
/	O
urban	O
residence	O
,	O
and	O
by	O
age	O
categories	O
.	O
From	O
a	O
policy	O
perspective	O
these	O
results	O
point	O
to	O
the	O
importance	O
of	O
social	O
capital	O
measures	O
in	O
moderating	O
the	O
influence	O
of	O
poor	B-T033
health	I-T033
,	O
particularly	O
in	O
the	O
Activities	O
of	O
Daily	O
Living	O
.	O
      
Comparing	O
Time	O
Perception	O
among	O
Morphine	B-T121
-	O
Derived	O
Drugs	B-T121
Addicts	O
and	O
Controls	O
The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
compare	O
time	O
perception	O
among	O
drug	B-T033
addicts	I-T033
and	O
controls	O
.	O
30	O
drug	B-T033
addicts	I-T033
were	O
selected	O
,	O
and	O
30	O
non	O
-	O
addict	O
individuals	O
were	O
selected	O
as	O
the	O
control	O
group	O
.	O
The	O
two	O
groups	O
performed	O
three	O
tests	O
of	O
time	O
reproduction	O
,	O
time	O
estimation	O
,	O
and	O
time	O
discrimination	O
.	O
There	O
was	O
a	O
significant	O
difference	O
between	O
the	O
addicts	O
group	O
and	O
the	O
control	O
group	O
regarding	O
the	O
error	O
of	O
time	O
reproduction	O
and	O
time	O
estimation	O
.	O
The	O
addict	O
group	O
in	O
comparison	O
to	O
the	O
control	O
group	O
had	O
a	O
lower	O
under-	O
reproduction	O
and	O
a	O
higher	O
over-	O
reproduction	O
error	O
,	O
and	O
also	O
a	O
lower	O
under-	O
estimation	O
and	O
higher	O
over-	O
estimation	O
error	O
.	O
However	O
,	O
regarding	O
time	O
discrimination	O
,	O
no	O
significant	O
difference	O
was	O
observed	O
between	O
the	O
errors	O
committed	O
by	O
both	O
groups	O
.	O
On	O
the	O
other	O
hand	O
,	O
when	O
showing	O
images	O
of	O
drug	O
consumption	O
tools	O
and	O
normal	O
images	O
with	O
same	O
durations	O
,	O
the	O
normal	O
group	O
believed	O
that	O
the	O
images	O
related	O
to	O
drug	O
consumption	O
tools	O
were	O
shown	O
for	O
a	O
shorter	O
period	O
of	O
time	O
.	O
Time	O
perception	O
is	O
different	O
between	O
morphine	B-T121
-	O
derived	O
drugs	B-T121
addicts	O
and	O
controls	O
.	O
      
Pancreatic	B-T023
neuroendocrine	B-T191
cancer	I-T191
with	O
liver	B-T191
metastases	I-T191
and	O
multiple	B-T191
peritoneal	I-T191
metastases	I-T191
:	O
report	O
of	O
one	O
case	O
Pancreatic	B-T023
neuroendocrine	B-T191
tumor	I-T191
(	O
pNET	B-T191
)	O
is	O
a	O
rare	O
pancreatic	B-T191
tumor	I-T191
,	O
with	O
its	O
incidence	O
showing	O
a	O
rising	O
trend	O
in	O
recent	O
years	O
.	O
Most	O
of	O
its	O
distant	O
metastases	O
are	O
found	B-T033
in	O
the	O
liver	B-T023
.	O
This	O
article	O
describes	O
a	O
59	O
-	O
year	O
-	O
old	O
male	O
patient	O
with	O
pNET	B-T191
with	O
liver	B-T191
metastasis	I-T191
and	O
multiple	B-T191
abdominal	I-T191
metastases	I-T191
,	O
focusing	O
on	O
the	O
management	B-T058
of	O
this	O
tumor	B-T191
in	O
its	O
advanced	O
stage	O
.	O
      
Intestinal	B-T023
micropatches	O
for	O
oral	O
insulin	B-T061
delivery	I-T061
Diabetes	B-T047
mellitus	I-T047
has	O
become	O
a	O
major	O
public	O
health	O
issue	O
that	O
has	O
almost	O
reached	O
epidemic	O
proportions	O
worldwide	O
.	O
Injectable	O
insulin	O
has	O
been	O
typically	O
utilized	O
for	O
the	O
management	B-T058
of	O
this	O
chronic	B-T047
disease	I-T047
.	O
However	O
,	O
lack	B-T033
of	I-T033
patient	I-T033
compliance	I-T033
with	O
injectable	B-T121
formulations	O
has	O
spurred	O
the	O
development	O
of	O
oral	O
insulin	B-T121
formulations	O
,	O
which	O
although	O
appealing	O
,	O
face	O
several	O
delivery	B-T061
challenges	B-T058
.	O
We	O
have	O
developed	O
novel	O
mucoadhesive	O
intestinal	B-T023
patches	O
,	O
several	O
hundred	O
micrometers	O
in	O
dimension	O
(	O
micropatches	O
)	O
that	O
address	O
the	O
challenges	B-T058
of	O
oral	O
insulin	B-T061
delivery	I-T061
.	O
The	O
micropatches	O
adhere	O
to	O
the	O
intestinal	O
mucosa	O
,	O
release	O
their	O
drug	B-T121
load	O
rapidly	O
within	O
30	O
min	O
and	O
are	O
effective	O
in	O
lowering	B-T033
blood	I-T033
glucose	I-T033
levels	I-T033
in	O
vivo	O
.	O
When	O
insulin	B-T121
-loaded	O
micropatches	O
were	O
administered	B-T061
with	O
a	O
permeation	B-T121
enhancer	I-T121
and	O
protease	B-T121
inhibitor	I-T121
,	O
a	O
peak	O
efficacy	O
of	O
34	O
%	O
drop	B-T033
in	I-T033
blood	I-T033
glucose	I-T033
levels	I-T033
was	O
observed	O
within	O
3	O
h.	O
Efficacy	O
further	O
improved	O
to	O
41	O
%	O
when	O
micropatches	O
were	O
administered	B-T061
in	O
multiple	O
doses	O
.	O
Here	O
,	O
we	O
describe	O
the	O
design	O
of	O
micropatches	O
as	O
an	O
oral	O
insulin	B-T121
formulation	O
and	O
report	O
their	O
in	O
vivo	O
efficacy	O
.	O
      
Do	O
dynamic	O
global	O
vegetation	O
models	O
capture	O
the	O
seasonality	O
of	O
carbon	O
fluxes	O
in	O
the	O
Amazon	O
basin	O
?	O
A	O
data	O
-	O
model	O
intercomparison	O
To	O
predict	O
forest	O
response	O
to	O
long	O
-	O
term	O
climate	O
change	O
with	O
high	O
confidence	O
requires	O
that	O
dynamic	O
global	O
vegetation	O
models	O
(	O
DGVMs	O
)	O
be	O
successfully	O
tested	O
against	O
ecosystem	O
response	O
to	O
short	O
-	O
term	O
variations	O
in	O
environmental	O
drivers	O
,	O
including	O
regular	O
seasonal	O
patterns	O
.	O
Here	O
,	O
we	O
used	O
an	O
integrated	O
dataset	O
from	O
four	O
forests	O
in	O
the	O
Brasil	O
flux	O
network	O
,	O
spanning	O
a	O
range	O
of	O
dry	O
-	O
season	O
intensities	O
and	O
lengths	O
,	O
to	O
determine	O
how	O
well	O
four	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
models	O
(	O
IBIS	O
,	O
ED2	O
,	O
JULES	O
,	O
and	O
CLM3.5	O
)	O
simulated	O
the	O
seasonality	O
of	O
carbon	O
exchanges	O
in	O
Amazonian	O
tropical	O
forests	O
.	O
We	O
found	O
that	O
most	O
DGVMs	O
poorly	O
represented	O
the	O
annual	O
cycle	O
of	O
gross	O
primary	O
productivity	O
(	O
GPP	O
)	O
,	O
of	O
photosynthetic	O
capacity	O
(	O
Pc	O
)	O
,	O
and	O
of	O
other	O
fluxes	O
and	O
pools	O
.	O
Models	O
simulated	O
consistent	O
dry	O
-	O
season	O
declines	O
in	O
GPP	O
in	O
the	O
equatorial	O
Amazon	O
(	O
Manaus	O
K34	O
,	O
Santarem	O
K67	O
,	O
and	O
Caxiuanã	O
CAX	O
)	O
;	O
a	O
contrast	O
to	O
observed	O
GPP	O
increases	O
.	O
Model	O
simulated	O
dry	O
-	O
season	O
GPP	O
reductions	O
were	O
driven	O
by	O
an	O
external	O
environmental	O
factor	O
,	O
'	O
soil	B-T033
water	I-T033
stress	I-T033
'	O
and	O
consequently	O
by	O
a	O
constant	O
or	O
decreasing	O
photosynthetic	O
infrastructure	O
(	O
Pc	O
)	O
,	O
while	O
observed	O
dry	O
-	O
season	O
GPP	O
resulted	O
from	O
a	O
combination	O
of	O
internal	O
biological	O
(	O
leaf	O
-flush	O
and	O
abscission	O
and	O
increased	O
Pc	O
)	O
and	O
environmental	O
(	O
incoming	O
radiation	O
)	O
causes	O
.	O
Moreover	O
,	O
we	O
found	O
models	O
generally	O
overestimated	O
observed	O
seasonal	O
net	O
ecosystem	O
exchange	O
(	O
NEE	O
)	O
and	O
respiration	O
(	O
Re	O
)	O
at	O
equatorial	O
locations	O
.	O
In	O
contrast	O
,	O
a	O
southern	O
Amazon	O
forest	O
(	O
Jarú	O
RJA	O
)	O
exhibited	O
dry	O
-	O
season	O
declines	O
in	O
GPP	O
and	O
Re	O
consistent	O
with	O
most	O
DGVMs	O
simulations	O
.	O
While	O
water	O
limitation	O
was	O
represented	O
in	O
models	O
and	O
the	O
primary	O
driver	O
of	O
seasonal	O
photosynthesis	O
in	O
southern	O
Amazonia	O
,	O
changes	O
in	O
internal	O
biophysical	O
processes	O
,	O
light	O
-	O
harvesting	O
adaptations	O
(	O
e.g.	O
,	O
variations	O
in	O
leaf	O
area	O
index	O
(	O
LAI	O
)	O
and	O
increasing	O
leaf	O
-level	O
assimilation	O
rate	O
related	O
to	O
leaf	O
demography	O
)	O
,	O
and	O
allocation	O
lags	O
between	O
leaf	O
and	O
wood	O
,	O
dominated	O
equatorial	O
Amazon	O
carbon	O
flux	O
dynamics	O
and	O
were	O
deficient	O
or	O
absent	O
from	O
current	O
model	O
formulations	O
.	O
Correctly	O
simulating	O
flux	O
seasonality	O
at	O
tropical	O
forests	O
requires	O
a	O
greater	O
understanding	O
and	O
the	O
incorporation	O
of	O
internal	O
biophysical	O
mechanisms	O
in	O
future	O
model	O
developments	O
.	O
      
Stem	O
cell	O
registry	O
programme	O
for	O
patients	O
with	O
ischemic	B-T047
cardiomyopathy	I-T047
undergoing	O
coronary	B-T061
artery	I-T061
bypass	I-T061
grafting	I-T061
:	O
what	O
benefits	O
does	O
it	O
derive	O
?	O
Standardization	O
of	O
stem	B-T061
cell	I-T061
therapy	I-T061
requires	O
application	O
of	O
appropriate	O
methods	O
to	O
evaluate	B-T058
safety	B-T058
and	I-T058
efficac	I-T058
y	O
,	O
including	O
long	O
-	O
term	O
pharmacovigilance	O
.	O
To	O
accomplish	O
this	O
objective	O
,	O
a	O
long	O
-	O
term	O
registry	O
programme	O
was	O
installed	O
.	O
We	O
analysed	O
150	O
patients	O
with	O
ischemic	B-T047
cardiomyopathy	I-T047
,	O
who	O
received	O
intramyocardial	O
CD133	O
+	O
bone	O
marrow	O
mononuclear	O
stem	O
cell	O
treatment	B-T061
combined	O
with	O
coronary	B-T061
artery	I-T061
bypass	I-T061
grafting	I-T061
(	O
CABG	B-T061
)	O
or	O
CABG	B-T061
alone	O
.	O
The	O
mortality	O
rate	O
,	O
major	O
adverse	B-T033
cerebral	I-T033
and	O
cardiac	B-T033
events	I-T033
,	O
and	O
functional	O
outcome	O
parameters	O
were	O
evaluated	B-T058
for	O
the	O
time	O
period	O
up	O
to	O
14	O
years	O
follow	B-T058
-	I-T058
up	I-T058
.	O
As	O
a	O
result	O
,	O
we	O
have	O
stratified	O
the	O
patient	O
population	O
(	O
96	O
patients	O
)	O
into	O
responders	B-T033
and	O
non	B-T033
-	I-T033
responders	I-T033
.	O
Furthermore	O
,	O
the	O
analysis	O
of	O
relevant	O
predictors	O
of	O
good	B-T033
response	I-T033
to	O
CD133	O
+	O
bone	O
marrow	O
mononuclear	O
stem	O
cell	O
treatment	B-T061
was	O
performed	O
.	O
Several	O
positive	O
tendencies	O
related	O
to	O
stem	B-T061
cells	I-T061
transplantation	I-T061
were	O
demonstrated	O
.	O
First	O
,	O
no	B-T033
significant	I-T033
difference	O
in	O
major	O
adverse	B-T033
cardiovascular	I-T033
and	O
cerebral	B-T033
events	I-T033
was	O
observed	O
between	O
stem	O
cell	O
and	O
control	O
group	O
up	O
to	O
14	O
years	O
follow	B-T058
-	I-T058
up	I-T058
.	O
Second	O
,	O
an	O
improvement	O
of	O
left	O
ventricle	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
in	O
stem	O
cell	O
group	O
retained	O
for	O
5	O
years	O
in	O
contrast	O
with	O
CABG	B-T061
-	O
only	O
group	O
,	O
where	O
no	O
significant	O
changes	O
in	O
LVEF	O
after	O
2	O
years	O
were	O
observed	O
.	O
In	O
addition	O
,	O
LVEF	O
under	O
30	O
%	O
and	O
left	B-T060
ventricle	I-T060
end	I-T060
diastolic	I-T060
diameter	I-T060
above	O
60	O
mm	O
were	O
independent	O
predictors	O
of	O
functional	O
response	O
to	O
CD133	O
+	O
cell	O
therapy	B-T061
.	O
Participants	O
with	O
overt	B-T047
heart	I-T047
failure	I-T047
benefit	O
most	O
from	O
CABG	B-T061
combined	O
with	O
intramyocardial	O
injection	B-T061
of	O
CD133	O
+	O
bone	O
marrow	O
mononuclear	O
cell	O
within	O
the	O
group	O
.	O
An	O
improvement	O
LVEF	O
in	O
stem	O
cell	O
group	O
remained	O
for	O
5	O
years	O
in	O
contrast	O
with	O
the	O
CABG	B-T061
-	O
only	O
group	O
.	O
The	O
patients	O
,	O
in	O
whom	O
the	O
improvement	O
of	O
both	O
LVEF	O
and	O
LVED	B-T060
was	O
observed	O
,	O
have	O
benefited	O
by	O
increased	O
life	O
expectancy	O
.	O
      
Tetrabromobisphenol	O
A	O
activates	O
the	O
hepatic	B-T023
interferon	O
pathway	O
in	O
rats	O
Tetrabromobisphenol	O
A	O
(	O
TBBPA	O
)	O
is	O
a	O
widely	O
used	O
flame	O
retardant	O
in	O
printed	O
circuit	O
boards	O
,	O
paper	O
,	O
and	O
textiles	O
.	O
In	O
a	O
two	O
-	O
year	O
study	O
,	O
TBBPA	O
showed	O
evidence	O
of	O
uterine	B-T191
tumors	I-T191
in	O
female	O
Wistar	O
-	O
Han	O
rats	O
and	O
liver	B-T191
and	O
colon	B-T191
tumors	I-T191
in	O
B6C3F1	O
mice	O
.	O
In	O
order	O
to	O
gain	O
further	O
insight	O
into	O
early	O
gene	O
and	O
pathway	O
changes	O
leading	O
to	O
cancer	B-T191
,	O
we	O
exposed	O
female	O
Wistar	O
Han	O
rats	O
to	O
TBBPA	O
at	O
0	O
,	O
25	O
,	O
250	O
,	O
or	O
1000mg	O
/	O
kg	O
(	O
oral	O
gavage	O
in	O
corn	O
oil	O
,	O
5×/	O
week	O
)	O
for	O
13	O
weeks	O
.	O
Because	O
at	O
the	O
end	O
of	O
the	O
TBBPA	O
exposure	O
period	O
,	O
there	O
were	O
no	O
treatment	O
-	O
related	O
effects	O
on	O
body	O
weights	O
,	O
liver	B-T033
or	O
uterus	B-T033
lesions	I-T033
,	O
and	O
liver	B-T023
and	O
uterine	B-T023
organ	I-T023
weights	O
were	O
within	O
10	O
%	O
of	O
controls	O
,	O
only	O
the	O
high	O
dose	O
animals	O
were	O
analyzed	O
.	O
Analysis	O
of	O
the	O
hepatic	B-T023
and	O
uterine	B-T023
transcriptomes	O
showed	O
TBBPA	O
-induced	O
changes	O
primarily	O
in	O
the	O
liver	B-T023
(	O
1000mg	O
/	O
kg	O
)	O
,	O
with	O
159	O
transcripts	O
corresponding	O
to	O
132	O
genes	O
differentially	O
expressed	O
compared	O
to	O
controls	O
(	O
FDR=0.05	O
)	O
.	O
Pathway	O
analysis	O
showed	O
activation	O
of	O
interferon	B-T121
(	O
IFN	B-T121
)	O
and	O
metabolic	O
networks	O
.	O
TBBPA	O
induced	O
few	O
molecular	O
changes	O
in	O
the	O
uterus	B-T023
.	O
Activation	O
of	O
the	O
interferon	O
pathway	O
in	O
the	O
liver	B-T023
occurred	O
after	O
13	O
-	O
weeks	O
of	O
TBBPA	O
exposure	O
,	O
and	O
with	O
longer	O
term	O
TBBPA	O
exposure	O
this	O
may	O
lead	O
to	O
immunomodulatory	B-T061
changes	O
that	O
contribute	O
to	O
carcinogenic	B-T191
processes	I-T191
.	O
      
Boston	O
Keratoprosthesis	O
Type	O
1	O
:	O
A	O
Randomized	O
Controlled	O
Trial	O
of	O
Fresh	O
versus	O
Frozen	O
Corneal	O
Donor	O
Carriers	O
with	O
Long	O
-	O
Term	O
Follow	B-T058
-	I-T058
up	I-T058
To	O
compare	O
the	O
long	O
-	O
term	O
clinical	O
outcomes	O
of	O
fresh	O
versus	O
frozen	O
corneal	O
graft	O
carriers	O
for	O
the	O
Boston	O
Keratoprosthesis	O
type	O
1	O
(	O
B	O
-	O
KPro	O
)	O
.	O
Prospective	O
,	O
single	O
-	O
center	O
,	O
nonblinded	O
,	O
randomized	O
controlled	O
trial	O
.	O
All	O
participants	O
were	O
followed	O
through	O
the	O
initial	O
study	O
protocol	O
of	O
24	O
months	O
and	O
were	O
approached	O
to	O
enter	O
an	O
extension	O
phase	O
,	O
with	O
continuing	O
follow	B-T058
-	I-T058
up	I-T058
visits	I-T058
to	O
60	O
months	O
.	O
All	O
patients	O
undergoing	O
B	B-T061
-	I-T061
KPro	I-T061
surgery	I-T061
between	O
October	O
2008	O
and	O
December	O
2009	O
by	O
a	O
single	O
experienced	O
surgeon	O
at	O
the	O
Centre	O
Hospitalier	O
de	O
l'Université	O
de	O
Montréal	O
using	O
an	O
allograft	O
carrier	O
were	O
considered	O
.	O
Patients	O
were	O
excluded	O
if	O
they	O
had	O
previously	O
undergone	O
B	O
-	O
KPro	O
implantation	B-T061
.	O
Participants	O
were	O
randomized	B-T033
individually	O
to	O
receive	O
a	O
B	O
-	O
KPro	O
using	O
a	O
frozen	O
or	O
a	O
fresh	O
corneal	O
graft	O
carrier	O
on	O
the	O
basis	O
of	O
tissue	O
availability	O
on	O
the	O
day	O
of	O
surgery	B-T061
,	O
as	O
determined	O
by	O
the	O
local	O
eye	O
bank	O
.	O
The	O
primary	O
outcome	O
measure	O
was	O
device	B-T033
retention	I-T033
at	O
24	O
and	O
60	O
months	O
.	O
Secondary	O
outcome	O
measures	O
included	O
surgical	B-T033
feasibility	I-T033
,	O
visual	O
acuity	O
(	O
VA	O
)	O
,	O
and	O
complications	O
.	O
Thirty	O
-	O
seven	O
eyes	B-T023
of	O
37	O
patients	O
were	O
enrolled	O
in	O
the	O
initial	O
study	O
protocol	O
,	O
with	O
19	O
eyes	B-T023
randomized	O
to	O
fresh	O
and	O
18	O
to	O
frozen	O
carrier	O
grafts	O
.	O
Thirty	O
-	O
six	O
eyes	B-T023
were	O
followed	O
through	O
to	O
24	O
months	O
,	O
with	O
1	O
lost	O
to	O
follow	B-T058
-	I-T058
up	I-T058
.	O
Of	O
these	O
,	O
26	O
were	O
enrolled	O
in	O
the	O
extension	O
(	O
11	O
eyes	B-T023
with	O
a	O
frozen	O
and	O
15	O
eyes	B-T023
with	O
a	O
fresh	O
carrier	O
graft	O
)	O
.	O
There	O
were	O
no	B-T033
differences	I-T033
in	O
the	O
baseline	O
characteristics	O
of	O
patients	O
enrolled	O
in	O
the	O
extension	O
phase	O
versus	O
those	O
who	O
were	O
not	O
.	O
At	O
60	O
months	O
,	O
median	O
corrected	O
distance	O
VA	O
)	O
in	O
the	O
fresh	O
group	O
had	O
improved	B-T033
to	O
20/150	O
from	O
a	O
baseline	O
of	O
counting	O
fingers	O
,	O
whereas	O
the	O
frozen	O
group	O
improved	B-T033
to	O
20/400	O
from	O
a	O
baseline	O
of	O
hand	O
motions	O
.	O
Device	B-T033
retention	I-T033
was	O
100	O
%	O
at	O
24	O
months	O
and	O
96	O
%	O
at	O
60	O
months	O
.	O
There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
rate	O
of	O
complications	O
between	O
groups	O
.	O
Fresh	O
and	O
frozen	O
corneal	O
donors	O
offer	O
similar	O
clinical	O
outcomes	O
when	O
used	O
as	O
carriers	O
for	O
the	O
B	O
-	O
KPro	O
,	O
with	O
no	O
significant	O
differences	O
in	O
device	B-T033
retention	I-T033
,	O
visual	B-T033
rehabilitation	I-T033
,	O
or	O
rates	O
of	O
complications	O
at	O
24	O
or	O
60	O
months	O
.	O
      
Spatio	O
-	O
Temporal	O
Distribution	O
of	O
Bark	O
and	O
Ambrosia	O
Beetles	O
in	O
a	O
Brazilian	O
Tropical	O
Dry	O
Forest	O
Bark	O
and	O
the	O
ambrosia	O
beetles	O
dig	O
into	O
host	O
plants	O
and	O
live	O
most	O
of	O
their	O
lives	O
in	O
concealed	O
tunnels	O
.	O
We	O
assessed	O
beetle	O
community	O
dynamics	O
in	O
tropical	O
dry	O
forest	O
sites	O
in	O
early	O
,	O
intermediate	O
,	O
and	O
late	O
successional	O
stages	O
,	O
evaluating	O
the	O
influence	O
of	O
resource	O
availability	O
and	O
seasonal	O
variations	O
in	O
guild	O
structure	O
.	O
We	O
collected	O
a	O
total	O
of	O
763	O
beetles	O
from	O
23	O
species	O
,	O
including	O
14	O
bark	O
beetle	O
species	O
,	O
and	O
9	O
ambrosia	O
beetle	O
species	O
.	O
Local	O
richness	O
of	O
bark	O
and	O
ambrosia	O
beetles	O
was	O
estimated	O
at	O
31	O
species	O
.	O
Bark	O
and	O
ambrosia	O
composition	O
was	O
similar	O
over	O
the	O
successional	O
stages	O
gradient	O
,	O
and	O
beta	O
diversity	O
among	O
sites	O
was	O
primarily	O
determined	O
by	O
species	O
turnover	O
,	O
mainly	O
in	O
the	O
bark	O
beetle	O
community	O
.	O
Bark	O
beetle	O
richness	O
and	O
abundance	O
were	O
higher	O
at	O
intermediate	O
stages	O
;	O
availability	O
of	O
wood	O
was	O
the	O
main	O
spatial	O
mechanism	O
.	O
Climate	O
factors	O
were	O
effectively	O
non	O
-	O
seasonal	O
.	O
Ambrosia	O
beetles	O
were	O
not	O
influenced	O
by	O
successional	O
stages	O
,	O
however	O
the	O
increase	O
in	O
wood	O
resulted	O
in	O
increased	O
abundance	O
.	O
We	O
found	O
higher	O
richness	O
at	O
the	O
end	O
of	O
the	O
dry	O
and	O
wet	O
seasons	O
,	O
and	O
abundance	O
increased	O
with	O
air	O
moisture	O
and	O
decreased	O
with	O
higher	O
temperatures	O
and	O
greater	O
rainfall	O
.	O
In	O
summary	O
,	O
bark	O
beetle	O
species	O
accumulation	O
was	O
higher	O
at	O
sites	O
with	O
better	O
wood	O
production	O
,	O
while	O
the	O
needs	O
of	O
fungi	O
(	O
host	O
and	O
air	O
moisture	O
)	O
,	O
resulted	O
in	O
a	O
favorable	O
conditions	O
for	O
species	O
accumulation	O
of	O
ambrosia	O
.	O
The	O
overall	O
biological	O
pattern	O
among	O
guilds	O
differed	O
from	O
tropical	O
rain	O
forests	O
,	O
showing	O
patterns	O
similar	O
to	O
dry	O
forest	O
areas	O
.	O
      
Combined	O
exposures	O
of	O
whole	B-T033
-	I-T033
body	I-T033
vibration	I-T033
and	O
awkward	B-T033
posture	I-T033
:	O
a	O
cross	O
sectional	O
investigation	O
among	O
occupational	O
drivers	O
by	O
means	O
of	O
simultaneous	O
field	O
measurements	O
Multifactorial	B-T033
workloads	O
such	O
as	O
whole	B-T033
-	I-T033
body	I-T033
vibration	I-T033
(	O
WBV	B-T033
)	O
,	O
awkward	B-T033
posture	I-T033
and	O
heavy	O
lifting	O
are	O
potential	O
predictors	B-T033
for	O
low	B-T184
back	I-T184
pain	I-T184
(	O
LBP	B-T184
)	O
.	O
In	O
this	O
study	O
,	O
we	O
investigate	O
the	O
association	O
between	O
LBP	B-T184
and	O
these	O
exposures	O
among	O
102	O
professional	O
drivers	O
.	O
The	O
combined	O
exposures	O
of	O
WBV	B-T033
and	O
posture	O
are	O
measured	O
at	O
different	O
workplaces	O
.	O
Health	O
and	O
personal	O
data	O
as	O
well	O
as	O
information	O
about	O
lifting	O
tasks	O
are	O
collected	O
by	O
a	O
questionnaire	O
.	O
The	O
daily	O
vibration	O
exposure	O
value	O
(	O
odds	O
ratio	O
1.69	O
)	O
and	O
an	O
index	O
for	O
awkward	B-T033
posture	I-T033
(	O
odds	O
ratio	O
1.63	O
)	O
show	O
significant	O
association	O
with	O
the	O
occurence	O
of	O
LBP	B-T184
.	O
Awkward	B-T033
posture	I-T033
and	O
heavy	O
lifting	O
appear	O
to	O
be	O
more	O
strongly	O
associated	O
with	O
sick	O
leave	O
than	O
WBV	B-T033
exposure	O
.	O
Furthermore	O
,	O
a	O
combination	O
of	O
the	O
measurement	O
results	O
of	O
WBV	B-T033
and	O
awkward	B-T033
posture	I-T033
into	O
one	O
quantity	O
also	O
shows	O
significant	O
correlation	O
to	O
LBP	B-T184
.	O
The	O
combined	O
exposure	O
of	O
WBV	B-T033
and	O
awkward	B-T033
posture	I-T033
can	O
be	O
described	O
in	O
terms	O
of	O
the	O
daily	O
vibration	O
exposure	O
and	O
the	O
index	O
for	O
awkward	B-T033
posture	I-T033
.	O
This	O
facilitates	O
work	O
place	O
assessments	O
and	O
future	O
research	O
in	O
this	O
area	O
.	O
Practitioner	O
Summary	O
:	O
For	O
the	O
first	O
time	O
,	O
quantitative	O
measures	O
combining	O
whole	B-T033
-	I-T033
body	I-T033
vibration	I-T033
and	O
awkward	B-T033
posture	I-T033
exposures	O
have	O
shown	O
to	O
correlate	O
with	O
the	O
occurrence	O
of	O
low	B-T184
back	I-T184
pain	I-T184
significantly	O
.	O
This	O
validates	O
the	O
proposed	O
quantities	O
and	O
measurement	O
methods	O
,	O
which	O
facilitate	O
workplace	O
assessments	O
and	O
assist	O
in	O
the	O
design	O
of	O
further	O
studies	O
which	O
are	O
necessary	O
to	O
establish	O
a	O
causal	O
exposure	O
-	O
response	O
relationship	O
.	O
      
Spontaneous	O
activity	O
is	O
correlated	O
with	O
coding	O
density	O
in	O
primary	O
auditory	O
cortex	O
Sensory	O
neurons	O
across	O
sensory	O
modalities	O
and	O
specific	O
processing	O
areas	O
have	O
diverse	O
levels	O
of	O
spontaneous	O
firing	O
rates	O
(	O
SFRs	O
)	O
in	O
the	O
absence	O
of	O
sensory	O
stimuli	O
.	O
However	O
,	O
the	O
functional	O
significance	O
of	O
this	O
spontaneous	O
activity	O
is	O
not	O
well	O
-	O
understood	O
.	O
Previous	O
studies	O
in	O
the	O
auditory	O
system	O
have	O
demonstrated	O
that	O
different	O
levels	O
of	O
spontaneous	O
activity	O
are	O
correlated	O
with	O
a	O
variety	O
of	O
physiological	O
and	O
anatomic	O
properties	O
,	O
suggesting	O
that	O
neurons	O
with	O
differing	O
SFRs	O
make	O
unique	O
contributions	O
to	O
the	O
encoding	O
of	O
auditory	O
stimuli	O
.	O
Additionally	O
,	O
altered	O
SFRs	O
are	O
a	O
correlate	O
of	O
tinnitus	B-T033
,	O
arising	O
in	O
several	O
auditory	B-T023
areas	I-T023
after	O
exposure	O
to	O
ototoxic	O
substances	O
and	O
noise	O
trauma	O
.	O
In	O
this	O
study	O
,	O
we	O
recorded	B-T059
single	I-T059
-	I-T059
unit	I-T059
activity	I-T059
from	O
primary	O
auditory	O
cortex	O
of	O
awake	O
marmoset	O
monkeys	O
while	O
delivering	O
wide	O
-	O
band	O
random	O
-	O
spectrum	O
stimuli	O
and	O
white	O
Gaussian	O
noise	O
(	O
WGN	O
)	O
to	O
examine	O
any	O
divergences	O
in	O
stimulus	O
encoding	O
properties	O
across	O
SFR	O
classes	O
.	O
We	O
found	O
that	O
higher	O
levels	O
of	O
spontaneous	O
activity	O
were	O
associated	O
with	O
both	O
higher	O
levels	O
of	O
activation	O
relative	O
to	O
suppression	O
across	O
a	O
variety	O
of	O
wide	O
-	O
band	O
stimuli	O
and	O
higher	O
driven	O
rates	O
in	O
response	O
to	O
WGN	O
.	O
Moreover	O
,	O
response	O
latencies	O
to	O
WGN	O
were	O
negatively	O
correlated	O
with	O
the	O
level	O
of	O
activation	O
in	O
response	O
to	O
both	O
stimulus	O
types	O
.	O
These	O
findings	O
are	O
consistent	O
with	O
a	O
novel	O
view	O
of	O
the	O
role	O
spontaneous	O
spiking	O
may	O
play	O
during	O
normal	O
stimulus	O
processing	O
in	O
primary	O
auditory	O
cortex	O
and	O
how	O
it	O
may	O
malfunction	O
in	O
cases	O
of	O
tinnitus	B-T033
.	O
      
Expression	O
of	O
caspase	O
3	O
in	O
ovarian	B-T023
follicle	I-T023
cells	O
of	O
the	O
lizard	O
Podarcis	O
sicula	O
In	O
this	O
study	O
,	O
our	O
aim	O
was	O
to	O
determine	O
whether	O
caspase	O
3	O
plays	O
a	O
role	O
,	O
during	O
previtellogenesis	O
,	O
in	O
the	O
ovarian	B-T023
follicular	O
epithelium	O
of	O
the	O
lizard	O
Podarcis	O
sicula	O
.	O
We	O
investigated	O
the	O
presence	O
and	O
localization	O
of	O
proform	O
and	O
active	O
caspase	O
3	O
by	O
enzyme	B-T059
assay	I-T059
,	O
Western	B-T059
blotting	I-T059
and	O
immunocytochemistry	B-T059
.	O
In	O
parallel	O
,	O
a	O
fragment	O
of	O
caspase	O
3	O
was	O
cloned	B-T059
for	O
the	O
first	O
time	O
in	O
this	O
species	O
,	O
sequenced	O
and	O
used	O
for	O
in	O
situ	O
hybridization	O
to	O
localize	O
messengers	O
and	O
analysed	O
by	O
a	O
phylogenetic	O
survey	O
to	O
shed	O
light	O
on	O
its	O
homology	O
with	O
reptilian	O
caspases	O
.	O
Results	O
demonstrated	O
that	O
:	O
(	O
1	O
)	O
the	O
follicle	B-T023
cells	O
expressed	O
a	O
caspase	O
of	O
the	O
3/7	O
group	O
and	O
the	O
mRNA	O
for	O
caspase	O
3	O
was	O
transcribed	O
in	O
the	O
stem	O
phase	O
and	O
was	O
completely	O
translated	O
during	O
cell	O
differentiation	O
;	O
(	O
2	O
)	O
the	O
proform	O
protein	O
was	O
stored	O
during	O
the	O
differentiated	O
(	O
nurse	O
)	O
stage	O
and	O
activated	O
at	O
the	O
end	O
of	O
previtellogenesis	O
provoking	O
the	O
degeneration	O
of	O
cells	O
;	O
(	O
3	O
)	O
the	O
predicted	O
protein	O
sequence	O
,	O
although	O
partial	O
,	O
had	O
a	O
strong	O
similarity	O
with	O
the	O
known	O
reptilian	O
caspases	O
3	O
.	O
The	O
epithelial	O
cells	O
of	O
the	O
ovarian	B-T023
follicle	I-T023
,	O
therefore	O
,	O
do	O
not	O
employ	O
caspase	O
3	O
during	O
the	O
nurse	O
stage	O
but	O
,	O
instead	O
,	O
prepare	O
for	O
apoptosis	O
long	O
before	O
the	O
process	O
actually	O
begins	O
.	O
The	O
relevance	O
of	O
this	O
strategy	O
is	O
discussed	O
.	O
      
Incident	O
fracture	O
associated	O
with	O
increased	O
risk	O
of	O
mortality	O
even	O
after	O
adjusting	O
for	O
frailty	B-T033
status	O
in	O
elderly	O
Japanese	O
men	O
:	O
the	O
Fujiwara	O
-	O
kyo	O
Osteoporosis	O
Risk	O
in	O
Men	O
(	O
FORMEN	O
)	O
Cohort	O
Study	O
Frail	B-T033
elderly	O
individuals	O
have	O
elevated	O
risks	O
of	O
both	O
fracture	O
and	O
mortality	O
.	O
We	O
found	O
that	O
incident	O
fractures	O
were	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	B-T033
even	O
after	O
adjusting	O
for	O
pre	O
-	O
fracture	O
frailty	B-T033
status	O
as	O
represented	O
by	O
physical	B-T060
performance	I-T060
tests	I-T060
and	O
laboratory	B-T059
tests	I-T059
for	O
common	O
geriatric	O
diseases	B-T047
in	O
community	O
-	O
dwelling	O
elderly	O
Japanese	O
men	O
.	O
While	O
fractures	O
reportedly	O
increase	O
the	O
risk	O
of	O
mortality	O
,	O
frailty	B-T033
may	O
complicate	O
this	O
association	O
,	O
generating	O
a	O
false	B-T033
-	I-T033
positive	I-T033
result	I-T033
.	O
We	O
evaluated	B-T058
this	O
association	O
after	O
adjusting	O
for	O
pre	O
-	O
fracture	O
levels	O
of	O
frailty	B-T033
.	O
We	O
examined	B-T033
1998	O
community	O
-	O
dwelling	O
ambulatory	O
men	O
aged	O
≥65	O
years	O
at	O
baseline	O
in	O
the	O
Fujiwara	O
-	O
kyo	O
Osteoporosis	O
Risk	O
in	O
Men	O
Study	O
for	O
frailty	B-T033
status	O
as	O
represented	O
by	O
activities	O
of	O
daily	O
living	O
(	O
ADL	O
)	O
,	O
physical	B-T060
performance	I-T060
tests	I-T060
(	O
grip	O
strength	O
,	O
one	B-T033
-	I-T033
foot	I-T033
standing	I-T033
balance	I-T033
with	I-T033
eyes	I-T033
open	I-T033
,	O
timed	B-T060
10	I-T060
-	I-T060
m	I-T060
walk	I-T060
)	O
,	O
and	O
laboratory	B-T059
sera	I-T059
tests	I-T059
.	O
Participants	O
were	O
then	O
followed	O
for	O
5	O
years	O
for	O
incident	O
clinical	O
fractures	O
and	O
death	B-T033
.	O
Effects	O
of	O
incident	O
fracture	O
on	O
death	B-T033
were	O
determined	O
by	O
Cox	O
proportional	O
hazards	O
model	O
with	O
the	O
first	O
fracture	O
during	O
follow	B-T058
-	I-T058
up	I-T058
as	O
a	O
time	O
-	O
dependent	O
predictor	O
and	O
with	O
frailty	O
status	O
indices	O
as	O
covariates	O
.	O
We	O
identified	O
111	O
fractures	O
in	O
99	O
men	O
and	O
138	O
deaths	B-T033
during	O
the	O
follow	B-T058
-	I-T058
up	I-T058
period	O
(	O
median	O
follow	B-T058
-	I-T058
up	I-T058
,	O
4.5	O
years	O
)	O
.	O
Participants	O
with	O
incident	O
fractures	O
did	O
not	B-T033
have	I-T033
significantly	I-T033
worse	I-T033
frailty	B-T033
statuses	O
,	O
but	O
did	O
show	O
a	O
significantly	O
higher	O
cumulative	O
mortality	O
rate	O
than	O
those	O
without	O
fractures	O
(	O
p	O
=	O
0.0047	O
)	O
.	O
Age	O
-	O
adjusted	O
hazard	O
ratio	O
(	O
HR	O
)	O
of	O
death	B-T033
for	O
incident	O
fracture	O
was	O
3.57	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
2.05	O
,	O
6.24	O
)	O
.	O
When	O
adjusted	O
for	O
physical	O
performance	O
,	O
this	O
decreased	O
to	O
2.77	O
(	O
1.51	O
,	O
5.06	O
)	O
,	O
but	O
remained	O
significant	O
.	O
The	O
HR	O
showed	O
no	B-T033
significant	I-T033
change	I-T033
when	O
adjusted	O
for	O
laboratory	O
test	O
results	O
(	O
3.96	O
(	O
2.26	O
,	O
6.94	O
)	O
)	O
.	O
Exclusion	O
of	O
deaths	B-T033
within	O
the	O
first	O
24	O
months	O
of	O
follow	B-T058
-	I-T058
up	I-T058
did	O
not	B-T033
alter	I-T033
these	O
results	O
.	O
Incident	O
clinical	O
fracture	O
was	O
associated	O
with	O
an	O
elevated	O
risk	O
of	O
death	B-T033
independently	B-T033
of	O
pre	O
-	O
fracture	O
levels	O
of	O
frailty	B-T033
in	O
community	O
-	O
dwelling	O
elderly	O
men	O
.	O
      
Management	O
of	O
tachyarrhythmia	B-T033
during	O
pregnancy	O
Maternal	B-T033
tachyarrhythmia	B-T033
is	O
a	O
common	O
complication	O
during	O
pregnancy	O
due	O
to	O
hormonal	B-T033
changes	I-T033
that	O
enhance	O
pre	O
-	O
existing	O
arrhythmias	B-T033
or	O
induce	O
new	O
arrhythmias	B-T033
in	O
the	O
presence	B-T033
of	O
congenital	B-T019
heart	I-T019
defects	I-T019
in	O
pregnant	O
females	O
.	O
Presence	B-T033
of	O
tachyarrhythmia	B-T033
during	O
pregnancy	O
poses	O
risk	O
to	O
the	O
mother	O
and	O
fetus	B-T018
,	O
calling	O
for	O
proper	B-T061
treatment	I-T061
with	O
medications	B-T121
.	O
Use	O
of	O
antiarrhythmic	B-T121
drugs	I-T121
in	O
cases	O
of	O
maternal	B-T033
tachyarrhythmia	B-T033
must	O
give	O
due	O
consideration	O
of	O
potential	O
teratogenic	O
side	O
effects	O
.	O
Utilization	O
of	O
antiarrhythmic	B-T121
drugs	I-T121
during	O
pregnancy	O
has	O
been	O
well	O
studied	O
;	O
some	O
result	O
in	O
minimal	O
fetal	B-T018
harm	O
or	O
none	O
at	O
all	O
.	O
New	O
techniques	O
,	O
such	O
as	O
cardiac	B-T061
ablation	I-T061
,	O
have	O
also	O
been	O
implemented	O
with	O
minimal	O
or	O
no	O
radiation	O
exposure	O
to	O
the	O
fetus	B-T018
or	O
mother	O
.	O
Pregnant	O
women	O
with	O
tachyarrhythmia	B-T033
have	O
been	O
successfully	O
treated	B-T033
with	O
little	O
to	O
no	O
impact	O
on	O
the	O
developing	O
fetus	O
as	O
result	O
of	O
increasing	O
experience	O
with	O
antiarrhythmic	B-T121
drugs	I-T121
and	O
progress	O
of	O
new	O
procedural	O
techniques	O
.	O
      
Assessment	B-T058
of	O
demographic	O
and	O
pathoanatomic	B-T033
risk	I-T033
factors	I-T033
in	O
recurrent	O
patellofemoral	O
instability	B-T033
The	O
WARPS	O
/	O
STAID	O
classification	O
employs	O
clinical	O
assessment	B-T058
of	O
presenting	O
features	O
and	O
anatomic	O
characteristics	O
to	O
identify	O
two	O
distinct	O
subsets	O
of	O
patients	O
within	O
the	O
patellofemoral	B-T033
instability	I-T033
population	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
further	O
define	O
the	O
specific	O
demographics	O
and	O
the	O
prevalence	O
of	O
risky	O
pathoanatomies	O
in	O
patients	O
classified	O
as	O
either	O
WARPS	O
or	O
STAID	O
presenting	O
with	O
recurrent	O
patellofemoral	O
instability	B-T033
.	O
A	O
secondary	O
purpose	O
was	O
to	O
further	O
validate	O
the	O
WARPS	O
/	O
STAID	O
classification	O
with	O
the	O
Banff	O
Patella	O
Instability	O
Instrument	O
(	O
BPII	O
)	O
,	O
the	O
Marx	O
activity	O
scale	O
and	O
the	O
Patellar	B-T023
Instability	O
Severity	O
Score	O
(	O
ISS	O
)	O
.	O
A	O
convenience	O
sample	O
of	O
50	O
patients	O
with	O
recurrent	O
patellofemoral	O
instability	B-T033
,	O
including	O
25	O
WARPS	O
and	O
25	O
STAID	O
subtype	O
patients	O
,	O
were	O
assessed	O
.	O
Clinical	O
data	O
were	O
collected	O
including	O
assessment	B-T058
of	O
demographic	O
risk	B-T033
factors	I-T033
(	O
sex	O
,	O
BMI	O
,	O
bilaterality	O
of	O
symptoms	B-T184
,	O
affected	O
limb	B-T023
side	I-T023
and	O
age	O
at	O
first	O
dislocation	O
)	O
and	O
pathoanatomic	B-T033
risk	I-T033
factors	I-T033
(	O
TT	O
-	O
TG	O
distance	O
,	O
patella	B-T023
height	O
,	O
patellar	O
tilt	O
,	O
grade	O
of	O
trochlear	B-T047
dysplasia	I-T047
,	O
Beighton	B-T033
score	I-T033
and	O
rotational	B-T033
abnormalities	I-T033
of	O
the	O
tibia	B-T023
or	O
femur	B-T023
)	O
.	O
Patients	O
completed	O
the	O
BPII	O
and	O
the	O
Marx	O
activity	O
scale	O
.	O
The	O
ISS	O
was	O
calculated	B-T059
from	O
the	O
clinical	O
assessment	O
data	O
.	O
Patients	O
were	O
stratified	O
into	O
the	O
WARPS	O
or	O
STAID	O
subtypes	O
for	O
comparative	O
analysis	O
.	O
An	O
independent	O
t	O
test	O
was	O
used	O
to	O
compare	O
demographics	O
,	O
the	O
pathoanatomic	B-T033
risk	I-T033
factors	I-T033
and	O
subjective	O
measures	O
between	O
the	O
groups	O
.	O
Convergent	O
validity	O
was	O
tested	O
with	O
a	O
Pearson	O
r	O
correlation	O
coefficient	O
between	O
the	O
WARPS	O
/	O
STAID	O
and	O
ISS	O
scores	O
.	O
Demographic	O
risk	O
factors	O
statistically	O
associated	O
with	O
a	O
WARPS	O
subtype	O
included	O
female	O
sex	O
,	O
age	O
at	O
first	O
dislocation	O
and	O
bilaterality	O
.	O
Pathoanatomic	B-T033
risk	I-T033
factors	I-T033
statistically	O
associated	O
with	O
a	O
WARPS	O
subtype	O
included	O
trochlear	B-T047
dysplasia	I-T047
,	O
TT	O
-	O
TG	O
distance	O
,	O
generalized	O
ligamentous	O
laxity	O
,	O
patellar	O
tilt	O
and	O
rotational	B-T033
abnormalities	I-T033
.	O
The	O
independent	O
t	O
test	O
revealed	O
a	O
significant	O
difference	O
between	O
the	O
ISS	O
scores	O
:	O
WARPS	O
subtype	O
(	O
M	O
=	O
4.4	O
,	O
SD	O
=	O
1.1	O
)	O
and	O
STAID	O
subtype	O
(	O
M	O
=	O
2.5	O
,	O
SD	O
=	O
1.5	O
)	O
;	O
t(48	O
)	O
=	O
5.2	O
,	O
p	O
<	O
0.001	O
.	O
The	O
relationship	O
between	O
the	O
WARPS	O
/	O
STAID	O
and	O
the	O
ISS	O
scores	O
,	O
measured	O
using	O
a	O
Pearson	O
r	O
correlation	O
coefficient	O
,	O
demonstrated	O
a	O
strong	O
relationship	O
:	O
r	O
=	O
-0.61	O
,	O
n	O
=	O
50	O
,	O
p	O
<	O
0.001	O
.	O
This	O
study	O
has	O
demonstrated	O
statistically	O
significant	O
evidence	O
that	O
certain	O
demographics	O
and	O
pathoanatomies	O
are	O
more	O
prevalent	O
in	O
each	O
of	O
the	O
WARPS	O
and	O
STAID	O
patellofemoral	O
instability	B-T033
subtypes	O
.	O
There	O
was	O
no	O
difference	O
in	O
quality	O
-	O
of	O
-	O
life	O
or	O
activity	B-T033
level	I-T033
between	O
the	O
subtypes	O
.	O
The	O
WARPS	O
/	O
STAID	O
score	O
demonstrated	O
convergent	O
validity	O
to	O
the	O
ISS	O
and	O
divergent	O
validity	O
to	O
the	O
BPII	O
score	O
and	O
the	O
Marx	O
activity	O
scale	O
.	O
This	O
study	O
has	O
further	O
validated	O
both	O
the	O
WARPS	O
/	O
STAID	O
classification	O
and	O
the	O
ISS	O
of	O
patients	O
that	O
present	O
with	O
recurrent	O
patellofemoral	O
instability	B-T033
.	O
III	O
.	O
      
Complications	O
and	O
Near	O
-	O
Miss	O
Events	O
After	O
Hepatectomy	B-T061
for	O
Living	B-T061
-	I-T061
Related	I-T061
Liver	I-T061
Donation	I-T061
:	O
An	O
Italian	O
Single	O
Center	O
Report	O
of	O
One	O
Hundred	O
Cases	O
BACKGROUND	O
In	O
healthy	O
individuals	O
,	O
such	O
as	O
liver	O
living	O
donors	O
,	O
potential	O
complications	O
may	O
occur	O
during	O
surgery	B-T061
.	O
Reporting	O
such	O
complications	O
and	O
near	O
-	O
miss	O
events	O
is	O
mandatory	O
to	O
improve	O
living	O
donor	O
management	O
and	O
safety	O
.	O
MATERIAL	O
AND	O
METHODS	O
This	O
retrospective	O
study	O
was	O
performed	O
on	O
a	O
prospective	O
database	O
with	O
the	O
aim	O
of	O
providing	O
a	O
brief	O
analysis	O
of	O
the	O
perioperative	O
,	O
medium	O
-	O
term	O
,	O
and	O
long	O
-	O
term	O
complications	O
,	O
and	O
the	O
near	O
-	O
miss	O
events	O
in	O
a	O
single	O
center	O
series	O
of	O
100	O
consecutive	O
liver	B-T061
resections	I-T061
for	O
adult	O
-to-	O
adult	O
living	O
-	O
donor	O
liver	B-T061
transplantation	I-T061
.	O
RESULTS	O
Only	O
23.3	O
%	O
of	O
potential	O
living	O
donors	O
underwent	O
surgery	B-T061
.	O
No	B-T033
living	O
donor	O
mortality	O
was	O
reported	O
;	O
29	O
patients	O
(	O
29	O
%	O
)	O
experienced	O
at	O
least	O
one	O
complication	O
.	O
Five	O
patients	O
developed	O
mild	O
long	O
-	O
term	O
dysfunction	O
;	O
two	O
aborted	O
hepatectomies	B-T061
,	O
and	O
there	O
were	O
two	O
near	O
-	O
miss	O
events	O
reported	O
.	O
CONCLUSIONS	O
A	O
strategy	O
for	O
an	O
accurate	O
assessment	B-T058
of	O
living	O
donor	O
complications	O
and	O
strict	O
selection	O
criterion	O
can	O
not	O
be	O
overemphasized	O
,	O
as	O
well	O
as	O
the	O
need	O
to	O
continuously	O
update	O
center	O
patient	O
outcome	O
reports	O
.	O
      
Production	O
of	O
Laccase	O
by	O
Cochliobolus	O
sp	O
.	O
Isolated	O
from	O
Plastic	O
Dumped	O
Soils	O
and	O
Their	O
Ability	O
to	O
Degrade	O
Low	O
Molecular	O
Weight	O
PVC	O
One	O
of	O
the	O
utmost	O
man	O
-	O
made	O
problems	O
faced	O
today	O
has	O
been	O
the	O
ever	O
-	O
increasing	O
plastic	O
waste	O
filling	O
the	O
world	O
.	O
It	O
accounts	O
for	O
an	O
estimated	O
20	O
-	O
30	O
%	O
(	O
by	O
volume	O
)	O
of	O
municipal	O
solid	O
waste	O
in	O
landfill	O
sites	O
worldwide	O
.	O
Research	O
on	O
plastic	O
biodegradation	O
has	O
been	O
steadily	O
growing	O
over	O
the	O
past	O
four	O
decades	O
.	O
Several	O
fungi	O
have	O
been	O
identified	O
that	O
produce	O
enzymes	O
capable	O
of	O
plastic	O
degradation	O
in	O
various	O
laboratory	O
conditions	O
.	O
This	O
paper	O
presents	O
a	O
study	O
that	O
determined	O
the	O
ability	O
of	O
fungi	O
to	O
degrade	O
low	O
molecular	O
weight	O
polyvinyl	O
chloride	O
(	O
PVC	O
)	O
by	O
the	O
enzyme	O
laccase	O
.	O
We	O
have	O
isolated	O
a	O
fungal	O
species	O
,	O
Cochliobolus	O
sp	O
.	O
,	O
from	O
plastic	O
dumped	O
soils	O
and	O
they	O
were	O
cultured	B-T059
on	O
Czapek	O
Dox	O
Agar	O
slants	O
at	O
30	O
°	O
C	O
.	O
The	O
effectiveness	O
of	O
this	O
fungal	O
species	O
on	O
the	O
degradation	O
of	O
commercial	O
low	O
molecular	O
weight	O
polyvinyl	O
chloride	O
(	O
PVC	O
)	O
was	O
studied	O
under	O
laboratory	O
conditions	O
.	O
Significant	O
differences	O
were	O
observed	O
from	O
the	O
FTIR	O
,	O
GC	B-T059
-	I-T059
MS	I-T059
,	O
and	O
SEM	B-T059
results	O
in	O
between	O
control	O
and	O
Cochliobolus	O
sp	O
.	O
treated	O
PVC	O
.	O
      
Empty	O
Capsids	B-T017
and	O
Macrophage	O
Inhibition	O
/	O
Depletion	O
Increase	O
rAAV	B-T121
Transgene	O
Expression	O
in	O
Joints	O
of	O
Both	O
Healthy	O
and	O
Arthritic	B-T047
Mice	O
Gene	B-T061
therapy	I-T061
has	O
potential	O
to	O
treat	B-T061
rheumatic	B-T047
diseases	I-T047
;	O
however	O
,	O
the	O
presence	B-T033
of	O
macrophages	O
in	O
the	O
joint	O
might	O
hamper	O
adeno	B-T005
-	I-T005
associated	I-T005
viral	I-T005
vector	B-T121
-mediated	O
gene	O
delivery	O
.	O
Here	O
we	O
demonstrate	O
that	O
in	O
arthritic	B-T047
,	O
but	O
also	O
in	O
healthy	O
,	O
mice	O
administration	B-T058
of	I-T058
agents	I-T058
that	O
influence	O
macrophage	O
activity	O
/	O
number	O
and/or	O
addition	O
of	O
empty	O
decoy	B-T017
capsids	I-T017
substantially	O
improve	B-T033
the	O
efficacy	O
of	O
recombinant	B-T001
adeno	B-T005
-	I-T005
associated	I-T005
viral	I-T005
vector	B-T121
5	O
transgene	O
expression	O
in	O
the	O
joint	O
.	O
Pretreatment	O
with	O
triamcinolone	B-T121
or	O
clodronate	B-T121
liposomes	O
improved	B-T033
luciferase	O
expression	O
over	O
a	O
period	O
of	O
4	O
weeks	O
.	O
Similar	O
results	B-T033
were	O
seen	O
when	O
empty	O
decoy	B-T017
capsids	I-T017
were	O
added	O
to	O
full	O
genome	O
containing	O
capsids	B-T017
in	O
a	O
5:1	O
ratio	O
.	O
In	O
a	O
study	O
to	O
assess	O
the	O
duration	O
of	O
expression	O
as	O
well	O
as	O
to	O
investigate	O
the	O
combination	O
of	O
these	O
two	O
approaches	O
,	O
we	O
observed	O
a	O
synergistic	O
enhancement	O
of	O
gene	O
expression	O
,	O
sustained	O
for	O
at	O
least	O
12	O
weeks	O
.	O
The	O
enhancement	O
of	O
gene	O
expression	O
was	O
independent	O
of	O
the	O
route	O
of	O
administration	O
of	O
triamcinolone	B-T121
(	O
intra	O
-	O
articular	O
or	O
intramuscular	O
)	O
.	O
In	O
healthy	O
mice	O
it	O
was	O
demonstrated	O
that	O
the	O
combination	O
improved	B-T033
expression	O
of	O
the	O
transgene	O
significantly	O
,	O
in	O
a	O
serotype	O
independent	O
manner	O
.	O
These	O
data	O
have	O
implications	O
for	O
future	O
applications	O
of	O
gene	B-T061
therapy	I-T061
to	O
the	O
joint	O
and	O
for	O
other	O
tissues	O
with	O
an	O
abundance	O
of	O
macrophages	O
.	O
      
Thymosin	O
β4	O
:	O
Roles	O
in	O
Development	O
,	O
Repair	O
,	O
and	O
Engineering	O
of	O
the	O
Cardiovascular	O
System	O
The	O
burden	O
of	O
cardiovascular	B-T047
disease	I-T047
is	O
a	O
growing	O
worldwide	O
issue	O
that	O
demands	O
attention	O
.	O
While	O
many	O
clinical	O
trials	O
are	O
ongoing	O
to	O
test	O
therapies	B-T061
for	O
treating	O
the	O
heart	B-T023
after	O
myocardial	B-T047
infarction	I-T047
(	O
MI	B-T047
)	O
and	O
heart	B-T047
failure	I-T047
,	O
there	O
are	O
few	O
options	O
doctors	O
able	O
to	O
currently	O
give	O
patients	O
to	O
repair	B-T061
the	I-T061
heart	I-T061
.	O
This	O
eventually	O
leads	O
to	O
decreased	O
ventricular	O
contractility	O
and	O
increased	O
systemic	B-T047
disease	I-T047
,	O
including	O
vascular	B-T047
disorders	I-T047
that	O
could	O
result	O
in	O
stroke	B-T047
.	O
Small	O
peptides	O
such	O
as	O
thymosin	O
β4	O
(	O
Tβ4	O
)	O
are	O
upregulated	O
in	O
the	O
cardiovascular	O
niche	O
during	O
fetal	O
development	O
and	O
after	O
injuries	O
such	O
as	O
MI	B-T047
,	O
providing	O
increased	O
neovasculogenesis	B-T191
and	O
paracrine	O
signals	O
for	O
endogenous	O
stem	O
cell	O
recruitment	O
to	O
aid	O
in	O
wound	O
repair	O
.	O
New	O
research	O
is	O
looking	O
into	O
the	O
effects	O
of	O
in	O
vivo	O
administration	B-T061
of	O
Tβ4	O
through	O
injections	B-T061
and	O
coatings	B-T121
on	O
implants	O
,	O
as	O
well	O
as	O
its	O
effect	O
on	O
cell	O
differentiation	O
.	O
Results	O
so	O
far	O
demonstrate	O
Tβ4	O
administration	B-T061
leads	O
to	O
robust	O
increases	O
in	O
angiogenesis	O
and	O
wound	O
healing	O
in	O
the	O
heart	B-T023
after	O
MI	B-T047
and	O
the	O
brain	B-T023
after	O
stroke	B-T047
,	O
and	O
can	O
differentiate	O
adult	O
stem	O
cells	O
toward	O
the	O
cardiac	B-T023
lineage	O
for	O
implantation	B-T061
to	O
the	O
heart	B-T023
to	O
increase	O
contractility	O
and	O
survival	O
.	O
Future	O
work	O
,	O
some	O
of	O
which	O
is	O
currently	O
in	O
clinical	O
trials	O
,	O
will	O
demonstrate	O
the	O
in	O
vivo	O
effect	O
of	O
these	O
therapies	B-T061
on	O
human	O
patients	O
,	O
with	O
the	O
goal	O
of	O
helping	O
the	O
millions	O
of	O
people	O
worldwide	O
affected	O
by	O
cardiovascular	B-T047
disease	I-T047
.	O
      
Involvement	O
of	O
apoptotic	O
pathways	O
in	O
docosahexaenoic	B-T121
acid	I-T121
-induced	O
benefit	O
in	O
prostate	B-T191
cancer	I-T191
:	O
Pathway	O
-	O
focused	O
gene	O
expression	O
analysis	O
using	O
RT(2	O
)	O
Profile	O
PCR	O
Array	O
System	O
Present	O
study	O
aimed	O
to	O
better	O
understand	O
the	O
potential	O
apoptotic	O
pathways	O
that	O
involved	O
in	O
docosahexaenoic	B-T121
acid	I-T121
DHA	B-T121
(	O
DHA)-induced	O
apoptosis	O
of	O
prostate	B-T191
cancer	I-T191
cells	O
.	O
Human	O
prostate	B-T191
cancer	I-T191
DU145	O
cells	O
were	O
treated	O
with	O
different	O
concentrations	O
of	O
fish	B-T121
oil	I-T121
,	O
omega-3	B-T121
PUFA	I-T121
(	O
DHA	B-T121
,	O
and	O
Eicosapentaenoic	B-T121
acid	I-T121
,	O
EPA	B-T121
)	O
,	O
or	O
omega-6	O
PUFA	O
(	O
Arachidonic	O
acid	O
,	O
AA	O
)	O
.	O
Cell	O
viability	O
and	O
apoptosis	O
were	O
evaluated	O
by	O
MTT	O
assay	O
and	O
Hoechst	B-T059
staining	I-T059
.	O
Pathway	O
-	O
focused	O
gene	B-T059
expression	I-T059
profiling	I-T059
of	O
DU145	O
cells	O
was	O
analyzed	O
with	O
the	O
RT(2	O
)	O
Profile	O
PCR	O
Array	O
System	O
.	O
The	O
results	O
were	O
verified	O
by	O
real	O
time	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
qPCR	O
)	O
.	O
AA	O
exposure	O
showed	O
no	O
obvious	O
effect	O
on	O
viability	O
of	O
DU145	O
cells	O
.	O
However	O
,	O
exposure	O
with	O
fish	B-T121
oil	I-T121
,	O
EPA	B-T121
,	O
or	O
DHA	B-T121
for	O
24	O
h	O
significantly	O
affected	O
cell	O
viability	O
.	O
The	O
growth	O
inhibition	O
of	O
DHA	B-T121
was	O
more	O
pronounced	O
than	O
that	O
of	O
EPA	B-T121
and	O
showed	O
a	O
time	O
-	O
dependent	O
increase	O
.	O
DHA	B-T121
exposure	O
caused	O
typical	O
apoptotic	O
characteristics	O
.	O
Ten	O
genes	O
were	O
more	O
expressed	O
,	O
while	O
5	O
genes	O
were	O
less	O
expressed	O
following	O
DHA	B-T121
exposure	O
.	O
RT	O
-	O
qPCR	O
confirmed	O
the	O
time	O
dependent	O
effect	O
of	O
DHA	B-T121
on	O
the	O
expression	O
of	O
these	O
differentially	O
expressed	O
genes	O
.	O
KEGG	O
pathway	O
analysis	O
showed	O
that	O
DHA	B-T121
may	O
induce	O
the	O
apoptosis	O
of	O
cancer	O
cells	O
preferentially	O
through	O
mediating	O
P53	O
,	O
MAPK	O
,	O
TNF	O
,	O
PI3K	O
/	O
AKT	O
,	O
and	O
NF	O
-	O
κB	O
signaling	O
pathways	O
.	O
Our	O
study	O
demonstrated	O
the	O
beneficial	O
action	O
of	O
DHA	B-T121
on	O
human	O
prostate	B-T191
carcinoma	I-T191
cell	O
line	O
DU145	O
.	O
The	O
pro	O
-	O
apoptotic	O
effect	O
of	O
DHA	B-T121
on	O
DU145	O
cells	O
may	O
involve	O
mediation	O
various	O
pathways	O
,	O
especially	O
P53	O
,	O
MAPK	O
,	O
TNF	O
,	O
PI3K	O
/	O
AKT	O
,	O
and	O
NF	O
-	O
κB	O
signaling	O
pathways	O
.	O
Molecular	O
mechanisms	O
of	O
DHA	B-T121
on	O
apoptosis	O
of	O
cancer	O
cells	O
still	O
need	O
to	O
be	O
further	O
clarified	O
.	O
      
New	O
Diterpenoids	O
from	O
Clerodendranthus	O
spicatus	O
Two	O
new	O
diterpenoids	O
,	O
neoorthosiphonones	O
B	O
and	O
C	O
(	O
1	O
and	O
2	O
)	O
,	O
and	O
one	O
known	O
diterpenoid	O
,	O
were	O
isolated	O
from	O
the	O
aerial	O
parts	O
of	O
Clerodendranthus	O
spicatus	O
.	O
Their	O
structures	O
including	O
absolute	O
configurations	O
were	O
determined	O
by	O
comprehensive	O
spectroscopic	B-T059
analyses	I-T059
and	O
X	B-T059
-	I-T059
ray	I-T059
crystallographic	I-T059
methods	I-T059
.	O
No	O
compound	O
was	O
found	O
to	O
inhibit	O
fibronectin	O
production	O
at	O
the	O
concentration	O
of	O
20	O
μM.	O
      
The	O
Impact	O
of	O
Diabetes	B-T047
on	O
the	O
Risk	O
of	O
Prostate	B-T191
Cancer	I-T191
Development	O
according	O
to	O
Body	O
Mass	O
Index	O
:	O
A	O
10	O
-	O
year	O
Nationwide	O
Cohort	O
Study	O
Purpose	O
:	O
We	O
examined	O
the	O
association	O
between	O
obesity	B-T047
and	O
prostate	B-T191
cancer	I-T191
both	O
with	O
and	O
without	O
diabetic	B-T047
patients	O
included	O
in	O
the	O
analysis	O
using	O
nationally	O
representative	O
data	O
of	O
the	O
Korean	O
population	O
from	O
the	O
National	B-T058
Health	I-T058
Insurance	I-T058
System	I-T058
(	O
NHIS	B-T058
)	O
.	O
Materials	O
and	O
Methods	O
:	O
Of	O
the	O
424,712	O
participants	O
who	O
underwent	O
health	B-T061
examinations	I-T061
in	O
2002	O
-	O
2008	O
,	O
139,519	O
men	O
≥40	O
years	O
old	O
and	O
without	O
prostate	B-T191
cancer	I-T191
were	O
followed	O
from	O
the	O
beginning	O
of	O
2002	O
to	O
the	O
end	O
of	O
2012	O
.	O
Multivariate	O
adjusted	O
Cox	O
regression	O
analysis	O
was	O
conducted	O
to	O
examine	O
the	O
hazard	O
ratio	O
(	O
HR	O
)	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
for	O
the	O
association	O
between	O
prostate	B-T191
cancer	I-T191
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
both	O
with	O
and	O
without	O
diabetes	B-T047
.	O
Results	O
:	O
The	O
HR	O
for	O
prostate	B-T191
cancer	I-T191
according	O
to	O
the	O
existence	O
of	O
diabetes	B-T047
was	O
stratified	O
by	O
BMI	O
in	O
both	O
age	O
-	O
and	O
multivariable	O
-	O
adjusted	O
models	O
.	O
In	O
the	O
population	O
without	O
diabetes	B-T047
,	O
the	O
HR	O
for	O
prostate	B-T191
cancer	I-T191
significantly	O
increased	O
as	O
BMI	O
increased	O
beyond	O
the	O
reference	O
range	O
in	O
a	O
model	O
adjusted	O
for	O
age	O
and	O
multiple	O
variables	O
;	O
however	O
,	O
the	O
increase	O
in	O
the	O
HR	O
was	O
small	O
.	O
In	O
the	O
population	O
with	O
diabetes	B-T047
,	O
the	O
HR	O
for	O
prostate	B-T191
cancer	I-T191
significantly	O
increased	O
as	O
BMI	O
increased	O
from	O
<	O
18.5	O
kg	O
/	O
m(2	O
)	O
to	O
within	O
the	O
reference	O
range	O
(	O
18.5	O
to	O
22.9	O
)	O
in	O
the	O
multivariable	O
-	O
adjusted	O
model	O
.	O
In	O
addition	O
,	O
a	O
marked	O
decrease	O
in	O
HR	O
in	O
the	O
population	O
with	O
BMI	O
of	O
<	O
18.5	O
kg	O
/	O
m(2	O
)	O
was	O
seen	O
compared	O
to	O
the	O
reference	O
or	O
higher	O
BMI	O
population	O
.	O
Conclusion	O
:	O
This	O
population	O
-based	O
study	O
shows	O
the	O
evidence	O
of	O
association	O
between	O
obesity	B-T047
and	O
development	O
of	O
prostate	B-T191
cancer	I-T191
,	O
and	O
the	O
risk	B-T033
increases	I-T033
vary	O
according	O
to	O
the	O
change	O
of	O
BMI	O
category	O
and	O
the	O
existence	O
of	O
diabetes	B-T047
.	O
      
Endoscopic	B-T060
endonasal	O
surgery	B-T061
for	O
remission	B-T033
of	O
Cushing	B-T047
's	I-T047
Disease	I-T047
caused	O
by	O
ectopic	O
intracavernous	O
macroadenoma	B-T191
:	O
case	O
report	O
and	O
literature	O
review	O
Complete	O
surgical	B-T061
resection	I-T061
of	O
an	O
ACTH	B-T191
-	I-T191
secreting	I-T191
pituitary	I-T191
adenoma	I-T191
is	O
the	O
gold	O
standard	O
of	O
treatment	B-T061
of	O
Cushing	B-T047
's	I-T047
Disease	I-T047
.	O
Ectopic	O
location	O
of	O
these	O
adenomas	B-T191
is	O
an	O
extremely	O
rare	O
condition	O
that	O
may	O
compromise	O
the	O
diagnosis	B-T033
and	O
surgical	B-T061
success	O
.	O
We	O
present	O
the	O
first	O
case	O
of	O
an	O
ectopic	O
intracavernous	O
ACTH	B-T191
-	I-T191
secreting	I-T191
macroadenoma	I-T191
totally	O
resected	O
with	O
endoscopic	B-T060
endonasal	O
surgery	B-T061
(	O
EES	B-T061
)	O
.	O
A	O
36	O
year	O
old	O
female	O
presented	O
with	O
Cushing	B-T047
syndrome	I-T047
.	O
Increased	O
ACTH	B-T121
,	O
serum	O
cortisol	O
and	O
free	O
urine	O
cortisol	O
levels	O
were	O
identified	O
,	O
however	O
the	O
pituitary	B-T060
MRI	I-T060
failed	O
to	O
reveal	O
a	O
pituitary	B-T191
tumor	I-T191
;	O
instead	O
,	O
a	O
parasellar	B-T033
lesion	I-T033
in	O
the	O
left	O
cavernous	O
sinus	O
(	O
CS	O
)	O
was	O
noticed	O
.	O
Inferior	B-T060
petrosal	I-T060
sinus	I-T060
sampling	I-T060
demonstrated	O
a	O
significant	O
central	O
-to-	O
peripheral	O
and	O
lateralized	O
left	O
-	O
sided	O
ACTH	B-T121
gradient	O
.	O
The	O
patient	O
underwent	O
EES	B-T061
.	O
No	B-T033
tumor	I-T033
was	O
found	O
in	O
the	O
sella	B-T023
,	O
however	O
,	O
the	O
left	O
CS	O
was	O
widely	O
explored	O
and	O
a	O
tumor	B-T191
was	O
found	O
lateral	O
to	O
the	O
paraclival	O
segment	O
of	O
the	O
carotid	B-T023
artery	I-T023
.	O
There	O
were	O
no	B-T033
complications	O
following	O
EES	B-T061
.	O
Pathology	O
confirmed	O
the	O
diagnosis	B-T033
of	O
an	O
ACTH	B-T191
-	I-T191
secreting	I-T191
adenoma	I-T191
.	O
During	O
the	O
immediately	O
postoperative	O
course	O
serum	O
cortisol	O
levels	O
dropped	O
below	O
5	O
mcg	O
/	O
dl	O
.	O
Postoperative	O
MRI	B-T060
demonstrated	O
complete	O
tumor	B-T061
resection	I-T061
.	O
At	O
20	O
months	O
follow	B-T058
-	I-T058
up	I-T058
,	O
the	O
patient	O
remains	O
in	O
clinical	O
and	O
biochemical	O
remission	B-T033
of	O
Cushing	B-T047
's	I-T047
Disease	I-T047
.	O
Only	O
12	O
cases	O
of	O
ectopic	O
intracavernous	O
ACTH	B-T191
-	I-T191
secreting	I-T191
adenomas	I-T191
have	O
been	O
reported	O
to	O
date	O
and	O
all	O
were	O
microadenomas	B-T191
.	O
The	O
presence	O
of	O
an	O
ectopic	O
ACTH	B-T191
-	I-T191
secreting	I-T191
macroadenoma	I-T191
in	O
the	O
CS	O
represents	O
a	O
surgical	B-T061
challenge	O
.	O
EES	B-T061
is	O
the	O
ideal	O
approach	O
for	O
complete	O
resection	B-T061
of	O
ectopic	O
intracavernous	O
adenomas	B-T191
allowing	O
for	O
a	O
wide	O
exploration	B-T061
of	O
the	O
CS	O
with	O
no	B-T033
surgical	B-T061
complications	O
.	O
      
Highly	O
fluorescent	O
gold	B-T121
nanoclusters	O
stabilized	O
by	O
food	O
proteins	O
:	O
From	O
preparation	O
to	O
application	O
in	O
detection	B-T061
of	O
food	O
contaminants	O
and	O
bioactive	O
nutrients	O
Applications	O
of	O
nanotechnology	O
in	O
food	O
have	O
rapidly	O
increased	O
in	O
the	O
past	O
decades	O
.	O
Ultra	O
-	O
small	O
gold	O
nanoclusters	O
(	O
Au	O
NCs	O
)	O
,	O
composed	O
of	O
several	O
to	O
roughly	O
a	O
hundred	O
atoms	O
,	O
represent	O
a	O
kind	O
of	O
novel	O
nanomaterials	O
.	O
The	O
Au	O
NCs	O
directed	O
by	O
food	O
proteins	O
have	O
drawn	O
considerable	O
research	O
attention	O
due	O
to	O
their	O
environmentally	O
friendly	O
preparation	O
,	O
strong	O
fluorescence	O
,	O
excellent	O
photo	O
-	O
stability	O
and	O
favorable	O
biocompatibility	O
.	O
These	O
interesting	O
protein	O
-	O
Au	O
hybrids	O
have	O
opened	O
up	O
a	O
new	O
area	O
at	O
the	O
nano	O
-	O
bio	O
-	O
food	O
interface	O
,	O
not	O
only	O
did	O
they	O
provide	O
the	O
missing	O
link	O
between	O
single	O
metal	O
atoms	O
and	O
plasmonic	O
metal	O
nanoparticles	O
,	O
but	O
also	O
developed	O
the	O
hybrid	O
system	O
between	O
biomacromolecule	O
and	O
inorganic	O
ions	O
.	O
In	O
this	O
review	O
,	O
we	O
highlighted	O
the	O
synthesis	O
strategies	O
and	O
optical	O
properties	O
of	O
the	O
Au	O
NCs	O
stabilized	O
by	O
typical	O
food	O
proteins	O
as	O
well	O
as	O
their	O
applications	O
in	O
detection	B-T061
of	O
food	O
contaminants	O
or	O
bioactive	O
nutrients	O
.	O
In	O
addition	O
,	O
we	O
discussed	O
current	O
challenges	O
and	O
future	O
development	O
in	O
food	O
proteins	O
directed	O
gold	O
nanoclusters	O
for	O
size	O
-	O
controlled	O
synthesis	O
and	O
multifunctional	O
applications	O
.	O
      
CXCL14	O
-	O
CXCR4	O
and	O
CXCL12	O
-	O
CXCR4	O
Axes	O
May	O
Play	O
Important	O
Roles	O
in	O
the	O
Unique	O
Invasion	B-T033
Process	O
of	O
Endometrioid	B-T191
Carcinoma	I-T191
With	O
MELF	O
-	O
Pattern	O
Myoinvasion	B-T033
The	O
term	O
"	O
MELF	O
-	O
pattern	O
myometrial	O
invasion	B-T033
"	O
(	O
MELF	O
pattern	O
)	O
denotes	O
an	O
unusual	O
morphology	O
of	O
myometrial	O
invasion	B-T033
in	O
endometrioid	B-T191
carcinomas	I-T191
,	O
and	O
is	O
associated	O
with	O
frequent	O
lymphovascular	B-T033
invasion	I-T033
and	O
lymph	B-T191
node	I-T191
metastasis	I-T191
.	O
In	O
this	O
study	O
,	O
tumor	O
cells	O
were	O
directly	O
collected	O
from	O
a	O
MELF	O
pattern	O
site	O
,	O
using	O
laser	B-T059
microdissection	I-T059
.	O
Comprehensive	O
microarray	B-T059
analysis	I-T059
of	O
the	O
genes	O
was	O
conducted	O
,	O
and	O
based	O
on	O
the	O
results	O
,	O
expression	O
of	O
a	O
metastasis	O
progression	O
gene	O
,	O
CXCR4	O
,	O
and	O
its	O
ligands	O
CXCL14	O
and	O
CXCL12	O
,	O
was	O
further	O
investigated	O
.	O
In	O
vitro	O
studies	O
of	O
endometrioid	B-T191
carcinoma	I-T191
cell	O
lines	O
revealed	O
elevated	O
invasion	B-T033
activity	O
in	O
a	O
manner	O
dependent	O
on	O
the	O
CXCL14	O
-	O
CXCR4	O
or	O
CXCL12	O
-	O
CXCR4	O
axis	O
.	O
Immunohistochemical	B-T059
analysis	I-T059
of	O
93	O
(	O
MELF	O
group	O
,	O
46	O
;	O
non	O
-	O
MELF	O
group	O
,	O
47	O
)	O
cases	O
illustrated	O
CXCR4	O
was	O
expressed	O
in	O
all	O
endometrioid	B-T191
carcinomas	I-T191
,	O
while	O
based	O
on	O
CXCL14	O
and	O
CXCL12	O
expression	O
score	O
,	O
high	O
proportions	O
of	O
cells	O
were	O
positive	B-T033
at	O
the	O
sites	O
of	O
the	O
MELF	O
pattern	O
(	O
P<0.01	O
)	O
.	O
There	O
was	O
no	B-T033
significant	I-T033
difference	I-T033
in	O
progression	O
-	O
free	O
survival	O
or	O
overall	O
survival	O
between	O
MELF	O
group	O
and	O
non	O
-	O
MELF	O
group	O
by	O
Kaplan	O
-	O
Meier	O
analysis	O
.	O
These	O
findings	O
suggest	O
a	O
possibility	O
that	O
cells	O
at	O
the	O
sites	O
of	O
MELF	O
pattern	O
had	O
acquired	O
increased	O
invasiveness	O
through	O
the	O
function	O
of	O
the	O
CXCL14	O
-	O
CXCR4	O
and	O
CXCL12	O
-	O
CXCR4	O
axes	O
.	O
      
Systems	O
Toxicology	O
:	O
Real	O
World	O
Applications	O
and	O
Opportunities	O
Systems	O
Toxicology	O
aims	O
to	O
change	O
the	O
basis	O
of	O
how	O
adverse	O
biological	O
effects	O
of	O
xenobiotics	O
are	O
characterized	O
from	O
empirical	O
end	O
points	O
to	O
describing	O
modes	O
of	O
action	O
as	O
adverse	O
outcome	O
pathways	O
and	O
perturbed	O
networks	O
.	O
Toward	O
this	O
aim	O
,	O
Systems	O
Toxicology	O
entails	O
the	O
integration	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
toxicity	O
data	O
with	O
computational	O
modeling	O
.	O
This	O
evolving	O
approach	O
depends	O
critically	O
on	O
data	O
reliability	O
and	O
relevance	O
,	O
which	O
in	O
turn	O
depends	O
on	O
the	O
quality	O
of	O
experimental	O
models	O
and	O
bioanalysis	O
techniques	O
used	O
to	O
generate	O
toxicological	O
data	O
.	O
Systems	O
Toxicology	O
involves	O
the	O
use	O
of	O
large	O
-	O
scale	O
data	O
streams	O
(	O
"	O
big	O
data	O
"	O
)	O
,	O
such	O
as	O
those	O
derived	O
from	O
omics	O
measurements	O
that	O
require	O
computational	O
means	O
for	O
obtaining	O
informative	O
results	O
.	O
Thus	O
,	O
integrative	O
analysis	O
of	O
multiple	O
molecular	O
measurements	O
,	O
particularly	O
acquired	O
by	O
omics	B-T059
strategies	I-T059
,	O
is	O
a	O
key	O
approach	O
in	O
Systems	O
Toxicology	O
.	O
In	O
recent	O
years	O
,	O
there	O
have	O
been	O
significant	O
advances	O
centered	O
on	O
in	O
vitro	O
test	O
systems	O
and	O
bioanalytical	B-T059
strategies	I-T059
,	O
yet	O
a	O
frontier	O
challenge	O
concerns	O
linking	O
observed	O
network	O
perturbations	O
to	O
phenotypes	O
,	O
which	O
will	O
require	O
understanding	O
pathways	O
and	O
networks	O
that	O
give	O
rise	O
to	O
adverse	O
responses	O
.	O
This	O
summary	O
perspective	O
from	O
a	O
2016	O
Systems	O
Toxicology	O
meeting	O
,	O
an	O
international	O
conference	O
held	O
in	O
the	O
Alps	O
of	O
Switzerland	O
,	O
describes	O
the	O
limitations	O
and	O
opportunities	O
of	O
selected	O
emerging	O
applications	O
in	O
this	O
rapidly	O
advancing	O
field	O
.	O
Systems	O
Toxicology	O
aims	O
to	O
change	O
the	O
basis	O
of	O
how	O
adverse	O
biological	O
effects	O
of	O
xenobiotics	O
are	O
characterized	O
,	O
from	O
empirical	O
end	O
points	O
to	O
pathways	O
of	O
toxicity	O
.	O
This	O
requires	O
the	O
integration	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
data	O
with	O
computational	O
modeling	O
.	O
Test	O
systems	O
and	O
bioanalytical	B-T059
technologies	I-T059
have	O
made	O
significant	O
advances	O
,	O
but	O
ensuring	O
data	O
reliability	O
and	O
relevance	O
is	O
an	O
ongoing	O
concern	O
.	O
The	O
major	O
challenge	O
facing	O
the	O
new	O
pathway	O
approach	O
is	O
determining	O
how	O
to	O
link	O
observed	O
network	O
perturbations	O
to	O
phenotypic	O
toxicity	O
.	O
      
Mobile	O
phone	O
use	O
,	O
behavioural	B-T048
problems	I-T048
and	O
concentration	O
capacity	O
in	O
adolescents	O
:	O
A	O
prospective	O
study	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
prospectively	O
investigate	O
whether	O
exposure	O
to	O
radiofrequency	O
electromagnetic	O
fields	O
(	O
RF	O
-	O
EMF	O
)	O
emitted	O
by	O
mobile	O
phones	O
and	O
other	O
wireless	O
communication	O
devices	O
is	O
related	O
to	O
behavioural	B-T048
problems	I-T048
or	O
concentration	O
capacity	O
in	O
adolescents	O
.	O
The	O
HERMES	O
(	O
Health	O
Effects	O
Related	O
to	O
Mobile	O
phonE	O
use	O
in	O
adolescentS	O
)	O
study	O
sample	O
consisted	O
of	O
439	O
Swiss	O
adolescents	O
aged	O
12	O
-	O
17	O
years	O
.	O
Behavioural	B-T048
problems	I-T048
were	O
assessed	O
using	O
the	O
Strengths	O
and	O
Difficulties	O
Questionnaire	O
(	O
SDQ	O
)	O
,	O
concentration	O
capacity	O
of	O
the	O
adolescents	O
was	O
measured	O
by	O
means	O
of	O
a	O
standardized	O
computerized	O
cognitive	O
test	O
named	O
FAKT	O
.	O
Cross	O
-	O
sectional	O
and	O
longitudinal	O
(	O
1year	O
of	O
follow	B-T033
-	I-T033
up	I-T033
)	O
analyses	O
were	O
performed	O
to	O
investigate	O
possible	O
associations	O
between	O
behavioural	B-T048
problems	I-T048
and	O
concentration	O
capacity	O
and	O
different	O
exposure	O
measures	O
:	O
self	O
-	O
reported	O
and	O
operator	O
-recorded	O
wireless	O
communication	O
device	O
use	O
,	O
cumulative	O
RF	O
-	O
EMF	O
brain	B-T023
and	O
whole	B-T017
body	I-T017
dose	O
and	O
measured	O
personal	O
RF	O
-	O
EMF	O
exposure	O
.	O
In	O
the	O
cross	O
-	O
sectional	O
analyses	O
behavioural	B-T048
problems	I-T048
were	O
associated	O
with	O
several	O
self	O
-	O
reported	O
wireless	O
device	O
use	O
measures	O
but	O
not	O
operator	O
-recorded	O
mobile	O
phone	O
use	O
measures	O
,	O
concentration	O
capacity	O
was	O
associated	O
with	O
several	O
self	O
-	O
reported	O
and	O
operator	O
-recorded	O
exposures	O
.	O
The	O
longitudinal	O
analyses	O
point	O
towards	O
absence	O
of	O
associations	O
.	O
The	O
lack	O
of	O
consistent	O
exposure	O
-response	O
patterns	O
in	O
the	O
longitudinal	O
analyses	O
suggests	O
that	O
behavioural	B-T048
problems	I-T048
and	O
concentration	O
capacity	O
are	O
not	O
affected	O
by	O
the	O
use	O
of	O
wireless	O
communication	O
devices	O
or	O
RF	O
-	O
EMF	O
exposure	O
.	O
Information	O
bias	O
and	O
reverse	O
causality	O
are	O
likely	O
explanations	O
for	O
the	O
observed	O
cross	O
-	O
sectional	O
findings	O
.	O
      
Temporal	O
upregulation	O
of	O
host	O
surface	O
receptors	O
provides	O
a	O
window	O
of	O
opportunity	O
for	O
bacterial	O
adhesion	O
and	O
disease	B-T047
Host	O
surface	O
receptors	O
provide	O
bacteria	B-T007
with	O
a	O
foothold	O
from	O
which	O
to	O
attach	O
,	O
colonize	O
and	O
,	O
in	O
some	O
cases	O
,	O
invade	O
tissue	O
and	O
elicit	O
human	O
disease	B-T047
.	O
In	O
this	O
review	O
,	O
we	O
discuss	O
several	O
key	O
host	O
receptors	O
and	O
cognate	O
adhesins	O
that	O
function	O
in	O
bacterial	B-T007
pathogenesis	O
.	O
In	O
particular	O
,	O
we	O
examine	O
the	O
elevated	O
expression	O
of	O
host	O
surface	O
receptors	O
such	O
as	O
CEACAM-1	O
,	O
CEACAM-6	O
,	O
ICAM-1	O
and	O
PAFR	O
in	O
response	O
to	O
specific	O
stimuli	O
.	O
We	O
explore	O
how	O
upregulated	O
receptors	O
,	O
in	O
turn	O
,	O
expose	O
the	O
host	B-T001
to	O
a	O
range	O
of	O
bacterial	B-T047
infections	I-T047
in	O
the	O
respiratory	O
tract	O
.	O
It	O
is	O
apparent	O
that	O
exploitation	O
of	O
receptor	O
induction	O
for	O
bacterial	O
adherence	O
is	O
not	O
unique	O
to	O
one	O
body	O
system	O
,	O
but	O
is	O
also	O
observed	O
in	O
the	O
central	O
nervous	O
,	O
gastrointestinal	O
and	O
urogenital	O
systems	O
.	O
Prokaryotic	B-T001
pathogens	O
which	O
utilize	O
this	O
mechanism	O
for	O
their	O
infectivity	O
include	O
Streptococcus	B-T007
pneumoniae	I-T007
,	O
Haemophilus	B-T007
influenzae	I-T007
,	O
Neisseria	B-T007
meningitidis	I-T007
and	O
Escherichia	B-T007
coli	I-T007
.	O
A	O
number	O
of	O
approaches	O
have	O
been	O
used	O
,	O
in	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
experimental	O
models	O
,	O
to	O
inhibit	O
bacterial	O
attachment	O
to	O
temporally	O
expressed	O
host	O
receptors	O
.	O
Some	O
of	O
these	O
novel	O
strategies	O
may	O
advance	O
future	O
targeted	O
interventions	B-T058
for	O
the	O
prevention	B-T061
and	O
treatment	B-T061
of	O
bacterial	B-T047
disease	I-T047
.	O
      
Pre	B-T047
-	I-T047
hypertension	I-T047
,	O
pre	B-T047
-	I-T047
diabetes	I-T047
or	O
both	O
:	O
which	O
is	O
best	O
at	O
predicting	O
cardiovascular	B-T033
events	I-T033
in	O
the	O
long	O
term	O
?	O
The	O
present	O
study	O
aimed	O
to	O
assess	O
the	O
value	O
of	O
pre	B-T047
-	I-T047
diabetes	I-T047
and	O
pre	B-T047
-	I-T047
hypertension	I-T047
in	O
predicting	O
cardiovascular	B-T033
events	I-T033
.	O
A	O
population	O
-based	O
,	O
cross	O
-	O
sectional	O
survey	O
was	O
conducted	O
,	O
representing	O
a	O
large	O
sample	O
of	O
the	O
general	O
Iranian	O
population	O
aged	O
35	O
years	O
and	O
older	O
from	O
the	O
Isfahan	O
Province	O
and	O
determined	O
using	O
a	O
random	O
,	O
multistage	O
cluster	O
-	O
sampling	O
10	O
-	O
year	O
cohort	O
.	O
The	O
five	O
end	O
points	O
considered	O
as	O
study	O
outcome	O
were	O
unstable	B-T047
angina	I-T047
(	O
UA	B-T047
)	O
,	O
acute	O
occurrence	O
of	O
myocardial	B-T047
infarction	I-T047
(	O
MI	B-T047
)	O
,	O
sudden	O
cardiac	O
death	O
(	O
SCD	O
)	O
,	O
brain	B-T047
stroke	I-T047
and	O
cardiovascular	B-T047
disease	I-T047
(	O
CVD	B-T047
)	O
.	O
Of	O
the	O
6323	O
subjects	O
scheduled	O
for	O
assessment	B-T058
of	O
diabetes	B-T047
state	I-T047
617	O
were	O
diabetics	B-T033
and	O
712	O
were	O
pre	B-T033
-	I-T033
diabetic	I-T033
.	O
In	O
addition	O
,	O
of	O
these	O
subjects	O
,	O
1754	O
had	O
hypertension	B-T047
and	O
2500	O
had	O
pre	B-T047
-	I-T047
hypertension	I-T047
.	O
Analysing	O
only	O
pre	B-T047
-	I-T047
hypertension	I-T047
,	O
pre	B-T047
-	I-T047
diabetes	I-T047
and	O
its	O
combination	O
and	O
adjusted	O
for	O
gender	O
and	O
age	O
variables	O
,	O
pre	B-T047
-	I-T047
hypertension	I-T047
and	O
pre	B-T047
-	I-T047
diabetes	I-T047
status	O
together	O
,	O
could	O
only	O
effectively	O
predict	O
occurrence	O
of	O
MI	B-T047
(	O
hazard	O
ratio	O
(	O
HR)=3.21	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
):	O
1.06	O
-	O
9.76	O
,	O
P=0.04	O
)	O
.	O
In	O
the	O
same	O
COX	O
regression	O
models	O
,	O
pre	B-T047
-	I-T047
hypertension	I-T047
status	O
could	O
predict	O
UA	B-T047
and	O
CVD	B-T047
occurrence	O
(	O
HR	O
=	O
2.94	O
,	O
95	O
%	O
CI	O
:	O
1.68	O
-	O
5.14	O
,	O
P<0.001	O
and	O
HR	O
=	O
1.74	O
,	O
95	O
%	O
CI	O
:	O
1.23	O
-	O
2.47	O
,	O
P=0.002	O
,	O
respectively	O
)	O
.	O
However	O
,	O
pre	B-T047
-	I-T047
diabetes	I-T047
status	O
could	O
not	O
predict	O
any	O
of	O
these	O
events	O
after	O
adjustment	O
for	O
gender	O
and	O
age	O
.	O
Our	O
data	O
provide	O
valuable	O
evidence	O
of	O
the	O
triggering	O
role	O
of	O
pre	B-T047
-	I-T047
hypertension	I-T047
and	O
pre	B-T047
-	I-T047
diabetes	I-T047
together	O
,	O
on	O
appearance	O
and	O
progression	O
of	O
MI	B-T047
even	O
in	O
healthy	O
individuals	O
and	O
the	O
significant	O
predicting	O
value	O
of	O
pre	B-T047
-	I-T047
hypertension	I-T047
on	O
the	O
occurrence	O
of	O
UA	B-T047
and	O
CVD	B-T047
.	O
In	O
this	O
regard	O
,	O
the	O
value	O
of	O
pre	B-T047
-	I-T047
hypertension	I-T047
and	O
pre	B-T047
-	I-T047
diabetes	I-T047
together	O
,	O
and	O
the	O
pre	B-T047
-	I-T047
hypertension	I-T047
state	O
alone	O
,	O
are	O
clearly	O
superior	O
to	O
pre	B-T047
-	I-T047
diabetes	I-T047
state	O
alone	O
in	O
predicting	O
cardiovascular	B-T033
events	I-T033
.	O
      
Breakthrough	O
viridans	B-T047
streptococcal	I-T047
bacteremia	I-T047
in	O
allogeneic	B-T061
hematopoietic	I-T061
stem	I-T061
cell	I-T061
transplant	I-T061
recipients	O
receiving	O
levofloxacin	B-T195
prophylaxis	B-T061
in	O
a	O
Japanese	O
hospital	O
Breakthrough	O
viridans	B-T047
streptococcal	I-T047
bacteremia	I-T047
(	O
VSB	B-T047
)	O
in	O
patients	O
with	O
hematological	B-T191
malignancy	I-T191
receiving	O
levofloxacin	B-T195
prophylaxis	B-T061
is	O
a	O
major	O
blood	B-T047
stream	I-T047
infection	I-T047
(	O
BSI	B-T047
)	O
occurring	O
during	O
febrile	B-T047
neutropenia	I-T047
.	O
However	O
,	O
clinical	O
data	O
focused	O
on	O
VSB	B-T047
in	O
allogeneic	B-T061
hematopoietic	I-T061
stem	I-T061
cell	I-T061
transplant	I-T061
(	O
allo	B-T061
-	I-T061
HSCT	I-T061
)	O
recipients	O
are	O
lacking	O
.	O
The	O
medical	O
records	O
of	O
allo	B-T061
-	I-T061
HSCT	I-T061
recipients	O
who	O
received	O
oral	O
levofloxacin	B-T195
prophylaxis	B-T061
between	O
January	O
2011	O
and	O
August	O
2013	O
at	O
Toranomon	O
Hospital	O
were	O
reviewed	O
to	O
evaluate	B-T058
breakthrough	O
VSB	B-T047
.	O
Stored	O
viridans	B-T007
streptococcal	I-T007
(	O
VGS	B-T007
)	O
species	O
were	O
identified	O
by	O
using	O
sodA	O
gene	O
sequencing	B-T059
,	O
and	O
were	O
assessed	O
for	O
drug	O
susceptibility	O
.	O
Among	O
the	O
184	O
allo	B-T061
-	I-T061
HSCT	I-T061
recipients	O
on	O
levofloxacin	B-T195
prophylaxis	B-T061
,	O
28	O
(	O
15.2	O
%	O
)	O
experienced	O
breakthrough	O
VSB	B-T047
.	O
All	O
of	O
the	O
28	O
recipients	O
with	O
VSB	B-T047
were	O
treated	O
with	O
a	O
cefepime	B-T195
-	O
based	O
or	O
piperacillin	B-T121
/	I-T121
tazobactam	I-T121
-	O
based	O
regimen	B-T061
.	O
The	O
susceptibility	O
rates	O
of	O
the	O
VGS	B-T007
strains	B-T001
for	O
levofloxacin	B-T195
,	O
cefepime	B-T195
,	O
piperacillin	B-T121
/	I-T121
tazobactam	I-T121
,	O
meropenem	B-T195
,	O
and	O
vancomycin	B-T195
were	O
0	O
%	O
,	O
95	O
%	O
,	O
100	O
%	O
,	O
100	O
%	O
,	O
and	O
100	O
%	O
,	O
respectively	O
.	O
Both	O
the	O
MIC50	B-T059
(	O
minimum	B-T059
inhibitory	I-T059
concentration	I-T059
)	O
and	O
the	O
MIC90	B-T059
of	O
ceftazidim	B-T195
(	O
0.5	O
μg	O
/	O
mL	O
and	O
2	O
μg	O
/	O
mL	O
,	O
respectively	O
)	O
were	O
higher	O
than	O
the	O
MIC90	B-T059
of	O
all	O
the	O
other	O
anti	B-T121
-	I-T121
pseudomonal	I-T121
beta	I-T121
-	I-T121
lactams	I-T121
(	O
APBLs	B-T121
)	O
.	O
Only	O
1	O
VGS	B-T007
strain	B-T001
had	O
a	O
penicillin	B-T195
MIC	B-T059
≥	O
2	O
μg	O
/	O
mL	O
by	O
the	O
Etest	B-T059
(	O
3.6	O
%	O
)	O
.	O
There	O
were	O
no	O
cases	O
with	O
acute	B-T033
respiratory	I-T033
distress	I-T033
syndrome	I-T033
(	O
ARDS	B-T033
)	O
that	O
was	O
associated	O
with	O
VSB	B-T047
,	O
although	O
the	O
rate	O
of	O
viridans	B-T047
group	I-T047
streptococcal	I-T047
shock	I-T047
syndrome	I-T047
was	O
high	O
(	O
26	O
%	O
)	O
.	O
The	O
crude	O
30	O
-	O
day	O
mortality	O
rate	O
in	O
the	O
VSB	B-T047
group	O
(	O
10.7	O
%	O
)	O
did	O
not	O
differ	O
significantly	O
from	O
that	O
in	O
the	O
BSI	B-T047
without	O
VSB	B-T047
group	O
(	O
9.3	O
%	O
)	O
or	O
non	O
-	O
BSI	B-T047
group	O
(	O
7.0	O
%	O
)	O
(	O
P	O
=	O
0.77	O
)	O
.	O
Also	O
,	O
VSB	B-T047
was	O
not	O
a	O
risk	B-T033
factor	I-T033
for	O
all	O
-	O
cause	O
mortality	O
up	O
to	O
60	O
days	O
following	O
allo	B-T061
-	I-T061
HSCT	I-T061
(	O
P	O
=	O
0.43	O
)	O
.	O
APBL	B-T121
with	O
increased	O
anti	B-T033
-	I-T033
VGS	I-T033
activity	I-T033
(	O
APBL	B-T033
-	I-T033
VA	I-T033
)	O
monotherapy	B-T061
would	O
typically	O
be	O
optimal	O
for	O
treating	O
the	O
VGS	B-T007
strains	B-T001
in	O
this	O
setting	O
.	O
Indication	O
of	O
adding	O
an	O
empiric	O
anti	B-T121
-	I-T121
gram	I-T121
-	I-T121
positive	I-T121
agent	I-T121
to	O
APBL	B-T033
-	I-T033
VA	I-T033
for	O
treating	O
VSB	B-T047
should	O
depend	O
on	O
local	O
factors	O
,	O
such	O
as	O
the	O
susceptibility	O
results	O
.	O
In	O
addition	O
,	O
breakthrough	O
VSB	B-T047
is	O
probably	O
not	O
a	O
major	O
cause	B-T033
of	I-T033
death	I-T033
in	O
allo	B-T061
-	I-T061
HSCT	I-T061
settings	O
,	O
where	O
beta	B-T195
-	I-T195
lactam	I-T195
non	B-T007
-	I-T007
susceptible	I-T007
VGS	I-T007
and	O
the	O
ARDS	B-T033
are	O
rare	O
.	O
      
Exercise	O
increases	O
lactoferrin	O
,	O
but	O
decreases	O
lysozyme	B-T121
in	O
salivary	O
granulocytes	O
Intracellular	O
lactoferrin	O
(	O
Lac	O
)	O
and	O
lysozyme	B-T121
(	O
Lys	B-T121
)	O
content	O
play	O
an	O
important	O
role	O
in	O
regulating	O
inflammation	O
and	O
promoting	O
host	O
protection	O
.	O
While	O
exercise	O
has	O
demonstrated	O
an	O
increase	O
in	O
Lac	O
and	O
Lys	B-T121
concentration	O
in	O
exocrine	O
solutions	O
,	O
little	O
is	O
known	O
regarding	O
intracellular	O
concentration	O
changes	O
in	O
response	O
to	O
exercise	O
.	O
To	O
quantify	O
intracellular	O
Lac	O
and	O
Lys	B-T121
concentration	O
before	O
and	O
after	O
exercise	O
in	O
salivary	O
CD45(+)CD15(+	O
)	O
cells	O
.	O
11	O
males	O
(	O
20.3	O
±	O
0.8	O
years	O
,	O
57.2	O
±	O
7.6	O
mL	O
/	O
kg	O
/	O
min	O
V̇O2pk	O
,	O
11.1	O
±	O
3.9	O
%	O
body	O
fat	O
)	O
ran	O
for	O
45	O
min	O
at	O
75	O
%	O
of	O
VO2pk	O
.	O
12	O
mL	O
of	O
stimulated	O
saliva	O
were	O
collected	O
pre	O
and	O
immediately	O
post	O
exercise	O
.	O
Saliva	O
was	O
filtered	O
through	O
a	O
30-µm	O
filter	O
before	O
analysis	O
of	O
leukocytes	O
(	O
CD45(+	O
)	O
)	O
and	O
granulocytes	O
(	O
CD45(+)CD15(+	O
)	O
)	O
using	O
flow	B-T059
cytometry	I-T059
.	O
Median	O
fluorescent	O
intensity	O
(	O
MFI	O
)	O
of	O
Lac	O
increased	O
from	O
pre	O
(	O
64,268	O
±	O
46,036	O
MFI	O
)	O
to	O
post	O
(	O
117,134	O
±	O
88,115	O
MFI	O
)	O
exercise	O
(	O
p	O
<	O
0.05	O
)	O
.	O
Lys	B-T121
MFI	O
decreased	O
with	O
exercise	O
(	O
pre	O
:	O
16,933	O
±	O
8249	O
;	O
post	O
:	O
11,616	O
±	O
6875	O
)	O
(	O
p	O
<	O
0.05	O
)	O
.	O
Acute	O
running	O
resulted	O
in	O
an	O
increased	O
Lac	O
concentration	O
which	O
could	O
lead	O
to	O
a	O
decrease	O
in	O
inflammation	O
,	O
adding	O
further	O
evidence	O
of	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
exercise	O
.	O
Conversely	O
,	O
the	O
exercise	O
-associated	O
decrease	O
of	O
intracellular	B-T121
Lys	I-T121
content	O
could	O
be	O
the	O
cause	O
of	O
increased	O
Lys	B-T121
in	O
exocrine	O
solutions	O
.	O
      
Functional	O
Result	O
After	O
Cochlear	B-T061
Implantation	I-T061
in	O
Children	O
and	O
Adults	O
With	O
Single	B-T047
-	I-T047
sided	I-T047
Deafness	I-T047
Patients	O
with	O
single	B-T047
-	I-T047
sided	I-T047
deafness	I-T047
(	O
SSD	B-T047
)	O
suffer	O
from	O
reduced	O
binaural	O
hearing	O
(	O
i.e.	O
,	O
sound	O
localization	O
and	O
speech	O
in	O
noise	O
discrimination	O
)	O
.	O
Cochlear	B-T061
implantation	I-T061
has	O
recently	O
been	O
introduced	O
for	O
patients	O
with	O
SSD	B-T047
,	O
as	O
an	O
alternative	O
to	O
hearing	O
devices	O
that	O
employ	O
contralateral	O
routing	O
of	O
the	O
signal	O
.	O
Application	B-T058
to	O
children	O
has	O
also	O
been	O
started	O
.	O
We	O
retrospectively	O
analyze	O
a	O
case	O
series	O
of	O
4	O
children	O
and	O
17	O
adults	O
with	O
SSD	B-T047
,	O
treated	B-T061
with	I-T061
cochlear	B-T061
implantation	I-T061
.	O
The	O
outcome	O
of	O
adult	O
patients	O
was	O
compared	O
with	O
a	O
control	O
group	O
of	O
27	O
patients	O
with	O
bilateral	B-T047
profound	I-T047
hearing	I-T047
loss	I-T047
using	O
a	O
cochlear	O
implant	O
.	O
During	O
12	O
months	O
,	O
the	O
mean	B-T033
speech	O
recognition	O
score	O
increased	O
from	O
30	O
to	O
41	O
%	O
for	O
monosyllabic	O
words	O
in	O
adults	O
,	O
and	O
from	O
58	O
to	O
89	O
%	O
for	O
multisyllabic	O
numbers	O
.	O
The	O
cochlear	O
implant	O
(	O
CI	O
)	O
improved	B-T033
hearing	I-T033
in	O
noise	O
in	O
all	O
SSD	B-T047
patients	O
,	O
as	O
was	O
demonstrated	O
by	O
a	O
significant	O
improvement	O
of	O
the	O
speech	O
reception	O
threshold	O
in	O
different	O
speech	O
and	O
noise	O
configurations	O
.	O
Sound	O
localization	O
-correlated	O
angle	O
detection	O
error	O
improved	O
with	O
CI	O
use	O
at	O
every	O
time	O
point	O
.	O
The	O
maximum	O
word	O
recognition	O
score	O
for	O
monosyllabic	O
words	O
in	O
quiet	O
correlated	O
with	O
the	O
logarithm	O
of	O
the	O
duration	O
of	O
deafness	B-T033
;	O
improvement	O
of	O
the	O
speech	O
reception	O
threshold	O
and	O
RMS	O
angle	O
detection	O
error	O
by	O
the	O
CI	O
did	O
not	O
.	O
All	O
SSD	B-T047
patients	O
benefitted	O
from	O
the	O
CI	O
in	O
different	O
hearing	O
situations	O
.	O
Patients	O
with	O
SSD	B-T047
for	O
a	O
long	O
period	O
can	O
improve	O
after	O
cochlear	B-T061
implantation	I-T061
.	O
      
Host	O
plant	O
affects	O
the	O
sexual	B-T001
attractiveness	I-T001
of	O
the	O
female	O
white	O
-	O
spotted	O
longicorn	O
beetle	O
,	O
Anoplophora	O
malasiaca	O
Anoplophora	O
malasiaca	O
(	O
Coleoptera	O
:	O
Cerambycidae	O
)	O
is	O
a	O
serious	O
pest	O
that	O
destroys	O
various	O
landscape	O
and	O
crop	O
trees	O
in	O
Japan	O
.	O
We	O
evaluated	O
the	O
precopulatory	O
responses	O
of	O
three	O
different	O
A.	O
malasiaca	O
populations	O
collected	O
from	O
mandarin	O
orange	O
,	O
willow	O
and	O
blueberry	O
trees	O
.	O
Most	O
of	O
the	O
males	O
accepted	O
mates	O
from	O
within	O
the	O
same	O
host	O
plant	O
population	O
as	O
well	O
as	O
females	O
from	O
the	O
willow	O
and	O
blueberry	O
populations	O
.	O
However	O
,	O
significant	O
number	O
of	O
males	O
from	O
the	O
blueberry	O
and	O
willow	O
populations	O
rejected	O
females	O
from	O
the	O
mandarin	O
orange	O
population	O
immediately	O
after	O
touching	O
them	O
with	O
their	O
antennae	B-T023
.	O
Because	O
all	O
three	O
of	O
the	O
female	O
populations	O
produced	O
contact	O
sex	O
pheromones	O
on	O
their	O
elytra	B-T023
,	O
the	O
females	O
of	O
the	O
mandarin	O
orange	O
population	O
were	O
predicted	O
to	O
possess	O
extra	O
chemicals	O
that	O
repelled	O
the	O
males	O
of	O
the	O
other	O
two	O
populations	O
.	O
β	O
-	O
Elemene	O
was	O
identified	O
as	O
a	O
key	O
component	O
that	O
was	O
only	O
found	O
in	O
mandarin	O
orange	O
-fed	O
females	O
and	O
induced	O
a	O
rejection	O
response	O
in	O
willow	O
-fed	O
males	O
.	O
Our	O
results	O
represent	O
the	O
first	O
example	O
of	O
a	O
female	O
-acquired	O
repellent	O
against	O
conspecific	O
males	O
of	O
different	O
host	O
plant	O
populations	O
,	O
indicating	O
that	O
the	O
host	O
plant	O
greatly	O
affects	O
the	O
female	O
's	O
sexual	B-T001
attractiveness	I-T001
.	O
      
The	O
four	O
-	O
component	O
aureocin	O
A70	O
as	O
a	O
promising	O
agent	O
for	O
food	O
biopreservation	O
Aureocin	O
A70	O
is	O
the	O
only	O
four	O
-	O
component	O
bacteriocin	O
described	O
to	O
date	O
.	O
As	O
it	O
inhibits	O
the	O
growth	O
of	O
a	O
wide	O
range	O
of	O
Gram	B-T007
-	I-T007
positive	I-T007
bacteria	I-T007
,	O
including	O
Listeria	B-T007
monocytogenes	I-T007
strains	B-T001
isolated	O
from	O
food	O
,	O
its	O
potential	O
for	O
improving	O
food	O
safety	O
was	O
investigated	O
in	O
this	O
study	O
.	O
Aureocin	O
A70	O
(	O
10,240AU	O
/	O
mL	O
)	O
proved	O
to	O
be	O
bactericidal	B-T195
,	O
but	O
not	O
extensively	O
lytic	O
,	O
against	O
listerial	B-T007
strains	B-T001
.	O
The	O
antibacterial	O
activity	O
of	O
aureocin	O
A70	O
(	O
16AU	O
/	O
mL	O
)	O
was	O
then	O
tested	O
in	O
UHT	B-T061
-	I-T061
treated	I-T061
skimmed	O
milk	O
inoculated	B-T059
with	O
the	O
food	O
-associated	O
L.	B-T007
monocytogenes	I-T007
L12	I-T007
strain	I-T007
(	O
4	O
-	O
log	O
CFU	O
/	O
mL	O
)	O
during	O
storage	O
at	O
4	O
°	O
C	O
for	O
one	O
week	O
.	O
Aureocin	O
A70	O
caused	O
a	O
time	O
-	O
dependent	O
reduction	O
in	O
the	O
listerial	B-T007
viable	B-T059
cell	I-T059
counts	I-T059
(	O
5.51	O
-	O
log	O
units	O
)	O
up	O
to	O
7days	O
of	O
incubation	B-T059
.	O
Aureocin	O
A70	O
was	O
neither	O
toxic	O
to	O
the	O
Vero	O
and	O
the	O
L-929	O
cell	O
lines	O
nor	O
exhibited	O
a	O
hemolytic	O
activity	O
against	O
sheep	O
red	O
blood	O
cells	O
.	O
Aureocin	O
A70	O
proved	O
to	O
be	O
completely	O
stable	O
for	O
one	O
month	O
at	O
25	O
°	O
C	O
,	O
16weeks	O
at	O
4	O
°	O
C	O
and	O
20weeks	O
at	O
-20	O
°	O
C	O
.	O
Aureocin	O
A70	O
exhibited	O
a	O
time	O
-	O
dependent	O
susceptibility	O
to	O
simulated	O
gastric	O
juice	O
and	O
bile	O
salts	O
mimicking	O
gastrointestinal	B-T033
conditions	I-T033
.	O
The	O
entrapment	O
of	O
aureocin	O
A70	O
in	O
an	O
alginate	O
/	O
gelatin	O
matrix	O
revealed	O
that	O
this	O
bacteriocin	O
can	O
be	O
released	O
from	O
this	O
matrix	O
.	O
Moreover	O
,	O
it	O
remained	O
adsorbed	O
to	O
and	O
active	O
on	O
a	O
low	O
-	O
density	O
polyethylene	O
plastic	O
surface	O
suggesting	O
that	O
aureocin	O
A70	O
may	O
be	O
employed	O
in	O
bioactive	O
packaging	O
to	O
control	O
the	O
growth	O
of	O
undesirable	O
bacteria	B-T007
.	O
Taken	O
together	O
these	O
results	O
suggest	O
that	O
aureocin	O
A70	O
is	O
a	O
promising	O
alternative	O
to	O
be	O
used	O
in	O
food	O
applications	O
.	O
      
Lightweight	O
Open	O
-	O
Cell	O
Scaffolds	O
from	O
Sea	O
Urchin	O
Spines	O
with	O
Superior	O
Material	O
Properties	O
for	O
Bone	B-T061
Defect	I-T061
Repair	I-T061
Sea	O
urchin	O
spines	O
(	O
Heterocentrotus	O
mammillatus	O
)	O
,	O
with	O
a	O
hierarchical	O
open	O
-	O
cell	O
structure	O
similar	O
to	O
that	O
of	O
human	O
trabecular	O
bone	O
and	O
superior	O
mechanical	O
property	O
(	O
compressive	O
strength	O
∼43.4	O
MPa	O
)	O
suitable	O
for	O
machining	O
to	O
shape	O
,	O
were	O
explored	O
for	O
potential	O
applications	O
of	O
bone	B-T061
defect	I-T061
repair	I-T061
.	O
Finite	O
element	O
analyses	O
reveal	O
that	O
the	O
compressive	O
stress	B-T033
concentrates	O
along	O
the	O
dense	O
growth	O
rings	O
and	O
dissipates	O
through	O
strut	O
structures	B-T017
of	I-T017
the	I-T017
stereoms	I-T017
,	O
indicating	O
that	O
the	O
exquisite	O
mesostructures	O
play	O
an	O
important	O
role	O
in	O
high	O
strength	O
-to-	O
weight	O
ratios	O
.	O
The	O
fracture	O
strength	O
of	O
magnesium	O
-	O
substituted	O
tricalcium	O
phosphate	O
(	O
β	O
-	O
TCMP	O
)	O
scaffolds	O
produced	O
by	O
hydrothermal	O
conversion	O
of	O
urchin	O
spines	O
is	O
about	O
9.3	O
MPa	O
,	O
comparable	O
to	O
that	O
of	O
human	O
trabecular	O
bone	O
.	O
New	O
bone	B-T023
forms	O
along	O
outer	O
surfaces	O
of	O
β	O
-	O
TCMP	O
scaffolds	O
after	O
implantation	B-T061
in	O
rabbit	O
femoral	O
defects	O
for	O
one	O
month	O
and	O
grows	O
into	O
the	O
majority	O
of	O
the	O
inner	O
open	O
-	O
cell	O
spaces	O
postoperation	O
in	O
three	O
month	O
s	O
,	O
showing	O
tight	O
interface	O
between	O
the	O
scaffold	O
and	O
regenerative	O
bone	O
tissue	O
.	O
Fusion	B-T061
of	O
beagle	O
lumbar	O
facet	O
joints	O
using	O
a	O
Ti-6Al-4V	O
cage	O
and	O
β	O
-	O
TCMP	O
scaffold	O
can	O
be	O
completed	O
within	O
seven	O
months	O
with	O
obvious	O
biodegradation	O
of	O
the	O
β	O
-	O
TCMP	O
scaffold	O
,	O
which	O
is	O
nearly	O
completely	O
degraded	O
and	O
replaced	O
by	O
newly	O
formed	O
bone	B-T023
ten	O
months	O
after	O
implantation	B-T061
.	O
Thus	O
,	O
sea	O
urchin	O
spines	O
suitable	O
for	O
machining	O
to	O
shape	O
have	O
advantages	O
for	O
production	O
of	O
biodegradable	O
artificial	O
grafts	O
for	O
bone	B-T061
defect	I-T061
repair	I-T061
.	O
      
Management	B-T058
of	O
skin	B-T047
and	I-T047
soft	I-T047
-	I-T047
tissue	I-T047
infections	I-T047
at	O
a	O
community	O
teaching	O
hospital	O
using	O
a	O
severity	O
-	O
of	O
-	O
illness	O
tool	O
Skin	B-T047
and	I-T047
soft	I-T047
-	I-T047
tissue	I-T047
infections	I-T047
(	O
SSTIs	B-T047
)	O
encompass	O
a	O
diverse	O
range	O
of	O
infections	O
of	O
varying	O
severity	O
.	O
The	O
Clinical	O
Resource	O
Efficiency	O
Support	O
Team	O
(	O
CREST	O
)	O
scoring	O
system	O
stratifies	O
patients	O
into	O
four	O
classes	O
(	O
I	O
=	O
least	O
severe	O
to	O
IV	O
=	O
most	O
severe	O
)	O
based	O
on	O
the	O
Standardized	O
Early	O
Warning	O
Score	O
(	O
SEWS	O
)	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
apply	O
CREST	O
to	O
hospitalized	O
patients	O
with	O
SSTIs	B-T047
in	O
order	O
to	O
quantify	O
disease	O
severity	O
and	O
evaluate	B-T058
appropriateness	O
of	O
antibiotic	B-T195
management	O
.	O
This	O
was	O
a	O
retrospective	O
,	O
hypothesis	O
-generating	O
,	O
single	O
-	O
centre	O
evaluation	B-T058
of	O
hospitalized	O
patients	O
with	O
SSTIs	B-T047
admitted	B-T058
in	O
2011	O
.	O
Based	O
on	O
CREST	O
classification	O
,	O
the	O
empirical	O
antimicrobial	B-T121
choices	O
were	O
categorized	O
as	O
appropriate	O
,	O
over	B-T058
-	I-T058
treatment	I-T058
or	O
under	B-T061
-	I-T061
treatment	I-T061
.	O
A	O
total	O
of	O
369	O
patients	O
were	O
screened	O
and	O
200	O
met	O
the	O
inclusion	O
criteria	O
.	O
The	O
majority	O
of	O
patients	O
were	O
classified	O
as	O
either	O
CREST	O
class	O
I	O
(	O
n	O
=	O
68	O
)	O
or	O
class	O
I	O
I	O
(	O
n	O
=	O
102	O
)	O
.	O
Over	B-T058
-	I-T058
treatment	I-T058
was	O
more	O
common	O
in	O
the	O
less	O
severe	O
classes	O
(	O
88	O
%	O
and	O
32	O
%	O
in	O
class	O
I	O
and	O
class	O
II	O
,	O
respectively	O
;	O
P	O
<	O
0.05	O
)	O
.	O
Sixty	O
-	O
three	O
percent	O
of	O
class	O
I	O
(	O
n	O
=	O
43	O
)	O
were	O
over	B-T058
-	I-T058
treated	I-T058
due	O
to	O
both	O
the	O
use	O
of	O
intravenous	O
antibiotic	B-T195
s	O
when	O
oral	B-T061
therapy	I-T061
was	O
sufficient	O
and	O
use	O
of	O
unnecessarily	O
broad	B-T195
-	I-T195
spectrum	I-T195
antibiotics	I-T195
.	O
In	O
contrast	O
,	O
25	O
%	O
(	O
n	O
=	O
26	O
)	O
of	O
class	O
II	O
were	O
over	B-T058
-	I-T058
treated	I-T058
due	O
to	O
use	O
of	O
unnecessarily	O
broad	B-T195
-	I-T195
spectrum	I-T195
antibiotics	I-T195
.	O
Overall	O
clinical	B-T033
failure	I-T033
rates	O
remained	O
low	O
with	O
only	O
1	O
%	O
,	O
4	O
%	O
and	O
17	O
%	O
of	O
patients	O
unable	O
to	O
achieve	O
initial	O
response	O
in	O
class	O
II	O
,	O
class	O
III	O
and	O
class	O
IV	O
.	O
Retrospective	O
application	B-T058
of	O
CREST	O
identified	O
opportunities	O
to	O
improve	O
the	O
management	B-T058
of	O
SSTIs	B-T047
.	O
CREST	O
can	O
be	O
of	O
great	O
value	O
in	O
discriminating	O
less-	O
severe	O
SSTIs	B-T047
,	O
which	O
can	O
be	O
treated	B-T061
on	O
an	O
outpatient	O
basis	O
.	O
      
Fingerprint	O
-based	O
background	B-T033
checks	I-T033
for	O
personal	O
care	O
workers	O
:	O
Stakeholder	O
views	O
of	O
policy	O
criteria	O
Decision	O
makers	O
face	O
difficult	O
choices	O
when	O
tasked	O
with	O
identifying	O
and	O
implementing	O
appropriate	O
mechanisms	O
for	O
protecting	B-T033
the	O
elderly	O
and	O
other	O
vulnerable	B-T033
adults	I-T033
from	O
abuse	O
.	O
A	O
pilot	O
project	O
involving	O
fingerprint	O
-based	O
criminal	O
history	O
background	B-T033
checks	I-T033
for	O
personal	O
care	O
workers	O
in	O
Michigan	O
has	O
supplied	O
an	O
opportunity	O
to	O
examine	O
one	O
such	O
mechanism	O
.	O
In	O
conjunction	O
with	O
the	O
pilot	O
project	O
,	O
we	O
have	O
conducted	O
a	O
stakeholder	O
analysis	O
with	O
the	O
aim	O
of	O
informing	O
decision	O
makers	O
about	O
stakeholder	O
perceptions	O
of	O
standard	O
policy	O
criteria	O
like	O
effectiveness	O
,	O
efficiency	O
,	O
and	O
equity	O
.	O
We	O
employed	O
focus	O
groups	O
and	O
a	O
web	O
-	O
based	O
survey	O
to	O
collect	O
data	O
from	O
stakeholders	O
.	O
While	O
stakeholders	O
generally	O
see	O
fingerprint	O
-based	O
background	B-T033
checks	I-T033
for	O
personal	O
care	O
workers	O
as	O
potentially	O
effective	O
and	O
as	O
a	O
net	O
benefit	O
,	O
they	O
also	O
point	O
to	O
a	O
variety	O
of	O
contingencies	O
.	O
They	O
also	O
recognize	O
difficulties	B-T033
and	O
constraints	O
for	O
government	O
involvement	O
.	O
This	O
preliminary	O
analysis	O
provides	O
solid	O
foundational	O
information	O
for	O
decision	O
makers	O
and	O
for	O
more	O
extensive	O
benefit	O
-	O
cost	O
analysis	O
.	O
      
Longitudinal	O
study	O
of	O
bovine	O
rotavirus	B-T005
group	I-T005
A	I-T005
in	O
newborn	O
calves	O
from	O
vaccinated	B-T033
and	O
unvaccinated	B-T033
dairy	O
herds	O
Reports	O
of	O
rotavirus	B-T005
excretion	O
in	O
calves	O
usually	O
result	O
from	O
cross	O
-	O
sectional	O
studies	O
,	O
and	O
in	O
face	O
of	O
the	O
conflicting	O
results	O
regarding	O
protection	B-T061
of	O
calves	O
born	O
to	O
vaccinated	B-T033
dams	O
against	O
diarrhea	B-T184
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
rotavirus	B-T005
excretion	O
in	O
dairy	O
calves	O
born	O
to	O
vaccinated	B-T033
or	O
unvaccinated	B-T033
dams	O
,	O
to	O
identify	O
the	O
genotypes	O
of	O
bovine	O
rotavirus	B-T005
group	I-T005
A	I-T005
(	O
RVA	B-T005
)	O
strains	B-T001
isolated	O
from	O
these	O
animals	O
as	O
well	O
as	O
to	O
investigate	O
characteristics	O
of	O
the	O
disease	B-T047
in	O
naturally	O
occurring	O
circumstances	O
throughout	O
the	O
first	B-T033
month	I-T033
of	I-T033
life	I-T033
.	O
Five	O
hundred	O
fifty	O
-	O
two	O
fecal	O
samples	O
were	O
taken	O
from	O
56	O
calves	O
,	O
28	O
from	O
each	O
farm	O
and	O
,	O
in	O
the	O
vaccinated	B-T033
herd	O
,	O
11/281	O
samples	O
(	O
3.91	O
%	O
)	O
taken	O
from	O
six	O
different	O
calves	O
tested	B-T033
positive	I-T033
for	O
RVA	B-T005
while	O
in	O
the	O
unvaccinated	B-T033
herd	O
,	O
3/271	O
samples	O
(	O
1.11	O
%	O
)	O
taken	O
from	O
3	O
different	O
calves	O
tested	B-T033
positive	I-T033
.	O
The	O
genotyping	B-T059
of	O
the	O
VP7	O
genes	O
showed	O
91.2	O
%	O
nucleotide	O
sequence	O
identity	O
to	O
G6	O
genotype	O
(	O
NCDV	B-T001
strain	I-T001
)	O
,	O
and	O
for	O
the	O
VP4	O
gene	O
,	O
strains	B-T001
from	O
the	O
vaccinated	B-T033
herd	O
were	O
96.6	O
%	O
related	O
to	O
B223	B-T001
strain	I-T001
,	O
while	O
strains	B-T001
from	O
the	O
unvaccinated	B-T033
herd	O
were	O
88	O
%	O
related	O
to	O
P[5	O
]	O
genotype	O
(	O
UK	B-T001
strain	I-T001
)	O
.	O
Genotypes	O
found	O
in	O
this	O
study	O
were	O
G6P[11	O
]	O
in	O
the	O
vaccinated	B-T033
herd	O
and	O
G6P[5	O
]	O
in	O
the	O
unvaccinated	B-T033
herd	O
.	O
All	O
calves	O
infected	B-T033
with	O
rotavirus	B-T005
presented	O
an	O
episode	O
of	O
diarrhea	B-T184
in	O
the	O
first	O
month	O
of	O
life	O
,	O
and	O
the	O
discrepancy	O
between	O
the	O
genotypes	O
found	O
in	O
the	O
commercial	B-T121
vaccine	I-T121
(	O
G6P[1	O
]	O
and	O
G10P[11	O
]	O
)	O
and	O
the	O
rotavirus	B-T005
strains	B-T001
circulating	O
in	O
both	O
vaccinated	B-T033
and	O
unvaccinated	B-T033
herds	O
show	O
the	O
importance	O
of	O
keeping	O
constant	O
surveillance	B-T061
in	O
order	O
to	O
avoid	O
potential	O
causes	O
of	O
vaccination	B-T061
failure	B-T033
.	O
      
A	O
Tobramycin	B-T195
Vector	I-T195
Enhances	O
Synergy	O
and	O
Efficacy	O
of	O
Efflux	B-T121
Pump	I-T121
Inhibitors	I-T121
against	O
Multidrug	O
-	O
Resistant	O
Gram	B-T007
-	I-T007
Negative	I-T007
Bacteria	I-T007
Drug	O
efflux	O
mechanisms	O
interact	O
synergistically	O
with	O
the	O
outer	O
membrane	O
permeability	O
barrier	O
of	O
Gram	B-T007
-	I-T007
negative	I-T007
bacteria	I-T007
,	O
leading	O
to	O
intrinsic	O
resistance	O
that	O
presents	O
a	O
major	O
challenge	B-T058
for	O
antibiotic	B-T195
drug	O
development	O
.	O
Efflux	B-T121
pump	I-T121
inhibitors	I-T121
(	O
EPIs	B-T121
)	O
which	O
block	O
the	O
efflux	O
of	O
antibiotics	B-T195
synergize	O
antibiotics	B-T195
,	O
but	O
the	O
clinical	O
development	O
of	O
EPI	B-T121
/	O
antibiotic	B-T195
combination	B-T061
therapy	I-T061
to	O
treat	B-T061
multidrug	O
-	O
resistant	O
(	O
MDR	O
)	O
Gram	B-T047
-	I-T047
negative	I-T047
infections	I-T047
has	O
been	O
challenging	B-T058
.	O
This	O
is	O
in	O
part	O
caused	O
by	O
the	O
inefficiency	B-T033
of	O
current	O
EPIs	B-T121
to	O
penetrate	O
the	O
outer	O
membrane	O
and	O
resist	O
efflux	O
.	O
We	O
demonstrate	O
that	O
conjugation	O
of	O
a	O
tobramycin	B-T195
(	O
TOB	B-T195
)	O
vector	O
to	O
EPIs	B-T121
like	O
NMP	B-T121
,	O
paroxetine	B-T121
,	O
or	O
DBP	O
enhances	O
synergy	O
and	O
efficacy	O
of	O
EPIs	B-T121
in	O
combination	O
with	O
tetracycline	B-T195
antibiotics	I-T195
against	O
MDR	O
Gram	B-T007
-	I-T007
negative	I-T007
bacteria	I-T007
including	O
Pseudomonas	B-T007
aeruginosa	I-T007
.	O
Besides	O
potentiating	O
tetracycline	B-T195
antibiotics	I-T195
,	O
TOB	B-T195
-	O
EPI	B-T121
conjugates	O
can	O
also	O
suppress	O
resistance	O
development	O
to	O
the	O
tetracycline	B-T195
antibiotic	I-T195
minocycline	B-T195
,	O
thereby	O
providing	O
a	O
strategy	O
to	O
develop	O
more	O
effective	O
adjuvants	O
to	O
rescue	O
tetracycline	B-T195
antibiotics	I-T195
from	O
resistance	O
in	O
MDR	O
Gram	B-T007
-	I-T007
negative	I-T007
bacteria	I-T007
.	O
      
The	O
use	O
of	O
neonatal	O
extracorporeal	B-T061
life	I-T061
support	I-T061
in	O
pediatric	O
cardiac	O
intensive	O
care	O
unit	O
The	O
aim	O
of	O
the	O
study	O
is	O
to	O
evaluate	B-T058
extracorporeal	B-T061
life	I-T061
support	I-T061
system	I-T061
(	O
ECLS	B-T061
)	O
employed	O
in	O
neonates	O
in	O
pediatric	O
cardiac	O
intensive	O
care	O
unit	O
.	O
Twenty	O
-	O
five	O
neonates	O
that	O
required	O
ECLS	B-T061
in	O
between	O
November	O
2010	O
and	O
November	O
2015	O
were	O
evaluated	B-T058
.	O
The	O
median	O
age	O
was	O
12	O
days	O
(	O
range	O
3	O
-	O
28	O
days	O
)	O
and	O
the	O
median	O
body	O
weight	O
was	O
3	O
kg	O
(	O
range	O
2.5	O
-	O
5	O
kg	O
)	O
.	O
Venoarterial	O
ECLS	B-T061
was	O
performed	O
in	O
all	O
of	O
the	O
cases	O
.	O
Ascendan	B-T023
aorta	I-T023
-	O
right	B-T023
atrial	I-T023
cannulation	B-T061
in	O
22	O
patients	O
and	O
neck	O
cannulation	B-T061
in	O
three	O
patients	O
were	O
performed	O
.	O
The	O
reason	O
for	O
ECLS	B-T061
was	O
E	B-T061
-	I-T061
CPR	I-T061
in	O
two	O
patients	O
,	O
inability	B-T033
to	I-T033
wean	I-T033
from	O
cardiopulmonary	B-T061
bypass	I-T061
(	O
CPB	B-T061
)	O
in	O
seven	O
patients	O
,	O
respiratory	O
insufficiency	O
and	O
hypoxia	O
in	O
nine	O
patients	O
,	O
low	O
cardiac	O
output	O
(	O
LCOS	O
)	O
in	O
seven	O
patients	O
.	O
Median	O
duration	O
of	O
ECLS	B-T061
was	O
four	O
days	O
(	O
range	O
1	O
-	O
15	O
)	O
.	O
Hemorrhagic	O
complications	O
developed	O
in	O
15	O
,	O
renal	O
complications	O
in	O
13	O
,	O
pulmonary	O
complications	O
in	O
12	O
,	O
infectious	B-T047
complications	O
in	O
11	O
,	O
neurologic	O
complications	O
in	O
three	O
and	O
mechanical	O
complications	O
in	O
two	O
of	O
the	O
patients	O
.	O
Weaning	B-T033
was	O
successful	O
in	O
15	O
of	O
the	O
patients	O
.	O
Eleven	O
patients	O
were	O
successfully	O
discharged	B-T058
.	O
ECLS	B-T061
is	O
an	O
important	O
treatment	B-T061
option	I-T061
that	O
is	O
performed	O
successfully	O
in	O
many	O
centers	O
around	O
the	O
world	O
to	O
maintain	O
life	B-T061
support	I-T061
in	O
patients	O
unresponsive	O
to	O
medical	O
treatment	O
.	O
The	O
utilization	O
of	O
this	O
modality	O
especially	O
in	O
newborns	O
with	O
congenital	B-T019
heart	I-T019
disease	I-T019
should	O
be	O
taken	O
into	O
consideration	O
.	O
      
Anti	O
-	O
Inflammatory	O
Properties	O
of	O
Menthol	B-T121
and	O
Menthone	O
in	O
Schistosoma	B-T047
mansoni	I-T047
Infection	I-T047
Schistosomiasis	B-T047
is	O
a	O
parasitic	B-T047
disease	I-T047
caused	O
by	O
several	O
species	O
of	O
trematode	O
worms	O
and	O
it	O
is	O
believed	O
that	O
more	O
than	O
261	O
million	O
people	O
are	O
affected	O
worldwide	O
.	O
New	O
drug	O
development	O
has	O
become	O
essential	O
because	O
there	O
is	O
a	O
risk	O
of	O
the	O
parasite	O
becoming	O
resistant	O
to	O
Praziquantel	B-T121
,	O
the	O
only	O
drug	B-T121
available	O
for	O
this	O
infection	O
.	O
This	O
study	O
evaluated	B-T058
parasitological	O
,	O
immunological	O
and	O
histological	O
parameters	B-T033
in	O
mice	O
infected	B-T033
with	O
Schistosoma	O
mansoni	O
and	O
treated	B-T061
with	I-T061
an	O
herbal	B-T121
commercial	I-T121
medicine	I-T121
.	O
This	O
drug	B-T121
consists	O
of	O
menthol	B-T121
(	O
30	O
-	O
55	O
%	O
)	O
and	O
menthone	O
(	O
14	O
-	O
32	O
%	O
)	O
.	O
A	O
60	O
day	O
treatment	B-T061
regimen	I-T061
with	O
the	O
herbal	B-T121
medicine	I-T121
decreased	O
the	O
number	O
of	O
S.	O
mansoni	O
eggs	O
in	O
the	O
feces	O
,	O
liver	B-T023
,	O
and	O
intestine	B-T023
and	O
reduced	O
the	O
number	O
of	O
hepatic	B-T047
granulomas	I-T047
.	O
We	O
observed	O
a	O
reduction	B-T061
of	O
84	O
%	O
in	O
blood	B-T047
eosinophilia	I-T047
and	O
a	O
decrease	O
in	O
the	O
IL-4	O
and	O
IL-10	O
blood	O
levels	O
after	O
treatment	B-T061
.	O
Therefore	O
,	O
we	O
propose	O
that	O
schistosomiasis	B-T047
treatment	B-T061
with	O
this	O
herbal	B-T121
medicine	I-T121
for	O
60	O
days	O
has	O
an	O
immunomodulatory	O
and	O
anti	O
-	O
inflammatory	O
action	O
in	O
this	O
animal	O
model	O
for	O
schistosomiasis	B-T047
thus	O
contributing	O
to	O
the	O
decrease	O
in	O
physio	O
pathological	O
effects	O
caused	O
by	O
S.	B-T047
mansoni	I-T047
infection	I-T047
.	O
      
Histopathology	O
of	O
the	O
filum	B-T023
terminale	I-T023
in	O
children	O
with	O
and	O
without	O
tethered	B-T047
cord	I-T047
syndrome	I-T047
with	O
attention	O
to	O
the	O
elastic	O
tissue	O
within	O
the	O
filum	B-T023
To	O
compare	O
histologically	O
transected	O
fila	B-T023
from	O
pediatric	O
patients	O
with	O
tethered	B-T047
cord	I-T047
syndrome	I-T047
(	O
TCS	B-T047
)	O
,	O
with	O
and	O
without	O
a	O
low	O
conus	B-T023
,	O
with	O
controls	O
,	O
focusing	O
on	O
collagenous	O
and	O
elastic	O
tissue	O
.	O
Thirty	O
fila	B-T023
from	O
patients	O
with	O
TCS	B-T047
,	O
including	O
5	O
where	O
minimal	O
cautery	B-T061
was	O
used	O
prior	O
to	O
filum	B-T023
section	B-T059
,	O
were	O
compared	O
with	O
fila	B-T023
from	O
27	O
pediatric	O
cadavers	B-T017
without	O
TCS	B-T047
(	O
controls	O
)	O
.	O
Sections	O
of	O
fila	B-T023
were	O
stained	B-T059
with	O
H&E	B-T059
,	O
Masson	B-T059
trichrome	I-T059
and	O
Verhoeff	B-T059
von	I-T059
Gieson	I-T059
elastic	I-T059
stains	I-T059
,	O
and	O
7	O
with	O
Gordon	B-T059
and	I-T059
Sweet	I-T059
's	I-T059
reticulin	I-T059
stain	I-T059
.	O
Fila	B-T023
from	O
controls	O
showed	O
loose	O
fibrous	O
connective	O
tissue	O
(	O
FCT	O
)	O
with	O
thin	O
and	O
evenly	O
dispersed	O
elastic	O
fibers	O
(	O
EFs	O
)	O
.	O
Reticulin	O
fibers	O
(	O
RFs	O
)	O
were	O
seen	O
in	O
blood	B-T023
vessel	I-T023
walls	I-T023
and	O
nerve	O
twigs	O
.	O
Fat	B-T121
was	O
identified	O
microscopically	O
in	O
2	O
fila	B-T023
.	O
All	O
fila	B-T023
from	O
patients	O
with	O
TCS	B-T047
had	O
dense	O
FCT	O
.	O
The	O
EFs	O
were	O
in	O
normal	O
numbers	O
in	O
17	O
,	O
and	O
focally	O
or	O
diffusely	O
decreased	O
in	O
13	O
.	O
All	O
25	O
patients	O
where	O
the	O
fila	B-T023
were	O
cauterized	B-T061
during	O
resection	B-T061
had	O
thick	O
and	O
coiled	O
EFs	O
.	O
Coiling	O
was	O
not	O
seen	O
when	O
minimal	O
cautery	B-T061
was	O
applied	O
.	O
RFs	O
were	O
seen	O
in	O
blood	B-T023
vessel	I-T023
walls	I-T023
and	O
nerve	O
twigs	O
.	O
Fat	B-T121
was	O
identified	O
in	O
19	O
patients	O
.	O
Findings	B-T033
were	O
similar	O
,	O
whether	O
the	O
conus	B-T023
termination	O
was	O
normal	O
or	O
low	O
.	O
The	O
fila	B-T023
of	O
all	O
patients	O
with	O
TCS	B-T047
,	O
whether	O
or	O
not	O
the	O
conus	B-T023
was	O
low	O
,	O
showed	O
abnormal	B-T033
FCT	O
.	O
EFs	O
were	O
decreased	O
in	O
48	O
%	O
of	O
patients	O
;	O
however	O
,	O
there	O
were	O
thick	O
and	O
coiled	O
EFs	O
in	O
all	O
patients	O
.	O
Coiling	O
of	O
EFs	O
,	O
initially	O
thought	O
to	O
be	O
an	O
abnormality	B-T033
in	O
patients	O
,	O
is	O
considered	O
most	O
likely	O
to	O
be	O
a	O
result	B-T033
of	O
cautery	B-T061
(	O
i.e.	O
,	O
artifactual	O
/	O
iatrogenic	O
coiling	O
)	O
.	O
      
Genetic	O
diversity	O
of	O
Taenia	O
saginata	O
(	O
Cestoda	O
:	O
Cyclophyllidea	O
)	O
from	O
Lao	O
People	O
's	O
Democratic	O
Republic	O
and	O
northeastern	O
Thailand	O
based	O
on	O
mitochondrial	O
DNA	O
Taenia	O
saginata	O
is	O
a	O
tapeworm	O
found	O
in	O
cattle	O
worldwide	O
.	O
Analysis	O
of	O
genetic	O
diversity	O
in	O
different	O
geographical	O
populations	O
of	O
T.	O
saginata	O
not	O
only	O
helps	O
to	O
understand	O
the	O
origin	O
,	O
transmission	O
and	O
spread	O
of	O
this	O
organism	B-T001
,	O
but	O
also	O
to	O
evaluate	O
the	O
selection	O
pressures	O
acting	O
on	O
T.	O
saginata	O
and	O
how	O
it	O
is	O
responding	O
to	O
them	O
.	O
However	O
,	O
there	O
are	O
few	O
reports	O
of	O
the	O
genetic	O
variability	O
of	O
T.	O
saginata	O
populations	O
in	O
different	O
regions	O
of	O
the	O
world	O
,	O
including	O
Lao	O
PDR	O
and	O
Thailand	O
.	O
We	O
report	O
the	O
genetic	O
diversity	O
of	O
T.	O
saginata	O
populations	O
in	O
Lao	O
PDR	O
and	O
northeastern	O
Thailand	O
together	O
with	O
sequences	O
of	O
T.	O
saginata	O
from	O
other	O
countries	O
deposited	O
in	O
GenBank	O
.	O
Mitochondrial	O
cox1	O
sequence	B-T059
analysis	I-T059
revealed	O
that	O
15	O
and	O
8	O
haplotypes	O
were	O
identified	O
in	O
30	O
and	O
21	O
T.	O
saginata	O
isolates	O
from	O
Lao	O
PDR	O
and	O
northeastern	O
Thailand	O
,	O
respectively	O
.	O
Fifty	O
-	O
three	O
haplotypes	O
were	O
identified	O
from	O
98	O
sequences	O
.	O
Phylogenetic	O
tree	O
and	O
haplotype	O
network	O
analyses	O
revealed	O
that	O
global	O
isolates	O
of	O
T.	O
saginata	O
were	O
genetically	O
divided	O
into	O
five	O
groups	O
(	O
A	O
,	O
B	O
,	O
C1	O
,	O
C2	O
and	O
D	O
)	O
.	O
Taenia	O
saginata	O
isolates	O
from	O
Lao	O
PDR	O
and	O
northeastern	O
Thailand	O
belonged	O
to	O
either	O
Group	O
A	O
or	O
B.	O
Taenia	O
saginata	O
from	O
western	O
Thailand	O
clustered	O
in	O
groups	O
C1	O
,	O
C2	O
and	O
D	O
,	O
and	O
populations	O
from	O
the	O
northeast	O
and	O
western	O
Thailand	O
were	O
found	O
to	O
be	O
genetically	O
distinct	O
.	O
Taenia	O
saginata	O
isolates	O
in	O
Lao	O
PDR	O
and	O
Thailand	O
were	O
also	O
found	O
to	O
be	O
genetically	O
diverse	O
but	O
the	O
degree	O
of	O
genetic	O
differentiation	O
was	O
low	O
.	O
Taenia	O
saginata	O
populations	O
from	O
Lao	O
PDR	O
and	O
northeastern	O
Thailand	O
are	O
genetically	O
distinct	O
from	O
the	O
population	O
in	O
western	O
Thailand	O
and	O
it	O
is	O
proposed	O
that	O
T.	O
saginata	O
has	O
been	O
dispersed	O
by	O
different	O
transmission	O
routes	O
in	O
Southeast	O
Asia	O
.	O
      
Application	B-T058
of	O
BRAF	B-T033
V600E	I-T033
mutation	O
-	O
specific	O
immunohistochemistry	B-T060
in	O
diagnosis	B-T033
of	O
gastrointestinal	B-T191
stromal	I-T191
tumors	I-T191
To	O
evaluate	B-T058
the	O
utility	O
of	O
BRAF	B-T033
V600E	I-T033
allele	O
-	O
specific	O
antibody	O
in	O
the	O
diagnosis	B-T033
of	O
gastrointestinal	B-T191
stromal	I-T191
tumors	I-T191
(	O
GISTs	B-T191
)	O
.	O
BRAF	B-T033
V600E	I-T033
mutation	O
-	O
specific	O
immunohistochemistry	B-T060
and	O
BRAF	O
sequencing	O
were	O
performed	O
in	O
24	O
consecutive	O
GISTs	B-T191
,	O
including	O
14	O
cases	O
of	O
KIT	O
or	O
PDGFRA	O
mutations	O
and	O
10	O
cases	O
of	O
KIT	O
/	O
PDGFRA	O
wild	O
GISTs	B-T191
.	O
GISTs	B-T191
of	O
11	O
men	O
and	O
13	O
women	O
with	O
a	O
mean	O
age	O
54	O
years(range	O
29	O
-	O
75	O
years	O
)	O
were	O
included	O
with	O
tumors	B-T191
arising	O
from	O
stomach	B-T023
(	O
16	O
cases	O
)	O
,	O
small	B-T023
bowel	I-T023
(	O
7	O
cases	O
)	O
,	O
and	O
peritoneal	O
cavity	O
(	O
1	O
case	O
)	O
.	O
Strong	O
and	O
diffuse	O
cytoplasmic	O
BRAF	O
staining	B-T033
was	O
noted	O
in	O
4	O
of	O
24	O
cases	O
(	O
17	O
%	O
)	O
,	O
while	O
1	O
of	O
24	O
cases	O
(	O
4	O
%	O
)	O
showed	O
weak	O
staining	B-T033
,	O
and	O
19	O
of	O
24	O
cases	O
(	O
79	O
%	O
)	O
had	O
no	O
staining	B-T033
.	O
The	O
four	O
cases	O
with	O
strong	O
BRAF	O
immunostain	O
were	O
confirmed	O
to	O
have	O
BRAF	O
mutations	O
,	O
including	O
3	O
cases	O
in	O
the	O
stomach	B-T023
and	O
1	O
case	O
in	O
the	O
small	B-T023
intestine	I-T023
.	O
All	O
tumors	B-T191
showed	O
spindle	O
cell	O
morphology	O
.	O
Only	O
one	O
case	O
had	O
progressive	B-T047
disease	I-T047
.	O
No	O
BRAF	O
mutations	O
were	O
detected	B-T033
in	O
cases	O
with	O
weak	O
or	O
negative	B-T033
BRAF	O
immunostain	O
.	O
BRAF	B-T033
V600E	I-T033
mutation	O
-	O
specific	O
immunohistochemistry	B-T060
is	O
a	O
highly	O
sensitive	O
and	O
specific	O
marker	O
for	O
detecting	B-T033
BRAF	O
-	O
mutated	O
GISTs	B-T191
.	O
      
Measurement	O
of	O
fidgeting	B-T033
in	O
patients	O
with	O
anorexia	B-T048
nervosa	I-T048
using	O
a	O
novel	O
shoe	O
-based	O
monitor	O
To	O
objectively	O
assess	O
seated	B-T033
non	O
-	O
exercise	O
physical	O
activity	O
in	O
patients	O
with	O
anorexia	B-T048
nervosa	I-T048
(	O
AN	B-T048
)	O
relative	O
to	O
healthy	O
controls	O
(	O
HCs	O
)	O
and	O
examine	O
the	O
associations	O
between	O
this	O
physical	O
activity	O
,	O
eating	B-T048
disorder	I-T048
pathology	O
,	O
and	O
levels	O
of	O
anxiety	B-T033
and	O
depression	B-T048
.	O
Eleven	O
inpatients	O
with	O
AN	B-T048
and	O
10	O
HCs	O
wore	O
a	O
shoe	O
-based	O
accelerometer	O
(	O
SmartShoe	O
)	O
at	O
three	O
time	O
points	O
:	O
a	O
)	O
while	O
eating	O
lunch	O
,	O
b	O
)	O
filling	O
out	O
questionnaires	O
,	O
and	O
c	O
)	O
watching	O
television	O
for	O
1h	O
.	O
Across	O
all	O
three	O
tasks	O
,	O
patients	O
with	O
AN	B-T048
were	O
significantly	O
more	O
active	O
than	O
HCs	O
,	O
thereby	O
engaging	O
in	O
a	O
greater	O
degree	O
of	O
restless	B-T184
or	O
fidgeting	B-T033
behavior	O
.	O
Degree	O
of	O
physical	O
activity	O
was	O
positively	B-T033
correlated	I-T033
with	O
eating	B-T048
disorder	I-T048
psychopathology	O
in	O
the	O
sample	O
with	O
AN	B-T048
,	O
and	O
a	O
trend	O
towards	O
a	O
positive	B-T033
association	I-T033
between	O
physical	O
activity	O
and	O
levels	O
of	O
depression	B-T048
and	O
anxiety	B-T033
was	O
also	O
found	O
in	O
this	O
sample	O
.	O
Among	O
individuals	O
with	O
AN	B-T048
,	O
physical	O
activity	O
was	O
not	B-T033
significantly	O
correlated	O
with	O
BMI	O
,	O
duration	O
of	O
illness	O
,	O
or	O
number	O
of	O
days	O
since	O
hospital	B-T058
admission	I-T058
.	O
Use	O
of	O
a	O
minimally	O
invasive	O
,	O
shoe	O
-based	O
monitor	O
revealed	O
patients	O
with	O
AN	B-T048
engaged	O
in	O
a	O
greater	O
degree	O
of	O
fidgeting	B-T033
relative	O
to	O
HCs	O
during	O
quiet	O
,	O
seated	B-T033
tasks	O
and	O
this	O
heightened	O
activity	O
was	O
related	O
to	O
measures	O
of	O
pathology	O
.	O
Non	O
-	O
exercise	O
physical	O
activity	O
,	O
including	O
fidgeting	B-T033
,	O
may	O
warrant	O
further	O
clinical	O
attention	O
in	O
this	O
patient	O
population	O
.	O
      
Linking	O
phenological	O
events	O
in	O
migratory	O
passerines	O
with	O
a	O
changing	O
climate	O
:	O
50	O
years	O
in	O
the	O
Laurel	O
Highlands	O
of	O
Pennsylvania	O
Advanced	O
timing	O
of	O
both	O
seasonal	O
migration	O
and	O
reproduction	O
in	O
birds	O
has	O
been	O
strongly	O
associated	O
with	O
a	O
warming	O
climate	O
for	O
many	O
bird	O
species	O
.	O
Phenological	O
responses	O
to	O
climate	O
linking	O
these	O
stages	O
may	O
ultimately	O
impact	O
fitness	O
.	O
We	O
analyzed	O
five	O
decades	O
of	O
banding	O
data	O
from	O
17	O
migratory	O
bird	O
species	O
to	O
investigate	O
1	O
)	O
how	O
spring	O
arrival	O
related	O
to	O
timing	O
of	O
breeding	O
,	O
2	O
)	O
if	O
the	O
interval	O
between	O
arrival	O
and	O
breeding	O
has	O
changed	O
with	O
increasing	O
spring	O
temperatures	O
,	O
and	O
3	O
)	O
whether	O
arrival	O
timing	O
or	O
breeding	O
timing	O
best	O
predicted	O
local	B-T033
productivity	I-T033
.	O
Four	O
of	O
17	O
species	O
,	O
all	O
mid-	O
to	O
long	O
-	O
distance	O
migrants	O
,	O
hatched	O
young	O
earlier	O
in	O
years	O
when	O
migrants	O
arrived	O
earlier	O
to	O
the	O
breeding	O
grounds	O
(	O
~1:1	O
day	O
advancement	O
)	O
.	O
The	O
interval	O
between	O
arrival	O
on	O
breeding	O
grounds	O
and	O
appearance	O
of	O
juveniles	O
shortened	O
with	O
warmer	O
spring	O
temperatures	O
for	O
12	O
species	O
(	O
1	O
-	O
6	O
days	O
for	O
every	O
1	O
°	O
C	O
increase	O
)	O
and	O
over	O
time	O
for	O
seven	O
species	O
(	O
1	O
-	O
8	O
days	O
per	O
decade	O
)	O
,	O
suggesting	O
that	O
some	O
migratory	O
passerines	O
adapt	O
to	O
climate	O
change	O
by	O
laying	O
more	B-T033
quickly	I-T033
after	O
arrival	B-T033
or	O
reducing	O
the	O
time	O
from	O
laying	O
to	O
fledging	O
.	O
We	O
found	O
more	O
support	O
for	O
the	O
former	O
,	O
that	O
the	O
rate	O
of	O
reproductive	O
advancement	O
was	O
higher	O
than	O
that	O
for	O
arrival	B-T033
in	O
warm	O
years	O
.	O
Timing	O
of	O
spring	O
arrival	O
and	O
breeding	O
were	O
both	O
poor	O
predictors	O
of	O
avian	O
productivity	O
for	O
most	O
migrants	O
analyzed	O
.	O
Nevertheless	O
,	O
we	O
found	O
evidence	O
that	O
fitness	O
benefits	O
may	O
occur	O
from	O
shifts	O
to	O
earlier	O
spring	O
arrival	O
for	O
the	O
multi	O
-	O
brooded	O
Song	O
Sparrow	O
.	O
Our	O
results	O
uniquely	O
demonstrate	O
that	O
co	O
-	O
occurring	O
avian	O
species	O
are	O
phenologically	O
plastic	O
in	O
their	O
response	O
to	O
climate	O
change	O
on	O
their	O
breeding	O
grounds	O
.	O
If	O
migrants	O
continue	O
to	O
show	O
a	O
weaker	O
response	O
to	O
temperatures	O
during	O
migration	O
than	O
breeding	O
,	O
and	O
the	O
window	O
between	O
arrival	O
and	O
optimal	O
breeding	O
shortens	O
further	O
,	O
biological	O
constraints	O
to	O
plasticity	O
may	O
limit	O
the	O
ability	O
of	O
species	O
to	O
adapt	O
successfully	O
to	O
future	O
warming	O
.	O
      
Prevalence	O
of	O
Self	O
-	O
Reported	O
Prescription	B-T121
Drug	I-T121
Use	O
in	O
a	O
National	O
Sample	O
of	O
U.S.	O
Drivers	O
Drug	B-T121
-involved	O
driving	O
has	O
become	O
an	O
increasing	O
concern	O
.	O
Although	O
the	O
focus	O
has	O
been	O
on	O
illegal	O
drugs	O
,	O
there	O
is	O
evidence	O
that	O
prescribed	B-T121
medications	I-T121
can	O
impair	B-T033
driving	I-T033
ability	I-T033
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	B-T059
the	O
self	O
-	O
reported	O
prevalence	O
of	O
prescription	B-T121
drug	I-T121
use	O
,	O
including	O
medical	O
and	O
nonmedical	B-T033
use	O
,	O
among	O
a	O
nationally	O
representative	O
sample	O
of	O
drivers	O
and	O
to	O
report	O
related	O
driver	O
characteristics	O
.	O
As	O
part	O
of	O
the	O
2013	O
-	O
2014	O
National	O
Roadside	O
Survey	O
,	O
drivers	O
from	O
60	O
sites	O
were	O
randomly	O
recruited	O
and	O
asked	O
to	O
complete	O
a	O
survey	O
on	O
prescription	B-T121
drug	I-T121
use	O
.	O
Almost	O
20	O
%	O
of	O
drivers	O
reported	O
using	O
a	O
prescription	B-T121
drug	I-T121
within	O
the	O
past	O
2	O
days	O
,	O
with	O
the	O
most	O
common	B-T121
drug	I-T121
class	I-T121
being	O
sedatives	B-T121
(	O
8.0	O
%	O
)	O
,	O
followed	O
by	O
antidepressants	B-T121
(	O
7.7	O
%	O
)	O
,	O
narcotics	B-T121
(	O
7.5	O
%	O
)	O
,	O
and	O
stimulants	B-T121
(	O
3.9	O
%	O
)	O
.	O
Drivers	O
who	O
reported	O
prescription	B-T121
drug	I-T121
use	O
were	O
significantly	O
more	O
likely	O
to	O
be	O
female	O
,	O
older	O
,	O
non	O
-	O
Hispanic	O
White	O
,	O
and	O
report	O
disability	B-T033
.	O
Three	O
of	O
four	O
drivers	O
who	O
reported	O
medication	B-T121
use	O
(	O
78.2	O
%	O
)	O
said	O
the	O
drug	B-T121
was	O
prescribed	B-T058
for	O
their	O
use	O
;	O
the	O
odds	O
of	O
using	O
without	O
a	O
prescription	O
were	O
significantly	O
higher	O
for	O
males	O
,	O
Black	O
/	O
African	O
American	O
,	O
and	O
Hispanic	O
drivers	O
,	O
and	O
lower	O
for	O
older	O
drivers	O
.	O
Among	O
those	O
with	O
a	O
prescription	O
,	O
taking	O
more	O
than	O
prescribed	B-T058
was	O
most	O
common	O
for	O
narcotics	B-T121
(	O
6.8	O
%	O
)	O
,	O
followed	O
by	O
sedatives	B-T121
(	O
4.8	O
%	O
)	O
,	O
stimulants	B-T121
(	O
3.8	O
%	O
)	O
,	O
and	O
antidepressants	B-T121
(	O
1.5	O
%	O
)	O
.	O
These	O
findings	O
help	O
to	O
identify	O
drivers	O
using	O
potentially	O
impairing	O
prescription	B-T121
drugs	I-T121
,	O
both	O
medically	O
and	O
nonmedically	B-T033
,	O
and	O
may	O
inform	O
the	O
targeting	O
of	O
interventions	B-T058
to	O
reduce	O
impaired	B-T033
driving	I-T033
related	O
to	O
medications	O
.	O
      
Molecular	O
detection	B-T061
of	O
infection	O
homogeneity	O
and	O
impact	O
of	O
miltefosine	B-T121
treatment	O
in	O
a	O
Syrian	O
golden	O
hamster	O
model	O
of	O
Leishmania	O
donovani	O
and	O
L.	O
infantum	O
visceral	B-T047
leishmaniasis	I-T047
Control	O
of	O
visceral	B-T047
leishmaniasis	I-T047
caused	O
by	O
Leishmania	O
infantum	O
and	O
Leishmania	O
donovani	O
primarily	O
relies	O
on	O
chemotherapy	B-T061
using	O
an	O
increasingly	O
compromised	B-T033
repertoire	O
of	O
antileishmanial	B-T121
compounds	I-T121
.	O
For	O
evaluation	B-T058
of	O
novel	O
drugs	B-T121
,	O
the	O
Syrian	O
golden	O
hamster	O
is	O
considered	O
as	O
a	O
clinically	O
relevant	O
laboratory	O
model	O
.	O
In	O
this	O
study	O
,	O
two	O
molecular	B-T059
parasite	I-T059
detection	I-T059
assays	I-T059
were	O
developed	O
targeting	O
cathepsin	O
-	O
like	O
cysteine	O
protease	O
B	O
(	O
CPB	O
)	O
DNA	O
and	O
18S	O
rRNA	O
to	O
achieve	O
absolute	O
amastigote	O
quantification	O
in	O
the	O
major	O
target	O
organs	B-T023
liver	B-T023
and	O
spleen	B-T023
.	O
Both	O
quantitative	O
PCR	O
(	O
qPCR	O
)	O
techniques	O
showed	O
excellent	O
agreement	O
with	O
a	O
strong	O
correlation	O
with	O
the	O
conventional	O
microscopic	B-T059
reading	I-T059
of	O
Giemsa	B-T059
-	I-T059
stained	I-T059
tissue	O
smears	B-T059
.	O
Using	O
multiple	O
single	O
tissue	O
pieces	O
and	O
all	O
three	O
detection	B-T033
methods	O
,	O
we	O
confirmed	O
homogeneity	O
of	O
infection	O
in	O
liver	B-T023
and	O
spleen	B-T023
and	O
the	O
robustness	O
of	O
extrapolating	O
whole	O
organ	O
burdens	O
from	O
a	O
small	O
single	O
tissue	O
piece	O
.	O
Comparison	O
of	O
pre	O
-	O
and	O
post	O
-	O
treatment	O
burdens	O
in	O
infected	B-T033
hamsters	O
using	O
the	O
three	O
detection	B-T033
methods	O
consistently	O
revealed	O
a	O
stronger	O
parasite	O
reduction	O
in	O
the	O
spleen	B-T023
compared	O
to	O
the	O
liver	B-T023
,	O
indicating	O
an	O
organ	B-T023
-	O
dependent	O
clearance	O
efficacy	O
for	O
miltefosine	B-T121
.	O
In	O
conclusion	O
,	O
this	O
study	O
in	O
the	O
hamster	O
demonstrated	O
high	O
homogeneity	O
of	O
infection	O
in	O
liver	B-T023
and	O
spleen	B-T023
and	O
advocates	O
the	O
use	O
of	O
molecular	O
detection	B-T061
methods	O
for	O
assessment	B-T058
of	O
low	O
(	O
post	O
-	O
treatment	O
)	O
tissue	O
burdens	O
.	O
      
Doxifluridine	B-T121
-	O
conjugated	O
2	B-T121
-	I-T121
5A	I-T121
analog	O
shows	O
strong	O
RNase	O
L	O
activation	O
ability	O
and	O
tumor	O
suppressive	O
effect	O
RNase	O
L	O
is	O
activated	O
by	O
2',5'-oligoadenylates	B-T121
(	O
2	B-T121
-	I-T121
5A	I-T121
)	O
at	O
subnanomolar	O
levels	O
to	O
cleave	O
single	O
-	O
stranded	O
RNA	O
.	O
We	O
previously	O
reported	O
the	O
hypothesis	O
that	O
the	O
introduction	O
of	O
an	O
8	O
-	O
methyladenosine	O
residue	O
at	O
the	O
2'-	O
terminus	O
of	O
the	O
2	B-T121
-	I-T121
5A	I-T121
tetramer	I-T121
shifts	O
the	O
2	B-T121
-	I-T121
5A	I-T121
binding	O
site	O
of	O
RNase	O
L.	O
In	O
this	O
study	O
,	O
we	O
synthesized	O
various	O
5'-	O
modified	O
2	B-T121
-	I-T121
5A	I-T121
analog	O
s	O
with	O
8	O
-	O
methyladenosine	O
at	O
the	O
2'-	O
terminus	O
.	O
The	O
doxifluridine	B-T121
-	O
conjugated	O
8	O
-	O
methyladenosine	O
-	O
substituted	O
2	B-T121
-	I-T121
5A	I-T121
analog	O
was	O
significantly	O
more	O
effective	O
as	O
an	O
activator	O
of	O
RNase	O
L	O
than	O
the	O
parent	O
5'-	O
monophophorylated	O
2	B-T121
-	I-T121
5A	I-T121
tetramer	I-T121
and	O
showed	O
a	O
tumor	O
suppressive	O
effect	O
against	O
human	O
cervical	B-T191
cancer	I-T191
cells	O
.	O
      
The	O
Business	O
of	O
Health	O
Physics	O
-	O
Jobs	O
In	O
A	O
Changing	O
Market	O
The	O
health	O
physics	O
profession	O
was	O
born	O
abruptly	O
when	O
once	O
rare	O
and	O
precious	O
radioactive	O
materials	O
became	O
commonplace	O
.	O
The	O
technological	O
advancements	O
that	O
triggered	O
an	O
industrial	O
complex	O
and	O
ended	O
World	O
War	O
II	O
demanded	O
radiation	O
safety	O
on	O
an	O
unprecedented	O
scale	O
.	O
Until	O
then	O
,	O
protective	O
measures	O
against	O
radiation	O
were	O
largely	O
absent	O
in	O
laboratories	O
.	O
Over	O
the	O
subsequent	O
decades	O
,	O
health	O
physicists	O
began	O
protecting	B-T061
people	I-T061
and	O
the	O
environment	O
in	O
a	O
wide	O
range	O
of	O
settings	O
including	O
medical	B-T058
,	O
research	O
,	O
and	O
industrial	O
.	O
The	O
use	B-T033
of	I-T033
radioactive	I-T033
materials	I-T033
and	O
radiation	O
-	O
generating	O
devices	O
is	O
prevalent	O
today	O
.	O
Radiation	O
doses	O
occur	O
continuously	O
including	O
during	O
airline	O
flights	O
,	O
in	O
our	O
homes	O
,	O
during	O
medical	B-T058
procedures	I-T058
,	O
and	O
in	O
energy	O
production	O
.	O
Radiation	O
is	O
integral	O
to	O
numerous	O
applications	O
including	O
those	O
in	O
medicine	O
,	O
dentistry	O
,	O
manufacturing	O
,	O
construction	O
,	O
scientific	O
research	O
,	O
nuclear	O
electric	O
power	O
generation	O
,	O
and	O
oil	O
and	O
gas	O
exploration	O
.	O
Activities	O
that	O
were	O
once	O
groundbreaking	O
have	O
now	O
become	O
routine	O
and	O
scripted	O
.	O
At	O
higher	O
doses	O
,	O
health	B-T033
effects	I-T033
are	O
understood	O
and	O
avoided	O
.	O
Instruments	O
for	O
the	O
detection	O
and	O
measurement	O
of	O
radiation	O
are	O
at	O
times	O
smarter	O
than	O
their	O
users	O
.	O
Ironically	O
,	O
the	O
same	O
health	O
physics	O
community	O
that	O
has	O
been	O
successful	O
in	O
demonstrating	O
that	O
exposures	O
to	O
radiation	O
and	O
to	O
radioactive	O
materials	O
can	O
be	O
effectively	B-T058
managed	I-T058
is	O
shrinking	O
at	O
an	O
increasingly	O
rapid	O
rate	O
.	O
This	O
paper	O
highlights	O
the	O
creation	O
of	O
past	O
and	O
current	O
jobs	O
,	O
predicts	O
the	O
future	O
opportunities	O
in	O
the	O
profession	O
,	O
and	O
makes	O
recommendations	O
necessary	O
to	O
protect	O
the	O
disappearing	O
specialties	O
.	O
      
Annexin	B-T121
A1	I-T121
restores	O
Aβ1	O
-	O
42	O
-induced	O
blood	B-T061
-	I-T061
brain	I-T061
barrier	I-T061
disruption	I-T061
through	O
the	O
inhibition	O
of	O
RhoA	O
-	O
ROCK	O
signaling	O
pathway	O
The	O
blood	B-T023
-	I-T023
brain	I-T023
barrier	I-T023
(	O
BBB	B-T023
)	O
is	O
composed	O
of	O
brain	B-T023
capillary	I-T023
endothelial	O
cells	O
and	O
has	O
an	O
important	O
role	O
in	O
maintaining	O
homeostasis	O
of	O
the	O
brain	B-T023
separating	O
the	O
blood	O
from	O
the	O
parenchyma	B-T023
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O
It	O
is	O
widely	O
known	O
that	O
disruption	B-T061
of	I-T061
the	I-T061
BBB	I-T061
occurs	O
in	O
various	O
neurodegenerative	B-T047
diseases	I-T047
,	O
including	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
(	O
AD	B-T047
)	O
.	O
Annexin	B-T121
A1	I-T121
(	O
ANXA1	B-T121
)	O
,	O
an	O
anti	B-T121
-	I-T121
inflammatory	I-T121
messenger	I-T121
,	O
is	O
expressed	O
in	O
brain	O
endothelial	O
cells	O
and	O
regulates	O
the	O
BBB	B-T023
integrity	O
.	O
However	O
,	O
its	O
role	O
and	O
mechanism	O
for	O
protecting	O
BBB	B-T023
in	O
AD	B-T047
have	O
not	O
been	O
identified	O
.	O
We	O
found	O
that	O
β	O
-	O
Amyloid	O
1	O
-	O
42	O
(	O
Aβ42)-induced	O
BBB	B-T061
disruption	I-T061
was	O
rescued	O
by	O
human	O
recombinant	O
ANXA1	O
(	O
hrANXA1	O
)	O
in	O
the	O
murine	B-T121
brain	O
endothelial	O
cell	O
line	O
bEnd.3	O
.	O
Also	O
,	O
ANXA1	B-T121
was	O
decreased	O
in	O
the	O
bEnd.3	O
cells	O
,	O
the	O
capillaries	B-T023
of	O
5XFAD	B-T001
mice	I-T001
,	O
and	O
the	O
human	O
serum	O
of	O
patients	O
with	O
AD	B-T047
.	O
To	O
find	O
out	O
the	O
mechanism	O
by	O
which	O
ANXA1	B-T121
recovers	O
the	O
BBB	B-T023
integrity	O
in	O
AD	B-T047
,	O
the	O
RhoA	O
-	O
ROCK	O
signaling	O
pathway	O
was	O
examined	O
in	O
both	O
Aβ42	O
-treated	O
bEnd.3	O
cells	O
and	O
the	O
capillaries	B-T023
of	O
5XFAD	B-T001
mice	I-T001
as	O
RhoA	O
was	O
activated	O
in	O
both	O
cases	O
.	O
RhoA	O
inhibitors	O
alleviated	O
Aβ42	O
-induced	O
BBB	B-T061
disruption	I-T061
and	O
constitutively	O
overexpressed	O
RhoA	O
-	O
GTP	O
(	O
active	O
form	O
of	O
RhoA	O
)	O
attenuated	O
the	O
protective	O
effect	O
of	O
ANXA1	B-T121
.	O
When	O
pericytes	O
were	O
cocultured	B-T059
with	O
bEnd.3	O
cells	O
,	O
Aβ42	O
-induced	O
RhoA	O
activation	O
of	O
bEnd.3	O
cells	O
was	O
inhibited	O
by	O
the	O
secretion	O
of	O
ANXA1	B-T121
from	O
pericytes	O
.	O
Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
ANXA1	B-T121
restores	O
Aβ42	O
-induced	O
BBB	B-T061
disruption	I-T061
through	O
inhibition	O
of	O
RhoA	O
-	O
ROCK	O
signaling	O
pathway	O
and	O
we	O
propose	O
ANXA1	B-T121
as	O
a	O
therapeutic	B-T121
reagent	I-T121
,	O
protecting	O
against	O
the	O
breakdown	B-T061
of	I-T061
the	I-T061
BBB	I-T061
in	O
AD	B-T047
.	O
      
Results	O
of	O
a	O
Multicenter	O
,	O
Randomized	O
,	O
Controlled	O
Trial	O
of	O
a	O
Hydrogen	B-T121
Peroxide	I-T121
-based	O
Kit	O
versus	O
a	O
Benzoyl	B-T121
Peroxide	I-T121
-based	O
Kit	O
in	O
Mild	O
-	O
to	O
-	O
moderate	O
Acne	B-T047
Objective	O
:	O
To	O
evaluate	B-T058
the	O
efficacy	O
and	O
tolerability	O
of	O
a	O
novel	O
hydrogen	B-T121
peroxide	I-T121
-based	O
regimen	B-T061
versus	O
a	O
benzoyl	B-T121
peroxide	I-T121
-based	O
regimen	B-T061
in	O
mild	O
-	O
to	O
-	O
moderate	O
acne	B-T047
.	O
Methods	O
:	O
In	O
this	O
eight-	O
week	O
multicenter	O
study	O
,	O
patients	O
were	O
randomized	O
to	O
either	O
a	O
hydrogen	B-T121
peroxide	I-T121
-based	O
or	O
a	O
benzoyl	B-T121
peroxide	I-T121
-based	O
regimen	B-T061
.The	O
primary	O
outcome	O
measure	O
of	O
clinical	B-T033
response	I-T033
was	O
assessed	O
using	O
the	O
Global	B-T058
Acne	I-T058
Grading	I-T058
System	I-T058
(	O
GAGS	B-T058
)	O
at	O
baseline	O
,	O
four	O
weeks	O
,	O
and	O
eight	O
weeks	O
.	O
At	O
Week	O
8	O
,	O
a	O
patient	O
self	O
-	O
satisfaction	O
questionnaire	O
was	O
administered	O
.	O
Investigators	O
were	O
also	O
queried	O
at	O
that	O
time	O
regarding	O
assessment	B-T058
of	O
tolerability	O
and	O
cosmetic	O
acceptability	O
.	O
Tolerability	O
was	O
also	O
measured	O
at	O
each	O
visit	B-T058
.	O
Results	O
:	O
Both	O
treatment	B-T061
regimens	I-T061
were	O
associated	O
with	O
improvement	O
of	O
GAGS	O
score	O
at	O
Week	O
8	O
compared	O
to	O
baseline	O
(	O
p<0.0001	O
)	O
.	O
GAGS	O
score	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
regimens	B-T061
over	O
the	O
same	O
period	O
(	O
p=0.7765	O
)	O
.	O
No	B-T033
significant	I-T033
adverse	I-T033
events	I-T033
were	O
reported	B-T058
or	O
observed	O
in	O
either	O
treatment	O
arm	O
.	O
Both	O
patients	O
and	O
investigators	O
found	O
both	O
regimens	B-T061
to	O
be	O
similarly	O
effective	O
and	O
cosmetically	O
acceptable	O
.	O
Conclusion	O
:	O
A	O
novel	O
hydrogen	B-T121
peroxide	I-T121
-based	O
regimen	B-T061
was	O
shown	O
to	O
be	O
comparable	O
in	O
efficacy	O
,	O
safety	O
,	O
and	O
cosmetic	O
acceptability	O
to	O
a	O
benzoyl	B-T121
peroxide	I-T121
-based	O
regimen	B-T061
in	O
the	O
treatment	B-T061
of	O
mild	O
-	O
to	O
-	O
moderate	O
acne	B-T047
.	O
      
Active	O
diffusion	O
and	O
microtubule	O
-	O
based	O
transport	O
oppose	O
myosin	O
forces	O
to	O
position	O
organelles	O
in	O
cells	O
Even	O
distribution	O
of	O
peroxisomes	O
(	O
POs	O
)	O
and	O
lipid	O
droplets	O
(	O
LDs	O
)	O
is	O
critical	O
to	O
their	O
role	O
in	O
lipid	O
and	O
reactive	O
oxygen	O
species	O
homeostasis	O
.	O
How	O
even	O
distribution	O
is	O
achieved	O
remains	O
elusive	O
,	O
but	O
diffusive	O
motion	O
and	O
directed	O
motility	O
may	O
play	O
a	O
role	O
.	O
Here	O
we	O
show	O
that	O
in	O
the	O
fungus	O
Ustilago	O
maydis	O
~95	O
%	O
of	O
POs	O
and	O
LDs	O
undergo	O
diffusive	O
motions	O
.	O
These	O
movements	O
require	O
ATP	B-T121
and	O
involve	O
bidirectional	O
early	O
endosome	O
motility	O
,	O
indicating	O
that	O
microtubule	O
-	O
associated	O
membrane	O
trafficking	O
enhances	O
diffusion	O
of	O
organelles	O
.	O
When	O
early	O
endosome	O
transport	O
is	O
abolished	O
,	O
POs	O
and	O
LDs	O
drift	O
slowly	O
towards	O
the	O
growing	O
cell	O
end	O
.	O
This	O
pole	O
-	O
ward	O
drift	O
is	O
facilitated	O
by	O
anterograde	O
delivery	O
of	O
secretory	O
cargo	O
to	O
the	O
cell	O
tip	O
by	O
myosin-5	O
.	O
Modelling	O
reveals	O
that	O
microtubule	O
-	O
based	O
directed	O
transport	O
and	O
active	O
diffusion	O
support	O
distribution	O
,	O
mobility	O
and	O
mixing	O
of	O
POs	O
.	O
In	O
mammalian	O
COS-7	O
cells	O
,	O
microtubules	O
and	O
F	O
-	O
actin	O
also	O
counteract	O
each	O
other	O
to	O
distribute	O
POs	O
.	O
This	O
highlights	O
the	O
importance	O
of	O
opposing	O
cytoskeletal	O
forces	O
in	O
organelle	O
positioning	O
in	O
eukaryotes	O
.	O
      
Polysaccharide	O
-	O
Specific	O
Memory	O
B	O
Cells	O
Predict	O
Protection	B-T033
against	O
Experimental	O
Human	O
Pneumococcal	B-T007
Carriage	B-T033
We	O
have	O
previously	O
demonstrated	O
that	O
experimental	O
pneumococcal	B-T007
carriage	B-T033
enhances	O
immunity	O
and	O
protects	B-T033
healthy	O
adults	O
against	O
carriage	B-T033
reacquisition	O
after	O
rechallenge	B-T061
with	O
a	O
homologous	O
strain	B-T001
.	O
To	O
investigate	O
the	O
role	O
of	O
naturally	O
acquired	O
pneumococcal	O
protein	O
and	O
polysaccharide	O
(	O
PS)-	O
specific	O
immunity	O
in	O
protection	B-T033
against	O
carriage	B-T033
acquisition	O
using	O
a	O
heterologous	O
challenge	O
model	O
.	O
We	O
identified	O
healthy	O
volunteers	O
that	O
were	O
naturally	O
colonized	O
with	O
pneumococcus	B-T007
and	O
,	O
after	O
clearance	O
of	O
their	O
natural	O
carriage	B-T033
episode	O
,	O
challenged	O
them	O
with	O
a	O
heterologous	O
6B	B-T007
strain	I-T007
.	O
In	O
another	O
cohort	O
of	O
volunteers	O
we	O
assessed	O
6BPS	O
-	O
specific	O
,	O
PspA	O
-	O
specific	O
,	O
and	O
PspC	O
-	O
specific	O
IgG	B-T121
and	O
IgA	O
plasma	O
and	O
memory	O
B	O
-	O
cell	O
populations	O
before	O
and	O
7	O
,	O
14	O
,	O
and	O
35	O
days	O
after	O
experimental	O
pneumococcal	B-T007
inoculation	B-T061
.	O
Heterologous	O
challenge	O
with	O
6B	B-T007
resulted	O
in	O
50	O
%	O
carriage	B-T033
among	O
volunteers	O
with	O
previous	O
natural	O
pneumococcal	B-T007
carriage	B-T033
.	O
Protection	B-T033
from	O
carriage	B-T033
was	O
associated	O
with	O
a	O
high	O
number	O
of	O
circulating	O
6BPS	O
IgG	B-T121
-	O
secreting	O
memory	O
B	O
cells	O
at	O
baseline	O
.	O
There	O
were	O
no	O
associations	O
between	O
protection	B-T033
from	O
carriage	B-T033
and	O
baseline	O
levels	O
of	O
6BPS	O
IgG	B-T121
in	O
serum	O
or	O
nasal	O
wash	O
,	O
PspA	O
-	O
specific	O
,	O
or	O
PspC	O
-	O
specific	O
memory	O
B	O
cells	O
or	O
plasma	O
cells	O
.	O
In	O
volunteers	O
who	O
did	O
not	B-T033
develop	I-T033
carriage	B-T033
,	O
the	O
number	O
of	O
circulating	O
6BPS	O
memory	O
B	O
cells	O
decreased	O
and	O
the	O
number	O
of	O
6BPS	O
plasma	O
cells	O
increased	O
postinoculation	B-T033
.	O
Our	O
data	O
indicate	O
that	O
naturally	O
acquired	O
PS	O
-	O
specific	O
memory	O
B	O
cells	O
,	O
but	O
not	B-T033
levels	I-T033
of	O
circulating	O
IgG	B-T121
at	O
time	O
of	O
pneumococcal	B-T007
exposure	O
,	O
are	O
associated	O
with	O
protection	B-T033
against	O
carriage	B-T033
acquisition	O
.	O
      
Selection	O
of	O
a	O
marker	O
gene	O
to	O
construct	O
a	O
reference	O
library	O
for	O
wetland	O
plants	O
,	O
and	O
the	O
application	O
of	O
metabarcoding	O
to	O
analyze	O
the	O
diet	O
of	O
wintering	O
herbivorous	O
waterbirds	O
Food	O
availability	O
and	O
diet	O
selection	O
are	O
important	O
factors	O
influencing	O
the	O
abundance	O
and	O
distribution	O
of	O
wild	O
waterbirds	O
.	O
In	O
order	O
to	O
better	O
understand	O
changes	O
in	O
waterbird	O
population	O
,	O
it	O
is	O
essential	O
to	O
figure	O
out	O
what	O
they	O
feed	O
on	O
.	O
However	O
,	O
analyzing	O
their	O
diet	O
could	O
be	O
difficult	O
and	O
inefficient	O
using	O
traditional	O
methods	O
such	O
as	O
microhistologic	B-T059
observation	I-T059
.	O
Here	O
,	O
we	O
addressed	O
this	O
gap	O
of	O
knowledge	O
by	O
investigating	O
the	O
diet	O
of	O
greater	O
white	O
-	O
fronted	O
goose	O
Anser	O
albifrons	O
and	O
bean	O
goose	O
Anser	O
fabalis	O
,	O
which	O
are	O
obligate	O
herbivores	O
wintering	O
in	O
China	O
,	O
mostly	O
in	O
the	O
Middle	O
and	O
Lower	O
Yangtze	O
River	O
floodplain	O
.	O
First	O
,	O
we	O
selected	O
a	O
suitable	O
and	O
high	O
-	O
resolution	O
marker	O
gene	O
for	O
wetland	O
plants	O
that	O
these	O
geese	O
would	O
consume	O
during	O
the	O
wintering	O
period	O
.	O
Eight	O
candidate	O
genes	O
were	O
included	O
:	O
rbcL	O
,	O
rpoC1	O
,	O
rpoB	O
,	O
matK	O
,	O
trnH	O
-	O
psbA	O
,	O
trnL	O
(	O
UAA	O
)	O
,	O
atpF	O
-	O
atpH	O
,	O
and	O
psbK	O
-	O
psbI.	O
The	O
selection	O
was	O
performed	O
via	O
analysis	O
of	O
representative	O
sequences	O
from	O
NCBI	O
and	O
comparison	O
of	O
amplification	O
efficiency	O
and	O
resolution	O
power	O
of	O
plant	O
samples	O
collected	O
from	O
the	O
wintering	O
area	O
.	O
The	O
trnL	O
gene	O
was	O
chosen	O
at	O
last	O
with	O
c	O
/	O
h	O
primers	O
,	O
and	O
a	O
local	O
plant	O
reference	O
library	O
was	O
constructed	O
with	O
this	O
gene	O
.	O
Then	O
,	O
utilizing	O
DNA	O
metabarcoding	O
,	O
we	O
discovered	O
15	O
food	O
items	O
in	O
total	O
from	O
the	O
feces	O
of	O
these	O
birds	O
.	O
Of	O
the	O
15	O
unique	O
dietary	O
sequences	O
,	O
10	O
could	O
be	O
identified	O
at	O
specie	O
level	O
.	O
As	O
for	O
greater	O
white	O
-	O
fronted	O
goose	O
,	O
73	O
%	O
of	O
sequences	O
belonged	O
to	O
Poaceae	O
spp	O
.	O
,	O
and	O
26	O
%	O
belonged	O
to	O
Carex	O
spp	O
.	O
In	O
contrast	O
,	O
almost	O
all	O
sequences	O
of	O
bean	O
goose	O
belonged	O
to	O
Carex	O
spp	O
.	O
(	O
99	O
%	O
)	O
.	O
Using	O
the	O
same	O
samples	O
,	O
microhistology	B-T059
provided	O
consistent	O
food	O
composition	O
with	O
metabarcoding	O
results	O
for	O
greater	O
white	O
-	O
fronted	O
goose	O
,	O
while	O
13	O
%	O
of	O
Poaceae	O
was	O
recovered	O
for	O
bean	O
goose	O
.	O
In	O
addition	O
,	O
two	O
other	O
taxa	O
were	O
discovered	O
only	O
through	O
microhistologic	B-T059
analysis	I-T059
.	O
Although	O
most	O
of	O
the	O
identified	O
taxa	O
matched	O
relatively	O
well	O
between	O
the	O
two	O
methods	O
,	O
DNA	O
metabarcoding	O
gave	O
taxonomically	O
more	O
detailed	O
information	O
.	O
Discrepancies	B-T033
were	O
likely	O
due	O
to	O
biased	O
PCR	O
amplification	O
in	O
metabarcoding	O
,	O
low	O
discriminating	O
power	O
of	O
current	O
marker	O
genes	O
for	O
monocots	O
,	O
and	O
biases	O
in	O
microhistologic	B-T059
analysis	I-T059
.	O
The	O
diet	O
differences	O
between	O
two	O
geese	O
species	O
might	O
indicate	O
deeper	O
ecological	O
significance	O
beyond	O
the	O
scope	O
of	O
this	O
study	O
.	O
We	O
concluded	O
that	O
DNA	O
metabarcoding	O
provides	O
new	O
perspectives	O
for	O
studies	O
of	O
herbivorous	O
waterbird	O
diets	O
and	O
inter	O
-	O
specific	O
interactions	O
,	O
as	O
well	O
as	O
new	O
possibilities	O
to	O
investigate	O
interactions	O
between	O
herbivores	O
and	O
plants	O
.	O
In	O
addition	O
,	O
microhistologic	B-T059
analysis	I-T059
should	O
be	O
used	O
together	O
with	O
metabarcoding	O
methods	O
to	O
integrate	O
this	O
information	O
.	O
      
Gender	O
and	O
Direction	O
of	O
Effect	O
of	O
Alcohol	B-T048
Problems	I-T048
and	O
Internalizing	O
Symptoms	O
in	O
a	O
Longitudinal	O
Sample	O
of	O
College	O
Students	O
Alcohol	B-T048
problems	I-T048
and	O
internalizing	O
symptoms	O
are	O
consistently	O
found	O
to	O
be	O
associated	O
but	O
how	O
they	O
relate	O
to	O
each	O
other	O
is	O
unclear	B-T033
.	O
The	O
present	O
study	O
aimed	O
to	O
address	O
limitations	O
in	O
the	O
literature	O
of	O
comorbidity	O
of	O
alcohol	B-T048
problems	I-T048
and	O
internalizing	O
symptoms	O
by	O
investigating	O
the	O
direction	O
of	O
effect	O
between	O
the	O
phenotypes	O
and	O
possible	O
gender	O
differences	O
in	O
college	O
students	O
.	O
We	O
utilized	O
data	O
from	O
a	O
large	O
longitudinal	O
study	O
of	O
college	O
students	O
from	O
the	O
United	O
States	O
(	O
N	O
=	O
2607	O
)	O
.	O
Three	O
waves	O
of	O
questionnaire	O
-	O
based	O
data	O
were	O
collected	O
over	O
the	O
first	O
two	O
years	O
of	O
college	O
(	O
in	O
2011	O
-	O
2013	O
)	O
.	O
Cross	O
-	O
lagged	O
models	O
were	O
applied	O
to	O
examine	O
the	O
possible	O
direction	O
of	O
effect	O
of	O
internalizing	O
symptoms	O
and	O
alcohol	B-T048
problems	I-T048
.	O
Possible	O
effects	O
of	O
gender	O
were	O
investigated	O
using	O
multigroup	O
modeling	O
.	O
There	O
were	O
significant	O
correlations	O
between	O
alcohol	B-T048
problems	I-T048
and	O
internalizing	O
symptoms	O
.	O
A	O
direction	O
of	O
effect	O
was	O
found	O
between	O
alcohol	B-T048
problems	I-T048
and	O
internalizing	O
symptoms	O
but	O
differed	O
between	O
genders	O
.	O
A	O
unidirectional	O
relationship	O
varying	O
with	O
age	O
was	O
identified	O
for	O
males	O
where	O
alcohol	B-T048
problems	I-T048
initially	O
predicted	O
internalizing	O
symptoms	O
followed	O
by	O
internalizing	O
symptoms	O
predicting	O
alcohol	B-T048
problems	I-T048
.	O
For	O
females	O
,	O
a	O
unidirectional	O
relationship	O
existed	O
wherein	O
alcohol	B-T048
problems	I-T048
predicted	O
internalizing	O
symptoms	O
.	O
Conclusions	O
/	O
Importance	O
:	O
We	O
conclude	O
that	O
the	O
relationship	O
between	O
alcohol	B-T048
problems	I-T048
and	O
internalizing	O
symptoms	O
is	O
complex	O
and	O
differ	O
between	O
genders	O
.	O
In	O
males	O
,	O
both	O
phenotypes	O
are	O
predictive	O
of	O
each	O
other	O
,	O
while	O
in	O
females	O
the	O
relationship	O
is	O
driven	O
by	O
alcohol	B-T048
problems	I-T048
.	O
Importantly	O
,	O
our	O
study	O
examines	O
a	O
population	O
-	O
based	O
sample	O
,	O
revealing	O
that	O
the	O
observed	O
relationships	O
between	O
alcohol	B-T048
problems	I-T048
and	O
internalizing	O
symptoms	O
are	O
not	O
limited	O
to	O
individuals	O
with	O
clinically	B-T060
diagnosed	I-T060
mental	O
health	O
or	O
substance	B-T048
use	I-T048
problems	I-T048
.	O
      
The	O
added	O
value	O
of	O
cardiac	B-T033
index	I-T033
and	O
pulse	O
pressure	O
variation	O
monitoring	B-T058
to	O
mean	B-T033
arterial	I-T033
pressure	I-T033
-	O
guided	B-T061
volume	I-T061
therapy	I-T061
in	O
moderate	B-T061
-	I-T061
risk	I-T061
abdominal	I-T061
surgery	I-T061
(	O
COGUIDE	B-T061
):	O
a	O
pragmatic	O
multicentre	O
randomised	O
controlled	O
trial	O
There	O
is	O
disagreement	O
regarding	O
the	O
benefits	O
of	O
goal	B-T061
-	I-T061
directed	I-T061
therapy	I-T061
in	O
moderate	B-T061
-	I-T061
risk	I-T061
abdominal	I-T061
surgery	I-T061
.	O
Therefore	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
the	O
addition	O
of	O
non	O
-	O
invasive	O
cardiac	B-T033
index	I-T033
and	O
pulse	O
pressure	O
variation	O
monitoring	B-T058
to	O
mean	B-T033
arterial	I-T033
pressure	I-T033
-based	O
goal	B-T061
-	I-T061
directed	I-T061
therapy	I-T061
would	O
reduce	O
the	O
incidence	O
of	O
postoperative	O
complications	O
in	O
patients	O
having	O
moderate	B-T061
-	I-T061
risk	I-T061
abdominal	I-T061
surgery	I-T061
.	O
In	O
this	O
pragmatic	O
multicentre	O
randomised	O
controlled	O
trial	O
,	O
we	O
randomly	O
allocated	O
244	O
patients	O
by	O
envelope	O
drawing	O
in	O
a	O
1:1	O
fashion	O
,	O
stratified	O
per	O
centre	O
.	O
All	O
patients	O
had	O
mean	B-T033
arterial	I-T033
pressure	I-T033
,	O
cardiac	B-T033
index	I-T033
and	O
pulse	O
pressure	O
variation	O
measured	O
continuously	O
.	O
In	O
one	O
group	O
,	O
healthcare	O
professionals	O
were	O
blinded	O
to	O
cardiac	B-T033
index	I-T033
and	O
pulse	O
pressure	O
variation	O
values	O
and	O
were	O
asked	O
to	O
guide	O
haemodynamic	B-T061
therapy	I-T061
only	O
based	O
on	O
mean	B-T033
arterial	I-T033
pressure	I-T033
(	O
control	O
group	O
)	O
.	O
In	O
the	O
second	O
group	O
,	O
cardiac	B-T033
index	I-T033
and	O
pulse	O
pressure	O
variation	O
values	O
were	O
displayed	O
and	O
kept	O
within	O
target	O
ranges	O
following	O
a	O
pre	O
-	O
defined	O
algorithm	O
(	O
CI	O
-	O
PPV	O
group	O
)	O
.	O
The	O
primary	O
endpoint	O
was	O
the	O
incidence	O
of	O
postoperative	O
complications	O
within	B-T033
30	I-T033
days	I-T033
.	O
One	O
hundred	O
and	O
seventy	O
-	O
five	O
patients	O
were	O
eligible	O
for	O
final	O
analysis	O
.	O
Overall	O
complication	O
rates	O
were	O
similar	O
(	O
42/94	O
(	O
44.7	O
%	O
)	O
vs.	O
38/81	O
(	O
46.9	O
%	O
)	O
in	O
the	O
control	O
and	O
CI	O
-	O
PPV	O
groups	O
,	O
respectively	O
;	O
p	O
=	O
0.95	O
)	O
.	O
The	O
CI	O
-	O
PPV	O
group	O
had	O
lower	O
mean	O
(	O
SD	O
)	O
pulse	O
pressure	O
variation	O
values	O
(	O
9.5	O
(	O
2.0)%	O
vs.	O
11.9	O
(	O
4.6)%	O
;	O
p	O
=	O
0.003	O
)	O
and	O
higher	O
mean	O
(	O
SD	O
)	O
cardiac	B-T033
indices	I-T033
(	O
2.76	O
(	O
0.62	O
)	O
l	O
min(-1	O
)	O
.m(-2	O
)	O
vs.	O
2.53	O
(	O
0.66	O
)	O
l	O
min(-1	O
)	O
.m(-2	O
)	O
;	O
p	O
=	O
0.004	O
)	O
than	O
the	O
control	O
group	O
.	O
In	O
moderate	B-T061
-	I-T061
risk	I-T061
abdominal	I-T061
surgery	I-T061
,	O
we	O
observed	O
no	O
additional	O
value	O
of	O
cardiac	B-T033
index	I-T033
and	O
pulse	O
pressure	O
variation	O
-	O
guided	B-T061
haemodynamic	I-T061
therapy	I-T061
to	O
mean	B-T033
arterial	I-T033
pressure	I-T033
-	O
guided	B-T061
volume	I-T061
therapy	I-T061
with	O
regard	O
to	O
postoperative	O
complications	O
.	O
      
Effects	O
of	O
argan	O
oil	O
on	O
the	O
mitochondrial	O
function	O
,	O
antioxidant	O
system	O
and	O
the	O
activity	O
of	O
NADPH	O
-	O
generating	O
enzymes	O
in	O
acrylamide	O
treated	B-T061
rat	O
brain	B-T023
Argan	O
oil	O
(	O
AO	O
)	O
is	O
rich	O
in	O
minor	O
compounds	O
such	O
as	O
polyphenols	B-T121
and	O
tocopherols	B-T121
which	O
are	O
powerful	O
antioxidants	B-T121
.	O
Acrylamide	O
(	O
ACR	O
)	O
has	O
been	O
classified	O
as	O
a	O
neurotoxic	O
agent	O
in	O
animals	O
and	O
humans	O
.	O
Mitochondrial	O
oxidative	O
stress	O
and	O
dysfunction	B-T033
is	O
one	O
of	O
the	O
most	O
probable	O
molecular	O
mechanisms	O
of	O
neurodegenerative	B-T047
diseases	I-T047
.	O
Female	O
Sprague	O
Dawley	O
rats	O
were	O
exposed	O
to	O
ACR	O
(	O
50mg	O
/	O
kg	O
i.p	O
.	O
three	O
times	O
a	O
week	O
)	O
,	O
AO	O
(	O
6ml	O
/	O
kg	O
,	O
o.p	O
,	O
per	O
day	O
)	O
or	O
together	O
for	O
30days	O
.	O
The	O
activities	O
of	O
cytosolic	O
enzymes	O
such	O
as	O
xanthine	O
oxidase	O
(	O
XO	O
)	O
,	O
glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PDH	O
)	O
,	O
glutathione	O
-	O
S	O
-	O
transferase	O
(	O
GST	O
)	O
,	O
mitochondrial	O
oxidative	O
stress	O
,	O
oxidative	O
phosphorylation	O
(	O
OXPHOS	O
)	O
and	O
tricarboxylic	O
acid	O
cycle	O
(	O
TCA	O
)	O
enzymes	O
,	O
mitochondrial	O
metabolic	O
function	O
,	O
adenosine	B-T121
triphosphate	I-T121
(	O
ATP	B-T121
)	O
level	O
and	O
acetylcholinesterase	O
(	O
AChE	O
)	O
activity	O
were	O
assessed	O
in	O
rat	O
brain	B-T023
.	O
Cytosolic	O
and	O
mitochondrial	O
antioxidant	O
enzymes	O
were	O
significantly	O
diminished	O
in	O
the	O
brains	B-T023
of	O
rats	O
treated	B-T061
with	I-T061
ACR	O
compared	O
to	O
those	O
in	O
control	O
.	O
Besides	O
,	O
ACR	O
treatment	B-T061
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
brain	B-T023
ATP	B-T121
level	O
,	O
mitochondrial	O
metabolic	O
function	O
,	O
OXPHOS	O
and	O
TCA	O
enzymes	O
.	O
Administration	B-T061
of	O
AO	O
restored	O
both	O
the	O
cytosolic	O
and	O
mitochondrial	O
oxidative	O
stress	O
by	O
normalizing	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate	O
(	O
NADPH	O
)	O
generating	O
enzymes	O
.	O
In	O
addition	O
,	O
improved	B-T033
mitochondrial	O
function	O
primarily	O
enhancing	O
nicotinamide	B-T121
adenine	I-T121
dinucleotide	I-T121
(	O
NADH	B-T121
)	O
generated	O
enzymes	O
activities	O
and	O
ATP	B-T121
level	O
in	O
the	O
mitochondria	O
.	O
The	O
reason	O
for	O
AO	O
's	O
obvious	O
beneficial	O
effects	O
in	O
this	O
study	O
may	O
be	O
due	O
to	O
synergistic	O
effects	O
of	O
its	O
different	O
bioactive	O
compounds	O
which	O
is	O
especially	O
effective	O
on	O
mitochondria	O
.	O
Modulation	O
of	O
the	O
brain	B-T023
mitochondrial	O
functions	O
and	O
antioxidant	O
systems	O
by	O
AO	O
may	O
lead	O
to	O
the	O
development	O
of	O
new	O
mitochondria	O
-	O
targeted	O
antioxidants	B-T121
in	O
the	O
future	O
.	O
      
The	O
effects	O
of	O
captopril	B-T121
on	O
lipopolysaccharide	O
induced	O
learning	B-T048
and	O
memory	B-T048
impairments	I-T048
and	O
the	O
brain	B-T023
cytokine	O
levels	O
and	O
oxidative	O
damage	O
in	O
rats	O
Renin	O
-	O
angiotensin	O
system	O
has	O
a	O
role	O
in	O
inflammation	O
and	O
also	O
involves	O
in	O
learning	O
and	O
memory	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
captopril	B-T121
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induced	O
learning	B-T048
and	O
memory	B-T048
impairments	I-T048
,	O
hippocampal	B-T023
cytokine	O
levels	O
and	O
brain	B-T023
tissues	I-T023
oxidative	O
damage	O
was	O
investigated	O
.	O
The	O
rats	O
were	O
divided	O
and	O
treated	O
:	O
[	O
1	O
]	O
saline	O
(	O
Control	O
)	O
,	O
[	O
2	O
]	O
LPS	O
(	O
1mg	O
/	O
kg	O
)	O
,	O
[	O
3	O
-	O
5	O
]	O
10	O
,	O
50	O
or	O
100mg	O
/	O
kg	O
captopril	B-T121
30min	O
before	O
LPS	O
.	O
The	O
treatment	B-T061
was	O
started	O
since	O
six	O
days	O
before	O
the	O
behavioral	B-T060
experiments	I-T060
and	O
continued	O
during	O
the	O
behavioral	B-T060
tests	I-T060
(	O
LPS	O
injection	B-T061
two	O
h	O
before	O
each	O
behavioral	B-T060
experiment	I-T060
)	O
.	O
Administration	B-T061
of	O
LPS	O
prolonged	O
the	O
escape	O
latency	O
and	O
traveled	O
path	O
to	O
find	O
the	O
platform	O
in	O
Morris	B-T060
water	I-T060
maze	I-T060
(	I-T060
MWM	I-T060
)	I-T060
test	I-T060
(	O
P<0.01	O
-	O
P<0.001	O
)	O
while	O
,	O
shortened	O
the	O
latency	O
to	O
enter	O
the	O
dark	B-T058
compartment	I-T058
in	O
passive	O
avoidance	O
(	O
PA	O
)	O
test	B-T060
(	O
P<0.001	O
)	O
.	O
Pretreatment	O
by	O
all	O
doses	O
of	O
captopril	B-T121
improved	O
performances	O
of	O
the	O
rats	O
in	O
MWM	B-T060
(	O
P<0.05	O
-	O
P<0.001	O
)	O
and	O
also	O
prolonged	O
the	O
latency	O
to	O
enter	O
the	O
dark	B-T058
in	O
PA	O
test	B-T060
(	O
P<0.001	O
)	O
.	O
LPS	O
also	O
increased	O
IL-6	O
,	O
TNF	O
-	O
α	O
,	O
malondialdehyde	O
(	O
MDA	O
)	O
and	O
nitric	B-T121
oxide	I-T121
(	O
NO	B-T121
)	O
metabolites	O
in	O
the	O
hippocampal	B-T023
tissues	B-T023
(	O
P<0.05	O
-	O
P<0.001	O
)	O
which	O
were	O
prevented	B-T061
by	O
captopril	B-T121
(	O
P<0.05	O
-	O
P<0.001	O
)	O
.	O
The	O
thiol	O
,	O
superoxide	B-T121
dismutase	I-T121
(	O
SOD	B-T121
)	O
and	O
catalase	O
(	O
CAT	O
)	O
in	O
the	O
hippocampus	B-T023
of	O
LPS	O
group	O
were	O
lower	O
than	O
the	O
control	O
(	O
P<0.001	O
)	O
while	O
,	O
they	O
were	O
enhanced	O
when	O
the	O
aniamls	O
were	O
pretreated	O
by	O
captopril	B-T121
(	O
P<0.01	O
-	O
P<0.001	O
)	O
.	O
The	O
results	O
of	O
present	O
study	O
showed	O
that	O
captopril	B-T121
improved	O
the	O
LPS	O
-	O
induced	O
learning	B-T048
and	O
memory	B-T048
impairments	I-T048
in	O
rats	O
which	O
were	O
accompanied	O
with	O
attenuating	O
hippocampal	B-T023
cytokine	O
levels	O
and	O
improving	O
the	O
brain	B-T023
tissues	I-T023
oxidative	O
damage	O
criteria	O
.	O
      
NF	O
-	O
κB	O
Links	O
TLR2	O
and	O
PAR1	O
to	O
Soluble	O
Immunomodulator	B-T121
Factor	I-T121
Secretion	O
in	O
Human	O
Platelets	O
The	O
primary	O
toll	O
-	O
like	O
receptor	O
(	O
TLR)-mediated	O
immune	O
cell	O
response	O
pathway	O
common	O
for	O
all	O
TLRs	O
is	O
MyD88	O
-dependent	O
activation	O
of	O
NF	O
-	O
κB	O
,	O
a	O
seminal	B-T023
transcription	O
factor	O
for	O
many	O
chemokines	O
and	O
cytokines	O
.	O
Remarkably	O
,	O
anucleate	O
platelets	O
express	O
the	O
NF	O
-	O
κB	O
machinery	O
,	O
whose	O
role	O
in	O
platelets	O
remains	O
poorly	O
understood	O
.	O
Here	O
,	O
we	O
investigated	O
the	O
contribution	O
of	O
NF	O
-	O
κB	O
in	O
the	O
release	O
of	O
cytokines	O
and	O
serotonin	O
by	O
human	O
platelets	O
,	O
following	O
selective	O
stimulation	O
of	O
TLR2	O
and	O
protease	O
activated	O
receptor	O
1	O
(	O
PAR1	O
)	O
,	O
a	O
classical	O
and	O
non	O
-	O
classical	O
pattern	O
-	O
recognition	O
receptor	O
,	O
respectively	O
,	O
able	O
to	O
participate	O
to	O
the	O
innate	O
immune	O
system	O
.	O
We	O
discovered	O
that	O
platelet	O
PAR1	O
activation	O
drives	O
the	O
process	O
of	O
NF	O
-	O
κB	O
phosphorylation	O
,	O
in	O
contrast	O
to	O
TLR2	O
activation	O
,	O
which	O
induces	O
a	O
slower	O
phosphorylation	O
process	O
.	O
Conversely	O
,	O
platelet	O
PAR1	O
and	O
TLR2	O
activation	O
induces	O
similar	O
ERK1/2	O
,	O
p38	O
,	O
and	O
AKT	O
phosphorylation	O
.	O
Moreover	O
,	O
we	O
found	O
that	O
engagement	O
of	O
platelet	O
TLR2	O
with	O
its	O
ligand	O
,	O
Pam3CSK4	O
,	O
significantly	O
increases	O
the	O
release	O
of	O
sCD62P	O
,	O
RANTES	O
,	O
and	O
sCD40L	O
;	O
this	O
effect	O
was	O
attenuated	O
by	O
incubating	B-T059
platelets	O
with	O
a	O
blocking	O
anti	O
-	O
TLR2	O
antibody	O
.	O
This	O
effect	O
appeared	O
selective	O
since	O
no	O
modulation	O
of	O
serotonin	O
secretion	O
was	O
observed	O
following	O
platelet	O
TLR2	O
activation	O
.	O
Platelet	O
release	O
of	O
sCD62P	O
,	O
RANTES	O
,	O
and	O
sCD40L	O
following	O
TLR2	O
or	O
PAR1	O
triggering	O
was	O
abolished	O
in	O
the	O
presence	B-T033
of	O
the	O
NF	O
-	O
κB	O
inhibitor	O
Bay11	O
-	O
7082	O
,	O
while	O
serotonin	O
release	O
following	O
PAR1	O
activation	O
was	O
significantly	O
decreased	O
.	O
These	O
new	O
findings	O
support	O
the	O
concept	O
that	O
NF	O
-	O
κB	O
is	O
an	O
important	O
player	O
in	O
platelet	O
immunoregulations	O
and	O
functions	O
.	O
      
Efficacy	O
of	O
pegylated	B-T121
liposomal	I-T121
etoposide	I-T121
nanoparticles	I-T121
on	O
breast	O
cancer	O
cell	O
lines	O
This	O
study	O
aimed	O
to	O
investigate	O
the	O
efficacy	O
of	O
pegylated	B-T121
liposomal	I-T121
etoposide	I-T121
nanoparticles	I-T121
(	O
NPs	O
)	O
against	O
T-47D	B-T050
and	O
MCF-7	O
breast	O
cancer	O
cell	O
lines	O
.	O
Pegylated	B-T121
liposomal	I-T121
etoposide	I-T121
NPs	I-T121
were	O
prepared	O
by	O
reverse	O
phase	O
evaporation	O
method	O
.	O
The	O
size	O
,	O
size	O
distribution	O
,	O
and	O
zeta	O
potential	O
of	O
the	O
NPs	B-T121
was	O
measured	O
by	O
a	O
Zetasizer	O
instrument	O
.	O
The	O
cytotoxicity	O
of	O
NPs	B-T121
was	O
inspected	O
by	O
methyl	O
thiazol	O
tetrazolium	O
assay	O
.	O
The	O
release	O
pattern	O
of	O
the	O
drug	O
from	O
the	O
vesicles	O
was	O
studied	O
by	O
the	O
dialysis	B-T061
method	I-T061
.	O
Drug	O
loading	O
and	O
encapsulation	O
efficiency	O
(	O
EE	O
)	O
were	O
also	O
measured	O
.	O
The	O
mean	O
size	O
,	O
size	O
distribution	O
,	O
and	O
zeta	O
potential	O
of	O
pegylated	B-T121
liposomal	I-T121
etoposide	I-T121
NPs	I-T121
were	O
491	O
±	O
15.5	O
nm	O
,	O
0.504	O
±	O
0.14	O
,	O
and	O
-35.8	O
±	O
2.5	O
mV	O
,	O
respectively	O
.	O
Drug	O
loading	O
and	O
EE	O
were	O
10.3	O
±	O
1.6	O
%	O
and	O
99.1	O
±	O
2.8	O
%	O
,	O
respectively	O
.	O
The	O
etoposide	O
release	O
in	O
the	O
formulation	O
was	O
estimated	O
at	O
about	O
3.48	O
%	O
after	O
48	O
h.	O
The	O
cytotoxicity	O
effect	O
of	O
etoposide	B-T121
NPs	I-T121
on	O
T-47D	B-T050
and	O
MCF-7	O
cell	O
lines	O
of	O
breast	O
cancer	O
showed	O
higher	O
antitumor	O
activity	O
as	O
compared	O
with	O
those	O
of	O
the	O
free	O
drug	O
.	O
Liposome	B-T121
-	I-T121
based	I-T121
NPs	I-T121
may	O
hold	O
great	O
potential	O
as	O
a	O
drug	O
delivery	O
system	O
.	O
      
Hybrid	O
automata	O
models	O
of	O
cardiac	B-T023
ventricular	I-T023
electrophysiology	B-T060
for	O
real	O
-	O
time	O
computational	O
applications	O
Virtual	O
heart	O
models	O
have	O
been	O
proposed	O
for	O
closed	O
loop	O
validation	O
of	O
safety	O
-	O
critical	O
embedded	O
medical	O
devices	O
,	O
such	O
as	O
pacemakers	O
.	O
These	O
models	O
must	O
react	O
in	O
real	O
-	O
time	O
to	O
off	O
-	O
the	O
-	O
shelf	O
medical	O
devices	O
.	O
Real	O
-	O
time	O
performance	O
can	O
be	O
obtained	O
by	O
implementing	O
models	O
in	O
computer	O
hardware	O
,	O
and	O
methods	O
of	O
compiling	O
classes	O
of	O
Hybrid	O
Automata	O
(	O
HA	O
)	O
onto	O
FPGA	O
have	O
been	O
developed	O
.	O
Models	O
of	O
ventricular	O
cardiac	O
cell	O
electrophysiology	B-T060
have	O
been	O
described	O
using	O
HA	O
which	O
capture	O
the	O
complex	O
nonlinear	O
behavior	O
of	O
biological	O
systems	O
.	O
However	O
,	O
many	O
models	O
that	O
have	O
been	O
used	O
for	O
closed	O
-	O
loop	O
validation	O
of	O
pacemakers	O
are	O
highly	O
abstract	O
and	O
do	O
not	O
capture	O
important	O
characteristics	O
of	O
the	O
dynamic	O
rate	O
response	O
.	O
We	O
developed	O
a	O
new	O
HA	O
model	O
of	O
cardiac	O
cells	O
which	O
captures	O
dynamic	O
behavior	O
and	O
we	O
implemented	O
the	O
model	O
in	O
hardware	O
.	O
This	O
potentially	O
enables	O
modeling	O
the	O
heart	B-T023
with	O
over	O
1	O
million	O
dynamic	O
cells	O
,	O
making	O
the	O
approach	O
ideal	O
for	O
closed	O
loop	O
testing	O
of	O
medical	O
devices	O
.	O
      
Methylation	O
dynamics	O
during	O
folliculogenesis	O
and	O
early	O
embryo	O
development	O
in	O
sheep	O
Genome	O
-wide	O
DNA	O
methylation	O
reprogramming	O
occurs	O
during	O
mammalian	O
gametogenesis	O
and	O
early	O
embryogenesis	O
.	O
Post	O
-	O
fertilization	O
demethylation	O
of	O
paternal	O
and	O
maternal	B-T033
genomes	O
is	O
considered	O
to	O
occur	O
by	O
an	O
active	O
and	O
passive	O
mechanism	O
respectively	O
,	O
in	O
most	O
mammals	O
but	O
sheep	O
;	O
in	O
this	O
species	O
no	O
loss	O
of	O
methylation	O
was	O
observed	O
in	O
either	O
pronucleus	O
.	O
Post	O
-	O
fertilization	O
reprogramming	O
relies	O
on	O
methylating	O
and	O
demethylating	O
enzymes	O
and	O
co	O
-	O
factors	O
that	O
are	O
stored	O
during	O
oocyte	O
growth	O
,	O
concurrently	O
with	O
the	O
re	O
-	O
methylation	O
of	O
the	O
oocyte	O
itself	O
.	O
The	O
crucial	O
remodelling	O
of	O
the	O
oocyte	O
epigenetic	O
baggage	O
often	O
overlaps	O
with	O
potential	O
interfering	O
events	O
such	O
as	O
exposure	O
to	O
assisted	O
reproduction	B-T061
technologies	I-T061
or	O
environmental	B-T033
changes	I-T033
.	O
Here	O
,	O
we	O
report	O
a	O
temporal	O
analysis	O
of	O
methylation	O
dynamics	O
during	O
folliculogenesis	O
and	O
early	O
embryo	O
development	O
in	O
sheep	O
.	O
We	O
characterized	O
global	O
DNA	O
methylation	O
and	O
hydroxymethylation	O
by	O
immunofluorescence	B-T059
and	O
relatively	O
quantified	O
the	O
expression	O
of	O
the	O
enzymes	O
and	O
co	O
-	O
factors	O
mainly	O
responsible	O
for	O
their	O
remodelling	O
(	O
DNA	O
methyltransferases	O
(	O
DNMTs	O
)	O
,	O
ten	O
-	O
eleven	O
translocation	O
(	O
TET	O
)	O
proteins	O
and	O
methyl	O
-	O
CpG	O
-	O
binding	O
domain	O
(	O
MBD	O
)	O
proteins	O
)	O
.	O
Our	O
results	O
illustrate	O
for	O
the	O
first	O
time	O
the	O
patterns	O
of	O
hydroxymethylation	O
during	O
oocyte	O
growth	O
.	O
We	O
observed	O
different	O
patterns	O
of	O
methylation	O
and	O
hydroxymethylation	O
between	O
the	O
two	O
parental	O
pronuclei	O
,	O
suggesting	O
that	O
male	O
pronucleus	O
undergoes	O
active	O
demethylation	O
also	O
in	O
sheep	O
.	O
Finally	O
,	O
we	O
describe	O
gene	O
-specific	O
accumulation	O
dynamics	O
for	O
methylating	O
and	O
demethylating	O
enzymes	O
during	O
oocyte	O
growth	O
and	O
observe	O
patterns	O
of	O
expression	O
associated	O
with	O
developmental	O
competence	O
in	O
a	O
differential	O
model	O
of	O
oocyte	O
potential	O
.	O
Our	O
work	O
contributes	O
to	O
the	O
understanding	O
of	O
the	O
methylation	O
dynamics	O
during	O
folliculogenesis	O
and	O
early	O
embryo	O
development	O
and	O
improves	O
the	O
overall	O
picture	O
of	O
early	O
rearrangements	O
that	O
will	O
originate	O
the	O
embryo	B-T018
epigenome	O
.	O
      
Effects	O
of	O
Cerium	O
and	O
Titanium	B-T121
Oxide	I-T121
Nanoparticles	O
in	O
Soil	O
on	O
the	O
Nutrient	O
Composition	O
of	O
Barley	O
(	O
Hordeum	O
vulgare	O
L	O
.	O
)	O
Kernels	O
The	O
implications	O
of	O
metal	O
nanoparticles	O
(	O
MeNPs	O
)	O
are	O
still	O
unknown	O
for	O
many	O
food	O
crops	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
cerium	O
oxide	O
(	O
nCeO₂	O
)	O
and	O
titanium	B-T121
oxide	I-T121
(	O
nTiO₂	B-T121
)	O
nanoparticles	O
in	O
soil	O
at	O
0	O
,	O
500	O
and	O
1000	O
mg·kg(-1	O
)	O
on	O
the	O
nutritional	O
parameters	O
of	O
barley	O
(	O
Hordeum	O
vulgare	O
L.	O
)	O
kernels	O
.	O
Mineral	O
nutrients	O
,	O
amylose	O
,	O
β	B-T121
-	I-T121
glucans	I-T121
,	O
amino	B-T121
acid	I-T121
and	O
crude	O
protein	O
(	O
CP	O
)	O
concentrations	O
were	O
measured	O
in	O
kernels	O
.	O
Whole	O
flour	O
samples	O
were	O
analyzed	O
by	O
ICP	B-T059
-	I-T059
AES	I-T059
/	I-T059
MS	I-T059
,	O
HPLC	B-T059
and	O
Elemental	O
CHNS	O
Analyzer	O
.	O
Results	O
showed	O
that	O
Ce	B-T121
and	O
Ti	O
accumulation	B-T033
under	O
MeNPs	O
treatments	O
did	O
not	O
differ	O
from	O
the	O
control	O
treatment	O
.	O
However	O
,	O
nCeO₂	O
and	O
nTiO₂	B-T121
had	O
an	O
impact	O
on	O
composition	O
and	O
nutritional	O
quality	O
of	O
barley	O
kernels	O
in	O
contrasting	O
ways	O
.	O
Both	O
MeNPs	O
left	O
β	B-T121
-	I-T121
glucans	I-T121
unaffected	O
but	O
reduced	O
amylose	O
content	O
by	O
approximately	O
21	O
%	O
.	O
Most	O
amino	B-T121
acids	I-T121
and	O
CP	O
increased	O
.	O
Among	O
amino	B-T121
acids	I-T121
,	O
lysine	B-T121
followed	O
by	O
proline	O
saw	O
the	O
largest	O
increase	O
(	O
51	O
%	O
and	O
37	O
%	O
,	O
respectively	O
)	O
.	O
Potassium	O
and	O
S	B-T121
were	O
both	O
negatively	O
impacted	O
by	O
MeNPs	O
,	O
while	O
B	O
was	O
only	O
affected	O
by	O
500	O
mg	O
nCeO₂	O
·	O
kg(-1	O
)	O
.	O
On	O
the	O
contrary	O
Zn	B-T059
and	O
Mn	B-T059
concentrations	I-T059
were	O
improved	O
by	O
500	O
mg	O
nTiO₂	B-T121
·	O
kg(-1	O
)	O
,	O
and	O
Ca	O
by	O
both	O
nTiO₂	B-T121
treatments	O
.	O
Generally	O
,	O
our	O
findings	O
demonstrated	O
that	O
kernels	O
are	O
negatively	B-T033
affected	I-T033
by	O
nCeO₂	O
while	O
nTiO₂	B-T121
can	O
potentially	O
have	O
beneficial	O
effects	O
.	O
However	O
,	O
both	O
MeNPs	O
have	O
the	O
potential	O
to	O
negatively	O
impact	O
malt	O
and	O
feed	O
production	O
.	O
      
International	O
validation	O
of	O
a	O
urinary	O
biomarker	O
panel	B-T059
for	O
identification	O
of	O
active	O
lupus	B-T047
nephritis	I-T047
in	O
children	O
Conventional	O
markers	O
of	O
juvenile	B-T047
-	I-T047
onset	I-T047
systemic	I-T047
lupus	I-T047
erythematosus	I-T047
(	O
JSLE	B-T047
)	O
disease	B-T060
activity	I-T060
fail	O
to	O
adequately	O
identify	O
lupus	B-T047
nephritis	I-T047
(	O
LN	B-T047
)	O
.	O
While	O
individual	O
novel	O
urine	O
biomarkers	O
are	O
good	O
at	O
detecting	B-T061
LN	B-T047
flares	B-T184
,	O
biomarker	O
panels	B-T059
may	O
improve	O
diagnostic	O
accuracy	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
performance	O
of	O
a	O
biomarker	O
panel	B-T059
to	O
identify	O
active	O
LN	B-T047
in	O
two	O
international	O
JSLE	B-T047
cohorts	O
.	O
Novel	O
urinary	O
biomarkers	O
,	O
namely	O
vascular	O
cell	O
adhesion	O
molecule-1	O
(	O
VCAM-1	O
)	O
,	O
monocyte	O
chemoattractant	O
protein	O
1	O
(	O
MCP-1	O
)	O
,	O
lipocalin	O
-	O
like	O
prostaglandin	O
D	O
synthase	O
(	O
LPGDS	O
)	O
,	O
transferrin	O
(	O
TF	O
)	O
,	O
ceruloplasmin	O
,	O
alpha-1	O
-	O
acid	O
glycoprotein	O
(	O
AGP	O
)	O
and	O
neutrophil	O
gelatinase	O
-	O
associated	O
lipocalin	O
(	O
NGAL	O
)	O
,	O
were	O
quantified	O
in	O
a	O
cross	O
-	O
sectional	O
study	O
that	O
included	O
participants	O
of	O
the	O
UK	O
JSLE	B-T047
Cohort	O
Study	O
(	O
Cohort	O
1	O
)	O
and	O
validated	O
within	O
the	O
Einstein	O
Lupus	O
Cohort	O
(	O
Cohort	O
2	O
)	O
.	O
Binary	O
logistic	O
regression	O
modelling	O
and	O
receiver	O
operating	O
characteristic	O
curve	O
analysis	O
[	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
]	O
were	O
used	O
to	O
identify	O
and	O
assess	O
combinations	O
of	O
biomarkers	O
for	O
diagnostic	O
accuracy	O
.	O
A	O
total	O
of	O
91	O
JSLE	B-T047
patients	O
were	O
recruited	O
across	O
both	O
cohorts	O
,	O
of	O
whom	O
31	O
(	O
34	O
%	O
)	O
had	O
active	O
LN	B-T047
and	O
60	O
(	O
66	O
%	O
)	O
had	O
no	O
LN	B-T047
.	O
Urinary	O
AGP	O
,	O
ceruloplasmin	O
,	O
VCAM-1	O
,	O
MCP-1	O
and	O
LPGDS	O
levels	O
were	O
significantly	O
higher	O
in	O
those	O
patients	O
with	O
active	O
LN	B-T047
than	O
in	O
non	O
-	O
LN	B-T047
patients	O
[	O
all	O
corrected	O
p	O
values	O
(	O
p	O
c	O
)	O
<	O
0.05	O
]	O
across	O
both	O
cohorts	O
.	O
Urinary	O
TF	O
also	O
differed	O
between	O
patient	O
groups	O
in	O
Cohort	O
2	O
(	O
p	O
c	O
=	O
0.001	O
)	O
.	O
Within	O
Cohort	O
1	O
,	O
the	O
optimal	O
biomarker	O
panel	B-T059
included	O
AGP	O
,	O
ceruloplasmin	O
,	O
LPGDS	O
and	O
TF	O
(	O
AUC	O
0.920	O
for	O
active	O
LN	B-T047
identification	O
)	O
.	O
These	O
results	O
were	O
validated	O
in	O
Cohort	O
2	O
,	O
with	O
the	O
same	O
markers	O
resulting	O
in	O
the	O
optimal	O
urine	O
biomarker	O
panel	B-T059
(	O
AUC	O
0.991	O
)	O
.	O
In	O
two	O
international	O
JSLE	B-T047
cohorts	O
,	O
urinary	O
AGP	O
,	O
ceruloplasmin	O
,	O
LPGDS	O
and	O
TF	O
demonstrate	O
an	O
'	O
excellent	O
'	O
ability	O
for	O
accurately	O
identifying	O
active	O
LN	B-T047
in	O
children	O
.	O
      
Conditional	B-T059
reprogramming	I-T059
and	O
long	O
-	O
term	O
expansion	O
of	O
normal	O
and	O
tumor	O
cells	O
from	O
human	O
biospecimens	O
Historically	O
,	O
it	O
has	O
been	O
difficult	O
to	O
propagate	O
cells	O
in	O
vitro	O
that	O
are	O
derived	O
directly	O
from	O
human	O
tumors	B-T191
or	O
healthy	O
tissue	O
.	O
However	O
,	O
in	O
vitro	O
preclinical	O
models	O
are	O
essential	O
tools	O
for	O
both	O
the	O
study	O
of	O
basic	O
cancer	O
biology	O
and	O
the	O
promotion	O
of	O
translational	O
research	O
,	O
including	O
drug	O
discovery	O
and	O
drug	O
target	O
identification	O
.	O
This	O
protocol	B-T059
describes	O
conditional	O
reprogramming	O
(	O
CR	O
)	O
,	O
which	O
involves	O
coculture	B-T059
of	O
irradiated	O
mouse	O
fibroblast	O
feeder	O
cells	O
with	O
normal	O
and	O
tumor	B-T191
human	O
epithelial	O
cells	O
in	O
the	O
presence	O
of	O
a	O
Rho	O
kinase	O
inhibitor	B-T121
(	O
Y-27632	B-T121
)	O
.	O
CR	B-T059
cells	O
can	O
be	O
used	O
for	O
various	O
applications	O
,	O
including	O
regenerative	O
medicine	O
,	O
drug	B-T059
sensitivity	I-T059
testing	I-T059
,	O
gene	B-T059
expression	I-T059
profiling	I-T059
and	O
xenograft	B-T061
studies	I-T061
.	O
The	O
method	B-T059
requires	O
a	O
pathologist	O
to	O
differentiate	O
healthy	O
tissue	O
from	O
tumor	O
tissue	O
,	O
and	O
basic	B-T059
tissue	I-T059
culture	I-T059
skills	O
.	O
The	O
protocol	B-T059
can	O
be	O
used	O
with	O
cells	O
derived	O
from	O
both	O
fresh	O
and	O
cryopreserved	O
tissue	O
samples	O
.	O
As	O
approximately	O
1	O
million	O
cells	O
can	O
be	O
generated	O
in	O
7	O
d	O
,	O
the	O
technique	B-T059
is	O
directly	O
applicable	O
to	O
diagnostic	O
and	O
predictive	O
medicine	B-T121
.	O
Moreover	O
,	O
the	O
epithelial	O
cells	O
can	O
be	O
propagated	O
indefinitely	O
in	O
vitro	O
,	O
yet	O
retain	O
the	O
capacity	O
to	O
become	O
fully	O
differentiated	O
when	O
placed	O
into	O
conditions	O
that	O
mimic	O
their	O
natural	O
environment	O
.	O
      
The	O
Indications	O
for	O
Laparoscopic	B-T061
Pancreatectomy	I-T061
Laparoscopic	B-T061
pancreatectomy	I-T061
is	O
not	O
yet	O
established	O
as	O
a	O
routine	B-T061
procedure	I-T061
everywhere	O
in	O
Germany	O
or	O
in	O
other	O
countries	O
.	O
Few	O
data	O
are	O
available	O
on	O
its	O
short-	O
and	O
long	O
-	O
term	O
outcomes	O
.	O
From	O
2008	O
onward	O
,	O
a	O
working	O
group	O
initiated	O
by	O
10	O
centers	O
and	O
currently	O
comprising	O
34	O
centers	O
has	O
gathered	O
data	O
on	O
all	O
cases	O
of	O
laparoscopic	B-T061
pancreatectomy	I-T061
.	O
Procedures	B-T061
in	O
which	O
laparoscopy	B-T061
was	O
converted	O
to	O
open	B-T061
surgery	I-T061
are	O
also	O
included	O
.	O
The	O
registry	O
now	O
contains	O
550	O
data	O
sets	O
representing	O
267	O
cases	O
of	O
benign	B-T191
disease	I-T191
,	O
244	O
malignancies	B-T191
,	O
and	O
39	O
borderline	B-T191
tumors	I-T191
.	O
The	O
most	O
common	O
procedure	B-T061
was	O
laparoscopic	B-T061
left	I-T061
pancreatectomy	I-T061
,	O
followed	O
by	O
resection	B-T061
of	O
the	O
head	B-T023
of	I-T023
the	I-T023
pancreas	I-T023
and	O
tumor	B-T191
enucleation	B-T061
.	O
The	O
most	O
common	O
intraoperative	O
complication	O
was	O
hemorrhage	O
,	O
with	O
a	O
frequency	O
of	O
3	O
%	O
.	O
The	O
rate	O
of	O
conversion	O
to	O
open	B-T061
surgery	I-T061
was	O
35	O
%	O
;	O
if	O
minilaparotomies	B-T058
are	O
excluded	O
,	O
the	O
conversion	O
rate	O
was	O
only	O
16	O
%	O
.	O
39	O
%	O
of	O
patients	O
developed	O
a	O
pancreatic	B-T047
fistula	I-T047
after	O
surgery	B-T061
(	O
usually	O
grade	O
A	O
or	O
B	O
,	O
with	O
1.5	O
%	O
grade	O
C	O
)	O
and	O
3	O
%	O
underwent	O
reoperation	B-T061
because	O
of	O
postoperative	O
hemorrhage	O
.	O
The	O
procedure	B-T033
-	I-T033
related	I-T033
mortality	I-T033
was	O
1.3	O
%	O
.	O
91	O
%	O
of	O
the	O
patients	O
reported	O
only	O
very	O
mild	O
postoperative	B-T184
pain	I-T184
.	O
6.7	O
%	O
newly	O
developed	O
diabetes	B-T047
mellitus	I-T047
after	O
the	O
procedure	B-T061
.	O
The	O
patient	O
cohort	O
in	O
the	O
registry	O
consists	O
of	O
persons	O
who	O
were	O
selected	O
to	O
undergo	O
laparoscopic	B-T061
pancreatectomy	I-T061
by	O
the	O
participating	O
hospital	O
teams	O
,	O
and	O
the	O
data	O
are	O
thus	O
inherently	O
affected	O
by	O
selection	O
bias	O
.	O
The	O
operative	B-T061
procedures	I-T061
that	O
they	O
underwent	O
reflect	O
the	O
current	O
practice	O
of	O
laparoscopic	B-T061
pancreatectomy	I-T061
in	O
Germany	O
.	O
The	O
complication	O
rates	O
are	O
similar	O
to	O
those	O
of	O
open	B-T061
surgery	I-T061
.	O
Selection	O
bias	O
can	O
be	O
avoided	O
only	O
by	O
a	O
randomized	O
trial	O
.	O
      
Traumatic	O
Brain	O
Injury	O
and	O
Depression	B-T048
in	O
a	O
Community	O
-	O
Based	O
Sample	O
:	O
A	O
Cohort	O
Study	O
Across	O
the	O
Adult	O
Life	O
Span	O
To	O
determine	O
whether	O
self	O
-	O
reported	O
traumatic	O
brain	O
injuries	O
(	O
TBIs	O
)	O
are	O
associated	O
with	O
"	O
cases	O
"	O
of	O
clinically	B-T033
significant	I-T033
depression	B-T048
in	O
the	O
general	O
community	O
.	O
To	O
examine	O
interactions	O
between	O
variables	O
previously	O
linked	O
to	O
depression	B-T048
after	O
a	O
TBI	O
.	O
Population	O
-based	O
community	O
study	O
(	O
Canberra	O
and	O
Queanbeyan	O
,	O
Australia	O
)	O
.	O
Three	O
age	O
cohorts	O
:	O
young	O
,	O
middle	O
-	O
aged	O
,	O
and	O
older	O
adults	O
(	O
aged	O
20	O
-	O
24	O
,	O
40	O
-	O
44	O
,	O
and	O
60	O
-	O
64	O
years	O
at	O
baseline	O
)	O
randomly	O
selected	O
from	O
the	O
electoral	O
roll	O
and	O
followed	O
across	O
3	O
waves	O
(	O
4	O
years	O
apart	O
)	O
.	O
A	O
total	O
of	O
7397	O
,	O
6621	O
,	O
and	O
6042	O
people	O
provided	O
their	O
TBI	O
history	O
in	O
waves	O
1	O
to	O
3	O
.	O
Lifetime	O
(	O
TBIlifetime	O
:	O
sustained	O
at	O
any	O
time	O
since	O
birth	O
)	O
,	O
recent	O
(	O
TBIrecent	O
:	O
in	O
the	O
preceding	O
4	O
years	O
)	O
,	O
and	O
multiple	O
(	O
TBImultiple	O
:	O
more	O
than	O
1	O
)	O
TBIs	O
,	O
current	O
depression	B-T048
,	O
and	O
known	O
risk	B-T033
factors	I-T033
for	O
depression	B-T048
(	O
age	O
,	O
sex	O
,	O
marital	O
/	O
employment	B-T033
status	I-T033
,	O
prior	B-T033
history	I-T033
of	O
depression	B-T048
,	O
medical	B-T033
conditions	I-T033
,	O
recent	O
life	O
events	O
,	O
alcohol	O
consumption	O
,	O
social	O
support	O
,	O
physical	O
activity	O
)	O
.	O
Generalized	O
estimating	O
equations	O
demonstrated	O
a	O
significant	O
association	O
between	O
sustaining	O
a	O
TBI	O
and	O
experiencing	O
clinically	B-T033
significant	I-T033
depression	B-T048
(	O
cases	O
)	O
,	O
even	O
after	O
controlling	O
for	O
multiple	O
demographic	O
and	O
health	O
/	O
lifestyle	O
factors	O
.	O
There	O
is	O
an	O
enduring	O
association	O
between	O
depression	B-T048
and	O
TBI	O
,	O
suggesting	O
that	O
,	O
following	O
a	O
TBI	O
,	O
individuals	O
should	O
be	O
monitored	O
and	O
supported	O
to	O
optimize	O
their	O
long	O
-	O
term	O
psychological	O
health	O
.	O
      
Fine	O
structure	O
of	O
the	O
anterior	B-T023
median	I-T023
eyes	I-T023
of	O
the	O
funnel	O
-	O
web	O
spider	O
Agelena	O
labyrinthica	O
(	O
Araneae	O
:	O
Agelenidae	O
)	O
Only	O
few	O
electron	B-T059
microscopic	I-T059
studies	I-T059
exist	O
on	O
the	O
structure	O
of	O
the	O
main	O
eyes	B-T023
(	O
anterior	B-T023
median	I-T023
eyes	I-T023
,	O
AME	B-T023
)	O
of	O
web	O
spiders	O
.	O
The	O
present	O
paper	O
provides	O
details	O
on	O
the	O
anatomy	B-T017
of	O
the	O
AME	B-T023
in	O
the	O
funnel	O
-	O
web	O
spider	O
Agelena	O
labyrinthica	O
.	O
The	O
retina	B-T023
consists	O
of	O
two	O
separate	O
regions	O
with	O
differently	O
arranged	O
photoreceptor	O
cells	O
.	O
Its	O
central	O
part	O
has	O
sensory	O
cells	O
with	O
rhabdomeres	O
on	O
2	O
,	O
3	O
,	O
or	O
4	O
sides	O
,	O
whereas	O
those	O
of	O
the	O
ventral	O
retina	B-T023
have	O
only	O
two	O
rhabdomeres	O
on	O
opposite	O
sides	O
.	O
In	O
addition	O
,	O
the	O
rhabdomeres	O
of	O
the	O
ventral	O
retina	B-T023
are	O
arranged	O
in	O
a	O
specific	O
way	O
:	O
Whereas	O
in	O
the	O
most	O
ventral	O
part	O
they	O
form	O
long	O
tangential	O
rows	O
,	O
those	O
towards	O
the	O
center	O
are	O
detached	O
and	O
are	O
arranged	O
radially	O
.	O
All	O
sensory	O
cells	O
are	O
wrapped	O
by	O
unpigmented	B-T033
pigment	O
cell	O
processes	O
.	O
In	O
agelenid	O
spiders	O
the	O
axons	O
of	O
the	O
sensory	O
cells	O
exit	O
from	O
the	O
middle	O
of	O
the	O
cell	O
body	O
;	O
their	O
fine	O
structure	O
and	O
course	O
through	O
the	O
eye	O
cup	O
is	O
described	O
in	O
detail	O
.	O
In	O
the	O
central	O
part	O
of	O
the	O
retina	B-T023
efferent	O
nerve	O
fibres	O
were	O
found	O
forming	O
synapses	O
along	O
the	O
distal	O
region	O
of	O
the	O
receptor	O
cells	O
.	O
A	O
muscle	O
is	O
attached	O
laterally	O
to	O
each	O
eye	O
cup	O
that	O
allows	O
mainly	O
rotational	O
movements	O
of	O
the	O
eyes	B-T023
.	O
The	O
optical	O
performance	O
(	O
image	O
resolution	O
)	O
of	O
these	O
main	O
eyes	B-T023
with	O
relatively	O
few	O
visual	O
cells	O
is	O
discussed	O
.	O
      
Involvement	O
Of	O
Vascular	B-T023
Aldosterone	O
Synthase	O
In	O
Phosphate	B-T121
-	O
Induced	O
Osteogenic	B-T033
Transformation	I-T033
Of	O
Vascular	B-T023
Smooth	O
Muscle	O
Cells	O
Vascular	O
calcification	O
resulting	O
from	O
hyperphosphatemia	B-T047
is	O
a	O
major	O
determinant	O
of	O
mortality	O
in	O
chronic	B-T047
kidney	I-T047
disease	I-T047
(	O
CKD	B-T047
)	O
.	O
Vascular	O
calcification	O
is	O
driven	O
by	O
aldosterone	B-T121
-sensitive	O
osteogenic	B-T033
transformation	I-T033
of	O
vascular	B-T023
smooth	O
muscle	O
cells	O
(	O
VSMCs	O
)	O
.	O
We	O
show	O
that	O
even	O
in	O
absence	O
of	O
exogenous	O
aldosterone	B-T121
,	O
silencing	O
and	O
pharmacological	O
inhibition	O
(	O
spironolactone	B-T121
,	O
eplerenone	B-T121
)	O
of	O
the	O
mineralocorticoid	O
receptor	O
(	O
MR	O
)	O
ameliorated	O
phosphate	B-T121
-	O
induced	O
osteo-	B-T033
/	O
chondrogenic	B-T033
transformation	I-T033
of	O
primary	O
human	O
aortic	B-T023
smooth	O
muscle	O
cells	O
(	O
HAoSMCs	O
)	O
.	O
High	O
phosphate	B-T121
concentrations	O
up	O
-	O
regulated	O
aldosterone	O
synthase	O
(	O
CYP11B2	O
)	O
expression	O
in	O
HAoSMCs	O
.	O
Silencing	O
and	O
deficiency	B-T047
of	O
CYP11B2	O
in	O
VSMCs	O
ameliorated	O
phosphate	B-T121
-	O
induced	O
osteogenic	O
reprogramming	O
and	O
calcification	O
.	O
Phosphate	B-T121
treatment	O
was	O
followed	O
by	O
nuclear	O
export	O
of	O
APEX1	O
,	O
a	O
CYP11B2	O
transcriptional	O
repressor	O
.	O
APEX1	O
silencing	O
up	O
-	O
regulated	O
CYP11B2	O
expression	O
and	O
stimulated	O
osteo-	B-T033
/	O
chondrogenic	B-T033
transformation	I-T033
.	O
APEX1	O
overexpression	O
blunted	O
the	O
phosphate	B-T121
-	O
induced	O
osteo-	B-T033
/	O
chondrogenic	B-T033
transformation	I-T033
and	O
calcification	O
of	O
HAoSMCs	O
.	O
Cyp11b2	O
expression	O
was	O
higher	O
in	O
aortic	B-T023
tissue	O
of	O
hyperphosphatemic	B-T047
klotho	O
-	O
hypomorphic	O
(	O
kl	O
/	O
kl	O
)	O
mice	O
than	O
in	O
wild	O
-	O
type	O
mice	O
.	O
In	O
adrenalectomized	O
kl	O
/	O
kl	O
mice	O
,	O
spironolactone	B-T121
treatment	O
still	O
significantly	O
ameliorated	O
aortic	B-T023
osteoinductive	O
reprogramming	O
.	O
Our	O
findings	O
suggest	O
that	O
VSMCs	O
express	O
aldosterone	O
synthase	O
,	O
which	O
is	O
up	O
-	O
regulated	O
by	O
phosphate	B-T121
-	O
induced	O
disruption	O
of	O
APEX1	O
-dependent	O
gene	O
suppression	O
.	O
Vascular	B-T023
CYP11B2	O
may	O
contribute	O
to	O
stimulation	O
of	O
VSMCs	O
osteo-	B-T033
/	O
chondrogenic	B-T033
transformation	I-T033
during	O
hyperphosphatemia	B-T047
.	O
      
Automated	O
characterization	O
and	O
counting	O
of	O
Ki-67	O
protein	O
for	O
breast	B-T191
cancer	I-T191
prognosis	B-T058
:	O
A	O
quantitative	O
immunohistochemistry	B-T060
approach	O
Ki-67	O
protein	O
expression	O
plays	O
an	O
important	O
role	O
in	O
predicting	O
the	O
proliferative	O
status	O
of	O
tumour	O
cell	O
s	O
and	O
deciding	O
the	O
future	O
course	O
of	O
therapy	B-T061
in	O
breast	B-T191
cancer	I-T191
.	O
Immunohistochemical	B-T060
(	I-T060
IHC	I-T060
)	I-T060
determination	I-T060
of	O
Ki-67	B-T059
score	I-T059
or	O
labelling	B-T059
index	I-T059
,	O
by	O
estimating	O
the	O
fraction	O
of	O
Ki67	O
positively	B-T033
stained	O
tumour	O
cells	O
,	O
is	O
the	O
most	O
widely	O
practiced	O
method	B-T060
to	O
assess	B-T058
tumour	B-T191
proliferation	O
(	O
Dowsett	O
et	O
al	O
.	O
2011	O
)	O
.	O
Accurate	O
manual	B-T059
counting	I-T059
of	O
these	O
cells	O
(	O
specifically	O
nuclei	O
)	O
due	O
to	O
complex	O
and	O
dense	O
distribution	O
of	O
cells	O
,	O
therefore	O
,	O
becomes	O
critical	O
and	O
presents	O
a	O
major	O
challenge	O
to	O
pathologists	O
.	O
In	O
this	O
paper	O
,	O
we	O
suggest	O
a	O
hybrid	O
clustering	O
algorithm	O
to	O
quantify	O
the	O
proliferative	O
index	O
of	O
breast	O
cancer	O
cells	O
based	O
on	O
automated	B-T059
counting	I-T059
of	O
Ki-67	O
nuclei	O
.	O
The	O
proposed	O
methodology	B-T060
initially	O
pre	O
-	O
processes	O
the	O
IHC	B-T060
images	O
of	O
Ki-67	O
stained	O
slides	O
of	O
breast	B-T191
cancer	I-T191
.	O
The	O
RGB	O
images	O
are	O
converted	O
to	O
grey	O
,	O
L*a*b	O
*	O
,	O
HSI	O
,	O
YCbCr	O
,	O
YIQ	O
and	O
XYZ	O
colour	O
space	O
.	O
All	O
the	O
stained	O
cells	O
are	O
then	O
characterized	O
by	O
two	B-T059
stage	I-T059
segmentation	I-T059
process	I-T059
.	O
Fuzzy	O
C	O
-	O
means	O
quantifies	O
all	O
the	O
stained	O
cells	O
as	O
one	O
cluster	O
.	O
The	O
blue	O
channel	O
of	O
the	O
first	O
stage	O
output	O
is	O
given	O
as	O
input	O
to	O
k	O
-	O
means	O
algorithm	O
,	O
which	O
provides	O
separate	O
cluster	O
for	O
Ki-67	O
positive	B-T033
and	I-T033
negative	I-T033
cells	O
.	O
The	O
count	O
of	O
positive	B-T033
and	I-T033
negative	I-T033
nuclei	O
is	O
used	O
to	O
calculate	B-T059
the	O
F	O
-	O
measure	O
for	O
each	O
colour	O
space	O
.	O
A	O
comparative	O
study	O
of	O
our	O
work	O
with	O
the	O
expert	O
opinion	O
is	O
studied	O
to	O
evaluate	O
the	O
error	O
rate	O
.	O
The	O
positive	B-T033
and	I-T033
negative	I-T033
nuclei	O
detection	B-T033
results	O
for	O
all	O
colour	O
space	O
s	O
are	O
compared	O
with	O
the	O
ground	O
truth	O
for	O
validation	O
and	O
F	O
-	O
measure	O
is	O
calculated	B-T059
.	O
The	O
F	O
-	O
measure	O
for	O
L*a*b	O
*	O
colour	O
space	O
(	O
0.8847	O
)	O
provides	O
the	O
best	O
statistical	O
result	O
as	O
compared	O
to	O
grey	O
,	O
HSI	O
,	O
YCbCr	O
,	O
YIQ	O
and	O
XYZ	O
colour	O
space	O
.	O
Further	O
,	O
a	O
study	O
is	O
carried	O
out	O
to	O
count	O
nuclei	O
manually	B-T059
and	O
automatically	B-T059
from	O
the	O
proposed	O
algorithm	O
with	O
an	O
average	O
error	O
rate	O
of	O
6.84	O
%	O
which	O
is	O
significant	O
.	O
The	O
study	O
provides	O
an	O
automated	O
count	O
of	O
positive	B-T033
and	I-T033
negative	I-T033
nuclei	O
using	O
L*a*b	O
*	O
colour	O
space	O
and	O
hybrid	O
segmentation	O
technique	O
.	O
Computerized	B-T059
evaluation	I-T059
of	O
proliferation	O
index	O
can	O
aid	O
pathologist	O
in	O
assessing	O
breast	B-T191
cancer	I-T191
severity	O
.	O
The	O
proposed	O
methodology	B-T060
,	O
further	O
,	O
has	O
the	O
potential	O
advantage	O
of	O
saving	O
time	O
and	O
assisting	B-T058
in	O
decision	O
making	O
over	O
the	O
present	O
manual	B-T059
procedure	I-T059
and	O
could	O
evolve	O
as	O
an	O
assistive	O
pathological	O
decision	O
support	O
system	O
.	O
      
Datasets	O
for	O
the	O
validation	O
of	O
the	O
"	O
in	O
vivo	O
"	O
siRNA	O
-	O
silencing	O
of	O
CD40	O
and	O
for	O
the	O
detection	B-T061
of	O
new	O
markers	O
of	O
atherosclerosis	B-T047
progression	O
in	O
ApoE	O
-	O
deficient	O
mice	O
Data	O
presented	O
in	O
this	O
Data	O
in	O
Brief	O
article	O
correspond	O
to	O
the	O
article	O
"	O
in	O
vivo	O
"	O
silencing	O
of	O
CD40	O
reduces	O
progression	O
of	O
experimental	O
atherogenesis	O
through	O
a	O
NFκB	O
/	O
miR-125b	O
axis	O
and	O
reveals	O
new	O
potential	O
mediators	O
in	O
the	O
pathogenesis	O
of	O
atherosclerosis	B-T047
"	O
(	O
M.	O
Hueso	O
,	O
L.	O
De	O
Ramon	O
,	O
E.	O
Navarro	O
,	O
E.	O
Ripoll	O
,	O
J.M.	O
Cruzado	O
,	O
J.M.	O
Grinyo	O
,	O
J.	O
Torras	O
,	O
2016	O
)	O
[	O
1	O
]	O
.	O
Here	O
,	O
we	O
describe	O
the	O
validation	O
of	O
the	O
silencing	O
of	O
CD40	O
expression	O
with	O
a	O
specific	O
siRNA	O
in	O
ApoE(-/-	O
)	O
mouse	O
aortas	B-T023
,	O
and	O
its	O
systemic	O
effects	O
on	O
splenic	B-T023
lymphocytic	O
subpopulations	O
as	O
well	O
as	O
on	O
the	O
infiltration	O
of	O
aortic	B-T023
intima	I-T023
by	O
F4/80(+	O
)	O
,	O
galectin-3(+	O
)	O
macrophages	O
or	O
by	O
NF	O
-	O
κB(+	O
)	O
cells	O
.	O
We	O
also	O
show	O
the	O
output	O
of	O
a	O
Gene	O
Ontology	O
and	O
TLDA	O
analysis	O
which	O
allowed	O
the	O
detection	B-T061
of	O
potential	O
mediators	O
of	O
atherosclerosis	B-T047
progression	O
.	O
We	O
provide	O
the	O
scientific	O
community	O
with	O
a	O
set	O
of	O
genes	O
whose	O
expression	O
is	O
increased	O
during	O
atherosclerosis	B-T047
progression	O
but	O
downregulated	O
upon	O
CD40	O
silencing	O
.	O
      
Impact	O
sports	O
and	O
bone	O
fractures	O
among	O
adolescents	O
The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
different	O
sports	O
on	O
stress	O
fractures	O
among	O
adolescents	O
during	O
a	O
9-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
period	O
.	O
The	O
sample	O
was	O
composed	O
of	O
184	O
adolescents	O
divided	O
into	O
three	O
groups	O
(	O
impact	O
sports	O
[	O
n	O
=	O
102	O
]	O
;	O
swimming	O
[	O
n	O
=	O
35	O
]	O
;	O
non	O
-	O
sports	O
[	O
n	O
=	O
47	O
]	O
)	O
.	O
The	O
occurrence	O
of	O
stress	O
fracture	O
was	O
reported	O
by	O
participants	O
and	O
coaches	O
.	O
As	O
potential	O
confounders	O
we	O
considered	O
age	O
,	O
sex	O
,	O
resistance	B-T061
training	I-T061
,	O
body	O
composition	O
variables	O
and	O
age	O
at	O
peak	O
of	O
height	O
velocity	O
.	O
There	O
were	O
13	O
adolescents	O
who	O
reported	O
fractures	O
during	O
the	O
9-	O
month	O
period	O
.	O
Bone	O
mineral	O
density	O
values	O
were	O
higher	O
in	O
adolescents	O
engaged	O
in	O
impact	O
sports	O
(	O
P	O
-	O
value	O
=	O
0.002	O
)	O
.	O
Independently	O
of	O
confounders	O
,	O
the	O
risk	O
of	O
stress	O
fracture	O
was	O
lower	O
in	O
adolescents	O
engaged	O
in	O
impact	O
sports	O
than	O
in	O
non	O
-	O
active	O
adolescents	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
=	O
0.23	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
0.05	O
to	O
0.98	O
]	O
)	O
,	O
while	O
swimming	O
practice	O
was	O
not	O
associated	O
to	O
lower	O
risk	O
of	O
fracture	O
(	O
HR	O
=	O
0.49	O
[	O
95	O
%	O
CI	O
=	O
0.09	O
to	O
2.55	O
]	O
)	O
.	O
In	O
conclusion	O
,	O
the	O
findings	B-T033
from	O
this	O
study	O
indicate	O
the	O
importance	O
of	O
sports	O
participation	O
among	O
adolescents	O
in	O
the	O
reduction	O
of	O
stress	O
fracture	O
risk	O
,	O
especially	O
with	O
impact	O
sports	O
.	O
More	O
importantly	O
,	O
these	O
results	O
could	O
be	O
relevant	O
for	O
recognising	O
adolescents	O
in	O
danger	O
of	O
not	O
reaching	O
their	O
potential	O
for	O
peak	O
bone	O
mass	O
and	O
later	O
an	O
increased	O
risk	O
of	O
fractures	O
.	O
      
A	O
missense	O
variant	O
,	O
rs373863828	O
-	O
A	O
(	O
p.	O
Arg457Gln	O
)	O
,	O
of	O
CREBRF	O
and	O
body	O
mass	O
index	O
in	O
Oceanic	O
populations	O
It	O
has	O
been	O
suggested	O
that	O
a	O
'	O
thrifty	O
'	O
genotype	O
hypothesis	O
can	O
account	O
for	O
high	O
prevalence	O
of	O
obesity	B-T047
in	O
the	O
island	O
populations	O
of	O
Oceania	O
.	O
A	O
recent	O
genome	O
-	O
wide	O
association	O
study	O
revealed	O
that	O
a	O
missense	O
variant	O
,	O
rs373863828	O
-	O
A	O
(	O
p.	O
Arg457Gln	O
)	O
,	O
of	O
the	O
CREBRF	O
gene	O
(	O
encoding	O
CREB3	O
regulatory	O
factor	O
)	O
was	O
associated	O
with	O
an	O
excessive	O
increase	O
in	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
in	O
Samoans	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
association	O
of	O
rs373863828	O
-	O
A	O
with	O
an	O
increase	O
in	O
BMI	O
was	O
examined	B-T033
in	O
four	O
Austronesian	O
(	O
AN)-	O
speaking	O
populations	O
in	O
Oceania	O
.	O
We	O
found	O
that	O
rs373863828	O
-	O
A	O
was	O
frequently	O
observed	O
(	O
frequency	O
of	O
0.15	O
)	O
in	O
Tongans	O
(	O
Polynesians	O
)	O
,	O
and	O
was	O
strongly	O
associated	O
with	O
higher	O
BMI	O
(	O
P=6.1	O
×	O
10(-4	O
)	O
)	O
.	O
A	O
single	O
copy	O
of	O
the	O
rs373863828	O
-	O
A	O
allele	O
increased	O
BMI	O
by	O
3.09	O
kg	O
m(-2	O
)	O
after	O
adjustment	O
of	O
age	O
and	O
sex	O
.	O
No	B-T033
significant	I-T033
association	O
was	O
detected	B-T061
in	O
the	O
other	O
three	O
AN	O
-	O
speaking	O
populations	O
(	O
Melanesians	O
and	O
Micronesians	O
)	O
living	O
in	O
Solomon	O
Islands	O
.	O
This	O
was	O
probably	O
due	O
to	O
the	O
low	O
allele	O
frequency	O
(	O
0.02	O
-	O
0.06	O
)	O
of	O
rs373863828	O
-	O
A	O
as	O
well	O
as	O
small	O
sample	O
size	O
.	O
The	O
rs373863828	O
-	O
A	O
allele	O
was	O
not	O
found	O
in	O
both	O
AN	O
-	O
speaking	O
and	O
non-	O
AN	O
-	O
speaking	O
Melanesians	O
living	O
in	O
Papua	O
New	O
Guinea	O
.	O
Our	O
results	O
suggest	O
that	O
rs373863828	O
-	O
A	O
of	O
CREBRF	O
,	O
a	O
promising	O
thrifty	O
variant	O
,	O
arose	O
in	O
recent	O
ancestors	O
of	O
AN	O
-	O
speaking	O
Polynesians	O
.Journal	O
of	O
Human	O
Genetics	O
advance	O
online	O
publication	O
,	O
13	O
April	O
2017	O
;	O
doi:10.1038	O
/	O
jhg.2017.44	O
.	O
      
Associations	O
between	O
major	O
life	O
events	O
and	O
adherence	O
,	O
glycemic	B-T061
control	I-T061
,	I-T061
and	O
psychosocial	O
characteristics	O
in	O
teens	O
with	O
type	B-T047
1	I-T047
diabetes	I-T047
This	O
cross	O
-	O
sectional	O
study	O
assessed	O
the	O
type	O
of	O
major	O
life	O
events	O
occurring	O
in	O
a	O
contemporary	O
sample	O
of	O
teens	O
with	O
type	B-T047
1	I-T047
diabetes	I-T047
and	O
the	O
association	O
between	O
event	O
frequency	O
and	O
demographic	O
,	O
diabetes	B-T061
management	I-T061
,	O
and	O
psychosocial	O
characteristics	O
.	O
Parents	O
of	O
178	O
teens	O
completed	O
the	O
Life	O
Events	O
Checklist	O
to	O
report	O
major	O
events	O
teens	O
had	O
experienced	O
in	O
the	O
last	O
year	O
:	O
42	O
%	O
experienced	O
0	O
to	O
1	O
event	O
(	O
n	O
=	O
75	O
)	O
,	O
32	O
%	O
experienced	O
2	O
to	O
3	O
events	O
(	O
n	O
=	O
57	O
)	O
,	O
and	O
26	O
%	O
experienced	O
4	O
+	O
events	O
(	O
n	O
=	O
46	O
)	O
.	O
Teens	O
and	O
parents	O
completed	O
validated	O
measures	O
of	O
treatment	B-T033
adherence	I-T033
,	O
diabetes	B-T047
-specific	O
self	O
-	O
efficacy	O
,	O
quality	O
of	O
life	O
,	O
and	O
diabetes	B-T047
-specific	O
family	B-T033
conflict	I-T033
.	O
Parent	O
-	O
youth	O
interview	O
and	O
chart	B-T058
review	I-T058
provided	O
demographics	O
and	O
diabetes	B-T061
management	I-T061
data	O
.	O
Mean	O
number	O
of	O
events	O
/	O
teen	O
was	O
2.6	O
±	O
2.7	O
(	O
range	O
=	O
0	O
-	O
15	O
)	O
.	O
The	O
most	O
common	O
events	O
were	O
"	O
Hospitalization	B-T058
of	O
a	O
family	O
member	O
"	O
(	O
24	O
%	O
)	O
,	O
"	O
Getting	B-T033
a	I-T033
bad	I-T033
report	I-T033
card	I-T033
"	O
(	O
20	O
%	O
)	O
,	O
"	O
Serious	O
arguments	O
between	O
parents	O
"	O
(	O
19	O
%	O
)	O
,	O
and	O
"	O
Serious	B-T184
illness	I-T184
/	O
injury	O
in	O
a	O
family	O
member	O
"	O
(	O
19	O
%	O
)	O
.	O
Compared	O
with	O
teens	O
experiencing	O
0	O
to	O
1	O
event	O
,	O
teens	O
experiencing	O
4	O
+	O
events	O
were	O
less	O
likely	O
to	O
have	O
married	O
parents	O
(	O
P	O
=	O
.01	O
)	O
and	O
a	O
parent	O
with	O
a	O
college	O
degree	O
(	O
P	O
=	O
.006	O
)	O
.	O
Teen	O
s	O
with	O
4	O
+	O
events	O
had	O
significantly	O
poorer	O
adherence	O
(	O
P	O
=	O
.002	O
teen	O
,	O
P	O
=	O
.02	O
parent	O
)	O
,	O
lower	O
self	O
-	O
efficacy	O
(	O
P	O
=	O
.03	O
teen	O
,	O
P	O
<	O
.0001	O
parent	O
)	O
,	O
poorer	O
quality	O
of	O
life	O
(	O
P	O
<	O
.0001	O
teen	O
,	O
P	O
<	O
.0001	O
parent	O
)	O
,	O
and	O
more	O
conflict	B-T033
(	O
P	O
=	O
.006	O
teen	O
,	O
P	O
=	O
.02	O
parent	O
)	O
than	O
teens	O
with	O
fewer	O
events	O
.	O
In	O
a	O
multivariate	O
model	O
(	O
R	O
(	O
2	O
)	O
=	O
0.21	O
,	O
P	O
<	O
.0001	O
)	O
controlling	O
for	O
demographic	O
and	O
diabetes	B-T061
management	I-T061
characteristics	O
,	O
fewer	O
events	O
was	O
associated	O
with	O
lower	O
A1c	O
(	O
P	O
=	O
.0009	O
)	O
.	O
Occurrence	O
of	O
more	O
major	O
life	O
events	O
was	O
associated	O
with	O
poorer	O
diabetes	B-T061
care	I-T061
and	O
A1c	O
and	O
more	O
negative	O
psychosocial	O
qualities	O
in	O
teens	O
with	O
type	B-T047
1	I-T047
diabetes	I-T047
.	O
      
20S	O
immunoproteasomes	O
remove	O
formaldehyde	B-T121
-	O
damaged	O
cytoplasmic	O
proteins	O
suppressing	O
caspase	O
-	O
independent	O
cell	O
death	O
Immunoproteasomes	O
are	O
known	O
for	O
their	O
involvement	O
in	O
antigen	O
presentation	O
.	O
However	O
,	O
their	O
broad	O
tissue	O
presence	B-T033
and	O
other	O
evidence	O
are	O
indicative	O
of	O
nonimmune	O
functions	O
.	O
We	O
examined	O
a	O
role	O
for	O
immunoproteasomes	O
in	O
cellular	O
responses	O
to	O
the	O
endogenous	O
and	O
environmental	O
carcinogen	O
formaldehyde	B-T121
(	O
FA	B-T121
)	O
that	O
binds	O
to	O
cytosolic	O
and	O
nuclear	O
proteins	O
producing	O
proteotoxic	O
stress	O
and	O
genotoxic	O
DNA	O
-	O
histone	O
crosslinks	O
.	O
We	O
found	O
that	O
immunoproteasomes	O
were	O
important	O
for	O
suppression	O
of	O
a	O
caspase	O
-	O
independent	O
cell	O
death	O
and	O
the	O
long	O
-	O
term	O
survival	O
of	O
FA	O
-	O
treated	O
cells	O
.	O
All	O
major	O
genotoxic	O
responses	O
to	O
FA	B-T121
,	O
including	O
replication	O
inhibition	O
and	O
activation	O
of	O
the	O
transcription	O
factor	O
p53	O
and	O
the	O
apical	O
ATM	O
and	O
ATR	O
kinases	O
,	O
were	O
unaffected	O
by	O
immunoproteasome	O
inactivity	O
.	O
Immunoproteasome	O
inhibition	O
enhanced	O
activation	O
of	O
the	O
cytosolic	O
protein	O
damage	O
sensor	O
HSF1	O
,	O
elevated	O
levels	O
of	O
K48	O
-	O
polyubiquitinated	O
cytoplasmic	O
proteins	O
and	O
increased	O
depletion	O
of	O
unconjugated	O
ubiquitin	O
.	O
We	O
further	O
found	O
that	O
FA	B-T121
induced	O
the	O
disassembly	O
of	O
26S	O
immunoproteasomes	O
,	O
but	O
not	O
standard	O
26S	O
proteasomes	O
,	O
releasing	O
the	O
20S	O
catalytic	O
immunoproteasome	O
.	O
FA	O
-	O
treated	O
cells	O
also	O
had	O
higher	O
amounts	O
of	O
small	O
activators	O
PA28αβ	O
and	O
PA28γ	O
bound	O
to	O
20S	O
particles	O
.	O
Our	O
findings	O
highlight	O
the	O
significance	O
of	O
nonnuclear	O
damage	O
in	O
FA	B-T121
injury	O
and	O
reveal	O
a	O
major	O
role	O
for	O
immunoproteasomes	O
in	O
elimination	O
of	O
FA	O
-	O
damaged	O
cytoplasmic	O
proteins	O
through	O
ubiquitin	O
-	O
independent	O
proteolysis	O
.	O
      
A	O
peptide	O
from	O
human	O
β	O
thymosin	O
as	O
a	O
platform	O
for	O
the	O
development	O
of	O
new	O
anti	B-T121
-	I-T121
biofilm	I-T121
agents	I-T121
for	O
Staphylococcus	B-T007
spp	I-T007
.	I-T007
and	O
Pseudomonas	B-T007
aeruginosa	I-T007
Conventional	O
antibiotics	B-T195
might	O
fail	O
in	O
the	O
treatment	O
of	O
biofilm	B-T007
-associated	O
infections	O
causing	O
infection	O
recurrence	O
and	O
chronicity	O
.	O
The	O
search	O
for	O
antimicrobial	B-T121
peptides	I-T121
has	O
been	O
performed	O
with	O
the	O
aim	O
to	O
discover	O
novel	O
anti	B-T121
-	I-T121
infective	I-T121
agents	I-T121
active	O
on	O
pathogens	B-T001
in	O
both	O
planktonic	B-T007
and	O
biofilm	B-T007
associated	O
forms	O
.	O
The	O
fragment	O
9	O
-	O
19	O
of	O
human	O
thymosin	O
β4	O
was	O
studied	O
through	O
1	O
μs	O
MD	O
simulation	O
.	O
Two	O
main	O
conformations	O
of	O
the	O
peptide	O
were	O
detected	O
,	O
both	O
constituted	O
by	O
a	O
central	O
hydrophobic	O
core	O
and	O
by	O
the	O
presence	O
of	O
peripheral	O
charged	O
residues	O
suggesting	O
a	O
possible	O
mechanism	O
of	O
interaction	O
with	O
two	O
models	O
of	O
biological	O
membranes	O
,	O
related	O
to	O
eukaryotic	O
or	O
bacterial	O
membrane	O
respectively	O
.	O
In	O
addition	O
,	O
the	O
peptide	O
was	O
chemically	O
synthesized	O
and	O
its	O
antimicrobial	O
activity	O
was	O
tested	O
in	O
vitro	O
against	O
planktonic	B-T007
and	O
biofilm	B-T007
form	O
of	O
a	O
group	O
of	O
reference	O
strains	B-T001
of	O
Staphylococcus	B-T007
spp	I-T007
.	I-T007
and	O
one	O
P.	B-T007
aeruginosa	I-T007
strain	B-T001
.	O
The	O
human	O
thymosin	O
β4	O
fragment	O
EIEKFDKSKLK	O
showed	O
antibacterial	O
activity	O
against	O
staphylococcal	B-T007
strains	B-T001
and	O
Pseudomonas	B-T007
aeruginosa	I-T007
ATCC	O
15442	O
at	O
concentrations	O
from	O
12.5	O
to	O
6.2	O
mg	O
/	O
ml	O
and	O
inhibited	O
biofilm	O
formation	O
at	O
sub	O
-	O
inhibitory	O
concentrations	O
(	O
3.1	O
-	O
0.75	O
mg	O
/	O
ml	O
)	O
.	O
The	O
activity	O
of	O
the	O
fragment	O
in	O
inhibiting	O
biofilm	O
formation	O
,	O
could	O
be	O
due	O
to	O
the	O
conformations	O
highlighted	O
by	O
the	O
MD	O
simulations	O
,	O
suggesting	O
its	O
interaction	O
with	O
the	O
bacterial	O
membrane	O
.	O
Human	O
thymosin	O
β4	O
fragment	O
can	O
be	O
considered	O
a	O
promising	O
lead	B-T121
compound	I-T121
to	O
develop	O
novel	O
synthetic	O
or	O
recombinant	O
derivatives	O
with	O
improved	O
pharmaceutical	O
potential	O
.	O
      
The	O
clinical	O
and	O
economic	O
burden	O
of	O
significant	O
bleeding	O
during	O
lung	B-T061
resection	I-T061
surgery	I-T061
:	O
A	O
retrospective	O
matched	O
cohort	O
analysis	O
of	O
real	O
-	O
world	O
data	O
The	O
objective	O
of	O
this	O
retrospective	O
study	O
was	O
to	O
quantify	O
the	O
clinical	O
and	O
economic	O
burden	O
of	O
significant	O
bleeding	O
in	O
lung	B-T061
resection	I-T061
surgery	I-T061
in	O
the	O
US	O
.	O
This	O
study	O
utilized	O
2009	O
-	O
2012	O
data	O
from	O
the	O
Premier	O
Perspective	O
Database(TM	O
)	O
.	O
Adult	O
patients	O
with	O
primary	B-T061
pulmonary	I-T061
lobectomy	I-T061
or	O
segmentectomy	B-T061
procedures	I-T061
were	O
categorized	O
by	O
the	O
surgical	O
approach	O
(	O
VATS	B-T061
vs	O
open	B-T061
)	O
and	O
primary	O
diagnosis	O
(	O
primary	B-T060
or	O
metastatic	B-T060
lung	I-T060
cancer	I-T060
vs	O
non	B-T060
-	I-T060
lung	I-T060
cancer	I-T060
)	O
.	O
Patients	O
requiring	O
≥3	O
units	O
of	O
blood	B-T121
products	I-T121
with	O
at	O
least	O
1	O
unit	O
of	O
PRBCs	B-T121
:	O
"	O
significant	O
bleeding	O
"	O
cohort	O
;	O
those	O
requiring	O
<3	O
units	O
:	O
"	O
non	B-T033
-	I-T033
significant	I-T033
bleeding	O
"	O
cohort	O
;	O
and	O
those	O
not	O
requiring	O
blood	B-T121
products	I-T121
:	O
"	O
no	O
bleeding	O
"	O
cohort	O
.	O
A	O
matched	O
cohort	O
analysis	O
was	O
performed	O
between	O
the	O
"	O
significant	O
bleeding	O
"	O
and	O
the	O
"	O
no	O
bleeding	O
cohort	O
"	O
using	O
matching	O
variables	O
:	O
hospital	O
,	O
lung	B-T060
cancer	I-T060
diagnosis	I-T060
,	O
year	O
of	O
surgery	O
,	O
APR	O
-	O
DRG	O
severity	O
score	O
,	O
procedure	O
type	O
and	O
approach	O
,	O
age	O
,	O
and	O
gender	O
.	O
The	O
"	O
All	O
-	O
patient	O
"	O
cohort	O
comprised	O
21,429	O
patients	O
:	O
213	O
"	O
significant	O
bleeding	O
"	O
;	O
2,780	O
"	O
non	B-T033
-	I-T033
significant	I-T033
bleeding	O
"	O
;	O
and	O
18,436	O
"	O
no	O
bleeding	O
"	O
.	O
Overall	O
incidence	O
of	O
significant	O
chest	O
bleeding	O
was	O
0.99	O
%	O
.	O
Patients	O
from	O
"	O
significant	O
bleeding	O
"	O
cohort	O
and	O
"	O
non	B-T033
-	I-T033
significant	I-T033
bleeding	O
"	O
cohort	O
had	O
2.5	O
days	O
and	O
2	O
days	O
(	O
p	O
<	O
0.0001	O
)	O
longer	O
length	O
of	O
stay	O
in	O
the	O
hospital	O
compared	O
to	O
those	O
in	O
the	O
"	O
no	O
bleeding	O
"	O
cohort	O
,	O
respectively	O
.	O
Overall	O
,	O
hospital	O
costs	O
for	O
"	O
significant	O
bleeding	O
"	O
cohort	O
were	O
higher	O
than	O
"	O
no	O
bleeding	O
"	O
cohort	O
for	O
those	O
who	O
were	O
covered	O
under	O
Medicare	O
(	O
$	O
59,871	O
vs	O
$	O
23,641	O
)	O
,	O
were	O
≥76	O
years	O
of	O
age	O
(	O
$	O
64,010	O
vs	O
$	O
24,243	O
)	O
,	O
had	O
greater	O
severity	O
of	O
illness	O
(	O
$	O
97,813	O
vs	O
$	O
51,871	O
)	O
and	O
underwent	O
open	O
segmentectomy	B-T061
(	O
$	O
74,220	O
vs	O
$	O
21,903	O
)	O
.	O
Hospital	O
costs	O
for	O
"	O
significant	O
bleeding	O
"	O
cohort	O
and	O
"	O
non	B-T033
-	I-T033
significant	I-T033
bleeding	O
"	O
were	O
significantly	O
higher	O
(	O
$	O
11,589	O
and	O
$	O
5,280	O
,	O
respectively	O
,	O
p	O
<	O
0.0001	O
)	O
than	O
no	O
bleeding	O
cohort	O
.	O
Although	O
significant	O
bleeding	O
during	O
lung	B-T061
resection	I-T061
surgery	I-T061
is	O
rare	O
,	O
patients	O
with	O
such	O
complication	O
could	O
stay	O
longer	O
at	O
the	O
hospital	O
and	O
cost	O
an	O
average	O
of	O
$	O
13,103	O
more	O
than	O
those	O
without	O
.	O
      
Directing	O
traffic	O
on	O
DNA	O
-How	O
transcription	O
factors	O
relieve	O
or	O
induce	O
transcriptional	O
interference	O
Transcriptional	O
interference	O
(	O
TI	O
)	O
is	O
increasingly	O
recognized	O
as	O
a	O
widespread	O
mechanism	O
of	O
gene	O
control	O
,	O
particularly	O
given	O
the	O
pervasive	O
nature	O
of	O
transcription	O
,	O
both	O
sense	O
and	O
antisense	O
,	O
across	O
all	O
kingdoms	O
of	O
life	O
.	O
Here	O
,	O
we	O
discuss	O
how	O
transcription	O
factor	O
binding	O
kinetics	O
strongly	O
influence	O
the	O
ability	O
of	O
a	O
transcription	O
factor	O
to	O
relieve	O
or	O
induce	O
TI	O
.	O
      
The	O
Association	O
between	O
C9orf72	O
Repeats	O
and	O
Risk	O
of	O
Alzheimer	B-T047
's	I-T047
Disease	I-T047
and	O
Amyotrophic	B-T047
Lateral	I-T047
Sclerosis	I-T047
:	O
A	O
Meta	O
-	O
Analysis	O
C9orf72	O
is	O
the	O
most	O
common	O
genetic	O
cause	O
of	O
amyotrophic	B-T047
lateral	I-T047
sclerosis	I-T047
(	O
ALS	B-T047
)	O
and	O
frontotemporal	B-T047
dementia	I-T047
(	O
FTD	B-T047
)	O
in	O
Caucasian	O
populations	O
.	O
However	O
,	O
the	O
relationship	O
between	O
C9orf72	O
repeats	O
and	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
(	O
AD	B-T047
)	O
was	O
not	B-T033
clear	I-T033
.	O
Additionally	O
,	O
there	O
were	O
few	O
articles	O
assessing	O
C9orf72	O
in	O
other	O
ethnicities	O
with	O
ALS	B-T047
.	O
In	O
this	O
meta	O
-	O
analysis	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
relationship	O
between	O
C9orf72	O
repeat	O
expansions	O
(	O
≥30	O
repeats	O
)	O
and	O
intermediate	O
repeat	O
copies	O
(	O
20	O
-	O
29	O
repeats	O
)	O
and	O
AD	B-T047
or	O
ALS	B-T047
.	O
The	O
results	O
suggested	O
positive	B-T033
correlations	O
between	O
C9orf72	O
repeat	O
expansions	O
and	O
the	O
risk	O
of	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
(	O
OR	O
=	O
6.36	O
,	O
95	O
%	O
CI	O
=	O
3.13	O
-	O
12.92	O
,	O
and	O
p	O
<	O
0.00001	O
)	O
,	O
while	O
intermediate	O
repeat	O
copies	O
of	O
C9orf72	O
gene	O
were	O
not	O
associated	O
with	O
the	O
risk	O
of	O
the	O
disease	B-T047
.	O
C9orf72	O
repeat	O
expansions	O
were	O
positively	B-T033
correlated	O
with	O
the	O
risk	O
of	O
familial	B-T047
and	O
sporadic	B-T047
ALS	I-T047
(	O
OR	O
=	O
293.25	O
,	O
95	O
%	O
CI	O
=	O
148.17	O
-	O
580.38	O
,	O
and	O
p	O
<	O
0.00001	O
;	O
OR	O
=	O
35.57	O
,	O
95	O
%	O
CI	O
=	O
19.61	O
-	O
64.51	O
,	O
and	O
p	O
<	O
0.00001	O
)	O
.	O
There	O
was	O
a	O
positive	B-T033
correlation	O
between	O
the	O
gene	O
variations	O
and	O
ALS	B-T047
risk	O
among	O
Caucasians	O
and	O
Asians	O
(	O
OR	O
=	O
57.56	O
,	O
95	O
%	O
CI	O
=	O
36.73	O
-	O
90.22	O
,	O
and	O
p	O
<	O
0.00001	O
;	O
OR	O
=	O
6.35	O
,	O
95	O
%	O
CI	O
=	O
1.39	O
-	O
29.02	O
,	O
and	O
p	O
=	O
0.02	O
)	O
.	O
      
Obstructive	O
Acute	B-T047
Pancreatitis	I-T047
Secondary	O
to	O
PEG	O
Tube	O
Migration	B-T033
Percutaneous	B-T061
gastrostomy	I-T061
is	O
a	O
well	O
-	O
established	O
method	O
of	O
providing	O
enteral	B-T061
nutrition	I-T061
to	O
patients	O
incapable	B-T033
of	O
oral	B-T033
intake	I-T033
,	O
or	O
for	O
whom	O
oral	B-T033
intake	I-T033
is	O
insufficient	O
to	O
meet	O
metabolic	O
needs	O
.	O
In	O
comparison	O
to	O
total	B-T061
parenteral	I-T061
nutrition	I-T061
,	O
enteral	B-T058
feeding	I-T058
is	O
advantageous	O
in	O
that	O
it	O
helps	O
maintain	O
gut	B-T023
mucosal	O
integrity	O
,	O
which	O
decreases	O
the	O
risk	O
of	O
bacterial	O
translocation	O
through	O
the	O
gastrointestinal	O
tract	O
.	O
Complications	O
include	O
bleeding	O
,	O
aspiration	O
,	O
internal	O
organ	O
injury	O
,	O
perforation	B-T047
,	O
periostomal	B-T047
leaks	I-T047
,	O
tube	O
dislodgement	O
,	O
and	O
occlusion	O
.	O
Acute	B-T047
pancreatitis	I-T047
secondary	O
to	O
percutaneous	O
gastrostomy	O
tube	O
migration	B-T033
is	O
rare	O
.	O
We	O
present	O
a	O
patient	O
with	O
acute	O
obstructive	O
pancreatitis	B-T047
secondary	O
to	O
percutaneous	O
gastrostomy	O
tube	O
migration	B-T033
.	O
      
Nosocomial	B-T047
pneumonia	I-T047
caused	O
by	O
methicillin	B-T007
-	I-T007
resistant	I-T007
Staphylococcus	I-T007
aureus	I-T007
treated	B-T061
with	I-T061
linezolid	B-T121
or	O
vancomycin	B-T195
:	O
A	O
secondary	O
economic	O
analysis	O
of	O
resource	O
use	O
from	O
a	O
Spanish	O
perspective	O
Adopting	O
a	O
unique	O
Spanish	O
perspective	O
,	O
this	O
study	O
aims	O
to	O
assess	O
healthcare	O
resource	O
utilization	O
(	O
HCRU	O
)	O
and	O
the	O
costs	O
of	O
treating	O
nosocomial	B-T047
pneumonia	I-T047
(	O
NP	B-T047
)	O
produced	O
by	O
methicillin	B-T007
-	I-T007
resistant	I-T007
Staphylococcus	I-T007
aureus	I-T007
(	O
MRSA	B-T007
)	O
in	O
hospitalized	B-T033
adults	I-T033
using	O
linezolid	B-T121
or	O
vancomycin	B-T195
.	O
An	O
evaluation	O
is	O
also	O
made	O
of	O
the	O
renal	B-T047
failure	I-T047
rate	O
and	O
related	O
economic	O
outcomes	O
between	O
study	O
groups	O
.	O
An	O
economic	O
post	B-T058
hoc	I-T058
evaluation	I-T058
of	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
multicenter	O
phase	O
4	O
study	O
was	O
carried	O
out	O
.	O
Nosocomial	B-T047
pneumonia	I-T047
due	O
to	O
MRSA	B-T007
in	O
hospitalized	B-T033
adults	I-T033
.	O
The	O
modified	O
intent	O
to	O
treat	O
(	O
mITT	O
)	O
population	O
comprised	O
224	O
linezolid	B-T121
-	O
and	O
224	O
vancomycin	B-T195
-	O
treated	B-T061
patients	O
.	O
Costs	O
and	O
HCRU	O
were	O
evaluated	O
between	O
patients	O
administered	O
either	O
linezolid	B-T121
or	O
vancomycin	B-T195
,	O
and	O
between	O
patients	O
who	O
developed	O
renal	B-T047
failure	I-T047
and	O
those	O
who	O
did	O
not	O
.	O
Analysis	O
of	O
HCRU	O
outcomes	O
and	O
costs	O
.	O
Total	O
costs	O
were	O
similar	O
between	O
the	O
linezolid	B-T121
-	O
(	O
€	O
17,782±€9,615	O
)	O
and	O
vancomycin	B-T195
-	O
treated	B-T061
patients	O
(	O
€	O
17,423±€9,460	O
)	O
(	O
P=.69	O
)	O
.	O
The	O
renal	B-T047
failure	I-T047
rate	O
was	O
significantly	O
lower	O
in	O
the	O
linezolid	B-T121
-	O
treated	B-T061
patients	O
(	O
4	O
%	O
vs.	O
15	O
%	O
;	O
P<.001	O
)	O
.	O
The	O
total	O
costs	O
tended	O
to	O
be	O
higher	O
in	O
patients	O
who	O
developed	O
renal	B-T047
failure	I-T047
(	O
€	O
19,626±€10,840	O
vs.	O
€	O
17,388±€9,369	O
;	O
P=.14	O
)	O
.	O
Among	O
the	O
patients	O
who	O
developed	O
renal	B-T047
failure	I-T047
,	O
HCRU	O
(	O
days	O
on	O
mechanical	B-T061
ventilation	I-T061
:	O
13.2±10.7	O
vs.	O
7.6±3.6	O
days	O
;	O
P=.21	O
;	O
ICU	O
stay	O
:	O
14.4±10.5	O
vs.	O
9.9±6.6	O
days	O
;	O
P=.30	O
;	O
hospital	O
stay	O
:	O
19.5±9.5	O
vs.	O
16.1±11.0	O
days	O
;	O
P=.26	O
)	O
and	O
cost	O
(	O
€	O
17,219±€8,792	O
vs.	O
€	O
20,263±€11,350	O
;	O
P=.51	O
)	O
tended	O
to	O
be	O
lower	O
in	O
the	O
linezolid	B-T121
-	O
vs.	O
vancomycin	B-T195
-	O
treated	B-T061
patients	O
.	O
There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
costs	O
per	O
patient	O
-	O
day	O
between	O
cohorts	O
after	O
correcting	O
for	O
mortality	O
(	O
€	O
1000	O
vs.	O
€	O
1,010	O
;	O
P=.98	O
)	O
.	O
From	O
a	O
Spanish	O
perspective	O
,	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
total	O
costs	O
between	O
the	O
linezolid	B-T121
and	O
vancomycin	B-T195
pneumonia	B-T047
cohorts	O
.	O
The	O
drug	O
cost	O
corresponding	O
to	O
linezolid	B-T121
was	O
partially	O
offset	O
by	O
fewer	O
renal	B-T047
failure	I-T047
adverse	O
events	O
.	O
      
Peptide	O
-Mediated	O
Interference	O
of	O
PB2	O
-	O
eIF4G1	O
Interaction	O
Inhibits	O
Influenza	B-T005
A	I-T005
Viruses	I-T005
'	O
Replication	O
in	O
Vitro	O
and	O
in	O
Vivo	O
Influenza	B-T005
viruses	I-T005
are	O
obligate	O
parasites	O
that	O
hijack	O
the	O
host	O
cellular	O
system	O
.	O
Previous	O
results	O
have	O
shown	O
that	O
the	O
influenza	O
virus	O
PB2	O
subunit	O
confers	O
a	O
dependence	O
of	O
host	O
eukaryotic	O
translation	O
initiation	O
factor	O
4	O
-	O
γ	O
1	O
(	O
eIF4G1	O
)	O
for	O
viral	O
mRNA	O
translation	O
.	O
Here	O
,	O
we	O
demonstrated	O
that	O
peptide	O
-mediated	O
interference	O
of	O
the	O
PB2	O
-	O
eIF4G1	O
interaction	O
inhibited	O
virus	O
replication	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Remarkably	O
,	O
intranasal	B-T061
administration	I-T061
of	O
the	O
peptide	O
provided	O
100	O
%	O
protection	B-T033
against	O
lethal	B-T033
challenges	B-T058
of	O
influenza	B-T005
A	I-T005
viruses	I-T005
in	O
BALB	O
/	O
c	O
mice	O
,	O
including	O
H1N1	B-T005
,	O
H5N1	B-T005
,	O
and	O
H7N9	B-T005
influenza	I-T005
virus	I-T005
subtypes	I-T005
.	O
Mapping	O
of	O
the	O
PB2	O
protein	O
indicated	O
that	O
the	O
eIF4G1	O
binding	O
sites	O
resided	O
within	O
the	O
PB2	O
cap	O
-	O
binding	O
domain	O
.	O
Virtual	O
docking	O
analysis	O
suggested	O
that	O
the	O
inhibitory	O
peptide	O
associated	O
with	O
the	O
conserved	O
amino	B-T121
acid	I-T121
residues	I-T121
that	O
were	O
essential	O
to	O
PB2	O
cap	B-T059
-	I-T059
binding	I-T059
activity	I-T059
.	O
Overall	O
,	O
our	O
results	O
identified	O
the	O
PB2	O
-	O
eIF4G1	O
interactive	O
site	O
as	O
a	O
druggable	B-T121
target	O
for	O
influenza	B-T047
therapeutics	B-T061
.	O
      
Development	O
of	O
chrysin	B-T121
loaded	O
poloxamer	O
micelles	O
and	O
toxicity	O
evaluation	B-T058
in	O
fish	O
embryos	B-T018
Poloxamer	O
micelles	O
promise	O
safety	O
and	O
efficacy	O
for	O
many	O
water	B-T121
insoluble	O
drugs	B-T121
.	O
Chrysin	B-T121
has	O
been	O
reported	O
to	O
have	O
anticancer	O
,	O
anti	O
-	O
inflammatory	O
,	O
antioxidant	O
,	O
and	O
anti	O
-	O
aromatase	O
activities	O
but	O
its	O
water	B-T121
insoluble	O
properties	O
limit	O
its	O
pharmaceutical	O
application	O
.	O
In	O
the	O
present	O
study	O
,	O
chrysin	B-T121
loaded	O
poloxamer	O
micelles	O
were	O
developed	O
.	O
Two	O
types	O
of	O
poloxamers	O
,	O
Pluronic	O
F-68	O
and	O
Pluronic	B-T121
F-127	I-T121
were	O
compared	O
.	O
It	O
was	O
found	O
that	O
chrysin	B-T121
loaded	O
Pluronic	O
F-68	O
micelles	O
(	O
CS	O
-	O
P68	O
)	O
and	O
chrysin	B-T121
loaded	O
Pluronic	B-T121
F-127	I-T121
micelles	O
(	O
CS	O
-	O
P127	O
)	O
obviously	O
increase	O
the	O
aqueous	O
solubility	O
of	O
chrysin	B-T121
.	O
The	O
results	O
also	O
indicated	O
that	O
the	O
type	O
of	O
polymer	O
and	O
ratio	O
of	O
drug	B-T121
to	O
polymer	O
affected	O
size	O
and	O
desirable	O
characteristics	O
of	O
the	O
micelles	O
.	O
The	O
micelle	O
system	O
of	O
CS	O
-	O
P68	O
and	O
CS	O
-	O
P127	O
formed	O
at	O
drug	B-T121
to	O
polymer	O
ratios	O
of	O
1:4	O
and	O
1:2	O
,	O
respectively	O
,	O
was	O
found	O
to	O
be	O
the	O
most	O
suitable	O
monodispersed	O
system	O
with	O
a	O
nanosize	O
-	O
range	O
diameter	O
.	O
The	O
in	O
vivo	O
study	O
in	O
zebrafish	O
eggs	O
indicates	O
that	O
the	O
toxicity	O
of	O
CS	O
-	O
P68	O
and	O
CS	O
-	O
P127	O
is	O
a	O
dose	O
response	O
.	O
CS	O
-	O
P68	O
and	O
CS	O
-	O
P127	O
at	O
a	O
drug	O
dose	O
of	O
10	O
ng	O
/	O
mL	O
or	O
less	O
is	O
safe	O
for	O
zebrafish	O
embryo	B-T018
growth	O
.	O
The	O
results	O
of	O
this	O
study	O
indicate	O
enhanced	O
water	O
solubility	O
of	O
chrysin	B-T121
.	O
Chrysin	B-T121
loaded	O
poloxamer	O
micelles	O
are	O
promising	O
for	O
further	O
use	O
in	O
in	O
vivo	O
studies	O
in	O
mammalian	O
animals	O
and	O
humans	O
.	O
      
Spermatocytic	B-T191
Tumor	I-T191
With	O
Sarcoma	B-T191
:	O
A	O
Rare	O
Testicular	B-T191
Neoplasm	I-T191
Spermatocytic	B-T191
tumor	I-T191
,	O
formerly	O
known	O
as	O
spermatocytic	B-T191
seminoma	I-T191
,	O
is	O
an	O
uncommon	O
testicular	B-T191
neoplasm	I-T191
which	O
is	O
a	O
distinct	O
clinicopathologic	O
entity	O
from	O
classic	O
seminoma	B-T191
.	O
These	O
tumors	B-T191
are	O
not	O
associated	O
with	O
germ	B-T191
cell	I-T191
neoplasia	I-T191
in	O
situ	O
,	O
other	O
germ	B-T191
cell	I-T191
tumors	I-T191
,	O
or	O
isochromosome	O
12p	O
.	O
Although	O
typically	O
,	O
these	O
tumors	B-T191
have	O
an	O
excellent	O
prognosis	B-T058
occasional	O
cases	O
are	O
associated	O
with	O
sarcoma	B-T191
and	O
have	O
a	O
very	B-T033
poor	I-T033
prognosis	I-T033
.	O
We	O
present	O
a	O
case	O
of	O
spermatocytic	B-T191
tumor	I-T191
with	O
sarcoma	B-T191
showing	O
a	O
chondrosarcomatous	B-T191
component	I-T191
,	O
discuss	O
the	O
pathologic	B-T033
findings	I-T033
and	O
differential	B-T060
diagnosis	I-T060
and	O
provide	O
follow	B-T058
-	I-T058
up	I-T058
information	O
.	O
      
Signature	O
of	O
an	O
aggregation	O
-	O
prone	O
conformation	O
of	O
tau	O
The	O
self	O
-	O
assembly	O
of	O
the	O
microtubule	O
associated	O
tau	O
protein	O
into	O
fibrillar	O
cell	O
inclusions	O
is	O
linked	O
to	O
a	O
number	O
of	O
devastating	O
neurodegenerative	B-T047
disorders	I-T047
collectively	O
known	O
as	O
tauopathies	B-T047
.	O
The	O
mechanism	O
by	O
which	O
tau	O
self	O
-	O
assembles	O
into	O
pathological	O
entities	O
is	O
a	O
matter	O
of	O
much	O
debate	O
,	O
largely	O
due	O
to	O
the	O
lack	O
of	O
direct	O
experimental	O
insights	O
into	O
the	O
earliest	O
stages	O
of	O
aggregation	O
.	O
We	O
present	O
pulsed	B-T059
double	I-T059
electron	I-T059
-	I-T059
electron	I-T059
resonance	I-T059
measurements	O
of	O
two	O
key	O
fibril	O
-	O
forming	O
regions	O
of	O
tau	O
,	O
PHF6	O
and	O
PHF6	O
*	O
,	O
in	O
transient	O
as	O
aggregation	O
happens	O
.	O
By	O
monitoring	O
the	O
end	O
-	O
to	O
-	O
end	O
distance	O
distribution	O
of	O
these	O
segments	O
as	O
a	O
function	O
of	O
aggregation	O
time	O
,	O
we	O
show	O
that	O
the	O
PHF6	O
(	O
(	O
*	O
)	O
)	O
regions	O
dramatically	O
extend	O
to	O
distances	O
commensurate	O
with	O
extended	O
β	O
-	O
strand	O
structures	O
within	O
the	O
earliest	O
stages	O
of	O
aggregation	O
,	O
well	O
before	O
fibril	O
formation	O
.	O
Combined	O
with	O
simulations	O
,	O
our	O
experiments	O
show	O
that	O
the	O
extended	O
β	O
-	O
strand	O
conformational	O
state	O
of	O
PHF6	O
(	O
(	O
*	O
)	O
)	O
is	O
readily	O
populated	O
under	O
aggregating	O
conditions	O
,	O
constituting	O
a	O
defining	O
signature	O
of	O
aggregation	O
-	O
prone	O
tau	O
,	O
and	O
as	O
such	O
,	O
a	O
possible	O
target	O
for	O
therapeutic	B-T061
interventions	I-T061
.	O
      
Natural	O
competence	O
for	O
transformation	O
While	O
most	O
molecular	O
biologists	O
are	O
familiar	O
with	O
the	O
artificial	O
transformation	O
of	O
bacteria	O
in	O
the	O
context	O
of	O
laboratory	O
cloning	O
experiments	O
,	O
natural	O
competence	O
for	O
transformation	O
refers	O
to	O
a	O
specific	O
physiological	O
state	O
in	O
which	O
prokaryotes	B-T001
are	O
able	O
to	O
take	O
up	O
genetic	O
material	O
from	O
their	O
surroundings	O
.	O
Occasionally	O
,	O
such	O
absorbed	O
DNA	O
is	O
recombined	O
into	O
the	O
organism	B-T001
's	I-T001
own	O
genome	O
,	O
resulting	O
in	O
natural	O
transformation	O
(	O
Figure	O
1	O
)	O
.	O
As	O
a	O
consequence	O
,	O
natural	O
competence	O
for	O
transformation	O
is	O
considered	O
a	O
primary	O
mode	O
of	O
horizontal	O
gene	O
transfer	O
(	O
HGT	O
)	O
in	O
prokaryotes	B-T001
,	O
together	O
with	O
conjugation	O
(	O
direct	O
cell	O
to	O
cell	O
transfer	O
of	O
DNA	O
via	O
a	O
specialized	O
conjugal	O
pilus	O
)	O
and	O
phage	B-T005
transduction	O
(	O
DNA	O
transfer	O
mediated	O
by	O
viruses	B-T005
)	O
.	O
HGT	O
plays	O
a	O
major	O
role	O
in	O
bacterial	O
evolution	O
,	O
and	O
past	O
research	O
has	O
demonstrated	O
that	O
HGT	O
,	O
including	O
natural	O
competence	O
for	O
transformation	O
,	O
contributes	O
to	O
the	O
emergence	O
of	O
pathogens	B-T001
and	O
the	O
spread	O
of	O
virulence	O
factors	O
.	O
Indeed	O
,	O
Frederick	O
Griffith	O
discovered	O
natural	O
competence	O
for	O
transformation	O
in	O
1928	O
while	O
he	O
was	O
investigating	O
the	O
exchange	O
of	O
pathogenic	B-T033
traits	O
in	O
pneumococci	B-T007
.	O
Due	O
to	O
the	O
increase	O
in	O
the	O
abundance	O
and	O
spread	O
of	O
multidrug	B-T007
-	I-T007
resistant	I-T007
microbes	I-T007
,	O
research	O
on	O
HGT	O
is	O
even	O
more	O
important	O
today	O
than	O
ever	O
before	O
.	O
      
Trans	O
-	O
oral	O
fine	B-T060
needle	I-T060
aspiration	I-T060
cytology	I-T060
in	O
cervical	B-T023
(	I-T023
C1	I-T023
and	I-T023
C2	I-T023
)	I-T023
vertebral	I-T023
lesions	B-T033
:	O
a	O
novel	O
diagnostic	B-T060
approach	I-T060
Fine	B-T060
needle	I-T060
aspiration	I-T060
(	I-T060
FNA	I-T060
)	I-T060
cytology	I-T060
is	O
a	O
relatively	O
non	O
-	O
invasive	O
method	O
for	O
diagnosing	B-T033
both	O
superficial	B-T033
and	O
deep	B-T191
-	I-T191
seated	I-T191
neoplastic	I-T191
and	O
non	B-T033
-	I-T033
neoplastic	I-T033
lesions	I-T033
.	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
diagnostic	O
utility	O
of	O
trans	O
-	O
oral	O
FNA	B-T060
in	O
cervical	B-T023
(	I-T023
C1	I-T023
and	I-T023
C2	I-T023
)	I-T023
vertebral	I-T023
and	O
paravertebral	O
lesions	B-T033
.	O
Eighteen	O
FNA	B-T060
cases	O
of	O
cervical	B-T023
vertebral	I-T023
and	O
paravertebral	O
lesions	B-T033
performed	O
by	O
a	O
trans	O
-	O
oral	O
route	O
without	O
any	O
image	B-T058
-	I-T058
guidance	I-T058
between	O
1995	O
and	O
2014	O
were	O
retrieved	O
from	O
the	O
archives	O
of	O
the	O
cytology	O
department	O
at	O
PGIMER	O
,	O
Chandigarh	O
and	O
reviewed	O
.	O
Out	O
of	O
18	O
cases	O
,	O
a	O
definite	O
diagnosis	B-T033
was	O
given	O
in	O
15	O
cases	O
(	O
83.3	O
%	O
)	O
.	O
The	O
commonest	O
diagnosis	B-T033
seen	O
was	O
granulomatous	O
inflammation	O
consistent	O
with	O
tuberculosis	B-T047
(	O
33.3	O
%	O
)	O
.	O
Trans	O
-	O
oral	O
FNA	B-T060
is	O
a	O
quick	O
,	O
inexpensive	O
and	O
relatively	O
safe	O
outpatient	B-T061
procedure	I-T061
for	O
sampling	O
C1	B-T023
and	I-T023
C2	I-T023
vertebral	I-T023
and	O
paravertebral	O
lesions	B-T033
,	O
which	O
are	O
clinically	O
and	O
radiologically	O
difficult	O
to	O
approach	O
.	O
It	O
helps	O
in	O
the	O
early	B-T060
diagnosis	I-T060
and	O
management	B-T058
of	I-T058
these	I-T058
patients	I-T058
.	O
      
Three	O
-	O
Dimensional	O
HyCoSy	B-T060
With	O
Perfluoropropane	O
-	O
Albumin	O
Microspheres	O
as	O
Contrast	O
Agents	O
and	O
Normal	O
Saline	O
Injections	B-T061
Into	O
the	O
Pelvic	O
Cavity	O
for	O
Morphological	O
Assessment	B-T058
of	O
the	O
Fallopian	B-T023
Tube	I-T023
in	O
Infertile	O
Women	O
To	O
apply	O
the	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
hysterosalpingo	B-T060
-	I-T060
contrast	I-T060
sonography	I-T060
(	O
HyCoSy	B-T060
)	O
with	O
perfluoropropane	O
-	O
albumin	O
microspheres	O
as	O
contrast	O
agents	O
and	O
normal	O
saline	O
injections	B-T061
into	O
the	O
pelvic	O
cavity	O
for	O
assessment	B-T060
of	I-T060
the	I-T060
tubal	I-T060
patency	I-T060
and	O
adhesions	B-T047
of	I-T047
fimbrial	I-T047
parts	I-T047
.	O
Fifty	O
-	O
five	O
infertile	O
female	O
patients	O
were	O
recruited	O
to	O
undergo	O
3D	O
HyCoSy	B-T060
with	O
normal	O
saline	O
injected	B-T061
into	O
the	O
pelvic	O
cavity	O
,	O
in	O
which	O
the	O
tubal	O
patency	O
was	O
observed	O
by	O
visualizing	O
the	O
spillage	O
of	O
contrast	O
agents	O
from	O
the	O
fimbriae	B-T023
,	O
and	O
the	O
fimbrial	B-T047
adhesion	I-T047
was	O
confirmed	O
by	O
the	O
finger	O
-	O
like	O
projections	O
of	O
the	O
fimbriae	B-T023
and	O
their	O
floating	O
and	O
moving	O
status	O
.	O
Of	O
the	O
55	O
patients	O
,	O
bilateral	B-T033
tubal	I-T033
patency	I-T033
was	O
observed	O
in	O
44	O
(	O
80.0	O
%	O
)	O
,	O
unilateral	B-T033
tubal	I-T033
patency	I-T033
and	O
the	O
other	O
partial	B-T047
occlusion	I-T047
in	O
7	O
(	O
12.7	O
%	O
)	O
,	O
unilateral	O
partial	B-T047
occlusion	I-T047
and	O
the	O
other	O
complete	O
occlusion	O
in	O
3	O
(	O
5.4	O
%	O
)	O
,	O
and	O
bilateral	O
complete	O
occlusion	O
in	O
1	O
(	O
1.8	O
%	O
)	O
.	O
The	O
fimbrial	B-T023
parts	I-T023
were	O
observed	O
in	O
105	O
fallopian	B-T023
tubes	I-T023
,	O
among	O
which	O
101	O
were	O
seen	O
with	O
the	O
finger	O
-	O
like	O
fimbriae	B-T023
floated	O
and	O
moved	O
in	O
the	O
pelvic	O
cavity	O
,	O
whereas	O
4	O
tubes	O
were	O
not	O
because	O
of	O
adhesion	B-T047
to	O
the	O
pelvic	O
cavity	O
(	O
n	O
=	O
3	O
)	O
or	O
the	O
ovary	B-T023
and	O
intestine	B-T023
(	O
n	O
=	O
1	O
)	O
.	O
More	O
than	O
three	O
visible	O
,	O
quite	O
long	O
,	O
and	O
distributed	O
evenly	O
finger	O
-	O
like	O
projection	O
s	O
were	O
present	O
for	O
the	O
patent	O
fimbrial	B-T023
parts	I-T023
;	O
however	O
,	O
fewer	O
,	O
flat	O
,	O
and	O
not	O
evenly	O
distributed	O
finger	O
-	O
like	O
projection	O
s	O
were	O
present	O
for	O
the	O
adhesive	B-T047
tubes	I-T047
.	O
No	O
serious	O
complications	O
occurred	O
during	O
or	O
after	O
this	O
procedure	B-T060
.	O
Combination	O
of	O
3D	O
HyCoSy	B-T060
with	O
normal	O
saline	O
injected	B-T061
into	O
the	O
pelvic	O
cavity	O
may	O
be	O
a	O
feasible	O
and	O
safe	O
procedure	B-T060
to	O
assess	O
tubal	O
patency	O
and	O
adhesions	B-T047
of	I-T047
the	I-T047
fimbrial	I-T047
parts	I-T047
.	O
      
Microbiomes	B-T001
of	O
Muricea	O
californica	O
and	O
M.	O
fruticosa	O
:	O
Comparative	O
Analyses	O
of	O
Two	O
Co	O
-	O
occurring	O
Eastern	O
Pacific	O
Octocorals	O
Octocorals	O
are	O
sources	O
of	O
novel	O
but	O
understudied	O
microbial	B-T001
diversity	O
.	O
Conversely	O
,	O
scleractinian	O
or	O
reef	B-T001
-	I-T001
building	I-T001
coral	I-T001
microbiomes	I-T001
have	O
been	O
heavily	O
examined	B-T033
in	O
light	O
of	O
the	O
threats	O
of	O
climate	O
change	O
.	O
Muricea	O
californica	O
and	O
Muricea	O
fruticosa	O
are	O
two	O
co	O
-	O
occurring	O
species	O
of	O
gorgonian	O
octocoral	O
abundantly	B-T033
found	I-T033
in	O
the	O
kelp	O
forests	O
of	O
southern	O
California	O
,	O
and	O
thus	O
provide	O
an	O
excellent	O
basis	O
to	O
determine	O
if	O
octocoral	O
microbiomes	B-T001
are	O
host	B-T001
specific	O
.	O
Using	O
Illumina	O
MiSeq	O
amplicon	O
sequencing	O
and	O
replicate	O
samples	O
,	O
we	O
evaluated	O
the	O
microbiomes	B-T001
collected	O
from	O
multiple	O
colonies	O
of	O
both	O
species	O
of	O
Muricea	O
to	O
measure	O
both	O
inter-	O
and	O
intra	O
-	O
colony	O
microbiome	B-T001
variabilities	O
.	O
In	O
addition	O
,	O
microbiomes	B-T001
from	O
overlying	O
sea	O
water	O
and	O
nearby	O
zoanthids	O
(	O
another	O
benthic	O
invertebrate	O
)	O
were	O
also	O
included	O
in	O
the	O
analysis	O
to	O
evaluate	O
whether	O
bacterial	O
taxa	O
specifically	O
associate	O
with	O
octocorals	O
.	O
This	O
is	O
also	O
the	O
first	O
report	O
of	O
microbiomes	B-T001
from	O
these	O
species	O
of	O
Muricea	O
.	O
We	O
show	O
that	O
microbiomes	B-T001
isolated	O
from	O
each	O
sample	O
type	O
are	O
distinct	O
,	O
and	O
specifically	O
,	O
that	O
octocoral	O
species	O
type	O
had	O
the	O
greatest	O
effect	O
on	O
predicting	O
the	O
composition	O
of	O
the	O
Muricea	O
microbiome	B-T001
.	O
Bacterial	O
taxa	O
contributing	O
to	O
compositional	O
differences	O
include	O
distinct	O
strains	B-T001
of	O
Mycoplasma	B-T007
associated	O
with	O
either	O
M.	O
californica	O
or	O
M.	O
fruticosa	O
,	O
an	O
abundance	O
of	O
Spirochaetes	B-T007
observed	O
on	O
M.	O
californica	O
,	O
and	O
a	O
greater	O
diversity	O
of	O
γ	B-T007
-	I-T007
Proteobacteria	I-T007
associated	O
with	O
M.	O
fruticosa	O
.	O
Many	O
of	O
the	O
bacterial	O
taxa	O
contributing	O
to	O
these	O
differences	O
are	O
known	O
for	O
their	O
presence	B-T033
in	O
photosymbiont	O
-	O
containing	O
invertebrate	O
microbiomes	B-T001
.	O
      
Bioinformatic	O
Analysis	O
of	O
Codon	O
Usage	O
and	O
Phylogenetic	O
Relationships	O
in	O
Different	O
Genotypes	O
of	O
the	O
Hepatitis	B-T005
C	I-T005
Virus	I-T005
The	O
hepatitis	B-T005
C	I-T005
virus	I-T005
(	O
HCV	B-T005
)	O
has	O
six	O
major	O
genotypes	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
phylogenetically	O
investigate	O
the	O
differences	O
between	O
the	O
genotypes	O
of	O
HCV	B-T005
,	O
and	O
to	O
determine	O
the	O
types	O
of	O
amino	B-T121
acid	I-T121
codon	O
usage	O
in	O
the	O
structure	B-T017
of	I-T017
the	I-T017
virus	I-T017
in	O
order	O
to	O
discover	O
new	O
methods	O
for	O
treatment	B-T058
regimes	I-T058
.	O
The	O
codon	O
usage	O
of	O
the	O
six	O
genotypes	O
of	O
the	O
HCV	B-T005
nucleotide	O
sequence	O
was	O
investigated	O
through	O
the	O
online	O
application	O
available	O
on	O
the	O
website	O
Gene	O
Infinity	O
.	O
Also	O
,	O
phylogenetic	O
analysis	O
and	O
the	O
evolutionary	O
relationship	O
of	O
HCV	B-T005
genotypes	O
were	O
analyzed	O
with	O
MEGA	O
7	O
software	O
.	O
The	O
six	O
genotypes	O
of	O
HCV	B-T005
were	O
divided	O
into	O
two	O
groups	O
based	O
on	O
their	O
codon	O
usage	O
properties	O
.	O
In	O
the	O
first	O
group	O
,	O
genotypes	O
1	O
and	O
5	O
(	O
74.02	O
%	O
)	O
,	O
and	O
in	O
the	O
second	O
group	O
,	O
genotypes	O
2	O
and	O
6	O
(	O
72.43	O
%	O
)	O
were	O
shown	O
to	O
have	O
the	O
most	O
similarity	O
in	O
terms	O
of	O
codon	O
usage	O
.	O
Unlike	O
the	O
results	O
with	O
respect	O
to	O
determining	O
the	O
similarity	O
of	O
codon	O
usage	O
,	O
the	O
phylogenetic	O
analysis	O
showed	O
the	O
closest	O
resemblance	O
and	O
correlation	O
between	O
genotypes	O
1	O
and	O
4	O
.	O
The	O
results	O
also	O
showed	O
that	O
HCV	B-T005
has	O
a	O
GC	O
(	O
guanine	O
-	O
cytosine	O
)	O
abundant	O
genome	O
structure	O
and	O
prefers	O
codons	O
with	O
GC	O
for	O
translation	O
.	O
Genotypes	O
1	O
and	O
4	O
demonstrated	O
remarkable	O
similarity	O
in	O
terms	O
of	O
genome	O
sequences	O
and	O
proteins	O
,	O
but	O
surprisingly	O
,	O
in	O
terms	O
of	O
the	O
preferred	O
codons	O
for	O
gene	O
expression	O
,	O
they	O
showed	O
the	O
greatest	O
difference	O
.	O
More	O
studies	O
are	O
therefore	O
needed	O
to	O
confirm	O
the	O
results	O
and	O
select	O
the	O
best	O
approach	O
for	O
treatment	O
of	O
these	O
genotypes	O
based	O
on	O
their	O
codon	O
usage	O
properties	O
.	O
      
Expression	O
and	O
methylation	O
in	O
posttraumatic	B-T048
stress	I-T048
disorder	I-T048
and	O
resilience	O
;	O
evidence	O
of	O
a	O
role	O
for	O
odorant	O
receptors	O
Post	B-T048
-	I-T048
traumatic	I-T048
stress	I-T048
disorder	I-T048
(	O
PTSD	B-T048
)	O
is	O
a	O
common	O
and	O
potentially	O
disabling	B-T047
disorder	I-T047
that	O
develops	O
in	O
1/5	O
to	O
1/3	O
of	O
people	O
exposed	O
to	O
severe	O
trauma	O
.	O
Twin	O
studies	O
indicate	O
that	O
genetic	O
factors	O
account	O
for	O
at	O
least	O
one	O
third	O
of	O
the	O
variance	O
in	O
the	O
risk	O
for	O
developing	O
PTSD	B-T048
,	O
however	O
,	O
the	O
specific	O
role	O
for	O
genetic	O
factors	O
in	O
the	O
pathogenesis	O
of	O
PTSD	B-T048
is	O
not	O
well	O
understood	O
.	O
We	O
studied	O
genome	O
-	O
wide	O
gene	O
expression	O
and	O
DNA	O
methylation	O
profiles	O
in	O
12	O
participants	O
with	O
PTSD	B-T048
and	O
12	O
participants	O
who	O
were	O
resilient	O
to	O
similar	O
severity	O
trauma	O
exposure	O
.	O
Close	O
to	O
4000	O
genes	O
were	O
differentially	O
expressed	O
with	O
adjusted	O
p<0.05	O
,	O
fold	O
-	O
change	O
>	O
2	O
,	O
with	O
all	O
but	O
3	O
upregulated	O
with	O
PTSD	B-T048
.	O
Eight	O
odorant	O
/	O
olfactory	O
receptor	O
related	O
genes	O
were	O
up	O
-	O
regulated	O
with	O
PTSD	B-T048
as	O
well	O
as	O
genes	O
related	O
to	O
immune	O
activation	O
,	O
the	O
Gamma	O
-	O
Aminobutyric	O
Acid	O
A	O
(	O
GABAA	O
)	O
receptor	O
,	O
and	O
vitamin	O
D	O
synthesis	O
.	O
No	O
differences	O
with	O
adjusted	O
significance	O
for	O
DNA	O
methylation	O
were	O
found	O
.	O
We	O
conclude	O
that	O
increased	O
gene	O
expression	O
may	O
play	O
an	O
important	O
role	O
in	O
PTSD	B-T048
and	O
this	O
expression	O
may	O
not	O
be	O
a	O
consequence	O
of	O
DNA	O
methylation	O
.	O
The	O
role	O
of	O
odorant	O
receptor	O
expression	O
warrants	O
independent	O
replication	O
.	O
      
An	O
Inhibitory	O
Septum	O
to	O
Lateral	O
Hypothalamus	O
Circuit	O
That	O
Suppresses	O
Feeding	O
Feeding	O
behavior	O
is	O
orchestrated	O
by	O
neural	O
circuits	O
primarily	O
residing	O
in	O
the	O
hypothalamus	B-T023
and	O
hindbrain	B-T023
.	O
However	O
,	O
the	O
relative	O
influence	O
of	O
cognitive	O
and	O
emotional	O
brain	O
circuits	O
to	O
the	O
feeding	O
circuitry	O
in	O
the	O
hypothalamus	B-T023
and	O
hindbrain	B-T023
remains	O
unclear	B-T033
.	O
Here	O
,	O
using	O
the	O
cell	O
-	O
type	O
selectivity	O
of	O
genetic	O
methods	O
,	O
circuit	B-T060
mapping	I-T060
,	O
and	O
behavior	O
assays	B-T059
,	O
we	O
sought	O
to	O
decipher	O
neural	O
circuits	O
emanating	O
from	O
the	O
septal	B-T023
nucleus	I-T023
to	O
the	O
lateral	O
hypothalamus	O
(	O
LH	O
)	O
that	O
contribute	O
to	O
neural	O
regulation	O
of	O
food	O
intake	O
in	O
mice	O
.	O
We	O
found	O
that	O
chemogenetic	O
and	O
optogenetic	O
activation	O
of	O
septal	O
vesicular	O
GABA	O
transporter	O
(	O
vGAT)-	O
containing	O
neurons	O
or	O
their	O
projections	O
in	O
the	O
LH	O
reduced	O
food	O
intake	O
in	O
mice	O
.	O
Consistently	O
,	O
chemogenetic	O
inhibition	O
of	O
septal	O
vGAT	O
neurons	O
increased	O
food	O
intake	O
.	O
Furthermore	O
,	O
we	O
investigated	O
a	O
previously	O
unknown	O
neural	O
circuit	O
originating	O
from	O
septal	O
vGAT	O
neurons	O
to	O
a	O
subset	O
of	O
vGAT	O
neurons	O
in	O
the	O
LH	O
,	O
an	O
area	O
involved	O
in	O
homeostatic	O
and	O
hedonic	O
control	O
of	O
energy	B-T033
states	I-T033
.	O
Collectively	O
,	O
our	O
data	O
reveal	O
an	O
inhibitory	O
septohypothalamic	O
feeding	O
circuit	O
that	O
might	O
serve	O
as	O
a	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
eating	B-T048
disorders	I-T048
such	O
as	O
anorexia	B-T048
nervosa	I-T048
.	O
Our	O
results	O
demonstrate	O
that	O
top	O
-	O
down	O
projections	O
from	O
the	O
septum	O
to	O
the	O
hypothalamus	B-T023
control	O
food	O
intake	O
negatively	B-T033
.	O
Given	O
the	O
known	O
role	O
for	O
both	O
of	O
these	O
brain	O
regions	O
in	O
the	O
control	O
of	O
feeding	O
and	O
emotion	O
-	O
related	O
behaviors	O
,	O
these	O
findings	B-T033
reveal	O
previously	O
unknown	O
neural	O
circuitry	O
that	O
is	O
likely	O
implicated	O
in	O
emotional	O
aspects	O
of	O
food	O
intake	O
and	O
provide	O
new	O
insights	O
into	O
the	O
development	O
of	O
therapeutic	O
targets	O
for	O
the	O
treatment	O
of	O
eating	B-T048
disorders	I-T048
.	O
      
A	O
Practical	O
Guide	O
to	O
Forensic	O
Nursing	O
:	O
Incorporating	O
forensic	O
principles	O
into	O
nursing	B-T058
practice	I-T058
Amar	O
Angela	O
F	O
and	O
Sekula	O
L	O
Kathleen	O
A	O
Practical	O
Guide	O
to	O
Forensic	O
Nursing	O
:	O
Incorporating	O
forensic	O
principles	O
into	O
nursing	B-T058
practice	I-T058
392pp	O
US$	O
59.95	O
Sigma	O
Theta	O
Tau	O
International	O
Honor	O
Society	O
of	O
Nursing	O
9781940446349	O
1940446341	O
[	O
Formula	O
:	O
see	O
text	O
George	O
Bernard	O
Shaw	O
described	O
Britons	O
and	O
Americans	O
as	O
'	O
divided	O
by	O
a	O
common	O
language	O
'	O
,	O
and	O
that	O
is	O
made	O
very	O
clear	O
in	O
this	O
fascinating	O
publication	O
that	O
describes	O
in	O
depth	O
the	O
roles	O
and	O
responsibilities	O
of	O
forensic	O
nurses	O
in	O
the	O
US	O
.	O
      
Soymilk	O
residue	O
(	O
okara	O
)	O
as	O
a	O
natural	O
immobilization	O
carrier	O
for	O
Lactobacillus	B-T007
plantarum	I-T007
cells	O
enhances	O
soymilk	O
fermentation	O
,	O
glucosidic	B-T121
isoflavone	I-T121
bioconversion	O
,	O
and	O
cell	O
survival	O
under	O
simulated	O
gastric	O
and	O
intestinal	B-T023
conditions	O
Cell	O
immobilization	O
is	O
an	O
alternative	O
to	O
microencapsulation	B-T061
for	O
the	O
maintenance	O
of	O
cells	O
in	O
a	O
liquid	O
medium	O
.	O
However	O
,	O
artificial	O
immobilization	O
carriers	O
are	O
expensive	O
and	O
pose	O
a	O
high	O
safety	O
risk	O
.	O
Okara	O
,	O
a	O
food	O
-	O
grade	O
byproduct	O
from	O
soymilk	O
production	O
,	O
is	O
rich	O
in	O
prebiotics	O
.	O
Lactobacilli	B-T007
could	O
provide	O
health	O
enhancing	O
effects	O
to	O
the	O
host	B-T001
.	O
This	O
study	O
aimed	O
to	O
evaluate	O
the	O
potential	O
of	O
okara	O
as	O
a	O
natural	O
immobilizer	O
for	O
L.	O
plantarum	O
70810	O
cells	O
.	O
The	O
study	O
also	O
aimed	O
to	O
evaluate	O
the	O
effects	O
of	O
okara	O
-	O
immobilized	O
L.	O
plantarum	O
70810	O
cells	O
(	O
IL	O
)	O
on	O
soymilk	O
fermentation	O
,	O
glucosidic	B-T121
isoflavone	I-T121
bioconversion	O
,	O
and	O
cell	O
resistance	O
to	O
simulated	O
gastric	O
and	O
intestinal	B-T023
stresses	O
.	O
Scanning	B-T059
electron	I-T059
microscopy	I-T059
(	O
SEM	B-T059
)	O
was	O
used	O
to	O
show	O
cells	O
adherence	O
to	O
the	O
surface	O
of	O
okara	O
.	O
Lactic	B-T121
acid	I-T121
,	O
acetic	B-T121
acid	I-T121
and	O
isoflavone	B-T121
analyses	O
in	O
unfermented	O
and	O
fermented	O
soymilk	O
were	O
performed	O
by	O
HPLC	B-T059
with	I-T059
UV	I-T059
detection	I-T059
.	O
Viability	O
and	O
growth	O
kinetics	O
of	O
immobilized	O
and	O
free	O
L.	O
plantarum	O
70810	O
cells	O
(	O
FL	O
)	O
were	O
followed	O
during	O
soymilk	O
fermentation	O
.	O
Moreover	O
,	O
changes	O
in	O
pH	O
,	O
titrable	O
acidity	O
and	O
viscosity	O
were	O
measured	O
by	O
conventional	O
methods	O
.	O
For	O
in	O
vitro	O
testing	O
of	O
simulated	O
gastrointestinal	O
resistance	O
,	O
fermented	O
soymilk	O
was	O
inoculated	B-T061
with	O
FL	O
or	O
IL	O
and	O
an	O
aliquot	O
incubated	B-T059
into	O
acidic	O
MRS	O
broth	O
which	O
was	O
conveniently	O
prepared	O
to	O
simulate	O
gastric	O
,	O
pancreatic	O
juices	O
and	O
bile	O
salts	O
.	O
Survival	O
to	O
simulated	O
gastric	O
and	O
intestinal	B-T023
stresses	O
was	O
evaluated	O
by	O
plate	B-T059
count	I-T059
of	I-T059
colony	I-T059
forming	I-T059
units	I-T059
on	O
MRS	O
agar	O
.	O
SEM	B-T059
revealed	O
that	O
the	O
lactobacilli	B-T007
cells	O
attached	O
and	O
bound	O
to	O
the	O
surface	O
of	O
okara	O
.	O
Compared	O
with	O
FL	O
,	O
IL	O
exhibited	O
a	O
significantly	O
higher	O
specific	O
growth	O
rate	O
,	O
shorter	O
lag	O
phase	O
of	O
growth	O
,	O
higher	O
productions	O
of	O
lactic	B-T121
and	O
acetic	B-T121
acids	I-T121
,	O
a	O
faster	O
decrease	O
in	O
pH	O
and	O
increase	O
in	O
titrable	O
acidity	O
,	O
and	O
a	O
higher	O
soymilk	O
viscosity	O
.	O
Similarly	O
,	O
IL	O
in	O
soymilk	O
showed	O
higher	O
productions	O
of	O
daizein	B-T121
and	O
genistein	B-T121
compared	O
with	O
the	O
control	O
.	O
Compared	O
with	O
FL	O
,	O
IL	O
showed	O
reinforced	O
resistance	O
to	O
simulatedgastric	O
and	O
intestinal	B-T023
stresses	O
in	O
vitro	O
that	O
included	O
low	B-T033
pH	I-T033
,	O
low	B-T033
pH	I-T033
plus	I-T033
pepsin	O
,	O
pancreatin	B-T121
,	O
and	O
bile	O
salt	O
.	O
Our	O
results	O
indicate	O
that	O
okara	O
is	O
a	O
new	O
potential	O
immobilization	O
carrier	O
to	O
enhance	O
the	O
growth	O
and	O
glucosidic	B-T121
isoflavone	I-T121
bioconversion	O
activities	O
of	O
L.	B-T007
plantarum	I-T007
in	O
soymilk	O
and	O
improve	B-T033
cell	O
survivability	O
following	O
simulated	O
gastric	O
and	O
intestinal	B-T023
conditions	O
.	O
      
Systematic	O
mapping	O
of	O
functional	O
enhancer	O
-	O
promoter	O
connections	O
with	O
CRISPR	B-T059
interference	I-T059
Gene	O
expression	O
in	O
mammals	O
is	O
regulated	O
by	O
noncoding	O
elements	O
that	O
can	O
affect	O
physiology	O
and	O
disease	B-T047
,	O
yet	O
the	O
functions	O
and	O
target	O
genes	O
of	O
most	O
noncoding	O
elements	O
remain	O
unknown	O
.	O
We	O
present	O
a	O
high	O
-	O
throughput	O
approach	O
that	O
uses	O
clustered	B-T059
regularly	I-T059
interspaced	I-T059
short	I-T059
palindromic	I-T059
repeats	I-T059
(	I-T059
CRISPR	I-T059
)	I-T059
interference	I-T059
(	O
CRISPRi	B-T059
)	O
to	O
discover	O
regulatory	O
elements	O
and	O
identify	O
their	O
target	O
genes	O
.	O
We	O
assess	B-T058
>	O
1	O
megabase	O
of	O
sequence	O
in	O
the	O
vicinity	O
of	O
two	O
essential	O
transcription	O
factors	O
,	O
MYC	O
and	O
GATA1	O
,	O
and	O
identify	O
nine	O
distal	O
enhancers	O
that	O
control	O
gene	O
expression	O
and	O
cellular	O
proliferation	O
.	O
Quantitative	O
features	O
of	O
chromatin	O
state	O
and	O
chromosome	O
conformation	B-T033
distinguish	O
the	O
seven	O
enhancers	O
that	O
regulate	O
MYC	O
from	O
other	O
elements	O
that	O
do	O
not	O
,	O
suggesting	O
a	O
strategy	O
for	O
predicting	O
enhancer	O
-	O
promoter	O
connectivity	O
.	O
This	O
CRISPRi	B-T059
-based	O
approach	O
can	O
be	O
applied	O
to	O
dissect	O
transcriptional	O
networks	O
and	O
interpret	O
the	O
contributions	O
of	O
noncoding	O
genetic	O
variation	O
to	O
human	O
disease	B-T047
.	O
      
Epidemiological	O
patterns	O
of	O
bovine	O
besnoitiosis	B-T047
in	O
an	O
endemic	O
beef	O
cattle	O
herd	O
reared	O
under	O
extensive	O
conditions	O
Bovine	O
besnoitiosis	B-T047
is	O
a	O
parasitic	B-T047
disease	I-T047
caused	O
by	O
the	O
protozoan	O
Besnoitia	O
besnoiti	O
.	O
Described	O
many	O
decades	O
ago	O
,	O
recent	O
epidemiological	O
studies	O
reveal	O
its	O
important	O
spread	O
within	O
Europe	O
in	O
the	O
last	O
years	O
.	O
To	O
date	O
,	O
many	O
epidemiological	O
aspects	O
related	O
to	O
life	O
cycle	O
,	O
routes	O
of	O
transmission	O
,	O
incidence	O
rates	O
and	O
associated	O
risk	B-T033
factors	I-T033
are	O
lacking	O
;	O
hence	O
,	O
the	O
establishment	O
of	O
appropriate	B-T058
disease	I-T058
control	I-T058
programmes	O
poses	O
an	O
important	O
challenge	O
.	O
Thus	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
epidemiological	O
pattern	O
of	O
the	O
disease	B-T047
in	O
an	O
endemic	O
herd	O
reared	O
under	O
extensive	O
conditions	O
(	O
Spanish	O
Pyrenees	O
)	O
by	O
identifying	O
main	O
factors	O
associated	O
with	O
infection	O
and	O
clinical	B-T047
disease	I-T047
dynamics	O
.	O
The	O
study	O
population	O
consisted	O
of	O
276	O
Brown	O
Swiss	O
and	O
Pirenaica	O
adult	O
animals	O
and	O
145	O
calves	O
born	O
and	O
weaned	B-T033
at	O
the	O
farm	O
during	O
the	O
study	O
.	O
Three	O
sampling	O
time	O
frames	O
were	O
used	O
:	O
January	O
2010	O
,	O
September	O
2010	O
and	O
February	O
2011	O
,	O
which	O
allowed	O
us	O
to	O
differentiate	O
two	O
periods	O
designated	O
as	O
mountain	O
and	O
valley	O
periods	O
.	O
The	O
data	O
related	O
to	O
animals	O
(	O
breed	O
,	O
sex	O
and	O
age	O
)	O
and	O
herd	O
management	O
(	O
animal	O
grouping	O
and	O
time	O
in	O
housing	O
)	O
were	O
recorded	O
.	O
The	O
data	O
collection	O
methodology	O
was	O
mainly	O
based	O
on	O
clinical	B-T033
examinations	I-T033
and	O
defining	O
the	O
serological	O
status	O
against	O
bovine	O
besnoitiosis	B-T047
by	O
the	O
immunofluorescent	B-T059
antibody	I-T059
testing	I-T059
of	O
blood	O
samples	O
.	O
The	O
total	O
prevalence	O
among	O
adult	O
animals	O
was	O
38.34	O
%	O
(	O
CI	O
95	O
%	O
:	O
34.53	O
-	O
42.07	O
)	O
,	O
with	O
18.54	O
%	O
of	O
seropositive	O
animals	O
showing	O
clinical	O
signs	O
.	O
In	O
regard	O
to	O
the	O
cumulative	O
incidence	O
,	O
34.57	O
%	O
of	O
new	O
infections	O
were	O
detected	B-T033
during	O
the	O
mountain	O
period	O
,	O
in	O
contrast	O
to	O
the	O
24.59	O
%	O
observed	O
in	O
the	O
valley	O
period	O
.	O
The	O
incidence	O
density	O
was	O
0.058	O
and	O
0.061	O
new	O
infections	O
per	O
animal	O
-	O
month	O
for	O
the	O
mountain	O
and	O
valley	O
periods	O
,	O
respectively	O
.	O
According	O
to	O
the	O
seroepidemiological	O
study	O
,	O
the	O
seroconversion	O
probability	O
of	O
B.	O
besnoiti	O
infection	O
was	O
directly	O
associated	O
with	O
the	O
number	O
of	O
seropositive	O
cows	O
with	O
whom	O
an	O
animal	O
had	O
been	O
stabled	O
as	O
well	O
as	O
the	O
housing	O
period	O
duration	O
,	O
supporting	O
horizontal	O
transmission	O
by	O
close	O
contact	O
as	O
one	O
of	O
the	O
most	O
important	O
methods	O
of	O
disease	B-T047
spread	O
.	O
In	O
addition	O
,	O
the	O
risk	O
of	O
developing	O
the	O
clinical	O
course	O
increased	O
with	O
age	O
,	O
and	O
the	O
presence	B-T033
of	O
clinical	B-T033
signs	I-T033
was	O
related	O
to	O
higher	O
antibody	O
responses	O
.	O
Among	O
calves	O
(	O
from	O
3.1	O
to	O
7.1	O
months	O
old	O
)	O
sampled	O
once	O
at	O
weaning	B-T033
,	O
the	O
total	O
seroprevalence	O
was	O
15.17	O
%	O
(	O
CI	O
95	O
%	O
:	O
9.36	O
-	O
21.04	O
)	O
,	O
and	O
the	O
chronic	O
stage	O
was	O
observed	O
in	O
three	O
animals	O
,	O
supporting	O
the	O
ability	O
of	O
B.	O
besnoiti	O
to	O
infect	O
and	O
even	O
cause	O
disease	B-T047
in	O
animals	O
less	O
than	O
6	O
months	O
old	O
.	O
Finally	O
,	O
the	O
risk	O
of	O
calf	O
seroconversion	O
was	O
positively	O
related	O
to	O
the	O
serological	O
status	O
of	O
the	O
cows	O
,	O
suggesting	O
postnatal	O
transmission	O
between	O
dams	O
and	O
offspring	O
by	O
contact	O
during	O
the	O
suckling	O
period	O
.	O
      
Barriers	O
to	O
access	O
and	O
uptake	O
of	O
antiretroviral	B-T061
therapy	I-T061
among	O
HIV	O
-	O
positive	O
men	O
who	O
have	O
sex	O
with	O
men	O
in	O
Hanoi	O
,	O
Vietnam	O
:	O
from	O
HIV	B-T059
testing	I-T059
to	O
treatment	B-T061
Little	O
is	O
known	O
about	O
the	O
experiences	O
of	O
Vietnamese	O
men	O
who	O
have	O
sex	O
with	O
men	O
in	O
accessing	O
HIV	B-T059
testing	I-T059
and	O
treatment	B-T061
.	O
We	O
aimed	O
to	O
explore	O
barriers	O
to	O
access	O
and	O
uptake	O
of	O
antiretroviral	B-T061
therapy	I-T061
(	O
ART	B-T061
)	O
among	O
HIV	O
-	O
positive	O
men	O
who	O
have	O
sex	O
with	O
men	O
in	O
Hanoi	O
.	O
During	O
2015	O
,	O
we	O
conducted	O
qualitative	O
interviews	O
with	O
35	O
participants	O
recruited	O
using	O
snowball	O
sampling	O
based	O
on	O
previous	O
research	O
and	O
social	O
networks	O
.	O
Key	O
individual	O
impediments	O
to	O
ART	B-T061
uptake	O
included	O
inadequate	O
preparation	O
for	O
a	O
positive	B-T033
diagnosis	B-T033
and	O
the	O
dual	O
stigmatisation	O
of	O
homosexuality	O
and	O
HIV	B-T005
and	O
its	O
consequences	O
,	O
leading	O
to	O
fear	O
of	O
disclosure	O
of	O
HIV	B-T033
status	I-T033
.	O
Health	O
system	O
barriers	O
included	O
lack	O
of	O
clarity	O
and	O
consistency	O
about	O
how	O
to	O
register	O
for	O
and	O
access	O
ART	B-T061
,	O
failure	O
to	O
protect	O
patient	O
confidentiality	O
and	O
a	O
reticence	O
by	O
providers	O
to	O
discuss	O
sexual	O
identity	O
and	O
same	O
-	O
sex	O
issues	O
.	O
Results	O
suggest	O
fundamental	O
problems	O
in	O
the	O
way	O
HIV	B-T059
testing	I-T059
is	O
currently	O
delivered	O
in	O
Hanoi	O
,	O
including	O
a	O
lack	O
of	O
client	O
-	O
centred	O
counselling	B-T058
,	O
peer	B-T061
support	I-T061
and	O
clear	B-T058
referral	I-T058
pathways	O
.	O
Overcoming	O
these	O
barriers	O
will	O
require	O
educating	O
men	O
who	O
have	O
sex	O
with	O
men	O
about	O
the	O
benefits	O
of	O
routine	B-T060
testing	I-T060
,	O
improving	O
access	O
to	O
quality	O
diagnostic	B-T058
services	I-T058
and	O
building	O
a	O
safe	O
,	O
confidential	B-T033
treatment	B-T061
environment	O
for	O
HIV	O
-	O
positive	O
men	O
to	O
access	O
,	O
receive	O
and	O
remain	O
in	O
care	O
.	O
      
Costing	O
'	O
healthy	O
'	O
food	O
baskets	O
in	O
Australia	O
-	O
a	O
systematic	O
review	O
of	O
food	O
price	O
and	O
affordability	O
monitoring	O
tools	O
,	O
protocols	O
and	O
methods	O
To	O
undertake	O
a	O
systematic	O
review	O
to	O
determine	O
similarities	O
and	O
differences	O
in	O
metrics	O
and	O
results	O
between	O
recently	O
and/or	O
currently	O
used	O
tools	O
,	O
protocols	O
and	O
methods	O
for	O
monitoring	B-T058
Australian	O
healthy	O
food	O
prices	O
and	O
affordability	O
.	O
Electronic	O
databases	O
of	O
peer	O
-	O
reviewed	O
literature	O
and	O
online	O
grey	O
literature	O
were	O
systematically	O
searched	O
using	O
the	O
PRISMA	O
approach	O
for	O
articles	O
and	O
reports	O
relating	O
to	O
healthy	O
food	O
and	O
diet	O
price	O
assessment	O
tools	O
,	O
protocols	O
,	O
methods	O
and	O
results	O
that	O
utilised	O
retail	O
pricing	O
.	O
National	O
,	O
state	O
,	O
regional	O
and	O
local	O
areas	O
of	O
Australia	O
from	O
1995	O
to	O
2015	O
.	O
Assessment	O
tools	O
,	O
protocols	O
and	O
methods	O
to	O
measure	O
the	O
price	O
of	O
'	O
healthy	O
'	O
foods	O
and	O
diets	O
.	O
The	O
search	O
identified	O
fifty	O
-	O
nine	O
discrete	O
surveys	O
of	O
'	O
healthy	O
'	O
food	O
pricing	O
incorporating	O
six	O
major	O
food	O
pricing	O
tools	O
(	O
those	O
used	O
in	O
multiple	O
areas	O
and	O
time	O
periods	O
)	O
and	O
five	O
minor	O
food	O
pricing	O
tools	O
(	O
those	O
used	O
in	O
a	O
single	O
survey	O
area	O
or	O
time	O
period	O
)	O
.	O
Analysis	O
demonstrated	O
methodological	O
differences	O
regarding	O
:	O
included	O
foods	O
;	O
reference	O
households	O
;	O
use	O
of	O
availability	O
and/or	O
quality	O
measures	O
;	O
household	B-T033
income	I-T033
sources	B-T033
;	O
store	O
sampling	O
methods	O
;	O
data	O
collection	O
protocols	O
;	O
analysis	O
methods	O
;	O
and	O
results	O
.	O
'	O
Healthy	O
'	O
food	O
price	O
assessment	O
methods	O
used	O
in	O
Australia	O
lack	O
comparability	O
across	O
all	O
metrics	O
and	O
most	O
do	O
not	O
fully	O
align	O
with	O
a	O
'	O
healthy	O
'	O
diet	O
as	O
recommended	O
by	O
the	O
current	O
Australian	O
Dietary	O
Guidelines	O
.	O
None	O
have	O
been	O
applied	O
nationally	O
.	O
Assessment	O
of	O
the	O
price	O
,	O
price	O
differential	O
and	O
affordability	O
of	O
healthy	B-T061
(	O
recommended	O
)	O
and	O
current	O
(	O
unhealthy	O
)	O
diets	O
would	O
provide	O
more	O
robust	O
and	O
meaningful	O
data	O
to	O
inform	O
health	O
and	O
fiscal	O
policy	O
in	O
Australia	O
.	O
The	O
INFORMAS	O
'	O
optimal	O
'	O
approach	O
provides	O
a	O
potential	O
framework	O
for	O
development	O
of	O
these	O
methods	O
.	O
      
Gut	B-T001
microbiome	I-T001
alterations	O
in	O
patients	O
with	O
stage	O
4	O
hepatitis	B-T047
C	I-T047
Hepatitis	B-T005
C	I-T005
virus	I-T005
(	O
HCV	B-T005
)	O
causes	O
debilitating	O
liver	B-T047
diseases	I-T047
,	O
which	O
may	O
progress	O
to	O
cirrhosis	B-T047
and	O
cancer	B-T191
,	O
and	O
claims	O
500,000	O
annual	O
lives	O
worldwide	O
.	O
While	O
HCV	B-T005
epidemiology	O
,	O
pathophysiology	O
,	O
and	O
therapy	O
are	O
being	O
deeply	O
studied	O
,	O
rare	O
attention	O
is	O
given	O
to	O
reciprocal	O
interactions	O
between	O
HCV	B-T047
infection	I-T047
,	O
HCV	B-T005
-induced	O
chronic	B-T047
liver	I-T047
diseases	I-T047
,	O
and	O
the	O
human	O
gut	B-T001
microbiome	I-T001
.	O
As	O
Egypt	O
has	O
the	O
world	O
's	O
highest	O
prevalence	O
of	O
HCV	B-T047
infections	I-T047
,	O
we	O
launched	O
this	O
study	O
to	O
monitor	O
differences	O
in	O
the	O
gut	B-T001
microbial	I-T001
community	I-T001
composition	O
of	O
Egyptian	O
HCV	B-T005
patients	O
that	O
may	O
affect	O
,	O
or	O
result	O
from	O
,	O
the	O
patients	O
'	O
liver	B-T023
state	O
.	O
To	O
this	O
end	O
,	O
we	O
analyzed	O
stool	O
samples	O
from	O
six	O
stage	O
4	O
-	O
HCV	B-T005
patients	O
and	O
eight	O
healthy	O
individuals	O
by	O
high	B-T060
-	I-T060
throughput	I-T060
16S	B-T059
rRNA	I-T059
gene	I-T059
sequencing	I-T059
using	O
Illumina	O
MiSeq	O
.	O
Overall	O
,	O
the	O
alpha	O
-	O
diversity	O
of	O
the	O
healthy	O
persons	O
'	O
gut	B-T001
microbiomes	I-T001
was	O
higher	O
than	O
those	O
of	O
the	O
HCV	B-T005
patients	O
.	O
Whereas	O
members	O
of	O
phylum	B-T007
Bacteroidetes	I-T007
were	O
more	O
abundant	O
in	O
HCV	B-T005
patients	O
,	O
healthy	O
individuals	O
had	O
higher	O
abundance	O
of	O
Firmicutes	B-T007
,	O
Proteobacteria	B-T007
,	O
and	O
Actinobacteria	B-T007
.	O
Genus	O
-level	O
analysis	O
showed	O
differential	O
abundance	O
of	O
Prevotella	B-T007
and	O
Faecalibacterium	B-T007
(	O
higher	O
in	O
HCV	B-T005
patients	O
)	O
vs.	O
Ruminococcus	B-T007
and	O
Clostridium	B-T007
(	O
healthy	O
group	O
)	O
,	O
indicating	O
that	O
the	O
higher	O
abundance	O
of	O
Bacteroidetes	B-T007
in	O
HCV	B-T005
patients	O
is	O
most	O
likely	O
due	O
to	O
Prevotella	B-T007
overabundance	O
.	O
The	O
probiotic	B-T007
genus	I-T007
,	O
Bifidobacterium	B-T007
,	O
was	O
only	O
observed	O
in	O
the	O
microbiotas	B-T001
of	O
healthy	O
individuals	O
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
study	O
provides	O
a	O
first	O
overview	O
of	O
major	O
phyla	O
and	O
genera	O
differentiating	O
stage	O
4	O
-	O
HCV	B-T005
patients	O
from	O
healthy	O
individuals	O
and	O
suggests	O
possible	O
microbiome	B-T001
remodeling	O
in	O
chronic	B-T047
hepatitis	I-T047
C	I-T047
,	O
possibly	O
shaped	O
by	O
bacterial	O
translocation	O
as	O
well	O
as	O
the	O
liver	B-T023
's	I-T023
impaired	B-T033
role	I-T033
in	O
digestion	O
and	O
protein	O
synthesis	O
.	O
Future	O
studies	O
will	O
investigate	O
the	O
microbiome	B-T001
composition	O
and	O
functional	O
capabilities	O
in	O
more	O
patients	O
while	O
tracing	O
some	O
potential	O
biomarker	O
taxa	O
(	O
e.g.	O
,	O
Prevotella	B-T007
,	O
Faecalibacterium	B-T007
vs.	O
Bifidobacterium	B-T007
)	O
.	O
      
Untypeable	O
hepatitis	B-T005
C	I-T005
virus	I-T005
subtypes	O
in	O
Pakistan	O
:	O
A	O
neglected	O
section	O
Diagnostically	O
untypeable	O
subtypes	O
contribute	O
a	O
considerable	O
percent	O
of	O
hepatitis	B-T005
C	I-T005
virus	I-T005
(	O
HCV	B-T005
)	O
subtypes	O
in	O
Pakistan	O
.	O
In	O
the	O
present	O
study	O
,	O
chronically	B-T047
infected	I-T047
HCV	B-T005
patients	O
with	O
known	O
viremia	B-T047
were	O
subjected	O
to	O
HCV	B-T005
genotyping	B-T059
.	O
Among	O
the	O
total	O
retrieved	O
samples	O
,	O
92.7	O
%	O
(	O
64/69	O
)	O
were	O
found	O
typeable	O
while	O
7.24	O
%	O
(	O
5/69	O
)	O
were	O
diagnostically	O
untypeable	O
.	O
In	O
conclusion	O
,	O
the	O
presence	O
of	O
large	O
number	O
of	O
untypeable	O
HCV	B-T005
subtypes	O
emphasizes	O
the	O
need	O
of	O
an	O
updated	O
type	O
-	O
specific	O
genotyping	B-T059
assay	B-T059
and	O
consideration	O
of	O
primers	O
for	O
proportionally	O
rare	O
subtypes	O
to	O
minimize	O
the	O
number	O
of	O
untypeable	O
HCV	B-T005
subtypes	O
.	O
      
Testing	O
the	O
Ret	O
and	O
Sema3d	O
genetic	O
interaction	O
in	O
mouse	O
enteric	O
nervous	O
system	O
development	O
For	O
most	O
multigenic	B-T047
disorders	I-T047
,	O
clinical	O
manifestation	O
(	O
penetrance	O
)	O
and	O
presentation	O
(	O
expressivity	O
)	O
are	O
likely	O
to	O
be	O
an	O
outcome	O
of	O
genetic	O
interaction	O
between	O
multiple	O
susceptibility	O
genes	O
.	O
Here	O
,	O
using	O
gene	O
knockouts	O
in	O
mice	O
we	O
evaluated	O
genetic	O
interaction	O
between	O
loss	O
of	O
Ret	O
and	O
loss	O
of	O
Sema3d	O
,	O
two	O
Hirschsprung	B-T019
disease	I-T019
susceptibility	O
genes	O
.	O
We	O
intercrossed	O
Ret	O
and	O
Sema3d	O
double	O
null	O
heterozygotes	O
to	O
generate	O
mice	O
with	O
the	O
nine	O
possible	O
genotypes	O
and	O
assessed	O
survival	O
by	O
counting	B-T059
various	I-T059
genotypes	I-T059
,	O
myenteric	B-T023
plexus	I-T023
presence	O
by	O
acetylcholinesterase	B-T059
staining	I-T059
and	O
embryonic	O
day	O
12.5	O
(	O
E12.5	O
)	O
intestine	O
transcriptome	O
by	O
RNA	O
-	O
sequencing	O
.	O
Survival	O
rates	O
of	O
Ret	O
wildtype	O
,	O
null	O
heterozygote	O
and	O
null	O
homozygote	O
mice	O
at	O
E12.5	O
,	O
birth	O
and	O
weaning	B-T033
were	O
not	O
influenced	O
by	O
the	O
genotypes	O
at	O
Sema3d	O
locus	O
and	O
vice	O
-	O
versa	O
.	O
Loss	O
of	O
myenteric	B-T023
plexus	I-T023
was	O
observed	O
only	O
in	O
all	O
Ret	O
null	O
homozygotes	O
,	O
irrespective	O
of	O
the	O
genotypes	O
at	O
Sema3d	O
locus	O
,	O
and	O
Sema3d	O
null	O
heterozygote	O
and	O
homozygote	O
mice	O
had	O
normal	O
intestinal	O
innervation	O
.	O
As	O
compared	O
to	O
wildtype	O
mice	O
intestinal	O
gene	O
expression	O
,	O
loss	O
of	O
Ret	O
in	O
null	O
homozygotes	O
led	O
to	O
differential	O
expression	O
of	O
∼300	O
genes	O
,	O
whereas	O
loss	O
of	O
Sema3d	O
in	O
null	O
homozygotes	O
had	O
no	O
major	O
consequence	O
and	O
there	O
was	O
no	O
evidence	O
supporting	O
major	O
interaction	O
between	O
the	O
two	O
genes	O
influencing	O
intestine	O
transcriptome	O
.	O
Overall	O
,	O
given	O
the	O
null	O
alleles	O
and	O
phenotypic	B-T059
assays	I-T059
used	O
,	O
we	O
did	O
not	O
find	O
evidence	O
for	O
genetic	O
interaction	O
between	O
Ret	O
and	O
Sema3d	O
affecting	O
survival	O
,	O
presence	O
of	O
myenteric	B-T023
plexus	I-T023
or	O
intestine	O
transcriptome	O
.	O
      
A	O
quasi	O
-	O
experimental	O
study	O
of	O
a	O
reminiscence	B-T061
program	I-T061
focused	O
on	O
autobiographical	O
memory	O
in	O
institutionalized	O
older	O
adults	O
with	O
cognitive	B-T048
impairment	I-T048
Working	O
with	O
past	O
memories	O
through	O
reminiscence	B-T061
interventions	I-T061
has	O
been	O
practiced	O
for	O
several	O
decades	O
with	O
successful	O
outcomes	O
on	O
mental	O
health	O
in	O
older	O
adults	O
.	O
Few	O
studies	O
however	O
have	O
focused	O
on	O
autobiographical	O
memory	O
recall	O
in	O
older	O
individuals	O
with	O
cognitive	B-T048
impairment	I-T048
.	O
This	O
study	O
aims	O
to	O
analyze	O
the	O
impact	O
of	O
an	O
individual	O
reminiscence	B-T061
program	I-T061
in	O
a	O
group	O
of	O
older	O
persons	O
with	O
cognitive	O
decline	O
living	O
in	O
nursing	O
homes	O
on	O
the	O
dimensions	O
of	O
cognition	O
,	O
autobiographical	O
memory	O
,	O
mood	O
,	O
behavior	O
and	O
anxiety	B-T048
.	O
A	O
two	O
-	O
group	O
pre	O
-	O
test	O
and	O
post	O
-	O
test	O
design	O
with	O
single	B-T058
blinded	I-T058
assessment	I-T058
was	O
conducted	O
.	O
Forty	O
-	O
one	O
participants	O
were	O
randomized	O
to	O
an	O
experimental	O
group	O
(	O
n=20	O
)	O
and	O
a	O
control	O
group	O
(	O
n=21	O
)	O
.	O
The	O
first	O
group	O
attended	O
five	O
weekly	O
individual	O
reminiscence	O
sessions	O
.	O
Changes	O
in	O
the	O
outcome	O
measures	O
were	O
examined	B-T033
for	O
cognition	O
(	O
Montreal	O
Cognitive	O
Assessment	O
;	O
Autobiographical	O
Memory	O
Test	O
)	O
,	O
behavior	O
(	O
Alzheimer	O
Disease	O
Assessment	O
Subscale	O
Non	O
-	O
Cog	O
)	O
and	O
emotional	B-T033
status	I-T033
(	O
Cornell	O
Scale	O
for	O
Depression	O
in	O
Dementia	B-T048
;	O
Geriatric	O
Depression	O
Scale	O
,	O
and	O
Geriatric	O
Anxiety	O
Inventory	O
)	O
.	O
Participants	O
attending	O
reminiscence	O
sessions	O
exhibited	O
better	O
outcomes	O
compared	O
to	O
the	O
control	O
group	O
in	O
cognition	O
,	O
anxiety	B-T048
and	O
depression	B-T048
(	O
p<0.001	O
)	O
,	O
and	O
presented	O
a	O
higher	O
number	O
of	O
retrieved	O
autobiographical	O
events	O
,	O
specificity	O
of	O
evoked	O
memories	O
and	O
positive	O
valence	O
of	O
events	O
(	O
p<0.001	O
)	O
,	O
and	O
also	O
presented	O
lower	O
latency	O
time	O
for	O
recalling	O
events	O
,	O
and	O
lower	O
negative	O
recalled	O
events	O
(	O
p<0.01	O
)	O
.	O
This	O
study	O
supports	O
the	O
potential	O
value	O
of	O
reminiscence	B-T061
therapy	I-T061
in	O
improving	O
the	O
recall	O
of	O
autobiographical	O
memory	O
.	O
Reminiscence	B-T061
therapy	I-T061
can	O
be	O
helpful	O
to	O
maintain	O
or	O
improve	O
cognitive	O
function	O
,	O
decrease	O
anxiety	B-T048
and	O
manage	O
depressive	B-T184
symptoms	I-T184
and	O
altered	O
behavior	O
,	O
but	O
further	O
investigation	O
is	O
needed	O
to	O
clarify	O
long	O
-	O
term	O
effects	O
.	O
      
An	O
approach	O
for	O
liposome	O
immobilization	B-T061
using	O
sterically	O
stabilized	O
micelles	O
(	O
SSMs	O
)	O
as	O
a	O
precursor	O
for	O
bio	B-T059
-	I-T059
layer	I-T059
interferometry	I-T059
-	O
based	O
interaction	O
studies	O
Non	O
-	O
fluidic	O
bio	B-T059
-	I-T059
layer	I-T059
interferometry	I-T059
(	O
BLI	B-T059
)	O
has	O
rapidly	O
become	O
a	O
standard	O
tool	O
for	O
monitoring	O
almost	O
all	O
biomolecular	O
interactions	O
in	O
a	O
label	O
-	O
free	O
,	O
real	O
-	O
time	O
and	O
high	O
-	O
throughput	O
manner	O
.	O
High	O
-	O
efficiency	O
screening	B-T059
methods	I-T059
which	O
measure	O
the	O
kinetics	O
of	O
liposomes	O
with	O
a	O
variety	O
of	O
compounds	O
require	O
the	O
immobilization	B-T061
of	O
liposomes	O
.	O
In	O
this	O
work	O
,	O
a	O
method	O
is	O
described	O
for	O
immobilizing	B-T061
liposomes	O
for	O
interaction	O
studies	O
,	O
based	O
on	O
the	O
biophysical	O
principles	O
of	O
this	O
biosensor	O
platform	O
.	O
The	O
immobilization	B-T061
approach	O
includes	O
the	O
loading	O
of	O
DSPE	O
-	O
PEG(2000	O
)	O
-	O
biotin	B-T121
containing	O
sterically	O
stabilized	O
micelles	O
(	O
SSMs	O
)	O
which	O
are	O
restructured	O
in	O
a	O
buffer	O
change	O
step	O
,	O
resulting	O
in	O
an	O
accessible	O
substrate	O
for	O
liposome	O
immobilization	B-T061
.	O
Liposomes	O
in	O
a	O
concentration	O
of	O
5mM	O
of	O
varying	O
composition	O
and	O
fluidity	O
were	O
immobilized	B-T061
on	O
the	O
sensor	O
surface	O
by	O
inserting	O
the	O
hydrophobic	O
residues	O
of	O
the	O
former	O
loaded	O
SSMs	O
.	O
This	O
proof	O
of	O
principle	O
was	O
carried	O
out	O
using	O
Cytochrome	O
C	O
as	O
a	O
membrane	O
-	O
interacting	O
model	O
protein	O
.	O
The	O
binding	O
of	O
Cytochrome	O
C	O
to	O
the	O
immobilized	B-T061
liposomes	O
was	O
demonstrated	O
,	O
and	O
the	O
derived	O
kinetic	O
and	O
affinity	O
constants	O
were	O
similar	O
to	O
values	O
given	O
in	O
the	O
literature	O
.	O
In	O
order	O
to	O
obtain	O
a	O
detailed	O
understanding	O
of	O
this	O
surface	O
,	O
and	O
to	O
show	O
the	O
integrity	O
of	O
the	O
liposomes	O
,	O
confocal	B-T059
fluorescence	I-T059
microscopy	I-T059
was	O
used	O
.	O
Images	O
of	O
immobilized	B-T061
liposomes	O
containing	O
calcein	O
in	O
the	O
aqueous	O
core	O
indicated	B-T033
intact	O
vesicles	O
.	O
A	O
combination	O
of	O
this	O
simple	O
liposome	O
immobilization	B-T061
approach	O
,	O
the	O
possibility	O
of	O
automation	O
on	O
BLI	B-T059
systems	O
with	O
high	O
throughput	O
within	O
an	O
acceptable	O
timescale	O
and	O
excellent	O
reproducibility	O
makes	O
this	O
assay	B-T059
suitable	O
for	O
basic	O
research	O
as	O
well	O
as	O
for	O
industrial	O
and	O
regulatory	O
applications	O
.	O
      
Preventing	O
Youth	O
Internalizing	B-T048
Symptoms	I-T048
Through	O
the	O
Familias	O
Unidas	O
Intervention	O
:	O
Examining	O
Variation	O
in	O
Response	O
Prevention	O
programs	O
that	O
strengthen	O
parenting	O
and	O
family	O
functioning	O
have	O
been	O
found	O
to	O
reduce	B-T061
poor	B-T184
behavioral	I-T184
outcomes	O
in	O
adolescents	O
,	O
including	O
substance	B-T048
use	I-T048
,	O
HIV	B-T033
risk	I-T033
,	O
externalizing	O
and	O
internalizing	B-T048
problems	I-T048
.	O
However	O
,	O
there	O
is	O
evidence	O
that	O
not	O
all	O
youth	O
benefit	O
similarly	O
from	O
these	O
programs	O
.	O
Familias	O
Unidas	O
is	O
a	O
family	O
-	O
focused	O
intervention	O
designed	O
to	O
prevent	O
substance	B-T048
use	I-T048
and	O
sexual	B-T033
risk	I-T033
among	O
Hispanic	O
youth	O
and	O
has	O
recently	O
demonstrated	O
unanticipated	O
reductions	B-T061
in	O
internalizing	B-T048
symptoms	I-T048
for	O
some	O
youth	O
.	O
This	O
paper	O
examines	O
variation	O
in	O
intervention	O
response	O
for	O
internalizing	B-T048
symptoms	I-T048
using	O
individual	O
-	O
level	O
data	O
pooled	O
across	O
four	O
distinct	O
Familias	O
Unidas	O
trials	O
:	O
(	O
1	O
)	O
266	O
eighth	B-T033
grade	I-T033
students	O
recruited	O
from	O
the	O
general	O
school	O
population	O
;	O
(	O
2	O
)	O
160	O
ninth	B-T033
grade	I-T033
students	O
from	O
the	O
general	O
school	O
population	O
;	O
(	O
3	O
)	O
213	O
adolescents	O
with	O
conduct	B-T048
,	O
aggression	O
,	O
and/or	O
attention	B-T033
problems	I-T033
;	O
and	O
(	O
4	O
)	O
242	O
adolescents	O
with	O
a	O
delinquency	B-T048
history	O
.	O
Causal	O
inference	O
growth	O
mixture	O
modeling	O
suggests	O
a	O
three-	O
class	O
model	O
.	O
The	O
two	O
largest	O
classes	O
represent	O
youth	O
with	O
low	O
(	O
60	O
%	O
)	O
and	O
medium	O
(	O
27	O
%	O
)	O
internalizing	B-T048
symptoms	I-T048
at	O
baseline	O
,	O
and	O
both	O
intervention	O
and	O
control	O
participants	O
show	O
reductions	B-T061
in	O
internalizing	B-T048
symptoms	I-T048
.	O
The	O
third	O
class	O
(	O
13	O
%	O
)	O
represents	O
youth	O
with	O
high	O
levels	O
of	O
baseline	O
internalizing	B-T048
symptoms	I-T048
who	O
remain	O
at	O
steady	O
levels	O
of	O
internalizing	B-T048
symptoms	I-T048
when	O
exposed	O
to	O
the	O
intervention	O
,	O
but	O
who	O
experience	O
an	O
increase	O
in	O
symptoms	B-T048
under	O
the	O
control	O
condition	O
.	O
Female	O
gender	O
,	O
low	O
baseline	O
levels	O
of	O
parent	O
-	O
adolescent	O
communication	O
,	O
and	O
older	O
age	O
were	O
associated	O
with	O
membership	O
in	O
the	O
high	B-T033
-	I-T033
risk	I-T033
class	O
.	O
These	O
synthesis	O
analyses	O
involving	O
a	O
large	O
sample	O
of	O
youth	O
with	O
varying	O
initial	O
risk	O
levels	O
represent	O
a	O
further	O
step	O
toward	O
strengthening	O
our	O
knowledge	O
of	O
preventive	O
intervention	O
response	O
and	O
improving	O
preventive	O
interventions	O
.	O
      
The	O
Impact	O
of	O
Deployment	O
on	O
Parental	O
,	O
Family	O
and	O
Child	O
Adjustment	O
in	O
Military	O
Families	O
Since	O
9/11	O
,	O
military	O
service	O
in	O
the	O
United	O
States	O
has	O
been	O
characterized	O
by	O
wartime	O
deployments	O
and	O
reintegration	O
challenges	O
that	O
contribute	O
to	O
a	O
context	O
of	O
stress	B-T033
for	O
military	O
families	O
.	O
Research	O
indicates	O
the	O
negative	B-T033
impact	I-T033
of	O
wartime	O
deployment	O
on	O
the	O
well	O
being	O
of	O
service	O
members	O
,	O
military	O
spouses	O
,	O
and	O
children	O
.	O
Yet	O
,	O
few	O
studies	O
have	O
considered	O
how	O
parental	O
deployments	O
may	O
affect	O
adjustment	O
in	O
young	O
children	O
and	O
their	O
families	O
.	O
Using	O
deployment	O
records	O
and	O
parent	O
-	O
reported	O
measures	O
from	O
primary	O
caregiving	O
(	O
N	O
=	O
680	O
)	O
and	O
military	O
(	O
n	O
=	O
310	O
)	O
parents	O
,	O
we	O
examined	O
the	O
influence	O
of	O
deployment	O
on	O
adjustment	O
in	O
military	O
families	O
with	O
children	O
ages	O
0	O
-	O
10	O
years	O
.	O
Greater	O
deployment	O
exposure	O
was	O
related	O
to	O
impaired	O
family	O
functioning	O
and	O
marital	B-T033
instability	B-T033
.	O
Parental	O
depressive	B-T048
and	O
posttraumatic	B-T048
stress	I-T048
symptoms	I-T048
were	O
associated	O
with	O
impairments	O
in	O
social	O
emotional	B-T033
adjustment	O
in	O
young	O
children	O
,	O
increased	O
anxiety	B-T033
in	O
early	O
childhood	O
,	O
and	O
adjustment	O
problems	O
in	O
school	O
-	O
age	O
children	O
.	O
Conversely	O
,	O
parental	O
sensitivity	O
was	O
associated	O
with	O
improved	O
social	O
and	O
emotional	B-T033
outcomes	I-T033
across	O
childhood	O
.	O
These	O
findings	B-T033
provide	O
guidance	O
to	O
developing	O
preventive	O
approaches	O
for	O
military	O
families	O
with	O
young	O
children	O
.	O
      
Multivariate	O
Imaging	B-T060
Genetics	O
Study	O
of	O
MRI	B-T060
Gray	O
Matter	O
Volume	O
and	O
SNPs	O
Reveals	O
Biological	O
Pathways	O
Correlated	O
with	O
Brain	B-T023
Structural	O
Differences	O
in	O
Attention	B-T048
Deficit	I-T048
Hyperactivity	I-T048
Disorder	I-T048
Attention	B-T048
deficit	I-T048
hyperactivity	I-T048
disorder	I-T048
(	O
ADHD	B-T048
)	O
is	O
a	O
prevalent	O
neurodevelopmental	B-T048
disorder	I-T048
affecting	O
children	O
,	O
adolescents	O
,	O
and	O
adults	O
.	O
Its	O
etiology	O
is	O
not	O
well	O
understood	O
,	O
but	O
it	O
is	O
increasingly	O
believed	O
to	O
result	O
from	O
diverse	O
pathophysiologies	O
that	O
affect	O
the	O
structure	O
and	O
function	O
of	O
specific	O
brain	O
circuits	O
.	O
Although	O
one	O
of	O
the	O
best	O
-	O
studied	O
neurobiological	B-T047
abnormalities	I-T047
in	O
ADHD	B-T048
is	O
reduced	O
fronto	B-T023
-	I-T023
striatal	I-T023
-	I-T023
cerebellar	I-T023
gray	I-T023
matter	I-T023
(	O
GM	O
)	O
volume	O
,	O
its	O
specific	O
genetic	O
correlates	O
are	O
largely	O
unknown	O
.	O
In	O
this	O
study	O
,	O
T1	B-T060
-	I-T060
weighted	I-T060
MR	I-T060
images	I-T060
of	I-T060
brain	I-T060
structure	I-T060
were	O
collected	O
from	O
198	O
adolescents	O
(	O
63	O
ADHD	B-T048
-	O
diagnosed	B-T033
)	O
.	O
A	O
multivariate	O
parallel	O
independent	O
component	O
analysis	O
(	O
Para	O
-	O
ICA	O
)	O
technique	O
-identified	O
imaging	B-T060
genetic	O
relationships	O
between	O
regional	O
GM	O
volume	O
and	O
single	O
nucleotide	O
polymorphism	O
data	O
.	O
Para	O
-	O
ICA	O
analyses	O
extracted	O
14	O
components	O
from	O
genetic	O
data	O
and	O
9	O
from	O
MR	B-T060
data	O
.	O
An	O
iterative	O
cross	O
-	O
validation	O
using	O
randomly	O
chosen	O
subsamples	O
indicated	O
acceptable	O
stability	O
of	O
these	O
ICA	O
solutions	O
.	O
A	O
series	O
of	O
partial	O
correlation	O
analyses	O
controlling	O
for	O
age	O
,	O
sex	O
,	O
and	O
ethnicity	O
revealed	O
two	O
genotype	O
-	O
phenotype	O
component	O
pairs	O
significantly	O
differed	O
between	O
ADHD	B-T048
and	O
non	B-T033
-	I-T033
ADHD	I-T033
groups	O
,	O
after	O
a	O
Bonferroni	O
correction	O
for	O
multiple	O
comparisons	O
.	O
The	O
brain	B-T023
phenotype	O
component	O
not	O
only	O
included	O
structures	O
frequently	O
found	O
to	O
have	O
abnormally	O
low	O
volume	O
in	O
previous	O
ADHD	B-T048
studies	O
but	O
was	O
also	O
significantly	O
associated	O
with	O
ADHD	B-T048
differences	O
in	O
symptom	B-T033
severity	I-T033
and	O
performance	O
on	O
cognitive	O
tests	O
frequently	O
found	O
to	O
be	O
impaired	O
in	O
patients	O
diagnosed	B-T033
with	O
the	O
disorder	B-T047
.	O
Pathway	O
analysis	O
of	O
the	O
genotype	O
component	O
identified	O
several	O
different	O
biological	O
pathways	O
linked	O
to	O
these	O
structural	O
abnormalities	B-T033
in	O
ADHD	B-T048
.	O
Some	O
of	O
these	O
pathways	O
implicate	O
well	O
-	O
known	O
dopaminergic	O
neurotransmission	O
and	O
neurodevelopment	O
hypothesized	O
to	O
be	O
abnormal	B-T033
in	O
ADHD	B-T048
.	O
Other	O
more	O
recently	O
implicated	O
pathways	O
included	O
glutamatergic	O
and	O
GABA	O
-	O
eric	O
physiological	O
systems	O
;	O
others	O
might	O
reflect	O
sources	O
of	O
shared	O
liability	O
to	O
disturbances	O
commonly	O
found	O
in	O
ADHD	B-T048
,	O
such	O
as	O
sleep	B-T184
abnormalities	I-T184
.	O
      
Heart	O
rate	O
variability	O
:	O
Pre	O
-	O
deployment	O
predictor	O
of	O
post	O
-	O
deployment	O
PTSD	B-T048
symptoms	B-T184
Heart	O
rate	O
variability	O
is	O
a	O
physiological	O
measure	O
associated	O
with	O
autonomic	O
nervous	O
system	O
activity	O
.	O
This	O
study	O
hypothesized	O
that	O
lower	O
pre	O
-	O
deployment	O
HRV	O
would	O
be	O
associated	O
with	O
higher	O
post	O
-	O
deployment	O
post	B-T048
-	I-T048
traumatic	I-T048
stress	I-T048
disorder	I-T048
(	O
PTSD	B-T048
)	O
symptoms	B-T184
.	O
Three	O
-	O
hundred	O
-	O
forty	O
-	O
three	O
Army	O
National	O
Guard	O
soldiers	O
enrolled	O
in	O
the	O
Warriors	O
Achieving	O
Resilience	O
(	O
WAR	O
)	O
study	O
were	O
analyzed	O
.	O
The	O
primary	O
outcome	O
was	O
PTSD	B-T048
symptom	B-T184
severity	O
using	O
the	O
PTSD	B-T048
Checklist	O
-	O
Military	O
version	O
(	O
PCL	O
)	O
measured	O
at	O
baseline	O
,	O
3-	O
and	O
12-	O
month	O
post	O
-	O
deployment	O
.	O
Heart	O
rate	O
variability	O
predictor	O
variables	O
included	O
:	O
high	O
frequency	O
power	O
(	O
HF	O
)	O
and	O
standard	O
deviation	O
of	O
the	O
normal	O
cardiac	O
inter	O
-	O
beat	O
interval	O
(	O
SDNN	O
)	O
.	O
Generalized	O
linear	O
mixed	O
models	O
revealed	O
that	O
the	O
pre	O
-	O
deployment	O
PCL	O
*	O
ln(HF	O
)	O
interaction	O
term	O
was	O
significant	O
(	O
p<0.0001	O
)	O
.	O
Pre	O
-	O
deployment	O
SDNN	O
was	O
not	O
a	O
significant	O
predictor	O
of	O
post	O
-	O
deployment	O
PCL	O
.	O
Covariates	O
included	O
age	O
,	O
pre	O
-	O
deployment	O
PCL	O
,	O
race	O
/	O
ethnicity	O
,	O
marital	O
status	O
,	O
tobacco	O
use	O
,	O
childhood	B-T048
abuse	I-T048
,	O
pre	O
-	O
deployment	O
traumatic	O
brain	O
injury	O
,	O
and	O
previous	O
combat	O
zone	O
deployment	O
.	O
Pre	O
-	O
deployment	O
heart	O
rate	O
variability	O
predicts	O
post	O
-	O
deployment	O
PTSD	B-T048
symptoms	B-T184
in	O
the	O
context	O
of	O
higher	O
pre	O
-	O
deployment	O
PCL	O
scores	O
.	O
      
Prescription	O
of	O
opioids	B-T121
for	O
breathlessness	B-T184
in	O
end	O
-	O
stage	O
COPD	B-T047
:	O
a	O
national	O
population	O
-	O
based	O
study	O
Low	O
-	O
dose	O
opioids	B-T121
can	O
relieve	O
breathlessness	B-T184
but	O
may	O
be	O
underused	O
in	O
late	O
-	O
stage	O
COPD	B-T047
due	O
to	O
fear	O
of	O
complications	O
,	O
contributing	O
to	O
poor	O
symptom	B-T061
control	I-T061
.	O
We	O
aimed	O
to	O
study	O
the	O
period	O
prevalence	O
and	O
indications	O
of	O
opioids	B-T121
actually	O
prescribed	B-T058
in	O
people	O
with	O
end	O
-	O
stage	O
COPD	B-T047
.	O
The	O
study	O
was	O
a	O
longitudinal	O
,	O
population	O
-	O
based	O
study	O
of	O
patients	O
starting	O
long	B-T061
-	I-T061
term	I-T061
oxygen	I-T061
therapy	I-T061
(	O
LTOT	B-T061
)	O
for	O
COPD	B-T047
between	O
October	O
1	O
,	O
2005	O
and	O
June	O
30	O
,	O
2009	O
in	O
Sweden	O
.	O
A	O
random	O
sample	O
(	O
n=2,000	O
)	O
of	O
their	O
dispensed	B-T058
opioid	B-T121
prescriptions	O
was	O
obtained	O
from	O
the	O
national	O
Prescribed	O
Drugs	O
Register	O
from	O
91	O
days	O
before	O
starting	O
LTOT	B-T061
until	O
the	O
first	O
of	O
LTOT	B-T061
withdrawal	O
,	O
death	O
,	O
or	O
study	O
end	O
(	O
December	O
31	O
,	O
2009	O
)	O
.	O
We	O
analyzed	O
medication	O
type	O
,	O
dispensed	O
quantity	O
,	O
date	B-T033
of	I-T033
dispensing	I-T033
,	O
and	O
indications	O
categorized	O
as	O
pain	B-T184
,	O
breathlessness	B-T184
,	O
other	O
,	O
or	O
unknown	O
.	O
In	O
total	O
,	O
2,249	O
COPD	B-T047
patients	O
(	O
59	O
%	O
women	O
)	O
were	O
included	O
.	O
During	O
a	O
median	O
follow	B-T058
-	I-T058
up	I-T058
of	O
1.1	O
(	O
interquartile	O
range	O
0.6	O
-	O
2.0	O
)	O
years	O
,	O
1,034	O
patients	O
(	O
46	O
%	O
)	O
were	O
dispensed	B-T058
≥1	O
opioid	B-T121
prescription	B-T058
(	O
N=13,722	O
prescriptions	B-T058
)	O
.	O
The	O
most	O
frequently	O
prescribed	B-T058
opioids	B-T121
were	O
tramadol	B-T121
(	O
23	O
%	O
)	O
,	O
oxycodone	B-T121
(	O
23	O
%	O
)	O
,	O
morphine	B-T121
(	O
16	O
%	O
)	O
,	O
and	O
codeine	B-T121
(	O
16	O
%	O
)	O
.	O
Average	O
dispensed	O
quantity	O
was	O
9.3	O
(	O
interquartile	O
range	O
3.7	O
-	O
16.7	O
)	O
defined	O
daily	O
doses	O
per	O
prescription	B-T058
.	O
In	O
the	O
random	O
sample	O
,	O
the	O
most	O
commonly	O
stated	O
indication	O
was	O
pain	B-T184
(	O
97	O
%	O
)	O
,	O
with	O
only	O
2	O
%	O
for	O
breathlessness	B-T184
and	O
1	O
%	O
for	O
other	O
reasons	O
.	O
Despite	O
evidence	O
that	O
supported	O
the	O
use	O
of	O
opioids	B-T121
for	O
the	O
relief	O
of	O
breathlessness	B-T184
predating	O
this	O
study	O
,	O
opioids	B-T121
are	O
rarely	O
prescribed	B-T058
to	O
relieve	O
breathlessness	B-T184
in	O
oxygen	O
-	O
dependent	O
COPD	B-T047
,	O
potentially	O
contributing	O
to	O
less	O
-	O
than	O
-	O
optimal	O
symptom	B-T061
control	I-T061
.	O
This	O
study	O
creates	O
a	O
baseline	O
against	O
which	O
to	O
compare	O
future	O
changes	O
in	O
morphine	B-T121
prescribing	O
in	O
this	O
setting	O
.	O
      
Pathways	O
and	O
Genes	O
Associated	O
with	O
Immune	O
Dysfunction	O
in	O
Sheep	O
Paratuberculosis	B-T047
Multibacillary	B-T033
and	O
paucibacillary	B-T033
paratuberculosis	B-T047
are	O
both	O
caused	O
by	O
Mycobacterium	B-T007
avium	I-T007
subspecies	I-T007
paratuberculosis	I-T007
.	O
Multibacillary	B-T033
lesions	B-T033
are	O
composed	O
largely	O
of	O
infected	B-T033
epithelioid	O
macrophages	O
and	O
paucibacillary	B-T033
lesions	B-T033
contain	O
T	O
cells	O
but	O
few	O
bacteria	B-T007
.	O
Multibacillary	B-T033
disease	B-T047
is	O
similar	O
to	O
human	O
lepromatous	B-T047
leprosy	I-T047
,	O
with	O
variable	O
/	O
high	O
levels	O
of	O
antibody	O
and	O
a	O
dysfunctional	O
immune	O
response	O
.	O
Animals	O
with	O
paucibacillary	B-T033
disease	B-T047
have	O
high	O
cell	O
-	O
mediated	O
immunity	O
and	O
variable	O
levels	O
of	O
antibody	O
.	O
This	O
study	O
aims	O
to	O
characterize	O
the	O
immunological	B-T047
dysfunction	I-T047
using	O
TruSeq	O
analysis	O
of	O
the	O
ileocaecal	O
lymph	B-T023
node	I-T023
that	O
drains	O
disease	B-T047
lesions	B-T033
.	O
Immune	O
dysfunction	O
is	O
highlighted	O
by	O
repression	O
of	O
TCR	O
/	O
CD3	O
genes	O
,	O
T	O
cell	O
co	O
-	O
receptors	O
/	O
co	B-T121
-	I-T121
stimulators	I-T121
,	O
T	O
cell	O
activation	O
and	O
signal	O
-	O
transduction	O
genes	O
.	O
Inflammation	O
was	O
an	O
acute	O
phase	O
response	O
and	O
chronic	O
inflammation	O
,	O
with	O
little	O
evidence	O
of	O
acute	B-T033
inflammation	I-T033
.	O
The	O
high	O
levels	O
of	O
immunoglobulin	O
and	O
plasma	O
cell	O
transcripts	O
is	O
consistent	O
with	O
the	O
anti	O
-	O
MAP	O
antibody	O
responses	O
in	O
paratuberculosis	B-T047
sheep	O
.	O
Also	O
notable	O
was	O
the	O
overwhelming	O
reduction	O
in	O
mast	O
cell	O
transcripts	O
,	O
potentially	O
affecting	O
DC	O
activation	O
of	O
the	O
immune	O
response	O
.	O
This	O
study	O
also	O
shows	O
that	O
there	O
were	O
no	O
fundamental	O
differences	O
in	O
the	O
gene	O
expression	O
patterns	O
in	O
multibacillary	B-T033
and	O
paucibacillary	B-T033
disease	B-T047
,	O
no	O
shift	O
in	O
T	O
cell	O
genes	O
from	O
Th1	O
to	O
Th2	O
pattern	O
but	O
rather	O
an	O
incremental	O
decline	O
into	O
immune	O
dysfunction	O
leading	O
to	O
multibacillary	B-T033
pathology	B-T047
.	O
      
Acute	O
sensitivity	O
of	O
the	O
vernal	O
pool	O
fairy	O
shrimp	O
,	O
Branchinecta	O
lynchi	O
(	O
Anostraca	O
;	O
Branchinectidae	O
)	O
,	O
and	O
surrogate	O
species	O
to	O
10	O
chemicals	O
Vernal	O
pool	O
fairy	O
shrimp	O
,	O
Branchinecta	O
lynchi	O
,	O
(	O
Branchiopoda	O
;	O
Anostraca	O
)	O
and	O
other	O
fairy	O
shrimp	O
species	O
have	O
been	O
listed	O
as	O
threatened	O
or	O
endangered	O
under	O
the	O
US	O
Endangered	O
Species	O
Act	O
.	O
Because	O
few	O
data	O
exist	O
about	O
the	O
sensitivity	O
of	O
Branchinecta	O
spp	O
.	O
to	O
toxic	O
effects	O
of	O
contaminants	O
,	O
it	O
is	O
difficult	O
to	O
determine	O
whether	O
they	O
are	O
adequately	O
protected	O
by	O
water	O
quality	O
criteria	O
.	O
A	O
series	O
of	O
acute	B-T059
(	I-T059
24	I-T059
-	I-T059
h	I-T059
)	I-T059
lethality	I-T059
/	I-T059
immobilization	I-T059
tests	I-T059
was	O
conducted	O
with	O
3	O
species	O
of	O
fairy	O
shrimp	O
(	O
B.	O
lynchi	O
,	O
Branchinecta	O
lindahli	O
,	O
and	O
Thamnocephalus	O
platyurus	O
)	O
and	O
10	O
chemicals	O
with	O
varying	O
modes	O
of	O
toxic	O
action	O
:	O
ammonia	B-T121
,	O
potassium	O
,	O
chloride	O
,	O
sulfate	O
,	O
chromium(VI	O
)	O
,	O
copper	B-T121
,	O
nickel	O
,	O
zinc	B-T121
,	O
alachlor	O
,	O
and	O
metolachlor	O
.	O
The	O
same	O
chemicals	O
were	O
tested	O
in	O
48-	O
h	O
tests	B-T059
with	O
other	O
branchiopods	O
(	O
the	O
cladocerans	O
Daphnia	O
magna	O
and	O
Ceriodaphnia	O
dubia	O
)	O
and	O
an	O
amphipod	O
(	O
Hyalella	O
azteca	O
)	O
,	O
and	O
in	O
96-	O
h	O
tests	B-T059
with	O
snails	O
(	O
Physa	O
gyrina	O
and	O
Lymnaea	O
stagnalis	O
)	O
.	O
Median	O
effect	O
concentrations	O
(	O
EC50s	O
)	O
for	O
B.	O
lynchi	O
were	O
strongly	O
correlated	O
(	O
r(2	O
)	O
=	O
0.975	O
)	O
with	O
EC50s	O
for	O
the	O
commercially	O
available	O
fairy	O
shrimp	O
species	O
T.	O
platyurus	O
for	O
most	O
chemicals	O
tested	O
.	O
Comparison	O
of	O
EC50s	O
for	O
fairy	O
shrimp	O
and	O
EC50s	O
for	O
invertebrate	O
taxa	O
tested	O
concurrently	O
and	O
with	O
other	O
published	O
toxicity	O
data	O
indicated	O
that	O
fairy	O
shrimp	O
were	O
relatively	O
sensitive	O
to	O
potassium	O
and	O
several	O
trace	B-T121
metals	I-T121
compared	O
with	O
other	O
invertebrate	O
taxa	O
,	O
although	O
cladocerans	O
,	O
amphipods	O
,	O
and	O
mussels	O
had	O
similar	O
broad	O
toxicant	O
sensitivity	O
.	O
Interspecies	O
correlation	O
estimation	O
models	O
for	O
predicting	O
toxicity	O
to	O
fairy	O
shrimp	O
from	O
surrogate	O
species	O
indicated	O
that	O
models	O
with	O
cladocerans	O
and	O
freshwater	O
mussels	O
as	O
surrogates	O
produced	O
the	O
best	O
predictions	O
of	O
the	O
sensitivity	O
of	O
fairy	O
shrimp	O
to	O
contaminants	O
.	O
The	O
results	O
of	O
these	O
studies	O
indicate	O
that	O
fairy	O
shrimp	O
are	O
relatively	O
sensitive	O
to	O
a	O
range	O
of	O
toxicants	O
,	O
but	O
Endangered	O
Species	O
Act	O
-listed	O
fairy	O
shrimp	O
of	O
the	O
genus	O
Branchinecta	O
were	O
not	O
consistently	O
more	O
sensitive	O
than	O
other	O
fairy	O
shrimp	O
taxa	O
.	O
Environ	O
Toxicol	O
Chem	O
2016;9999:1	O
-	O
10	O
.	O
Published	O
2016	O
Wiley	O
Periodicals	O
Inc.	O
on	O
behalf	O
of	O
SETAC	O
.	O
This	O
article	O
is	O
a	O
US	O
government	O
work	O
and	O
,	O
as	O
such	O
,	O
is	O
in	O
the	O
public	O
domain	O
in	O
the	O
United	O
States	O
of	O
America	O
.	O
      
Barriers	O
and	O
facilitators	O
to	O
smoking	O
cessation	O
in	O
a	O
cancer	B-T191
context	O
:	O
A	O
qualitative	O
study	O
of	O
patient	O
,	O
family	O
and	O
professional	O
views	O
Continued	O
smoking	O
after	O
cancer	B-T191
adversely	O
affects	O
quality	B-T184
of	I-T184
life	I-T184
and	O
survival	O
,	O
but	O
one	O
fifth	O
of	O
cancer	B-T191
survivors	O
still	O
smoke	O
.	O
Despite	O
its	O
demands	O
,	O
cancer	B-T191
presents	O
an	O
opportunity	O
for	O
positive	B-T033
behaviour	O
change	O
.	O
Smoking	O
often	O
occurs	O
in	O
social	O
groups	O
,	O
therefore	O
interventions	B-T061
which	O
target	O
families	O
and	O
individuals	O
may	O
be	O
more	O
successful	O
.	O
This	O
qualitative	O
study	O
explored	O
patients	O
,	O
family	O
members	O
and	O
health	O
professionals	O
'	O
views	O
and	O
experiences	O
of	O
smoking	O
and	O
smoking	O
cessation	O
after	O
cancer	B-T191
,	O
in	O
order	O
to	O
inform	O
future	O
interventions	B-T061
.	O
In	B-T058
-	I-T058
depth	I-T058
qualitative	I-T058
interviews	I-T058
(	O
n	O
=	O
67	O
)	O
with	O
29	O
patients	O
,	O
14	O
family	O
members	O
and	O
24	O
health	O
professionals	O
.	O
Data	O
were	O
analysed	O
using	O
the	O
'	O
Framework	O
'	O
method	O
.	O
Few	O
patient	O
s	O
and	O
family	O
members	O
had	O
used	O
National	B-T058
Health	I-T058
Service	I-T058
(	O
NHS	B-T058
)	O
smoking	O
cessation	O
services	B-T058
and	O
more	O
than	O
half	O
still	O
smoked	O
.	O
Most	O
recalled	O
little	O
'	O
smoking	O
-related	O
'	O
discussion	B-T061
with	O
clinicians	O
but	O
were	O
receptive	O
to	O
talking	O
openly	O
.	O
Clinicians	O
revealed	O
several	O
barriers	O
to	O
discussion	B-T061
.	O
Participants	O
'	O
continued	O
smoking	O
was	O
explained	O
by	O
the	O
stress	B-T033
of	O
diagnosis	B-T060
;	O
desire	O
to	O
maintain	O
personal	O
control	O
;	O
and	O
lack	O
of	O
connection	O
between	O
smoking	O
,	O
cancer	B-T191
and	O
health	O
.	O
A	O
range	O
of	O
barriers	O
to	O
smoking	O
cessation	O
exist	O
for	O
patients	O
and	O
family	O
members	O
.	O
These	O
are	O
insufficiently	O
assessed	O
and	O
considered	O
by	O
clinicians	O
.	O
Interventions	B-T061
must	O
be	O
more	O
effectively	O
integrated	O
into	O
routine	O
practice	O
.	O
      
Total	O
Fluorescence	O
Fingerprinting	O
of	O
Pesticides	O
:	O
A	O
Reliable	O
Approach	O
for	O
Continuous	O
Monitoring	O
of	O
Soils	O
and	O
Waters	O
The	O
present	O
work	O
relates	O
to	O
the	O
creation	O
/	O
extension	O
of	O
a	O
database	O
of	O
Total	B-T059
Excitation	I-T059
-	I-T059
Emission	I-T059
and	I-T059
Total	I-T059
Synchronous	I-T059
Fluorescence	I-T059
Matrices	I-T059
(	O
TEEMs	B-T059
and	I-T059
TSFMs	I-T059
)	O
along	O
with	O
optimal	B-T059
Synchronous	I-T059
Fluorescence	I-T059
Spectra	I-T059
(	O
SFS	B-T059
)	O
to	O
fingerprint	O
pesticides	O
widely	O
used	O
in	O
Morocco	O
.	O
This	O
spectrometric	B-T059
multi	I-T059
-	I-T059
component	I-T059
fingerprinting	I-T059
may	O
permit	O
the	O
direct	O
detection	B-T059
of	I-T059
pesticides	I-T059
persisting	O
in	O
soil	O
or	O
water	O
.	O
The	O
objective	O
of	O
the	O
current	O
investigation	O
is	O
to	O
detect	B-T059
four	I-T059
pesticide	I-T059
remains	O
in	O
agricultural	O
soils	O
by	O
applying	O
the	O
spectrometric	B-T059
fingerprinting	I-T059
results	O
.	O
They	O
are	O
the	O
commercial	O
:	O
i	O
)	O
insecticide	O
Axlera	O
5	O
G	O
(	O
carbamate	O
)	O
,	O
ii	O
)	O
fungicide	O
Orsalis	O
5	O
%	O
SC	O
(	O
triazole	O
)	O
,	O
iii	O
)	O
insecticide	O
Force	O
0,5	O
G	O
(	O
pyrethrinoid	O
)	O
and	O
iv	O
)	O
insecticide	O
Proclaim	O
05	O
SG	O
(	O
non	O
-	O
assigned	O
)	O
.	O
The	O
agricultural	O
plantations	O
monitored	O
are	O
located	O
in	O
the	O
great	O
agricultural	O
Doukkala	O
region	O
at	O
the	O
western	O
Atlantic	O
side	O
of	O
Morocco	O
,	O
where	O
these	O
chemicals	O
are	O
in	O
large	O
sale	O
and	O
use	O
.	O
      
Aurantimonas	B-T007
endophytica	I-T007
sp	I-T007
.	I-T007
nov	I-T007
.	I-T007
,	O
a	O
novel	O
endophytic	O
bacterium	O
isolated	O
from	O
roots	O
of	O
Anabasis	O
elatior	O
(	O
C.	O
A.	O
Mey	O
.	O
)	O
Schischk	O
An	O
orange	O
-	O
coloured	O
,	O
aerobic	O
,	O
motile	B-T033
and	O
short	B-T007
-	I-T007
rods	I-T007
bacterial	I-T007
strain	I-T007
,	O
designated	O
EGI	B-T007
6500337	I-T007
T	I-T007
,	O
was	O
isolated	O
from	O
the	O
surface	O
-	O
sterilized	O
root	O
of	O
a	O
halophyte	O
Anabasis	O
elatior	O
(	O
C.	O
A.	O
Mey	O
.	O
)	O
Schischk	O
collected	O
from	O
Urumqi	O
,	O
Xinjiang	O
province	O
,	O
north	O
-	O
west	O
China	O
.	O
Growth	O
occurred	O
at	O
5	O
-	O
35	O
°	O
C	O
(	O
optimum	O
30	O
°	O
C	O
)	O
,	O
at	O
pH	O
6.0	O
-	O
9.0	O
(	O
optimum	O
pH	O
7.0	O
)	O
,	O
and	O
in	O
the	O
presence	O
of	O
0	O
-	O
6	O
%	O
NaCl	B-T121
(	O
w	O
/	O
v	O
)	O
(	O
optimum	O
0	O
-	O
1	O
%	O
)	O
.	O
Phylogenetic	O
tree	O
based	O
on	O
16S	O
rRNA	O
gene	O
sequences	O
indicated	O
that	O
strain	B-T007
EGI	I-T007
6500337	I-T007
T	I-T007
formed	O
a	O
distinct	O
lineage	O
in	O
the	O
cluster	O
that	O
comprised	O
the	O
genera	B-T007
Aurantimonas	I-T007
and	O
Aureimonas	B-T007
in	O
the	O
family	B-T007
Aurantimonadaceae	I-T007
.	O
The	O
16S	O
rRNA	O
gene	O
sequence	O
of	O
strain	B-T007
EGI	I-T007
6500337	I-T007
T	I-T007
shared	O
the	O
highest	O
similarities	O
to	O
those	O
of	O
Aurantimonas	B-T007
coralicida	I-T007
DSM	I-T007
14790	I-T007
T	I-T007
(	O
97.15	O
%	O
)	O
and	O
Aurantimonas	B-T007
manganoxydans	I-T007
DSM	I-T007
21871	I-T007
T	I-T007
(	O
97.15	O
%	O
)	O
.	O
Strain	B-T007
EGI	I-T007
6500337	I-T007
T	I-T007
contained	O
Q-10	O
as	O
the	O
dominant	O
isoprenoid	O
quinone	O
.	O
The	O
major	O
cellular	O
fatty	O
acids	O
were	O
C18:1	O
7c	O
(	O
66.4	O
%	O
)	O
and	O
C19:0	O
8c	O
cyclo	O
(	O
23.3	O
%	O
)	O
.	O
The	O
polar	O
lipid	O
profile	O
of	O
strain	B-T007
EGI	I-T007
6500337	I-T007
T	I-T007
contained	O
diphosphatidylglycerol	O
,	O
phosphatidylglycerol	O
,	O
phosphatidylcholine	B-T121
,	O
phosphatidylethanolamine	O
as	O
major	O
components	O
,	O
similarly	O
to	O
the	O
members	O
of	O
the	O
genus	B-T007
Aurantimonas	I-T007
.	O
The	O
DNA	O
G+C	O
content	O
of	O
strain	B-T007
EGI	I-T007
6500337	I-T007
T	I-T007
was	O
66.8	O
mol%	O
.	O
The	O
DNA	O
-	O
DNA	O
relatedness	O
between	O
strain	B-T007
EGI	I-T007
6500337	I-T007
T	I-T007
and	O
Aurantimonas	B-T007
coralicida	I-T007
DSM	I-T007
14790	I-T007
T	I-T007
was	O
24.7	O
±	O
2.9	O
%	O
.	O
On	O
the	O
basis	O
of	O
the	O
phylogenetic	O
analysis	O
,	O
chemotaxonomic	O
data	O
and	O
phenotypic	O
characteristics	O
,	O
strain	B-T007
EGI	I-T007
6500337	I-T007
T	I-T007
represents	O
a	O
novel	O
species	O
of	O
the	O
genus	B-T007
Aurantimonas	I-T007
,	O
for	O
which	O
the	O
name	O
Aurantimonas	B-T007
endophytica	I-T007
sp	I-T007
.	I-T007
nov	I-T007
.	I-T007
is	O
proposed	O
.	O
The	O
type	O
strain	B-T007
is	O
EGI	B-T007
6500337	I-T007
T	I-T007
(=	O
KCTC	B-T007
52296	I-T007
T	I-T007
=	O
CPCC	B-T007
100904	I-T007
T	I-T007
)	O
.	O
      
Is	O
the	O
inactivation	O
of	O
dentin	O
proteases	O
by	O
crosslinkers	O
reversible	O
?	O
Inactivation	O
of	O
dentin	O
proteases	O
by	O
crosslinkers	O
has	O
been	O
suggested	O
as	O
a	O
way	O
to	O
prevent	O
the	O
degradation	O
of	O
dentin	O
collagen	O
in	O
the	O
hybrid	O
layer	O
.	O
However	O
,	O
it	O
is	O
not	O
known	O
if	O
the	O
inhibition	O
is	O
reversible	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
inactivation	O
effect	O
of	O
various	O
crosslinkers	O
on	O
dentin	O
protease	O
activity	O
over	O
a	O
period	O
of	O
6	O
months	O
.	O
Demineralized	O
dentin	O
beams	O
(	O
1×2×6	O
mm	O
,	O
n=10	O
/	O
group	O
)	O
were	O
treated	O
with	O
(	O
1	O
)	O
1	O
%	O
glutaraldehyde	O
(	O
GA1	O
)	O
,	O
(	O
2	O
)	O
5	O
%	O
glutaraldehyde	O
(	O
GA5	O
)	O
,	O
(	O
3	O
)	O
1	O
%	O
grape	B-T121
seed	I-T121
extract	I-T121
(	O
GS1	B-T121
)	O
,	O
(	O
4	O
)	O
5	O
%	O
grape	B-T121
seed	I-T121
extract	I-T121
(	O
GS5	B-T121
)	O
,	O
(	O
5	O
)	O
10	O
%	O
sumac	O
berry	O
extract	O
(	O
S	O
)	O
,	O
(	O
6	O
)	O
20μM	B-T121
curcumin	I-T121
(	O
CR20	B-T121
)	O
,	O
and	O
(	O
7	O
)	O
200μM	O
curcumin	B-T121
(	O
CR200	B-T121
)	O
for	O
5min	O
.	O
Untreated	B-T033
beams	O
served	O
as	O
control	O
.	O
The	O
beams	O
were	O
incubated	B-T059
up	O
to	O
6	O
months	O
and	O
incubation	O
media	O
were	O
used	O
to	O
analyze	O
solubilized	O
telopeptide	O
(	O
ICTP	O
and	O
CTX	O
)	O
fragments	O
as	O
indicators	O
of	O
MMP	O
-	O
and	O
cathepsin	O
K	O
-mediated	O
degradation	O
after	O
1	O
,	O
3	O
and	O
6	O
months	O
of	O
incubation	B-T059
.	O
The	O
relative	O
MMP	O
activity	O
of	O
dentin	O
beams	O
was	O
tested	O
using	O
a	O
generic	O
MMP	O
assay	B-T059
.	O
Data	O
were	O
analyzed	O
using	O
repeated	O
-	O
measures	O
ANOVA	O
,	O
α=0.05	O
.	O
All	O
treated	O
groups	O
showed	O
significant	O
decrease	O
in	O
CTX	O
release	O
(	O
32.2	O
-	O
469.5pg	O
/	O
mg	O
dentin	O
)	O
and	O
ICTP	O
(	O
1.8	O
-	O
47.6ng	O
/	O
mg	O
dentin	O
)	O
fragments	O
during	O
the	O
first	O
month	O
of	O
incubation	B-T059
compared	O
to	O
control	O
(	O
1159pg	O
/	O
mg	O
and	O
72.9ng	O
/	O
mg	O
dentin	O
,	O
respectively	O
)	O
.	O
GA5	O
,	O
GS5	B-T121
and	O
CR200	B-T121
maintained	O
their	O
inhibitory	O
effect	O
during	O
6	O
-	O
month	O
incubation	B-T059
.	O
The	O
results	O
were	O
confirmed	O
by	O
dry	O
mass	O
loss	O
and	O
relative	O
MMP	O
activity	O
following	O
6	O
months	O
.	O
The	O
results	B-T033
of	O
this	O
study	O
indicate	O
that	O
the	O
long	O
-	O
term	O
effect	O
is	O
both	O
crosslinker	O
and	O
dose	O
dependent	O
.	O
      
The	O
Corneal	O
Epithelial	O
Barrier	B-T033
and	O
Its	O
Developmental	O
Role	O
in	O
Isolating	O
Corneal	O
Epithelial	O
and	O
Conjunctival	O
Cells	O
From	O
One	O
Another	O
During	O
development	O
,	O
the	O
corneal	O
epithelium	O
(	O
CE	O
)	O
and	O
the	O
conjunctiva	B-T023
are	O
derived	O
from	O
the	O
surface	B-T018
ectoderm	I-T018
.	O
Here	O
we	O
have	O
examined	B-T033
how	O
,	O
during	O
development	O
,	O
the	O
cells	O
of	O
these	O
two	O
issues	O
become	O
isolated	O
from	O
each	O
other	O
.	O
Epithelia	O
from	O
the	O
anterior	B-T023
eyes	I-T023
of	O
chicken	B-T018
embryos	I-T018
were	O
labeled	O
with	O
the	O
fluorescent	O
,	O
lipophilic	O
dye	O
,	O
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine	O
perchlorate	O
(	O
DiI	O
)	O
.	O
DiI	O
was	O
placed	O
on	O
the	O
epithelial	O
surface	O
of	O
the	O
developing	O
anterior	B-T023
eye	I-T023
and	O
its	O
diffusion	O
was	O
monitored	O
by	O
fluorescence	B-T059
microscopy	I-T059
.	O
Concomitant	O
morphologic	O
changes	O
in	O
the	O
surface	O
cells	O
of	O
these	O
epithelial	O
were	O
examined	B-T033
by	O
scanning	B-T059
electron	I-T059
microscopy	I-T059
.	O
Immunofluorescence	B-T059
was	O
used	O
to	O
analyze	O
the	O
expression	O
of	O
cytokeratin	O
K3	O
,	O
ZO-1	O
,	O
N	O
-	O
cadherin	O
and	O
Connexin-43	O
and	O
the	O
function	O
of	O
gap	O
junctions	O
was	O
analyzed	O
using	O
a	O
cut	O
-	O
loading	O
with	O
the	O
fluorescent	O
dye	O
rhodamine	O
-	O
dextran	O
.	O
Prior	O
to	O
embryonic	O
day	O
8	O
(	O
E	O
8)	O
,	O
DiI	O
placed	O
on	O
the	O
surface	O
of	O
the	O
CE	O
spreads	O
throughout	O
all	O
the	O
epithelial	O
cells	O
of	O
the	O
anterior	B-T023
eye	I-T023
.	O
When	O
older	B-T023
eyes	I-T023
were	O
similarly	O
labeled	O
,	O
dye	O
diffusion	O
was	O
restricted	O
to	O
the	O
CE	O
.	O
Similarly	O
,	O
diffusion	O
of	O
DiI	O
placed	O
on	O
the	O
conjunctival	B-T023
surface	O
after	O
E	O
8	O
was	O
restricted	O
to	O
the	O
conjunctiva	B-T023
.	O
Scanning	B-T059
electron	I-T059
microscopy	I-T059
showed	O
that	O
developmentally	O
(	O
1	O
)	O
physical	B-T033
separations	I-T033
progressively	O
form	O
between	O
the	O
cells	O
of	O
the	O
CE	O
and	O
those	O
of	O
the	O
conjunctiva	B-T023
,	O
and	O
(	O
2	O
)	O
by	O
E	O
8	O
these	O
separations	O
form	O
a	O
ring	B-T023
that	O
completely	O
encompasses	O
the	O
cornea	B-T023
.	O
The	O
functional	O
restriction	O
of	O
gap	O
junctions	O
between	O
these	O
tissues	O
did	O
not	O
occur	O
until	O
E	O
14	O
.	O
During	O
ocular	O
development	O
,	O
a	O
barrier	B-T033
to	O
the	O
diffusion	O
of	O
DiI	O
forms	O
between	O
the	O
contiguous	O
CE	O
and	O
conjunctiva	B-T023
prior	O
to	O
the	O
differential	O
expression	O
of	O
gap	O
junctions	O
within	O
these	O
tissues	O
.	O
      
Body	O
burden	O
of	O
heavy	O
metals	O
among	O
HIV	B-T033
high	O
risk	O
population	O
in	O
USA	O
HIV	B-T033
high	O
risk	O
population	O
may	O
face	O
not	O
only	O
the	O
threat	O
of	O
HIV	B-T047
infection	I-T047
but	O
also	O
a	O
higher	O
chance	O
of	O
exposure	O
to	O
environmental	O
contaminants	O
.	O
However	O
,	O
no	O
previous	O
studies	O
have	O
examined	O
the	O
body	O
burden	O
of	O
environmental	O
pollutants	O
including	O
heavy	O
metals	O
among	O
HIV	B-T033
high	O
risk	O
populations	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
adults	O
aged	O
20	O
-	O
59	O
years	O
old	O
at	O
high	B-T033
risk	I-T033
of	I-T033
HIV	B-T047
infection	I-T047
have	O
higher	O
blood	B-T033
levels	I-T033
of	I-T033
heavy	I-T033
metals	I-T033
compared	O
to	O
those	O
with	O
low	O
risk	O
of	O
HIV	B-T047
infection	I-T047
in	O
United	O
States	O
.	O
We	O
used	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
NHANES	O
)	O
1999	O
-	O
2010	O
to	O
compare	O
exposures	O
to	O
heavy	O
metals	O
including	O
cadmium	O
,	O
lead	O
,	O
and	O
total	O
mercury	O
by	O
HIV	B-T033
risk	B-T033
status	I-T033
.	O
The	O
results	O
showed	O
that	O
people	O
at	O
high	B-T033
risk	I-T033
of	I-T033
HIV	B-T033
had	O
higher	O
blood	O
concentrations	O
of	O
all	O
heavy	O
metals	O
compared	O
to	O
their	O
counterparts	O
with	O
lower	O
HIV	B-T033
risks	I-T033
.	O
In	O
multivariate	O
linear	O
regression	O
models	O
,	O
HIV	B-T033
risk	I-T033
status	O
was	O
significantly	O
associated	O
with	O
increased	O
blood	B-T059
cadmium	I-T059
,	O
lead	B-T059
,	O
and	O
total	B-T059
mercury	I-T059
after	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
race	O
,	O
education	O
,	O
and	O
poverty	O
income	O
ratio	O
.	O
Our	O
study	O
suggests	O
that	O
people	O
at	O
high	B-T033
risk	I-T033
of	I-T033
HIV	B-T033
have	O
significantly	O
higher	O
body	O
burden	O
of	O
heavy	O
metals	O
including	O
cadmium	O
,	O
lead	O
,	O
and	O
mercury	O
compared	O
to	O
those	O
with	O
low	O
risk	O
of	O
HIV	B-T033
.	O
Further	O
longitudinal	O
study	O
collecting	O
more	O
pollutants	O
are	O
warranted	O
to	O
determine	O
the	O
potential	O
health	O
effects	O
of	O
these	O
elevated	O
pollutants	O
on	O
both	O
HIV	B-T047
-	I-T047
infected	I-T047
and	O
HIV	B-T033
high	O
-	O
risk	O
populations	O
.	O
      
Double	B-T121
-	I-T121
Network	I-T121
Hydrogel	I-T121
with	O
Tunable	O
Mechanical	O
Performance	O
and	O
Biocompatibility	O
for	O
the	O
Fabrication	O
of	O
Stem	O
Cells	O
-	O
Encapsulated	B-T121
Fibers	I-T121
and	O
3D	O
Assemble	O
Fabrication	O
of	O
cell	O
-	O
encapsulated	B-T121
fibers	I-T121
could	O
greatly	O
contribute	O
to	O
tissue	B-T061
engineering	I-T061
and	O
regenerative	O
medicine	O
.	O
However	O
,	O
existing	O
methods	O
suffered	O
from	O
not	O
only	O
unavoidability	O
of	O
cell	O
damaging	O
conditions	O
and/or	O
sophisticated	O
equipment	O
,	O
but	O
also	O
unavailability	O
of	O
proper	O
materials	O
to	O
satisfy	O
both	O
mechanical	O
and	O
biological	O
expectations	O
.	O
In	O
this	O
work	O
,	O
a	O
simple	O
method	O
is	O
proposed	O
to	O
prepare	O
cell	O
-	O
encapsulated	B-T121
fibers	I-T121
with	O
tunable	O
mechanical	O
strength	O
and	O
stretching	O
behavior	O
as	O
well	O
as	O
diameter	O
and	O
microstructure	O
.	O
The	O
hydrogel	B-T121
fibers	B-T121
are	O
made	O
from	O
optimal	O
combination	O
of	O
alginate	O
and	O
poly(N	O
-	O
iso	O
-	O
propylacrylamide)-poly(ethylene	O
glycol	O
)	O
,	O
characteristics	O
of	O
double	B-T121
-	I-T121
network	I-T121
hydrogel	I-T121
,	O
with	O
enough	O
stiffness	B-T184
and	O
flexibility	O
to	O
create	O
a	O
variety	O
of	O
three	O
dimensional	O
structures	O
like	O
parallel	O
helical	O
and	O
different	O
knots	O
without	O
crack	O
.	O
Furthermore	O
,	O
such	O
hydrogel	B-T121
fibers	B-T121
exhibit	O
better	O
compatibility	O
as	O
indicated	B-T033
by	O
the	O
viability	O
,	O
proliferation	O
and	O
expression	O
of	O
pluripotency	O
markers	O
of	O
embryonic	O
stem	O
cells	O
encapsulated	O
after	O
4	B-T033
-	I-T033
day	I-T033
culture	B-T059
.	O
The	O
double	B-T121
-	I-T121
network	I-T121
hydrogel	I-T121
possesses	B-T048
specific	O
quick	O
responses	O
to	O
either	O
of	O
alginate	O
lyase	O
,	O
EDTA	B-T121
or	O
lower	O
environmental	O
temperature	O
which	O
facilitate	O
the	O
optional	O
degradation	O
of	O
fibers	B-T121
or	O
fibrous	O
assemblies	O
to	O
release	O
the	O
cells	O
encapsulated	O
for	O
subsequent	O
assay	B-T059
or	O
treatment	B-T061
.	O
      
Mimiviruses	B-T005
and	O
the	O
Human	O
Interferon	B-T121
System	O
:	O
Viral	O
Evasion	O
of	O
Classical	O
Antiviral	O
Activities	O
,	O
But	O
Inhibition	O
By	O
a	O
Novel	O
Interferon	B-T121
-	I-T121
β	I-T121
Regulated	O
Immunomodulatory	B-T061
Pathway	O
In	O
this	O
review	O
we	O
discuss	O
the	O
role	O
of	O
mimiviruses	B-T005
as	O
potential	O
human	O
pathogens	B-T001
focusing	O
on	O
clinical	O
and	O
evolutionary	O
evidence	O
.	O
We	O
also	O
propose	O
a	O
novel	O
antiviral	O
immunomodulatory	B-T121
pathway	O
controlled	O
by	O
interferon	B-T121
-	I-T121
β	I-T121
(	O
IFN	B-T121
-	I-T121
β	I-T121
)	O
and	O
mediated	O
by	O
immune	O
-	O
responsive	O
gene	O
1	O
(	O
IRG1	O
)	O
and	O
itaconic	O
acid	O
,	O
its	O
product	O
.	O
Acanthamoeba	B-T005
polyphaga	I-T005
Mimivirus	I-T005
(	O
APMV	B-T005
)	O
was	O
isolated	O
from	O
amoebae	O
in	O
a	O
hospital	O
while	O
investigating	O
a	O
pneumonia	B-T047
outbreak	O
.	O
Mimivirus	B-T005
ubiquity	O
and	O
role	O
as	O
protist	B-T001
pathogens	B-T001
are	O
well	O
understood	O
,	O
and	O
its	O
putative	O
status	O
as	O
a	O
human	O
pathogen	B-T001
has	O
been	O
gaining	O
strength	O
as	O
more	O
evidence	O
is	O
being	O
found	O
.	O
The	O
study	O
of	O
APMV	B-T005
and	O
human	O
cells	O
interaction	O
revealed	O
that	O
the	O
virus	B-T005
is	O
able	O
to	O
evade	O
the	O
IFN	B-T121
system	O
by	O
inhibiting	O
the	O
regulation	O
of	O
interferon	B-T121
-stimulated	O
genes	O
,	O
suggesting	O
that	O
the	O
virus	B-T005
and	O
humans	O
have	O
had	O
host	O
-	O
pathogen	O
interactions	O
.	O
It	O
also	O
has	O
shown	O
that	O
the	O
virus	B-T005
is	O
capable	O
of	O
growing	O
on	O
IFN	O
-	O
α2	O
,	O
but	O
not	O
on	O
IFN	B-T121
-	I-T121
β	I-T121
-	O
treated	O
cells	O
,	O
hinting	O
at	O
an	O
exclusive	O
IFN	B-T121
-	I-T121
β	I-T121
antiviral	O
pathway	O
.	O
Our	O
hypothesis	O
based	O
on	O
preliminary	O
data	O
and	O
published	O
articles	O
is	O
that	O
IFN	B-T121
-	I-T121
β	I-T121
preferentially	O
upregulates	O
IRG1	O
in	O
human	O
macrophagic	O
cells	O
,	O
which	O
in	O
turn	O
produces	O
itaconic	O
acid	O
.	O
This	O
metabolite	O
links	O
metabolism	O
to	O
antiviral	O
activity	O
by	O
inactivating	O
the	O
virus	B-T005
,	O
in	O
a	O
novel	O
immunomodulatory	B-T061
pathway	O
relevant	O
for	O
APMV	B-T005
infections	O
and	O
probably	O
to	O
other	O
infectious	B-T047
diseases	I-T047
as	O
well	O
.	O
      
Optimization	O
of	O
Early	O
Response	B-T058
Monitoring	I-T058
and	O
Prediction	O
of	O
Cancer	B-T191
Antiangiogenesis	B-T061
Therapy	I-T061
via	O
Noninvasive	O
PET	B-T060
Molecular	I-T060
Imaging	I-T060
Strategies	O
of	O
Multifactorial	B-T033
Bioparameters	O
Objective	O
:	O
Antiangiogenesis	B-T061
therapy	I-T061
(	O
AAT	B-T061
)	O
has	O
provided	O
substantial	O
benefits	O
regarding	O
improved	O
outcomes	O
and	O
survival	O
for	O
suitable	O
patients	O
in	O
clinical	O
settings	O
.	O
Therefore	O
,	O
the	O
early	O
definition	O
of	O
therapeutic	O
effects	O
is	O
urgently	O
needed	O
to	O
guide	O
cancer	B-T191
AAT	B-T061
.	O
We	O
aimed	O
to	O
optimize	O
the	O
early	O
response	B-T058
monitoring	I-T058
and	O
prediction	O
of	O
AAT	B-T061
efficacy	O
,	O
as	O
indicated	O
by	O
the	O
multi	O
-	O
targeted	O
anti	B-T121
-	I-T121
angiogenic	I-T121
drug	I-T121
sunitinib	B-T121
in	O
U87MG	B-T191
tumors	I-T191
,	O
using	O
noninvasive	O
positron	B-T060
emission	I-T060
computed	I-T060
tomography	I-T060
(	I-T060
PET	I-T060
)	I-T060
molecular	I-T060
imaging	I-T060
strategies	O
of	O
multifactorial	B-T033
bioparameters	O
.	O
Methods	O
:	O
U87MG	B-T191
tumor	I-T191
mice	O
were	O
treated	O
via	O
intragastric	O
injections	B-T061
of	O
sunitinib	B-T121
(	O
80	O
mg	O
/	O
kg	O
)	O
or	O
vehicle	O
for	O
7	O
consecutive	O
days	O
.	O
Longitudinal	O
MicroPET	B-T060
/	I-T060
CT	I-T060
scans	I-T060
with	O
(	O
18)F	O
-	O
FDG	O
,	O
(	B-T121
18)F	I-T121
-	I-T121
FMISO	I-T121
,	I-T121
(	O
18)F	O
-	O
ML-10	O
and	O
(	O
18)F	O
-	O
Alfatide	O
II	O
were	O
acquired	O
to	O
quantitatively	O
measure	O
metabolism	O
,	O
hypoxia	O
,	O
apoptosis	O
and	O
angiogenesis	B-T191
on	O
days	O
0	O
,	O
1	O
,	O
3	O
,	O
7	O
and	O
13	O
following	O
therapy	B-T061
initiation	O
.	O
Tumor	O
tissues	O
from	O
a	O
dedicated	O
group	O
of	O
mice	O
were	O
collected	O
for	O
immunohistochemical	B-T059
(	O
IHC	B-T059
)	O
analysis	O
of	O
key	O
biomarkers	O
(	O
Glut-1	O
,	O
CA	O
-	O
IX	O
,	O
TUNEL	O
,	O
ανβ3	O
and	O
CD31	O
)	O
at	O
the	O
time	O
points	O
of	O
PET	B-T060
imaging	I-T060
.	O
The	O
tumor	O
sizes	O
and	O
mouse	O
weights	O
were	O
measured	O
throughout	O
the	O
study	O
.	O
The	O
tumor	B-T191
uptake	O
(	O
ID%/gmax	O
)	O
,	O
the	O
ratios	O
of	O
the	O
tumor	B-T191
/	O
muscle	O
(	O
T	B-T191
/	O
M	O
)	O
for	O
each	O
probe	O
,	O
and	O
the	O
tumor	B-T191
growth	I-T191
ratios	O
(	O
TGR	O
)	O
were	O
calculated	O
and	O
used	O
for	O
statistical	O
analyses	O
of	O
the	O
differences	O
and	O
correlations	O
.	O
Results	O
:	O
Sunitinib	B-T121
successfully	O
inhibited	O
U87MG	B-T191
tumor	I-T191
growth	I-T191
with	O
significant	O
differences	O
in	O
the	O
tumor	O
size	O
from	O
day	O
9	O
after	O
sunitinib	B-T121
treatment	B-T061
compared	O
with	O
the	O
control	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O
The	O
uptakes	O
of	O
(	B-T121
18)F	I-T121
-	I-T121
FMISO	I-T121
(	O
reduced	O
hypoxia	O
)	O
,	O
(	O
18)F	O
-	O
ML-10	O
(	O
increased	O
apoptosis	O
)	O
and	O
(	O
18)F	O
-	O
Alfatide	O
II	O
(	O
decreased	O
angiogenesis	B-T191
)	O
in	O
the	O
tumor	B-T191
lesions	B-T033
significantly	O
changed	O
during	O
the	O
early	O
stage	O
(	O
days	O
1	O
to	O
3	O
)	O
of	O
sunitinib	B-T121
treatment	B-T061
;	O
however	O
,	O
the	O
uptake	O
of	O
(	O
18)F	O
-	O
FDG	O
(	O
increased	O
glucose	O
metabolism	O
)	O
was	O
significantly	O
different	O
during	O
the	O
late	O
stage	O
.	O
The	O
PET	B-T060
imaging	I-T060
data	O
of	O
each	O
probe	O
were	O
all	O
confirmed	O
via	O
ex	O
vivo	O
IHC	B-T059
of	O
the	O
relevant	O
biomarkers	O
.	O
Notably	O
,	O
the	O
PET	B-T060
imaging	I-T060
of	O
(	O
18)F	O
-	O
Alfatide	O
II	O
and	O
(	B-T121
18)F	I-T121
-	I-T121
FMISO	I-T121
was	O
significantly	O
correlated	O
(	O
all	O
P	O
<	O
0.05	O
)	O
with	O
TGR	O
,	O
whereas	O
the	O
imaging	O
of	O
(	O
18)F	O
-	O
FDG	O
and	O
(	O
18)F	O
-	O
ML-10	O
was	O
not	O
significantly	O
correlated	O
with	O
TGR	O
.	O
Conclusion	O
:	O
Based	O
on	O
the	O
tumor	B-T191
uptake	O
of	O
the	O
PET	B-T060
probes	O
and	O
their	O
correlations	O
with	O
MVD	O
and	O
TGR	O
,	O
(	O
18)F	O
-	O
Alfatide	O
II	O
PET	B-T060
may	O
not	O
only	O
monitor	O
the	O
early	O
response	B-T058
but	O
also	O
precisely	O
predict	O
the	O
therapeutic	O
efficacy	O
of	O
the	O
multi	O
-	O
targeted	O
,	O
anti	B-T121
-	I-T121
angiogenic	I-T121
drug	I-T121
sunitinib	B-T121
in	O
U87MG	B-T191
tumors	I-T191
.	O
In	O
conclusion	O
,	O
it	O
is	O
feasible	O
to	O
optimize	O
the	O
early	O
response	B-T058
monitoring	I-T058
and	O
efficacy	O
prediction	O
of	O
cancer	B-T191
AAT	B-T061
using	O
noninvasive	O
PET	B-T060
molecular	I-T060
imaging	I-T060
strategies	O
of	O
multifactorial	B-T033
bioparameters	O
,	O
such	O
as	O
angiogenesis	B-T191
imaging	B-T060
with	O
(	O
18)F	O
-	O
Alfatide	O
II	O
,	O
which	O
represents	O
an	O
RGD	O
-based	O
probe	O
.	O
      
Allergen	O
Valency	O
,	O
Dose	O
,	O
and	O
FcεRI	O
Occupancy	O
Set	O
Thresholds	O
for	O
Secretory	O
Responses	O
to	O
Pen	O
a	O
1	O
and	O
Motivate	O
Design	O
of	O
Hypoallergens	O
Ag	O
-mediated	O
crosslinking	O
of	O
IgE	O
-	O
FcεRI	O
complexes	O
activates	O
mast	O
cells	O
and	O
basophils	O
,	O
initiating	O
the	O
allergic	O
response	O
.	O
Of	O
34	O
donors	O
recruited	O
having	O
self	O
-	O
reported	O
shrimp	O
allergy	O
,	O
only	O
35	O
%	O
had	O
significant	O
levels	O
of	O
shrimp	O
-	O
specific	O
IgE	O
in	O
serum	O
and	O
measurable	O
basophil	O
secretory	O
responses	O
to	O
rPen	O
a	O
1	O
(	O
shrimp	O
tropomyosin	O
)	O
.	O
We	O
report	O
that	O
degranulation	O
is	O
linked	O
to	O
the	O
number	O
of	O
FcεRI	O
occupied	O
with	O
allergen	O
-	O
specific	O
IgE	O
,	O
as	O
well	O
as	O
the	O
dose	O
and	O
valency	O
of	O
Pen	O
a	O
1	O
.	O
Using	O
clustered	O
regularly	O
interspaced	O
palindromic	O
repeat	O
-	O
based	O
gene	O
editing	O
,	O
human	O
RBL(rαKO	O
)	O
cells	O
were	O
created	O
that	O
exclusively	O
express	O
the	O
human	O
FcεRIα	O
subunit	O
.	O
Pen	O
a	O
1	O
-	O
specific	O
IgE	O
was	O
affinity	O
purified	O
from	O
shrimp	O
-	O
positive	B-T033
plasma	O
.	O
Cells	O
primed	O
with	O
a	O
range	O
of	O
Pen	O
a	O
1	O
-	O
specific	O
IgE	O
and	O
challenged	O
with	O
Pen	O
a	O
1	O
showed	O
a	O
bell	O
-	O
shaped	O
dose	O
response	O
for	O
secretion	O
,	O
with	O
optimal	O
Pen	O
a	O
1	O
doses	O
of	O
0.1	O
-	O
10	O
ng	O
/	O
ml	O
.	O
Mathematical	O
modeling	O
provided	O
estimates	O
of	O
receptor	O
aggregation	O
kinetics	O
based	O
on	O
FcεRI	O
occupancy	O
with	O
IgE	O
and	O
allergen	O
dose	O
.	O
Maximal	O
degranulation	O
was	O
elicited	O
when	O
∼2700	O
I	O
gE	O
-	O
FcεRI	O
complexes	O
were	O
occupied	O
with	O
specific	O
IgE	O
and	O
challenged	O
with	O
Pen	O
a	O
1	O
(	O
IgE	O
epitope	O
valency	O
of	O
≥8	O
)	O
,	O
although	O
measurable	O
responses	O
were	O
achieved	O
when	O
only	O
a	O
few	O
hundred	O
FcεRI	O
were	O
occupied	O
.	O
Prolonged	O
periods	O
of	O
pepsin	B-T121
-mediated	O
Pen	O
a	O
1	O
proteolysis	O
,	O
which	O
simulates	O
gastric	O
digestion	O
,	O
were	O
required	O
to	O
diminish	O
secretory	O
responses	O
.	O
Recombinant	O
fragments	O
(	O
60	O
-	O
79	O
aa	O
)	O
,	O
which	O
together	O
span	O
the	O
entire	O
length	O
of	O
tropomyosin	O
,	O
were	O
weak	O
secretagogues	O
.	O
These	O
fragments	O
have	O
reduced	O
dimerization	O
capacity	O
,	O
compete	O
with	O
intact	O
Pen	O
a	O
1	O
for	O
binding	O
to	O
IgE	O
-	O
FcεRI	O
complexes	O
,	O
and	O
represent	O
a	O
starting	O
point	O
for	O
the	O
design	O
of	O
promising	O
hypoallergens	O
for	O
immunotherapy	B-T061
.	O
      
Identification	O
of	O
a	O
group	O
of	O
XTHs	O
genes	O
responding	O
to	O
heavy	O
metal	O
mercury	O
,	O
salinity	O
and	O
drought	O
stresses	O
in	O
Medicago	O
truncatula	O
Xyloglucan	O
endotransglucosylase	O
/	O
hydrolases	O
(	O
XTH	O
)	O
are	O
one	O
of	O
the	O
key	O
enzymes	O
regulating	O
cell	O
wall	O
construction	O
,	O
extension	O
and	O
metabolism	O
.	O
In	O
the	O
study	O
,	O
44	O
XTH	O
protein	O
genes	O
from	O
Medicago	O
truncatula	O
genome	O
were	O
identified	O
using	O
bioinformatics	O
,	O
microarray	O
and	O
RT	O
-	O
PCR	O
.	O
Each	O
XTH	O
was	O
showed	O
to	O
possess	O
a	O
highly	O
conserved	O
domain	O
(	O
(	O
D	O
/	O
N)-E-(I	O
/	O
L	O
/	O
F	O
/	O
V)-D-(F	O
/	O
I	O
/	O
L)-E-(F	O
/	O
L)-L	O
-	O
G	O
)	O
,	O
and	O
most	O
of	O
XTHs	O
possess	O
four	O
Cys	O
in	O
the	O
C	O
terminal	O
region	O
,	O
which	O
suggests	O
the	O
potential	O
for	O
generating	O
disulfide	O
bonds	O
.	O
Based	O
on	O
the	O
XTH	O
protein	O
sequences	O
,	O
these	O
XTHs	O
can	O
be	O
classified	O
into	O
three	O
major	O
families	O
and	O
each	O
family	O
can	O
be	O
subdivided	O
into	O
more	O
groups	O
.	O
Examination	O
of	O
the	O
genomic	O
location	O
of	O
XTH	O
genes	O
on	O
M.	O
truncatula	O
chromosomes	O
showed	O
that	O
the	O
evolutional	O
expansion	O
of	O
the	O
genes	O
was	O
possibly	O
attributed	O
to	O
localized	O
gene	O
duplications	O
.	O
To	O
investigate	O
the	O
possible	O
involvement	O
of	O
the	O
XTHs	O
responding	O
to	O
heavy	O
metals	O
and	O
other	O
abiotic	O
stresses	O
,	O
the	O
XTH	O
genes	O
were	O
exposed	O
to	O
heavy	O
metal	O
(	O
Hg	O
or	O
Cu	B-T121
)	O
,	O
salt	O
and	O
drought	O
stresses	O
.	O
There	O
were	O
28	O
,	O
21	O
and	O
21	O
MtXTH	O
genes	O
found	O
to	O
respond	O
to	O
HgCl2	B-T121
,	O
salt	O
and	O
drought	O
stresses	O
,	O
respectively	O
,	O
but	O
their	O
expression	O
were	O
different	O
under	O
the	O
stresses	O
.	O
Some	O
of	O
the	O
XTH	O
genes	O
were	O
well	O
confirmed	O
by	O
quantitative	O
RT	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
.	O
We	O
further	O
specified	O
expression	O
of	O
a	O
XTH	O
gene	O
Medtr4g128580	O
(	O
MtXTH3	O
)	O
under	O
different	O
environmental	O
stresses	O
,	O
and	O
showed	O
that	O
MtXTH3	O
was	O
induced	O
by	O
Hg	O
exposure	O
.	O
These	O
results	O
indicated	O
that	O
a	O
group	O
of	O
MtXTHs	O
could	O
be	O
differentially	O
expressed	O
under	O
the	O
environmental	O
stresses	O
.	O
      
Functional	O
analyses	O
of	O
OcRhS1	O
and	O
OcUER1	O
involved	O
in	O
UDP	O
-	O
L	O
-	O
rhamnose	O
biosynthesis	O
in	O
Ornithogalum	O
caudatum	O
UDP	O
-	O
L	O
-	O
rhamnose	O
(	O
UDP	O
-	O
Rha	O
)	O
is	O
an	O
important	O
sugar	B-T121
donor	I-T121
for	O
the	O
synthesis	O
of	O
rhamnose	O
-containing	O
compounds	O
in	O
plants	O
.	O
However	O
,	O
only	O
a	O
few	O
enzymes	O
and	O
their	O
encoding	O
genes	O
involved	O
in	O
UDP	O
-	O
Rha	O
biosynthesis	O
are	O
available	O
in	O
plants	O
.	O
Here	O
,	O
two	O
genes	O
encoding	O
rhamnose	O
synthase	O
(	O
RhS	O
)	O
and	O
bi	O
-	O
functional	O
UDP-4	O
-	O
keto-6	O
-	O
deoxy	O
-	O
D	O
-	O
glucose	O
(	O
UDP-4K6DG	O
)	O
3	O
,	O
5	O
-	O
epimerase	O
/	O
UDP-4	O
-	O
keto	O
-	O
L	O
-	O
rhamnose	O
(	O
UDP-4KR	O
)	O
4	O
-	O
keto	O
-	O
reductase	O
(	O
UER	O
)	O
were	O
isolated	O
from	O
Ornithogalum	O
caudatum	O
based	O
on	O
the	O
RNA	O
-	O
Seq	O
data	O
.	O
The	O
OcRhS1	O
gene	O
has	O
an	O
ORF	O
(	O
open	O
reading	O
frame	O
)	O
of	O
2019	O
bp	O
encoding	O
a	O
tri	O
-	O
functional	O
RhS	O
enzyme	O
.	O
In	O
vitro	O
enzymatic	B-T059
assays	I-T059
revealed	O
OcRhS1	O
can	O
really	O
convert	O
UDP	O
-	O
D	O
-	O
glucose	O
(	O
UDP	O
-	O
Glc	O
)	O
into	O
UDP	O
-	O
Rha	O
via	O
three	O
consecutive	O
reactions	O
.	O
Biochemical	O
evidences	O
indicated	O
that	O
the	O
recombinant	O
OcRhS1	O
was	O
active	O
in	O
the	O
pH	O
range	O
of	O
5	O
-	O
11	O
and	O
over	O
the	O
temperature	O
range	O
of	O
0	O
-	O
60	O
°	O
C	O
.	O
The	O
Km	O
value	O
of	O
OcRhS1	O
for	O
UDP	O
-	O
Glc	O
was	O
determined	O
to	O
be	O
1.52	O
×	O
10(-4	O
)	O
M.	O
OcRhS1	O
is	O
a	O
multi	O
-	O
domain	O
protein	O
with	O
two	O
sets	O
of	O
cofactor	O
-	O
binding	O
motifs	O
.	O
The	O
cofactors	O
dependent	O
properties	O
of	O
OcRhS1	O
were	O
thus	O
characterized	O
in	O
this	O
research	O
.	O
Moreover	O
,	O
the	O
N	O
-	O
terminal	O
portion	O
of	O
OcRhS1	O
(	O
OcRhS1	O
-	O
N	O
)	O
was	O
observed	O
to	O
metabolize	O
UDP	O
-	O
Glc	O
to	O
form	O
intermediate	O
UDP-4K6DG	O
.	O
OcUER1	O
contains	O
an	O
ORF	O
of	O
906	O
bp	O
encoding	O
a	O
polypeptide	O
of	O
301	O
aa	B-T121
.	O
OcUER1	O
shared	O
high	O
similarity	O
with	O
the	O
carboxy	O
-	O
terminal	O
domain	O
of	O
OcRhS1	O
(	O
OcRhS1	O
-	O
C	O
)	O
,	O
suggesting	O
its	O
intrinsic	O
ability	O
of	O
converting	O
UDP-4K6DG	O
into	O
UDP	O
-	O
Rha	O
.	O
It	O
was	O
thus	O
reasonably	O
inferred	O
that	O
UDP	O
-	O
Glc	O
could	O
be	O
bio	O
-	O
transformed	O
into	O
UDP	O
-	O
Rha	O
under	O
the	O
collaborating	O
action	O
of	O
OcRhS1	O
-	O
N	O
and	O
OcUER1	O
.	O
The	O
subsequently	O
biochemical	B-T059
assay	I-T059
verified	O
this	O
notion	O
.	O
Importantly	O
,	O
expression	O
profiles	O
of	O
OcRhS1	O
and	O
OcUER1	O
revealed	O
their	O
possible	O
involvement	O
in	O
the	O
biosynthesis	O
of	O
rhamnose	O
-containing	O
polysaccharides	B-T121
in	O
O.	O
caudatum	O
.	O
      
Iodine	O
Storage	O
and	O
Metabolism	O
of	O
Mild	O
to	O
Moderate	O
Iodine	O
-	O
Deficient	O
Pregnant	O
Rats	O
Severe	O
iodine	O
deficiency	O
during	O
pregnancy	O
results	O
in	O
neurodevelopmental	B-T048
disorders	I-T048
in	O
children	O
,	O
while	O
the	O
consequences	O
of	O
mild	O
to	O
moderate	O
iodine	O
deficiency	O
(	O
MMID	O
)	O
are	O
uncertain	B-T033
.	O
The	O
concentration	B-T059
of	I-T059
iodine	I-T059
in	O
the	O
thyroid	B-T023
is	O
the	O
most	O
accurate	O
indicator	O
of	O
iodine	O
nutrition	O
.	O
This	O
study	O
aimed	O
to	O
evaluate	O
whether	O
the	O
iodine	O
stores	O
in	O
the	O
thyroid	B-T023
cover	I-T023
the	O
needs	O
of	O
the	O
mother	O
and	O
the	O
fetus	O
in	O
iodine	B-T121
-	O
sufficient	O
and	O
MMID	O
conditions	O
by	O
inductively	B-T059
coupled	I-T059
plasma	I-T059
-	I-T059
mass	I-T059
spectrometry	I-T059
.	O
One	O
hundred	O
four	O
-	O
week	O
-	O
old	O
female	O
Wistar	O
rats	O
were	O
randomly	O
divided	O
into	O
MMID	O
(	O
low	B-T033
iodine	I-T033
intake	I-T033
[	O
L	O
]	O
)	O
and	O
normal	B-T033
(	O
normal	B-T033
iodine	I-T033
intake	I-T033
[	O
N	O
]	O
)	O
groups	O
.	O
The	O
rats	O
were	O
fed	O
for	O
the	O
next	O
three	O
months	O
,	O
and	O
after	O
pregnancy	O
they	O
were	O
further	O
divided	O
into	O
two	O
subgroups	O
,	O
respectively	O
:	O
low	B-T033
iodine	I-T033
pregnancy	O
(	O
LP	B-T033
)	O
and	O
low	B-T033
iodine	I-T033
pregnancy	O
with	O
iodine	O
supplement	O
(	O
LP+	O
)	O
,	O
and	O
normal	B-T033
iodine	I-T033
intake	I-T033
pregnancy	O
(	O
NP	O
)	O
and	O
normal	B-T033
iodine	I-T033
intake	I-T033
pregnancy	O
with	O
iodine	O
supplement	O
(	O
NP+	O
)	O
.	O
The	O
iodine	B-T033
intake	I-T033
of	O
pregnant	O
rats	O
in	O
the	O
NP+	O
and	O
LP+	O
groups	O
was	O
twice	O
as	O
much	O
as	O
in	O
the	O
NP	B-T033
and	O
LP	B-T033
groups	I-T033
.	O
The	O
rats	O
were	O
sacrificed	O
on	O
gestational	O
day	O
15	O
and	O
postnatal	O
day	O
7	O
.	O
The	O
iodine	B-T059
concentration	I-T059
in	O
the	O
thyroid	B-T023
of	O
the	O
maternal	B-T033
and	O
newborn	B-T033
rats	O
,	O
maternal	B-T059
serum	I-T059
,	O
placenta	B-T018
,	O
and	O
amniotic	O
fluid	O
were	O
determined	O
by	O
inductively	B-T059
coupled	I-T059
plasma	I-T059
-	I-T059
mass	I-T059
spectrometry	I-T059
.	O
The	O
concentration	B-T059
of	I-T059
iodine	I-T059
in	O
the	O
thyroid	B-T023
of	O
the	O
N	B-T033
group	I-T033
was	O
significantly	O
higher	O
than	O
that	O
in	O
the	O
L	B-T033
group	I-T033
before	B-T033
pregnancy	I-T033
.	O
The	O
concentration	B-T059
of	I-T059
iodine	I-T059
in	O
the	O
maternal	B-T058
thyroids	I-T058
of	O
the	O
LP	B-T033
group	I-T033
decreased	O
during	O
pregnancy	O
,	O
whereas	O
that	O
of	O
the	O
NP	B-T033
group	I-T033
did	O
not	O
change	O
significantly	O
.	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
iodine	B-T059
concentration	I-T059
in	O
the	O
thyroid	B-T023
of	O
mothers	O
and	O
offspring	O
between	O
the	O
NP	B-T033
and	O
NP+	O
groups	O
,	O
but	O
it	O
was	O
significant	O
between	O
LP	O
and	O
LP+	O
groups	O
.	O
The	O
concentration	B-T059
of	I-T059
iodine	I-T059
in	O
amniotic	O
fluid	O
was	O
significantly	O
different	O
between	O
the	O
four	O
groups	O
.	O
There	O
is	O
sufficient	O
iodine	O
storage	O
in	O
the	O
thyroid	B-T023
of	O
maternal	B-T033
rats	O
with	O
normal	B-T033
iodine	I-T033
intake	I-T033
during	O
pregnancy	O
,	O
and	O
there	O
is	O
no	O
need	O
for	O
iodine	B-T058
supplementation	I-T058
.	O
However	O
,	O
iodine	O
stores	O
are	O
insufficient	O
in	O
rats	O
with	O
MMID	O
.	O
Iodine	B-T058
supplementation	I-T058
can	O
increase	O
the	O
iodine	B-T059
concentration	I-T059
in	O
the	O
thyroid	B-T023
of	O
maternal	B-T033
rats	O
with	O
MMID	O
and	O
their	O
offspring	O
,	O
as	O
well	O
as	O
in	O
the	O
amniotic	O
fluid	O
during	O
pregnancy	O
.	O
      
Methods	O
to	O
Study	O
Autophagy	O
in	O
Zebrafish	O
Autophagy	O
(	O
cellular	O
self	O
-	O
eating	O
)	O
is	O
a	O
highly	O
regulated	O
degradation	O
process	O
of	O
the	O
eukaryotic	O
cell	O
during	O
which	O
parts	O
of	O
the	O
cytoplasm	O
are	O
delivered	O
into	O
,	O
and	O
broken	O
down	O
within	O
,	O
the	O
lysosomal	O
compartment	O
.	O
The	O
process	O
serves	O
as	O
a	O
main	O
route	O
for	O
the	O
elimination	O
of	O
superfluous	O
and	O
damaged	O
cellular	O
constituents	O
,	O
thereby	O
mediating	O
macromolecular	O
and	O
organellar	O
turnover	O
.	O
In	O
addition	O
to	O
maintaining	O
cellular	O
homeostasis	O
,	O
autophagy	O
is	O
involved	O
in	O
various	O
other	O
cellular	O
and	O
developmental	O
processes	O
by	O
degrading	O
specific	O
regulatory	O
proteins	O
,	O
and	O
contributing	O
to	O
the	O
clearance	O
of	O
intracellular	O
pathogens	B-T001
.	O
The	O
physiological	O
roles	O
and	O
pathological	O
involvement	O
of	O
autophagy	O
can	O
be	O
effectively	O
studied	O
in	O
divergent	O
eukaryotic	O
model	O
systems	O
ranging	O
from	O
yeast	O
to	O
mice	O
.	O
Such	O
a	O
tractable	O
animal	O
model	O
applied	O
only	O
recently	O
for	O
autophagy	O
researchis	O
the	O
zebrafish	O
Danio	O
rerio	O
,	O
which	O
also	O
facilitates	O
the	O
analysis	O
of	O
more	O
specific	O
biological	O
processes	O
such	O
as	O
tissue	O
regeneration	O
.	O
In	O
this	O
chapter	O
,	O
we	O
overview	O
the	O
main	O
methods	O
and	O
tools	O
that	O
are	O
used	O
to	O
monitor	O
autophagic	O
structures	O
and	O
to	O
assay	B-T059
autophagic	O
responses	O
in	O
this	O
vertebrate	O
organism	O
.	O
We	O
place	O
emphasis	O
on	O
genetic	O
(	O
functional	O
)	O
approaches	O
applied	O
for	O
exploring	O
novel	O
cellular	O
and	O
developmental	O
roles	O
of	O
the	O
autophagic	O
process	O
.	O
      
Prostate	B-T061
external	I-T061
beam	I-T061
radiotherapy	I-T061
combined	O
with	O
high	B-T061
-	I-T061
dose	I-T061
-	I-T061
rate	I-T061
brachytherapy	I-T061
:	O
dose	O
-	O
volume	O
parameters	B-T033
from	O
deformably	O
-	O
registered	O
plans	O
correlate	O
with	O
late	O
gastrointestinal	O
complications	O
Derivation	O
of	O
dose	O
-	O
volume	O
correlated	O
with	O
toxicity	O
for	O
multi	B-T061
-	I-T061
modal	I-T061
treatments	I-T061
can	O
be	O
difficult	O
due	O
to	O
the	O
perceived	O
need	O
for	O
voxel	B-T059
-	I-T059
by	I-T059
-	I-T059
voxel	I-T059
dose	I-T059
accumulation	I-T059
.	O
With	O
data	O
available	O
for	O
a	O
single	O
-	O
institution	O
cohort	O
with	O
long	O
follow	B-T058
-	I-T058
up	I-T058
,	O
an	O
investigation	O
was	O
undertaken	O
into	O
rectal	O
dose	O
-	O
volume	O
effects	O
for	O
gastrointestinal	B-T033
toxicities	I-T033
after	O
deformably	O
-	O
registering	O
each	O
phase	O
of	O
a	O
combined	O
external	B-T061
beam	I-T061
radiotherapy	I-T061
EBRT	B-T061
(	O
EBRT)/	O
high	B-T061
-	I-T061
dose	I-T061
-	I-T061
rate	I-T061
(	I-T061
HDR	I-T061
)	I-T061
brachytherapy	I-T061
prostate	B-T061
treatment	I-T061
.	O
One	O
hundred	O
and	O
eighteen	O
patients	O
received	O
EBRT	B-T061
in	O
23	O
fractions	O
of	O
2	O
Gy	O
and	O
HDR	B-T061
(	O
TG43	O
algorithm	O
)	O
in	O
3	O
fractions	O
of	O
6.5	O
Gy	O
.	O
Results	B-T033
for	O
the	O
Late	O
Effects	O
of	O
Normal	O
Tissues	O
-	O
Subjective	O
,	O
Objective	O
,	O
Management	O
and	O
Analytic	O
toxicity	O
assessments	O
were	O
available	O
with	O
a	O
median	O
follow	B-T058
-	I-T058
up	I-T058
of	O
72	O
months	O
.	O
The	O
HDR	B-T061
CT	B-T060
was	O
deformably	O
-	O
registered	O
to	O
the	O
EBRT	B-T061
CT	B-T060
.	O
Doses	O
were	O
corrected	O
for	O
dose	B-T061
fractionation	I-T061
.	O
Rectum	B-T023
dose	O
-	O
volume	O
histogram	O
(	O
DVH	O
)	O
parameters	B-T033
were	O
calculated	O
in	O
two	O
ways	O
.	O
(	O
1	O
)	O
Distribution	O
-	O
adding	O
:	O
parameters	B-T033
were	O
calculated	O
after	O
the	O
EBRT	B-T061
dose	O
distribution	O
was	O
3D	O
-	O
summed	O
with	O
the	O
registered	O
HDR	B-T061
dose	O
distribution	O
.	O
(	O
2	O
)	O
Parameter	O
-	O
adding	O
:	O
the	O
EBRT	B-T061
DVH	O
parameters	B-T033
were	O
added	O
to	O
HDR	B-T061
DVH	O
parameters	B-T033
.	O
Logistic	O
regressions	O
and	O
Mann	O
-	O
Whitney	O
U	O
-	O
tests	O
were	O
used	O
to	O
correlate	O
parameters	B-T033
with	O
late	O
peak	O
toxicity	O
(	O
dichotomised	O
at	O
grade	O
1	O
or	O
2	O
)	O
.	O
The	O
48	O
-	O
80	O
,	O
40	O
-	O
63	O
and	O
49	O
-	O
55	O
Gy	O
dose	O
regions	O
from	O
distribution	O
-	O
adding	O
were	O
significantly	O
correlated	O
with	O
rectal	O
bleeding	O
,	O
urgency	B-T047
/	O
tenesmus	B-T184
and	O
stool	B-T033
frequency	I-T033
respectively	O
.	O
Additionally	O
,	O
urgency	B-T047
/	O
tenesmus	B-T184
and	O
anorectal	B-T184
pain	I-T184
were	O
associated	O
with	O
the	O
25	O
-	O
26	O
Gy	O
and	O
44	O
-	O
48	O
Gy	O
dose	O
regions	O
from	O
distribution	O
-	O
adding	O
respectively	O
.	O
Parameter	O
-	O
adding	O
also	O
indicated	O
the	O
low	O
-	O
mid	O
dose	O
region	O
was	O
significantly	O
correlated	O
with	O
stool	B-T033
frequency	I-T033
and	O
proctitis	B-T047
.	O
This	O
study	O
confirms	B-T033
significant	O
dose	O
-	O
histogram	O
effects	O
for	O
gastrointestinal	B-T033
toxicities	I-T033
after	O
including	O
deformable	O
registration	O
to	O
combine	O
phases	O
of	O
EBRT	B-T061
/	O
HDR	B-T061
prostate	B-T191
cancer	I-T191
treatment	B-T061
.	O
The	O
findings	B-T033
from	O
distribution	O
-	O
adding	O
were	O
in	O
most	O
cases	O
consistent	O
with	O
those	O
from	O
parameter	O
-	O
adding	O
.	O
The	O
mid	O
-	O
high	O
dose	O
range	O
and	O
near	O
maximum	O
doses	O
were	O
important	O
for	O
rectal	O
bleeding	O
.	O
The	O
distribution	O
-	O
adding	O
mid	O
-	O
high	O
dose	O
range	O
was	O
also	O
important	O
for	O
stool	B-T033
frequency	I-T033
and	O
urgency	B-T047
/	O
tenesmus	B-T184
.	O
We	O
encourage	O
additional	O
studies	O
in	O
a	O
variety	O
of	O
institutions	O
using	O
a	O
variety	O
of	O
dose	B-T059
accumulation	I-T059
methods	I-T059
with	O
appropriate	O
inter	B-T058
-	I-T058
fraction	I-T058
motion	I-T058
management	I-T058
.	O
NCT	O
NCT00193856	O
.	O
Retrospectively	O
registered	O
12	O
September	O
2005	O
.	O
      
Utilization	O
Pattern	O
and	O
Drug	O
Use	O
of	O
Traditional	O
Chinese	O
Medicine	O
,	O
Western	O
Medicine	O
,	O
and	O
Integrated	O
Chinese	O
-	O
Western	O
Medicine	O
Treatments	B-T061
for	O
Allergic	B-T047
Rhinitis	I-T047
Under	O
the	O
National	B-T058
Health	I-T058
Insurance	I-T058
Program	I-T058
in	O
Taiwan	O
Patients	O
in	O
Taiwan	O
with	O
allergic	B-T047
rhinitis	I-T047
seek	O
not	O
only	O
Western	O
medicine	O
treatment	B-T061
but	O
also	O
Traditional	O
Chinese	O
Medicine	O
treatment	B-T061
or	O
integrated	O
Chinese	O
-	O
Western	O
medicine	O
treatment	B-T061
.	O
Various	O
studies	O
have	O
conducted	O
pairwise	O
comparison	O
on	O
Traditional	O
Chinese	O
Medicine	O
,	O
Western	O
medicine	O
,	O
and	O
integrated	O
Chinese	O
-	O
Western	O
medicine	O
treatments	B-T061
.	O
However	O
,	O
none	O
conducted	O
simultaneous	O
analysis	O
of	O
the	O
three	O
treatments	B-T061
.	O
This	O
study	O
analyzed	O
patients	O
with	O
allergic	B-T047
rhinitis	I-T047
receiving	O
the	O
three	O
treatments	B-T061
to	O
identify	O
differences	O
in	O
demographic	O
characteristic	O
and	O
medical	O
use	O
and	O
thereby	O
to	O
determine	O
drug	O
use	O
patterns	O
of	O
different	O
treatments	B-T061
.	O
The	O
National	O
Health	O
Insurance	O
Research	O
Database	O
was	O
the	O
data	O
source	O
,	O
and	O
included	O
patients	O
were	O
those	O
diagnosed	B-T033
with	O
allergic	B-T047
rhinitis	I-T047
(	O
International	O
Classification	O
of	O
Diseases	O
,	O
Ninth	O
Revision	O
,	O
Clinical	O
Modification	O
codes	O
470	O
-	O
478	O
)	O
.	O
Chi	O
-	O
square	O
test	O
and	O
Tukey	O
studentized	O
range	O
(	O
honest	O
significant	O
difference	O
)	O
test	O
were	O
conducted	O
to	O
investigate	O
the	O
differences	O
among	O
the	O
three	O
treatments	B-T061
.	O
Visit	O
frequency	O
for	O
allergic	B-T047
rhinitis	I-T047
treatment	B-T061
was	O
higher	O
in	O
female	O
than	O
male	O
patients	O
,	O
regardless	O
of	O
treatment	B-T061
with	O
Traditional	O
Chinese	O
Medicine	O
,	O
Western	O
medicine	O
,	O
or	O
integrated	O
Chinese	O
-	O
Western	O
medicine	O
.	O
Persons	O
aged	O
0	O
-	O
19	O
years	O
ranked	O
the	O
highest	O
in	O
proportion	O
of	O
visits	B-T058
for	O
allergic	B-T047
rhinitis	I-T047
.	O
Traditional	O
Chinese	O
Medicine	O
treatment	B-T061
had	O
more	O
medical	O
items	O
per	O
person	O
-	O
time	O
and	O
daily	O
drug	O
cost	O
per	O
person	O
-	O
time	O
and	O
had	O
the	O
lowest	O
total	O
expenditure	O
per	O
person	O
-	O
time	O
.	O
In	O
contrast	O
,	O
Western	O
medicine	O
had	O
the	O
lowest	O
daily	O
drug	O
cost	O
per	O
person	O
-	O
time	O
and	O
the	O
highest	O
total	O
expenditure	O
per	O
person	O
-	O
time	O
.	O
The	O
total	O
expenditure	O
per	O
person	O
-	O
time	O
,	O
daily	O
drug	O
cost	O
per	O
person	O
-	O
time	O
,	O
and	O
medical	O
items	O
per	O
person	O
-	O
time	O
of	O
integrated	O
Chinese	O
-	O
Western	O
medicine	O
treatment	B-T061
lay	O
between	O
those	O
seen	O
with	O
Traditional	O
Chinese	O
Medicine	O
and	O
Western	O
medicine	O
treatments	B-T061
.	O
Although	O
only	O
6.82	O
%	O
of	O
patients	O
with	O
allergic	B-T047
rhinitis	I-T047
chose	O
integrated	O
Chinese	O
-	O
Western	O
medicine	O
treatment	B-T061
,	O
the	O
visit	O
frequency	O
per	O
person	O
-	O
year	O
of	O
integrated	O
Chinese	O
-	O
Western	O
medicine	O
ranked	O
highest	O
.	O
In	O
addition	O
,	O
multiple	O
-	O
composition	O
medicines	B-T121
were	O
used	O
more	O
frequently	O
than	O
single	O
-	O
composition	O
medicines	B-T121
,	O
and	O
mar	B-T121
huang	I-T121
(	O
Ephedra	O
sinica	O
Stapf	O
)	O
was	O
seldom	O
used	O
to	O
decrease	O
the	O
risk	O
of	O
combining	O
medications	B-T121
.	O
      
5	O
-	O
Bromo-2	O
-	O
aryl	O
benzimidazole	O
derivatives	O
as	O
non	B-T121
-	I-T121
cytotoxic	I-T121
potential	O
dual	O
inhibitors	B-T121
of	O
α	B-T121
-	I-T121
glucosidase	I-T121
and	O
urease	O
enzymes	O
On	O
the	O
basis	O
of	O
previous	O
report	O
on	O
promising	O
α	B-T121
-	I-T121
glucosidase	I-T121
inhibitory	O
activity	O
of	O
5	O
-	O
bromo-2	O
-	O
aryl	O
benzimidazole	O
derivatives	O
,	O
these	O
derivatives	O
were	O
further	O
screened	B-T059
for	O
urease	O
inhibitory	O
and	O
cytotoxicity	B-T059
activity	I-T059
in	O
order	O
to	O
get	O
more	O
potent	O
and	O
non	B-T121
-	I-T121
cytotoxic	I-T121
potential	O
dual	O
inhibitor	B-T121
for	O
the	O
patients	O
suffering	O
from	O
diabetes	B-T047
as	O
well	O
as	O
peptic	B-T047
ulcer	I-T047
.	O
In	O
this	O
study	O
,	O
all	O
compounds	B-T121
showed	O
varying	O
degree	O
of	O
potency	O
in	O
the	O
range	O
of	O
(	O
IC50	O
=	O
8.15±0.03	O
-	O
354.67±0.19μM	O
)	O
as	O
compared	O
to	O
standard	O
thiourea	O
(	O
IC50	O
=	O
21.25±0.15μM	O
)	O
.	O
It	O
is	O
worth	O
mentioning	O
that	O
derivatives	B-T121
7	I-T121
(	O
IC50	O
=	O
12.07±0.05μM	O
)	O
,	O
8	B-T121
(	O
IC50	O
=	O
10.57±0.12μM	O
)	O
,	O
11	B-T121
(	O
IC50	O
=	O
13.76±0.02μM	O
)	O
,	O
14	B-T121
(	O
IC50	O
=	O
15.70±0.12μM	O
)	O
and	O
22	B-T121
(	O
IC50	O
=	O
8.15±0.03μM	O
)	O
were	O
found	O
to	O
be	O
more	O
potent	B-T121
inhibitors	I-T121
than	O
standard	O
.	O
All	O
compounds	B-T121
were	O
also	O
evaluated	O
for	O
cytotoxicity	B-T059
towards	O
3T3	O
mouse	O
fibroblast	O
cell	O
line	O
and	O
found	O
to	O
be	O
completely	O
non	B-T033
-	I-T033
toxic	I-T033
.	O
Previously	O
benzimidazole	O
1	O
-	O
25	O
were	O
also	O
showed	O
α	B-T121
-	I-T121
glucosidase	I-T121
inhibitory	O
potential	O
.	O
In	O
silico	O
studies	O
were	O
performed	O
on	O
the	O
lead	B-T121
molecules	I-T121
i.e.	O
2	B-T121
,	O
7	B-T121
,	O
8	B-T121
,	O
11	B-T121
,	O
14	B-T121
,	O
and	O
22	B-T121
,	O
in	O
order	O
to	O
rationalize	O
the	O
binding	O
interaction	O
of	O
compounds	B-T121
with	O
the	O
active	O
site	O
of	O
urease	O
enzyme	O
.	O
      
Radiologic	B-T060
assessment	I-T060
of	O
quality	O
of	O
root	B-T061
canal	I-T061
fillings	I-T061
and	O
periapical	O
status	O
in	O
an	O
Austrian	O
subpopulation	O
-	O
An	O
observational	O
study	O
Progress	O
in	O
endodontic	B-T061
techniques	I-T061
and	O
methodological	O
advances	O
have	O
altered	O
root	B-T061
canal	I-T061
therapy	I-T061
over	O
the	O
last	O
decades	O
.	O
These	O
techniques	O
and	O
methods	O
need	O
periodical	O
documentation	O
.	O
This	O
observational	O
study	O
determined	O
the	O
current	O
prevalence	O
of	O
endodontic	B-T061
treatments	I-T061
,	I-T061
and	O
investigated	O
the	O
relationship	O
of	O
various	O
factors	O
with	O
the	O
periapical	O
status	O
in	O
a	O
Lower	O
Austrian	O
subpopulation	O
.	O
One	O
thousand	O
orthopantomograms	B-T060
of	O
first	O
-	O
time	O
university	O
adult	O
patients	O
radiographed	B-T060
at	O
an	O
outpatient	O
clinic	O
were	O
evaluated	B-T058
.	O
For	O
each	O
tooth	B-T023
,	O
the	O
presence	B-T033
of	O
periradicular	B-T047
pathosis	I-T047
and/or	O
endodontic	B-T061
treatment	I-T061
was	O
recorded	O
,	O
as	O
was	O
the	O
quality	O
of	O
(	O
post-	O
)	O
endodontic	B-T061
treatment	I-T061
(	O
homogeneity	O
and	O
length	O
of	O
root	B-T061
canal	I-T061
fillings	I-T061
;	O
preparation	B-T033
failures	I-T033
;	O
posts	O
/	O
screws	O
;	O
apicoectomies	B-T061
;	O
coronal	B-T061
restorations	I-T061
)	O
.	O
Two	O
evaluators	O
,	O
blinded	O
to	O
each	O
other	O
,	O
scored	O
all	O
teeth	B-T023
.	O
In	O
cases	O
of	O
disagreement	O
,	O
they	O
joined	O
for	O
a	O
consensus	O
score	O
.	O
In	O
all	O
,	O
22,586	O
teeth	O
were	O
counted	O
.	O
Of	O
these	O
,	O
2,907	O
teeth	B-T023
(	O
12.9	O
%	O
)	O
had	O
periapical	B-T047
pathosis	I-T047
,	O
while	O
2,504	O
teeth	B-T023
had	O
undergone	O
root	B-T061
canal	I-T061
treatment	I-T061
.	O
Of	O
the	O
endodontically	B-T047
treated	I-T047
teeth	I-T047
,	O
52	O
%	O
showed	O
no	O
radiographic	O
signs	O
of	O
apical	B-T047
periodontitis	I-T047
,	O
while	O
44.9	O
%	O
had	O
overt	O
apical	B-T047
lesions	I-T047
,	O
and	O
3,1	O
%	O
revealed	O
widened	B-T047
periodontal	I-T047
ligament	I-T047
space	I-T047
.	O
The	O
majority	O
of	O
the	O
root	B-T061
canal	I-T061
fillings	I-T061
was	O
inhomogeneous	O
(	O
70.4	O
%	O
)	O
;	O
75.4	O
%	O
were	O
rated	O
too	O
short	O
,	O
and	O
3.8	O
%	O
too	O
long	O
.	O
The	O
presence	B-T033
of	O
apical	B-T023
pathosis	B-T047
was	O
significantly	O
correlated	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
2.556	O
[	O
confidence	O
interval	O
(	O
CI	O
)	O
2.076	O
-	O
3.146	O
]	O
;	O
P<0.0001	O
)	O
with	O
poor	O
root	B-T061
canal	I-T061
fillings	I-T061
(	O
length	O
and	O
homogeneity	O
)	O
.	O
Posts	O
or	O
screws	O
positively	O
affected	O
periapical	O
status	O
(	O
OR	O
1.853	O
[	O
CI	O
1.219	O
-	O
2.819	O
]	O
;	O
P	O
=	O
0.004	O
)	O
,	O
but	O
endodontically	B-T047
treated	I-T047
posterior	I-T047
teeth	I-T047
were	O
infrequently	O
restored	B-T061
(	O
posts	O
,	O
7.5	O
%	O
;	O
screws	O
,	O
2.7	O
%	O
)	O
.	O
Best	O
results	O
were	O
found	O
for	O
teeth	B-T023
with	O
both	O
appropriate	O
endodontic	B-T061
treatment	I-T061
and	O
adequate	O
coronal	B-T061
restoration	I-T061
.	O
A	O
high	O
prevalence	O
of	O
periradicular	B-T033
radiolucencies	I-T033
was	O
observed	O
with	O
root	B-T023
canal	I-T023
filled	I-T023
teeth	I-T023
,	O
along	O
with	O
high	O
numbers	O
of	O
unmet	O
treatment	B-T061
needs	O
.	O
Periapical	O
health	O
was	O
associated	O
with	O
adequate	O
root	B-T061
canal	I-T061
obturation	I-T061
and	O
high	O
-	O
grade	O
postendodontic	B-T061
restorations	I-T061
,	O
and	O
quality	O
regarding	O
these	O
latter	O
aspects	O
is	O
considered	O
mandatory	O
to	O
promote	O
periapical	O
health	O
.	O
      
Molecular	O
simulation	O
study	O
on	O
concentration	O
effects	O
of	O
rofecoxib	B-T121
with	O
POPC	O
bilayer	O
The	O
interactions	O
between	O
rofecoxib	B-T121
and	O
POPC	O
(	O
1	O
-	O
palmitoyl-2	O
-	O
oleoyl	O
-	O
sn	O
-	O
glycero-3	O
-	O
phosphocholine	O
)	O
bilayer	O
were	O
studied	O
using	O
all	O
-	O
atom	O
molecular	O
dynamics	O
simulation	O
method	O
.	O
Four	O
POPC	O
bilayer	O
systems	O
with	O
different	O
number	O
of	O
rofecoxib	B-T121
molecules	O
were	O
constructed	O
to	O
simulate	O
different	O
drug	B-T121
concentration	O
.	O
The	O
free	O
energy	O
of	O
rofecoxib	B-T121
passing	O
across	O
pure	O
POPC	O
bilayer	O
has	O
two	O
minima	O
(	O
at	O
z	O
∼1.2	O
nm	O
or	O
1.6	O
nm	O
)	O
.	O
As	O
for	O
the	O
high	O
concentration	O
model	O
,	O
the	O
minimum	O
of	O
the	O
free	O
energy	O
profile	O
slightly	O
shifts	O
to	O
the	O
bilayer	O
center	O
.	O
Moreover	O
,	O
the	O
energy	O
change	O
from	O
bulk	B-T121
water	I-T121
to	O
POPC	O
bilayer	O
increases	O
while	O
the	O
central	O
barrier	O
to	O
cross	O
the	O
hydrophobic	O
core	O
of	O
bilayer	O
slightly	O
decreases	O
,	O
suggesting	O
that	O
increasing	O
drug	B-T121
concentration	O
makes	O
it	O
favorable	B-T033
for	O
rofecoxib	B-T121
to	O
partition	O
into	O
the	O
bilayer	O
and	O
easier	O
to	O
pass	O
across	O
bialyer	O
center	O
.	O
Energy	O
analysis	O
show	O
that	O
the	O
stabilization	O
between	O
the	O
selected	O
rofecoxib	B-T121
and	O
other	O
pre	O
-	O
inserted	O
rofecoxib	B-T121
molecule	O
is	O
mainly	O
due	O
to	O
van	O
der	O
Waals	O
interaction	O
energy	O
.	O
The	O
predicted	O
permeability	O
of	O
rofecoxib	B-T121
in	O
high	O
concentration	O
model	O
slightly	O
weakens	O
as	O
compared	O
with	O
low	O
concentration	O
model	O
.	O
      
MicroRNA	O
101b	O
Is	O
Downregulated	O
in	O
the	O
Prefrontal	B-T023
Cortex	I-T023
of	O
a	O
Genetic	O
Model	O
of	O
Depression	B-T048
and	O
Targets	O
the	O
Glutamate	O
Transporter	O
SLC1A1	O
(	O
EAAT3	O
)	O
in	O
Vitro	O
MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
regulatory	O
molecules	O
that	O
cause	O
translational	O
repression	O
by	O
base	O
pairing	O
with	O
target	O
mRNAs	O
.	O
Cumulative	O
evidence	O
suggests	O
that	O
changes	O
in	O
miRNA	O
expression	O
may	O
in	O
part	O
underlie	O
the	O
pathophysiology	O
and	O
treatment	B-T061
of	O
neuropsychiatric	B-T047
disorders	I-T047
,	O
including	O
major	B-T048
depressive	I-T048
disorder	I-T048
(	O
MDD	B-T048
)	O
.	O
A	O
miRNA	O
expression	O
assay	B-T059
that	O
can	O
simultaneously	O
detect	O
423	O
rat	O
miRNAs	O
(	O
miRBase	O
v.17	O
)	O
was	O
used	O
to	O
profile	B-T059
the	O
prefrontal	B-T023
cortex	I-T023
(	O
PFC	B-T023
)	O
of	O
a	O
genetic	O
rat	O
model	O
of	O
MDD	B-T048
(	O
the	O
Flinders	O
Sensitive	O
Line	O
[	O
FSL	O
]	O
)	O
and	O
the	O
controls	O
,	O
the	O
Flinders	O
Resistant	O
Line	O
(	O
FRL	O
)	O
.	O
Gene	O
expression	O
data	O
from	O
the	O
PFC	B-T023
of	O
FSL	O
/	O
FRL	O
animals	O
(	O
GEO	O
accession	O
no	O
.	O
GSE20388	O
)	O
were	O
used	O
to	O
guide	O
mRNA	O
target	O
selection	O
.	O
Luciferase	B-T059
reporter	I-T059
assays	I-T059
were	O
used	O
to	O
verify	O
miRNA	O
targets	O
in	O
vitro	O
.	O
We	O
identified	O
23	O
miRNAs	O
that	O
were	O
downregulated	O
in	O
the	O
PFC	B-T023
of	O
the	O
FSL	O
model	O
compared	O
with	O
controls	O
.	O
Interestingly	O
,	O
one	O
of	O
the	O
identified	O
miRNAs	O
(	O
miR-101b	O
)	O
is	O
highly	O
conserved	O
between	O
rat	O
and	O
human	O
and	O
was	O
recently	O
found	O
to	O
be	O
downregulated	O
in	O
the	O
PFC	B-T023
of	O
depressed	B-T184
suicide	B-T033
subjects	O
.	O
Using	O
a	O
combination	O
of	O
in	O
silico	O
and	O
in	O
vitro	O
analyses	O
,	O
we	O
found	O
that	O
miR-101b	O
targets	O
the	O
neuronal	O
glutamate	O
transporter	O
SLC1A1	O
(	O
also	O
known	O
as	O
EAAC1	O
or	O
EAAT3	O
)	O
.	O
Accordingly	O
,	O
both	O
mRNA	O
and	O
protein	O
levels	O
of	O
SLC1A1	O
were	O
found	O
to	O
be	O
upregulated	O
in	O
the	O
PFC	B-T023
of	O
the	O
FSL	O
model	O
.	O
Besides	O
providing	O
a	O
list	O
of	O
novel	O
miRNAs	O
associated	O
with	O
depression	B-T033
-	I-T033
like	I-T033
states	I-T033
,	O
this	O
preclinical	O
study	O
replicated	O
the	O
human	O
association	O
of	O
miR-101	O
with	O
depression	B-T048
.	O
In	O
addition	O
,	O
since	O
one	O
of	O
the	O
targets	O
of	O
miR-101b	O
appears	O
to	O
be	O
a	O
glutamate	O
transporter	O
,	O
our	O
preclinical	O
data	O
support	O
the	O
hypothesis	O
of	O
a	O
glutamatergic	B-T121
dysregulation	B-T033
being	O
implicated	O
in	O
the	O
etiology	O
of	O
depression	B-T048
.	O
      
A	O
randomized	O
trial	O
of	O
TLR-2	O
agonist	B-T121
CADI-05	B-T121
targeting	O
desmocollin-3	O
for	O
advanced	O
non	B-T191
-	I-T191
small	I-T191
-	I-T191
cell	I-T191
lung	I-T191
cancer	I-T191
Randomized	O
controlled	O
trial	O
to	O
evaluate	B-T058
synergy	O
between	O
taxane	B-T121
plus	O
platinum	O
chemotherapy	B-T061
and	O
CADI-05	B-T121
,	O
a	O
Toll	O
like	O
receptor-2	O
agonist	B-T121
targeting	O
desmocollin-3	O
as	O
a	O
first	B-T061
-	I-T061
line	I-T061
therapy	I-T061
in	O
advanced	O
non	B-T191
-	I-T191
small	I-T191
-	I-T191
cell	I-T191
lung	I-T191
cancer	I-T191
(	O
NSCLC	B-T191
)	O
.	O
Patients	O
with	O
advanced	O
NSCLC	B-T191
(	O
stage	O
IIIB	O
or	O
IV	O
)	O
were	O
randomized	B-T033
to	O
cisplatin	B-T061
-	I-T061
paclitaxel	I-T061
(	O
chemotherapy	B-T061
group	O
,	O
N	O
=	O
112	O
)	O
or	O
cisplatin	B-T061
-	I-T061
paclitaxel	I-T061
plus	O
CADI-05	B-T121
(	O
chemoimmunotherapy	B-T061
group	O
,	O
N	O
=	O
109	O
)	O
.	O
CADI-05	B-T121
was	O
administered	O
a	O
week	O
before	O
chemotherapy	B-T061
and	O
on	O
days	O
8	O
and	O
15	O
of	O
each	O
cycle	B-T061
and	O
every	O
month	O
subsequently	O
for	O
12	O
months	O
or	O
disease	O
progression	O
.	O
Overall	O
survival	O
was	O
compared	O
using	O
a	O
log	O
-	O
rank	O
test	O
.	O
Computed	B-T060
tomography	I-T060
was	O
carried	O
out	O
at	O
baseline	O
,	O
end	O
of	O
two	O
cycles	B-T061
and	O
four	O
cycles	B-T061
.	O
Response	O
rate	O
was	O
evaluated	B-T058
using	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumors	O
criteria	O
by	O
an	O
independent	O
radiologist	O
.	O
As	O
per	O
intention	O
-	O
to	O
-	O
treat	O
analysis	O
,	O
no	O
survival	O
benefit	O
was	O
observed	O
between	O
two	O
groups	O
[	O
208	O
versus	O
196	O
days	O
;	O
hazard	O
ratio	O
,	O
0.86	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.63	O
-	O
1.19	O
;	O
P	O
=	O
0.3804	O
]	O
.	O
In	O
a	O
subgroup	O
analysis	O
,	O
improvement	O
in	O
median	O
survival	O
by	O
127	O
days	O
was	O
observed	O
in	O
squamous	B-T191
NSCC	I-T191
with	O
chemoimmunotherapy	B-T061
(	O
hazard	O
ratio	O
,	O
0.55	O
;	O
95	O
%	O
CI	O
0.32	O
-	O
0.95	O
;	O
P	O
=	O
0.046	O
)	O
.	O
In	O
patients	O
receiving	O
planned	O
four	O
cycles	B-T061
of	O
chemotherapy	B-T061
,	O
there	O
was	O
improved	O
median	O
overall	O
survival	O
by	O
66	O
days	O
(	O
299	O
versus	O
233	O
days	O
;	O
hazard	O
ratio	O
,	O
0.64	O
;	O
95	O
%	O
CI	O
0.41	O
to	O
0.98	O
;	O
P	O
=	O
0.04	O
)	O
in	O
the	O
chemoimmunotherapy	B-T061
group	O
compared	O
with	O
the	O
chemotherapy	B-T061
group	O
.	O
This	O
was	O
associated	O
with	O
the	O
improved	O
survival	O
by	O
17.48	O
%	O
at	O
the	O
end	O
of	O
1	O
year	O
,	O
in	O
the	O
chemoimmunotherapy	B-T061
group	O
.	O
Systemic	O
adverse	O
events	O
were	O
identical	O
in	O
both	O
the	O
group	O
s.	O
There	O
was	O
no	O
survival	O
benefit	O
with	O
the	O
addition	O
of	O
CADI-05	B-T121
to	O
the	O
combination	O
of	O
cisplatin	B-T061
-	I-T061
paclitaxel	I-T061
in	O
patients	O
with	O
advanced	O
NSCLC	B-T191
;	O
however	O
,	O
the	O
squamous	O
cell	O
subset	O
did	O
demonstrate	O
a	O
survival	O
advantage	O
.	O
      
High	O
-	O
Intensity	O
Intermittent	O
Training	O
Positively	B-T033
Affects	O
Aerobic	B-T061
and	O
Anaerobic	O
Performance	O
in	O
Judo	O
Athletes	O
Independently	O
of	O
Exercise	O
Mode	O
The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
high	O
-	O
intensity	O
intermittent	O
training	O
(	O
HIIT	O
)	O
on	O
lower	B-T023
-	O
and	O
upper	B-T023
-	I-T023
body	I-T023
graded	O
exercise	O
and	O
high	O
-	O
intensity	O
intermittent	O
exercise	O
(	O
HIIE	O
,	O
four	O
Wingate	O
bouts	O
)	O
performance	O
,	O
and	O
on	O
physiological	O
and	O
muscle	B-T020
damage	I-T020
markers	B-T033
responses	I-T033
in	O
judo	O
athletes	O
.	O
Thirty	O
-	O
five	O
subjects	O
were	O
randomly	O
allocated	O
to	O
a	O
control	O
group	O
(	O
n	O
=	O
8)	O
or	O
to	O
one	O
of	O
the	O
following	O
HIIT	O
groups	O
(	O
n	O
=	O
9	O
for	O
each	O
)	O
and	O
tested	O
pre-	O
and	O
post	O
-four	O
weeks	O
(	O
2	O
training	O
d·wk(-1	O
)	O
):	O
(	O
1	O
)	O
lower	B-T023
-	I-T023
body	I-T023
cycle	B-T061
-	I-T061
ergometer	I-T061
;	O
(	O
2	O
)	O
upper	O
-	O
body	O
cycle	B-T061
-	I-T061
ergometer	I-T061
;	O
(	O
3	O
)	O
uchi	O
-	O
komi	O
(	O
judo	O
technique	O
entrance	O
)	O
.	O
All	O
HIIT	O
were	O
constituted	O
by	O
two	O
blocks	O
of	O
10	O
sets	O
of	O
20	O
s	O
of	O
all	O
out	O
effort	O
interspersed	O
by	O
10	O
s	O
set	O
intervals	O
and	O
5	O
-	O
min	O
between	O
blocks	O
.	O
For	O
the	O
upper	B-T023
-	I-T023
body	I-T023
group	O
there	O
was	O
an	O
increase	O
in	O
maximal	O
aerobic	O
power	O
in	O
graded	O
upper	B-T023
-	I-T023
body	I-T023
exercise	B-T033
test	I-T033
(	O
12.3	O
%	O
)	O
.	O
The	O
lower	B-T023
-	I-T023
body	I-T023
group	O
increased	O
power	O
at	O
onset	B-T121
blood	I-T121
lactate	I-T121
in	O
graded	O
upper	B-T023
-	I-T023
body	I-T023
exercise	B-T033
test	I-T033
(	O
22.1	O
%	O
)	O
.	O
The	O
uchi	O
-	O
komi	O
group	O
increased	O
peak	O
power	O
in	O
upper	B-T023
-	O
(	O
16.7	O
%	O
)	O
and	O
lower	B-T023
-	I-T023
body	I-T023
(	O
8.5	O
%	O
)	O
,	O
while	O
the	O
lower	B-T023
-	I-T023
body	I-T023
group	O
increased	O
lower	B-T023
-	I-T023
body	I-T023
mean	O
power	O
(	O
14.2	O
%	O
)	O
during	O
the	O
HIIE	O
.	O
There	O
was	O
a	O
decrease	O
in	O
the	O
delta	B-T121
blood	I-T121
lactate	I-T121
for	O
the	O
uchi	O
-	O
komi	O
training	O
group	O
and	O
in	O
the	O
third	O
and	O
fourth	O
bouts	O
for	O
the	O
upper	B-T023
-	I-T023
body	I-T023
training	O
group	O
.	O
Training	O
induced	O
testosterone	O
-	O
cortisol	O
ratio	O
increased	O
in	O
the	O
lower	B-T023
-	I-T023
body	I-T023
HIIE	O
for	O
the	O
lower	B-T023
-	I-T023
body	I-T023
(	O
14.9	O
%	O
)	O
and	O
uchi	O
-	O
komi	O
(	O
61.4	O
%	O
)	O
training	O
groups	O
.	O
Thus	O
,	O
short	O
-	O
duration	O
low	O
-	O
volume	O
HIIT	O
added	O
to	O
regular	O
judo	O
training	O
was	O
able	O
to	O
increase	O
upper	B-T023
-	I-T023
body	I-T023
aerobic	O
power	O
,	O
lower	B-T023
-	O
and	O
upper	B-T023
-	I-T023
body	I-T023
HIIE	O
performance	O
.	O
      
What	O
can	O
the	O
Canadians	O
and	O
Americans	O
learn	O
from	O
each	O
other	O
's	O
health	O
care	O
systems	O
?	O
Numerous	O
papers	O
have	O
been	O
written	O
comparing	O
the	O
Canadian	O
and	O
US	O
healthcare	O
systems	O
,	O
and	O
a	O
number	O
of	O
health	O
policy	O
experts	O
have	O
recommended	O
that	O
the	O
Americans	O
implement	O
their	O
single	B-T058
-	I-T058
payer	I-T058
system	I-T058
to	O
save	O
12	O
-	O
20	O
%	O
of	O
its	O
healthcare	O
expenditures	O
.	O
This	O
paper	O
is	O
different	O
in	O
that	O
it	O
assumes	O
that	O
neither	O
country	O
will	O
undertake	O
a	O
significant	O
philosophic	O
or	O
structural	O
change	O
in	O
their	O
healthcare	O
system	O
,	O
but	O
there	O
are	O
lessons	O
to	O
be	O
learned	O
that	O
are	O
inherent	O
in	O
one	O
that	O
could	O
be	O
a	O
major	O
breakthrough	O
for	O
the	O
other	O
.	O
Following	O
the	O
model	O
in	O
Canada	O
and	O
in	O
Western	O
Europe	O
,	O
the	O
USA	O
could	O
implement	O
universal	O
health	B-T058
insurance	I-T058
so	O
that	O
the	O
32.0	O
million	O
(	O
2015	O
)	O
Americans	O
still	O
uninsured	O
would	O
have	O
at	O
least	O
minimal	O
coverage	O
when	O
incurring	O
medical	O
expenditures	O
.	O
Also	O
,	O
the	O
USA	O
could	O
use	O
smart	O
cards	O
to	O
evaluate	B-T058
eligibility	I-T058
and	O
to	O
process	O
health	B-T058
insurance	I-T058
claims	I-T058
;	O
these	O
changes	O
resulting	O
in	O
an	O
estimated	O
15	O
%	O
reduction	O
in	O
US	O
health	O
expenditures	O
without	O
adversely	O
effecting	O
access	O
or	O
quality	B-T058
of	I-T058
care	I-T058
.	O
Such	O
a	O
strategy	O
would	O
result	O
in	O
the	O
eventual	O
loss	O
of	O
2.5	O
million	O
white	O
-	O
collar	O
jobs	O
at	O
hospitals	O
,	O
physician	O
offices	O
and	O
insurance	O
companies	O
,	O
a	O
long	O
-	O
term	O
economic	O
gain	O
.	O
Only	O
a	O
few	O
would	O
agree	O
with	O
the	O
statement	O
that	O
Canada	O
already	O
functions	O
with	O
a	O
multi	O
-	O
payer	O
reimbursement	O
system	O
as	O
evidenced	O
by	O
(	O
1	O
)	O
a	O
federal	O
-	O
provincial	O
,	O
tax	O
-	O
supported	O
plan	B-T058
,	O
administered	O
by	O
each	O
of	O
the	O
provinces	O
,	O
providing	O
universal	O
coverage	O
for	O
hospital	O
and	O
physician	B-T058
services	I-T058
and	O
(	O
2	O
)	O
roughly	O
60	O
%	O
of	O
its	O
residents	O
receiving	O
employer	O
-	O
paid	O
health	B-T058
insurance	I-T058
benefits	O
,	O
underwritten	O
primarily	O
by	O
investor	O
-	O
owned	O
plans	O
,	O
that	O
are	O
less	O
than	O
effective	O
to	O
reimburse	O
for	O
pharmaceuticals	B-T058
,	O
dental	B-T058
and	O
other	O
healthcare	B-T058
services	I-T058
.	O
What	O
could	O
be	O
learned	O
from	O
the	O
USA	O
and	O
particularly	O
from	O
Western	O
European	O
countries	O
is	O
possibly	O
implementing	O
an	O
approach	O
,	O
whereby	O
at	O
least	O
upper	O
-	O
income	O
Canadians	O
could	O
opt	O
out	O
of	O
their	O
federal	O
-	O
provincial	O
plan	B-T058
and	O
purchase	O
private	O
insurance	O
coverage	O
-	O
being	O
eligible	O
for	O
far	O
more	O
comprehensive	O
"	O
private	O
"	O
benefits	O
for	O
hospital	O
,	O
physician	B-T058
,	O
pharmaceutical	B-T058
,	O
dental	B-T058
and	O
other	O
healthcare	B-T058
services	I-T058
.	O
Aside	O
from	O
generating	O
billions	O
of	O
additional	O
needed	O
revenues	O
from	O
the	O
private	O
sector	O
,	O
it	O
could	O
(	O
1	O
)	O
help	O
eliminate	O
long	O
waits	O
for	O
non	O
-	O
emergent	O
physicians	O
'	O
care	O
by	O
appointing	O
newly	O
minted	O
specialists	O
to	O
their	O
medical	O
staffs	O
;	O
(	O
2	O
)	O
offer	O
prompt	O
admissions	B-T058
for	O
elective	B-T033
cases	I-T033
to	O
"	O
private	O
"	O
wings	O
of	O
hospitals	O
;	O
(	O
3	O
)	O
increase	O
available	O
funding	O
for	O
what	O
is	O
currently	O
an	O
undercapitalized	B-T033
system	O
;	O
(	O
4	O
)	O
enhance	O
the	O
system	O
's	O
sluggish	B-T033
operations	O
;	O
and	O
(	O
5	O
)	O
encourage	O
more	O
competition	O
among	O
various	O
providers	O
.	O
Although	O
such	O
a	O
two	O
-	O
tier	O
approach	O
,	O
such	O
as	O
available	O
in	O
the	O
USA	O
and	O
elsewhere	O
,	O
is	O
politically	O
dead	O
on	O
arrival	O
in	O
Canada	O
today	O
,	O
private	O
insurance	O
being	O
already	O
legal	O
and	O
commonly	O
available	O
there	O
.	O
Interestingly	O
,	O
this	O
recommended	O
solution	O
is	O
utilized	O
in	O
most	O
western	O
European	O
countries	O
where	O
there	O
is	O
a	O
higher	O
percentagea	O
than	O
in	O
Canada	O
of	O
public	O
(	O
versus	O
private	O
)	O
funding	O
of	O
their	O
total	O
health	O
expenditures	O
.	O
Because	O
of	O
various	O
vested	O
interests	O
,	O
attempts	O
to	O
implement	O
any	O
of	O
the	O
aforementioned	O
proposals	O
will	O
undoubtedly	O
result	O
in	O
considerable	O
political	O
rancor	O
.	O
There	O
is	O
greater	O
likelihood	O
,	O
however	O
,	O
that	O
the	O
Canadians	O
because	O
their	O
need	O
to	O
be	O
more	O
effective	O
and	O
efficient	O
in	O
their	O
delivery	B-T058
of	I-T058
care	I-T058
,	O
and	O
their	O
overall	O
long	O
-	O
term	O
fiscal	O
outlook	O
will	O
agree	B-T033
to	O
the	O
further	O
privatization	O
of	O
their	O
healthcare	O
system	O
before	O
the	O
Americans	O
will	O
mandate	O
universal	O
access	O
,	O
use	O
the	O
smart	O
card	O
to	O
process	O
insurance	O
eligibility	O
and	O
claims	O
or	O
will	O
impose	O
price	O
controls	O
on	O
high	O
-	O
tech	O
services	O
and	O
on	O
pharmaceuticals	B-T121
.	O
Copyright	O
©	O
2016	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O
      
Multi	O
-	O
component	O
model	O
of	O
intramural	O
hematoma	O
A	O
novel	O
multi	O
-	O
component	O
model	O
is	O
introduced	O
for	O
studying	O
interaction	O
between	O
blood	O
flow	O
and	O
deforming	B-T033
aortic	B-T023
wall	I-T023
with	O
intramural	O
hematoma	O
(	O
IMH	O
)	O
.	O
The	O
aortic	B-T023
wall	I-T023
is	O
simulated	O
by	O
a	O
composite	O
structure	O
submodel	O
representing	O
material	O
properties	O
of	O
the	O
three	O
main	O
wall	B-T023
layers	I-T023
.	O
The	O
IMH	O
is	O
described	O
by	O
a	O
poroelasticity	O
submodel	O
which	O
takes	O
into	O
account	O
both	O
the	O
pressure	O
inside	O
hematoma	O
and	O
its	O
deformation	B-T033
.	O
The	O
submodel	O
of	O
the	O
hematoma	O
is	O
fully	O
coupled	O
with	O
the	O
aortic	O
submodel	O
as	O
well	O
as	O
with	O
the	O
submodel	O
of	O
the	O
pulsatile	O
blood	O
flow	O
.	O
Model	O
simulations	O
are	O
used	O
to	O
investigate	O
the	O
relation	O
between	O
the	O
peak	O
wall	O
stress	O
,	O
hematoma	O
thickness	O
and	O
permeability	O
in	O
patients	O
of	O
different	O
age	O
.	O
The	O
results	O
indicate	O
that	O
an	O
increase	O
in	O
hematoma	O
thickness	O
leads	O
to	O
larger	O
wall	B-T033
stress	I-T033
,	O
which	O
is	O
in	O
agreement	O
with	O
clinical	O
data	O
.	O
Further	O
simulations	O
demonstrate	O
that	O
a	O
hematoma	O
with	O
smaller	O
permeability	O
results	O
in	O
larger	O
wall	B-T033
stress	I-T033
,	O
suggesting	O
that	O
blood	O
coagulation	O
in	O
hematoma	O
might	O
increase	O
its	O
mechanical	B-T033
stability	I-T033
.	O
This	O
is	O
in	O
agreement	O
with	O
previous	O
experimental	O
observations	O
of	O
coagulation	O
having	O
a	O
beneficial	O
effect	O
on	O
the	O
condition	O
of	O
a	O
patient	O
with	O
the	O
IMH	O
.	O
      
Discovery	O
of	O
Orally	O
Efficacious	O
Phosphoinositide-3	O
-	O
Kinase	O
delta	O
Inhibitors	B-T121
with	O
Improved	B-T033
Metabolic	O
Stability	O
Aberrant	O
signaling	O
of	O
phosphoinositide-3	O
-	O
kinase	O
delta	O
(	O
PI3K	O
-	O
delta	O
)	O
has	O
been	O
implicated	O
in	O
numerous	O
pathologies	O
including	O
hematological	B-T191
malignancies	I-T191
and	O
rheumatoid	B-T047
arthritis	I-T047
.	O
Described	O
in	O
this	O
manuscript	O
is	O
the	O
discovery	O
,	O
optimization	O
and	O
in	O
vivo	O
evaluation	B-T058
of	O
a	O
novel	O
series	O
of	O
pyridine	O
-	O
containing	O
PI3K	O
-	O
delta	O
inhibitors	B-T121
.	O
This	O
work	O
led	O
to	O
the	O
discovery	O
of	O
35	B-T121
,	O
a	O
highly	O
selective	O
inhibitor	B-T121
of	O
PI3K	O
-	O
delta	O
which	O
displays	O
an	O
excellent	O
pharmacokinetic	O
profile	O
and	O
is	O
efficacious	O
in	O
a	O
rodent	B-T050
model	I-T050
of	O
rheumatoid	B-T047
arthritis	I-T047
.	O
      
Novel	O
Observations	O
in	O
11	O
Heteroresistant	O
Vancomycin	B-T195
-	I-T195
Intermediate	I-T195
Methicillin	B-T007
-	I-T007
Resistant	I-T007
Staphylococcus	I-T007
aureus	I-T007
Strains	I-T007
from	O
South	O
India	O
We	O
report	O
here	O
the	O
draft	O
genome	O
sequences	O
of	O
11	O
heteroresistant	O
vancomycin	B-T007
-	I-T007
intermediate	I-T007
Staphylococcus	I-T007
aureus	I-T007
(	I-T007
hVISA	I-T007
)	I-T007
strains	I-T007
from	O
bloodstream	O
infection	O
.	O
All	O
strains	B-T001
harbor	O
mutations	O
in	O
vraSR	O
,	O
graSR	O
,	O
walKR	O
,	O
and/or	O
tcaRAB	O
and	O
are	O
often	O
implicated	O
as	O
the	O
frequently	O
mutated	O
candidate	O
genes	O
in	O
hVISA	B-T007
phenotypes	O
.	O
      
Obesogenic	B-T047
eating	O
behaviors	O
mediate	O
the	O
relationships	O
between	O
psychological	B-T033
problems	I-T033
and	O
BMI	O
in	O
children	O
To	O
examine	O
the	O
association	O
between	O
psychological	B-T033
problems	I-T033
and	O
weight	O
status	O
in	O
children	O
aged	O
3.5	O
to	O
4	O
years	O
and	O
test	O
whether	O
obesogenic	B-T047
eating	O
behaviors	O
mediate	O
this	O
relationship	O
.	O
This	O
study	O
is	O
a	O
cross	O
-	O
sectional	O
secondary	O
analysis	O
of	O
data	O
from	O
first	O
-	O
time	O
mothers	O
(	O
N	O
=	O
194	O
)	O
in	O
the	O
control	O
arm	O
of	O
the	O
NOURISH	O
randomized	O
controlled	O
trial	O
.	O
At	O
child	O
age	O
3.5	O
to	O
4	O
years	O
,	O
maternal	O
-reported	O
child	O
eating	O
behaviors	O
and	O
psychological	B-T033
problems	I-T033
were	O
collected	O
via	O
valid	O
tools	O
,	O
and	O
child	O
weight	O
and	O
height	O
data	O
were	O
collected	O
by	O
trained	O
study	O
staff	O
.	O
Pearson	O
's	O
correlations	O
and	O
linear	O
regressions	O
examined	O
associations	O
between	O
eating	O
behaviors	O
,	O
psychological	B-T033
problems	I-T033
,	O
and	O
BMI	O
z	O
score	O
.	O
Multiple	O
mediation	O
models	O
were	O
tested	O
by	O
assessing	O
indirect	O
effects	O
of	O
psychological	B-T033
problems	I-T033
on	O
BMI	O
z	O
score	O
via	O
obesogenic	B-T047
eating	O
behaviors	O
.	O
Peer	O
problems	B-T033
were	O
associated	O
with	O
both	O
higher	O
food	O
responsiveness	O
and	O
emotional	B-T048
overeating	I-T048
and	O
directly	O
with	O
higher	O
BMI	O
z	O
score	O
.	O
This	O
relationship	O
was	O
partially	O
mediated	O
by	O
emotional	B-T048
overeating	I-T048
.	O
Both	O
emotional	B-T048
overeating	I-T048
and	O
food	O
responsiveness	O
fully	O
mediated	O
the	O
association	O
between	O
emotional	B-T048
problems	I-T048
and	O
BMI	O
z	O
score	O
,	O
and	O
food	O
responsiveness	O
fully	O
mediated	O
the	O
association	O
between	O
conduct	B-T048
problems	I-T048
and	O
BMI	O
z	O
score	O
.	O
The	O
findings	O
suggest	O
that	O
children	O
with	O
psychological	B-T033
problems	I-T033
may	O
also	O
display	O
obesogenic	B-T047
eating	O
behaviors	O
,	O
which	O
may	O
result	O
in	O
higher	O
BMI	O
.	O
This	O
needs	O
to	O
be	O
considered	O
in	O
the	O
clinical	B-T058
management	I-T058
of	O
both	O
pediatric	O
overweight	B-T184
/	O
obesity	B-T047
and	O
psychological	B-T033
problems	I-T033
.	O
      
Anti	O
-	O
tumor	O
activity	O
of	O
SL4	O
against	O
breast	O
cancer	O
cells	O
:	O
induction	O
of	O
G2	O
/	O
M	O
arrest	O
through	O
modulation	O
of	O
the	O
MAPK	O
-dependent	O
p21	O
signaling	O
pathway	O
SL4	O
,	O
a	O
chalcone	O
-based	O
compound	O
,	O
has	O
been	O
shown	O
to	O
retard	O
tumor	B-T033
invasion	I-T033
and	O
angiogenesis	B-T191
by	O
suppressing	O
HIF1	O
activity	O
and	O
to	O
induce	O
apoptosis	O
by	O
promoting	O
ROS	O
release	O
.	O
Here	O
,	O
we	O
report	O
that	O
SL4	O
is	O
able	O
to	O
inhibit	O
the	O
proliferation	O
of	O
different	O
types	O
of	O
breast	O
cancer	O
cell	O
in	O
vitro	O
and	O
in	O
vivo	O
by	O
inducing	O
G2	O
/	O
M	O
cell	O
cycle	O
arrest	O
.	O
Our	O
results	B-T033
showed	O
that	O
SL4	O
exhibited	O
strong	O
anti	B-T121
-	I-T121
proliferative	I-T121
activity	O
in	O
several	O
human	O
breast	B-T191
cancer	I-T191
cell	O
lines	O
,	O
with	O
IC50	O
values	O
lower	O
than	O
1.3	O
μM.	O
Further	O
studies	O
indicated	B-T033
that	O
SL4	O
induced	O
G2	O
/	O
M	O
arrest	O
in	O
these	O
cell	O
lines	O
.	O
Mechanistically	O
,	O
SL4	O
reduces	O
the	O
expression	O
of	O
cyclin	O
A2	O
and	O
cdc25C	O
and	O
decreases	O
the	O
activity	O
of	O
the	O
cdc2	O
/	O
cyclin	O
B1	O
complex	O
.	O
Notably	O
,	O
SL4	O
treatment	B-T061
resulted	O
in	O
an	O
obvious	O
increase	O
in	O
p21	O
mRNA	O
and	O
protein	O
levels	O
through	O
activation	O
of	O
MAPK	O
signaling	O
pathways	O
,	O
but	O
not	O
the	O
TGF	O
-	O
β	O
pathway	O
.	O
SP600125	B-T121
and	O
PD98059	B-T121
,	O
specific	O
inhibitors	O
of	O
JNK	O
kinase	O
and	O
ERK	O
kinase	O
,	O
significantly	O
blocked	O
the	O
SL4	O
-	O
induced	O
G2	O
/	O
M	O
phase	O
arrest	O
and	O
upregulation	O
of	O
p21	O
.	O
Furthermore	O
,	O
SL4	O
suppressed	O
the	O
growth	O
of	O
established	O
breast	B-T191
tumors	I-T191
in	O
nude	O
mice	O
through	O
upregulation	O
of	O
p21	O
and	O
downregulation	O
of	O
cdc25C	O
,	O
and	O
displayed	O
a	O
good	O
safety	O
profile	O
.	O
Taken	O
together	O
,	O
these	O
findings	B-T033
demonstrate	O
the	O
potential	O
value	O
of	O
SL4	O
as	O
a	O
novel	O
multi	B-T121
-	I-T121
target	I-T121
anti	I-T121
-	I-T121
tumor	I-T121
drug	I-T121
candidate	I-T121
.	O
      
The	O
Daniel	O
K.	O
Inouye	O
College	O
of	O
Pharmacy	O
Scripts	O
:	O
Poha	O
Berry	O
(	O
Physalis	O
peruviana	O
)	O
with	O
Potential	O
Anti	O
-	O
inflammatory	O
and	O
Cancer	B-T061
Prevention	I-T061
Activities	O
The	O
Daniel	O
K.	O
Inouye	O
College	O
of	O
Pharmacy	O
,	O
during	O
a	O
historic	O
event	O
in	O
Spring	O
2016	O
,	O
graduated	O
the	O
first	O
two	O
students	O
in	O
the	O
Pacific	O
region	O
to	O
earn	O
a	O
PhD	O
in	O
pharmaceutical	O
sciences	O
at	O
the	O
University	O
of	O
Hawai'i	O
at	O
Hilo	O
.	O
The	O
college	O
offers	O
PhD	O
programs	O
in	O
these	O
five	O
disciplines	O
:	O
Cancer	O
Biology	O
,	O
Medicinal	O
Chemistry	O
,	O
Pharmaceutics	O
,	O
Pharmacognosy	O
,	O
and	O
Pharmacology	O
.	O
One	O
of	O
the	O
Pharmacognosy	O
dissertations	O
focused	O
on	O
plant	O
-	O
derived	O
natural	O
products	O
with	O
potential	O
anti	O
-	O
inflammatory	O
and	O
cancer	B-T191
chemopreventive	O
activities	O
.	O
Physalis	O
peruviana	O
(	O
Pp	O
)	O
L.	O
originated	O
in	O
tropical	O
South	O
America	O
.	O
It	O
has	O
become	O
naturalized	O
and	O
is	O
found	O
readily	O
on	O
the	O
Island	O
of	O
Hawai'i	O
.	O
The	O
edible	O
fruits	O
are	O
commonly	O
known	O
as	O
cape	O
gooseberry	O
or	O
poha	O
in	O
Hawai'i	O
.	O
In	O
part	O
of	O
our	O
study	O
,	O
three	O
new	O
withanolides	O
,	O
physaperuvin	B-T121
G	I-T121
(	O
1	O
)	O
,	O
physaperuvins	B-T121
I	I-T121
-	I-T121
J	I-T121
(	O
2	O
-	O
3	O
)	O
,	O
along	O
with	O
four	O
known	O
withanolides	O
,	O
namely	O
,	O
4β	B-T121
-	I-T121
hydroxywithanolide	I-T121
E	I-T121
(	O
4	O
)	O
,	O
withaperuvin	B-T121
C	I-T121
(	O
5	O
)	O
,	O
and	O
physalactone	B-T121
(	O
6	O
)	O
,	O
coagulin	B-T121
(	O
7	O
)	O
were	O
isolated	O
from	O
the	O
aerial	O
parts	O
of	O
P.	O
peruviana	O
.	O
In	O
addition	O
,	O
two	O
known	O
compounds	O
,	O
phyperunolide	B-T121
F	I-T121
(	O
8)	O
,	O
and	O
withanolide	B-T121
S	I-T121
(	O
9	O
)	O
,	O
were	O
isolated	O
and	O
identified	O
from	O
the	O
poha	O
berry	O
fruits	O
.	O
The	O
structures	O
and	O
absolute	O
stereochemistry	O
of	O
new	O
compounds	O
from	O
poha	O
were	O
elucidated	O
by	O
several	O
spectroscopy	O
methods	O
:	O
Nuclear	B-T060
Magnetic	I-T060
Resonance	I-T060
(	I-T060
NMR	I-T060
)	I-T060
spectroscopy	I-T060
,	O
X	B-T059
-	I-T059
ray	I-T059
diffraction	I-T059
,	O
and	O
mass	B-T059
spectrometry	I-T059
analyses	O
.	O
All	O
isolated	O
poha	O
compounds	O
(	O
aerial	O
parts	O
and	O
fruits	O
)	O
were	O
evaluated	O
for	O
their	O
anti	O
-	O
inflammatory	O
activity	O
with	O
lipopolysaccharide	O
(	O
LPS)-activated	O
murine	O
macrophage	O
RAW	O
264.7	O
cells	O
,	O
and	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
α)-activated	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
κB	O
)	O
with	O
transfected	O
human	O
embryonic	O
kidney	O
cells	O
293	O
.	O
Most	O
of	O
the	O
isolated	O
natural	O
compounds	O
showed	O
activity	O
with	O
these	O
assays	B-T059
.	O
Additional	O
studies	O
were	O
performed	O
with	O
models	O
of	O
colon	B-T191
cancer	I-T191
.	O
Specifically	O
,	O
4β	B-T121
-	I-T121
hydroxywithanolide	I-T121
E	I-T121
(	O
4HWE	B-T121
)	O
inhibited	O
the	O
growth	O
of	O
colon	B-T191
cancer	I-T191
monolayer	B-T059
and	O
spheroid	O
cultures	B-T059
.	O
The	O
compound	O
induced	O
cell	O
cycle	O
arrest	O
at	O
low	O
concentrations	O
and	O
apoptosis	O
at	O
higher	O
concentrations	O
.	O
These	O
data	O
suggest	O
the	O
ingestion	O
of	O
poha	O
berries	O
may	O
have	O
some	O
effect	O
on	O
the	O
prevalence	O
of	O
colon	B-T191
cancer	I-T191
.	O
Additionally	O
,	O
poha	O
isolates	O
compounds	O
were	O
evaluated	O
for	O
their	O
growth	O
inhibitory	O
effects	O
with	O
U251MG	B-T191
glioblastoma	I-T191
and	O
MDA	B-T050
-	I-T050
MB-231	I-T050
breast	I-T050
cancer	I-T050
cells	I-T050
that	O
harbor	O
aberrantly	O
-	O
active	O
signal	O
transducer	O
and	O
activation	O
of	O
transcription	O
3	O
(	O
STAT3	O
)	O
,	O
compared	O
to	O
normal	O
NIH-3T3	O
mouse	O
fibroblasts	O
.	O
This	O
work	O
has	O
led	O
to	O
the	O
filing	O
of	O
three	O
provisional	O
patents	O
with	O
the	O
University	O
of	O
Hawai'i	O
Office	O
of	O
Technology	O
Transfer	O
and	O
Economic	O
Development	O
.	O
      
Metabolite	O
mapping	O
by	O
consecutive	O
nanostructure	O
and	O
silver	B-T059
-	I-T059
assisted	I-T059
mass	I-T059
spectrometry	I-T059
imaging	I-T059
on	O
tissue	O
sections	O
Nanostructure	B-T059
-	I-T059
based	I-T059
mass	I-T059
spectrometry	I-T059
imaging	I-T059
(	O
MSI	B-T059
)	O
is	O
a	O
promising	O
technology	O
for	O
molecular	B-T060
imaging	I-T060
of	O
small	O
molecules	O
,	O
without	O
the	O
complex	O
chemical	O
background	O
typically	O
encountered	O
in	O
matrix	B-T060
-	I-T060
assisted	I-T060
molecular	I-T060
imaging	I-T060
approaches	O
.	O
Here	O
,	O
we	O
have	O
enhanced	O
these	O
surfaces	O
with	O
silver	O
(	O
Ag	O
)	O
to	O
provide	O
a	O
second	O
tier	O
of	O
MSI	O
data	O
from	O
a	O
single	O
sample	O
.	O
MSI	O
data	O
was	O
acquired	O
through	O
the	O
application	O
of	O
laser	B-T059
desorption	I-T059
/	I-T059
ionization	I-T059
mass	I-T059
spectrometry	I-T059
to	O
biological	O
samples	O
imprinted	O
onto	O
desorption	O
/	O
ionization	O
on	O
silicon	O
(	O
DIOS	O
)	O
substrates	O
.	O
Following	O
initial	O
analysis	O
,	O
ultra	O
-	O
thin	O
Ag	O
layers	O
were	O
overlaid	O
onto	O
the	O
followed	O
by	O
MSI	B-T059
analysis	I-T059
(	O
Ag	B-T059
-	I-T059
DIOS	I-T059
MSI	I-T059
)	O
.	O
This	O
approach	O
was	O
first	O
demonstrated	O
for	O
fingermark	O
small	O
molecules	O
including	O
environmental	O
contaminants	O
and	O
sebum	O
components	O
.	O
Subsequently	O
,	O
this	O
bimodal	O
method	O
was	O
translated	O
to	O
lipids	O
and	O
metabolites	O
in	O
fore	O
-	O
stomach	O
sections	O
from	O
a	O
6	O
-	O
bromoisatin	O
chemopreventative	O
murine	B-T050
mouse	I-T050
model	I-T050
.	O
DIOS	B-T059
MSI	I-T059
allowed	O
mapping	O
of	O
common	O
ions	O
in	O
fingermarks	O
as	O
well	O
as	O
6	O
-	O
bromoisatin	O
metabolites	O
and	O
lipids	O
in	O
murine	O
fore	O
-	O
stomach	O
.	O
Furthermore	O
,	O
DIOS	B-T059
MSI	I-T059
was	O
complemented	O
by	O
the	O
Ag	B-T059
-	I-T059
DIOS	I-T059
MSI	I-T059
of	O
Ag	O
-	O
adductable	O
lipids	O
such	O
as	O
wax	O
esters	O
in	O
fingermarks	O
and	O
cholesterol	O
in	O
murine	O
fore	O
-	O
stomach	O
.	O
Gastrointestinal	O
acid	O
condensation	O
products	O
of	O
6	O
-	O
bromoisatin	O
,	O
such	O
as	O
the	O
6,6'-dibromoindirubin	O
mapped	O
herein	O
,	O
are	O
very	O
challenging	O
to	O
isolate	B-T059
and	O
characterize	O
.	O
By	O
re	O
-	O
analyzing	O
the	O
same	O
tissue	O
imprints	O
,	O
this	O
metabolite	O
was	O
readily	O
detected	O
by	O
DIOS	O
,	O
placed	O
in	O
a	O
tissue	O
-	O
specific	O
spatial	O
context	O
,	O
and	O
subsequently	O
overlaid	O
with	O
additional	O
lipid	O
distributions	O
acquired	O
using	O
Ag	B-T059
-	I-T059
DIOS	I-T059
MSI	I-T059
.	O
The	O
ability	O
to	O
place	O
metabolite	O
and	O
lipid	O
classes	O
in	O
a	O
tissue	O
-	O
specific	O
context	O
makes	O
this	O
novel	O
method	O
suited	O
to	O
MSI	B-T059
analyses	I-T059
where	O
the	O
collection	O
of	O
additional	O
information	O
from	O
the	O
same	O
sample	O
maximises	O
resource	O
use	O
,	O
and	O
also	O
maximises	O
the	O
number	O
of	O
annotated	O
small	O
molecules	O
,	O
in	O
particular	O
for	O
metabolites	O
that	O
are	O
typically	O
undetectable	O
with	O
traditional	O
platforms	O
.	O
Copyright	O
©	O
2017	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O
      
Targeting	O
accuracy	O
of	O
single	O
-	O
isocenter	O
intensity	B-T061
-	I-T061
modulated	I-T061
radiosurgery	B-T061
for	O
multiple	O
lesions	B-T033
To	O
investigate	O
the	O
targeting	O
accuracy	O
of	O
intensity	B-T061
-	I-T061
modulated	I-T061
SRS	B-T061
(	O
IMRS	B-T061
)	O
plans	O
designed	O
to	O
simultaneously	O
treat	O
multiple	O
brain	B-T023
metastases	O
with	O
a	O
single	O
isocenter	O
.	O
A	O
home	O
-	O
made	O
acrylic	O
phantom	O
able	O
to	O
support	O
a	O
film	O
(	O
EBT3	O
)	O
in	O
its	O
coronal	O
plane	O
was	O
used	O
.	O
The	O
phantom	O
was	O
CT	B-T060
scanned	I-T060
and	O
three	O
coplanar	O
small	O
targets	O
(	O
a	O
central	O
and	O
two	O
peripheral	O
)	O
were	O
outlined	O
in	O
the	O
Eclipse	B-T061
system	I-T061
.	O
Peripheral	O
targets	O
were	O
6	O
cm	O
apart	O
from	O
the	O
central	O
one	O
.	O
A	O
reference	O
IMRS	B-T061
plan	O
was	O
designed	O
to	O
simultaneously	O
treat	O
the	O
three	O
targets	O
,	O
but	O
only	O
a	O
single	O
isocenter	O
located	O
at	O
the	O
center	O
of	O
the	O
central	O
target	O
was	O
used	O
.	O
After	O
positioning	O
the	O
phantom	O
on	O
the	O
linac	O
using	O
the	O
room	O
lasers	O
,	O
a	O
CBCT	B-T060
scan	I-T060
was	O
acquired	O
and	O
the	O
reference	O
plan	O
were	O
mapped	O
on	O
it	O
,	O
by	O
placing	O
the	O
planned	O
isocenter	O
at	O
the	O
intersection	O
of	O
the	O
landmarks	O
used	O
in	O
the	O
film	O
showing	O
the	O
linac	O
isocenter	O
.	O
The	O
mapped	O
plan	O
was	O
then	O
recalculated	O
and	O
delivered	O
.	O
The	O
film	O
dose	B-T061
distribution	I-T061
was	O
derived	O
using	O
a	O
cloud	O
computing	O
application	O
(	O
www.radiochromic.com	O
)	O
that	O
uses	O
a	O
triple	O
-	O
channel	O
dosimetry	B-T059
algorithm	O
.	O
Comparison	O
of	O
dose	B-T061
distributions	I-T061
using	O
the	O
gamma	O
index	O
(	O
5%/1	O
mm	O
)	O
were	O
performed	O
over	O
a	O
5	O
×	O
5	O
cm(2	O
)	O
region	O
centered	O
over	O
each	O
target	O
.	O
2D	O
shifts	O
required	O
to	O
get	O
the	O
best	O
gamma	O
passing	O
rates	O
on	O
the	O
peripheral	O
target	O
regions	O
were	O
compared	O
with	O
the	O
reported	O
ones	O
for	O
the	O
central	O
target	O
.	O
The	O
experiment	O
was	O
repeated	O
ten	O
times	O
in	O
different	O
sessions	B-T061
.	O
Average	O
2D	O
shifts	O
required	O
to	O
achieve	O
optimal	O
gamma	O
passing	O
rates	O
(	O
99	O
%	O
,	O
97	O
%	O
,	O
99	O
%	O
)	O
were	O
0.7	O
mm	O
(	O
SD	O
:	O
0.3	O
mm	O
)	O
,	O
0.8	O
mm	O
(	O
SD	O
:	O
0.4	O
mm	O
)	O
and	O
0.8	O
mm	O
(	O
SD	O
:	O
0.3	O
mm	O
)	O
,	O
for	O
the	O
central	O
and	O
the	O
two	O
peripheral	O
targets	O
,	O
respectively	O
.	O
No	O
statistical	O
differences	O
(	O
p	O
>	O
0.05	O
)	O
were	O
found	O
for	O
targeting	O
accuracy	O
between	O
the	O
central	O
and	O
the	O
two	O
peripheral	O
targets	O
.	O
The	O
study	O
revealed	O
a	O
targeting	O
accuracy	O
within	O
1	O
mm	O
for	O
off-	O
isocenter	O
targets	O
within	O
6	O
cm	O
of	O
the	O
linac	O
isocenter	O
,	O
when	O
a	O
single	O
-	O
isocenter	O
IMRS	B-T061
plan	O
is	O
designed	O
.	O
      
Maternal	O
vitamin	B-T121
D	I-T121
levels	O
and	O
the	O
risk	O
of	O
perinatal	O
death	O
To	O
determine	O
the	O
association	O
between	O
maternal	O
vitamin	B-T121
D	I-T121
levels	O
and	O
perinatal	O
death	O
.	O
A	O
retrospective	O
cross	O
-	O
sectional	O
study	O
of	O
all	O
non	O
-	O
anomalous	O
,	O
singleton	O
births	O
(	O
≥24	O
weeks	O
)	O
with	O
perinatal	O
death	O
compared	O
to	O
a	O
matched	O
control	O
group	O
.	O
Only	O
pregnancies	O
with	O
a	O
recorded	O
vitamin	B-T121
D	I-T121
level	O
at	O
booking	O
(	O
8	O
-	O
19	O
weeks	O
gestation	O
)	O
were	O
included	O
for	O
analysis	O
.	O
Maternal	O
vitamin	B-T121
D	I-T121
levels	O
were	O
categorized	O
into	O
normal	O
,	O
deficient	O
and	O
insufficient	O
cohorts	O
and	O
variables	O
compared	O
between	O
the	O
three	O
groups	O
.	O
There	O
were	O
31	O
perinatal	O
deaths	O
which	O
were	O
compared	O
to	O
111	O
controls	O
.	O
Median	O
vitamin	B-T121
D	I-T121
levels	O
were	O
lower	O
in	O
the	O
perinatal	O
death	O
cohort	O
compared	O
to	O
the	O
control	O
group	O
(	O
55	O
nmol	O
/	O
L	O
versus	O
64	O
nmol	O
/	O
L	O
,	O
p	O
=	O
0.43	O
)	O
.	O
There	O
was	O
no	O
significant	O
increase	O
in	O
deaths	O
between	O
the	O
normal	O
and	O
deficient	O
(	O
p	O
=	O
0.33	O
)	O
or	O
insufficient	O
(	O
p	O
=	O
0.09	O
)	O
groups	O
.	O
Low	O
maternal	O
vitamin	B-T121
D	I-T121
levels	O
at	O
booking	O
were	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
perinatal	O
demise	O
.	O
      
Post	O
-	O
synthetic	O
conversion	O
of	O
5	O
-	O
pivaloyloxymethyluridine	O
present	B-T033
in	O
a	O
support	O
-	O
bound	O
RNA	O
oligomer	O
into	O
biologically	O
relevant	O
derivatives	O
of	O
5	O
-	O
methyluridine	O
A	O
post	O
-	O
synthetic	O
reaction	O
of	O
5	O
-	O
pivaloyloxymethyluridine	O
(	O
present	B-T033
in	O
a	O
support	O
-	O
bound	O
RNA	O
oligomer	O
)	O
with	O
various	O
nucleophilic	O
reagents	O
furnished	O
efficiently	O
the	O
corresponding	O
products	O
bearing	O
one	O
aof	O
the	O
tRNA	O
wobble	O
5	O
-	O
methyluridines	O
(	O
mnm(5)U	O
,	O
cmnm(5)U	O
,	O
τm(5)U	O
,	O
nm(5)U	O
,	O
inm(5)U	O
or	O
cnm(5)U	O
)	O
.	O
The	O
syntheses	O
of	O
oligoribonucleotides	O
modified	O
with	O
inm(5)U	O
and	O
cnm(5)U	O
are	O
reported	O
for	O
the	O
first	O
time	O
.	O
      
DT	B-T060
MRI	I-T060
microstructural	O
cortical	B-T023
lesion	B-T047
damage	O
does	O
not	O
explain	O
cognitive	B-T048
impairment	I-T048
in	O
MS	B-T047
We	O
combined	O
double	B-T060
inversion	I-T060
recovery	I-T060
(	O
DIR	B-T060
)	O
and	O
diffusion	B-T060
tensor	I-T060
(	I-T060
DT	I-T060
)	I-T060
magnetic	I-T060
resonance	I-T060
imaging	I-T060
(	I-T060
MRI	I-T060
)	I-T060
to	O
quantify	O
the	O
severity	O
of	O
cortical	B-T023
lesion	B-T047
(	O
CL	B-T047
)	O
microstructural	O
tissue	O
abnormalities	B-T020
in	O
a	O
large	O
cohort	O
of	O
relapse	O
-	O
onset	O
multiple	B-T047
sclerosis	I-T047
(	O
MS	B-T047
)	O
patients	O
and	O
its	O
contribution	O
to	O
cognitive	B-T048
dysfunction	I-T048
.	O
DIR	B-T060
,	O
DT	B-T060
,	O
dual	B-T060
-	I-T060
echo	I-T060
,	O
and	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
T1	B-T060
-	I-T060
weighted	I-T060
scans	I-T060
were	O
acquired	O
from	O
149	O
MS	B-T047
patients	O
and	O
40	O
controls	O
.	O
Cognitively	B-T048
impaired	I-T048
(	O
CI	B-T048
)	O
patients	O
had	O
⩾2	O
abnormal	B-T033
neuropsychological	B-T060
tests	I-T060
.	O
Diffusivity	O
values	O
in	O
CLs	B-T047
,	O
cortex	B-T023
,	O
white	B-T033
matter	I-T033
(	I-T033
WM	I-T033
)	I-T033
lesions	I-T033
,	O
and	O
normal	O
-	O
appearing	O
(	O
NA	O
)	O
WM	O
were	O
assessed	O
.	O
Predictors	O
of	O
cognitive	B-T048
impairment	I-T048
were	O
identified	O
using	O
a	O
random	O
forest	O
analysis	O
.	O
Compared	O
to	O
controls	O
,	O
MS	B-T047
patients	O
had	O
lower	O
normalized	O
brain	O
volume	O
(	O
NBV	O
)	O
,	O
gray	O
matter	O
volume	O
(	O
GMV	O
)	O
,	O
WM	B-T033
volume	I-T033
,	O
lower	O
fractional	O
anisotropy	O
(	O
FA	O
)	O
,	O
and	O
higher	O
mean	O
diffusivity	O
in	O
cortex	B-T023
and	O
normal	O
-	O
appearing	O
white	O
matter	O
(	O
NAWM	O
)	O
.	O
A	O
total	O
of	O
44	O
(	O
29.5	O
%	O
)	O
patients	O
were	O
CI	B-T048
.	O
Compared	O
to	O
cognitively	O
preserved	O
(	O
CP	O
)	O
,	O
CI	B-T048
patients	O
had	O
higher	O
T2	O
WM	O
lesion	O
volume	O
(	O
LV	O
)	O
,	O
lower	O
NBV	O
and	O
GMV	O
,	O
and	O
more	O
severe	O
diffusivity	O
abnormalities	B-T020
in	O
WM	B-T033
lesions	I-T033
,	O
cortex	B-T023
,	O
and	O
NAWM	O
.	O
CL	B-T047
measures	O
did	O
not	B-T033
differ	I-T033
between	O
CI	O
and	O
CP	O
patients	O
.	O
Cortex	B-T023
FA	O
,	O
age	O
,	O
disease	O
duration	O
,	O
T2	O
WM	O
LV	O
,	O
and	O
GMV	O
best	O
predicted	O
MS	B-T047
-related	O
cognitive	B-T048
impairment	I-T048
(	O
C	O
-	O
statistic	O
=	O
0.88	O
)	O
.	O
"	O
Diffuse	O
"	O
GM	O
and	O
NAWM	O
damage	O
and	O
WM	B-T033
lesions	I-T033
,	O
rather	O
than	O
intrinsic	O
CL	B-T047
damage	O
,	O
contribute	O
to	O
cognitive	B-T048
impairment	I-T048
in	O
MS	B-T047
.	O
      
Post	O
endodontic	B-T184
pain	I-T184
following	O
single	O
-	O
visit	O
root	B-T061
canal	I-T061
preparation	I-T061
with	O
rotary	O
vs	O
reciprocating	O
instruments	O
:	O
a	O
meta	O
-	O
analysis	O
of	O
randomized	O
clinical	O
trials	O
In	O
endodontic	B-T061
therapy	I-T061
,	O
continuous	O
rotary	O
instrumentation	O
reduced	O
debris	O
compared	O
to	O
reciprocal	O
instrumentation	O
,	O
which	O
might	O
affect	O
the	O
incidence	O
of	O
post	B-T184
-	I-T184
endodontic	I-T184
pain	I-T184
(	O
PP	B-T184
)	O
.	O
The	O
aim	O
of	O
our	O
study	O
was	O
to	O
assess	O
whether	O
PP	B-T184
incidence	O
and	O
levels	O
were	O
influenced	O
by	O
the	O
choice	O
of	O
rotary	O
or	O
reciprocal	O
instruments	O
.	O
In	O
this	O
meta	O
-	O
analysis	O
the	O
Pubmed	O
and	O
EM	O
databases	O
were	O
searched	O
for	O
prospective	O
clinical	O
randomized	O
trials	O
published	O
before	O
April	O
20	O
,	O
2016	O
,	O
using	O
combinations	O
of	O
the	O
keywords	O
:	O
root	B-T061
canal	I-T061
preparation	I-T061
/	O
instrumentation	O
/	O
treatment	B-T061
/	O
therapy	B-T061
;	O
post	O
-	O
operative	O
/	O
endodontic	B-T184
pain	I-T184
;	O
reciprocal	O
and	O
rotary	O
instruments	O
.	O
Three	O
studies	O
were	O
included	O
,	O
involving	O
a	O
total	O
of	O
1,317	O
patients	O
,	O
659	O
treated	O
with	O
reciprocating	O
instruments	O
and	O
658	O
treated	O
with	O
rotary	O
instruments	O
.	O
PP	B-T184
was	O
reported	O
in	O
139	O
patients	O
in	O
the	O
reciprocating	O
group	O
and	O
172	O
in	O
the	O
rotary	O
group	O
.	O
The	O
PP	B-T184
incidence	O
odds	O
ratio	O
was	O
1.27	O
with	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
(	O
0.25	O
,	O
6.52	O
)	O
favoring	O
rotary	O
instruments	O
.	O
The	O
mild	O
,	O
moderate	O
and	O
severe	O
PP	B-T184
levels	O
odds	O
ratios	O
were	O
0.31	O
(	O
0.11	O
,	O
0.84	O
)	O
,	O
2.24	O
(	O
0.66	O
,	O
7.59	O
)	O
and	O
11.71	O
(	O
0.63	O
,	O
218.15	O
)	O
,	O
respectively	O
.	O
No	O
evidence	O
of	O
publication	O
bias	O
was	O
found	O
.	O
Rotary	O
instrument	O
choice	O
in	O
endodontic	B-T061
therapy	I-T061
is	O
associated	O
with	O
a	O
lower	O
incidence	O
of	O
PP	B-T184
than	O
reciprocating	O
instruments	O
,	O
while	O
reciprocating	O
instruments	O
are	O
associated	O
with	O
less	O
mild	O
PP	B-T184
incidence	O
.	O
      
Efficacy	O
of	O
Intravenous	O
Chlorothiazide	B-T121
for	O
Refractory	O
Acute	B-T047
Decompensated	I-T047
Heart	I-T047
Failure	I-T047
Unresponsive	O
to	O
Adjunct	O
Metolazone	B-T121
To	O
assess	O
the	O
efficacy	O
of	O
intravenous	O
chlorothiazide	B-T121
in	O
patients	O
with	O
acute	B-T047
decompensated	I-T047
heart	I-T047
failure	I-T047
(	O
ADHF	B-T047
)	O
who	O
were	O
determined	O
to	O
be	O
loop	B-T121
diuretic	I-T121
resistant	O
and	O
refractory	O
to	O
metolazone	B-T121
.	O
Retrospective	O
cohort	O
study	O
with	O
patients	O
serving	O
as	O
their	O
own	O
controls	O
.	O
Large	O
,	O
academic	O
,	O
tertiary	O
care	O
hospital	O
.	O
Forty	O
-	O
five	O
patients	O
with	O
ADHF	B-T047
who	O
had	O
an	O
inadequate	O
response	O
to	O
high	O
-	O
dose	O
loop	B-T121
diuretics	I-T121
and	O
then	O
received	O
at	O
least	O
one	O
dose	O
of	O
oral	O
metolazone	B-T121
5	O
mg	O
or	O
greater	O
(	O
metolazone	B-T121
index	O
dose	O
)	O
followed	O
by	O
at	O
least	O
one	O
dose	O
of	O
intravenous	O
chlorothiazide	B-T121
500	O
mg	O
(	O
chlorothiazide	B-T121
index	O
dose	O
)	O
if	O
the	O
response	O
to	O
metolazone	B-T121
was	O
considered	O
inadequate	O
,	O
according	O
to	O
the	O
institutional	O
protocol	O
,	O
between	O
February	O
4	O
,	O
2013	O
,	O
and	O
February	O
28	O
,	O
2015	O
,	O
were	O
included	O
.	O
If	O
multiple	O
doses	O
of	O
metolazone	B-T121
were	O
administered	B-T058
,	O
the	O
last	O
dose	O
given	O
before	O
the	O
chlorothiazide	B-T121
index	O
dose	O
was	O
considered	O
the	O
index	O
dose	O
;	O
the	O
metolazone	B-T121
index	O
dose	O
had	O
to	O
have	O
been	O
administered	B-T058
more	O
than	O
2	O
hours	O
before	O
the	O
chlorothiazide	B-T121
index	O
dose	O
.	O
Data	O
for	O
a	O
total	O
of	O
90	O
diuretic	B-T121
doses	O
(	O
45	O
metolazone	B-T121
,	O
45	O
chlorothiazide	B-T121
)	O
were	O
included	O
in	O
the	O
analysis	O
.	O
The	O
median	O
dose	O
of	O
loop	B-T121
diuretic	I-T121
in	O
intravenous	O
furosemide	B-T121
equivalents	O
given	O
over	O
the	O
24-	O
hour	O
period	O
before	O
the	O
metolazone	B-T121
index	O
dose	O
was	O
400	O
mg	O
.	O
The	O
average	O
length	O
of	O
stay	O
was	O
34.7	O
days	O
,	O
and	O
in	O
-	O
hospital	O
mortality	O
was	O
35.6	O
%	O
(	O
16/45	O
patients	O
)	O
.	O
The	O
primary	O
end	O
point	O
of	O
a	O
net	B-T033
-	I-T033
negative	I-T033
urine	O
output	O
of	O
500	O
ml	O
or	O
greater	O
during	O
the	O
12	O
hours	O
after	O
the	O
index	O
dose	O
occurred	O
in	O
42.2	O
%	O
(	O
19/45	O
patients	O
)	O
and	O
35.5	O
%	O
(	O
16/45	O
patients	O
)	O
for	O
the	O
chlorothiazide	B-T121
and	O
metolazone	B-T121
doses	O
,	O
respectively	O
(	O
p=0.581	O
)	O
.	O
The	O
median	O
12-	O
hour	O
urine	O
output	O
following	O
administration	O
of	O
metolazone	B-T121
was	O
810	O
ml	O
(	O
interquartile	O
range	O
[	O
IQR	O
]	O
866	O
ml	O
)	O
versus	O
1075	O
ml	O
(	O
IQR	O
940	O
ml	O
)	O
following	O
administration	O
of	O
chlorothiazide	B-T121
(	O
p=0.363	O
)	O
.	O
Compared	O
with	O
metolazone	B-T121
,	O
the	O
chlorothiazide	B-T121
doses	O
did	O
not	O
result	O
in	O
an	O
increase	O
in	O
urine	O
output	O
of	O
at	O
least	O
500	O
ml	O
during	O
the	O
12	O
hours	O
following	O
the	O
dose	O
relative	O
to	O
the	O
12	O
hours	O
before	O
the	O
dose	O
(	O
31.1	O
%	O
vs	O
22.2	O
%	O
,	O
p=0.754	O
)	O
.	O
No	O
significant	O
difference	O
in	O
achievement	O
of	O
net	B-T033
-	I-T033
negative	I-T033
urine	O
output	O
of	O
500	O
ml	O
or	O
greater	O
during	O
the	O
12	O
hours	O
following	O
the	O
chlorothiazide	B-T121
or	O
metolazone	B-T121
dose	O
was	O
noted	O
(	O
42.2	O
%	O
for	O
chlorothiazide	B-T121
vs	O
35.5	O
%	O
for	O
metolazone	B-T121
,	O
p=0.581	O
)	O
.	O
The	O
addition	O
of	O
intravenous	O
chlorothiazide	B-T121
did	O
not	O
result	O
in	O
improved	B-T033
diuresis	O
in	O
patients	O
with	O
ADHF	B-T047
determined	O
to	O
be	O
refractory	O
to	O
loop	B-T121
diuretic	I-T121
s	O
and	O
adjunctive	O
oral	O
metolazone	B-T121
.	O
      
Fine	O
structure	O
of	O
interleukin	O
18	O
(	O
IL-18	O
)	O
receptor	O
-	O
immunoreactive	O
neurons	O
in	O
the	O
retrosplenial	B-T023
cortex	I-T023
and	O
its	O
changes	O
in	O
IL18	O
knockout	O
mice	O
Interleukin	O
18	O
(	O
IL-18	O
)	O
participates	O
in	O
the	O
inflammatory	O
immune	O
response	O
of	O
lymphocytes	O
.	O
Delay	O
in	O
learning	O
or	O
memory	O
are	O
common	O
in	O
the	O
IL-18	O
knockout	O
mouse	O
.	O
Many	O
IL-18	O
-	O
immunoreactive	O
neurons	O
are	O
found	O
in	O
the	O
retrosplenial	B-T023
cortex	I-T023
(	O
RSC	B-T023
)	O
and	O
the	O
subiculum	B-T023
.	O
These	O
neurons	O
also	O
contain	O
the	O
IL-18	O
receptor	O
.	O
We	O
determined	O
the	O
location	O
and	O
the	O
ultrastructure	O
of	O
the	O
IL-18	O
receptor	O
-	O
immunoreactive	O
neurons	O
in	O
the	O
RSC	B-T023
and	O
observed	O
changes	O
in	O
the	O
IL-18	O
receptor	O
-	O
immunoreactive	O
neurons	O
of	O
the	O
IL-18	O
knockout	O
mouse	O
.	O
The	O
IL-18	O
receptor	O
-	O
immunoreactive	O
neurons	O
were	O
found	O
specifically	O
in	O
layer	O
V	O
of	O
the	O
granular	O
RSC	O
.	O
They	O
were	O
medium	O
-	O
sized	O
neurons	O
with	O
a	O
light	O
oval	O
nucleus	O
and	O
had	O
little	O
cytoplasm	O
with	O
many	O
free	O
ribosomes	O
,	O
rough	O
endoplasmic	O
reticulum	O
and	O
many	O
mitochondria	O
,	O
but	O
no	O
Nissl	O
bodies	O
.	O
The	O
number	O
of	O
axosomatic	O
terminals	O
was	O
about	O
six	O
per	O
section	O
.	O
The	O
IL-18	O
receptor	O
-	O
immunoreactive	O
neurons	O
were	O
not	O
found	O
in	O
the	O
RSC	B-T023
in	O
the	O
IL-18	O
knockout	O
mouse	O
at	O
5	O
or	O
9	O
weeks	O
of	O
age	O
.	O
However	O
,	O
many	O
small	O
electron	O
-	O
dense	O
neurons	O
were	O
found	O
in	O
layer	O
V.	O
Both	O
the	O
nucleus	O
and	O
cytoplasm	O
were	O
electron	O
-	O
dense	O
,	O
but	O
not	O
necrotic	O
.	O
The	O
mitochondria	O
and	O
rough	O
endoplasmic	O
reticulum	O
were	O
swollen	B-T033
.	O
The	O
IL-18	O
receptor	O
-	O
immunoreactive	O
neurons	O
were	O
presumed	O
to	O
be	O
degenerating	B-T033
.	O
The	O
degeneration	O
of	O
the	O
IL18	O
-	O
receptor	O
-	O
immunoreactive	O
neurons	O
in	O
the	O
RSC	B-T023
may	O
cause	O
the	O
abnormal	B-T048
behaviors	I-T048
of	O
the	O
IL-18	O
knockout	O
mice	O
.	O
      
Problem	O
-	O
based	O
learning	O
using	O
patient	O
-simulated	O
videos	O
showing	O
daily	O
life	O
for	O
a	O
comprehensive	O
clinical	O
approach	O
We	O
examined	O
whether	O
problem	O
-	O
based	O
learning	O
tutorials	O
using	O
patient	O
-simulated	O
videos	O
showing	O
daily	O
life	O
are	O
more	O
practical	O
for	O
clinical	O
learning	O
,	O
compared	O
with	O
traditional	O
paper	O
-	O
based	O
problem	O
-	O
based	O
learning	O
,	O
for	O
the	O
consideration	O
rate	B-T033
of	I-T033
psychosocial	I-T033
issues	I-T033
and	O
the	O
recall	B-T033
rate	I-T033
for	O
experienced	O
learning	O
.	O
Twenty	O
-	O
two	O
groups	O
with	O
120	O
fifth-	O
year	O
students	O
were	O
each	O
assigned	O
paper	O
-	O
based	O
problem	O
-	O
based	O
learning	O
and	O
video	O
-based	O
problem	O
-	O
based	O
learning	O
using	O
patient	O
-simulated	O
videos	O
.	O
We	O
compared	O
target	O
achievement	B-T033
rates	I-T033
in	O
questionnaires	O
using	O
the	O
Wilcoxon	O
signed	O
-	O
rank	O
test	O
and	O
discussion	O
contents	O
diversity	O
using	O
the	O
Mann	O
-	O
Whitney	O
U	O
test	O
.	O
A	O
follow	O
-	O
up	O
survey	O
used	O
a	O
chi	O
-	O
square	O
test	O
to	O
measure	O
students	O
'	O
recall	O
of	O
cases	O
in	O
three	O
categories	O
:	O
video	O
,	O
paper	O
,	O
and	O
non	O
-	O
experienced	O
.	O
Video	O
-based	O
problem	O
-	O
based	O
learning	O
displayed	O
significantly	O
higher	O
achievement	B-T033
rates	I-T033
for	O
imagining	O
authentic	O
patients	O
(	O
p=0.001	O
)	O
,	O
incorporating	O
a	O
comprehensive	O
approach	O
including	O
psychosocial	O
aspects	O
(	O
p<0.001	O
)	O
,	O
and	O
satisfaction	O
with	O
sessions	O
(	O
p=0.001	O
)	O
.	O
No	B-T033
significant	I-T033
differences	I-T033
existed	O
in	O
the	O
discussion	O
contents	O
diversity	O
regarding	O
the	O
International	O
Classification	O
of	O
Primary	O
Care	O
Second	O
Edition	O
codes	O
and	O
chapter	O
types	O
or	O
in	O
the	O
rate	B-T033
of	I-T033
psychological	I-T033
codes	I-T033
.	O
In	O
a	O
follow	O
-	O
up	O
survey	O
comparing	O
video	O
and	O
paper	O
groups	O
to	O
non	O
-	O
experienced	O
groups	O
,	O
the	O
rates	O
were	O
higher	O
for	O
video	O
(	O
χ(2)=24.319	O
,	O
p<0.001	O
)	O
and	O
paper	O
(	O
χ(2)=11.134	O
,	O
p=0.001	O
)	O
.	O
Although	O
the	O
video	O
rate	O
tended	O
to	O
be	O
higher	O
than	O
the	O
paper	O
rate	O
,	O
no	B-T033
significant	I-T033
difference	I-T033
was	O
found	O
between	O
the	O
two	O
.	O
Patient	O
-simulated	O
videos	O
showing	O
daily	O
life	O
facilitate	O
imagining	O
true	O
patients	O
and	O
support	O
a	O
comprehensive	O
approach	O
that	O
fosters	O
better	O
memory	O
.	O
The	O
clinical	O
patient	O
-simulated	O
video	O
method	O
is	O
more	O
practical	O
and	O
clinical	O
problem	O
-	O
based	O
tutorials	O
can	O
be	O
implemented	O
if	O
we	O
create	O
patient	O
-simulated	O
videos	O
for	O
each	O
symptom	B-T184
as	O
teaching	O
materials	O
.	O
      
Antiviral	B-T033
activities	I-T033
of	O
selected	O
antimalarials	B-T121
against	O
dengue	B-T005
virus	I-T005
type	I-T005
2	I-T005
and	O
Zika	B-T005
virus	I-T005
In	O
a	O
previous	O
study	O
,	O
twelve	O
antimalarial	B-T121
compounds	I-T121
,	O
amodiaquine	B-T121
(	O
AQ	B-T121
)	O
and	O
derivatives	O
,	O
were	O
shown	O
to	O
have	O
potent	O
anti	B-T033
-	I-T033
dengue	I-T033
viral	I-T033
(	I-T033
DENV	I-T033
)	I-T033
activity	I-T033
by	O
using	O
the	O
stable	O
DENV2	B-T005
Renilla	O
luciferase	O
reporter	O
replicon	O
expressing	O
BHK-21	O
cells	O
,	O
infectivity	O
(	O
plaque	B-T059
)	O
,	O
and	O
the	O
qRT	O
-	O
PCR	O
assays	O
.	O
In	O
this	O
study	O
,	O
we	O
performed	O
molecular	O
modeling	O
on	O
these	O
compounds	B-T121
to	O
determine	O
their	O
stereo	O
-	O
electronic	O
properties	O
required	O
for	O
optimal	O
antiviral	B-T033
activity	I-T033
.	O
Based	O
on	O
the	O
similarity	O
of	O
calculated	O
stereo	O
-	O
electronic	O
profiles	O
,	O
specifically	O
the	O
electrostatic	O
potential	O
profiles	O
of	O
the	O
compounds	B-T121
,	O
and	O
in	O
silico	O
screening	O
of	O
related	O
compounds	B-T121
from	O
literature	O
,	O
we	O
identified	O
three	O
additional	O
compounds	B-T121
,	O
Quinacrine	B-T121
(	O
QC	B-T121
)	O
,	O
Mefloquine	B-T121
(	O
MQ	B-T121
)	O
,	O
and	O
GSK369796	B-T121
.	O
Analysis	O
of	O
their	O
antiviral	B-T033
activities	I-T033
indicated	O
that	O
all	O
three	B-T121
compounds	I-T121
have	O
high	O
anti	B-T033
-	I-T033
DENV	I-T033
activity	I-T033
in	O
the	O
DENV2	B-T005
replicon	O
expressing	O
cells	O
with	O
EC50	O
values	O
of	O
5.30	O
±	O
1.31	O
μM	O
(	O
QC	B-T121
)	O
,	O
3.22	O
±	O
0.37	O
μM	O
(	O
MQ	B-T121
)	O
,	O
and	O
5.06	O
±	O
0.86	O
μM	O
(	O
GSK369796	B-T121
)	O
.	O
The	O
infectivity	B-T059
assays	I-T059
revealed	O
the	O
EC50	O
values	O
of	O
7.09	O
±	O
1.67	O
μM	O
(	O
QC	B-T121
)	O
,	O
4.36	O
±	O
0.31	O
μM	O
(	O
MQ	B-T121
)	O
and	O
3.03	O
±	O
0.35	O
μM	O
(	O
GSK369796	B-T121
)	O
.	O
The	O
mode	O
of	O
action	O
of	O
these	O
compounds	B-T121
is	O
through	O
inhibition	O
of	O
autophagy	O
,	O
thereby	O
affecting	O
DENV2	B-T005
replication	O
.	O
Moreover	O
,	O
these	O
compounds	B-T121
also	O
showed	O
antiviral	B-T033
activity	I-T033
against	O
the	O
rapidly	O
emerging	O
Zika	B-T005
virus	I-T005
(	O
ZIKV	B-T005
)	O
with	O
EC50	O
values	O
of	O
2.27	O
±	O
0.14	O
μM	O
(	O
QC	B-T121
)	O
,	O
3.95	O
±	O
0.21	O
μM	O
(	O
MQ	B-T121
)	O
,	O
and	O
2.57	O
±	O
0.09	O
μM	O
(	O
GSK369796	B-T121
)	O
.	O
      
Sub	B-T033
-	I-T033
lethal	I-T033
effects	I-T033
of	O
dietary	O
neonicotinoid	O
insecticide	O
exposure	O
on	O
honey	O
bee	O
queen	O
fecundity	O
and	O
colony	O
development	O
Many	O
factors	O
can	O
negatively	B-T033
affect	O
honey	O
bee	O
(	O
Apis	O
mellifera	O
L.	O
)	O
health	O
including	O
the	O
pervasive	O
use	O
of	O
systemic	O
neonicotinoid	O
insecticides	O
.	O
Through	O
direct	O
consumption	O
of	O
contaminated	O
nectar	O
and	O
pollen	O
from	O
treated	O
plants	O
,	O
neonicotinoids	O
can	O
affect	O
foraging	O
,	O
learning	O
,	O
and	O
memory	O
in	O
worker	O
bees	O
.	O
Less	O
well	O
studied	O
are	O
the	O
potential	O
effects	O
of	O
neonicotinoids	O
on	O
queen	O
bees	O
,	O
which	O
may	O
be	O
exposed	O
indirectly	O
through	O
trophallaxis	O
,	O
or	O
food	O
-	O
sharing	O
.	O
To	O
assess	B-T058
effects	O
on	O
queen	O
productivity	O
,	O
small	O
colonies	O
of	O
different	O
sizes	O
(	O
1500	O
,	O
3000	O
,	O
and	O
7000	O
bees	O
)	O
were	O
fed	O
imidacloprid	O
(	O
0	O
,	O
10	O
,	O
20	O
,	O
50	O
,	O
and	O
100	O
ppb	O
)	O
in	O
syrup	O
for	O
three	O
weeks	O
.	O
We	O
found	O
adverse	O
effects	O
of	O
imidacloprid	O
on	O
queens	O
(	O
egg	O
-	O
laying	O
and	O
locomotor	O
activity	O
)	O
,	O
worker	O
bees	O
(	O
foraging	O
and	O
hygienic	O
activities	O
)	O
,	O
and	O
colony	O
development	O
(	O
brood	O
production	O
and	O
pollen	O
stores	O
)	O
in	O
all	O
treated	O
colonies	O
.	O
Some	O
effects	O
were	O
less	O
evident	O
as	O
colony	O
size	O
increased	O
,	O
suggesting	O
that	O
larger	O
colony	O
populations	O
may	O
act	O
as	O
a	O
buffer	O
to	O
pesticide	B-T033
exposure	I-T033
.	O
This	O
study	O
is	O
the	O
first	O
to	O
show	O
adverse	O
effects	O
of	O
imidacloprid	O
on	O
queen	O
bee	O
fecundity	O
and	O
behavior	O
and	O
improves	O
our	O
understanding	O
of	O
how	O
neonicotinoids	O
may	O
impair	O
short	O
-	O
term	O
colony	O
functioning	O
.	O
These	O
data	O
indicate	O
that	O
risk	O
-	O
mitigation	O
efforts	O
should	O
focus	O
on	O
reducing	O
neonicotinoid	O
exposure	O
in	O
the	O
early	O
spring	O
when	O
colonies	O
are	O
smallest	O
and	O
queens	O
are	O
most	O
vulnerable	O
to	O
exposure	O
.	O
      
Keeping	O
the	O
Spirits	O
Up	O
:	O
The	O
Effect	O
of	O
Teachers	O
'	O
and	O
Parents	O
'	O
Emotional	B-T058
Support	I-T058
on	O
Children	O
's	O
Working	O
Memory	O
Performance	O
Working	O
memory	O
,	O
used	O
to	O
temporarily	O
store	O
and	O
mentally	O
manipulate	O
information	O
,	O
is	O
important	O
for	O
children	O
's	O
learning	O
.	O
It	O
is	O
therefore	O
valuable	O
to	O
understand	O
which	O
(	O
contextual	O
)	O
factors	O
promote	O
or	O
hinder	O
working	O
memory	O
performance	O
.	O
Recent	O
research	O
shows	O
positive	B-T033
associations	O
between	O
positive	B-T033
parent	O
-	O
child	O
and	O
teacher	O
-	O
student	O
interactions	O
and	O
working	O
memory	O
performance	O
and	O
development	O
.	O
However	O
,	O
no	O
study	O
has	O
yet	O
experimentally	O
investigated	O
how	O
parents	O
and	O
teachers	O
affect	O
working	O
memory	O
performance	O
.	O
Based	O
on	O
attachment	O
theory	O
,	O
the	O
current	O
study	O
investigated	O
the	O
role	O
of	O
parent	O
and	O
teacher	O
emotional	B-T058
support	I-T058
in	O
promoting	O
working	O
memory	O
performance	O
by	O
buffering	O
the	O
negative	B-T033
effect	O
of	O
social	B-T048
stress	I-T048
.	O
Questionnaires	O
and	O
an	O
experimental	O
session	O
were	O
completed	O
by	O
170	O
children	O
from	O
grade	O
1	O
to	O
2	O
(	O
Mage	O
=	O
7	O
years	O
6	O
months	O
,	O
SD	O
=	O
7	O
months	O
)	O
.	O
Questionnaires	O
were	O
used	O
to	O
assess	O
children	O
's	O
perceptions	O
of	O
the	O
teacher	O
-	O
student	O
and	O
parent	O
-	O
child	O
relationship	O
.	O
During	O
an	O
experimental	O
session	O
,	O
working	O
memory	O
was	O
measured	O
with	O
the	O
Corsi	O
task	O
backward	O
(	O
Milner	O
,	O
1971	O
)	O
in	O
a	O
pre-	O
and	O
post	O
-	O
test	O
design	O
.	O
In	O
-	O
between	O
the	O
tests	O
stress	B-T033
was	O
induced	O
in	O
the	O
children	O
using	O
the	O
Cyberball	O
paradigm	O
(	O
Williams	O
et	O
al	O
.	O
,	O
2000	O
)	O
.	O
Emotional	B-T058
support	I-T058
was	O
manipulated	O
(	O
between	O
-	O
subjects	O
)	O
through	O
an	O
audio	O
message	O
(	O
either	O
a	O
weather	O
report	O
,	O
a	O
supportive	B-T058
message	O
of	O
a	O
stranger	O
,	O
a	O
supportive	B-T058
message	O
of	O
a	O
parent	O
,	O
or	O
a	O
supportive	B-T058
message	O
of	O
a	O
teacher	O
)	O
.	O
Results	O
of	O
repeated	O
measures	O
ANOVA	O
showed	O
no	O
clear	O
effect	O
of	O
the	O
stress	B-T033
induction	O
.	O
Nevertheless	O
,	O
an	O
effect	O
of	O
parent	O
and	O
teacher	O
support	B-T058
was	O
found	O
and	O
depended	O
on	O
the	O
quality	O
of	O
the	O
parent	O
-	O
child	O
relationship	O
.	O
When	O
children	O
had	O
a	O
positive	B-T033
relationship	O
with	O
their	O
parent	O
,	O
support	B-T058
of	O
parents	O
and	O
teachers	O
had	O
little	O
effect	O
on	O
working	O
memory	O
performance	O
.	O
When	O
children	O
had	O
a	O
negative	B-T033
relationship	O
with	O
their	O
parent	O
,	O
a	O
supportive	B-T058
message	O
of	O
that	O
parent	O
decreased	O
working	O
memory	O
performance	O
,	O
while	O
a	O
supportive	B-T058
message	O
from	O
the	O
teacher	O
increased	O
performance	O
.	O
In	O
sum	O
,	O
the	O
current	O
study	O
suggests	O
that	O
parents	O
and	O
teachers	O
can	O
support	B-T058
working	O
memory	O
performance	O
by	O
being	O
supportive	B-T058
for	O
the	O
child	O
.	O
Teacher	O
support	B-T058
is	O
most	O
effective	O
when	O
the	O
child	O
has	O
a	O
negative	B-T033
relationship	O
with	O
the	O
parent	O
.	O
These	O
insights	O
can	O
give	O
direction	O
to	O
specific	O
measures	O
aimed	O
at	O
preventing	O
and	O
resolving	B-T033
working	O
memory	O
problems	B-T033
and	O
related	O
issues	B-T033
.	O
      
Lignans	O
from	O
the	O
fruits	O
of	O
Schisandra	O
chinensis	O
(	O
Turcz	O
.	O
)	O
Baill	O
inhibit	O
proprotein	O
convertase	O
subtilisin	O
/	O
kexin	O
type	O
9	O
expression	O
Bioactivity	B-T059
-	I-T059
guided	I-T059
fractionation	I-T059
of	O
the	O
fruits	O
of	O
Schisandra	O
chinensis	O
,	O
using	O
the	O
proprotein	O
convertase	O
subtilisin	O
-	O
kexin	O
type	O
9	O
(	O
PCSK9	O
)	O
mRNA	O
expression	O
screening	B-T059
assay	I-T059
,	O
led	O
to	O
isolation	O
of	O
two	O
previously	O
unknown	O
lignans	O
,	O
14	O
-	O
tigloylschinlignan	O
D	O
and	O
rel-(7R	O
,	O
8R	O
,	O
7'R	O
,	O
8'R)-manglisin	O
E	O
,	O
along	O
with	O
28	O
known	O
compounds	O
.	O
All	O
structures	O
were	O
established	O
by	O
NMR	B-T060
spectroscopic	I-T060
data	O
as	O
well	O
as	O
CD	B-T059
and	O
MS	B-T059
analysis	O
.	O
All	O
isolates	O
were	O
tested	O
for	O
their	O
inhibitory	O
activities	O
on	O
the	O
mRNA	O
expression	O
of	O
PCSK9	O
.	O
Of	O
the	O
tested	O
compounds	O
,	O
four	O
of	O
the	O
compounds	O
rel-(7R	O
,	O
8R	O
,	O
7'R	O
,	O
8'R)-manglisin	O
E	O
,	O
(	B-T121
-)-schisandrin	I-T121
C	I-T121
,	O
schinlignan	O
D	O
,	O
and	O
(	B-T121
+	I-T121
)	I-T121
-schisandrol	I-T121
B	I-T121
potently	O
inhibited	O
PCSK9	O
mRNA	O
expression	O
with	O
IC50	O
values	O
of	O
3.15	O
,	O
3.85	O
,	O
0.36	O
,	O
and	O
1.10	O
μM	O
,	O
respectively	O
.	O
Furthermore	O
,	O
schinlignan	O
D	O
and	O
(	B-T121
+	I-T121
)	I-T121
-schisandrol	I-T121
B	I-T121
were	O
found	O
to	O
suppress	O
PCSK9	O
protein	O
expressions	O
and	O
schinlignan	O
D	O
deemed	O
to	O
increase	O
low	O
density	O
lipoprotein	O
receptor	O
expression	O
.	O
      
Histopathological	O
Evaluation	B-T058
of	O
the	O
Effectiveness	O
of	O
Glycyrrhizic	B-T121
Acid	I-T121
as	O
a	O
Radioprotector	B-T061
Against	O
the	O
Development	O
of	O
Radiation	B-T047
-	I-T047
Induced	I-T047
Lung	I-T047
Fibrosis	I-T047
Radiotherapy	B-T061
of	O
the	O
thorax	O
often	O
causes	O
lung	B-T047
inflammation	I-T047
leading	O
to	O
fibrosis	B-T047
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
use	O
of	O
glycyrrhizic	B-T121
acid	I-T121
(	O
GLA	B-T121
)	O
could	O
improve	O
the	O
development	O
of	O
lung	B-T047
fibrosis	I-T047
in	O
irradiated	B-T061
animals	O
.	O
Wistar	O
rats	O
were	O
divided	O
into	O
four	O
groups	O
.	O
Group	O
A	O
rats	O
received	O
thoracic	B-T061
irradiation	I-T061
.	O
Rats	O
in	O
group	O
B	O
received	O
GLA	B-T121
and	O
irradiation	B-T061
.	O
Group	O
C	O
received	O
GLA	B-T121
and	O
no	O
irradiation	B-T061
.	O
Group	O
D	O
received	O
no	O
GLA	B-T121
and	O
irradiation	B-T061
.	O
GLA	B-T121
was	O
administered	O
at	O
a	O
dose	O
of	O
4	O
mg	O
/	O
kg	O
body	O
weight	O
using	O
an	O
intraperitoneal	B-T061
injection	I-T061
one	O
hour	O
before	O
thoracic	B-T061
irradiation	I-T061
.	O
Radiation	B-T061
therapy	I-T061
was	O
delivered	O
on	O
a	O
Cobalt-60	O
unit	O
using	O
a	O
single	O
fraction	O
of	O
16	O
Gy	O
.	O
The	O
animals	O
were	O
sacrificed	O
at	O
32	O
weeks	O
following	O
thoracic	B-T061
irradiation	I-T061
.	O
The	O
lungs	B-T023
were	O
dissected	O
and	O
blind	O
histopathological	O
evaluation	B-T058
was	O
performed	O
.	O
Histopathologically	O
,	O
a	O
decrease	O
(	O
statistically	O
not	O
significant	O
)	O
in	O
the	O
thickening	B-T033
of	O
alveolar	B-T023
or	O
bronchial	B-T023
wall	I-T023
,	O
formation	O
of	O
fibrous	B-T020
bands	I-T020
,	O
and	O
superimposed	O
collagen	O
were	O
noted	O
in	O
the	O
animals	O
in	O
group	O
B	O
as	O
compared	O
to	O
the	O
animals	O
in	O
group	O
A.	O
In	O
this	O
experimental	O
study	O
,	O
administration	O
of	O
GLA	B-T121
one	O
hour	O
before	O
thoracic	B-T061
irradiation	I-T061
may	O
be	O
a	O
protective	B-T121
agent	I-T121
against	O
radiation	B-T047
-	I-T047
induced	I-T047
fibrosis	I-T047
in	O
animals	O
and	O
this	O
model	B-T050
could	O
be	O
used	O
in	O
future	O
studies	O
.	O
      
Botulinum	B-T121
Toxin	I-T121
Use	O
in	O
Refractory	B-T184
Pain	I-T184
and	O
Other	O
Symptoms	B-T184
in	O
Parkinsonism	B-T047
Parkinson	B-T047
's	I-T047
disease	I-T047
(	O
PD	B-T047
)	O
and	O
other	O
parkinsonian	B-T047
syndromes	I-T047
are	O
chronic	O
,	O
progressive	O
neurodegenerative	B-T047
diseases	I-T047
.	O
With	O
advancing	O
disease	B-T047
,	O
both	O
motor	B-T184
and	O
non	B-T184
-	I-T184
motor	I-T184
symptoms	I-T184
represent	O
a	O
considerable	O
burden	O
and	O
symptom	B-T184
relief	B-T033
and	O
quality	O
of	O
life	O
improvement	O
become	O
the	O
main	O
goal	O
of	O
treatment	B-T061
.	O
Botulinum	B-T121
toxins	I-T121
(	O
BTX	B-T121
)	O
are	O
an	O
effective	O
treatment	B-T061
modality	O
for	O
many	O
neurological	B-T047
conditions	I-T047
.	O
To	O
understand	O
the	O
potential	O
usefulness	O
of	O
BTX	B-T121
in	O
this	O
population	O
,	O
we	O
performed	O
a	O
retrospective	O
chart	B-T058
review	I-T058
of	O
all	O
patients	O
with	O
a	O
clinical	B-T060
diagnosis	I-T060
of	O
idiopathic	B-T047
PD	I-T047
and	O
atypical	B-T047
parkinsonism	I-T047
who	O
received	O
treatment	O
with	O
BTX	B-T061
injections	I-T061
in	O
our	O
center	O
from	O
1995	O
to	O
2014	O
for	O
a	O
variety	O
of	O
symptoms	B-T184
.	O
Response	O
to	O
BTX	B-T121
was	O
assessed	O
using	O
a	O
subjective	O
Clinical	O
Global	O
Impression	O
.	O
Records	O
of	O
160	O
patients	O
were	O
reviewed	O
.	O
Probable	O
idiopathic	B-T047
PD	I-T047
was	O
the	O
diagnosis	B-T033
in	O
117	O
patients	O
(	O
73.1	O
%	O
)	O
.	O
The	O
main	O
indication	O
for	O
BTX	B-T121
treatment	B-T061
was	O
pain	B-T184
(	O
50.6	O
%	O
of	O
cases	O
)	O
.	O
Other	O
indications	O
were	O
the	O
treatment	B-T061
of	O
functional	B-T033
impairment	I-T033
resulting	O
from	O
dystonia	B-T184
(	O
26.25	O
%	O
)	O
,	O
sialorrhea	B-T047
(	O
18.75	O
%	O
)	O
,	O
freezing	B-T184
of	I-T184
gait	I-T184
,	O
and	O
camptocormia	B-T020
.	O
Considering	O
pain	B-T184
as	O
indication	O
,	O
81	O
%	O
of	O
all	O
patients	O
with	O
PD	B-T047
reported	B-T058
benefits	O
after	O
the	O
first	O
BTX	B-T061
injections	I-T061
.	O
This	O
benefit	O
was	O
maintained	O
after	O
the	O
last	B-T058
recorded	I-T058
visit	I-T058
without	O
significant	O
difference	O
in	O
outcome	O
compared	O
with	O
the	O
first	O
injection	B-T061
(	O
p=0.067	O
)	O
.	O
Similar	O
results	O
were	O
observed	O
in	O
patients	O
with	O
atypical	B-T047
parkinsonism	I-T047
.	O
Our	O
results	O
confirm	O
the	O
safety	O
and	O
efficacy	O
of	O
different	O
uses	O
of	O
BTX	B-T121
in	O
the	O
symptomatic	O
treatment	O
of	O
patients	O
with	O
parkinsonism	B-T047
even	O
in	O
advanced	O
stages	O
of	O
the	O
disease	B-T047
,	O
and	O
suggest	O
BTX	B-T121
treatment	B-T061
could	O
have	O
a	O
safe	O
and	O
useful	O
role	O
in	O
the	O
treatment	O
of	O
pain	B-T184
in	O
this	O
population	O
.	O
      
Sedation	B-T061
of	O
Patients	O
With	O
Disorders	B-T048
of	I-T048
Consciousness	I-T048
During	O
Neuroimaging	B-T060
:	O
Effects	O
on	O
Resting	B-T060
State	I-T060
Functional	I-T060
Brain	I-T060
Connectivity	I-T060
To	O
reduce	O
head	O
movement	O
during	O
resting	B-T060
state	I-T060
functional	I-T060
magnetic	I-T060
resonance	I-T060
imaging	I-T060
,	O
post	O
-	O
coma	O
patients	O
with	O
disorders	B-T048
of	I-T048
consciousness	I-T048
(	O
DOC	B-T048
)	O
are	O
frequently	O
sedated	B-T061
with	O
propofol	B-T121
.	O
However	O
,	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
this	O
sedation	B-T061
on	O
the	O
brain	O
connectivity	O
patterns	O
in	O
the	O
damaged	O
brain	O
essential	O
for	O
differential	B-T060
diagnosis	I-T060
.	O
In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
assess	B-T058
these	O
effects	O
.	O
Using	O
resting	B-T060
state	I-T060
functional	I-T060
magnetic	I-T060
resonance	I-T060
imaging	I-T060
3	O
T	O
data	O
obtained	O
over	O
several	O
years	O
of	O
scanning	B-T060
patients	O
for	O
diagnostic	O
and	O
research	O
purposes	O
,	O
we	O
employed	O
a	O
seed	O
-	O
based	O
approach	O
to	O
examine	O
resting	O
state	O
connectivity	O
in	O
higher	O
-	O
order	O
(	O
default	O
mode	O
,	O
bilateral	O
external	O
control	O
,	O
and	O
salience	O
)	O
and	O
lower	O
-	O
order	O
(	O
auditory	O
,	O
sensorimotor	O
,	O
and	O
visual	O
)	O
resting	O
state	O
networks	O
and	O
connectivity	O
with	O
the	O
thalamus	B-T023
,	O
in	O
20	O
healthy	O
unsedated	B-T033
controls	O
,	O
8	O
unsedated	B-T033
patients	O
with	O
DOC	B-T048
,	O
and	O
8	O
patients	O
with	O
DOC	B-T048
sedated	B-T061
with	O
propofol	B-T121
.	O
The	O
DOC	B-T048
groups	O
were	O
matched	O
for	O
age	O
at	O
onset	O
,	O
etiology	O
,	O
time	B-T033
spent	I-T033
in	O
DOC	B-T048
,	O
diagnosis	B-T033
,	O
standardized	O
behavioral	O
assessment	O
scores	O
,	O
movement	O
intensities	O
,	O
and	O
pattern	O
of	O
structural	O
brain	O
injury	O
(	O
as	O
assessed	O
with	O
T1	B-T059
-	I-T059
based	I-T059
voxel	I-T059
-	I-T059
based	I-T059
morphometry	I-T059
)	O
.	O
DOC	B-T048
were	O
associated	O
with	O
severely	O
impaired	O
resting	O
state	O
network	O
connectivity	O
in	O
all	O
but	O
the	O
visual	O
network	O
.	O
Thalamic	B-T023
connectivity	O
to	O
higher	O
-	O
order	O
network	O
regions	O
was	O
also	O
reduced	O
.	O
Propofol	B-T121
administration	B-T061
to	O
patients	O
was	O
associated	O
with	O
minor	O
further	O
decreases	O
in	O
thalamic	B-T023
and	O
insular	B-T023
connectivity	O
.	O
Our	O
findings	O
indicate	O
that	O
connectivity	O
decreases	O
associated	O
with	O
propofol	B-T121
sedation	B-T061
,	O
involving	O
the	O
thalamus	B-T023
and	O
insula	B-T023
,	O
are	O
relatively	O
small	O
compared	O
with	O
those	O
already	O
caused	O
by	O
DOC	B-T048
-associated	O
structural	O
brain	O
injury	O
.	O
Nonetheless	O
,	O
given	O
the	O
known	O
importance	O
of	O
the	O
thalamus	B-T023
in	O
brain	O
arousal	O
,	O
its	O
disruption	O
could	O
well	O
reflect	O
the	O
diminished	O
movement	O
obtained	O
in	O
these	O
patients	O
.	O
However	O
,	O
more	O
research	O
is	O
needed	O
on	O
this	O
topic	O
to	O
fully	O
address	O
the	O
research	O
question	O
.	O
      
Bxb1	B-T005
phage	I-T005
recombinase	O
assists	O
genome	O
engineering	O
in	O
Drosophila	O
melanogaster	O
Rapid	O
and	O
reliable	O
genome	O
modifications	O
provide	O
the	O
basis	O
for	O
detailed	O
in	O
vivo	O
functional	B-T058
analysis	I-T058
of	O
any	O
genomic	O
entity	O
(	O
gene	O
,	O
regulatory	O
DNA	O
,	O
non	O
-	O
coding	O
RNA	O
,	O
etc	O
)	O
.	O
With	O
the	O
advent	O
of	O
CRISPR	O
/	O
Cas9	O
genome	O
editing	O
technology	O
,	O
manipulation	O
of	O
a	O
particular	O
genomic	O
locus	O
has	O
become	O
a	O
routine	O
undertaking	O
in	O
variety	O
of	O
model	B-T001
organisms	I-T001
,	O
including	O
the	O
fruit	O
fly	O
Drosophila	O
melanogaster	O
.	O
To	O
further	O
diversify	O
the	O
available	O
tools	O
for	O
genome	O
engineering	O
,	O
we	O
successfully	O
harnessed	O
the	O
phage	B-T005
recombinase	O
Bxb1	O
to	O
perform	O
recombinase	O
-	O
mediated	O
cassette	O
exchange	O
(	O
RMCE	O
)	O
in	O
D.	O
melanogaster	O
.	O
We	O
demonstrate	O
that	O
Bxb1	B-T005
possesses	O
highly	O
efficient	O
recombinase	O
activity	O
and	O
could	O
be	O
used	O
alone	O
or	O
in	O
conjunction	O
with	O
other	O
currently	O
available	O
recombinases	O
for	O
creating	O
platforms	O
for	O
cassette	O
exchange	O
of	O
targeted	O
loci	O
.	O
      
Apixaban	B-T121
5	O
mg	O
Twice	O
Daily	O
and	O
Clinical	O
Outcomes	O
in	O
Patients	O
With	O
Atrial	B-T047
Fibrillation	I-T047
and	O
Advanced	O
Age	O
,	O
Low	O
Body	O
Weight	O
,	O
or	O
High	O
Creatinine	O
:	O
A	O
Secondary	O
Analysis	O
of	O
a	O
Randomized	O
Clinical	O
Trial	O
In	O
the	O
Apixaban	B-T121
for	O
Reduction	O
of	O
Stroke	B-T047
and	O
Other	O
Thromboembolic	O
Complications	O
in	O
Atrial	B-T047
Fibrillation	I-T047
(	O
ARISTOTLE	O
)	O
trial	O
,	O
the	O
standard	O
dose	O
of	O
apixaban	B-T121
was	O
5	O
mg	O
twice	O
daily	O
;	O
patients	O
with	O
at	O
least	O
2	O
dose	O
-	O
reduction	O
criteria-80	O
years	O
or	O
older	O
,	O
weight	O
60	O
kg	O
or	O
less	O
,	O
and	O
creatinine	B-T033
level	I-T033
1.5	O
mg	O
/	O
dL	O
or	O
higher	O
-	O
received	O
a	O
reduced	O
dose	O
of	O
apixaban	B-T121
of	O
2.5	O
mg	O
twice	O
daily	O
.	O
Little	O
is	O
known	O
about	O
patients	O
with	O
1	O
dose	O
-	O
reduction	O
criterion	O
who	O
received	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-T121
.	O
To	O
determine	O
the	O
frequency	O
of	O
1	O
dose	O
-	O
reduction	O
criterion	O
and	O
whether	O
the	O
effects	O
of	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-T121
on	O
stroke	B-T047
or	O
systemic	O
embolism	O
and	O
bleeding	O
varied	O
among	O
patients	O
with	O
1	O
or	O
no	O
dose	O
-	O
reduction	O
criteria	O
.	O
Among	O
18	O
201	O
patients	O
in	O
the	O
ARISTOTLE	O
trial	O
,	O
17	O
322	O
were	O
included	O
in	O
this	O
analysis	O
.	O
Annualized	O
event	O
rates	O
of	O
stroke	B-T047
or	O
systemic	O
embolism	O
and	O
major	O
bleeding	O
and	O
hazard	O
ratios	O
(	O
HRs	O
)	O
and	O
95	O
%	O
CIs	O
were	O
evaluated	B-T058
.	O
Interactions	O
between	O
the	O
effects	O
of	O
apixaban	B-T121
vs	O
warfarin	B-T121
and	O
the	O
presence	O
of	O
1	O
or	O
no	O
dose	O
-	O
reduction	O
criteria	O
were	O
assessed	O
.	O
The	O
first	O
patient	O
was	O
enrolled	O
in	O
the	O
ARISTOTLE	O
trial	O
on	O
December	O
19	O
,	O
2006	O
,	O
and	O
follow	B-T058
-	I-T058
up	I-T058
was	O
completed	O
on	O
January	O
30	O
,	O
2011	O
.	O
Data	O
were	O
analyzed	O
from	O
January	O
2015	O
to	O
May	O
30	O
,	O
2016	O
.	O
Analysis	O
of	O
major	O
bleeding	O
included	O
events	O
during	O
study	O
drug	B-T061
treatment	I-T061
.	O
Analysis	O
of	O
stroke	B-T047
or	O
systemic	O
embolism	O
was	O
based	O
on	O
intention	O
to	O
treat	O
.	O
Of	O
the	O
patients	O
with	O
1	O
or	O
no	O
dose	O
-	O
reduction	O
criteria	O
assigned	O
to	O
receive	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-T121
or	O
warfarin	B-T121
,	O
3966	O
had	O
1	O
dose	O
-	O
reduction	O
criterion	O
;	O
these	O
patients	O
had	O
higher	O
rates	O
of	O
stroke	B-T047
or	O
systemic	O
embolism	O
(	O
HR	O
,	O
1.47	O
;	O
95	O
%	O
CI	O
,	O
1.20	O
-	O
1.81	O
)	O
and	O
major	O
bleeding	O
(	O
HR	O
,	O
1.89	O
;	O
95	O
%	O
CI	O
,	O
1.62	O
-	O
2.20	O
)	O
compared	O
with	O
those	O
with	O
no	O
dose	O
-	O
reduction	O
criteria	O
(	O
n	O
=	O
13	O
356	O
)	O
.	O
The	O
benefit	O
of	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-T121
(	O
n	O
=	O
8665	O
)	O
compared	O
with	O
warfarin	B-T121
(	O
n	O
=	O
8657	O
)	O
on	O
stroke	B-T047
or	O
systemic	O
embolism	O
in	O
patients	O
with	O
1	O
dose	O
-	O
reduction	O
criterion	O
(	O
HR	O
,	O
0.94	O
;	O
95	O
%	O
CI	O
,	O
0.66	O
-	O
1.32	O
)	O
and	O
no	O
dose	O
-	O
reduction	O
criterion	O
(	O
HR	O
,	O
0.77	O
;	O
95	O
%	O
CI	O
,	O
0.62	O
-	O
0.97	O
)	O
were	O
similar	O
(	O
P	O
for	O
interaction	O
=	O
.36	O
)	O
.	O
Similarly	O
,	O
the	O
benefit	O
of	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-T121
compared	O
with	O
warfarin	B-T121
on	O
major	O
bleeding	O
in	O
patients	O
with	O
1	O
dose	O
-	O
reduction	O
criterion	O
(	O
HR	O
,	O
0.68	O
;	O
95	O
%	O
CI	O
,	O
0.53	O
-	O
0.87	O
)	O
and	O
no	O
dose	O
-	O
reduction	O
criterion	O
(	O
HR	O
,	O
0.72	O
;	O
95	O
%	O
CI	O
,	O
0.60	O
-	O
0.86	O
)	O
were	O
similar	O
(	O
P	O
for	O
interaction	O
=	O
.71	O
)	O
.	O
Similar	O
patterns	O
were	O
seen	O
for	O
each	O
dose	O
-	O
reduction	O
criterion	O
and	O
across	O
the	O
spectrum	O
of	O
age	O
,	O
body	O
weight	O
,	O
creatinine	B-T033
level	I-T033
,	O
and	O
creatinine	O
clearance	O
.	O
Patients	O
with	O
atrial	B-T047
fibrillation	I-T047
and	O
isolated	O
advanced	O
age	O
,	O
low	O
body	O
weight	O
,	O
or	O
renal	B-T033
dysfunction	I-T033
have	O
a	O
higher	O
risk	O
of	O
stroke	B-T047
or	O
systemic	O
embolism	O
and	O
major	O
bleeding	O
but	O
show	O
consistent	O
benefits	O
with	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-T121
vs	O
warfarin	B-T121
compared	O
with	O
patients	O
without	O
these	O
characteristics	O
.	O
The	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-T121
is	O
safe	O
,	O
efficacious	O
,	O
and	O
appropriate	O
for	O
patients	O
with	O
only	O
1	O
dose	O
-	O
reduction	O
criterion	O
.	O
clinicaltrials.gov	O
Identifier	O
:	O
NCT00412984	O
.	O
      
Prospective	O
Evaluation	B-T058
of	O
Opioid	B-T048
Consumption	I-T048
After	O
Distal	O
Radius	O
Fracture	O
Repair	B-T061
Surgery	I-T061
Pain	B-T061
management	I-T061
and	O
opioid	B-T048
consumption	I-T048
after	O
distal	O
radius	O
fracture	O
(	O
DRF	O
)	O
open	B-T061
reduction	I-T061
and	I-T061
internal	I-T061
fixation	I-T061
(	I-T061
ORIF	I-T061
)	I-T061
are	O
highly	O
variable	O
and	O
poorly	O
understood	O
.	O
To	O
optimize	B-T061
postoperative	O
opioid	B-T121
dosage	O
and	O
better	O
understand	O
opioid	B-T048
consumption	I-T048
patterns	O
after	O
DRF	O
-	O
ORIF	B-T061
,	O
we	O
conducted	O
a	O
prospective	O
study	O
with	O
the	O
hypothesis	O
that	O
opioid	B-T048
consumption	I-T048
would	O
increase	O
with	O
worsening	O
fracture	O
classification	O
and	O
various	O
patient	O
demographics	O
.	O
All	O
patients	O
who	O
underwent	O
DRF	O
-	O
ORIF	B-T061
were	O
consecutively	O
enrolled	O
over	O
a	O
6	O
-	O
month	O
period	O
.	O
Information	O
collected	O
included	O
patient	O
demographics	O
,	O
fracture	O
type	O
,	O
anesthesia	O
type	O
,	O
amount	O
and	O
type	O
of	O
opioid	B-T121
prescribed	B-T058
,	O
number	O
of	O
pills	B-T121
taken	O
,	O
reason	O
for	O
stopping	B-T061
,	O
and	O
adverse	O
events	O
.	O
Statistical	O
analysis	O
was	O
performed	O
.	O
Ninety	O
-	O
eight	O
patients	O
(	O
79	O
female	O
,	O
19	O
male	O
)	O
were	O
eligible	O
for	O
the	O
study	O
.	O
Mean	O
age	O
was	O
58	O
years	O
.	O
Of	O
the	O
98	O
patients	O
,	O
45	O
received	O
general	B-T061
anesthesia	I-T061
,	O
and	O
53	O
received	O
regional	B-T061
anesthesia	I-T061
with	O
a	O
single	O
-	O
shot	O
peripheral	B-T061
nerve	I-T061
block	I-T061
.	O
Mean	O
opioid	B-T048
consumption	I-T048
(	O
morphine	B-T121
equivalence	O
)	O
over	O
a	O
mean	O
of	O
4.8	O
postoperative	O
days	O
(	O
range	O
,	O
0	O
-	O
16	O
days	O
)	O
was	O
58.5	O
mg	O
(	O
range	O
,	O
0	O
-	O
280	O
mg	O
)	O
.	O
There	O
were	O
no	B-T033
significant	I-T033
differences	O
in	O
opioid	B-T048
consumption	I-T048
between	O
the	O
general	B-T061
and	O
regional	B-T061
anesthesia	I-T061
groups	O
.	O
Mean	O
opioid	B-T048
consumption	I-T048
for	O
the	O
3	O
fracture	O
-	O
type	O
groups	O
(	O
AO	O
/	O
OTA	O
[	O
Arbeitsgemeinschaft	O
für	O
Osteosynthesefragen	O
/	O
Orthopaedic	O
Trauma	O
Association	O
]	O
classification	O
)	O
was	O
57.7	O
mg	O
(	O
class	O
A	O
)	O
,	O
60.3	O
mg	O
(	O
class	O
B	O
)	O
,	O
and	O
62.0	O
mg	O
(	O
class	O
C	O
)	O
.	O
Demographic	O
analysis	O
revealed	O
an	O
inverse	O
relationship	O
between	O
age	O
and	O
opioid	B-T048
use	I-T048
.	O
Similarly	O
,	O
there	O
was	O
a	O
trend	O
toward	O
more	O
opioid	B-T048
consumption	I-T048
among	O
self	B-T033
-	I-T033
pay	I-T033
and	O
Medicaid	O
patients	O
.	O
Opioid	B-T048
consumption	I-T048
after	O
DRF	O
-	O
ORIF	B-T061
was	O
equivalent	O
for	O
general	B-T061
and	O
regional	B-T061
anesthesia	I-T061
.	O
A	O
significant	O
relationship	O
was	O
found	O
between	O
increasing	B-T033
age	I-T033
and	O
decreasing	B-T033
opioid	B-T048
consumption	I-T048
.	O
Worsening	O
fracture	O
classification	O
and	O
self	B-T033
-	I-T033
payment	I-T033
/	O
Medicaid	O
payment	O
trended	O
toward	O
increasing	O
opioid	B-T048
consumption	I-T048
.	O
Mean	O
overall	O
opioid	B-T048
consumption	I-T048
(	O
morphine	B-T121
equivalence	O
)	O
was	O
58.5	O
mg	O
,	O
or	O
14.6	O
pills	O
of	O
oxycodone	B-T121
/	I-T121
acetaminophen	I-T121
5/325	O
mg	O
.	O
Surgeons	O
should	O
take	O
these	O
findings	O
into	O
account	O
when	O
optimizing	B-T061
opioid	B-T121
prescribing	O
after	O
DRF	O
repair	B-T061
.	O
      
Delineation	O
of	O
B	O
-	O
cell	O
Epitopes	O
of	O
Salmonella	B-T007
enterica	I-T007
serovar	I-T007
Typhi	I-T007
Hemolysin	O
E	O
:	O
Potential	O
antibody	O
therapeutic	B-T061
target	O
Hemolysin	O
E	O
(	O
HlyE	O
)	O
is	O
an	O
immunogenic	O
novel	O
pore	O
-forming	O
toxin	O
involved	O
in	O
the	O
pathogenesis	O
of	O
typhoid	B-T047
fever	I-T047
.	O
Thus	O
,	O
mapping	O
of	O
B	O
-	O
cell	O
epitopes	O
of	O
Salmonella	B-T007
enterica	I-T007
serovar	I-T007
Typhi	I-T007
(	O
S.	B-T007
Typhi	I-T007
)	O
is	O
critical	O
to	O
identify	O
key	O
immunogenic	O
regions	O
of	O
HlyE.	O
A	O
random	O
20	O
-	O
mer	O
peptide	O
library	O
was	O
used	O
for	O
biopanning	O
with	O
enriched	O
anti	O
-	O
HlyE	O
polyclonal	O
antibodies	O
from	O
typhoid	B-T047
patient	O
sera	O
.	O
Bioinformatic	O
tools	O
were	O
used	O
to	O
refine	O
,	O
analyze	O
and	O
map	O
the	O
enriched	O
peptide	O
sequences	O
against	O
the	O
protein	O
to	O
identify	O
the	O
epitopes	O
.	O
The	O
analysis	O
identified	O
both	O
linear	O
and	O
conformational	O
epitopes	O
on	O
the	O
HlyE	O
protein	O
.	O
The	O
predicted	O
linear	O
GAAAGIVAG	O
and	O
conformational	O
epitope	O
PYSQESVLSADSQNQK	O
were	O
further	O
validated	O
against	O
the	O
pooled	O
sera	O
.	O
The	O
identified	O
epitopes	O
were	O
then	O
used	O
to	O
isolate	B-T061
epitope	O
specific	O
monoclonal	O
antibodies	O
by	O
antibody	O
phage	O
display	O
.	O
Monoclonal	O
scFv	O
antibodies	O
were	O
enriched	O
for	O
both	O
linear	O
and	O
conformational	O
epitopes	O
.	O
Molecular	O
docking	O
was	O
performed	O
to	O
elucidate	O
the	O
antigen	O
-	O
antibody	O
interaction	O
of	O
the	O
monoclonal	O
antibodies	O
against	O
the	O
epitopes	O
on	O
the	O
HlyE	O
monomer	O
and	O
oligomer	O
structure	O
.	O
An	O
in	O
-	O
depth	O
view	O
of	O
the	O
mechanistic	O
and	O
positional	B-T033
characteristics	O
of	O
the	O
antibodies	O
and	O
epitope	O
for	O
HlyE	O
was	O
successfully	O
accomplished	O
by	O
a	O
combination	O
of	O
phage	O
display	O
and	O
bioinformatic	O
analysis	O
.	O
The	O
predicted	O
function	O
and	O
structure	O
of	O
the	O
antibodies	O
highlights	O
the	O
possibility	O
of	O
utilizing	O
the	O
antibodies	O
as	O
neutralizing	B-T121
agents	I-T121
for	O
typhoid	B-T047
fever	I-T047
.	O
      
Approximate	O
Bayesian	O
computation	O
for	O
estimating	O
number	O
concentrations	O
of	O
monodisperse	O
nanoparticles	O
in	O
suspension	O
by	O
optical	B-T059
microscopy	I-T059
We	O
present	O
an	O
approximate	O
Bayesian	O
computation	O
scheme	O
for	O
estimating	O
number	O
concentrations	O
of	O
monodisperse	O
diffusing	O
nanoparticles	O
in	O
suspension	O
by	O
optical	B-T059
particle	I-T059
tracking	I-T059
microscopy	I-T059
.	O
The	O
method	O
is	O
based	O
on	O
the	O
probability	O
distribution	O
of	O
the	O
time	O
spent	O
by	O
a	O
particle	O
inside	O
a	O
detection	B-T061
region	O
.	O
We	O
validate	O
the	O
method	O
on	O
suspensions	O
of	O
well	O
-	O
controlled	O
reference	O
particles	O
.	O
We	O
illustrate	O
its	O
usefulness	O
with	O
an	O
application	O
in	O
gene	B-T061
therapy	I-T061
,	O
applying	O
the	O
method	O
to	O
estimate	O
number	O
concentrations	O
of	O
plasmid	O
DNA	O
molecules	O
and	O
the	O
average	O
number	O
of	O
DNA	O
molecules	O
complexed	O
with	O
liposomal	O
drug	O
delivery	O
particles	O
.	O
      
On	O
the	O
Relation	O
between	O
Face	O
and	O
Object	O
Recognition	O
in	O
Developmental	B-T048
Prosopagnosia	I-T048
:	O
No	O
Dissociation	B-T048
but	O
a	O
Systematic	O
Association	O
There	O
is	O
an	O
ongoing	O
debate	O
about	O
whether	O
face	O
recognition	O
and	O
object	O
recognition	O
constitute	O
separate	O
domains	O
.	O
Clarification	O
of	O
this	O
issue	B-T033
can	O
have	O
important	O
theoretical	O
implications	O
as	O
face	O
recognition	O
is	O
often	O
used	O
as	O
a	O
prime	O
example	O
of	O
domain	O
-	O
specificity	O
in	O
mind	O
and	O
brain	B-T023
.	O
An	O
important	O
source	B-T033
of	O
input	O
to	O
this	O
debate	O
comes	O
from	O
studies	O
of	O
individuals	O
with	O
developmental	B-T048
prosopagnosia	I-T048
,	O
suggesting	O
that	O
face	O
recognition	O
can	O
be	O
selectively	O
impaired	O
.	O
We	O
put	O
the	O
selectivity	O
hypothesis	O
to	O
test	O
by	O
assessing	O
the	O
performance	O
of	O
10	O
individuals	O
with	O
developmental	B-T048
prosopagnosia	I-T048
on	O
demanding	O
tests	O
of	O
visual	O
object	O
processing	O
involving	O
both	O
regular	O
and	O
degraded	B-T033
drawings	O
.	O
None	O
of	O
the	O
individuals	O
exhibited	O
a	O
clear	O
dissociation	B-T048
between	O
face	O
and	O
object	O
recognition	O
,	O
and	O
as	O
a	O
group	O
they	O
were	O
significantly	O
more	O
affected	O
by	O
degradation	B-T033
of	O
objects	O
than	O
control	O
participants	O
.	O
Importantly	O
,	O
we	O
also	O
find	O
positive	B-T033
correlations	O
between	O
the	O
severity	O
of	O
the	O
face	O
recognition	O
impairment	O
and	O
the	O
degree	O
of	O
impaired	O
performance	O
with	O
degraded	B-T033
objects	O
.	O
This	O
suggests	O
that	O
the	O
face	O
and	O
object	O
deficits	O
are	O
systematically	O
related	O
rather	O
than	O
coincidental	O
.	O
We	O
conclude	O
that	O
at	O
present	O
,	O
there	O
is	O
no	O
strong	O
evidence	O
in	O
the	O
literature	O
on	O
developmental	B-T048
prosopagnosia	I-T048
supporting	O
domain	O
-	O
specific	O
accounts	O
of	O
face	O
recognition	O
.	O
      
Exploring	O
the	O
genetic	O
variability	O
in	O
water	B-T121
use	O
efficiency	O
:	O
Evaluation	O
of	O
inter	O
and	O
intra	O
cultivar	O
genetic	O
diversity	O
in	O
grapevines	O
Genetic	O
improvement	O
of	O
crop	O
Water	B-T121
Use	O
Efficiency	O
(	O
WUE	O
)	O
is	O
a	O
general	O
goal	O
because	O
the	O
increasing	O
water	B-T121
scarcity	O
and	O
the	O
trend	O
to	O
a	O
more	O
sustainable	O
agriculture	O
.	O
For	O
grapevines	O
,	O
this	O
subject	O
is	O
relevant	O
and	O
need	O
an	O
urgent	O
response	O
because	O
their	O
wide	O
distribution	O
in	O
semi	O
-	O
arid	O
areas	O
.	O
New	O
cultivars	O
are	O
difficult	O
to	O
introduce	O
in	O
viticulture	O
due	O
to	O
the	O
narrow	O
dependency	O
of	O
consumer	O
appreciation	O
often	O
linked	O
to	O
a	O
certain	O
particular	O
wine	O
taste	O
.	O
Clones	O
of	O
reputed	O
cultivars	O
would	O
presumably	O
be	O
more	O
accepted	O
but	O
little	O
is	O
known	O
on	O
the	O
intra	O
-	O
cultivar	O
genetic	O
variability	O
of	O
the	O
WUE	O
.	O
The	O
present	O
work	O
compares	O
,	O
on	O
the	O
basis	O
of	O
two	O
field	O
assays	O
,	O
the	O
variability	O
of	O
intrinsic	O
water	B-T121
use	O
efficiency	O
(	O
WUEi	O
)	O
in	O
a	O
large	O
collection	O
of	O
cultivars	O
in	O
contrast	O
with	O
a	O
collection	O
of	O
clones	O
of	O
Tempranillo	O
cultivar	O
.	O
The	O
results	O
show	O
that	O
clonal	O
variability	O
of	O
WUEi	O
was	O
around	O
80	O
%	O
of	O
the	O
inter	O
-	O
cultivar	O
,	O
thus	O
providing	O
a	O
first	O
assessment	O
on	O
the	O
opportunity	O
for	O
clonal	O
selection	O
by	O
WUE	O
.	O
Plotting	O
the	O
WUEi	O
data	O
against	O
stem	O
water	B-T121
potential	O
or	O
stomatal	O
conductance	O
it	O
was	O
possible	B-T033
to	O
identify	O
cultivars	O
and	O
clones	O
out	O
of	O
the	O
confidence	O
intervals	O
of	O
this	O
linear	O
regression	O
thus	O
with	O
significantly	O
higher	O
and	O
lower	O
WUEi	O
values	O
.	O
The	O
present	O
results	O
contribute	O
to	O
open	O
the	O
expectative	O
for	O
a	O
genetic	O
improvement	O
of	O
grapevine	O
WUE	O
.	O
      
Types	O
of	O
internal	O
facilitation	O
activities	O
in	O
hospitals	O
implementing	B-T058
evidence	I-T058
-	I-T058
based	I-T058
interventions	I-T058
Implementation	O
models	O
,	O
frameworks	O
,	O
and	O
theories	O
recognize	O
the	O
importance	O
of	O
activities	O
that	O
facilitate	O
implementation	O
success	O
.	O
However	O
,	O
little	O
is	O
known	O
about	O
internal	O
facilitation	O
activities	O
that	O
hospital	O
personnel	O
engage	O
in	O
during	O
implementation	O
efforts	O
.	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
examine	O
internal	O
facilitation	O
activities	O
at	O
10	O
critical	O
access	O
hospitals	O
in	O
rural	O
Iowa	O
during	O
their	O
implementation	O
of	O
TeamSTEPPS	O
,	O
a	O
patient	B-T058
safety	I-T058
intervention	B-T061
,	O
and	O
to	O
identify	O
characteristics	O
that	O
distinguish	O
different	O
types	O
of	O
facilitation	O
activities	O
.	O
We	O
followed	O
10	O
critical	O
access	O
hospitals	O
for	O
2	O
years	O
after	O
the	O
onset	O
of	O
implementation	O
,	O
conducting	O
quarterly	O
interviews	O
with	O
key	O
informants	O
.	O
On	O
the	O
basis	O
of	O
the	O
transcripts	O
from	O
the	O
first	O
two	O
quarters	O
,	O
a	O
coding	O
template	O
was	O
developed	O
using	O
inductive	O
analyses	O
.	O
The	O
template	O
was	O
then	O
applied	O
deductively	O
to	O
code	O
all	O
interview	O
transcripts	O
.	O
Using	O
comparative	O
analysis	O
,	O
we	O
examined	O
the	O
characteristics	O
that	O
distinguish	O
between	O
the	O
facilitation	O
types	O
.	O
We	O
identified	O
four	O
types	O
of	O
facilitation	O
activities	O
-	O
Leadership	O
,	O
Buy	O
-	O
in	O
,	O
Customization	O
,	O
and	O
Accountability	O
.	O
Individuals	O
and	O
teams	O
engaged	O
in	O
different	O
types	O
of	O
facilitation	O
activities	O
,	O
both	O
in	O
a	O
planned	O
and	O
an	O
ad	B-T033
hoc	I-T033
manner	I-T033
.	O
These	O
activities	O
targeted	O
at	O
both	O
people	O
and	O
practices	O
and	O
exhibited	O
varying	O
temporal	O
patterns	O
(	O
start	O
and	O
peak	O
time	O
)	O
.	O
There	O
are	O
four	O
types	O
of	O
facilitation	O
activities	O
that	O
hospitals	O
engage	O
in	O
while	O
implementing	O
evidence	O
-	O
based	O
practices	O
,	O
offering	O
a	O
parsimonious	O
way	O
to	O
characterize	O
facilitation	O
activities	O
.	O
New	O
theoretical	O
and	O
empirical	O
research	O
opportunities	O
are	O
discussed	O
.	O
Understanding	O
the	O
types	O
of	O
facilitation	O
activities	O
and	O
their	O
distinguishing	O
characteristics	O
can	O
assist	O
managers	O
in	O
planning	O
and	O
executing	O
implementations	O
of	O
evidence	O
-	O
based	O
interventions	O
.	O
      
Effect	O
of	O
an	O
immunomodulatory	B-T061
regimen	I-T061
for	O
cancer	B-T061
prevention	I-T061
:	O
A	O
case	O
report	O
In	O
the	O
present	B-T033
case	O
study	O
,	O
an	O
immunomodulatory	B-T061
regimen	I-T061
for	O
cancer	B-T061
prevention	I-T061
is	O
reported	B-T058
.	O
A	O
patient	O
with	O
an	O
abnormally	O
high	O
level	O
of	O
the	O
tumor	O
markers	O
,	O
carbohydrate	O
antigen-724	O
(	O
CA724	O
)	O
,	O
CA19	O
-	O
9	O
and	O
carcinoembryonic	O
antigen	O
(	O
CEA	O
)	O
,	O
although	O
without	O
any	O
detectable	O
tumor	B-T191
,	O
was	O
treated	B-T061
with	I-T061
an	O
immunomodulatory	B-T061
therapy	I-T061
featuring	O
an	O
infusion	B-T061
of	O
cytokine	O
-	O
induced	O
autologous	O
killer	O
cells	O
(	O
CIKs	O
)	O
at	O
the	O
request	O
of	O
the	O
patient	O
.	O
Following	O
the	O
therapy	B-T061
,	O
the	O
three	O
tumor	O
markers	O
rapidly	O
decreased	O
to	O
below	O
the	O
normal	O
reference	O
level	O
,	O
although	O
there	O
still	O
were	O
slight	O
fluctuations	O
within	O
a	O
narrow	O
range	O
frequently	O
.	O
The	O
patient	O
was	O
monitored	B-T058
for	O
21	O
months	O
to	O
the	O
present	B-T033
day	O
and	O
no	B-T033
abnormality	I-T033
was	O
observed	O
.	O
The	O
results	B-T033
indicated	O
that	O
this	O
therapy	B-T061
may	O
be	O
applied	O
as	O
a	O
novel	O
strategy	O
that	O
is	O
effective	O
and	O
reliable	O
for	O
cancer	B-T061
prevention	I-T061
.	O
As	O
there	O
is	O
no	O
promising	O
regimen	B-T061
for	O
the	O
prevention	B-T061
of	I-T061
malignancies	I-T061
to	O
date	O
,	O
such	O
a	O
treatment	B-T061
may	O
become	O
a	O
major	O
cancer	B-T191
prophylactic	B-T061
regimen	I-T061
,	O
particularly	O
for	O
patients	O
who	O
are	O
at	O
a	O
high	B-T033
risk	I-T033
of	I-T033
cancer	B-T191
.	O
      
Incidence	O
of	O
Diabetes	B-T047
Mellitus	I-T047
and	O
Obesity	B-T047
and	O
the	O
Overlap	O
of	O
Comorbidities	O
in	O
HIV+	O
Hispanics	O
Initiating	O
Antiretroviral	B-T061
Therapy	I-T061
Cardiovascular	B-T047
disease	I-T047
(	O
CVD	B-T047
)	O
is	O
a	O
leading	O
health	O
threat	O
for	O
HIV+	O
patients	O
on	O
antiretroviral	B-T061
therapy	I-T061
(	O
ART	B-T061
)	O
;	O
cardiometabolic	B-T047
comorbidities	O
are	O
key	O
predictors	B-T033
of	I-T033
risk	I-T033
.	O
Data	O
are	O
limited	O
on	O
incidence	O
of	O
metabolic	O
comorbidities	O
in	O
HIV+	O
individuals	O
initiating	O
ART	B-T061
in	O
low	O
and	O
middle	O
income	O
countries	O
(	O
LMICs	O
)	O
,	O
particularly	O
for	O
Hispanics	O
.	O
We	O
examined	B-T033
incidence	O
of	O
diabetes	B-T047
and	O
obesity	B-T047
in	O
a	O
prospective	O
cohort	O
of	O
those	O
initiating	O
ART	B-T061
in	O
the	O
Dominican	O
Republic	O
.	O
Participants	O
≥18	O
years	O
,	O
initiating	O
ART	B-T061
<	O
90	O
days	O
prior	O
to	O
study	O
enrollment	B-T058
,	O
were	O
examined	B-T033
for	O
incidence	O
of	O
impaired	B-T033
fasting	I-T033
glucose	I-T033
(	O
IFG	B-T033
)	O
,	O
diabetes	B-T047
mellitus	I-T047
(	O
DM	B-T047
)	O
,	O
overweight	B-T047
,	I-T047
and	I-T047
obesity	I-T047
.	O
Fasting	B-T059
plasma	I-T059
glucose	I-T059
(	O
FPG	B-T059
)	O
100	O
-	O
125mg	O
/	O
dl	O
defined	O
IFG	B-T033
;	O
FPG	B-T059
≥126	O
mg	O
/	O
dl	O
,	O
diagnosis	O
per	O
medical	O
record	O
,	O
or	O
use	O
of	O
hypoglycemic	B-T121
medication	I-T121
defined	O
DM	B-T047
.	O
Overweight	B-T047
and	I-T047
obesity	I-T047
were	O
BMI	O
25	O
-	O
30	O
and	O
≥30kg	O
/	O
m2	O
,	O
respectively	O
.	O
Dyslipidemia	B-T047
was	O
total	O
cholesterol	O
≥240mg	O
/	O
dl	O
or	O
use	O
of	O
lipid	B-T121
-	I-T121
lowering	I-T121
medication	I-T121
.	O
Framingham	O
risk	O
equation	O
was	O
used	B-T033
to	O
determine	O
ten	O
-	O
year	O
CVD	B-T047
risk	B-T058
at	O
the	O
end	O
of	O
observation	O
.	O
Of	O
153	O
initiating	O
ART	B-T061
,	O
8	O
(	O
6	O
%	O
)	O
had	O
DM	B-T047
and	O
23	O
(	O
16	O
%	O
)	O
had	O
IFG	B-T033
at	O
baseline	O
,	O
6	O
developed	O
DM	B-T047
(	O
28/1000	O
person	O
-	O
years	O
follow	B-T058
up	I-T058
[	O
PYFU	B-T058
]	O
)	O
and	O
46	O
developed	O
IFG	B-T033
(	O
329/1000	O
PYFU	B-T058
)	O
.	O
At	O
baseline	O
,	O
24	O
(	O
18	O
%	O
)	O
were	O
obese	B-T047
and	O
36	O
(	O
27	O
%	O
)	O
were	O
overweight	B-T184
,	O
15	O
became	O
obese	B-T047
(	O
69/1000	O
PYFU	B-T058
)	O
and	O
22	O
became	O
overweight	B-T184
(	O
163/1000	O
PYFU	B-T058
)	O
.	O
Median	O
observation	B-T058
periods	O
for	O
the	O
diabetes	B-T047
and	O
obesity	B-T047
analyses	O
were	O
23.5	O
months	O
and	O
24.3	O
months	O
,	O
respectively	O
.	O
Increased	O
CVD	B-T047
risk	B-T058
(	O
≥10	O
%	O
10	B-T033
-	I-T033
year	I-T033
Framingham	I-T033
risk	I-T033
score	I-T033
)	O
was	O
present	B-T033
for	O
13	O
%	O
of	O
the	O
cohort	O
;	O
79	O
%	O
of	O
the	O
cohort	O
had	O
≥1	O
cardiometabolic	O
comorbidity	O
,	O
48	O
%	O
had	O
≥2	O
,	O
and	O
13	O
%	O
had	O
all	O
three	O
.	O
In	O
this	O
Hispanic	O
cohort	O
in	O
an	O
LMIC	O
,	O
incidences	O
of	O
IFG	B-T033
/	O
DM	B-T047
and	O
overweight	B-T184
/	O
obesity	B-T047
were	O
similar	O
to	O
or	O
higher	O
than	O
that	O
found	B-T033
in	O
high	B-T033
income	I-T033
countries	O
,	O
and	O
cardiometabolic	B-T047
disorders	I-T047
affected	O
three	O
-	O
quarters	O
of	O
those	O
initiating	O
ART	B-T061
.	O
Care	O
models	O
incorporating	O
cardiovascular	B-T047
risk	I-T047
reduction	B-T061
into	O
HIV	B-T047
treatment	B-T058
programs	I-T058
are	O
needed	O
to	O
prevent	O
CVD	B-T047
-	O
associated	O
mortality	O
in	O
this	O
vulnerable	O
population	O
.	O
      
Intraspinal	B-T191
meningioma	I-T191
with	O
malignant	B-T191
transformation	I-T191
and	O
distant	O
metastasis	O
Meningioma	B-T191
is	O
typically	O
considered	O
to	O
be	O
a	O
benign	B-T191
tumor	I-T191
.	O
Malignant	B-T191
transformation	I-T191
and	O
metastasis	B-T191
of	O
meningiomas	B-T191
are	O
rare	O
.	O
Moreover	O
,	O
most	O
meningiomas	B-T191
are	O
intracranial	O
,	O
and	O
there	O
are	O
few	O
reports	O
on	O
intraspinal	B-T191
meningiomas	I-T191
.	O
This	O
report	O
aimed	O
to	O
describe	O
the	O
clinical	O
features	O
and	O
pathological	O
findings	B-T033
of	O
a	O
case	O
of	O
malignant	B-T191
transformation	I-T191
and	O
distant	O
metastasis	O
of	O
intraspinal	B-T191
meningioma	I-T191
,	O
with	O
a	O
review	O
of	O
the	O
literature	O
.	O
A	O
44	O
-	O
year	O
-	O
old	O
man	O
with	O
a	O
bilateral	O
lower	B-T184
limb	I-T184
paresis	I-T184
was	O
diagnosed	B-T033
with	O
an	O
intradural	B-T191
extramedullary	I-T191
tumor	I-T191
of	I-T191
the	I-T191
thoracic	I-T191
spine	I-T191
.	O
Primary	O
tumor	B-T061
resection	I-T061
was	O
performed	O
,	O
and	O
the	O
histological	B-T033
findings	I-T033
revealed	O
atypical	B-T191
meningioma	I-T191
.	O
The	O
meningioma	B-T191
recurred	O
2	O
years	O
after	O
the	O
primary	O
surgery	B-T061
,	O
and	O
a	O
second	O
resection	B-T061
was	O
performed	O
,	O
but	O
only	O
partial	O
resection	B-T061
was	O
possible	O
because	O
of	O
decreased	O
motor	O
evoked	O
potential	O
.	O
At	O
age	O
48	O
,	O
the	O
patient	O
's	O
lower	B-T184
limb	I-T184
weakness	I-T184
returned	O
,	O
and	O
a	O
third	O
resection	B-T061
was	O
performed	O
,	O
and	O
the	O
histological	B-T033
finding	I-T033
remained	O
atypical	B-T191
meningioma	I-T191
.	O
At	O
age	O
54	O
,	O
the	O
tumor	B-T191
increased	O
and	O
stereotactic	B-T061
irradiation	I-T061
was	O
performed	O
.	O
At	O
age	O
60	O
,	O
the	O
patient	O
was	O
diagnosed	B-T033
with	O
metastatic	B-T191
tumors	I-T191
of	O
the	O
rib	B-T023
,	O
lumbar	B-T023
vertebra	I-T023
,	O
cervical	B-T023
spine	I-T023
,	O
and	O
sacrum	B-T023
.	O
Biopsy	B-T060
of	O
the	O
rib	B-T023
metastatic	B-T191
tumor	I-T191
was	O
performed	O
,	O
and	O
the	O
histological	B-T033
findings	I-T033
revealed	O
anaplastic	B-T191
meningioma	I-T191
.	O
This	O
case	O
is	O
the	O
first	O
report	O
of	O
an	O
intraspinal	B-T191
meningioma	I-T191
that	O
transformed	B-T191
from	O
atypical	B-T191
to	O
anaplastic	B-T191
meningioma	I-T191
with	O
distant	O
hematogenous	B-T033
metastasis	O
.	O
      
Surgical	B-T061
Guidance	B-T061
via	O
Multiplexed	B-T060
Molecular	I-T060
Imaging	I-T060
of	O
Fresh	O
Tissues	O
Labeled	O
with	O
SERS	O
-Coded	O
Nanoparticles	O
The	O
imaging	B-T060
of	O
dysregulated	O
cell	O
-	O
surface	O
receptors	O
(	O
or	O
biomarkers	O
)	O
is	O
a	O
potential	O
means	O
of	O
identifying	O
the	O
presence	B-T033
of	O
cancer	B-T191
with	O
high	O
sensitivity	O
and	O
specificity	O
.	O
However	O
,	O
due	O
to	O
heterogeneities	O
in	O
the	O
expression	O
of	O
protein	O
biomarkers	O
in	O
tumors	B-T191
,	O
molecular	B-T060
imaging	I-T060
technologies	B-T058
should	O
ideally	O
be	O
capable	O
of	O
visualizing	O
a	O
multiplexed	O
panel	O
of	O
cancer	O
biomarkers	O
.	O
Recently	O
,	O
surface	O
-	O
enhanced	O
Raman	O
-	O
scattering	O
(	O
SERS	O
)	O
nanoparticles	O
(	O
NPs	O
)	O
have	O
attracted	O
wide	O
interest	O
due	O
to	O
their	O
potential	O
for	O
sensitive	O
and	O
multiplexed	O
biomarker	O
detection	B-T061
.	O
In	O
this	O
review	O
,	O
we	O
focus	O
on	O
the	O
most	O
recent	O
advances	O
in	O
tumor	B-T191
imaging	B-T060
using	O
SERS	O
-coded	O
NPs	O
.	O
A	O
brief	O
introduction	O
of	O
the	O
structure	O
and	O
optical	O
properties	O
of	O
SERS	O
NPs	O
is	O
provided	O
,	O
followed	O
by	O
a	O
detailed	O
discussion	O
of	O
key	O
imaging	B-T060
issues	O
such	O
as	O
the	O
administration	O
of	O
NPs	O
in	O
tissue	O
(	O
topical	O
versus	O
systemic	O
)	O
,	O
the	O
optical	O
configuration	O
and	O
imaging	B-T060
approach	O
of	O
Raman	B-T059
imaging	I-T059
systems	I-T059
,	O
spectral	B-T060
demultiplexing	I-T060
methods	I-T060
for	O
quantifying	O
NP	O
concentrations	O
,	O
and	O
the	O
disambiguation	O
of	O
specific	O
vs.	O
nonspecific	O
sources	O
of	O
contrast	O
through	O
ratiometric	B-T060
imaging	I-T060
of	O
targeted	O
and	O
untargeted	O
(	O
control	O
)	O
NP	O
pairs	O
.	O
Finally	O
,	O
future	O
challenges	O
and	O
directions	O
are	O
briefly	O
outlined	O
.	O
      
Food	O
security	O
and	O
the	O
nutritional	B-T033
status	I-T033
of	O
children	O
in	O
foster	O
care	O
:	O
new	O
horizons	O
in	O
the	O
protection	O
of	O
a	O
fragile	O
population	O
The	O
nutritional	B-T033
status	I-T033
of	O
foster	O
children	O
,	O
the	O
quality	O
of	O
daily	O
menus	O
in	O
group	O
homes	O
and	O
the	O
Food	O
Security	O
inside	O
these	O
organizations	O
have	O
been	O
poorly	O
studied	O
and	O
this	O
study	O
means	O
to	O
investigate	O
them	O
.	O
A	O
sample	O
of	O
125	O
children	O
,	O
ranging	O
in	O
age	O
from	O
0	O
-	O
17	O
years	O
,	O
among	O
seven	O
group	O
homes	O
(	O
group	O
A	O
)	O
was	O
compared	O
with	O
121	O
children	O
of	O
the	O
general	O
population	O
we	O
(	O
group	O
B	O
)	O
.	O
To	O
evaluate	O
nutritional	B-T033
status	I-T033
,	O
BMI	B-T033
percentiles	I-T033
were	O
used	O
.	O
Mean	O
percentiles	O
of	O
both	O
groups	O
were	O
compared	O
through	O
statistical	O
analysis	O
.	O
Both	O
nutritional	B-T033
and	O
caloric	B-T033
daily	I-T033
distributions	I-T033
in	O
each	O
organization	O
were	O
obtained	O
using	O
the	O
24	O
-	O
hour	O
recall	O
method	O
.	O
A	O
specific	O
questionnaire	O
was	O
administered	O
to	O
evaluate	O
Food	O
Security	O
.	O
From	O
the	O
analysis	O
of	O
mean	O
BMI	O
-for-	O
age	O
(	O
or	O
height	O
-	O
for	O
-	O
length	O
)	O
percentiles	O
,	O
did	O
not	O
observe	O
statistically	O
significant	O
differences	B-T033
between	O
group	O
A	O
and	O
group	O
B.	O
The	O
average	O
daily	O
nutrient	B-T033
and	O
calorie	B-T033
distribution	I-T033
in	O
group	O
homes	O
proves	O
to	O
be	O
nearly	B-T033
optimal	I-T033
with	O
the	O
exception	O
of	O
a	O
slight	O
excess	O
in	O
proteins	O
and	O
a	O
slight	O
deficiency	O
in	O
PUFAs	O
.	O
Moreover	O
,	O
a	O
low	B-T033
intake	I-T033
of	O
iron	B-T033
and	O
calcium	O
was	O
revealed	O
.	O
All	O
organizations	O
obtained	O
a	O
"	O
High	O
Food	O
Security	O
"	O
profile	O
.	O
Nutritional	B-T033
conditions	I-T033
of	O
foster	O
children	O
are	O
no	O
worse	O
than	O
that	O
of	O
children	O
of	O
the	O
general	O
population	O
.	O
Foster	O
care	O
provides	O
the	O
necessary	O
conditions	O
to	O
support	O
their	O
growth	O
.	O
      
Expert	O
position	O
paper	O
on	O
prolonged	O
dual	B-T061
antiplatelet	I-T061
therapy	I-T061
in	O
secondary	B-T061
prevention	I-T061
following	O
myocardial	B-T047
infarction	I-T047
The	O
protective	O
effect	O
of	O
dual	B-T061
antiplatelet	I-T061
therapy	I-T061
(	O
DAPT	B-T061
)	O
following	O
acute	B-T047
coronary	I-T047
syndrome	I-T047
is	O
undisputed	O
,	O
but	O
its	O
duration	O
is	O
subject	O
of	O
debate	O
.	O
Several	O
studies	O
show	O
that	O
prolonged	O
therapy	B-T061
provides	O
a	O
clinical	O
benefit	O
in	O
patients	O
following	O
acute	B-T047
coronary	I-T047
syndrome	I-T047
.	O
The	O
aim	O
of	O
this	O
position	O
paper	O
authored	O
by	O
Austrian	O
experts	O
is	O
to	O
outline	O
the	O
current	O
evidence	O
and	O
provide	O
an	O
overview	O
of	O
recent	O
studies	O
.	O
It	O
is	O
also	O
intended	O
to	O
serve	O
as	O
a	O
practical	O
guide	O
to	O
identify	O
those	O
patients	O
who	O
may	O
benefit	O
from	O
prolonged	O
DAPT	B-T061
.	O
      
CXCR4	O
(	O
CD184	O
)	O
expression	O
on	O
stem	B-T061
cell	I-T061
harvest	I-T061
and	O
CD34(+	O
)	O
cells	O
post	O
-	O
transplant	O
CXCR4	O
is	O
a	O
receptor	O
for	O
stromal	O
-	O
derived	O
factor-1	O
(	O
SDF-1	O
)	O
,	O
a	O
molecule	O
that	O
has	O
a	O
chemotactic	O
activity	O
for	O
lymphocytes	O
and	O
is	O
important	O
in	O
homing	O
of	O
hematopoietic	O
stem	O
cells	O
to	O
their	O
adult	O
marrow	O
.	O
We	O
evaluated	B-T058
the	O
CXCR4	O
(	O
CD184	O
)	O
expression	O
in	O
the	O
harvest	O
cells	O
and	O
in	O
the	O
post	O
-	O
transplant	O
bone	O
marrow	O
(	O
BM	O
)	O
and	O
its	O
relation	O
to	O
engraftment	O
,	O
as	O
determined	O
by	O
the	O
consensus	O
criteria	O
and	O
chimerism	O
.	O
This	O
is	O
a	O
prospective	O
study	O
which	O
included	O
30	O
patients	O
undergoing	O
hematopoietic	B-T061
stem	I-T061
cell	I-T061
transplantation	I-T061
;	O
15	O
patients	O
received	O
autograft	B-T061
and	O
15	O
patients	O
received	O
allograft	B-T061
on	O
dates	O
between	O
January	O
2012	O
and	O
May	O
2014	O
.	O
We	O
assessed	O
CD184	O
(	O
CXCR4	O
)	O
using	O
flow	B-T059
cytometry	I-T059
in	O
the	O
harvest	O
cells	O
together	O
with	O
post	O
-	O
transplant	O
BM	O
assessment	B-T058
on	O
Day	O
28	O
and	O
Day	O
90	O
for	O
complete	O
morphologic	O
,	O
molecular	B-T059
studies	I-T059
,	O
and	O
detection	B-T061
of	O
CD184	O
expression	O
on	O
CD34(+	O
)	O
cells	O
with	O
chimerism	O
studies	O
on	O
total	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
Diagnoses	B-T033
of	O
the	O
enrolled	O
patients	O
were	O
as	O
follows	O
:	O
seven	O
(	O
24.1	O
%	O
)	O
with	O
acute	B-T191
myeloid	I-T191
leukemia	I-T191
,	O
eight	O
(	O
27.6	O
%	O
)	O
with	O
multiple	B-T191
myeloma	I-T191
,	O
four	O
(	O
13.8	O
%	O
)	O
with	O
acute	B-T191
lymphoblastic	I-T191
leukemia	I-T191
,	O
three	O
(	O
10.3	O
%	O
)	O
with	O
non	B-T191
-	I-T191
Hodgkin	I-T191
lymphoma	I-T191
,	O
two	O
(	O
6.9	O
%	O
)	O
with	O
myelodysplastic	B-T191
syndromes	I-T191
,	O
two	O
(	O
6.9	O
%	O
)	O
with	O
aplastic	B-T047
anemia	I-T047
,	O
two	O
(	O
6.9	O
%	O
)	O
with	O
chronic	B-T191
myeloid	I-T191
leukemia	I-T191
,	O
one	O
(	O
3.4	O
%	O
)	O
with	O
Hodgkin	B-T191
lymphoma	I-T191
,	O
and	O
one	O
(	O
3.4	O
%	O
)	O
with	O
plasmacytomas	B-T191
.	O
One	O
patient	O
died	B-T033
and	O
was	O
excluded	O
from	O
the	O
study	O
because	O
there	O
were	O
not	O
enough	O
data	O
about	O
engraftment	O
.	O
There	O
was	O
no	B-T033
statistical	O
significance	O
between	O
the	O
level	O
of	O
CD184	O
in	O
stem	B-T061
cell	I-T061
harvest	I-T061
and	O
the	O
prediction	O
of	O
successful	O
engraftment	O
(	O
p>0.05	O
)	O
as	O
well	O
as	O
in	O
Day	O
28	O
BM	O
sample	O
(	O
p>0.05	O
)	O
,	O
whereas	O
there	O
was	O
a	O
statistical	O
significance	O
between	O
the	O
level	O
of	O
CD184	O
in	O
Day	O
90	O
BM	O
sample	O
and	O
the	O
occurrence	O
of	O
successful	O
engraftment	O
(	O
p=0.002	O
)	O
.	O
SDF-1	O
/	O
CXCR4	O
axis	O
plays	O
a	O
crucial	O
role	O
in	O
engraftment	O
;	O
however	O
,	O
more	O
studies	O
are	O
warranted	O
to	O
assess	O
their	O
expression	O
post	O
-	O
transplant	O
.	O
Evaluating	O
the	O
ligand	O
(	O
chemokine	O
,	O
SDF-1	O
)	O
or	O
its	O
receptor	O
(	O
CXCR4	O
)	O
may	O
serve	O
as	O
potential	O
surrogate	O
markers	O
for	O
assessment	B-T058
of	O
engraftment	O
.	O
      
Characterizing	O
sexual	O
function	O
in	O
patients	O
with	O
generalized	B-T048
anxiety	I-T048
disorder	I-T048
:	O
a	O
pooled	O
analysis	O
of	O
three	O
vilazodone	B-T121
studies	O
Vilazodone	B-T121
has	O
been	O
shown	O
to	O
reduce	O
core	B-T184
symptoms	I-T184
of	O
generalized	B-T048
anxiety	I-T048
disorder	I-T048
(	O
GAD	B-T048
)	O
in	O
three	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trials	O
.	O
Since	O
sexual	B-T047
dysfunction	I-T047
(	O
SD	B-T047
)	O
is	O
not	O
well	O
characterized	O
in	O
GAD	B-T048
,	O
a	O
post	O
hoc	O
analysis	O
of	O
these	O
trials	O
was	O
conducted	O
to	O
evaluate	B-T058
the	O
effects	O
of	O
vilazodone	B-T121
on	O
sexual	O
functioning	O
in	O
GAD	B-T048
patients	O
.	O
Data	O
were	O
pooled	O
from	O
one	O
fixed	O
-	O
dose	O
trial	O
of	O
vilazodone	B-T121
20	O
and	O
40	O
mg	O
/	O
day	O
(	O
NCT01629966	O
)	O
and	O
two	O
flexible	O
-	O
dose	O
studies	O
of	O
vilazodone	B-T121
20	O
-	O
40	O
mg	O
/	O
day	O
(	O
NCT01766401	O
,	O
NCT01844115	O
)	O
in	O
adults	O
with	O
GAD	B-T048
.	O
Sexual	O
functioning	O
was	O
assessed	O
using	O
the	O
Changes	O
in	O
Sexual	O
Functioning	O
Questionnaire	O
(	O
CSFQ	O
)	O
.	O
Outcomes	O
included	O
mean	O
change	O
from	O
baseline	O
to	O
end	O
of	O
treatment	O
(	O
EOT	O
)	O
in	O
CSFQ	B-T033
total	I-T033
score	I-T033
and	O
percentage	O
of	O
patients	O
shifting	O
from	O
SD	B-T047
at	O
baseline	O
(	O
CSFQ	B-T033
total	I-T033
score	I-T033
≤47	O
for	O
males	O
,	O
≤41	O
for	O
females	O
)	O
to	O
normal	B-T033
functioning	I-T033
at	O
EOT	O
.	O
Treatment	O
-	O
emergent	O
adverse	O
events	O
related	O
to	O
sexual	O
functioning	O
were	O
also	O
analyzed	O
.	O
A	O
total	O
of	O
1,373	O
patients	O
were	O
included	O
in	O
the	O
analyses	O
.	O
SD	B-T047
at	O
baseline	O
was	O
more	O
common	O
in	O
females	O
(	O
placebo	O
,	O
46.4	O
%	O
;	O
vilazodone	B-T121
,	O
49	O
%	O
)	O
than	O
in	O
males	O
(	O
placebo	O
,	O
35.1	O
%	O
;	O
vilazodone	B-T121
,	O
40.9	O
%	O
)	O
.	O
CSFQ	B-T033
total	I-T033
score	I-T033
improvement	O
was	O
found	O
in	O
both	O
females	O
(	O
placebo	O
,	O
+1.2	O
;	O
vilazodone	B-T121
,	O
+1.6	O
)	O
and	O
males	O
(	O
placebo	O
,	O
+2.1	O
;	O
vilazodone	B-T121
,	O
+1.0	O
)	O
,	O
with	O
no	B-T033
statistically	I-T033
significant	I-T033
differences	I-T033
between	O
treatment	O
groups	O
.	O
The	O
percentage	O
of	O
patients	O
who	O
shifted	O
from	O
SD	B-T047
at	O
baseline	O
to	O
normal	O
sexual	O
functioning	O
at	O
EOT	O
was	O
higher	O
in	O
males	O
(	O
placebo	O
,	O
40.6	O
%	O
;	O
vilazodone	B-T121
,	O
35.7	O
%	O
)	O
than	O
in	O
females	O
(	O
placebo	O
,	O
24.9	O
%	O
;	O
vilazodone	B-T121
,	O
34.9	O
%	O
)	O
;	O
no	B-T033
statistical	I-T033
testing	I-T033
was	O
performed	O
.	O
Except	O
for	O
erectile	B-T047
dysfunction	I-T047
and	O
delayed	O
ejaculation	O
in	O
vilazodone	B-T121
-	O
treated	O
males	O
(	O
2.4	O
%	O
and	O
2.1	O
%	O
,	O
respectively	O
)	O
,	O
no	B-T033
treatment	I-T033
-	I-T033
emergent	I-T033
adverse	I-T033
events	I-T033
related	O
to	O
sexual	O
functioning	O
occurred	O
in	O
≥2	O
%	O
of	O
patients	O
in	O
either	O
treatment	O
group	O
.	O
Approximately	O
35%-50	O
%	O
of	O
patients	O
in	O
the	O
vilazodone	B-T121
GAD	B-T048
studies	O
had	O
SD	B-T047
at	O
baseline	O
.	O
Vilazodone	B-T121
and	O
placebo	O
had	O
similar	O
effects	O
on	O
CSFQ	O
outcomes	O
in	O
both	O
females	O
and	O
males	O
,	O
indicating	O
a	O
limited	O
adverse	O
impact	O
on	O
sexual	O
functioning	O
with	O
vilazodone	B-T121
.	O
      
Simultaneously	O
Targeting	O
Myofibroblast	O
Contractility	O
and	O
Extracellular	O
Matrix	O
Cross	O
-	O
Linking	O
as	O
a	O
Therapeutic	O
Concept	O
in	O
Airway	B-T023
Fibrosis	O
Fibrosis	O
after	O
solid	B-T061
organ	I-T061
transplantation	I-T061
is	O
considered	O
an	O
irreversible	O
process	O
and	O
remains	O
the	O
major	O
cause	O
of	O
graft	O
dysfunction	O
and	O
death	O
with	O
limited	O
therapies	B-T061
.	O
This	O
remodeling	O
is	O
characterized	O
by	O
aberrant	O
accumulation	B-T033
of	O
contractile	O
myofibroblasts	O
that	O
deposit	O
excessive	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
and	O
increase	O
tissue	B-T184
stiffness	I-T184
.	O
Studies	O
demonstrate	O
,	O
however	O
,	O
that	O
a	O
stiff	B-T184
ECM	O
itself	O
promotes	O
fibroblast	O
-to-	O
myofibroblast	O
differentiation	O
,	O
stimulating	O
further	O
ECM	O
production	O
.	O
This	O
creates	O
a	O
positive	O
feedback	O
loop	O
that	O
perpetuates	O
fibrosis	O
.	O
We	O
hypothesized	O
that	O
simultaneously	O
targeting	O
myofibroblast	O
contractility	O
with	O
relaxin	B-T121
and	O
ECM	O
stiffness	B-T184
with	O
lysyl	O
oxidase	O
inhibitors	B-T121
could	O
break	O
the	O
feedback	O
loop	O
,	O
reversing	O
established	O
fibrosis	O
.	O
To	O
test	O
this	O
,	O
we	O
used	O
the	O
orthotopic	B-T061
tracheal	I-T061
transplantation	I-T061
(	O
OTT	B-T061
)	O
mouse	B-T050
model	I-T050
,	O
which	O
develops	O
robust	O
fibrotic	O
airway	B-T023
remodeling	O
.	O
Mice	O
with	O
established	O
fibrosis	O
were	O
treated	O
with	O
saline	O
,	O
mono-	B-T061
,	O
or	O
combination	B-T061
therapies	I-T061
.	O
Although	O
monotherapies	B-T061
had	O
no	O
effect	O
,	O
combining	B-T121
these	I-T121
agents	I-T121
decreased	O
collagen	O
deposition	O
and	O
promoted	O
re	O
-	O
epithelialization	O
of	O
remodeled	B-T033
airways	I-T033
.	O
Relaxin	B-T121
inhibited	O
myofibroblast	O
differentiation	O
and	O
contraction	O
in	O
a	O
matrix	O
-	O
stiffness	B-T184
-	O
dependent	O
manner	O
through	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
.	O
Furthermore	O
,	O
the	O
effect	O
of	O
combination	B-T061
therapy	I-T061
was	O
lost	O
in	O
PGE2	O
receptor	O
knockout	O
and	O
PGE2	O
-	O
inhibited	O
OTT	B-T061
mice	O
.	O
This	O
study	O
revealed	O
the	O
important	O
synergistic	O
roles	O
of	O
cellular	O
contractility	O
and	O
tissue	B-T184
stiffness	I-T184
in	O
the	O
maintenance	O
of	O
fibrotic	O
tissue	O
and	O
suggests	O
a	O
new	O
therapeutic	O
principle	O
for	O
fibrosis	O
.	O
      
Skeletal	O
muscle	O
metabolic	O
adaptations	O
to	O
endurance	O
exercise	O
training	O
are	O
attainable	O
in	O
mice	O
with	O
simvastatin	B-T121
treatment	B-T061
We	O
tested	O
the	O
hypothesis	O
that	O
a	O
6	O
-	O
week	O
regimen	B-T061
of	O
simvastatin	B-T121
would	O
attenuate	O
skeletal	O
muscle	O
adaptation	O
to	O
low	O
-	O
intensity	O
exercise	O
.	O
Male	O
C57BL/6J	O
wildtype	O
mice	O
were	O
subjected	O
to	O
6	O
-	O
weeks	O
of	O
voluntary	O
wheel	O
running	O
or	O
normal	O
cage	O
activities	O
with	O
or	O
without	O
simvastatin	B-T121
treatment	B-T061
(	O
20	O
mg	O
/	O
kg	O
/	O
d	O
,	O
n	O
=	O
7	O
-	O
8	O
per	O
group	O
)	O
.	O
Adaptations	O
in	O
in	O
vivo	O
fatigue	B-T184
resistance	O
were	O
determined	O
by	O
a	O
treadmill	B-T060
running	I-T060
test	I-T060
,	O
and	O
by	O
ankle	B-T023
plantarflexor	I-T023
contractile	O
assessment	O
.	O
The	O
tibialis	B-T023
anterior	I-T023
,	O
gastrocnemius	B-T023
,	O
and	O
plantaris	B-T023
muscles	I-T023
were	O
evaluated	B-T058
for	O
exercised	O
-induced	O
mitochondrial	O
adaptations	O
(	O
i.e.	O
,	O
biogenesis	O
,	O
function	O
,	O
autophagy	O
)	O
.	O
There	O
was	O
no	B-T033
difference	I-T033
in	O
weekly	O
wheel	O
running	O
distance	O
between	O
control	O
and	O
simvastatin	B-T121
-	O
treated	O
mice	O
(	O
P	O
=	O
0.51	O
)	O
.	O
Trained	O
mice	O
had	O
greater	O
treadmill	O
running	O
distance	O
(	O
296	O
%	O
,	O
P<0.001	O
)	O
,	O
and	O
ankle	B-T023
plantarflexor	I-T023
contractile	O
fatigue	B-T184
resistance	O
(	O
9	O
%	O
,	O
P<0.05	O
)	O
compared	O
to	O
sedentary	O
mice	O
,	O
independent	O
of	O
simvastatin	B-T121
treatment	B-T061
.	O
At	O
the	O
cellular	O
level	O
,	O
trained	O
mice	O
had	O
greater	O
mitochondrial	O
biogenesis	O
(	O
e.g.	O
,	O
~2	O
-	O
fold	O
greater	O
PGC1α	O
expression	O
,	O
P<0.05	O
)	O
and	O
mitochondrial	O
content	O
(	O
e.g.	O
,	O
25	O
%	O
greater	O
citrate	O
synthase	O
activity	O
,	O
P<0.05	O
)	O
,	O
independent	O
of	O
simvastatin	B-T121
treatment	B-T061
.	O
Mitochondrial	O
autophagy	O
-related	O
protein	O
contents	O
were	O
greater	O
in	O
trained	O
mice	O
(	O
e.g.	O
,	O
40	O
%	O
greater	O
Bnip3	O
,	O
P<0.05	O
)	O
,	O
independent	O
of	O
simvastatin	B-T121
treatment	B-T061
.	O
However	O
,	O
Drp1	O
,	O
a	O
marker	O
of	O
mitochondrial	O
fission	O
,	O
was	O
less	O
in	O
simvastatin	B-T121
treated	O
mice	O
,	O
independent	O
of	O
exercise	O
training	O
,	O
and	O
there	O
was	O
a	O
significant	O
interaction	O
between	O
training	O
and	O
statin	O
treatment	B-T061
(	O
P<0.022	O
)	O
for	O
LC3	O
-	O
II	O
protein	O
content	O
,	O
a	O
marker	O
of	O
autophagy	O
flux	O
.	O
These	O
data	O
indicate	O
that	O
whole	B-T017
body	I-T017
and	O
skeletal	O
muscle	O
adaptations	O
to	O
endurance	O
exercise	O
training	O
are	O
attainable	O
with	O
simvastatin	B-T121
treatment	B-T061
,	O
but	O
simvastatin	B-T121
may	O
have	O
side	O
effects	O
on	O
muscle	O
mitochondrial	O
maintenance	O
via	O
autophagy	O
,	O
which	O
could	O
have	O
long	O
-	O
term	O
implications	O
on	O
muscle	O
health	O
.	O
      
Delayed	O
Recognition	O
of	O
Deterioration	B-T033
of	O
Patients	O
in	O
General	O
Wards	O
Is	O
Mostly	O
Caused	O
by	O
Human	O
Related	O
Monitoring	B-T058
Failures	O
:	O
A	O
Root	O
Cause	O
Analysis	O
of	O
Unplanned	O
ICU	B-T058
Admissions	I-T058
An	O
unplanned	O
ICU	B-T058
admission	I-T058
of	O
an	O
inpatient	O
is	O
a	O
serious	B-T033
adverse	I-T033
event	I-T033
(	O
SAE	B-T033
)	O
.	O
So	O
far	O
,	O
no	O
in	O
depth	O
-	O
study	O
has	O
been	O
performed	O
to	O
systematically	O
analyse	O
the	O
root	O
causes	O
of	O
unplanned	O
ICU	B-T058
-	I-T058
admissions	I-T058
.	O
The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
healthcare	O
worker	O
-	O
,	O
organisational	O
-	O
,	O
technical	O
,	O
-	O
disease	B-T047
-	O
and	O
patient	O
-	O
related	O
causes	O
that	O
contribute	O
to	O
acute	O
unplanned	O
ICU	B-T058
admissions	I-T058
from	O
general	O
wards	O
using	O
a	O
Root	O
-	O
Cause	O
Analysis	O
Tool	O
called	O
PRISMA	B-T058
-	I-T058
medical	I-T058
.	O
Although	O
a	O
Track	O
and	O
Trigger	O
System	O
(	O
MEWS	O
)	O
was	O
introduced	O
in	O
our	O
hospital	O
a	O
few	O
years	O
ago	O
,	O
it	O
was	O
implemented	O
without	O
a	O
clear	O
protocol	B-T061
.	O
Therefore	O
,	O
the	O
secondary	O
aim	O
was	O
to	O
assess	O
the	O
adherence	O
to	O
a	O
Track	O
and	O
Trigger	O
system	O
to	O
identify	O
deterioration	B-T033
on	O
general	O
hospital	O
wards	O
in	O
patients	O
eventually	O
transferred	O
to	O
the	O
ICU	O
.	O
Retrospective	O
observational	O
study	O
in	O
49	O
consecutive	O
adult	O
patients	O
acutely	O
admitted	B-T058
to	O
the	O
Intensive	O
Care	O
Unit	O
from	O
a	O
general	B-T058
nursing	I-T058
ward	I-T058
.	O
1	O
.	O
PRISMA	O
-	O
analysis	O
on	O
root	O
causes	O
of	O
unplanned	O
ICU	B-T058
admissions	I-T058
2	O
.	O
Assessment	O
of	O
protocol	B-T061
adherence	O
to	O
the	O
early	B-T033
warning	I-T033
score	I-T033
system	I-T033
.	O
Out	O
of	O
49	O
cases	O
,	O
156	O
root	O
causes	O
were	O
identified	O
.	O
The	O
most	O
frequent	O
root	O
causes	O
were	O
healthcare	O
worker	O
related	O
(	O
46	O
%	O
)	O
,	O
which	O
were	O
mainly	O
failures	O
in	O
monitoring	B-T058
the	O
patient	O
.	O
They	O
were	O
followed	O
by	O
disease	B-T047
-related	O
(	O
45	O
%	O
)	O
,	O
patient	O
-related	O
causes	O
(	O
7	O
,	O
5	O
%	O
)	O
,	O
and	O
organisational	O
root	O
causes	O
(	O
3	O
%	O
)	O
.	O
In	O
only	O
40	O
%	O
of	O
the	O
patients	O
vital	O
parameters	O
were	O
monitored	O
as	O
was	O
instructed	O
by	O
the	O
doctor	O
.	O
477	O
vital	O
parameter	O
sets	O
were	O
found	O
in	O
the	O
48	O
hours	O
before	O
ICU	B-T058
admission	I-T058
,	O
in	O
only	O
1	O
%	O
a	O
correct	O
MEWS	O
was	O
explicitly	O
documented	B-T058
in	O
the	O
record	O
.	O
This	O
in	O
-	O
depth	O
analysis	O
demonstrates	O
that	O
almost	O
half	O
of	O
the	O
unplanned	O
ICU	B-T058
admissions	I-T058
from	O
the	O
general	O
ward	O
had	O
healthcare	O
worker	O
related	O
root	O
causes	O
,	O
mostly	O
due	O
to	O
monitoring	B-T058
failures	O
in	O
clinically	B-T033
deteriorating	I-T033
patients	O
.	O
In	O
order	O
to	O
reduce	O
unplanned	O
ICU	B-T058
admissions	I-T058
,	O
improving	O
the	O
monitoring	B-T058
of	O
patients	O
is	O
therefore	O
warranted	O
.	O
      
Comparisons	O
of	O
Safety	O
and	O
Clinical	O
Outcomes	O
Between	O
Multiple	B-T061
-	I-T061
level	I-T061
and	O
Single	B-T061
-	I-T061
level	I-T061
Cervical	I-T061
Disk	I-T061
Replacement	I-T061
for	O
Cervical	B-T047
Spondylosis	I-T047
:	O
A	O
Systematic	O
Review	O
and	O
Meta	O
-	O
analysis	O
This	O
is	O
a	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
multiple	B-T061
-	I-T061
level	I-T061
cervical	I-T061
disk	I-T061
replacement	I-T061
(	O
CDR	B-T061
)	O
over	O
single	B-T061
-	I-T061
level	I-T061
CDR	I-T061
for	O
the	O
treatment	B-T061
of	O
cervical	B-T047
spondylosis	I-T047
.	O
Some	O
authors	O
advocate	O
for	O
the	O
multiple	B-T061
-	I-T061
level	I-T061
CDR	I-T061
instead	O
of	O
anterior	O
decompression	B-T061
and	O
fusion	B-T061
in	O
cervical	B-T047
multiple	I-T047
-	I-T047
level	I-T047
spondylosis	I-T047
.	O
However	O
,	O
whether	O
the	O
efficacy	O
and	O
safety	O
of	O
multi	B-T061
-	I-T061
level	I-T061
CDR	I-T061
are	O
as	O
favorable	O
as	O
that	O
of	O
single	B-T061
-	I-T061
level	I-T061
CDR	I-T061
remains	O
controversial	O
.	O
MEDLINE	O
,	O
EMBASE	O
,	O
and	O
Cochrane	O
library	O
databases	O
were	O
searched	O
up	O
to	O
November	O
2015	O
for	O
controlled	O
studies	O
that	O
compared	O
the	O
clinical	O
outcomes	O
of	O
single	B-T061
-	I-T061
level	I-T061
and	O
multiple	B-T061
-	I-T061
level	I-T061
CDR	I-T061
for	O
the	O
treatment	B-T061
of	O
cervical	B-T047
spondylosis	I-T047
.	O
The	O
following	O
outcomes	O
were	O
extracted	O
and	O
analyzed	O
:	O
prevalence	O
of	O
heterotopic	O
ossification	O
and	O
reoperation	B-T061
,	O
preoperative	O
and	O
postoperative	O
Neck	B-T033
Disability	I-T033
Index	I-T033
scores	I-T033
,	O
preoperative	O
and	O
postoperative	O
Visual	O
Analog	O
Scale	O
scores	O
,	O
and	O
success	O
rate	O
using	O
the	O
Odom	O
grading	O
system	O
.	O
Ten	O
studies	O
involving	O
1402	O
patients	O
were	O
included	O
:	O
including	O
3	O
randomized	O
controlled	O
trials	O
,	O
5	O
prospective	O
studies	O
,	O
and	O
3	O
retrospective	O
studies	O
.	O
No	O
significant	O
differences	O
between	O
single	B-T061
-	I-T061
level	I-T061
and	O
multiple	B-T061
-	I-T061
level	I-T061
groups	O
were	O
found	O
in	O
terms	O
of	O
the	O
prevalence	O
of	O
heterotopic	O
ossification	O
and	O
reoperation	B-T061
rate	O
,	O
Neck	B-T033
Disability	I-T033
Index	I-T033
score	I-T033
,	O
Visual	O
Analog	O
Scale	O
score	O
,	O
and	O
success	O
rate	O
using	O
the	O
Odom	O
grading	O
system	O
.	O
On	O
the	O
basis	O
of	O
this	O
meta	O
-	O
analysis	O
,	O
clinical	O
outcomes	O
of	O
multiple	B-T061
-	I-T061
level	I-T061
CDR	I-T061
are	O
similar	O
to	O
those	O
of	O
single	B-T061
-	I-T061
level	I-T061
CDR	I-T061
for	O
cervical	B-T047
spondylosis	I-T047
,	O
which	O
suggests	O
the	O
multiple	B-T061
-	I-T061
level	I-T061
CDR	I-T061
is	O
as	O
effective	O
and	O
safe	O
as	O
the	O
single	B-T061
-	I-T061
level	I-T061
CDR	I-T061
.	O
Nonetheless	O
,	O
more	O
well	O
-	O
designed	O
studies	O
are	O
needed	O
for	O
further	O
evaluation	O
.	O
      
Open	O
-	O
label	O
,	O
multicentre	O
safety	O
study	O
of	O
vemurafenib	B-T121
in	O
3219	O
patients	O
with	O
BRAF(V600	O
)	O
mutation	O
-	O
positive	B-T033
metastatic	B-T191
melanoma	I-T191
:	O
2	O
-	O
year	O
follow	B-T058
-	I-T058
up	I-T058
data	O
and	O
long	O
-	O
term	O
responders	O
'	O
analysis	O
The	O
orally	O
available	O
BRAF	B-T121
kinase	I-T121
inhibitor	I-T121
vemurafenib	B-T121
is	O
an	O
effective	O
and	O
tolerable	O
treatment	B-T061
option	I-T061
for	O
patients	O
with	O
metastatic	B-T191
melanoma	I-T191
harbouring	O
BRAF(V600	O
)	O
mutations	O
.	O
We	O
assessed	O
the	O
safety	O
of	O
vemurafenib	B-T121
in	O
a	O
large	O
population	O
of	O
patients	O
with	O
few	O
alternative	O
treatment	B-T061
options	I-T061
;	O
we	O
report	O
updated	O
2	O
-	O
year	O
safety	O
.	O
This	O
was	O
an	O
open	O
-	O
label	O
,	O
multicentre	O
study	O
of	O
vemurafenib	B-T121
(	O
960	O
mg	O
bid	O
)	O
in	O
patients	O
with	O
previously	O
treated	O
or	O
untreated	B-T033
BRAF	O
mutation	O
-	O
positive	B-T033
metastatic	B-T191
melanoma	I-T191
(	O
cobas	O
(	O
®	O
)	O
4800	O
BRAF	B-T059
V600	I-T059
Mutation	I-T059
Test	I-T059
)	O
.	O
The	O
primary	O
end	O
-	O
point	O
was	O
safety	O
;	O
efficacy	O
end	O
-	O
points	O
were	O
secondary	O
.	O
An	O
exploratory	O
analysis	O
was	O
performed	O
to	O
assess	B-T058
safety	O
outcomes	O
in	O
patients	O
with	O
long	O
duration	O
of	O
response	O
(	O
DOR	O
)	O
(	O
≥12	O
or	O
≥24	O
months	O
)	O
.	O
After	O
a	O
median	O
follow	B-T058
-	I-T058
up	I-T058
of	O
32.2	O
months	O
(	O
95	O
%	O
CI	O
,	O
31.1	O
-	O
33.2	O
months	O
)	O
,	O
3079/3219	O
patients	O
(	O
96	O
%	O
)	O
had	O
discontinued	B-T033
treatment	I-T033
.	O
Adverse	O
events	O
(	O
AEs	O
)	O
were	O
largely	O
consistent	O
with	O
previous	O
reports	O
;	O
the	O
most	O
common	O
all	O
-	O
grade	O
treatment	O
-related	O
AEs	O
were	O
arthralgia	B-T184
(	O
37	O
%	O
)	O
,	O
alopecia	B-T047
(	O
25	O
%	O
)	O
and	O
hyperkeratosis	B-T047
(	O
23	O
%	O
)	O
;	O
the	O
most	O
common	O
grade	O
3/4	O
treatment	O
-related	O
AEs	O
were	O
squamous	B-T191
cell	I-T191
carcinoma	I-T191
of	I-T191
the	I-T191
skin	I-T191
(	O
8	O
%	O
)	O
and	O
keratoacanthoma	B-T191
(	O
8	O
%	O
)	O
.	O
In	O
the	O
exploratory	O
analysis	O
,	O
patients	O
with	O
DOR	O
≥12	O
months	O
(	O
n	O
=	O
287	O
)	O
or	O
≥24	O
months	O
(	O
n	O
=	O
133	O
)	O
were	O
more	O
likely	O
to	O
experience	O
grade	O
3/4	O
AEs	O
than	O
the	O
overall	O
population	O
.	O
No	O
new	O
specific	O
safety	O
signals	O
were	O
observed	O
with	O
longer	O
vemurafenib	B-T121
vemurafenib	B-T033
exposure	I-T033
.	O
After	O
2	O
years	O
'	O
follow	B-T058
-	I-T058
up	I-T058
,	O
safety	O
was	O
maintained	O
in	O
this	O
large	O
group	O
of	O
patients	O
with	O
BRAF(V600	O
)	O
mutation	O
-	O
positive	B-T033
metastatic	B-T191
melanoma	I-T191
who	O
are	O
more	O
representative	O
of	O
routine	O
clinical	O
practice	O
than	O
typical	O
clinical	O
trial	O
populations	O
.	O
These	O
data	O
suggest	O
that	O
long	O
-	O
term	O
vemurafenib	B-T121
treatment	O
is	O
effective	O
and	O
tolerable	O
without	O
the	O
development	O
of	O
new	O
safety	O
signals	O
.	O
      
Attenuation	O
of	O
High	B-T121
Glucose	I-T121
-	O
Induced	O
Rat	O
Cardiomyocyte	O
Apoptosis	O
by	O
Exendin-4	B-T121
via	O
Intervention	B-T061
of	O
HO-1	O
/	O
Nrf-2	O
and	O
the	O
PI3K	O
/	O
AKT	O
Signaling	O
Pathway	O
Exendin-4	B-T121
,	O
a	O
glucagon	B-T121
-	I-T121
like	I-T121
peptide-1	I-T121
receptor	I-T121
agonist	I-T121
,	O
demonstrated	O
cytoprotective	O
actions	O
beyond	O
glycemic	B-T033
control	I-T033
in	O
recent	O
studies	O
.	O
The	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
investigate	O
the	O
effects	O
of	O
exendin-4	B-T121
on	O
high	B-T121
glucose	I-T121
HG	B-T121
(	O
HG)-	O
induced	O
cardiomyocyte	O
apoptosis	O
and	O
the	O
possible	O
mechanisms	O
.	O
Rat	O
cardiomyocytes	O
were	O
divided	O
into	O
3	O
groups	O
:	O
normal	B-T121
glucose	I-T121
group	O
(	O
NG	B-T121
group	O
)	O
,	O
HG	B-T121
group	O
and	O
HG	B-T121
+	O
exendin-4	B-T121
group	O
(	O
HG	B-T121
+	O
Ex	B-T121
Group	O
)	O
.	O
Cardiomyocyte	O
apoptosis	O
was	O
evaluated	O
by	O
double	B-T059
-	I-T059
staining	I-T059
with	O
annexin	O
V	O
-	O
fluorescein	O
isothiocyanate	O
(	O
FITC)/	O
propidium	O
iodide	O
(	O
PI	O
)	O
and	O
flow	B-T059
cytometry	I-T059
.	O
Intracellular	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
production	O
was	O
detected	B-T033
by	O
2’,7’-dichlorodihydrofluorescein	O
diacetate	O
(	O
DCHF	O
-	O
DA	O
)	O
incubation	B-T059
and	O
fluorescence	B-T059
microscopy	I-T059
.	O
LY294002	B-T121
(	O
LY	B-T121
)	O
,	O
a	O
phosphoinositide	O
3	O
-	O
kinase	O
(	O
PI3	O
K	O
)	O
pathway	O
inhibitor	O
,	O
was	O
added	O
to	O
the	O
medium	O
of	O
the	O
HG	B-T121
+	O
Ex	B-T121
+	O
LY	B-T121
Group	O
for	O
further	O
western	B-T059
blot	I-T059
analysis	I-T059
.	O
The	O
proteins	O
analyzed	O
involved	O
oxidative	O
stress	O
-	O
associated	O
proteins	O
,	O
heme	O
oxygenase-1	O
(	O
HO-1	O
)	O
and	O
nuclear	O
factor	O
E2	O
-	O
related	O
factor	O
2	O
(	O
Nrf-2	O
)	O
,	O
and	O
apoptosis	O
-	O
associated	O
proteins	O
,	O
caspase-3	O
,	O
Bax	O
/	O
B	O
-	O
cell	O
lymphoma	O
2	O
(	O
Bcl-2	O
)	O
and	O
p	O
-	O
AKT	O
/	O
AKT	O
.	O
HG	B-T121
treatment	O
induced	O
cardiomyocyte	O
apoptosis	O
(	O
P	O
=	O
0.00	O
)	O
and	O
clearly	O
upregulated	O
ROS	O
production	O
(	O
P	O
=	O
0.00	O
)	O
;	O
exendin-4	B-T121
co	B-T059
-	I-T059
incubation	I-T059
also	O
ameliorated	O
cardiomyocyte	O
apoptosis	O
(	O
P	O
=	O
0.004	O
)	O
and	O
decreased	O
ROS	O
(	O
P	O
=	O
0.00	O
)	O
level	O
significantly	O
.	O
HO-1	O
and	O
Nrf-2	O
protein	O
expression	O
levels	O
decreased	O
significantly	O
in	O
the	O
HG	B-T121
group	O
(	O
P	O
<	O
0.05	O
)	O
,	O
but	O
the	O
levels	O
were	O
elevated	O
by	O
exendin-4	B-T121
intervention	B-T061
(	O
P	O
<	O
0.05	O
)	O
.	O
Furthermore	O
,	O
exendin-4	B-T121
attenuated	O
HG	B-T121
-	O
induced	O
higher	O
protein	O
expression	O
,	O
including	O
cleaved	O
caspase-3	O
and	O
Bax	O
,	O
increased	O
the	O
expression	O
of	O
Bcl-2	O
protein	O
(	O
P	O
<	O
0.05	O
)	O
.	O
However	O
,	O
these	O
impacts	O
of	O
exendin-4	B-T121
were	O
counteracted	O
significantly	O
by	O
co	B-T059
-	I-T059
incubation	I-T059
with	O
LY294002	B-T121
.	O
In	O
addition	O
,	O
exendin-4	B-T121
ameliorated	O
HG	B-T121
-	O
induced	O
p	O
-	O
AKT	O
/	O
AKT	O
lower	O
expression	O
,	O
and	O
this	O
impact	O
was	O
also	O
suppressed	O
by	O
LY294002	B-T121
.	O
Exendin-4	B-T121
ameliorates	O
HG	B-T121
-	O
induced	O
cardiomyocyte	O
apoptosis	O
,	O
and	O
the	O
mechanisms	O
may	O
involve	O
anti	O
-	O
oxidative	O
stress	O
via	O
the	O
HO-1	O
/	O
Nrf-2	O
system	O
,	O
as	O
well	O
as	O
intervention	B-T061
of	O
the	O
PI3K	O
/	O
AKT	O
signaling	O
pathway	O
.	O
      
Pre	O
-	O
existing	O
renal	B-T023
lesions	B-T033
revealed	O
after	O
renal	B-T023
trauma	O
,	O
Difficulties	O
in	O
diagnosis	O
and	O
accountability	O
:	O
About	O
14	O
cases	O
Pre	O
-	O
existing	O
renal	B-T023
lesions	B-T033
(	O
PERL	B-T033
)	O
may	O
interfere	O
with	O
the	O
patho	O
-	O
physiology	O
of	O
trauma	O
,	O
alter	O
the	O
radiographic	B-T060
imaging	I-T060
and	O
influence	O
the	O
therapeutic	B-T061
approach	O
.	O
The	O
aims	O
of	O
this	O
study	O
were	O
to	O
record	O
the	O
PERL	B-T033
found	O
incidentally	O
during	O
blunt	O
renal	B-T023
trauma	O
,	O
to	O
specify	O
the	O
place	O
for	O
effective	O
conservative	B-T061
management	I-T061
and	O
to	O
determin	O
the	O
estimated	O
partial	B-T033
permanent	I-T033
disability	I-T033
(	O
PPD	B-T033
)	O
.	O
The	O
medical	O
records	O
of	O
14	O
patients	O
with	O
PERL	B-T033
and	O
blunt	O
renal	B-T023
trauma	O
were	O
reviewed	O
.	O
In	O
each	O
patient	O
,	O
pre	O
-	O
existing	O
renal	B-T023
abnormalities	O
,	O
clinical	O
symptoms	B-T184
,	O
CT	B-T060
scan	I-T060
study	O
findings	B-T033
,	O
associated	O
injuries	O
,	O
therapeutic	B-T061
approach	O
,	O
the	O
accountability	O
criteria	O
and	O
the	O
estimated	O
PPD	B-T033
were	O
recorded	O
.	O
There	O
were	O
11	O
men	O
and	O
3	O
women	O
with	O
a	O
mean	O
age	O
of	O
35,6	O
years	O
(	O
range	O
19	O
-	O
66	O
years	O
)	O
.	O
Renal	B-T023
trauma	O
was	O
due	O
to	O
a	O
traffic	O
accident	O
in	O
8	O
patients	O
.	O
Renal	B-T023
damage	O
appeared	O
to	O
be	O
disproportionate	O
to	O
the	O
severity	O
of	O
the	O
trauma	O
(	O
minor	O
trauma	O
)	O
.	O
They	O
had	O
a	O
lower	O
rate	O
of	O
associated	O
trauma	O
to	O
other	O
abdominal	B-T023
organs	I-T023
(	O
four	O
patients	O
only	O
)	O
.	O
Urinary	O
stones	O
were	O
present	O
in	O
5	O
patients	O
,	O
pelvi	O
-	O
ureteric	O
junction	O
obstruction	O
in	O
3	O
,	O
horseshoe	B-T019
kidny	I-T019
in	O
3	O
,	O
ectopic	B-T019
kidney	I-T019
in	O
2	O
and	O
upper	O
urinary	B-T191
tract	I-T191
carcinoma	I-T191
in	O
one	O
case	O
.	O
Early	O
nephrectomy	B-T061
was	O
required	O
in	O
three	O
cases	O
for	O
hemodynamic	B-T047
instability	I-T047
.	O
Ureteral	O
stenting	O
was	O
indicated	O
in	O
3	O
cases	O
.	O
Six	O
patients	O
were	O
operated	B-T061
later	O
because	O
of	O
their	O
underlying	O
renal	B-T023
pathology	B-T059
.	O
A	O
conservative	B-T061
treatment	I-T061
was	O
possible	O
only	O
in	O
7	O
of	O
cases	O
.	O
The	O
PPD	B-T033
related	O
to	O
renal	B-T023
trauma	O
varide	O
from	O
0	O
to	O
13	O
%	O
in	O
all	O
cases	O
.	O
PERL	B-T033
may	O
complicate	O
a	O
negligible	O
renal	B-T023
trauma	O
while	O
in	O
some	O
cases	O
they	O
may	O
be	O
of	O
vital	O
importance	O
for	O
the	O
patient	O
's	O
final	O
outcome	O
.	O
The	O
imaging	O
findings	B-T033
are	O
crucial	O
but	O
may	O
be	O
confusing	O
.	O
The	O
therapeutic	B-T061
approach	O
is	O
,	O
to	O
a	O
large	O
extent	O
,	O
dependent	O
on	O
the	O
type	O
of	O
PERL	B-T033
and	O
the	O
severity	O
of	O
damage	O
,	O
and	O
is	O
often	O
conservative	O
in	O
the	O
hemo	B-T033
-	I-T033
dynamically	I-T033
stable	I-T033
patient	O
.	O
Accountability	O
link	O
may	O
be	O
difficult	O
to	O
establish	O
and	O
the	O
PPD	B-T033
depends	O
on	O
the	O
PERL	B-T033
and	O
the	O
renal	O
injuries	O
severity	O
.	O
We	O
have	O
no	O
involvement	O
with	O
funding	O
in	O
this	O
case	O
.	O
Ethical	O
approval	O
:	O
Not	O
required	O
Conflicts	O
of	O
interest	O
:	O
None	O
.	O
      
GH32	B-T121
family	I-T121
activity	O
:	O
a	O
topological	O
approach	O
through	O
protein	O
contact	O
networks	O
The	O
application	O
of	O
Protein	O
Contact	O
Networks	O
methodology	O
allowed	O
to	O
highlight	O
a	O
novel	O
response	O
of	O
border	O
region	O
between	O
the	O
two	O
domains	O
to	O
substrate	O
binding	O
.	O
Glycoside	B-T121
hydrolases	I-T121
(	O
GH	B-T121
)	O
are	O
enzymes	O
that	O
mainly	O
hydrolyze	O
the	O
glycosidic	O
bond	O
between	O
two	O
carbohydrates	O
or	O
a	O
carbohydrate	O
and	O
a	O
non	O
-	O
carbohydrate	O
moiety	O
.	O
These	O
enzymes	O
are	O
involved	O
in	O
many	O
fundamental	O
and	O
diverse	O
biological	O
processes	O
in	O
plants	O
.	O
We	O
have	O
focused	O
on	O
the	O
GH32	B-T121
family	I-T121
,	O
including	O
enzymes	O
very	O
similar	O
in	O
both	O
sequence	O
and	O
structure	O
,	O
each	O
having	O
however	O
clear	O
specificities	O
of	O
substrate	O
preferences	O
and	O
kinetic	O
properties	O
.	O
Structural	O
and	O
topological	O
differences	O
among	O
proteins	O
of	O
the	O
GH32	B-T121
family	I-T121
have	O
been	O
here	O
identified	O
by	O
means	O
of	O
an	O
emerging	O
approach	O
(	O
Protein	O
Contact	O
network	O
,	O
PCN	O
)	O
based	O
on	O
the	O
formalization	O
of	O
3D	O
structures	O
as	O
contact	O
networks	O
among	O
amino	O
-	O
acid	O
residues	O
.	O
The	O
PCN	O
approach	O
proved	O
successful	O
in	O
both	O
reconstructing	O
the	O
already	O
known	O
functional	O
domains	O
and	O
in	O
identifying	O
the	O
structural	O
counterpart	O
of	O
the	O
properties	O
of	O
GH32	B-T121
enzymes	I-T121
,	O
which	O
remain	O
uncertain	O
,	O
like	O
their	O
allosteric	O
character	O
.	O
The	O
main	O
outcome	O
of	O
the	O
study	O
was	O
the	O
discovery	O
of	O
the	O
activation	O
upon	O
binding	O
of	O
the	O
border	O
(	O
cleft	O
)	O
region	O
between	O
the	O
two	O
domains	O
.	O
This	O
reveals	O
the	O
allosteric	O
nature	O
of	O
the	O
enzymatic	O
activity	O
for	O
all	O
the	O
analyzed	O
forms	O
in	O
the	O
GH32	B-T121
family	I-T121
,	O
a	O
character	O
yet	O
to	O
be	O
highlighted	O
in	O
biochemical	B-T059
studies	I-T059
.	O
Furthermore	O
,	O
we	O
have	O
been	O
able	O
to	O
recognize	O
a	O
topological	O
signature	O
(	O
graph	O
energy	O
)	O
of	O
the	O
different	O
affinity	O
of	O
the	O
enzymes	B-T121
towards	O
small	O
and	O
large	O
substrates	O
.	O
      
Molecular	B-T059
subtyping	I-T059
of	O
Treponema	B-T007
pallidum	I-T007
and	O
associated	O
factors	O
of	O
serofast	B-T033
status	O
in	O
early	B-T047
syphilis	I-T047
patients	O
:	O
Identified	O
novel	O
genotype	O
and	O
cytokine	O
marker	O
Serofast	B-T033
,	O
a	O
persistent	O
nontreponemal	O
serological	O
response	O
observed	O
in	O
early	B-T047
syphilis	I-T047
patients	O
after	O
conventional	B-T061
treatment	I-T061
,	O
remains	O
a	O
concern	O
of	O
clinicians	O
and	O
syphilis	B-T047
patients	O
.	O
No	O
consensus	O
has	O
been	O
established	O
,	O
however	O
,	O
that	O
defines	O
an	O
effective	O
treatment	B-T061
strategy	I-T061
and	O
clarifies	O
the	O
pathogenesis	O
.	O
In	O
this	O
study	O
,	O
517	O
patients	O
with	O
early	B-T047
syphilis	I-T047
were	O
enrolled	B-T058
and	O
treated	O
.	O
Twelve	O
months	O
after	O
treatment	B-T061
,	O
79.3	O
%	O
(	O
410/517	O
)	O
of	O
patients	O
achieved	O
serological	O
cure	O
,	O
20.1	O
%	O
(	O
104/517	O
)	O
were	O
serofast	B-T033
,	O
and	O
0.6	O
%	O
(	O
3/517	O
)	O
were	O
serological	O
failures	O
.	O
Multivariate	O
analysis	O
demonstrated	O
that	O
older	O
age	O
(	O
>	O
40	O
years	O
)	O
and	O
lower	O
baseline	O
RPR	B-T059
titer	I-T059
(	O
≤	O
1:8	O
)	O
were	O
associated	O
with	O
serofast	B-T033
status	O
.	O
We	O
also	O
identified	O
21	O
T.	B-T007
pallidum	I-T007
molecular	O
subtypes	O
among	O
early	B-T047
syphilis	I-T047
patients	O
and	O
detected	O
a	O
new	O
subtype	O
,	O
14i	O
/	O
a.	O
We	O
found	O
that	O
the	O
proportion	O
of	O
14i	O
/	O
a	O
type	O
in	O
serofast	B-T033
patients	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
patients	O
with	O
serological	O
cure	O
,	O
predicting	O
an	O
increasing	O
risk	O
of	O
serofast	B-T033
status	O
.	O
Levels	O
of	O
chemerin	O
were	O
higher	O
in	O
the	O
serum	O
of	O
serofast	B-T033
cases	O
than	O
serological	O
cure	O
cases	O
,	O
potentially	O
indicating	O
a	O
novel	O
cytokine	O
marker	O
for	O
serofast	B-T033
in	O
early	B-T047
syphilis	I-T047
patients	O
after	O
therapy	B-T061
.	O
We	O
hope	O
that	O
these	O
results	O
contribute	O
to	O
improve	B-T033
guidelines	O
for	O
the	O
management	B-T058
of	O
syphilis	B-T047
patients	O
who	O
experience	O
serofast	B-T033
.	O
      
Discovery	O
of	O
<	O
i	O
>	O
Neopanorpa	O
chillcotti</i	O
>	O
Byers	O
(	O
Mecoptera	O
:	O
Panorpidae	O
)	O
from	O
Tibet	O
,	O
China	O
,	O
with	O
discussion	O
of	O
its	O
generic	O
status	O
Neopanorpa	O
chillcotti	O
Byers	O
,	O
1971	O
was	O
originally	O
described	O
from	O
Kathmandu	O
in	O
Nepal	O
and	O
is	O
now	O
found	O
to	O
be	O
distributed	O
in	O
Gyirong	O
,	O
Tibet	O
in	O
China	O
.	O
The	O
species	O
is	O
redescribed	O
and	O
illustrated	O
based	O
on	O
new	O
material	O
from	O
China	O
and	O
Nepal	O
.	O
The	O
generic	O
status	O
of	O
this	O
species	O
is	O
briefly	O
discussed	O
.	O
      
The	O
prognostic	O
value	O
of	O
extranodal	B-T033
extension	I-T033
in	O
human	B-T005
papillomavirus	I-T005
-associated	O
oropharyngeal	B-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
Extranodal	B-T033
(	I-T033
or	I-T033
extracapsular	I-T033
)	I-T033
extension	I-T033
(	O
ENE	B-T033
)	O
is	O
an	O
adverse	O
prognostic	O
factor	O
in	O
patients	O
with	O
head	B-T191
and	I-T191
neck	I-T191
cancers	I-T191
who	O
undergo	O
primary	B-T058
surgery	I-T058
.	O
However	O
,	O
the	O
significance	O
of	O
ENE	B-T033
in	O
human	B-T191
papillomavirus	I-T191
(	I-T191
HPV)-positive	I-T191
oropharyngeal	I-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
(	I-T191
OPSCC	I-T191
)	I-T191
is	O
not	O
well	O
established	O
,	O
and	O
single	O
-	O
institution	O
studies	O
have	O
not	O
established	O
that	O
ENE	B-T033
predicts	O
inferior	O
outcome	O
.	O
The	O
authors	O
investigated	O
the	O
prognostic	O
value	O
of	O
ENE	B-T033
in	O
HPV	B-T005
-	O
positive	B-T033
patients	O
who	O
underwent	O
primary	B-T058
surgery	I-T058
and	O
whether	O
adjuvant	B-T061
chemoradiation	I-T061
improved	O
overall	O
survival	O
(	O
OS	O
)	O
compared	O
with	O
radiation	O
alone	O
in	O
ENE	B-T033
-	O
positive	B-T033
patients	O
.	O
Patients	O
who	O
underwent	O
primary	B-T058
surgery	I-T058
for	O
pathologic	O
T1	O
(	O
pT1	O
)	O
through	O
pT4	B-T191
tumors	I-T191
,	O
pathologic	O
N1	O
(	O
pN1	O
)	O
through	O
pN3	B-T023
lymph	I-T023
node	I-T023
status	O
,	O
HPV	B-T191
-	I-T191
positive	I-T191
OPSCC	I-T191
were	O
identified	O
in	O
the	O
National	O
Cancer	O
Data	O
Base	O
from	O
2010	O
through	O
2012	O
.	O
Features	O
associated	O
with	O
ENE	B-T033
were	O
analyzed	O
.	O
Univariable	O
and	O
multivariable	O
Cox	O
regression	O
analyses	O
identified	O
predictors	O
of	O
OS	O
.	O
The	O
effect	O
of	O
adjuvant	B-T061
treatment	I-T061
on	O
OS	O
in	O
ENE	B-T033
-	O
positive	B-T033
cohort	O
was	O
also	O
evaluated	B-T058
.	O
In	O
total	O
,	O
1043	O
patients	O
met	O
inclusion	O
criteria	O
,	O
among	O
whom	O
43.5	O
%	O
were	O
ENE	B-T033
-	O
positive	B-T033
.	O
Of	O
the	O
ENE	B-T033
-	O
positive	B-T033
patients	O
who	O
had	O
treatment	B-T061
details	O
available	O
,	O
72	O
%	O
received	O
concurrent	B-T061
chemoradiotherapy	I-T061
,	O
16	O
%	O
received	O
radiotherapy	B-T061
,	O
and	O
12	O
%	O
received	O
no	O
adjuvant	B-T061
treatment	I-T061
.	O
After	O
a	O
median	O
follow	B-T058
-	I-T058
up	I-T058
of	O
28.4	O
months	O
,	O
ENE	B-T033
was	O
associated	O
with	O
worse	B-T033
3-	O
year	O
OS	O
(	O
89.3	O
%	O
vs	O
93.6	O
%	O
;	O
P	O
=	O
.01	O
)	O
.	O
On	O
multivariable	O
analysis	O
that	O
included	O
involved	O
lymph	B-T023
nodes	I-T023
,	O
only	O
ENE	B-T033
,	O
lymphovascular	B-T033
invasion	I-T033
,	O
pT3	B-T191
/	I-T191
pT4	I-T191
tumors	I-T191
,	O
and	O
Charlson	O
-	O
Deyo	O
score	O
were	O
associated	O
with	O
worse	B-T033
OS	O
.	O
Among	O
ENE	B-T033
-	O
positive	B-T033
patients	O
,	O
there	O
was	O
no	B-T033
difference	I-T033
in	O
3-	O
year	O
OS	O
between	O
those	O
who	O
received	O
adjuvant	B-T061
concurrent	I-T061
chemoradiotherapy	I-T061
versus	O
radiotherapy	B-T061
alone	I-T061
(	O
89.6	O
%	O
vs	O
89.3	O
%	O
,	O
respectively	O
;	O
P	O
=	O
.55	O
)	O
.	O
Propensity	O
score	O
-	O
matched	O
comparison	O
revealed	O
similar	O
results	O
.	O
ENE	B-T033
is	O
associated	O
with	O
inferior	O
OS	O
in	O
patients	O
with	O
HPV	B-T191
-	I-T191
positive	I-T191
OPSCC	I-T191
.	O
However	O
,	O
OS	O
was	O
not	B-T033
better	I-T033
with	O
adjuvant	B-T061
chemoradiotherapy	I-T061
compared	O
with	O
radiotherapy	B-T061
alone	I-T061
in	O
ENE	B-T033
-	O
positive	B-T033
patients	O
.	O
The	O
current	O
findings	O
support	O
the	O
need	O
for	O
prospective	O
studies	O
of	O
adjuvant	B-T061
chemoradiation	I-T061
in	O
HPV	B-T005
-	O
positive	B-T033
patients	O
with	O
ENE	B-T033
.	O
Cancer	O
2017	O
.	O
©	O
2017	O
American	O
Cancer	O
Society	O
.	O
      
Chemosensitivity	B-T033
,	O
Cardiovascular	B-T033
Risk	I-T033
,	O
and	O
the	O
Ventilatory	O
Response	O
to	O
Exercise	O
in	O
COPD	B-T047
COPD	B-T047
is	O
associated	O
with	O
elevated	O
cardiovascular	B-T033
risk	I-T033
and	O
a	O
potentiated	O
ventilatory	O
response	O
to	O
exercise	O
.	O
Enhanced	O
carotid	B-T023
chemoreceptor	O
(	O
CC	O
)	O
activity	O
/	O
sensitivity	O
is	O
present	O
in	O
other	O
clinical	O
conditions	O
,	O
has	O
been	O
shown	O
to	O
contribute	O
to	O
sympathetic	O
vasoconstrictor	O
outflow	O
,	O
and	O
is	O
predictive	O
of	O
mortality	B-T033
.	O
CC	O
activity	O
/	O
sensitivity	O
,	O
and	O
the	O
resulting	O
functional	O
significance	O
,	O
has	O
not	O
been	O
well	O
examined	O
in	O
COPD	B-T047
.	O
We	O
hypothesized	O
that	O
CC	O
activity	O
/	O
sensitivity	O
would	O
be	O
elevated	O
in	O
COPD	B-T047
,	O
and	O
related	O
to	O
increased	O
pulse	O
wave	O
velocity	O
(	O
a	O
marker	O
of	O
CV	B-T033
risk	I-T033
)	O
and	O
the	O
ventilatory	O
response	O
to	O
exercise	O
.	O
30	O
COPD	B-T047
patients	O
and	O
10	O
healthy	O
age	O
-	O
matched	O
controls	O
were	O
examined	B-T033
.	O
Participants	O
performed	O
baseline	O
cardiopulmonary	B-T060
exercise	I-T060
and	O
pulmonary	B-T060
function	I-T060
testing	I-T060
.	O
CC	O
activity	O
was	O
later	O
evaluated	B-T058
by	O
the	O
drop	B-T033
in	I-T033
ventilation	O
with	O
breathing	O
100	O
%	O
O2	B-T121
,	O
and	O
CC	O
sensitivity	O
was	O
then	O
assessed	O
by	O
the	O
ventilatory	B-T060
response	I-T060
to	I-T060
hypoxia	I-T060
(	O
ΔVE	O
/	O
ΔS	O
pO2	B-T059
)	O
.	O
Peripheral	O
arterial	O
stiffness	O
was	O
subsequently	O
evaluated	B-T058
by	O
measurement	O
of	O
pulse	O
wave	O
velocity	O
(	O
PWV	O
)	O
using	O
applanation	B-T060
tonometry	I-T060
while	O
the	O
subjects	O
were	O
breathing	O
room	B-T033
air	I-T033
,	O
and	O
then	O
following	O
chemoreceptor	O
inhibition	O
by	O
breathing	O
100	O
%	O
O2	B-T121
for	O
2	O
minutes	O
.	O
CC	O
activity	O
,	O
CC	O
sensitivity	O
,	O
PWV	O
and	O
the	O
ventilatory	O
response	O
to	O
exercise	O
were	O
all	O
increased	O
in	O
COPD	B-T047
relative	O
to	O
controls	O
.	O
CC	O
sensitivity	O
was	O
related	O
to	O
PWV	O
;	O
however	O
,	O
neither	O
CC	O
activity	O
nor	O
CC	O
sensitivity	O
was	O
related	O
to	O
the	O
ventilatory	O
response	O
to	O
exercise	O
in	O
COPD	B-T047
.	O
CC	O
inhibition	O
by	O
breathing	O
100	O
%	O
O2	B-T121
normalized	O
PWV	O
in	O
COPD	B-T047
,	O
while	O
no	O
effect	O
was	O
observed	O
in	O
controls	O
.	O
CC	O
activity	O
and	O
sensitivity	O
are	O
elevated	O
in	O
COPD	B-T047
,	O
and	O
appear	O
related	O
to	O
cardiovascular	B-T033
risk	I-T033
;	O
however	O
,	O
CC	O
activity	O
/	O
sensitivity	O
does	O
not	O
contribute	O
to	O
the	O
potentiated	O
ventilatory	O
response	O
to	O
exercise	O
.	O
      
Salvage	B-T061
Therapy	I-T061
with	O
Ceftolozane	B-T121
-	I-T121
Tazobactam	I-T121
for	O
Multidrug	B-T007
-	I-T007
Resistant	I-T007
Pseudomonas	I-T007
aeruginosa	I-T007
Infections	B-T047
Infections	B-T047
caused	O
by	O
multidrug	B-T007
-	I-T007
resistant	I-T007
Pseudomonas	I-T007
aeruginosa	I-T007
(	O
MDRPA	B-T007
)	O
present	O
a	O
major	O
problem	O
for	O
therapeutic	B-T058
management	I-T058
.	O
We	O
report	O
here	O
our	O
experience	O
with	O
12	O
patients	O
with	O
a	O
severe	O
MDRPA	B-T007
infection	B-T047
(	O
6	O
of	O
which	O
were	O
pneumonia	B-T047
)	O
who	O
received	O
salvage	B-T061
therapy	I-T061
with	O
ceftolozane	B-T121
-	I-T121
tazobactam	I-T121
after	O
inappropriate	O
empirical	B-T061
treatment	I-T061
and/or	O
suboptimal	O
targeted	O
treatment	B-T061
.	O
Although	O
10	O
of	O
the	O
12	O
patients	O
(	O
83.3	O
%	O
)	O
experienced	O
septic	O
shock	O
,	O
only	O
3	O
patients	O
(	O
25	O
%	O
)	O
died	O
during	O
the	O
follow	B-T058
-	I-T058
up	I-T058
period	O
.	O
Microbiological	B-T059
cure	O
in	O
7	O
patients	O
(	O
58.3	O
%	O
)	O
was	O
observed	O
.	O
      
Assessing	B-T058
nitrous	B-T121
oxide	I-T121
effect	O
using	O
electroencephalographically	B-T060
-based	O
depth	B-T033
of	I-T033
anesthesia	I-T033
measures	O
cortical	B-T023
state	O
and	O
cortical	B-T023
input	O
Existing	O
electroencephalography	B-T060
(	O
EEG	B-T060
)	O
based	O
depth	B-T033
of	I-T033
anesthesia	I-T033
monitors	B-T058
can	O
not	O
reliably	O
track	O
sedative	B-T121
or	O
anesthetic	B-T121
states	O
during	O
n	B-T121
-	I-T121
methyl	I-T121
-	I-T121
D	I-T121
-	I-T121
aspartate	I-T121
(	I-T121
NMDA	I-T121
)	I-T121
receptor	I-T121
antagonist	I-T121
based	O
anesthesia	B-T061
with	O
ketamine	B-T121
or	O
nitrous	B-T121
oxide	I-T121
(	O
N2O	B-T121
)	O
.	O
Here	O
,	O
a	O
physiologically	O
-motivated	O
depth	B-T033
of	I-T033
anesthesia	I-T033
monitoring	B-T058
algorithm	O
based	O
on	O
autoregressive	O
-	O
moving	O
-	O
average	O
(	O
ARMA	O
)	O
modeling	O
and	O
derivative	O
measures	O
of	O
interest	O
,	O
Cortical	B-T023
State	O
(	O
CS	O
)	O
and	O
Cortical	B-T023
Input	O
(	O
CI	O
)	O
,	O
is	O
retrospectively	O
applied	O
in	O
an	O
exploratory	O
manner	O
to	O
the	O
NMDA	B-T121
receptor	I-T121
antagonist	I-T121
N2O	B-T121
,	O
an	O
adjuvant	B-T121
anesthetic	I-T121
gas	I-T121
used	O
in	O
clinical	O
practice	O
.	O
Composite	O
Cortical	O
State	O
(	O
CCS	O
)	O
and	O
Composite	O
Cortical	O
State	O
distance	O
(	O
CCSd	O
)	O
,	O
two	O
new	O
modifications	B-T033
of	O
CS	O
,	O
along	O
with	O
CS	O
and	O
CI	O
were	O
evaluated	B-T058
on	O
electroencephalographic	B-T060
(	O
EEG	B-T060
)	O
data	O
of	O
healthy	O
control	O
individuals	O
undergoing	O
N2O	B-T121
inhalation	O
up	O
to	O
equilibrated	O
peak	O
gas	O
concentrations	O
of	O
20	O
,	O
40	O
or	O
60	O
%	O
N2O	B-T121
/	O
O2	B-T121
.	O
In	O
particular	O
,	O
CCSd	O
has	O
been	O
devised	O
to	O
vary	O
consistently	O
for	O
increasing	O
levels	O
of	O
anesthetic	B-T033
concentration	I-T033
independent	O
of	O
the	O
anesthetic	B-T121
's	I-T121
microscopic	O
mode	O
of	O
action	O
for	O
both	O
N2O	B-T121
and	O
propofol	B-T121
.	O
The	O
strongest	O
effects	O
were	O
observed	O
for	O
the	O
60	O
%	O
peak	O
gas	O
concentration	O
group	O
.	O
For	O
the	O
50	O
-	O
60	O
%	O
peak	O
gas	O
levels	O
,	O
individuals	O
showed	O
statistically	O
significant	O
reductions	B-T061
in	O
responsiveness	B-T033
compared	O
to	O
rest	O
,	O
and	O
across	O
the	O
group	O
CS	O
and	O
CCS	O
increased	O
by	O
39	O
and	O
42	O
%	O
,	O
respectively	O
,	O
while	O
CCSd	O
was	O
found	O
to	O
decrease	O
by	O
398	O
%	O
.	O
On	O
the	O
other	O
hand	O
a	O
clear	O
conclusion	O
regarding	O
the	O
changes	O
in	O
CI	O
could	O
not	O
be	O
reached	O
.	O
These	O
results	O
indicate	O
that	O
,	O
contrary	O
to	O
previous	O
depth	B-T033
of	I-T033
anesthesia	I-T033
monitoring	B-T058
measures	O
,	O
the	O
CS	O
,	O
CCS	O
,	O
and	O
especially	O
CCSd	O
measures	O
derived	O
from	O
frontal	O
EEG	B-T060
are	O
potentially	O
useful	O
for	O
differentiating	O
gas	O
concentration	O
and	O
responsiveness	B-T033
levels	I-T033
N2O	B-T121
in	O
people	O
under	O
N2O.	O
On	O
the	O
other	O
hand	O
,	O
determining	O
the	O
utility	O
of	O
CI	O
in	O
this	O
regard	O
will	O
require	O
larger	O
sample	O
sizes	O
and	O
potentially	O
higher	O
gas	O
concentrations	O
.	O
Future	O
work	O
will	O
assess	B-T058
the	O
sensitivity	O
of	O
CS	O
-based	O
and	O
CI	O
measures	O
to	O
other	O
anesthetics	B-T121
and	O
their	O
utility	O
in	O
a	O
clinical	O
environment	O
.	O
      
Systemic	O
matrix	O
metalloproteinase-8	O
response	O
in	O
chronic	B-T047
tonsillitis	I-T047
The	O
development	O
of	O
several	O
life	O
-	O
long	O
diseases	B-T047
,	O
such	O
as	O
coronary	B-T047
heart	I-T047
disease	I-T047
,	O
is	O
affected	O
by	O
low	O
-	O
grade	O
systemic	O
inflammation	O
.	O
Data	O
on	O
the	O
potential	O
long	O
-	O
term	O
health	O
effects	O
of	O
chronic	B-T047
tonsillitis	I-T047
are	O
limited	O
.	O
Many	O
inflammatory	O
conditions	O
present	O
with	O
enhanced	O
systemic	O
matrix	O
metalloproteinase	O
(	O
MMP)-8	O
response	O
.	O
In	O
head	B-T191
and	I-T191
neck	I-T191
cancer	I-T191
,	O
high	O
plasma	O
level	O
of	O
tissue	O
inhibitor	O
of	O
metalloproteinase	O
(	O
TIMP)-1	O
predicts	O
poor	B-T033
prognosis	I-T033
.	O
We	O
analyzed	O
S	O
-	O
MMP-8	O
with	O
immunofluorometric	B-T059
assay	I-T059
and	O
S	O
-	O
TIMP-1	O
with	O
an	O
immunosorbent	B-T059
assay	I-T059
in	O
175	O
consecutive	O
patients	O
undergoing	O
tonsillectomy	B-T061
for	O
benign	B-T191
tonsillar	I-T191
disease	I-T191
,	O
and	O
in	O
33	O
control	O
patients	O
with	O
tonsillar	B-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
.	O
Tonsillar	B-T023
human	B-T005
papillomavirus	I-T005
(	O
HPV	B-T005
)	O
status	O
was	O
determined	O
by	O
PCR	O
.	O
In	O
patients	O
with	O
benign	B-T191
tonsillar	I-T191
disease	I-T191
,	O
chronic	B-T047
tonsillitis	I-T047
without	O
hypertrophy	O
was	O
associated	O
with	O
enhanced	O
systemic	O
MMP-8	O
response	O
.	O
Compared	O
to	O
patients	O
with	O
benign	B-T191
tonsillar	I-T191
disease	I-T191
,	O
patients	O
with	O
tonsillar	B-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
had	O
significantly	O
higher	O
concentrations	O
of	O
S	O
-	O
MMP-8	O
and	O
S	O
-	O
TIMP-1	O
.	O
Neither	O
S	O
-	O
MMP-8	O
nor	O
S	O
-	O
TIMP-1	O
correlated	O
with	O
tonsillar	B-T023
HPV	B-T005
positivity	B-T033
.	O
      
Accurate	O
Lungs	B-T023
Segmentation	B-T058
on	O
CT	B-T060
Chest	O
Images	O
by	O
Adaptive	O
Appearance	O
-	O
Guided	O
Shape	O
Modeling	O
To	O
accurately	O
segment	B-T058
pathological	O
and	O
healthy	O
lungs	B-T023
for	O
reliable	O
computer	B-T060
-	I-T060
aided	I-T060
disease	I-T060
diagnostics	I-T060
,	O
a	O
stack	O
of	O
chest	O
CT	B-T060
scans	B-T060
is	O
modeled	O
as	O
a	O
sample	O
of	O
a	O
spatially	O
inhomogeneous	O
joint	O
3D	O
Markov	O
-	O
Gibbs	O
random	O
field	O
(	O
MGRF	O
)	O
of	O
voxel	O
-	O
wise	O
lung	B-T023
and	O
chest	O
CT	B-T060
image	O
signals	O
(	O
intensities	O
)	O
.	O
The	O
proposed	O
learnable	O
MGRF	O
integrates	O
two	O
visual	O
appearance	O
sub	O
-	O
models	O
with	O
an	O
adaptive	O
lung	B-T023
shape	O
submodel	O
.	O
The	O
first	O
-	O
order	O
appearance	O
submodel	O
accounts	O
for	O
both	O
the	O
original	O
CT	B-T060
image	O
and	O
its	O
Gaussian	O
scale	O
space	O
(	O
GSS	O
)	O
filtered	O
version	O
to	O
specify	O
local	O
and	O
global	O
signal	O
properties	O
,	O
respectively	O
.	O
Each	O
empirical	O
marginal	O
probability	O
distribution	O
of	O
signals	O
is	O
closely	O
approximated	O
with	O
a	O
linear	O
combination	O
of	O
discrete	O
Gaussians	O
(	O
LCDG	O
)	O
,	O
containing	O
two	O
positive	O
dominant	O
and	O
multiple	O
sign	O
-	O
alternate	O
subordinate	O
DGs	O
.	O
The	O
approximation	O
is	O
separated	O
into	O
two	O
LCDGs	O
to	O
describe	O
individually	O
the	O
lungs	B-T023
and	O
their	O
background	O
,	O
i.e.	O
,	O
all	O
other	O
chest	O
tissues	O
.	O
The	O
second	O
-	O
order	O
appearance	O
submodel	O
quantifies	O
conditional	O
pairwise	O
intensity	O
dependencies	O
in	O
the	O
nearest	O
voxel	O
26	O
-	O
neighborhood	O
in	O
both	O
the	O
original	O
and	O
GSS	O
-	O
filtered	O
images	O
.	O
The	O
shape	O
submodel	O
is	O
built	O
for	O
a	O
set	O
of	O
training	O
data	O
and	O
is	O
adapted	O
during	O
segmentation	B-T058
using	O
both	O
the	O
lung	B-T023
and	O
chest	O
appearances	O
.	O
The	O
accuracy	O
of	O
the	O
proposed	O
segmentation	B-T058
framework	O
is	O
quantitatively	O
assessed	O
using	O
two	O
public	O
databases	O
(	O
ISBI	O
VESSEL12	O
challenge	O
and	O
MICCAI	O
LOLA11	O
challenge	O
)	O
and	O
our	O
own	O
database	O
with	O
,	O
respectively	O
,	O
20	O
,	O
55	O
,	O
and	O
30	O
CT	B-T060
images	O
of	O
various	O
lung	B-T023
pathologies	O
acquired	O
with	O
different	O
scanners	O
and	O
protocols	B-T061
.	O
Quantitative	O
assessment	O
of	O
our	O
framework	O
in	O
terms	O
of	O
Dice	O
similarity	O
coefficients	O
,	O
95	O
-	O
percentile	O
bidirectional	O
Hausdorff	O
distances	O
,	O
and	O
percentage	O
volume	O
differences	O
confirms	O
the	O
high	O
accuracy	O
of	O
our	O
model	O
on	O
both	O
our	O
database	O
(	O
98.4±1.0	O
%	O
,	O
2.2±1.0	O
mm	O
,	O
0.42±0.10	O
%	O
)	O
and	O
the	O
VESSEL12	O
database	O
(	O
99.0±0.5	O
%	O
,	O
2.1±1.6	O
mm	O
,	O
0.39±0.20	O
%	O
)	O
,	O
respectively	O
.	O
Similarly	O
,	O
the	O
accuracy	O
of	O
our	O
approach	O
is	O
further	O
verified	O
via	O
a	O
blind	O
evaluation	O
by	O
the	O
organizers	O
of	O
the	O
LOLA11	O
competition	O
,	O
where	O
an	O
average	O
overlap	O
of	O
98.0	O
%	O
with	O
the	O
expert	O
's	O
segmentation	B-T058
is	O
yielded	O
on	O
all	O
55	O
subjects	O
with	O
our	O
framework	O
being	O
ranked	O
first	O
among	O
all	O
the	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
techniques	O
compared	O
.	O
      
HERG1	O
potassium	O
channel	O
expression	O
in	O
potentially	O
malignant	B-T191
disorders	I-T191
of	O
the	O
oral	B-T023
mucosa	I-T023
and	O
prognostic	O
relevance	O
in	O
oral	B-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
HERG1	O
potassium	O
channel	O
plays	O
a	O
critical	O
role	O
in	O
the	O
cell	O
proliferation	O
.	O
HERG1	O
protein	O
expression	O
was	O
analyzed	O
by	O
immunohistochemistry	B-T060
(	O
IHC	B-T060
)	O
in	O
62	O
patients	O
with	O
oral	B-T191
leukoplakias	I-T191
and	O
100	O
patients	O
with	O
oral	B-T191
squamous	I-T191
cell	I-T191
carcinomas	I-T191
(	O
OSCC	B-T191
)	O
.	O
HERG1	O
mRNA	O
levels	O
were	O
assessed	O
by	O
real	O
-	O
time	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
in	O
22	O
patients	O
with	O
primary	O
head	B-T191
and	I-T191
neck	I-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
(	O
HNSCC	B-T191
)	O
.	O
Statistically	O
significant	O
associations	O
were	O
found	O
between	O
HERG1	O
expression	O
and	O
tobacco	O
consumption	O
,	O
disease	B-T060
stage	I-T060
,	O
tumor	B-T191
differentiation	O
,	O
tumor	B-T191
recurrence	I-T191
,	O
and	O
reduced	O
survival	O
.	O
There	O
was	O
no	O
association	O
between	O
HERG1	O
expression	O
and	O
the	O
risk	O
of	O
progression	B-T191
from	O
oral	B-T191
leukoplakia	I-T191
to	O
OSCC	B-T191
.	O
In	O
addition	O
,	O
a	O
high	O
proportion	O
of	O
tumors	B-T191
(	O
80	O
%	O
)	O
showed	O
increased	O
HERG1	O
mRNA	O
levels	O
compared	O
to	O
normal	O
mucosa	O
from	O
nononcologic	O
patients	O
.	O
Aberrant	O
HERG1	O
expression	O
increases	O
as	O
oral	O
tumorigenesis	B-T191
progresses	I-T191
from	O
oral	O
hyperplasia	O
to	O
OSCC	B-T191
.	O
Increased	O
HERG1	O
mRNA	O
levels	O
were	O
also	O
frequently	O
detected	B-T033
in	O
OSCC	B-T191
and	O
other	O
HNSCC	B-T191
subsites	O
.	O
HERG1	O
expression	O
emerges	O
as	O
a	O
clinically	O
relevant	O
feature	O
during	O
tumor	B-T191
progression	I-T191
and	O
a	O
potential	O
poor	O
prognostic	O
biomarker	O
for	O
OSCC	B-T191
.	O
©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc.	O
Head	O
Neck	O
38	O
:	O
1708	O
-	O
1716	O
,	O
2016	O
.	O
      
Spatio	O
-	O
Temporal	O
History	O
of	O
HIV-1	O
CRF35_AD	O
in	O
Afghanistan	O
and	O
Iran	O
HIV-1	B-T005
Circulating	I-T005
Recombinant	I-T005
Form	I-T005
35_AD	I-T005
(	O
CRF35_AD	O
)	O
has	O
an	O
important	O
position	O
in	O
the	O
epidemiological	O
profile	O
of	O
Afghanistan	O
and	O
Iran	O
.	O
Despite	O
the	O
presence	O
of	O
this	O
clade	B-T001
in	O
Afghanistan	O
and	O
Iran	O
for	O
over	O
a	O
decade	O
,	O
our	O
understanding	O
of	O
its	O
origin	O
and	O
dissemination	O
patterns	O
is	O
limited	O
.	O
In	O
this	O
study	O
,	O
we	O
performed	O
a	O
Bayesian	O
phylogeographic	O
analysis	O
to	O
reconstruct	O
the	O
spatio	O
-	O
temporal	O
dispersion	O
pattern	O
of	O
this	O
clade	B-T001
using	O
eligible	O
CRF35_AD	O
gag	O
and	O
pol	O
sequences	O
available	O
in	O
the	O
Los	O
Alamos	O
HIV	O
database	O
(	O
432	O
sequences	O
available	O
from	O
Iran	O
,	O
16	O
sequences	O
available	O
from	O
Afghanistan	O
,	O
and	O
a	O
single	O
CRF35_AD	O
-like	O
pol	O
sequence	O
available	O
from	O
USA	O
)	O
.	O
Bayesian	O
Markov	O
Chain	O
Monte	O
Carlo	O
algorithm	O
was	O
implemented	O
in	O
BEAST	O
v1.8.1	O
.	O
Between	O
-	O
country	O
dispersion	O
rates	O
were	O
tested	O
with	O
Bayesian	O
stochastic	O
search	O
variable	O
selection	O
method	O
and	O
were	O
considered	O
significant	O
where	O
Bayes	O
factor	O
values	O
were	O
greater	O
than	O
three	O
.	O
The	O
findings	O
suggested	O
that	O
CRF35_AD	O
sequences	O
were	O
genetically	O
similar	O
to	O
parental	O
sequences	O
from	O
Kenya	O
and	O
Uganda	O
,	O
and	O
to	O
a	O
set	O
of	O
subtype	O
A1	O
sequences	O
available	O
from	O
Afghan	O
refugees	O
living	O
in	O
Pakistan	O
.	O
Our	O
results	O
also	O
showed	O
that	O
across	O
all	O
phylogenies	O
,	O
Afghan	O
and	O
Iranian	O
CRF35_AD	O
sequences	O
formed	O
a	O
monophyletic	O
cluster	O
(	O
posterior	O
clade	O
credibility	O
>	O
0.7	O
)	O
.	O
The	O
divergence	O
date	O
of	O
this	O
cluster	O
was	O
estimated	O
to	O
be	O
between	O
1990	O
and	O
1992	O
.	O
Within	O
this	O
cluster	O
,	O
a	O
bidirectional	O
dispersion	O
of	O
the	O
virus	B-T005
was	O
observed	O
across	O
Afghanistan	O
and	O
Iran	O
.	O
We	O
could	O
not	O
clearly	O
identify	O
if	O
Afghanistan	O
or	O
Iran	O
first	O
established	O
or	O
received	O
this	O
epidemic	B-T047
,	O
as	O
the	O
root	O
location	O
of	O
this	O
cluster	O
could	O
not	O
be	O
robustly	O
estimated	O
.	O
Three	O
CRF35_AD	O
sequences	O
from	O
Afghan	O
refugees	O
living	O
in	O
Pakistan	O
nested	O
among	O
Afghan	O
and	O
Iranian	O
CRF35_AD	O
branches	O
.	O
However	O
,	O
the	O
CRF35_AD	O
-like	O
sequence	O
available	O
from	O
USA	O
diverged	O
independently	O
from	O
Kenyan	O
subtype	O
A1	O
sequences	O
,	O
suggesting	O
it	O
not	O
to	O
be	O
a	O
true	O
CRF35_AD	O
lineage	O
.	O
Potential	O
factors	O
contributing	O
to	O
viral	B-T005
exchange	O
between	O
Afghanistan	O
and	O
Iran	O
could	O
be	O
injection	O
drug	O
networks	O
and	O
mass	O
migration	O
of	O
Afghan	O
refugees	O
and	O
labours	O
to	O
Iran	O
,	O
which	O
calls	O
for	O
extensive	O
preventive	O
efforts	O
.	O
      
The	O
ErbB3	O
receptor	O
tyrosine	O
kinase	O
negatively	O
regulates	O
Paneth	O
cells	O
by	O
PI3	O
K	O
-	O
dependent	O
suppression	O
of	O
Atoh1	O
Paneth	O
cells	O
(	O
PCs	O
)	O
,	O
a	O
secretory	O
population	O
located	O
at	O
the	O
base	O
of	O
the	O
intestinal	B-T023
crypt	I-T023
,	O
support	O
the	O
intestinal	B-T023
stem	O
cells	O
(	O
ISC	O
)	O
with	O
growth	O
factors	O
and	O
participate	O
in	O
innate	O
immunity	O
by	O
releasing	O
antimicrobial	B-T121
peptides	I-T121
,	O
including	O
lysozyme	B-T121
and	O
defensins	B-T121
.	O
PC	O
dysfunction	O
is	O
associated	O
with	O
disorders	B-T047
such	O
as	O
Crohn	B-T047
's	I-T047
disease	I-T047
and	O
necrotizing	B-T047
enterocolitis	I-T047
,	O
but	O
the	O
specific	O
pathways	O
regulating	O
PC	O
development	O
and	O
function	O
are	O
not	O
fully	O
understood	O
.	O
Here	O
we	O
tested	O
the	O
role	O
of	O
the	O
neuregulin	O
receptor	O
ErbB3	O
in	O
control	O
of	O
PC	O
differentiation	O
and	O
the	O
ISC	O
niche	O
.	O
Intestinal	B-T023
epithelial	O
ErbB3	O
knockout	O
caused	O
precocious	O
appearance	O
of	O
PCs	O
as	O
early	O
as	O
postnatal	O
day	B-T033
7	I-T033
,	O
and	O
substantially	O
increased	O
the	O
number	O
of	O
mature	O
PCs	O
in	O
adult	O
mouse	O
ileum	B-T023
.	O
ErbB3	O
loss	O
had	O
no	O
effect	O
on	O
other	O
secretory	O
lineages	O
,	O
but	O
increased	O
expression	O
of	O
the	O
ISC	O
marker	O
Lgr5	O
.	O
ErbB3	O
-null	O
intestines	B-T023
had	O
elevated	O
levels	O
of	O
the	O
Atoh1	O
transcription	O
factor	O
,	O
which	O
is	O
required	O
for	O
secretory	O
fate	O
determination	O
,	O
while	O
Atoh1(+	O
)	O
cells	O
had	O
reduced	O
ErbB3	O
,	O
suggesting	O
reciprocal	O
negative	B-T033
regulation	O
.	O
ErbB3	O
-null	O
intestinal	O
progenitor	O
cells	O
showed	O
reduced	O
activation	O
of	O
the	O
PI3K	O
-	O
Akt	O
and	O
ERK	O
MAPK	O
pathways	O
.	O
Inhibiting	O
these	O
pathways	O
in	O
HT29	O
cells	O
increased	O
levels	O
of	O
ATOH1	O
and	O
the	O
PC	O
marker	O
LYZ	O
.	O
Conversely	O
,	O
ErbB3	O
activation	O
suppressed	O
LYZ	O
and	O
ATOH1	O
in	O
a	O
PI3	O
K	O
-	O
dependent	O
manner	O
.	O
Expansion	O
of	O
the	O
PC	O
compartment	O
in	O
ErbB3	O
-null	O
intestines	B-T023
was	O
accompanied	O
with	O
elevated	O
ER	O
stress	O
and	O
inflammation	O
markers	O
,	O
raising	O
the	O
possibility	O
that	O
negative	B-T033
regulation	O
of	O
PCs	O
by	O
ErbB3	O
is	O
necessary	O
to	O
maintain	O
homeostasis	O
.	O
Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
ErbB3	O
restricts	O
PC	O
numbers	O
through	O
PI3	O
K	O
-mediated	O
suppression	O
of	O
Atoh1	O
levels	O
leading	O
to	O
inhibition	O
of	O
PC	O
differentiation	O
,	O
with	O
important	O
implications	O
for	O
regulation	O
of	O
the	O
ISC	O
niche	O
.	O
      
On	O
-	O
Site	O
Fertility	B-T061
Preservation	I-T061
Services	I-T061
for	O
Adolescents	O
and	O
Young	O
Adults	O
in	O
a	O
Comprehensive	O
Cancer	O
Center	O
Adolescents	O
and	O
young	O
adults	O
(	O
AYAs	O
)	O
receiving	O
cancer	B-T061
treatments	I-T061
that	O
may	O
impair	O
fertility	O
should	O
receive	O
counseling	B-T058
about	O
risk	B-T033
of	I-T033
infertility	I-T033
and	O
options	O
for	O
fertility	B-T061
preservation	I-T061
(	O
FP	B-T061
)	O
before	O
treatment	B-T061
and/or	O
during	O
survivorship	O
.	O
Our	O
objective	O
was	O
to	O
define	O
the	O
AYA	O
patient	O
population	O
referred	O
to	O
an	O
on	B-T058
-	I-T058
site	I-T058
fertility	I-T058
consultation	I-T058
service	I-T058
within	O
a	O
comprehensive	O
cancer	O
center	O
and	O
determine	O
factors	O
associated	O
with	O
patients	O
proceeding	O
with	O
FP	B-T061
treatment	I-T061
.	O
We	O
conducted	O
a	O
retrospective	O
chart	O
review	O
of	O
AYA	O
women	O
who	O
completed	O
a	O
consultation	B-T058
at	O
the	O
MD	B-T058
Anderson	I-T058
Fertility	I-T058
Preservation	I-T058
and	I-T058
Family	I-T058
Building	I-T058
Service	I-T058
during	O
the	O
first	O
year	O
of	O
service	O
.	O
Records	O
of	O
154	O
referred	O
AYA	O
patients	O
were	O
reviewed	O
for	O
age	O
,	O
ethnicity	O
,	O
cancer	B-T033
type	I-T033
gravidity	B-T033
and	O
parity	B-T033
,	O
survivorship	O
status	O
,	O
and	O
decision	O
to	O
pursue	O
FP	B-T061
treatment	I-T061
.	O
Patients	O
(	O
mean	O
age	O
29.7	O
)	O
were	O
Caucasian	O
(	O
55	O
%	O
)	O
,	O
Hispanic	O
(	O
23	O
%	O
)	O
,	O
and	O
African	O
American	O
(	O
10	O
%	O
)	O
.	O
The	O
majority	O
of	O
women	O
(	O
67	O
%	O
)	O
were	O
seen	O
for	O
FP	B-T061
before	O
cancer	B-T061
treatment	I-T061
and	O
the	O
remaining	O
sought	O
options	O
for	O
family	B-T058
building	I-T058
while	O
in	O
survivorship	O
.	O
The	O
most	O
common	O
cancer	B-T033
types	I-T033
were	O
hematologic	B-T191
(	O
29	O
%	O
)	O
,	O
breast	B-T191
(	O
25	O
%	O
)	O
,	O
and	O
gynecologic	B-T191
(	O
23	O
%	O
)	O
.	O
Patients	O
referred	O
to	O
an	O
on	B-T058
-	I-T058
site	I-T058
fertility	I-T058
consultation	I-T058
service	I-T058
were	O
medically	O
and	O
ethnically	O
diverse	O
.	O
Interest	O
in	O
fertility	O
counseling	O
and	O
treatment	B-T061
was	O
apparent	O
in	O
both	O
survivorship	O
pre-	B-T061
and	I-T061
postcancer	I-T061
treatment	I-T061
.	O
Although	O
the	O
referral	B-T058
group	O
was	O
ethnically	O
diverse	O
,	O
Caucasian	O
women	O
were	O
most	O
likely	O
to	O
pursue	O
FP	B-T061
treatment	I-T061
compared	O
to	O
women	O
of	O
other	O
ethnicities	O
.	O
      
Comparison	O
of	O
electrospun	O
and	O
solvent	O
cast	O
polylactic	O
acid	O
(	O
PLA)/	O
poly(vinyl	O
alcohol	O
)	O
(	O
PVA	O
)	O
inserts	O
as	O
potential	O
ocular	B-T023
drug	O
delivery	O
vehicles	O
The	O
purpose	O
of	O
this	O
work	O
was	O
to	O
develop	O
,	O
characterize	O
and	O
compare	O
electrospun	O
nanofiber	O
inserts	O
(	O
ENIs	O
)	O
and	O
solvent	O
cast	O
polymeric	O
inserts	O
(	O
SCIs	O
)	O
for	O
ocular	B-T023
drug	O
delivery	O
.	O
ENI	O
and	O
SCI	O
of	O
1	O
%	O
,	O
5	O
%	O
and	O
10	O
%	O
w	O
/	O
w	O
dexamethasone	B-T121
were	O
fabricated	O
using	O
a	O
blend	O
of	O
poly	O
-	O
lactic	O
acid	O
(	O
PLA	O
)	O
and	O
poly	O
-	O
vinyl	O
alcohol	O
(	O
PVA	O
)	O
.	O
Inserts	O
were	O
characterized	O
for	O
morphology	O
,	O
thickness	O
,	O
pH	O
,	O
drug	O
content	O
,	O
drug	O
crystallinity	O
,	O
in	O
vitro	O
drug	O
release	O
,	O
sterility	O
,	O
dimethylformamide	O
(	O
DMF	O
)	O
and	O
chloroform	O
content	O
,	O
and	O
cytotoxicity	O
.	O
The	O
thickness	O
of	O
1	O
%	O
,	O
5	O
%	O
,	O
and	O
10	O
%	O
dexamethasone	B-T121
-loaded	O
ENIs	O
were	O
found	O
to	O
be	O
50μm	O
,	O
62.5μm	O
,	O
and	O
93.3μm	O
,	O
respectively	O
,	O
with	O
good	O
folding	B-T033
endurance	I-T033
.	O
SCIs	O
were	O
brittle	B-T033
,	O
with	O
thickness	O
values	O
>	O
200μm	O
.	O
Drug	O
release	O
rates	O
from	O
1	O
%	O
,	O
5	O
%	O
and	O
10	O
%	O
ENIs	O
were	O
found	O
to	O
be	O
0.62μg	O
/	O
h	O
,	O
1.46μg	O
/	O
h	O
,	O
and	O
2.30μg	O
/	O
h	O
,	O
respectively	O
,	O
while	O
those	O
from	O
SCIs	O
were	O
erratic	O
.	O
DMF	O
content	O
in	O
ENIs	O
and	O
SCIs	O
were	O
0.007	O
%	O
w	O
/	O
w	O
and	O
0.123	O
%	O
w	O
/	O
w	O
,	O
respectively	O
,	O
while	O
chloroform	O
was	O
not	B-T033
detected	I-T033
.	O
No	B-T033
cytotoxicity	O
was	O
observed	O
from	O
ENIs	O
in	O
cultured	O
bovine	O
corneal	O
endothelial	O
cells	O
for	O
up	O
to	O
24h	O
.	O
We	O
conclude	O
that	O
ENIs	O
are	O
better	O
than	O
SCIs	O
and	O
could	O
be	O
utilized	O
as	O
a	O
potential	O
delivery	O
system	O
for	O
treating	O
anterior	O
segment	O
ocular	B-T047
diseases	I-T047
.	O
      
Repetitive	B-T061
transcranial	I-T061
magnetic	I-T061
stimulation	I-T061
improves	O
cognitive	O
function	O
of	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
patients	O
Repetitive	B-T061
transcranial	I-T061
magnetic	I-T061
stimulation	I-T061
(	O
rTMS	B-T061
)	O
acts	O
as	O
a	O
kind	O
of	O
widely	O
-	O
applied	O
and	O
non	O
-	O
invasive	O
method	O
in	O
the	O
intervention	B-T061
of	O
some	O
neurological	B-T047
disorders	I-T047
.	O
This	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
investigates	O
the	O
effect	O
of	O
rTMS	B-T061
on	O
30	O
cases	O
of	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
(	O
AD	B-T047
)	O
participants	O
,	O
who	O
were	O
classified	O
into	O
mild	O
and	O
moderate	O
groups	O
.	O
Neuropsychological	B-T060
tests	I-T060
were	O
carried	O
out	O
using	O
the	O
AD	O
Assessment	O
Scale	O
-	O
cognitive	O
subscale	O
(	O
ADAS	O
-	O
cog	O
)	O
,	O
Mini	B-T060
-	I-T060
Mental	I-T060
State	I-T060
Examination	I-T060
(	O
MMSE	B-T060
)	O
,	O
Montreal	O
Cognitive	O
Assessment	O
(	O
MoCA	O
)	O
,	O
and	O
World	O
Health	O
Organization	O
University	O
of	O
California	O
-	O
Los	O
Angeles	O
,	O
Auditory	O
Verbal	O
Learning	O
Test	O
(	O
WHO	O
-	O
UCLA	O
AVLT	O
)	O
before	O
,	O
immediately	O
after	O
,	O
and	O
6	O
weeks	O
after	O
the	O
intervention	B-T061
.	O
In	O
this	O
work	O
,	O
data	O
from	O
30	O
AD	B-T047
patients	O
revealed	O
that	O
there	O
was	O
no	O
obvious	O
interaction	O
effect	O
of	O
time	O
-	O
by	O
-	O
group	O
.	O
The	O
ADAS	O
-	O
cog	O
,	O
MMSE	B-T060
and	O
WHO	O
-	O
UCLA	O
AVLT	O
score	O
in	O
the	O
rTMS	B-T061
group	O
was	O
significantly	O
improved	O
compared	O
with	O
baselines	O
at	O
6	O
weeks	O
after	O
treatment	B-T061
(	O
all	O
p<0.05	O
)	O
.	O
Meanwhile	O
,	O
MoCA	O
scores	O
were	O
also	O
obviously	O
ameliorated	B-T033
in	O
the	O
mild	O
AD	B-T047
patients	O
with	O
rTMS	B-T061
.	O
Besides	O
,	O
subgroup	O
analysis	O
showed	O
that	O
the	O
effect	O
of	O
rTMS	B-T061
on	O
the	O
memory	O
and	O
language	O
of	O
mild	O
AD	B-T047
patients	O
was	O
superior	O
to	O
those	O
of	O
moderate	O
AD	B-T047
patients	O
.	O
In	O
conclusion	O
,	O
our	O
findings	B-T033
suggested	O
that	O
repetitive	B-T061
transcranial	I-T061
magnetic	I-T061
stimulation	I-T061
improves	O
cognitive	O
function	O
,	O
memory	O
and	O
language	O
level	O
of	O
AD	B-T047
patients	O
,	O
especially	O
in	O
the	O
mild	O
stage	O
of	O
AD	B-T047
.	O
Thus	O
,	O
rTMS	B-T061
can	O
be	O
recommended	O
as	O
a	O
promising	O
adjuvant	B-T061
therapy	I-T061
combined	O
with	O
cholinesterase	B-T121
inhibitors	I-T121
at	O
the	O
mild	O
stage	O
of	O
AD	B-T047
patients	O
.	O
      
Emergency	B-T061
general	I-T061
surgery	I-T061
specific	O
frailty	O
index	O
:	O
A	O
validation	O
study	O
Assessment	B-T058
of	O
operative	O
risk	O
in	O
geriatric	O
patients	O
undergoing	O
emergency	B-T061
general	I-T061
surgery	I-T061
(	O
EGS	B-T061
)	O
is	O
challenging	O
.	O
Frailty	B-T033
is	O
an	O
established	O
measure	O
for	O
risk	B-T058
assessment	I-T058
in	O
surgical	O
cases	O
.	O
The	O
aim	O
of	O
our	O
study	O
was	O
to	O
validate	O
a	O
modified	O
15	O
variable	O
emergency	B-T058
general	I-T058
surgery	I-T058
specific	I-T058
frailty	I-T058
index	I-T058
(	O
EGSFI	B-T058
)	O
.	O
We	O
prospectively	O
collected	O
geriatric	O
(	O
age	O
>	O
65	O
)	O
emergency	B-T061
general	I-T061
surgery	I-T061
patients	O
for	O
1-	O
year	O
.	O
Post	O
-	O
operative	O
complications	O
were	O
collected	O
.	O
Frailty	O
Index	O
was	O
calculated	B-T059
for	O
200	O
patients	O
based	O
on	O
their	O
pre	O
-	O
admission	O
condition	O
using	O
50-	O
variable	O
modified	O
Rockwood	O
Frailty	O
Index	O
(	O
FI	O
)	O
.	O
EGSFI	B-T058
was	O
developed	O
based	O
on	O
the	O
regression	O
model	O
for	O
complications	O
and	O
the	O
most	O
significant	O
factors	O
in	O
the	O
FI	O
.	O
ROC	O
curve	O
analysis	O
was	O
performed	O
to	O
determine	O
cutoff	O
for	O
frail	B-T033
status	O
.	O
We	O
validated	O
our	O
results	O
using	O
60	O
patients	O
for	O
predicting	O
complications	O
.	O
A	O
total	O
of	O
260	O
patients	O
(	O
200	O
developing	O
,	O
60	O
Validation	O
)	O
were	O
enrolled	B-T058
in	O
this	O
study	O
.	O
Mean	O
age	O
was	O
71	O
±	O
11	O
years	O
,	O
and	O
33	O
%	O
developed	O
complications	O
.	O
Most	O
common	O
complications	O
were	O
pneumonia	B-T047
(	O
12	O
%	O
)	O
,	O
UTI	B-T047
(	O
9	O
%	O
)	O
,	O
and	O
wound	O
infection	O
(	O
7	O
%	O
)	O
.	O
Univariate	O
analysis	O
identified	O
15	O
variables	O
significantly	O
associated	O
with	O
complications	O
that	O
were	O
used	O
to	O
develop	O
the	O
EGSFI	B-T058
.	O
A	O
cutoff	O
frailty	B-T033
score	I-T033
of	O
0.325	O
was	O
identified	O
using	O
ROC	O
curve	O
analysis	O
for	O
frail	B-T033
status	O
.Sixty-	O
patients	O
(	O
frail	B-T033
:	O
18	O
,	O
non	B-T033
-	I-T033
frail	I-T033
:	O
42	O
)	O
were	O
enrolled	B-T058
in	O
the	O
validation	O
cohort	O
.	O
Frail	B-T033
patients	O
were	O
more	O
likely	O
to	O
have	O
post	O
-	O
operative	O
complications	O
(	O
47	O
%	O
vs.	O
20	O
%	O
,	O
p	O
<	O
0.001	O
)	O
compared	O
to	O
nonfrail	O
patients	O
.	O
Frail	B-T033
status	O
based	O
on	O
EGSFI	B-T058
was	O
a	O
significant	O
predictor	O
of	O
post	O
-	O
operative	O
complications	O
(	O
OR	O
=	O
7.3	O
,	O
95	O
%	O
CI	O
=	O
1.7	O
-	O
19.8	O
;	O
p=0.006	O
)	O
.	O
Age	O
was	O
not	O
associated	O
with	O
postoperative	O
complications	O
(	O
OR	O
=	O
0.99	O
,	O
95	O
%	O
CI	O
=	O
0.92	O
-1.06	O
;	O
p=0.86	O
)	O
.	O
The	O
15-	O
variable	O
validated	O
EGSFI	B-T058
is	O
a	O
simple	O
and	O
reliable	O
bedside	O
tool	O
to	O
determine	O
the	O
frailty	B-T033
status	I-T033
of	O
patients	O
undergoing	O
emergency	B-T061
general	I-T061
surgery	I-T061
.	O
Frail	B-T033
status	O
as	O
determined	O
by	O
Abstract	O
the	O
EGSFI	B-T058
is	O
an	O
independent	O
predictor	O
of	O
post	O
-	O
operative	O
complications	O
and	O
mortality	O
in	O
geriatric	O
emergency	B-T061
general	I-T061
surgery	I-T061
patients	O
.	O
Level	O
II	O
,	O
Prognostic	O
Studies	O
-	O
Investigating	O
the	O
Effect	O
of	O
a	O
Patient	O
Characteristic	O
on	O
the	O
Outcome	B-T033
of	I-T033
Disease	I-T033
.	O
      
Basic	O
science	O
and	O
pathogenesis	O
of	O
ageing	O
with	O
HIV	B-T047
:	O
potential	O
mechanisms	O
and	O
biomarkers	O
:	O
The	O
increased	O
prevalence	O
of	O
age	O
-related	O
comorbidities	O
and	O
mortality	O
is	O
worrisome	B-T033
in	O
ageing	O
HIV	B-T047
-	I-T047
infected	I-T047
patients	O
.	O
Here	O
,	O
we	O
aim	O
to	O
analyse	O
the	O
different	O
ageing	O
mechanisms	O
with	O
regard	O
to	O
HIV	B-T047
infection	I-T047
.	O
Ageing	O
results	O
from	O
the	O
time	O
-	O
dependent	O
accumulation	B-T033
of	O
random	O
cellular	O
damage	O
.	O
Epigenetic	O
modifications	O
and	O
mitochondrial	O
DNA	O
haplogroups	O
modulate	O
ageing	O
.	O
In	O
antiretroviral	B-T061
treatment	I-T061
-controlled	O
patients	O
,	O
epigenetic	O
clock	O
appears	O
to	O
be	O
advanced	O
,	O
and	O
some	O
haplogroups	O
are	O
associated	O
with	O
HIV	B-T047
infection	I-T047
severity	O
.	O
Telomere	O
shortening	O
is	O
enhanced	O
in	O
HIV	B-T047
-	I-T047
infected	I-T047
patients	O
because	O
of	O
HIV	B-T005
and	O
some	O
nucleoside	B-T121
analogue	I-T121
reverse	B-T121
transcriptase	I-T121
inhibitors	I-T121
.	O
Mitochondria	O
-related	O
oxidative	O
stress	O
and	O
mitochondrial	O
DNA	O
mutations	O
are	O
increased	O
during	O
ageing	O
and	O
also	O
by	O
some	O
nucleoside	B-T121
analogue	I-T121
reverse	B-T121
transcriptase	I-T121
inhibitors	I-T121
.	O
Overall	O
,	O
increased	O
inflammation	O
or	O
'	O
inflammageing	O
'	O
is	O
a	O
major	O
driver	O
of	O
ageing	O
and	O
could	O
result	O
from	O
cell	O
senescence	O
with	O
secreted	O
proinflammatory	B-T121
mediators	I-T121
,	O
altered	O
gut	B-T001
microbiota	I-T001
,	O
and	O
coinfections	B-T047
.	O
In	O
HIV	B-T047
-	I-T047
infected	I-T047
patients	O
,	O
the	O
level	O
of	O
inflammation	O
and	O
innate	O
immunity	O
activation	O
is	O
enhanced	O
and	O
related	O
to	O
most	O
comorbidities	O
and	O
to	O
mortality	O
.	O
This	O
status	O
could	O
result	O
,	O
in	O
addition	O
to	O
age	O
,	O
from	O
the	O
virus	B-T005
itself	O
or	O
viral	O
protein	O
released	O
from	O
reservoirs	O
,	O
from	O
HIV	B-T005
-enhanced	O
gut	B-T023
permeability	O
and	O
dysbiosis	O
,	O
from	O
antiretroviral	B-T061
treatment	I-T061
,	O
from	O
frequent	O
cytomegalovirus	B-T005
and	O
hepatitis	B-T005
C	I-T005
virus	I-T005
coinfections	B-T047
,	O
and	O
also	O
from	O
personal	O
and	O
environmental	O
factors	O
,	O
as	O
central	O
fat	B-T033
accumulation	I-T033
or	O
smoking	O
.	O
Adaptive	O
immune	O
activation	O
and	O
immunosenescence	O
are	O
associated	O
with	O
comorbidities	O
and	O
mortality	O
in	O
the	O
general	O
population	O
but	O
are	O
less	O
predictive	O
in	O
HIV	B-T047
-	I-T047
infected	I-T047
patients	O
.	O
Biomarkers	O
to	O
evaluate	B-T058
ageing	O
in	O
HIV	B-T047
-	I-T047
infected	I-T047
patients	O
are	O
required	O
.	O
Numerous	O
systemic	O
or	O
cellular	O
inflammatory	O
,	O
immune	O
activation	O
,	O
oxidative	O
stress	O
,	O
or	O
senescence	O
markers	O
can	O
be	O
tested	O
in	O
serum	O
or	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
The	O
novel	O
European	O
Study	O
to	O
Establish	O
Biomarkers	O
of	O
Human	O
Ageing	O
MARK	O
-	O
AGE	O
algorithm	O
,	O
evaluating	B-T058
the	O
biological	O
age	O
,	O
is	O
currently	O
assessed	O
in	O
HIV	B-T047
-	I-T047
infected	I-T047
patients	O
and	O
reveals	O
an	O
advanced	O
biological	O
age	O
.	O
Some	O
enhanced	O
inflammatory	O
or	O
innate	O
immune	O
activation	O
markers	O
are	O
interesting	O
but	O
still	O
not	O
validated	O
for	O
the	O
patient	O
's	O
follow	B-T058
-	I-T058
up	I-T058
.	O
To	O
be	O
able	O
to	O
assess	O
patients	O
'	O
biological	O
age	O
is	O
an	O
important	O
objective	O
to	O
improve	O
their	O
healthspan	O
.	O
      
Extended	O
release	O
of	O
flurbiprofen	B-T121
from	O
tromethamine	B-T121
-	O
buffered	B-T121
HPMC	B-T121
hydrophilic	O
matrix	O
tablets	O
The	O
pH	O
-	O
dependent	O
solubility	O
of	O
a	O
drug	B-T121
can	O
lead	O
to	O
pH	O
-	O
dependent	O
drug	O
release	O
from	O
hydrophilic	O
matrix	O
tablets	O
.	O
Adding	O
buffer	B-T121
salts	I-T121
to	O
the	O
formulation	O
to	O
attempt	O
to	O
mitigate	O
this	O
can	O
impair	O
matrix	O
hydration	O
and	O
negatively	B-T033
impact	O
drug	O
release	O
.	O
An	O
evaluation	B-T058
of	O
the	O
buffering	B-T121
of	O
hydrophilic	O
matrix	O
tablets	O
containing	O
a	O
pH	O
-	O
dependent	O
solubility	O
weak	B-T121
acid	I-T121
drug	I-T121
(	O
flurbiprofen	B-T121
)	O
,	O
identified	O
as	O
possessing	O
a	O
deleterious	O
effect	O
on	O
hydroxypropyl	B-T121
methylcellulose	I-T121
(	O
HPMC	B-T121
)	O
solubility	O
,	O
swelling	O
and	O
gelation	O
,	O
with	O
respect	O
to	O
drug	O
dissolution	O
and	O
the	O
characteristics	O
of	O
the	O
hydrophilic	O
matrix	O
gel	O
layer	O
in	O
the	O
presence	O
of	O
tromethamine	B-T121
as	O
a	O
buffer	B-T121
was	O
undertaken	O
.	O
The	O
inclusion	O
of	O
tromethamine	B-T121
as	O
an	O
alkalizing	B-T121
agent	I-T121
afforded	O
pH	O
-	O
independent	O
flurbiprofen	B-T121
release	O
from	O
matrices	O
based	O
on	O
both	O
HPMC	B-T121
2910	I-T121
(	I-T121
E	I-T121
series	I-T121
)	I-T121
and	O
2208	B-T121
(	I-T121
K	I-T121
series	I-T121
)	I-T121
,	O
while	O
concomitantly	O
decreasing	B-T033
the	O
apparent	O
critical	O
effect	O
on	O
dissolution	O
mediated	O
by	O
this	O
drug	B-T121
with	O
respect	O
to	O
the	O
early	O
pseudo	O
-	O
gel	O
layer	O
formation	O
and	O
functionality	O
.	O
Drug	O
release	O
profiles	O
were	O
unaffected	O
by	O
matrix	O
pH	B-T033
-	I-T033
changes	I-T033
resulting	O
from	O
loss	O
of	O
tromethamine	B-T121
over	O
time	O
,	O
suggesting	O
that	O
HPMC	B-T121
inhibited	O
precipitation	O
of	O
drug	B-T121
from	O
supersaturated	O
solution	O
in	O
the	O
hydrated	O
matrix	O
.	O
We	O
propose	O
that	O
facilitation	O
of	O
diffusion	O
-	O
based	O
release	O
of	O
potentially	O
deleterious	B-T121
drugs	I-T121
in	O
hydrophilic	O
matrices	O
may	O
be	O
achieved	O
through	O
judicious	O
selection	O
of	O
a	O
buffering	B-T121
species	I-T121
.	O
      
Custom	O
ocular	O
prosthesis	O
in	O
rehabilitation	B-T061
of	O
a	O
child	O
operated	O
for	O
retinoblastoma	B-T191
A	O
maxillofacial	B-T061
prosthodontist	I-T061
forms	O
an	O
important	O
link	O
in	O
the	O
interdisciplinary	O
management	B-T058
of	I-T058
a	I-T058
patient	I-T058
with	O
anopthalmosis	B-T019
.	O
Prosthetic	B-T061
management	I-T061
of	O
an	O
anopthalmic	B-T019
defect	I-T019
aims	O
to	O
deliver	O
a	O
well	O
-	O
fitting	O
ocular	O
prosthesis	O
that	O
can	O
mimic	O
the	O
original	O
eye	B-T023
as	O
closely	O
as	O
possible	O
,	O
and	O
thus	O
restoring	O
the	O
patient	O
's	O
self	O
-	O
confidence	O
and	O
thereby	O
rehabilitating	O
them	O
in	O
the	O
society	O
.	O
The	O
fabrication	B-T061
of	O
a	O
custom	O
ocular	O
prosthesis	O
is	O
a	O
demanding	O
art	O
.	O
This	O
case	O
report	O
presents	O
a	O
simplified	O
technique	O
for	O
the	O
fabrication	B-T061
of	O
a	O
custom	O
ocular	O
prosthesis	O
for	O
a	O
child	O
who	O
had	O
lost	O
his	O
eye	B-T023
to	O
enucleation	B-T061
following	O
retinoblastoma	B-T191
.	O
Early	O
and	O
effective	O
rehabilitation	B-T061
of	O
the	O
defect	O
goes	O
a	O
long	O
way	O
in	O
restoring	O
the	O
self	B-T058
-	I-T058
image	I-T058
of	O
a	O
child	O
in	O
its	O
early	O
character	O
building	O
age	O
.	O
      
Defining	O
categories	O
of	O
actionability	O
for	O
secondary	O
findings	B-T033
in	O
next	B-T059
-	I-T059
generation	I-T059
sequencing	I-T059
Next	B-T059
-	I-T059
generation	I-T059
sequencing	I-T059
is	O
increasingly	O
used	O
in	O
clinical	O
practice	O
for	O
the	O
diagnosis	B-T033
of	O
Mendelian	B-T047
diseases	I-T047
.	O
Because	O
of	O
the	O
high	O
likelihood	O
of	O
secondary	O
findings	B-T033
associated	O
with	O
this	O
technique	O
,	O
the	O
process	O
of	O
informing	B-T058
patients	I-T058
is	O
beset	O
with	O
new	O
challenges	O
.	O
One	O
of	O
them	O
is	O
regarding	O
the	O
type	O
of	O
secondary	O
findings	B-T033
that	O
ought	O
to	O
be	O
disclosed	O
to	O
patients	O
.	O
The	O
aim	O
of	O
this	O
research	O
is	O
to	O
propose	O
a	O
practical	O
implementation	O
of	O
the	O
notion	O
of	O
actionability	O
,	O
a	O
common	O
criteria	O
justifying	O
the	O
disclosure	O
of	O
secondary	O
findings	B-T033
but	O
whose	O
interpretation	O
varies	O
greatly	O
among	O
professionals	O
.	O
We	O
distinguish	O
three	O
types	O
of	O
actionability	O
corresponding	O
to	O
(	O
1	O
)	O
well	O
-	O
established	O
medical	O
actions	O
,	O
(	O
2	O
)	O
patient	O
-initiated	O
health	O
-	O
related	O
actions	O
and	O
(	O
3	O
)	O
life	O
-	O
plan	O
decisions	O
.	O
We	O
argue	O
that	O
actionability	O
depends	O
on	O
the	O
characteristics	O
of	O
the	O
mutation	O
or	O
gene	O
and	O
on	O
the	O
values	O
of	O
patients	O
.	O
In	O
discussing	O
the	O
return	O
of	O
secondary	O
findings	B-T033
,	O
it	O
is	O
important	O
that	O
the	O
physician	O
tries	O
to	O
get	O
an	O
impression	O
of	O
the	O
specific	O
situation	O
and	O
values	O
of	O
patients	O
.	O
Regarding	O
variants	O
of	O
uncertain	O
clinical	B-T033
significance	I-T033
in	O
actionable	O
genes	O
,	O
we	O
found	O
that	O
different	O
understandings	O
of	O
autonomy	O
lead	O
to	O
different	O
conclusions	O
and	O
that	O
,	O
for	O
some	O
of	O
them	O
,	O
it	O
may	O
be	O
legitimate	O
to	O
refrain	O
from	O
returning	O
uncertain	O
information	O
.	O
      
Mapping	O
circulating	O
serum	O
miRNAs	O
to	O
their	O
immune	O
-	O
related	O
target	O
mRNAs	O
Evidence	O
suggests	O
that	O
circulating	O
serum	O
microRNAs	O
(	O
miRNAs	O
)	O
might	O
preferentially	O
target	O
immune	O
-	O
related	O
mRNAs	O
.	O
If	O
this	O
were	O
the	O
case	O
,	O
we	O
hypothesized	O
that	O
immune	O
-	O
related	O
mRNAs	O
would	O
have	O
more	O
predicted	O
serum	O
miRNA	O
binding	O
sites	O
than	O
other	O
mRNAs	O
and	O
,	O
reciprocally	O
,	O
that	O
serum	O
miRNAs	O
would	O
have	O
more	O
immune	O
-	O
related	O
mRNA	O
targets	O
than	O
non	O
-	O
serum	O
miRNAs	O
.	O
We	O
developed	O
a	O
consensus	O
target	O
predictor	O
using	O
the	O
random	O
forest	O
framework	O
and	O
calculated	O
the	O
number	O
of	O
predicted	O
miRNA	O
-	O
mRNA	O
interactions	O
in	O
various	O
subsets	O
of	O
miRNAs	O
(	O
serum	O
,	O
non	O
-	O
serum	O
)	O
and	O
mRNAs	O
(	O
immune	O
related	O
,	O
nonimmune	O
related	O
)	O
.	O
Immune	O
-	O
related	O
mRNAs	O
were	O
predicted	O
to	O
be	O
targeted	O
by	O
serum	O
miRNA	O
more	O
than	O
other	O
mRNAs	O
.	O
Moreover	O
,	O
serum	O
miRNAs	O
were	O
predicted	O
to	O
target	O
many	O
more	O
immune	O
-	O
related	O
mRNA	O
targets	O
than	O
non	O
-	O
serum	O
miRNAs	O
;	O
however	O
,	O
these	O
two	O
biases	O
in	O
immune	O
-	O
related	O
mRNAs	O
and	O
serum	O
miRNAs	O
appear	O
to	O
be	O
completely	O
independent	O
.	O
Immune	O
-	O
related	O
mRNAs	O
have	O
more	O
miRNA	O
binding	O
sites	O
in	O
general	O
,	O
not	O
just	O
for	O
serum	O
miRNAs	O
;	O
likewise	O
,	O
serum	O
miRNAs	O
target	O
many	O
more	O
mRNAs	O
than	O
non	O
-	O
serum	O
miRNAs	O
overall	O
,	O
regardless	O
of	O
whether	O
they	O
are	O
immune	O
related	O
or	O
not	O
.	O
Nevertheless	O
,	O
these	O
two	O
independent	O
phenomena	O
result	O
in	O
a	O
significantly	O
larger	O
number	O
of	O
predicted	O
serum	O
miRNA	O
-	O
immune	O
mRNA	O
interactions	O
than	O
would	O
be	O
expected	O
by	O
chance	O
.	O
      
Outcomes	O
of	O
chest	B-T061
wall	I-T061
resections	I-T061
in	O
pediatric	O
sarcoma	B-T191
patients	O
Chest	B-T191
wall	I-T191
tumors	I-T191
in	O
pediatric	O
patients	O
are	O
rare	O
.	O
This	O
study	O
evaluates	O
outcomes	O
in	O
pediatric	O
patients	O
who	O
have	O
undergone	O
chest	B-T061
wall	I-T061
resections	I-T061
secondary	O
to	O
sarcomas	B-T191
.	O
A	O
retrospective	O
review	O
was	O
performed	O
for	O
patients	O
<	O
19years	O
old	O
who	O
underwent	O
chest	B-T061
wall	I-T061
resections	I-T061
for	O
sarcoma	B-T191
1999	O
-	O
2014	O
at	O
the	O
University	O
of	O
Texas	O
MD	O
Anderson	O
Cancer	O
Center	O
.	O
Of	O
44	O
patients	O
,	O
Ewing	B-T191
's	I-T191
sarcoma	I-T191
(	O
n=18	O
)	O
and	O
osteosarcoma	B-T191
(	O
n=16	O
)	O
were	O
most	O
common	O
.	O
Other	O
sarcomas	B-T191
included	O
synovial	B-T191
sarcoma	I-T191
,	O
chondrosarcoma	B-T191
,	O
and	O
rhabdomyosarcoma	B-T191
.	O
Gore	O
-	O
Tex	O
®	O
or	O
a	O
Marlex	O
™	O
mesh	O
and	O
methyl	O
methacrylate	O
sandwich	O
was	O
used	O
in	O
22	O
patients	O
,	O
and	O
9	O
children	O
did	O
not	B-T033
require	I-T033
reconstruction	I-T033
.	O
Twenty	O
-	O
four	O
(	O
54.5	O
%	O
)	O
patients	O
had	O
normal	O
activity	O
,	O
3	O
(	O
6.8	O
%	O
)	O
had	O
occasional	B-T184
discomfort	I-T184
,	O
2	O
(	O
4.5	O
%	O
)	O
had	O
pain	O
impairing	O
function	O
,	O
7	O
(	O
15.9	O
%	O
)	O
required	O
medication	B-T121
or	O
physical	B-T061
therapy	I-T061
for	O
impairment	O
,	O
and	O
8	O
(	O
18.2	O
%	O
)	O
needed	O
additional	O
surgery	O
.	O
Five	O
children	O
(	O
11.4	O
%	O
)	O
developed	O
scoliosis	B-T190
,	O
and	O
all	O
of	O
these	O
patients	O
had	O
posterior	O
rib	B-T191
tumors	I-T191
.	O
Median	O
overall	O
survival	O
for	O
the	O
entire	O
cohort	O
was	O
41.9±11.82	O
months	O
.	O
Histology	O
(	O
p=0.003	O
)	O
,	O
location	O
of	O
tumor	B-T191
on	O
the	O
ribs	B-T023
(	O
p=0.007	O
)	O
,	O
and	O
surgical	B-T023
margins	I-T023
(	O
p=0.011	O
)	O
were	O
significantly	O
associated	O
with	O
overall	O
survival	O
.	O
Tumors	B-T191
on	O
the	O
middle	O
and	O
posterior	O
(	O
p=0.003	O
)	O
portions	O
of	O
the	O
ribs	B-T023
had	O
a	O
lower	O
chance	O
of	O
death	O
.	O
Scoliosis	B-T190
is	O
more	O
common	O
in	O
posterior	O
rib	B-T061
resections	I-T061
.	O
Histology	O
,	O
location	O
of	O
the	O
tumor	B-T191
,	O
and	O
surgical	B-T023
margins	I-T023
impact	O
survival	O
,	O
but	O
,	O
type	O
of	O
reconstruction	O
does	O
not	O
.	O
III	O
.	O
Treatment	O
Study	O
.	O
      
Nationwide	O
reduction	O
in	O
the	O
number	O
of	O
corneal	B-T061
transplantations	I-T061
for	O
keratoconus	B-T047
following	O
the	O
implementation	O
of	O
cross	B-T061
-	I-T061
linking	I-T061
Keratoconus	B-T047
is	O
characterized	O
by	O
corneal	B-T047
ectasia	I-T047
and	O
irregular	B-T047
astigmatism	I-T047
,	O
which	O
can	O
lead	O
to	O
diminished	B-T047
vision	I-T047
and	O
corneal	B-T033
scarring	I-T033
.	O
Approximately	O
10	O
-	O
20	O
%	O
of	O
patients	O
with	O
keratoconus	B-T047
eventually	O
require	O
a	O
corneal	B-T061
transplant	I-T061
.	O
Corneal	B-T061
cross	I-T061
-	I-T061
linking	I-T061
(	O
CXL	B-T061
)	O
is	O
a	O
relatively	O
new	O
treatment	B-T061
that	O
may	O
help	O
prevent	O
the	O
need	O
for	O
corneal	B-T061
transplantation	I-T061
.	O
Here	O
,	O
we	O
investigated	O
whether	O
the	O
introduction	O
of	O
CXL	B-T061
has	O
reduced	O
the	O
number	O
of	O
corneal	B-T061
transplants	I-T061
performed	O
annually	O
.	O
Data	O
regarding	O
the	O
transplantation	B-T061
procedures	I-T061
performed	O
in	O
patients	O
under	O
the	O
age	O
of	O
50	O
years	O
were	O
extracted	O
from	O
the	O
Dutch	O
National	O
Organ	O
Transplant	O
Registry	O
.	O
The	O
number	O
of	O
corneal	B-T061
transplants	I-T061
performed	O
prior	O
to	O
(	O
i.e.	O
in	O
2005	O
through	O
2007	O
)	O
and	O
following	O
the	O
introduction	O
of	O
CXL	B-T061
(	O
i.e.	O
in	O
2012	O
through	O
2014	O
)	O
were	O
compared	O
.	O
Furthermore	O
,	O
a	O
trend	O
analysis	O
on	O
annual	O
keratoplasties	B-T061
over	O
time	O
was	O
performed	O
.	O
Approximately	O
25	O
%	O
fewer	O
corneal	B-T061
transplants	I-T061
were	O
performed	O
in	O
the	O
3-	O
year	O
period	O
following	O
the	O
introduction	O
of	O
CXL	B-T061
compared	O
to	O
the	O
3-	O
year	O
period	O
prior	O
to	O
the	O
introduction	O
of	O
CXL	B-T061
(	O
201	O
versus	O
269	O
transplants	B-T061
,	O
respectively	O
;	O
p	O
=	O
0.005	O
)	O
.	O
Age	O
,	O
gender	O
and	O
visual	O
acuity	O
were	O
similar	O
between	O
the	O
patient	O
groups	O
in	O
the	O
two	O
time	O
periods	O
.	O
Trend	O
analysis	O
also	O
demonstrated	O
a	O
significant	O
decrease	O
in	O
the	O
amount	O
of	O
corneal	B-T061
transplants	I-T061
(	O
p	O
=	O
0.001	O
)	O
.	O
Significantly	O
fewer	O
corneal	B-T061
transplants	I-T061
were	O
performed	O
for	O
treating	O
keratoconus	B-T047
following	O
the	O
nationwide	O
introduction	O
of	O
CXL	B-T061
.	O
This	O
reduction	O
suggests	O
that	O
corneal	B-T061
cross	I-T061
-	I-T061
linking	I-T061
can	O
significantly	O
reduce	O
the	O
need	O
for	O
corneal	B-T061
transplantation	I-T061
.	O
      
First	O
and	O
second	O
generation	O
DESs	O
reduce	O
diabetes	B-T047
adverse	O
effect	O
on	O
mortality	O
and	O
re	B-T061
-	I-T061
intervention	I-T061
in	O
multivessel	B-T023
coronary	B-T047
disease	I-T047
:	O
9-	O
Year	O
analysis	O
Diabetes	B-T047
portends	O
an	O
increased	O
risk	O
of	O
adverse	O
early	O
and	O
late	O
outcomes	O
in	O
patients	O
undergoing	O
PCI	B-T061
.	O
In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
if	O
the	O
adverse	O
effect	O
of	O
diabetes	B-T047
mellitus	I-T047
(	O
DM	B-T047
)	O
on	O
early	O
and	O
late	O
PCI	B-T061
outcomes	O
is	O
reduced	O
with	O
drug	O
-	O
eluting	O
(	O
DES	O
)	O
compared	O
to	O
bare	O
-	O
metal	O
(	O
BMS	O
)	O
stents	O
.	O
We	O
reviewed	O
the	O
Mount	O
Sinai	O
Beth	O
Israel	O
Hospital	O
first	O
PCI	B-T061
experience	O
for	O
multivessel	B-T023
coronary	B-T047
artery	I-T047
disease	I-T047
(	O
CAD	B-T047
,	O
1998	O
-	O
2009	O
)	O
.	O
Patients	O
were	O
excluded	O
if	O
they	O
had	O
single	B-T047
-	I-T047
vessel	I-T047
CAD	I-T047
,	O
emergency	O
,	O
no	B-T033
stent	O
,	O
prior	O
bypass	B-T061
graft	I-T061
or	O
myocardial	B-T047
infarction	I-T047
<	O
24h	O
.	O
Diabetes	B-T047
-	O
effect	O
was	O
derived	O
from	O
9-	O
year	O
all	O
-	O
cause	O
mortality	O
and	O
re	B-T061
-	I-T061
intervention	I-T061
risk	O
-	O
adjusted	O
hazard	O
ratios	O
[	O
AHR	O
(	O
95	O
%	O
confidence	O
intervals	O
)	O
]	O
for	O
DES	O
(	O
N=2679	O
;	O
48	O
%	O
three	B-T047
-	I-T047
vessel	I-T047
;	O
39	O
%	O
DM	B-T047
)	O
and	O
BMS	O
(	O
N=2651	O
;	O
40	O
%	O
three	B-T047
-	I-T047
vessel	I-T047
;	O
33	O
%	O
DM	B-T047
)	O
and	O
then	O
stratified	O
based	O
on	O
stent	O
(	O
DES	O
/	O
BMS	O
)	O
and	O
vessel	B-T047
disease	I-T047
(	O
two	B-T047
/	O
three	B-T047
)	O
.	O
Diabetes	B-T047
-	O
effect	O
on	O
mortality	O
was	O
lower	O
for	O
DES	O
(	O
AHRDM	O
/	O
NoDM	O
=	O
1.41	O
[	O
1.14	O
-	O
1.74	O
]	O
)	O
versus	O
BMS	O
(	O
AHRDM	O
/	O
NoDM	O
=	O
1.71	O
[	O
1.50	O
-	O
2.01	O
]	O
)	O
,	O
but	O
this	O
was	O
predominantly	O
driven	O
by	O
two	B-T047
-	I-T047
vessel	I-T047
patients	O
.	O
This	O
diabetes	B-T047
effect	O
was	O
similar	O
for	O
first	O
(	O
DES1	O
:	O
AHRDM	O
/	O
NoDM	O
=	O
1.43	O
[	O
1.14	O
-	O
1.79	O
]	O
)	O
and	O
second	O
(	O
DES2	O
:	O
AHRDM	O
/	O
NoDM	O
=	O
1.53	O
[	O
0.77	O
-	O
3.07	O
]	O
)	O
generation	O
DES	O
.	O
Re	B-T061
-	I-T061
intervention	I-T061
comparisons	O
were	O
similarly	O
increased	O
by	O
diabetes	B-T047
in	O
all	O
sub	O
-	O
cohorts	O
.	O
Our	O
analysis	O
of	O
a	O
large	O
real	O
-	O
world	O
PCI	B-T061
series	O
indicates	O
that	O
diabetes	B-T047
is	O
associated	O
with	O
worse	B-T033
9-	O
year	O
mortality	O
irrespective	O
of	O
stent	O
type	O
,	O
albeit	O
this	O
is	O
mitigated	O
to	O
varying	O
degrees	O
with	O
DES	O
,	O
particularly	O
in	O
DES2	O
and	O
in	O
case	O
of	O
2	B-T047
-	I-T047
vessel	I-T047
disease	I-T047
.	O
A	O
complementary	O
stent	O
-	O
effect	O
analysis	O
confirmed	B-T033
DES	O
-to-	O
BMS	O
and	O
DES2	O
-to-	O
DES1	O
superiority	O
in	O
both	O
diabetics	B-T033
and	O
non	B-T033
-	I-T033
diabetics	I-T033
.	O
      
Molar	B-T020
loss	I-T020
and	O
powder	B-T061
diet	I-T061
leads	O
to	O
memory	B-T048
deficit	I-T048
and	O
modifies	O
the	O
mRNA	O
expression	O
of	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
in	O
the	O
hippocampus	B-T023
of	O
adult	O
mice	O
It	O
is	O
known	O
that	O
tooth	B-T020
loss	I-T020
is	O
known	O
to	O
be	O
a	O
risk	B-T033
factor	I-T033
for	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
and	O
soft	B-T061
diet	I-T061
feeding	O
induces	O
memory	B-T048
impairment	I-T048
.	O
Recent	O
studies	O
have	O
shown	O
that	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
BDNF	O
)	O
is	O
associated	O
with	O
tooth	B-T020
loss	I-T020
or	O
soft	B-T061
diet	I-T061
in	O
young	O
animal	O
model	O
,	O
and	O
that	O
BDNF	O
expression	O
is	O
decreased	O
in	O
patients	O
with	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
.	O
However	O
,	O
single	O
or	O
combined	O
effect	O
of	O
tooth	B-T020
loss	I-T020
and/or	O
soft	B-T061
diet	I-T061
on	O
brain	O
function	O
has	O
not	O
fully	O
understood	O
.	O
Here	O
we	O
examined	O
the	O
effect	O
of	O
molar	B-T020
loss	I-T020
and	O
powder	B-T061
diet	I-T061
on	O
memory	O
ability	O
and	O
the	O
expression	O
of	O
BDNF	O
mRNA	O
in	O
the	O
hippocampus	B-T023
of	O
adult	O
C57BL/6J	O
mice	O
.	O
Twenty	O
eight	O
-	O
weeks	O
-	O
old	O
C57BL/6J	O
mice	O
were	O
divided	O
into	O
intact	O
molar	O
group	O
and	O
extracted	O
molar	O
group	O
.	O
They	O
were	O
randomly	O
divided	O
into	O
the	O
I	O
/	O
S	O
group	O
(	O
Intact	O
upper	B-T023
molar	I-T023
teeth	I-T023
/	O
Solid	O
diet	O
feeding	O
)	O
,	O
the	O
E	O
/	O
S	O
group	O
(	O
Extracted	B-T061
upper	B-T023
molar	I-T023
teeth	I-T023
/	O
Solid	O
diet	O
feeding	O
)	O
,	O
the	O
I	O
/	O
P	O
group	O
(	O
Intact	O
upper	B-T023
molar	I-T023
teeth	I-T023
/	O
Powder	B-T061
diet	I-T061
feeding	O
)	O
,	O
and	O
the	O
E	O
/	O
P	O
group	O
(	O
Extracted	O
upper	B-T023
molar	I-T023
teeth	I-T023
/	O
Powder	B-T061
diet	I-T061
feeding	O
)	O
.	O
The	O
observation	O
periods	O
were	O
4	O
and	O
16	O
-	O
week	O
.	O
To	O
analyze	O
the	O
memory	O
ability	O
,	O
the	O
step	O
-	O
through	O
passive	O
avoidance	O
test	O
was	O
conducted	O
.	O
BDNF	O
-	O
related	O
mRNA	O
in	O
the	O
hippocampus	B-T023
was	O
analyzed	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O
At	O
4	O
weeks	O
later	O
,	O
we	O
performed	O
memory	B-T059
test	I-T059
and	O
isolated	O
brains	B-T023
to	O
analyze	O
.	O
There	O
were	O
no	B-T033
differences	I-T033
in	O
memory	O
function	O
and	O
BDNF	O
mRNA	O
level	O
between	O
these	O
four	O
groups	O
.	O
However	O
,	O
at	O
16	O
weeks	O
later	O
,	O
E	O
/	O
S	O
and	O
E	O
/	O
P	O
group	O
showed	O
memory	B-T048
impairment	I-T048
,	O
and	O
decreased	O
level	O
of	O
BDNF	O
mRNA	O
.	O
Whereas	O
,	O
the	O
powder	B-T061
diet	I-T061
had	O
no	O
effect	O
on	O
memory	O
function	O
and	O
BDNF	O
mRNA	O
level	O
even	O
at	O
16	O
weeks	O
later	O
.	O
These	O
results	O
suggest	O
that	O
the	O
effect	O
of	O
molar	B-T020
loss	I-T020
and	O
powder	B-T061
diet	I-T061
on	O
memory	O
function	O
and	O
BDNF	O
mRNA	O
levels	O
were	O
different	O
,	O
molar	B-T020
loss	I-T020
may	O
have	O
a	O
greater	O
long	O
-	O
term	O
effect	O
on	O
memory	O
ability	O
than	O
powder	B-T061
diet	I-T061
does	O
.	O
      
Associations	O
of	O
NEUROD2	O
polymorphisms	O
and	O
change	O
of	O
cognitive	B-T048
dysfunctions	I-T048
in	O
schizophrenia	B-T048
and	O
schizoaffective	B-T048
disorder	I-T048
after	O
eight	O
weeks	O
of	O
antipsychotic	B-T121
treatment	B-T061
NEUROD2	O
is	O
a	O
neurospecific	O
helix	O
-	O
loop	O
-	O
helix	O
transcription	O
factor	O
which	O
has	O
an	O
impact	O
on	O
the	O
regulation	O
of	O
glutamatergic	O
and	O
GABAergic	O
genes	O
.	O
We	O
investigated	O
an	O
association	O
of	O
NEUROD2	O
with	O
neurocognitive	B-T048
dysfunctions	I-T048
in	O
schizophrenia	B-T048
and	O
schizoaffective	B-T048
disorder	I-T048
patients	O
before	O
and	O
during	O
treatment	B-T061
with	O
different	O
second	B-T121
-	I-T121
generation	I-T121
antipsychotics	I-T121
.	O
Patients	O
were	O
genotyped	O
for	O
four	O
different	O
polymorphisms	O
of	O
the	O
NEUROD2	O
gene	O
(	O
(	O
rs9889354(A	O
/	O
G	O
)	O
,	O
rs1877032(C	O
/	O
T	O
)	O
,	O
rs12453682(C	O
/	O
T	O
)	O
and	O
rs11078918(C	O
/	O
G	O
)	O
)	O
.	O
Cognitive	O
function	O
was	O
assessed	O
at	O
baseline	O
and	O
week	O
8	O
.	O
Results	O
of	O
individual	O
neuropsychological	B-T060
tests	I-T060
were	O
assigned	O
to	O
six	O
cognitive	O
domains	O
(	O
reaction	O
time	O
and	O
quality	O
;	O
executive	O
function	O
;	O
working	O
,	O
verbal	O
and	O
visual	O
memory	O
)	O
and	O
a	O
general	O
cognitive	O
index	O
.	O
167	O
patients	O
were	O
included	O
in	O
the	O
study	O
.	O
The	O
NEUROD2	O
exonic	O
polymorphism	O
rs11078918	O
showed	O
significant	O
associations	O
with	O
verbal	O
memory	O
and	O
executive	O
functions	O
,	O
whereas	O
the	O
NEUROD2	O
polymorphism	O
rs12453682	O
was	O
significantly	O
associated	O
with	O
working	O
and	O
verbal	O
memory	O
,	O
executive	O
functions	O
and	O
with	O
a	O
cognitive	O
index	O
.	O
Significant	O
associations	O
were	O
found	O
at	O
baseline	O
and	O
after	O
eight	O
weeks	O
.	O
Moreover	O
,	O
significant	O
associations	O
between	O
the	O
change	O
in	O
neuropsychological	B-T060
test	I-T060
results	O
during	O
antipsychotic	B-T121
treatment	B-T061
and	O
the	O
NEUROD2	O
polymorphisms	O
rs11078918	O
and	O
rs12453682	O
were	O
observed	O
.	O
Our	O
findings	O
suggest	O
that	O
the	O
NEUROD2	O
gene	O
could	O
play	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
neurocognitive	B-T048
dysfunctions	I-T048
as	O
well	O
as	O
in	O
the	O
change	O
of	O
cognitive	B-T184
symptoms	I-T184
under	O
antipsychotic	B-T121
treatment	B-T061
in	O
schizophrenia	B-T048
and	O
schizoaffective	B-T048
disorder	I-T048
.	O
      
It	O
takes	O
biking	O
to	O
learn	O
:	O
Physical	O
activity	O
improves	B-T033
learning	O
a	O
second	B-T033
language	I-T033
Recent	O
studies	O
have	O
shown	O
that	O
concurrent	O
physical	O
activity	O
enhances	O
learning	O
a	O
completely	O
unfamiliar	O
L2	B-T033
vocabulary	O
as	O
compared	O
to	O
learning	O
it	O
in	O
a	O
static	O
condition	O
.	O
In	O
this	O
paper	O
we	O
report	O
a	O
study	O
whose	O
aim	O
is	O
twofold	O
:	O
to	O
test	O
for	O
possible	B-T033
positive	B-T033
effects	O
of	O
physical	O
activity	O
when	O
L2	B-T033
learning	O
has	O
already	O
reached	O
some	O
level	O
of	O
proficiency	O
,	O
and	O
to	O
test	O
whether	O
the	O
assumed	O
better	O
performance	O
when	O
engaged	O
in	O
physical	O
activity	O
is	O
limited	O
to	O
the	O
linguistic	O
level	O
probed	O
at	O
training	O
(	O
i.e.	O
L2	B-T033
vocabulary	O
tested	O
by	O
means	O
of	O
a	O
Word	O
-	O
Picture	O
Verification	O
task	O
)	O
,	O
or	O
whether	O
it	O
extends	O
also	O
to	O
the	O
sentence	O
level	O
(	O
which	O
was	O
tested	O
by	O
means	O
of	O
a	O
Sentence	O
Semantic	O
Judgment	O
Task	O
)	O
.	O
The	O
results	O
show	O
that	O
Chinese	O
speakers	O
with	O
basic	B-T033
knowledge	I-T033
of	O
English	O
benefited	O
from	O
physical	O
activity	O
while	O
learning	O
a	O
set	O
of	O
new	O
words	O
.	O
Furthermore	O
,	O
their	O
better	O
performance	O
emerged	O
also	O
at	O
the	O
sentential	O
level	O
,	O
as	O
shown	O
by	O
their	O
performance	O
in	O
a	O
Semantic	O
Judgment	O
task	O
.	O
Finally	O
,	O
an	O
interesting	O
temporal	O
asymmetry	O
between	O
the	O
lexical	O
and	O
the	O
sentential	O
level	O
emerges	O
,	O
with	O
the	O
difference	O
between	O
the	O
experimental	O
and	O
control	O
group	O
emerging	O
from	O
the	O
1st	O
testing	O
session	O
at	O
the	O
lexical	O
level	O
but	O
after	O
several	O
weeks	O
at	O
the	O
sentential	O
level	O
.	O
      
Functional	O
Characterization	O
of	O
Pneumocystis	O
carinii	O
Inositol	O
Transporter	O
1	O
Fungi	O
in	O
the	O
genus	O
Pneumocystis	O
live	O
in	O
the	O
lungs	B-T023
of	O
mammals	O
,	O
where	O
they	O
can	O
cause	O
a	O
fatal	O
pneumonia	B-T047
(	O
PCP	B-T047
[	O
Pneumocystis	B-T047
pneumonia	I-T047
]	O
)	O
in	O
hosts	B-T001
with	O
compromised	O
immune	O
systems	O
.	O
The	O
absence	O
of	O
a	O
continuous	O
in	O
vitro	O
culture	B-T059
system	I-T059
for	O
any	O
species	O
of	O
Pneumocystis	O
has	O
led	O
to	O
limited	O
understanding	O
of	O
these	O
fungi	O
,	O
especially	O
for	O
the	O
discovery	O
of	O
new	O
therapies	B-T061
.	O
We	O
recently	O
reported	O
that	O
Pneumocystis	O
carinii	O
,	O
Pneumocystis	O
murina	O
,	O
and	O
most	O
significantly	O
,	O
Pneumocystis	O
jirovecii	O
lack	O
both	O
enzymes	O
necessary	O
for	O
myo	O
-	O
inositol	O
biosynthesis	O
but	O
contain	O
genes	O
with	O
homologies	O
to	O
fungal	O
myo	B-T121
-	I-T121
inositol	I-T121
transporters	O
.	O
Since	O
myo	B-T121
-	I-T121
inositol	I-T121
is	O
essential	O
for	O
eukaryotic	O
viability	O
,	O
the	O
primary	O
transporter	O
,	O
ITR1	O
,	O
was	O
functionally	O
and	O
structurally	O
characterized	O
in	O
P.	O
carinii	O
The	O
predicted	O
structure	O
of	O
P.	O
carinii	O
ITR1	O
(	O
PcITR1	O
)	O
contained	O
12	O
transmembrane	O
alpha	O
-	O
helices	O
with	O
intracellular	O
C	O
and	O
N	O
termini	O
,	O
consistent	O
with	O
other	O
inositol	B-T121
transporters	O
.	O
The	O
apparent	O
Km	O
was	O
0.94	O
±	O
0.08	O
(	O
mean	O
±	O
standard	O
deviation	O
)	O
,	O
suggesting	O
that	O
myo	O
-	O
inositol	O
transport	O
in	O
P.	O
carinii	O
is	O
likely	O
through	O
a	O
low	O
-	O
affinity	O
,	O
highly	O
selective	O
transport	O
system	O
,	O
as	O
no	O
other	O
sugars	B-T121
or	O
inositol	B-T121
stereoisomers	O
were	O
significant	O
competitive	O
inhibitors	O
.	O
Glucose	O
transport	O
was	O
shown	O
to	O
use	O
a	O
different	O
transport	O
system	O
.	O
The	O
myo	O
-	O
inositol	O
transport	O
was	O
distinct	O
from	O
mammalian	O
transporters	O
,	O
as	O
it	O
was	O
not	O
sodium	O
dependent	O
and	O
was	O
cytochalasin	B-T121
B	I-T121
resistant	O
.	O
Inositol	O
transport	O
in	O
these	O
fungi	O
offers	O
an	O
attractive	O
new	O
drug	B-T121
target	O
because	O
of	O
the	O
reliance	O
of	O
the	O
fungi	O
on	O
its	O
transport	O
,	O
clear	O
differences	O
between	O
the	O
mammalian	O
and	O
fungal	O
transporters	O
,	O
and	O
the	O
ability	O
of	O
the	O
host	B-T001
to	O
both	O
synthesize	O
and	O
transport	O
this	O
critical	O
nutrient	O
,	O
predicting	O
low	O
toxicity	O
of	O
potential	O
inhibitors	O
to	O
the	O
fungal	O
transporter	O
.	O
myo	B-T121
-	I-T121
Inositol	I-T121
is	O
a	O
sugarlike	B-T121
nutrient	O
that	O
is	O
essential	O
for	O
life	O
in	O
most	O
organisms	B-T001
.	O
Humans	O
and	O
microbes	B-T001
alike	O
can	O
obtain	O
it	O
by	O
making	O
it	O
,	O
which	O
involves	O
only	O
2	O
enzymes	O
,	O
by	O
taking	O
it	O
from	O
the	O
environment	O
by	O
a	O
transport	O
process	O
,	O
or	O
by	O
recycling	O
it	O
from	O
other	O
cellular	O
constituents	O
.	O
Inspection	O
of	O
the	O
genomes	O
of	O
the	O
pathogenic	O
fungi	O
of	O
the	O
genus	O
Pneumocystis	O
showed	O
that	O
these	O
pneumonia	B-T047
-	O
causing	O
parasites	O
could	O
not	O
make	O
myo	B-T121
-	I-T121
inositol	I-T121
,	O
as	O
they	O
lacked	O
the	O
2	O
enzymes	O
.	O
Instead	O
,	O
we	O
found	O
evidence	O
of	O
inositol	B-T121
transporters	O
,	O
which	O
would	O
import	O
the	O
sugar	B-T121
from	O
the	O
lungs	B-T023
where	O
the	O
fungi	O
reside	O
.	O
In	O
the	O
present	O
report	O
,	O
we	O
characterized	O
the	O
transport	O
of	O
myo	B-T121
-	I-T121
inositol	I-T121
in	O
the	O
fungus	O
and	O
found	O
that	O
the	O
transporter	O
was	O
highly	O
selective	O
for	O
myo	B-T121
-	I-T121
inositol	I-T121
and	O
did	O
not	O
transport	O
any	O
other	O
molecules	O
.	O
The	O
transport	O
was	O
distinct	O
from	O
that	O
in	O
mammalian	O
cells	O
,	O
and	O
since	O
mammals	O
can	O
both	O
make	O
and	O
transport	O
myo	B-T121
-	I-T121
inositol	I-T121
,	O
while	O
Pneumocystis	O
fungi	O
must	O
transport	O
it	O
,	O
this	O
process	O
offers	O
a	O
potential	O
new	O
drug	B-T121
target	O
.	O
      
Enhancing	O
Comparative	O
Effectiveness	O
Research	O
With	O
Automated	O
Pediatric	O
Pneumonia	B-T047
Detection	B-T061
in	O
a	O
Multi	O
-	O
Institutional	O
Clinical	O
Repository	O
:	O
A	O
PHIS	O
+	O
Pilot	O
Study	O
Community	B-T047
-	I-T047
acquired	I-T047
pneumonia	I-T047
is	O
a	O
leading	O
cause	O
of	O
pediatric	O
morbidity	O
.	O
Administrative	O
data	O
are	O
often	O
used	O
to	O
conduct	O
comparative	O
effectiveness	O
research	O
(	O
CER	O
)	O
with	O
sufficient	O
sample	O
sizes	O
to	O
enhance	O
detection	B-T033
of	O
important	O
outcomes	O
.	O
However	O
,	O
such	O
studies	O
are	O
prone	O
to	O
misclassification	O
errors	O
because	O
of	O
the	O
variable	O
accuracy	O
of	O
discharge	B-T033
diagnosis	I-T033
codes	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
an	O
automated	O
,	O
scalable	O
,	O
and	O
accurate	O
method	O
to	O
determine	O
the	O
presence	B-T033
or	O
absence	O
of	O
pneumonia	B-T047
in	O
children	O
using	O
chest	B-T060
imaging	I-T060
reports	O
.	O
The	O
multi	O
-	O
institutional	O
PHIS	O
+	O
clinical	O
repository	O
was	O
developed	O
to	O
support	O
pediatric	O
CER	O
by	O
expanding	O
an	O
administrative	O
database	O
of	O
children	O
's	O
hospitals	O
with	O
detailed	O
clinical	O
data	O
.	O
To	O
develop	O
a	O
scalable	O
approach	O
to	O
find	B-T033
patients	O
with	O
bacterial	B-T047
pneumonia	I-T047
more	O
accurately	O
,	O
we	O
developed	O
a	O
Natural	O
Language	O
Processing	O
(	O
NLP	O
)	O
application	O
to	O
extract	O
relevant	O
information	O
from	O
chest	B-T060
diagnostic	I-T060
imaging	I-T060
reports	O
.	O
Domain	O
experts	O
established	O
a	O
reference	O
standard	O
by	O
manually	B-T033
annotating	O
282	O
reports	O
to	O
train	O
and	O
then	O
test	O
the	O
NLP	O
application	O
.	O
Findings	O
of	O
pleural	B-T047
effusion	I-T047
,	O
pulmonary	B-T033
infiltrate	I-T033
,	O
and	O
pneumonia	B-T047
were	O
automatically	B-T033
extracted	O
from	O
the	O
reports	O
and	O
then	O
used	O
to	O
automatically	B-T033
classify	O
whether	O
a	O
report	O
was	O
consistent	O
with	O
bacterial	B-T047
pneumonia	I-T047
.	O
Compared	O
with	O
the	O
annotated	O
diagnostic	B-T060
imaging	I-T060
reports	O
reference	O
standard	O
,	O
the	O
most	O
accurate	O
implementation	O
of	O
machine	O
learning	O
algorithms	O
in	O
our	O
NLP	O
application	O
allowed	O
extracting	O
relevant	O
findings	O
with	O
a	O
sensitivity	O
of	O
.939	O
and	O
a	O
positive	B-T033
predictive	O
value	O
of	O
.925	O
.	O
It	O
allowed	O
classifying	O
reports	O
with	O
a	O
sensitivity	O
of	O
.71	O
,	O
a	O
positive	B-T033
predictive	O
value	O
of	O
.86	O
,	O
and	O
a	O
specificity	O
of	O
.962	O
.	O
When	O
compared	O
with	O
each	O
of	O
the	O
domain	O
experts	O
manually	B-T033
annotating	O
these	O
reports	O
,	O
the	O
NLP	O
application	O
allowed	O
for	O
significantly	O
higher	O
sensitivity	O
(	O
.71	O
vs	O
.527	O
)	O
and	O
similar	O
positive	B-T033
predictive	O
value	O
and	O
specificity	O
.	O
NLP	O
-based	O
pneumonia	B-T047
information	O
extraction	O
of	O
pediatric	O
diagnostic	B-T060
imaging	I-T060
reports	O
performed	O
better	O
than	O
domain	O
experts	O
in	O
this	O
pilot	O
study	O
.	O
NLP	O
is	O
an	O
efficient	O
method	O
to	O
extract	O
information	O
from	O
a	O
large	O
collection	O
of	O
imaging	O
reports	O
to	O
facilitate	O
CER	O
.	O
      
Bacteria	B-T007
and	O
Hoverflies	O
(	O
Diptera	O
:	O
Syrphidae	O
)	O
in	O
Tree	B-T023
Hollows	I-T023
From	O
the	O
Iberian	O
Mediterranean	O
Forest	O
Saproxylic	O
insect	O
communities	O
inhabiting	O
tree	B-T023
hollows	I-T023
in	O
Mediterranean	O
forests	O
depend	O
on	O
a	O
combination	O
of	O
physical	O
characteristics	O
and	O
interactions	O
occurring	O
between	O
community	O
member	O
species	O
.	O
Despite	O
the	O
need	O
to	O
preserve	O
these	O
organisms	B-T001
,	O
little	O
is	O
known	O
about	O
their	O
interrelationships	O
,	O
in	O
particular	O
those	O
relationships	O
between	O
saproxylic	O
insects	O
and	O
microbiota	B-T001
occurring	O
in	O
these	O
microhabitats	O
.	O
In	O
tree	B-T023
hollows	I-T023
of	O
Quercus	O
rotundifolia	O
Lamark	O
that	O
hold	O
water	O
and	O
contain	O
dead	O
leaves	O
,	O
abundant	B-T001
microbial	I-T001
populations	I-T001
can	O
be	O
found	O
.	O
Developing	O
on	O
them	O
are	O
the	O
larvae	O
of	O
Mallota	O
dusmeti	O
Andréu	O
,	O
1926	O
(	O
Diptera	O
:	O
Syrphidae	O
)	O
,	O
a	O
vulnerable	O
species	O
(	O
IUCN	O
category	O
:	O
Marcos	O
-	O
García	O
and	O
Quinto	O
2011	O
)	O
.	O
This	O
study	O
provides	O
the	O
first	O
data	O
on	O
the	O
microbiota	B-T001
living	O
inside	O
the	O
gut	B-T023
of	O
the	O
larvae	O
of	O
M.	O
dusmeti	O
,	O
as	O
well	O
as	O
the	O
microbiota	B-T001
in	O
the	O
hollow	O
where	O
these	O
larvae	O
develop	O
.	O
Bacteria	B-T007
were	O
identified	O
by	O
amplification	B-T059
and	I-T059
partial	I-T059
sequencing	I-T059
of	O
the	O
V1	O
-	O
V3	O
regions	O
and	O
the	O
complete	O
nucleotide	O
sequence	O
of	O
16S	O
rRNA	O
genes	O
.	O
We	O
found	O
eight	O
species	B-T007
of	I-T007
bacteria	I-T007
living	O
in	O
tree	B-T023
hollows	I-T023
and	O
three	O
species	O
in	B-T023
the	I-T023
gut	I-T023
of	O
M.	O
dusmeti	O
larvae	O
:	O
Bacillus	B-T007
cereus	I-T007
,	O
Bacillus	B-T007
toyonensis	I-T007
,	O
and	O
Lysinibacillus	B-T007
sphaericus	I-T007
The	O
filter	B-T033
-	I-T033
feeding	I-T033
mechanism	I-T033
characteristic	I-T033
of	O
M.	O
dusmeti	O
larvae	O
is	O
selective	O
in	O
enabling	O
ingestion	O
of	O
bacteria	B-T007
only	O
above	O
2.1	O
µm	O
in	O
diameter	O
.	O
      
Predictors	O
of	O
neurologic	O
and	O
nonneurologic	B-T033
death	I-T033
in	O
patients	O
with	O
brain	B-T191
metastasis	I-T191
initially	O
treated	O
with	O
upfront	B-T061
stereotactic	I-T061
radiosurgery	I-T061
without	O
whole	B-T061
-	I-T061
brain	I-T061
radiation	I-T061
therapy	I-T061
In	O
this	O
study	O
we	O
attempted	O
to	O
discern	O
the	O
factors	O
predictive	O
of	O
neurologic	O
death	O
in	O
patients	O
with	O
brain	B-T191
metastasis	I-T191
treated	O
with	O
upfront	B-T061
stereotactic	I-T061
radiosurgery	I-T061
(	O
SRS	B-T061
)	O
without	O
whole	B-T061
brain	I-T061
radiation	I-T061
therapy	I-T061
(	O
WBRT	B-T061
)	O
while	O
accounting	O
for	O
the	O
competing	O
risk	O
of	O
nonneurologic	B-T033
death	I-T033
.	O
We	O
performed	O
a	O
retrospective	O
single	O
-	O
institution	O
analysis	O
of	O
patients	O
with	O
brain	B-T191
metastasis	I-T191
treated	O
with	O
upfront	O
SRS	B-T061
without	O
WBRT	B-T061
.	O
Competing	O
risks	O
analysis	O
was	O
performed	O
to	O
estimate	O
the	O
subdistribution	O
hazard	O
ratios	O
(	O
HRs	O
)	O
for	O
neurologic	O
and	O
nonneurologic	B-T033
death	I-T033
for	O
predictor	O
variables	O
of	O
interest	O
.	O
Of	O
738	O
patients	O
treated	O
with	O
upfront	B-T061
SRS	I-T061
alone	O
,	O
neurologic	O
death	O
occurred	O
in	O
226	O
(	O
30.6	O
%	O
)	O
,	O
while	O
nonneurologic	B-T033
death	I-T033
occurred	O
in	O
309	O
(	O
41.9	O
%	O
)	O
.	O
Multivariate	O
competing	O
risks	O
analysis	O
identified	O
an	O
increased	O
hazard	O
of	O
neurologic	O
death	O
associated	O
with	O
diagnosis	O
-	O
specific	O
graded	O
prognostic	O
assessment	O
(	O
DS	O
-	O
GPA	O
)	O
≤	O
2	O
(	O
P	O
=	O
.005	O
)	O
,	O
melanoma	B-T191
histology	B-T059
(	O
P	O
=	O
.009	O
)	O
,	O
and	O
increased	O
number	O
of	O
brain	B-T191
metastases	I-T191
(	O
P<.001	O
)	O
,	O
while	O
there	O
was	O
a	O
decreased	O
hazard	O
associated	O
with	O
higher	O
SRS	B-T061
dose	O
(	O
P	O
=	O
.004	O
)	O
.	O
Targeted	B-T121
agents	I-T121
were	O
associated	O
with	O
a	O
decreased	O
HR	O
of	O
neurologic	O
death	O
in	O
the	O
first	O
1.5	O
years	O
(	O
P	O
=	O
.04	O
)	O
but	O
not	O
afterwards	O
.	O
An	O
increased	O
hazard	O
of	O
nonneurologic	B-T033
death	I-T033
was	O
seen	O
with	O
increasing	O
age	O
(	O
P	O
=	O
.03	O
)	O
,	O
nonmelanoma	B-T059
histology	I-T059
(	O
P<.001	O
)	O
,	O
presence	O
of	O
extracranial	B-T047
disease	I-T047
(	O
P<.001	O
)	O
,	O
and	O
progressive	O
systemic	B-T047
disease	I-T047
(	O
P	O
=	O
.004	O
)	O
.	O
Melanoma	B-T191
,	O
DS	O
-	O
GPA	O
,	O
number	O
of	O
brain	B-T191
metastases	I-T191
,	O
and	O
SRS	B-T061
dose	O
are	O
predictive	O
of	O
neurologic	O
death	O
,	O
while	O
age	O
,	O
nonmelanoma	B-T059
histology	I-T059
,	O
and	O
more	O
advanced	O
systemic	B-T047
disease	I-T047
are	O
predictive	O
of	O
nonneurologic	B-T033
death	I-T033
.	O
Targeted	B-T121
agents	I-T121
appear	O
to	O
delay	O
neurologic	O
death	O
.	O
      
Factors	O
affecting	O
the	O
formation	O
of	O
nitrogenous	B-T061
disinfection	I-T061
by	O
-	O
products	O
during	O
chlorination	O
of	O
aspartic	O
acid	O
in	O
drinking	O
water	O
The	O
formation	O
of	O
emerging	O
nitrogenous	B-T061
disinfection	I-T061
by	O
-	O
products	O
(	O
N	O
-	O
DBPs	O
)	O
from	O
the	O
chlorination	O
of	O
aspartic	O
acid	O
(	O
Asp	O
)	O
was	O
investigated	O
.	O
The	O
yield	O
of	O
dichloroacetonitrile	O
(	O
DCAN	O
)	O
was	O
higher	O
than	O
other	O
N	O
-	O
DBPs	O
,	O
such	O
as	O
dichloroacetamide	O
(	O
DCAcAm	O
)	O
and	O
chloropicrin	B-T121
(	O
TCNM	B-T121
)	O
during	O
the	O
chlorination	O
of	O
Asp	O
.	O
The	O
formation	O
of	O
DCAN	O
,	O
DCAcAm	O
,	O
and	O
TCNM	B-T121
all	O
showed	O
a	O
trend	O
of	O
first	O
increasing	O
and	O
then	O
decreasing	B-T033
during	O
the	O
chlorination	O
of	O
Asp	O
with	O
increasing	O
contact	O
time	O
.	O
The	O
dosage	O
of	O
chlorine	O
had	O
an	O
impact	O
on	O
the	O
formation	O
of	O
DCAN	O
,	O
DCAcAm	O
,	O
and	O
TCNM	B-T121
.	O
The	O
highest	O
yields	O
of	O
DCAN	O
and	O
DCAcAm	O
appeared	O
when	O
the	O
Cl2	O
/	O
Asp	O
molar	O
ratio	O
was	O
about	O
20	O
,	O
the	O
yield	O
of	O
TCNM	B-T121
increased	O
with	O
increasing	O
the	O
Cl2	O
/	O
Asp	O
molar	O
ratio	O
from	O
5	O
to	O
30	O
and	O
TCNM	B-T121
was	O
not	O
produced	O
when	O
the	O
ratio	O
was	O
less	O
than	O
5	O
.	O
Cyanogen	O
chloride	O
(	O
CNCl	O
)	O
was	O
detected	O
when	O
the	O
Cl2	O
/	O
Asp	O
molar	O
ratio	O
was	O
lower	O
than	O
5	O
.	O
N	O
-	O
DBPs	O
formation	O
was	O
influenced	O
by	O
pH.	O
DCAN	O
formation	O
increased	O
with	O
increasing	O
pH	O
from	O
5	O
to	O
6	O
and	O
then	O
decreased	O
with	O
increasing	O
pH	O
from	O
6	O
to	O
9	O
,	O
but	O
DCAcAm	O
and	O
TCNM	B-T121
increased	O
with	O
increasing	O
pH	O
from	O
5	O
to	O
8	O
and	O
then	O
decreased	O
.	O
Higher	O
temperatures	O
reduced	O
the	O
formation	O
of	O
DCAN	O
and	O
DCAcAm	O
,	O
but	O
increased	O
TCNM	B-T121
formation	O
.	O
DCAN	O
and	O
DCAcAm	O
formation	O
decreased	O
,	O
and	O
relatively	O
stable	O
TCNM	B-T121
formation	O
increased	O
,	O
with	O
increasing	O
free	O
chlorine	O
contact	O
time	O
during	O
chloramination	O
.	O
N	O
-	O
nitrosodimethylamine	O
(	O
NDMA	O
)	O
was	O
produced	O
during	O
chloramination	O
of	O
Asp	O
and	O
increased	O
with	O
prolonged	O
chloramination	O
contact	O
time	O
.	O
The	O
presence	O
of	O
bromide	B-T121
ions	I-T121
enhanced	O
the	O
yields	O
of	O
haloacetonitriles	O
and	O
shifted	O
N	O
-	O
DBPs	O
to	O
more	O
brominated	O
species	O
.	O
      
Does	O
Intrawound	B-T195
Vancomycin	I-T195
Application	O
During	O
Spine	B-T061
Surgery	I-T061
Create	O
Vancomycin	O
-	O
Resistant	O
Organism	B-T001
?	O
Surgical	O
site	O
infection	O
(	O
SSI	O
)	O
following	O
spine	B-T061
surgery	I-T061
is	O
a	O
morbid	O
and	O
expensive	O
complication	O
.	O
The	O
use	O
of	O
intrawound	B-T195
vancomycin	I-T195
is	O
emerging	O
as	O
a	O
solution	O
to	O
reduce	O
SSI	O
.	O
The	O
development	O
of	O
vancomycin	O
-	O
resistant	O
pathogens	B-T001
is	O
an	O
understandable	O
concern	O
.	O
To	O
determine	O
the	O
occurrence	O
of	O
vancomycin	O
-	O
resistant	O
SSI	O
in	O
patients	O
with	O
and	O
without	O
use	O
of	O
intrawound	B-T195
vancomycin	I-T195
.	O
Patients	O
undergoing	O
elective	O
spine	B-T061
surgery	I-T061
were	O
dichotomized	O
based	O
on	O
whether	O
intrawound	B-T195
vancomycin	I-T195
was	O
applied	O
.	O
Outcome	O
was	O
occurrence	O
of	O
SSI	O
requiring	O
return	O
to	O
the	O
operating	O
room	O
within	O
postoperative	O
90	O
days	O
.	O
The	O
intrawound	B-T059
culture	I-T059
and	O
vancomycin	B-T195
minimal	B-T059
inhibitory	I-T059
concentrations	I-T059
(	O
MIC	B-T059
)	O
were	O
reviewed	O
.	O
Analyses	O
were	O
conducted	O
to	O
compare	O
the	O
pathogen	B-T001
profile	I-T001
and	O
MIC	B-T059
for	O
vancomycin	B-T195
in	O
patients	O
who	O
received	O
vancomycin	B-T195
and	O
those	O
who	O
did	O
not	O
.	O
Of	O
the	O
total	O
2802	O
patients	O
,	O
43	O
%	O
(	O
n	O
=	O
1215	O
)	O
had	O
intrawound	B-T195
vancomycin	I-T195
application	O
during	O
the	O
index	O
surgery	O
.	O
The	O
use	O
of	O
vancomycin	B-T195
was	O
associated	O
with	O
significantly	O
lower	O
deep	O
SSI	O
rates	B-T023
(	O
1.6	O
%	O
[	O
n	O
=	O
20	O
]	O
vs	O
2.5	O
%	O
[	O
n	O
=	O
40	O
]	O
,	O
P	O
=	O
.02	O
)	O
.	O
The	O
occurrence	O
of	O
Staphylococcus	B-T007
aureus	I-T007
SSI	O
was	O
significantly	O
lower	O
in	O
the	O
patients	O
who	O
had	O
application	O
of	O
intrawound	B-T195
vancomycin	I-T195
(	O
32	O
%	O
vs	O
65	O
%	O
,	O
P	O
=	O
.003	O
)	O
.	O
None	O
of	O
the	O
patients	O
who	O
had	O
application	O
of	O
intrawound	B-T195
vancomycin	I-T195
powder	I-T195
,	O
and	O
subsequently	O
developed	O
an	O
S	B-T007
aureus	I-T007
SSI	O
,	O
demonstrated	O
pathogens	B-T001
with	O
resistance	B-T033
to	I-T033
vancomycin	I-T033
.	O
All	O
patients	O
had	O
MIC	B-T059
<	O
2	O
μg	O
/	O
mL	O
,	O
the	O
vancomycin	B-T195
susceptibility	O
threshold	O
.	O
The	O
occurrence	O
of	O
gram	B-T047
-	I-T047
negative	I-T047
SSI	O
(	O
28	O
%	O
vs	O
7	O
%	O
)	O
and	O
culture	B-T033
negative	I-T033
fluid	I-T033
collection	I-T033
(	O
16	O
%	O
vs	O
5	O
%	O
)	O
was	O
higher	O
in	O
the	O
vancomycin	B-T195
cohort	O
.	O
The	O
use	O
of	O
intrawound	B-T195
vancomycin	I-T195
during	O
the	O
index	O
spine	B-T061
surgery	I-T061
was	O
protective	O
against	O
SSI	O
following	O
spine	B-T061
surgery	I-T061
.	O
The	O
application	O
of	O
intrawound	B-T195
vancomycin	I-T195
during	O
index	O
surgery	O
does	O
not	O
appear	O
to	O
create	O
vancomycin	O
-	O
resistant	O
organisms	B-T001
in	O
the	O
event	O
of	O
an	O
SSI	O
.	O
      
Optimal	O
Duration	O
of	O
Coronary	B-T061
Ligation	I-T061
and	O
Reperfusion	B-T061
for	O
Reperfusion	O
Injury	O
Study	O
in	O
a	O
Rat	O
Model	O
Reperfusion	O
injury	O
(	O
RI	O
)	O
has	O
an	O
important	O
impact	O
on	O
the	O
clinical	O
prognosis	O
for	O
patients	O
with	O
acute	O
myocardial	O
injury	O
who	O
had	O
their	O
coronary	O
blood	O
flow	O
reestablished	O
.	O
However	O
,	O
no	O
studies	O
to	O
date	O
have	O
investigated	O
the	O
timeframe	O
of	O
coronary	B-T047
occlusion	I-T047
and	O
reperfusion	B-T061
effects	O
on	O
RI	O
.	O
A	O
total	O
of	O
100	O
rats	O
were	O
divided	O
into	O
4	O
groups	O
based	O
on	O
the	O
coronary	B-T061
ligation	I-T061
period	O
:	O
30	O
,	O
60	O
,	O
120	O
,	O
and	O
180	O
min	O
,	O
and	O
each	O
group	O
was	O
further	O
divided	O
into	O
5	O
subgroups	O
with	O
different	O
reperfusion	B-T061
periods	O
:	O
0	O
,	O
30	O
,	O
60	O
,	O
120	O
,	O
and	O
180	O
min	O
.	O
R0	O
was	O
the	O
baseline	O
of	O
each	O
subgroup	O
.	O
All	O
animals	O
received	O
the	O
same	O
protocols	O
for	O
designed	O
ligation	B-T061
and	O
reperfusion	B-T061
periods	O
.	O
Evans	O
blue	O
and	O
2,3,5	B-T121
-	I-T121
triphenyltetrazolium	I-T121
chloride	I-T121
were	O
used	O
to	O
distinguish	O
different	O
myocardial	O
injury	O
areas	O
:	O
area	O
at	O
risk	O
(	O
AAR	O
)	O
and	O
myocardial	B-T047
necrosis	I-T047
.	O
The	O
differences	O
of	O
the	O
ratios	O
of	O
the	O
necrotic	O
area	O
to	O
AAR	O
between	O
each	O
subgroup	O
and	O
baseline	O
were	O
further	O
averaged	O
to	O
calculate	O
an	O
overall	O
value	O
of	O
each	O
heart	B-T023
.	O
The	O
relative	O
RI	O
percentages	O
showed	O
significant	O
differences	O
(	O
0.8	O
±	O
2.3	O
%	O
,	O
4.9	O
±	O
3.3	O
%	O
,	O
10.8	O
±	O
3.1	O
%	O
,	O
and	O
20.3	O
±	O
3.6	O
%	O
respectively	O
,	O
p	O
<	O
0.001	O
)	O
at	O
different	O
time	O
points	O
of	O
reperfusion	B-T061
but	O
not	O
at	O
different	O
time	O
points	O
of	O
ligation	B-T061
(	O
p	O
=	O
0.593	O
)	O
.	O
The	O
effects	O
of	O
different	O
time	O
courses	O
in	O
RI	O
showed	O
that	O
the	O
L120R180	O
group	O
(	O
43.4	O
±	O
2.3	O
%	O
)	O
had	O
the	O
highest	O
RI	O
difference	O
with	O
the	O
baseline	O
group	O
.	O
Maximal	O
RI	O
occurred	O
at	O
the	O
timeframe	O
of	O
L120R180	O
in	O
our	O
animal	O
model	O
.	O
This	O
result	O
may	O
be	O
utilized	O
to	O
assess	O
the	O
substantial	O
benefits	O
of	O
RI	B-T061
therapies	I-T061
in	O
an	O
experimental	B-T050
rat	I-T050
model	I-T050
setting	O
.	O
      
Investigating	O
Effects	O
of	O
Acidic	O
pH	O
on	O
Proliferation	O
,	O
Invasion	O
and	O
Drug	B-T121
-	O
Induced	O
Apoptosis	O
in	O
Lymphoblastic	B-T191
Leukemia	I-T191
Some	O
studies	O
have	O
shown	O
that	O
extracellular	O
pH	O
in	O
tumors	B-T191
,	O
which	O
results	O
in	O
tumor	B-T191
progression	I-T191
,	O
is	O
less	O
than	O
that	O
in	O
normal	O
tissues	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
extracellular	O
acidic	O
pH	O
on	O
proliferation	O
,	O
invasion	O
,	O
and	O
drug	B-T121
-	O
induced	O
apoptosis	O
in	O
acute	O
lymphoblastic	O
cells	O
.	O
The	O
cells	O
were	O
cultured	O
in	O
different	O
pH	O
(	O
pH	O
6.6	O
and	O
pH	O
7.4	O
)	O
for	O
12	O
days	O
.	O
Cell	O
proliferation	O
was	O
assessed	O
by	O
MTT	O
assay	O
and	O
cell	O
invasion	O
was	O
assayed	O
by	O
invasion	B-T059
assay	I-T059
and	O
gene	O
expression	O
analysis	O
of	O
MMP-9	O
.	O
Drug	B-T121
-	O
induced	O
apoptosis	O
was	O
evaluated	O
after	O
exposure	O
to	O
doxorubicin	B-T195
for	O
24	O
hours	O
by	O
annexin	O
V	O
/	O
PI	O
staining	B-T059
and	O
gene	O
expression	O
analysis	O
of	O
BAX	O
pro	O
-	O
apoptotic	O
protein	O
.	O
The	O
results	O
indicated	O
the	O
enhanced	O
growth	O
and	O
invasion	O
of	O
leukemic	B-T191
cells	O
at	O
pH	O
6.6	O
(	O
P	O
≤	O
0.05	O
)	O
.	O
Furthermore	O
,	O
the	O
cells	O
at	O
pH	O
6.6	O
were	O
resistant	O
to	O
apoptosis	O
by	O
doxorubicin	B-T195
(	O
P	O
≤	O
0.05	O
)	O
.	O
It	O
can	O
be	O
concluded	O
that	O
acidic	O
pH	O
increases	O
the	O
proliferation	O
,	O
invasion	O
and	O
reduces	O
the	O
drug	B-T121
-	O
induced	O
apoptosis	O
in	O
acute	B-T191
lymphoblastic	I-T191
leukemia	I-T191
.	O
Extracellular	O
acidity	O
can	O
influence	O
the	O
behavior	O
of	O
leukemic	B-T191
cells	O
and	O
therefore	O
,	O
the	O
manipulation	O
of	O
extracellular	O
liquid	O
can	O
be	O
selected	O
as	O
a	O
therapeutic	B-T061
strategy	I-T061
for	O
leukemia	B-T191
,	O
especially	O
for	O
acute	B-T191
lymphoblastic	I-T191
leukemia	I-T191
.	O
      
Breast	B-T191
Cancer	I-T191
Detection	O
Rate	O
,	O
Incidence	O
,	O
Prevalence	O
and	O
Interval	O
Cancer	B-T191
-related	O
Mammography	B-T061
Screening	I-T061
Times	O
among	O
Thai	O
Women	O
A	O
recent	O
guideline	O
by	O
the	O
American	O
Cancer	O
Society	O
recommended	O
that	O
mammography	B-T060
(	O
MMG	B-T060
)	O
should	O
be	O
done	O
for	O
women	O
starting	O
in	O
their	O
mid-40s	O
.	O
In	O
Thailand	O
,	O
information	O
on	O
opportunistic	B-T058
mammography	I-T058
screening	I-T058
is	O
limited	O
and	O
data	O
on	O
the	O
total	O
incidence	O
of	O
breast	B-T191
cancer	I-T191
are	O
also	O
lacking	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
breast	B-T191
cancer	I-T191
detection	B-T058
,	O
incident	O
and	O
prevalence	O
rates	O
among	O
Thai	O
women	O
.	O
We	O
retrospectively	O
reviewed	O
the	O
opportunistic	B-T058
mammography	I-T058
screening	I-T058
of	O
normal	O
women	O
between	O
30	O
and	O
80	O
years	O
who	O
underwent	O
the	O
procedure	B-T058
between	O
2001	O
and	O
2010	O
.	O
All	O
cases	O
were	O
followed	O
until	O
2012	O
.	O
The	O
detection	O
rate	O
was	O
calculated	O
for	O
the	O
whole	O
period	O
of	O
observation	O
using	O
'	O
number	O
of	O
women	O
with	O
positive	B-T033
findings	I-T033
'	O
divided	O
by	O
'	O
total	O
number	O
of	O
women	O
screened	B-T060
'	O
.	O
The	O
incidence	O
rate	O
was	O
calculated	O
only	O
at	O
the	O
first	O
MMG	B-T060
while	O
the	O
subsequence	O
rate	O
was	O
calculated	O
based	O
on	O
all	O
new	O
cases	O
detected	B-T033
at	O
each	O
subsequent	O
MMG	B-T060
.	O
Among	O
the	O
47,430	O
women	O
,	O
there	O
were	O
152,091	O
MMGs	B-T060
or	O
approximately	O
3.2	O
occasions	O
per	O
person	O
(	O
range	O
,	O
1	O
-	O
10	O
)	O
.	O
The	O
average	O
duration	O
of	O
the	O
interval	O
between	O
each	O
subsequence	O
visit	O
was	O
1.8	O
years	O
.	O
Overall	O
,	O
breast	B-T191
cancer	I-T191
was	O
detected	B-T033
in	O
543	O
women	O
,	O
with	O
a	O
detection	O
rate	O
of	O
10.3	O
per	O
1,000	O
persons	O
.	O
The	O
prevalence	O
rate	O
of	O
breast	B-T191
cancer	I-T191
at	O
the	O
first	O
visit	O
was	O
5.78	O
per	O
1,000	O
person	O
s.	O
The	O
incidence	O
or	O
new	O
cases	O
detected	B-T033
at	O
any	O
follow	O
-	O
up	O
visit	O
was	O
10.4	O
per	O
1,000	O
person	O
s.	O
The	O
overall	O
interval	O
cancer	O
was	O
0.91	O
per	O
1,000	O
women	O
,	O
mainly	O
detected	B-T033
before	O
their	O
second	O
and	O
third	O
MMG	B-T060
,	O
with	O
a	O
rate	O
of	O
0.0.47	O
and	O
0.76	O
per	O
1,000	O
women	O
.	O
Opportunistic	B-T058
mammography	I-T058
screening	I-T058
in	O
Thailand	O
detected	B-T033
10	O
cases	O
of	O
breast	B-T191
cancer	I-T191
from	O
each	O
1,000	O
women	O
.	O
This	O
paper	O
indicated	O
a	O
high	O
rate	O
of	O
cancer	B-T058
detection	I-T058
during	O
a	O
two	O
year	O
interval	O
,	O
hence	O
,	O
a	O
screening	B-T061
mammogram	I-T061
should	O
be	O
performed	O
more	O
often	O
.	O
      
Gestational	O
age	O
specific	O
stillbirth	B-T033
risk	O
among	O
Indigenous	O
and	O
non	O
-	O
Indigenous	O
women	O
in	O
Queensland	O
,	O
Australia	O
:	O
a	O
population	O
based	O
study	O
In	O
Australia	O
,	O
significant	O
disparity	O
persists	O
in	O
stillbirth	B-T033
rates	O
between	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
(	O
Indigenous	O
Australian	O
)	O
and	O
non	O
-	O
Indigenous	O
women	O
.	O
Diabetes	B-T047
,	O
hypertension	B-T047
,	O
antepartum	O
haemorrhage	O
and	O
small	O
-	O
for	O
-	O
gestational	O
age	O
(	O
SGA	O
)	O
have	O
been	O
identified	O
as	O
important	O
contributors	O
to	O
higher	O
rates	O
among	O
Indigenous	O
women	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
examine	O
gestational	O
age	O
specific	O
risk	O
of	O
stillbirth	B-T033
associated	O
with	O
these	O
conditions	O
among	O
Indigenous	O
and	O
non	O
-	O
Indigenous	O
women	O
.	O
Retrospective	O
population	O
-	O
based	O
study	O
of	O
all	O
singleton	O
births	O
of	O
at	O
least	O
20	O
weeks	O
gestation	O
or	O
at	O
least	O
400	O
grams	O
birthweight	O
in	O
Queensland	O
between	O
July	O
2005	O
and	O
December	O
2011	O
using	O
data	O
from	O
the	O
Queensland	O
Perinatal	O
Data	O
Collection	O
,	O
which	O
is	O
a	O
routinely	O
-	O
maintained	O
database	O
that	O
collects	O
data	O
on	O
all	O
births	O
in	O
Queensland	O
.	O
Multivariate	O
logistic	O
regression	O
was	O
used	O
to	O
calculate	O
adjusted	O
odds	O
ratios	O
(	O
aOR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
,	O
adjusting	O
for	O
maternal	B-T033
demographic	O
and	O
pregnancy	B-T033
factors	I-T033
.	O
Of	O
360987	O
births	O
analysed	O
,	O
20273	O
(	O
5.6	O
%	O
)	O
were	O
to	O
Indigenous	O
women	O
and	O
340714	O
(	O
94.4	O
%	O
)	O
were	O
to	O
non	O
-	O
Indigenous	O
women	O
.	O
Stillbirth	B-T033
rates	O
were	O
7.9	O
(	O
95	O
%	O
CI	O
6.8	O
-	O
9.2	O
)	O
and	O
4.1	O
(	O
95	O
%	O
CI	O
3.9	O
-	O
4.3	O
)	O
per	O
1000	O
births	O
,	O
respectively	O
.	O
For	O
both	O
Indigenous	O
and	O
non	O
-	O
Indigenous	O
women	O
across	O
most	O
gestational	O
age	O
groups	O
,	O
antepartum	O
haemorrhage	O
,	O
SGA	O
,	O
pre	B-T033
-	I-T033
existing	I-T033
diabetes	I-T033
and	O
pre	B-T033
-	I-T033
existing	I-T033
hypertension	I-T033
were	O
associated	O
with	O
increased	O
risk	O
of	O
stillbirth	B-T033
.	O
There	O
were	O
mixed	O
results	O
for	O
pre	O
-	O
eclampsia	O
and	O
eclampsia	B-T047
and	O
a	O
consistently	O
raised	O
risk	O
of	O
stillbirth	B-T033
was	O
not	O
seen	O
for	O
gestational	B-T047
diabetes	I-T047
.	O
This	O
study	O
highlights	O
gestational	O
age	O
specific	O
stillbirth	B-T033
risk	O
for	O
Indigenous	O
and	O
non	O
-	O
Indigenous	O
women	O
;	O
and	O
disparity	O
in	O
risk	O
at	O
term	O
gestations	O
.	O
Improving	O
access	O
to	O
and	O
utilisation	O
of	O
appropriate	O
and	O
responsive	O
healthcare	B-T058
may	O
help	O
to	O
address	O
disparities	O
in	O
stillbirth	B-T033
risk	O
for	O
Indigenous	O
women	O
.	O
      
Doxorubicin	B-T195
Has	O
Dose	O
-	O
Dependent	O
Toxicity	O
on	O
Mouse	O
Ovarian	B-T023
Follicle	I-T023
Development	O
,	O
Hormone	O
Secretion	O
,	O
and	O
Oocyte	O
Maturation	O
Doxorubicin	B-T195
(	O
DOX	B-T195
)	O
,	O
one	O
of	O
the	O
most	O
commonly	O
used	O
anticancer	B-T121
medications	I-T121
,	O
has	O
been	O
reported	O
to	O
affect	O
fertility	O
by	O
damaging	O
ovarian	B-T023
follicles	I-T023
;	O
however	O
,	O
the	O
dose	O
-	O
dependent	O
toxicity	O
of	O
DOX	B-T195
on	O
the	O
dynamic	O
follicle	B-T023
development	O
and	O
oocyte	O
maturation	O
has	O
not	O
been	O
well	O
-	O
defined	O
.	O
Our	O
objective	O
is	O
to	O
determine	O
the	O
effects	O
of	O
human	O
-	O
relevant	O
exposure	O
levels	O
of	O
DOX	B-T195
on	O
follicular	B-T023
functions	O
across	O
developmental	O
time	O
.	O
In	O
vitro	O
cultured	B-T059
multilayered	B-T023
secondary	I-T023
mouse	I-T023
follicles	I-T023
were	O
treated	O
with	O
DOX	B-T195
at	O
0	O
,	O
2	O
,	O
20	O
,	O
100	O
,	O
and	O
200	O
nM	O
for	O
24	O
h	O
,	O
and	O
follicle	B-T023
development	O
,	O
hormone	O
secretion	O
,	O
and	O
oocyte	O
maturation	O
were	O
analyzed	O
.	O
DOX	B-T195
caused	O
dose	O
-	O
dependent	O
toxicity	O
on	O
follicle	O
growth	O
,	O
survival	O
,	O
and	O
secretion	O
of	O
17β	B-T121
-	I-T121
estradiol	I-T121
(	O
E2	B-T121
)	O
.	O
At	O
200	O
nM	O
,	O
DOX	B-T195
induced	O
DNA	O
damage	O
and	O
apoptosis	O
in	O
follicle	B-T023
somatic	O
cells	O
first	O
and	O
then	O
in	O
oocytes	O
,	O
which	O
was	O
correlated	O
with	O
the	O
uptake	O
of	O
DOX	B-T195
first	O
to	O
the	O
somatic	O
cells	O
followed	O
by	O
germ	O
cells	O
.	O
Follicles	B-T023
treated	O
with	O
DOX	B-T195
at	O
0	O
,	O
2	O
,	O
and	O
20	O
nM	O
showed	O
similar	O
oocyte	O
metaphase	O
II	O
(	O
MII	O
)	O
percentages	O
after	O
in	O
vitro	O
oocyte	O
maturation	O
;	O
however	O
,	O
20	O
nM	O
DOX	B-T195
significantly	O
increased	O
the	O
number	O
of	O
MII	O
oocytes	O
with	O
abnormal	B-T033
spindle	O
morphology	O
and	O
chromosome	O
misalignment	O
.	O
In	O
an	O
effort	O
to	O
harmonize	O
the	O
in	O
vitro	O
study	O
to	O
in	O
vivo	O
treatment	O
,	O
dose	O
-	O
dependent	O
toxicity	O
on	O
oocyte	O
meiotic	O
maturation	O
was	O
found	O
in	O
16	O
-	O
day	O
-	O
old	O
CD-1	O
mice	O
treated	O
with	O
DOX	B-T195
at	O
0	O
,	O
0.4	O
,	O
2	O
,	O
and	O
10	O
mg	O
/	O
kg	O
,	O
consistent	O
with	O
the	O
in	O
vitro	O
oocyte	O
maturation	O
outcomes	O
.	O
Our	O
study	O
demonstrates	O
that	O
DOX	B-T195
has	O
dose	O
-	O
dependent	O
toxicity	O
on	O
ovarian	B-T023
follicle	I-T023
development	O
,	O
hormone	O
secretion	O
,	O
and	O
oocyte	O
maturation	O
,	O
which	O
are	O
three	O
key	O
factors	O
to	O
support	O
the	O
female	O
reproductive	O
and	O
endocrine	O
functions	O
.	O
      
Angiotensin	B-T033
-	I-T033
converting	I-T033
enzyme	I-T033
insertion	I-T033
/	I-T033
deletion	I-T033
polymorphism	I-T033
association	O
with	O
obesity	B-T047
and	O
some	O
related	O
disorders	B-T047
in	O
Egyptian	O
females	O
:	O
a	O
case	O
-	O
control	O
observational	O
study	O
According	O
to	O
the	O
WHO	O
report	O
in	O
2015	O
,	O
obesity	B-T047
is	O
the	O
fifth	O
leading	O
cause	B-T033
of	I-T033
death	I-T033
worldwide	O
,	O
and	O
the	O
prevalence	O
of	O
Egyptian	O
female	O
obesity	B-T047
is	O
37.5	O
%	O
.	O
Since	O
obesity	B-T047
is	O
highly	O
influenced	O
by	O
genetics	O
,	O
and	O
adipose	O
tissue	O
renin	O
-	O
angiotensin	O
system	O
is	O
over	O
-	O
activated	O
in	O
obesity	B-T047
,	O
the	O
effect	O
of	O
angiotensin	B-T033
-	I-T033
converting	I-T033
enzyme	I-T033
(	I-T033
ACE	I-T033
)	I-T033
insertion	I-T033
/	I-T033
deletion	I-T033
(	I-T033
I	I-T033
/	I-T033
D	I-T033
)	I-T033
polymorphism	I-T033
on	O
obesity	B-T047
and	O
related	O
disorders	B-T047
was	O
studied	O
in	O
several	O
populations	O
,	O
because	O
of	O
its	O
effect	O
on	O
ACE	O
activity	O
.	O
Our	O
objective	O
was	O
to	O
study	O
the	O
association	O
of	O
ACE	B-T033
I	I-T033
/	I-T033
D	I-T033
polymorphism	I-T033
with	O
obesity	B-T047
and	O
certain	O
related	O
disorders	B-T047
,	O
namely	O
hypertension	B-T047
,	O
insulin	O
resistance	O
and	O
metabolic	B-T047
syndrome	I-T047
,	O
in	O
Egyptian	O
females	O
.	O
Eighty	O
female	O
volunteers	O
were	O
recruited	O
,	O
blood	B-T058
pressure	I-T058
and	O
body	B-T060
measurements	I-T060
were	O
recorded	O
and	O
a	O
fasting	B-T033
blood	O
sample	O
was	O
obtained	O
for	O
the	O
quantitation	O
of	O
glucose	B-T121
,	O
lipid	B-T059
profile	I-T059
,	O
insulin	B-T121
,	I-T121
leptin	O
and	O
identification	O
of	O
ACE	B-T033
I	I-T033
/	I-T033
D	I-T033
polymorphs	I-T033
.	O
Subjects	O
were	O
grouped	O
based	O
on	O
hypertension	B-T047
and	O
obesity	B-T033
states	I-T033
.	O
Comparisons	O
of	O
continuous	O
parameters	B-T033
were	O
made	O
with	O
independent	O
sample	O
t	O
-	O
test	O
between	O
two	O
groups	O
.	O
The	O
frequencies	O
of	O
ACE	O
genotypes	O
and	O
alleles	O
,	O
and	O
the	O
association	O
between	O
gene	O
polymorphism	O
and	O
metabolic	O
parameters	B-T033
were	O
assessed	O
using	O
chi	O
-	O
square	O
or	O
Fisher	O
's	O
exact	O
test	O
.	O
Genotype	O
frequencies	O
were	O
in	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
for	O
all	O
groups	O
.	O
Genotype	O
distribution	O
did	O
not	O
differ	O
significantly	O
between	O
controls	O
and	O
cases	O
of	O
all	O
the	O
studied	O
disorders	B-T047
.	O
Although	O
DD	B-T033
carriers	I-T033
had	O
apparently	O
higher	O
parameters	B-T033
of	O
blood	O
pressure	O
,	O
lipid	B-T059
profile	I-T059
and	O
insulin	O
resistance	O
,	O
only	O
diastolic	O
blood	O
pressure	O
was	O
almost	O
significant	O
(	O
p	O
=	O
0.057	O
)	O
.	O
I	B-T033
-	I-T033
carriers	I-T033
were	O
significantly	O
less	O
susceptible	O
to	O
hypertension	B-T047
than	O
DD	B-T033
carriers	I-T033
having	O
normal	O
waist	O
/	O
hip	O
ratio	O
(	O
p	O
=	O
0.007	O
,	O
OR	O
=	O
17.29	O
,	O
CI	O
=	O
1.81	O
-	O
164.96	O
)	O
and	O
normal	O
conicity	O
index	O
(	O
p	O
=	O
0.024	O
,	O
OR	O
=	O
7.00	O
,	O
CI	O
=	O
1.36	O
-	O
35.93	O
)	O
.	O
In	O
DD	B-T033
genotype	I-T033
carriers	I-T033
,	O
a	O
significant	O
association	O
was	O
found	O
between	O
insulin	O
resistance	O
and	O
high	B-T033
body	I-T033
mass	I-T033
index	I-T033
(	O
p	O
=	O
0.004	O
,	O
OR	O
=	O
8.89	O
,	O
CI	O
=	O
1.94	O
-	O
40.71	O
)	O
,	O
waist	O
circumference	O
(	O
p	O
=	O
0.003	O
,	O
OR	O
=	O
9.63	O
,	O
CI	O
=	O
2.14	O
-	O
43.36	O
)	O
and	O
waist	B-T033
/	I-T033
height	I-T033
ratio	I-T033
(	O
p	O
=	O
0.034	O
,	O
OR	O
=	O
6.86	O
,	O
CI	O
=	O
1.25	O
-	O
37.61	O
)	O
,	O
although	O
the	O
variations	O
in	O
percentages	O
between	O
DD	B-T033
and	O
I	B-T033
-	I-T033
carriers	I-T033
were	O
not	O
high	O
enough	O
to	O
conclude	O
an	O
effect	O
of	O
ACE	B-T033
I	I-T033
/	I-T033
D	I-T033
on	O
such	O
an	O
association	O
.	O
In	O
this	O
sample	O
of	O
Egyptian	O
females	O
,	O
ACE	B-T033
I	I-T033
/	I-T033
D	I-T033
polymorphism	I-T033
was	O
not	B-T033
significantly	I-T033
associated	O
with	O
obesity	B-T047
nor	O
with	O
any	O
of	O
its	O
related	O
disorders	B-T047
studied	O
.	O
The	O
I	O
allele	O
seemed	O
protective	O
against	O
hypertension	B-T047
in	O
subjects	O
with	O
normal	O
,	O
not	O
high	O
,	O
waist	O
/	O
hip	O
ratio	O
and	O
conicity	O
index	O
compared	O
to	O
DD	B-T033
genotype	I-T033
carriers	I-T033
.	O
      
Influence	O
of	O
yeast	O
and	O
lactic	B-T007
acid	I-T007
bacterium	I-T007
on	O
the	O
constituent	O
profile	B-T059
of	O
soy	O
sauce	O
during	O
fermentation	O
Soy	O
sauce	O
is	O
a	O
Japanese	O
traditional	O
seasoning	O
composed	O
of	O
various	O
constituents	O
that	O
are	O
produced	O
by	O
various	O
microbes	B-T001
during	O
a	O
long	O
-	O
term	O
fermentation	O
process	O
.	O
Due	O
to	O
the	O
complexity	O
of	O
the	O
process	O
,	O
the	O
investigation	O
of	O
the	O
constituent	O
profile	B-T059
during	O
fermentation	O
is	O
difficult	B-T033
.	O
Metabolomics	O
,	O
the	O
comprehensive	O
study	O
of	O
low	O
molecular	O
weight	O
compounds	O
in	O
biological	O
samples	O
,	O
is	O
thought	O
to	O
be	O
a	O
promising	O
strategy	O
for	O
deep	O
understanding	O
of	O
the	O
constituent	O
contribution	O
to	O
food	O
flavor	O
characteristics	O
.	O
Therefore	O
,	O
metabolomics	O
is	O
suitable	O
for	O
the	O
analysis	O
of	O
soy	O
sauce	O
fermentation	O
.	O
Unfortunately	O
,	O
only	O
few	O
and	O
unrefined	O
studies	O
of	O
soy	O
sauce	O
fermentation	O
using	O
metabolomics	O
approach	O
have	O
been	O
reported	O
.	O
Therefore	O
,	O
we	O
investigated	O
changes	O
in	O
low	O
molecular	O
weight	O
hydrophilic	O
and	O
volatile	O
compounds	O
of	O
soy	O
sauce	O
using	O
gas	B-T059
chromatography	I-T059
/	I-T059
mass	I-T059
spectrometry	I-T059
(	O
GC	B-T059
/	I-T059
MS	I-T059
MS)-	O
based	O
non	O
-	O
targeted	O
metabolic	O
profiling	O
.	O
The	O
data	O
were	O
analyzed	O
by	O
statistical	O
analysis	O
to	O
evaluate	O
influences	O
of	O
yeast	O
and	O
lactic	B-T007
acid	I-T007
bacterium	I-T007
on	O
the	O
constituent	O
profile	B-T059
.	O
Consequently	O
,	O
our	O
results	O
suggested	O
a	O
novel	O
finding	B-T033
that	O
lactic	B-T007
acid	I-T007
bacterium	I-T007
affected	O
the	O
production	O
of	O
several	O
constituents	O
such	O
as	O
cyclotene	O
,	O
furfural	O
,	O
furfuryl	O
alcohol	O
and	O
methional	O
in	O
the	O
soy	O
sauce	O
fermentation	O
process	O
.	O
      
Fyn	O
regulates	O
multipolar	O
-	O
bipolar	O
transition	O
and	O
neurite	O
morphogenesis	O
of	O
migrating	O
neurons	O
in	O
the	O
developing	O
neocortex	O
Fyn	O
is	O
a	O
non	B-T033
-	I-T033
receptor	I-T033
protein	O
tyrosine	O
kinase	O
that	O
belongs	O
to	O
Src	O
family	O
kinases	O
.	O
Fyn	O
plays	O
a	O
critical	O
role	O
in	O
neuronal	O
migration	O
,	O
but	O
the	O
mechanism	O
remains	O
unclear	B-T033
.	O
Here	O
,	O
we	O
reported	O
that	O
suppression	O
of	O
Fyn	O
expression	O
in	O
mouse	O
cerebral	O
cortex	O
led	O
to	O
migration	B-T033
defects	I-T033
of	O
both	O
early	O
-	O
born	O
and	O
late	O
-	O
born	O
neurons	O
.	O
Morphological	O
analysis	O
showed	O
that	O
loss	O
of	O
Fyn	O
function	O
impaired	O
multipolar	O
-	O
bipolar	O
transition	O
of	O
newly	O
generated	O
neurons	O
and	O
neurite	O
formation	O
in	O
the	O
early	O
phase	O
of	O
migration	O
.	O
Moreover	O
,	O
Fyn	O
inhibition	O
increased	O
the	O
length	O
of	O
leading	O
process	O
and	O
decreased	O
the	O
branching	O
number	O
of	O
the	O
migrating	O
cortical	O
neurons	O
.	O
Together	O
,	O
these	O
results	O
indicate	O
that	O
Fyn	O
controls	O
neuronal	O
migration	O
by	O
regulating	O
the	O
cytoskeletal	O
dynamics	O
and	O
multipolar	O
-	O
bipolar	O
transition	O
of	O
newly	O
generated	O
neurons	O
during	O
cortical	O
development	O
.	O
      
Fluorescence	B-T060
hyperspectral	I-T060
imaging	I-T060
(	O
fHSI	B-T060
)	O
using	O
a	O
spectrally	O
resolved	B-T033
detector	O
array	O
The	O
ability	O
to	O
resolve	O
multiple	O
fluorescent	O
emissions	O
from	O
different	O
biological	O
targets	O
in	O
video	O
rate	O
applications	O
,	O
such	O
as	O
endoscopy	B-T060
and	O
intraoperative	B-T060
imaging	I-T060
,	O
has	O
traditionally	O
been	O
limited	O
by	O
the	O
use	O
of	O
filter	O
-	O
based	O
imaging	O
systems	O
.	O
Hyperspectral	B-T060
imaging	I-T060
(	O
HSI	B-T060
)	O
facilitates	O
the	O
detection	B-T061
of	O
both	O
spatial	O
and	O
spectral	O
information	O
in	O
a	O
single	O
data	O
acquisition	O
,	O
however	O
,	O
instrumentation	O
for	O
HSI	B-T060
is	O
typically	O
complex	O
,	O
bulky	O
and	O
expensive	O
.	O
We	O
sought	O
to	O
overcome	O
these	O
limitations	O
using	O
a	O
novel	O
robust	O
and	O
low	O
cost	O
HSI	B-T060
camera	O
based	O
on	O
a	O
spectrally	O
resolved	O
detector	O
array	O
(	O
SRDA	O
)	O
.	O
We	O
integrated	O
this	O
HSI	B-T060
camera	O
into	O
a	O
wide	B-T033
-	I-T033
field	I-T033
reflectance	B-T059
-	I-T059
based	I-T059
imaging	O
system	O
operating	O
in	O
the	O
near	O
-	O
infrared	O
range	O
to	O
assess	B-T058
the	O
suitability	O
for	O
in	B-T059
vivo	I-T059
imaging	I-T059
of	O
exogenous	O
fluorescent	O
contrast	O
agents	O
.	O
Using	O
this	O
fluorescence	B-T060
HSI	I-T060
(	O
fHSI	B-T060
)	O
system	O
,	O
we	O
were	O
able	O
to	O
accurately	O
resolve	O
the	O
presence	O
and	O
concentration	O
of	O
at	O
least	O
7	O
fluorescent	O
dyes	O
in	O
solution	O
.	O
We	O
also	O
demonstrate	O
high	O
spectral	O
unmixing	O
precision	O
,	O
signal	O
linearity	O
with	O
dye	O
concentration	O
and	O
at	O
depth	O
in	O
tissue	O
mimicking	O
phantoms	O
,	O
and	O
delineate	B-T033
4	O
fluorescent	O
dyes	O
in	O
vivo	O
.	O
Our	O
approach	O
,	O
including	O
statistical	O
background	O
removal	O
,	O
could	O
be	O
directly	O
generalised	O
to	O
broader	O
spectral	O
ranges	O
,	O
for	O
example	O
,	O
to	O
resolve	O
tissue	O
reflectance	B-T059
or	O
autofluorescence	B-T059
and	O
in	O
future	O
be	O
tailored	O
to	O
video	O
rate	O
applications	O
requiring	O
snapshot	O
HSI	B-T060
data	O
acquisition	O
.	O
      
Ventricular	B-T061
pacing	I-T061
site	O
separation	O
by	O
cardiac	O
computed	B-T060
tomography	I-T060
:	O
validation	O
for	O
the	O
prediction	O
of	O
clinical	B-T033
response	I-T033
to	O
cardiac	B-T061
resynchronization	I-T061
therapy	I-T061
Cardiac	B-T061
Resynchronization	I-T061
Therapy	I-T061
(	O
CRT	B-T061
)	O
fails	O
to	O
provide	O
benefit	O
in	O
up	O
to	O
one	O
-	O
third	O
of	O
patients	O
.	O
Maximizing	O
the	O
geographic	O
separation	O
of	O
right	O
and	O
left	O
ventricular	B-T061
pacing	I-T061
lead	O
sites	O
has	O
been	O
suggested	O
as	O
one	O
way	O
to	O
improve	B-T033
response	O
.	O
Cardiac	B-T060
CT	I-T060
provides	O
an	O
opportunity	O
to	O
explore	O
3	O
-	O
dimensional	O
inter	O
-	O
lead	O
distance	O
(	O
ILD	O
)	O
measures	O
for	O
the	O
prediction	O
of	O
CRT	B-T061
response	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
associations	O
between	O
standardized	O
measures	O
of	O
ILD	O
by	O
cardiac	B-T060
CT	I-T060
and	O
echocardiographic	B-T060
response	O
to	O
CRT	B-T061
.	O
Forty	O
-	O
two	O
consecutive	O
patients	O
undergoing	O
CRT	B-T061
had	O
serial	O
clinical	B-T058
and	O
echocardiographic	B-T060
evaluations	B-T058
performed	O
in	O
addition	O
to	O
a	O
post	O
-	O
procedural	O
cardiac	O
-gated	O
CT	B-T060
with	O
blinded	O
measurement	O
of	O
direct	O
and	O
circumferential	O
(	O
via	O
the	O
myocardium	O
)	O
ILD	O
measures	O
.	O
Clinical	B-T033
response	I-T033
to	O
CRT	B-T061
,	O
the	O
primary	O
clinical	O
outcome	O
,	O
was	O
defined	O
as	O
a	O
≥15	O
%	O
reduction	O
in	O
LVESV	B-T033
using	O
echocardiography	B-T060
at	O
6	O
-	O
months	O
.	O
The	O
mean	O
age	O
and	O
ejection	B-T033
fraction	I-T033
was	O
63.6	O
±	O
8.9	O
years	O
and	O
25.2	O
±	O
7.8	O
%	O
,	O
respectively	O
.	O
The	O
primary	O
outcome	O
occurred	O
in	O
35	O
of	O
42	O
patients	O
(	O
83	O
%	O
)	O
.	O
Both	O
direct	O
and	O
circumferential	O
CT	B-T060
-based	O
ILD	O
measures	O
were	O
associated	O
with	O
the	O
primary	O
outcome	O
by	O
univariate	O
analysis	O
.	O
Receiver	O
Operator	O
Characteristic	O
analysis	O
identified	O
Circumferential	O
ILD	O
to	O
have	O
the	O
strongest	O
predictive	O
accuracy	O
(	O
AUC	O
0.78	O
)	O
.	O
Inter-	O
and	O
intra	O
-	O
observer	O
reproducibility	O
of	O
CT	B-T060
-derived	O
ILD	O
measures	O
was	O
excellent	O
.	O
Circumferential	O
ILD	O
measures	O
on	O
cardiac	B-T060
CT	I-T060
are	O
predictive	O
of	O
clinical	B-T033
response	I-T033
to	O
CRT	B-T061
.	O
Incorporation	O
of	O
these	O
measures	O
into	O
the	O
selection	O
of	O
optimal	O
pacing	B-T061
targets	O
,	O
particularly	O
from	O
pre	O
-	O
procedural	O
CT	B-T060
coronary	B-T023
vein	I-T023
imaging	B-T060
may	O
be	O
of	O
therapeutic	O
benefit	O
and	O
warrants	O
further	O
investigation	B-T058
.	O
      
No	O
free	O
bed	O
with	O
ventilator	O
:	O
experience	O
of	O
a	O
public	O
health	O
specialist	O
While	O
the	O
author	O
was	O
dealing	O
with	O
a	O
poor	O
elderly	O
father	O
struggling	O
to	O
shift	O
his	O
gravely	O
injured	O
young	O
son	O
to	O
a	O
government	O
hospital	O
due	O
to	O
the	O
high	O
cost	O
of	O
intensive	B-T058
care	I-T058
,	O
her	O
friends	O
across	O
the	O
globe	O
were	O
discussing	O
euthanasia	B-T058
in	O
the	O
social	O
media	O
.	O
While	O
marginalised	O
groups	O
of	O
people	O
are	O
struggling	O
to	O
access	O
care	O
in	O
India	O
,	O
friends	O
who	O
have	O
moved	O
to	O
developed	O
parts	O
of	O
the	O
world	O
were	O
discussing	O
one	O
's	O
choice	O
to	O
live	O
or	O
die	O
!	O
The	O
poor	O
father	O
,	O
after	O
battling	B-T048
to	O
save	O
his	O
son	O
and	O
reaching	O
out	O
to	O
many	O
people	O
for	O
help	O
,	O
could	O
not	O
save	O
him	O
.	O
Early	O
treatment	O
might	O
have	O
helped	O
the	O
young	O
boy	O
.	O
The	O
incident	O
left	O
the	O
author	O
thinking	O
about	O
how	O
the	O
poor	O
are	O
denied	O
care	O
simply	O
because	O
they	O
can	O
not	O
afford	O
it	O
.	O
Others	O
debate	O
when	O
to	O
pull	O
the	O
plug	O
on	O
the	O
patient	O
.	O
…	O
How	O
many	O
families	O
can	O
afford	O
such	O
care	O
in	O
India	O
?	O
When	O
nearly	O
71	O
%	O
of	O
the	O
people	O
are	O
paying	O
out	O
of	O
pocket	O
for	O
healthcare	B-T058
and	O
16	O
%	O
are	O
pushed	O
below	O
the	O
poverty	O
line	O
every	O
year	O
,	O
can	O
we	O
even	O
think	O
of	O
universal	O
health	O
coverage	O
?	O
It	O
just	O
sounds	O
like	O
a	O
fancy	O
term	O
to	O
be	O
used	O
at	O
conferences	B-T058
and	I-T058
meetings	I-T058
because	O
the	O
ground	O
reality	O
is	O
completely	O
different	O
.	O
      
Development	O
of	O
a	O
liquid	B-T059
chromatography	I-T059
-	I-T059
tandem	I-T059
mass	I-T059
spectrometry	I-T059
method	O
for	O
quantitative	O
analysis	O
of	O
trace	O
d	B-T121
-	I-T121
amino	I-T121
acids	I-T121
d	B-T121
-	I-T121
Amino	I-T121
acids	I-T121
have	O
recently	O
attracted	O
much	O
attention	O
in	O
various	O
research	O
fields	O
including	O
medical	O
,	O
clinical	O
and	O
food	O
industry	O
due	O
to	O
their	O
important	O
biological	O
functions	O
that	O
differ	O
from	O
l	B-T121
-	I-T121
amino	I-T121
acid	I-T121
.	O
Most	O
chiral	O
amino	B-T121
acid	I-T121
separation	B-T059
techniques	O
require	O
complicated	O
derivatization	O
procedures	O
in	O
order	O
to	O
achieve	O
the	O
desirable	O
chromatographic	O
behavior	O
and	O
detectability	B-T033
.	O
Thus	O
,	O
the	O
aim	O
of	O
this	O
research	O
is	O
to	O
develop	O
a	O
highly	O
sensitive	O
analytical	O
method	O
for	O
the	O
enantioseparation	B-T059
of	O
chiral	O
amino	B-T121
acids	I-T121
without	O
any	O
derivatization	O
process	O
using	O
liquid	B-T059
chromatography	I-T059
-	I-T059
tandem	I-T059
mass	I-T059
spectrometry	I-T059
(	O
LC	B-T059
-	I-T059
MS	I-T059
/	I-T059
MS	I-T059
)	O
.	O
By	O
optimizing	O
MS	B-T059
/	I-T059
MS	I-T059
parameters	O
,	O
we	O
established	O
a	O
quantification	O
method	O
that	O
allowed	O
the	O
simultaneous	O
analysis	O
of	O
18	O
d	B-T121
-	I-T121
amino	I-T121
acids	I-T121
with	O
high	O
sensitivity	O
and	O
reproducibility	O
.	O
Additionally	O
,	O
we	O
applied	O
the	O
method	O
to	O
food	O
sample	O
(	O
vinegar	B-T121
)	O
for	O
the	O
validation	O
,	O
and	O
successfully	O
quantified	O
trace	O
levels	O
of	O
d	B-T121
-	I-T121
amino	I-T121
acids	I-T121
in	O
samples	O
.	O
These	O
results	O
demonstrated	O
the	O
applicability	O
and	O
feasibility	O
of	O
the	O
LC	B-T059
-	I-T059
MS	I-T059
/	I-T059
MS	I-T059
method	O
as	O
a	O
novel	O
,	O
effective	O
tool	O
for	O
d	B-T121
-	I-T121
amino	I-T121
acid	I-T121
measurement	O
in	O
various	O
biological	O
samples	O
.	O
      
Targeting	O
HIF2	O
in	O
Clear	B-T191
Cell	I-T191
Renal	I-T191
Cell	I-T191
Carcinoma	I-T191
Inactivation	O
of	O
the	O
von	O
Hippel	O
-	O
Lindau	O
tumor	O
-	O
suppressor	O
protein	O
(	O
pVHL	O
)	O
is	O
the	O
signature	B-T033
"	I-T033
truncal	I-T033
"	I-T033
event	I-T033
in	O
clear	B-T191
cell	I-T191
renal	I-T191
cell	I-T191
carcinoma	I-T191
,	O
which	O
is	O
the	O
most	O
common	O
form	O
of	O
kidney	B-T191
cancer	I-T191
.	O
pVHL	O
is	O
part	O
of	O
a	O
ubiquitin	O
ligase	O
the	O
targets	O
the	O
α	O
subunit	O
of	O
the	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
transcription	O
factor	O
for	O
destruction	O
when	O
oxygen	O
is	O
available	O
.	O
Preclinical	O
studies	O
strongly	O
suggest	O
that	O
deregulation	O
of	O
HIF	O
,	O
and	O
particularly	O
HIF2	O
,	O
drives	O
pVHL	O
-defective	O
renal	B-T191
carcinogenesis	I-T191
.	O
Although	O
HIF2α	O
was	O
classically	O
considered	O
undruggable	O
,	O
structural	O
and	O
chemical	O
work	O
by	O
Rick	O
Bruick	O
and	O
Kevin	O
Gardner	O
at	O
University	O
of	O
Texas	O
Southwestern	O
laid	O
the	O
foundation	O
for	O
the	O
development	O
of	O
small	O
molecule	O
direct	O
HIF2α	O
antagonists	O
(	O
PT2385	B-T121
and	O
the	O
related	O
tool	O
compound	O
PT2399	O
)	O
by	O
Peloton	O
Therapeutics	O
that	O
block	O
the	O
dimerization	O
of	O
HIF2α	O
with	O
its	O
partner	O
protein	O
ARNT1	O
.	O
These	O
compounds	O
inhibit	O
clear	O
cell	O
renal	O
cell	O
carcinoma	O
growth	O
in	O
preclinical	O
models	O
,	O
and	O
PT2385	B-T121
has	O
now	O
entered	O
the	O
clinic	O
.	O
Nonetheless	O
,	O
the	O
availability	O
of	O
such	B-T121
compounds	I-T121
,	O
together	O
with	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeat	O
(	O
CRISPR)-based	O
gene	O
editing	O
approaches	O
,	O
has	O
revealed	O
a	O
previously	O
unappreciated	O
heterogeneity	O
among	O
clear	B-T191
cell	I-T191
renal	I-T191
carcinomas	I-T191
and	O
patient	O
-derived	O
xenografts	B-T061
with	O
respect	O
to	O
HIF2	O
dependence	O
,	O
suggesting	O
that	O
predictive	O
biomarkers	O
will	O
be	O
needed	O
to	O
optimize	O
the	O
use	O
of	O
such	B-T121
agents	I-T121
in	O
the	O
clinic	O
.	O
      
Autologous	O
vs	O
Irradiated	O
Homologous	O
Costal	O
Cartilage	O
as	O
Graft	O
Material	O
in	O
Rhinoplasty	B-T061
Studies	O
comparing	O
surgical	O
results	O
of	O
rhinoplasty	B-T061
using	O
autologous	O
costal	O
cartilage	O
(	O
ACC	O
)	O
and	O
irradiated	O
homologous	O
costal	O
cartilage	O
(	O
IHCC	O
)	O
are	O
rare	O
.	O
To	O
compare	O
the	O
clinical	O
results	O
of	O
major	O
augmentation	B-T061
rhinoplasty	I-T061
using	O
ACC	O
vs	O
IHCC	O
and	O
analyze	O
the	O
histologic	O
properties	O
of	O
both	O
types	O
of	O
cartilage	O
.	O
A	O
retrospective	O
clinical	O
study	O
was	O
conducted	O
among	O
patients	O
who	O
had	O
undergone	O
rhinoseptoplasty	B-T061
using	O
ACC	O
or	O
IHCC	O
from	O
January	O
1	O
,	O
2009	O
,	O
to	O
December	O
31	O
,	O
2014	O
.	O
Patients	O
were	O
followed	B-T058
up	I-T058
for	O
more	O
than	O
1	O
year	O
after	O
surgery	B-T061
and	O
the	O
histologic	O
characteristics	O
of	O
ACC	O
and	O
IHCC	O
were	O
compared	O
.	O
The	O
details	O
of	O
the	O
surgical	B-T061
procedures	I-T061
and	O
complications	B-T033
,	O
including	O
warping	B-T033
,	O
infection	O
,	O
resorption	O
,	O
and/or	O
donor	O
-	O
site	O
morbidity	O
,	O
were	O
evaluated	B-T058
by	O
reviewing	O
medical	O
records	O
and	O
facial	O
photographs	O
.	O
Patients	O
'	O
subjective	O
satisfaction	O
with	O
aesthetic	O
and	O
functional	O
results	O
was	O
evaluated	B-T058
using	O
a	O
questionnaire	O
.	O
The	O
details	O
of	O
the	O
surgical	B-T061
procedures	I-T061
and	O
complications	B-T033
,	O
including	O
warping	B-T033
,	O
infection	O
,	O
resorption	O
,	O
and/or	O
donor	O
-	O
site	O
morbidity	O
;	O
patients	O
'	O
subjective	O
satisfaction	O
with	O
aesthetic	O
and	O
functional	O
results	O
'	O
objective	O
evaluation	B-T058
of	O
surgical	B-T061
outcomes	O
,	O
including	O
symmetry	O
,	O
dorsal	O
height	O
,	O
dorsal	O
length	O
,	O
dorsal	O
width	O
,	O
tip	B-T033
projection	I-T033
,	O
tip	B-T033
rotation	I-T033
,	O
tip	B-T033
width	I-T033
,	O
and	O
overall	O
result	O
;	O
and	O
histologic	O
structures	O
.	O
Objective	O
evaluation	B-T058
of	O
surgical	B-T061
outcomes	O
was	O
graded	O
using	O
the	O
Objective	O
Rhinoplasty	B-T061
Outcome	B-T033
Score	I-T033
,	O
which	O
assessed	O
symmetry	O
,	O
dorsal	O
height	O
,	O
dorsal	O
length	O
,	O
dorsal	O
width	O
,	O
tip	B-T033
projection	I-T033
,	O
tip	B-T033
rotation	I-T033
,	O
tip	B-T033
width	I-T033
,	O
and	O
overall	O
result	O
.	O
Histologic	O
structures	O
were	O
evaluated	B-T058
using	O
hematoxylin	B-T059
and	I-T059
eosin	I-T059
,	O
Masson	B-T059
trichrome	I-T059
,	O
Alcian	B-T059
blue	I-T059
,	O
and	O
Verhoeff	B-T059
elastic	I-T059
stains	I-T059
.	O
A	O
total	O
of	O
63	O
patients	O
(	O
27	O
males	O
and	O
36	O
females	O
;	O
mean	O
[	O
SD	O
]	O
age	O
,	O
30.6	O
[	O
9.5	O
]	O
years	O
)	O
had	O
rhinoseptoplasty	B-T061
using	O
ACC	O
and	O
20	O
(	O
9	O
males	O
and	O
11	O
females	O
;	O
mean	O
[	O
SD	O
]	O
age	O
,	O
35.4	O
[	O
15.4	O
]	O
years	O
)	O
had	O
rhinoseptoplasty	B-T061
using	O
IHCC	O
.	O
Among	O
observed	O
complications	B-T033
,	O
only	O
notable	O
resorption	O
occurred	O
more	O
frequently	O
in	O
patients	O
using	O
IHCC	O
(	O
6	O
[	O
30	O
%	O
]	O
)	O
than	O
with	O
ACC	O
(	O
2	O
[	O
3	O
%	O
]	O
)	O
(	O
P	O
=	O
.002	O
)	O
.	O
In	O
subjective	O
evaluations	B-T058
of	O
aesthetic	O
satisfaction	O
,	O
patients	O
who	O
received	O
ACC	O
showed	O
significantly	O
greater	O
satisfaction	O
(	O
37	O
of	O
51	O
patients	O
[	O
73	O
%	O
]	O
were	O
very	B-T033
satisfied	I-T033
)	O
than	O
did	O
those	O
who	O
received	O
IHCC	O
(	O
6	O
of	O
20	O
[	O
30	O
%	O
]	O
)	O
(	O
P	O
=	O
.001	O
)	O
.	O
However	O
,	O
there	O
was	O
no	O
between	O
-	O
group	O
difference	O
in	O
subjective	O
functional	O
outcomes	O
:	O
4	O
of	O
51	O
patients	O
receiving	O
ACC	O
(	O
8	O
%	O
)	O
and	O
5	O
of	O
20	O
receiving	O
IHCC	O
(	O
25	O
%	O
)	O
were	O
satisfied	O
(	O
P	O
=	O
.50	O
)	O
and	O
45	O
of	O
51	O
receiving	O
ACC	O
(	O
88	O
%	O
)	O
and	O
15	O
of	O
20	O
receiving	O
IHCC	O
(	O
75	O
%	O
)	O
were	O
very	B-T033
satisfied	I-T033
(	O
P	O
=	O
.15	O
)	O
.	O
Regarding	O
objective	O
aesthetic	O
outcomes	O
,	O
all	O
scores	O
for	O
both	O
ACC	O
and	O
IHCC	O
were	O
more	O
than	O
3.1	O
(	O
between	O
good	O
and	O
excellent	O
)	O
.	O
Histologic	B-T059
analyses	I-T059
showed	O
larger	O
,	O
more	O
evenly	O
distributed	O
,	O
uniform	O
chondrocytes	O
and	O
more	O
collagens	O
and	O
proteoglycan	O
contents	O
in	O
ACC	O
than	O
in	O
IHCC	O
.	O
Compared	O
with	O
patients	O
receiving	O
IHCC	O
,	O
those	O
receiving	O
ACC	O
for	O
rhinoseptoplasty	B-T061
showed	O
superior	O
aesthetic	O
satisfaction	O
;	O
ACC	O
also	O
had	O
less	O
frequent	O
notable	O
resorption	O
.	O
Autologous	O
costal	O
cartilage	O
also	O
had	O
better	O
histologic	O
properties	O
than	O
IHCC	O
did	O
,	O
suggesting	O
it	O
as	O
an	O
ideal	O
graft	O
material	O
with	O
less	O
chance	O
of	O
long	O
-	O
term	O
resorption	O
.	O
3	O
.	O
      
Impact	O
of	O
Strategically	O
Located	O
White	O
Matter	O
Hyperintensities	O
on	O
Cognition	O
in	O
Memory	O
Clinic	O
Patients	O
with	O
Small	B-T047
Vessel	I-T047
Disease	I-T047
Studies	O
on	O
the	O
impact	O
of	O
small	B-T047
vessel	I-T047
disease	I-T047
(	O
SVD	B-T047
)	O
on	O
cognition	O
generally	O
focus	O
on	O
white	O
matter	O
hyperintensity	O
(	O
WMH	O
)	O
volume	O
.	O
The	O
extent	O
to	O
which	O
WMH	O
location	O
relates	O
to	O
cognitive	O
performance	O
has	O
received	O
less	O
attention	O
,	O
but	O
is	O
likely	O
to	O
be	O
functionally	O
important	O
.	O
We	O
examined	O
the	O
relation	O
between	O
WMH	O
location	O
and	O
cognition	O
in	O
a	O
memory	O
clinic	O
cohort	O
of	O
patients	O
with	O
sporadic	O
SVD	B-T047
.	O
A	O
total	O
of	O
167	O
patients	O
with	O
SVD	B-T047
were	O
recruited	O
from	O
memory	O
clinics	O
.	O
Assumption	O
-	O
free	O
region	O
of	O
interest	O
-	O
based	O
analyses	O
based	O
on	O
major	O
white	O
matter	O
tracts	B-T023
and	O
voxel	O
-	O
wise	O
analyses	O
were	O
used	O
to	O
determine	O
the	O
association	O
between	O
WMH	O
location	O
and	O
executive	O
functioning	O
,	O
visuomotor	O
speed	O
and	O
memory	O
.	O
Region	O
of	O
interest	O
-	O
based	O
analyses	O
showed	O
that	O
WMHs	O
located	O
particularly	O
within	O
the	O
anterior	B-T023
thalamic	I-T023
radiation	I-T023
and	O
forceps	B-T023
minor	I-T023
were	O
inversely	O
associated	O
with	O
both	O
executive	O
functioning	O
and	O
visuomotor	O
speed	O
,	O
independent	O
of	O
total	O
WMH	O
volume	O
.	O
Memory	O
was	O
significantly	O
associated	O
with	O
WMH	O
volume	O
in	O
the	O
forceps	B-T023
minor	I-T023
,	O
independent	O
of	O
total	O
WMH	O
volume	O
.	O
An	O
independent	O
assumption	O
-	O
free	O
voxel	O
-	O
wise	O
analysis	O
identified	O
strategic	O
voxels	O
in	O
these	O
same	O
tracts	B-T023
.	O
Region	O
of	O
interest	O
-	O
based	O
analyses	O
showed	O
that	O
WMH	O
volume	O
within	O
the	O
anterior	B-T023
thalamic	I-T023
radiation	I-T023
explained	O
6.8	O
%	O
of	O
variance	O
in	O
executive	O
functioning	O
,	O
compared	O
to	O
3.9	O
%	O
for	O
total	O
WMH	O
volume	O
;	O
WMH	O
volume	O
within	O
the	O
forceps	B-T023
minor	I-T023
explained	O
4.6	O
%	O
of	O
variance	O
in	O
visuomotor	O
speed	O
and	O
4.2	O
%	O
of	O
variance	O
in	O
memory	O
,	O
compared	O
to	O
1.8	O
%	O
and	O
1.3	O
%	O
respectively	O
for	O
total	O
WMH	O
volume	O
.	O
Our	O
findings	B-T033
identify	O
the	O
anterior	B-T023
thalamic	I-T023
radiation	I-T023
and	O
forceps	B-T023
minor	I-T023
as	O
strategic	O
white	O
matter	O
tracts	B-T023
in	O
which	O
WMHs	O
are	O
most	O
strongly	O
associated	O
with	O
cognitive	B-T048
impairment	I-T048
in	O
memory	O
clinic	O
patients	O
with	O
SVD	B-T047
.	O
WMH	O
volumes	O
in	O
individual	O
tracts	B-T023
explained	O
more	O
variance	O
in	O
cognition	O
than	O
total	O
WMH	O
burden	O
,	O
emphasizing	O
the	O
importance	O
of	O
lesion	B-T033
location	I-T033
when	O
addressing	O
the	O
functional	O
consequences	O
of	O
WMHs	O
.	O
      
Healthcare	B-T058
usage	O
and	O
economic	O
impact	O
of	O
non	B-T033
-	I-T033
treated	I-T033
obesity	B-T047
in	O
Italy	O
:	O
findings	O
from	O
a	O
retrospective	O
administrative	B-T033
and	O
clinical	O
database	O
analysis	O
Investigate	O
the	O
prevalence	O
of	O
obesity	B-T047
in	O
Italy	O
and	O
examine	O
its	O
resource	O
consumption	B-T033
and	O
economic	O
impact	O
on	O
the	O
Italian	O
national	O
healthcare	O
system	O
(	O
NHS	O
)	O
.	O
Retrospective	O
,	O
observational	O
and	O
real	O
-	O
life	O
study	O
.	O
Data	O
from	O
three	O
health	O
units	O
from	O
Northern	O
(	O
Bergamo	O
,	O
Lombardy	O
)	O
,	O
Central	O
(	O
Grosseto	O
,	O
Tuscany	O
)	O
and	O
Southern	O
(	O
Naples	O
,	O
Campania	O
)	O
Italy	O
.	O
All	O
patients	O
aged	O
≥18	O
years	O
with	O
at	O
least	O
one	O
recorded	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
measurement	O
between	O
1	O
January	O
2009	O
and	O
31	O
December	O
2012	O
were	O
included	O
.	O
Information	O
retrieved	O
from	O
the	O
databases	O
included	O
primary	O
care	O
data	O
,	O
medical	O
prescriptions	O
,	O
specialist	B-T058
consultations	I-T058
and	O
hospital	O
discharge	O
records	O
from	O
2009	O
-	O
2013	O
.	O
Costs	O
associated	O
with	O
these	O
data	O
were	O
also	O
calculated	O
.	O
Data	O
are	O
presented	O
for	O
two	O
time	O
periods	O
(	O
1	O
year	O
after	O
BMI	O
measurement	O
and	O
study	O
end	O
)	O
.	O
Primary	O
-to	O
estimate	O
health	O
resources	O
consumption	B-T033
and	O
the	O
associated	O
economic	O
impact	O
on	O
the	O
Italian	O
NHS	O
.	O
Secondary	O
-the	O
prevalence	O
and	O
characteristics	O
of	O
subjects	O
by	O
BMI	O
category	O
.	O
20	O
159	O
adult	O
subjects	O
with	O
at	O
least	O
one	O
documented	B-T033
BMI	I-T033
measurement	O
.	O
Subjects	O
with	O
BMI	O
≥30	O
kg	O
/	O
m(2	O
)	O
were	O
defined	O
as	O
obese	B-T047
.	O
The	O
prevalence	O
of	O
obesity	B-T047
was	O
22.2	O
%	O
(	O
N=4471	O
)	O
and	O
increased	O
with	O
age	O
.	O
At	O
the	O
1	O
-	O
year	O
observation	O
period	O
,	O
obese	B-T047
subjects	O
who	O
did	O
not	O
receive	O
treatment	B-T061
for	O
their	O
obesity	B-T047
experienced	O
longer	O
durations	O
of	O
hospitalisation	B-T058
(	O
median	O
length	O
:	O
5	O
days	O
vs	O
3	O
days	O
)	O
,	O
used	O
more	O
prescription	B-T121
drugs	I-T121
(	O
75.0	O
%	O
vs	O
57.7	O
%	O
)	O
,	O
required	O
more	O
specialised	O
outpatient	O
healthcare	B-T058
(	O
mean	O
number	O
:	O
5.3	O
vs	O
4.4	O
)	O
and	O
were	O
associated	O
with	O
greater	O
costs	O
,	O
primarily	O
owing	O
to	O
prescription	B-T121
drugs	I-T121
and	O
hospital	B-T058
admissions	I-T058
(	O
mean	O
annual	O
cost	O
per	O
year	O
per	O
patient	O
:	O
€	O
460.6	O
vs	O
€	O
288.0	O
for	O
drug	O
prescriptions	O
,	O
€	O
422.7	O
vs	O
€	O
279.2	O
for	O
hospitalisations	B-T058
and	O
€	O
283.2	O
vs	O
€	O
251.7	O
for	O
outpatient	B-T058
care	I-T058
)	O
,	O
compared	O
with	O
normal	B-T033
weight	I-T033
subjects	O
.	O
Similar	O
findings	O
were	O
observed	O
for	O
the	O
period	O
up	O
to	O
data	O
cut	O
-	O
off	O
(	O
mean	O
follow	B-T058
-	I-T058
up	I-T058
of	O
2.7	O
years	O
)	O
.	O
Untreated	B-T033
obesity	B-T047
has	O
a	O
significant	O
economic	O
impact	O
on	O
the	O
Italian	O
healthcare	O
system	O
,	O
highlighting	O
the	O
need	O
to	O
raise	O
awareness	O
and	O
proactively	O
treat	B-T061
obese	O
subjects	O
.	O
      
Endpoints	O
for	O
screening	B-T060
thyroid	B-T191
cancer	I-T191
in	O
the	O
Republic	O
of	O
Korea	O
:	O
thyroid	B-T023
specialists	O
'	O
perspectives	O
Cancer	B-T060
screening	I-T060
is	O
aimed	O
primarily	O
at	O
reducing	O
deaths	B-T033
from	O
the	O
specific	O
cancer	B-T191
.	O
Thyroid	B-T191
-	I-T191
specific	I-T191
cancer	I-T191
mortality	O
may	O
be	O
the	O
most	O
ambitious	O
endpoint	O
for	O
obtaining	O
estimates	O
of	O
screening	B-T058
effect	O
.	O
Numerous	O
observations	B-T060
have	O
accumulated	B-T033
over	O
the	O
years	O
,	O
indicating	O
that	O
thyroid	B-T191
cancer	I-T191
mortality	O
endpoint	O
has	O
been	O
difficult	O
to	O
study	O
and	O
is	O
confounded	O
by	O
population	O
heterogeneity	O
,	O
provision	B-T058
of	O
randomization	O
,	O
and	O
requirement	O
of	O
large	O
cohorts	O
with	O
sufficiently	O
long	B-T058
follow	I-T058
-	I-T058
up	I-T058
due	O
to	O
the	O
excellent	O
prognosis	O
of	O
the	O
cancer	O
.	O
Accordingly	O
,	O
it	O
may	O
be	O
important	O
to	O
reconsider	O
how	O
to	O
best	O
measure	O
thyroid	B-T191
cancer	I-T191
screening	B-T060
efficacy	O
.	O
Recommendations	O
against	O
thyroid	B-T191
cancer	I-T191
screening	B-T060
should	O
be	O
based	O
upon	O
trials	O
designed	O
to	O
evaluate	O
its	O
effectiveness	O
not	O
only	O
in	O
significant	O
reduction	O
in	O
cancer	B-T191
mortality	O
,	O
but	O
also	O
of	O
other	O
distinct	O
endpoint	O
s.	O
It	O
is	O
desirable	O
to	O
evaluate	O
derivative	O
endpoints	O
that	O
can	O
reliably	O
predict	O
reductions	O
in	O
mortality	O
.	O
The	O
term	O
"	O
derivative	O
"	O
means	O
a	O
variable	O
that	O
is	O
related	O
to	O
the	O
true	O
endpoint	O
and	O
is	O
likely	O
to	O
be	O
observable	O
before	O
the	O
primary	O
endpoint	O
.	O
Derivative	O
endpoints	O
may	O
include	O
thyroid	B-T191
cancer	I-T191
incidence	O
,	O
the	O
proportion	O
of	O
early	O
-	O
stage	O
tumors	B-T191
detected	B-T033
,	O
more	O
treatable	O
stage	O
,	O
the	O
identification	O
of	O
small	O
tumors	O
(	O
to	O
maintain	O
in	O
observation	O
)	O
,	O
decrease	B-T058
in	I-T058
the	I-T058
number	I-T058
of	I-T058
people	I-T058
who	O
develop	O
metastatic	B-T191
disease	I-T191
,	O
the	O
increased	O
chance	O
of	O
lesser	O
extent	O
surgery	B-T061
,	O
and	O
the	O
application	O
of	O
minimally	O
invasive	O
approaches	O
,	O
as	O
well	O
as	O
no	O
need	O
for	O
lifelong	O
thyroid	B-T061
replacement	I-T061
therapy	I-T061
,	O
a	O
consistent	O
follow	B-T058
-	I-T058
up	I-T058
,	O
low	O
-	O
dose	O
or	O
no	O
RAI	B-T060
administration	I-T060
and	O
risk	O
factor	O
assessments	O
where	O
case	B-T058
findings	I-T058
should	O
be	O
continuous	O
.	O
The	O
Korean	O
guidelines	O
for	O
thyroid	B-T191
cancer	I-T191
national	O
-	O
level	O
screening	B-T058
were	O
published	O
by	O
a	O
relevant	O
group	O
of	O
multidisciplinary	B-T060
thyroid	I-T060
experts	I-T060
.	O
It	O
was	O
concluded	O
that	O
the	O
evidence	O
is	O
insufficient	O
to	O
balance	O
the	O
benefits	O
and	O
harms	O
of	O
thyroid	B-T191
cancer	I-T191
screening	B-T060
.	O
However	O
,	O
the	O
paper	O
seems	O
to	O
raise	O
the	O
necessary	O
investments	O
in	O
future	O
research	O
and	O
demand	O
a	O
complete	O
analysis	O
for	O
derivative	O
endpoints	O
,	O
and	O
offer	O
screening	B-T058
participants	O
with	O
complete	O
information	O
necessary	O
to	O
make	O
decisions	O
that	O
will	O
provide	O
them	O
with	O
the	O
most	O
value	O
when	O
a	O
small	O
thyroid	B-T191
cancer	I-T191
is	O
screen-	O
identified	O
.	O
      
The	O
nurse	O
-	O
patient	O
communication	O
:	O
voices	O
from	O
nursing	O
students	O
Effective	O
communication	O
skills	O
have	O
been	O
found	O
to	O
be	O
one	O
of	O
the	O
pivotal	O
factors	O
in	O
building	O
positive	O
interpersonal	O
relationships	O
.	O
Little	O
is	O
known	O
about	O
nursing	O
undergraduates	O
'	O
perspectives	O
on	O
communicating	O
with	O
patients	O
.	O
This	O
study	O
aimed	O
to	O
explore	O
nursing	O
students	O
'	O
perspectives	O
and	O
experiences	O
of	O
nurse	O
-	O
patient	O
communication	O
in	O
their	O
clinical	O
placement	O
.	O
The	O
participants	O
included	O
21	O
second	O
-	O
year	O
undergraduates	O
and	O
21	O
first	O
-	O
year	O
master	O
's	O
students	O
.	O
Interviews	O
were	O
conducted	O
in	O
Cantonese	O
and	O
then	O
transcribed	O
in	O
Chinese	O
and	O
translated	O
into	O
English	O
.	O
A	O
content	O
analysis	O
approach	O
was	O
adopted	O
to	O
analyze	O
the	O
data	O
.	O
Five	O
themes	O
emerged	O
from	O
the	O
interview	O
data	O
.	O
'	O
The	O
necessity	O
of	O
nurse	O
-	O
patient	O
communication	O
'	O
reveals	O
why	O
the	O
students	O
valued	O
nurse	O
-	O
patient	O
communication	O
.	O
'	O
The	O
conversation	B-T033
contents	I-T033
'	O
describes	O
the	O
content	B-T033
of	I-T033
the	I-T033
conversations	I-T033
that	O
students	O
typically	O
had	O
with	O
patients	O
.	O
The	O
third	O
theme	O
is	O
'	O
self	B-T033
-	I-T033
reflection	I-T033
on	O
the	O
nurse	O
-	O
patient	O
communication	O
'	O
.	O
The	O
last	O
two	O
themes	O
,	O
'	O
the	O
communication	B-T033
pattern	I-T033
in	I-T033
different	I-T033
hospital	O
settings	O
'	O
and	O
'	O
the	O
obstacles	O
impeding	O
nurse	O
-	O
patient	O
communication	O
'	O
,	O
are	O
about	O
the	O
students	O
'	O
communication	O
styles	O
in	O
different	O
hospitals	O
and	O
the	O
barriers	O
they	O
encounter	O
.	O
To	O
improve	B-T033
students	O
'	O
communication	O
skills	O
,	O
educators	O
and	O
clinical	O
staff	O
should	O
listen	O
to	O
students	O
,	O
enhance	O
students	O
'	O
reflective	O
skills	O
and	O
strengthen	O
their	O
confidence	O
.	O
Through	O
understanding	O
students	O
'	O
difficulties	O
in	O
the	O
nurse	O
-	O
patient	O
communication	O
experience	O
and	O
the	O
skills	O
that	O
they	O
lack	O
,	O
educators	O
can	O
provide	O
them	O
with	O
helpful	O
recommendations	O
to	O
improve	B-T033
their	O
communication	O
skills	O
in	O
clinical	O
practice	O
.	O
The	O
results	O
of	O
this	O
study	O
reveal	O
that	O
students	O
'	O
nurse	O
-	O
patient	O
communication	O
skills	O
need	O
to	O
be	O
improved	B-T033
.	O
      
Accounting	O
for	O
linkage	O
disequilibrium	O
in	O
genome	B-T061
scans	I-T061
for	O
selection	O
without	O
individual	O
genotypes	O
:	O
The	O
local	O
score	O
approach	O
Detecting	O
genomic	O
footprints	O
of	O
selection	O
is	O
an	O
important	O
step	O
in	O
the	O
understanding	O
of	O
evolution	O
.	O
Accounting	O
for	O
linkage	O
disequilibrium	O
in	O
genome	B-T061
scans	I-T061
increases	O
detection	B-T061
power	O
,	O
but	O
haplotype	O
-based	O
methods	O
require	O
individual	O
genotypes	O
and	O
are	O
not	O
applicable	O
on	O
pool	O
-	O
sequenced	O
samples	O
.	O
We	O
propose	O
to	O
take	O
advantage	O
of	O
the	O
local	O
score	O
approach	O
to	O
account	O
for	O
linkage	O
disequilibrium	O
in	O
genome	B-T061
scans	I-T061
for	O
selection	O
,	O
cumulating	O
(	O
possibly	O
small	O
)	O
signals	O
from	O
single	O
markers	O
over	O
a	O
genomic	O
segment	O
,	O
to	O
clearly	O
pinpoint	O
a	O
selection	O
signal	O
.	O
Using	O
computer	O
simulations	O
,	O
we	O
demonstrate	O
that	O
this	O
approach	O
detects	B-T033
selection	O
with	O
higher	O
power	O
than	O
several	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
single	O
-	O
marker	O
,	O
windowing	O
or	O
haplotype	O
-based	O
approaches	O
.	O
We	O
illustrate	O
this	O
on	O
two	O
benchmark	O
data	O
sets	O
including	O
individual	O
genotypes	O
,	O
for	O
which	O
we	O
obtain	O
similar	O
results	O
with	O
the	O
local	O
score	O
and	O
one	O
haplotype	O
-based	O
approach	O
.	O
Finally	O
,	O
we	O
apply	O
the	O
local	O
score	O
approach	O
to	O
Pool	O
-	O
Seq	O
data	O
obtained	O
from	O
a	O
divergent	O
selection	O
experiment	O
on	O
behaviour	O
in	O
quail	O
and	O
obtain	O
precise	O
and	O
biologically	O
coherent	B-T033
selection	O
signals	O
:	O
while	O
competing	O
methods	O
fail	O
to	O
highlight	O
any	O
clear	O
selection	O
signature	O
,	O
our	O
method	O
detects	B-T033
several	O
regions	O
involving	O
genes	O
known	O
to	O
act	O
on	O
social	O
responsiveness	O
or	O
autistic	B-T033
traits	I-T033
.	O
Although	O
we	O
focus	O
here	O
on	O
the	O
detection	B-T033
of	O
positive	B-T033
selection	O
from	O
multiple	O
population	O
data	O
,	O
the	O
local	O
score	O
approach	O
is	O
general	O
and	O
can	O
be	O
applied	O
to	O
other	O
genome	B-T061
scans	I-T061
for	O
selection	O
or	O
other	O
genomewide	O
analyses	O
such	O
as	O
GWAS	O
.	O
      
Right	B-T023
Ventricular	I-T023
Response	O
During	O
Exercise	O
in	O
Patients	O
with	O
Chronic	B-T047
Obstructive	I-T047
Pulmonary	I-T047
Disease	I-T047
Right	B-T023
ventricular	I-T023
(	O
RV	B-T023
)	O
pump	O
function	O
is	O
of	O
essential	O
clinical	O
and	O
prognostic	O
importance	O
in	O
a	O
variety	O
of	O
heart	B-T047
and	O
lung	B-T047
diseases	I-T047
.	O
While	O
the	O
evaluation	B-T058
of	O
RV	B-T023
performance	O
at	O
rest	O
has	O
been	O
implemented	O
in	O
the	O
clinical	O
setting	O
,	O
it	O
is	O
unknown	O
whether	O
this	O
assessment	B-T058
during	O
exercise	O
may	O
provide	O
additional	O
benefit	O
.	O
With	O
this	O
aim	O
,	O
we	O
evaluated	B-T058
the	O
exercise	O
-	O
induced	O
pulmonary	B-T060
arterial	I-T060
systolic	I-T060
pressure	I-T060
(	O
PASP	B-T060
)	O
increase	O
during	O
exercise	O
in	O
patients	O
with	O
severe	O
chronic	B-T047
obstructive	I-T047
pulmonary	I-T047
disease	I-T047
(	O
COPD	B-T047
)	O
as	O
an	O
expression	O
of	O
RV	B-T023
contractile	O
reserve	O
.	O
Cardiopulmonary	B-T060
exercise	I-T060
testing	I-T060
(	O
CPET	B-T060
)	O
with	O
synchronic	B-T060
echocardiography	I-T060
was	O
performed	O
in	O
81	O
patients	O
.	O
Patients	O
were	O
classified	O
into	O
two	O
groups	O
according	O
to	O
an	O
exercise	O
-	O
induced	O
PASP	B-T060
increase	O
above	O
30mmHg	O
(	O
High	O
PSAP	B-T060
)	O
or	O
below	O
30mmHg	O
(	O
Low	O
PSAP	B-T060
)	O
during	O
maximal	O
exercise	O
.	O
Patients	O
were	O
then	O
followed	O
for	O
three	O
years	O
.	O
Sixteen	O
patients	O
(	O
20	O
%	O
)	O
had	O
low	O
PSAP	B-T060
and	O
65	O
(	O
80	O
%	O
)	O
showed	O
high	O
PSAP	B-T060
.	O
These	O
were	O
not	B-T033
significant	I-T033
clinical	O
and	O
functional	O
differences	O
.	O
Low	O
PSAP	B-T060
was	O
associated	O
with	O
a	O
significantly	O
lower	O
peak	O
VO2	B-T033
(	O
mean	O
(	O
SD	O
)	O
,	O
35	O
(	O
2	O
)	O
%	O
predicted	O
)	O
compared	O
to	O
high	O
PSAP	B-T060
response	O
(	O
peak	O
VO2	B-T033
45	O
(	O
3	O
)	O
%	O
predicted	O
)	O
,	O
p=0.045	O
.	O
Factors	O
associated	O
with	O
mortality	O
were	O
age	O
and	O
exercise	O
-	O
induced	O
PASP	B-T060
.	O
Seventeen	O
patients	O
died	O
during	O
the	O
three	O
years	O
of	O
follow	B-T058
-	I-T058
up	I-T058
(	O
7	O
(	O
39	O
%	O
)	O
in	O
the	O
low	O
PSAP	B-T060
group	O
and	O
only	O
10	O
(	O
1	O
%	O
)	O
in	O
the	O
high	O
PSAP	B-T060
group	O
,	O
p=0.041	O
)	O
.	O
Cardiopulmonary	B-T060
exercise	I-T060
testing	I-T060
with	O
a	O
synchronic	B-T060
echocardiography	I-T060
may	O
be	O
a	O
useful	O
tool	O
for	O
the	O
assessment	B-T058
of	O
RV	B-T023
contractile	O
reserve	O
in	O
severe	O
COPD	B-T047
patients	O
.	O
Exercise	O
-	O
induced	O
PSAP	B-T060
emerges	O
as	O
a	O
possible	O
prognostic	O
factor	O
in	O
these	O
patients	O
.	O
      
Clinicopathological	B-T058
and	O
Immunohistochemical	B-T059
Characteristics	O
of	O
Verruciform	B-T047
Xanthoma	I-T047
of	O
the	O
Lower	B-T023
Gingiva	I-T023
:	O
A	O
Case	O
Report	O
Verruciform	B-T047
xanthoma	I-T047
(	O
VX	B-T047
)	O
is	O
a	O
rare	O
benign	B-T191
lesion	I-T191
and	O
mainly	O
effects	O
the	O
oral	B-T023
mucosa	I-T023
.	O
This	O
slow	B-T033
-	I-T033
growing	I-T033
asymptomatic	B-T033
lesion	B-T191
typically	O
develops	O
along	O
the	O
gingival	O
margin	O
of	O
the	O
masticatory	O
mucosa	O
,	O
followed	O
by	O
the	O
hard	B-T023
palate	I-T023
,	O
tongue	B-T023
,	O
buccal	B-T023
mucosa	I-T023
,	O
floor	O
of	O
the	O
mouth	O
,	O
alveolar	O
mucosa	O
,	O
soft	B-T023
palate	I-T023
and	O
junction	O
between	O
the	O
hard	B-T023
and	O
soft	B-T023
palate	I-T023
.	O
Moreover	O
,	O
this	O
lesion	B-T191
can	O
also	O
affect	O
the	O
skin	O
and	O
genital	B-T023
organs	I-T023
.	O
Clinically	O
,	O
VX	B-T047
generally	O
presents	O
a	O
sessile	B-T033
or	O
pedunculated	B-T033
appearance	I-T033
,	O
forming	O
a	O
papule	B-T033
or	O
single	B-T033
plaque	I-T033
with	O
verrucous	B-T191
or	O
papillomatous	B-T191
mucosal	O
growth	O
.	O
The	O
colour	O
(	O
white	O
,	O
pink	O
,	O
grey	O
,	O
or	O
yellow	O
)	O
depends	O
on	O
the	O
thickness	O
of	O
the	O
overlying	O
epidermis	O
.	O
In	O
fact	O
,	O
the	O
clinical	O
findings	B-T033
of	O
VX	B-T047
are	O
similar	O
to	O
those	O
of	O
verrucous	B-T191
carcinoma	I-T191
and	O
other	O
benign	B-T191
tumours	I-T191
,	O
such	O
as	O
squamous	B-T191
papilloma	I-T191
,	O
verruca	B-T047
vulgaris	I-T047
and	O
mucosal	B-T191
fibroma	I-T191
.	O
For	O
this	O
reason	O
,	O
clinical	O
and	O
histopathological	O
examinations	B-T058
are	O
essential	O
for	O
accurate	B-T060
differential	I-T060
diagnosis	I-T060
.	O
Histologically	O
,	O
VX	B-T047
is	O
characterized	O
by	O
parakeratosis	B-T047
,	O
rete	O
ridges	O
of	O
uniform	O
depth	O
and	O
the	O
accumulation	B-T033
of	O
foam	O
cells	O
,	O
which	O
are	O
also	O
called	O
"	O
xanthoma	O
cells	O
"	O
.	O
Here	O
,	O
we	O
describe	O
the	O
clinicopathological	B-T058
and	O
immunohistochemical	B-T059
findings	B-T033
of	O
a	O
VX	B-T047
located	O
on	O
the	O
lower	B-T023
gingiva	I-T023
of	O
a	O
64	O
-	O
year	O
-	O
old	O
male	O
patient	O
.	O
      
The	O
Urokinase	B-T121
/	O
Urokinase	O
Receptor	O
System	O
in	O
Mast	O
Cells	O
:	O
Effects	O
of	O
its	O
Functional	O
Interaction	O
with	O
fMLF	O
Receptors	O
Mast	O
cell	O
and	O
basophils	O
express	O
the	O
high	O
affinity	O
receptor	O
for	O
IgE	O
(	O
FcɛRI	O
)	O
and	O
are	O
primary	O
effector	O
cells	O
of	O
allergic	O
disorders	O
.	O
The	O
urokinase	B-T121
uPA	B-T121
(	O
uPA)-mediated	O
plasminogen	O
activation	O
system	O
is	O
involved	O
in	O
physiological	O
and	O
pathological	O
events	O
based	O
on	O
cell	O
migration	O
and	O
tissue	O
remodelling	O
,	O
such	O
as	O
inflammation	O
,	O
wound	O
healing	O
,	O
angiogenesis	O
and	O
metastasis	O
.	O
uPA	B-T121
is	O
a	O
serine	O
protease	O
that	O
binds	O
uPAR	O
,	O
a	O
high	O
affinity	O
glycosyl	O
-	O
phosphatidyl	O
-	O
inositol	O
(	O
GPI)-anchored	O
receptor	O
.	O
uPAR	O
focuses	O
uPA	B-T121
activity	O
at	O
the	O
cell	O
surface	O
and	O
activates	O
intracellular	O
signaling	O
through	O
lateral	O
interactions	O
with	O
integrins	O
,	O
receptor	O
tyrosine	O
kinases	O
and	O
the	O
G	O
-	O
protein	O
-	O
coupled	O
family	O
of	O
fMLF	O
chemotaxis	O
receptors	O
(	O
FPRs	O
)	O
.	O
We	O
investigated	O
the	O
expression	O
of	O
the	O
uPA	B-T121
-	O
uPAR	O
system	O
and	O
its	O
functional	O
interaction	O
with	O
FPRs	O
in	O
human	O
mast	O
cells	O
(	O
MCs	O
)	O
.	O
Differently	O
from	O
basophils	O
,	O
MCs	O
produced	O
uPA	B-T121
that	O
was	O
able	O
to	O
induce	O
their	O
chemotaxis	O
.	O
Indeed	O
,	O
MCs	O
also	O
expressed	O
uPAR	O
,	O
both	O
in	O
the	O
intact	O
and	O
in	O
a	O
cleaved	O
form	O
(	O
DII	O
-	O
DIII	O
-	O
uPAR	O
)	O
that	O
can	O
expose	O
,	O
at	O
the	O
N	O
-	O
terminus	O
,	O
the	O
SRSRY	O
sequence	O
,	O
able	O
to	O
interact	O
with	O
FPRs	O
and	O
to	O
mediate	O
cell	O
chemotaxis	O
.	O
MCs	O
also	O
expressed	O
mRNAs	O
for	O
FPRs	O
that	O
were	O
functionally	O
active	O
;	O
indeed	O
,	O
uPA	B-T121
and	O
a	O
soluble	O
peptide	O
(	O
uPAR84	O
-	O
95	O
)	O
,	O
containing	O
the	O
SRSRY	O
chemotactic	O
sequence	O
of	O
uPAR	O
and	O
able	O
to	O
interact	O
with	O
FPRs	O
,	O
were	O
able	O
to	O
induce	O
MCs	O
chemotaxis	O
.	O
Thus	O
,	O
uPA	B-T121
is	O
a	O
potent	O
chemoattractant	O
for	O
MCs	O
acting	O
through	O
the	O
exposure	O
of	O
the	O
chemotactic	O
epitope	O
of	O
uPAR	O
,	O
that	O
is	O
an	O
endogenous	O
ligand	O
for	O
FPRs	O
.	O
The	O
same	O
mechanism	O
could	O
be	O
involved	O
in	O
VEGF	O
-	O
A	O
secretion	O
by	O
human	O
MCs	O
,	O
also	O
induced	O
by	O
uPA	B-T121
and	O
uPAR84	O
-	O
95	O
stimulation	O
.	O
      
Yersinia	B-T007
ruckeri	I-T007
Isolates	O
Recovered	O
from	O
Diseased	B-T047
Atlantic	O
Salmon	O
(	O
Salmo	O
salar	O
)	O
in	O
Scotland	O
Are	O
More	O
Diverse	O
than	O
Those	O
from	O
Rainbow	O
Trout	O
(	O
Oncorhynchus	O
mykiss	O
)	O
and	O
Represent	O
Distinct	O
Subpopulations	O
Yersinia	B-T007
ruckeri	I-T007
is	O
the	O
etiological	O
agent	O
of	O
enteric	B-T047
redmouth	I-T047
(	O
ERM	B-T047
)	O
disease	B-T047
of	O
farmed	O
salmonids	O
.	O
Enteric	B-T047
redmouth	I-T047
disease	I-T047
is	O
traditionally	O
associated	O
with	O
rainbow	O
trout	O
(	O
Oncorhynchus	O
mykiss	O
,	O
Walbaum	O
)	O
,	O
but	O
its	O
incidence	O
in	O
Atlantic	O
salmon	O
(	O
Salmo	O
salar	O
)	O
is	O
increasing	O
.	O
Yersinia	B-T007
ruckeri	I-T007
isolates	O
recovered	O
from	O
diseased	B-T047
Atlantic	O
salmon	O
have	O
been	O
poorly	O
characterized	O
,	O
and	O
very	O
little	O
is	O
known	O
about	O
the	O
relationship	O
of	O
the	O
isolates	O
associated	O
with	O
these	O
two	O
species	O
.	O
Phenotypic	O
approaches	O
were	O
used	O
to	O
characterize	O
109	O
Y.	B-T007
ruckeri	I-T007
isolates	O
recovered	O
over	O
a	O
14	O
-	O
year	O
period	O
from	O
infected	B-T033
Atlantic	O
salmon	O
in	O
Scotland	O
;	O
26	O
isolates	O
from	O
infected	B-T033
rainbow	O
trout	O
were	O
also	O
characterized	O
.	O
Biotyping	B-T059
,	O
serotyping	B-T059
,	O
and	O
comparison	O
of	O
outer	O
membrane	O
protein	O
profiles	O
identified	O
19	O
Y.	B-T007
ruckeri	I-T007
clones	O
associated	O
with	O
Atlantic	O
salmon	O
but	O
only	O
five	O
associated	O
with	O
rainbow	O
trout	O
;	O
none	O
of	O
the	O
Atlantic	O
salmon	O
clones	O
occurred	O
in	O
rainbow	O
trout	O
and	O
vice	O
versa	O
These	O
findings	B-T033
suggest	O
that	O
distinct	O
subpopulations	O
of	O
Y.	B-T007
ruckeri	I-T007
are	O
associated	O
with	O
each	O
species	O
.	O
A	O
new	O
O	O
serotype	O
(	O
designated	O
O8	O
)	O
was	O
identified	O
in	O
56	O
biotype	O
1	O
Atlantic	O
salmon	O
isolates	O
and	O
was	O
the	O
most	O
common	O
serotype	O
identified	O
from	O
2006	O
to	O
2011	O
and	O
in	O
2014	O
,	O
suggesting	O
an	O
increased	O
prevalence	O
during	O
the	O
time	O
period	O
sampled	O
.	O
Rainbow	O
trout	O
isolates	O
were	O
represented	O
almost	O
exclusively	O
by	O
the	O
same	O
biotype	O
2	O
,	O
serotype	O
O1	O
clone	O
that	O
has	O
been	O
responsible	O
for	O
the	O
majority	O
of	O
ERM	B-T047
outbreaks	O
in	O
this	O
species	O
within	O
the	O
United	O
Kingdom	O
since	O
the	O
1980s	O
.	O
However	O
,	O
the	O
identification	O
of	O
two	O
biotype	O
2	O
,	O
serotype	O
O8	O
isolates	O
in	O
rainbow	O
trout	O
suggests	O
that	O
vaccines	B-T121
containing	O
serotypes	O
O1	O
and	O
O8	O
should	O
be	O
evaluated	O
in	O
both	O
rainbow	O
trout	O
and	O
Atlantic	O
salmon	O
for	O
application	O
in	O
Scotland	O
.	O
Vaccination	B-T061
plays	O
an	O
important	O
role	O
in	O
protecting	O
Atlantic	O
salmon	O
against	O
the	O
bacterial	B-T007
pathogen	O
Yersinia	B-T007
ruckeri	I-T007
,	O
but	O
,	O
in	O
recent	O
years	O
,	O
there	O
has	O
been	O
an	O
increasing	O
incidence	O
of	O
vaccine	B-T121
breakdown	O
in	O
salmon	O
.	O
This	O
is	O
largely	O
because	O
current	O
vaccines	B-T121
are	O
aimed	O
at	O
rainbow	O
trout	O
and	O
are	O
based	O
on	O
serotypes	O
specific	O
for	O
this	O
species	O
.	O
A	O
wider	O
range	O
of	O
serotypes	O
is	O
responsible	O
for	O
infection	O
in	O
Atlantic	O
salmon	O
,	O
but	O
very	O
little	O
is	O
known	O
about	O
the	O
diversity	O
of	O
these	O
strains	O
and	O
their	O
relationships	O
to	O
those	O
recovered	O
from	O
rainbow	O
trout	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
Y.	B-T007
ruckeri	I-T007
isolates	O
recovered	O
from	O
diseased	B-T047
Atlantic	O
salmon	O
in	O
Scotland	O
are	O
more	O
diverse	O
than	O
those	O
from	O
rainbow	O
trout	O
;	O
furthermore	O
,	O
isolates	O
from	O
the	O
two	O
species	O
represent	O
distinct	O
subpopulations	O
.	O
In	O
addition	O
,	O
a	O
new	O
O	O
serotype	O
was	O
identified	O
that	O
is	O
responsible	O
for	O
a	O
significant	O
proportion	O
of	O
the	O
disease	B-T047
in	O
Atlantic	O
salmon	O
.	O
Our	O
findings	B-T033
are	O
likely	O
to	O
have	O
important	O
implications	O
for	O
the	O
development	O
of	O
improved	O
vaccines	O
against	O
Y.	B-T007
ruckeri	I-T007
.	O
      
Assessment	O
of	O
groundwater	O
vulnerability	O
in	O
the	O
Daule	O
aquifer	O
,	O
Ecuador	O
,	O
using	O
the	O
susceptibility	B-T059
index	I-T059
method	I-T059
The	O
Guayas	O
region	O
in	O
Ecuador	O
is	O
economically	O
very	O
important	O
,	O
producing	O
68	O
%	O
of	O
the	O
national	O
crops	O
.	O
The	O
main	O
agricultural	O
activities	O
threaten	O
the	O
groundwater	O
therein	O
with	O
nitrate	O
contamination	O
given	O
the	O
large	O
fertiliser	O
and	O
water	B-T121
needs	O
.	O
The	O
present	O
work	O
tests	O
the	O
applicability	O
of	O
the	O
susceptibility	B-T059
index	I-T059
assessment	I-T059
method	I-T059
in	O
evaluating	O
the	O
impact	O
of	O
agricultural	O
activities	O
on	O
groundwater	O
quality	O
,	O
using	O
as	O
a	O
case	O
study	O
an	O
aquifer	O
of	O
the	O
Guayas	O
river	O
basin	O
in	O
Ecuador	O
.	O
The	O
index	O
adapts	O
four	O
parameters	O
of	O
the	O
DRASTIC	B-T059
method	I-T059
and	O
incorporated	O
a	O
new	O
land	O
use	O
parameter	O
.	O
Results	O
show	O
that	O
the	O
areas	O
highly	O
vulnerable	O
to	O
contamination	O
are	O
located	O
in	O
irrigation	O
perimeters	O
of	O
dominant	O
paddy	O
fields	O
associated	O
with	O
the	O
high	O
recharge	O
rates	O
in	O
the	O
alluvial	O
deposits	O
.	O
Respectively	O
,	O
moderately	O
vulnerable	O
and	O
low	O
-	O
vulnerability	O
areas	O
correspond	O
to	O
aquatic	O
environments	O
and	O
forests	O
,	O
semi	O
-	O
natural	O
zones	O
and	O
water	O
bodies	O
.	O
One	O
of	O
the	O
main	O
contributions	O
of	O
the	O
Daule	O
aquifer	O
vulnerability	O
is	O
likely	O
its	O
wide	O
,	O
flat	O
topography	O
.	O
A	O
great	O
part	O
of	O
the	O
aquifer	O
is	O
at	O
high	B-T033
risk	I-T033
of	I-T033
contamination	I-T033
by	O
nitrates	O
if	O
a	O
code	O
of	O
good	O
agricultural	O
practices	O
is	O
not	O
applied	O
.	O
Therefore	O
the	O
implementation	O
of	O
a	O
monitoring	B-T033
network	I-T033
to	I-T033
control	I-T033
the	O
nitrates	O
concentrations	O
is	O
the	O
first	O
step	O
to	O
assure	O
groundwater	O
quality	O
for	O
drinking	O
purposes	O
.	O
      
Assessing	O
the	O
physiological	O
relevance	O
of	O
alternate	O
architectures	O
of	O
the	O
p7	O
protein	O
of	O
hepatitis	B-T005
C	I-T005
virus	I-T005
in	O
different	O
environments	O
The	O
viroporin	O
p7	O
of	O
the	O
hepatitis	B-T005
C	I-T005
virus	I-T005
forms	O
multimeric	O
channels	O
eligible	O
for	O
ion	O
transport	O
across	O
the	O
endoplasmic	O
reticulum	O
membrane	O
.	O
Currently	O
the	O
subject	O
of	O
many	O
studies	O
and	O
discussion	O
,	O
the	O
molecular	O
assembly	O
of	O
the	O
ion	O
channel	O
and	O
the	O
structural	O
characteristics	O
of	O
the	O
p7	O
monomer	O
are	O
not	O
yet	O
fully	O
understood	O
.	O
Structural	O
investigation	O
of	O
p7	O
has	O
been	O
carried	O
out	O
only	O
in	O
detergent	O
environments	O
,	O
making	O
the	O
interpretation	O
of	O
the	O
experimental	O
results	O
somewhat	O
questionable	O
.	O
Here	O
,	O
we	O
analyze	O
by	O
means	O
of	O
molecular	O
dynamics	O
simulations	O
the	O
structure	O
of	O
the	O
p7	O
monomer	O
as	O
a	O
function	O
of	O
its	O
sequence	O
,	O
initial	O
conformation	O
and	O
environment	O
.	O
We	O
investigate	O
the	O
conductance	O
properties	O
of	O
three	O
models	O
of	O
a	O
hexameric	O
p7	O
ion	O
channel	O
by	O
examining	O
ion	O
translocation	O
in	O
a	O
pure	O
lipid	O
bilayer	O
.	O
It	O
is	O
noteworthy	O
that	O
although	O
none	O
of	O
the	O
models	O
reflects	O
the	O
experimentally	O
observed	O
trend	O
to	O
conduct	O
preferentially	O
cations	O
,	O
we	O
were	O
able	O
to	O
identify	O
the	O
position	O
and	O
orientation	O
of	O
titratable	O
acidic	O
or	O
basic	O
residues	O
playing	O
a	O
crucial	O
role	O
in	O
ion	O
selectivity	O
and	O
in	O
the	O
overall	O
conductance	O
of	O
the	O
channel	O
.	O
In	O
addition	O
,	O
too	O
compact	O
a	O
packing	O
of	O
the	O
monomers	O
leads	O
to	O
channel	O
collapse	O
rather	O
than	O
formation	O
of	O
a	O
reasonable	O
pore	O
,	O
amenable	O
to	O
ion	O
translocation	O
.	O
The	O
present	O
findings	O
are	O
envisioned	O
to	O
help	O
assess	O
the	O
physiological	O
relevance	O
of	O
p7	O
ion	O
channel	O
models	O
consisting	O
of	O
multimeric	O
structures	O
obtained	O
in	O
non	O
-	O
native	O
environments	O
.	O
      
Locating	O
the	O
Seventh	B-T023
Cervical	I-T023
Spinous	I-T023
Process	I-T023
:	O
Development	O
and	O
Validation	O
of	O
a	O
Multivariate	O
Model	O
Using	O
Palpation	B-T060
and	O
Personal	O
Information	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
and	O
validate	O
a	O
multivariate	O
prediction	O
model	O
,	O
guided	O
by	O
palpation	B-T060
and	O
personal	O
information	O
,	O
for	O
locating	O
the	O
seventh	B-T023
cervical	I-T023
spinous	I-T023
process	I-T023
(	O
C7SP	B-T023
)	O
.	O
A	O
single	O
-	O
blinded	O
,	O
cross	O
-	O
sectional	O
study	O
at	O
a	O
primary	O
to	O
tertiary	O
health	O
care	O
center	O
was	O
conducted	O
for	O
model	O
development	O
and	O
temporal	O
validation	O
.	O
One	O
-	O
hundred	O
sixty	O
participants	O
were	O
prospectively	O
included	O
for	O
model	O
development	O
(	O
n	O
=	O
80	O
)	O
and	O
time	O
-	O
split	O
validation	O
stages	O
(	O
n	O
=	O
80	O
)	O
.	O
The	O
C7SP	B-T023
was	O
located	O
using	O
the	O
thorax	B-T060
-	I-T060
rib	I-T060
static	I-T060
method	I-T060
(	O
TRSM	B-T060
)	O
.	O
Participants	O
underwent	O
chest	B-T060
radiography	I-T060
for	O
assessment	O
of	O
the	O
inner	O
body	B-T017
structure	I-T017
located	O
with	O
TRSM	B-T060
and	O
using	O
radio	O
-	O
opaque	O
markers	O
placed	O
over	O
the	O
skin	O
.	O
Age	O
,	O
sex	O
,	O
height	O
,	O
body	B-T033
mass	I-T033
,	O
body	O
mass	O
index	O
,	O
and	O
vertex	O
-	O
marker	O
distanc	O
e	O
(	O
DV	O
-	O
M	O
)	O
were	O
used	O
to	O
predict	O
the	O
distance	O
from	O
the	O
C7SP	B-T023
to	O
the	O
vertex	O
(	O
DV	O
-	O
C7	O
)	O
.	O
Multivariate	O
linear	O
regression	O
modeling	O
,	O
limits	O
of	O
agreement	O
plot	O
,	O
histogram	O
of	O
residues	O
,	O
receiver	O
operating	O
characteristic	O
curves	O
,	O
and	O
confusion	O
tables	O
were	O
analyzed	O
.	O
The	O
multivariate	O
linear	O
prediction	O
model	O
for	O
DV	O
-	O
C7	O
(	O
in	O
centimeters	O
)	O
was	O
DV	O
-	O
C7	O
=	O
0.986DV	O
-	O
M	O
+	O
0.018(mass	O
)	O
+	O
0.014(age	O
)	O
-	O
1.008	O
.	O
Receiver	O
operating	O
characteristic	O
curves	O
had	O
better	O
discrimination	O
of	O
DV	O
-	O
C7	O
(	O
area	O
under	O
the	O
curve	O
=	O
0.661	O
;	O
95	O
%	O
confidence	O
interval	O
=	O
0.541	O
-	O
0.782	O
;	O
P	O
=	O
.015	O
)	O
than	O
DV	O
-	O
M	O
(	O
area	O
under	O
the	O
curve	O
=	O
0.480	O
;	O
95	O
%	O
confidence	O
interval	O
=	O
0.345	O
-	O
0.614	O
;	O
P	O
=	O
.761	O
)	O
,	O
with	O
respective	O
cutoff	O
points	O
at	O
23.40	O
cm	O
(	O
sensitivity	O
=	O
41	O
%	O
,	O
specificity	O
=	O
63	O
%	O
)	O
and	O
24.75	O
cm	O
(	O
sensitivity	O
=	O
69	O
%	O
,	O
specificity	O
=	O
52	O
%	O
)	O
.	O
The	O
C7SP	B-T023
was	O
correctly	O
located	O
more	O
often	O
when	O
using	O
predicted	O
DV	O
-	O
C7	O
in	O
the	O
validation	O
sample	O
than	O
when	O
using	O
the	O
TRSM	B-T060
in	O
the	O
development	O
sample	O
:	O
n	O
=	O
53	O
(	O
66	O
%	O
)	O
vs	O
n	O
=	O
32	O
(	O
40	O
%	O
)	O
,	O
P	O
<	O
.001	O
.	O
Better	O
accuracy	O
was	O
obtained	O
when	O
locating	O
the	O
C7SP	B-T023
by	O
use	O
of	O
a	O
multivariate	O
model	O
that	O
incorporates	O
palpation	B-T060
and	O
personal	O
information	O
.	O
      
Effects	O
of	O
morphology	O
and	O
surface	O
hydroxyl	O
on	O
the	O
toxicity	O
of	O
BiOCl	B-T121
in	O
human	O
HaCaT	O
cells	O
Recently	O
,	O
bismuth	B-T121
oxychloride	I-T121
nanomaterials	O
(	O
BiOCls	B-T121
)	O
are	O
showing	O
great	O
promise	O
in	O
pollutant	O
removal	O
.	O
Residues	O
from	O
these	O
environmental	O
remediations	O
are	O
potential	O
hazardous	O
materials	O
.	O
Unfortunately	O
,	O
human	O
health	B-T058
risks	I-T058
of	O
BiOCls	B-T121
are	O
still	O
unexplored	O
widely	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
focused	O
on	O
the	O
influence	O
of	O
physicochemical	O
properties	O
on	O
the	O
cytotoxicity	O
of	O
BiOCls	B-T121
toward	O
a	O
human	O
skin	O
derived	O
cell	O
line	O
(	O
HaCaT	O
)	O
.	O
Results	O
showed	O
that	O
morphology	O
and	O
surface	O
hydroxyl	O
both	O
had	O
a	O
profound	O
effect	O
on	O
the	O
toxicity	O
of	O
BiOCls	B-T121
.	O
Microsphere	O
-	O
shaped	O
BiOCl	B-T121
caused	O
less	O
toxicity	O
than	O
nanosheet	O
-	O
shaped	O
BiOCl	B-T121
because	O
of	O
weaker	O
particle	O
-	O
membrane	O
interactions	O
,	O
while	O
the	O
presence	O
of	O
surface	O
hydroxyl	O
on	O
microsphere	O
-	O
shaped	O
BiOCl	B-T121
significantly	O
raised	O
the	O
toxicity	O
owing	O
to	O
the	O
increased	O
interaction	O
with	O
cell	O
membrane	O
.	O
Both	O
microsphere	O
-	O
shaped	O
BiOCl	B-T121
with	O
surface	O
hydroxyl	O
and	O
nanosheet	O
-	O
shaped	O
BiOCl	B-T121
caused	O
significant	O
cell	O
membrane	O
damage	O
(	O
PI	B-T059
uptake	I-T059
and	O
LDH	B-T059
release	I-T059
)	O
,	O
however	O
,	O
based	O
on	O
the	O
different	O
mechanism	O
.	O
The	O
former	O
may	O
be	O
a	O
predominant	O
"	O
chemical	O
"	O
mechanism	O
involved	O
an	O
oxidative	O
stress	O
paradigm	O
,	O
as	O
manifested	O
by	O
elevated	O
ROS	O
and	O
depleted	O
GSH	O
,	O
while	O
the	O
latter	O
is	O
mainly	O
due	O
to	O
a	O
direct	O
"	O
physical	O
"	O
damage	O
to	O
cell	O
membrane	O
.	O
Both	O
"	O
physical	O
"	O
and	O
"	O
chemical	O
"	O
response	O
led	O
to	O
cell	O
death	O
.	O
Furthermore	O
,	O
a	O
set	O
of	O
experiments	O
including	O
MMP	O
collapse	O
,	O
cell	O
cycle	O
arrest	O
,	O
and	O
apoptosis	O
/	O
necrosis	O
were	O
conducted	O
to	O
propose	O
a	O
scenario	O
for	O
toxicological	O
aspects	O
of	O
BiOCls	B-T121
.	O
Data	O
presented	O
here	O
would	O
help	O
to	O
enable	O
the	O
rational	O
design	O
of	O
BiOCls	B-T121
for	O
either	O
reducing	O
their	O
unintended	O
consequences	O
or	O
increasing	O
their	O
application	O
potentials	O
.	O
      
Binding	O
of	O
DEAD	O
-	O
box	O
helicase	O
Dhh1	O
to	O
the	O
5'UTR	O
of	O
ASH1	O
mRNA	O
represses	O
localized	O
translation	O
of	O
ASH1	O
in	O
yeast	O
cells	O
Local	O
translation	O
of	O
specific	O
mRNAs	O
is	O
regulated	O
by	O
dynamic	O
changes	O
in	O
their	O
subcellular	O
localization	O
,	O
and	O
these	O
changes	O
are	O
due	O
to	O
complex	O
mechanisms	O
controlling	O
cytoplasmic	O
mRNA	O
transport	O
.	O
The	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
is	O
well	O
suited	O
to	O
studying	O
these	O
mechanisms	O
because	O
many	O
of	O
its	O
transcripts	O
are	O
transported	O
from	O
the	O
mother	O
cell	O
to	O
the	O
budding	O
daughter	O
cell	O
.	O
Here	O
,	O
we	O
investigated	O
the	O
translational	O
control	O
of	O
ASH1	O
mRNA	O
after	O
transport	O
and	O
localization	O
.	O
We	O
show	O
that	O
although	O
ASH1	O
transcripts	O
were	O
translated	O
after	O
they	O
reached	O
the	O
bud	O
-	O
tip	O
,	O
some	O
mRNAs	O
were	O
bound	O
by	O
the	O
RNA	O
-	O
binding	O
protein	O
Puf6	O
and	O
were	O
non	B-T033
-	I-T033
polysomal	I-T033
.	O
We	O
also	O
found	O
that	O
the	O
DEAD	O
-	O
box	O
helicase	O
Dhh1	O
complexed	O
with	O
the	O
untranslated	O
ASH1	O
mRNA	O
and	O
Puf6	O
.	O
Loss	O
of	O
Dhh1	O
affected	O
local	O
translation	O
of	O
ASH1	O
mRNA	O
and	O
resulted	O
in	O
delocalization	O
of	O
ASH1	O
transcript	O
in	O
the	O
bud	O
.	O
Forcibly	O
shifting	O
the	O
non	B-T033
-	I-T033
polysomal	I-T033
ASH1	O
mRNA	O
into	O
polysomes	O
was	O
associated	O
with	O
Dhh1	O
dissociation	B-T048
.	O
We	O
further	O
demonstrated	O
that	O
Dhh1	O
is	O
not	O
recruited	O
to	O
ASH1	O
mRNA	O
co	O
-	O
transcriptionally	O
,	O
suggesting	O
that	O
it	O
could	O
bind	O
to	O
ASH1	O
mRNA	O
within	O
the	O
cytoplasm	O
.	O
Of	O
note	O
,	O
Dhh1	O
bound	O
to	O
the	O
5	O
UTR	O
of	O
ASH1	O
mRNA	O
and	O
inhibited	O
its	O
translation	O
in	O
vitro	O
.	O
These	O
results	O
suggest	O
that	O
after	O
localization	O
to	O
the	O
bud	O
tip	O
,	O
a	O
portion	O
of	O
the	O
localized	O
ASH1	O
mRNA	O
becomes	O
translationally	O
inactive	O
,	O
because	O
of	O
binding	O
of	O
Dhh1	O
and	O
Puf6	O
to	O
the	O
5	O
'	O
and	O
3	O
'	O
UTRs	O
of	O
ASH1	O
mRNA	O
.	O
      
Antigen	O
Masking	O
During	O
Fixation	B-T059
and	O
Embedding	B-T059
,	O
Dissected	O
Antigen	O
masking	O
in	O
routinely	O
processed	O
tissue	O
is	O
a	O
poorly	O
understood	O
process	O
caused	O
by	O
multiple	O
factors	O
.	O
We	O
sought	O
to	O
dissect	O
the	O
effect	O
on	O
antigenicity	O
of	O
each	O
step	O
of	O
processing	O
by	O
using	O
frozen	O
sections	O
as	O
proxies	O
of	O
the	O
whole	O
tissue	O
.	O
An	O
equivalent	O
extent	O
of	O
antigen	O
masking	O
occurs	O
across	O
variable	O
fixation	B-T059
times	O
at	O
room	O
temperature	O
.	O
Most	O
antigens	O
benefit	O
from	O
longer	O
fixation	B-T059
times	O
(	O
>	O
24	O
hr	O
)	O
for	O
optimal	O
detection	B-T033
after	O
antigen	O
retrieval	B-T058
(	O
AR	B-T058
;	O
for	O
example	O
,	O
Ki-67	O
,	O
bcl-2	O
,	O
ER	O
)	O
.	O
The	O
transfer	O
to	O
a	O
graded	B-T121
alcohol	I-T121
series	O
results	O
in	O
an	O
enhanced	O
staining	B-T033
effect	I-T033
,	O
reproduced	O
by	O
treating	O
the	O
sections	O
with	O
detergents	O
,	O
possibly	O
because	O
of	O
a	O
better	O
access	O
of	O
the	O
polymeric	O
immunohistochemical	B-T059
detection	B-T033
system	O
to	O
tissue	O
structures	O
.	O
A	O
second	O
round	O
of	O
masking	O
occurs	O
upon	O
entering	O
the	O
clearing	O
agent	O
,	O
mostly	O
at	O
the	O
paraffin	O
embedding	B-T059
step	O
.	O
This	O
may	O
depend	O
on	O
the	O
non	O
-	O
freezable	O
water	B-T121
removal	O
.	O
AR	B-T058
fully	O
reverses	O
the	O
masking	O
due	O
both	O
to	O
the	O
fixation	B-T059
time	O
and	O
the	O
paraffin	O
embedding	B-T059
.	O
AR	B-T058
itself	O
destroys	O
some	O
epitopes	O
which	O
do	O
not	O
survive	O
routine	O
processing	O
.	O
Processed	O
frozen	O
sections	O
are	O
a	O
tool	O
to	O
investigate	O
fixation	B-T059
and	O
processing	O
requirements	O
for	O
antigens	O
in	O
routine	O
specimens	O
.	O
      
Visualization	B-T060
for	O
Understanding	O
Uncertainty	B-T033
in	O
Activation	O
Volumes	O
for	O
Deep	B-T061
Brain	I-T061
Stimulation	I-T061
We	O
have	O
created	O
the	O
Neurostimulation	O
Uncertainty	O
Viewer	O
(	O
nuView	O
or	O
νView	O
)	O
tool	O
for	O
exploring	O
data	O
arising	O
from	O
deep	B-T061
brain	I-T061
stimulation	I-T061
(	O
DBS	B-T061
)	O
.	O
Simulated	O
volume	O
of	O
tissue	O
activated	O
(	O
VTA	O
)	O
,	O
using	O
clinical	B-T060
electrode	I-T060
placements	I-T060
,	O
are	O
recorded	O
along	O
with	O
patient	O
outcomes	O
in	O
the	O
Unified	O
Parkinson	O
's	O
disease	O
rating	O
scale	O
(	O
UPDRS	O
)	O
.	O
The	O
data	O
is	O
volumetric	O
and	O
sparse	O
,	O
with	O
multi	O
-	O
value	O
patient	O
results	O
for	O
each	O
activated	O
voxel	O
in	O
the	O
simulation	O
.	O
νView	O
provides	O
a	O
collection	O
of	O
visual	O
methods	O
to	O
explore	O
the	O
activated	O
tissue	O
to	O
enhance	O
understanding	O
of	O
electrode	O
usage	O
for	O
improved	O
therapy	B-T061
with	O
DBS	B-T061
.	O
      
PCVMZM	O
:	O
Using	O
the	O
Probabilistic	O
Classification	O
Vector	O
Machines	O
Model	O
Combined	O
with	O
a	O
Zernike	O
Moments	O
Descriptor	O
to	O
Predict	O
Protein	O
-	O
Protein	O
Interactions	O
from	O
Protein	O
Sequences	O
Protein	O
-	O
protein	O
interactions	O
(	O
PPIs	O
)	O
are	O
essential	O
for	O
most	O
living	B-T001
organisms	I-T001
'	O
process	O
.	O
Thus	O
,	O
detecting	O
PPIs	O
is	O
extremely	O
important	O
to	O
understand	O
the	O
molecular	O
mechanisms	O
of	O
biological	O
systems	O
.	O
Although	O
many	O
PPIs	O
data	O
have	O
been	O
generated	O
by	O
high	O
-	O
throughput	O
technologies	O
for	O
a	O
variety	O
of	O
organisms	B-T001
,	O
the	O
whole	O
interatom	O
is	O
still	O
far	O
from	O
complete	O
.	O
In	O
addition	O
,	O
the	O
high	O
-	O
throughput	O
technologies	O
for	O
detecting	O
PPIs	O
has	O
some	O
unavoidable	O
defects	O
,	O
including	O
time	O
consumption	O
,	O
high	O
cost	O
,	O
and	O
high	O
error	O
rate	O
.	O
In	O
recent	O
years	O
,	O
with	O
the	O
development	O
of	O
machine	O
learning	O
,	O
computational	O
methods	O
have	O
been	O
broadly	O
used	O
to	O
predict	O
PPIs	O
,	O
and	O
can	O
achieve	O
good	O
prediction	O
rate	O
.	O
In	O
this	O
paper	O
,	O
we	O
present	O
here	O
PCVMZM	O
,	O
a	O
computational	O
method	O
based	O
on	O
a	O
Probabilistic	O
Classification	O
Vector	O
Machines	O
(	O
PCVM	O
)	O
model	O
and	O
Zernike	O
moments	O
(	O
ZM	O
)	O
descriptor	O
for	O
predicting	O
the	O
PPIs	O
from	O
protein	O
amino	O
acids	O
sequences	O
.	O
Specifically	O
,	O
a	O
Zernike	O
moments	O
(	O
ZM	O
)	O
descriptor	O
is	O
used	O
to	O
extract	O
protein	O
evolutionary	O
information	O
from	O
Position	O
-	O
Specific	O
Scoring	O
Matrix	O
(	O
PSSM	O
)	O
generated	O
by	O
Position	O
-	O
Specific	O
Iterated	O
Basic	O
Local	O
Alignment	O
Search	O
Tool	O
(	O
PSI	O
-	O
BLAST	O
)	O
.	O
Then	O
,	O
PCVM	O
classifier	O
is	O
used	O
to	O
infer	O
the	O
interactions	O
among	O
protein	O
.	O
When	O
performed	O
on	O
PPIs	O
datasets	O
of	O
Yeast	O
and	O
H.	B-T007
Pylori	I-T007
,	O
the	O
proposed	O
method	O
can	O
achieve	O
the	O
average	O
prediction	O
accuracy	O
of	O
94.48	O
%	O
and	O
91.25	O
%	O
,	O
respectively	O
.	O
In	O
order	O
to	O
further	O
evaluate	O
the	O
performance	O
of	O
the	O
proposed	O
method	O
,	O
the	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
support	O
vector	O
machines	O
(	O
SVM	O
)	O
classifier	O
is	O
used	O
and	O
compares	O
with	O
the	O
PCVM	O
model	O
.	O
Experimental	B-T033
results	I-T033
on	O
the	O
Yeast	O
dataset	O
show	O
that	O
the	O
performance	O
of	O
PCVM	O
classifier	O
is	O
better	O
than	O
that	O
of	O
SVM	O
classifier	O
.	O
The	O
experimental	B-T033
results	I-T033
indicate	O
that	O
our	O
proposed	O
method	O
is	O
robust	O
,	O
powerful	O
and	O
feasible	O
,	O
which	O
can	O
be	O
used	O
as	O
a	O
helpful	O
tool	O
for	O
proteomics	O
research	O
.	O
      
Abundance	O
and	O
Characterization	O
of	O
Perfect	O
Microsatellites	O
on	O
the	O
Cattle	O
Y	O
Chromosome	O
Microsatellites	O
or	O
simple	O
sequence	O
repeats	O
(	O
SSRs	O
)	O
are	O
found	O
in	O
most	O
organisms	B-T001
and	O
play	O
an	O
important	O
role	O
in	O
genomic	O
organization	O
and	O
function	O
.	O
To	O
characterize	O
the	O
abundance	O
of	O
SSRs	O
(	O
1	O
-	O
6	O
base	O
-	O
pairs	O
[	O
bp	O
]	O
)	O
on	O
the	O
cattle	O
Y	O
chromsome	O
,	O
the	O
relative	O
frequency	O
and	O
density	O
of	O
perfect	O
or	O
uninterrupted	O
SSRs	O
based	O
on	O
the	O
published	O
Y	O
chromosome	O
sequence	O
were	O
examined	B-T033
.	O
A	O
total	O
of	O
17,273	O
perfect	O
SSRs	O
were	O
found	O
,	O
with	O
total	O
length	O
of	O
324.78	O
kb	O
,	O
indicating	O
that	O
approximately	O
0.75	O
%	O
of	O
the	O
cattle	O
Y	O
chromosome	O
sequence	O
(	O
43.30	O
Mb	O
)	O
comprises	O
perfect	O
SSRs	O
,	O
with	O
an	O
average	O
length	O
of	O
18.80	O
bp	O
.	O
The	O
relative	O
frequency	O
and	O
density	O
were	O
398.92	O
loci	O
/	O
Mb	O
and	O
7500.62	O
bp	O
/Mb	O
,	O
respectively	O
.	O
The	O
proportions	O
of	O
the	O
six	O
classes	O
of	O
perfect	O
SSRs	O
were	O
highly	O
variable	O
on	O
the	O
cattle	O
Y	O
chromosome	O
.	O
Mononucleotide	O
repeats	O
had	O
a	O
total	O
number	O
of	O
8073	O
(	O
46.74	O
%	O
)	O
and	O
an	O
average	O
length	O
of	O
15.45	O
bp	O
,	O
and	O
were	O
the	O
most	O
abundant	O
SSRs	O
class	O
,	O
while	O
the	O
percentages	O
of	O
di-	O
,	O
tetra-	O
,	O
tri-	O
,	O
penta-	O
,	O
and	O
hexa	O
-	O
nucleotide	O
repeats	O
were	O
22.86	O
%	O
,	O
11.98	O
%	O
,	O
11.58	O
%	O
,	O
6.65	O
%	O
,	O
and	O
0.19	O
%	O
,	O
respectively	O
.	O
Different	O
classes	O
of	O
SSRs	O
varied	O
in	O
their	O
repeat	O
number	O
,	O
with	O
the	O
highest	O
being	O
42	O
for	O
dinucleotides	O
.	O
Results	O
reveal	O
that	O
repeat	O
categories	O
A	O
,	O
AC	O
,	O
AT	O
,	O
AAC	O
,	O
AGC	O
,	O
GTTT	O
,	O
CTTT	O
,	O
ATTT	O
,	O
and	O
AACTG	O
predominate	O
on	O
the	O
Y	O
chromosome	O
.	O
This	O
study	O
provides	O
insight	O
into	O
the	O
organization	O
of	O
cattle	O
Y	O
chromosome	O
repetitive	O
DNA	O
,	O
as	O
well	O
as	O
information	O
useful	O
for	O
developing	O
more	O
polymorphic	O
cattle	O
Y	O
-	O
chromosome	O
-specific	O
SSRs	O
.	O
      
Burden	O
of	O
cervical	B-T191
cancer	I-T191
and	O
role	O
of	O
screening	B-T058
in	O
India	O
Cervical	B-T191
cancer	I-T191
is	O
a	O
major	O
cause	O
of	O
cancer	O
mortality	O
in	O
women	O
and	O
more	O
than	O
a	O
quarter	O
of	O
its	O
global	O
burden	O
is	O
contributed	O
by	O
developing	O
countries	O
.	O
In	O
India	O
,	O
in	O
spite	O
of	O
alarmingly	O
high	O
figures	O
,	O
there	O
is	O
no	O
nationwide	O
government	O
-	O
sponsored	O
screening	O
program	O
.	O
This	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
burden	O
of	O
cervical	B-T191
cancer	I-T191
in	O
India	O
and	O
review	O
the	O
performance	O
characteristics	O
of	O
available	O
cervical	B-T191
cancer	I-T191
screening	B-T058
tools	O
,	O
so	O
as	O
to	O
provide	O
evidence	O
-based	O
recommendations	O
for	O
application	O
of	O
most	O
practically	O
suited	O
screening	B-T060
test	I-T060
to	O
be	O
used	O
in	O
resource	O
-poor	O
field	O
settings	O
.	O
MEDLINE	O
and	O
Web	O
of	O
Science	O
electronic	O
database	O
were	O
searched	O
from	O
January	O
1990	O
to	O
December	O
2015	O
,	O
using	O
the	O
keywords	O
such	O
as	O
"	O
cervical	B-T191
cancer	I-T191
"	O
,	O
"	O
screening	B-T060
"	O
,	O
"	O
early	B-T060
detection	I-T060
"	O
,	O
"	O
cervical	B-T059
cytology	I-T059
"	O
and	O
"	O
visual	B-T058
inspection	I-T058
"	O
,	O
and	O
their	O
corresponding	O
MeSH	O
terms	O
in	O
combination	O
with	O
Boolean	O
operators	O
"	O
OR	O
,	O
AND	O
.	O
"	O
Two	O
authors	O
independently	O
selected	O
studies	O
that	O
are	O
published	O
in	O
English	O
and	O
conducted	O
in	O
India	O
.	O
A	O
total	O
of	O
11	O
studies	O
were	O
found	B-T033
to	O
be	O
relevant	O
and	O
eligible	O
to	O
be	O
included	O
in	O
the	O
present	B-T033
study	O
.	O
In	O
India	O
,	O
cervical	B-T191
cancer	I-T191
contributes	O
to	O
approximately	O
6	O
-	O
29	O
%	O
of	O
all	O
cancers	B-T191
in	O
women	O
.	O
The	O
age	O
-	O
adjusted	O
incidence	O
rate	O
of	O
cervical	B-T191
cancer	I-T191
varies	O
widely	O
among	O
registries	O
;	O
highest	O
is	O
23.07/100,000	O
in	O
Mizoram	O
state	O
and	O
the	O
lowest	O
is	O
4.91/100,000	O
in	O
Dibrugarh	O
district	O
.	O
The	O
pooled	O
estimates	O
of	O
sensitivity	O
and	O
specificity	O
of	O
visual	B-T060
inspection	I-T060
with	I-T060
acetic	I-T060
acid	I-T060
(	O
VIA	B-T060
)	O
,	O
magnified	B-T060
VIA	I-T060
,	O
visual	B-T060
inspection	I-T060
with	I-T060
Lugol	I-T060
's	I-T060
iodine	I-T060
(	O
VILI	B-T060
)	O
,	O
cytology	B-T059
(	O
Pap	B-T060
smear	I-T060
)	O
,	O
and	O
human	B-T059
papillomavirus	I-T059
DNA	I-T059
were	O
found	O
to	O
be	O
67.65	O
%	O
and	O
84.32	O
%	O
,	O
65.36	O
%	O
and	O
85.76	O
%	O
,	O
78.27	O
%	O
and	O
87.10	O
%	O
,	O
62.11	O
%	O
and	O
93.51	O
%	O
,	O
and	O
77.81	O
%	O
and	O
91.54	O
%	O
,	O
respectively	O
.	O
In	O
developing	O
countries	O
because	O
of	O
lack	O
of	O
necessary	O
infrastructure	O
and	O
quality	O
control	O
,	O
high	O
-	O
quality	O
cytology	B-T060
screening	I-T060
may	O
not	O
be	O
feasible	O
for	O
wide	O
-	O
scale	O
implementation	O
.	O
Hence	O
,	O
cervical	B-T191
cancer	I-T191
screening	B-T058
program	O
based	O
on	O
visual	B-T060
screening	I-T060
test	I-T060
such	O
as	O
VIA	B-T060
/	O
VILI	B-T060
should	O
be	O
adopted	O
as	O
an	O
integral	O
part	O
of	O
primary	O
health	B-T058
-	I-T058
care	I-T058
setup	I-T058
in	O
resource	O
-	O
poor	O
countries	O
like	O
India	O
.	O
      
Catastrophic	B-T047
health	O
expenditure	O
:	O
a	O
comparative	O
analysis	O
of	O
empty	O
-	O
nest	O
and	O
non	O
-	O
empty	O
-	O
nest	O
households	O
with	O
seniors	O
in	O
Shandong	O
,	O
China	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
catastrophic	B-T047
health	O
expenditure	O
(	O
CHE	O
)	O
prevalence	O
and	O
its	O
determinants	O
between	O
empty	O
-	O
nest	O
and	O
non	O
-	O
empty	O
-	O
nest	O
elderly	O
households	O
.	O
Shandong	O
province	O
of	O
China	O
.	O
A	O
total	O
of	O
2761	O
elderly	O
households	O
are	O
included	O
in	O
the	O
analysis	O
.	O
CHE	O
incidence	O
among	O
elderly	O
households	O
was	O
44.9	O
%	O
.	O
The	O
CHE	O
incidence	O
of	O
empty	O
-	O
nest	O
singles	B-T033
(	O
59.3	O
%	O
,	O
p=0.000	O
,	O
OR=3.19	O
)	O
and	O
empty	O
-	O
nest	O
couples	O
(	O
52.9	O
%	O
,	O
p=0.000	O
,	O
OR=2.45	O
)	O
are	O
both	O
statistically	O
higher	O
than	O
that	O
of	O
non	O
-	O
empty	O
-	O
nest	O
elderly	O
households	O
(	O
31.4	O
%	O
)	O
.	O
An	O
inverse	O
association	O
was	O
observed	O
between	O
CHE	O
incidence	O
and	O
income	O
level	O
in	O
all	O
elderly	O
household	O
types	O
.	O
Factors	O
including	O
1	O
or	O
more	O
household	O
elderly	O
members	O
with	O
non	B-T047
-	I-T047
communicable	I-T047
chronic	I-T047
diseases	I-T047
in	O
the	O
past	O
6	O
months	O
,	O
1	O
or	O
more	O
elderly	O
household	O
members	O
being	O
hospitalised	B-T033
in	O
the	O
past	O
year	O
and	O
lower	O
household	O
income	O
,	O
are	O
significant	O
risk	B-T033
factors	I-T033
for	O
CHE	O
in	O
all	O
3	O
household	O
types	O
(	O
p<0.05	O
)	O
.	O
Health	B-T058
insurance	I-T058
status	O
was	O
found	O
to	O
be	O
a	O
significant	O
determinant	O
of	O
CHE	O
among	O
empty	O
-	O
nest	O
singles	B-T033
and	O
non	O
-	O
empty	O
-	O
nest	O
households	O
(	O
p<0.05	O
)	O
.	O
CHE	O
incidence	O
among	O
elderly	O
households	O
is	O
high	O
in	O
China	O
.	O
Empty	O
-	O
nest	O
households	O
are	O
at	O
higher	O
risk	O
for	O
CHE	O
than	O
non	O
-	O
empty	O
-	O
nest	O
households	O
.	O
Based	O
on	O
these	O
findings	B-T033
,	O
we	O
suggest	O
that	O
special	O
insurance	B-T058
be	O
developed	O
to	O
broaden	O
the	O
coverage	O
of	O
health	B-T058
services	I-T058
and	O
heighten	O
the	O
reimbursement	B-T058
rate	I-T058
for	O
empty	O
-	O
nest	O
elderly	O
in	O
the	O
existing	O
health	B-T058
insurance	I-T058
schemes	O
.	O
Financial	O
and	O
social	O
protection	O
interventions	B-T058
are	O
also	O
essential	O
for	O
identifie	O
d	O
at	O
-	O
risk	O
subgroups	O
among	O
different	O
types	O
of	O
elderly	O
households	O
.	O
      
Permanence	O
can	O
be	O
Defended	O
In	O
donation	O
after	O
the	O
circulatory	B-T060
-	I-T060
respiratory	I-T060
determination	I-T060
of	I-T060
death	I-T060
(	O
DCDD	B-T060
)	O
,	O
the	O
dead	O
donor	O
rule	O
requires	O
that	O
the	O
donor	O
be	O
dead	O
before	O
organ	B-T058
procurement	I-T058
can	O
proceed	O
.	O
Under	O
the	O
relevant	O
limb	O
of	O
the	O
Uniform	O
Determination	O
of	O
Death	O
Act	O
1981	O
(	O
USA	O
)	O
,	O
a	O
person	O
is	O
dead	O
when	O
the	O
cessation	O
of	O
circulatory	O
-	O
respiratory	O
function	O
is	O
'	O
irreversible	B-T033
'	O
.	O
Critics	O
of	O
current	O
practice	O
in	O
DCDD	B-T060
have	O
argued	O
that	O
the	O
donor	O
is	O
not	O
dead	O
at	O
the	O
time	O
organs	B-T023
are	O
procured	B-T058
,	O
and	O
so	O
the	O
procurement	B-T058
of	I-T058
organs	I-T058
from	O
these	O
donors	O
violates	O
the	O
dead	O
donor	O
rule	O
.	O
We	O
offer	B-T033
a	O
new	O
argument	O
here	O
in	O
defence	O
of	O
current	O
DCDD	B-T060
practice	O
,	O
and	O
,	O
in	O
particular	O
,	O
of	O
the	O
interpretation	O
of	O
the	O
requirement	O
of	O
'	O
irreversibility	B-T033
'	O
as	O
permanence	O
.	O
      
Total	O
colectomy	B-T061
for	O
colon	O
perforation	O
after	O
kayexalate	B-T121
administration	B-T061
:	O
a	O
case	O
report	O
and	O
literature	O
review	O
of	O
a	O
rare	O
complication	O
Kayexalate	B-T121
is	O
an	O
ion	B-T121
exchange	I-T121
resin	I-T121
that	O
is	O
commonly	O
used	O
to	O
acutely	O
treat	B-T061
patients	O
with	O
hyperkalemia	B-T033
.	O
Bowel	B-T047
ulceration	I-T047
and	O
necrosis	O
is	O
a	O
rare	O
and	O
uncommonly	O
recognized	O
complication	O
of	O
kayexalate	B-T121
administration	B-T061
.	O
More	O
often	O
,	O
concomitant	O
administration	B-T061
with	O
sorbitol	B-T121
is	O
reported	O
to	O
damage	O
the	O
bowel	B-T023
;	O
however	O
,	O
there	O
are	O
reports	O
of	O
kayexalate	B-T121
administration	B-T061
causing	O
bowel	B-T047
necrosis	I-T047
without	O
sorbitol	B-T121
.	O
We	O
present	O
a	O
case	O
of	O
a	O
critically	B-T047
ill	I-T047
patient	O
who	O
underwent	O
total	O
colectomy	B-T061
for	O
colonic	B-T047
necrosis	I-T047
secondary	O
to	O
oral	O
kayexalate	B-T121
administration	B-T061
that	O
was	O
not	O
recognized	O
until	O
late	O
in	O
the	O
pathologic	O
process	O
.	O
We	O
also	O
review	O
the	O
literature	O
to	O
further	O
investigate	O
this	O
progression	O
.	O
      
The	O
binding	O
orientations	O
of	O
structurally	O
-related	O
ligands	O
can	O
differ	O
;	O
A	O
cautionary	O
note	O
Crystal	O
structures	O
can	O
identify	O
ligand	O
-	O
receptor	O
interactions	O
and	O
assist	O
the	O
development	O
of	O
novel	O
therapeutics	B-T061
,	O
but	O
experimental	O
challenges	O
sometimes	O
necessitate	O
the	O
use	O
of	O
homologous	O
proteins	O
.	O
Tropisetron	B-T121
is	O
an	O
orthosteric	O
ligand	O
at	O
both	O
5	O
-	O
HT3	O
and	O
α7	O
nACh	O
receptors	O
and	O
its	O
binding	O
orientation	O
has	O
been	O
determined	O
in	O
the	O
structural	O
homologue	O
AChBP	O
(	O
pdbid	O
:	O
2WNC	O
)	O
.	O
Co	O
-	O
crystallisation	O
with	O
a	O
structurally	O
-related	O
ligand	O
,	O
granisetron	B-T121
,	O
reveals	O
an	O
almost	O
identical	O
orientation	O
(	O
pdbid	O
;	O
2YME	O
)	O
.	O
However	O
,	O
there	O
is	O
a	O
>	O
1000	O
-	O
fold	O
difference	O
in	O
the	O
affinity	O
of	O
tropisetron	B-T121
at	O
5	O
-	O
HT3	O
versus	O
α7	O
nACh	O
receptors	O
,	O
and	O
α7	O
nACh	O
receptors	O
do	O
not	O
bind	O
granisetron	B-T121
.	O
These	O
striking	O
pharmacological	O
differences	O
prompt	O
questions	O
about	O
which	O
receptor	O
the	O
crystal	O
structures	O
most	O
closely	O
represent	O
and	O
whether	O
the	O
ligand	O
orientations	O
are	O
correct	O
.	O
Here	O
we	O
probe	O
the	O
binding	O
orientation	O
of	O
tropisetron	B-T121
and	O
granisetron	B-T121
at	O
5	O
-	O
HT3	O
receptors	O
by	O
in	O
silico	O
modelling	O
and	O
docking	O
,	O
radioligand	O
binding	O
on	O
cysteine	O
-	O
substituted	O
5	O
-	O
HT3	O
receptor	O
mutants	O
transiently	O
expressed	O
in	O
HEK	O
293	O
cells	O
,	O
and	O
synthetic	O
modification	O
of	O
the	O
ligands	O
.	O
For	O
15	O
of	O
the	O
23	O
cysteine	O
substitutions	O
,	O
the	O
effects	O
on	O
tropisetron	B-T121
and	O
granisetron	B-T121
were	O
different	O
.	O
Structure	O
-	O
activity	O
relationships	O
on	O
synthesised	O
derivatives	O
of	O
both	O
ligands	O
were	O
also	O
consistent	O
with	O
different	O
orientations	O
,	O
revealing	O
that	O
contrary	O
to	O
the	O
crystallographic	B-T059
evidence	O
from	O
AChBP	O
,	O
the	O
two	O
ligands	O
adopt	O
different	O
orientations	O
in	O
the	O
5	O
-	O
HT3	O
receptor	O
binding	O
site	O
.	O
Our	O
results	O
show	O
that	O
even	O
quite	O
structurally	O
similar	O
molecules	O
can	O
adopt	O
different	O
orientations	O
in	O
the	O
same	O
binding	O
site	O
,	O
and	O
that	O
caution	O
may	O
be	O
needed	O
when	O
using	O
homologous	O
proteins	O
to	O
predict	O
ligand	O
binding	O
.	O
      
Recessive	O
mutations	O
in	O
MSTO1	O
cause	O
mitochondrial	O
dynamics	O
impairment	O
,	O
leading	O
to	O
myopathy	B-T047
and	O
ataxia	B-T184
We	O
report	O
here	O
the	O
first	O
families	O
carrying	O
recessive	O
variants	O
in	O
the	O
MSTO1	O
gene	O
:	O
compound	B-T033
heterozygous	I-T033
mutations	O
were	O
identified	O
in	O
two	O
sisters	O
and	O
in	O
an	O
unrelated	B-T033
singleton	O
case	O
,	O
who	O
presented	O
a	O
multisystem	O
complex	O
phenotype	O
mainly	O
characterized	O
by	O
myopathy	B-T047
and	O
cerebellar	B-T184
ataxia	I-T184
.	O
Human	O
MSTO1	O
is	O
a	O
poorly	O
studied	O
protein	O
,	O
suggested	O
to	O
have	O
mitochondrial	O
localization	O
and	O
to	O
regulate	O
morphology	O
and	O
distribution	O
of	O
mitochondria	O
.	O
As	O
for	O
other	O
mutations	O
affecting	O
genes	O
involved	O
in	O
mitochondrial	O
dynamics	O
,	O
no	O
biochemical	O
defects	O
typical	O
of	O
mitochondrial	B-T047
disorders	I-T047
were	O
reported	B-T058
.	O
Studies	O
in	O
patients	O
'	O
fibroblasts	O
revealed	O
that	O
MSTO1	O
protein	O
levels	O
were	O
strongly	O
reduced	O
,	O
the	O
mitochondrial	B-T033
network	I-T033
was	I-T033
fragmented	I-T033
and	O
the	O
fusion	O
events	O
among	O
mitochondria	O
were	O
decreased	O
,	O
confirming	O
the	O
deleterious	O
effect	O
of	O
the	O
identified	O
variants	O
and	O
the	O
role	O
of	O
MSTO1	O
in	O
modulating	O
mitochondrial	O
dynamics	O
.	O
We	O
also	O
found	O
that	O
MSTO1	O
is	O
mainly	O
a	O
cytosolic	O
protein	O
.	O
These	O
findings	O
indicate	O
recessive	O
mutations	O
in	O
MSTO1	O
as	O
a	O
new	O
cause	O
for	O
inherited	O
neuromuscular	B-T047
disorders	I-T047
with	O
multisystem	O
features	O
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O
      
Safety	B-T058
Precautions	I-T058
and	O
Operating	O
Procedures	O
in	O
an	O
(	O
A	O
)	O
BSL-4	O
Laboratory	O
:	O
1	O
.	O
Biosafety	O
Level	O
4	O
Suit	O
Laboratory	O
Suite	O
Entry	O
and	O
Exit	O
Procedures	O
Biosafety	O
level	O
4	O
(	O
BSL-4	O
)	O
suit	O
laboratories	O
are	O
specifically	O
designed	O
to	O
study	O
high	B-T001
-	I-T001
consequence	I-T001
pathogens	I-T001
for	O
which	O
neither	O
infection	O
prophylaxes	B-T061
nor	O
treatment	B-T061
options	O
exist	O
.	O
The	O
hallmarks	O
of	O
these	O
laboratories	O
are	O
:	O
custom	O
-	O
designed	O
airtight	O
doors	O
,	O
dedicated	O
supply	O
and	O
exhaust	O
airflow	O
systems	O
,	O
a	O
negative	O
-	O
pressure	O
environment	O
,	O
and	O
mandatory	O
use	O
of	O
positive	O
-	O
pressure	O
(	O
"	O
space	O
"	O
)	O
suits	O
.	O
The	O
risk	O
for	O
laboratory	O
specialists	O
working	O
with	O
highly	O
pathogenic	B-T001
agents	I-T001
is	O
minimized	O
through	O
rigorous	O
training	O
and	O
adherence	O
to	O
stringent	O
safety	O
protocols	O
and	O
standard	O
operating	O
procedures	O
.	O
Researchers	O
perform	O
the	O
majority	O
of	O
their	O
work	O
in	O
BSL-2	O
laboratories	O
and	O
switch	O
to	O
BSL-4	O
suit	O
laboratories	O
when	O
work	O
with	O
a	O
high	B-T001
-	I-T001
consequence	I-T001
pathogen	I-T001
is	O
required	O
.	O
Collaborators	O
and	O
scientists	O
considering	O
BSL-4	O
projects	O
should	O
be	O
aware	O
of	O
the	O
challenges	B-T033
associated	O
with	O
BSL-4	O
research	O
both	O
in	O
terms	O
of	O
experimental	O
technical	O
limitations	O
in	O
BSL-4	O
laboratory	O
space	O
and	O
the	O
increased	O
duration	O
of	O
such	O
experiments	O
.	O
Tasks	O
such	O
as	O
entering	O
and	O
exiting	O
the	O
BSL-4	O
suit	O
laboratories	O
are	O
considerably	O
more	O
complex	O
and	O
time	O
-	O
consuming	O
compared	O
to	O
BSL-2	O
and	O
BSL-3	O
laboratories	O
.	O
The	O
focus	O
of	O
this	O
particular	O
article	O
is	O
to	O
address	O
basic	O
biosafety	O
concerns	O
and	O
describe	O
the	O
entrance	O
and	O
exit	O
procedures	O
for	O
the	O
BSL-4	O
laboratory	O
at	O
the	O
NIH	O
/	O
NIAID	O
Integrated	O
Research	O
Facility	O
at	O
Fort	O
Detrick	O
.	O
Such	O
procedures	O
include	O
checking	O
external	O
systems	O
that	O
support	O
the	O
BSL-4	O
laboratory	O
,	O
and	O
inspecting	O
and	O
donning	O
positive	O
-	O
pressure	O
suits	O
,	O
entering	O
the	O
laboratory	O
,	O
moving	O
through	O
air	O
pressure	O
-	O
resistant	O
doors	O
,	O
and	O
connecting	O
to	O
air	O
-	O
supply	O
hoses	O
.	O
We	O
will	O
also	O
discuss	O
moving	O
within	O
and	O
exiting	O
the	O
BSL-4	O
suit	O
laboratories	O
,	O
including	O
using	O
the	O
chemical	O
shower	O
and	O
removing	O
and	O
storing	O
positive	O
-	O
pressure	O
suits	O
.	O
      
Timing	O
of	O
False	O
Ring	O
Formation	O
in	O
Pinus	O
halepensis	O
and	O
Arbutus	O
unedo	O
in	O
Southern	O
Italy	O
:	O
Outlook	O
from	O
an	O
Analysis	O
of	O
Xylogenesis	O
and	O
Tree	O
-	O
Ring	O
Chronologies	O
Mediterranean	O
tree	O
rings	O
are	O
characterized	O
by	O
intra	O
-	O
annual	O
density	O
fluctuations	O
(	O
IADFs	O
)	O
due	O
to	O
partly	O
climate	O
-	O
driven	O
cambial	O
activity	O
.	O
IADFs	O
are	O
used	O
as	O
structural	O
signals	O
to	O
gain	O
information	O
on	O
relations	O
between	O
environmental	O
conditions	O
and	O
eco	O
-	O
physiological	O
processes	O
during	O
xylogenesis	O
,	O
with	O
intra	O
-	O
annual	O
resolution	O
.	O
To	O
reach	O
an	O
unbiased	O
synchronization	O
of	O
the	O
IADF	O
position	O
within	O
tree	O
rings	O
and	O
seasonal	O
fluctuations	B-T184
in	O
environmental	O
conditions	O
,	O
it	O
is	O
necessary	O
to	O
know	O
the	O
timing	O
of	O
cambial	O
activity	O
and	O
wood	O
formation	O
,	O
which	O
are	O
species-	O
and	O
site	O
-	O
specific	O
processes	O
.	O
We	O
applied	O
the	O
microcoring	O
technique	O
to	O
analyze	O
xylogenesis	O
in	O
Pinus	O
halepensis	O
and	O
Arbutus	O
unedo	O
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
attempt	O
to	O
study	O
xylogenesis	O
in	O
a	O
hardwood	O
species	O
forming	O
frequent	O
IADFs	O
.	O
Both	O
species	O
co	O
-	O
occur	O
at	O
a	O
site	O
in	O
southern	O
Italy	O
characterized	O
by	O
a	O
Mediterranean	O
climate	O
.	O
To	O
facilitate	O
tree	O
-	O
ring	O
dating	O
and	O
identification	O
of	O
IADFs	O
,	O
we	O
performed	O
traditional	O
dendroecological	O
analysis	O
.	O
We	O
analyzed	O
xylogenesis	O
during	O
summer	O
,	O
which	O
is	O
considered	O
a	O
constraint	O
for	O
xylogenesis	O
and	O
a	O
trigger	O
for	O
IADF	O
formation	O
.	O
We	O
followed	O
the	O
different	O
phases	O
of	O
cell	O
development	O
in	O
the	O
current	O
wood	O
increment	O
with	O
the	O
aim	O
of	O
evaluating	O
whether	O
and	O
which	O
type	O
of	O
IADFs	O
were	O
formed	O
.	O
We	O
additionally	O
analyzed	O
the	O
same	O
phases	O
again	O
in	O
September	O
and	O
in	O
winter	O
to	O
verify	O
the	O
possible	B-T033
formation	O
of	O
IADFs	O
in	O
fall	O
and	O
whether	O
cell	O
production	O
and	O
differentiation	O
was	O
completed	O
by	O
the	O
end	O
of	O
the	O
calendar	O
year	O
.	O
Both	O
species	O
formed	O
the	O
same	O
type	O
of	O
IADFs	O
(	O
earlywood	O
-like	O
cells	O
within	O
latewood	O
)	O
,	O
due	O
to	O
temporary	O
growth	O
restoration	B-T033
triggered	O
by	O
rain	O
events	O
during	O
the	O
period	O
of	O
summer	O
drought	O
.	O
At	O
the	O
end	O
of	O
the	O
calendar	O
year	O
,	O
no	O
cells	O
in	O
the	O
phases	O
of	O
enlargement	O
and	O
secondary	O
cell	O
wall	O
deposition	O
occurred	O
.	O
A.	O
unedo	O
was	O
more	O
sensitive	O
than	O
P.	O
halepensis	O
because	O
IADF	O
s	O
were	O
formed	O
earlier	O
in	O
the	O
season	O
and	O
were	O
more	O
frequent	O
in	O
the	O
tree	O
-	O
ring	O
series	O
.	O
The	O
dendro	O
-	O
anatomical	O
approach	O
,	O
combining	O
analysis	O
of	O
tree	O
-	O
ring	O
series	O
and	O
of	O
xylogenesis	O
,	O
helped	O
to	O
detect	B-T033
the	O
period	O
of	O
IADF	O
formation	O
in	O
the	O
two	O
species	O
.	O
Results	O
are	O
discussed	O
in	O
functional	O
terms	O
,	O
highlighting	O
the	O
environmental	O
conditions	O
triggering	O
IADFs	O
,	O
and	O
also	O
in	O
methodological	O
terms	O
,	O
evaluating	O
the	O
applicability	O
of	O
xylogenesis	O
analysis	O
in	O
Mediterranean	O
woods	O
,	O
especially	O
when	O
the	O
formation	O
of	O
IADFs	O
is	O
not	O
uniform	O
around	O
the	O
stem	O
.	O
      
High	O
tacrolimus	B-T121
blood	O
concentrations	O
early	O
after	O
lung	B-T061
transplantation	I-T061
and	O
the	O
risk	O
of	O
kidney	O
injury	O
Lung	B-T023
transplant	O
recipients	O
often	O
develop	O
acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
evolving	O
into	O
chronic	B-T047
kidney	I-T047
disease	I-T047
(	O
CKD	B-T047
)	O
.	O
The	O
immunosuppressant	B-T121
tacrolimus	B-T121
might	O
be	O
associated	O
with	O
the	O
emergence	O
of	O
AKI	O
.	O
We	O
analyzed	O
the	O
development	O
and	O
recovery	O
of	O
kidney	O
injury	O
after	O
lung	B-T061
transplantation	I-T061
and	O
related	O
AKI	O
to	O
whole	O
-	O
blood	O
tacrolimus	B-T121
trough	O
concentrations	O
and	O
other	O
factors	O
causing	O
kidney	O
injury	O
.	O
We	O
retrospectively	O
studied	O
kidney	O
injury	O
in	O
186	O
lung	B-T061
-	I-T061
transplantation	I-T061
patients	O
at	O
the	O
UMC	O
Utrecht	O
between	O
2001	O
and	O
2011	O
.	O
Kidney	O
function	O
and	O
whole	O
-	O
blood	O
tacrolimus	B-T121
trough	O
concentrations	O
were	O
determined	O
from	O
day	O
1	O
to	O
14	O
and	O
at	O
1	O
,	O
3	O
,	O
6	O
,	O
and	O
12	O
months	O
postoperative	O
.	O
Systemic	B-T047
inflammatory	I-T047
response	I-T047
syndrome	I-T047
(	O
SIRS	B-T047
)	O
,	O
septic	O
shock	O
,	O
and	O
nephrotoxic	O
medications	O
were	O
evaluated	O
as	O
covariates	O
for	O
AKI	O
.	O
We	O
analyzed	O
liver	O
injury	O
and	O
drug	O
-	O
drug	O
interactions	O
.	O
AKI	O
was	O
present	B-T033
in	O
85	O
(	O
46	O
%	O
)	O
patients	O
.	O
Tacrolimus	B-T121
concentrations	O
were	O
supra	O
-	O
therapeutic	O
in	O
135	O
of	O
186	O
patients	O
(	O
73	O
%	O
)	O
.	O
AKI	O
in	O
the	O
first	O
week	O
after	O
transplantation	B-T061
was	O
related	O
to	O
supra	O
-	O
therapeutic	O
tacrolimus	B-T121
concentrations	O
(	O
OR	O
1.55	O
;	O
95	O
%	O
CI	O
1.06	O
-	O
2.27	O
)	O
,	O
≥3	O
other	O
nephrotoxic	B-T061
drugs	I-T061
(	O
OR	O
1.96	O
;	O
95	O
%	O
CI	O
1.02	O
-	O
3.77	O
)	O
,	O
infection	O
(	O
OR	O
2.48	O
;	O
95	O
%	O
CI	O
1.31	O
-	O
4.70	O
)	O
,	O
and	O
cystic	B-T047
fibrosis	I-T047
(	O
OR	O
2.17	O
;	O
95	O
%	O
CI	O
1.16	O
-	O
4.06	O
)	O
.	O
Recovery	O
rate	O
of	O
AKI	O
was	O
lower	O
than	O
expected	O
(	O
19	O
%	O
)	O
,	O
and	O
the	O
cumulative	O
incidence	O
of	O
severe	O
CKD	B-T047
at	O
1	O
year	O
was	O
15	O
%	O
.	O
After	O
lung	B-T061
transplantation	I-T061
,	O
AKI	O
is	O
common	O
and	O
often	O
evolves	O
into	O
severe	O
CKD	B-T047
,	O
which	O
is	O
a	O
known	O
cause	O
of	O
morbidity	O
and	O
mortality	O
.	O
Supra	O
-	O
therapeutic	O
whole	O
-	O
blood	O
tacrolimus	B-T121
trough	O
concentrations	O
are	O
related	O
to	O
the	O
early	O
onset	O
of	O
AKI	O
.	O
Conscientious	B-T033
targeting	O
tacrolimus	B-T121
blood	O
concentrations	O
might	O
be	O
vital	O
in	O
the	O
early	O
phase	O
after	O
lung	B-T061
transplantation	I-T061
.	O
What	O
is	O
known	O
about	O
this	O
subject	O
?	O
•	O
Lung	B-T023
transplant	O
recipients	O
often	O
develop	O
acute	O
kidney	O
injury	O
evolving	O
into	O
chronic	B-T047
kidney	I-T047
disease	I-T047
increasing	O
both	O
morbidity	O
and	O
mortality	O
.	O
•	O
To	O
date	O
,	O
the	O
pathophysiology	O
of	O
kidney	O
injury	O
after	O
lung	B-T061
transplantation	I-T061
has	O
not	O
been	O
fully	O
elucidated	O
.	O
•	O
The	O
immunosuppressant	B-T121
tacrolimus	B-T121
is	O
difficult	O
to	O
dose	O
,	O
especially	O
in	O
the	O
unstable	B-T033
clinical	O
setting	O
,	O
and	O
is	O
nephrotoxic	O
.	O
•	O
For	O
the	O
first	O
time	O
,	O
supra	O
-	O
therapeutic	O
whole	O
-	O
blood	O
tacrolimus	B-T121
trough	O
concentrations	O
are	O
related	O
to	O
the	O
emergence	O
of	O
acute	O
kidney	O
injury	O
in	O
the	O
first	O
days	O
after	O
lung	B-T061
transplantation	I-T061
.	O
•	O
Supra	O
-	O
therapeutic	O
whole	O
-	O
blood	O
tacrolimus	B-T121
trough	O
concentrations	O
often	O
occur	O
early	O
after	O
lung	B-T061
transplantation	I-T061
.	O
•	O
AKI	O
after	O
lung	B-T061
transplantation	I-T061
shows	O
low	O
recovery	O
rates	O
.	O
      
Real	O
-	O
time	O
monitoring	B-T058
of	O
vesicle	O
pH	O
in	O
an	O
endocytic	O
pathway	O
using	O
an	O
EGF	B-T121
-	O
conjugated	O
two	O
-	O
photon	O
probe	O
Herein	O
,	O
we	O
developed	O
a	O
ratiometric	O
two	O
-	O
photon	O
probe	O
(	O
BHS3	O
-	O
EGF	B-T121
)	O
,	O
derived	O
from	O
a	O
pH	O
sensitive	O
dye	O
and	O
epidermal	B-T121
growth	I-T121
factor	I-T121
(	O
EGF	B-T121
)	O
,	O
for	O
real	O
-	O
time	O
monitoring	B-T058
and	O
quantitative	O
analysis	O
of	O
acidic	O
luminal	O
pH	O
values	O
during	O
endocytic	O
pathway	O
activity	O
.	O
Two	B-T059
-	I-T059
photon	I-T059
microscopy	I-T059
imaging	I-T059
with	O
BHS3	O
-	O
EGF	B-T121
allows	O
the	O
quantitative	O
analysis	O
of	O
pH	O
distributions	O
of	O
single	O
vesicles	O
and	O
their	O
dynamics	O
in	O
receptor	O
-	O
mediated	O
endocytosis	O
in	O
real	O
-	O
time	O
.	O
      
Ecohydrological	O
modeling	O
and	O
environmental	O
flow	O
regime	O
in	O
the	O
Formoso	O
River	O
,	O
Minas	O
Gerais	O
State	O
,	O
Brazil	O
This	O
paper	O
aimed	O
at	O
determining	O
the	O
environmental	O
flow	O
regime	O
in	O
a	O
1	O
km	O
stretch	O
of	O
the	O
Formoso	O
River	O
,	O
MG	O
,	O
using	O
River2D	O
model	O
.	O
To	O
carry	O
out	O
the	O
ecohydrological	O
modeling	O
,	O
the	O
following	O
information	O
was	O
used	O
:	O
bathymetry	O
,	O
physical	O
and	O
hydraulic	O
features	O
,	O
and	O
the	O
Habitat	O
Suitability	O
Index	O
for	O
species	O
of	O
the	O
Hypostomus	O
auroguttatus	O
.	O
In	O
the	O
River2D	O
,	O
the	O
Weighted	O
Usable	O
Areas	O
were	O
determined	O
from	O
the	O
average	O
long	O
-	O
term	O
streamflows	O
with	O
percentage	O
from	O
10	O
%	O
to	O
100	O
%	O
.	O
Those	O
streamflows	O
were	O
simulated	O
for	O
the	O
later	O
construction	O
of	O
optimization	O
matrices	O
that	O
maximize	O
the	O
habitat	O
area	O
throughout	O
the	O
year	O
.	O
For	O
H.	O
auroguttatus	O
Juvenile	O
,	O
higher	O
values	O
of	O
Weighted	O
Usable	O
Area	O
were	O
associated	O
with	O
the	O
percentage	O
of	O
60	O
%	O
and	O
70	O
%	O
of	O
the	O
average	O
long	O
-	O
term	O
streamflows	O
in	O
October	O
and	O
September	O
,	O
respectively	O
.	O
For	O
H.	O
auroguttatus	O
Adult	O
,	O
the	O
highest	O
value	O
of	O
Weighted	O
Usable	O
Area	O
was	O
associated	O
with	O
the	O
percentage	O
of	O
100	O
%	O
of	O
the	O
average	O
long	O
-	O
term	O
streamflow	O
in	O
September	O
.	O
The	O
environmental	O
flows	O
found	B-T033
for	O
this	O
stretch	O
of	O
the	O
Formoso	O
River	O
varied	O
over	O
the	O
year	O
.	O
The	O
lowest	O
environmental	O
flow	O
was	O
observed	O
in	O
December	O
(	O
2.85	O
m3	O
s-1	O
)	O
,	O
while	O
the	O
highest	O
was	O
observed	O
in	O
May	O
(	O
4.13	O
m3	O
s-1	O
)	O
.	O
This	O
paper	O
shows	O
the	O
importance	O
of	O
ecohydrological	O
studies	O
in	O
forming	O
a	O
basis	O
for	O
water	O
resources	O
management	O
actions	O
.	O
      
Thyroid	B-T191
cancer	I-T191
burden	O
in	O
Central	O
and	O
South	O
America	O
Incidence	O
of	O
thyroid	B-T191
cancer	I-T191
(	O
TC	B-T191
)	O
is	O
rapidly	O
increasing	O
worldwide	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
TC	B-T191
burden	O
in	O
Central	O
and	O
South	O
America	O
(	O
CSA	O
)	O
.	O
We	O
describe	O
the	O
geographic	O
patterns	O
and	O
trends	O
of	O
TC	B-T191
by	O
sex	O
in	O
CSA	O
.	O
We	O
obtained	O
regional	O
-	O
and	O
national	O
-	O
level	O
incidence	O
data	O
from	O
48	O
population	O
-	O
based	O
cancer	O
registries	O
in	O
13	O
countries	O
and	O
nationwide	O
cancer	O
deaths	O
from	O
the	O
WHO	O
mortality	O
database	O
for	O
18	O
countries	O
.	O
We	O
estimated	O
world	O
population	O
age	O
-	O
standardized	O
incidence	O
rates	O
(	O
ASRs	O
)	O
and	O
age	O
-	O
standardized	O
mortality	O
rates	O
(	O
ASMRs	O
)	O
per	O
100,000	O
person	O
-	O
years	O
.	O
We	O
calculated	O
ASRs	O
by	O
histological	O
subtype	O
.	O
We	O
estimated	O
the	O
annual	O
percentage	O
change	O
(	O
EAPC	O
)	O
to	O
describe	O
time	O
trends	O
.	O
Between	O
CSA	O
countries	O
,	O
TC	B-T191
incidence	O
and	O
mortality	O
rates	O
varied	O
from	O
8	O
-	O
fold	O
to	O
12	O
-	O
fold	O
and	O
from	O
2	O
-	O
fold	O
to	O
5	O
-	O
fold	O
,	O
respectively	O
.	O
In	O
2003	O
-	O
2007	O
,	O
the	O
highest	O
TC	B-T191
ASRs	O
in	O
females	O
and	O
males	O
were	O
in	O
Ecuador	O
(	O
16.0	O
and	O
3.5	O
,	O
respectively	O
)	O
,	O
Brazil	O
(	O
14.4	O
and	O
3.4	O
)	O
,	O
Costa	O
Rica	O
(	O
12.6	O
and	O
2.1	O
)	O
and	O
Colombia	O
(	O
10.7	O
and	O
2.5	O
)	O
.	O
The	O
highest	O
ASMRs	O
were	O
in	O
Ecuador	O
,	O
Colombia	O
,	O
Mexico	O
,	O
Peru	O
and	O
Panama	O
(	O
0.68	O
-	O
0.91	O
in	O
females	O
and	O
0.41	O
-	O
0.48	O
in	O
males	O
)	O
.	O
Papillary	B-T191
TC	I-T191
was	O
the	O
most	O
commonly	O
diagnosed	B-T033
histological	O
subtype	O
,	O
following	O
the	O
same	O
incidence	O
pattern	O
as	O
overall	O
TC	B-T191
.	O
In	O
Argentinean	O
,	O
Brazilian	B-T033
,	O
Chilean	O
and	O
Costa	O
Rican	O
females	O
TC	B-T191
incidence	O
increased	O
by	O
2.2	O
-	O
17.9	O
%	O
annually	O
,	O
and	O
papillary	B-T191
TC	I-T191
increased	O
by	O
9.1	O
-	O
15.0	O
%	O
annually	O
,	O
while	O
mortality	O
remained	O
stable	O
between	O
1997	O
and	O
2008	O
.	O
In	O
males	O
,	O
trends	O
in	O
TC	B-T191
were	O
stable	O
.	O
TC	B-T191
occurred	O
more	O
frequently	O
in	O
females	O
than	O
in	O
males	O
.	O
The	O
overall	O
high	O
incidence	O
and	O
low	O
mortality	O
of	O
TC	B-T191
suggest	O
identification	O
of	O
subclinical	B-T047
disease	I-T047
due	O
to	O
improved	O
detection	O
methods	O
.	O
      
Three	O
-	O
dimensional	O
constructive	O
interference	O
in	O
steady	O
-	O
state	O
(	O
3D	O
-	O
CISS	O
)	O
sequences	O
and	O
Phase	B-T060
-	I-T060
contrast	I-T060
MRI	I-T060
of	O
arrested	B-T047
hydrocephalus	I-T047
to	O
evaluate	O
role	O
of	O
three	O
-	O
dimensional	O
constructive	O
interference	O
in	O
steady	O
-	O
state	O
(	O
3D	O
-	O
CISS	O
)	O
sequences	O
and	O
phase	B-T060
-	I-T060
contrast	I-T060
magnetic	I-T060
resonance	I-T060
imaging	I-T060
(	O
PC	B-T060
-	I-T060
MRI	I-T060
)	O
in	O
patients	O
with	O
arrested	B-T047
hydrocephalus	I-T047
.	O
Prospective	O
study	O
was	O
conducted	O
on	O
20	O
patients	O
with	O
arrested	B-T047
hydrocephalus	I-T047
.	O
All	O
patients	O
underwent	O
PC	B-T060
-	I-T060
MRI	I-T060
and	O
3D	O
-	O
CISS	O
for	O
assessment	B-T058
of	O
the	O
aqueduct	O
.	O
Axial	O
(	O
through	O
-	O
plane	O
)	O
,	O
sagittal	O
(	O
in	O
-	O
plane	O
)	O
PC	B-T060
-	I-T060
MRI	I-T060
and	O
sagittal	O
3D	O
-	O
CISS	O
were	O
applied	O
to	O
assess	B-T058
the	O
cerebral	O
aqueduct	O
and	O
the	O
spontaneous	O
third	B-T061
ventriculostomy	I-T061
if	O
present	O
.	O
Aqueductal	O
patency	O
was	O
graded	O
using	O
3D	O
-	O
CISS	O
and	O
PC	B-T060
-	I-T060
MRI	I-T060
.	O
Quantitative	B-T059
analysis	I-T059
of	O
flow	O
through	O
the	O
aqueduct	O
was	O
done	O
using	O
PC	B-T060
-	I-T060
MRI	I-T060
.	O
The	O
causes	O
of	O
obstruction	O
were	O
aqueductal	O
obstruction	O
in	O
75	O
%	O
(	O
n=15	O
)	O
,	O
3rd	O
ventricular	B-T047
obstruction	I-T047
in	O
5	O
%	O
(	O
n=1	O
)	O
and	O
4th	O
ventricular	B-T047
obstruction	I-T047
in	O
20	O
%	O
(	O
n=4	O
)	O
.	O
The	O
cause	O
of	O
arrest	O
of	O
hydrocephalus	B-T047
was	O
spontaneous	O
third	B-T061
ventriculostomy	I-T061
in	O
65	O
%	O
(	O
n=13	O
)	O
,	O
endoscopic	B-T061
third	I-T061
ventriculostomy	I-T061
in	O
10	O
%	O
(	O
n=2	O
)	O
,	O
ventriculo	O
-	O
peritoneal	O
shunt	O
in	O
5	O
%	O
(	O
n=1	O
)	O
and	O
no	O
cause	O
could	O
be	O
detected	B-T033
in	O
20	O
%	O
of	O
patients	O
(	O
n=4	O
)	O
.	O
There	O
is	O
a	O
positive	B-T033
correlation	O
(	O
r=	O
0.80	O
)	O
and	O
moderate	O
agreement	O
(	O
κ=	O
0.509	O
)	O
of	O
grading	O
with	O
PC	B-T060
-	I-T060
MRI	I-T060
and	O
3D	O
-	O
CISS	O
sequences	O
.	O
The	O
mean	O
peak	O
systolic	O
velocity	O
of	O
CSF	O
was	O
1.86	O
±	O
2.48	O
cm	O
/	O
sec	O
,	O
the	O
stroke	O
volume	O
was	O
6.43	O
±	O
13.81μl	O
/	O
cycle	O
,	O
and	O
the	O
mean	O
flow	O
was	O
0.21	O
±	O
0.32	O
ml	O
/	O
min	O
.	O
We	O
concluded	O
that	O
3D	O
-	O
CISS	O
and	O
PC	B-T060
-	I-T060
MRI	I-T060
are	O
non	O
-	O
invasive	O
sequences	O
for	O
diagnosis	B-T033
of	O
the	O
level	O
and	O
cause	O
of	O
arrested	B-T047
hydrocephalus	I-T047
.	O
      
Total	B-T033
Energy	I-T033
Expenditure	I-T033
in	O
Obese	B-T047
Kuwaiti	O
Primary	O
School	O
Children	O
Assessed	O
by	O
the	O
Doubly	O
-	O
Labeled	O
Water	O
Technique	O
The	O
aim	O
of	O
this	O
pilot	O
study	O
was	O
to	O
assess	O
body	O
composition	O
and	O
total	B-T033
energy	I-T033
expenditure	I-T033
(	O
TEE	B-T033
)	O
in	O
35	O
obese	B-T047
7	O
-	O
9	O
years	O
old	O
Kuwaiti	O
children	O
(	O
18	O
girls	O
and	O
17	O
boys	O
)	O
.	O
Total	B-T033
body	I-T033
water	I-T033
(	O
TBW	B-T033
)	O
and	O
TEE	B-T033
were	O
assessed	O
by	O
doubly	O
-	O
labeled	O
water	O
technique	O
.	O
TBW	B-T033
was	O
derived	O
from	O
the	O
intercept	O
of	O
the	O
elimination	B-T033
rate	I-T033
of	O
deuterium	O
and	O
TEE	B-T033
from	O
the	O
difference	O
in	O
elimination	B-T033
rates	I-T033
of	O
(	B-T121
18)O	I-T121
and	O
deuterium	O
.	O
TBW	B-T033
was	O
used	O
to	O
estimate	O
fat	B-T033
-	I-T033
free	I-T033
mass	I-T033
(	O
FFM	B-T033
)	O
,	O
using	O
hydration	O
factors	O
for	O
different	O
ages	O
and	O
gender	O
.	O
Fat	O
mass	O
(	O
FM	O
)	O
was	O
calculated	O
as	O
the	O
difference	O
between	O
body	O
weight	O
and	O
FFM	B-T033
.	O
Body	O
weight	O
was	O
not	O
statistically	O
different	O
but	O
TBW	B-T033
was	O
significantly	O
higher	O
(	O
p	O
=	O
0.018	O
)	O
in	O
boys	O
(	O
44.9	O
%	O
±	O
3.3	O
%	O
)	O
than	O
girls	O
(	O
42.4	O
%	O
±	O
3.0	O
%	O
)	O
,	O
while	O
girls	O
had	O
significantly	O
higher	O
estimated	O
FM	O
(	O
45.2	O
±	O
3.9	O
weight	O
%	O
versus	O
41.6	O
%	O
±	O
4.3	O
%	O
;	O
p	O
=	O
0.014	O
)	O
.	O
TEE	B-T033
was	O
significantly	O
higher	O
in	O
boys	O
(	O
2395	O
±	O
349	O
kcal	O
/	O
day	O
)	O
compared	O
with	O
girls	O
(	O
1978	O
±	O
169	O
kcal	O
/	O
day	O
)	O
;	O
p	O
=	O
0.001	O
.	O
Estimated	O
physical	B-T033
activity	I-T033
level	I-T033
(	O
PAL	B-T033
)	O
was	O
significantly	O
higher	O
in	O
boys	O
;	O
1.61	O
±	O
0.167	O
versus	O
1.51	O
±	O
0.870	O
;	O
p	O
=	O
0.034	O
.	O
Our	O
results	O
provide	O
the	O
first	O
dataset	O
of	O
TEE	B-T033
in	O
7	O
-	O
9	O
years	O
old	O
obese	B-T047
Kuwaiti	O
children	O
and	O
highlight	O
important	O
gender	O
differences	O
to	O
be	O
considered	O
during	O
the	O
development	O
of	O
school	B-T058
based	I-T058
interventions	I-T058
targeted	O
to	O
combat	O
childhood	B-T047
obesity	I-T047
.	O
      
Oxidative	O
stress	O
and	O
immunosenescence	O
in	O
spleen	B-T023
of	O
obese	O
mice	O
can	O
be	O
reversed	O
by	O
2	B-T121
-	I-T121
hydroxyoleic	I-T121
acid	I-T121
We	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
obesity	B-T047
on	O
oxidative	O
stress	O
and	O
leukocyte	O
function	O
in	O
spleen	B-T023
of	O
mice	O
,	O
and	O
to	O
assess	O
whether	O
supplementation	B-T061
with	O
2	B-T121
-	I-T121
hydroxyoleic	I-T121
acid	I-T121
(	O
2	B-T121
-	I-T121
OHOA	I-T121
)	O
or	O
n-3	B-T121
polyunsaturated	I-T121
fatty	I-T121
acids	I-T121
(	O
PUFA	B-T121
)	O
could	O
reverse	O
those	O
effects	O
.	O
Female	O
ICR	O
/	O
CD1	O
mice	O
(	O
8	O
weeks	O
old	O
,	O
n	O
=	O
24	O
)	O
received	O
an	O
obesogenic	O
diet	O
(	O
22	O
%	O
fat	O
for	O
4	O
weeks	O
and	O
60	O
%	O
fat	O
for	O
14	O
weeks	O
)	O
.	O
After	O
6	O
weeks	O
,	O
mice	O
were	O
split	O
in	O
three	O
groups	O
(	O
n	O
=	O
8/	O
group	O
):	O
no	O
supplementation	O
,	O
2	O
-	O
OHOA	O
supplementation	O
(	O
1500	O
mg	O
kg(-1	O
)	O
)	O
and	O
n-3	O
PUFA	O
supplementation	O
(	O
EPA	B-T121
+	O
DHA	B-T121
,	O
3000	O
mg	O
kg(-1	O
)	O
diet	O
)	O
.	O
Eight	O
mice	O
were	O
fed	O
standard	O
diet	O
for	O
the	O
whole	O
duration	O
of	O
the	O
study	O
(	O
control	O
group	O
)	O
.	O
At	O
the	O
end	O
of	O
the	O
experiment	O
,	O
the	O
following	O
variables	O
were	O
assessed	O
in	O
spleens	B-T023
:	O
levels	O
of	O
reduced	O
(	O
GSH	O
)	O
and	O
oxidized	B-T121
(	I-T121
GSSG	I-T121
)	I-T121
glutathione	I-T121
,	O
GSH	O
/	O
GSSG	B-T121
,	O
xanthine	O
oxidase	O
(	O
XO	O
)	O
activity	O
,	O
lipid	O
peroxidation	O
,	O
lymphocyte	O
chemotaxis	O
,	O
natural	O
killer	O
(	O
NK	O
)	O
activity	O
and	O
mitogen	B-T121
(	O
ConA	O
and	O
LPS)-induced	O
lymphocyte	O
proliferation	O
.	O
Obese	O
animals	O
presented	O
higher	O
GSSG	B-T121
levels	O
(	O
P	O
=	O
0.003	O
)	O
,	O
GSSG	B-T121
/	O
GSH	O
ratio	O
(	O
P	O
=	O
0.013	O
)	O
,	O
lipid	O
peroxidation	O
(	O
P	O
=	O
0.004	O
)	O
,	O
XO	O
activity	O
(	O
P	O
=	O
0.015	O
)	O
and	O
lymphocyte	O
chemotaxis	O
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
lower	O
NK	O
activity	O
(	O
P	O
=	O
0.003	O
)	O
and	O
proliferation	O
in	O
response	O
to	O
ConA	O
(	O
P	O
<	O
0.001	O
)	O
than	O
controls	O
.	O
2	B-T121
-	I-T121
OHOA	I-T121
reversed	O
totally	O
or	O
partially	O
most	O
of	O
the	O
changes	O
(	O
body	O
weight	O
,	O
fat	O
content	O
,	O
GSSG	B-T121
levels	O
,	O
GSH	O
/	O
GSSG	B-T121
,	O
lipid	O
peroxidation	O
,	O
chemotaxis	O
and	O
proliferation	O
,	O
all	O
P	O
<	O
0.05	O
)	O
,	O
while	O
n-3	B-T121
PUFA	I-T121
reversed	O
the	O
increase	O
in	O
XO	O
activity	O
(	O
P	O
=	O
0.032	O
)	O
.	O
In	O
conclusion	O
,	O
2	B-T121
-	I-T121
OHOA	I-T121
,	O
and	O
to	O
a	O
lesser	O
extent	O
n-3	B-T121
PUFA	I-T121
,	O
could	O
ameliorate	O
the	O
oxidative	O
stress	O
and	O
alteration	O
of	O
leukocyte	O
function	O
in	O
spleen	B-T023
of	O
obese	O
mice	O
.	O
Our	O
findings	B-T033
support	O
a	O
link	O
between	O
obesity	B-T047
and	O
immunosenescence	O
and	O
suggest	O
a	O
potential	O
therapeutic	O
tool	O
for	O
obesity	B-T047
-related	O
immune	B-T047
dysfunction	I-T047
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O
      
Prolyl-4	O
-	O
hydroxylase	O
2	O
and	O
3	O
coregulate	O
murine	B-T121
erythropoietin	B-T121
in	O
brain	B-T023
pericytes	O
A	O
classic	O
response	B-T033
to	O
systemic	O
hypoxia	O
is	O
the	O
increased	O
production	O
of	O
red	O
blood	O
cells	O
due	O
to	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF)-mediated	O
induction	O
of	O
erythropoietin	B-T121
(	O
EPO	B-T121
)	O
.	O
EPO	B-T121
is	O
a	O
glycoprotein	O
hormone	O
that	O
is	O
essential	O
for	O
normal	O
erythropoiesis	O
and	O
is	O
predominantly	O
synthesized	O
by	O
peritubular	O
renal	O
interstitial	O
fibroblast	O
-	O
like	O
cells	O
,	O
which	O
express	O
cellular	O
markers	O
characteristic	O
of	O
neuronal	O
cells	O
and	O
pericytes	O
.	O
To	O
investigate	O
whether	O
the	O
ability	O
to	O
synthesize	O
EPO	B-T121
is	O
a	O
general	O
functional	O
feature	O
of	O
pericytes	O
,	O
we	O
used	O
conditional	O
gene	O
targeting	O
to	O
examine	O
the	O
von	B-T047
Hippel	I-T047
-	I-T047
Lindau	I-T047
/	O
prolyl-4	O
-	O
hydroxylase	O
domain	O
(	O
PHD)/HIF	O
axis	O
in	O
cell	O
-	O
expressing	O
neural	O
glial	O
antigen	O
2	O
,	O
a	O
known	O
molecular	O
marker	O
of	O
pericytes	O
in	O
multiple	B-T023
organs	I-T023
.	O
We	O
found	O
that	O
pericytes	O
in	O
the	O
brain	B-T023
synthesized	O
EPO	B-T121
in	O
mice	O
with	O
genetic	O
HIF	O
activation	O
and	O
were	O
capable	O
of	O
responding	O
to	O
systemic	O
hypoxia	O
with	O
the	O
induction	O
of	O
Epo	B-T121
.	O
Using	O
high	B-T059
-	I-T059
resolution	I-T059
multiplex	O
in	O
situ	O
hybridization	O
,	O
we	O
determined	O
that	O
brain	B-T023
pericytes	O
represent	O
an	O
important	O
cellular	O
source	O
of	O
Epo	B-T121
in	O
the	O
hypoxic	O
brain	B-T023
(	O
up	O
to	O
70	O
%	O
of	O
all	O
Epo	B-T121
-	O
expressing	O
cells	O
)	O
.	O
We	O
furthermore	O
determined	O
that	O
Epo	B-T121
transcription	O
in	O
brain	B-T023
pericytes	O
was	O
HIF-2	O
dependent	O
and	O
cocontrolled	O
by	O
PHD2	O
and	O
PHD3	O
,	O
oxygen	B-T121
-	O
and	O
2	B-T121
-	I-T121
oxoglutarate	I-T121
-dependent	O
prolyl-4	O
-	O
hydroxylases	O
that	O
regulate	O
HIF	O
activity	O
.	O
In	O
summary	O
,	O
our	O
studies	O
provide	O
experimental	O
evidence	O
that	O
pericytes	O
in	O
the	O
brain	B-T023
have	O
the	O
ability	O
to	O
function	O
as	O
oxygen	O
sensors	O
and	O
respond	O
to	O
hypoxia	O
with	O
EPO	B-T121
synthesis	O
.	O
Our	O
findings	O
furthermore	O
suggest	O
that	O
the	O
ability	O
to	O
synthesize	O
EPO	B-T121
may	O
represent	O
a	O
functional	O
feature	O
of	O
pericytes	O
in	O
the	O
brain	B-T023
and	O
kidney	B-T023
.	O
      
Vaginal	B-T047
Infections	I-T047
of	O
Albanian	O
women	O
Infected	O
with	O
HPV	B-T005
and	O
their	O
impact	O
in	O
intraepithelial	B-T191
cervical	I-T191
lesions	I-T191
evidenced	O
by	O
Pap	B-T059
test	I-T059
Cervical	B-T059
cytology	I-T059
is	O
the	O
best	O
single	O
method	O
for	O
large	O
screening	B-T060
of	O
the	O
population	O
in	O
identifying	O
precancerous	B-T191
lesions	I-T191
of	O
the	O
uterine	B-T023
cervix	I-T023
.	O
To	O
estimate	O
the	O
frequency	O
of	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
positivity	O
in	O
a	O
group	O
of	O
Albanian	O
women	O
,	O
the	O
prevalence	O
of	O
vaginal	B-T047
coinfections	I-T047
,	O
and	O
the	O
relationship	O
of	O
coinfections	B-T047
with	O
HPV	B-T005
,	O
as	O
well	O
as	O
their	O
role	O
in	O
metaplasia	O
or	O
cervical	B-T191
intraepithelial	I-T191
lesions	I-T191
(	O
CIN	B-T191
)	O
.	O
In	O
this	O
retrospective	O
study	O
,	O
2075	O
vaginal	B-T060
smears	I-T060
were	O
examined	O
.	O
The	O
Papanicolaou	B-T060
stain	I-T060
was	O
used	O
for	O
all	O
slides	O
.	O
The	O
New	B-T059
Bethesda	I-T059
System	I-T059
2001	O
was	O
used	O
for	O
the	O
interpretations	B-T059
of	I-T059
the	I-T059
smears	I-T059
.	O
Data	O
analysis	O
was	O
completed	O
using	O
the	O
Statistical	O
Package	O
for	O
the	O
Social	O
Sciences	O
version	O
19.0	O
.	O
Prevalence	O
of	O
HPV	O
positivity	O
was	O
43.9	O
%	O
with	O
an	O
average	O
age	O
of	O
35.48	O
±	O
9.27	O
years	O
.	O
Candida	B-T047
coinfection	I-T047
resulted	O
in	O
57.8	O
%	O
of	O
HPV	O
positive	O
women	O
with	O
a	O
significant	O
relationship	O
between	O
them	O
.	O
Gardnerella	B-T047
coinfection	I-T047
resulted	O
in	O
36	O
(	O
23	O
%	O
)	O
,	O
mixed	B-T047
flora	I-T047
in	O
34	O
(	O
8	O
%	O
)	O
,	O
and	O
Trichomonas	B-T047
vaginalis	I-T047
in	O
50	O
%	O
of	O
HPV	O
positive	O
woman	O
.	O
Among	O
the	O
women	O
with	O
positive	O
HPV	O
,	O
19	O
%	O
had	O
CIN	B-T191
,	O
8	O
%	O
had	O
metaplasia	O
,	O
and	O
1	O
%	O
had	O
metaplasia	O
and	O
CIN	B-T191
;	O
9	O
%	O
of	O
the	O
women	O
with	O
HPV	B-T005
had	O
CIN1	B-T191
and	O
one	O
of	O
the	O
coinfections	B-T047
.	O
There	O
is	O
a	O
strong	O
relationship	O
between	O
CIN1	B-T191
and	O
HPV	O
positivity	O
as	O
well	O
as	O
between	O
CIN1	B-T191
and	O
coinfections	B-T047
.	O
HPV	B-T047
infection	I-T047
is	O
a	O
major	O
factor	O
contributing	O
to	O
metaplasia	O
,	O
and	O
bacterial	B-T047
coinfections	I-T047
in	O
HPV	O
positive	O
women	O
have	O
a	O
statistically	O
significant	O
impact	O
in	O
the	O
development	O
of	O
metaplasia	O
.	O
      
Beneficial	O
effects	O
of	O
dark	O
chocolate	O
on	O
exercise	O
capacity	O
in	O
sedentary	O
subjects	O
:	O
underlying	O
mechanisms	O
.	O
A	O
double	O
blind	O
,	O
randomized	O
,	O
placebo	O
controlled	O
trial	O
In	O
heart	B-T047
failure	I-T047
patients	O
the	O
consumption	O
of	O
(	B-T121
-)-epicatechin	I-T121
(	O
(	B-T121
-)-Epi	I-T121
-)-Epi)-rich	O
cocoa	O
can	O
restore	O
skeletal	O
muscle	O
(	O
SkM	O
)	O
mitochondrial	O
structure	O
and	O
decrease	O
biomarkers	O
of	O
oxidative	O
stress	O
.	O
However	O
,	O
nothing	O
is	O
known	O
about	O
its	O
effects	O
on	O
exercise	O
capacity	O
and	O
underlying	O
mechanisms	O
in	O
normal	O
,	O
sedentary	O
subjects	O
.	O
Twenty	O
normal	O
,	O
sedentary	O
subjects	O
(	O
∼50	O
years	O
old	O
)	O
were	O
randomized	O
to	O
placebo	B-T061
or	O
dark	O
chocolate	O
(	O
DC	O
)	O
groups	O
and	O
consumed	O
20	O
g	O
of	O
the	O
products	O
for	O
3	O
months	O
.	O
Subjects	O
underwent	O
before	O
and	O
after	O
treatment	B-T061
,	O
bicycle	B-T060
ergometry	I-T060
to	O
assess	B-T058
VO2	B-T033
max	I-T033
and	O
work	O
,	O
SkM	B-T060
biopsy	I-T060
to	O
assess	B-T058
changes	O
in	O
mitochondrial	O
density	O
,	O
function	O
and	O
oxidative	O
stress	O
and	O
blood	B-T060
sampling	I-T060
to	O
assess	B-T058
metabolic	O
endpoints	O
.	O
Seventeen	O
subjects	O
completed	O
the	O
trial	O
.	O
In	O
the	O
DC	O
group	O
(	O
n	O
=	O
9	O
)	O
,	O
VO2	B-T033
max	I-T033
increased	O
(	O
17	O
%	O
increase	O
,	O
p	O
=	O
0.056	O
)	O
as	O
well	O
as	O
maximum	O
work	O
(	O
watts	O
)	O
achieved	O
(	O
p	O
=	O
0.026	O
)	O
with	O
no	O
changes	O
with	O
placebo	B-T061
(	O
n	O
=	O
8)	O
.	O
The	O
DC	O
group	O
evidenced	O
increases	O
in	O
HDL	O
levels	O
(	O
p	O
=	O
0.005	O
)	O
and	O
decreased	O
triglycerides	O
(	O
p	O
=	O
0.07	O
)	O
.	O
With	O
DC	O
,	O
SkM	O
evidenced	O
significant	O
increases	O
in	O
protein	O
levels	O
for	O
LKB1	O
,	O
AMPK	O
and	O
PGC1α	O
and	O
in	O
their	O
active	O
forms	O
(	O
phosphorylated	O
AMPK	O
and	O
LKB1	O
)	O
as	O
well	O
as	O
in	O
citrate	O
synthase	O
activity	O
while	O
no	O
changes	O
were	O
observed	O
in	O
mitochondrial	O
density	O
.	O
With	O
DC	O
,	O
significant	O
increases	O
in	O
SkM	O
reduced	O
glutathione	O
levels	O
and	O
decreases	O
in	O
protein	O
carbonylation	O
were	O
observed	O
.	O
Improvements	O
in	O
maximum	O
work	O
achieved	O
and	O
VO2	B-T033
max	I-T033
may	O
be	O
due	O
to	O
DC	O
activation	O
of	O
upstream	O
control	O
systems	O
and	O
enhancement	O
of	O
SkM	O
mitochondria	O
efficiency	O
.	O
Larger	O
clinical	O
studies	O
are	O
warranted	O
to	O
confirm	O
these	O
observations	O
.	O
      
Medication	B-T058
Reconciliation	I-T058
During	O
Hospitalization	B-T058
and	O
in	O
Hospital	B-T058
-	I-T058
Home	I-T058
Interface	I-T058
:	O
An	O
Observational	O
Retrospective	O
Study	O
Medication	O
errors	O
are	O
one	O
of	O
the	O
leading	O
causes	O
of	O
patient	O
harms	O
.	O
Medication	B-T058
reconciliation	I-T058
is	O
a	O
fundamental	O
process	O
that	O
to	O
be	O
effective	O
,	O
it	O
should	O
be	O
embraced	O
during	O
each	O
single	O
care	B-T058
transition	I-T058
.	O
Our	O
objectives	O
were	O
to	O
investigate	O
current	O
medication	B-T058
reconciliation	I-T058
practices	O
in	O
the	O
2	O
Fondazione	O
Toscana	O
Gabriele	O
Monasterio	O
hospitals	O
and	O
comprehensively	O
assess	O
the	O
quality	O
of	O
medication	B-T058
reconciliation	I-T058
practices	O
between	O
inpatient	O
and	O
outpatient	O
care	O
by	O
analyzing	O
the	O
medication	B-T058
patterns	I-T058
6	O
months	O
before	O
admission	B-T058
,	O
during	O
hospitalization	B-T058
,	O
and	O
9	O
months	O
after	O
discharge	B-T058
for	O
a	O
selected	O
group	O
of	O
patients	O
with	O
cardiovascular	B-T047
diseases	I-T047
.	O
A	O
retrospective	O
observational	O
study	O
was	O
conducted	O
in	O
the	O
Cardiothoracic	O
Department	O
of	O
the	O
Fondazione	O
Toscana	O
Gabriele	O
Monasterio	O
hospitals	O
.	O
Medication	O
history	O
was	O
reviewed	O
for	O
all	O
the	O
patients	O
admitted	B-T058
from	O
and	O
discharged	B-T058
to	O
the	O
community	O
,	O
from	O
January	O
to	O
March	O
2013	O
.	O
Patients	O
were	O
excluded	O
if	O
they	O
had	O
less	O
than	O
4	O
drugs	B-T061
or	O
less	O
than	O
2	O
drugs	B-T061
for	O
cardiovascular	O
system	O
in	O
their	O
prescription	O
list	O
at	O
admission	B-T058
or	O
if	O
they	O
died	B-T033
during	O
follow	B-T058
-	I-T058
up	I-T058
.	O
We	O
selected	O
714	O
patients	O
,	O
and	O
we	O
obtained	O
the	O
clinical	O
charts	O
and	O
all	O
drug	O
prescriptions	O
collected	O
during	O
patients	O
'	O
hospitalization	B-T058
by	O
the	O
electronic	O
clinical	O
recording	O
system	O
.	O
We	O
also	O
analyzed	O
the	O
list	O
of	O
prescriptions	O
of	O
this	O
sample	O
of	O
patients	O
,	O
from	O
6	O
months	O
before	O
admission	B-T058
to	O
9	O
months	O
after	O
discharge	B-T058
,	O
extracted	O
from	O
the	O
regional	O
prescription	O
registry	O
.	O
In	O
the	O
resulting	O
sample	O
,	O
prescriptions	O
were	O
analyzed	O
to	O
assess	O
unintentional	O
discrepancies	B-T033
.	O
The	O
study	O
included	O
298	O
patients	O
(	O
mean	O
age	O
,	O
71.2	O
years	O
)	O
,	O
according	O
to	O
the	O
inclusion	O
and	O
exclusion	O
criteria	O
.	O
Among	O
14,573	O
prescriptions	O
analyzed	O
,	O
we	O
found	O
4363	O
discrepancies	B-T033
(	O
14.6	O
discrepancies	B-T033
per	O
patient	O
)	O
.	O
Among	O
these	O
discrepancies	B-T033
,	O
1310	O
were	O
classified	O
as	O
unintentional	O
(	O
4.4	O
discrepancies	B-T033
per	O
patient	O
)	O
.	O
Among	O
unintentional	O
discrepancies	B-T033
,	O
only	O
63	O
(	O
4.8	O
%	O
)	O
took	O
place	O
during	O
hospitalization	B-T058
.	O
Although	O
at	O
the	O
hospital	B-T058
-	I-T058
home	I-T058
interface	I-T058
,	O
33.1	O
%	O
of	O
unintentional	O
discrepancies	B-T033
were	O
detected	O
through	O
the	O
comparison	O
between	O
the	O
patients	O
'	O
declared	O
therapy	O
and	O
the	O
previous	O
medication	B-T058
consumption	I-T058
and	O
62.1	O
%	O
were	O
identified	O
in	O
the	O
comparison	O
between	O
the	O
prescription	O
at	O
the	O
discharge	B-T058
and	O
the	O
following	O
medication	B-T058
pattern	I-T058
at	O
home	O
.	O
Medication	O
errors	O
have	O
important	O
implications	O
for	O
patient	B-T058
safety	I-T058
,	O
and	O
their	O
identification	O
is	O
a	O
main	O
target	O
for	O
improving	O
clinical	B-T058
practice	I-T058
.	O
The	O
comparison	O
between	O
the	O
medication	B-T058
patterns	I-T058
acquired	O
through	O
the	O
regional	O
prescription	O
registry	O
before	O
and	O
after	O
hospitalization	B-T058
outlined	O
critical	O
touchpoint	O
in	O
the	O
current	O
medication	B-T058
reconciliation	I-T058
process	O
,	O
calling	O
for	O
the	O
definition	O
of	O
shared	O
medication	B-T058
reconciliation	I-T058
standards	O
between	O
hospitals	O
and	O
primary	B-T058
care	I-T058
services	I-T058
to	O
minimize	O
medication	O
discrepancies	O
and	O
enhance	O
patient	B-T058
safety	I-T058
.	O
      
PI3	O
K	O
/	O
Akt	O
pathway	O
:	O
a	O
potential	O
therapeutic	O
target	O
for	O
chronic	B-T184
pain	I-T184
Chronic	B-T184
pain	I-T184
is	O
among	O
the	O
most	O
disabling	B-T047
and	O
costly	O
disorders	B-T047
,	O
with	O
prevalence	O
ranging	O
from	O
10	O
%	O
to	O
55	O
%	O
.	O
However	O
,	O
current	O
therapeutic	O
strategies	O
for	O
chronic	B-T184
pain	I-T184
are	O
unsatisfactory	O
due	O
to	O
our	O
poor	O
understanding	O
of	O
its	O
mechanisms	O
.	O
Thus	O
,	O
novel	O
therapeutic	O
targets	O
need	O
to	O
be	O
found	O
in	O
order	O
to	O
improve	B-T033
these	O
patients	O
'	O
quality	O
of	O
life	O
.	O
PI3	O
K	O
and	O
its	O
downstream	O
Akt	O
are	O
widely	O
expressed	O
in	O
the	O
spinal	B-T023
cord	I-T023
,	O
particularly	O
in	O
the	O
laminae	B-T023
I	I-T023
-	I-T023
IV	I-T023
of	O
the	O
dorsal	B-T023
horn	I-T023
,	O
where	O
nociceptive	O
C	O
and	O
Aδ	O
fibers	O
of	O
primary	O
afferents	B-T023
principally	O
terminate	O
.	O
Recent	O
studies	O
have	O
demonstrated	O
their	O
critical	O
roles	O
in	O
the	O
development	O
and	O
maintenance	O
of	O
chronic	B-T184
pain	I-T184
.	O
In	O
this	O
review	O
,	O
we	O
summarized	O
the	O
roles	O
and	O
mechanisms	O
of	O
PI3	O
K	O
/	O
Akt	O
pathway	O
in	O
the	O
progression	O
of	O
chronic	B-T184
pain	I-T184
through	O
sciatic	O
nerve	O
injury	O
,	O
diabetic	B-T047
neuropathy	I-T047
,	O
spinal	O
cord	O
injury	O
,	O
bone	B-T191
cancer	I-T191
,	O
opioid	O
tolerance	O
,	O
or	O
opioid	B-T121
-	O
induced	O
hyperalgesia	B-T184
.	O
      
Improved	B-T033
protocol	O
for	O
the	O
isolation	B-T059
of	O
naïve	O
follicular	O
dendritic	O
cells	O
Follicular	O
dendritic	O
cells	O
(	O
FDCs	O
)	O
in	O
lymphoid	B-T023
organs	I-T023
play	O
an	O
important	O
role	O
in	O
the	O
humoral	O
immune	O
response	O
.	O
However	O
,	O
because	O
the	O
isolation	B-T061
of	O
FDCs	O
is	O
difficult	O
due	O
to	O
their	O
very	O
small	O
population	O
size	O
and	O
fragility	O
under	O
mechanical	O
and	O
chemical	O
stresses	O
,	O
the	O
genetic	O
and	O
biochemical	O
characteristics	O
of	O
FDCs	O
remain	O
unclear	B-T033
.	O
Previously	O
,	O
we	O
identified	O
FDCs	O
as	O
ICAM-1(+	O
)	O
cells	O
in	O
the	O
CD45	O
(	B-T033
-	I-T033
)	I-T033
non	O
-	O
hematopoietic	O
cell	O
fraction	O
from	O
naïve	O
mouse	O
spleen	O
after	O
cell	B-T059
separation	I-T059
by	O
means	O
of	O
digestion	O
with	O
a	O
combination	O
of	O
enzymes	O
.	O
In	O
the	O
present	O
study	O
,	O
using	O
a	O
new	O
combination	O
of	O
enzymes	O
,	O
we	O
found	O
that	O
FDCs	O
are	O
highly	O
enriched	O
in	O
the	O
CD45	O
(	B-T033
-	I-T033
)	I-T033
ICAM-1(+	O
)	O
CD21	O
/	O
35(+	O
)	O
cell	O
fraction	O
.	O
CD45	O
(	B-T033
-	I-T033
)	I-T033
ICAM-1(+	O
)	O
CD21	O
/	O
35(+	O
)	O
cells	O
in	O
the	O
mouse	O
spleen	O
retained	O
an	O
antigen	O
administered	O
in	O
vivo	O
for	O
more	O
than	O
7	O
days	O
.	O
Moreover	O
,	O
CD45	O
(	B-T033
-	I-T033
)	I-T033
ICAM-1(+	O
)	O
CD21	O
/	O
35(+	O
)	O
cells	O
isolated	O
from	O
the	O
spleen	O
of	O
mice	O
administered	O
with	O
a	O
cognate	O
antigen	O
enhanced	O
the	O
survival	O
and	O
proliferation	O
of	O
antigen	O
-	O
specific	O
B	O
cells	O
in	O
vitro	O
.	O
Our	O
improved	B-T033
protocol	O
for	O
the	O
isolation	B-T059
of	O
naïve	O
FDCs	O
will	O
be	O
useful	O
for	O
the	O
analysis	O
of	O
FDCs	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
      
Psychometric	B-T060
properties	O
of	O
the	O
Japanese	O
version	O
of	O
short	O
forms	O
of	O
the	O
Pain	O
Catastrophizing	O
Scale	O
in	O
participants	O
with	O
musculoskeletal	B-T033
pain	I-T033
:	O
A	O
cross	O
-	O
sectional	O
study	O
The	O
Pain	O
Catastrophizing	O
Scale	O
(	O
PCS	O
)	O
is	O
a	O
commonly	O
used	O
as	O
measure	O
of	O
pain	O
catastrophizing	O
.	O
The	O
scale	O
comprises	O
13	O
items	O
related	O
to	O
magnification	B-T060
,	O
rumination	O
,	O
and	O
helplessness	B-T048
.	O
To	O
facilitate	O
quick	O
screening	B-T058
and	O
to	O
reduce	O
participant	O
's	O
burden	O
,	O
the	O
four-	O
item	O
and	O
six-	O
item	O
short	O
forms	O
of	O
the	O
English	O
version	O
of	O
the	O
PCS	O
were	O
developed	O
.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	B-T058
the	O
psychometric	B-T060
properties	O
of	O
a	O
Japanese	O
version	O
of	O
the	O
short	O
forms	O
of	O
PCS	O
using	O
a	O
contemporary	O
approach	O
called	O
Rasch	O
analysis	O
.	O
A	O
total	O
of	O
216	O
patients	O
with	O
musculoskeletal	B-T047
disorders	I-T047
were	O
recruited	O
in	O
this	O
study	O
.	O
Participants	O
completed	O
study	O
measures	O
,	O
which	O
included	O
the	O
pain	O
intensity	O
,	O
the	O
Pain	O
Catastrophizing	O
Scale	O
(	O
PCS	O
)	O
,	O
and	O
the	O
Tampa	O
Scale	O
of	O
Kinesiophobia	O
(	O
TSK	O
)	O
.	O
Furthermore	O
,	O
the	O
four-	O
item	O
(	O
items	O
3	O
,	O
6	O
,	O
8	O
,	O
and	O
11	O
)	O
and	O
six-	O
item	O
(	O
items	O
4	O
,	O
5	O
,	O
6	O
,	O
10	O
,	O
11	O
,	O
and	O
13	O
)	O
short	O
forms	O
of	O
the	O
Japanese	O
version	O
of	O
PCS	O
were	O
measured	O
.	O
We	O
used	O
Rasch	O
analysis	O
to	O
analyze	O
the	O
psychometric	B-T060
properties	O
of	O
the	O
original	O
,	O
four-	O
item	O
,	O
and	O
six-	O
item	O
short	O
forms	O
of	O
PCS	O
.	O
Rasch	O
analysis	O
showed	O
that	O
both	O
short	O
forms	O
of	O
PCS	O
had	O
acceptable	O
internal	O
consistency	O
,	O
unidimensionality	O
,	O
and	O
no	O
notable	O
DIF	O
and	O
were	O
functional	O
on	O
the	O
category	O
rating	O
scale	O
.	O
However	O
,	O
four-	O
item	O
short	O
form	O
of	O
PCS	O
had	O
two	O
misfit	O
items	O
.	O
Six-	O
item	O
short	O
form	O
of	O
PCS	O
has	O
acceptable	O
psychometric	B-T060
properties	O
and	O
is	O
suitable	O
for	O
use	O
in	O
participants	O
with	O
musculoskeletal	B-T033
pain	I-T033
.	O
Thus	O
,	O
six-	O
item	O
can	O
be	O
used	O
as	O
brief	O
instruments	O
to	O
evaluate	B-T058
pain	O
catastrophizing	O
.	O
      
Using	O
language	O
for	O
social	B-T033
interaction	I-T033
:	O
Communication	O
mechanisms	O
promote	O
recovery	O
from	O
chronic	O
non	B-T048
-	I-T048
fluent	I-T048
aphasia	I-T048
Clinical	O
research	O
highlights	O
the	O
importance	O
of	O
massed	O
practice	O
in	O
the	O
rehabilitation	B-T061
of	O
chronic	O
post	O
-	O
stroke	O
aphasia	B-T048
.	O
However	O
,	O
while	O
necessary	O
,	O
massed	O
practice	O
may	O
not	O
be	O
sufficient	O
for	O
ensuring	O
progress	O
in	O
speech	B-T058
-	I-T058
language	I-T058
therapy	I-T058
.	O
Motivated	O
by	O
recent	O
advances	O
in	O
neuroscience	O
,	O
it	O
has	O
been	O
claimed	O
that	O
using	O
language	O
as	O
a	O
tool	O
for	O
communication	O
and	O
social	B-T033
interaction	I-T033
leads	O
to	O
synergistic	O
effects	O
in	O
left	O
perisylvian	O
eloquent	O
areas	O
.	O
Here	O
,	O
we	O
conducted	O
a	O
crossover	O
randomized	O
controlled	O
trial	O
to	O
determine	O
the	O
influence	O
of	O
communicative	O
language	O
function	O
on	O
the	O
outcome	O
of	O
intensive	B-T061
aphasia	I-T061
therapy	I-T061
.	O
Eighteen	O
individuals	O
with	O
left	B-T033
-	I-T033
hemisphere	I-T033
lesions	I-T033
and	O
chronic	O
non	B-T048
-	I-T048
fluent	I-T048
aphasia	I-T048
each	O
received	O
two	O
types	O
of	O
training	O
in	O
counterbalanced	O
order	O
:	O
(	O
i	O
)	O
Intensive	B-T061
Language	I-T061
-	I-T061
Action	I-T061
Therapy	I-T061
(	O
ILAT	B-T061
,	O
an	O
extended	O
form	O
of	O
Constraint	B-T061
-	I-T061
Induced	I-T061
Aphasia	I-T061
Therapy	I-T061
)	O
embedding	O
verbal	B-T061
utterances	I-T061
in	O
the	O
context	O
of	O
communication	O
and	O
social	B-T033
interaction	I-T033
,	O
and	O
(	O
ii	O
)	O
Naming	O
Therapy	O
focusing	O
on	O
speech	B-T060
production	I-T060
per	I-T060
se	I-T060
.	O
Both	O
types	O
of	O
training	O
were	O
delivered	O
with	O
the	O
same	O
high	O
intensity	O
(	O
3.5	O
h	O
per	O
session	O
)	O
and	O
duration	O
(	O
six	O
consecutive	O
working	O
days	O
)	O
,	O
with	O
therapy	B-T061
materials	O
and	O
number	B-T033
of	I-T033
utterances	I-T033
matched	O
between	O
treatment	B-T061
groups	I-T061
.	O
A	O
standardized	O
aphasia	B-T048
test	B-T060
battery	I-T060
revealed	O
significantly	O
improved	O
language	O
performance	O
with	O
ILAT	B-T061
,	O
independent	O
of	O
when	O
this	O
method	O
was	O
administered	O
.	O
In	O
contrast	O
,	O
Naming	O
Therapy	O
tended	O
to	O
benefit	O
language	O
performance	O
only	O
when	O
given	O
at	O
the	O
onset	O
of	O
the	O
treatment	B-T061
,	O
but	O
not	O
when	O
applied	O
after	O
previous	O
intensive	O
training	O
.	O
The	O
current	O
results	O
challenge	O
the	O
notion	O
that	O
massed	O
practice	O
alone	O
promotes	O
recovery	O
from	O
chronic	O
post	O
-	O
stroke	O
aphasia	B-T048
.	O
Instead	O
,	O
our	O
results	O
demonstrate	O
that	O
using	O
language	O
for	O
communication	O
and	O
social	B-T033
interaction	I-T033
increases	O
the	O
efficacy	O
of	O
intensive	B-T061
aphasia	I-T061
therapy	I-T061
.	O
      
A	O
neuronal	O
PI(3,4,5)P3	O
-dependent	O
program	O
of	O
oligodendrocyte	O
precursor	O
recruitment	O
and	O
myelination	O
The	O
molecular	O
trigger	O
of	O
CNS	O
myelination	O
is	O
unknown	O
.	O
By	O
targeting	O
Pten	O
in	O
cerebellar	O
granule	O
cells	O
and	O
activating	O
the	O
AKT1	O
-	O
mTOR	O
pathway	O
,	O
we	O
increased	O
the	O
caliber	O
of	O
normally	O
unmyelinated	O
axons	O
and	O
the	O
expression	O
of	O
numerous	O
genes	O
encoding	O
regulatory	O
proteins	O
.	O
This	O
led	O
to	O
the	O
expansion	O
of	O
genetically	O
wild	O
-	O
type	O
oligodendrocyte	O
progenitor	O
cells	O
,	O
oligodendrocyte	O
differentiation	O
and	O
de	O
novo	O
myelination	O
of	O
parallel	O
fibers	O
.	O
Thus	O
,	O
a	O
neuronal	O
program	O
dependent	O
on	O
the	O
phosphoinositide	O
PI(3,4,5)P3	O
is	O
sufficient	O
to	O
trigger	O
all	O
steps	O
of	O
myelination	O
.	O
      
Increased	O
RhoA	O
Activity	O
Predicts	O
Worse	B-T033
Overall	O
Survival	O
in	O
Patients	O
Undergoing	O
Surgical	B-T061
Resection	I-T061
for	O
Lauren	O
Diffuse	B-T191
-	I-T191
Type	I-T191
Gastric	I-T191
Adenocarcinoma	I-T191
Several	O
studies	O
have	O
reported	O
a	O
high	O
rate	O
of	O
RHOA	O
mutations	O
in	O
the	O
Lauren	O
diffuse	B-T191
-	I-T191
type	I-T191
gastric	I-T191
adenocarcinoma	I-T191
(	O
GA	B-T191
)	O
but	O
not	O
in	O
intestinal	B-T191
-	I-T191
type	I-T191
GA	I-T191
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
RhoA	O
activity	O
is	O
prognostic	O
for	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
patients	O
with	O
resectable	O
GA	B-T191
.	O
Retrospective	O
review	O
was	O
performed	O
on	O
a	O
prospective	O
database	O
of	O
GA	B-T191
patients	O
who	O
underwent	O
potentially	O
curative	B-T061
resection	I-T061
between	O
2003	O
and	O
2012	O
at	O
a	O
single	O
institution	O
.	O
Tissue	O
microarrays	O
were	O
constructed	O
from	O
surgical	B-T059
specimens	I-T059
and	O
analyzed	O
for	O
phosphorylated	O
RhoA	O
,	O
a	O
marker	O
of	O
inactive	O
RhoA	O
signaling	O
.	O
OS	O
was	O
estimated	O
by	O
the	O
Kaplan	O
-	O
Meier	O
method	O
,	O
and	O
multivariate	O
analysis	O
was	O
performed	O
by	O
Cox	O
proportional	O
hazards	O
regression	O
modeling	O
.	O
One	O
hundred	O
thirty	O
-	O
six	O
patients	O
with	O
diffuse	B-T191
-	I-T191
type	I-T191
GA	I-T191
and	O
129	O
patients	O
with	O
intestinal	B-T191
-	I-T191
type	I-T191
GA	I-T191
were	O
examined	O
.	O
Compared	O
to	O
intestinal	B-T191
-	I-T191
type	I-T191
GA	I-T191
,	O
diffuse	B-T191
-	I-T191
type	I-T191
GA	I-T191
tumors	B-T191
were	O
significantly	O
associated	O
with	O
increased	O
tumor	O
size	O
and	O
advanced	O
tumor	O
,	O
node	O
,	O
metastasis	O
(	O
TNM	O
)	O
classification	O
system	O
stage	O
.	O
In	O
patients	O
with	O
diffuse	B-T191
-	I-T191
type	I-T191
GA	I-T191
,	O
high	O
RhoA	O
activity	O
was	O
associated	O
with	O
significantly	O
worse	B-T033
OS	O
when	O
compared	O
to	O
low	O
RhoA	O
activity	O
(	O
5	O
-	O
year	O
OS	O
52.5	O
vs.	O
81.0	O
%	O
,	O
p	O
=	O
0.017	O
)	O
.	O
This	O
difference	O
in	O
OS	O
was	O
not	O
observed	O
in	O
patients	O
with	O
intestinal	B-T191
-	I-T191
type	I-T191
GA	I-T191
(	O
5	O
-	O
year	O
OS	O
83.9	O
vs.	O
81.6	O
%	O
,	O
p	O
=	O
0.766	O
)	O
.	O
On	O
multivariate	O
analysis	O
of	O
diffuse	B-T191
-	I-T191
type	I-T191
GA	I-T191
patients	O
,	O
high	O
RhoA	O
activity	O
was	O
an	O
independent	O
negative	O
prognostic	O
factor	O
for	O
OS	O
(	O
hazard	O
ratio	O
2.38	O
,	O
95	O
%	O
confidence	O
interval	O
1.07	O
-	O
5.28	O
)	O
.	O
Increased	O
RhoA	O
activity	O
is	O
predictive	O
of	O
worse	B-T033
OS	O
in	O
patients	O
with	O
diffuse	B-T191
-	I-T191
type	I-T191
GA	I-T191
who	O
undergo	O
potentially	O
curative	B-T061
surgical	I-T061
resection	I-T061
.	O
Along	O
with	O
findings	O
from	O
genomic	O
studies	O
,	O
these	O
results	O
suggest	O
RhoA	O
may	O
be	O
a	O
novel	O
therapeutic	B-T061
target	O
in	O
diffuse	B-T191
-	I-T191
type	I-T191
GA	I-T191
.	O
      
Evaluation	B-T058
of	O
response	O
from	O
axitinib	B-T121
per	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumors	O
versus	O
Choi	O
criteria	O
in	O
previously	O
treated	B-T033
patients	O
with	O
metastatic	B-T191
renal	I-T191
cell	I-T191
carcinoma	I-T191
Axitinib	B-T121
,	O
a	O
selective	O
and	O
potent	O
tyrosine	B-T121
kinase	I-T121
inhibitor	I-T121
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptors	O
,	O
was	O
available	O
to	O
patients	O
from	O
Canada	O
and	O
Australia	O
,	O
prior	O
to	O
regulatory	O
approval	O
of	O
axitinib	B-T121
in	O
these	O
countries	O
,	O
for	O
treatment	B-T061
of	O
clear	B-T191
-	I-T191
cell	I-T191
metastatic	I-T191
renal	I-T191
cell	I-T191
carcinoma	I-T191
(	O
mRCC	B-T191
)	O
after	O
failure	O
of	O
one	O
prior	O
systemic	O
regimen	B-T061
.	O
This	O
single	O
-	O
arm	O
,	O
open	O
-	O
label	O
study	O
of	O
axitinib	B-T121
evaluated	O
the	O
efficacy	O
,	O
safety	O
,	O
and	O
quality	O
of	O
life	O
(	O
QoL	O
)	O
in	O
patients	O
with	O
mRCC	B-T191
whose	O
disease	B-T047
progressed	O
after	O
one	O
prior	O
systemic	O
first	B-T061
-	I-T061
line	I-T061
regimen	I-T061
.	O
Primary	O
objective	O
was	O
objective	O
response	O
rate	O
evaluated	B-T058
per	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumors	O
(	O
RECIST	O
)	O
and	O
Choi	O
criteria	O
.	O
Progression	O
-	O
free	O
survival	O
,	O
overall	O
survival	O
,	O
safety	O
,	O
and	O
QoL	O
were	O
secondary	O
end	O
points	O
.	O
Due	O
to	O
the	O
small	O
study	O
size	O
,	O
analyses	O
comprised	O
of	O
descriptive	O
statistics	O
.	O
Fifteen	O
patients	O
were	O
recruited	O
,	O
five	O
from	O
Canada	O
and	O
ten	O
from	O
Australia	O
,	O
over	O
a	O
limited	O
recruitment	O
period	O
.	O
Thirteen	O
patients	O
received	O
sunitinib	B-T121
as	O
prior	O
therapy	B-T061
.	O
All	O
patients	O
had	O
clear	B-T191
-	I-T191
cell	I-T191
carcinoma	I-T191
,	O
eleven	O
had	O
prior	O
nephrectomy	B-T061
.	O
Liver	B-T023
,	O
lung	B-T023
,	O
and	O
lymph	B-T023
nodes	I-T023
were	O
the	O
most	O
frequent	O
sites	O
of	O
metastases	B-T191
;	O
one	O
patient	O
had	O
brain	B-T191
metastasis	I-T191
.	O
Median	O
time	O
on	O
axitinib	B-T121
was	O
118.0	O
days	O
(	O
range	O
:	O
3.5	O
-	O
645.0	O
days	O
)	O
;	O
estimated	O
survival	O
probability	O
at	O
12	O
months	O
was	O
57.8	O
%	O
.	O
Two	O
(	O
13.3	O
%	O
)	O
patients	O
had	O
objective	O
responses	O
per	O
RECIST	O
versus	O
nine	O
(	O
60.0	O
%	O
)	O
per	O
Choi	O
criteria	O
.	O
Six	O
patients	O
had	O
progressive	O
disease	B-T047
based	O
on	O
RECIST	O
versus	O
three	O
per	O
Choi	O
criteria	O
.	O
Nine	O
(	O
60.0	O
%	O
)	O
events	O
of	O
progression	O
or	O
death	O
occurred	O
by	O
the	O
end	O
of	O
study	O
,	O
and	O
three	O
patients	O
continued	O
to	O
receive	O
the	O
study	O
drug	B-T121
.	O
Fatigue	B-T184
(	O
33	O
%	O
)	O
and	O
diarrhea	B-T184
(	O
20	O
%	O
)	O
were	O
the	O
most	O
common	O
grade	O
≥3	O
all	O
-	O
causality	O
,	O
treatment	B-T061
-emergent	O
adverse	O
events	O
.	O
The	O
mean	O
change	O
in	O
European	O
Quality	O
of	O
Life	O
-	O
5	O
Dimensions	O
score	O
from	O
baseline	O
to	O
end	O
of	O
treatment	B-T061
was	O
-0.0837	O
.	O
The	O
small	O
number	O
of	O
patients	O
and	O
lack	O
of	O
a	O
comparator	O
arm	O
limit	O
the	O
ability	O
to	O
draw	O
definitive	O
conclusions	O
;	O
however	O
,	O
safety	O
and	O
efficacy	O
profiles	O
of	O
axitinib	B-T121
were	O
consistent	O
with	O
reports	O
from	O
previous	O
studies	O
in	O
patients	O
with	O
mRCC	B-T191
,	O
and	O
patients	O
generally	O
maintained	O
QoL.	O
The	O
sizeable	O
difference	O
observed	O
in	O
objective	O
response	O
rate	O
by	O
RECIST	O
versus	O
Choi	O
criteria	O
merits	O
further	O
research	O
.	O
      
Musculoskeletal	B-T033
pain	I-T033
profile	O
of	O
obese	B-T047
individuals	O
attending	O
a	O
multidisciplinary	O
weight	O
management	O
service	O
Obesity	B-T047
is	O
associated	O
with	O
numerous	O
chronic	B-T047
diseases	I-T047
,	O
including	O
musculoskeletal	B-T033
(	I-T033
MSK	I-T033
)	I-T033
pain	I-T033
,	O
which	O
impacts	O
on	O
quality	O
of	O
life	O
(	O
QoL	O
)	O
.	O
There	O
is	O
,	O
however	O
,	O
limited	O
research	O
providing	O
a	O
comprehensive	O
MSK	B-T033
pain	I-T033
profile	O
of	O
an	O
obese	B-T047
cohort	O
.	O
This	O
retrospective	O
study	O
utilized	O
a	O
patient	O
database	O
at	O
a	O
national	O
weight	O
management	O
service	O
(	O
WMS	O
)	O
.	O
Following	O
ethical	O
approval	O
,	O
anonymized	O
patient	O
data	O
were	O
statistically	O
analyzed	O
to	O
develop	O
a	O
pain	B-T184
profile	O
,	O
investigate	O
relationships	O
between	O
pain	B-T184
,	O
sleep	O
,	O
and	O
function	B-T033
,	O
and	O
explore	O
variables	O
associated	O
with	O
having	O
low	B-T184
back	I-T184
pain	I-T184
(	O
LBP	B-T184
)	O
and	O
knee	B-T033
pain	I-T033
.	O
Overall	O
,	O
915	O
individuals	O
attended	O
the	O
WMS	O
from	O
January	O
2011	O
to	O
September	O
2015	O
[	O
male	O
,	O
35	O
%	O
(	O
n=318	O
;	O
CI	O
=	O
32	O
-	O
38	O
)	O
;	O
female	O
,	O
65	O
%	O
(	O
n=597	O
;	O
CI	O
=	O
62	O
-	O
68	O
)	O
;	O
mean	O
age	O
44.6	O
]	O
.	O
Mean	O
BMI	O
was	O
50.7	O
kg	O
/	O
m2	O
[	O
Class	O
III	O
obese	B-T047
(	O
BMI	O
≥40	O
kg	O
/	O
m2	O
)	O
,	O
92	O
%	O
(	O
n=835	O
;	O
CI	O
=	O
91	O
-	O
94	O
)	O
]	O
.	O
Approximately	O
91	O
%	O
reported	O
MSK	B-T033
pain	I-T033
:	O
LBP	B-T184
,	O
69	O
%	O
(	O
n=539	O
;	O
CI	O
=	O
65-	O
72	O
)	O
[	O
mean	O
NRS	O
7.4	O
]	O
;	O
knee	B-T033
pain	I-T033
,	O
58	O
%	O
(	O
n=447	O
;	O
CI	O
=	O
55	O
-	O
61	O
)	O
[	O
mean	O
NRS	O
6.8	O
]	O
.	O
Class	O
III	O
obese	B-T047
and	O
multi	O
-	O
site	O
pain	B-T184
patients	O
had	O
lower	O
QoL	O
and	O
physical	O
activity	O
levels	O
,	O
reduced	O
sleep	O
,	O
and	O
poorer	O
physical	B-T033
function	I-T033
than	O
less	O
obese	B-T047
patients	O
and	O
those	O
without	O
pain	B-T184
(	O
p<0.05	O
)	O
.	O
Relationships	O
were	O
found	O
between	O
demographic	O
,	O
pain	B-T184
,	O
self	O
-	O
report	O
,	O
psychological	O
,	O
and	O
functional	O
measures	O
(	O
p<0.05	O
)	O
.	O
Patients	O
who	O
slept	B-T033
fewer	I-T033
hours	I-T033
and	O
had	O
poorer	O
functional	B-T033
outcomes	I-T033
were	O
more	O
likely	O
to	O
have	O
LBP	B-T184
;	O
patients	O
who	O
were	O
divorced	B-T033
,	O
had	O
lower	O
QoL	O
,	O
and	O
more	O
frequent	O
nocturia	B-T047
were	O
more	O
likely	O
to	O
have	O
knee	B-T033
pain	I-T033
(	O
p<0.05	O
)	O
.	O
Multi	O
-	O
site	O
MSK	B-T033
pain	I-T033
is	O
prevalent	O
and	O
severe	O
in	O
obese	B-T047
patients	O
and	O
is	O
negatively	B-T033
associated	O
with	O
most	O
self	O
-	O
report	O
and	O
functional	B-T033
outcomes	I-T033
.	O
This	O
high	O
prevalence	O
suggests	O
pain	B-T061
management	I-T061
strategies	O
must	O
be	O
considered	O
when	O
treating	B-T061
obesity	B-T047
.	O
      
Chasing	O
ghosts	O
:	O
allopolyploid	O
origin	O
of	O
Oxyria	O
sinensis	O
(	O
Polygonaceae	O
)	O
from	O
its	O
only	O
diploid	O
congener	O
and	O
an	O
unknown	O
ancestor	O
Reconstructing	O
the	O
origin	O
of	O
a	O
polyploid	O
species	O
is	O
particularly	O
challenging	O
when	O
an	O
ancestor	O
has	O
become	O
extinct	O
.	O
Under	O
such	O
circumstances	O
,	O
the	O
extinct	O
donor	O
of	O
a	O
genome	O
found	O
in	O
the	O
polyploid	O
may	O
be	O
treated	O
as	O
a	O
'	O
ghost	O
'	O
species	O
in	O
that	O
its	O
prior	O
existence	O
is	O
recognized	O
through	O
the	O
presence	O
of	O
its	O
genome	O
in	O
the	O
polyploid	O
.	O
In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
determine	O
the	O
polyploid	O
origin	O
of	O
Oxyria	O
sinensis	O
(	O
2n	O
=	O
40	O
)	O
for	O
which	O
only	O
one	O
congeneric	O
species	O
is	O
known	O
,	O
that	O
is	O
diploid	O
O.	O
digyna	O
(	O
2n	O
=	O
14	O
)	O
.	O
Genomic	O
in	O
situ	O
hybridization	O
(	O
GISH	O
)	O
,	O
transcriptome	B-T059
,	O
phylogenetic	O
and	O
demographic	O
analyses	O
,	O
and	O
ecological	O
niche	O
modelling	O
were	O
conducted	O
for	O
this	O
purpose	O
.	O
GISH	O
revealed	O
that	O
O.	O
sinensis	O
comprised	O
14	O
chromosomes	O
from	O
O.	O
digyna	O
and	O
26	O
chromosomes	O
from	O
an	O
unknown	O
ancestor	O
.	O
Transcriptome	B-T059
analysis	I-T059
indicated	O
that	O
following	O
divergence	O
from	O
O.	O
digyna	O
,	O
involving	O
genome	O
duplication	O
around	O
12	O
million	O
years	O
ago	O
(	O
Ma	O
)	O
,	O
a	O
second	O
genome	O
duplication	O
occurred	O
approximately	O
6	O
Ma	O
to	O
give	O
rise	O
to	O
O.	O
sinensis	O
.	O
Oxyria	O
sinensis	O
was	O
shown	O
to	O
contain	O
homologous	O
gene	O
sequences	O
divergent	O
from	O
those	O
present	O
in	O
O.	O
digyna	O
in	O
addition	O
to	O
a	O
set	O
that	O
clustered	O
with	O
those	O
in	O
O.	O
digyna	O
.	O
Coalescent	O
simulations	O
indicated	O
that	O
O.	O
sinensis	O
expanded	O
its	O
distribution	O
approximately	O
6	O
-	O
7	O
Ma	O
,	O
possibly	O
following	O
the	O
second	O
polyploidization	O
event	O
,	O
whereas	O
O.	O
digyna	O
expanded	O
its	O
range	O
much	O
later	O
.	O
It	O
was	O
also	O
indicated	O
that	O
the	O
distributions	O
of	O
both	O
species	O
contracted	O
and	O
re	O
-	O
expanded	O
during	O
the	O
Pleistocene	O
climatic	O
oscillations	O
.	O
Ecological	O
niche	O
modelling	O
similarly	O
suggested	O
that	O
both	O
species	O
experienced	O
changes	O
in	O
their	O
distributional	O
ranges	O
in	O
response	O
to	O
Quaternary	O
climatic	O
changes	O
.	O
The	O
extinction	O
of	O
the	O
unknown	O
'	O
ghost	O
'	O
tetraploid	O
species	O
implicated	O
in	O
the	O
origin	O
of	O
O.	O
sinensis	O
could	O
have	O
resulted	O
from	O
superior	O
adaptation	O
of	O
O.	O
sinensis	O
to	O
repeated	O
climatic	O
changes	O
in	O
the	O
region	O
where	O
it	O
now	O
occurs	O
.	O
      
Synthesis	O
,	O
characterization	O
and	O
drug	B-T121
loading	O
property	O
of	O
Monomethoxy	O
-	O
Poly(ethylene	O
glycol)-Poly(ε	O
-	O
caprolactone)-Poly(D	O
,	O
L	O
-	O
lactide	O
)	O
(	O
MPEG	O
-	O
PCLA	O
)	O
copolymers	O
Amphiphilic	O
block	O
copolymers	O
have	O
attracted	O
a	O
great	O
deal	O
of	O
attention	O
in	O
drug	O
delivery	O
systems	O
.	O
In	O
this	O
work	O
,	O
a	O
series	O
of	O
monomethoxy	O
-	O
poly	O
(	O
ethylene	O
glycol)-poly	O
(	O
ε	O
-	O
caprolactone	O
-	O
co	O
-	O
D	O
,	O
L	O
-	O
lactide	O
)	O
(	O
MPEG	O
-	O
PCLA	O
)	O
copolymers	O
with	O
variable	O
composition	O
of	O
poly	O
(	O
ε	O
-	O
caprolactone	O
)	O
(	O
PCL	O
)	O
and	O
poly	O
(	O
D	O
,	O
L	O
-	O
lactide	O
)	O
(	O
PDLLA	O
)	O
were	O
prepared	O
via	O
ring	O
-	O
opening	O
copolymerization	O
of	O
ε	O
-	O
CL	O
and	O
D	O
,	O
L	O
-	O
LA	O
in	O
the	O
presence	O
of	O
MPEG	O
and	O
stannous	O
octoate	O
.	O
The	O
structure	O
and	O
molecular	O
weight	O
were	O
characterized	O
by	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
and	O
gel	B-T059
permeation	I-T059
chromatography	I-T059
(	O
GPC	B-T059
)	O
.	O
The	O
crystallinity	O
,	O
hydrophilicity	O
,	O
thermal	O
stability	O
and	O
hydrolytic	O
degradation	O
behavior	O
were	O
investigated	O
in	O
detail	O
,	O
respectively	O
.	O
The	O
results	O
showed	O
that	O
the	O
prepared	O
amphiphilic	O
MPEG	O
-	O
PCLA	O
copolymers	O
have	O
adjustable	O
properties	O
by	O
altering	O
the	O
composition	O
of	O
PCLA	O
,	O
which	O
make	O
it	O
convenient	O
for	O
clinical	O
applications	O
.	O
Besides	O
,	O
the	O
drug	B-T121
loading	O
properties	O
were	O
also	O
studied	O
.	O
Docetaxel	B-T121
(	O
DTX	B-T121
)	O
could	O
be	O
entrapped	O
in	O
MPEG	O
-	O
PCLA	O
micelles	O
with	O
high	O
loading	O
capacity	O
and	O
encapsulation	O
efficiency	O
.	O
And	O
all	O
lyophilized	O
DTX	B-T121
-loaded	O
MPEG	O
-	O
PCLA	O
micelles	O
except	O
MPEG	O
-	O
PCL	O
micelles	O
were	O
readily	O
re	O
-	O
dissolved	O
in	O
normal	B-T121
saline	I-T121
at	O
25	O
°	O
C	O
.	O
In	O
addition	O
,	O
DTX	B-T121
-loaded	O
MPEG	O
-	O
PCLA	O
micelles	O
showed	O
a	O
slightly	O
enhanced	O
antitumor	O
activity	O
compared	O
with	O
free	O
DTX	B-T121
.	O
Furthermore	O
,	O
DTX	B-T121
micelles	O
exhibited	O
a	O
slower	O
and	O
sustained	O
release	O
behavior	O
in	O
vitro	O
,	O
and	O
higher	O
DTX	B-T121
concentration	O
and	O
longer	O
retention	O
time	O
in	O
vivo	O
.	O
The	O
results	O
suggested	O
that	O
the	O
MPEG	O
-	O
PCLA	O
copolymer	O
with	O
the	O
adjustable	O
ratio	O
of	O
PCL	O
to	O
PDLLA	O
may	O
be	O
a	O
promising	O
drug	O
delivery	O
carrier	O
for	O
DTX	B-T121
.	O
      
Multiparametric	O
estimation	O
of	O
brain	O
hemodynamics	O
with	O
MR	B-T060
fingerprinting	I-T060
ASL	I-T060
Assessment	B-T058
of	O
brain	O
hemodynamics	O
without	O
exogenous	O
contrast	O
agents	O
is	O
of	O
increasing	O
importance	O
in	O
clinical	O
applications	O
.	O
This	O
study	O
aims	O
to	O
develop	O
an	O
MR	B-T060
perfusion	I-T060
technique	I-T060
that	O
can	O
provide	O
noncontrast	B-T033
and	O
multiparametric	O
estimation	O
of	O
hemodynamic	O
markers	O
.	O
We	O
devised	O
an	O
arterial	B-T060
spin	I-T060
labeling	I-T060
(	O
ASL	B-T060
)	O
method	O
based	O
on	O
the	O
principle	O
of	O
MR	B-T060
fingerprinting	I-T060
(	O
MRF	B-T060
)	O
,	O
referred	O
to	O
as	O
MRF	B-T060
-	I-T060
ASL	I-T060
.	O
By	O
taking	O
advantage	O
of	O
the	O
rich	O
information	O
contained	O
in	O
MRF	B-T060
sequence	I-T060
,	O
up	O
to	O
seven	O
hemodynamic	O
parameters	B-T033
can	O
be	O
estimated	O
concomitantly	O
.	O
Feasibility	O
demonstration	O
,	O
flip	O
angle	O
optimization	O
,	O
comparison	O
with	O
Look	B-T060
-	I-T060
Locker	I-T060
ASL	I-T060
,	O
reproducibility	O
test	O
,	O
sensitivity	O
to	O
hypercapnia	B-T033
challenge	I-T033
,	O
and	O
initial	O
clinical	O
application	O
in	O
an	O
intracranial	B-T061
steno	I-T061
-	I-T061
occlusive	I-T061
process	I-T061
,	O
Moyamoya	B-T047
disease	I-T047
,	O
were	O
performed	O
to	O
evaluate	O
this	O
technique	O
.	O
Magnetic	B-T060
resonance	I-T060
fingerprinting	I-T060
ASL	I-T060
provided	O
estimation	O
of	O
up	O
to	O
seven	O
parameters	B-T033
,	O
including	O
B1	O
+	O
,	O
tissue	B-T023
T1	O
,	O
cerebral	B-T033
blood	I-T033
flow	I-T033
(	O
CBF	B-T033
)	O
,	O
tissue	O
bolus	B-T033
arrival	I-T033
time	I-T033
(	O
BAT	B-T033
)	O
,	O
pass	O
-	O
through	O
arterial	B-T023
BAT	B-T033
,	O
pass	O
-	O
through	O
blood	O
volume	O
,	O
and	O
pass	O
-	O
through	O
blood	B-T060
travel	I-T060
time	I-T060
.	O
Coefficients	O
of	O
variation	O
of	O
the	O
estimated	O
parameters	B-T033
ranged	O
from	O
0.2	O
to	O
9.6	O
%	O
.	O
Hypercapnia	B-T033
resulted	O
in	O
an	O
increase	O
in	O
CBF	B-T033
by	O
57.7	O
%	O
,	O
and	O
a	O
decrease	O
in	O
BAT	B-T033
by	O
13.7	O
and	O
24.8	O
%	O
in	O
tissue	O
and	O
vessels	B-T023
,	O
respectively	O
.	O
Patients	O
with	O
Moyamoya	B-T047
disease	I-T047
showed	O
diminished	O
CBF	B-T033
and	O
lengthened	O
BAT	B-T033
that	O
could	B-T033
not	I-T033
be	I-T033
detected	I-T033
with	O
regular	O
ASL	B-T060
.	O
Magnetic	B-T060
resonance	I-T060
fingerprinting	I-T060
ASL	I-T060
is	O
a	O
promising	O
technique	O
for	O
noncontrast	B-T033
,	O
multiparametric	O
perfusion	B-T058
assessment	I-T058
.	O
Magn	O
Reson	O
Med	O
,	O
2016	O
.	O
©	O
2016	O
International	O
Society	O
for	O
Magnetic	O
Resonance	O
in	O
Medicine	O
.	O
      
Uridine	B-T121
stimulate	O
laxative	B-T121
effect	O
in	O
the	O
loperamide	B-T121
-	O
induced	O
constipation	B-T184
of	O
SD	O
rats	O
through	O
regulation	O
of	O
the	O
mAChRs	O
signaling	O
pathway	O
and	O
mucin	O
secretion	O
Uridine	B-T121
(	O
Urd	B-T121
)	O
,	O
which	O
has	O
been	O
reported	B-T058
as	O
a	O
major	O
component	O
of	O
RNA	O
,	O
plays	O
an	O
important	O
role	O
in	O
various	O
biological	O
process	O
including	O
neuroprotection	O
,	O
biochemical	O
modulation	O
and	O
glycolysis	O
,	O
although	O
its	O
role	O
in	O
constipation	B-T184
has	O
yet	O
to	O
be	O
established	O
.	O
Therefore	O
,	O
in	O
this	O
study	O
,	O
we	O
investigated	O
the	O
laxative	B-T121
effects	O
of	O
Urd	B-T121
on	O
chronic	O
constipation	B-T184
.	O
The	O
constipation	B-T184
phenotypes	O
and	O
their	O
related	O
mechanisms	O
were	O
investigated	O
in	O
the	O
transverse	B-T023
colons	I-T023
of	O
SD	O
rats	O
with	O
loperamide	B-T121
Lop	B-T121
(	O
Lop)-	O
induced	O
constipation	B-T184
after	O
treatment	B-T061
with	O
100	O
mg	O
/	O
kg	O
of	O
Urd	B-T121
.	O
The	O
number	O
,	O
weight	O
and	O
water	B-T121
contents	O
of	O
stools	O
were	O
significantly	O
higher	O
in	O
the	O
Lop	B-T121
+	O
Urd	B-T121
treated	B-T033
group	O
than	O
the	O
Lop	B-T121
+	O
Vehicle	O
treated	B-T033
group	O
,	O
while	O
food	O
intake	O
and	O
water	O
consumption	O
of	O
the	O
same	O
group	O
were	O
maintained	O
at	O
a	O
constant	O
level	O
.	O
The	O
thickness	O
of	O
the	O
mucosa	O
layer	O
,	O
muscle	O
and	O
flat	O
luminal	O
surface	O
,	O
as	O
well	O
as	O
the	O
number	O
of	O
goblet	O
cells	O
,	O
paneth	O
cells	O
and	O
lipid	O
droplets	O
were	O
enhanced	O
in	O
the	O
Lop	B-T121
+	O
Urd	B-T121
treated	B-T033
group	O
.	O
Furthermore	O
,	O
the	O
expression	O
of	O
the	O
muscarinic	O
acetylcholine	O
receptors	O
M2	O
and	O
M3	O
(	O
mAChR	O
M2	O
and	O
M3	O
)	O
at	O
the	O
transcriptional	O
and	O
translational	O
level	O
was	O
recovered	O
in	O
the	O
Lop	B-T121
+	O
Urd	B-T121
treated	B-T033
group	O
,	O
while	O
some	O
markers	O
such	O
as	O
Gα	O
and	O
inositol	O
triphosphate	O
(	O
IP3	O
)	O
in	O
their	O
downstream	O
signaling	O
pathway	O
were	O
completely	O
recovered	O
by	O
Urd	B-T121
treatment	B-T061
.	O
Moreover	O
,	O
the	O
ability	O
for	O
mucin	O
secretion	O
and	O
the	O
expression	O
of	O
membrane	O
water	O
channel	O
(	O
aquaporine	O
8	O
,	O
AQP8	O
)	O
were	O
increased	O
significantly	O
in	O
the	O
Lop	B-T121
+	O
Urd	B-T121
treated	B-T033
group	O
compared	O
with	O
Lop	B-T121
+	O
Vehicle	O
treated	B-T033
group	O
.	O
Finally	O
,	O
the	O
activity	O
of	O
Urd	B-T121
was	O
confirmed	O
in	O
primary	O
smooth	O
muscle	O
of	O
rat	O
intestine	O
cells	O
(	O
pRISMC	O
)	O
based	O
on	O
Gα	O
expression	O
and	O
IP3	O
concentration	O
.	O
The	O
results	B-T033
of	O
the	O
present	O
study	O
provide	O
the	O
first	O
strong	O
evidence	O
that	O
Urd	B-T121
can	O
be	O
considered	O
an	O
important	O
candidate	O
for	O
improving	O
chronic	O
constipation	B-T184
induced	O
by	O
Lop	B-T121
treatment	B-T061
in	O
animal	O
models	O
.	O
      
Intravitreal	O
chemotherapy	B-T061
in	O
the	O
management	B-T058
of	O
vitreous	B-T047
disease	I-T047
in	O
retinoblastoma	B-T191
To	O
evaluate	O
the	O
therapeutic	O
outcome	O
of	O
intravitreal	O
melphalan	B-T121
injection	O
in	O
the	O
management	B-T058
of	O
vitreous	B-T047
disease	I-T047
in	O
patients	O
with	O
retinoblastoma	B-T191
.	O
We	O
particularly	O
aimed	O
to	O
assess	O
whether	O
higher	O
melphalan	B-T121
dose	O
with	O
lower	O
number	O
of	O
injections	O
was	O
more	O
effective	O
and	O
associated	O
with	O
fewer	O
side	O
effects	O
.	O
This	O
retrospective	O
,	O
interventional	O
,	O
noncomparative	O
,	O
and	O
nonrandomized	O
study	O
included	O
39	O
eyes	B-T023
of	O
37	O
patients	O
.	O
Vitreous	B-T033
seeds	I-T033
were	O
classified	O
as	O
dust	B-T191
,	O
sphere	B-T191
,	O
and	O
cloud	B-T191
types	I-T191
.	O
Intravitreal	O
injections	O
were	O
performed	O
through	O
pars	B-T023
plana	I-T023
free	O
of	O
any	O
visible	O
tumor	B-T191
using	O
30	O
-	O
G	O
needle	O
.	O
Response	O
of	O
the	O
seeds	O
(	O
disappearance	B-T033
,	O
conversion	O
into	O
inactive	B-T033
debris	I-T033
,	O
or	O
progression	B-T191
)	O
and	O
enucleation	B-T061
rate	O
were	O
determined	O
as	O
outcome	O
measures	O
.	O
All	O
patients	O
previously	O
received	O
systemic	B-T061
or	O
intra	B-T061
-	I-T061
arterial	I-T061
chemotherapy	I-T061
.	O
Vitreous	B-T033
seeding	I-T033
was	O
primary	O
in	O
54	O
%	O
of	O
eyes	B-T023
and	O
secondary	O
in	O
46	O
%	O
of	O
eyes	B-T023
.	O
Vitreous	B-T033
seeds	I-T033
were	O
classified	O
as	O
dust	B-T191
in	O
9	O
(	O
23.1	O
%	O
)	O
eyes	B-T023
,	O
sphere	B-T191
in	O
24	O
(	O
61.5	O
%	O
)	O
eyes	B-T023
,	O
and	O
cloud	B-T191
in	O
6	O
(	O
15.4	O
%	O
)	O
eyes	B-T023
.	O
Melphalan	B-T121
dose	O
varied	O
between	O
20	O
and	O
40	O
µg	O
and	O
20	O
(	O
51.3	O
%	O
)	O
eyes	B-T023
received	O
>	O
30	O
µg	O
.	O
The	O
total	O
number	O
of	O
injections	O
was	O
70	O
(	O
range	O
1	O
-	O
5	O
,	O
mean	O
1.8	O
per	O
eye	B-T023
)	O
.	O
Various	O
types	O
of	O
regression	O
were	O
obtained	O
in	O
27	O
(	O
69.2	O
%	O
)	O
eyes	B-T023
.	O
Sphere	B-T191
-	I-T191
type	I-T191
seeds	I-T191
were	O
the	O
most	O
responsive	O
to	O
melphalan	B-T121
.	O
Nonresponse	B-T033
and	O
disease	O
progression	O
were	O
noted	O
in	O
12	O
(	O
30.8	O
%	O
)	O
eyes	B-T023
.	O
After	O
a	O
mean	O
follow	B-T058
-	I-T058
up	I-T058
of	O
11.8	O
months	O
,	O
17	O
(	O
44	O
%	O
)	O
eyes	B-T023
were	O
enucleated	O
.	O
Vitreous	O
hemorrhage	O
(	O
18	O
%	O
)	O
and	O
retinal	B-T023
pigment	I-T023
epithelial	I-T023
alterations	O
(	O
8	O
%	O
)	O
were	O
the	O
most	O
common	O
side	O
effects	O
.	O
Intravitreal	O
melphalan	B-T121
at	O
30	O
-	O
40	O
µg	O
in	O
1	O
or	O
2	O
injections	O
proved	O
effective	O
in	O
69.2	O
%	O
of	O
eyes	B-T023
with	O
vitreous	B-T047
disease	I-T047
.	O
      
Development	O
and	O
initial	O
validation	O
of	O
the	O
Respirator	O
Comfort	O
,	O
Wearing	O
Experience	O
,	O
and	O
Function	O
Instrument	O
[	O
R	O
-	O
COMFI	O
Filtering	O
face	O
-	O
piece	O
respirators	O
(	O
FFRs	O
)	O
are	O
worn	O
to	O
protect	B-T033
health	O
care	O
personnel	O
from	O
airborne	O
particles	O
;	O
however	O
,	O
clinical	O
studies	O
have	O
demonstrated	O
that	O
FFR	O
adherence	O
is	O
relatively	O
low	O
in	O
some	O
settings	O
,	O
in	O
part	O
,	O
due	O
to	O
discomfort	B-T184
and	O
intolerance	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
develop	O
and	O
initially	O
evaluate	O
the	O
psychometric	O
properties	O
of	O
an	O
instrument	O
designed	O
to	O
measure	O
the	O
comfort	O
and	O
tolerability	O
of	O
FFRs	O
.	O
Instrument	O
items	O
were	O
developed	O
through	O
literature	O
reviews	O
,	O
focus	O
groups	O
,	O
and	O
several	O
iterations	B-T033
of	O
ranking	O
and	O
refining	O
by	O
experts	O
.	O
Psychometric	B-T060
evaluation	I-T060
of	O
the	O
instrument	O
was	O
conducted	O
using	O
Rasch	O
partial	O
credit	O
model	O
(	O
PCM	O
)	O
analysis	O
.	O
Pivot	O
anchoring	O
was	O
used	O
to	O
specify	O
the	O
threshold	O
defining	O
item	O
difficulty	O
;	O
in	O
our	O
analyses	O
,	O
this	O
was	O
the	O
point	O
that	O
participants	O
moved	O
from	O
possessing	O
none	O
of	O
the	O
trait	O
to	O
some	O
of	O
the	O
trait	O
.	O
The	O
final	O
instrument	O
was	O
completed	O
by	O
165	O
health	O
care	O
personnel	O
from	O
3	O
Veterans	O
Health	B-T058
Administration	I-T058
facilities	I-T058
,	O
and	O
data	O
were	O
analyzed	O
using	O
Rasch	O
PCM	O
.	O
Seven	O
items	O
were	O
removed	O
because	O
they	O
:	O
(	O
1	O
)	O
violated	O
the	O
assumption	O
of	O
independence	O
;	O
(	O
2	O
)	O
were	O
mis	O
-	O
fitting	O
;	O
and/or	O
(	O
3	O
)	O
were	O
deemed	O
not	O
relevant	O
.	O
Category	O
function	O
analysis	O
demonstrated	O
that	O
all	O
categories	O
progressed	O
monotonically	O
.	O
Principal	O
components	O
analysis	O
demonstrated	O
the	O
existence	O
of	O
three	O
subscales	O
(	O
Discomfort	B-T184
,	O
General	O
Wearing	O
Experience	O
,	O
and	O
Function	O
)	O
.	O
Final	O
reliability	O
analyses	O
showed	O
that	O
the	O
scale	O
had	O
moderate	O
to	O
high	O
person	O
reliability	O
and	O
high	O
item	O
reliability	O
.	O
The	O
final	O
instrument	O
contained	O
21	O
items	O
.	O
Until	O
now	O
,	O
to	O
our	O
knowledge	O
no	O
instrument	O
with	O
evidence	O
supporting	O
its	O
reliability	O
and	O
validity	O
to	O
assess	O
discomfort	B-T184
and	O
tolerance	O
of	O
FFRs	O
among	O
health	O
care	O
personnel	O
has	O
been	O
published	O
.	O
A	O
21	O
-	O
item	O
psychometrically	O
sound	O
measure	O
of	O
comfort	O
and	O
tolerability	O
of	O
FFRs	O
,	O
Respirator	O
Comfort	O
,	O
Wearing	O
Experience	O
,	O
and	O
Function	O
Instrument	O
(	O
R	O
-	O
COMFI	O
)	O
,	O
was	O
developed	O
.	O
The	O
significance	O
of	O
developing	O
such	O
an	O
instrument	O
is	O
that	O
it	O
will	O
help	O
identify	O
respirators	O
that	O
are	O
likely	O
to	O
have	O
better	O
adherence	O
in	O
practice	O
settings	O
.	O
The	O
R	O
-	O
COMFI	O
may	O
be	O
used	O
within	O
and	O
beyond	O
the	O
VA	O
healthcare	O
system	O
as	O
a	O
psychometrically	O
sound	O
instrument	O
to	O
evaluate	O
the	O
comfort	O
and	O
tolerability	O
of	O
respirators	O
,	O
including	O
developmental	O
prototypes	O
.	O
      
Radiosensitization	B-T061
of	O
non	B-T191
-	I-T191
small	I-T191
-	I-T191
cell	I-T191
lung	I-T191
cancer	I-T191
cells	O
and	O
xenografts	B-T061
by	O
the	O
interactive	O
effects	O
of	O
pemetrexed	B-T121
and	O
methoxyamine	B-T121
The	O
anti	B-T121
-	I-T121
folate	I-T121
pemetrexed	B-T121
is	O
a	O
radiosensitizer	B-T121
.	O
In	O
pre	O
-	O
clinical	O
models	O
,	O
pemetrexed	B-T121
is	O
more	O
effective	O
along	O
with	O
the	O
base	O
-	O
excision	O
-	O
repair	O
inhibitor	O
methoxyamine	B-T121
.	O
We	O
tested	O
whether	O
methoxyamine	B-T121
enhances	O
pemetrexed	B-T121
-mediated	O
radiosensitization	B-T061
of	O
lung	B-T191
adenocarcinoma	I-T191
cells	O
and	O
xenografts	B-T061
.	O
A549	O
and	O
H1299	O
cells	O
were	O
evaluated	O
for	O
cell	O
cycle	O
distribution	O
by	O
flow	B-T059
cytometry	I-T059
,	O
radiosensitization	B-T061
by	O
clonogenic	B-T059
assay	I-T059
,	O
and	O
DNA	O
repair	O
by	O
neutral	O
comet	O
assay	O
and	O
repair	O
protein	O
activation	O
.	O
H460	O
cells	O
were	O
included	O
in	O
some	O
studies	O
.	O
Xenografts	B-T061
in	O
nude	O
mice	O
received	B-T033
drug	I-T033
(	O
s	O
)	O
and/or	O
radiation	O
,	O
and	O
tumor	B-T191
growth	I-T191
was	O
monitored	O
by	O
caliper	O
and	O
in	O
vivo	O
toxicity	O
by	O
animal	O
weight	O
.	O
Exposure	O
to	O
pemetrexed	B-T121
/	O
methoxyamine	B-T121
for	O
24	O
(	O
H1299	O
,	O
H460	O
)	O
or	O
48	O
(	O
A549)hours	O
before	O
irradiation	O
resulted	O
in	O
accumulation	B-T033
of	O
cells	O
near	O
the	O
radiosensitive	O
G1	O
/	O
S	O
border	O
;	O
dose	O
-	O
enhancement	O
factors	O
of	O
1.62±0.19	O
,	O
1.97±0.25	O
,	O
and	O
1.67±0.30	O
,	O
respectively	O
;	O
reduction	O
of	O
mean	O
inactivation	O
dose	O
by	O
32	O
%	O
,	O
30	O
%	O
,	O
and	O
46	O
%	O
,	O
respectively	O
;	O
and	O
significant	O
reductions	O
of	O
SF2	O
and	O
SF4	O
(	O
p<0.05	O
)	O
.	O
Radiosensitization	B-T061
was	O
associated	O
with	O
rapid	O
DNA	O
double	O
-	O
strand	O
-	O
break	O
rejoining	O
and	O
increased	O
levels	O
of	O
DNA	O
-	O
PKcs	O
.	O
Both	O
tumor	B-T191
-	I-T191
growth	I-T191
rate	O
and	O
tumor	B-T191
-	I-T191
growth	I-T191
delay	O
were	O
significantly	O
improved	O
by	O
adding	O
methoxyamine	B-T121
to	O
pemetrexed	B-T121
pre	O
-	O
irradiation	O
(	O
p<0.0001	O
)	O
;	O
no	O
mice	O
lost	O
weight	O
during	O
treatment	O
.	O
Addition	O
of	O
methoxyamine	B-T121
to	O
pemetrexed	B-T121
and	O
fractionated	O
radiotherapy	O
may	O
improve	O
outcome	O
for	O
patients	O
with	O
locally	O
advanced	O
non	B-T191
-	I-T191
squamous	I-T191
non	I-T191
-	I-T191
small	I-T191
-	I-T191
cell	I-T191
lung	I-T191
cancer	I-T191
.	O
      
Isolation	B-T059
of	I-T059
Cells	I-T059
Specialized	O
in	O
Anticancer	B-T121
Alkaloid	O
Metabolism	O
by	O
Fluorescence	B-T059
-	I-T059
Activated	I-T059
Cell	I-T059
Sorting	I-T059
Plant	O
specialized	O
metabolism	O
often	O
presents	O
a	O
complex	O
cell	O
-	O
specific	O
compartmentation	O
essential	O
to	O
accomplish	O
the	O
biosynthesis	O
of	O
valuable	O
plant	O
natural	O
products	O
.	O
Hence	O
,	O
the	O
disclosure	O
and	O
potential	O
manipulation	O
of	O
such	O
pathways	O
may	O
depend	O
on	O
the	O
capacity	O
to	O
isolate	B-T059
and	O
characterize	O
specific	O
cell	O
types	O
.	O
Catharanthus	O
roseus	O
is	O
the	O
source	O
of	O
several	O
medicinal	B-T121
terpenoid	O
indole	O
alkaloids	O
,	O
including	O
the	O
low	O
-	O
level	O
anticancer	B-T121
vinblastine	B-T121
and	O
vincristine	B-T121
,	O
for	O
which	O
the	O
late	O
biosynthetic	O
steps	O
occur	O
in	O
specialized	O
mesophyll	O
cells	O
called	O
idioblasts	O
.	O
Here	O
,	O
the	O
optical	O
,	O
fluorescence	O
,	O
and	O
alkaloid	O
-	O
accumulating	B-T033
properties	O
of	O
C.	O
roseus	O
leaf	O
idioblasts	O
are	O
characterized	O
,	O
and	O
a	O
methodology	O
for	O
the	O
isolation	B-T059
of	O
idioblast	O
protoplasts	O
by	O
fluorescence	B-T059
-	I-T059
activated	I-T059
cell	I-T059
sorting	I-T059
is	O
established	O
,	O
taking	O
advantage	O
of	O
the	O
distinctive	O
autofluorescence	B-T059
of	O
these	O
cells	O
.	O
This	O
achievement	O
represents	O
a	O
crucial	O
step	O
for	O
the	O
development	O
of	O
differential	O
omic	O
strategies	O
leading	O
to	O
the	O
identification	O
of	O
candidate	O
genes	O
putatively	O
involved	O
in	O
the	O
biosynthesis	O
,	O
pathway	O
regulation	O
,	O
and	O
transmembrane	O
transport	O
leading	O
to	O
the	O
anticancer	B-T033
alkaloids	O
from	O
C.	O
roseus	O
.	O
      
Transforming	B-T121
Growth	I-T121
Factor	I-T121
Beta	I-T121
1	I-T121
(	O
TGF	B-T121
-	I-T121
β1	I-T121
)	O
in	O
Thyroid	B-T191
Cancer	I-T191
Patients	O
:	O
a	O
View	O
from	O
the	O
Peripheral	O
Blood	O
Transforming	O
growth	O
factor	O
beta	O
(	O
TGF	O
-	O
β	O
)	O
plays	O
an	O
important	O
role	O
in	O
many	O
pathophysiological	O
conditions	O
,	O
including	O
cancer	B-T191
.	O
The	O
level	O
of	O
TGF	O
-	O
β	O
in	O
patients	O
with	O
differentiated	B-T191
thyroid	I-T191
cancer	I-T191
(	O
DTC	B-T191
)	O
has	O
not	O
been	O
examined	B-T033
so	O
far	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
measure	O
TGF	O
-	O
β	O
concentration	O
in	O
serum	O
samples	O
and	O
in	O
PHA	O
-	O
stimulated	O
whole	O
blood	O
culture	B-T059
in	O
vitro	O
and	O
to	O
analyze	O
possible	O
associations	O
of	O
TGF	B-T121
-	I-T121
β1	I-T121
levels	O
with	O
leukocyte	O
,	O
lymphocyte	O
and	O
platelets	O
counts	B-T059
,	O
the	O
histological	O
type	O
of	O
thyroid	B-T191
cancer	I-T191
,	O
and	O
stage	B-T060
of	I-T060
disease	I-T060
.	O
TGF	B-T121
-	I-T121
β1	I-T121
was	O
measured	O
in	O
22	O
DTC	B-T191
patients	O
and	O
20	O
healthy	O
controls	O
using	O
the	O
duoSet	O
ELISA	O
Development	O
kit	O
for	O
human	O
TGF	O
-	O
β1	O
.	O
The	O
concentration	O
of	O
TGF	B-T121
-	I-T121
β1	I-T121
in	O
serum	O
samples	O
from	O
both	O
groups	O
correlated	O
positively	O
with	O
the	O
platelet	O
counts	B-T059
.	O
There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
serum	O
concentrations	O
of	O
TGF	B-T121
-	I-T121
β1	I-T121
between	O
DTC	B-T191
patients	O
and	O
control	O
subjects	O
,	O
but	O
PHA	O
stimulated	O
whole	O
blood	O
cultures	B-T059
of	O
DTC	B-T191
patients	O
produced	O
less	O
TGF	B-T121
-	I-T121
β1	I-T121
than	O
those	O
from	O
controls	O
.	O
Additional	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
significance	O
of	O
these	O
in	O
vitro	O
findings	B-T033
.	O
      
Reduced	B-T033
Chest	I-T033
and	O
Abdominal	B-T023
Wall	I-T023
Mobility	O
and	O
Their	O
Relationship	O
to	O
Lung	O
Function	O
,	O
Respiratory	O
Muscle	O
Strength	O
,	O
and	O
Exercise	O
Tolerance	O
in	O
Subjects	O
With	O
COPD	B-T047
Advanced	O
air	O
-	O
flow	O
limitation	O
in	O
patients	O
with	O
COPD	B-T047
leads	O
to	O
a	O
reduction	O
in	O
vital	O
capacity	O
,	O
respiratory	O
muscle	O
strength	O
,	O
and	O
exercise	O
capacity	O
.	O
However	O
,	O
its	O
impact	O
on	O
chest	O
and	O
abdominal	B-T023
wall	I-T023
mobility	O
is	O
unknown	O
.	O
This	O
study	O
aimed	O
to	O
ascertain	O
the	O
prevalence	O
of	O
patients	O
with	O
COPD	B-T047
with	O
reduced	B-T033
chest	I-T033
and	O
abdominal	B-T023
wall	I-T023
mobility	O
and	O
to	O
investigate	O
the	O
effect	O
of	O
reduced	B-T033
chest	I-T033
and	O
abdominal	B-T023
wall	I-T023
mobility	O
on	O
pulmonary	O
function	O
,	O
respiratory	O
muscle	O
strength	O
,	O
and	O
exercise	O
capacity	O
.	O
In	O
51	O
elderly	O
male	O
subjects	O
with	O
COPD	B-T047
,	O
chest	O
and	O
abdominal	B-T023
wall	I-T023
mobility	O
,	O
FVC	O
,	O
FEV1	B-T060
,	O
FEV1	B-T059
/	I-T059
FVC	I-T059
,	O
maximal	B-T060
inspiratory	I-T060
pressure	I-T060
(	O
PImax	B-T060
)	O
,	O
maximal	B-T060
expiratory	I-T060
pressure	I-T060
(	O
PEmax	B-T060
)	O
,	O
and	O
the	O
6	B-T060
-	I-T060
min	I-T060
walk	I-T060
distance	I-T060
(	O
6MWD	B-T060
)	O
were	O
assessed	O
.	O
Chest	B-T023
and	O
abdominal	B-T023
wall	I-T023
mobility	O
were	O
measured	O
using	O
the	O
breathing	O
movement	B-T059
scale	I-T059
(	O
0	O
-	O
8)	O
at	O
the	O
3	O
regions	O
(	O
upper	O
chest	O
,	O
lower	O
chest	O
,	O
and	O
abdomen	O
)	O
.	O
Reduced	B-T033
mobility	I-T033
was	O
defined	O
as	O
a	O
value	O
lower	O
than	O
the	O
lower	O
limit	O
of	O
the	O
normal	O
scale	O
.	O
The	O
unpaired	O
t	O
test	O
,	O
Mann	O
-	O
Whitney	O
test	O
,	O
and	O
multiple	O
regression	O
analysis	O
were	O
performed	O
.	O
The	O
percentages	O
of	O
subjects	O
with	O
reduced	B-T033
mobility	I-T033
were	O
78	O
%	O
for	O
the	O
upper	O
chest	O
,	O
76	O
%	O
for	O
the	O
lower	O
chest	O
,	O
and	O
53	O
%	O
for	O
the	O
abdomen	O
.	O
The	O
subjects	O
with	O
reduced	B-T033
mobility	I-T033
had	O
significantly	O
low	O
FVC	O
,	O
FEV1	B-T060
,	O
and	O
6MWD	B-T060
in	O
each	O
region	O
and	O
significantly	O
low	O
FEV1	B-T059
/	I-T059
FVC	I-T059
,	O
PImax	B-T060
,	O
and	O
PEmax	B-T060
in	O
the	O
abdominal	O
region	O
compared	O
with	O
those	O
with	O
nonreduced	O
mobility	O
.	O
FVC	O
and	O
6MWD	B-T060
were	O
independently	O
associated	O
with	O
the	O
scale	O
values	O
in	O
each	O
region	O
and	O
with	O
the	O
abdominal	O
scale	O
value	O
,	O
respectively	O
.	O
The	O
majority	O
of	O
subjects	O
with	O
COPD	B-T047
had	O
reduced	B-T033
chest	I-T033
and	O
abdominal	B-T023
wall	I-T023
mobility	O
,	O
which	O
was	O
independently	O
associated	O
with	O
FVC	O
.	O
Even	O
though	O
abdominal	B-T023
wall	I-T023
mobility	O
was	O
relatively	O
preserved	O
compared	O
with	O
chest	B-T023
wall	I-T023
mobility	O
,	O
it	O
was	O
also	O
independently	O
associated	O
with	O
6MWD	B-T060
.	O
      
Successful	B-T061
Restoration	I-T061
of	O
Severely	O
Mutilated	O
Primary	B-T023
Incisors	I-T023
Using	O
a	O
Novel	O
Method	O
to	O
Retain	O
Zirconia	O
Crowns	O
-	O
Two	O
Year	O
Results	O
This	O
manuscript	O
describes	O
a	O
simple	O
reliable	O
technique	O
for	O
restoring	B-T061
severely	O
mutilated	O
primary	B-T023
anterior	I-T023
teeth	I-T023
.	O
A	O
rigid	O
glass	O
ionomer	O
post	O
is	O
created	O
over	O
which	O
zirconia	O
crowns	O
can	O
be	O
fitted	O
to	O
achieve	O
a	O
long	O
-	O
term	O
stable	O
esthetic	B-T061
restoration	B-T061
for	O
primary	B-T023
anterior	I-T023
teeth	I-T023
.	O
Children	O
aged	O
2	O
-	O
5	O
years	O
with	O
two	O
up	O
to	O
six	O
extensively	O
decayed	B-T047
upper	B-T023
primary	I-T023
incisors	I-T023
were	O
included	O
.	O
Fuji	O
IX	O
was	O
condensed	O
into	O
an	O
intracanal	B-T061
space	I-T061
created	O
to	O
a	O
depth	O
of	O
3	O
mm	O
,	O
to	O
provide	O
a	O
core	O
which	O
also	O
extended	O
3	O
mm	O
supragingivally	B-T061
.	O
Crown	B-T061
preparations	I-T061
were	O
completed	O
upon	O
these	O
cores	O
.	O
Zirconia	O
crowns	O
(	O
Nusmile	O
,	O
Houston	O
Texas	O
USA	O
)	O
were	O
fitted	O
and	O
cemented	O
over	O
the	O
prepared	O
cores	O
.	O
All	O
patients	O
were	O
recalled	B-T061
at	O
regular	O
intervals	O
.	O
Twenty	O
-	O
three	O
healthy	O
children	O
with	O
86	O
restorations	B-T061
participated	O
in	O
the	O
study	O
.	O
The	O
overall	O
survival	O
of	O
the	O
restorations	B-T061
was	O
95.3	O
%	O
after	O
12	O
months	O
and	O
80.2	O
%	O
after	O
24	O
months	O
.	O
According	O
to	O
Kaplan	O
-	O
Meier	O
survival	O
analysis	O
,	O
the	O
median	O
survival	O
time	O
was	O
not	O
reached	O
while	O
the	O
estimated	O
mean	O
survival	O
time	O
was	O
22.9	O
months	O
.	O
This	O
newly	O
described	O
clinical	B-T058
technique	I-T058
is	O
simple	O
and	O
reliable	O
to	O
use	O
for	O
restoration	B-T061
of	O
extensively	O
decayed	B-T047
primary	B-T023
incisors	I-T023
.	O
Use	O
of	O
zirconia	O
crowns	O
retained	O
using	O
this	O
technique	O
offers	O
superior	O
esthetic	O
,	O
durable	O
restorations	B-T061
with	O
remarkable	O
gingival	B-T033
response	I-T033
up	O
to	O
24	O
months	O
.	O
      
Efficacy	O
of	O
42	O
Pharmacologic	B-T121
Cotreatment	B-T061
Strategies	O
Added	O
to	O
Antipsychotic	B-T121
Monotherapy	B-T061
in	O
Schizophrenia	B-T048
:	O
Systematic	O
Overview	O
and	O
Quality	O
Appraisal	O
of	O
the	O
Meta	O
-	O
analytic	O
Evidence	O
Limited	O
treatment	B-T061
responses	O
in	O
schizophrenia	B-T048
prompted	O
the	O
testing	O
of	O
combining	O
an	O
antipsychotic	B-T121
drug	I-T121
treatment	B-T061
with	O
a	O
second	O
psychotropic	B-T121
medication	B-T121
.	O
A	O
comprehensive	O
evaluation	B-T058
of	O
the	O
efficacy	O
of	O
multiple	O
medication	B-T121
combinations	B-T121
is	O
missing	O
.	O
To	O
summarize	O
and	O
compare	O
the	O
meta	O
-	O
analytically	O
determined	O
efficacy	O
of	O
pharmacologic	B-T121
combination	B-T121
strategies	O
of	O
antipsychotic	B-T121
drugs	I-T121
in	O
adults	O
with	O
schizophrenia	B-T048
.	O
Systematic	O
search	O
of	O
PubMed	O
and	O
PsycInfo	O
until	O
May	O
13	O
,	O
2016	O
.	O
Meta	O
-	O
analyses	O
of	O
randomized	O
clinical	O
trials	O
comparing	O
the	O
efficacy	O
of	O
antipsychotic	B-T121
drugs	I-T121
combined	O
with	O
other	O
antipsychotic	B-T121
or	O
nonantipsychotic	B-T121
medications	I-T121
vs	O
placebos	O
or	O
antipsychotic	B-T121
monotherapy	B-T061
among	O
adults	O
with	O
schizophrenia	B-T048
.	O
Independent	O
reviewers	O
extracted	O
the	O
data	O
and	O
assessed	O
the	O
quality	O
of	O
the	O
methods	O
of	O
the	O
included	O
meta	O
-	O
analyses	O
using	O
A	O
Measurement	O
Tool	O
to	O
Assess	O
Systematic	O
Reviews	O
(	O
AMSTAR	O
)	O
,	O
adding	O
6	O
new	O
items	O
to	O
rate	O
their	O
quality	O
.	O
Effect	O
sizes	O
,	O
expressed	O
as	O
standardized	O
mean	O
difference	O
/Hedges	O
g	O
or	O
risk	O
ratio	O
,	O
were	O
compared	O
separately	O
for	O
combinations	B-T121
with	O
any	O
antipsychotic	B-T121
drug	I-T121
and	O
for	O
combinations	B-T121
with	O
clozapine	B-T121
.	O
The	O
primary	O
outcome	O
was	O
total	O
symptom	B-T184
reduction	O
.	O
Secondary	O
outcomes	O
included	O
positive	B-T033
and	O
negative	B-T033
symptoms	B-T184
,	O
treatment	B-T058
recommendations	I-T058
by	O
authors	O
,	O
study	O
-	O
defined	O
inefficacies	B-T033
,	O
cognitive	O
and	O
depressive	B-T184
symptoms	I-T184
,	O
discontinuation	B-T058
of	O
treatment	B-T061
because	O
of	O
any	O
cause	O
,	O
and	O
inefficacies	B-T033
or	O
intolerabilities	O
.	O
Of	O
3397	O
publications	O
,	O
29	O
meta	O
-	O
analyses	O
testing	O
42	O
combination	B-T121
strategies	O
in	O
381	O
individual	O
trials	O
and	O
among	O
19	O
833	O
participants	O
were	O
included	O
.	O
For	O
total	O
symptom	B-T184
reductions	B-T061
,	O
32	O
strategies	O
that	O
augmented	O
any	O
antipsychotic	B-T121
drug	I-T121
and	O
5	O
strategies	O
that	O
augmented	O
clozapine	B-T121
were	O
examined	O
.	O
Fourteen	O
combination	B-T121
treatments	B-T061
outperformed	O
controls	O
(	O
standard	O
mean	O
difference	O
/Hedges	O
g	O
,	O
-1.27	O
[	O
95	O
%	O
CI	O
,	O
-2.35	O
to	O
-0.19	O
]	O
to	O
-0.23	O
[	O
95	O
%	O
CI	O
,	O
-0.44	O
to	O
-0.02	O
]	O
;	O
P	O
=	O
.05	O
)	O
.	O
No	O
combination	B-T121
strategies	O
with	O
clozapine	B-T121
outperformed	O
controls	O
.	O
The	O
quality	O
of	O
the	O
methods	O
of	O
the	O
meta	O
-	O
analyses	O
was	O
generally	O
high	O
(	O
mean	B-T033
score	I-T033
,	O
9	O
of	O
a	O
maximum	O
score	O
of	O
11	O
)	O
but	O
the	O
quality	O
of	O
the	O
meta	O
-	O
analyzed	O
studies	O
was	O
low	O
(	O
mean	B-T033
score	I-T033
,	O
2.8	O
of	O
a	O
maximum	O
score	O
of	O
8)	O
.	O
Treatment	B-T058
recommendations	I-T058
correlated	O
with	O
the	O
effect	O
size	O
(	O
correlation	O
coefficient	O
,	O
0.22	O
;	O
95	O
%	O
CI	O
,	O
0.35	O
-	O
0.10	O
;	O
P	O
<	O
.001	O
)	O
,	O
yet	O
effect	O
sizes	O
were	O
inversely	O
correlated	O
with	O
study	O
quality	O
(	O
correlation	O
coefficient	O
,	O
-0.06	O
;	O
95	O
%	O
CI	O
,	O
0.01	O
to	O
-0.12	O
;	O
P	O
=	O
.02	O
)	O
.	O
Meta	O
-	O
analyses	O
of	O
21	O
interventions	O
fully	O
or	O
partially	O
recommended	O
their	O
use	O
,	O
with	O
recommendations	O
being	O
positively	B-T033
correlated	O
with	O
the	O
effect	O
sizes	O
of	O
the	O
pooled	O
intervention	O
.	O
However	O
,	O
the	O
effect	O
sizes	O
were	O
inversely	O
correlated	O
with	O
meta	O
-	O
analyzed	O
study	O
quality	O
,	O
reducing	O
confidence	O
in	O
these	O
recommendations	O
.	O
Higher	O
-	O
quality	O
trials	O
and	O
patient	O
-based	O
meta	O
-	O
analyses	O
are	O
needed	O
to	O
determine	O
whether	O
subpopulations	O
might	O
benefit	O
from	O
combination	B-T121
treatment	B-T061
,	O
as	O
no	O
single	O
strategy	O
can	O
be	O
recommended	O
for	O
patients	O
with	O
schizophrenia	B-T048
based	O
on	O
the	O
current	O
meta	O
-	O
analytic	O
literature	O
.	O
      
High	O
throughput	O
resistance	O
profiling	O
of	O
Plasmodium	O
falciparum	O
infections	O
based	O
on	O
custom	O
dual	O
indexing	O
and	O
Illumina	O
next	O
generation	O
sequencing	O
-	O
technology	O
Genetic	O
polymorphisms	O
in	O
P.	O
falciparum	O
can	O
be	O
used	O
to	O
indicate	O
the	O
parasite	O
's	O
susceptibility	B-T033
to	O
antimalarial	B-T121
drugs	I-T121
as	O
well	O
as	O
its	O
geographical	O
origin	O
.	O
Both	O
of	O
these	O
factors	O
are	O
key	O
to	O
monitoring	B-T058
development	O
and	O
spread	O
of	O
antimalarial	B-T121
drug	O
resistance	O
.	O
In	O
this	O
study	O
,	O
we	O
combine	O
multiplex	B-T059
PCR	I-T059
,	O
custom	O
designed	O
dual	O
indexing	O
and	O
Miseq	O
sequencing	B-T059
for	O
high	O
throughput	O
SNP	O
-	O
profiling	O
of	O
457	O
malaria	B-T047
infections	O
from	O
Guinea	O
-	O
Bissau	O
,	O
at	O
the	O
cost	O
of	O
10	O
USD	O
per	O
sample	O
.	O
By	O
amplifying	O
and	O
sequencing	B-T059
15	O
genetic	O
fragments	O
,	O
we	O
cover	O
20	O
resistance	O
-conferring	O
SNPs	O
occurring	O
in	O
pfcrt	O
,	O
pfmdr1	O
,	O
pfdhfr	O
,	O
pfdhps	O
,	O
as	O
well	O
as	O
the	O
entire	O
length	O
of	O
pfK13	O
,	O
and	O
the	O
mitochondrial	O
barcode	O
for	O
parasite	O
origin	B-T033
.	O
SNPs	O
of	O
interest	O
were	O
sequenced	O
with	O
an	O
average	O
depth	O
of	O
2,043	O
reads	O
,	O
and	O
bases	O
were	O
called	O
for	O
the	O
various	O
SNP	O
-	O
positions	O
with	O
a	O
p	O
-	O
value	O
below	O
0.05	O
,	O
for	O
89.8	O
-	O
100	O
%	O
of	O
samples	O
.	O
The	O
SNP	O
data	O
indicates	O
that	O
artemisinin	B-T121
resistance	O
-conferring	O
SNPs	O
in	O
pfK13	O
are	O
absent	O
from	O
the	O
studied	O
area	O
of	O
Guinea	O
-	O
Bissau	O
,	O
while	O
the	O
pfmdr1	O
86	O
N	O
allele	O
is	O
found	O
at	O
a	O
high	O
prevalence	O
.	O
The	O
mitochondrial	O
barcodes	O
are	O
unanimous	O
and	O
accommodate	O
a	O
West	B-T033
African	I-T033
origin	I-T033
of	O
the	O
parasites	O
.	O
With	O
this	O
method	O
,	O
very	O
reliable	O
high	O
throughput	O
surveillance	B-T061
of	O
antimalarial	B-T121
drug	O
resistance	O
becomes	O
more	O
affordable	O
than	O
ever	O
before	O
.	O
      
Interleukin-21	O
plays	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
and	O
severity	O
of	O
type	B-T047
I	I-T047
autoimmune	I-T047
hepatitis	I-T047
Recently	O
,	O
the	O
number	O
of	O
follicular	B-T023
helper	O
T	O
(	O
Tfh	O
)	O
cells	O
expressing	O
interleukin	O
(	O
IL)-21	O
was	O
found	O
to	O
increase	O
in	O
peripheral	O
blood	O
of	O
human	O
and	O
murine	O
models	B-T050
of	O
autoimmune	B-T047
hepatitis	I-T047
(	O
AIH	B-T047
)	O
.	O
IL-21	O
,	O
the	O
most	O
recently	O
discovered	O
member	O
of	O
the	O
type	O
-	O
I	O
cytokine	O
family	O
,	O
exerts	O
various	O
effects	O
on	O
the	O
immune	O
system	O
,	O
including	O
B	O
cell	O
activation	O
,	O
plasma	O
cell	O
differentiation	O
,	O
and	O
immunoglobulin	O
production	O
.	O
We	O
aimed	O
to	O
assess	O
the	O
relationship	O
of	O
serum	O
IL-21	O
levels	O
in	O
patients	O
with	O
type	B-T047
I	I-T047
AIH	I-T047
with	O
clinical	O
and	O
laboratory	O
parameters	O
and	O
histology	O
.	O
Ninety	O
-	O
two	O
Japanese	O
patients	O
with	O
liver	B-T047
disease	I-T047
(	O
22	O
AIH	B-T047
,	O
20	O
primary	B-T047
biliary	I-T047
cholangitis	I-T047
,	O
19	O
drug	B-T047
-	I-T047
induced	I-T047
liver	I-T047
injury	I-T047
,	O
8	O
acute	B-T047
hepatitis	I-T047
B	I-T047
,	O
8	O
chronic	B-T047
hepatitis	I-T047
C	I-T047
,	O
10	O
non	B-T047
-	I-T047
alcoholic	I-T047
steatohepatitis	I-T047
,	O
5	O
viral	B-T047
hepatitis	I-T047
)	O
and	O
10	O
healthy	O
volunteers	O
were	O
recruited	O
.	O
Serum	O
IL-21	O
levels	O
were	O
detected	O
by	O
enzyme	B-T059
-	I-T059
linked	I-T059
immunosorbent	I-T059
assay	I-T059
.	O
Real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
measured	O
mRNA	O
levels	O
of	O
Bcl-6	O
,	O
IL-21	O
,	O
and	O
CXCR5	O
(	O
Tfh	O
-	O
related	O
factors	O
)	O
in	O
peripheral	O
mononuclear	O
cells	O
.	O
Mean	O
age	O
at	O
diagnosis	B-T033
of	O
AIH	B-T047
was	O
58.6	O
years	O
,	O
male	B-T033
-	I-T033
to	I-T033
-	I-T033
female	I-T033
ratio	I-T033
was	O
4:18	O
,	O
18.2	O
%	O
of	O
participants	O
had	O
cirrhosis	B-T047
,	O
and	O
22.7	O
%	O
had	O
severe	O
disease	B-T047
.	O
IL-21	O
levels	O
were	O
significantly	O
increased	O
in	O
the	O
serum	O
of	O
patients	O
with	O
AIH	B-T047
compared	O
to	O
those	O
with	O
other	O
liver	O
diseases	O
and	O
controls	O
(	O
p	O
<	O
0.0001	O
)	O
.	O
Particularly	O
,	O
serum	O
IL-21	O
levels	O
were	O
significantly	O
increased	O
in	O
severe	O
AIH	B-T047
cases	O
compared	O
to	O
non	O
-	O
severe	O
cases	O
(	O
p	O
<	O
0.05	O
)	O
.	O
Serum	O
IL-21	O
levels	O
correlated	O
positively	O
with	O
total	O
serum	O
bilirubin	B-T059
levels	I-T059
(	O
r	O
=	O
0.46	O
,	O
p	O
<	O
0.05	O
)	O
,	O
grading	B-T033
of	I-T033
necroinflammatory	I-T033
activity	I-T033
(	O
r	O
=	O
0.68	O
,	O
p	O
<	O
0.005	O
)	O
and	O
negatively	O
with	O
serum	O
albumin	O
levels	O
in	O
patients	O
with	O
AIH	B-T047
(	O
r	O
=	O
-0.49	O
,	O
p	O
<	O
0.05	O
)	O
.	O
In	O
patients	O
with	O
biochemical	O
remission	B-T033
of	O
AIH	B-T047
,	O
serum	O
IL-21	O
levels	O
remained	O
elevated	O
and	O
correlated	O
positively	B-T033
with	O
serum	B-T059
IgG	I-T059
levels	I-T059
(	O
r	O
=	O
0.84	O
,	O
p	O
<	O
0.01	O
)	O
.	O
Expression	O
of	O
Tfh	O
-	O
related	O
factors	O
,	O
such	O
as	O
Bcl-6	O
and	O
IL-21	O
,	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
patients	O
with	O
AIH	B-T047
was	O
significantly	O
higher	O
than	O
that	O
in	O
healthy	O
volunteers	O
.	O
IL-21	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
and	O
severity	O
of	O
AIH	B-T047
,	O
and	O
may	O
present	O
a	O
promising	O
target	O
for	O
AIH	B-T047
therapy	O
.	O
      
Caribbean	O
massive	O
corals	O
not	O
recovering	O
from	O
repeated	O
thermal	O
stress	O
events	O
during	O
2005	O
-	O
2013	O
Massive	O
coral	O
bleaching	O
events	O
associated	O
with	O
high	O
sea	O
surface	O
temperatures	O
are	O
forecast	O
to	O
become	O
more	O
frequent	O
and	O
severe	O
in	O
the	O
future	O
due	O
to	O
climate	O
change	O
.	O
Monitoring	O
colony	O
recovery	O
from	O
bleaching	O
disturbances	O
over	O
multiyear	O
time	O
frames	O
is	O
important	O
for	O
improving	O
predictions	O
of	O
future	O
coral	O
community	O
changes	O
.	O
However	O
,	O
there	O
are	O
currently	O
few	O
multiyear	O
studies	O
describing	O
long	O
-	O
term	O
outcomes	O
for	O
coral	O
colonies	O
following	O
acute	O
bleaching	O
events	O
.	O
We	O
recorded	O
colony	O
pigmentation	O
and	O
size	O
for	O
bleached	O
and	O
unbleached	O
groups	O
of	O
co	O
-	O
located	O
conspecifics	O
of	O
three	O
major	O
reef	O
-	O
building	O
scleractinian	O
corals	O
(	O
Orbicella	O
franksi	O
,	O
Siderastrea	O
siderea	O
,	O
and	O
Stephanocoenia	O
michelini	O
;	O
n	O
=	O
198	O
total	O
)	O
in	O
Bocas	O
del	O
Toro	O
,	O
Panama	O
,	O
during	O
the	O
major	O
2005	O
bleaching	O
event	O
and	O
then	O
monitored	O
pigmentation	O
status	O
and	O
changes	O
live	O
tissue	O
colony	O
size	O
for	O
8	O
years	O
(	O
2005	O
-	O
2013	O
)	O
.	O
Corals	O
that	O
were	O
bleached	O
in	O
2005	O
demonstrated	O
markedly	O
different	O
response	O
trajectories	O
compared	O
to	O
unbleached	O
colony	O
groups	O
,	O
with	O
extensive	O
live	O
tissue	O
loss	O
for	O
bleached	O
corals	O
of	O
all	O
species	O
following	O
bleaching	O
,	O
with	O
mean	O
live	O
tissue	O
losses	O
per	O
colony	O
9	O
months	O
postbleaching	O
of	O
26.2	O
%	O
(	O
±5.4	O
SE	O
)	O
for	O
O.	O
franksi	O
,	O
35.7	O
%	O
(	O
±4.7	O
SE	O
)	O
for	O
S.	O
michelini	O
,	O
and	O
11.2	O
%	O
(	O
±3.9	O
SE	O
)	O
for	O
S.	O
siderea	O
.	O
Two	O
species	O
,	O
O.	O
franksi	O
and	O
S.	O
michelini	O
,	O
later	O
recovered	O
to	O
net	O
positive	B-T033
growth	O
,	O
which	O
continued	O
until	O
a	O
second	O
thermal	O
stress	O
event	O
in	O
2010	O
.	O
Following	O
this	O
event	O
,	O
all	O
species	O
again	O
lost	O
tissue	O
,	O
with	O
previously	O
unbleached	O
colony	O
species	O
groups	O
experiencing	O
greater	O
declines	O
than	O
conspecific	O
sample	O
groups	O
,	O
which	O
were	O
previously	O
bleached	O
,	O
indicating	O
a	O
possible	O
positive	O
acclimative	O
response	O
.	O
However	O
,	O
despite	O
this	O
beneficial	O
effect	O
for	O
previously	O
bleached	O
corals	O
,	O
all	O
groups	O
experienced	O
substantial	O
net	O
tissue	O
loss	O
between	O
2005	O
and	O
2013	O
,	O
indicating	O
that	O
many	O
important	O
Caribbean	O
reef	O
-	O
building	O
corals	O
will	O
likely	O
suffer	O
continued	O
tissue	O
loss	O
and	O
may	O
be	O
unable	O
to	O
maintain	O
current	O
benthic	O
coverage	O
when	O
faced	O
with	O
future	O
thermal	O
stress	O
forecast	O
for	O
the	O
region	O
,	O
even	O
with	O
potential	O
benefits	O
from	O
bleaching	O
-related	O
acclimation	O
.	O
      
Enhanced	O
Performance	O
of	O
Colorimetric	B-T059
Biosensing	B-T059
on	O
Paper	O
Microfluidic	B-T059
Platforms	I-T059
Through	O
Chemical	O
Modification	O
and	O
Incorporation	O
of	O
Nanoparticles	O
This	O
chapter	O
describes	O
two	O
different	O
methodologies	O
used	O
to	O
improve	O
the	O
analytical	O
performance	O
of	O
colorimetric	B-T059
paper	O
-based	O
biosensors	O
.	O
Microfluidic	O
paper	O
-	O
based	O
analytical	O
devices	O
(	O
μPADs	O
)	O
have	O
been	O
produced	O
by	O
a	O
stamping	O
process	O
and	O
CO2	O
laser	B-T061
ablation	I-T061
and	O
modified	O
,	O
respectively	O
,	O
through	O
an	O
oxidation	O
step	O
and	O
incorporation	O
of	O
silica	O
nanoparticles	O
on	O
the	O
paper	O
structure	O
.	O
Both	O
methods	O
are	O
employed	O
in	O
order	O
to	O
overcome	O
the	O
largest	O
problem	B-T033
associated	O
with	O
colorimetric	B-T059
detection	I-T059
,	O
the	O
heterogeneity	O
of	O
the	O
color	O
distribution	O
in	O
the	O
detection	O
zones	O
.	O
The	O
modification	O
steps	O
are	O
necessary	O
to	O
improve	O
the	O
interaction	O
between	O
the	O
paper	O
surface	O
and	O
the	O
selected	O
enzymes	O
.	O
The	O
enhanced	O
performance	O
has	O
ensured	O
reliability	O
for	O
quantitative	O
analysis	O
of	O
clinically	O
relevant	O
compounds	O
.	O
      
Scoparone	B-T121
Inhibits	O
LPS	O
-	O
Simulated	O
Inflammatory	O
Response	O
by	O
Suppressing	O
IRF3	O
and	O
ERK	O
in	O
BV-2	O
Microglial	O
Cells	O
Microglia	O
activation	O
and	O
the	O
release	O
of	O
various	O
inflammatory	O
cytokines	O
are	O
largely	O
related	O
to	O
neurological	B-T047
diseases	I-T047
,	O
including	O
Parkinson	B-T047
's	I-T047
,	O
Alzheimer	B-T047
's	I-T047
,	O
and	O
other	O
brain	B-T047
diseases	I-T047
.	O
The	O
suppression	O
of	O
microglial	O
cells	O
using	O
natural	O
bioactive	O
compounds	O
has	O
become	O
increasingly	O
important	O
for	O
brain	B-T061
therapy	I-T061
owing	O
to	O
the	O
expected	O
beneficial	O
effect	O
of	O
lower	O
toxicity	O
.	O
Scoparone	B-T121
(	O
6,7	B-T121
-	I-T121
dimethoxycoumarin	I-T121
)	O
,	O
a	O
major	O
bioactive	O
compound	O
found	B-T033
in	O
various	O
plant	O
parts	O
,	O
including	O
the	O
inner	O
shell	O
of	O
chestnut	O
(	O
Castanea	O
crenata	O
)	O
,	O
was	O
evaluated	O
on	O
lipopolysaccharide	O
(	O
LPS)-	O
activated	O
BV-2	O
microglia	O
cells	O
.	O
The	O
results	O
indicated	B-T033
that	O
scoparone	B-T121
suppresses	O
the	O
LPS	O
-	O
stimulated	O
increase	O
of	O
neuroinflammatory	O
responses	O
and	O
inhibited	O
the	O
pro	O
-	O
inflammatory	O
cytokine	O
production	O
in	O
the	O
BV-2	O
microglial	O
cells	O
.	O
A	O
mechanistic	O
study	O
showed	O
that	O
scoparone	B-T121
specifically	O
inhibited	O
the	O
LPS	O
-	O
stimulated	O
activation	O
via	O
a	O
major	O
regulation	O
of	O
IRF-3	O
and	O
a	O
regulation	O
of	O
ERK	O
,	O
whereby	O
the	O
phosphorylation	O
in	O
the	O
BV-2	O
microglial	O
cells	O
is	O
blocked	O
.	O
These	O
data	O
suggest	O
that	O
scoparone	B-T121
has	O
anti	O
-	O
neuroinflammatory	O
effects	O
in	O
LPS	O
-	O
activated	O
BV-2	O
microglial	O
cells	O
,	O
and	O
could	O
possibly	O
be	O
used	O
in	O
the	O
development	O
of	O
novel	O
drugs	B-T121
for	O
the	O
prevention	O
and	O
treatment	O
of	O
neuroinflammatory	B-T047
diseases	I-T047
.	O
      
Intra	O
-	O
articular	O
corticosteroids	B-T121
versus	O
intra	O
-	O
articular	O
corticosteroids	B-T121
plus	O
methotrexate	B-T121
in	O
oligoarticular	B-T047
juvenile	I-T047
idiopathic	I-T047
arthritis	I-T047
:	O
a	O
multicentre	O
,	O
prospective	O
,	O
randomised	O
,	O
open	O
-	O
label	O
trial	O
Little	O
evidence	O
-	O
based	O
information	O
is	O
available	O
to	O
guide	O
the	O
treatment	B-T061
of	O
oligoarticular	B-T047
juvenile	I-T047
idiopathic	I-T047
arthritis	I-T047
.	O
We	O
aimed	O
to	O
investigate	O
whether	O
oral	B-T200
methotrexate	I-T200
increases	O
the	O
efficacy	O
of	O
intra	B-T061
-	I-T061
articular	I-T061
corticosteroid	I-T061
therapy	I-T061
.	O
We	O
did	O
this	O
prospective	O
,	O
open	O
-	O
label	O
,	O
randomised	O
trial	O
at	O
ten	O
hospitals	O
in	O
Italy	O
.	O
Using	O
a	O
concealed	O
computer	O
-	O
generated	O
list	O
,	O
children	O
younger	B-T033
than	I-T033
18	O
years	O
with	O
oligoarticular	O
-	O
onset	O
disease	O
were	O
randomly	O
assigned	O
(	O
1:1	O
)	O
to	O
intra	O
-	O
articular	O
corticosteroids	B-T121
alone	O
or	O
in	O
combination	O
with	O
oral	B-T200
methotrexate	I-T200
(	O
15	O
mg	O
/	O
m(2	O
)	O
;	O
maximum	O
20	O
mg	O
)	O
.	O
Corticosteroids	B-T121
used	O
were	O
triamcinolone	B-T121
hexacetonide	I-T121
(	O
shoulder	O
,	O
elbow	O
,	O
wrist	O
,	O
knee	O
,	O
and	O
tibiotalar	O
joints	O
)	O
or	O
methylprednisolone	B-T121
acetate	I-T121
(	O
ie	O
,	O
subtalar	O
and	O
tarsal	O
joints	O
)	O
.	O
We	O
did	O
not	O
mask	O
patients	O
or	O
investigators	O
to	O
treatment	B-T061
assignments	O
.	O
Our	O
primary	O
outcome	O
was	O
the	O
proportion	O
of	O
patients	O
in	O
the	O
intention	O
-	O
to	O
-	O
treat	O
population	O
who	O
had	O
remission	B-T033
of	O
arthritis	B-T047
in	O
all	O
injected	B-T061
joints	O
at	O
12	O
months	O
.	O
This	O
trial	O
is	O
registered	B-T058
with	O
European	B-T058
Union	I-T058
Clinical	I-T058
Trials	I-T058
Register	I-T058
,	O
EudraCT	O
number	O
2008	O
-	O
006741	O
-	O
70	O
.	O
Between	O
July	O
7	O
,	O
2009	O
,	O
and	O
March	O
31	O
,	O
2013	O
,	O
we	O
screened	O
226	O
participants	O
and	O
randomly	O
assigned	O
102	O
to	O
intra	O
-	O
articular	O
corticosteroids	B-T121
alone	O
and	O
105	O
to	O
intra	O
-	O
articular	O
corticosteroids	B-T121
plus	O
methotrexate	B-T121
.	O
33	O
(	O
32	O
%	O
)	O
patients	O
assigned	O
to	O
intra	O
-	O
articular	O
corticosteroids	B-T121
alone	O
and	O
39	O
(	O
37	O
%	O
)	O
assigned	O
to	O
intra	O
-	O
articular	O
corticosteroids	B-T121
and	O
methotrexate	B-T121
therapy	B-T061
had	O
remission	B-T033
of	O
arthritis	B-T047
in	O
all	O
injected	B-T061
joints	O
(	O
p=0·48	O
)	O
.	O
Adverse	O
events	O
were	O
recorded	O
for	O
20	O
(	O
17	O
%	O
)	O
patients	O
who	O
received	O
methotrexate	B-T121
,	O
which	O
led	O
to	O
permanent	O
treatment	B-T061
discontinuation	B-T033
in	O
two	O
patients	O
(	O
one	O
due	O
to	O
increased	B-T033
liver	I-T033
transaminases	I-T033
and	O
one	O
due	O
to	O
gastrointestinal	B-T184
discomfort	I-T184
)	O
.	O
No	B-T033
patient	O
had	O
a	O
serious	O
adverse	O
event	O
.	O
Concomitant	O
administration	O
of	O
methotrexate	B-T121
did	O
not	O
augment	O
the	O
effectiveness	O
of	O
intra	B-T061
-	I-T061
articular	I-T061
corticosteroid	I-T061
therapy	I-T061
.	O
Future	O
studies	O
are	O
needed	O
to	O
define	O
the	O
optimal	O
therapeutic	B-T061
strategies	I-T061
for	O
oligoarticular	B-T047
juvenile	I-T047
idiopathic	I-T047
arthritis	I-T047
.	O
Italian	O
Agency	O
of	O
Drug	O
Evaluation	O
.	O
      
Human	O
Umbilical	O
Cord	O
Blood	O
-	O
Derived	O
Neural	O
Stem	O
Cell	O
Line	O
as	O
a	O
Screening	B-T058
Model	O
for	O
Toxicity	O
The	O
aim	O
was	O
to	O
investigate	O
whether	O
a	O
human	O
neural	O
stem	O
cell	O
(	O
NSC	O
)	O
line	O
derived	O
from	O
human	O
umbilical	O
cord	O
blood	O
(	O
hUCB	O
)	O
can	O
be	O
used	O
for	O
toxicity	O
study	O
.	O
Toxicity	O
of	O
both	O
neurotoxic	O
environmental	O
xenobiotics	O
,	O
methyl	O
mercury	O
chloride	O
(	O
CH3HgCl	O
)	O
,	O
lead	B-T121
acetate	I-T121
(	O
CH3COOPb	B-T121
)	O
,	O
and	O
chlorpyrifos	O
(	O
CP	O
)	O
,	O
and	O
non	B-T033
-	I-T033
neurotoxic	I-T033
insecticide	O
,	O
dichlorvos	O
,	O
as	O
well	O
as	O
non	B-T033
-	I-T033
neurotoxic	I-T033
drugs	B-T121
,	O
theophylline	B-T121
and	O
acetaminophen	B-T121
were	O
assessed	O
.	O
Additionally	O
,	O
differentiation	O
of	O
neuronal	O
and	O
glial	O
cell	O
lines	O
derived	O
from	O
hUCB	O
was	O
elucidated	O
.	O
It	O
was	O
observed	O
that	O
CH3HgCl	O
was	O
more	O
toxic	O
to	O
human	O
NSCs	O
in	O
comparison	O
to	O
CH3COOPb	B-T121
and	O
CP	O
.	O
The	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
value	O
against	O
NSCs	O
was	O
3	O
,	O
10	O
,	O
and	O
300	O
mg	O
/	O
L	O
,	O
in	O
each	O
staining	B-T059
process	I-T059
,	O
acridine	O
orange	O
/	O
ethidium	B-T121
bromide	I-T121
(	O
AO	O
/	O
EB	B-T121
)	O
staining	B-T059
,	O
3-(4,5	B-T121
-	I-T121
dimethylthiazol-2	I-T121
-	I-T121
yl)2,5	I-T121
-	I-T121
diphenyl	I-T121
tetrazolium	I-T121
bromide	I-T121
(	O
MTT	B-T121
)	O
assay	B-T059
,	O
and	O
Hoechst	B-T059
staining	I-T059
,	O
for	O
CH3HgCl	O
,	O
CP	O
,	O
and	O
CH3COOPb	B-T121
,	O
respectively	O
.	O
CH3HgCl	O
had	O
the	O
LC25	O
value	O
as	O
10.0	O
,	O
14.4	O
,	O
and	O
12.7	O
mg	O
/	O
L	O
,	O
by	O
staining	B-T059
method	I-T059
mentioned	O
in	O
succession	O
.	O
CP	O
had	O
the	O
LC25	O
value	O
as	O
21.9	O
,	O
23.7	O
,	O
and	O
18.4	O
mg	O
/	O
L	O
;	O
similarly	O
,	O
CH3COOPb	B-T121
had	O
LC25	O
values	O
,	O
successively	O
as	O
616.9	O
,	O
719.2	O
,	O
and	O
890.3	O
mg	O
/	O
L.	O
LC50	O
values	O
ranged	O
from	O
18.2	O
to	O
21.7	O
mg	O
/	O
L	O
for	O
CH3HgCl	O
,	O
56.4	O
to	O
60.2	O
mg	O
/	O
L	O
for	O
CP	O
,	O
and	O
1000	O
to	O
1460.1	O
for	O
CH3COOPb	B-T121
.	O
Theophylline	B-T121
,	O
acetaminophen	B-T121
,	O
and	O
dichlorvos	O
had	O
no	O
impact	O
on	O
the	O
viability	O
of	O
NSCs	O
.	O
This	O
work	O
justified	O
that	O
hUCB	O
-	O
NSC	O
model	O
can	O
be	O
used	O
for	O
toxicity	O
study	O
.	O
      
An	O
Automated	O
,	O
Pharmacist	O
-Driven	O
Initiative	O
Improves	B-T033
Quality	B-T058
of	I-T058
Care	I-T058
for	O
Staphylococcus	B-T047
aureus	I-T047
Bacteremia	I-T047
Infectious	B-T047
diseases	I-T047
(	O
ID	B-T047
)	O
consultation	B-T058
and	O
antimicrobial	B-T058
stewardship	I-T058
intervention	I-T058
have	O
been	O
shown	O
to	O
improve	B-T033
the	O
management	B-T058
of	O
Staphylococcus	B-T047
aureus	I-T047
bacteremia	I-T047
(	O
SAB	B-T047
)	O
.	O
As	O
the	O
workload	O
of	O
antimicrobial	B-T058
stewardship	I-T058
programs	I-T058
(	O
ASPs	B-T058
)	O
continues	O
to	O
increase	O
,	O
ASPs	B-T058
must	O
find	O
a	O
way	O
to	O
maximize	O
the	O
efficiency	O
of	O
the	O
program	O
while	O
optimizing	O
patient	O
outcomes	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	B-T058
the	O
impact	O
of	O
incorporating	O
health	O
informatics	O
into	O
the	O
management	B-T058
of	O
SAB	B-T047
via	O
a	O
pharmacist	O
-driven	O
initiative	O
.	O
Retrospective	O
,	O
single	O
-	O
center	O
quasi	O
-	O
experimental	O
study	O
of	O
hospitalized	O
patients	O
with	O
SAB	B-T047
.	O
During	O
the	O
intervention	B-T061
period	O
,	O
pharmacists	O
were	O
alerted	O
to	O
patients	O
with	O
SAB	B-T047
via	O
a	O
patient	O
scoring	O
tool	O
integrated	O
into	O
the	O
electronic	O
medical	O
record	O
.	O
Pharmacists	O
utilized	O
the	O
scoring	O
tool	O
and	O
the	O
institution	O
's	O
evidence	O
-	O
based	O
practice	O
guideline	O
to	O
make	O
standardized	O
recommendations	O
to	O
promote	O
adherence	O
to	O
SAB	B-T047
quality	B-T058
-	I-T058
of	I-T058
-	I-T058
care	I-T058
measures	O
and	O
encourage	O
ID	B-T047
consultation	B-T058
.	O
The	O
primary	O
outcome	O
was	O
overall	O
compliance	B-T033
along	O
with	O
adherence	O
to	O
individual	O
quality	B-T058
-	I-T058
of	I-T058
-	I-T058
care	I-T058
components	O
.	O
Secondary	O
clinical	O
outcomes	O
were	O
also	O
analyzed	O
.	O
84	O
patients	O
were	O
identified	O
for	O
study	O
inclusion	O
,	O
45	O
in	O
the	O
pre-	O
intervention	B-T061
and	O
39	O
in	O
the	O
intervention	B-T061
group	O
.	O
As	O
a	O
whole	O
,	O
all	O
four	O
quality	B-T058
-	I-T058
of	I-T058
-	I-T058
care	I-T058
components	O
for	O
the	O
management	B-T058
of	O
SAB	B-T047
were	O
significantly	O
more	O
frequently	O
adhered	O
to	O
in	O
the	O
intervention	B-T061
group	O
(	O
68.9	O
%	O
vs.	O
92.3	O
%	O
;	O
P=0.008	O
)	O
.	O
The	O
incidence	O
of	O
ID	B-T047
consult	B-T058
improved	B-T033
significantly	O
by	O
almost	O
20	O
%	O
in	O
the	O
intervention	B-T061
group	O
(	O
75.6	O
%	O
vs.	O
94.9	O
%	O
,	O
P=0.015	O
)	O
.	O
No	O
statistically	O
significant	O
differences	O
in	O
duration	O
of	O
bacteremia	B-T047
,	O
length	O
-	O
of	O
-	O
stay	O
,	O
infection	O
-related	O
length	O
-	O
of	O
-	O
stay	O
,	O
or	O
readmission	B-T058
were	O
observed	O
between	O
the	O
groups	O
.	O
The	O
incidence	O
of	O
all	O
-	O
cause	O
mortality	O
was	O
6	O
-	O
fold	O
higher	O
in	O
the	O
pre-	O
intervention	B-T061
group	O
compared	O
to	O
the	O
intervention	B-T061
group	O
(	O
15.6	O
%	O
vs.	O
2.6	O
%	O
,	O
P=0.063	O
)	O
.	O
An	O
automated	O
,	O
pharmacist	O
-driven	O
intervention	B-T061
for	O
the	O
management	B-T058
of	O
patients	O
with	O
SAB	B-T047
demonstrated	O
a	O
significant	O
improvement	O
in	O
patients	O
receiving	O
an	O
ID	B-T047
consult	B-T058
,	O
targeted	O
antimicrobial	B-T121
therapy	I-T121
,	O
and	O
adherence	O
to	O
all	O
SAB	B-T047
quality	B-T058
-	I-T058
of	I-T058
-	I-T058
care	I-T058
measures	O
.	O
As	O
antimicrobial	B-T058
stewardship	I-T058
becomes	O
a	O
mandatory	O
aspect	O
of	O
healthcare	B-T058
in	O
all	O
hospitals	O
in	O
the	O
U.S.	O
,	O
ASPs	B-T058
will	O
be	O
forced	O
to	O
find	B-T033
ways	O
to	O
provide	O
more	O
efficient	O
,	O
impactful	O
,	O
disease	B-T047
state	O
-	O
based	O
patient	B-T058
care	I-T058
.	O
Our	O
study	O
provides	O
the	O
framework	O
for	O
and	O
data	O
to	O
support	O
this	O
intervention	B-T061
in	O
one	O
of	O
the	O
most	O
clinically	O
important	O
infectious	B-T047
diseases	I-T047
.	O
      
Expressing	O
sexuality	O
in	O
nursing	O
homes	O
.	O
The	O
experience	O
of	O
older	O
women	O
:	O
A	O
qualitative	O
study	O
In	O
nursing	O
homes	O
,	O
a	O
number	O
of	O
barriers	O
to	O
the	O
expression	O
of	O
sexuality	O
exist	O
,	O
such	O
as	O
the	O
lack	B-T033
of	I-T033
privacy	I-T033
,	O
certain	O
attitudes	O
on	O
behalf	O
of	O
the	O
staff	O
and	O
the	O
family	O
,	O
the	O
lack	O
of	O
a	O
sexual	O
partner	O
,	O
and	O
physical	B-T033
limitations	I-T033
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
lived	O
experience	O
of	O
sexuality	O
in	O
elderly	O
Spanish	O
women	O
residing	O
in	O
nursing	O
homes	O
.	O
A	O
qualitative	O
phenomenological	O
approach	O
was	O
followed	O
.	O
Data	O
were	O
collected	O
over	O
an	O
18-	O
month	O
period	O
between	O
2013	O
and	O
2015	O
.	O
Purposeful	O
sampling	O
was	O
conducted	O
with	O
Spanish	O
residents	O
in	O
nursing	O
homes	O
in	O
Madrid	O
.	O
Data	O
were	O
collected	O
using	O
unstructured	O
and	O
semi	O
-	O
structured	O
interviews	O
.	O
The	O
data	O
were	O
analyzed	O
using	O
thematic	O
analysis	O
.	O
Twenty	O
female	O
residents	O
participated	O
.	O
Three	O
main	O
themes	O
emerged	O
from	O
the	O
data	O
:	O
a	O
)	O
expressing	O
sexuality	O
,	O
b	O
)	O
sexuality	O
as	O
a	O
duty	B-T058
and	O
c	O
)	O
respecting	O
vows	O
.	O
Female	O
residents	O
reported	O
key	O
elements	O
influencing	O
how	O
they	O
manage	B-T058
their	O
sexuality	O
in	O
Nursing	O
Homes	O
.	O
These	O
results	O
serve	O
to	O
improve	O
our	O
understanding	O
regarding	O
the	O
expression	O
of	O
sexuality	O
in	O
older	O
female	O
nursing	O
home	O
residents	O
.	O
      
Epigenetic	O
Editing	O
of	O
Ascl1	O
Gene	O
in	O
Neural	O
Stem	O
Cells	O
by	O
Optogenetics	O
Enzymes	O
involved	O
in	O
epigenetic	O
processes	O
such	O
as	O
methyltransferases	O
or	O
demethylases	O
are	O
becoming	O
highly	O
utilized	O
for	O
their	O
persistent	O
DNA	O
or	O
histone	O
modifying	O
efficacy	O
.	O
Herein	O
,	O
we	O
have	O
developed	O
an	O
optogenetic	O
toolbox	O
fused	O
to	O
the	O
catalytic	O
domain	O
(	O
CD	O
)	O
of	O
DNA	O
-	O
methyltransferase3A	O
(	O
DNMT3A	O
-	O
CD	O
)	O
or	O
Ten	O
-	O
Eleven	O
Dioxygenase-1	O
(	O
TET1	O
-	O
CD	O
)	O
for	O
loci	O
-	O
specific	O
alteration	O
of	O
the	O
methylation	O
state	O
at	O
the	O
promoter	O
of	O
Ascl1	O
(	O
Mash1	O
)	O
,	O
a	O
candidate	O
proneuron	O
gene	O
.	O
Optogenetical	O
protein	O
pairs	O
,	O
CRY2	O
linked	O
to	O
DNMT3A	O
-	O
CD	O
or	O
TET1	O
-	O
CD	O
and	O
CIB1	O
fused	O
to	O
a	O
Transcription	O
Activator	O
-	O
Like	O
Element	O
(	O
TALE	O
)	O
locating	O
an	O
Ascl1	O
promoter	O
region	O
,	O
were	O
designed	O
for	O
site	O
specific	O
epigenetic	O
editing	O
.	O
A	O
differentially	O
methylated	O
region	O
at	O
the	O
Ascl1	O
promoter	O
,	O
isolated	O
from	O
murine	O
dorsal	B-T023
root	I-T023
ganglion	I-T023
(	O
hypermethylated	O
)	O
and	O
striated	O
cells	O
(	O
hypomethylated	O
)	O
,	O
was	O
targeted	O
with	O
these	O
optogenetic	O
-	O
epigenetic	O
constructs	O
.	O
Optimized	O
blue	O
-	O
light	O
illumination	B-T059
triggered	O
the	O
co	O
-	O
localization	O
of	O
TALE	O
constructs	O
with	O
DNMT3A	O
-	O
CD	O
or	O
TET1	O
-	O
CD	O
fusion	O
proteins	O
at	O
the	O
targeted	O
site	O
of	O
the	O
Ascl1	O
promoter	O
.	O
We	O
found	O
that	O
this	O
spatiotemporal	O
association	O
of	O
the	O
fusion	O
proteins	O
selectively	O
alters	O
the	O
methylation	O
state	O
and	O
also	O
regulates	O
gene	O
activity	O
.	O
This	O
proof	O
of	O
concept	O
developed	O
herein	O
holds	O
immense	O
promise	O
for	O
the	O
ability	O
to	O
regulate	O
gene	O
activity	O
via	O
epigenetic	O
modulation	O
with	O
spatiotemporal	O
precision	O
.	O
      
Modulation	O
of	O
IL-6	O
induced	O
RANKL	O
expression	O
in	O
arthritic	B-T047
synovium	B-T023
by	O
a	O
transcription	O
factor	O
SOX5	O
Receptor	O
activator	O
of	O
nuclear	O
factor	O
κB	O
ligand	O
(	O
RANKL	O
)	O
is	O
critically	O
involved	O
in	O
bone	O
erosion	O
of	O
rheumatoid	B-T047
arthritis	I-T047
(	O
RA	B-T047
)	O
.	O
We	O
previously	O
reported	O
association	O
between	O
younger	O
age	O
at	O
onset	O
of	O
RA	B-T047
and	O
a	O
RANKL	O
promoter	O
SNP	O
that	O
conferred	O
an	O
elevated	O
promoter	O
activity	O
via	O
binding	O
to	O
a	O
transcription	O
factor	O
SOX5	O
.	O
Here	O
we	O
study	O
the	O
regulation	O
of	O
SOX5	O
levels	O
in	O
relation	O
to	O
RANKL	O
expression	O
in	O
RA	B-T047
synovial	B-T023
fibroblasts	O
(	O
SF	O
)	O
and	O
the	O
development	O
of	O
bone	O
erosion	O
in	O
the	O
collagen	B-T050
-	I-T050
induced	I-T050
arthritis	I-T050
(	O
CIA	B-T050
)	O
mouse	O
.	O
Our	O
data	O
indicated	B-T033
SOX5	O
levels	O
were	O
higher	O
in	O
synovium	B-T023
and	O
synovial	O
fluid	O
from	O
RA	B-T047
compared	O
to	O
osteoarthritis	B-T047
patients	O
.	O
Pro	O
-	O
inflammatory	O
cytokines	O
upregulated	O
SOX5	O
and	O
RANKL	O
expression	O
in	O
both	O
primary	O
RA	B-T047
SF	O
and	O
the	O
rheumatoid	O
synovial	O
fibroblast	O
cell	O
line	O
,	O
MH7A.	O
Overexpression	O
of	O
SOX5	O
resulted	O
in	O
significantly	O
increased	O
RANKL	O
levels	O
,	O
while	O
knockdown	O
of	O
SOX5	O
resulted	O
in	O
diminished	O
IL-6	O
mediated	O
RANKL	O
upregulation	O
in	O
MH7A	O
cells	O
.	O
Chromatin	B-T059
immunoprecipitation	I-T059
(	O
ChIP	B-T059
)	O
showed	O
approximately	O
3	O
-	O
fold	O
enrichment	O
of	O
RANKL	O
-	O
specific	O
DNA	O
in	O
anti	O
-	O
SOX5	O
immunoprecipitate	O
in	O
IL-6	O
treated	O
MH7A	O
cells	O
as	O
compared	O
to	O
untreated	B-T033
cells	I-T033
.	O
Locally	O
silencing	O
SOX5	O
gene	O
significantly	O
diminished	O
RANKL	O
positive	B-T033
cells	O
and	O
bone	O
erosion	O
in	O
CIA	B-T050
mice	O
.	O
These	O
findings	B-T033
suggest	O
SOX5	O
is	O
an	O
important	O
regulator	O
of	O
IL-6	O
-	O
induced	O
RANKL	O
expression	O
in	O
RA	B-T047
SF	O
.	O
      
Transfemoral	B-T061
aortic	I-T061
valve	I-T061
implantation	I-T061
with	O
the	O
repositionable	O
Lotus	O
valve	O
for	O
treatment	B-T061
of	O
patients	O
with	O
symptomatic	O
severe	O
aortic	B-T047
stenosis	I-T047
:	O
results	O
from	O
a	O
single	O
-	O
centre	O
experience	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	B-T058
the	O
procedural	O
and	O
30-	O
day	O
results	O
for	O
the	O
repositionable	O
Lotus	O
valve	O
in	O
patients	O
undergoing	O
transfemoral	B-T061
aortic	I-T061
valve	I-T061
implantation	I-T061
in	O
a	O
single	O
-	O
centre	O
experience	O
.	O
We	O
prospectively	O
enrolled	O
110	O
patients	O
with	O
severe	O
symptomatic	O
aortic	B-T047
stenosis	I-T047
(	O
NCT02162069	O
)	O
.	O
All	O
procedures	O
were	O
performed	O
without	O
general	B-T061
anaesthesia	I-T061
by	O
the	O
transfemoral	B-T061
approach	I-T061
.	O
Patients	O
were	O
followed	O
for	O
30	O
days	O
.	O
Patients	O
received	O
the	O
23	O
mm	O
(	O
n=20	O
)	O
,	O
25	O
mm	O
(	O
n=43	O
)	O
or	O
27	O
mm	O
(	O
n=47	O
)	O
Lotus	O
device	O
.	O
Mean	O
oversizing	O
in	O
relation	O
to	O
annulus	O
or	O
left	B-T023
ventricular	I-T023
outflow	I-T023
tract	I-T023
(	O
LVOT	B-T023
)	O
did	O
not	O
differ	O
among	O
groups	O
.	O
There	O
was	O
no	O
residual	O
moderate	O
or	O
severe	O
aortic	B-T047
regurgitation	I-T047
.	O
The	O
rate	O
of	O
mild	O
aortic	B-T047
regurgitation	I-T047
was	O
low	O
at	O
9.1	O
%	O
.	O
There	O
was	O
no	O
valve	B-T023
embolisation	B-T061
,	O
no	O
need	O
for	O
a	O
second	O
valve	B-T023
and	O
no	B-T033
conversion	I-T033
to	O
surgery	B-T061
.	O
The	O
need	O
for	O
a	O
new	O
pacemaker	B-T061
implantation	I-T061
due	O
to	O
complete	B-T047
(	O
third	B-T047
degree	I-T047
)	O
or	O
type	B-T047
II	I-T047
(	I-T047
Mobitz	I-T047
)	I-T047
second	I-T047
degree	I-T047
atrioventricular	I-T047
block	I-T047
was	O
24.1	O
%	O
,	O
excluding	O
patients	O
with	O
previously	O
implanted	B-T061
devices	I-T061
.	O
Within	O
30	O
days	O
the	O
rates	O
of	O
all	O
-	O
cause	O
mortalit	O
y	O
and	O
stroke	B-T047
were	O
low	O
.	O
In	O
patients	O
with	O
severe	O
aortic	B-T047
stenosis	I-T047
,	O
transfemoral	B-T061
TAVI	I-T061
with	O
the	O
repositionable	O
Lotus	O
valve	O
was	O
associated	O
with	O
a	O
high	O
rate	O
of	O
device	O
success	O
,	O
no	O
moderate	O
or	O
severe	O
residual	O
aortic	B-T047
regurgitation	I-T047
,	O
low	O
rates	O
of	O
major	O
vascular	B-T047
complications	I-T047
and	O
mortality	O
within	O
30	O
days	O
.	O
      
Association	O
between	O
XRCC1	O
and	O
ERCC1	O
single	O
-	O
nucleotide	O
polymorphisms	O
and	O
the	O
efficacy	O
of	O
concurrent	B-T061
radiochemotherapy	I-T061
in	O
patients	O
with	O
esophageal	B-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
association	O
between	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
X	O
-	O
ray	O
repair	O
cross	O
-	O
complementing	O
1	O
-	O
399	O
(	O
XRCC1	O
-	O
399	O
)	O
or	O
excision	O
repair	O
cross	O
-	O
complementation	O
group	O
1	O
-	O
118	O
(	O
ERCC1	O
-	O
118	O
)	O
and	O
the	O
short	O
-	O
term	O
efficacy	O
of	O
radiochemotherapy	B-T061
,	O
tumor	B-T191
metastasis	I-T191
and	O
relapse	O
,	O
as	O
well	O
as	O
the	O
survival	O
time	O
in	O
patients	O
with	O
esophageal	B-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
(	O
ESCC	B-T191
)	O
.	O
TaqMan	O
probe	O
-	O
based	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
qPCR	O
)	O
was	O
conducted	O
to	O
examine	B-T033
the	O
levels	O
of	O
XRCC1	O
-	O
399	O
and	O
ERCC1	O
-	O
118	O
SNPs	O
in	O
the	O
peripheral	O
blood	O
of	O
50	O
patients	O
with	O
pathologically	O
confirmed	B-T033
ESCC	B-T191
.	O
In	O
addition	O
,	O
the	O
associations	O
between	O
different	O
genotypes	O
and	O
short	O
-	O
term	O
therapeutic	O
efficacy	O
[	O
the	O
complete	B-T033
remission	I-T033
(	O
CR	B-T033
)	O
rate	O
]	O
,	O
tumor	B-T191
metastasis	I-T191
and	O
relapse	O
,	O
as	O
well	O
as	O
the	O
survival	O
time	O
following	O
concurrent	B-T061
radiochemotherapy	I-T061
,	O
were	O
determined	O
.	O
A	O
total	O
of	O
50	O
ESCC	B-T191
patients	O
who	O
received	O
concurrent	B-T061
radiochemotherapy	I-T061
were	O
enrolled	O
.	O
It	O
was	O
found	O
that	O
the	O
short	O
-	O
term	O
therapeutic	O
efficacy	O
(	O
CR	B-T033
rate	O
)	O
was	O
higher	O
in	O
the	O
group	O
of	O
patients	O
carrying	O
the	O
homozygous	O
mutation	O
of	O
XRCC1	O
-	O
399	O
(	O
A	B-T121
/	O
A	B-T121
genotype	O
)	O
than	O
in	O
the	O
group	O
of	O
patients	O
without	O
the	O
XRCC1	O
-	O
399	O
mutation	O
(	O
G	B-T121
/	O
G	B-T121
genotype	O
)	O
.	O
In	O
addition	O
,	O
the	O
CR	B-T033
rate	O
was	O
significantly	O
increased	O
in	O
patients	O
carrying	O
one	O
or	O
two	O
ERCC1	O
-	O
118	O
C	O
alleles	O
(	O
C	O
/	O
C	O
or	O
C	O
/	O
T	O
genotype	O
)	O
compared	O
with	O
patients	O
lacking	O
the	O
C	O
allele	O
(	O
T	O
/	O
T	O
genotype	O
)	O
.	O
The	O
differences	O
were	O
statistically	O
significant	O
(	O
A	B-T121
/	O
A	B-T121
vs.	O
G	B-T121
/	O
G	B-T121
,	O
P=0.014	O
;	O
T	O
T	O
vs.	O
C	O
/	O
T	O
+	O
C	O
/	O
C	O
,	O
P=0.040	O
)	O
.	O
During	O
the	O
follow	B-T033
-	I-T033
up	I-T033
period	I-T033
,	O
the	O
group	O
of	O
patients	O
carrying	O
the	O
homozygous	O
mutation	O
of	O
XRCC1	O
-	O
399	O
(	O
A	B-T121
/	O
A	B-T121
genotype	O
)	O
exhibited	O
a	O
markedly	O
reduced	O
risk	O
of	O
metastasis	O
and	O
relapse	O
compared	O
with	O
the	O
group	O
of	O
patients	O
carrying	O
non	O
-	O
mutated	O
XRCC1	O
-	O
399	O
(	O
G	B-T121
/	O
G	B-T121
genotype	O
;	O
P=0.031	O
)	O
.	O
By	O
contrast	O
,	O
ERCC1	O
-	O
118	O
SNP	O
was	O
not	O
associated	O
with	O
the	O
risk	O
of	O
metastasis	O
and	O
recurrence	O
(	O
P>0.05	O
)	O
.	O
The	O
combined	O
results	O
of	O
univariate	O
and	O
multivariate	O
Cox	O
regression	O
analysis	O
showed	O
that	O
the	O
SNP	O
in	O
ERCC1	O
-	O
118	O
was	O
closely	O
associated	O
with	O
survival	O
time	O
.	O
The	O
mean	O
survival	O
time	O
was	O
significantly	O
prolonged	O
in	O
patients	O
carrying	O
1	O
or	O
2	O
C	O
alleles	O
(	O
C	O
/	O
C	O
or	O
C	O
/	O
T	O
genotype	O
)	O
compared	O
with	O
patients	O
lacking	O
the	O
C	O
allele	O
(	O
T	O
/	O
T	O
genotype	O
)	O
[	O
T	O
/	O
T	O
vs.	O
C	O
/	O
C	O
,	O
HR	O
=	O
12.96	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI)=3.08	O
-	O
54.61	O
,	O
P<0.001	O
;	O
T	O
T	O
vs.	O
C	O
/	O
T	O
+	O
C	O
/	O
C	O
,	O
HR	O
=	O
11.71	O
,	O
95	O
%	O
CI	O
=	O
3.06	O
-	O
44.83	O
,	O
P<0.001	O
]	O
.	O
However	O
,	O
XRCC1	O
-	O
399	O
SNP	O
had	O
no	O
effect	O
on	O
survival	O
time	O
(	O
P>0.05	O
)	O
.	O
XRCCl-399	O
SNP	O
was	O
associated	O
with	O
the	O
short	O
-	O
term	O
therapeutic	O
efficacy	O
(	O
the	O
CR	B-T033
rate	O
)	O
and	O
tumor	B-T191
metastasis	I-T191
/	O
relapse	O
in	O
ESCC	B-T191
patients	O
who	O
received	O
the	O
docetaxel	B-T061
plus	I-T061
cisplatin	I-T061
(	I-T061
TP	I-T061
)	I-T061
regimen	I-T061
-based	O
concurrent	B-T061
radiochemotherapy	I-T061
.	O
By	O
contrast	O
,	O
ERCC1	O
-	O
118	O
SNP	O
was	O
significantly	O
associated	O
with	O
the	O
short	O
-	O
term	O
therapeutic	O
efficacy	O
(	O
the	O
CR	B-T033
rate	O
)	O
and	O
survival	O
time	O
in	O
ESCC	B-T191
patients	O
who	O
received	O
TP	B-T061
regimen	I-T061
-based	O
concurrent	B-T061
radiochemotherapy	I-T061
.	O
      
Eliminating	O
Cancer	O
Stem	O
Cells	O
in	O
CML	B-T191
with	O
Combination	O
Transcriptional	O
Therapy	B-T061
Leukemia	B-T191
stem	O
cells	O
(	O
LSCs	O
)	O
are	O
resistant	O
to	O
current	O
therapies	B-T061
used	O
to	O
treat	O
chronic	B-T191
myeloid	I-T191
leukemia	I-T191
(	O
CML	B-T191
)	O
.	O
Abraham	O
et	O
al	O
.	O
(	O
2016	O
)	O
have	O
identified	O
a	O
molecular	O
network	O
critical	O
for	O
CML	B-T191
LSC	O
survival	O
and	O
propose	O
that	O
simultaneously	O
targeting	O
two	O
of	O
their	O
major	O
transcriptional	O
regulators	O
,	O
p53	O
and	O
c	O
-	O
Myc	O
,	O
may	O
facilitate	O
their	O
eradication	O
.	O
      
Family	O
close	B-T033
but	O
friends	O
closer	B-T033
:	O
exploring	O
social	O
support	O
and	O
resilience	O
in	O
older	O
spousal	O
dementia	B-T048
carers	O
Spousal	O
dementia	B-T048
carers	O
have	O
unique	O
support	O
needs	O
;	O
they	O
are	O
likely	O
to	O
disengage	O
from	O
their	O
existing	O
social	O
networks	O
as	O
they	O
need	O
to	O
devote	O
more	O
time	O
to	O
caring	O
as	O
the	O
disease	O
progresses	O
.	O
Previously	O
we	O
showed	O
that	O
support	O
resources	O
can	O
facilitate	O
resilience	O
in	O
carers	O
,	O
but	O
the	O
relationship	O
is	O
complex	O
and	O
varies	O
by	O
relationship	O
type	O
.	O
The	O
current	O
paper	O
aims	O
to	O
explore	O
social	O
support	O
as	O
a	O
key	O
component	O
of	O
resilience	O
to	O
identify	O
the	O
availability	O
,	O
function	O
and	O
perceived	O
functional	O
aspects	O
of	O
support	O
provided	O
to	O
older	O
spousal	O
dementia	B-T048
carers	O
.	O
We	O
conducted	O
23	O
in	O
-	O
depth	O
qualitative	O
interviews	O
with	O
spousal	O
carers	O
from	O
two	O
carer	O
support	O
groups	O
and	O
a	O
care	O
home	O
in	O
North	O
West	O
England	O
.	O
Family	O
and	O
friends	O
served	O
a	O
wide	O
range	O
of	O
functions	O
but	O
were	O
equally	O
available	O
to	O
resilient	O
and	O
non	O
-	O
resilient	O
participants	O
.	O
Family	B-T061
support	I-T061
was	O
perceived	O
as	O
unhelpful	O
if	O
it	O
created	O
feelings	O
of	O
over	O
-	O
dependence	O
.	O
Participants	O
were	O
less	O
likely	O
to	O
resist	O
involvement	O
of	O
grandchildren	O
due	O
to	O
their	O
relatively	O
narrow	O
and	O
low	O
-	O
level	O
support	O
functions	O
.	O
Friend	O
support	O
was	O
perceived	O
as	O
most	O
helpful	O
when	O
it	O
derived	O
from	O
those	O
in	O
similar	O
circumstances	O
.	O
Neighbours	O
played	O
a	O
functionally	O
unique	O
role	O
of	O
crisis	B-T061
management	I-T061
.	O
These	O
perceptions	O
may	O
moderate	O
the	O
effect	O
of	O
support	O
on	O
resilience	O
.	O
Family	B-T061
and	O
friend	O
support	O
is	O
not	O
always	O
sufficient	O
to	O
facilitate	O
resilience	O
.	O
Support	O
functions	O
facilitate	O
resilience	O
only	O
if	O
they	O
are	O
perceived	O
to	O
match	O
need	O
.	O
Implications	B-T033
of	O
these	O
findings	O
are	O
discussed	O
.	O
      
Pupillary	O
response	O
abnormalities	B-T033
in	O
depressive	B-T048
disorders	I-T048
Depressive	B-T048
disorders	I-T048
lack	O
objective	O
physiological	O
measurements	O
to	O
characterize	O
the	O
affected	O
population	O
and	O
facilitate	O
study	O
of	O
relevant	O
mechanisms	O
.	O
The	O
melanopsin	O
-	O
mediated	O
light	O
signaling	O
pathway	O
may	O
contribute	O
to	O
seasonal	O
variation	O
and	O
can	O
be	O
measured	O
non	O
-	O
invasively	O
by	O
pupillometry	B-T060
.	O
We	O
prospectively	O
studied	O
changes	O
in	O
melanopsin	O
-	O
mediated	O
pupillary	O
constriction	O
in	O
19	O
participants	O
with	O
major	B-T048
depressive	I-T048
disorder	I-T048
(	O
MDD	B-T048
)	O
and	O
10	O
control	O
across	O
the	O
summer	O
and	O
winter	O
solstices	O
.	O
The	O
melanopsin	O
-	O
mediated	O
response	O
,	O
as	O
measured	O
by	O
the	O
pupil	B-T033
's	I-T033
sustained	I-T033
constriction	I-T033
six	O
s	O
after	O
a	O
high	O
intensity	O
blue	O
light	O
stimulus	O
,	O
was	O
marginally	O
attenuated	O
in	O
those	O
with	O
MDD	B-T048
relative	O
to	O
controls	O
(	O
p	O
=	O
0.071	O
)	O
.	O
The	O
participants	O
with	O
MDD	B-T048
unexpectedly	O
showed	O
a	O
significantly	O
reduced	O
transient	O
pupillary	O
response	O
to	O
low	O
intensity	O
red	O
(	O
p	O
=	O
0.011	O
)	O
and	O
blue	O
light	O
(	O
p	O
=	O
0.013	O
)	O
,	O
but	O
not	O
high	O
intensity	O
red	O
and	O
blue	O
light	O
.	O
Sustained	O
pupillary	O
constriction	O
in	O
response	O
to	O
high	O
intensity	O
blue	O
light	O
was	O
more	O
pronounced	O
with	O
increasing	O
daylight	O
hours	O
(	O
p	O
=	O
0.037	O
)	O
and	O
was	O
more	O
strongly	O
related	O
to	O
objectively	O
measured	O
versus	O
estimated	O
light	O
exposure	O
.	O
Melanopsin	O
-	O
mediated	O
impairments	O
in	O
pupil	O
response	O
may	O
serve	O
as	O
a	O
biological	O
marker	O
for	O
vulnerability	B-T033
to	O
depression	B-T048
in	O
low	O
light	O
conditions	O
.	O
Assessment	B-T058
of	O
these	O
and	O
other	O
responses	O
to	O
light	O
stimuli	O
,	O
such	O
as	O
response	O
to	O
low	O
intensity	O
light	O
,	O
may	O
be	O
useful	O
for	O
the	O
study	O
of	O
the	O
neurobiology	O
of	O
MDD	B-T048
and	O
related	O
mood	B-T048
disorders	I-T048
.	O
      
Prostate	O
-	O
specific	O
antigen	O
increase	O
during	O
dutasteride	B-T121
to	O
indicate	O
the	O
need	O
for	O
prostate	B-T060
biopsy	I-T060
:	O
influence	O
of	O
prostatic	B-T047
inflammation	I-T047
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
significance	O
of	O
an	O
increase	O
in	O
total	B-T059
prostate	I-T059
-	I-T059
specific	I-T059
antigen	I-T059
(	I-T059
PSA	I-T059
)	I-T059
serum	I-T059
levels	I-T059
despite	O
dutasteride	B-T121
treatment	B-T061
as	O
a	O
predictor	O
of	O
prostate	B-T191
cancer	I-T191
(	O
PC	B-T191
)	O
at	O
biopsy	B-T060
.	O
We	O
focused	O
our	O
attention	O
on	O
the	O
rate	O
of	O
the	O
first	O
PSA	O
increase	O
and	O
on	O
the	O
influence	O
of	O
prostatic	B-T047
inflammation	I-T047
.	O
From	O
2011	O
to	O
2016	O
,	O
365	O
men	O
with	O
a	O
previous	O
negative	O
prostate	B-T060
biopsy	I-T060
and	O
persistent	O
elevated	O
PSA	B-T059
levels	I-T059
received	O
dutasteride	B-T121
treatment	B-T061
.	O
The	O
population	O
was	O
followed	O
for	O
a	O
range	O
of	O
12	O
-	O
48	O
months	O
.	O
One	O
hundred	O
twelve	O
cases	O
with	O
a	O
confirmed	O
PSA	O
increase	O
>	O
0.5	O
ng	O
/	O
ml	O
over	O
the	O
nadir	O
value	O
during	O
the	O
follow	B-T058
-	I-T058
up	I-T058
were	O
included	O
in	O
Group	O
A	O
and	O
underwent	O
a	O
new	O
prostate	B-T060
biopsy	I-T060
.	O
In	O
Group	O
A	O
,	O
the	O
PSA	O
increase	O
was	O
associated	O
with	O
PC	B-T191
at	O
the	O
re	B-T060
-	I-T060
biopsy	I-T060
in	O
66	O
%	O
of	O
cases	O
.	O
The	O
percentage	O
of	O
PSA	B-T033
reduction	I-T033
after	O
6	O
months	O
of	O
treatment	B-T061
was	O
not	O
a	O
significant	O
indicator	O
of	O
the	O
risk	O
for	O
PC	B-T191
.	O
The	O
distribution	O
of	O
inflammatory	B-T033
infiltrates	I-T033
significantly	O
(	O
p<00.01	O
)	O
varied	O
from	O
positive	O
to	O
negative	O
prostate	B-T060
biopsies	I-T060
.	O
The	O
relative	O
risk	O
for	O
PC	B-T191
at	O
biopsy	B-T060
significantly	O
increase	O
d	O
according	O
to	O
PSA	B-T059
level	I-T059
during	O
dutasteride	B-T121
.	O
Treatment	B-T061
with	O
dutasteride	B-T121
can	O
help	O
to	O
analyze	O
PSA	O
kinetic	O
.	O
A	O
persistent	O
prostatic	B-T047
inflammation	I-T047
is	O
a	O
factor	O
able	O
to	O
reduce	O
the	O
performance	O
of	O
PSA	O
kinetic	O
during	O
dutasteride	B-T121
treatment	B-T061
.	O
      
Polymorphisms	O
in	O
Inflammatory	O
Mediator	O
Genes	O
and	O
Risk	O
of	O
Preeclampsia	O
in	O
Taiyuan	O
,	O
China	O
Excessive	O
maternal	B-T033
inflammatory	O
response	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
preeclampsia	O
.	O
Few	O
epidemiologic	O
studies	O
have	O
investigated	O
the	O
associations	O
between	O
genetic	O
variations	O
in	O
the	O
inflammatory	O
mediator	O
genes	O
and	O
preeclampsia	O
risk	O
,	O
and	O
these	O
studies	O
have	O
reached	O
inconsistent	O
results	O
.	O
We	O
examined	O
31	O
single	O
-	O
nucleotide	O
polymorphisms	O
in	O
IL-1A	O
,	O
IL-1B	O
,	O
IL-1R1	O
,	O
IL-2RA	O
,	O
IL-5RA	O
,	O
IL-6	O
,	O
IL-6R	O
,	O
TNFSF11	O
,	O
TNFRSF11A	O
,	O
IL-28RA	O
,	O
IRAK4	O
,	O
and	O
KIT	O
genes	O
and	O
the	O
risk	O
of	O
preeclampsia	O
and	O
its	O
clinical	O
subtypes	O
in	O
a	O
nested	O
case	O
-	O
control	O
study	O
including	O
203	O
preeclampsia	O
cases	O
and	O
233	O
controls	O
.	O
We	O
found	O
that	O
IL-1R1	O
,	O
IL-5RA	O
,	O
IL-6R	O
,	O
and	O
TNFSF11	O
were	O
associated	O
with	O
the	O
risk	O
of	O
preeclampsia	O
.	O
Although	O
the	O
significant	O
associations	O
observed	O
for	O
preeclampsia	O
overall	O
were	O
mainly	O
seen	O
for	O
late	O
-	O
onset	O
preeclampsia	O
and	O
severe	O
preeclampsia	O
,	O
IL-6R	O
(	O
rs2229238	O
)	O
and	O
TNFSF11	O
(	O
rs9525643	O
)	O
polymorphisms	O
were	O
associated	O
with	O
the	O
risk	O
of	O
early	O
-	O
onset	O
preeclampsia	O
.	O
TNFSF11	O
(	O
rs2200287	O
and	O
rs2148072	O
)	O
polymorphisms	O
were	O
associated	O
with	O
risk	O
of	O
mild	O
preeclampsia	O
.	O
Our	O
study	O
provided	O
the	O
first	O
evidence	O
that	O
genetic	O
variations	O
in	O
inflammatory	O
mediator	O
genes	O
IL-1R1	O
,	O
IL-6R	O
,	O
TNFSF11	O
,	O
and	O
IL-5RA	O
were	O
associated	O
with	O
preeclampsia	O
risk	O
,	O
and	O
the	O
risk	O
varied	O
by	O
preeclampsia	O
subtypes	O
.	O
      
The	O
effects	O
of	O
gestational	O
use	O
of	O
antidepressants	B-T121
and	O
antipsychotics	B-T121
on	O
neonatal	O
outcomes	O
for	O
women	O
with	O
severe	O
mental	B-T048
illness	I-T048
Psychotropic	B-T121
medication	I-T121
use	O
occurs	O
in	O
8	O
%	O
of	O
pregnancies	O
,	O
with	O
rates	B-T033
increasing	O
,	O
and	O
often	O
multiple	O
medications	B-T121
prescribed	B-T058
.	O
This	O
study	O
aims	O
to	O
determine	O
if	O
the	O
use	O
of	O
psychotropic	B-T121
medication	I-T121
,	O
in	O
a	O
cohort	O
of	O
women	O
with	O
severe	O
mental	B-T048
illness	I-T048
,	O
increases	O
rates	O
of	O
special	B-T061
care	I-T061
nursery	I-T061
admission	B-T058
and	O
reports	O
differences	O
between	O
antidepressant	B-T121
and	O
antipsychotic	B-T121
medication	I-T121
use	O
either	O
alone	O
or	O
in	O
combination	B-T121
.	O
A	O
retrospective	O
database	O
analysis	O
from	O
a	O
cohort	O
with	O
severe	O
mental	B-T048
illness	I-T048
in	O
pregnancy	O
identified	O
268	O
pregnant	O
women	O
who	O
were	O
grouped	O
according	O
to	O
medication	B-T121
type	O
.	O
Demographic	O
,	O
obstetric	O
and	O
neonatal	O
variables	O
were	O
analysed	O
using	O
t	O
-	O
tests	O
,	O
χ(2	O
)	O
,	O
analysis	O
of	O
variance	O
and	O
logistic	O
regression	O
analysis	O
for	O
special	B-T061
care	I-T061
nursery	I-T061
admission	B-T058
.	O
The	O
medication	O
groups	O
consisted	O
of	O
:	O
women	O
taking	O
no	O
psychotropic	O
medications	O
(	O
n	O
=	O
67	O
)	O
;	O
those	O
taking	O
antipsychotics	O
(	O
n	O
=	O
87	O
)	O
;	O
those	O
taking	O
antidepressants	O
(	O
n	O
=	O
55	O
)	O
;	O
those	O
taking	O
and	O
a	O
combination	O
of	O
antidepressants	O
/	O
antipsychotics	O
(	O
n	O
=	O
59	O
)	O
.	O
Rates	B-T033
of	O
special	B-T061
care	I-T061
nursery	I-T061
admission	B-T058
in	O
women	O
who	O
took	O
psychotropic	B-T121
medication	I-T121
(	O
41.3	O
%	O
)	O
were	O
elevated	O
compared	O
to	O
those	O
who	O
did	O
not	O
(	O
26.9	O
%	O
)	O
(	O
P	O
=	O
0.035	O
)	O
,	O
and	O
were	O
significantly	O
raised	O
when	O
compared	O
to	O
the	O
general	O
population	O
(	O
P	O
<	O
0.000	O
)	O
.	O
No	B-T033
significant	I-T033
difference	I-T033
occurred	O
between	O
the	O
medication	O
groups	O
.	O
A	O
significant	O
adjusted	O
odds	O
ratio	O
of	O
2.79	O
(	O
95	O
%	O
CI	O
1.286	O
-	O
6.049	O
)	O
was	O
found	B-T033
for	O
special	B-T061
care	I-T061
nursery	I-T061
and	O
psychiatric	B-T058
admission	I-T058
during	O
pregnancy	O
but	O
not	O
for	O
psychotropic	B-T121
medication	I-T121
.	O
Rates	O
of	O
special	B-T061
care	I-T061
nursery	I-T061
admission	B-T058
are	O
elevated	O
in	O
neonates	O
of	O
women	O
with	O
severe	O
mental	B-T048
illness	I-T048
taking	O
psychotropic	B-T121
medication	I-T121
,	O
but	O
were	O
not	O
different	O
for	O
monotherapy	B-T061
or	O
polytherapy	B-T061
when	O
prescribing	B-T058
antidepressants	B-T121
or	O
antipsychotic	B-T121
medication	I-T121
.	O
Additional	O
vulnerability	B-T033
occurs	O
in	O
the	O
neonates	O
of	O
women	O
with	O
a	O
mental	B-T048
illness	I-T048
and	O
paediatric	O
presence	O
at	O
delivery	O
is	O
recommended	O
.	O
      
A	O
Randomized	O
,	O
Head	O
-	O
to	O
-	O
Head	O
Study	O
of	O
Virtual	B-T061
Reality	I-T061
Exposure	I-T061
Therapy	I-T061
for	O
Posttraumatic	B-T048
Stress	I-T048
Disorder	I-T048
Virtual	B-T061
reality	I-T061
exposure	I-T061
therapy	I-T061
(	O
VRET	B-T061
)	O
is	O
one	O
of	O
the	O
few	O
interventions	B-T058
supported	O
by	O
randomized	O
controlled	O
trials	O
for	O
the	O
treatment	B-T061
of	O
combat	B-T048
-	I-T048
related	I-T048
posttraumatic	I-T048
stress	I-T048
disorder	I-T048
(	O
PTSD	B-T048
)	O
in	O
active	B-T033
duty	I-T033
service	I-T033
members	O
.	O
A	O
comparative	O
effectiveness	O
study	O
was	O
conducted	O
to	O
determine	O
if	O
virtual	O
reality	O
technology	O
itself	O
improved	B-T033
outcomes	O
,	O
or	O
if	O
similar	O
results	O
could	O
be	O
achieved	O
with	O
a	O
control	B-T061
exposure	I-T061
therapy	I-T061
(	O
CET	B-T061
)	O
condition	O
.	O
Service	O
members	O
with	O
combat	B-T048
-	I-T048
related	I-T048
PTSD	I-T048
were	O
randomly	O
selected	O
to	O
receive	O
nine	O
weeks	O
of	O
VRET	B-T061
or	O
CET	B-T061
.	O
Assessors	O
,	O
but	O
not	O
therapists	O
,	O
were	O
blinded	O
.	O
PTSD	B-T048
symptom	B-T184
improvement	O
was	O
assessed	O
one	O
week	O
and	O
3	O
months	O
after	O
the	O
conclusion	O
of	O
treatment	B-T061
using	O
the	O
clinician	O
-	O
administered	O
PTSD	O
scale	O
(	O
CAPS	O
)	O
.	O
A	O
small	O
crossover	O
component	O
was	O
included	O
.	O
Results	O
demonstrated	O
that	O
PTSD	B-T048
symptoms	B-T184
improved	B-T033
with	O
both	O
treatments	B-T061
,	O
but	O
there	O
were	O
no	O
statistically	O
significant	O
differences	B-T033
between	O
groups	O
.	O
Dropout	O
rates	O
were	O
higher	O
in	O
VRET	B-T061
.	O
Of	O
those	O
who	O
received	O
VRET	B-T061
,	O
13/42	O
(	O
31	O
%	O
)	O
showed	O
>	O
30	O
%	O
improvement	O
on	O
the	O
CAPS	O
,	O
versus	O
16/43	O
(	O
37	O
%	O
)	O
who	O
received	O
CET	B-T061
.	O
Three	O
months	O
after	O
treatment	B-T061
,	O
>	O
30	O
%	O
improvement	O
was	O
seen	O
in	O
10/33	O
(	O
30	O
%	O
)	O
of	O
VRET	B-T061
participants	O
and	O
12/33	O
(	O
36	O
%	O
)	O
in	O
CET	B-T061
.	O
Participants	O
who	O
crossed	B-T033
over	I-T033
(	O
n	O
=	O
11	O
)	O
showed	O
no	O
statistically	O
significant	O
improvements	O
in	O
a	O
second	O
round	O
of	O
treatment	B-T061
,	O
regardless	O
of	O
condition	O
.	O
This	O
study	O
supported	O
the	O
utility	O
of	O
exposure	B-T061
therapy	I-T061
for	O
PTSD	B-T048
,	O
but	O
did	O
not	O
support	O
additional	O
benefit	O
by	O
the	O
inclusion	O
of	O
virtual	O
reality	O
.	O
      
Identifying	O
the	O
presence	B-T033
of	O
Parkinson	B-T047
's	I-T047
disease	I-T047
using	O
low	O
-	O
frequency	O
fluctuations	B-T184
in	O
BOLD	B-T060
signals	I-T060
Parkinson	B-T047
's	I-T047
disease	I-T047
(	O
PD	B-T047
)	O
is	O
a	O
chronic	O
,	O
progressive	O
,	O
and	O
degenerative	O
neurological	B-T047
disorder	I-T047
that	O
is	O
characterized	O
by	O
the	O
degeneration	O
of	O
dopamine	O
neurons	O
in	O
the	O
substantia	B-T023
nigra	I-T023
and	O
the	O
formation	O
of	O
intracellular	O
Lewy	O
inclusion	O
bodies	O
.	O
Resting	B-T060
-	I-T060
state	I-T060
functional	I-T060
magnetic	I-T060
resonance	I-T060
imaging	I-T060
(	O
RS	B-T060
-	I-T060
fMRI	I-T060
)	O
has	O
demonstrated	O
evidence	O
of	O
changes	O
in	O
metabolic	O
patterns	O
in	O
individuals	O
with	O
PD	B-T047
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
presence	B-T033
of	O
PD	B-T047
could	O
be	O
"	O
predicted	O
"	O
based	O
on	O
resting	O
fluctuations	B-T184
in	O
the	O
blood	O
oxygenation	O
level	O
dependent	O
signal	O
.	O
We	O
utilized	O
RS	B-T060
-	I-T060
fMRI	I-T060
to	O
measure	O
the	O
amplitude	O
of	O
low	O
-	O
frequency	O
fluctuation	B-T184
(	O
ALFF	B-T184
)	O
and	O
the	O
fractional	O
ALFF	B-T184
(	O
fALFF	B-T184
)	O
in	O
51	O
patients	O
with	O
PD	B-T047
and	O
50	O
age	O
-	O
and	O
sex	O
-matched	O
healthy	O
controls	O
.	O
Compared	O
with	O
the	O
healthy	O
controls	O
,	O
the	O
individuals	O
with	O
PD	B-T047
exhibited	O
altered	O
ALFFs	B-T184
in	O
the	O
bilateral	O
lingual	B-T023
gyrus	I-T023
and	O
left	B-T023
putamen	I-T023
and	O
an	O
altered	O
fALFF	B-T184
in	O
the	O
right	O
cerebellum	O
posterior	O
lobe	O
.	O
Support	O
vector	O
machines	O
(	O
SVMs	O
)	O
,	O
which	O
comprise	O
a	O
supervised	O
pattern	O
recognition	O
method	O
that	O
enables	O
predictions	O
at	O
the	O
individual	O
level	O
,	O
were	O
trained	O
to	O
separate	O
individuals	O
with	O
PD	B-T047
from	O
healthy	O
controls	O
based	O
on	O
the	O
ALFF	B-T184
and	O
fALFF	B-T184
.	O
Using	O
the	O
leave	O
-	O
one	O
-	O
out	O
cross	O
-	O
validation	O
method	O
to	O
analyze	O
our	O
sample	O
,	O
we	O
reliably	O
distinguished	O
the	O
participants	O
with	O
PD	B-T047
from	O
the	O
controls	O
with	O
92	O
%	O
sensitivity	O
and	O
87	O
%	O
specificity	O
.	O
Overall	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
SVM	O
-	O
neuroimaging	B-T060
approach	O
may	O
be	O
of	O
particular	O
clinical	O
value	O
because	O
it	O
enables	O
the	O
accurate	O
identification	O
of	O
PD	B-T047
at	O
the	O
individual	O
level	O
.	O
RS	B-T060
-	I-T060
fMRI	I-T060
should	O
be	O
considered	O
for	O
development	O
as	O
a	O
biomarker	O
and	O
an	O
analytical	O
tool	O
for	O
the	O
evaluation	B-T058
of	O
PD	B-T047
.	O
      
Common	O
Laboratory	O
Parameters	B-T033
for	O
Differentiating	O
Between	O
Community	B-T047
-	I-T047
Acquired	I-T047
and	O
Healthcare	B-T047
-	I-T047
Associated	I-T047
Pneumonia	I-T047
The	O
correct	O
diagnosis	B-T033
of	O
healthcare	B-T047
-	I-T047
associated	I-T047
pneumonia	I-T047
(	O
HCAP	B-T047
)	O
as	O
opposed	O
to	O
community	B-T047
-	I-T047
acquired	I-T047
pneumonia	I-T047
is	O
essential	O
for	O
the	O
selection	O
of	O
a	O
correct	O
empirical	O
antimicrobial	B-T121
approach	O
,	O
reserving	O
the	O
broad	O
-	O
spectrum	O
or	O
highly	O
potent	O
antimicrobial	B-T061
therapies	I-T061
for	O
resistant	O
strains	B-T001
most	O
commonly	O
present	O
in	O
HCAP	B-T047
,	O
whereas	O
treating	O
the	O
less	O
resistant	O
strains	B-T001
,	O
most	O
commonly	O
associated	O
with	O
community	O
and	O
long	O
-	O
term	O
care	O
facility	O
-	O
acquired	O
infections	O
,	O
with	O
a	O
more	O
targeted	O
empirical	O
approach	O
.	O
The	O
standard	O
approach	O
today	O
is	O
to	O
differentiate	O
between	O
the	O
two	O
based	O
on	O
the	O
medical	B-T033
history	I-T033
of	O
the	O
past	O
90	O
days	O
prior	O
to	O
admission	B-T058
.	O
Measurable	O
,	O
quantitative	O
assessment	B-T058
may	O
be	O
able	O
to	O
assist	O
in	O
this	O
decision	O
.	O
The	O
objective	O
of	O
this	O
study	O
is	O
to	O
find	O
a	O
measurable	O
method	O
of	O
differentiating	O
between	O
community	B-T047
-	I-T047
acquired	I-T047
and	O
healthcare	B-T047
-	I-T047
associated	I-T047
pneumonias	I-T047
.	O
The	O
records	O
of	O
126	O
patients	O
admitted	B-T058
with	O
a	O
diagnosis	B-T033
of	O
pneumonia	B-T047
were	O
divided	O
into	O
two	O
groups	O
based	O
on	O
the	O
probable	O
cause	O
of	O
their	O
disease	O
,	O
in	O
accordance	O
with	O
common	O
practice	O
.	O
The	O
routine	O
laboratory	B-T059
work	I-T059
taken	O
upon	O
admittance	B-T058
was	O
analyzed	O
using	O
logistical	O
regression	O
and	O
Student	O
's	O
t	O
-	O
test	O
.	O
We	O
have	O
found	O
that	O
the	O
red	B-T059
blood	I-T059
cell	I-T059
distribution	I-T059
width	I-T059
and	O
the	O
neutrophil	O
-to-	O
lymphocyte	O
ratio	O
,	O
both	O
routine	B-T033
parameters	I-T033
obtained	O
in	O
a	O
simple	O
blood	B-T059
count	I-T059
,	O
can	O
each	O
assist	O
in	O
differentiating	O
between	O
community	B-T047
-	I-T047
acquired	I-T047
and	O
healthcare	B-T047
-	I-T047
associated	I-T047
pneumonias	I-T047
.	O
We	O
have	O
found	O
two	O
statistically	O
significant	O
parameters	O
that	O
may	O
be	O
used	O
as	O
adjuncts	O
to	O
the	O
medical	B-T033
history	I-T033
,	O
chest	B-T060
radiography	I-T060
and	O
other	B-T033
parameters	I-T033
in	O
forming	O
an	O
immediate	O
clinical	B-T033
impression	I-T033
of	O
a	O
patient	O
presenting	O
with	O
pneumonia	B-T047
.	O
      
Long	O
Noncoding	O
RNAs	O
in	O
Cardiovascular	B-T047
Pathology	I-T047
,	O
Diagnosis	O
,	O
and	O
Therapy	B-T061
Vast	O
parts	O
of	O
mammalian	O
genomes	O
encode	O
for	O
transcripts	O
that	O
are	O
not	O
further	O
translated	O
into	O
proteins	O
.	O
The	O
purpose	O
of	O
the	O
majority	O
of	O
such	O
noncoding	O
ribonucleic	O
acids	O
(	O
RNAs	O
)	O
remained	O
paradoxical	O
for	O
a	O
long	O
time	O
.	O
However	O
,	O
a	O
growing	O
body	O
of	O
evidence	O
demonstrates	O
that	O
long	O
noncoding	O
RNAs	O
are	O
dynamically	O
expressed	O
in	O
different	O
cell	O
types	O
,	O
diseases	B-T047
,	O
or	O
developmental	O
stages	O
to	O
execute	O
a	O
wide	O
variety	O
of	O
regulatory	O
roles	O
at	O
virtually	O
every	O
step	O
of	O
gene	O
expression	O
and	O
translation	O
.	O
Indeed	O
,	O
long	O
noncoding	O
RNAs	O
influence	O
gene	O
expression	O
via	O
epigenetic	O
modulations	O
,	O
through	O
regulating	O
alternative	O
splicing	O
,	O
or	O
by	O
acting	O
as	O
molecular	O
sponges	O
.	O
The	O
abundance	O
of	O
long	O
noncoding	O
RNAs	O
in	O
the	O
cardiovascular	O
system	O
indicates	O
that	O
they	O
may	O
be	O
part	O
of	O
a	O
complex	O
regulatory	O
network	O
governing	O
physiology	O
and	O
pathology	O
of	O
the	O
heart	B-T023
.	O
In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
multifaceted	O
functions	O
of	O
long	O
noncoding	O
RNAs	O
and	O
highlight	O
the	O
current	O
literature	O
with	O
an	O
emphasis	O
on	O
cardiac	O
development	O
and	O
disease	B-T047
.	O
Furthermore	O
,	O
as	O
the	O
enormous	O
spectrum	O
of	O
long	O
noncoding	O
RNAs	O
potentially	O
opens	O
up	O
new	O
avenues	O
for	O
diagnosis	O
and	O
prevention	B-T061
of	O
heart	B-T047
failure	I-T047
,	O
we	O
ultimately	O
evaluate	O
the	O
futuristic	O
prospects	O
of	O
long	O
noncoding	O
RNAs	O
as	O
biomarkers	O
,	O
and	O
therapeutic	O
targets	O
for	O
the	O
treatment	B-T061
of	O
cardiovascular	B-T047
disorders	I-T047
,	O
as	O
well	O
.	O
      
Measuring	O
nonlinear	O
signal	O
combination	O
using	O
EEG	B-T060
Relatively	O
little	O
is	O
known	O
about	O
the	O
processes	O
,	O
both	O
linear	O
and	O
nonlinear	O
,	O
by	O
which	O
signals	O
are	O
combined	O
beyond	O
V1	O
.	O
By	O
presenting	O
two	O
stimulus	O
components	O
simultaneously	O
,	O
flickering	B-T033
at	O
different	O
temporal	O
frequencies	O
(	O
frequency	O
tagging	O
)	O
while	O
measuring	O
steady	O
-	O
state	O
visual	O
evoked	O
potentials	O
,	O
we	O
can	O
assess	B-T058
responses	O
to	O
the	O
individual	O
components	O
,	O
including	O
direct	O
measurements	O
of	O
suppression	O
on	O
each	O
other	O
,	O
and	O
various	O
nonlinear	O
responses	O
to	O
their	O
combination	O
found	O
at	O
intermodulation	O
frequencies	O
.	O
The	O
result	O
is	O
a	O
rather	O
rich	O
dataset	O
of	O
frequencies	O
at	O
which	O
responses	O
can	O
be	O
found	O
.	O
We	O
presented	O
pairs	O
of	O
sinusoidal	O
gratings	O
at	O
different	O
temporal	O
frequencies	O
,	O
forming	O
plaid	B-T033
patterns	I-T033
that	O
were	O
"	O
coherent	B-T033
"	O
(	O
looking	O
like	O
a	O
checkerboar	O
d	O
)	O
and	O
"	O
noncoherent	B-T033
"	O
(	O
looking	O
like	O
a	O
pair	O
of	O
transparently	O
overlaid	O
gratings	O
)	O
,	O
and	O
found	O
clear	O
intermodulation	O
responses	O
to	O
compound	O
stimuli	O
,	O
indicating	O
nonlinear	O
summation	O
.	O
This	O
might	O
have	O
been	O
attributed	O
to	O
cross	O
-	O
orientation	O
suppression	O
except	O
that	O
the	O
pattern	O
of	O
intermodulation	O
responses	O
differed	O
for	O
coherent	B-T033
and	O
noncoherent	B-T033
patterns	O
,	O
whereas	O
the	O
effects	O
of	O
suppression	O
(	O
measured	O
at	O
the	O
component	O
frequencies	O
)	O
did	O
not	O
.	O
A	O
two	O
-	O
stage	O
model	O
of	O
nonlinear	O
summation	O
involving	O
conjunction	O
detection	B-T061
with	O
a	O
logical	O
AND	O
gate	O
described	O
the	O
data	O
well	O
,	O
capturing	O
the	O
difference	O
between	O
coherent	B-T033
and	O
noncoherent	B-T033
plaids	O
over	O
a	O
wide	O
array	O
of	O
possible	B-T033
response	O
frequencies	O
.	O
Multistimulus	O
frequency	O
-tagged	O
EEG	B-T060
in	O
combination	O
with	O
computational	O
modeling	O
may	O
be	O
a	O
very	O
valuable	O
tool	O
in	O
studying	O
the	O
conjunction	O
of	O
these	O
signals	O
.	O
In	O
the	O
current	O
study	O
the	O
results	O
suggest	O
a	O
second	O
-	O
order	O
mechanism	O
responding	O
selectively	O
to	O
coherent	B-T033
plaid	B-T033
patterns	I-T033
.	O
      
C-5a	O
-	O
substituted	O
validamine	O
type	O
glycosidase	O
inhibitors	O
A	O
series	O
of	O
N	B-T121
-	I-T121
alkyl	I-T121
derivatives	I-T121
of	O
the	O
D	B-T121
-	I-T121
galactosidase	I-T121
inhibitor	B-T121
1,4	B-T121
-	I-T121
di	I-T121
-	I-T121
epi	I-T121
-	I-T121
validamine	I-T121
featuring	O
lipophilic	O
substituents	O
at	O
position	O
C-5a	O
was	O
prepared	O
and	O
screened	B-T059
for	O
their	O
glycosidase	B-T121
inhibitory	O
properties	O
.	O
Products	O
turned	O
out	O
selective	O
for	O
β	B-T121
-	I-T121
galactosidases	I-T121
as	O
well	O
as	O
β	O
-	O
glucosidases	O
.	O
      
Therapeutic	O
applications	O
of	O
CRISPR	O
RNA	O
-	O
guided	O
genome	O
editing	O
The	O
rapid	O
development	O
of	O
programmable	O
nuclease	O
-based	O
genome	O
editing	O
technologies	O
has	O
enabled	O
targeted	O
gene	O
disruption	O
and	O
correction	B-T061
both	O
in	O
vitro	O
and	O
in	O
vivo	O
This	O
revolution	O
opens	O
up	O
the	O
possibility	O
of	O
precise	O
genome	O
editing	O
at	O
target	O
genomic	O
sites	O
to	O
modulate	O
gene	O
function	O
in	O
animals	O
and	O
plants	O
.	O
Among	O
several	O
programmable	O
nucleases	O
,	O
the	O
type	O
II	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeats	O
(	O
CRISPR)-	O
CRISPR	O
-	O
associated	O
nuclease	O
9	O
(	O
Cas9	O
)	O
system	O
has	O
progressed	O
remarkably	O
in	O
recent	O
years	O
,	O
leading	O
to	O
its	O
widespread	O
use	O
in	O
research	O
,	O
medicine	O
and	O
biotechnology	O
.	O
In	O
particular	O
,	O
CRISPR	O
-	O
Cas9	O
shows	O
highly	O
efficient	O
gene	O
editing	O
activity	O
for	O
therapeutic	O
purposes	O
in	O
systems	O
ranging	O
from	O
patient	O
stem	O
cells	O
to	O
animal	O
models	O
.	O
However	O
,	O
the	O
development	O
of	O
therapeutic	O
approaches	O
and	O
delivery	B-T061
methods	I-T061
remains	O
a	O
great	O
challenge	O
for	O
biomedical	O
applications	O
.	O
Herein	O
,	O
we	O
review	O
therapeutic	O
applications	O
that	O
use	O
the	O
CRISPR	O
-	O
Cas9	O
system	O
and	O
discuss	O
the	O
possibilities	O
and	O
challenges	O
ahead	O
.	O
      
Non	O
-	O
specific	O
transient	O
mutualism	O
between	O
the	O
plant	O
parasitic	O
nematode	O
,	O
Bursaphelenchus	O
xylophilus	O
,	O
and	O
the	O
opportunistic	O
bacterium	B-T007
Serratia	B-T007
quinivorans	I-T007
BXF1	I-T007
,	O
a	O
plant	O
-	O
growth	O
promoting	O
pine	O
endophyte	O
with	O
antagonistic	O
effects	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
understand	O
the	O
biological	O
role	O
of	O
Serratia	B-T007
quinivorans	I-T007
BXF1	I-T007
,	O
a	O
bacterium	B-T007
commonly	O
found	O
associated	O
with	O
Bursaphelenchus	O
xylophilus	O
,	O
the	O
plant	O
parasitic	O
nematode	O
responsible	O
for	O
pine	O
wilt	B-T047
disease	I-T047
.	O
Therefore	O
,	O
we	O
studied	O
strain	B-T007
BXF1	I-T007
effect	O
in	O
pine	O
wilt	B-T047
disease	I-T047
.	O
We	O
found	O
that	O
strain	B-T007
BXF1	I-T007
promoted	O
in	O
vitro	O
nematode	O
reproduction	O
.	O
Moreover	O
,	O
the	O
presence	O
of	O
bacteria	B-T007
led	O
to	O
the	O
absence	O
of	O
nematode	O
chitinase	O
gene	O
(	O
Bxcht-1	O
)	O
expression	O
,	O
suggesting	O
an	O
effect	O
for	O
bacterial	B-T007
chitinase	O
in	O
nematode	O
reproduction	O
.	O
Nevertheless	O
,	O
strain	B-T007
BXF1	I-T007
was	O
unable	O
to	O
colonize	B-T033
the	O
nematode	O
interior	O
,	O
bind	O
to	O
its	O
cuticle	B-T023
with	O
high	O
affinity	O
or	O
protect	O
the	O
nematode	O
from	O
xenobiotic	O
stress	O
.	O
Interestingly	O
,	O
strain	B-T007
BXF1	I-T007
was	O
able	O
to	O
promote	O
tomato	O
and	O
pine	O
plant	O
-	O
growth	O
,	O
as	O
well	O
as	O
to	O
colonize	B-T033
its	O
interior	O
,	O
thus	O
,	O
acting	O
like	O
a	O
plant	O
-	O
growth	O
promoting	O
endophyte	O
.	O
Consequently	O
,	O
strain	B-T007
BXF1	I-T007
failed	O
to	O
induce	O
wilting	B-T184
symptoms	I-T184
when	O
inoculated	O
in	O
pine	O
shoot	O
artificial	O
incisions	O
.	O
This	O
bacterium	B-T007
also	O
presented	O
strong	O
antagonistic	O
activities	O
against	O
fungi	O
and	O
bacteria	B-T007
isolated	O
from	O
Pinus	O
pinaster	O
.	O
Our	O
results	O
suggest	O
that	O
B.	O
xylophilus	O
does	O
not	O
possess	O
a	O
strict	O
symbiotic	B-T001
community	I-T001
capable	O
of	O
inducing	O
pine	O
wilt	B-T047
disease	I-T047
symptoms	B-T184
as	O
previously	O
hypothesized	O
.	O
We	O
show	O
that	O
bacteria	B-T007
like	O
BXF1	B-T007
,	O
which	O
possess	O
plant	O
-	O
growth	O
promoting	O
and	O
antagonistic	O
effects	O
,	O
may	O
be	O
opportunistically	O
associated	O
with	O
B.	O
xylophilus	O
,	O
possibly	O
acquired	O
from	O
the	O
bacterial	B-T007
endophytic	O
community	O
of	O
the	O
host	B-T001
pine	O
.	O
      
Atypical	O
microglial	O
response	O
to	O
biodiesel	O
exhaust	O
in	O
healthy	O
and	O
hypertensive	B-T047
rats	O
Accumulating	O
evidence	O
suggests	O
a	O
deleterious	O
role	O
for	O
urban	O
air	O
pollution	O
in	O
central	B-T047
nervous	I-T047
system	I-T047
(	I-T047
CNS	I-T047
)	I-T047
diseases	I-T047
and	O
neurodevelopmental	B-T048
disorders	I-T048
.	O
Microglia	O
,	O
the	O
resident	O
innate	O
immune	O
cells	O
and	O
sentinels	O
in	O
the	O
brain	B-T023
,	O
are	O
a	O
common	O
source	B-T033
of	O
neuroinflammation	O
and	O
are	O
implicated	O
in	O
air	O
pollution	O
-	O
induced	O
CNS	B-T047
effects	I-T047
.	O
While	O
renewable	O
energy	O
,	O
such	O
as	O
soy	O
-	O
based	O
biofuel	O
,	O
is	O
of	O
increasing	O
public	O
interest	O
,	O
there	O
is	O
little	O
information	O
on	O
how	O
soy	O
biofuel	O
may	O
affect	O
the	O
brain	B-T023
,	O
especially	O
in	O
people	O
with	O
preexisting	B-T033
disease	I-T033
conditions	I-T033
.	O
To	O
address	O
this	O
,	O
male	O
spontaneously	O
hypertensive	O
rats	O
(	O
SHR	O
)	O
and	O
normotensive	B-T033
Wistar	O
Kyoto	O
(	O
WKY	O
)	O
rats	O
were	O
exposed	O
to	O
100	O
%	O
Soy	O
-	O
based	O
Biodiesel	O
Exhaust	O
(	O
100SBDE	O
;	O
0	O
,	O
50	O
,	O
150	O
and	O
500μg	O
/	O
m(3	O
)	O
)	O
by	O
inhalation	O
,	O
4h/	O
day	O
for	O
4	O
weeks	O
(	O
5	O
days	O
/	O
week	O
)	O
.	O
Ionized	O
calcium	O
-	O
binding	O
adapter	O
molecule-1	O
(	O
IBA-1	O
)	O
staining	B-T059
of	O
microglia	O
in	O
the	O
substantia	B-T023
nigra	I-T023
revealed	O
significant	O
changes	O
in	O
morphology	O
with	O
100SBDE	O
exposure	O
in	O
rats	O
from	O
both	O
genotypes	O
,	O
where	O
SHR	O
were	O
less	O
sensitive	O
.	O
Aconitase	O
activity	O
was	O
inhibited	O
in	O
the	O
frontal	B-T023
cortex	I-T023
and	O
cerebellum	B-T023
of	O
WKY	O
rats	O
exposed	O
to	O
100SBDE	O
.	O
No	O
consistent	O
changes	O
occurred	O
in	O
pro	O
-	O
inflammatory	O
cytokine	O
expression	O
,	O
nitrated	O
protein	O
,	O
or	O
arginase1	O
expression	O
in	O
brain	O
regions	O
from	O
either	O
rat	O
strain	O
exposed	O
to	O
100SBDE	O
.	O
However	O
,	O
while	O
IBA-1	O
mRNA	O
expression	O
was	O
not	O
modified	O
,	O
CX3CR1	O
mRNA	O
expression	O
was	O
lower	O
in	O
the	O
striatum	B-T023
of	O
100SBDE	O
exposed	O
rats	O
regardless	O
of	O
genotype	O
,	O
suggesting	O
a	O
downregulation	O
of	O
the	O
fractalkine	O
receptor	O
on	O
microglia	O
in	O
this	O
brain	O
region	O
.	O
Together	O
,	O
these	O
data	O
indicate	O
that	O
while	O
microglia	O
are	O
detecting	B-T033
and	O
responding	O
to	O
100SBDE	O
exposure	O
with	O
changes	O
in	O
morphology	O
,	O
there	O
is	O
reduced	O
expression	O
of	O
CX3CR1	O
regardless	O
of	O
genetic	O
background	O
and	O
the	O
activation	O
response	O
is	O
atypical	O
without	O
traditional	O
inflammatory	O
markers	O
of	O
M1	O
or	O
M2	O
activation	O
in	O
the	O
brain	B-T023
.	O
      
Identification	O
and	O
characterization	O
of	O
Dichelobacter	B-T007
nodosus	I-T007
serogroup	O
H	O
from	O
ovine	O
footrot	B-T047
in	O
India	O
A	O
total	O
of	O
56	O
foot	O
swabs	O
were	O
collected	O
from	O
inter	O
digital	O
spaces	O
of	O
sheep	O
with	O
footrot	B-T047
lesions	B-T033
were	O
screened	B-T060
for	O
16	O
rRNA	O
of	O
Dichelobacter	B-T007
nodosus	I-T007
by	O
PCR	O
.	O
Out	O
of	O
the	O
56	O
samples	O
,	O
38(67.85	O
%	O
)	O
were	O
found	O
to	O
be	O
positive	B-T033
.	O
All	O
the	O
positive	B-T033
samples	O
were	O
subjected	O
to	O
multiplex	O
PCR	O
targeting	O
fimA	O
gene	O
for	O
identification	O
of	O
serogroups	O
of	O
D.	B-T007
nodosus	I-T007
.	O
Serogroup	O
H	O
was	O
found	O
along	O
with	O
serogroup	O
B	O
in	O
12	O
(	O
55.26	O
%	O
)	O
samples	O
and	O
with	O
serogroup	O
I	O
in	O
8	O
(	O
22.2	O
%	O
)	O
samples	O
.	O
The	O
serogroup	O
H	O
was	O
identified	O
for	O
the	O
first	O
time	O
from	O
the	O
Indian	O
subcontinent	O
.	O
The	O
phylogenetic	O
analysis	O
of	O
the	O
present	O
sequence	O
with	O
the	O
available	O
serogroup	O
H	O
sequences	O
of	O
GenBank	O
revealed	O
to	O
be	O
in	O
close	O
association	O
with	O
the	O
serotype	O
H1	O
.	O
      
The	O
Role	O
of	O
the	O
Iron	B-T059
Stain	I-T059
in	O
Assessing	O
Intracranial	B-T047
Hemorrhage	I-T047
The	O
timing	O
of	O
the	O
breakdown	O
of	O
red	O
blood	O
cells	O
and	O
organization	O
of	O
hemorrhage	O
has	O
significance	O
in	O
the	O
catabolism	O
of	O
heme	O
and	O
the	O
processing	O
of	O
iron	B-T121
,	O
but	O
also	O
has	O
a	O
practical	O
application	O
in	O
terms	O
of	O
assigning	O
,	O
or	O
attempting	O
to	O
assign	O
,	O
a	O
time	O
course	O
with	O
respect	O
to	O
traumatic	O
events	O
(	O
e.g.	O
contusions	O
and	O
hemorrhages	O
)	O
.	O
Attempts	O
to	O
date	O
contusions	O
,	O
however	O
,	O
have	O
generally	O
been	O
unsuccessful	O
by	O
macroscopic	B-T059
observation	I-T059
,	O
whereas	O
the	O
microscopic	B-T059
observations	I-T059
provide	O
broad	O
data	O
but	O
are	O
also	O
anatomically	O
imprecise	O
as	O
a	O
function	O
of	O
time	O
.	O
Intracranial	B-T033
lesions	I-T033
are	O
of	O
particular	O
significance	O
with	O
respect	O
to	O
the	O
timing	O
of	O
organizing	O
hemorrhage	O
given	O
the	O
acute	O
,	O
and	O
often	O
life	B-T033
-	I-T033
threatening	I-T033
nature	O
of	O
the	O
hemorrhages	O
,	O
and	O
the	O
medicolegal	B-T060
investigation	I-T060
into	O
potential	O
crimes	O
.	O
Of	O
concern	O
is	O
that	O
the	O
Prussian	B-T059
Blue	I-T059
reaction	I-T059
for	O
iron	B-T121
,	O
a	O
relatively	O
straightforward	O
histochemical	B-T059
reaction	O
that	O
has	O
been	O
in	O
use	O
for	O
over	O
150	O
years	O
,	O
is	O
sometimes	O
suggested	O
as	O
a	O
diagnostic	B-T060
test	I-T060
for	O
chronicity	O
.	O
Therefore	O
,	O
this	O
study	O
examined	B-T033
the	O
utility	O
of	O
the	O
Prussian	B-T121
Blue	I-T121
iron	I-T121
stain	I-T121
in	O
living	O
patients	O
with	O
intracranial	B-T047
hemorrhages	I-T047
and	O
well	O
-	O
defined	O
symptom	O
onset	O
,	O
to	O
test	O
whether	O
the	O
presence	B-T033
of	O
Prussian	B-T121
Blue	I-T121
reactivity	O
could	O
be	O
correlated	O
with	O
chronicity	O
.	O
It	O
was	O
found	B-T033
that	O
out	O
of	O
12	O
cases	O
with	O
intracranial	B-T047
hemorrhage	I-T047
,	O
eight	O
cases	O
showed	O
at	O
least	O
focal	B-T121
iron	I-T121
reactivity	O
.	O
The	O
duration	O
from	O
symptom	O
onset	O
to	O
surgery	B-T061
in	O
those	O
eight	O
cases	O
ranged	O
from	O
<	O
24	O
hours	O
to	O
more	O
than	O
3	O
days	O
.	O
Of	O
those	O
cases	O
with	O
no	B-T033
iron	I-T033
reactivity	I-T033
,	O
the	O
duration	O
from	O
symptom	O
onset	O
to	O
surgery	B-T061
ranged	O
from	O
<	O
24	O
hours	O
to	O
six	O
days	O
.	O
In	O
conclusion	O
,	O
the	O
Prussian	B-T059
Blue	I-T059
reaction	I-T059
was	O
unreliable	O
as	O
an	O
indicator	O
of	O
timing	O
in	O
intracranial	B-T047
hemorrhage	I-T047
.	O
The	O
use	O
of	O
the	O
Prussian	B-T059
blue	I-T059
reaction	I-T059
as	O
an	O
independent	O
indicator	O
of	O
chronicity	O
is	O
therefore	O
not	O
valid	O
and	O
can	O
be	O
misleading	O
.	O
Caution	O
is	O
indicated	B-T033
when	O
employing	O
iron	B-T059
staining	I-T059
for	O
timing	O
purposes	O
,	O
as	O
its	O
only	O
use	O
is	O
to	O
highlight	O
,	O
as	O
opposed	O
to	O
identify	O
,	O
pre	O
-	O
existing	O
lesions	B-T033
.	O
With	O
respect	O
to	O
brain	B-T047
lesions	I-T047
,	O
the	O
Prussian	B-T059
blue	I-T059
reaction	I-T059
should	O
not	O
be	O
used	O
in	O
place	O
of	O
the	O
clinical	O
timing	O
of	O
the	O
neurologic	B-T033
decline	I-T033
,	O
or	O
clinical	O
data	O
that	O
is	O
otherwise	O
more	O
accurate	O
and	O
less	O
susceptible	O
to	O
false	O
positive	O
results	O
.	O
      
Gambling	B-T048
disorders	I-T048
,	O
gambling	O
type	O
preferences	O
,	O
and	O
psychiatric	O
comorbidity	O
among	O
the	O
Thai	O
general	O
population	O
:	O
Results	O
of	O
the	O
2013	O
National	O
Mental	O
Health	O
Survey	O
Background	O
and	O
aims	O
To	O
estimate	O
the	O
prevalence	O
of	O
problem	B-T048
and	O
pathological	B-T048
gambling	I-T048
,	O
gender	O
and	O
age	O
-	O
group	O
differences	O
in	O
gambling	O
types	O
,	O
and	O
comorbidities	O
with	O
other	O
psychiatric	B-T048
disorders	I-T048
among	O
the	O
Thai	O
general	O
population	O
.	O
Methods	O
Analysis	O
was	O
conducted	O
on	O
4,727	O
participants	O
of	O
Thailand	O
's	O
2013	O
National	O
Mental	O
Health	O
Survey	O
,	O
a	O
multistage	O
stratified	O
cluster	O
survey	O
,	O
using	O
the	O
Composite	O
International	O
Diagnostic	O
Interview	O
.	O
Diagnoses	B-T033
of	O
problem	B-T048
and	O
pathological	B-T048
gambling	I-T048
and	O
other	O
psychiatric	B-T048
disorders	I-T048
were	O
based	O
on	O
the	O
DSM	O
-	O
IV	O
-	O
TR	O
criteria	O
with	O
the	O
following	O
additional	O
criteria	O
for	O
gamblers	O
:	O
more	O
than	O
10	O
lifetime	O
gambling	O
episodes	O
and	O
a	O
single	O
year	O
loss	O
of	O
at	O
least	O
365	O
USD	O
from	O
gambling	O
.	O
Results	O
The	O
estimated	O
lifetime	O
prevalence	O
rates	O
of	O
pathological	B-T048
and	O
problem	B-T048
gambling	I-T048
were	O
0.90	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
):	O
0.51	O
-	O
1.29	O
]	O
and	O
1.14	O
%	O
(	O
95	O
%	O
CI	O
:	O
0.58	O
-	O
1.70	O
)	O
,	O
respectively	O
.	O
The	O
most	O
popular	O
type	O
of	O
gambling	O
was	O
playing	O
lotteries	O
[	O
69.5	O
%	O
,	O
standard	O
error	O
(	O
SE	O
)	O
=	O
1.9	O
]	O
,	O
the	O
prevalence	O
of	O
which	O
was	O
significantly	O
higher	O
among	O
females	O
and	O
older	O
age	O
groups	O
.	O
The	O
most	O
common	O
psychiatric	B-T048
disorders	I-T048
seen	O
among	O
pathological	B-T048
gamblers	I-T048
were	O
alcohol	B-T048
abuse	I-T048
(	O
57.4	O
%	O
)	O
,	O
nicotine	B-T048
dependence	I-T048
(	O
49.5	O
%	O
)	O
,	O
and	O
any	O
drug	B-T048
use	I-T048
disorder	I-T048
(	O
16.2	O
%	O
)	O
.	O
Pathological	B-T048
gambling	I-T048
was	O
highly	O
prevalent	O
among	O
those	O
who	O
ever	O
experienced	O
major	B-T048
depressive	I-T048
episodes	I-T048
(	O
5.5	O
%	O
)	O
,	O
any	O
drug	B-T048
dependence	I-T048
(	O
5.1	O
%	O
)	O
,	O
and	O
intermittent	B-T048
explosive	I-T048
disorder	I-T048
(	O
4.8	O
%	O
)	O
.	O
The	O
association	O
between	O
pathological	B-T048
gambling	I-T048
was	O
strongest	O
with	O
a	O
history	O
of	O
major	B-T048
depressive	I-T048
episode	I-T048
[	O
adjusted	O
odds	O
ratio	O
(	O
AOR	O
)	O
=	O
10.4	O
,	O
95	O
%	O
CI	O
:	O
2.80	O
-	O
38.4	O
]	O
.	O
Conclusion	O
The	O
study	O
confirms	O
the	O
recognition	O
of	O
gambling	B-T048
disorders	I-T048
as	O
a	O
public	O
health	O
concern	O
in	O
Thailand	O
and	O
suggests	O
a	O
need	O
for	O
culturally	O
specific	O
preventive	O
measures	O
for	O
pathological	B-T048
gamblers	I-T048
and	O
those	O
with	O
a	O
history	O
of	O
substance	B-T048
use	I-T048
disorders	I-T048
or	O
major	B-T048
depression	I-T048
.	O
      
Glucose	O
metabolism	O
-	O
weighted	B-T060
imaging	I-T060
with	O
chemical	B-T060
exchange	I-T060
-	I-T060
sensitive	I-T060
MRI	I-T060
of	O
2	O
-	O
deoxyglucose	O
(	O
2DG	O
)	O
in	O
brain	B-T023
:	O
Sensitivity	O
and	O
biological	O
sources	B-T033
Recent	O
proof	O
-	O
of	O
-	O
principle	O
studies	O
have	O
demonstrated	O
the	O
feasibility	O
of	O
measuring	O
the	O
uptake	O
and	O
metabolism	O
of	O
non	O
-	O
labeled	O
2	O
-	O
deoxy	O
-	O
D	O
-	O
glucose	O
(	O
2DG	O
)	O
by	O
a	O
chemical	B-T060
exchange	I-T060
-	I-T060
sensitive	I-T060
spin	I-T060
-	I-T060
lock	I-T060
(	I-T060
CESL	I-T060
)	I-T060
MRI	I-T060
approach	I-T060
.	O
In	O
order	O
to	O
gain	O
better	O
understanding	O
of	O
this	O
new	O
approach	O
,	O
we	O
performed	O
dynamic	O
in	O
vivo	O
CESL	B-T060
MRI	I-T060
on	O
healthy	O
rat	O
brains	B-T023
with	O
an	O
intravenous	O
injection	O
of	O
2DG	O
under	O
various	O
conditions	O
at	O
9.4T.	O
For	O
three	O
2DG	O
doses	O
of	O
0.25	O
,	O
0.5	O
and	O
1g	O
/	O
kg	O
,	O
we	O
found	O
that	O
2DG	O
-	O
CESL	B-T060
signals	O
increased	O
linearly	O
with	O
injection	B-T061
dose	O
at	O
the	O
initial	O
(	O
<	O
20min	O
)	O
but	O
not	O
the	O
later	O
period	O
(	O
>	O
40min	O
)	O
suggesting	O
time	O
-	O
dependent	O
differential	O
weightings	O
of	O
2DG	O
transport	O
and	O
metabolism	O
.	O
Remaining	O
2DG	O
-	O
CESL	B-T060
studies	O
were	O
performed	O
with	O
0.25g	O
/	O
kg	O
2DG	O
.	O
Since	O
a	O
higher	O
isoflurane	B-T121
level	O
reduces	O
glucose	O
metabolism	O
and	O
increases	O
blood	O
flow	O
,	O
2DG	O
-	O
CESL	B-T060
was	O
measured	O
under	O
0.5	O
%	O
,	O
1.5	O
%	O
and	O
2.2	O
%	O
isoflurane	B-T121
.	O
The	O
2DG	O
-	O
CESL	B-T060
signal	O
was	O
reduced	O
at	O
higher	O
isoflurane	B-T121
levels	O
correlating	O
well	O
with	O
the	O
2DG	O
phosphorylation	O
in	O
the	O
intracellular	O
space	O
.	O
To	O
detect	O
regional	O
heterogeneities	O
of	O
glucose	O
metabolism	O
,	O
2DG	O
-	O
CESL	B-T060
with	O
0.33×0.33×1.50mm(3	O
)	O
resolution	O
was	O
obtained	O
,	O
which	O
indeed	O
showed	O
a	O
higher	O
response	O
in	O
the	O
cortex	B-T023
compared	O
to	O
the	O
corpus	B-T023
callosum	I-T023
.	O
Lastly	O
,	O
unlike	O
CESL	B-T060
MRI	I-T060
with	O
the	O
injection	B-T061
of	O
non	B-T121
-	I-T121
transportable	I-T121
mannitol	I-T121
,	O
the	O
2DG	O
-	O
CESL	B-T060
response	O
decreased	O
with	O
an	O
increased	O
spin	O
-	O
lock	O
pulse	O
power	O
confirming	O
that	O
2DG	O
-	O
CESL	B-T060
is	O
dominated	O
by	O
chemical	O
exchange	O
processes	O
in	O
the	O
extravascular	O
space	O
.	O
Taken	O
together	O
,	O
our	O
results	O
showed	O
that	O
2DG	O
-	O
CESL	B-T060
MRI	I-T060
signals	O
mainly	O
indicate	O
glucose	O
transport	O
and	O
metabolism	O
and	O
may	O
be	O
a	O
useful	O
biomarker	O
for	O
metabolic	O
studies	O
of	O
normal	B-T023
and	O
diseased	B-T047
brains	B-T023
.	O
      
Robust	O
DLPP	O
With	O
Nongreedy	O
ℓ₁$-Norm	O
Minimization	O
and	O
Maximization	O
Recently	O
,	O
discriminant	O
locality	O
preserving	O
projection	O
based	O
on	O
L1	O
-	O
norm	O
(	O
DLPP	O
-	O
L1	O
)	O
was	O
developed	O
for	O
robust	O
subspace	O
learning	O
and	O
image	O
classification	O
.	O
It	O
obtains	O
projection	O
vectors	O
by	O
greedy	O
strategy	O
,	O
i.e.	O
,	O
all	O
projection	O
vectors	O
are	O
optimized	O
individually	O
through	O
maximizing	O
the	O
objective	O
function	O
.	O
Thus	O
,	O
the	O
obtained	O
solution	O
does	O
not	O
necessarily	O
best	O
optimize	O
the	O
corresponding	O
trace	O
ratio	O
optimization	O
algorithm	O
,	O
which	O
is	O
the	O
essential	O
objective	O
function	O
for	O
general	O
dimensionality	O
reduction	O
.	O
It	O
results	O
in	O
insufficient	O
recognition	O
accuracy	O
.	O
To	O
tackle	O
this	O
problem	O
,	O
we	O
propose	O
a	O
nongreedy	O
algorithm	O
to	O
solve	O
the	O
trace	O
ratio	O
formula	O
of	O
DLPP	O
-	O
L1	O
,	O
and	O
analyze	O
its	O
convergence	O
.	O
Experimental	O
results	O
on	O
three	O
databases	O
illustrate	O
the	O
effectiveness	O
of	O
our	O
proposed	O
algorithm	O
.	O
      
Developmental	O
Hypoxia	O
Has	O
Negligible	O
Effects	O
on	O
Long	O
-	O
Term	O
Hypoxia	O
Tolerance	O
and	O
Aerobic	O
Metabolism	O
of	O
Atlantic	O
Salmon	O
(	O
Salmo	O
salar	O
)	O
Exposure	O
to	O
developmental	O
hypoxia	O
can	O
have	O
long	O
-	O
term	O
impacts	O
on	O
the	O
physiological	O
performance	O
of	O
fish	O
because	O
of	O
irreversible	O
plasticity	O
.	O
Wild	O
and	O
captive	B-T033
-	I-T033
reared	I-T033
Atlantic	O
salmon	O
(	O
Salmo	O
salar	O
)	O
can	O
be	O
exposed	O
to	O
hypoxic	O
conditions	O
during	O
development	O
and	O
continue	O
to	O
experience	O
fluctuating	O
oxygen	B-T121
levels	O
as	O
juveniles	O
and	O
adults	O
.	O
Here	O
,	O
we	O
examine	B-T033
whether	O
developmental	O
hypoxia	O
impacts	O
subsequent	O
hypoxia	O
tolerance	O
and	O
aerobic	O
performance	O
of	O
Atlantic	O
salmon	O
.	O
Individuals	O
at	O
8	O
°	O
C	O
were	O
exposed	O
to	O
50	O
%	O
(	O
hypoxia	O
)	O
or	O
100	O
%	O
(	O
normoxia	O
)	O
dissolved	O
oxygen	O
(	O
DO	O
)	O
saturation	O
(	O
as	O
percent	O
of	O
air	O
saturation	O
)	O
from	O
fertilization	O
for	O
∼100	O
d	O
(	O
800	O
degree	O
days	O
)	O
and	O
then	O
raised	O
in	O
normoxic	O
conditions	O
for	O
a	O
further	O
15	O
mo	O
.	O
At	O
18	O
mo	O
after	O
fertilization	O
,	O
aerobic	O
scope	O
was	O
calculated	O
in	O
normoxia	O
(	O
100	O
%	O
DO	B-T121
)	O
and	O
acute	O
(	O
18	O
h	O
)	O
hypoxia	O
(	O
50	O
%	O
DO	B-T121
)	O
from	O
the	O
difference	O
between	O
the	O
minimum	O
and	O
maximum	O
oxygen	O
consumption	O
rates	O
(	O
[	O
Formula	O
:	O
see	O
text	O
]	O
and	O
[	O
Formula	O
:	O
see	O
text	O
]	O
,	O
respectively	O
)	O
at	O
10	O
°	O
C	O
.	O
Hypoxia	O
tolerance	O
was	O
determined	O
as	O
the	O
DO	B-T121
at	O
which	O
loss	B-T184
of	I-T184
equilibrium	I-T184
(	O
LOE	B-T184
)	O
occurred	O
in	O
a	O
constantly	O
decreasing	B-T033
DO	B-T121
environment	O
.	O
There	O
was	O
no	B-T033
difference	I-T033
in	O
[	O
Formula	O
:	O
see	O
text	O
]	O
,	O
[	O
Formula	O
:	O
see	O
text	O
]	O
,	O
or	O
aerobic	O
scope	O
between	O
fish	O
raised	O
in	O
hypoxia	O
or	O
normoxia	O
.	O
There	O
was	O
some	O
evidence	O
that	O
hypoxia	O
tolerance	O
was	O
lower	O
(	O
higher	O
DO	B-T121
at	O
LOE	B-T184
)	O
in	O
hypoxia	O
-	O
raised	O
fish	O
compared	O
with	O
those	O
raised	O
in	O
normoxia	O
,	O
but	O
the	O
magnitude	O
of	O
the	O
effect	O
was	O
small	O
(	O
12.52	O
%	O
DO	B-T121
vs.	O
11.73	O
%	O
DO	B-T121
at	O
LOE	B-T184
)	O
.	O
Acute	O
hypoxia	O
significantly	O
reduced	O
aerobic	O
scope	O
by	O
reducing	O
[	O
Formula	O
:	O
see	O
text	O
]	O
,	O
while	O
[	O
Formula	O
:	O
see	O
text	O
]	O
remained	O
unchanged	B-T033
.	O
Interestingly	O
,	O
acute	O
hypoxia	O
uncovered	O
individual	O
-level	O
relationships	O
between	O
DO	B-T121
at	O
LOE	B-T184
and	O
[	O
Formula	O
:	O
see	O
text	O
]	O
,	O
[	O
Formula	O
:	O
see	O
text	O
]	O
,	O
and	O
aerobic	O
scope	O
.	O
We	O
discuss	O
our	O
findings	O
in	O
the	O
context	O
of	O
developmental	O
trajectories	O
and	O
the	O
role	O
of	O
aerobic	O
performance	O
in	O
hypoxia	O
tolerance	O
.	O
      
2,8	O
-	O
Dihydroxyadenine	O
Nephropathy	B-T047
Identified	O
as	O
Cause	O
of	O
End	B-T047
-	I-T047
Stage	I-T047
Renal	I-T047
Disease	I-T047
After	O
Renal	B-T061
Transplant	I-T061
Adenine	B-T047
phosphoribosyltransferase	I-T047
deficiency	I-T047
is	O
a	O
rare	O
autosomal	B-T047
recessive	I-T047
disorder	I-T047
of	O
uric	O
acid	O
metabolism	O
that	O
leads	O
to	O
formation	O
and	O
excretion	O
of	O
2,8	O
-	O
dihydroxyadenine	O
into	O
urine	O
.	O
The	O
low	O
solubility	O
of	O
2,8	O
-	O
dihydroxyadenine	O
results	O
in	O
precipitation	O
and	O
formation	O
of	O
urinary	O
crystals	O
and	O
renal	B-T047
stones	I-T047
.	O
Patients	O
with	O
this	O
disorder	B-T047
usually	O
have	O
recurrent	B-T047
nephrolithiasis	I-T047
and	O
can	O
develop	O
nephropathy	B-T047
secondary	I-T047
to	O
crystal	O
precipitation	O
in	O
the	O
renal	B-T023
parenchyma	I-T023
.	O
The	O
disease	B-T047
is	O
most	O
often	O
underdiagnosed	B-T033
and	O
can	O
recur	O
in	O
renal	B-T061
transplant	I-T061
,	O
causing	O
graft	O
failure	O
.	O
Lack	O
of	O
specific	O
clinical	O
manifestations	O
,	O
chemical	O
and	O
radiologic	B-T033
features	I-T033
identical	O
to	O
those	O
shown	O
with	O
uric	O
acid	O
stones	O
,	O
and	O
lack	B-T033
of	I-T033
awareness	I-T033
among	O
clinicians	O
are	O
among	O
the	O
causes	O
for	O
the	O
underdiagnoses	B-T033
of	O
this	O
treatable	O
disease	B-T047
.	O
Allopurinol	B-T121
,	O
a	O
xanthine	O
dehydrogenase	O
inhibitor	B-T121
,	O
is	O
the	O
mainstay	O
of	O
treatment	O
,	O
supported	O
by	O
high	O
fluid	O
intake	O
and	O
dietary	B-T061
modifications	I-T061
.	O
The	O
possibility	O
of	O
adenine	B-T047
phosphoribosyl	I-T047
transferase	I-T047
deficiency	I-T047
should	O
be	O
considered	O
in	O
all	O
cases	O
of	O
urolithiasis	B-T047
in	O
children	O
,	O
patients	O
with	O
recurrent	O
urolithiasis	O
,	O
and	O
patients	O
with	O
urolithiasis	B-T047
associated	O
with	O
renal	B-T047
failure	I-T047
of	O
unknown	O
cause	O
,	O
including	O
patients	O
with	O
end	B-T047
-	I-T047
stage	I-T047
renal	I-T047
disease	I-T047
and	O
renal	O
transplant	O
recipients	O
.	O
Here	O
,	O
we	O
report	O
a	O
case	O
of	O
a	O
41	O
-	O
year	O
-	O
old	O
female	O
patient	O
who	O
had	O
a	O
late	O
diagnosis	O
of	O
2,8	O
-	O
dihydroxyadenine	O
nephropathy	B-T047
-induced	O
end	B-T047
-	I-T047
stage	I-T047
renal	I-T047
disease	I-T047
,	O
made	O
on	O
the	O
native	O
nephrectomy	B-T061
that	O
accompanied	O
the	O
renal	B-T061
transplant	I-T061
,	O
and	O
who	O
had	O
a	O
timely	O
intervention	O
that	O
prevented	O
recurrence	O
in	O
the	O
graft	B-T061
.	O
      
Diabetes	B-T047
and	O
breast	B-T191
cancer	I-T191
mortality	O
in	O
Black	O
women	O
Breast	B-T191
cancer	I-T191
mortality	O
is	O
higher	O
in	O
Black	O
women	O
than	O
in	O
White	O
women	O
.	O
The	O
prevalence	O
of	O
type	B-T047
2	I-T047
diabetes	I-T047
mellitus	I-T047
is	O
also	O
higher	O
,	O
yet	O
data	O
on	O
whether	O
diabetes	B-T047
affects	O
breast	B-T191
cancer	I-T191
mortality	O
in	O
this	O
population	O
are	O
lacking	O
.	O
We	O
investigated	O
the	O
relation	O
of	O
diabetes	B-T047
at	O
the	O
time	O
of	O
breast	B-T191
cancer	I-T191
diagnosis	B-T033
to	O
breast	B-T191
cancer	I-T191
mortality	O
in	O
the	O
Black	O
Women	O
's	O
Health	B-T058
Study	O
,	O
a	O
prospective	O
cohort	O
study	O
.	O
1,621	O
Black	O
women	O
with	O
invasive	O
breast	B-T191
cancer	I-T191
diagnosed	B-T033
in	O
1995	O
-	O
2013	O
were	O
followed	O
by	O
mailed	O
questionnaires	O
and	O
searches	O
of	O
the	O
National	O
Death	O
Index	O
.	O
Multivariable	O
Cox	O
regression	O
analysis	O
was	O
used	O
to	O
compute	O
hazard	O
ratios	O
(	O
HRs	O
)	O
for	O
diabetes	B-T047
in	O
relation	O
to	O
breast	B-T191
cancer	I-T191
mortality	O
and	O
all	O
-	O
cause	O
mortality	O
,	O
with	O
adjustment	O
for	O
age	O
,	O
stage	O
,	O
treatment	B-T061
modality	I-T061
,	O
estrogen	O
receptor	O
(	O
ER	O
)	O
status	O
,	O
and	O
body	O
mass	O
index	O
.	O
There	O
were	O
368	O
deaths	B-T033
during	O
follow	B-T058
-	I-T058
up	I-T058
,	O
of	O
which	O
273	O
were	O
due	O
to	O
breast	B-T191
cancer	I-T191
.	O
Breast	B-T191
cancer	I-T191
mortality	O
was	O
significantly	O
increased	O
in	O
women	O
who	O
had	O
been	O
diagnosed	B-T033
with	O
diabetes	B-T047
at	O
least	O
5	O
years	O
before	O
breast	B-T191
cancer	I-T191
occurrence	O
,	O
HR	O
1.86	O
(	O
95	O
%	O
CI	O
1.20	O
-	O
2.89	O
)	O
,	O
with	O
elevations	O
observed	O
for	O
both	O
ER+	B-T033
and	O
ER-	B-T033
breast	B-T191
cancer	I-T191
.	O
All	O
-	O
cause	O
mortality	O
was	O
also	O
higher	O
in	O
diabetics	B-T033
,	O
with	O
HRs	O
of	O
1.54	O
(	O
95	O
%	O
CI	O
1.12	O
-	O
2.07	O
)	O
overall	O
and	O
2.26	O
(	O
95	O
%	O
CI	O
1.62	O
-	O
3.15	O
)	O
for	O
≥5	O
-	O
year	O
duration	O
of	O
diabetes	B-T047
relative	O
to	O
non	B-T033
-	I-T033
diabetics	I-T033
.	O
Our	O
results	O
present	B-T033
the	O
first	O
solid	O
evidence	O
of	O
a	O
positive	B-T033
association	O
of	O
type	B-T047
2	I-T047
diabetes	I-T047
with	O
breast	B-T191
cancer	I-T191
mortality	O
in	O
Black	O
women	O
.	O
Given	O
the	O
higher	O
prevalence	O
and	O
earlier	B-T033
onset	I-T033
of	O
type	B-T047
2	I-T047
diabetes	I-T047
in	O
Black	O
women	O
,	O
it	O
is	O
likely	O
that	O
diabetes	B-T047
contributes	O
to	O
racial	O
disparities	B-T033
in	O
breast	B-T191
cancer	I-T191
mortality	O
.	O
      
Matrix	B-T059
solid	I-T059
-	I-T059
phase	I-T059
dispersion	I-T059
combined	O
to	O
liquid	B-T059
chromatography	I-T059
-	I-T059
tandem	I-T059
mass	I-T059
spectrometry	I-T059
for	O
the	O
determination	B-T059
of	O
paraben	B-T121
preservatives	O
in	O
mollusks	O
A	O
method	O
for	O
the	O
extraction	O
and	O
determination	B-T059
of	O
seven	O
parabens	B-T121
,	O
esters	O
of	O
4	B-T121
-	I-T121
hydroxybenzoic	I-T121
acid	I-T121
,	O
widely	O
used	O
as	O
preservatives	O
in	O
personal	O
care	O
products	O
,	O
pharmaceuticals	B-T121
,	O
etc	O
.	O
,	O
and	O
two	O
chlorinated	O
derivatives	O
(	O
mono-	B-T121
and	O
di	B-T121
-	I-T121
chloro	I-T121
methyl	I-T121
paraben	I-T121
)	O
from	O
mollusk	O
samples	O
was	O
developed	O
by	O
combining	O
matrix	B-T059
solid	I-T059
-	I-T059
phase	I-T059
dispersion	I-T059
(	O
MSPD	B-T059
)	O
and	O
liquid	B-T059
chromatography	I-T059
-	I-T059
tandem	I-T059
mass	I-T059
spectrometry	I-T059
.	O
MSPD	O
parameters	O
,	O
such	O
as	O
solvent	O
,	O
solid	O
support	O
and	O
clean	O
-	O
up	O
sorbent	O
,	O
were	O
optimized	O
.	O
Besides	O
,	O
since	O
blank	O
problems	O
were	O
observed	O
for	O
some	O
parabens	B-T121
,	O
these	O
were	O
investigated	O
and	O
blanks	O
were	O
tackled	O
by	O
precleaning	O
all	O
sorbents	O
prior	O
to	O
use	O
.	O
Under	O
final	O
conditions	O
,	O
0.5	O
g	O
of	O
freeze	B-T059
-	I-T059
dried	I-T059
mollusk	O
were	O
dispersed	O
with	O
1.2	O
g	O
of	O
silica	O
and	O
packed	O
into	O
a	O
cartridge	O
containing	O
3	O
g	O
of	O
C18	O
,	O
as	O
on	O
-	O
line	O
clean	O
-	O
up	O
sorbent	O
.	O
This	O
cartridge	O
was	O
eluted	O
with	O
10mL	O
of	O
acetonitrile	O
,	O
evaporated	O
and	O
reconstituted	O
in	O
methanol	O
for	O
analysis	O
.	O
In	O
the	O
validation	O
stage	O
,	O
successful	O
linearity	O
(	O
R(2)>0.999	O
)	O
,	O
recoveries	O
(	O
between	O
71	O
and	O
117	O
%	O
for	O
most	O
analytes	O
)	O
,	O
precision	O
(	O
RSD	O
lower	O
than	O
21	O
%	O
)	O
and	O
limits	O
of	O
detection	O
and	O
quantification	O
(	O
LOD	O
and	O
LOQ	O
,	O
lower	O
than	O
0.4	O
and	O
1.4ngg(-1	O
)	O
dry	O
weight	O
respectively	O
)	O
levels	O
were	O
achieved	O
.	O
Finally	O
,	O
the	O
new	O
methodology	O
was	O
applied	O
to	O
mussel	O
,	O
clam	O
and	O
cockle	O
samples	O
.	O
Methyl	B-T121
paraben	I-T121
was	O
above	O
the	O
LOQ	O
in	O
five	O
of	O
the	O
six	O
samples	O
(	O
not	O
found	O
in	O
one	O
clam	O
sample	O
)	O
at	O
concentrations	O
up	O
to	O
7ngg(-1	O
)	O
dry	O
weight	O
.	O
Ethyl	B-T121
paraben	I-T121
was	O
found	O
above	O
the	O
LOQ	O
in	O
mussel	O
and	O
cockle	O
samples	O
at	O
a	O
concentration	O
level	O
around	O
0.3ngg(-1	O
)	O
.	O
n	B-T121
-	I-T121
Propyl	I-T121
paraben	I-T121
was	O
only	O
above	O
the	O
LOQ	O
in	O
one	O
mussel	O
sample	O
.	O
      
Evidence	O
for	O
instructions	O
-based	O
updating	O
of	O
task	B-T061
-	I-T061
set	I-T061
representations	I-T061
:	O
the	O
informed	O
fadeout	O
effect	O
The	O
cognitive	O
system	O
can	O
be	O
updated	O
rapidly	O
and	O
efficiently	O
to	O
maximize	O
performance	B-T061
in	O
cognitive	O
tasks	O
.	O
This	O
paper	O
used	O
a	O
task	O
-	O
switching	O
task	O
to	O
explore	O
updating	O
at	O
the	O
level	O
of	O
the	O
plausible	O
task	O
-sets	O
held	O
for	O
future	O
performance	B-T061
.	O
Previous	O
research	O
suggested	O
a	O
"	O
fadeout	O
effect	O
"	O
,	O
performance	B-T061
improvement	B-T061
when	O
moving	O
from	O
task	O
-	O
switching	O
context	O
to	O
single	O
-	O
task	O
context	O
,	O
yet	O
this	O
effect	O
could	O
reflect	O
passive	O
learning	O
rather	O
than	O
intentional	O
control	O
.	O
In	O
a	O
novel	O
"	O
informed	O
fadeout	O
paradigm	O
"	O
,	O
one	O
of	O
two	O
tasks	O
was	O
canceled	O
for	O
a	O
certain	O
number	O
of	O
trials	O
and	O
participants	O
were	O
informed	O
or	O
uninformed	B-T033
regarding	O
task	O
cancelation	O
.	O
The	O
"	O
informed	O
fadeout	O
effect	O
"	O
indicates	O
better	O
performance	B-T061
in	O
the	O
informed	O
than	O
uninformed	B-T033
fadeout	O
after	O
one	O
informed	O
trial	O
had	O
been	O
executed	O
.	O
However	O
,	O
the	O
results	O
regarding	O
the	O
first	O
trial	O
were	O
inconclusive	O
.	O
Possible	O
underlying	O
mechanisms	O
are	O
discussed	O
.	O
      
Structural	O
Insights	O
into	O
5	O
-	O
HT1A	O
/	O
D4	O
Selectivity	O
of	O
WAY-100635	B-T121
Analogues	O
:	O
Molecular	O
Modeling	O
,	O
Synthesis	O
,	O
and	O
in	O
Vitro	O
Binding	O
The	O
resurgence	O
of	O
interest	O
in	O
5	O
-	O
HT1A	O
receptors	O
as	O
a	O
therapeutic	O
target	O
requires	O
the	O
existence	O
of	O
highly	O
selective	O
5	O
-	O
HT1A	O
ligands	O
.	O
To	O
date	O
,	O
WAY-100635	B-T121
has	O
been	O
the	O
prototypical	O
antagonist	O
of	O
these	O
receptors	O
.	O
However	O
,	O
this	O
compound	O
also	O
has	O
significant	O
affinity	O
for	O
and	O
activity	O
at	O
D4	O
dopamine	O
receptors	O
.	O
In	O
this	O
context	O
,	O
this	O
work	O
was	O
aimed	O
at	O
better	O
understanding	O
the	O
5	O
-	O
HT1A	O
/	O
D4	O
selectivity	O
of	O
WAY-100635	B-T121
and	O
analogues	O
from	O
a	O
structural	O
point	O
of	O
view	O
.	O
In	O
silico	O
investigations	O
revealed	O
two	O
key	O
interactions	O
for	O
the	O
5	O
-	O
HT1A	O
/	O
D4	O
selectivity	O
of	O
WAY-100635	B-T121
and	O
analogues	O
.	O
First	O
,	O
a	O
hydrogen	O
bond	O
only	O
found	O
with	O
the	O
Ser	B-T121
7.36	I-T121
of	O
D4	O
receptor	O
appeared	O
to	O
be	O
the	O
key	O
for	O
a	O
higher	O
D4	O
affinity	O
for	O
newly	O
synthesized	O
aza	O
analogues	O
.	O
The	O
role	O
of	O
Ser	B-T121
7.36	I-T121
was	O
confirmed	O
as	O
the	O
affinity	O
of	O
aza	O
analogues	O
for	O
the	O
mutant	O
D4	O
receptor	O
S7.36A	O
was	O
reduced	O
.	O
Then	O
,	O
the	O
formation	O
of	O
another	O
hydrogen	O
bond	O
with	O
the	O
conserved	O
Ser	B-T121
5.42	I-T121
residue	I-T121
appeared	O
to	O
be	O
also	O
critical	O
for	O
D4	O
binding	O
.	O
      
Heteroprotein	O
Complex	O
Formation	O
of	O
Bovine	O
Lactoferrin	O
and	O
Pea	O
Protein	O
Isolate	B-T121
:	O
A	O
Multiscale	O
Structural	O
Analysis	O
Associative	O
electrostatic	O
interactions	O
between	O
two	O
oppositely	O
charged	O
globular	O
proteins	O
,	O
lactoferrin	O
(	O
LF	O
)	O
and	O
pea	O
protein	O
isolate	B-T121
(	O
PPI	O
)	O
,	O
the	O
latter	O
being	O
a	O
mixture	O
of	O
vicilin	O
,	O
legumin	O
,	O
and	O
convicilin	O
,	O
was	O
studied	O
with	O
a	O
specific	O
PPI	O
/	O
LF	O
molar	O
ratio	O
at	O
room	B-T033
temperature	I-T033
.	O
Structural	O
aspects	O
of	O
the	O
electrostatic	O
complexes	O
probed	O
at	O
different	O
length	O
scales	O
were	O
investigated	O
as	O
a	O
function	O
of	O
pH	O
by	O
means	O
of	O
different	O
complementary	O
techniques	O
,	O
namely	O
,	O
with	O
dynamic	B-T059
light	I-T059
scattering	I-T059
,	O
small	B-T059
-	I-T059
angle	I-T059
X	I-T059
-	I-T059
ray	I-T059
scattering	I-T059
(	O
SAXS	B-T059
)	O
,	O
turbidity	B-T059
measurements	I-T059
,	O
and	O
atomic	B-T059
force	I-T059
microscopy	I-T059
(	O
AFM	B-T059
)	O
.	O
Irrespective	O
of	O
the	O
applied	O
techniques	O
,	O
the	O
results	O
consistently	O
displayed	O
that	O
complexation	O
between	O
LF	O
and	O
PPI	O
did	O
occur	O
.	O
In	O
an	O
optimum	O
narrow	O
range	O
of	O
pH	O
5.0	O
-	O
5.8	O
,	O
a	O
viscous	O
liquid	B-T033
phase	O
of	O
complex	O
coacervate	O
was	O
obtained	O
upon	O
mild	O
centrifugation	B-T059
of	O
the	O
turbid	O
LF	O
-	O
PPI	O
mixture	O
with	O
a	O
maximum	O
Rh	O
,	O
turbidity	O
and	O
the	O
ζ	O
-	O
potential	O
being	O
close	O
to	O
zero	O
observed	O
at	O
pH	O
5.4	O
.	O
In	O
particular	O
,	O
the	O
SAXS	B-T059
data	O
demonstrated	O
that	O
the	O
coacervates	O
were	O
densely	O
assembled	O
with	O
a	O
roughly	O
spherical	O
size	O
distribution	O
exhibiting	O
a	O
maximum	O
extension	O
of	O
∼80	O
nm	O
at	O
pH	O
5.4	O
.	O
Equally	O
,	O
AFM	B-T059
image	B-T059
analysis	I-T059
showed	O
size	O
distributions	O
containing	O
most	O
frequent	O
cluster	O
sizes	O
around	O
40	O
-	O
80	O
nm	O
with	O
spherical	O
to	O
elliptical	O
shapes	O
(	O
axis	O
aspect	O
ratio	O
≤	O
2	O
)	O
as	O
well	O
as	O
less	O
frequent	O
elongated	O
to	O
chainlike	O
structures	O
.	O
The	O
most	O
frequently	O
observed	O
compact	O
complexes	O
,	O
we	O
identify	O
as	O
mainly	O
leading	O
to	O
LF	O
-	O
PPI	O
coacervation	O
,	O
whereas	O
for	O
the	O
less	O
frequent	O
chain	O
-	O
like	O
aggregates	O
,	O
we	O
hypothesize	O
that	O
additionally	O
PPI	O
-	O
PPI	O
facilitated	O
complexes	O
exist	O
.	O
      
Genomic	B-T059
analysis	I-T059
of	O
nontypeable	B-T007
pneumococci	I-T007
causing	O
invasive	B-T047
pneumococcal	I-T047
disease	I-T047
in	O
South	O
Africa	O
,	O
2003	O
-	O
2013	O
The	O
capsular	O
polysaccharide	O
is	O
the	O
principal	O
virulence	O
factor	O
of	O
Streptococcus	B-T007
pneumoniae	I-T007
and	O
a	O
target	O
for	O
current	O
pneumococcal	B-T121
vaccines	I-T121
.	O
However	O
,	O
some	O
pathogenic	B-T033
pneumococci	B-T007
are	O
serologically	O
nontypeable	O
[	O
nontypeable	B-T007
pneumococci	I-T007
(	O
NTPn	B-T007
)	O
]	O
.	O
Due	O
to	O
their	O
relative	O
rarity	O
,	O
NTPn	B-T007
are	O
poorly	O
characterized	O
,	O
and	O
,	O
as	O
such	O
,	O
limited	O
data	O
exist	O
which	O
describe	O
these	O
organisms	B-T001
.	O
We	O
aimed	O
to	O
describe	O
disease	B-T047
and	O
genotypically	O
characterize	O
NTPn	B-T007
causing	O
invasive	B-T047
pneumococcal	I-T047
disease	I-T047
in	O
South	O
Africa	O
.	O
Isolates	O
were	O
detected	O
through	O
national	O
,	O
laboratory	O
-	O
based	O
surveillance	O
for	O
invasive	B-T047
pneumococcal	I-T047
disease	I-T047
in	O
South	O
Africa	O
and	O
characterized	O
by	O
whole	O
genome	B-T059
analysis	I-T059
.	O
We	O
predicted	O
ancestral	O
serotypes	O
(	O
serotypes	O
from	O
which	O
NTPn	B-T007
may	O
have	O
originated	O
)	O
for	O
Group	O
I	O
NTPn	B-T007
using	O
multilocus	O
sequence	O
typing	O
and	O
capsular	O
region	O
sequence	B-T059
analyses	I-T059
.	O
Antimicrobial	O
resistance	O
patterns	O
and	O
mutations	O
potentially	O
causing	O
nontypeability	O
were	O
identified	O
.	O
From	O
2003	O
-	O
2013	O
,	O
39	O
(	O
0.1	O
%	O
,	O
39/32,824	O
)	O
NTPn	B-T007
were	O
reported	O
.	O
Twenty	O
-	O
two	O
(	O
56	O
%	O
)	O
had	O
partial	O
capsular	O
genes	O
(	O
Group	O
I	O
)	O
and	O
17	O
(	O
44	O
%	O
)	O
had	O
complete	O
capsular	O
deletion	O
of	O
which	O
15	O
had	O
replacement	O
by	O
other	O
genes	O
(	O
Group	O
II	O
)	O
.	O
Seventy	O
-	O
nine	O
percent	O
(	O
31/39	O
)	O
of	O
our	O
NTPn	B-T007
isolates	O
were	O
derived	O
from	O
encapsulated	O
S.	B-T007
pneumoniae	I-T007
.	O
Ancestral	O
serotypes	O
1	O
(	O
27	O
%	O
,	O
6/22	O
)	O
and	O
8	O
(	O
14	O
%	O
,	O
3/22	O
)	O
were	O
most	O
prevalent	O
,	O
and	O
59	O
%	O
(	O
13/22	O
)	O
of	O
ancestral	O
serotypes	O
were	O
serotypes	O
included	O
in	O
the	O
13	B-T121
-	I-T121
valent	I-T121
pneumococcal	I-T121
conjugate	I-T121
vaccine	I-T121
.	O
We	O
identified	O
a	O
variety	O
of	O
mutations	O
within	O
the	O
capsular	O
region	O
of	O
Group	O
I	O
NTPn	B-T007
,	O
some	O
of	O
which	O
may	O
be	O
responsible	O
for	O
the	O
nontypeable	O
phenotype	O
.	O
Nonsusceptibility	O
to	O
tetracycline	B-T195
and	O
erythromycin	B-T195
was	O
higher	O
in	O
NTPn	B-T007
than	O
encapsulated	O
S.	B-T007
pneumoniae	I-T007
.	O
NTPn	B-T007
are	O
currently	O
a	O
rare	O
cause	O
of	O
invasive	B-T047
pneumococcal	I-T047
disease	I-T047
in	O
South	O
Africa	O
and	O
represent	O
a	O
genetically	O
diverse	O
collection	O
of	O
isolates	O
.	O
      
Engagement	O
of	O
cellular	O
prion	O
protein	O
with	O
the	O
co	O
-	O
chaperone	O
Hsp70	O
/	O
90	O
organizing	O
protein	O
regulates	O
the	O
proliferation	O
of	O
glioblastoma	B-T191
stem	O
-	O
like	O
cells	O
Glioblastoma	B-T191
(	O
GBM	B-T191
)	O
,	O
a	O
highly	O
aggressive	O
brain	B-T191
tumor	I-T191
,	O
contains	O
a	O
subpopulation	O
of	O
glioblastoma	B-T191
stem	O
-	O
like	O
cells	O
(	O
GSCs	O
)	O
that	O
play	O
roles	O
in	O
tumor	B-T191
maintenance	O
,	O
invasion	O
,	O
and	O
therapeutic	O
resistance	O
.	O
GSCs	O
are	O
therefore	O
a	O
promising	O
target	O
for	O
GBM	B-T191
treatment	O
.	O
Our	O
group	O
identified	O
the	O
cellular	O
prion	O
protein	O
(	O
PrP(C	O
)	O
)	O
and	O
its	O
partner	O
,	O
the	O
co	O
-	O
chaperone	O
Hsp70	O
/	O
90	O
organizing	O
protein	O
(	O
HOP	O
)	O
,	O
as	O
potential	O
target	O
candidates	O
due	O
to	O
their	O
role	O
in	O
GBM	B-T191
tumorigenesis	B-T191
and	O
in	O
neural	O
stem	O
cell	O
maintenance	O
.	O
GSCs	O
expressing	O
different	O
levels	O
of	O
PrP(C	O
)	O
were	O
cultured	B-T059
as	O
neurospheres	O
with	O
growth	O
factors	O
,	O
and	O
characterized	O
with	O
stem	O
cells	O
markers	O
and	O
adhesion	O
molecules	O
markers	O
through	O
immunofluorescence	B-T059
and	O
flow	B-T059
cytometry	I-T059
.	O
We	O
than	O
evaluated	O
GSC	O
self	O
-	O
renewal	O
and	O
proliferation	O
by	O
clonal	B-T059
density	I-T059
assays	I-T059
and	O
BrdU	B-T121
BrdU	B-T059
incorporation	I-T059
,	O
respectively	O
,	O
in	O
front	O
of	O
recombinant	O
HOP	O
treatment	O
,	O
combined	O
or	O
not	O
with	O
a	O
HOP	O
peptide	O
which	O
mimics	O
the	O
PrP(C	O
)	O
binding	O
site	O
.	O
Stable	O
silencing	O
of	O
HOP	O
was	O
also	O
performed	O
in	O
parental	O
and/or	O
PrP(C	O
)	O
-depleted	O
cell	O
populations	O
,	O
and	O
proliferation	O
in	O
vitro	O
and	O
tumor	B-T191
growth	I-T191
in	O
vivo	O
were	O
evaluated	O
.	O
Migration	B-T059
assays	I-T059
were	O
performed	O
on	O
laminin-1	O
pre	O
-	O
coated	O
glass	O
.	O
We	O
observed	O
that	O
,	O
when	O
GBM	B-T191
cells	O
are	O
cultured	B-T059
as	O
neurospheres	O
,	O
they	O
express	O
specific	O
stemness	O
markers	O
such	O
as	O
CD133	O
,	O
CD15	O
,	O
Oct4	O
,	O
and	O
SOX2	O
;	O
PrP(C	O
)	O
is	O
upregulated	O
compared	O
to	O
monolayer	B-T059
culture	I-T059
and	O
co	O
-	O
localizes	O
with	O
CD133	O
.	O
PrP(C	O
)	O
silencing	O
downregulates	O
the	O
expression	O
of	O
molecules	O
associated	O
with	O
cancer	O
stem	O
cells	O
,	O
upregulates	O
markers	O
of	O
cell	O
differentiation	O
and	O
affects	O
GSC	O
self	O
-	O
renewal	O
,	O
pointing	O
to	O
a	O
pivotal	O
role	O
for	O
PrP(C	O
)	O
in	O
the	O
maintenance	O
of	O
GSCs	O
.	O
Exogenous	O
HOP	O
treatment	O
increases	O
proliferation	O
and	O
self	O
-	O
renewal	O
of	O
GSCs	O
in	O
a	O
PrP(C	O
)	O
-dependent	O
manner	O
while	O
HOP	O
knockdown	O
disturbs	O
the	O
proliferation	O
process	O
.	O
In	O
vivo	O
,	O
PrP(C	O
)	O
and/or	O
HOP	O
knockdown	O
potently	O
inhibits	O
the	O
growth	O
of	O
subcutaneously	O
implanted	O
glioblastoma	B-T191
cells	O
.	O
In	O
addition	O
,	O
disruption	O
of	O
the	O
PrP(C	O
)	O
-	O
HOP	O
complex	O
by	O
a	O
HOP	O
peptide	O
,	O
which	O
mimics	O
the	O
PrP(C	O
)	O
binding	O
site	O
,	O
affects	O
GSC	O
self	O
-	O
renewal	O
and	O
proliferation	O
indicating	O
that	O
the	O
HOP	O
-	O
PrP(C	O
)	O
complex	O
is	O
required	O
for	O
GSC	O
stemness	O
.	O
Furthermore	O
,	O
PrP(C	O
)	O
-depleted	O
GSCs	O
downregulate	O
cell	O
adhesion	O
-	O
related	O
proteins	O
and	O
impair	O
cell	O
migration	O
indicating	O
a	O
putative	O
role	O
for	O
PrP(C	O
)	O
in	O
the	O
cell	B-T033
surface	I-T033
stability	I-T033
of	O
cell	O
adhesion	O
molecules	O
and	O
GBM	B-T191
cell	O
invasiveness	O
,	O
respectively	O
.	O
In	O
conclusion	O
,	O
our	O
results	O
show	O
that	O
the	O
modulation	O
of	O
HOP	O
-	O
PrP(C	O
)	O
engagement	O
or	O
the	O
decrease	O
of	O
PrP(C	O
)	O
and	O
HOP	O
expression	O
may	O
represent	O
a	O
potential	O
therapeutic	B-T061
intervention	I-T061
in	O
GBM	B-T191
,	O
regulating	O
glioblastoma	B-T191
stem	O
-	O
like	O
cell	O
self	O
-	O
renewal	O
,	O
proliferation	O
,	O
and	O
migration	O
.	O
      
Mildly	O
raised	O
tricuspid	B-T033
regurgitant	I-T033
velocity	I-T033
2.5	O
-	O
3.0	O
m	O
/	O
s	O
in	O
pregnant	O
women	O
with	O
sickle	B-T047
cell	I-T047
disease	I-T047
is	O
not	O
associated	O
with	O
poor	O
obstetric	O
outcome	O
-	O
An	O
observational	O
cross	O
-	O
sectional	O
study	O
Pulmonary	O
hypertension	O
is	O
associated	O
with	O
36	O
%	O
mortality	O
in	O
pregnancy	O
,	O
and	O
6	O
-	O
10	O
%	O
of	O
patients	O
with	O
sickle	B-T047
cell	I-T047
disease	I-T047
have	O
pulmonary	O
hypertension	O
.	O
Tricuspid	B-T033
regurgitant	I-T033
velocity	I-T033
≥2.5	O
m	O
/	O
s	O
on	O
echocardiography	B-T060
is	O
a	O
well	O
validated	O
means	O
of	O
screening	B-T058
for	O
pulmonary	O
hypertension	O
in	O
the	O
non	B-T033
-	I-T033
pregnant	I-T033
population	O
.	O
This	O
is	O
a	O
pilot	O
study	O
to	O
determine	O
if	O
this	O
is	O
a	O
useful	O
non	O
-	O
invasive	O
screening	B-T058
test	I-T058
for	O
pulmonary	O
hypertension	O
in	O
pregnancy	O
,	O
and	O
whether	O
raised	O
tricuspid	B-T033
regurgitant	I-T033
velocity	I-T033
≥2.5	O
m	O
/	O
s	O
was	O
associated	O
with	O
poor	O
outcomes	O
.	O
This	O
is	O
a	O
cross	O
-	O
sectional	O
study	O
over	O
a	O
five	O
-	O
year	O
period	O
in	O
a	O
tertiary	O
referral	O
centre	O
with	O
a	O
specialised	O
multidisciplinary	O
clinic	O
for	O
pregnant	O
women	O
with	O
sickle	B-T047
cell	I-T047
disease	I-T047
.	O
Women	O
with	O
sickle	B-T047
cell	I-T047
disease	I-T047
,	O
no	O
prior	O
pulmonary	O
hypertension	O
and	O
singleton	O
pregnancies	O
who	O
had	O
echocardiography	B-T060
with	O
a	O
measurable	O
tricuspid	B-T033
regurgitant	I-T033
velocity	I-T033
in	O
pregnancy	O
were	O
included	O
.	O
There	O
were	O
34	O
pregnancies	O
,	O
of	O
which	O
eight	O
had	O
tricuspid	B-T033
regurgitant	I-T033
velocity	I-T033
≥2.5	O
m	O
/	O
s.	O
There	O
were	O
no	B-T033
significant	I-T033
differences	O
in	O
their	O
characteristics	O
,	O
sickle	O
cell	O
-related	O
complications	O
or	O
medical	O
co	O
-	O
morbidities	O
.	O
The	O
women	O
with	O
tricuspid	B-T033
regurgitant	I-T033
velocity	I-T033
≥2.5	O
m	O
/	O
s	O
had	O
similar	O
obstetric	O
and	O
perinatal	O
outcomes	O
as	O
those	O
with	O
a	O
tricuspid	B-T033
regurgitant	I-T033
velocity	I-T033
<	O
2.5	O
m	O
/	O
s.	O
      
Abiraterone	B-T121
-	O
induced	O
rhabdomyolysis	O
resulting	O
in	O
acute	O
kidney	O
injury	O
:	O
A	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
Abiraterone	B-T121
,	O
a	O
CYP17	B-T121
inhibitor	I-T121
,	O
blocks	O
androgen	O
biosynthesis	O
in	O
multiple	O
tissue	O
types	O
.	O
In	O
combination	O
with	O
prednisone	B-T121
,	O
it	O
is	O
approved	O
as	O
a	O
first	B-T061
-	I-T061
line	I-T061
treatment	I-T061
for	O
metastatic	B-T191
castration	B-T191
-	I-T191
resistant	I-T191
prostate	I-T191
cancer	I-T191
.	O
We	O
present	O
a	O
case	O
of	O
rhabdomyolysis	O
associated	O
with	O
abiraterone	B-T121
therapy	B-T061
resulting	O
in	O
acute	O
on	O
chronic	O
kidney	O
injury	O
in	O
a	O
patient	O
with	O
metastatic	B-T191
castration	B-T191
-	I-T191
resistant	I-T191
prostate	I-T191
cancer	I-T191
.	O
Strict	O
monitoring	O
should	O
be	O
employed	O
in	O
patients	O
started	O
on	O
abiraterone	B-T121
who	O
have	O
additional	O
risk	B-T033
factors	I-T033
for	O
developing	O
rhabdomyolysis	O
.	O
      
Reassembly	O
of	O
Excitable	O
Domains	O
after	O
CNS	O
Axon	O
Regeneration	O
Action	O
potential	O
initiation	O
and	O
propagation	O
in	O
myelinated	O
axons	O
require	O
ion	O
channel	O
clustering	O
at	O
axon	O
initial	O
segments	O
(	O
AIS	O
)	O
and	O
nodes	O
of	O
Ranvier	O
.	O
Disruption	O
of	O
these	O
domains	O
after	O
injury	O
impairs	O
nervous	O
system	O
function	O
.	O
Traditionally	O
,	O
injured	O
CNS	O
axons	O
are	O
considered	O
refractory	O
to	O
regeneration	O
,	O
but	O
some	O
recent	O
approaches	O
challenge	O
this	O
view	O
by	O
showing	O
robust	O
long	O
-	O
distance	O
regeneration	O
.	O
However	O
,	O
whether	O
these	O
approaches	O
allow	O
remyelination	O
and	O
promote	O
the	O
reestablishment	O
of	O
AIS	O
and	O
nodes	O
of	O
Ranvier	O
is	O
unknown	O
.	O
Using	O
mouse	O
optic	B-T023
nerve	I-T023
crush	O
as	O
a	O
model	B-T050
for	O
CNS	O
traumatic	O
injury	O
,	O
we	O
performed	O
a	O
detailed	O
analysis	O
of	O
AIS	O
and	O
node	O
disruption	O
after	O
nerve	O
crush	O
.	O
We	O
found	O
significant	O
disruption	O
of	O
AIS	O
and	O
loss	O
of	O
nodes	O
within	O
days	O
of	O
the	O
crush	O
,	O
and	O
complete	O
loss	O
of	O
nodes	O
1	O
week	O
after	O
injury	O
.	O
Genetic	O
deletion	O
of	O
the	O
tumor	O
suppressor	O
phosphatase	O
and	O
tensin	O
homolog	O
(	O
Pten	O
)	O
in	O
retinal	O
ganglion	O
cells	O
(	O
RGCs	O
)	O
,	O
coupled	O
with	O
stimulation	O
of	O
RGCs	O
by	O
inflammation	O
and	O
cAMP	B-T121
,	O
dramatically	O
enhanced	O
regeneration	O
.	O
With	O
this	O
treatmen	O
t	O
,	O
we	O
found	O
significant	O
reestablishment	O
of	O
RGC	O
AIS	O
,	O
remyelination	O
,	O
and	O
even	O
reassembly	O
of	O
nodes	O
in	O
regions	O
proximal	O
,	O
within	O
,	O
and	O
distal	O
to	O
the	O
crush	O
site	O
.	O
Remyelination	O
began	O
near	O
the	O
retina	O
,	O
progressed	O
distally	O
,	O
and	O
was	O
confirmed	O
by	O
electron	B-T059
microscopy	I-T059
.	O
Although	O
axons	O
grew	O
rapidly	O
,	O
remyelination	O
and	O
nodal	O
ion	O
channel	O
clustering	O
was	O
much	O
slower	O
.	O
Finally	O
,	O
genetic	O
deletion	O
of	O
ankyrinG	O
from	O
RGCs	O
to	O
block	O
AIS	O
reassembly	O
did	O
not	O
affect	O
axon	O
regeneration	O
,	O
indicating	O
that	O
preservation	O
of	O
neuronal	O
polarity	O
is	O
not	B-T033
required	I-T033
for	O
axon	O
regeneration	O
.	O
Together	O
,	O
our	O
results	O
demonstrate	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
regenerating	O
CNS	O
axons	O
can	O
be	O
remyelinated	O
and	O
reassemble	O
new	O
AIS	O
and	O
nodes	O
of	O
Ranvier	O
.	O
We	O
show	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
regenerated	O
CNS	O
axons	O
have	O
the	O
capacity	O
to	O
both	O
remyelinate	O
and	O
reassemble	O
the	O
axon	O
initial	O
segments	O
and	O
nodes	O
of	O
Ranvier	O
necessary	O
for	O
rapid	O
and	O
efficient	O
action	O
potential	O
propagation	O
.	O
      
Unconventional	O
Protein	O
Secretion	O
in	O
Plants	O
Unconventional	O
protein	O
secretion	O
(	O
UPS	O
)	O
describes	O
secretion	O
pathways	O
that	O
bypass	O
one	O
or	O
several	O
of	O
the	O
canonical	O
secretion	O
pit	O
-	O
stops	O
on	O
the	O
way	O
to	O
the	O
plasma	O
membrane	O
,	O
and/or	O
involve	O
the	O
secretion	O
of	O
leaderless	O
proteins	O
.	O
So	O
far	O
,	O
alternatives	O
to	O
conventional	O
secretion	O
were	O
primarily	O
observed	O
and	O
studied	O
in	O
yeast	O
and	O
animal	O
cells	O
.	O
The	O
sessile	O
lifestyle	O
of	O
plants	O
brings	O
with	O
it	O
unique	O
restraints	O
on	O
how	O
they	O
adapt	O
to	O
adverse	O
conditions	O
and	O
environmental	O
challenges	O
.	O
Recently	O
,	O
attention	O
towards	O
unconventional	O
secretion	O
pathways	O
in	O
plant	O
cells	O
has	O
substantially	O
increased	O
,	O
with	O
the	O
large	O
number	O
of	O
leaderless	O
proteins	O
identified	O
through	O
proteomic	O
studies	O
.	O
While	O
UPS	O
pathways	O
in	O
plants	O
are	O
certainly	O
not	O
yet	O
exhaustively	O
researched	O
,	O
an	O
emerging	O
notion	O
is	O
that	O
induction	O
of	O
UPS	O
pathways	O
is	O
correlated	O
with	O
pathogenesis	O
and	O
stress	O
responses	O
.	O
Given	O
the	O
multitude	O
UPS	O
events	O
observed	O
,	O
comprehensively	O
organizing	O
the	O
routes	O
proteins	O
take	O
to	O
the	O
apoplast	O
in	O
defined	O
UPS	O
categories	O
is	O
challenging	O
.	O
With	O
the	O
establishment	O
of	O
a	O
larger	O
collection	O
of	O
studied	O
plant	O
proteins	O
taking	O
these	O
UPS	O
pathways	O
,	O
a	O
clearer	O
picture	O
of	O
endomembrane	O
trafficking	O
as	O
a	O
whole	O
will	O
emerge	O
.	O
There	O
are	O
several	O
novel	O
enabling	O
technologies	O
,	O
such	O
as	O
vesicle	O
proteomics	O
and	O
chemical	O
genomics	O
,	O
with	O
great	O
potential	O
for	O
dissecting	O
secretion	O
pathways	O
,	O
providing	O
information	O
about	O
the	O
cargo	O
that	O
travels	O
along	O
them	O
and	O
the	O
conditions	O
that	O
induce	O
them	O
.	O
      
Isolation	O
and	O
characterization	O
of	O
Burkholderia	B-T007
sp	I-T007
.	I-T007
strain	I-T007
CCA53	I-T007
exhibiting	O
ligninolytic	O
potential	O
Microbial	B-T001
degradation	O
of	O
lignin	O
releases	O
fermentable	B-T121
sugars	I-T121
,	O
effective	O
utilization	O
of	O
which	O
could	O
support	O
biofuel	O
production	O
from	O
lignocellulosic	O
biomass	O
.	O
In	O
the	O
present	O
study	O
,	O
a	O
lignin	O
-	O
degrading	O
bacterium	B-T007
was	O
isolated	O
from	O
leaf	O
soil	O
and	O
identified	O
as	O
Burkholderia	B-T007
sp	I-T007
.	I-T007
based	O
on	O
16S	O
rRNA	O
gene	B-T059
sequencing	I-T059
.	O
This	O
strain	O
was	O
named	O
CCA53	B-T007
,	O
and	O
its	O
lignin	O
-	O
degrading	O
capability	O
was	O
assessed	O
by	O
observing	O
its	O
growth	O
on	O
medium	O
containing	O
alkali	O
lignin	O
or	O
lignin	O
-associated	O
aromatic	O
monomers	O
as	O
the	O
sole	O
carbon	O
source	B-T033
.	O
Alkali	O
lignin	O
and	O
at	O
least	O
eight	O
lignin	O
-associated	O
aromatic	O
monomers	O
supported	O
growth	O
of	O
this	O
strain	O
,	O
and	O
the	O
most	O
effective	O
utilization	O
was	O
observed	O
for	O
p	O
-	O
hydroxybenzene	O
monomers	O
.	O
These	O
findings	B-T033
indicate	O
that	O
Burkholderia	B-T007
sp	I-T007
.	I-T007
strain	I-T007
CCA53	I-T007
has	O
fragmentary	O
activity	O
for	O
lignin	O
degradation	O
.	O
      
KMAP	B-T058
-	I-T058
O	I-T058
framework	I-T058
for	O
care	B-T058
management	I-T058
research	O
of	O
patients	O
with	O
type	B-T047
2	I-T047
diabetes	I-T047
To	O
review	O
impacts	O
of	O
interventions	B-T058
involving	O
self	B-T058
-	I-T058
management	I-T058
education	I-T058
,	O
health	O
coaching	O
,	O
and	O
motivational	B-T061
interviewing	I-T061
for	O
type	B-T047
2	I-T047
diabetes	I-T047
.	O
A	O
thorough	O
review	O
of	O
the	O
scientific	O
literature	O
on	O
diabetes	B-T047
care	B-T058
and	I-T058
management	I-T058
was	O
executed	O
by	O
a	O
research	O
team	O
.	O
This	O
article	O
summarizes	O
important	O
findings	O
in	O
regard	O
to	O
the	O
validity	O
of	O
developing	O
a	O
comprehensive	O
behavioral	O
system	O
as	O
a	O
framework	B-T058
for	O
empirical	O
investigation	B-T058
.	O
The	O
behavioral	O
system	O
framework	B-T058
consists	O
of	O
patients	O
'	O
knowledge	B-T033
(	O
K	B-T033
)	O
,	O
motivation	O
(	O
M	O
)	O
,	O
attitude	O
(	O
A	O
)	O
,	O
and	O
practice	O
(	O
P	O
)	O
as	O
predictor	O
variables	O
for	O
diabetes	B-T047
care	O
outcomes	O
(	O
O	O
)	O
.	O
Care	B-T058
management	I-T058
strategies	O
or	O
health	B-T058
education	I-T058
programs	I-T058
serve	O
as	O
the	O
intervention	B-T058
variable	O
that	O
directly	O
influences	O
K	B-T033
,	O
M	O
,	O
A	O
,	O
and	O
P	O
and	O
then	O
indirectly	O
affects	O
the	O
variability	O
in	O
patient	O
care	O
outcomes	O
of	O
patients	O
with	O
type	B-T047
2	I-T047
diabetes	I-T047
.	O
This	O
review	O
contributes	O
to	O
the	O
understanding	O
of	O
the	O
KMAP	B-T058
-	I-T058
O	I-T058
framework	I-T058
and	O
how	O
it	O
can	O
guide	O
the	O
care	B-T058
management	I-T058
of	O
patients	O
with	O
type	B-T047
2	I-T047
diabetes	I-T047
.	O
It	O
will	O
allow	O
the	O
tailoring	O
of	O
interventions	B-T058
to	O
be	O
more	O
effective	O
through	O
knowledge	B-T033
enhancement	O
,	O
increased	O
motivation	O
,	O
attitudinal	O
changes	O
,	O
and	O
improved	B-T033
preventive	B-T058
practice	I-T058
to	O
reduce	O
the	O
progression	O
of	O
type	B-T047
2	I-T047
diabetes	I-T047
and	O
comorbidities	O
.	O
Furthermore	O
,	O
the	O
use	O
of	O
health	O
information	O
technology	O
for	O
enhancing	O
changes	O
in	O
KMAP	B-T058
and	O
communications	O
is	O
advocated	O
in	O
health	B-T058
promotion	I-T058
and	O
development	O
.	O
      
SNAI1	O
promotes	O
the	O
development	O
of	O
HCC	B-T191
through	O
the	O
enhancement	O
of	O
proliferation	O
and	O
inhibition	O
of	O
apoptosis	O
SNAI1	O
,	O
a	O
zinc	O
-	O
finger	O
transcription	O
factor	O
,	O
plays	O
an	O
important	O
role	O
in	O
the	O
induction	O
of	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
in	O
various	O
cancers	B-T191
.	O
However	O
,	O
the	O
possible	O
functions	O
of	O
SNAI1	O
in	O
the	O
proliferation	O
and	O
apoptosis	O
of	O
hepatocellular	B-T191
carcinoma	I-T191
have	O
not	O
been	O
clearly	O
identified	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
and	O
mechanisms	O
of	O
SNAI1	O
in	O
the	O
proliferation	O
and	O
apoptosis	O
of	O
hepatocellular	B-T191
carcinoma	I-T191
using	O
clinical	O
samples	O
and	O
cell	O
lines	O
.	O
We	O
found	O
that	O
SNAI1	O
is	O
highly	O
expressed	O
in	O
the	O
tissues	O
of	O
liver	B-T191
cancer	I-T191
compared	O
with	O
adjacent	O
nontumor	O
tissues	O
.	O
SNAI1	O
is	O
also	O
highly	O
expressed	O
in	O
the	O
hepatoma	O
cell	O
lines	O
HepG2	O
,	O
SMMC-7721	O
,	O
and	O
BEL-7402	O
compared	O
with	O
the	O
human	O
normal	O
liver	O
cell	O
line	O
L02	O
.	O
We	O
also	O
observed	O
that	O
SNAI1	O
expression	O
was	O
correlated	O
with	O
distal	O
metastasis	O
,	O
incomplete	O
tumor	B-T191
capsule	I-T191
formation	I-T191
,	O
and	O
histological	O
differentiation	O
in	O
hepatocellular	B-T191
carcinoma	I-T191
(	O
HCC	B-T191
)	O
.	O
Moreover	O
,	O
we	O
demonstrated	O
that	O
knockdown	O
of	O
SNAI1	O
via	O
lentiviral	B-T005
vectors	B-T121
of	O
RNAi	O
against	O
SNAI	O
inhibited	O
cell	O
proliferation	O
by	O
inducing	O
G1	O
arrest	O
,	O
which	O
was	O
accompanied	O
by	O
the	O
downregulation	O
of	O
cyclin	O
D1	O
but	O
not	O
that	O
of	O
cyclin	O
A.	O
In	O
addition	O
,	O
knockdown	O
of	O
SNAI1	O
promoted	O
apoptosis	O
by	O
decreasing	O
the	O
expression	O
of	O
Bcl-2	O
.	O
In	O
conclusion	O
,	O
our	O
findings	O
revealed	O
that	O
SNAI1	O
is	O
involved	O
in	O
the	O
development	O
of	O
hepatocellular	B-T191
carcinoma	I-T191
via	O
regulating	O
the	O
growth	O
and	O
apoptosis	O
of	O
tumor	O
cells	O
.	O
      
Proliferation	O
-enhancing	O
effects	O
of	O
gastrodin	O
on	O
RSC96	O
Schwann	O
cells	O
by	O
regulating	O
ERK1	O
/	O
2	O
and	O
PI3	O
K	O
signaling	O
pathways	O
The	O
proliferation	O
and	O
migration	O
of	O
Schwann	O
cells	O
(	O
SCs	O
)	O
are	O
essential	O
in	O
the	O
process	O
of	O
peripheral	B-T061
nerve	I-T061
repair	I-T061
.	O
A	O
large	O
amount	O
of	O
studies	O
focused	O
on	O
the	O
promotion	O
of	O
the	O
growth	O
of	O
SCs	O
for	O
cell	B-T061
based	I-T061
therapy	I-T061
.	O
Gastrodin	O
(	O
GAS	O
)	O
,	O
the	O
main	O
constituent	O
of	O
a	O
Chinese	O
traditional	O
herbal	B-T121
medicine	I-T121
named	O
Gastrodia	O
elata	O
Blume	O
,	O
has	O
been	O
reported	B-T058
to	O
be	O
associated	O
with	O
neuroprotective	O
properties	O
.	O
Besides	O
,	O
GAS	O
activated	O
MAPK	O
and	O
PI3	O
K	O
signaling	O
pathways	O
which	O
are	O
often	O
involved	O
in	O
growth	O
of	O
nerve	O
cells	O
were	O
also	O
reported	B-T058
.	O
Based	O
on	O
the	O
hypothesis	O
that	O
GAS	O
may	O
have	O
an	O
effect	O
on	O
SCs	O
growth	O
,	O
we	O
studied	O
the	O
effect	O
of	O
GAS	O
on	O
rat	O
RSC96	O
Schwann	O
cells	O
(	O
SCs	O
)	O
and	O
further	O
explored	O
the	O
underlying	O
mechanism	O
.	O
Various	O
concentration	O
of	O
GAS	O
(	O
0μM	O
,	O
50μM	O
,	O
100μM	O
,	O
and	O
200μM	O
)	O
was	O
used	O
for	O
treatment	B-T061
of	O
RSC96	O
SCs	O
,	O
with	O
the	O
cell	O
proliferation	O
and	O
gene	O
expression	O
of	O
several	O
neurotrophic	O
factors	O
to	O
be	O
detected	O
.	O
Regulation	O
of	O
MAPK	O
and	O
PI3	O
K	O
signaling	O
pathways	O
were	O
assayed	O
by	O
detecting	O
phosphorylation	O
of	O
ERK1	O
/	O
2	O
and	O
Akt	O
.	O
The	O
results	O
showed	O
that	O
GAS	O
could	O
effectively	O
promote	O
proliferation	O
of	O
RSC96	O
SCs	O
in	O
a	O
dose	O
-	O
and	O
time	O
-dependent	O
manner	O
.	O
The	O
best	O
performance	O
was	O
obtained	O
at	O
the	O
concentration	O
of	O
200μM.	O
Exploration	B-T061
of	O
the	O
underlying	O
mechanism	O
showed	O
that	O
GAS	O
probably	O
affects	O
SCs	O
metabolism	O
through	O
inhibiting	O
ERK1	O
/	O
2	O
phosphorylation	O
and	O
activating	O
Akt	O
phosphorylation	O
in	O
RSC96	O
SCs	O
.	O
This	O
study	O
may	O
provide	O
reference	O
for	O
its	O
application	O
in	O
treatment	B-T061
of	O
peripheral	O
nerve	O
injuries	O
.	O
      
Technical	O
note	O
:	O
A	O
preliminary	O
comparative	O
study	O
between	O
classical	O
and	O
interventional	O
radiological	O
approaches	O
for	O
multi	O
-	O
phase	O
post	B-T060
-	I-T060
mortem	I-T060
CT	I-T060
angiography	B-T060
Multi	O
-	O
phase	O
post	B-T060
-	I-T060
mortem	I-T060
computed	I-T060
tomography	I-T060
angiography	I-T060
(	O
MPMCTA	B-T060
)	O
is	O
a	O
new	O
diagnostic	B-T060
tool	I-T060
,	O
used	O
in	O
forensic	O
pathology	O
.	O
On	O
the	O
one	O
hand	O
,	O
this	O
technique	O
allows	O
a	O
better	O
and	O
direct	B-T033
visualization	I-T033
of	O
vascular	B-T047
and	O
solid	B-T023
organ	I-T023
lesions	B-T033
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
invasiveness	O
of	O
the	O
procedure	O
-which	O
requires	O
surgical	B-T033
denudation	I-T033
(	O
inguinal	O
and/or	O
cervical	O
)	O
and	O
the	O
insertion	B-T061
of	O
surgical	O
cannulas	O
-leads	O
to	O
many	O
relatives	O
refusing	O
scientific	B-T060
autopsies	I-T060
.	O
Our	O
hypothesis	O
states	O
that	O
a	O
minimally	O
-	O
invasive	O
procedure	O
combining	O
interventional	B-T061
radiological	I-T061
techniques	I-T061
with	O
MPMCTA	B-T060
(	O
replacement	O
of	O
surgical	O
cannulas	O
by	O
radiological	O
catheters	O
)	O
will	O
improve	B-T033
the	O
approval	O
rate	O
of	O
scientific	B-T060
autopsies	I-T060
by	O
families	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
feasibility	O
of	O
the	O
minimally	O
-	O
invasive	O
MPMCTA	B-T060
approach	O
and	O
to	O
compare	O
its	O
performance	O
to	O
the	O
current	O
reference	O
-	O
standard	O
(	O
the	O
conventional	O
approach	O
)	O
.	O
We	O
included	O
consecutively	O
16	O
corpses	B-T017
divided	O
in	O
two	O
groups	O
according	O
to	O
the	O
contrast	O
enhancement	O
approach	O
:	O
radiological	O
catheters	O
(	O
n=8	O
)	O
,	O
and	O
surgical	O
cannulas	O
(	O
n=8	O
)	O
.	O
Corpses	B-T017
were	O
chosen	O
and	O
assigned	O
randomly	O
from	O
our	O
local	O
data	O
.	O
The	O
quality	O
of	O
the	O
imaging	B-T060
procedure	I-T060
was	O
compared	O
according	O
to	O
four	O
items	O
:	O
global	B-T023
vascular	I-T023
opacification	O
,	O
cerebral	O
venous	O
opacification	O
,	O
and	O
lower	B-T023
limbs	I-T023
opacification	O
(	O
arterial	O
and	O
venous	O
)	O
.	O
A	O
minimally	O
-	O
invasive	O
approach	O
for	O
scientific	B-T060
autopsies	I-T060
is	O
feasible	O
through	O
a	O
radiological	O
catheter	O
.	O
Vascular	B-T023
opacification	O
was	O
optimal	O
in	O
8	O
out	O
of	O
8	O
cases	O
and	O
was	O
no	O
less	O
effective	O
than	O
the	O
control	O
reference	O
group	O
using	O
surgical	O
cannula	O
incision	B-T061
associated	O
with	O
their	O
non	O
-	O
occlusive	O
aspects	O
.	O
      
Design	O
,	O
synthesis	O
,	O
molecular	O
docking	O
,	O
anti	B-T195
-	I-T195
Proteus	I-T195
mirabilis	I-T195
and	O
urease	O
inhibition	O
of	O
new	O
fluoroquinolone	B-T121
carboxylic	I-T121
acid	I-T121
derivatives	I-T121
New	O
hydroxamic	O
acid	O
,	O
hydrazide	O
and	O
amide	O
derivatives	O
of	O
ciprofloxacin	B-T121
in	O
addition	O
to	O
their	O
analogues	O
of	O
levofloxacin	B-T195
were	O
prepared	O
and	O
identified	O
by	O
different	O
spectroscopic	O
techniques	O
.	O
Some	O
of	O
the	O
prepared	O
compounds	B-T121
revealed	O
good	O
activity	O
against	O
the	O
urease	O
splitting	O
bacteria	B-T007
,	O
Proteus	B-T007
mirabilis	I-T007
.	O
The	O
urease	O
inhibitory	O
activity	O
was	O
investigated	O
using	O
indophenol	B-T059
method	I-T059
.	O
Most	O
of	O
the	O
tested	O
compounds	B-T121
showed	O
better	O
activity	O
than	O
the	O
reference	O
acetohydroxamic	B-T121
acid	I-T121
(	O
AHA	B-T121
)	O
.	O
The	O
ciprofloxacin	B-T121
hydrazide	I-T121
derivative	I-T121
3a	I-T121
and	O
levofloxacin	B-T121
hydroxamic	I-T121
acid	I-T121
7	I-T121
experienced	O
the	O
highest	O
activity	O
(	O
IC50	O
=	O
1.22μM	O
and	O
2.20μM	O
,	O
respectively	O
)	O
.	O
Molecular	O
docking	O
study	O
revealed	O
high	O
spontaneous	O
binding	O
ability	O
of	O
the	O
tested	O
compounds	B-T121
to	O
the	O
active	O
site	O
of	O
urease	O
.	O
      
Transcriptional	O
enhancement	O
of	O
Smn	O
levels	O
in	O
motoneurons	O
is	O
crucial	O
for	O
proper	O
axon	O
morphology	O
in	O
zebrafish	O
An	O
unresolved	O
mystery	O
in	O
the	O
field	O
of	O
spinal	B-T047
muscular	I-T047
atrophy	I-T047
(	O
SMA	B-T047
)	O
is	O
why	O
a	O
reduction	O
of	O
the	O
ubiquitously	O
expressed	O
Smn	O
protein	O
causes	O
defects	B-T033
mostly	O
in	O
motoneurons	O
.	O
We	O
addressed	O
the	O
possibility	O
that	O
this	O
restricted	O
vulnerability	O
stems	O
from	O
elevated	O
Smn	O
expression	O
in	O
motoneurons	O
.	O
To	O
explore	O
this	O
,	O
we	O
established	O
an	O
ex	O
vivo	O
zebrafish	O
culture	O
system	O
of	O
GFP	O
-	O
marked	O
motoneurons	O
to	O
quantitatively	O
measure	O
Smn	O
protein	O
and	O
smn	O
mRNA	O
levels	O
as	O
well	O
as	O
promoter	O
activity	O
in	O
motoneurons	O
versus	O
other	O
cell	O
types	O
.	O
Importantly	O
,	O
we	O
uncovered	O
that	O
Smn	O
levels	O
are	O
elevated	O
in	O
motoneurons	O
by	O
means	O
of	O
transcriptional	O
activation	O
.	O
In	O
addition	O
,	O
we	O
identified	O
the	O
ETS	O
family	O
transcription	O
factor	O
Etv5b	O
to	O
be	O
responsible	O
for	O
increased	O
smn	O
transcription	O
in	O
motoneurons	O
.	O
Moreover	O
,	O
we	O
established	O
that	O
the	O
additional	O
supply	O
of	O
Smn	O
protein	O
in	O
motoneurons	O
is	O
necessary	O
for	O
proper	O
axonogenesis	O
in	O
a	O
cell	O
-	O
autonomous	O
manner	O
.	O
These	O
findings	O
demonstrate	O
the	O
reliance	O
of	O
motoneurons	O
on	O
more	O
Smn	O
,	O
thereby	O
adding	O
a	O
novel	O
piece	O
of	O
evidence	O
for	O
their	O
increased	O
vulnerability	O
under	O
SMA	B-T047
conditions	I-T047
.	O
      
The	O
ABBA	O
study	O
-	O
approach	O
bias	O
modification	O
in	O
bulimia	B-T048
nervosa	I-T048
and	O
binge	B-T048
eating	I-T048
disorder	I-T048
:	O
study	O
protocol	O
for	O
a	O
randomised	O
controlled	O
trial	O
The	O
core	O
symptoms	B-T184
of	O
bulimia	B-T048
nervosa	I-T048
(	O
BN	B-T048
)	O
and	O
binge	B-T048
eating	I-T048
disorder	I-T048
(	O
BED	B-T048
)	O
are	O
recurrent	B-T033
episodes	I-T033
of	I-T033
binge	I-T033
eating	I-T033
.	O
Despite	O
negative	B-T048
psychological	I-T048
and	O
physical	B-T033
consequences	I-T033
,	O
BN	B-T048
/	I-T048
BED	I-T048
patients	O
show	O
uncontrollable	O
approach	O
tendencies	O
towards	O
food	O
.	O
This	O
cognitive	O
bias	O
occurs	O
at	O
an	O
early	O
stage	O
of	O
information	O
processing	O
.	O
Cognitive	B-T061
bias	I-T061
modification	I-T061
(	O
CBM	B-T061
)	O
directly	O
targets	O
such	O
biases	O
and	O
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
treating	B-T061
several	O
mental	B-T048
disorders	I-T048
.	O
In	O
alcohol	B-T048
addiction	I-T048
,	O
automatic	O
action	O
tendencies	O
towards	O
alcohol	O
cues	O
and	O
relapse	O
rates	O
were	O
successfully	O
reduced	O
by	O
a	O
specific	O
form	O
of	O
CBM	B-T061
,	O
termed	O
approach	O
bias	O
modification	O
.	O
Based	O
on	O
these	O
findings	O
and	O
data	O
from	O
a	O
proof	O
-	O
of	O
-	O
concept	O
study	O
in	O
people	O
with	O
high	O
levels	O
of	O
food	O
craving	O
,	O
CBM	O
is	O
considered	O
a	O
promising	O
new	O
treatment	O
approach	O
for	O
BN	B-T048
/	I-T048
BED	I-T048
.	O
Given	O
the	O
similarities	O
between	O
BN	B-T048
/	I-T048
BED	I-T048
and	O
addictive	B-T048
disorders	I-T048
,	O
the	O
rationale	O
for	O
using	O
approach	O
bias	O
modification	O
appears	O
to	O
be	O
particularly	O
strong	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
examine	O
whether	O
,	O
compared	O
to	O
a	O
sham	O
training	O
,	O
computerised	O
approach	O
bias	O
modification	O
(	O
10	O
sessions	O
)	O
can	O
reduce	O
binge	B-T033
-	I-T033
eating	I-T033
episodes	I-T033
in	O
BN	B-T048
/	I-T048
BED	I-T048
patients	O
from	O
pre	O
-	O
treatment	O
to	O
follow	O
-	O
up	O
.	O
Additionally	O
,	O
we	O
will	O
investigate	O
whether	O
this	O
CBM	B-T061
programme	O
also	O
reduces	O
global	O
eating	B-T048
disorder	I-T048
psychopathology	I-T048
,	O
trait	O
and	O
cue	O
-	O
elicited	O
food	O
craving	O
,	O
food	O
intake	O
as	O
well	O
as	O
approach	O
and	O
attentional	O
bias	O
towards	O
visual	O
food	O
cues	O
.	O
Treatment	B-T061
acceptance	I-T061
will	O
be	O
determined	O
by	O
attrition	O
rates	O
and	O
responses	O
on	O
a	O
feedback	O
form	O
.	O
This	O
is	O
a	O
double	O
-	O
blind	O
,	O
randomised	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
-	O
group	O
superiority	O
trial	O
with	O
two	O
parallel	O
arms	O
.	O
A	O
total	O
of	O
54	O
BN	B-T048
/	I-T048
BED	I-T048
patients	O
will	O
be	O
recruited	O
.	O
Approach	O
bias	O
towards	O
food	O
will	O
be	O
retrained	O
by	O
a	O
computer	O
task	O
adopting	O
an	O
implicit	O
learning	O
paradigm	O
.	O
Patients	O
in	O
the	O
control	O
condition	O
(	O
sham	O
)	O
will	O
conduct	O
a	O
similar	O
task	O
but	O
will	O
not	O
be	O
trained	O
to	O
avoid	O
food	O
cues	O
.	O
Methods	O
against	O
bias	O
include	O
public	O
registration	O
,	O
randomisation	O
by	O
a	O
central	O
study	O
office	O
,	O
standardisation	O
of	O
the	O
treatments	O
and	O
blinding	O
of	O
assessors	O
.	O
Furthermore	O
,	O
the	O
session	O
number	O
and	O
duration	O
will	O
be	O
equivalent	O
in	O
the	O
two	O
conditions	O
.	O
This	O
is	O
the	O
first	O
registered	O
randomised	O
controlled	O
trial	O
of	O
approach	O
bias	O
modification	O
in	O
a	O
clinical	O
BN	O
/	O
BED	O
sample	O
.	O
Results	O
from	O
this	O
study	O
will	O
provide	O
an	O
indication	O
of	O
the	O
efficacy	O
of	O
approach	O
bias	O
modification	O
training	O
for	O
BN	B-T048
/	I-T048
BED	I-T048
and	O
the	O
potential	O
mechanisms	O
of	O
action	O
underlying	O
this	O
treatment	B-T061
.	O
DRKS00010231	O
(	O
retrospectively	O
registered	O
on	O
24	O
March	O
2016	O
;	O
first	O
version	O
)	O
.	O
      
The	O
neural	O
legacy	O
of	O
a	O
single	O
concussion	O
It	O
has	O
been	O
hypothesized	O
that	O
concussions	O
impart	O
lasting	O
brain	O
damage	O
,	O
even	O
after	O
a	O
patient	O
has	O
ostensibly	O
recovered	O
.	O
This	O
hypothesis	O
is	O
based	O
largely	O
upon	O
neuropathological	O
studies	O
in	O
deceased	O
athletes	O
,	O
however	O
,	O
leaving	O
open	O
the	O
question	O
of	O
whether	O
it	O
can	O
be	O
detected	B-T061
in	O
vivo	O
.	O
We	O
measured	O
neural	O
responses	O
to	O
speech	O
in	O
collegiate	O
student	O
-	O
athletes	O
with	O
a	O
history	B-T033
of	O
a	O
single	O
concussion	O
from	O
which	O
they	O
had	O
recovered	O
.	O
These	O
student	O
-	O
athletes	O
had	O
weaker	O
responses	O
to	O
speech	O
than	O
age	O
-	O
and	O
position	O
-	O
matched	O
peers	O
.	O
This	O
group	O
difference	O
suggests	O
that	O
concussions	O
engender	O
small	O
,	O
but	O
detectable	O
,	O
changes	O
in	O
brain	O
function	O
prior	O
to	O
the	O
emergence	O
of	O
frank	O
behavioral	B-T184
indications	I-T184
.	O
      
Learned	O
helplessness	O
at	O
fifty	O
:	O
Insights	O
from	O
neuroscience	O
Learned	O
helplessness	O
,	O
the	O
failure	O
to	O
escape	O
shock	O
induced	O
by	O
uncontrollable	O
aversive	O
events	O
,	O
was	O
discovered	O
half	O
a	O
century	O
ago	O
.	O
Seligman	O
and	O
Maier	O
(	O
1967	O
)	O
theorized	O
that	O
animals	O
learned	O
that	O
outcomes	O
were	O
independent	O
of	O
their	O
responses	O
-that	O
nothing	O
they	O
did	O
mattered	O
-	O
and	O
that	O
this	O
learning	O
undermined	O
trying	O
to	O
escape	O
.	O
The	O
mechanism	O
of	O
learned	O
helplessness	O
is	O
now	O
very	O
well	O
-	O
charted	O
biologically	O
,	O
and	O
the	O
original	O
theory	O
got	O
it	O
backward	O
.	O
Passivity	O
in	O
response	O
to	O
shock	O
is	O
not	O
learned	O
.	O
It	O
is	O
the	O
default	O
,	O
unlearned	O
response	O
to	O
prolonged	O
aversive	O
events	O
and	O
it	O
is	O
mediated	O
by	O
the	O
serotonergic	O
activity	O
of	O
the	O
dorsal	B-T023
raphe	I-T023
nucleus	I-T023
,	O
which	O
in	O
turn	O
inhibits	O
escape	O
.	O
This	O
passivity	O
can	O
be	O
overcome	O
by	O
learning	O
control	O
,	O
with	O
the	O
activity	O
of	O
the	O
medial	B-T023
prefrontal	I-T023
cortex	I-T023
,	O
which	O
subserves	O
the	O
detection	B-T033
of	O
control	O
leading	O
to	O
the	O
automatic	O
inhibition	O
of	O
the	O
dorsal	B-T023
raphe	I-T023
nucleus	I-T023
.	O
So	O
animals	O
learn	O
that	O
they	O
can	O
control	O
aversive	O
events	O
,	O
but	O
the	O
passive	O
failure	O
to	O
learn	O
to	O
escape	O
is	O
an	O
unlearned	O
reaction	O
to	O
prolonged	O
aversive	B-T061
stimulation	I-T061
.	O
In	O
addition	O
,	O
alterations	O
of	O
the	O
ventromedial	B-T023
prefrontal	I-T023
cortex	I-T023
-	O
dorsal	B-T023
raphe	I-T023
pathway	O
can	O
come	O
to	O
subserve	O
the	O
expectation	O
of	O
control	O
.	O
We	O
speculate	O
that	O
default	O
passivity	O
and	O
the	O
compensating	O
detection	B-T033
and	O
expectation	O
of	O
control	O
may	O
have	O
substantial	O
implications	O
for	O
how	O
to	O
treat	O
depression	B-T048
.	O
(	O
PsycINFO	O
Database	O
Record	O
      
Intra	O
-	O
articular	O
implantation	B-T061
of	O
collagen	O
scaffold	O
carriers	O
is	O
safe	O
in	O
both	O
native	O
and	O
arthrofibrotic	B-T047
rabbit	O
knee	O
joints	O
Sustained	O
intra	O
-	O
articular	O
delivery	O
of	O
pharmacological	O
agents	O
is	O
an	O
attractive	O
modality	O
but	O
requires	O
use	O
of	O
a	O
safe	O
carrier	O
that	O
would	O
not	O
induce	O
cartilage	O
damage	O
or	O
fibrosis	O
.	O
Collagen	O
scaffolds	O
are	O
widely	O
available	O
and	O
could	O
be	O
used	O
intra	O
-	O
articularly	O
,	O
but	O
no	O
investigation	B-T058
has	O
looked	O
at	O
the	O
safety	O
of	O
collagen	O
scaffolds	O
within	O
synovial	O
joints	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
safety	O
of	O
collagen	O
scaffold	O
implantation	B-T061
in	O
a	O
validated	O
in	O
vivo	O
animal	O
model	O
of	O
knee	B-T047
arthrofibrosis	I-T047
.	O
A	O
total	O
of	O
96	O
rabbits	O
were	O
randomly	O
and	O
equally	O
assigned	O
to	O
four	O
different	O
groups	O
:	O
arthrotomy	B-T061
alone	O
;	O
arthrotomy	B-T061
and	O
collagen	O
scaffold	O
placement	B-T058
;	O
contracture	B-T190
surgery	B-T061
;	O
and	O
contracture	B-T190
surgery	B-T061
and	O
collagen	O
scaffold	O
placement	B-T058
.	O
Animals	O
were	O
killed	O
in	O
equal	O
numbers	O
at	O
72	O
hours	O
,	O
two	O
weeks	O
,	O
eight	O
weeks	O
,	O
and	O
24	O
weeks	O
.	O
Joint	B-T190
contracture	I-T190
was	O
measured	O
,	O
and	O
cartilage	O
and	O
synovial	B-T023
samples	O
underwent	O
histological	B-T059
analysis	I-T059
.	O
Animals	O
that	O
underwent	O
arthrotomy	B-T061
had	O
equivalent	O
joint	B-T190
contractures	I-T190
regardless	O
of	O
scaffold	O
implantation	B-T061
(	O
-13.9	O
°	O
versus	O
-10.9	O
°	O
,	O
equivalence	O
limit	O
15	O
°	O
)	O
.	O
Animals	O
that	O
underwent	O
surgery	B-T061
to	O
induce	O
contracture	B-T190
did	O
not	O
demonstrate	O
equivalent	O
joint	B-T190
contracture	I-T190
joint	B-T190
contracture	I-T190
s	I-T190
with	O
(	O
41.8	O
°	O
)	O
or	O
without	O
(	O
53.9	O
°	O
)	O
collagen	O
scaffold	O
implantation	B-T061
.	O
Chondral	O
damage	O
occurred	O
in	O
similar	O
rates	O
with	O
(	O
11	O
of	O
48	O
)	O
and	O
without	O
(	O
nine	O
of	O
48	O
)	O
scaffold	O
implantation	B-T061
.	O
No	O
significant	O
difference	O
in	O
synovitis	B-T047
was	O
noted	O
between	O
groups	O
.	O
Absorption	O
of	O
the	O
collagen	O
scaffold	O
occurred	O
within	O
eight	O
weeks	O
in	O
all	O
animals	O
CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
intra	O
-	O
articular	O
implantation	B-T061
of	O
a	O
collagen	O
sponge	O
does	O
not	O
induce	O
synovitis	B-T047
or	O
cartilage	O
damage	O
.	O
Implantation	B-T061
in	O
a	O
native	O
joint	O
does	O
not	O
seem	O
to	O
induce	O
contracture	B-T190
.	O
Implantation	B-T061
of	O
the	O
collagen	O
sponge	O
in	O
a	O
rabbit	O
knee	O
model	O
of	O
contracture	B-T190
may	O
decrease	O
the	O
severity	O
of	O
the	O
contracture	B-T190
.Cite	O
this	O
article	O
:	O
J.	O
A.	O
Walker	O
,	O
T.	O
J.	O
Ewald	O
,	O
E.	O
Lewallen	O
,	O
A.	O
Van	O
Wijnen	O
,	O
A.	O
D.	O
Hanssen	O
,	O
B.	O
F.	O
Morrey	O
,	O
M.	O
E.	O
Morrey	O
,	O
M.	O
P.	O
Abdel	O
,	O
J.	O
Sanchez	O
-	O
Sotelo	O
.	O
Intra	O
-	O
articular	O
implantation	O
of	O
collagen	O
scaffold	O
carriers	O
is	O
safe	O
in	O
both	O
native	O
and	O
arthrofibrotic	O
rabbit	O
knee	O
joints	O
.	O
Bone	O
Joint	O
Res	O
2016;6:162	O
-	O
171	O
.	O
DOI	O
:	O
10.1302/2046	O
-	O
3758.63.BJR-2016	O
-	O
0193	O
.	O
      
Masters	O
Athletes	O
:	O
Exemplars	O
of	O
Successful	O
Aging	O
?	O
Global	O
population	O
aging	O
has	O
raised	B-T033
academic	I-T033
interest	I-T033
in	O
successful	O
aging	O
to	O
a	O
public	O
policy	O
priority	O
.	O
Currently	O
there	O
is	O
no	O
consensus	O
regarding	O
the	O
definition	O
of	O
successful	O
aging	O
.	O
However	O
,	O
a	O
synthesis	O
of	O
research	O
shows	O
successful	O
aging	O
can	O
be	O
defined	O
as	O
a	O
late	B-T048
-	I-T048
life	I-T048
process	I-T048
of	I-T048
change	I-T048
characterized	O
by	O
high	B-T033
physical	I-T033
,	O
psychological	O
,	O
cognitive	O
,	O
and	O
social	O
functioning	O
.	O
Masters	O
athletes	O
systematically	O
train	O
for	O
,	O
and	O
compete	O
in	O
,	O
organized	O
forms	O
of	O
team	O
and	O
individual	O
sport	O
specifically	O
designed	O
for	O
older	O
adults	O
.	O
Masters	O
athletes	O
are	O
often	O
proposed	O
as	O
exemplars	O
of	O
successful	O
aging	O
.	O
However	O
,	O
their	O
aging	B-T033
status	I-T033
has	O
never	O
been	O
examined	O
using	O
a	O
comprehensive	O
multidimensional	O
successful	O
aging	O
definition	O
.	O
Here	O
,	O
we	O
examine	O
the	O
successful	O
aging	O
literature	O
,	O
propose	O
a	O
successful	O
aging	O
definition	O
based	O
on	O
this	O
literature	O
,	O
present	O
evidence	O
which	O
suggests	O
masters	O
athletes	O
could	O
be	O
considered	O
exemplars	O
of	O
successful	O
aging	O
according	O
to	O
the	O
proposed	O
definition	O
,	O
and	O
list	O
future	O
experimental	O
research	O
directions	O
.	O
      
Synovial	B-T191
sarcoma	I-T191
of	O
the	O
hypopharynx	O
in	O
a	O
pediatric	O
patient	O
:	O
Case	O
report	O
Synovial	B-T191
sarcoma	I-T191
(	O
SS	B-T191
)	O
is	O
uncommon	O
high	O
grade	O
soft	O
tissue	O
sarcoma	B-T191
,	O
accounting	O
for	O
less	O
than	O
10	O
%	O
of	O
all	O
head	B-T191
and	I-T191
neck	I-T191
sarcomas	I-T191
.	O
Also	O
,	O
about	O
10	O
%	O
of	O
SS	B-T191
occur	O
within	O
the	O
Head	O
&	O
Neck	O
.	O
In	O
the	O
pediatric	O
population	O
,	O
SS	B-T191
is	O
an	O
extremely	O
rare	O
head	B-T191
&	I-T191
neck	I-T191
malignancy	I-T191
.	O
We	O
present	O
a	O
case	O
of	O
sixteen	O
years	O
old	O
boy	O
diagnosed	B-T033
with	O
SS	B-T191
situated	O
of	O
the	O
hypopharynx	O
treated	B-T061
by	I-T061
surgical	B-T061
excision	I-T061
and	O
post	B-T033
operative	I-T033
radio	B-T061
-	O
chemotherapy	B-T061
.	O
This	O
anatomical	O
location	O
brings	O
additional	O
functional	O
challenges	B-T058
(	O
swallowing	O
,	O
phonation	O
,	O
respiration	O
)	O
,	O
especially	O
in	O
the	O
pediatric	O
population	O
.	O
Pre	O
-	O
operative	O
and	O
even	O
post	B-T033
-	I-T033
operative	I-T033
histopathological	O
diagnosis	B-T033
of	O
SS	B-T191
remains	O
difficult	O
.	O
Optimal	O
treatment	B-T061
of	O
Head	O
&	O
Neck	O
SS	B-T191
has	O
to	O
balance	O
functional	O
and	O
oncologic	O
aspects	O
.	O
SS	B-T191
is	O
an	O
extremely	O
rare	O
head	B-T191
&	I-T191
neck	I-T191
malignancy	I-T191
in	O
pediatric	O
population	O
.	O
It	O
has	O
multifaceted	O
challenges	B-T058
including	O
pre	O
and	O
post	B-T033
-	I-T033
operative	I-T033
histopathological	O
diagnosis	B-T033
and	O
optimal	O
modality	O
of	O
treatment	B-T061
.	O
Clinical	O
judgment	O
,	O
especially	O
in	O
the	O
pediatric	O
population	O
,	O
needs	O
to	O
balance	O
tumor	O
free	O
margins	O
and	O
organ	B-T061
preservation	I-T061
in	O
head	O
and	O
neck	O
region	O
.	O
      
Urticarial	B-T047
exanthema	B-T184
due	O
to	O
hepatitis	B-T047
B	I-T047
in	O
a	O
pregnant	O
woman	O
,	O
mimicking	O
a	O
polymorphic	B-T047
eruption	I-T047
of	O
pregnancy	O
Hepatitis	B-T047
B	I-T047
virus	I-T047
(	I-T047
HBV	I-T047
)	I-T047
infection	I-T047
in	I-T047
pregnant	I-T047
women	I-T047
is	O
very	O
rare	O
in	O
western	O
countries	O
,	O
thus	O
,	O
cutaneous	O
manifestation	O
of	O
HBV	B-T047
infection	I-T047
may	O
be	O
confused	O
with	O
a	O
dermatosis	B-T047
specific	O
of	O
pregnancy	O
.	O
We	O
report	O
a	O
39	O
-	O
year	O
-	O
old	O
woman	O
who	O
presented	O
in	O
her	O
20th	O
week	O
of	O
pregnancy	O
with	O
a	O
pruritic	B-T047
rash	I-T047
,	O
which	O
consisted	O
of	O
generalized	O
erythematous	B-T033
plaques	I-T033
,	O
some	O
of	O
them	O
with	O
a	O
purple	B-T033
centre	I-T033
.	O
Serology	B-T059
testing	I-T059
showed	O
acute	B-T047
HBV	I-T047
infection	I-T047
,	O
and	O
a	O
biopsy	B-T060
revealed	O
a	O
superficial	O
and	O
interstitial	B-T033
perivascular	I-T033
inflammatory	I-T033
infiltrate	I-T033
of	O
lymphocytes	O
and	O
eosinophils	O
.	O
A	O
diagnosis	B-T033
of	O
exanthema	B-T184
due	O
to	O
acute	B-T047
hepatitis	I-T047
B	I-T047
infection	I-T047
was	O
established	O
.	O
The	O
patient	O
delivered	B-T033
a	O
clinically	B-T033
healthy	I-T033
boy	I-T033
,	O
who	O
was	O
given	O
the	O
first	O
dose	O
of	O
the	O
HBV	B-T061
vaccine	I-T061
and	O
intravenous	B-T121
specific	I-T121
immunoglobulin	I-T121
,	O
followed	O
by	O
the	O
second	O
dose	O
2	O
months	O
later	O
,	O
and	O
did	O
not	O
get	O
infected	B-T033
with	O
HBV	B-T005
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
describing	O
HBV	B-T047
exanthema	B-T184
in	O
a	O
pregnant	O
woman	O
,	O
which	O
led	O
to	O
early	O
action	O
for	O
the	O
newborn	O
,	O
avoiding	O
vertical	O
transmission	O
and	O
its	O
high	O
prevalence	O
of	O
cirrhosis	B-T047
and	O
hepatocellular	B-T191
carcinoma	I-T191
.	O
      
Functional	O
Impairment	O
in	O
Children	O
With	O
Externalizing	B-T048
Behavior	I-T048
Disorders	I-T048
:	O
Psychometric	B-T060
Properties	O
of	O
the	O
Weiss	O
Functional	O
Impairment	O
Rating	O
Scale	O
-	O
Parent	O
Report	O
in	O
a	O
German	O
Clinical	O
Sample	O
To	O
examine	O
the	O
psychometric	B-T060
properties	O
of	O
a	O
German	O
adaptation	O
of	O
the	O
Weiss	O
Functional	O
Impairment	O
Rating	O
Scale	O
-	O
Parent	O
Report	O
(	O
WFIRS	O
-	O
P	O
)	O
in	O
a	O
clinical	O
sample	O
of	O
children	O
(	O
4	O
-	O
12	O
years	O
)	O
with	O
externalizing	B-T048
behavior	I-T048
disorders	I-T048
.	O
Data	O
were	O
collected	O
within	O
two	O
clinical	O
trials	O
(	O
N	O
=	O
264	O
)	O
.	O
Factorial	O
validity	O
,	O
reliability	O
,	O
and	O
divergent	O
validity	O
from	O
symptoms	B-T184
of	O
ADHD	B-T048
and	O
oppositional	B-T048
defiant	I-T048
disorder	I-T048
(	O
ODD	B-T048
)	O
were	O
assessed	O
.	O
Confirmatory	O
factor	O
analyses	O
revealed	O
that	O
a	O
bifactor	O
model	O
consistent	O
with	O
the	O
theoretical	O
assumption	O
of	O
a	O
general	O
construct	O
of	O
impairment	O
(	O
total	O
scale	O
)	O
and	O
additional	O
specific	O
factors	O
(	O
subscales	O
)	O
provided	O
satisfactory	O
data	O
fit	O
.	O
Model	O
-based	O
reliability	O
estimates	O
showed	O
that	O
both	O
the	O
general	O
construct	O
and	O
specific	O
factors	O
accounted	O
for	O
item	O
variance	O
.	O
Internal	O
consistencies	O
were	O
>	O
.70	O
,	O
part	O
-	O
whole	O
corrected	O
item	O
-	O
scale	O
correlations	O
mostly	O
>	O
.30	O
.	O
Correlations	O
between	O
the	O
WFIRS	O
-	O
P	O
Scales	O
and	O
ADHD	B-T048
and	O
ODD	B-T048
symptoms	B-T184
were	O
low	O
to	O
moderate	O
.	O
The	O
results	O
support	O
the	O
factorial	O
validity	O
,	O
reliability	O
,	O
and	O
divergent	O
validity	O
of	O
the	O
WFIRS	O
-	O
P.	O
      
Xylan	O
-	O
based	O
temperature	O
/	O
pH	O
sensitive	O
hydrogels	O
for	O
drug	O
controlled	O
release	O
Xylan	O
-	O
based	O
temperature	O
/	O
pH	O
sensitive	O
hydrogels	O
were	O
prepared	O
by	O
the	O
crosslinking	O
copolymerization	O
of	O
xylan	O
with	O
N	O
-	O
isopropylacrylamide	O
(	O
NIPAm	O
)	O
and	O
acrylic	O
acid	O
(	O
AA	O
)	O
using	O
N	O
,	O
Ń-methylenebis	O
-	O
acrylamide	O
(	O
MBA	O
)	O
as	O
a	O
cross	O
-	O
linker	O
and	O
2,2	O
-	O
dimethoxy-2	O
-	O
phenylacetophenone	O
as	O
a	O
photoinitiator	O
via	O
ultraviolet	O
irradiation	O
.	O
The	O
influence	O
of	O
the	O
NIPAm	O
,	O
AA	O
and	O
MBA	O
amount	O
on	O
properties	O
of	O
xylan	O
-	O
based	O
hydrogels	O
was	O
discussed	O
.	O
The	O
morphology	O
and	O
interactions	O
of	O
hydrogels	O
were	O
characterized	O
by	O
SEM	B-T059
and	O
FTIR	O
.	O
The	O
lower	O
critical	O
solution	O
temperature	O
(	O
LCST	O
)	O
of	O
hydrogels	O
was	O
investigated	O
by	O
DSC	B-T059
.	O
The	O
results	B-T033
indicated	O
that	O
the	O
LCST	O
of	O
hydrogels	O
emerged	O
at	O
around	O
34	O
°	O
C	O
and	O
increased	O
with	O
increasing	O
the	O
AA	O
content	O
.	O
The	O
drug	B-T121
encapsulation	O
efficiency	O
of	O
as	O
-	O
prepared	O
hydrogels	O
reached	O
to	O
97.60	O
%	O
and	O
the	O
cumulative	O
release	O
rate	O
of	O
acetylsalicylic	B-T121
acid	I-T121
was	O
90.12	O
%	O
and	O
26.35	O
%	O
in	O
the	O
intestinal	B-T023
and	O
gastric	O
fluid	O
,	O
respectively	O
.	O
Xylan	O
-	O
based	O
hydrogels	O
were	O
proved	O
to	O
be	O
biocompatible	O
with	O
NIH3T3	O
cell	O
by	O
MTT	O
assay	O
and	O
showed	O
the	O
promising	O
application	O
as	O
drug	O
carriers	O
for	O
the	O
intestinal	B-T023
-	O
targeted	O
oral	B-T061
drug	I-T061
delivery	I-T061
.	O
      
The	O
Benefits	O
of	O
Combination	B-T061
Therapy	I-T061
with	O
Esomeprazole	B-T121
and	O
Rebamipide	B-T121
in	O
Symptom	B-T184
Improvement	O
in	O
Reflux	B-T047
Esophagitis	I-T047
:	O
An	O
International	O
Multicenter	O
Study	O
To	O
investigate	O
the	O
effects	O
of	O
esomeprazole	B-T121
and	O
rebamipide	B-T121
combination	B-T061
therapy	I-T061
on	O
symptomatic	B-T184
improvement	O
in	O
patients	O
with	O
reflux	B-T047
esophagitis	I-T047
.	O
A	O
total	O
of	O
501	O
patients	O
with	O
reflux	B-T047
esophagitis	I-T047
were	O
randomized	O
into	O
one	O
of	O
the	O
following	O
two	O
treatment	B-T061
regimens	I-T061
:	O
40	O
mg	O
esomeprazole	B-T121
plus	O
300	O
mg	O
rebamipide	B-T121
daily	O
(	O
combination	B-T061
therapy	I-T061
group	O
)	O
or	O
40	O
mg	O
esomeprazole	B-T121
daily	O
(	O
monotherapy	B-T061
group	O
)	O
.	O
We	O
used	O
a	O
symptom	B-T184
questionnaire	O
that	O
evaluated	O
heartburn	B-T184
,	O
acid	B-T184
regurgitation	I-T184
,	O
and	O
four	O
upper	B-T047
gastrointestinal	I-T047
symptoms	I-T047
.	O
The	O
primary	O
efficacy	O
end	O
point	O
was	O
the	O
mean	O
decrease	O
in	O
the	O
total	O
symptom	B-T033
score	I-T033
.	O
The	O
mean	O
decreases	O
in	O
the	O
total	O
symptom	B-T033
score	I-T033
at	O
4	O
weeks	O
were	O
estimated	O
to	O
be	O
-18.1±13.8	O
in	O
the	O
combination	B-T061
therapy	I-T061
group	O
and	O
-15.1±11.9	O
in	O
the	O
monotherapy	B-T061
group	O
(	O
p=0.011	O
)	O
.	O
Changes	O
in	O
reflux	B-T047
symptom	B-T184
s	O
from	O
baseline	O
after	O
4	O
weeks	O
of	O
treatment	B-T061
were	O
-8.4±6.6	O
in	O
the	O
combination	B-T061
therapy	I-T061
group	O
and	O
-6.8±5.9	O
in	O
the	O
monotherapy	B-T061
group	O
(	O
p=0.009	O
)	O
.	O
Over	O
a	O
4-	O
week	O
treatment	B-T061
course	O
,	O
esomeprazole	B-T121
and	O
rebamipide	B-T121
combination	B-T061
therapy	I-T061
was	O
more	O
effective	O
in	O
decreasing	B-T033
the	O
symptoms	B-T184
of	O
reflux	B-T047
esophagitis	I-T047
than	O
esomeprazole	B-T121
monotherapy	B-T061
.	O
      
Association	O
of	O
Radiomics	O
and	O
Metabolic	O
Tumor	O
Volumes	O
in	O
Radiation	B-T061
Treatment	I-T061
of	O
Glioblastoma	B-T191
Multiforme	I-T191
To	O
build	O
a	O
framework	O
for	O
investigation	B-T058
of	O
the	O
associations	O
between	O
imaging	B-T060
,	O
clinical	O
target	O
volumes	O
(	O
CTVs	O
)	O
,	O
and	O
metabolic	O
tumor	O
volumes	O
(	O
MTVs	O
)	O
features	O
for	O
better	O
understanding	O
of	O
the	O
underlying	O
information	O
in	O
the	O
CTVs	O
and	O
dependencies	O
between	O
these	O
volumes	O
.	O
High	O
-	O
throughput	O
extraction	O
of	O
imaging	B-T060
and	O
metabolomic	O
quantitative	O
features	O
from	O
magnetic	B-T060
resonance	I-T060
imaging	I-T060
(	O
MRI	B-T060
)	O
and	O
magnetic	B-T060
resonance	I-T060
spectroscopic	I-T060
imaging	I-T060
of	O
glioblastoma	B-T191
multiforme	I-T191
(	O
GBM	B-T191
)	O
results	O
in	O
tens	O
of	O
variables	O
per	O
patient	O
.	O
In	O
radiation	B-T061
therapy	I-T061
of	O
GBM	B-T191
the	O
relevant	O
metabolic	O
tumor	O
volumes	O
(	O
MTVs	O
)	O
are	O
related	O
to	O
aberrant	O
levels	O
of	O
N	O
-	O
acetyl	O
aspartate	O
(	O
NAA	O
)	O
and	O
choline	B-T121
(	O
Cho	B-T121
)	O
.	O
The	O
corresponding	O
clinical	O
target	O
volumes	O
(	O
CTVs	O
)	O
for	O
radiation	B-T061
therapy	I-T061
are	O
based	O
on	O
contrast	B-T060
-	I-T060
enhanced	I-T060
T1	I-T060
-	I-T060
weighted	I-T060
(	O
CE	B-T060
-	I-T060
T1w	I-T060
)	O
and	O
T2	B-T060
-	I-T060
weighted	I-T060
(	I-T060
T2w)/fluid	I-T060
-	I-T060
attenuated	I-T060
inversion	I-T060
recovery	I-T060
MRI	I-T060
.	O
Necrotic	B-T033
portions	I-T033
,	O
enhancing	B-T033
lesion	I-T033
,	O
and	O
edema	B-T184
were	O
manually	O
contoured	O
on	O
CE	O
-	O
T1w	O
/	O
T2w	O
images	O
for	O
17	O
GBM	B-T191
patients	O
.	O
Clinical	O
target	O
volumes	O
and	O
MTVs	O
for	O
NAA	O
(	O
MTVNAA	O
)	O
and	O
Cho	B-T121
(	O
MTVCho	O
)	O
were	O
constructed	O
.	O
Imaging	B-T060
and	O
metabolic	O
features	O
related	O
to	O
size	O
,	O
shape	O
,	O
and	O
signal	O
intensities	O
of	O
the	O
volumes	O
were	O
extracted	O
.	O
Tumors	B-T191
were	O
also	O
scored	O
categorically	O
for	O
10	O
semantic	O
imaging	O
traits	O
by	O
a	O
neuroradiologist	O
.	O
All	O
features	O
were	O
investigated	O
for	O
redundancy	O
.	O
Two	O
-	O
way	O
correlations	O
between	O
imaging	O
and	O
CTVs	O
/	O
MTVs	O
features	O
were	O
visualized	O
as	O
heatmaps	O
.	O
Associations	O
between	O
MTVNAA	O
and	O
MTVCho	O
and	O
imaging	O
features	O
were	O
studied	O
using	O
Spearman	O
correlation	O
.	O
Forty	O
-	O
eight	O
imaging	O
features	O
were	O
extracted	O
per	O
patient	O
.	O
Half	O
of	O
the	O
imaging	O
traits	O
were	O
replaced	O
with	O
automatically	O
extracted	O
continuous	O
variables	O
.	O
Twenty	O
features	O
were	O
extracted	O
from	O
CTVs	O
and	O
MTVs	O
.	O
A	O
series	O
of	O
semantic	O
imaging	O
traits	O
were	O
replaced	O
with	O
automatically	O
extracted	O
continuous	O
variables	O
.	O
There	O
were	O
multiple	O
(	O
22	O
)	O
significant	O
correlations	O
of	O
imaging	O
measures	O
with	O
CTVs	O
/	O
MTVNAA	O
,	O
whereas	O
there	O
were	O
only	O
6	O
with	O
CTVs	O
/	O
MTVCho	O
.	O
A	O
framework	O
for	O
investigation	O
of	O
codependencies	O
between	O
MRI	B-T060
and	O
magnetic	B-T060
resonance	I-T060
spectroscopic	I-T060
imaging	I-T060
radiomic	O
features	O
and	O
CTVs	O
/	O
MTVs	O
has	O
been	O
established	O
.	O
The	O
MTV	O
for	O
NAA	O
was	O
found	O
to	O
be	O
closely	O
associated	O
with	O
MRI	B-T060
volumes	O
,	O
whereas	O
very	O
few	O
imaging	O
features	O
were	O
related	O
to	O
MTVCho	O
,	O
indicating	O
that	O
Cho	B-T121
provides	O
additional	O
information	O
to	O
imaging	B-T060
.	O
      
Cyclic	B-T047
thrombocytopenia	I-T047
synchronizing	O
with	O
the	O
menstrual	O
cycle	O
showing	O
periodic	O
phases	O
of	O
thrombocytopenia	B-T047
and	O
rebound	O
thrombocytosis	B-T047
A	O
37-	O
year	O
-old	O
woman	O
was	O
admitted	B-T058
to	O
our	O
hospital	O
for	O
purpura	B-T047
involving	O
the	O
extremities	B-T023
and	O
thrombocytopenia	B-T047
.	O
Prednisolone	B-T121
(	O
PSL	B-T121
)	O
was	O
administered	O
based	O
on	O
a	O
diagnosis	B-T033
of	O
idiopathic	B-T047
thrombocytopenic	I-T047
purpura	I-T047
(	O
ITP	B-T047
)	O
,	O
but	O
was	O
not	O
effective	O
for	O
maintaining	O
her	O
platelet	B-T059
count	I-T059
within	O
the	O
normal	O
range	O
,	O
which	O
showed	O
cyclic	O
fluctuation	O
corresponding	O
to	O
the	O
menstrual	O
cycle	O
.	O
Therefore	O
,	O
we	O
discontinued	B-T033
PSL	B-T121
,	O
and	O
cyclic	B-T047
thrombocytopenia	I-T047
(	O
CTP	B-T047
)	O
was	O
diagnosed	B-T033
.	O
CTP	B-T047
is	O
a	O
rare	B-T047
disease	I-T047
which	O
is	O
usually	O
treated	O
as	O
ITP	B-T047
but	O
with	O
no	B-T033
response	I-T033
.	O
Although	O
the	O
exact	O
cause	O
of	O
CTP	B-T047
is	O
uncertain	B-T033
,	O
in	O
our	O
case	O
,	O
a	O
hormonal	O
mechanism	O
may	O
be	O
responsible	O
for	O
fluctuating	O
platelet	B-T059
count	I-T059
.	O
      
LAMP-2	O
mediates	O
oxidative	O
stress	O
-dependent	O
cell	O
death	O
in	O
Zn(2	B-T121
+	I-T121
)	I-T121
-	O
treated	B-T061
lung	B-T023
epithelium	O
cells	O
Zinc	B-T121
is	O
an	O
essential	O
element	O
for	O
the	O
biological	O
system	O
.	O
However	O
,	O
excessive	O
exogenous	O
Zn(2	B-T121
+	I-T121
)	I-T121
would	O
disrupt	O
cellular	O
Zn(2	O
+	O
)	O
homeostasis	O
and	O
cause	O
toxicity	O
.	O
In	O
particular	O
,	O
Zinc	B-T121
salts	I-T121
or	O
ZnO	B-T121
nanoparticles	O
exposure	O
could	O
induce	O
respiratory	O
injury	O
.	O
Although	O
previous	O
studies	O
have	O
indicated	O
that	O
organelle	O
damage	O
(	O
including	O
mitochondria	O
or	O
lysosomes	O
)	O
and	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
production	O
are	O
involved	O
in	O
Zn(2	B-T121
+	I-T121
)	I-T121
-induced	O
toxicity	O
,	O
the	O
interplay	O
between	O
mitochondria	O
/	O
lysosomes	O
damage	O
and	O
ROS	O
production	O
is	O
obscure	O
.	O
Herein	O
,	O
we	O
demonstrated	O
that	O
Zn(2	B-T121
+	I-T121
)	I-T121
could	O
induce	O
deglycosylation	O
of	O
lysosome	O
-	O
associated	O
membrane	O
protein	O
1	O
and	O
2	O
(	O
LAMP-1	O
and	O
LAMP-2	O
)	O
,	O
which	O
primarily	O
locate	O
in	O
late	O
endosomes	O
/	O
lysosomes	O
,	O
in	O
A549	O
lung	O
epithelium	O
cells	O
.	O
Intriguingly	O
,	O
LAMP-2	O
knockdown	O
further	O
aggravated	O
Zn(2	B-T121
+	I-T121
)	I-T121
-mediated	O
ROS	O
production	O
and	O
cell	O
death	O
,	O
indicating	O
LAMP-2	O
(	O
not	O
LAMP-1	O
)	O
was	O
involved	O
in	O
Zn(2	B-T121
+	I-T121
)	I-T121
-induced	O
toxicity	O
.	O
Our	O
results	O
provide	O
a	O
new	O
insight	O
that	O
LAMP-2	O
contributes	O
to	O
the	O
ROS	O
clearance	O
and	O
cell	O
death	O
induced	O
by	O
Zn(2	B-T121
+	I-T121
)	I-T121
treatment	B-T061
,	O
which	O
would	O
help	O
us	O
to	O
get	O
a	O
better	O
understanding	O
of	O
Zn(2	B-T121
+	I-T121
)	I-T121
-induced	O
toxicity	O
in	O
respiratory	O
system	O
.	O
      
Impact	O
of	O
an	O
Educational	B-T061
Intervention	I-T061
to	O
Improve	B-T033
Antibiotic	B-T195
Prescribing	B-T058
for	O
Nurse	O
Practitioners	O
in	O
a	O
Pediatric	O
Urgent	O
Care	O
Center	O
Up	O
to	O
21	O
%	O
of	O
pediatric	B-T058
visits	I-T058
result	O
in	O
an	O
antibiotic	B-T195
prescription	B-T058
,	O
and	O
a	O
large	O
portion	O
of	O
these	O
are	O
unnecessary	O
.	O
To	O
determine	O
if	O
educational	O
sessions	O
would	O
reduce	O
inappropriate	O
antibiotic	B-T195
use	O
.	O
Intervention	O
study	O
evaluating	B-T058
antibiotic	B-T195
prescribing	B-T058
following	O
educational	O
sessions	O
for	O
urinary	B-T047
tract	I-T047
infection	I-T047
,	O
skin	B-T047
and	O
soft	B-T047
tissue	I-T047
infection	I-T047
,	O
pharyngitis	B-T047
,	O
upper	B-T047
respiratory	I-T047
tract	I-T047
infection	I-T047
,	O
acute	B-T047
otitis	I-T047
media	I-T047
,	O
and	O
acute	B-T047
bacterial	I-T047
sinusitis	I-T047
.	O
A	O
total	O
of	O
26	O
out	O
of	O
43	O
(	O
60	O
%	O
)	O
nurse	O
practitioners	O
in	O
4	O
urgent	O
care	O
centers	O
were	O
enrolled	B-T058
in	O
the	O
study	O
.	O
The	O
rate	O
of	O
inappropriate	O
antibiotic	B-T195
use	O
among	O
all	O
conditions	O
was	O
10	O
%	O
before	O
and	O
8	O
%	O
after	O
the	O
intervention	B-T061
(	O
p	O
=	O
.02	O
)	O
.	O
A	O
decrease	O
in	O
inappropriate	O
antibiotic	B-T195
prescribing	B-T058
was	O
seen	O
after	O
the	O
educational	O
session	O
(	O
p	O
<	O
.01	O
)	O
.	O
The	O
most	O
common	O
reasons	O
for	O
inappropriate	O
antibiotic	B-T195
prescribing	B-T058
were	O
too	O
broad	O
(	O
41	O
%	O
)	O
,	O
wrong	B-T033
dosage	I-T033
(	O
22	O
%	O
)	O
,	O
and	O
not	B-T033
indicated	I-T033
(	O
17	O
%	O
)	O
.	O
Educational	O
sessions	O
led	O
to	O
improvement	O
in	O
overall	O
inappropriate	O
antibiotic	B-T195
use	O
.	O
Additional	O
stewardship	O
interventions	B-T061
are	O
needed	O
to	O
further	O
reduce	O
unnecessary	O
antibiotic	B-T195
use	O
.	O
      
Optical	O
tweezers	O
studies	O
of	O
transcription	O
by	O
eukaryotic	O
RNA	O
polymerases	O
Transcription	O
is	O
the	O
first	O
step	O
in	O
the	O
expression	O
of	O
genetic	O
information	O
and	O
it	O
is	O
carried	O
out	O
by	O
large	O
macromolecular	O
enzymes	O
called	O
RNA	O
polymerases	O
.	O
Transcription	O
has	O
been	O
studied	O
for	O
many	O
years	O
and	O
with	O
a	O
myriad	O
of	O
experimental	O
techniques	O
,	O
ranging	O
from	O
bulk	O
studies	O
to	O
high	B-T059
-	I-T059
resolution	I-T059
transcript	I-T059
sequencing	I-T059
.	O
In	O
this	O
review	O
,	O
we	O
emphasise	O
the	O
advantages	O
of	O
using	O
single	O
-	O
molecule	O
techniques	O
,	O
particularly	O
optical	O
tweezers	O
,	O
to	O
study	O
transcription	O
dynamics	O
.	O
We	O
give	O
an	O
overview	O
of	O
the	O
latest	O
results	O
in	O
the	O
single	O
-	O
molecule	O
transcription	O
field	O
,	O
focusing	O
on	O
transcription	O
by	O
eukaryotic	O
RNA	O
polymerases	O
.	O
Finally	O
,	O
we	O
evaluate	O
recent	O
quantitative	O
models	O
that	O
describe	O
the	O
biophysics	O
of	O
RNA	O
polymerase	O
translocation	O
and	O
backtracking	O
dynamics	O
.	O
      
Comparison	O
of	O
Esophageal	O
,	O
Rectal	B-T033
,	O
and	O
Gastrointestinal	O
Temperatures	O
During	O
Passive	O
Rest	O
After	O
Exercise	O
in	O
The	O
Heat	O
:	O
The	O
Influence	O
of	O
Hydration	B-T033
It	O
is	O
unknown	O
how	O
valid	O
esophageal	O
,	O
rectal	B-T033
,	O
and	O
gastrointestinal	O
temperatures	O
(	O
TES	O
,	O
TRE	B-T033
,	O
and	O
TGI	O
)	O
compare	O
after	O
exercise	B-T184
-	I-T184
induced	I-T184
hyperthermia	B-T184
in	O
various	O
hydration	B-T033
states	I-T033
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
differences	O
between	O
TES	O
,	O
TRE	B-T033
,	O
and	O
TGI	O
during	O
passive	O
rest	O
following	O
exercise	B-T184
-	I-T184
induced	I-T184
hyperthermia	B-T184
under	O
two	O
different	O
hydration	B-T033
states	I-T033
:	O
euhydrated	B-T033
(	O
EU	B-T033
)	O
and	O
hypohydrated	B-T047
(	O
HY	B-T047
)	O
.	O
Randomized	O
-	O
crossover	O
design	O
.	O
Controlled	O
laboratory	O
setting	O
.	O
Nine	O
recreationally	O
active	O
male	O
participants	O
(	O
mean±	O
SD	O
;	O
age	O
,	O
24±4	O
;	O
height	O
,	O
177.3±9.9	O
cm	O
;	O
body	O
mass	O
,	O
76.7±11.6	O
kg	O
;	O
body	O
fat	O
,	O
14.7±5.8	O
%	O
)	O
.	O
Participants	O
completed	O
two	O
trials	O
(	O
EU	B-T033
and	O
HY	B-T047
)	O
consisting	O
of	O
a	O
bout	O
of	O
treadmill	O
exercise	O
(	O
a	O
10	O
minute	O
walk	O
ranging	O
4.8	O
-	O
7.2km·hr(-1	O
)	O
at	O
a	O
5	O
%	O
grade	O
followed	O
by	O
a	O
20	O
minute	O
jog	O
ranging	O
8.0	O
-	O
12.1km·hr(-1	O
)	O
at	O
a	O
1	O
%	O
grade	O
)	O
in	O
a	O
hot	O
environment	O
(	O
ambient	O
temperature	O
,	O
39.3±1.0	O
°	O
C	O
;	O
relative	O
humidity	O
,	O
37.6±6.0	O
%	O
;	O
wet	O
bulb	O
globe	O
temperature	O
,	O
31.3±1.5	O
°	O
C	O
)	O
followed	O
by	O
passive	O
rest	O
.	O
Root	O
mean	O
squared	O
difference	O
(	O
RMSD	O
)	O
was	O
used	O
to	O
compare	O
the	O
variance	O
of	O
temperature	O
readings	O
at	O
corresponding	O
time	O
points	O
for	O
TRE	B-T033
vs	O
TGI	O
,	O
TRE	B-T033
vs	O
TES	O
,	O
and	O
TGI	O
vs	O
TES	O
in	O
EU	B-T033
and	O
HY	B-T047
.	O
RMSD	O
values	O
were	O
compared	O
using	O
three	O
-	O
way	O
repeated	O
measures	O
ANOVA	O
.	O
Post	O
hoc	O
analysis	O
of	O
significant	O
main	O
effects	O
was	O
done	O
using	O
Tukey	O
's	O
HSD	O
with	O
significance	O
set	O
at	O
p<0.05	O
.	O
RMSD	O
values	O
(	O
°	O
C	O
)	O
for	O
all	O
device	O
comparisons	O
were	O
significantly	O
different	O
in	O
EU	B-T033
(	O
TRE	B-T033
-	O
TGI	O
,	O
0.11±0.12	O
;	O
TRE	B-T033
-	O
TES	O
,	O
1.58±1.01	O
;	O
TGI	O
-	O
TES	O
,	O
2.04±1.19	O
)	O
than	O
HY	B-T047
(	O
TRE	B-T033
-	O
TGI	O
,	O
0.22±0.28	O
;	O
TRE	B-T033
-	O
TES	O
,	O
1.27±0.61	O
;	O
TGI	O
-	O
TES	O
,	O
1.16±0.76	O
)	O
(	O
p<0.01	O
)	O
.	O
Across	O
the	O
45-	O
minute	O
bout	O
of	O
passive	O
rest	O
,	O
there	O
were	O
no	O
differences	O
in	O
TRE	B-T033
,	O
TGI	O
and	O
TES	O
between	O
EU	B-T033
and	O
HY	B-T047
trials	O
(	O
p=0.468	O
)	O
.	O
During	O
passive	O
rest	O
after	O
exercise	O
in	O
the	O
heat	O
,	O
TRE	B-T033
and	O
TGI	O
were	O
in	O
good	O
agreement	O
when	O
tracking	O
body	O
temperature	O
,	O
with	O
a	O
better	O
agreement	O
appearing	O
in	O
those	O
maintaining	O
a	O
state	O
of	O
euhydration	B-T033
versus	O
those	O
who	O
became	O
hypohydrated	B-T047
during	O
exercise	O
;	O
however	O
,	O
this	O
small	O
difference	O
does	O
not	O
appear	O
to	O
be	O
of	O
clinical	B-T033
significance	I-T033
.	O
      
Liquid	B-T059
chromatography	I-T059
-	I-T059
mass	I-T059
spectrometry	I-T059
-based	O
quantitative	B-T059
proteomics	I-T059
analysis	I-T059
reveals	O
chondroprotective	B-T033
effects	I-T033
of	O
astragaloside	B-T121
IV	I-T121
in	O
interleukin-1β	O
-	O
induced	O
SW1353	O
chondrocyte	O
-	O
like	O
cells	O
Chondrocyte	O
apoptosis	O
played	O
a	O
key	O
role	O
on	O
the	O
progression	O
of	O
Osteoarthritis	B-T047
(	O
OA	B-T047
)	O
.	O
Safe	O
and	O
effective	O
drugs	B-T061
are	O
urgently	O
needed	O
for	O
the	O
treatment	O
of	O
OA	B-T047
.	O
Previous	O
study	O
reported	O
that	O
Astragaloside	B-T121
IV	I-T121
(	O
ASG	B-T121
-	I-T121
IV	I-T121
)	O
had	O
exerted	O
a	O
protective	O
effect	O
against	O
articular	B-T047
cartilage	I-T047
degeneration	I-T047
by	O
promoting	O
rapid	O
proliferation	O
of	O
chondrocyte	O
.	O
Therefore	O
,	O
the	O
aim	O
of	O
our	O
study	O
is	O
to	O
explore	O
the	O
effects	O
and	O
mechanisms	O
of	O
ASG	B-T121
-	I-T121
IV	I-T121
in	O
chondrocyte	O
apoptosis	O
.	O
Isobaric	B-T059
Tags	I-T059
For	I-T059
Relative	I-T059
And	I-T059
Absolute	I-T059
Quantitation	I-T059
(	I-T059
iTRAQ)-based	I-T059
quantitative	I-T059
proteomics	I-T059
was	O
used	O
to	O
quantitatively	O
detect	B-T033
and	O
map	O
proteins	O
in	O
SW1353	O
chondrocyte	O
-	O
like	O
cells	O
pre	O
-	O
treated	O
with	O
ASG	B-T121
-	I-T121
IV	I-T121
or	O
interleukin-1β	O
(	O
IL-1β	O
)	O
or	O
ASG	B-T121
-	I-T121
IV	I-T121
+	O
IL-1β	O
.	O
The	O
iTRAQ	O
-	O
labeled	O
peptides	O
were	O
fractionated	O
by	O
high	B-T059
-	I-T059
accuracy	I-T059
liquid	I-T059
chromatography	I-T059
-	I-T059
mass	I-T059
spectrometry	I-T059
(	O
LC	B-T059
-	I-T059
MS	I-T059
)	O
.	O
Cell	O
apoptosis	O
and	O
differentially	O
expressed	O
proteins	O
was	O
detected	B-T033
by	O
flow	B-T059
cytometry	I-T059
(	O
FCM	B-T059
)	O
,	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
,	O
and	O
western	B-T059
blotting	I-T059
,	O
respectively	O
.	O
The	O
apoptosis	O
of	O
the	O
IL-1β	O
-	O
induced	O
SW1353	O
cells	O
treated	O
with	O
ASG	B-T121
-	I-T121
IV	I-T121
was	O
greatly	O
inhibited	O
.	O
Bioinformatics	B-T059
analysis	I-T059
revealed	O
that	O
gamma	O
actin	O
1	O
(	O
ACTG1	O
)	O
and	O
Yes	O
Associated	O
Protein	O
1	O
(	O
YAP1	O
)	O
,	O
participating	O
in	O
the	O
Hippo	O
signaling	O
pathway	O
and	O
Vitronectin	O
(	O
VTN	O
)	O
and	O
Collagen	O
Type	O
I	O
Alpha	O
1	O
Chain	O
(	O
COL1A1	O
)	O
,	O
involving	O
in	O
the	O
extracellular	O
matrix	O
(	O
ECM)-receptor	O
interaction	O
signaling	O
pathway	O
,	O
were	O
all	O
significantly	O
up	O
-	O
regulated	O
in	O
the	O
IL-1β	O
-	O
induced	O
SW1353	O
cells	O
after	O
treatment	O
with	O
ASG	B-T121
-	I-T121
IV	I-T121
.	O
The	O
qRT	O
-	O
PCR	O
and	O
Western	B-T059
blotting	I-T059
results	O
confirmed	O
the	O
up	O
-	O
regulation	O
of	O
these	O
four	O
genes	O
.	O
ASG	B-T121
-	I-T121
IV	I-T121
played	O
a	O
positive	B-T033
role	I-T033
in	O
human	O
osteoarthritic	O
chondrocyte	O
apoptosis	O
,	O
possibly	O
through	O
modulation	O
of	O
the	O
Hippo	O
signaling	O
pathway	O
by	O
up	O
-	O
regulating	O
YAP1	O
and	O
ACTG1	O
expression	O
,	O
and	O
also	O
by	O
up	O
-	O
regulating	O
VTN	O
and	O
COL1A1	O
,	O
which	O
are	O
involved	O
in	O
the	O
ECM	O
-	O
receptor	O
interaction	O
pathway	O
.	O
Taken	O
together	O
,	O
all	O
the	O
results	O
suggested	O
that	O
ASG	B-T121
-	I-T121
IV	I-T121
had	O
a	O
novel	O
therapeutic	O
potential	O
for	O
the	O
treatment	O
of	O
OA	B-T047
.	O
      
Intratympanic	O
steroid	O
delivery	O
by	O
an	O
indwelling	O
catheter	O
in	O
refractory	B-T047
severe	I-T047
sudden	I-T047
sensorineural	I-T047
hearing	I-T047
loss	I-T047
Many	O
studies	O
over	O
the	O
last	O
decade	O
showed	O
favorable	O
outcomes	O
with	O
intratympanic	O
(	O
IT	O
)	O
steroid	B-T061
treatment	I-T061
,	O
alone	O
as	O
salvage	B-T061
treatment	I-T061
or	O
in	O
combination	O
with	O
conventional	O
systemic	B-T061
therapy	I-T061
(	O
ST	B-T061
)	O
.	O
However	O
,	O
in	O
severe	O
to	O
profound	O
sensorineural	B-T047
hearing	I-T047
loss	I-T047
resistant	O
to	O
ST	B-T061
,	O
the	O
optimal	O
infusion	B-T061
mode	I-T061
,	O
the	O
type	O
and	O
concentration	O
of	O
the	O
solution	O
,	O
the	O
preferable	O
drug	B-T121
,	O
its	O
total	O
amount	O
,	O
and	O
the	O
duration	O
and	O
fractionation	B-T061
of	O
the	O
treatment	B-T061
are	O
still	O
debated	O
.	O
Aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
feasibility	O
and	O
the	O
outcomes	O
of	O
a	O
direct	O
and	O
constant	O
IT	O
delivery	O
of	O
dexamethasone	B-T121
(	O
DEX	B-T121
)	O
by	O
means	O
of	O
a	O
new	O
indwelling	O
catheter	O
.	O
A	O
prospective	O
case	O
-	O
control	O
study	O
in	O
a	O
tertiary	O
referral	O
university	O
hospital	O
.	O
Ninety	O
-	O
nine	O
subjects	O
treated	O
with	O
ST	B-T061
only	O
and	O
28	O
with	O
additional	O
IT	O
DEX	B-T121
have	O
been	O
included	O
in	O
the	O
study	O
.	O
A	O
4	O
Fr	O
catheter	O
inserted	B-T058
in	O
a	O
sub	O
-	O
annular	O
fashion	O
with	O
a	O
minimal	O
postero	O
-	O
inferior	O
tympanotomy	B-T061
through	O
and	O
endocanalar	O
approach	O
under	O
local	B-T061
anesthesia	I-T061
.	O
DEX	B-T121
4mg	O
/	O
ml	O
delivered	O
daily	O
,	O
up	O
to	O
7	O
days	O
.	O
Daily	O
bone	B-T060
and	I-T060
air	I-T060
-	I-T060
conducted	I-T060
pure	I-T060
tone	I-T060
and	O
speech	B-T060
audiometry	I-T060
were	O
performed	O
with	O
a	O
follow	O
-	O
up	O
at	O
1	O
,	O
3	O
,	O
6	O
months	O
after	O
treatment	B-T061
.	O
Twenty	O
-	O
one	O
out	O
of	O
28	O
patients	O
(	O
75	O
%	O
)	O
refractory	O
to	O
ST	B-T061
gained	O
on	O
average	O
24.0dB±20.5dB	O
HL	B-T033
after	O
IT	O
-	O
DEX	B-T121
,	O
compared	O
to	O
35.4	O
%	O
(	O
average	O
6.7dB±16.6dB	O
HL	B-T033
)	O
of	O
those	O
receiving	O
only	O
medical	O
ST	B-T061
(	O
p<0.001	O
)	O
.	O
No	O
significant	O
side	O
effects	O
were	O
noted	O
.	O
In	O
severe	O
to	O
profound	O
sudden	B-T184
deafness	I-T184
refractory	O
to	O
conventional	O
ST	B-T061
,	O
the	O
daily	O
perfusion	B-T061
of	O
4mg	O
/	O
ml	O
DEX	B-T121
through	O
an	O
intratympanic	O
catheter	O
is	O
an	O
easy	O
,	O
well	O
accepted	O
procedure	O
that	O
enables	O
patients	O
to	O
receive	O
a	O
drug	B-T121
in	O
the	O
middle	O
ear	O
in	O
a	O
repeatable	B-T061
or	O
sustained	O
form	O
,	O
with	O
minimal	O
discomfort	O
and	O
a	O
partial	O
rescue	O
(	O
67.86	O
%	O
)	O
and	O
a	O
speech	O
recognition	O
gain	O
of	O
39	O
%	O
.	O
      
Development	O
and	O
Validation	O
of	O
a	O
New	O
Reliable	O
Method	B-T059
for	O
the	O
Diagnosis	B-T033
of	O
Avian	O
Botulism	O
Liver	B-T023
is	O
a	O
reliable	O
matrix	O
for	O
laboratory	B-T059
confirmation	O
of	O
avian	O
botulism	O
using	O
real	O
-	O
time	O
PCR	O
.	O
Here	O
,	O
we	O
developed	O
,	O
optimized	O
,	O
and	O
validated	O
the	O
analytical	O
steps	O
preceding	O
PCR	O
to	O
maximize	O
the	O
detection	B-T033
of	O
Clostridium	B-T007
botulinum	I-T007
group	I-T007
III	I-T007
in	O
avian	O
liver	B-T023
.	O
These	O
pre	O
-	O
PCR	O
steps	O
included	O
enrichment	O
incubation	B-T059
of	O
the	O
whole	O
liver	B-T023
(	O
maximum	O
25	O
g	O
)	O
at	O
37	B-T059
°	I-T059
C	I-T059
for	O
at	O
least	O
24	O
h	O
in	O
an	O
anaerobic	O
chamber	O
and	O
DNA	O
extraction	O
using	O
an	O
enzymatic	B-T059
digestion	I-T059
step	O
followed	O
by	O
a	O
DNA	B-T059
purification	I-T059
step	O
.	O
Conditions	O
of	O
sample	O
storage	O
before	O
analysis	O
appear	O
to	O
have	O
a	O
strong	O
effect	O
on	O
the	O
detection	B-T033
of	O
group	B-T007
III	I-T007
C.	I-T007
botulinum	I-T007
strains	I-T007
and	O
our	O
results	O
recommend	O
storage	O
at	O
temperatures	O
below	O
-18	O
°	O
C	O
.	O
Short	O
-	O
term	O
storage	O
at	O
5	O
°	O
C	O
is	O
possible	O
for	O
up	O
to	O
24	O
h	O
,	O
but	O
a	O
decrease	O
in	O
sensitivity	O
was	O
observed	O
at	O
48	O
h	O
of	O
storage	O
at	O
this	O
temperature	O
.	O
Analysis	O
of	O
whole	O
livers	B-T023
(	O
maximum	O
25	O
g	O
)	O
is	O
required	O
and	O
pooling	O
samples	O
before	O
enrichment	B-T059
culturing	I-T059
must	O
be	O
avoided	O
.	O
Pooling	O
is	O
however	O
possible	O
before	O
or	O
after	O
DNA	O
extraction	O
under	O
certain	O
conditions	O
.	O
Whole	O
livers	B-T023
should	O
be	O
10	O
-	O
fold	O
diluted	O
in	O
enrichment	O
medium	O
and	O
homogenized	O
using	O
a	O
Pulsifier	O
®	O
blender	O
(	O
Microgen	O
,	O
Surrey	O
,	O
UK	O
)	O
instead	O
of	O
a	O
conventional	O
paddle	O
blender	O
.	O
Spiked	B-T023
liver	I-T023
samples	O
showed	O
a	O
limit	O
of	O
detection	B-T033
of	O
5	O
spores	B-T007
/g	O
liver	B-T023
for	O
types	B-T007
C	I-T007
and	O
D	B-T007
and	O
250	O
spores	B-T007
/g	O
for	O
type	B-T007
E	I-T007
E.	O
Using	O
the	O
method	B-T059
developed	O
here	O
,	O
the	O
analysis	O
of	O
268	O
samples	O
from	O
73	O
suspected	O
outbreaks	O
showed	O
100	O
%	O
specificity	O
and	O
95.35	O
%	O
sensitivity	O
compared	O
with	O
other	O
PCR	O
-based	O
methods	B-T059
considered	O
as	O
reference	O
.	O
The	O
mosaic	B-T007
type	I-T007
C	I-T007
/	O
D	B-T007
was	O
the	O
most	O
common	O
neurotoxin	O
type	O
found	O
in	O
examined	O
samples	O
,	O
which	O
included	O
both	O
wild	O
and	O
domestic	O
birds	O
.	O
      
Comparison	O
of	O
Leishmania	O
typing	B-T059
results	O
obtained	O
from	O
16	O
European	O
clinical	O
laboratories	O
in	O
2014	O
Leishmaniasis	B-T047
is	O
endemic	O
in	O
southern	O
Europe	O
,	O
and	O
in	O
other	O
European	O
countries	O
cases	O
are	O
diagnosed	B-T033
in	O
travellers	O
who	O
have	O
visited	O
affected	B-T033
areas	I-T033
both	O
within	O
the	O
continent	O
and	O
beyond	O
.	O
Prompt	O
and	O
accurate	O
diagnosis	B-T033
poses	O
a	O
challenge	O
in	O
clinical	O
practice	O
in	O
Europe	O
.	O
Different	O
methods	O
exist	O
for	O
identification	O
of	O
the	O
infecting	B-T033
Leishmania	O
species	O
.	O
Sixteen	O
clinical	O
laboratories	O
in	O
10	O
European	O
countries	O
,	O
plus	O
Israel	O
and	O
Turkey	O
,	O
conducted	O
a	O
study	O
to	O
assess	O
their	O
genotyping	B-T059
performance	O
.	O
DNA	O
from	O
21	O
promastigote	O
cultures	O
of	O
13	O
species	O
was	O
analysed	O
blindly	O
by	O
the	O
routinely	O
used	O
typing	B-T059
method	O
.	O
Five	O
different	O
molecular	O
targets	O
were	O
used	O
,	O
which	O
were	O
analysed	O
with	O
PCR	O
-	O
based	O
methods	O
.	O
Different	O
levels	O
of	O
identification	O
were	O
achieved	B-T033
,	O
and	O
either	O
the	O
Leishmania	O
subgenus	O
,	O
species	O
complex	O
,	O
or	O
actual	O
species	O
were	O
reported	O
.	O
The	O
overall	O
error	O
rate	O
of	O
strains	B-T001
placed	O
in	O
the	O
wrong	O
complex	O
or	O
species	O
was	O
8.5	O
%	O
.	O
Various	O
reasons	O
for	O
incorrect	O
typing	B-T059
were	O
identified	O
.	O
The	O
study	O
shows	O
there	O
is	O
considerable	O
room	O
for	O
improvement	O
and	O
standardisation	O
of	O
Leishmania	O
typing	B-T059
.	O
The	O
use	O
of	O
well	O
validated	O
standard	O
operating	O
procedures	O
is	O
recommended	O
,	O
covering	O
testing	O
,	O
interpretation	O
,	O
and	O
reporting	B-T058
guidelines	O
.	O
Application	O
of	O
the	O
internal	O
transcribed	O
spacer	O
1	O
of	O
the	O
rDNA	O
array	O
should	O
be	O
restricted	O
to	O
Old	O
World	O
samples	O
,	O
while	O
the	O
heat	O
-	O
shock	O
protein	O
70	O
gene	O
and	O
the	O
mini	O
-	O
exon	O
can	O
be	O
applied	O
globally	O
.	O
      
Anterolateral	O
entorhinal	B-T023
cortex	I-T023
volume	O
predicted	O
by	O
altered	O
intra	O
-	O
item	O
configural	O
processing	O
Recent	O
functional	O
imaging	B-T060
studies	I-T060
have	O
proposed	O
that	O
the	O
human	O
entorhinal	B-T023
cortex	I-T023
is	O
subdivided	O
into	O
functionally	O
distinct	O
anterolateral	O
(	O
alERC	B-T023
)	O
and	O
posteromedial	O
(	O
pmERC	B-T023
)	O
subregions	O
.	O
The	O
alERC	B-T023
overlaps	O
with	O
regions	O
that	O
are	O
affected	O
earliest	O
by	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
pathology	O
,	O
yet	O
its	O
cognitive	O
function	O
remains	O
poorly	O
understood	O
.	O
Previous	O
human	O
fMRI	B-T060
studies	I-T060
have	O
focused	O
on	O
its	O
role	O
in	O
object	O
memory	O
,	O
but	O
rodent	O
studies	O
on	O
the	O
putatively	O
homologous	O
lateral	O
entorhinal	B-T023
cortex	I-T023
suggest	O
that	O
it	O
also	O
plays	O
an	O
important	O
role	O
in	O
representing	O
spatial	O
properties	O
of	O
objects	O
.	O
In	O
order	O
to	O
investigate	O
the	O
cognitive	B-T033
effects	I-T033
of	O
human	O
alERC	B-T023
volume	O
differences	O
,	O
we	O
developed	O
an	O
eyetracking	O
-	O
based	O
task	O
to	O
evaluate	B-T058
intra	O
-	O
item	O
configural	O
processing	O
(	O
i.e.	O
,	O
processing	O
the	O
arrangement	O
of	O
an	O
object	O
's	O
features	O
)	O
,	O
and	O
used	O
manual	B-T058
segmentation	I-T058
based	O
on	O
a	O
recently-	O
developed	O
protocol	O
to	O
delineate	O
the	O
alERC	B-T023
/	O
pmERC	B-T023
as	O
well	O
as	O
other	O
medial	B-T023
temporal	I-T023
lobe	I-T023
(	O
MTL	B-T023
)	O
subregions	O
.	O
In	O
a	O
group	O
of	O
older	O
adult	O
men	O
and	O
women	O
at	O
varying	O
stages	O
of	O
brain	B-T047
atrophy	I-T047
and	O
cognitive	O
decline	O
,	O
we	O
found	O
that	O
intra	O
-	O
item	O
configural	O
processing	O
-	O
regardless	O
of	O
an	O
object	O
's	O
novelty	O
-	O
was	O
strongly	O
predicted	O
by	O
alERC	B-T023
volume	O
,	O
but	O
not	O
by	O
the	O
volume	O
of	O
any	O
other	O
MTL	B-T023
subregion	I-T023
.	O
These	O
results	O
provide	O
the	O
first	O
evidence	O
that	O
the	O
human	O
alERC	B-T023
plays	O
a	O
role	O
in	O
supporting	O
a	O
distinct	O
aspect	O
of	O
object	O
processing	O
,	O
namely	O
attending	O
to	O
the	O
arrangement	O
of	O
an	O
object	O
's	O
component	O
features	O
.	O
SIGNIFICANCE	O
STATEMENT	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
pathology	O
appears	O
earliest	O
in	O
brain	O
regions	O
that	O
overlap	O
with	O
the	O
anterolateral	O
entorhinal	B-T023
cortex	I-T023
(	O
alERC	B-T023
)	O
.	O
However	O
,	O
the	O
cognitive	O
role	O
of	O
the	O
alERC	B-T023
is	O
poorly	O
understood	O
.	O
Previous	O
human	O
studies	O
treat	B-T061
the	O
alERC	B-T023
as	O
an	O
extension	O
of	O
the	O
neighboring	O
perirhinal	O
cortex	O
,	O
supporting	O
object	O
memory	O
.	O
Animal	O
studies	O
suggest	O
that	O
the	O
alERC	B-T023
may	O
support	O
the	O
spatial	O
properties	O
of	O
objects	O
.	O
In	O
a	O
group	O
of	O
older	O
adult	O
humans	O
at	O
the	O
earliest	O
stages	O
of	O
cognitive	O
decline	O
,	O
we	O
show	O
that	O
alERC	B-T023
volume	O
selectively	O
predicted	O
configural	O
processing	O
(	O
attention	O
to	O
the	O
spatial	O
arrangement	O
of	O
an	O
object	O
's	O
parts	O
)	O
.	O
This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
a	O
cognitive	O
role	O
related	O
to	O
alERC	B-T023
volume	O
in	O
humans	O
.	O
This	O
task	O
can	O
be	O
adapted	O
to	O
serve	O
as	O
an	O
early	O
detection	O
method	O
for	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
pathology	O
.	O
      
Hounsfield	O
unit	O
recovery	O
in	O
clinical	O
cone	B-T060
beam	I-T060
CT	I-T060
images	O
of	O
the	O
thorax	O
acquired	O
for	O
image	B-T061
guided	I-T061
radiation	I-T061
therapy	I-T061
A	O
comprehensive	O
artefact	O
correction	O
method	O
for	O
clinical	O
cone	B-T060
beam	I-T060
CT	I-T060
(	O
CBCT	B-T060
)	O
images	O
acquired	O
for	O
image	B-T061
guided	I-T061
radiation	I-T061
therapy	I-T061
(	O
IGRT	B-T061
)	O
on	O
a	O
commercial	O
system	O
is	O
presented	O
.	O
The	O
method	O
is	O
demonstrated	O
to	O
reduce	O
artefacts	O
and	O
recover	O
CT	B-T060
-like	O
Hounsfield	O
units	O
(	O
HU	O
)	O
in	O
reconstructed	O
CBCT	B-T060
images	O
of	O
five	O
lung	B-T191
cancer	I-T191
patients	O
.	O
Projection	O
image	O
based	O
artefact	O
corrections	O
of	O
image	O
lag	O
,	O
detector	O
scatter	O
,	O
body	O
scatter	O
and	O
beam	B-T033
hardening	I-T033
are	O
described	O
and	O
applied	O
to	O
CBCT	B-T060
images	O
of	O
five	O
lung	B-T191
cancer	I-T191
patients	O
.	O
Image	O
quality	O
is	O
evaluated	B-T058
through	O
visual	O
appearance	O
of	O
the	O
reconstructed	O
images	O
,	O
HU	O
-correspondence	O
with	O
the	O
planning	O
CT	B-T060
images	O
,	O
and	O
total	O
volume	O
HU	O
error	O
.	O
Artefacts	O
are	O
reduced	O
and	O
CT	B-T060
-like	O
HUs	O
are	O
recovered	O
in	O
the	O
artefact	O
corrected	O
CBCT	B-T060
images	O
.	O
Visual	B-T058
inspection	I-T058
confirms	B-T033
that	O
artefacts	O
are	O
indeed	O
suppressed	O
by	O
the	O
proposed	O
method	O
,	O
and	O
the	O
HU	O
root	O
mean	O
square	O
difference	O
between	O
reconstructed	O
CBCTs	B-T060
and	O
the	O
reference	O
CT	B-T060
images	O
are	O
reduced	O
by	O
31	O
%	O
when	O
using	O
the	O
artefact	O
corrections	O
compared	O
to	O
the	O
standard	O
clinical	O
CBCT	B-T060
reconstruction	O
.	O
A	O
versatile	O
artefact	O
correction	O
method	O
for	O
clinical	O
CBCT	B-T060
images	O
acquired	O
for	O
IGRT	B-T061
has	O
been	O
developed	O
.	O
HU	O
values	O
are	O
recovered	O
in	O
the	O
corrected	O
CBCT	B-T060
images	O
.	O
The	O
proposed	O
method	O
relies	O
on	O
post	O
processing	O
of	O
clinical	O
projection	O
images	O
,	O
and	O
does	O
not	O
require	O
patient	O
specific	O
optimisation	O
.	O
It	O
is	O
thus	O
a	O
powerful	O
tool	O
for	O
image	O
quality	O
improvement	O
of	O
large	O
numbers	O
of	O
CBCT	B-T060
images	O
.	O
      
The	O
effects	O
of	O
clinical	O
supervision	O
on	O
supervisees	O
and	O
patients	O
in	O
cognitive	B-T061
-	I-T061
behavioral	I-T061
therapy	I-T061
:	O
a	O
study	O
protocol	O
for	O
a	O
systematic	O
review	O
Clinical	O
supervision	O
by	O
a	O
senior	O
therapist	O
is	O
a	O
very	O
common	O
practice	O
in	O
psychotherapist	O
training	O
and	O
psychiatric	B-T061
care	I-T061
settings	O
.	O
Though	O
clinical	O
supervision	O
is	O
advocated	O
by	O
most	O
educational	O
and	O
governing	O
institutions	O
,	O
the	O
effects	O
of	O
clinical	O
supervision	O
on	O
the	O
supervisees	O
'	O
competence	O
,	O
e.g.	O
,	O
attitudes	O
,	O
behaviors	O
,	O
and	O
skills	O
,	O
as	O
well	O
as	O
on	O
treatment	O
outcomes	O
and	O
other	O
patient	O
variables	O
are	O
debated	O
and	O
largely	O
unknown	O
.	O
Evidence	O
-	O
based	O
practice	O
is	O
advocated	O
in	O
clinical	O
settings	O
but	O
has	O
not	O
yet	O
been	O
fully	O
implemented	O
in	O
educational	O
or	O
clinical	O
training	O
settings	O
.	O
The	O
aim	O
of	O
this	O
systematic	O
review	O
is	O
to	O
synthesize	O
and	O
present	O
the	O
empirical	O
literature	O
regarding	O
effects	O
of	O
clinical	O
supervision	O
in	O
cognitive	B-T061
-	I-T061
behavioral	I-T061
therapy	I-T061
.	O
This	O
study	O
will	O
include	O
a	O
systematic	O
review	O
of	O
the	O
literature	O
to	O
identify	O
studies	O
that	O
have	O
empirically	O
investigated	O
the	O
effects	O
of	O
supervision	O
on	O
supervised	O
psychotherapists	O
and/or	O
the	O
supervisees	O
'	O
patients	O
.	O
A	O
comprehensive	O
search	O
strategy	O
will	O
be	O
conducted	O
to	O
identify	O
published	O
controlled	O
studies	O
indexed	O
in	O
the	O
MEDLINE	O
,	O
EMBASE	O
,	O
PsycINFO	O
,	O
and	O
Cochrane	O
Library	O
databases	O
.	O
Data	O
on	O
supervision	O
outcomes	O
in	O
both	O
psychotherapists	O
and	O
their	O
patients	O
will	O
be	O
extracted	O
,	O
synthesized	O
,	O
and	O
reported	O
.	O
Risk	O
of	O
bias	O
and	O
quality	O
of	O
the	O
included	O
studies	O
will	O
be	O
assessed	O
systematically	O
.	O
This	O
systematic	O
review	O
will	O
rigorously	O
follow	O
established	O
guidelines	O
for	O
systematic	O
reviews	O
in	O
order	O
to	O
summarize	O
and	O
present	O
the	O
evidence	O
base	O
for	O
clinical	O
supervision	O
in	O
cognitive	B-T061
-	I-T061
behavioral	I-T061
therapy	I-T061
and	O
may	O
aid	O
further	O
research	O
and	O
discussion	O
in	O
this	O
area	O
.	O
PROSPERO	O
CRD42016046834	O
.	O
      
The	O
genome	O
-scale	O
DNA	O
-	O
binding	O
profile	B-T059
of	O
BarR	O
,	O
a	O
β	B-T121
-	I-T121
alanine	I-T121
responsive	O
transcription	O
factor	O
in	O
the	O
archaeon	O
Sulfolobus	O
acidocaldarius	O
The	O
Leucine	O
-	O
responsive	O
Regulatory	O
Protein	O
(	O
Lrp	O
)	O
family	O
is	O
a	O
widespread	O
family	O
of	O
regulatory	O
transcription	O
factors	O
in	O
prokaryotes	B-T001
.	O
BarR	O
is	O
an	O
Lrp	O
-like	O
transcription	O
factor	O
in	O
the	O
model	O
archaeon	O
Sulfolobus	O
acidocaldarius	O
that	O
activates	O
the	O
expression	O
of	O
a	O
β	O
-	O
alanine	O
aminotransferase	O
gene	O
,	O
which	O
is	O
involved	O
in	O
β	O
-	O
alanine	O
degradation	O
.	O
In	O
contrast	O
to	O
classical	O
Lrp	O
-like	O
transcription	O
factors	O
,	O
BarR	O
is	O
not	B-T033
responsive	I-T033
to	O
any	O
of	O
the	O
α	O
-	O
amino	O
acids	O
but	O
interacts	O
specifically	O
with	O
β	B-T121
-	I-T121
alanine	I-T121
.	O
Besides	O
the	O
juxtaposed	O
β	O
-	O
alanine	O
aminotransferase	O
gene	O
,	O
other	O
regulatory	O
targets	O
of	O
BarR	O
have	O
not	O
yet	O
been	O
identified	O
although	O
β	B-T121
-	I-T121
alanine	I-T121
is	O
the	O
precursor	O
of	O
coenzyme	O
A	O
and	O
thus	O
an	O
important	O
central	O
metabolite	O
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
extend	O
the	O
knowledge	O
of	O
the	O
DNA	O
-	O
binding	O
characteristics	O
of	O
BarR	O
and	O
of	O
its	O
corresponding	O
regulon	O
from	O
a	O
local	O
to	O
a	O
genome	O
-wide	O
perspective	O
.	O
We	O
characterized	O
the	O
genome	B-T059
-	I-T059
wide	I-T059
binding	I-T059
profile	I-T059
of	O
BarR	O
using	O
chromatin	B-T059
immunoprecipation	I-T059
combined	O
with	O
high	O
-	O
throughput	O
sequencing	O
(	O
ChIP	O
-	O
seq	O
)	O
.	O
This	O
revealed	O
21	O
genomic	O
binding	O
loci	O
.	O
High	O
-	O
enrichment	O
binding	O
regions	O
were	O
validated	O
to	O
interact	O
with	O
purified	O
BarR	O
protein	O
in	O
vitro	O
using	O
electrophoretic	B-T059
mobility	I-T059
shift	I-T059
assays	I-T059
and	O
almost	O
all	O
targets	O
were	O
also	O
shown	O
to	O
harbour	O
a	O
conserved	O
semi	O
-	O
palindromic	O
binding	O
motif	O
.	O
Only	O
a	O
small	O
subset	O
of	O
enriched	O
genomic	O
sites	O
are	O
located	O
in	O
intergenic	O
regions	O
at	O
a	O
relative	O
short	O
distance	O
to	O
a	O
promoter	O
,	O
and	O
qRT	B-T059
-	I-T059
PCR	I-T059
analysis	I-T059
demonstrated	O
that	O
only	O
one	O
additional	O
operon	O
is	O
under	O
activation	O
of	O
BarR	O
,	O
namely	O
the	O
glutamine	O
synthase	O
operon	O
.	O
The	O
latter	O
is	O
also	O
a	O
target	O
of	O
other	O
Lrp	O
-like	O
transcription	O
factors	O
.	O
Detailed	O
inspection	O
of	O
the	O
BarR	O
ChIP	O
-	O
seq	O
profile	O
at	O
the	O
β	O
-	O
alanine	O
aminotransferase	O
promoter	O
region	O
in	O
combination	O
with	O
binding	O
motif	O
predictions	O
indicate	O
that	O
the	O
operator	O
structure	O
is	O
more	O
complicated	O
than	O
previously	O
anticipated	O
,	O
consisting	O
of	O
multiple	O
(	O
major	O
and	O
auxiliary	O
)	O
operators	O
.	O
BarR	O
has	O
a	O
limited	O
regulon	O
,	O
and	O
includes	O
also	O
glutamine	O
synthase	O
genes	O
besides	O
the	O
previously	O
characterized	O
β	O
-	O
alanine	O
aminotransferase	O
.	O
Regulation	O
of	O
glutamine	O
synthase	O
is	O
suggestive	O
of	O
a	O
link	O
between	O
β	O
-	O
alanine	O
and	O
α	O
-	O
amino	O
acid	O
metabolism	O
in	O
S.	O
acidocaldarius	O
.	O
Furthermore	O
,	O
this	O
work	O
reveals	O
that	O
the	O
BarR	O
regulon	O
overlaps	O
with	O
that	O
of	O
other	O
Lrp	O
-like	O
regulators	O
.	O
      
Air	O
Pollutant	O
Exposure	O
Within	O
a	O
Few	O
Days	O
of	O
Delivery	B-T061
and	O
Placental	O
Abruption	O
in	O
Japan	O
Placental	O
abruption	O
is	O
an	O
emergency	O
obstetric	O
complication	O
.	O
Although	O
the	O
etiology	O
of	O
abruption	O
is	O
not	O
fully	O
understood	O
,	O
acute	O
stimuli	O
,	O
such	O
as	O
ischemia	O
and/or	O
inflammation	O
,	O
are	O
associated	O
with	O
rupture	B-T047
of	I-T047
the	I-T047
decidual	I-T047
artery	I-T047
,	O
resulting	O
in	O
placental	O
separation	O
.	O
Ischemia	O
and	O
inflammation	O
are	O
acute	O
biologic	O
effects	O
of	O
air	O
pollution	O
.	O
Using	O
a	O
case	O
-	O
crossover	O
design	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
a	O
short	O
-	O
term	O
increase	O
in	O
exposure	O
to	O
air	O
pollutants	O
is	O
a	O
potential	O
trigger	O
of	O
placental	O
abruption	O
.	O
We	O
received	O
data	O
for	O
western	O
Japan	O
(	O
Kyushu	O
-	O
Okinawa	O
Districts	O
)	O
from	O
the	O
Japan	O
Perinatal	O
Registry	O
Network	O
database	O
.	O
From	O
2005	O
to	O
2010	O
,	O
821	O
singleton	O
pregnant	O
women	O
with	O
placental	O
abruption	O
were	O
identified	O
.	O
We	O
assigned	O
daily	O
concentrations	O
of	O
air	O
pollutants	O
,	O
including	O
nitrogen	O
dioxide	O
(	O
NO2	O
)	O
,	O
suspended	O
particulate	O
matter	O
,	O
ozone	O
,	O
and	O
sulfur	O
dioxide	O
(	O
SO2	O
)	O
,	O
from	O
the	O
nearest	O
monitoring	O
station	O
to	O
the	O
respective	O
delivery	B-T061
hospital	O
of	O
each	O
woman	O
.	O
Because	O
information	O
on	O
the	O
onset	O
day	O
of	O
abruption	O
was	O
not	O
obtained	O
,	O
we	O
assumed	O
the	O
case	O
day	O
to	O
be	O
1	O
day	O
before	O
the	O
day	O
of	O
delivery	B-T061
.	O
Exposure	O
to	O
NO2	O
at	O
2	O
days	O
'	O
lag	O
was	O
associated	O
with	O
placental	O
abruption	O
(	O
temperature	O
adjusted	O
odds	O
ratio	O
per	O
10	O
ppb	O
increase	O
=	O
1.4	O
;	O
95	O
%	O
confidence	O
interval	O
=	O
1.1	O
,	O
1.8	O
)	O
.	O
The	O
association	O
patterns	O
were	O
similar	O
,	O
when	O
we	O
restricted	O
to	O
participants	O
who	O
delivered	B-T061
by	O
emergency	B-T061
cesarean	I-T061
(	O
1.4	O
,	O
1.1	O
,	O
1.9	O
)	O
,	O
or	O
who	O
delivered	B-T061
after	O
35	O
weeks	O
of	O
gestation	O
(	O
1.4	O
,	O
1.0	O
,	O
2.0	O
)	O
.	O
There	O
was	O
no	B-T033
association	I-T033
with	O
suspended	O
particulate	O
matter	O
,	O
ozone	O
,	O
or	O
SO2	O
.	O
We	O
observed	O
an	O
association	O
between	O
NO2	O
exposure	O
at	O
2	O
days	O
before	O
the	O
day	O
of	O
delivery	B-T061
and	O
placental	O
abruption	O
in	O
pregnant	O
Japanese	O
women	O
.	O
      
Individual	O
Leg	B-T023
Muscle	I-T023
Contributions	O
to	O
the	O
Cost	O
of	O
Walking	O
:	O
Effects	O
of	O
Age	O
and	O
Walking	O
Speed	O
This	O
study	O
examined	B-T033
the	O
contributions	O
of	O
individual	O
muscles	O
to	O
changes	O
in	O
energetic	O
cost	O
of	O
transport	O
(	O
COT	O
)	O
over	O
seven	O
walking	O
speeds	O
,	O
and	O
compared	O
results	O
between	O
healthy	O
young	O
and	O
elderly	O
subjects	O
.	O
Twenty	O
six	O
participants	O
(	O
13	O
young	O
aged	O
18	O
-	O
30	O
;	O
13	O
old	O
aged	O
70	O
-	O
80	O
)	O
were	O
recruited	O
.	O
COT	O
(	O
O2	O
/	O
kg	O
body	O
mass	O
/	O
km	O
)	O
was	O
calculated	O
by	O
standardizing	O
the	O
mean	O
oxygen	O
consumption	O
recorded	O
during	O
steady	O
state	O
walking	O
.	O
Electromyography	B-T060
signals	O
from	O
10	O
leg	B-T023
muscles	I-T023
were	O
used	O
to	O
calculate	O
the	O
cumulative	O
activity	O
required	O
to	O
traverse	O
a	O
unit	O
of	O
distance	O
(	O
CMAPD	O
)	O
for	O
each	O
muscle	O
at	O
each	O
speed	O
.	O
In	O
the	O
old	O
group	O
CMAPD	O
was	O
correlated	O
with	O
COT	O
,	O
presented	O
higher	O
and	O
more	O
variable	O
values	O
,	O
and	O
showed	O
greater	O
increases	O
around	O
optimal	O
speed	O
for	O
all	O
studied	O
muscles	O
.	O
Soleus	B-T023
CMAPD	O
was	O
independent	O
of	O
speed	O
in	O
the	O
young	O
group	O
,	O
but	O
this	O
was	O
not	O
evident	O
with	O
aging	O
.	O
Greater	O
energy	O
cost	O
of	O
walking	O
in	O
older	O
individuals	O
seems	O
to	O
be	O
attributable	O
to	O
increased	O
energy	O
cost	O
of	O
all	O
lower	B-T023
limb	I-T023
muscles	I-T023
.	O
      
Emergence	O
of	O
family	O
medicine	O
in	O
Ethiopia	O
[	O
corrected	O
]	O
:	O
an	O
international	O
collaborative	O
education	O
model	O
Family	O
Medicine	O
(	O
FM	O
)	O
is	O
a	O
new	O
specialty	O
in	O
Ethiopia	O
.	O
The	O
first	O
seven	O
family	O
physicians	O
graduated	O
in	O
February	O
2016	O
from	O
the	O
inaugural	O
residency	O
programme	O
at	O
Addis	O
Ababa	O
University	O
.	O
Cooperation	O
amongst	O
Ethiopian	O
and	O
expatriate	B-T033
decision	O
-	O
makers	O
and	O
physicians	O
was	O
needed	O
to	O
begin	O
the	O
programme	O
.	O
Intentional	O
replacement	O
of	O
expatriates	B-T033
with	O
Ethiopian	O
family	O
physicians	O
has	O
begun	O
.	O
Barriers	O
include	O
lack	O
of	O
understanding	O
of	O
FM	O
and	O
the	O
human	O
and	O
financial	B-T033
resources	I-T033
needed	O
for	O
scaling	O
up	O
the	O
programme	O
.	O
Regular	O
programme	O
review	O
with	O
resident	O
physician	O
involvement	O
has	O
allowed	O
the	O
FM	O
training	O
programme	O
to	O
adapt	O
and	O
fit	O
the	O
Ethiopian	O
context	O
.	O
Further	O
successes	O
will	O
result	O
from	O
ongoing	O
support	O
and	O
advocacy	O
from	O
the	O
Federal	O
Ministry	O
of	O
Health	O
and	O
other	O
Ethiopian	O
,	O
African	O
,	O
and	O
international	O
primary	O
care	O
organisations	O
.	O
      
Classification	O
of	O
Edible	O
Oils	O
Based	O
on	O
ATR	O
-	O
FTIR	O
Spectral	O
Information	O
During	O
a	O
Long	O
Heating	O
Treatment	O
Identification	O
of	O
oil	O
type	O
and	O
its	O
QC	O
are	O
important	O
concerns	O
in	O
food	O
control	O
laboratories	O
.	O
Classifying	O
edible	O
oils	O
that	O
have	O
not	O
been	O
used	O
(	O
i.e.	O
,	O
unheated	O
)	O
with	O
the	O
aid	O
of	O
vibrational	B-T059
spectroscopy	I-T059
has	O
previously	O
been	O
reported	O
.	O
However	O
,	O
the	O
classification	O
of	O
used	O
(	O
i.e.	O
,	O
heat	O
-	O
treated	O
)	O
oils	O
needs	O
special	O
attention	O
.	O
The	O
effect	O
of	O
long	O
heating	O
times	O
on	O
the	O
classification	O
of	O
four	O
kinds	O
of	O
edible	O
oils	O
(	O
canola	O
,	O
corn	O
,	O
frying	O
,	O
and	O
sunflower	O
)	O
based	O
on	O
attenuated	O
total	O
reflectance	O
(	O
ATR)-FTIR	O
spectra	O
was	O
surveyed	O
.	O
The	O
sampling	O
was	O
done	O
on	O
the	O
oils	O
during	O
a	O
36	O
h	O
heating	O
process	O
(	O
at	O
170	O
°	O
C	O
)	O
.	O
The	O
ATR	O
-	O
FTIR	O
spectra	O
of	O
the	O
samples	O
were	O
collected	O
in	O
the	O
range	O
of	O
4000	O
-	O
550	O
cm-1	O
.	O
Interval	O
extended	O
canonical	O
variates	O
analysis	O
(	O
ECVA	O
)	O
,	O
as	O
a	O
variable	O
selection	O
and	O
classification	O
tool	O
,	O
was	O
used	O
to	O
determine	O
the	O
best	O
intervals	O
during	O
the	O
heating	O
procedure	O
for	O
classification	O
.	O
Principal	O
component	O
analysis	O
discriminate	O
analysis	O
,	O
partial	O
least	O
-	O
squares	O
discriminate	O
analysis	O
,	O
and	O
ECVA	O
were	O
performed	O
on	O
the	O
selected	O
intervals	O
and	O
on	O
the	O
total	O
heating	O
time	O
.	O
The	O
effect	O
of	O
autoscaling	B-T033
and	O
mean	B-T033
-	I-T033
centering	I-T033
,	O
as	O
data	O
preprocessing	O
methods	O
,	O
was	O
also	O
investigated	O
.	O
The	O
ECVA	O
method	O
resulted	O
in	O
the	O
best	O
performances	O
for	O
classification	O
,	O
with	O
a	O
94	O
%	O
cross	O
-	O
validated	O
nonerror	O
rate	O
(	O
one	O
misclassification	O
)	O
for	O
the	O
heating	O
process	O
times	O
of	O
24	O
-	O
27	O
and	O
33	O
-	O
36	O
h.	O
      
Reflections	O
on	O
Hip	B-T061
Fracture	I-T061
Recovery	I-T061
From	O
Older	O
Adults	O
Enrolled	O
in	O
a	O
Clinical	O
Trial	O
This	O
study	O
describes	O
patients	O
'	O
perspectives	O
on	O
recovery	O
during	O
participation	O
in	O
a	O
randomized	O
controlled	O
trial	O
that	O
tested	O
a	O
postoperative	O
hip	O
fracture	O
management	O
program	O
(	O
B4	O
Clinic	O
)	O
,	O
compared	O
with	O
usual	B-T058
care	I-T058
,	O
on	O
mobility	O
.	O
Semistructured	O
qualitative	O
interviews	O
were	O
conducted	O
with	O
50	O
older	O
adults	O
with	O
hip	O
fracture	O
(	O
from	O
both	O
groups	O
)	O
twice	O
over	O
12	O
months	O
.	O
A	O
total	O
of	O
32	O
women	O
(	O
64	O
%	O
)	O
and	O
18	O
men	O
(	O
36	O
%	O
)	O
participated	O
in	O
the	O
study	O
with	O
a	O
mean	O
age	O
at	O
baseline	O
of	O
82	O
(	O
range	O
=	O
65	O
-	O
98	O
)	O
years	O
.	O
A	O
total	O
of	O
40	O
participants	O
reported	B-T058
recovery	O
goals	O
at	O
some	O
point	O
during	O
their	O
recovery	O
from	O
hip	O
fracture	O
but	O
only	O
18	O
participants	O
realized	O
their	O
goals	O
within	O
12	O
months	O
.	O
Recovering	O
mobility	O
,	O
returning	O
to	O
prefracture	O
activities	O
,	O
and	O
obtaining	O
stable	O
health	O
were	O
the	O
most	O
commonly	O
reported	B-T058
goals	O
.	O
Participants	O
described	O
good	O
social	B-T058
support	I-T058
,	O
access	O
to	O
physiotherapy	B-T061
,	O
and	O
positive	B-T033
perspective	O
as	O
most	O
important	O
to	O
recovery	O
.	O
These	O
factors	O
were	O
influenced	O
by	O
participants	O
'	O
knowledge	O
,	O
resources	O
,	O
and	O
monthly	O
contact	O
with	O
study	O
staff	O
(	O
perceived	O
as	O
a	O
form	O
of	O
social	B-T058
support	I-T058
)	O
.	O
The	O
most	O
frequently	O
reported	B-T058
barriers	O
to	O
participants	O
'	O
recovery	O
were	O
the	O
onset	O
of	O
complications	O
,	O
pain	B-T184
,	O
and	O
limited	B-T033
access	I-T033
to	O
physiotherapy	B-T061
.	O
Potential	O
implications	O
of	O
these	O
findings	B-T033
include	O
design	O
and	O
modification	B-T033
of	O
new	O
or	O
preexisting	O
fracture	O
programs	O
,	O
prioritizing	O
patient	B-T058
engagement	I-T058
and	O
enhanced	O
knowledge	O
for	O
future	O
clinical	O
research	O
in	O
hip	B-T061
fracture	I-T061
recovery	I-T061
.	O
      
The	O
influence	O
of	O
slope	O
on	O
Spartium	O
junceum	O
root	O
system	O
:	O
morphological	O
,	O
anatomical	O
and	O
biomechanical	O
adaptation	O
Root	O
systems	O
have	O
a	O
pivotal	O
role	O
in	O
plant	O
anchorage	O
and	O
their	O
mechanical	O
interactions	O
with	O
the	O
soil	O
may	O
contribute	O
to	O
soil	O
reinforcement	O
and	O
stabilization	O
of	O
slide	O
-	O
prone	O
slopes	O
.	O
In	O
order	O
to	O
understand	O
the	O
responses	O
of	O
root	O
system	O
to	O
mechanical	O
stress	O
induced	O
by	O
slope	O
,	O
samples	O
of	O
Spartium	O
junceum	O
L.	O
,	O
growing	O
in	O
slope	O
and	O
in	O
plane	O
natural	O
conditions	O
,	O
were	O
compared	O
in	O
their	O
morphology	O
,	O
biomechanical	O
properties	O
and	O
anatomical	O
features	O
.	O
Soils	O
sampled	O
in	O
slope	O
and	O
plane	O
revealed	O
similar	O
characteristics	O
,	O
with	O
the	O
exception	O
of	O
organic	O
matter	O
content	O
and	O
penetrometer	O
resistance	O
,	O
both	O
higher	O
in	O
slope	O
.	O
Slope	O
significantly	O
influenced	O
root	O
morphology	O
and	O
in	O
particular	O
the	O
distribution	O
of	O
lateral	O
roots	O
along	O
the	O
soil	O
depth	O
.	O
Indeed	O
,	O
first	O
-	O
order	O
lateral	O
roots	O
of	O
plants	O
growing	O
on	O
slope	O
condition	O
showed	O
an	O
asymmetric	O
distribution	O
between	O
up-	O
and	O
down	O
-	O
slope	O
.	O
Contrarily	O
,	O
this	O
asymmetric	O
distribution	O
was	O
not	O
observed	O
in	O
plants	O
growing	O
in	O
plane	O
.	O
The	O
tensile	O
strength	O
was	O
higher	O
in	O
lateral	O
roots	O
growing	O
up	O
-	O
slope	O
and	O
in	O
plane	O
conditions	O
than	O
in	O
those	O
growing	O
down	O
-	O
slope	O
.	O
Anatomical	O
investigations	O
revealed	O
that	O
,	O
while	O
roots	O
grown	O
up	O
-	O
slope	O
had	O
higher	O
area	O
covered	O
by	O
xylem	O
fibers	O
,	O
the	O
ratio	O
of	O
xylem	O
and	O
phloem	O
fibers	O
to	O
root	O
diameter	O
did	O
not	O
differ	O
among	O
the	O
three	O
conditions	O
,	O
as	O
also	O
,	O
no	B-T033
differences	I-T033
were	O
found	O
for	O
xylem	O
fiber	O
cell	O
wall	O
thickness	O
.	O
Roots	O
growing	O
up	O
-	O
slope	O
were	O
the	O
main	O
contributors	O
to	O
anchorage	O
properties	O
,	O
which	O
included	O
higher	O
strength	O
and	O
higher	O
number	O
of	O
fibers	O
in	O
the	O
xylematic	O
tissues	O
.	O
Results	O
suggested	O
that	O
a	O
combination	O
of	O
root	O
-	O
specific	O
morphological	O
,	O
anatomical	O
and	O
biomechanical	O
traits	O
,	O
determines	O
anchorage	O
functions	O
in	O
slope	O
conditions	O
.	O
      
The	O
Longitudinal	O
Effects	O
of	O
Parenting	O
on	O
Adaptive	O
Behavior	O
in	O
Children	O
with	O
Fragile	B-T047
X	I-T047
Syndrome	I-T047
Several	O
studies	O
have	O
reported	O
declines	O
in	O
adaptive	O
behavior	O
amongst	O
children	O
with	O
fragile	B-T047
X	I-T047
syndrome	I-T047
(	O
FXS	B-T047
)	O
starting	O
in	O
middle	O
childhood	O
.	O
We	O
examined	B-T033
the	O
effects	O
of	O
maternal	O
responsivity	O
on	O
adaptive	O
behavior	O
in	O
55	O
children	O
with	O
FXS	B-T047
visited	O
5	O
-	O
6	O
times	O
in	O
their	O
homes	O
from	O
early	O
through	O
middle	O
childhood	O
.	O
Our	O
analyses	O
indicated	O
that	O
sustained	O
maternal	O
responsivity	O
had	O
a	O
significant	O
positive	O
impact	O
on	O
the	O
trajectories	O
of	O
communication	O
and	O
to	O
a	O
lesser	O
extent	O
other	O
adaptive	O
behavior	O
domains	O
through	O
middle	O
childhood	O
with	O
many	O
effects	O
remaining	O
significant	O
after	O
controlling	O
for	O
autism	B-T033
symptoms	I-T033
and	O
developmental	O
level	O
.	O
For	O
children	O
who	O
showed	O
declines	O
in	O
adaptive	O
behavior	O
during	O
middle	O
childhood	O
,	O
sustained	O
high	O
levels	O
of	O
maternal	O
responsivity	O
minimized	O
the	O
amount	O
of	O
decline	O
observed	O
in	O
the	O
communication	O
,	O
socialization	O
,	O
and	O
daily	O
living	O
domains	O
.	O
      
Prevalence	O
and	O
correlates	O
of	O
antibiotic	B-T195
sharing	O
in	O
the	O
Philippines	O
:	O
antibiotic	B-T195
misconceptions	O
and	O
community	O
-	O
level	O
access	O
to	O
non	O
-	O
medical	O
sources	B-T033
of	O
antibiotics	B-T195
To	O
identify	O
sociodemographic	O
,	O
knowledge	O
and	O
attitudinal	O
correlates	O
to	O
antibiotic	B-T195
sharing	O
among	O
a	O
community	O
-	O
based	O
sample	O
of	O
adults	O
(	O
age	O
18	O
and	O
older	O
)	O
in	O
a	O
low	B-T033
-	I-T033
income	I-T033
setting	I-T033
of	O
the	O
Philippines	O
and	O
to	O
explore	O
community	O
-	O
level	O
data	O
on	O
informal	B-T033
antibiotic	B-T195
distribution	O
in	O
roadside	O
stands	O
(	O
i.e.	O
,	O
sari	O
-	O
sari	O
stands	O
)	O
.	O
Participants	O
(	O
n	O
=	O
307	O
)	O
completed	O
self	O
-	O
administered	O
surveys	O
.	O
Correlates	O
to	O
antibiotic	B-T195
sharing	O
were	O
assessed	O
using	O
logistic	O
regression	O
with	O
Firth	O
's	O
bias	O
-	O
adjusted	O
estimate	O
s.	O
Study	O
staff	O
also	O
visited	O
106	O
roadside	O
stands	O
and	O
collected	B-T033
data	I-T033
on	O
availability	O
and	O
characteristics	O
of	O
antibiotics	B-T195
in	O
the	O
stands	O
.	O
78	O
%	O
had	O
shared	O
antibiotics	B-T195
in	O
their	O
lifetime	O
,	O
most	O
often	O
with	O
family	O
members	O
.	O
In	O
multivariable	O
analysis	O
,	O
agreement	O
with	O
the	O
belief	O
that	O
it	O
is	O
safe	O
to	O
prematurely	O
stop	O
an	O
antibiotic	B-T195
course	O
(	O
OR	O
:	O
2.8	O
,	O
CI	O
:	O
1.3	O
-	O
5.8	O
)	O
and	O
concerns	O
about	O
antibiotic	O
side	O
effects	O
(	O
OR	O
:	O
2.1	O
,	O
CI	O
:	O
1.1	O
-	O
4.4	O
)	O
were	O
significantly	O
associated	O
with	O
increased	O
odds	O
of	O
reported	O
antibiotic	B-T195
sharing	O
.	O
Antibiotic	B-T195
sharing	O
was	O
not	O
associated	O
with	O
sociodemographic	O
characteristics	O
or	O
antibiotic	B-T195
knowledge	O
.	O
Antibiotics	B-T195
were	O
widely	O
available	O
in	O
60	O
%	O
of	O
sampled	O
sari	O
-	O
sari	O
stands	O
,	O
in	O
which	O
59	O
%	O
of	O
antibiotics	B-T195
were	O
missing	B-T033
expiration	I-T033
dates	I-T033
.	O
Amoxicillin	B-T195
and	O
cephalexin	B-T195
were	O
the	O
most	O
commonly	O
available	O
antibiotics	B-T195
for	O
sale	O
at	O
the	O
stands	O
(	O
60	O
%	O
and	O
21	O
%	O
,	O
respectively	O
)	O
.	O
Antibiotic	B-T195
sharing	O
was	O
common	O
and	O
was	O
associated	O
with	O
misconceptions	O
about	O
proper	O
antibiotic	B-T195
use	O
.	O
Antibiotics	B-T195
were	O
widely	O
available	O
in	O
sari	O
-	O
sari	O
stands	O
,	O
and	O
usually	O
without	O
expiration	O
information	O
.	O
This	O
study	O
suggests	O
that	O
multipronged	O
and	O
locally	O
tailored	O
approaches	O
to	O
curbing	O
informal	B-T033
antibiotic	B-T195
access	O
are	O
needed	O
in	O
the	O
Philippines	O
and	O
similar	O
Southeast	O
-	O
Asian	O
countries	O
.	O
      
Historical	O
Environment	O
Is	O
Reflected	O
in	O
Modern	O
Population	O
Genetics	O
and	O
Biogeography	O
of	O
an	O
Island	O
Endemic	O
Lizard	O
(	O
Xantusia	O
riversiana	O
reticulata	O
)	O
The	O
restricted	O
distribution	O
and	O
isolation	O
of	O
island	O
endemics	O
often	O
produces	O
unique	O
genetic	O
and	O
phenotypic	O
diversity	O
of	O
conservation	O
interest	O
to	O
management	O
agencies	O
.	O
However	O
,	O
these	O
isolated	O
species	O
,	O
especially	O
those	O
with	O
sensitive	O
life	O
history	O
traits	O
,	O
are	O
at	O
high	B-T033
risk	I-T033
for	O
the	O
adverse	O
effects	O
of	O
genetic	O
drift	O
and	O
habitat	O
degradation	O
by	O
non	O
-	O
native	O
wildlife	O
.	O
Here	O
,	O
we	O
study	O
the	O
population	O
genetic	O
diversity	O
,	O
structure	O
,	O
and	O
stability	O
of	O
a	O
classic	O
"	O
island	O
giant	O
"	O
(	O
Xantusia	O
riversiana	O
,	O
the	O
Island	O
Night	O
Lizard	O
)	O
on	O
San	O
Clemente	O
Island	O
,	O
California	O
following	O
the	O
removal	O
of	O
feral	O
goats	O
.	O
Using	O
DNA	O
microsatellites	O
,	O
we	O
found	O
that	O
this	O
population	O
is	O
reasonably	O
genetically	O
robust	O
despite	O
historical	O
grazing	O
,	O
with	O
similar	O
effective	O
population	O
sizes	O
and	O
genetic	O
diversity	O
metrics	O
across	O
all	O
sampling	O
locations	O
irrespective	O
of	O
habitat	O
type	O
and	O
degree	O
of	O
degradation	O
.	O
However	O
,	O
we	O
also	O
found	O
strong	O
site	O
-	O
specific	O
patterns	O
of	O
genetic	O
variation	O
and	O
low	O
genetic	O
diversity	O
compared	O
to	O
mainland	O
congeners	O
,	O
warranting	O
continued	O
special	O
management	O
as	O
an	O
island	O
endemic	O
.	O
We	O
identify	O
both	O
high	O
and	O
low	O
elevation	O
areas	O
that	O
remain	O
valuable	O
repositories	O
of	O
genetic	O
diversity	O
and	O
provide	O
a	O
case	O
study	O
for	O
other	O
low	O
-	O
dispersal	O
coastal	O
organisms	B-T001
in	O
the	O
face	O
of	O
future	O
climate	O
change	O
.	O
      
Design	O
,	O
synthesis	O
and	O
anti	O
-	O
tumor	O
activity	O
study	O
of	O
novel	O
histone	B-T121
deacetylase	I-T121
inhibitors	I-T121
containing	O
isatin	B-T121
-based	O
caps	O
and	O
o	O
-	O
phenylenediamine	O
-based	O
zinc	O
binding	O
groups	O
As	O
a	O
hot	O
topic	O
of	O
epigenetic	O
studies	O
,	O
histone	O
deacetylases	O
(	O
HDACs	O
)	O
are	O
related	O
to	O
lots	O
of	O
diseases	B-T047
,	O
especially	O
cancer	B-T191
.	O
Further	O
researches	O
indicated	O
that	O
different	O
HDAC	O
isoforms	O
played	O
various	O
roles	O
in	O
a	O
wide	O
range	O
of	O
tumor	B-T033
types	I-T033
.	O
Herein	O
a	O
novel	O
series	O
of	O
HDAC	B-T121
inhibitors	I-T121
with	O
isatin	B-T121
-based	O
caps	O
and	O
o	O
-	O
phenylenediamine	O
-based	O
zinc	O
binding	O
groups	O
have	O
been	O
designed	O
and	O
synthesized	O
through	O
scaffold	B-T059
hopping	I-T059
strategy	I-T059
.	O
Among	O
these	O
compounds	O
,	O
the	O
most	O
potent	O
compound	O
9n	O
exhibited	O
similar	O
if	O
not	O
better	O
HDAC	O
inhibition	O
and	O
antiproliferative	O
activities	O
against	O
multiple	O
tumor	O
cell	O
lines	O
compared	O
with	O
the	O
positive	O
control	O
entinostat	B-T121
(	O
MS-275	B-T121
)	O
.	O
Additionally	O
,	O
compared	O
with	O
MS-275	B-T121
(	O
IC50	O
values	O
for	O
HDAC1	O
,	O
2	O
and	O
3	O
were	O
0.163	O
,	O
0.396	O
and	O
0.605µM	O
,	O
respectively	O
)	O
,	O
compound	O
9n	O
with	O
IC50	O
values	O
of	O
0.032	O
,	O
0.256	O
and	O
0.311µM	O
for	O
HDAC1	O
,	O
2	O
and	O
3	O
respectively	O
,	O
showed	O
a	O
moderate	O
HDAC1	O
selectivity	O
.	O
      
The	O
underlying	O
inflammatory	B-T047
chronic	I-T047
disease	I-T047
influences	O
infliximab	B-T121
pharmacokinetics	O
Infliximab	B-T121
is	O
an	O
anti	B-T121
-	I-T121
tumor	I-T121
necrosis	I-T121
factor	I-T121
monoclonal	O
antibody	O
approved	O
in	O
chronic	B-T047
inflammatory	I-T047
diseases	I-T047
such	O
as	O
rheumatoid	B-T047
arthritis	I-T047
(	O
RA	B-T047
)	O
,	O
psoriatic	B-T047
arthritis	I-T047
(	O
PsA	B-T047
)	O
,	O
ankylosing	B-T047
spondylitis	I-T047
(	O
AS	B-T047
)	O
,	O
Crohn	B-T047
's	I-T047
disease	I-T047
(	O
CD	B-T047
)	O
and	O
ulcerative	B-T047
colitis	I-T047
(	O
UC	B-T047
)	O
.	O
Infliximab	B-T121
pharmacokinetics	O
is	O
variable	O
between	O
patients	O
,	O
but	O
influence	O
of	O
the	O
underlying	B-T047
disease	I-T047
was	O
never	O
assessed	O
.	O
This	O
study	O
aimed	O
at	O
assessing	O
this	O
influence	O
using	O
a	O
cohort	O
of	O
patients	B-T058
monitored	I-T058
in	O
a	O
single	O
center	O
and	O
with	O
the	O
same	O
assay	B-T059
.	O
Infliximab	B-T121
trough	O
concentrations	O
were	O
determined	O
on	O
samples	B-T059
collected	I-T059
between	O
weeks	O
0	O
and	O
22	O
after	O
treatment	O
initiation	O
in	O
218	O
patients	O
treated	O
for	O
RA	B-T047
,	O
PsA	B-T047
,	O
AS	B-T047
,	O
CD	B-T047
or	O
UC	B-T047
.	O
Infliximab	B-T121
pharmacokinetics	O
was	O
analyzed	O
by	O
a	O
one	O
-	O
compartment	O
population	O
model	O
with	O
first	O
-	O
order	O
elimination	B-T033
rate	O
constant	O
.	O
In	O
AS	B-T047
patients	O
,	O
volume	O
of	O
distribution	O
(	O
V	O
)	O
and	O
elimination	B-T033
clearance	O
(	O
CL	O
)	O
were	O
5.4	O
L	O
and	O
0.24	O
L	O
/	O
day	O
,	O
respectively	O
.	O
In	O
CD	B-T047
and	O
UC	B-T047
patients	O
,	O
V	O
was	O
49	O
%	O
and	O
52	O
%	O
higher	O
than	O
in	O
AS	B-T047
,	O
respectively	O
,	O
and	O
CL	O
was	O
47	O
%	O
and	O
60	O
%	O
higher	O
than	O
in	O
AS	B-T047
,	O
respectively	O
.	O
In	O
RA	B-T047
patients	O
,	O
CL	O
was	O
49	O
%	O
higher	O
than	O
in	O
AS	B-T047
patients	O
.	O
Simulations	O
showed	O
that	O
without	O
methotrexate	B-T121
,	O
a	O
3	O
mg	O
/	O
kg	O
dosing	O
regimen	B-T061
would	O
lead	O
only	O
16	O
%	O
of	O
RA	B-T047
patients	O
to	O
reach	O
the	O
target	O
concentration	O
(	O
2.5	O
mg	O
/	O
L	O
)	O
at	O
week	O
22	O
,	O
whereas	O
target	O
concentrations	O
would	O
be	O
reached	O
in	O
approximately	O
half	O
of	O
RA	B-T047
patients	O
cotreated	O
with	O
methotrexate	B-T121
,	O
as	O
well	O
as	O
half	O
of	O
CD	B-T047
(	O
3.5	O
mg	O
/	O
L	O
)	O
and	O
UC	B-T047
(	O
3.7	O
mg	O
/	O
L	O
)	O
patients	O
.	O
The	O
suboptimality	O
of	O
approved	O
dosing	O
regimens	B-T061
supports	O
the	O
development	O
of	O
dosing	O
optimization	O
based	O
on	O
concentration	O
measurements	O
.	O
      
Synthesis	O
of	O
1,2	B-T121
-	I-T121
Dioxetanes	I-T121
as	O
Thermochemiluminescent	O
Labels	O
for	O
Ultrasensitive	B-T059
Bioassays	I-T059
:	O
Rational	O
Prediction	O
of	O
Olefin	O
Photooxygenation	O
Outcome	O
by	O
Using	O
a	O
Chemometric	B-T059
Approach	I-T059
Great	O
interest	O
in	O
new	O
thermochemiluminescent	O
(	O
TCL	O
)	O
molecules	O
,	O
for	O
example	O
,	O
in	O
bioanalytical	B-T059
assays	I-T059
,	O
has	O
prompted	O
the	O
design	O
and	O
synthesis	O
of	O
a	O
small	O
library	O
of	O
more	O
than	O
30	O
olefins	O
to	O
be	O
subjected	O
to	O
photooxygenation	O
,	O
with	O
the	O
aim	O
of	O
obtaining	O
new	O
1,2	B-T121
-	I-T121
dioxetane	I-T121
-	I-T121
based	I-T121
TCL	O
labels	O
with	O
optimized	O
properties	O
.	O
Fluorine	O
atoms	O
on	O
the	O
acridan	O
system	O
remarkably	O
stabilize	O
1,2	B-T121
-	I-T121
dioxetanes	I-T121
when	O
they	O
are	O
located	O
in	O
the	O
3-	O
and/or	O
6	O
-	O
position	O
(	O
4	O
h	O
and	O
4	O
i	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
2,7	O
-	O
difluorinated	O
acridan	O
dioxetane	O
(	O
4	O
j	O
)	O
showed	O
a	O
significantly	O
enhanced	O
fluorescence	O
quantum	O
yield	O
with	O
respect	O
to	O
the	O
unsubstituted	O
dioxetane	O
(	O
4	O
a	O
)	O
.	O
Some	O
of	O
the	O
synthesized	O
olefins	O
did	O
not	O
undergo	O
singlet	O
oxygen	O
addition	O
and	O
a	O
rationale	O
was	O
sought	O
to	O
ease	O
the	O
photooxygenation	O
step	O
,	O
leading	O
to	O
the	O
TCL	O
dioxetanes	O
.	O
A	O
chemometric	B-T059
approach	I-T059
has	O
been	O
adopted	O
to	O
exploit	O
principal	O
component	O
analysis	O
and	O
linear	O
discriminant	O
analysis	O
of	O
the	O
structural	O
and	O
electronic	O
molecular	O
descriptors	O
obtained	O
by	O
DFT	O
optimizations	O
of	O
olefins	O
3	O
.	O
This	O
approach	O
allows	O
the	O
steric	O
and	O
electronic	O
parameters	O
that	O
govern	O
dioxetane	O
formation	O
to	O
be	O
revealed	O
.	O
      
Development	O
of	O
the	O
pediatric	O
quality	O
of	O
life	O
inventory	O
neurofibromatosis	B-T191
type	I-T191
1	I-T191
module	O
items	O
for	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
:	O
qualitative	O
methods	O
Health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQOL	O
)	O
is	O
arguably	O
one	O
of	O
the	O
most	O
important	O
measures	O
in	O
evaluating	B-T058
effectiveness	O
of	O
clinical	B-T061
treatments	I-T061
.	O
At	O
present	O
,	O
there	O
is	O
no	O
disease	B-T047
-	O
specific	O
outcome	O
measure	O
to	O
assess	B-T058
the	O
HRQOL	O
of	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
with	O
Neurofibromatosis	B-T191
Type	I-T191
1	I-T191
(	O
NF1	B-T191
)	O
.	O
This	O
study	O
aimed	O
to	O
develop	O
the	O
items	O
and	O
support	O
the	O
content	O
validity	O
for	O
the	O
Pediatric	O
Quality	O
of	O
Life	O
Inventory	O
™	O
(	O
PedsQL	O
™	O
)	O
NF1	B-T191
Module	O
for	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
.	O
The	O
iterative	B-T033
process	O
included	O
multiphase	O
qualitative	O
methods	O
including	O
a	O
literature	O
review	O
,	O
survey	O
of	O
expert	O
opinions	O
,	O
semi	O
-	O
structured	O
interviews	O
,	O
cognitive	O
interviews	O
and	O
pilot	O
testing	O
.	O
Fifteen	O
domains	O
were	O
derived	O
from	O
the	O
qualitative	O
methods	O
,	O
with	O
content	O
saturation	O
achieved	O
,	O
resulting	O
in	O
115	O
items	O
.	O
The	O
domains	O
include	O
skin	O
,	O
pain	B-T184
,	O
pain	B-T184
impact	O
,	O
pain	B-T061
management	I-T061
,	O
cognitive	O
functioning	O
,	O
speech	O
,	O
fine	O
motor	O
,	O
balance	O
,	O
vision	O
,	O
perceived	O
physical	B-T184
appearance	I-T184
,	O
communication	O
,	O
worry	B-T033
,	O
treatment	B-T061
,	O
medicines	B-T121
and	O
gastrointestinal	B-T184
symptoms	I-T184
.	O
This	O
study	O
is	O
limited	O
because	O
all	O
participants	O
are	O
recruited	O
from	O
a	O
single	O
-	O
site	O
.	O
Qualitative	O
methods	O
support	O
the	O
content	O
validity	O
for	O
the	O
PedsQL	O
™	O
NF1	B-T191
Module	O
for	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
.	O
The	O
PedsQL	O
™	O
NF1	B-T191
Module	O
is	O
now	O
undergoing	O
national	O
multisite	O
field	O
testing	O
for	O
the	O
psychometric	B-T060
validation	O
of	O
the	O
instrument	O
development	O
.	O
      
Mental	O
health	O
and	O
associated	O
factors	O
among	O
young	O
offenders	O
in	O
Chile	O
:	O
a	O
cross	O
-	O
sectional	O
study	O
Few	O
studies	O
in	O
Latin	O
America	O
have	O
explored	O
mental	B-T048
disorder	I-T048
among	O
young	O
offenders	O
,	O
or	O
variables	O
associated	O
with	O
it	O
.	O
Our	O
aim	O
was	O
to	O
test	O
for	O
associations	O
between	O
childhood	O
adversity	O
or	O
substance	B-T033
misuse	I-T033
and	O
psychiatric	B-T048
disorders	I-T048
among	O
young	O
offenders	O
.	O
Sentenced	O
adolescent	O
offenders	O
were	O
recruited	O
from	O
young	O
offenders	O
'	O
institutions	O
or	O
community	B-T058
centres	I-T058
provided	O
by	O
the	O
Chilean	O
National	O
Service	O
for	O
Minors	O
.	O
Psychiatric	B-T048
disorders	I-T048
were	O
assessed	O
using	O
the	O
Mini	B-T060
International	I-T060
Neuropsychiatric	I-T060
Interview	I-T060
,	O
conducted	O
by	O
trained	O
psychologists	O
.	O
A	O
trained	O
sociologist	O
used	O
an	O
ad	O
hoc	O
interview	O
to	O
collect	O
information	O
about	O
childhood	O
experiences	O
,	O
including	O
parenting	B-T033
,	O
trauma	O
,	O
education	O
and	O
substance	B-T033
misuse	I-T033
.	O
Multivariable	O
logistic	O
regressions	O
were	O
used	O
to	O
analyse	O
data	O
.	O
The	O
most	O
prevalent	O
psychiatric	B-T048
disorders	I-T048
among	O
the	O
935	O
participants	O
were	O
marijuana	B-T048
dependence	I-T048
disorder	I-T048
,	O
major	B-T048
depressive	I-T048
disorder	I-T048
,	O
and	O
anxiety	B-T048
disorders	I-T048
.	O
Substance	B-T048
use	I-T048
disorders	I-T048
were	O
less	O
frequent	O
among	O
young	O
offenders	O
who	O
were	O
serving	O
their	O
sentence	B-T033
in	O
young	O
offenders	O
'	O
institutions	O
than	O
among	O
those	O
serving	O
in	O
community	B-T058
centres	I-T058
and	O
more	O
frequent	O
among	O
those	O
who	O
started	O
to	O
use	B-T048
marijuana	I-T048
at	O
an	O
earlier	O
age	O
.	O
Among	O
other	O
variables	O
,	O
childhood	B-T048
maltreatment	I-T048
was	O
related	O
to	O
major	B-T048
depressive	I-T048
disorder	I-T048
,	O
and	O
maternal	O
death	O
to	O
anxiety	B-T048
disorders	I-T048
.	O
Higher	O
educational	B-T033
status	I-T033
was	O
related	O
to	O
a	O
lower	O
frequency	O
of	O
depressive	B-T048
and	O
anxiety	B-T048
disorders	I-T048
.	O
Our	O
findings	B-T033
suggest	O
that	O
greater	O
efforts	O
must	O
be	O
made	O
to	O
identify	O
vulnerable	O
young	O
people	O
much	O
earlier	O
.	O
Few	O
of	O
these	O
young	O
offenders	O
with	O
mental	O
health	O
problems	B-T033
had	O
been	O
well	O
adjusted	O
in	O
health	O
,	O
education	O
or	O
socially	O
before	O
this	O
period	O
of	O
detention	O
.	O
©	O
2017	O
The	O
Authors	O
.	O
Criminal	O
Behaviour	O
and	O
Mental	O
Health	O
Published	O
by	O
John	O
Wiley	O
&	O
Sons	O
Ltd.	O
      
